PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CORNEJO, J; BEALE, SI; TERRY, MJ; LAGARIAS, JC				CORNEJO, J; BEALE, SI; TERRY, MJ; LAGARIAS, JC			PHYTOCHROME ASSEMBLY - THE STRUCTURE AND BIOLOGICAL-ACTIVITY OF 2(R),3(E)-PHYTOCHROMOBILIN DERIVED FROM PHYCOBILIPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; FREMYELLA-DIPLOSIPHON; CYANIDIUM-CALDARIUM; DIMETHYL ESTER; C-PHYCOCYANIN; BILE-PIGMENTS; BIOSYNTHESIS; PHYCOBILINS; INVITRO; CHROMOPHORE	The unicellular rhodophyte, Porphyridium cruentum, and the filamentous cyanobacterium, Calothrix sp. PCC 7601, contain phycobiliproteins that have covalently bound phycobilin chromophores. Overnight incubation of solvent-extracted cells at 40-degrees-C with methanol liberates free phycobilins that are derived from the protein-bound bilins by methanolytic cleavage of the thioether linkages between bilin and apoprotein. Two of the free bilins were identified as 3(E)-phycocyanobilin and 3(E)-phycoerythrobilin by comparative spectrophotometry and high pressure liquid chromatography. Methanolysis also yields a third bilin free acid whose absorption and H-1 NMR spectra support the assignment of the 3(E)-phytochromobilin structure. This novel bilin is the major pigment isolated from cells that are pre-extracted with acetone-containing solvents. Since phytochrome- or phytochromobilin-containing proteins are not present in either organism, the 3(E)-phytochromobilin must arise by oxidation of phycobilin chromophores. This pigment is not obtained by similar treatment of a cyanobacterium and a rhodophyte that lack phycoerythrin. Therefore, 3(E)-phytochromobilin appears to be derived from phycoerythrobilin-containing proteins. Comparative CD spectroscopy of 3(E)-phytochromobilin and 3(E)-phycocyanobilin suggests that the two bilins share the R stereochemistry at the 2-position in the reduced pyrrole ring. Incubation of 2(R),3(E)-phytochromobilin with recombinant oat apophytochrome yields a covalent bilin adduct that is photoactive and spectrally indistinguishable from native oat phytochrome isolated from etiolated seedlings. These results establish that the phycobiliprotein-derived 2(R),3(E)-phytochromobilin is a biologically active phytochrome chromophore precursor.	BROWN UNIV, DEPT BIOL & MED, PROVIDENCE, RI 02912 USA; UNIV CALIF DAVIS, DEPT BIOCHEM & BIOPHYS, DAVIS, CA 95616 USA	Brown University; University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Terry, Matthew/B-3000-2012; Terry, Matthew/ABE-6419-2020	Lagarias, John Clark/0000-0002-2093-0403; Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708				[Anonymous], [No title captured]; ARCIERO DM, 1988, J BIOL CHEM, V263, P18343; ARCIERO DM, 1988, J BIOL CHEM, V263, P18350; BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BEALE SI, 1991, NEW COMPREHENSIVE BI, V19, P155; BEGUIN S, 1985, BIOCHIMIE, V67, P109, DOI 10.1016/S0300-9084(85)80236-4; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BROCKMANN H, 1973, CHEM BER-RECL, V106, P803, DOI 10.1002/cber.19731060309; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5976, DOI 10.1021/ja00999a058; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CRESPI HL, 1967, J AM CHEM SOC, V89, P3642, DOI 10.1021/ja00990a054; CRESPI HL, 1969, PHYTOCHEMISTRY, V8, P759, DOI 10.1016/S0031-9422(00)85848-3; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; GLAZER AN, 1977, J BIOL CHEM, V252, P32; GOSSAUER A, 1978, J AM CHEM SOC, V100, P5928, DOI 10.1021/ja00486a053; GOSSAUER A, 1974, LIEBIGS ANN CHEM, P1496; JACKMAN LM, 1969, APPLICATIONS NMR SPE; KILLILEA SD, 1980, BIOCHEM J, V187, P311, DOI 10.1042/bj1870311; KLEIN G, 1977, H-S Z PHYSIOL CHEM, V358, P1077; KLEIN G, 1978, LIEBIGS ANN CHEM, P267; KROES HH, 1970, MEDED LANDBOUWHOGESC, V7018, P1; LAGARIAS JC, 1979, J AM CHEM SOC, V101, P5030, DOI 10.1021/ja00511a038; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; LITTS JC, 1983, J BIOL CHEM, V258, P1025; MANITTO P, 1979, EXPERIENTIA, V35, P1418, DOI 10.1007/BF01962757; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; MURAO S, 1982, AGR BIOL CHEM TOKYO, V46, P2031, DOI 10.1080/00021369.1982.10865379; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; RUDIGER W, 1967, H-S Z PHYSIOL CHEM, V348, P129, DOI 10.1515/bchm2.1967.348.1.129; RUDIGER W, 1967, H-S Z PHYSIOL CHEM, V348, P1554; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHRAM BL, 1971, EUR J BIOCHEM, V19, P581, DOI 10.1111/j.1432-1033.1971.tb01352.x; SIEGELMAN HW, 1966, PLANT PHYSIOL, V41, P1289, DOI 10.1104/pp.41.8.1289; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	46	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14790	14798						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634523				2022-12-27	WOS:A1992JF08800045
J	TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC				TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC			RECYCLING OF TRANSFERRIN RECEPTORS AND HEPARAN-SULFATE PROTEOGLYCANS IN A RAT PARATHYROID CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ENDOCYTOSIS; CALCIUM; SECRETION; TRANSPORT; PROTEINS; SURFACE; COMPARTMENTS; MICROTUBULES; MEMBRANE; PATHWAYS	We examined recycling of heparan sulfate (HS) proteoglycans and transferrin receptor (Tf-R) in a rat parathyroid cell line. While extracellular Ca2+ concentration ([Ca2+]e) regulates the recycling of HS proteoglycans in parathyroid cells, such that HS proteoglycans only recycle when [Ca2+]e is lowered below physiological levels, recycling of Tf-R occurs equally well both in 0.05 mM (low) and 2 mM (high) [Ca2+]e. Inhibiting endocytosis chemically with phenylarsine oxide or at low temperature (4-degrees-C) did not abolish the effects of changing [Ca2+], on HS proteoglycans in the recycling compartment even though transport of HS proteoglycans from the Golgi complex to the cell surface was inhibited in low [Ca2+]e. Microtubules are not involved in the recycling of HS proteoglycans or of Tf-R since nocodazole did not affect these processes. Inhibiting the increase of intracellular Ca2+ by an intracellular Ca2+ chelator sustained recycling of HS proteoglycans even in the presence of high [Ca2+]e. These observations show that the exocytosis pathway of HS proteoglycans in the recycling compartment is specifically regulated by [Ca2+]e, whereas that for constitutive secretion is not. Therefore, the recycling of HS proteoglycans may be directly related to some functions of parathyroid cells regulated by [Ca2+]e. Although the mechanism by which [Ca2+], regulates the exocytosis and recycling of HS proteoglycans is uncertain, it is suggested that an increase of intracellular Ca2+ is necessary, but not necessarily sufficient, for inhibiting their exocytosis.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BALCH WE, 1989, J BIOL CHEM, V264, P16965; BROWN EM, 1982, MINER ELECTROL METAB, V8, P130; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; FITZPATRICK LA, 1988, P NATL ACAD SCI USA, V859, P2115; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOMEZCAMBRONERO J, 1989, J BIOL CHEM, V264, P21699; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; KAPLAN J, 1985, J CELL BIOL, V101, P121, DOI 10.1083/jcb.101.1.121; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SHERWOOD LM, 1966, NATURE, V209, P52, DOI 10.1038/209052a0; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; STEIN BS, 1986, J BIOL CHEM, V261, P319; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14677; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; WILEMAN T, 1985, BIOCHEM J, V232, P1	19	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14685	14690						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634514				2022-12-27	WOS:A1992JF08800031
J	CHEN, J; MATTHEWS, KS				CHEN, J; MATTHEWS, KS			DELETION OF LACTOSE REPRESSOR CARBOXYL-TERMINAL DOMAIN AFFECTS TETRAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-RESISTANT CORE; OPERATOR DNA COMPLEX; LAC-REPRESSOR; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; BINDING; PROTEIN; EQUILIBRIUM; SEQUENCE; GENE	The carboxyl-terminal sequence of the lac repressor protein contains heptad repeats of leucines at positions 342, 349, and 356 that are required for tetramer assembly, as substitution of these leucine residues yields solely dimeric species (Chakerian, A. E., Tesmer, V. M., Manly, S. P., Brackett, J. K., Lynch, M. J., Hoh, J. T., and Matthews, K. S. (1991) J. Biol. Chem. 266, 1371-1374; Alberti, S., Oehler, S., von Wilcken-Bergmann, B., Kramer, H., and Muller-Hill, B. (1991) New Biol. 3, 57-62). To further investigate this region, which may form a leucine zipper motif, a family of lac repressor carboxyl-terminal deletion mutants eliminating the last 4, 5, 11, 18, and 32 amino acids (aa) has been constructed. The -4 aa mutant, in which all of the leucines in the presumed leucine zipper are intact, is tetrameric and displays operator and inducer binding properties similar to wild-type repressor. The -5 aa, -11 aa, -18 aa, and -32 aa deletion mutants, depleted of 1, 2, or all 3 of the leucines in the heptad repeats, are all dimeric, as demonstrated by gel filtration chromatography. Circular dichroism spectra and protease digestion studies indicate similar secondary/tertiary structures for the mutant and wild-type proteins. Differences in reaction with a monoclonal antibody specific for a subunit interface are observed for the dimeric versus tetrameric proteins, indicative of exposure of the target epitope as a consequence of deletion. Inducer binding properties of the deletion mutants are similar to wild-type tetrameric repressor at neutral pH. Only small differences in affinity and cooperativity from wild-type are evident at elevated pH; thus, the cooperative unit within the tetramer appears to be the dimer. "Apparent" operator binding affinity for the dimeric proteins is diminished, although minimal change in operator dissociation rate constants was observed. The diminution in apparent operator affinity may therefore derive from either 1) dissociation of the dimeric mutants to monomer generating a linked equilibrium or 2) alterations in intrinsic operator affinity of the dimers; the former explanation is favored. This detailed characterization of the purified mutant proteins confirms that the carboxyl-terminal region is involved in the dimer-dimer interface and demonstrates that cooperativity for inducer binding is contained within the dimer unit of the tetramer structure.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University				Chen, Jie/0000-0002-7887-3747	NIGMS NIH HHS [GM 22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BOURGEOIS S, 1979, BIOPOLYMERS, V18, P2625, DOI 10.1002/bip.1979.360181017; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHOU PY, 1975, J MOL BIOL, V96, P29, DOI 10.1016/0022-2836(75)90180-1; CULARD F, 1982, FEBS LETT, V146, P153, DOI 10.1016/0014-5793(82)80724-2; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FILES JG, 1976, J BIOL CHEM, V251, P3386; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LECLERC JE, 1988, J MOL BIOL, V203, P619, DOI 10.1016/0022-2836(88)90197-0; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; MILLER JH, 1970, LACTOSE OPERON, P343; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PLATT T, 1973, J BIOL CHEM, V248, P110; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SAUDEK V, 1990, PROTEIN ENG, V4, P3, DOI 10.1093/protein/4.1.3; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SHIRAI T, 1987, GENE, V57, P11; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WHITSON PA, 1987, J BIOL CHEM, V262, P4943	52	104	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13843	13850						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629185				2022-12-27	WOS:A1992JD32500012
J	GOPALAN, V; PASTUSZYN, A; GALEY, WR; GLEW, RH				GOPALAN, V; PASTUSZYN, A; GALEY, WR; GLEW, RH			EXOLYTIC HYDROLYSIS OF TOXIC PLANT GLUCOSIDES BY GUINEA-PIG LIVER CYTOSOLIC BETA-GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY	We demonstrate that although the guinea pig liver cytosolic beta-glucosidase does not catalyze the hydrolysis of gentiobiose, it does hydrolyze, disaccharide-containing glycosides such as p-nitrophenyl-beta-D-gentiobioside (Glc-beta-1-->Glc-beta-pNP) and mandelonitrile-beta-D-gentiobioside (amygdalin). Furthermore, we establish that the enzyme attacks disaccharide glycosides exolytically; specifically, we document the exolytic deglucosylation of amygdalin and the generation of the intermediate monosaccharide glycoside mandelonitrile-beta-D-glucoside prior to the formation of the aglycone (mandelonitrile). We also show that the cytosolic beta-glucosidase catalyzes the hydrolysis of various phenolic (e.g. arbutin and salicin) and cyanogenic plant glucosides (e.g. prunasin). Using the everted gut-sack technique, we demonstrate that the plant glucosides, amygdalin, prunasin, and vicine, are transported across the small intestine of the guinea pig efficiently and without being hydrolyzed. Based on thess data we speculate that the cytosolic beta-glucosidase may participate in biotransformation of toxic plant glucosides.	UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PHYSIOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM031357] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM31357] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONN EE, 1987, BIOCH PLANTS COMPREH, P479; DANIELS LB, 1981, J BIOL CHEM, V256, P3004; DISTLER JJ, 1977, ARCH BIOCHEM BIOPHYS, V178, P631, DOI 10.1016/0003-9861(77)90235-1; FREESE A, 1980, ARCH BIOCHEM BIOPHYS, V201, P363, DOI 10.1016/0003-9861(80)90523-8; GLEW RH, 1976, BIOCHIM BIOPHYS ACTA, V422, P179, DOI 10.1016/0005-2744(76)90018-8; GOPALAN V, 1989, BIOCHEM J, V262, P541, DOI 10.1042/bj2620541; HALIWELL B, 1989, FREE RADICAL BIO MED, P329; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; LAMARCO KL, 1986, BIOCHEM J, V237, P469, DOI 10.1042/bj2370469; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P429; MAGER J, 1980, TOXIC CONSTITUENTS P, P265; OSUNTOKUN BO, 1970, LANCET, V2, P372; OSUNTOKUN BO, 1968, BRAIN, V91, P215, DOI 10.1093/brain/91.2.215; PETERS SP, 1975, CLIN CHIM ACTA, V60, P391, DOI 10.1016/0009-8981(75)90083-2; POCSI I, 1988, BIOCHEM J, V256, P139, DOI 10.1042/bj2560139; REICHARDT PB, 1991, TOXICOLOGY PLANT FUN, P313; WILSON TH, 1954, J PHYSIOL-LONDON, V123, P116, DOI 10.1113/jphysiol.1954.sp005036	18	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14027	14032						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629201				2022-12-27	WOS:A1992JD32500040
J	SHIOI, J; ANDERSON, JP; RIPELLINO, JA; ROBAKIS, NK				SHIOI, J; ANDERSON, JP; RIPELLINO, JA; ROBAKIS, NK			CHONDROITIN SULFATE PROTEOGLYCAN FORM OF THE ALZHEIMERS BETA-AMYLOID PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEASE NEXIN-II; DISEASE; SURFACE; HEPARIN; PLAQUE; DOMAIN; BRAIN; CDNA; PURIFICATION; CHYMOTRYPSIN	The Alzheimer's amyloid beta-protein is derived from a family of membrane glycoproteins termed amyloid precursor proteins (APP). Here we show that APP exists as the core protein of a chondroitin sulfate (CS) proteoglycan, ranging in apparent molecular size from 140 to 250 kDa, secreted by glial cell line C6. After partial purification on ion-exchange and gel chromatography, the secreted APP proteoglycan was recognized on Western blots by several antibodies specific to different regions of APP. Chondroitinase AC or ABC treatment of our samples completely eliminated the high molecular weight proteoglycan with a concomitant increase in the APP protein. This digested product reacted with an anti-stub antibody which recognizes 4-sulfated disaccharide. Sequencing of the N terminus of the core protein of this CS proteoglycan yielded 18 residues identical to the N terminus sequence of the mature APP. Quantitative analysis showed that, in this cell line, about 90% of the secreted nexin II form of APP occurs in the proteoglycan form, suggesting that the CS chains have a role in the biological function of this protein. The close proximity of two consensus CS attachment sites to both the N terminus of the amyloid beta-protein and the secretase cleavage site, suggests that the CS chains may affect the proteolysis of APP and production of the amyloid beta-protein.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, 1 GUSTAVE LEVY PL, BOX 1229, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Robakis, Nikolaos/AAA-1838-2021		NATIONAL INSTITUTE ON AGING [P50AG005138, R01AG008200] Funding Source: NIH RePORTER; NIA NIH HHS [AG08200, AG05138] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GODINOT C, 1989, BIOCHIMIE, V71, P917, DOI 10.1016/0300-9084(89)90074-6; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOWDA DC, 1990, ARCH BIOCHEM BIOPHYS, V281, P219, DOI 10.1016/0003-9861(90)90435-2; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; Linker A., 1972, METHODS ENZYMOL, P902; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NELSON RB, 1990, J BIOL CHEM, V265, P3836; NEWMAN SA, 1987, P NATL ACAD SCI USA, V84, P4791, DOI 10.1073/pnas.84.14.4791; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAUCH U, 1991, J BIOL CHEM, V266, P14785; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROBAKIS NK, 1991, GROWTH FACTORS ALZHE, P208; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SILVA ME, 1974, BIOCHEM BIOPH RES CO, V56, P965, DOI 10.1016/S0006-291X(74)80283-4; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1989, NATURE, V341, P546; WAGNER WD, 1986, ARTERIOSCLEROSIS, V6, P407, DOI 10.1161/01.ATV.6.4.407; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523	45	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13819	13822						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629183				2022-12-27	WOS:A1992JD32500008
J	IMLER, JL; ZURAWSKI, G				IMLER, JL; ZURAWSKI, G			RECEPTOR-BINDING AND INTERNALIZATION OF MOUSE INTERLEUKIN-2 DERIVATIVES THAT ARE PARTIAL AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; BETA-CHAIN; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; LIGAND-BINDING; GROWTH; IL-2; ALPHA; EXPRESSION; PROTEINS	Mouse interleukin-2 (mIL-2) mutant proteins with subunit-specific receptor binding defects have been previously described. Some of these mutant proteins are unable to trigger a maximum proliferative response of T cells. In this study, mIL-2 and mIL-2 mutant proteins were labeled with P-32, and their association and dissociation kinetics with the high affinity IL-2 receptor (IL-2R) were investigated. A mIL-2 mutant protein with a partial defect in binding to the low affinity component of IL-2R had a slower on-rate than mIL-2. On the other hand, a mIL-2 antagonist with a binding defect to the intermediate affinity component of IL-2R had a normal on-rate, whereas its off-rate at 37-degrees-C was faster than mIL-2. This fast off-rate at physiological temperature interfered with mIL-2 internalization. When three mIL-2 partial agonists, each inducing a different maximal response, were examined, no difference was found between their dissociation rates or their internalization properties. The significance of these findings for the function of each receptor subunit in the IL-2R complex, as well as for the mechanism of activation of the receptor, is discussed.	DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Imler, Jean-Luc/GXH-4323-2022					CHOU CK, 1987, J BIOL CHEM, V262, P1842; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IMBER JL, 1992, IN PRESS EMBO J; KENAKIN TP, 1987, PHARM ANAL DRUG RECE, P190; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; KUMAR A, 1987, J IMMUNOL, V139, P3680; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PETERS DK, 1990, BLOOD, V76, P97; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; TSUDO M, 1990, J IMMUNOL, V145, P599; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZURAWSKI SM, 1988, EMBO J, V7, P1061, DOI 10.1002/j.1460-2075.1988.tb02914.x; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	35	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13185	13190						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618822				2022-12-27	WOS:A1992JB74600017
J	MASTERSON, C; BOEHMER, PE; MCDONALD, F; CHAUDHURI, S; HICKSON, ID; EMMERSON, PT				MASTERSON, C; BOEHMER, PE; MCDONALD, F; CHAUDHURI, S; HICKSON, ID; EMMERSON, PT			RECONSTITUTION OF THE ACTIVITIES OF THE RECBCD HOLOENZYME OF ESCHERICHIA-COLI FROM THE PURIFIED SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE-V; DEPENDENT DEOXYRIBONUCLEASE; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; ADENYLATE KINASE; DUPLEX DNA; RECC GENE; ENZYME; PURIFICATION; PROTEINS	The Escherichia coli RecBCD holoenzyme and the individual constituent subunits have been purified from overproducing strains. The purified RecBCD holoenzyme has a native molecular mass of approximately 330 kDa, indicative of a heterotrimer subunit assembly. The RecB, RecC, and RecD subunits can associate in vitro to give nuclease, helicase, ATPase, and Chi-specific endonuclease activities which are indistinguishable from those of the RecBCD holoenzyme. At concentrations at which the reconstituted RecB+C+D enzyme is very active, none of the individual RecB, RecC, or RecD subunits have readily detectable activities of the holoenzyme, except RecB protein which had previously been shown to exhibit DNA-dependent ATPase activity (Hickson, I. D, Robson, C. N., Atkinson, K. E., Hutton, L., and Emmerson, P. T. (1985) J. Biol. Chem. 260, 1224-1229). At higher concentrations and with shorter DNA substrates reconstituted RecBC protein exhibits low levels of helicase and exonuclease activity.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK			Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X; Boehmer, Paul/0000-0003-4479-0529				AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; BOEHMER PE, 1992, IN PRESS J BIOL CHEM; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DOWER NA, 1981, P NATL ACAD SCI-BIOL, V78, P7033, DOI 10.1073/pnas.78.11.7033; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P4437, DOI 10.1093/nar/14.11.4437; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HICKSON ID, 1984, NUCLEIC ACIDS RES, V12, P3807, DOI 10.1093/nar/12.9.3807; HICKSON ID, 1985, J BIOL CHEM, V260, P1224; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MACKAY V, 1974, J BIOL CHEM, V249, P4286; OISHI M, 1969, P NATL ACAD SCI USA, V64, P1292, DOI 10.1073/pnas.64.4.1292; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GR, 1988, MICROBIOL REV, V52, P1; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TELANDERMUSKAVI.KM, 1981, ENZYMES, V14, P233; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	46	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13564	13572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618858				2022-12-27	WOS:A1992JB74600074
J	SHINKI, T; JIN, CH; NISHIMURA, A; NAGAI, Y; OHYAMA, Y; NOSHIRO, M; OKUDA, K; SUDA, T				SHINKI, T; JIN, CH; NISHIMURA, A; NAGAI, Y; OHYAMA, Y; NOSHIRO, M; OKUDA, K; SUDA, T			PARATHYROID-HORMONE INHIBITS 25-HYDROXYVITAMIN-D(3)-24-HYDROXYLASE MESSENGER-RNA EXPRESSION STIMULATED BY 1-ALPHA,25-DIHYDROXYVITAMIN-D(3) IN RAT-KIDNEY BUT NOT IN INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							25-HYDROXYVITAMIN D3 24-HYDROXYLASE; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D3; INVITRO METABOLISM; 25-HYDROXYCHOLECALCIFEROL; RECEPTORS; ACID; ADENOSINE-3',5'-MONOPHOSPHATE; MITOCHONDRIA; CATABOLISM	Using a cDNA probe for rat renal 24-hydroxylase, expression of its mRNA was compared in the rat kidney and intestine. Vitamin D-deficient rats received a single injection of 1-alpha,25-dihydroxyvitamin D3. Expression of 24-hydroxylase mRNA was first detected in the kidney at 3-h post-injection and increased thereafter. Similarly, 24-hydroxylase mRNA was expressed in the intestine after 1-alpha,25-dihydroxyvitamin D3 injection. However, the dose level of 1-alpha,25-dihydroxyvitamin D3 required to induce the intestinal 24-hydroxylase mRNA expression was only 1/100 the amount required to induce renal 24-hydroxylase mRNA. Induction of intestinal 24-hydroxylase mRNA expression by 1-alpha,25-dihydroxyvitamin D3 was far more rapid than that of renal 24-hydroxylase mRNA. Thyroparathyroidectomy shortened the time required to induce expression of renal, but not intestinal, 24-hydroxylase mRNA. Administration of either parathyroid hormone or cAMP to vitamin D-deficient rats greatly reduced the expression of 24-hydroxylase mRNA in the kidney but not in the intestine. When rats were fed a vitamin D-repleted diet containing 0.7% (adequate) or 0.03% (low) calcium for 2 weeks, intestinal expression of 24-hydroxylase mRNA could be induced only in the low calcium group. In contrast, renal mRNA expression was preferentially stimulated in the adequate calcium group. These results clearly demonstrate that the expression of 24-hydroxylase mRNA is down-regulated by parathyroid hormone in the kidney but not in the intestine.	SHOWA UNIV, SCH DENT,DEPT BIOCHEM,1-5-8 HATANODAI,SHINAGAWA KU, TOKYO 142, JAPAN; HIROSHIMA UNIV, SCH DENT, DEPT BIOCHEM, MINATO KU, HIROSHIMA 734, JAPAN	Showa University; Hiroshima University								ARMBRECHT HJ, 1981, ENDOCRINOLOGY, V109, P218, DOI 10.1210/endo-109-1-218; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHAM KM, 1976, BIOCHEMISTRY-US, V15, P2130, DOI 10.1021/bi00655a016; BURGOSTRINIDAD M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P226, DOI 10.1016/0167-4838(91)90562-E; CHANDLER JS, 1984, J BIOL CHEM, V259, P2214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FROLIK CA, 1971, ARCH BIOCHEM BIOPHYS, V147, P143, DOI 10.1016/0003-9861(71)90320-1; GARABEDIAN M, 1972, P NATL ACAD SCI USA, V69, P1673, DOI 10.1073/pnas.69.7.1673; GARABEDIAN M, 1978, ENDOCRINOLOGY, V102, P1262, DOI 10.1210/endo-102-4-1262; HARRISON B, 1986, ANAL BIOCHEM, V158, P307, DOI 10.1016/0003-2697(86)90555-5; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HOLICK MF, 1987, KIDNEY INT, V32, P912, DOI 10.1038/ki.1987.295; HORIUCHI N, 1984, BIOCHEM BIOPH RES CO, V121, P174, DOI 10.1016/0006-291X(84)90703-4; HORIUCHI N, 1977, ENDOCRINOLOGY, V101, P969, DOI 10.1210/endo-101-3-969; INABA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P257, DOI 10.1016/0003-9861(91)90293-R; JONGEN MJ, 1987, HORM METAB RES, V19, P481, DOI 10.1055/s-2007-1011858; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; KISSMEYER AM, 1991, BIOCHEM PHARMACOL, V41, P1601, DOI 10.1016/0006-2952(91)90160-7; KUMAR R, 1984, PHYSIOL REV, V64, P478, DOI 10.1152/physrev.1984.64.2.478; KUMAR R, 1978, J BIOL CHEM, V253, P3804; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1989, FEBS LETT, V255, P405, DOI 10.1016/0014-5793(89)81133-0; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OHYAMA Y, 1990, DRUG METABOLIZING EN, P114; REINHARDT TA, 1990, ENDOCRINOLOGY, V127, P942, DOI 10.1210/endo-127-2-942; ROST CR, 1981, ENDOCRINOLOGY, V108, P1002, DOI 10.1210/endo-108-3-1002; SHIGEMATSU T, 1986, ENDOCRINOLOGY, V118, P1583, DOI 10.1210/endo-118-4-1583; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA Y, 1981, P NATL ACAD SCI-BIOL, V78, P196, DOI 10.1073/pnas.78.1.196; TANAKA Y, 1974, P NATL ACAD SCI USA, V71, P1040, DOI 10.1073/pnas.71.4.1040; TANAKA Y, 1975, ARCH BIOCHEM BIOPHYS, V171, P521, DOI 10.1016/0003-9861(75)90061-2; TENENHOUSE HS, 1988, J CLIN INVEST, V81, P461, DOI 10.1172/JCI113342; TOMON M, 1990, AM J PHYSIOL, V258, pG557, DOI 10.1152/ajpgi.1990.258.4.G557; TURNER RT, 1980, P NATL ACAD SCI-BIOL, V77, P1537, DOI 10.1073/pnas.77.3.1537; VIETH R, 1979, J BIOL CHEM, V254, P2455; WALTERS MR, 1983, J STEROID BIOCHEM, V19, P913, DOI 10.1016/0022-4731(83)90034-1; WASSERMAN RH, 1968, J BIOL CHEM, V243, P3978; YAMATO H, 1989, ENDOCRINOLOGY, V124, P511, DOI 10.1210/endo-124-1-511	46	159	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13757	13762						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618870				2022-12-27	WOS:A1992JB74600103
J	ARDUINI, A; MANCINELLI, G; RADATTI, GL; DOTTORI, S; MOLAJONI, F; RAMSAY, RR				ARDUINI, A; MANCINELLI, G; RADATTI, GL; DOTTORI, S; MOLAJONI, F; RAMSAY, RR			ROLE OF CARNITINE AND CARNITINE PALMITOYLTRANSFERASE AS INTEGRAL COMPONENTS OF THE PATHWAY FOR MEMBRANE PHOSPHOLIPID FATTY-ACID TURNOVER IN INTACT HUMAN ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; ACYLTRANSFERASE; MICROSOMES; BLOOD	The deacylation and reacylation process of phospholipids is the major pathway of turnover and repair in erythrocyte membranes. In this paper, we have investigated the role of carnitine palmitoyltransferase in erythrocyte membrane phospholipid fatty acid turnover. The role of acyl-L-carnitine as a reservoir of activated acyl groups, the buffer function of carnitine, and the importance of the acyl-CoA/free CoA ratio in t he reacylation process of erythrocyte membrane phospholipids have also been addressed. In intact erythrocytes, the incorporation of [1-C-14]palmitic acid into acyl-L-carnitine, phosphatidylcholine, and phosphatidylethanolamine was linear with time for at least 3 h. The greatest proportion of the radioactivity was found in acyl-L-carnitine. Competition experiments using [1-C-14]palmitic and [9,10-H-3]oleic acid demonstrated that [9,10-H-3]oleic acid was incorporated preferentially into the phospholipids and less into acyl-L-carnitine. When an erythrocyte suspension was incubated with [1-C-14]palmitoyl-L-carnitine, radiolabeled palmitate was recovered in the phospholipid fraction, and the carnitine palmitoyltransferase inhibitor, 2-tetradecylglycidic acid, completely abolished the incorporation. ATP depletion decreased incorporation of [1-C-14]palmitic and/or [9,10-H-3]oleic acid into acyl-L-carnitine, but the incorporation into phosphatidylcholine and phosphatidylethanolamine was unaffected. In contrast, ATP depletion enhanced the incorporation into phosphatidylcholine and phosphatidylethanolamine of the radiolabeled fatty acid from [1-C-14]palmitoyl-L-carnitine. These data are suggestive of the existence of an acyl-L-carnitine pool, in equilibrium with the acyl-CoA pool, which serves as a reservoir of activated acyl groups. The carnitine palmitoyltransferase inhibition by 2-tetradecylglycidic acid or palmitoyl-D-carnitine caused a significant reduction of radiolabeled fatty acid incorporation into membrane phospholipids, only when intact erythrocytes were incubated with [9,10-H-3]oleic acid. These latter data may be explained by the differences in rates and substrates specificities between acyl-CoA synthetase and the reacylating enzymes for palmitate and oleate, which support the importance of carnitine palmitoyltransferase in modulating the optimal acyl-CoA/free CoA ratio for the physiological expression of the membrane phospholipids fatty acid turnover.	SIGMA TAU PHARMACEUT CO,DIPARTIMENTO RIC & SVILUPPO,POMEZIA,ITALY; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; VET ADM MED CTR,DIV MOLEC BIOL,SAN FRANCISCO,CA 94121	Leadiant Biosciences; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	ARDUINI, A (corresponding author), UNIV G DANNUNZIO,IST SCI BIOCHIM,VIA VESTINI,I-66100 CHIETI,ITALY.		Arduini, Arduino/ABH-5284-2020; Ramsay, Rona/A-4065-2009; Ramsay, Rona R./A-6681-2008	Ramsay, Rona R./0000-0003-1535-4904	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041572] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams H., 1963, METHOD ENZYMAT AN, P539; ARDUINI A, 1992, AM HEART J, V123, P1726, DOI 10.1016/0002-8703(92)90850-U; ARDUINI A, 1990, BIOCHEM BIOPH RES CO, V173, P212, DOI 10.1016/S0006-291X(05)81043-5; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; BRORING K, 1989, BIOCHIM BIOPHYS ACTA, V986, P321, DOI 10.1016/0005-2736(89)90484-7; CLASSEN J, 1989, J MEMBRANE BIOL, V111, P169, DOI 10.1007/BF01871780; COOPER MB, 1988, BIOCHIM BIOPHYS ACTA, V959, P100, DOI 10.1016/0005-2760(88)90020-3; DAVIDSON BC, 1985, FEBS LETT, V193, P69, DOI 10.1016/0014-5793(85)80081-8; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; DISE CA, 1980, J LIPID RES, V21, P292; FRITZ IB, 1963, J BIOL CHEM, V238, P2509; KUNIMOTO M, 1988, LIPIDS, V19, P443; Lands W., 1976, ENZYMES BIOL MEMBRAN, V2, P3; LILLY K, 1990, ARCH BIOCHEM BIOPHYS, V280, P167, DOI 10.1016/0003-9861(90)90532-4; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MCLEOD ME, 1967, BIOCHIM BIOPHYS ACTA, V144, P391, DOI 10.1016/0005-2760(67)90168-3; MOK AYP, 1990, BIOCHEM CELL BIOL, V68, P1380, DOI 10.1139/o90-201; MOMCHILOVAPANKOVA AB, 1990, BIOCHIMIE, V72, P863, DOI 10.1016/0300-9084(90)90003-Y; MULDER E, 1965, BIOCHIM BIOPHYS ACTA, V106, P106, DOI 10.1016/0005-2760(65)90099-8; MULDER E, 1965, BIOCHIM BIOPHYS ACTA, V106, P348, DOI 10.1016/0005-2760(65)90043-3; OLIVEIRA MM, 1964, J LIPID RES, V5, P156; Pennell RB, 1964, RED BLOOD CELL, P29; RAMSAY RR, 1991, BIOCHEM J, V275, P685, DOI 10.1042/bj2750685; RENOOIJ W, 1974, BIOCHIM BIOPHYS ACTA, V363, P287, DOI 10.1016/0005-2736(74)90069-8; ROBERTSON AF, 1964, J LIPID RES, V5, P88; ROSE HG, 1965, J LIPID RES, V6, P428; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; SHOHET SB, 1968, J CLIN INVEST, V47, P1096, DOI 10.1172/JCI105799; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; THOMPSON GA, 1984, PHYSL MEMBRANE FLUID, V1, P99; Tutwiler G F, 1981, Methods Enzymol, V72, P533; WAKU K, 1968, J LIPID RES, V9, P12; WITTELS B, 1967, J BIOL CHEM, V242, P126; Yonetani T, 1967, METHODS ENZYMOL, V10, P332	39	109	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12673	12681						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618773				2022-12-27	WOS:A1992HZ48300047
J	DING, RC; POMMIER, Y; KANG, VH; SMULSON, M				DING, RC; POMMIER, Y; KANG, VH; SMULSON, M			DEPLETION OF POLY(ADP-RIBOSE) POLYMERASE BY ANTISENSE RNA EXPRESSION RESULTS IN A DELAY IN DNA STRAND BREAK REJOINING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-SENSE RNA; POLY(ADENOSINE DIPHOSPHATE RIBOSE); NUCLEAR-PROTEIN MODIFICATION; MAMMALIAN-CELLS; EXCISION REPAIR; GENE-EXPRESSION; CHROMATIN; GROWTH; DIFFERENTIATION; ONCOGENE	The effects of inducible expression of poly(ADP-ribose) polymerase (PADPRP) antisense RNA in HeLa cells were determined in order to gain further insight into the biological roles of the poly(ADP-ribosyl)ation modification of nuclear proteins. A recombinant expression plasmid was prepared with the mouse mammary tumor virus (MMTV) promoter upstream of the antisense-oriented PADPRP cDNA. Expression of the antisense RNA was under strict control, with negligible effects on cell growth being apparent in the absence of inducer. Consistent with the previously described stability of PADPRP (half-life of at least 2 days, in vivo), 48-72 h were required after induction of antisense RNA expression by dexamethasone for the abundant concentration of PADPRP, normally present in HeLa cells, to be reduced by greater than 80%. The depletion of endogenous PADPRP as mediated by induced antisense RNA expression was established by: (i) a progressive synthesis of antisense transcripts in cells as assessed by Northern analysis; (ii) an 80% decrease in activity of the enzyme; and (iii) a greater than 90% reduction in the cellular content of PADPRP protein, as demonstrated by both immunoblotting and immunohistochemical analysis in intact cells. Several biological parameters were monitored in cells depleted of PADPRP. The chromatin of PADPRP-depleted cells was shown to have an altered structure as assessed by deoxyribonuclease I susceptibility. Cell morphology was also altered, with multinucleated aggregates being evident 72 h after induction of antisense RNA expression. Cells depleted of PADPRP were not able to commence DNA strand break joining of damaged DNA. However, DNA repair capacity was re-established at later time periods, indicating that PADPRP may contribute to alterations in chromatin structure that occur initially in DNA strand break rejoining and that the concentration of the enzyme in nuclei exceeds the requirement for DNA repair/replication.	GEORGETOWN UNIV, DEPT BIOCHEM & MOLEC BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA; NCI, MOLEC PHARMACOL LAB, BALTIMORE, MD 21201 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [R01CA025344] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; ALTHAUS FR, 1985, ADP RIBOSYLATION PRO; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERGER NA, 1980, BIOCHEMISTRY-US, V19, P289, DOI 10.1021/bi00543a006; BHATIA K, 1990, CARCINOGENESIS, V11, P123, DOI 10.1093/carcin/11.1.123; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; BOORSTEIN RJ, 1984, J CELL PHYSIOL, V120, P335, DOI 10.1002/jcp.1041200312; BUTT TR, 1978, NUCLEIC ACIDS RES, V5, P2775, DOI 10.1093/nar/5.8.2775; BUTT TR, 1979, P NATL ACAD SCI USA, V76, P1628, DOI 10.1073/pnas.76.4.1628; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; CHERNEY BW, 1985, DEV BIOL, V112, P115, DOI 10.1016/0012-1606(85)90125-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DING R, 1985, MOL CELL BIOL, V5, P3293, DOI 10.1128/MCB.5.11.3293; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FARZANEH F, 1982, NATURE, V300, P362, DOI 10.1038/300362a0; FERRO AM, 1984, J BIOL CHEM, V259, P547; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDMAN HM, 1989, MOL CELL BIOL, V9, P2303, DOI 10.1128/MCB.9.6.2303; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JACOBSON EL, 1979, J CELL PHYSIOL, V99, P417, DOI 10.1002/jcp.1040990316; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JAUREZSALINAS H, 1979, NATURE, V282, P740; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1031, DOI 10.1021/bi00546a031; JUMP DB, 1979, BIOCHEMISTRY-US, V18, P983, DOI 10.1021/bi00573a008; JUMP DB, 1980, BIOCHEMISTRY-US, V19, P1024, DOI 10.1021/bi00546a030; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MALIK N, 1983, P NATL ACAD SCI-BIOL, V80, P2554, DOI 10.1073/pnas.80.9.2554; MATHIS G, 1990, CARCINOGENESIS, V11, P1237, DOI 10.1093/carcin/11.7.1237; MILAM KM, 1984, SCIENCE, V223, P589, DOI 10.1126/science.6420886; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROSOLEN A, 1990, CANCER RES, V50, P6316; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SMERDON MJ, 1989, NATO ADV SCI I A-LIF, V182, P271; SMULSON ME, 1977, CANCER RES, V37, P3006; TAN KB, 1987, NATL CANCER I MONOGR, V4, P95; THRAVES PJ, 1985, CANCER RES, V45, P386; UEDA K, 1982, ADP RIBOSYLATION REA, P561; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; YUH YS, 1989, J BIOL CHEM, V264, P10904	49	151	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12804	12812						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618781				2022-12-27	WOS:A1992HZ48300064
J	FURUTA, T; TAKAHASHI, H; SHIBASAKI, H; KASUYA, Y				FURUTA, T; TAKAHASHI, H; SHIBASAKI, H; KASUYA, Y			REVERSIBLE STEPWISE MECHANISM INVOLVING A CARBANION INTERMEDIATE IN THE ELIMINATION OF AMMONIA FROM L-HISTIDINE CATALYZED BY HISTIDINE AMMONIA-LYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; ACID; ASPARTASE	L-Histidine labeled with deuterium at the C-5' position of the imidazole ring, L-[5'-H-2]histidine (His-5'-D), was used as a probe for investigating a stepwise reversible mechanism via a carbanion intermediate in the elimination of ammonia catalyzed by histidine ammonia-lyase (EC 4.3.1.3). The labeled L-histidine (His-5'-D) (2.45 mM) was incubated with histidine ammonia-lyase (200 units) from Pseudomonas fluorescens at pH 7.0 or 9.0 at 25.0-degrees-C for 24 h. The time course of the reaction was examined to determine the rates of enzyme-catalyzed hydrogen exchange at C-5' of L-histidine and urocanic acid. The finding of the enzyme-catalyzed hydrogen exchange at C-5' of both L-histidine and urocanic acid in the presence Of L-histidine provided a rational explanation for a stepwise reversible mechanism via a carbanion intermediate in the elimination reaction. The rate of increase in the concentration of urocanic acid exchanged with hydrogen (UA-5'-H) did not depend on the formation rate of urocanic acid and UA-5'-H was continuously formed at a constant rate (25.6-mu-M/h) even after the completion of urocanic acid formation. These observations suggested the presence of the reversible reaction of urocanic acid and a carbanion intermediate. Since there was only a minor contribution for the formation of UA-5'-H from L-histidine exchanged with solvent hydrogen (His-5'-H), the main pathway in the enzymatic reaction of His-5'-D must be the formation of UA-5'-D via a carbanion intermediate (carbanion-D). Regeneration of the carbanion-D from UA-5'-D by its reverse reaction and subsequent hydrogen incorporation at C-5' would contribute to a large extent for the formation of UA-5'-H. The stability of carbanion was also demonstrated to be approximately three times higher at pH 7.0 than at pH 9.0.			FURUTA, T (corresponding author), TOKYO COLL PHARM,DEPT MED CHEM & CLIN PHARM,1432-1 HORINOUCHI,HACHIOJI,TOKYO 19203,JAPAN.							AKHTAR M, 1986, J CHEM SOC CHEM COMM, P1290, DOI 10.1039/c39860001290; BOTTING NP, 1988, BIOCHEMISTRY-US, V27, P2956, DOI 10.1021/bi00408a043; BOTTING NP, 1987, J CHEM SOC CHEM COMM, P1371, DOI 10.1039/c39870001371; BOTTING NP, 1988, BIOCHEMISTRY-US, V27, P2953, DOI 10.1021/bi00408a042; FURUTA T, 1987, J CHEM RES-S, P86; FURUTA T, 1988, BIOMED ENVIRON MASS, V16, P313, DOI 10.1002/bms.1200160160; FURUTA T, 1987, J CHROMATOGR-BIOMED, V413, P1, DOI 10.1016/0378-4347(87)80207-4; FURUTA T, 1992, J CHROMATOGR-BIOMED, V576, P213, DOI 10.1016/0378-4347(92)80195-V; FURUTA T, 1990, J AM CHEM SOC, V112, P3633, DOI 10.1021/ja00165a058; FURUTA T, 1991, J CHROMATOGR-BIOMED, V562, P363, DOI 10.1016/0378-4347(91)80591-Y; FURUTA T, 1989, 3RD P INT S SYNTH AP, P747; FURUTA T, 1992, IN PRESS J LABELLED; GIVOT IL, 1969, J BIOL CHEM, V244, P6341; HANSON KR, 1979, BIOCHEMISTRY-US, V18, P1431, DOI 10.1021/bi00575a007; Hanson KR, 1972, ENZYMES, P75; HERMES JD, 1985, BIOCHEMISTRY-US, V24, P2959, DOI 10.1021/bi00333a023; KLEE CB, 1974, FED PROC, V33, P1318; KLEE CB, 1979, BIOCHEM BIOPH RES CO, V87, P343, DOI 10.1016/0006-291X(79)91685-1; KLEE CB, 1975, J BIOL CHEM, V250, P5033; KLEE CB, 1972, J BIOL CHEM, V247, P1398; KURODA Y, 1979, CLIN CHIM ACTA, V96, P139; La Du BN, 1978, METABOLIC BASIS INHE, P317; MATSUDA I, 1982, LANCET, V1, P162; MATSUDA I, 1982, CLIN CHIM ACTA, V119, P319, DOI 10.1016/0009-8981(82)90345-X; NUIRY II, 1984, BIOCHEMISTRY-US, V23, P5168, DOI 10.1021/bi00317a013; PETERKOFSKY A, 1962, J BIOL CHEM, V237, P787; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; RETEY J, 1970, FEBS LETT, V6, P203, DOI 10.1016/0014-5793(70)80057-6; SAWADA S, 1974, BIOCHIM BIOPHYS ACTA, V350, P354, DOI 10.1016/0005-2744(74)90509-9; TAKAHASHI H, 1990, Journal of Pharmacobio-Dynamics, V13, pS59	30	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12600	12605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618765				2022-12-27	WOS:A1992HZ48300036
J	OHASHI, N; NASHIMOTO, H; IKEDA, H; TAMURA, A				OHASHI, N; NASHIMOTO, H; IKEDA, H; TAMURA, A			DIVERSITY OF IMMUNODOMINANT 56-KDA TYPE-SPECIFIC ANTIGEN (TSA) OF RICKETTSIA-TSUTSUGAMUSHI - SEQUENCE AND COMPARATIVE ANALYSES OF THE GENES ENCODING TSA HOMOLOGS FROM 4 ANTIGENIC VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PROTEIN GENE; ESCHERICHIA-COLI; TANDEM PROMOTERS; STRAIN; PURIFICATION; PATIENT; CLONING	There are several antigenic variants in Rickettsia tsutsugamushi, and a type-specific antigen (TSA) of 56-kilodaltons located on the rickettsial surface is responsible for the variation. The primary structures of the protein in two variants, Gilliam and Karp, have been reported independently by us and Stover et al. by cloning and sequencing the corresponding genes (Ohashi, N., Nashimoto, H., Ikeda, H., and Tamura, A. (1990) Gene (Amst.) 91, 119-122; Stover, C. K., Marana, D. P., Carter, J. M., Roe, B. A., Mardis, E., and Oaks, E. V. (1990) Infect. Immun. 58, 2076-2084). In the present study, genes encoding the TSA homologues of the other four variants, Kato, Kawasaki, Kuroki, and Shimokoshi, which are all distinguishable serologically, were cloned and sequenced, and consequently, it became possible to compare the primary structures of the six antigenic variants. The sequence analyses revealed a complete open reading frame encoding 55,308-56,745-dalton proteins with 521-532 amino acids, in which a putative signal peptide consisting of 22 amino acids was recognized at the NH2-terminal end. Transcription of the gene is regulated by several tandem promoters. All TSA molecules have the characteristics of transmembrane proteins with alternating hydrophobic and hydrophilic regions, and contain four variable domains with spans of 16-40 amino acids which are located in the hydrophilic regions in the molecule and show different amino acid sequences among the strains. Phylogenetic classification among the R. tsutsugamushi strains based on TSA homologues supports the antigenic relationships known in the closely and distantly related strains.	UNIV TOKYO, INST MED SCI, DEPT MOLEC BIOL, TOKYO 108, JAPAN; TEIKYO UNIV, DEPT BIOSCI, UTSUNOMIYA 320, JAPAN; NIIGATA COLL PHARM, DEPT MICROBIOL, NIIGATA 95021, JAPAN	University of Tokyo; Teikyo University								CHIBA M, 1989, J BIOL CHEM, V264, P12785; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GOTOH J, 1968, JPN J BACTERIOL, V23, P437; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KUMURA K, 1991, INT J SYST BACTERIOL, V41, P247, DOI 10.1099/00207713-41-2-247; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T., 1982, MOL CLONING; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MURATA M, 1986, MICROBIOL IMMUNOL, V30, P599, DOI 10.1111/j.1348-0421.1986.tb02987.x; MYERS WF, 1980, INT J SYST BACTERIOL, V30, P143, DOI 10.1099/00207713-30-1-143; Nei M., 1987, MOL EVOLUT GENET, P293; OHASHI N, 1990, J CLIN MICROBIOL, V28, P2111, DOI 10.1128/JCM.28.9.2111-2113.1990; OHASHI N, 1990, GENE, V91, P119, DOI 10.1016/0378-1119(90)90171-M; OHASHI N, 1989, INFECT IMMUN, V57, P1427, DOI 10.1128/IAI.57.5.1427-1431.1989; OLIVER D, 1985, ANNU REV MICROBIOL, V39, P615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHE JX, 1991, P NATL ACAD SCI USA, V88, P453, DOI 10.1073/pnas.88.2.453; SHISHIDO A, 1962, JPN J MED SCI BIOL, V15, P308; STEPHENS RS, 1988, J BACTERIOL, V170, P744, DOI 10.1128/jb.170.2.744-750.1988; STEPHENS RS, 1989, INTRACELLULAR PARASI, P51; STOVER CK, 1990, INFECT IMMUN, V58, P2076, DOI 10.1128/IAI.58.7.2076-2084.1990; TAMURA A, 1988, Japanese Journal of Bacteriology, V43, P629, DOI 10.3412/jsb.43.629; TAMURA A, 1982, MICROBIOL IMMUNOL, V26, P321, DOI 10.1111/j.1348-0421.1982.tb00181.x; TAMURA A, 1984, MICROBIOL IMMUNOL, V28, P873, DOI 10.1111/j.1348-0421.1984.tb00743.x; TAMURA A, 1985, INFECT IMMUN, V48, P671, DOI 10.1128/IAI.48.3.671-675.1985; TAMURA A, 1988, MICROBIOL SCI, V5, P228; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Weiss E., 1984, BERGEYS MANUAL SYSTE, VI, P688; WINKLER HH, 1988, BIOCHIMIE, V70, P977, DOI 10.1016/0300-9084(88)90262-3; YAMAMOTO S, 1986, MICROBIOL IMMUNOL, V30, P611, DOI 10.1111/j.1348-0421.1986.tb02988.x; YAMAMOTO S, 1989, J JPN ASS INFECT DIS, V63, P109; YUAN Y, 1990, INFECT IMMUN, V58, P2850, DOI 10.1128/IAI.58.9.2850-2855.1990	34	88	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12728	12735						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618776				2022-12-27	WOS:A1992HZ48300054
J	VELLEMAN, M; HEINZEL, T; SCHUSTER, H				VELLEMAN, M; HEINZEL, T; SCHUSTER, H			THE BOF PROTEIN OF BACTERIOPHAGE-P1 EXERTS ITS MODULATING FUNCTION BY FORMATION OF A TERNARY COMPLEX WITH OPERATOR DNA AND C1 REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITES; GEL-ELECTROPHORESIS; LAC REPRESSOR; P1; GENE; SEQUENCE; RECOMBINATION; EXPRESSION; MUTATION	Bacteriophage P1 encodes several regulatory elements for the lytic or lysogenic response, which are located in the immC, immI, and immT regions. Their products are the C1 repressor of lytic functions with the C1 inactivator protein Coi, the C4 repressor of antirepressor synthesis and the modulator protein Bof, respectively. We have studied in vitro the interaction of the components of the immC and immT regions with C1-controlled operators using highly purified Bof, C1, and Coi proteins. Bof protein (M(r) = 9,800) does not interact with C1 repressor alone, but as shown by DNA mobility shift experiments, in the presence of C1 repressor Bof binds to all operators tested by forming a C1.Bof.operator DNA ternary complex. The effect of this complex formation was studied in more detail with the operator of the c1 gene. Here, Bof only marginally alters the C1 repressor footprint at Op99a,b, but nevertheless considerably influences the repressibility of the operator.promoter element: (i) the autoregulated c1 mRNA synthesis is further down-regulated and (ii) the ability of Coi protein to dissociate the C1.operator DNA complex is strongly inhibited. We suggest that Bof protein functions by modulating C1 repression of many widely dispersed operators on the prophage genome.			VELLEMAN, M (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.		Heinzel, Thorsten/B-1013-2015					BAUMSTARK BR, 1987, VIROLOGY, V156, P404, DOI 10.1016/0042-6822(87)90420-X; BAUMSTARK BR, 1990, VIROLOGY, V179, P217, DOI 10.1016/0042-6822(90)90291-X; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CITRON M, 1990, CELL, V62, P591, DOI 10.1016/0092-8674(90)90023-8; CITRON M, 1989, J BIOL CHEM, V264, P3611; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; COHN EJ, 1965, PROTEINS AMINO ACIDS, P370; DARI R, 1975, J MOL BIOL, V94, P341, DOI 10.1016/0022-2836(75)90207-7; DREISEIKELMANN B, 1988, J BIOL CHEM, V263, P1391; ELIASON JL, 1987, J MOL BIOL, V198, P281, DOI 10.1016/0022-2836(87)90313-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; HEINZEL T, 1989, J MOL BIOL, V205, P127, DOI 10.1016/0022-2836(89)90370-7; HEINZEL T, 1992, J BIOL CHEM, V267, P4183; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUDSON JM, 1990, J MOL BIOL, V214, P381, DOI 10.1016/0022-2836(90)90188-R; JOHNSON BF, 1982, MOL GEN GENET, V186, P122, DOI 10.1007/BF00422923; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER TS, 1991, J BACTERIOL, V173, P6469, DOI 10.1128/jb.173.20.6469-6474.1991; SCHAEFER TS, 1990, J BACTERIOL, V172, P3269, DOI 10.1128/jb.172.6.3269-3277.1990; Scott J R, 1980, Curr Top Microbiol Immunol, V90, P49; SCOTT JR, 1977, VIROLOGY, V76, P39, DOI 10.1016/0042-6822(77)90279-3; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STERNBERG N, 1978, P NATL ACAD SCI USA, V75, P5594, DOI 10.1073/pnas.75.11.5594; STOFFLER G, 1971, P NATL ACAD SCI USA, V68, P2283, DOI 10.1073/pnas.68.9.2283; TOUATISCHWARTZ D, 1979, MOL GEN GENET, V174, P189, DOI 10.1007/BF00268355; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELLEMAN M, 1990, J BIOL CHEM, V265, P18511; VELLEMAN M, 1987, P NATL ACAD SCI USA, V84, P5570, DOI 10.1073/pnas.84.16.5570; WINDLE BE, 1986, P NATL ACAD SCI USA, V83, P3885, DOI 10.1073/pnas.83.11.3885; WINDLE BE, 1988, J BACTERIOL, V170, P4881, DOI 10.1128/jb.170.10.4881-4889.1988; WINDLE BE, 1986, THESIS U MARYLAND CA; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARMOLINSKY M, 1990, GENETIC MAPS, P52; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291	40	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12174	12181						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601883				2022-12-27	WOS:A1992HY94700078
J	BENJANNET, S; REUDELHUBER, T; MERCURE, C; RONDEAU, N; CHRETIEN, M; SEIDAH, NG				BENJANNET, S; REUDELHUBER, T; MERCURE, C; RONDEAU, N; CHRETIEN, M; SEIDAH, NG			PROPROTEIN CONVERSION IS DETERMINED BY A MULTIPLICITY OF FACTORS INCLUDING CONVERTASE PROCESSING, SUBSTRATE-SPECIFICITY, AND INTRACELLULAR ENVIRONMENT - CELL TYPE-SPECIFIC PROCESSING OF HUMAN PRORENIN BY THE CONVERTASE PC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ENDORPHIN; HUMAN RENIN; GENE; CDNA; SEQUENCE; PROTEINS; KEX2; SUBTILISIN; EXPRESSION; SECRETION	Proprotein and prohormone processing at pairs of basic residues is generally thought to be both tissue- and precursor-specific and to be developmentally regulated. Furin, PC1 (also called PC3), and PC2 represent three recently discovered subtilisin-like proteinases which cleave a number of precursors at the same pairs of basic residues normally processed in vivo. Using human prorenin as a model, we show that PC1 can process it to active renin in cells containing secretory granules, such as the somatomammotroph cell line GH4, but not in cells which lack granules, such as the Chinese hamster ovary or African green monkey kidney epithelial (BSC-40) cell lines. In contrast, in both cell types, human prorenin is not activated by either PC2 or furin. Using the vaccinia virus expression system, biosynthetic labeling experiments demonstrated that PC1 and PC2 are themselves cleaved intracellularly at pairs of basic residues and that these two proenzymes are processed to different extents independent of whether the cell line contains dense core secretory granules. Furthermore, we also show that the cells mostly secrete the cleaved forms of PC1 and PC2, and that intracellularly the pro- form of PC2 predominates. Our data demonstrate that propeptide removal from these enzymes, possibly leading to their activation, is not the only criterion which governs precursor processing.	UNIV MONTREAL, CLIN RES INST, JA DESEVE LAB BIOCHEM NEUROENDOCRINOL, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA; UNIV MONTREAL, CLIN RES INST, JA DESEVE LAB MOLEC NEUROENDOCRINOL, MONTREAL H2W 1RF, QUEBEC, CANADA; UNIV MONTREAL, CLIN RES INST, MOLEC BIOCHEM HYPERTENS LAB, MONTREAL H2W 1RF, QUEBEC, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; CHRETIEN, Michel/0000-0002-8588-4460				BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BAXTER JD, 1987, ENDOCRINOL METAB, P693; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; DO YS, 1987, J BIOL CHEM, V262, P1037; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; KIM SK, 1991, J BIOL CHEM, V266, P7044; LADENHEIM RG, 1991, EUR J BIOCHEM, V198, P535, DOI 10.1111/j.1432-1033.1991.tb16047.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RE RN, 1984, ARCH INTERN MED, V144, P2037, DOI 10.1001/archinte.144.10.2037; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SAINTANDRE JP, 1989, HISTOCHEMISTRY, V91, P291, DOI 10.1007/BF00493003; SAWYER N, 1991, DNA CELL BIOL, V10, P259, DOI 10.1089/dna.1991.10.259; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1978, P NATL ACAD SCI USA, V75, P3153, DOI 10.1073/pnas.75.7.3153; SEIDAH NG, 1991, GENOMICS, V11, P103, DOI 10.1016/0888-7543(91)90106-O; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEIDAH NG, 1992, IN PRESS TRENDS ENDO; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAUGNER R, 1987, HISTOCHEMISTRY, V86, P249; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1989, J BIOL CHEM, V264, P3545; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	45	160	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11417	11423						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597471				2022-12-27	WOS:A1992HX16900074
J	FORD, DA; ROSENBLOOM, KB; GROSS, RW				FORD, DA; ROSENBLOOM, KB; GROSS, RW			THE PRIMARY DETERMINANT OF RABBIT MYOCARDIAL ETHANOLAMINE PHOSPHOTRANSFERASE SUBSTRATE SELECTIVITY IS THE COVALENT NATURE OF THE SN-1 ALIPHATIC GROUP OF DIRADYL GLYCEROL ACCEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; HUMAN-PLATELETS; KIDNEY-CELLS; IDENTIFICATION; PLASMENYLETHANOLAMINE; PHOSPHOGLYCERIDES; PHOSPHOLIPASE-A2; PLASMALOGENS; METABOLISM	Plasmenylethanolamines represent the major endogenous phospholipid storage depot of arachidonic acid in many mammalian cells. To elucidate the biochemical mechanisms contributing to the high plasmalogen content and arachidonic acid enrichment present in myocardial ethanolamine glycerophospholipids, the substrate specificity of rabbit myocardial ethanolamine phosphotransferase (EPT) was quantified utilizing multiple molecular species of each subclass of diradyl glycerol substrate. Myocardial EPT demonstrated over a 16-fold selectivity for 1-O-alk-1'-enyl-2-acyl-sn-glycerol (AAG) compared to 1,2-diacyl-sn-glycerol (DAG) substrate utilizing individual molecular species of each subclass dispersed in Tween 20. The selective utilization of AAG by EPT was substantiated utilizing two independent assay systems which employed either the presentation of substrate to enzyme as a substitutional impurity in Triton X-100 mixed micelles or the obligatory utilization of endogenously generated diradyl glycerol substrates. Although rabbit myocardial microsomes contained over a 20-fold molar excess of endogenous DAG to AAG mass, incubation of rabbit myocardial microsomes with CDP-ethanolamine resulted in the highly selective synthesis of plasmenylethanolamines which were predominantly comprised of molecular species containing arachidonic acid at the sn-2 position (>75%). Endogenous AAG molecular species in rabbit myocardial microsomes were similarly enriched in arachidonic acid, and the distribution of AAG molecular species closely paralleled the distribution of plasmenylethanolamine (but not plasmenylcholine) molecular species. Thus, the subclass and molecular species distribution of the ethanolamine glycerophospholipids synthesized by rabbit myocardial EPT reflects independent contributions from the subclass selectivity of EPT for AAG substrate in conjunction with the enrichment of arachidonic acid in microsomal AAG molecular species.	WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	FORD, DA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665, R29HL042665] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42665] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; DANIEL LW, 1981, J BIOL CHEM, V256, P2830; FORD DA, 1988, J BIOL CHEM, V263, P2644; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; FORD DA, 1990, J BIOL CHEM, V265, P12280; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1990, BIOCHEMISTRY-US, V29, P4992, DOI 10.1021/bi00472a032; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; Kanoh H, 1981, Methods Enzymol, V71 Pt C, P536; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; LOEB LA, 1986, J BIOL CHEM, V261, P467; MUELLER HW, 1983, LIPIDS, V18, P814, DOI 10.1007/BF02534641; NIETO ML, 1991, J BIOL CHEM, V266, P18699; PALTAUF F, 1973, J BIOL CHEM, V248, P1609; PREISS J, 1986, J BIOL CHEM, V261, P8597; SHELTAWY A, 1968, J NEUROCHEM, V15, P144, DOI 10.1111/j.1471-4159.1968.tb06186.x; TAKAMURA H, 1989, J BIOCHEM-TOKYO, V105, P168, DOI 10.1093/oxfordjournals.jbchem.a122634; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WEISS SB, 1958, J BIOL CHEM, V231, P53; WOLF RA, 1985, J LIPID RES, V26, P629; WOLF RA, 1985, J BIOL CHEM, V260, P7295; WYKLE RL, 1972, J BIOL CHEM, V247, P5442	24	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11222	11228						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597457				2022-12-27	WOS:A1992HX16900047
J	HAUSSER, H; OBER, B; QUENTINHOFFMANN, E; SCHMIDT, B; KRESSE, H				HAUSSER, H; OBER, B; QUENTINHOFFMANN, E; SCHMIDT, B; KRESSE, H			ENDOCYTOSIS OF DIFFERENT MEMBERS OF THE SMALL CHONDROITIN DERMATAN SULFATE PROTEOGLYCAN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; GROWTH-FACTOR-BETA; HUMAN-FIBROBLASTS; CORE PROTEIN; PROTEODERMATAN SULFATE; COLLAGEN; DECORIN; BIOSYNTHESIS; LOCALIZATION; CHONDROCYTES	The family of small interstitial chondroitin/dermatan sulfate proteoglycans consists of at least three different molecular species: biglycan (proteoglycan I), decorin (proteoglycan II), and proteoglycan-100, which has a glycosylated core protein of about 100 kDa. The core protein of decorin has been shown to be responsible for receptor-mediated endocytosis of this proteoglycan species by a variety of mesenchymal cells. It is now demonstrated that skin fibroblasts and articular chondrocytes endocytose biglycan with an efficiency similar to that of decorin. Uptake of biglycan is also mediated by its core protein and can be inhibited by decorin in a partially competitive manner. In human fibroblasts, endosomal proteins of 51 and 26 kDa, which are known to bind decorin core protein, also interact with biglycan. This interaction can be inhibited by decorin. Bovine articular chondrocytes contained binding proteins of 48 and 25 kDa. Proteoglycan-100 can be distinguished from biglycan and decorin by its low clearance rate, which however, exceeds the rate of fluid phase endocytosis.	UNIV GOTTINGEN,INST BIOCHEM 2,W-3400 GOTTINGEN,GERMANY	University of Gottingen	HAUSSER, H (corresponding author), UNIV MUNSTER,INST PHYSIOL CHEM & PATHOBIOCHEM,W-4400 MUNSTER,GERMANY.							AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; Cantz M, 1972, METHOD ENZYMOL, V28, P884; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GLOSSL J, 1983, BIOCHEM J, V215, P295; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HAUSSER H, 1991, J CELL BIOL, V114, P45, DOI 10.1083/jcb.114.1.45; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKINLEY DN, 1988, J CELL PHYSIOL, V136, P389, DOI 10.1002/jcp.1041360302; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRINZ R, 1978, BIOCHEM J, V176, P671, DOI 10.1042/bj1760671; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1990, BIOCHEM J, V266, P591; SCHWARZ K, 1990, J BIOL CHEM, V265, P22023; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONFIGURA K, 1980, BIOL ARTICULAR CARTI, P189; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAGUCHI Y, 1988, NATURE, V336, P281; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270	41	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11559	11564						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597483				2022-12-27	WOS:A1992HX16900095
J	SCHMIDT, RP; KREUZER, KN				SCHMIDT, RP; KREUZER, KN			PURIFIED MOTA PROTEIN BINDS THE -30 REGION OF A BACTERIOPHAGE-T4 MIDDLE-MODE PROMOTER AND ACTIVATES TRANSCRIPTION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; RNA-POLYMERASE; REPLICATION ORIGIN; DNA-REPLICATION; T4 RNA; INITIATION; SEQUENCES; SYSTEM; GENE; RECOMBINATION	The bacteriophage T4-encoded MotA protein is critical for transcription from T4 middle-mode promoters. However, a direct interaction of this protein with a middle-mode promoter has not previously been demonstrated. We have cloned the motA gene and overexpressed the gene product using the T7 expression system. A simple procedure was then developed to purify the MotA protein to homogeneity. Using the purified protein we have demonstrated that MotA protein binds to the -30 region of the middle-mode promoter P(uvsY). This promoter has previously been shown to be a necessary component of a T4 replication origin, and thus MotA is also a T4 origin-binding protein. Modified RNA polymerase purified from T4-infected cells was used to establish middle-mode transcription in vitro. Transcription from P(uvsY) was markedly enhanced by the addition of MotA protein, whether or not the template contained the cytosine modifications characteristic of T4 DNA. However, transcription from P(uvsY) was apparently independent of the MotA protein when unmodified RNA polymerase from uninfected cells was used.	DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,PROGRAM CELL & MOLEC BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM34622, 5-T32-GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034622, T32GM007184, R37GM034622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRODY E, 1983, BACTERIOPHAGE T4, P174; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHRISTENSEN AC, 1983, BACTERIOPHAGE T, V4, P184; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4097; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4087; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V1, P93; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1989, J BIOL CHEM, V264, P14432; HINTON DM, 1991, J BIOL CHEM, V266, P18034; HO YS, 1988, BACTERIOPHAGES, V2, P725; INOUE N, 1991, J BACTERIOL, V173, P1208, DOI 10.1128/jb.173.3.1208-1214.1991; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KOWALSKI D, 1989, EMBO J, V8, P4335, DOI 10.1002/j.1460-2075.1989.tb08620.x; KREUZER KN, 1985, P NATL ACAD SCI USA, V82, P3345, DOI 10.1073/pnas.82.10.3345; KREUZER KN, 1988, J BIOL CHEM, V263, P11348; KUTTER EM, 1990, GENETIC MAPS; LIEBIG HD, 1989, J MOL BIOL, V208, P517, DOI 10.1016/0022-2836(89)90145-9; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; MALIK S, 1984, J BIOL CHEM, V259, P3292; Maniatis T., 1982, MOL CLONING; MASUKATA H, 1987, CELL, V51, P1123, DOI 10.1016/0092-8674(87)90598-8; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MATTSON T, 1978, J MOL BIOL, V126, P551, DOI 10.1016/0022-2836(78)90058-X; MATTSON T, 1974, NATURE, V250, P48, DOI 10.1038/250048a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCONNELL DJ, 1978, NUCLEIC ACIDS RES, V5, P1729, DOI 10.1093/nar/5.6.1729; MENKENS AE, 1988, J BIOL CHEM, V263, P11358; MOSIG G, 1988, BACTERIOPHAGES, V2, P521; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; OHMORI H, 1987, J MOL BIOL, V198, P223, DOI 10.1016/0022-2836(87)90308-1; ORSINI G, 1988, VIROLOGY, V162, P397, DOI 10.1016/0042-6822(88)90480-1; PULITZER JF, 1985, J MOL BIOL, V182, P249, DOI 10.1016/0022-2836(85)90343-2; PULITZER JF, 1979, J MOL BIOL, V135, P979, DOI 10.1016/0022-2836(79)90523-0; Rabussay D., 1983, BACTERIOPHAGE T4, P167; SCHULZ W, 1981, NUCLEIC ACIDS RES, V9, P6889, DOI 10.1093/nar/9.24.6889; SELICK HE, 1988, J BIOL CHEM, V263, P11336; SHINEDLING S, 1986, J VIROL, V60, P787, DOI 10.1128/JVI.60.2.787-792.1986; SNUSTAD DP, 1983, BACTERIOPHAGE T, V4, P40; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TSENG MJ, 1990, J BACTERIOL, V172, P6323, DOI 10.1128/jb.172.11.6323-6332.1990; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UZAN M, 1983, EMBO J, V2, P1207, DOI 10.1002/j.1460-2075.1983.tb01568.x; UZAN M, 1990, MOL MICROBIOL, V4, P1487, DOI 10.1111/j.1365-2958.1990.tb02059.x; UZAN M, 1985, J BIOL CHEM, V260, P633; WILLIAMS KP, 1987, J BIOL CHEM, V262, P12365	58	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11399	11407						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597469				2022-12-27	WOS:A1992HX16900072
J	BODDUPALLI, SS; OSTER, T; ESTABROOK, RW; PETERSON, JA				BODDUPALLI, SS; OSTER, T; ESTABROOK, RW; PETERSON, JA			RECONSTITUTION OF THE FATTY-ACID HYDROXYLATION FUNCTION OF CYTOCHROME-P-450BM-3 UTILIZING ITS INDIVIDUAL RECOMBINANT HEMOPROTEIN AND FLAVOPROTEIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-MEGATERIUM; MONOOXYGENASE; INDUCTION; BINDING; OMEGA-2; SYSTEM	Cytochrome P-450BM-3 is a catalytically self-sufficient fatty acid omega-hydroxylase with two domains. Functional and primary structure analyses of the hemo- and flavoprotein domains of cytochrome P-450BM-3 and the corresponding microsomal cytochrome P-450 system have shown that these proteins are highly homologous. Prior attempts to reconstitute the fatty acid hydroxylation function of cytochrome P-450BM-3, utilizing the two domains, obtained either by trypsinolysis or by recombinant methods, were unsuccessful. In this paper, we describe the reconstitution of the fatty acid hydroxylation activity of cytochrome P-450BM-3 UtiliZing the recombinantly produced flavoprotein domain (Oster, T., Boddupalli, S. S., and Peterson, J. A. (1991) J. Biol. Chem. 266, 22718-22725) and its hemoprotein counterpart. The rate of fatty acid-dependent oxygen consumption was shown to be linear when increasing concentrations of the hemoprotein domain are added to a fixed concentration of the flavoprotein domain and vice versa. The combination of the hemo- and flavoprotein domains in a ratio of 20:1 respectively, in the reaction mixture, results in the transfer of 80% of the reducing equivalents from NADPH for the hydroxylation of palmitate at 25-degrees-C. The ratio of the regioisomeric products obtained for lauric, myristic, and palmitic acids was similar to that obtained with the holoenzyme form of cytochrome P-450BM-3. The reconstitution of the fatty acid omega-hydroxylase activity, using the soluble domains of cytochrome P-450BM-3, without added factors such as lipids, may be useful for structure/function comparisons to their eukaryotic counterparts.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JE, 1991, P ROY SOC B-BIOL SCI, V245, P43, DOI 10.1098/rspb.1991.0086; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FULCO AJ, 1983, MOL CELL BIOCHEM, V53-4, P155; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; GUNSALUS IC, 1985, CURR TOP CELL REGUL, V26, P295; HARE RS, 1975, BIOCHEM BIOPH RES CO, V65, P665, DOI 10.1016/S0006-291X(75)80198-7; HORLE S, 1978, CYTOCHROME P450, P73; KIM BH, 1983, BIOCHEM BIOPH RES CO, V116, P843, DOI 10.1016/S0006-291X(83)80219-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HY, 1991, J BIOL CHEM, V266, P11909; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; MORELLE G, 1990, FOCUS, V11, P7; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; OSTER T, 1991, J BIOL CHEM, V266, P22718; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J, 1989, MOL CLONING LABORATO; Warburg O., 1942, BIOCHEM Z, V310, P384	31	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10375	10380						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587824				2022-12-27	WOS:A1992HV09000029
J	ESTEBAN, LM; RODRIGUEZCOUSINO, N; ESTEBAN, R				ESTEBAN, LM; RODRIGUEZCOUSINO, N; ESTEBAN, R			T-DOUBLE-STRANDED RNA (DSRNA) SEQUENCE REVEALS THAT T-DSRNAS AND W-DSRNAS FORM A NEW RNA FAMILY IN SACCHAROMYCES-CEREVISIAE - IDENTIFICATION OF 23-S-RNA AS THE SINGLE-STRANDED FORM OF T-DSRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; GENETIC ELEMENT; YEAST VIRUS; POLYMERASE; SPORULATION; EVOLUTION; PLASMID; MUTANT; MOTIF	Some strains of the yeast Saccharomyces cerevisiae harbor a double-stranded RNA (dsRNA) molecule, called T. We obtained T cDNA clones by random priming of denatured T dsRNA followed by reverse transcription. Sequence data of T show that only one strand ((+)-strand) has coding capacity for a protein with 940 amino acids which spans almost the entire length of the molecule (2.9 kilobases). Within this protein we found a sequence pattern characteristic of RNA-dependent RNA polymerases of (+)-strand and double-stranded RNA viruses. Although T has no homology with other dsRNAs found in S. cerevisiae, such as L-A, L-BC, M1, or W, the T-encoded protein shows a high degree of conservation with the W-encoded protein. This conservation extends beyond a region that contains the consensus sequences for RNA-dependent RNA polymerases, suggesting that both T and W are evolutionarily related. With a (+)-strand-specific probe for T we identified 23 S RNA, a new single-stranded RNA (ssRNA) species with a sedimentation coefficient of 23 S. T and 23 S RNA have the same mobility under denaturing conditions with glyoxal, suggesting that 23 S RNA is, in fact, the (+)-single-stranded RNA form of T dsRNA. 23 S RNA synthesis is induced under stress conditions such as heat shock and starvation. The relationship between T and 23 S RNA clearly resembles the one between W and its single-stranded derivative form, 20 S RNA. Thus T and W dsRNAs (and their respective single-stranded species) constitute a new RNA family in S. cerevisiae.	UNIV SALAMANCA,INST MICROBIOL BIOQUIM,CSIC,E-37071 SALAMANCA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca			Esteban, Rosa/K-4356-2014; Rodríguez-Cousiño, Nieves/K-6465-2014	Esteban, Rosa/0000-0001-6804-7209; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BRUENN JA, 1991, NUCLEIC ACIDS RES, V19, P217, DOI 10.1093/nar/19.2.217; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DIAMOND ME, 1989, J VIROL, V63, P3983, DOI 10.1128/JVI.63.9.3983-3990.1989; ESTEBAN R, 1987, GENETICS, V117, P399; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; FRIED HM, 1978, P NATL ACAD SCI USA, V75, P4224, DOI 10.1073/pnas.75.9.4224; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARVIK B, 1978, J BACTERIOL, V134, P261, DOI 10.1128/JB.134.1.261-269.1978; GEORGOPOULOS DE, 1986, EXTRACHROMOSOMAL ELE, P203; HANSEN DR, 1985, J GEN VIROL, V66, P2605, DOI 10.1099/0022-1317-66-12-2605; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; ICHO T, 1989, J BIOL CHEM, V264, P6716; INOKUCHI Y, 1988, NUCLEIC ACIDS RES, V16, P6205, DOI 10.1093/nar/16.13.6205; INOKUCHI Y, 1986, J BIOCHEM-TOKYO, V99, P1169, DOI 10.1093/oxfordjournals.jbchem.a135580; KADOWAKI K, 1971, J BACTERIOL, V105, P831, DOI 10.1128/JB.105.3.831-836.1971; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE M, 1986, J VIROL, V58, P402, DOI 10.1128/JVI.58.2.402-407.1986; LEFEBRE A, 1990, PLANT MOL BIOL, V14, P447; Maniatis T., 1982, MOL CLONING; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKIPPER N, 1984, EMBO J, V3, P107, DOI 10.1002/j.1460-2075.1984.tb01769.x; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THIELE DJ, 1982, NUCLEIC ACIDS RES, V10, P6903, DOI 10.1093/nar/10.21.6903; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; TOHE A, 1980, J BACTERIOL, V141, P413, DOI 10.1128/JB.141.1.413-416.1980; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1978, GENETICS, V88, P419; WICKNER RB, 1989, FASEB J, V3, P2257, DOI 10.1096/fasebj.3.11.2550303; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	43	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10874	10881						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587863				2022-12-27	WOS:A1992HV09000099
J	BLACK, ME; HRUBY, DE				BLACK, ME; HRUBY, DE			A SINGLE AMINO-ACID SUBSTITUTION ABOLISHES FEEDBACK INHIBITION OF VACCINIA VIRUS THYMIDINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GENE; IDENTIFICATION; POLYPEPTIDE; TYPE-1; SITE	Exploitation of differences in the substrate specificity of the type I and type H thymidine kinases (EC 2.7.1.21, TK) expressed by the Herpesviridae and Poxviridae (and human cells), respectively, has lead to the development of effective antiherpetic drugs such as acyclovir and gancyclovir. Analysis of type I TK protein sequences reveals a consensus sequence which corresponds to domain IV of type II TK proteins such as that encoded by vaccinia virus (VV). The type I descriptor (X(pho) - + + X(pho)) differs at the second position from the type II consensus sequence (X(pho X(phi) + + X(pho)) by having an aspartic acid residue (D) substituted for a glutamine (Q). To test the hypothesis that this substitution may be responsible for the observed differences in substrate specificity of these enzymes and as a approach to identify the nucleoside binding site of the type II VV TK, site-directed mutagenesis was employed to alter glutamine 114 (Q114) within domain IV of VV TK to a histidine (Q114H) or an aspartic acid (Q114D). All of the mutant enzymes retained full enzymatic activity as compared to wild-type VV TK when thymidine or bromodeoxyuridine were used as substrates. However, unlike the wild-type herpes simplex (type 1) TK enzyme, neither wild-type nor domain IV VV TK mutants were able to phosphorylate acyclovir or cytidine substrates. Surprisingly, the domain IV VVTK mutants displayed a dramatic loss of feedback inhibition by dTTP. Mutations of the Q114 position also lead to a difference in ATP binding as demonstrated by an altered elution pattern of Q114H and Q114D from an ATP-agarose affinity column with dTTP. Taken together, these results suggest that domain IV of VV TK is not involved directly in substrate discrimination but instead participates in feedback inhibition by dTTP.	OREGON STATE UNIV,CTR GENE RES & BIOTECHNOL,DEPT MICROBIOL,CORVALLIS,OR 97331	Oregon State University					NIAID NIH HHS [AI-20563] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLACK ME, 1990, J BIOL CHEM, V265, P17584; BLACK ME, 1990, BIOCHEM BIOPH RES CO, V169, P1080, DOI 10.1016/0006-291X(90)92005-K; BLACK ME, 1991, MOL MICROBIOL, V5, P373, DOI 10.1111/j.1365-2958.1991.tb02119.x; BLACK ME, 1992, J BIOL CHEM, V267, P6801; BOYLE DB, 1987, VIROLOGY, V156, P355, DOI 10.1016/0042-6822(87)90415-6; DARBY G, 1986, J GEN VIROL, V67, P753, DOI 10.1099/0022-1317-67-4-753; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; ESPOSITO JJ, 1984, VIROLOGY, V135, P561, DOI 10.1016/0042-6822(84)90212-5; FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9; FOLKERS G, 1987, MED SCI RES-BIOCHEM, V15, P1495; GERSHON PD, 1989, J GEN VIROL, V70, P525, DOI 10.1099/0022-1317-70-3-525; GOMPELS U, 1986, VIROLOGY, V153, P230, DOI 10.1016/0042-6822(86)90026-7; GRUIDL ME, 1992, VIROLOGY, V186, P507, DOI 10.1016/0042-6822(92)90016-I; HRUBY DE, 1985, VIRUS RES, V2, P151, DOI 10.1016/0168-1702(85)90245-X; HRUBY DE, 1981, VIROLOGY, V113, P594, DOI 10.1016/0042-6822(81)90187-2; KIT S, 1983, BIOCHIM BIOPHYS ACTA, V741, P158, DOI 10.1016/0167-4781(83)90056-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWOH TJ, 1984, NUCLEIC ACIDS RES, V12, P3959, DOI 10.1093/nar/12.9.3959; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P197; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LITTLER E, 1986, EMBO J, V5, P1959, DOI 10.1002/j.1460-2075.1986.tb04450.x; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; NUNBERG JH, 1989, J VIROL, V63, P3240, DOI 10.1128/JVI.63.8.3240-3249.1989; OSTUKA H, 1984, VIROLOGY, V135, P316; ROBERTSON GR, 1988, NUCLEIC ACIDS RES, V16, P11303, DOI 10.1093/nar/16.23.11303; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UPTON C, 1986, J VIROL, V60, P920, DOI 10.1128/JVI.60.3.920-927.1986; VALERIE K, 1986, NUCLEIC ACIDS RES, V21, P8637; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEIR JP, 1983, J VIROL, V46, P530, DOI 10.1128/JVI.46.2.530-537.1983; WILSON EM, 1989, GENE, V77, P69, DOI 10.1016/0378-1119(89)90360-0; ZIMMERMANN N, 1991, EUR J BIOCHEM, V200, P519, DOI 10.1111/j.1432-1033.1991.tb16213.x	34	26	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9743	9748						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577811				2022-12-27	WOS:A1992HT96500048
J	DAS, AK; HAJRA, AK				DAS, AK; HAJRA, AK			CRITICAL MICELLAR CONCENTRATIONS OF PALMITOYL DIHYDROXYACETONE PHOSPHATE AND 1-PALMITOYL-RAC-GLYCEROL 3-PHOSPHATE - APPENDIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								By fluorescent titration method, the critical micellar concentrations of palmitoyl CoA, palmitoyl dihydroxyacetone-P, and 1-palmitoyl-rac-glycerol-3-P in 75 mm Tris-HCl, pH 7.5, were determined to be 41, 58, and 70-mu-M, respectively.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	DAS, AK (corresponding author), UNIV MICHIGAN,MENTAL HLTH RES INST,NEUROSCI LAB,ANN ARBOR,MI 48104, USA.			Das, Arun/0000-0002-0883-1816				CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; HOROWITZ P, 1977, J COLLOID INTERF SCI, V61, P197, DOI 10.1016/0021-9797(77)90428-3; Mukerjee P., 1971, NSRDSNBS36; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4	4	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9731	9731						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577809				2022-12-27	WOS:A1992HT96500045
J	TRAXINGER, RR; MARSHALL, S				TRAXINGER, RR; MARSHALL, S			INSULIN REGULATION OF PYRUVATE-KINASE ACTIVITY IN ISOLATED ADIPOCYTES - CRUCIAL ROLE OF GLUCOSE AND THE HEXOSAMINE BIOSYNTHESIS PATHWAY IN THE EXPRESSION OF INSULIN ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED ADIPOCYTES; TRANSPORT SYSTEM; GENE-EXPRESSION; MESSENGER-RNAS; PROTEIN-KINASE; RAT; RECEPTOR; LIVER; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE; MECHANISM	We recently identified glutamine:fructose-6-phosphate amidotransferase (GFAT) as an insulin-regulated enzyme in adipocytes. Moreover, we found that loss of GFAT activity is not due to a direct action of insulin but rather is mediated by enhanced glucose uptake and the subsequent routing of glucose through the hexosamine biosynthesis pathway. To assess whether other cytosolic enzymes are controlled through formation of hexosamine products, we treated adipocytes for 5 h with physiological concentrations of insulin (ED50 = 0.33 ng/ml), glucose (ED50 = 4.5 mM), and glutamine (ED50 = 4.4 mM) and then measured pyruvate kinase (PK) activity. Combined treatment resulted in a progressive (t1/2 of 2.5 h) and marked (3-fold) increase in PK activity, whereas omission of one or more of these components failed to alter enzyme activity. Several lines of additional evidence implicated the hexosamine biosynthesis pathway in PK regulation; therefore, it appears that the M2 isoform of pyruvate kinase represents another enzyme regulated by insulin through stimulation of glucose uptake and formation of hexosamine products. Related studies revealed that enhancement of PK activity is dependent upon ongoing mRNA synthesis and de novo protein synthesis and is mediated by an increase in enzyme content. Considered together, these findings provide new insights into the cascade of metabolic events triggered by insulin and implicate a novel metabolic pathway in the pretranslational control of enzyme function.	UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,800 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008206] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05-5423] Funding Source: Medline; NIDDK NIH HHS [DK08206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKESI JG, 1969, J BIOL CHEM, V244, P5663; BUCHER T, 1955, METHOD ENZYMOL, V63, P441; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; CIMBALA MA, 1985, MOL BASIS INSULIN AC, P385; CLADARAS C, 1980, ARCH BIOCHEM BIOPHYS, V200, P426, DOI 10.1016/0003-9861(80)90373-2; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DELGIACCO R, 1964, J BIOL CHEM, V239, P2400; ENGSTROM L, 1987, ENZYMES, V18, P47; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; HARADA K, 1978, BIOCHIM BIOPHYS ACTA, V524, P327, DOI 10.1016/0005-2744(78)90169-9; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HERN EP, 1978, P SOC EXP BIOL MED, V158, P255; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; IMAMURA K, 1972, J BIOCHEM-TOKYO, V71, P1043, DOI 10.1093/oxfordjournals.jbchem.a129852; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN MJ, 1982, BIOCHIM BIOPHYS ACTA, V699, P77, DOI 10.1016/0167-4781(82)90140-3; MAHER F, 1989, MOL ENDOCRINOL, V3, P2128, DOI 10.1210/mend-3-12-2128; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1991, J BIOL CHEM, V266, P10155; MARSHALL S, 1989, J BIOL CHEM, V264, P2029; MARSHALL S, 1983, DIABETES, V32, P319, DOI 10.2337/diab.32.4.319; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MEDDIO F, 1990, EUR J BIOCHEM, V187, P89; MOLNAR J, 1964, J BIOL CHEM, V239, P3157; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NNOGUCHI T, 1983, J BIOL CHEM, V258, P15220; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; OREVI M, 1972, EUR J BIOCHEM, V30, P418, DOI 10.1111/j.1432-1033.1972.tb02113.x; POGSON CI, 1967, NATURE, V216, P156, DOI 10.1038/216156a0; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schauer R., 1982, ADV CARBOHYD CHEM BI, V40, P132; SCHWARTZ NB, 1986, TXB BIOCH CLIN CORRE, P329; SHOELSON SE, 1989, MOL CELLULAR BIOL DI, P23; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; WEBER A, 1984, J BIOL CHEM, V259, P1798; YUTEH B, 1982, ADV CARBOHY CHEM BIO, V40, P235; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zubay G., 1988, BIOCHEMISTRY	49	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9718	9723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577807				2022-12-27	WOS:A1992HT96500043
J	LUNARDI, J; HURKO, O; ENGEL, WK; ATTARDI, G				LUNARDI, J; HURKO, O; ENGEL, WK; ATTARDI, G			THE MULTIPLE ADP/ATP TRANSLOCASE GENES ARE DIFFERENTIALLY EXPRESSED DURING HUMAN MUSCLE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADENINE-NUCLEOTIDE TRANSLOCATOR; ADP ATP TRANSLOCASE; MOLECULAR-CLONING; MITOCHONDRIAL-DNA; SEQUENCE; CARRIER; MYOGENESIS; PATTERNS; ENCODE; CELLS	The expression of the genes encoding the three isoforms of the human ADP/ATP translocase (T1, T2, and T3) has been analyzed at different stages of myogenic differentiation in an in vitro muscle cell system and compared with that in mature muscle. The results indicate that the three stages of muscle differentiation corresponding to myoblast proliferation, myotube formation, and mature muscle fibers are characterized by a different pattern of expression of the ADP/ATP translocase genes. In particular, the two T2-specific mRNAs are present at high, similar levels in myoblasts and myotubes and markedly decrease in amount in mature adult muscle. By contrast, the T3-specific mRNA is present in high amount in growing myoblasts, decreases markedly in myotubes, and is barely detectable in adult muscle. Finally, the T1-specific mRNA is present at a high level in adult muscle and is not detectable in either myoblasts or myotubes. Therefore, T1 gene expression appears to be a marker of a late stage in myogenesis. A parallel investigation of expression of the myosin heavy chain mRNA revealed absence of hybridization with the specific probe in RNA from proliferating myoblasts, a significant hybridization in myotube RNA, and a strong signal in adult muscle RNA.	CALTECH,DIV BIOL,PASADENA,CA 91125; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; UNIV SO CALIF,SCH MED,CTR NEUROMUSCULAR,LOS ANGELES,CA 90033	California Institute of Technology; Johns Hopkins University; University of Southern California					NIAMS NIH HHS [AR38231] Funding Source: Medline; NIGMS NIH HHS [GM-11726] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038231] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AFFARA NA, 1980, J MOL BIOL, V140, P449; AMALDI F, 1968, J MOL BIOL, V33, P737, DOI 10.1016/0022-2836(68)90317-3; BATHGATE B, 1989, EUR J BIOCHEM, V183, P303, DOI 10.1111/j.1432-1033.1989.tb14929.x; BATTINI R, 1987, J BIOL CHEM, V262, P4355; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DUBIN DT, 1982, J MOL BIOL, V157, P1, DOI 10.1016/0022-2836(82)90510-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GEKAKIS N, 1989, J BIOL CHEM, V264, P3658; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; HURKO O, 1986, ANN NEUROL, V20, P573, DOI 10.1002/ana.410200504; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KU DH, 1990, J BIOL CHEM, V265, P16060; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LI K, 1989, J BIOL CHEM, V264, P13998; LI K, 1990, J BIOL CHEM, V265, P20585; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316	32	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15267	15270						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639771				2022-12-27	WOS:A1992JG11300003
J	LUVISETTO, S; SCHMEHL, I; INTRAVAIA, E; CONTI, E; AZZONE, GF				LUVISETTO, S; SCHMEHL, I; INTRAVAIA, E; CONTI, E; AZZONE, GF			MECHANISM OF LOSS OF THERMODYNAMIC CONTROL IN MITOCHONDRIA DUE TO HYPERTHYROIDISM AND TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CHARGE TRANSLOCATION STOICHIOMETRY; BROWN ADIPOSE-TISSUE; DELTA-MU-H; OXIDATIVE-PHOSPHORYLATION; INNER MEMBRANE; PROTON PUMPS; LOWER LIMITS; RESPIRATION; CONDUCTANCE	Incubation of normal mitochondria at 45-degrees-C results in increases of respiration and of total apparent proton conductance (TAPC, respiration/proton motive force) and in an upward shift of the flow-force relationships. Similar effects are observed during operation of the redox proton pumps at different sites of the respiratory chain. These effects are accompanied by an almost equivalent increase of the passive proton conductance (PPC, proton leakage/proton motive force). In mitochondria from 3,3,5-triiodo-L-thyronine (T3)-treated rats there are also increases of respiration and of TAPC and an upward shift of flow-force relationships, more pronounced at the level of the cytochrome oxidase proton pump. However, at variance from the incubation at 45-degrees-C, in mitochondria from T3-treated rats there is only a slight increase of PPC. Addition of bovine serum albumin to normal mitochondria incubated at 45-degrees-C results in a marked depression of TAPC in the nonlinear range of the flow-force relationships. An equivalent effect is not observed in mitochondria from T3-treated rats. The experimental results have been compared with computer simulations obtained on the basis of a chemiosmotic model of energy transduction. The increase of TAPC following incubation at high temperature is apparently due to changes of the proton conductance mainly at the level of PPC, while the increase of TAPC following T3 administration is rather due to changes presumably at the level of the redox or ATPase proton pumps.	CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR)	LUVISETTO, S (corresponding author), UNIV PADUA,INST GEN PATHOL,CTR NATL RICH MITOCHONDRIAL PHYSIOL,VIA TRIESTE 75,I-35131 PADUA,ITALY.		Luvisetto, Siro/K-1844-2019; Luvisetto, Siro/AAJ-6985-2021; Luvisetto, Siro/M-9557-2015	Luvisetto, Siro/0000-0003-1399-2152; Luvisetto, Siro/0000-0003-1399-2152				AZZONE GF, 1966, REGULATION METABOLIC, V7, P332; BEAVIS AD, 1987, J BIOL CHEM, V262, P6174; BEAVIS AD, 1987, J BIOL CHEM, V262, P6165; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1990, J THEOR BIOL, V145, P267, DOI 10.1016/S0022-5193(05)80131-6; CARR FE, 1984, P NATL ACAD SCI-BIOL, V81, P974, DOI 10.1073/pnas.81.3.974; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; DUSZYNSKI J, 1985, FEBS LETT, V182, P243, DOI 10.1016/0014-5793(85)80307-0; Eyring H., 1963, MODERN CHEM KINETICS; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Guernsey DL, 1983, MOL BASIS THYROID HO, P293; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LUVISETTO S, 1987, BIOCHEMISTRY-US, V26, P7332, DOI 10.1021/bi00397a021; LUVISETTO S, 1991, FEBS LETT, V291, P17, DOI 10.1016/0014-5793(91)81093-N; LUVISETTO S, 1989, BIOCHEMISTRY-US, V28, P1100, DOI 10.1021/bi00429a026; LUVISETTO S, 1990, J BIOL CHEM, V266, P1034; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; MITCHELL P, 1967, BIOCHEM J, V104, P588, DOI 10.1042/bj1040588; NICHOLLS DG, 1977, EUR J BIOCHEM, V77, P349, DOI 10.1111/j.1432-1033.1977.tb11674.x; OUHABI R, 1991, BIOCHIM BIOPHYS ACTA, V1060, P293, DOI 10.1016/S0005-2728(05)80319-6; PIETROBON D, 1981, EUR J BIOCHEM, V117, P389, DOI 10.1111/j.1432-1033.1981.tb06350.x; PIETROBON D, 1986, BIOCHEMISTRY-US, V25, P767, DOI 10.1021/bi00352a005; PIETROBON D, 1985, BIOCHEMISTRY-US, V24, P5764, DOI 10.1021/bi00342a012; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; ROSSI E, 1970, EUR J BIOCHEM, V12, P319, DOI 10.1111/j.1432-1033.1970.tb00853.x; ROTTENBERG H, 1986, BIOCHEMISTRY-US, V25, P1747, DOI 10.1021/bi00355a045; SHEARS SB, 1979, BIOCHEM J, V178, P505, DOI 10.1042/bj1780505; TONINELLO A, 1988, J BIOL CHEM, V263, P19407; WALZ D, 1990, BIOCHIM BIOPHYS ACTA, V1019, P171, DOI 10.1016/0005-2728(90)90196-B; WESTERHOFF HV, 1984, BIOCHIM BIOPHYS ACTA, V768, P257, DOI 10.1016/0304-4173(84)90019-3; WIKSTROM M, 1981, ANNU REV BIOCHEM, V50, P623, DOI 10.1146/annurev.bi.50.070181.003203; ZOLKIEWSKA A, 1989, ARCH BIOCHEM BIOPHYS, V275, P580; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1986, BIOCHIM BIOPHYS ACTA, V851, P123, DOI 10.1016/0005-2728(86)90255-0	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15348	15355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639781				2022-12-27	WOS:A1992JG11300017
J	DARNAY, BG; WANG, YL; RODWELL, VW				DARNAY, BG; WANG, YL; RODWELL, VW			IDENTIFICATION OF THE CATALYTICALLY IMPORTANT HISTIDINE OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; PSEUDOMONAS-MEVALONII; NUCLEOTIDE-SEQUENCE; DIRECTED MUTAGENESIS; ARABIDOPSIS-THALIANA; CDNA; BIOSYNTHESIS; INHIBITORS; PATHWAY; ENZYMES	We identify His381 of Pseudomonas mevalonii 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase as the basic residue functional in catalysis. The catalytic domain of 20 HMG-CoA reductases contains a single conserved histidine (His381 of the P. mevalonii enzyme). Diethyl pyrocarbonate inactivated the P. mevalonii enzyme, and hydroxylamine partially restored activity. We changed His381 to alanine, lysine, asparagine, and glutamine. The mutant proteins were overexpressed, purified to homogeneity, and characterized. His381 mutant enzymes were not inactivated by diethyl pyrocarbonate. All four mutant enzymes exhibited wild-type crystal morphology and chromatographed on substrate affinity supports like wild-type enzyme. The mutant enzymes had low catalytic activity (V(max) 0.06-0.5% that of wild-type enzyme), but K(m) values approximated those for wild-type enzyme. For wild-type enzyme and mutant enzymes H381A, H381N, and H381Q, K(m) values at pH 8.1 were 0.45, 0.27, 3.7, and 0.71 mM [(R,S)-mevalonate]; 0.05, 0.03, 0.20, and 0.11 mM [coenzyme A]; 0.22,0.14, 0.81, and 0.62 mM [NAD+]. K(m) values at pH 11 for wild-type enzyme and mutant enzyme H381K were 0.32 and 0.75 mM [(R,S)-mevalonate]; 0.24 and 0.50 mM [coenzyme A]; 0.15 and 1.23 mM [NAD+]. Both pK values for the enzyme-substrate complex increased relative to wild-type enzyme (by 1-2.5 pH units for pK1 and by 0.5-1.3 pH units for pK2). For mutant enzyme H381K, the pK1 of 10.2 is consistent with lysine acting as a general base at high pH. His381 of P. mevalonii HMG-CoA reductase, and consequently the histidine of the consensus Leu-Val-Lys-Ser-His-Met-Xaa-Xaa-Asn-Arg-Ser motif of the catalytic domain of eukaryotic HMG-CoA reductases, thus is the general base functional in catalysis.	PURDUE UNIV,DEPT BIOCHEM,1153 BIOCHEM BLDG,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACH TJ, 1991, LIPIDS, V26, P637, DOI 10.1007/BF02536429; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENDO A, 1988, KLIN WOCHENSCHR, V66, P421, DOI 10.1007/BF01745510; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GILL JF, 1985, J BIOL CHEM, V260, P9393; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17919; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM WL, 1992, J BIOL CHEM, V267, P5829; LAWRENCE CM, 1990, 40TH ANN M AM CRYST, P68; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; STERMER BA, 1991, PHYSIOL MOL PLANT P, V39, P1935; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tipton K F, 1979, Methods Enzymol, V63, P183; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG Y, 1989, J BACTERIOL, V171, P5567, DOI 10.1128/jb.171.10.5567-5571.1989; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; 1983, OLIGONUCLEOTIDE DIRE, P1	37	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15064	15070						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634543				2022-12-27	WOS:A1992JF08800082
J	SENGELOV, H; NIELSEN, MH; BORREGAARD, N				SENGELOV, H; NIELSEN, MH; BORREGAARD, N			SEPARATION OF HUMAN NEUTROPHIL PLASMA-MEMBRANE FROM INTRACELLULAR VESICLES CONTAINING ALKALINE-PHOSPHATASE AND NADPH OXIDASE ACTIVITY BY FREE-FLOW ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; CYTOCHROME-B; MICROBICIDAL OXIDASE; COMPARTMENT; PROTEINS; SYSTEM; TRANSLOCATION; MOBILIZATION; ACTIVATION; COMPONENT	A putative reservoir of functional plasma membrane proteins, the secretory vesicle identified by latent alkaline phosphatase and tetranectin, has previously been demonstrated based on indirect evidence (Borregaard, N., Miller, L. J., and Springer, T. A. (1987) Science 237, 1204-1206; Borregaard, N., Christensen, L., Bjerrum, 0. W., Birgens, H. S., and Clemmesen, I. (1990) J. Clin. Invest. 85, 408-416). Difficulties in separating plasma membranes from this entity by density gradient centrifugation has prohibited discriminative dynamic and quantitative studies of secretory vesicles and plasma membranes. By combining density centrifugation with free flow electrophoresis we overcame this obstacle. Freshly prepared unperturbed human neutrophils were subjected to nitrogen cavitation followed by density centrifugation on Percoll gradients. Light membrane fractions containing plasma membranes and secretory vesicles were applied to high voltage free flow electrophoresis on an Elphor VaP 22. Plasma membrane vesicles, identified by HLA class I antigen mixed enzyme-linked immunosorbent assay (Bjerrum, O. W., and Borregaard, N. (1990) Scand. J. Immunol. 31, 305-313) and I-125 applied to cells before cavitation, were clearly separated from secretory vesicles. Electron microscopy revealed a morphology typical of plasma membranes in the former fraction and a population of vesicles with markedly different appearance in the latter. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis profiles demonstrated distinct differences in protein patterns between the two fractions. Superoxide generating capacity induced by sodium dodecyl sulfate and cytosol, an entity traditionally ascribed to the plasma membrane, was largely confined to fractions containing secretory vesicles. Thus, the majority of membrane-bound NADPH oxidase components of light membranes of human neutrophils colocalize with secretory vesicles.	UNIV COPENHAGEN,RIGSHOSP,INST PATHOL ANAT,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	SENGELOV, H (corresponding author), RIGSHOSP,DEPT INTERNAL MED & HAEMATOL L,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.			Sengelov, Henrik/0000-0002-5991-2958				BJERRUM OW, 1990, SCAND J IMMUNOL, V31, P305, DOI 10.1111/j.1365-3083.1990.tb02773.x; BJERRUM OW, 1989, EUR J HAEMATOL, V43, P67; BJERRUM OW, 1987, J IMMUNOL, V138, P3913; BORREGAARD N, 1987, SCIENCE, V237, P1204, DOI 10.1126/science.3629236; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1987, J BIOL CHEM, V262, P4065; DEBANNE MT, 1982, NATURE, V298, P398, DOI 10.1038/298398a0; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DELBUONO BJ, 1989, J CELL PHYSIOL, V141, P636, DOI 10.1002/jcp.1041410323; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; FLETCHER MP, 1983, BLOOD, V62, P792; FRANCIS JW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P1, DOI 10.1016/0005-2736(90)90183-O; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; HANIG K, 1974, METHOD ENZYMOL, V31, P746; HARMS E, 1980, P NATL ACAD SCI-BIOL, V77, P6139, DOI 10.1073/pnas.77.10.6139; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; KLEMPNER MS, 1980, J CELL BIOL, V86, P21, DOI 10.1083/jcb.86.1.21; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; KRAUSE KH, 1987, J CLIN INVEST, V80, P107, DOI 10.1172/JCI113035; LACAL P, 1988, J BIOL CHEM, V263, P9946; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MENASHI S, 1981, J BIOL CHEM, V256, P4095; MILLER LJ, 1987, J CLIN INVEST, V80, P535, DOI 10.1172/JCI113102; MOLLINEDO F, 1984, J BIOL CHEM, V259, P7143; MORRE DJ, 1983, EUR J CELL BIOL, V31, P263; OHNO Y, 1985, J BIOL CHEM, V260, P2409; ROTROSEN D, 1988, J BIOL CHEM, V263, P10958; SEGAL AW, 1979, BIOCHEM J, V182, P181, DOI 10.1042/bj1820181	34	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14912	14917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634531				2022-12-27	WOS:A1992JF08800063
J	DONG, XR; LI, SF; DEMOSS, JA				DONG, XR; LI, SF; DEMOSS, JA			UPSTREAM SEQUENCE ELEMENTS REQUIRED FOR NARL-MEDIATED ACTIVATION OF TRANSCRIPTION FROM THE NARGHJI PROMOTER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENES; OPERON; REGION; K-12; DNA; FNR; CHLC	Transcription of the narGHJI operon (encoding nitrate reductase) in Escherichia coli is primarily dependent on the activation of the pleiotropic transacting factor Fnr, which interacts with the promoter through a cis element (Fnr box) located near the transcription start site. Further stimulation of transcription occurs in the presence of nitrate and is dependent on activation of the transacting factor NarL and a cis-acting sequence (NarL box) located approximately 200 base pairs upstream from the transcription start site. To define the structure of the NarL box, alterations in the NarL box region, generated by saturation mutagenesis of the sequence from positions -184 to -202 in the narGHJI promoter of a narG::lacZ fusion-bearing plasmid, were analyzed for their effects on NarL-mediated stimulation of transcription. Single base substitutions that significantly reduced the NarL-mediated stimulation were restricted to a 6-base sequence, TACTCC, located at positions -193 to -198 in the narGHJI promoter. When 2 bases were modified, NarL-mediated stimulation was severely reduced when one or both alterations were located within the 6-base sequence. Attempts to restore NarL-mediated stimulation with an inverted NarL box were not successful. Although previous studies suggested that NarL-mediated stimulation of transcription may occur by a DNA looping mechanism, the results presented here demonstrate that it does not involve the passive formation of a simple DNA loop. Replacement of 94 or 108 bases of the approximately 150 base sequence between the Fnr box and the NarL box with an unrelated sequence resulted in elimination of NarL-mediated stimulation of transcription. Furthermore, shifting of most of the intervening sequence or defined segments of the sequence by 4 bases while maintaining the position of the NarL box relative to sequences required for Fnr-dependent, anaerobic transcription also eliminated the NarL-mediated stimulation. We conclude that in addition to the 6-base NarL box located on a specific face of the promoter DNA, the stimulation of transcription by NarL requires some specific sequences and/or higher order structure specified by the DNA that separates the NarL box from the Fnr box.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019511] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19511] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG BL, 1990, GENETICS, V125, P691; BERG BL, 1991, J BIOL CHEM, V266, P22380; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BONNEFOY V, 1986, MOL GEN GENET, V204, P180, DOI 10.1007/BF00330207; CHIPPAUX M, 1981, J BACTERIOL, V151, P1320; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; EDWARDS ES, 1983, J BACTERIOL, V153, P1513, DOI 10.1128/JB.153.3.1513-1520.1983; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; GUNSALUS RP, 1989, NUCLEIC ACIDS RES, V17, P1965, DOI 10.1093/nar/17.5.1965; HIDAKA M, 1991, J BACTERIOL, V173, P391, DOI 10.1128/jb.173.1.391-393.1991; HILL DE, 1987, METHOD ENZYMOL, V155, P558; IUCHI S, 1987, P NATL ACAD SCI USA, V84, P3901, DOI 10.1073/pnas.84.11.3901; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LI S, 1985, J BACTERIOL, V164, P25, DOI 10.1128/JB.164.1.25-32.1985; LI SF, 1988, J BIOL CHEM, V263, P13700; LI SF, 1987, J BACTERIOL, V169, P4614, DOI 10.1128/jb.169.10.4614-4620.1987; LUI J, 1989, J BACTERIOL, V171, P1254; MANIATIS T, 1982, MOL CLONING LABORATO, P365; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Miller J. H, 1972, EXPT MOL GENETICS; NOHNO T, 1989, NUCLEIC ACIDS RES, V17, P2947, DOI 10.1093/nar/17.8.2947; NOJI S, 1989, FEBS LETT, V252, P139, DOI 10.1016/0014-5793(89)80906-8; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SHOWE MK, 1968, J BACTERIOL, V95, P1305, DOI 10.1128/JB.95.4.1305-1313.1968; SODERGREN EJ, 1988, J BACTERIOL, V170, P1721, DOI 10.1128/jb.170.4.1721-1729.1988; STEWART V, 1989, J BACTERIOL, V171, P2229, DOI 10.1128/jb.171.4.2229-2234.1989; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STEWART V, 1982, J BACTERIOL, V151, P1320, DOI 10.1128/JB.151.3.1320-1325.1982; UNDEN G, 1990, MOL MICROBIOL, V4, P315, DOI 10.1111/j.1365-2958.1990.tb00598.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER MS, 1992, J BACTERIOL, V174, P1119, DOI 10.1128/jb.174.4.1119-1123.1992; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x	32	45	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14122	14128						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629213				2022-12-27	WOS:A1992JD32500054
J	HUTCHISON, KA; CZAR, MJ; SCHERRER, LC; PRATT, WB				HUTCHISON, KA; CZAR, MJ; SCHERRER, LC; PRATT, WB			MONOVALENT CATION SELECTIVITY FOR ATP-DEPENDENT ASSOCIATION OF THE GLUCOCORTICOID RECEPTOR WITH HSP70 AND HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-BINDING DOMAIN; PROGESTERONE-RECEPTOR; DNA-BINDING; UNCOATING ATPASE; TRANSFORMATION; RECONSTITUTION; COMPLEX; PURIFICATION; TRANSLATION	We have reported previously that incubation of the immunopurified transformed hormone-free glucocorticoid receptor with rabbit reticulocyte lysate reconstitutes the receptor complex with hsp90 and that reconstitution is accompanied by concomitant repression of DNA binding activity and regeneration of the steroid binding conformation (Scherrer, L. C., Dalman, F. C., Massa, E., Meshinchi, S., and Pratt, W. B. (1990) J. Biol. Chem. 265, 21397-21400). In this work we further characterize this system by defining the small M(r) components of reticulocyte lysate required for both structural and functional reconstitution of the receptor-hsp90 complex. Reconstitution is ATP-dependent and there is a direct relationship between the extent of hsp90 binding to the receptor and the number of specific steroid binding sites that are generated. Dialysis of reticulocyte lysate inactivates its reconstituting activity. Addition of an ATP-regenerating system or readdition of small M(r) lysate components (in the form of a Centricon C30 filtrate) has little effect, but the ' presence of both restores full reconstituting activity to dialyzed lysate, as assayed by steroid binding activity and by the binding of hsp90 and hsp70 to the receptor. The small M(r) activity is heat-stable, and it can be completely replaced by NH4+, K+, and Rb+, with K+ producing a maximal effect at the concentration normally present in undialyzed lysate. Na+ and Li+ have no reconstituting activity. This ion selectivity demonstrates that a monovalent cation binding site is involved in receptor heterocomplex reconstitution. It is intriguing that the protein unfoldase (e.g. clathrin uncoating ATPase) activity of hsp70 is known to have a similar monovalent cation dependence, and that under all conditions where hsp90 becomes bound to the receptor, we find that hsp70 is also bound.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6448 MED SCI BLDG 1,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CADEPOND F, 1991, J BIOL CHEM, V266, P5384; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1989, J BIOL CHEM, V264, P6005; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; MENDEL DB, 1988, J BIOL CHEM, V263, P6695; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; REXIN M, 1991, J BIOL CHEM, V266, P24601; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLATTER LK, 1992, MOL ENDOCRINOL, V6, P132, DOI 10.1210/me.6.1.132; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996	32	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14047	14053						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629204				2022-12-27	WOS:A1992JD32500043
J	MARKWELL, J; BRUCE, BD; KEEGSTRA, K				MARKWELL, J; BRUCE, BD; KEEGSTRA, K			ISOLATION OF A CAROTENOID-CONTAINING SUB-MEMBRANE PARTICLE FROM THE CHLOROPLASTIC ENVELOPE OUTER-MEMBRANE OF PEA (PISUM-SATIVUM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANACYSTIS-NIDULANS; PROTEIN; ZEAXANTHIN; DNA	Chloroplastic envelope membranes isolated from pea (Pisum sativum) leaves are rich in carotenoids, containing approximately 2-mu-g of carotenoid mg-1 protein. We report here that envelopes can be surfactant-solubilized while maintaining association of carotenoids with protein components of the membrane. Treatment of isolated chloroplastic envelope membranes with 0.5% Deriphat 160 (N-lauryl-beta-imminodipropionate) causes general solubilization but preserves an envelope sub-membrane fragment which is fractionated by centrifugation in a sucrose gradient and by chromatography on a column of DEAE-Sephacel. The isolated submembrane complex contained five major proteins with M(r) values equivalent to 75,000, 36,000, 34,000 17,500, and 14,500. Spectroscopic and chromatographic analyses revealed that the complex contains violaxanthin and at least one other carotenoid. Carotenoid content of the fractionated complex was estimated as 4.8-mu-g mg-1 protein. Immunoblot analysis reveals that the constituent proteins of this complex are derived from the chloroplastic outer envelope membrane. These data suggest that at least some of the carotenoids of the chloroplastic envelope may be organized by apoproteins.	UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CERVANTESCERVANTES M, 1990, PLANT PHYSIOL, V92, P1241, DOI 10.1104/pp.92.4.1241; CLINE K, 1986, J BIOL CHEM, V261, P4804; COSTES C, 1979, FEBS LETT, V103, P17, DOI 10.1016/0014-5793(79)81241-7; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIVERSEPIERLUISSI M, 1988, BIOCHIM BIOPHYS ACTA, V933, P372, DOI 10.1016/0005-2728(88)90045-X; DOUCE R, 1990, ANNU REV CELL BIOL, V6, P173, DOI 10.1146/annurev.cb.06.110190.001133; ENGLE JM, 1991, ARCH MICROBIOL, V155, P453, DOI 10.1007/BF00244961; FOOTE CS, 1970, J AM CHEM SOC, V92, P5216, DOI 10.1021/ja00720a036; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; JEFFREY SW, 1974, P NATL ACAD SCI USA, V71, P807, DOI 10.1073/pnas.71.3.807; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; JOYARD J, 1976, PHYSIOL VEG, V14, P31; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLAUER SF, 1991, PLANT PHYSIOL, V97, P1306, DOI 10.1104/pp.97.4.1306; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MAKINO A, 1991, PHOTOSYNTH RES, V29, P79, DOI 10.1007/BF00035378; MARKWELL JP, 1979, P NATL ACAD SCI USA, V76, P1233, DOI 10.1073/pnas.76.3.1233; MARKWELL JP, 1986, PLANT PHYSIOL, V81, P329, DOI 10.1104/pp.81.2.329; MASAMOTO K, 1987, PLANT PHYSIOL, V84, P633, DOI 10.1104/pp.84.3.633; Moss G.P., 1976, CHEMISTRY BIOCHEMIST, P149; NOCTOR G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P320, DOI 10.1016/S0005-2728(05)80143-4; POWLS R, 1976, BIOCHIM BIOPHYS ACTA, V453, P270, DOI 10.1016/0005-2795(76)90273-7; REDDY KJ, 1989, J BACTERIOL, V171, P3486, DOI 10.1128/jb.171.6.3486-3493.1989; SCHMIDT W, 1984, BLUE LIGHT EFFECTS B, P81; SIEFERMANNHARMS D, 1978, PLANT PHYSIOL, V61, P530, DOI 10.1104/pp.61.4.530; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINHARDT J, 1969, MULTIPLE EQUILIBRIA, P85; WHATLEY JM, 1987, NEW PHYTOL, V106, P667, DOI 10.1111/j.1469-8137.1987.tb00167.x	32	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13933	13937						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629191				2022-12-27	WOS:A1992JD32500026
J	YANG, W; ABERNETHY, JL; ECKHARDT, AE; HILL, RL				YANG, W; ABERNETHY, JL; ECKHARDT, AE; HILL, RL			PURIFICATION AND CHARACTERIZATION OF A UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE SPECIFIC FOR GLYCOSYLATION OF THREONINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMAXILLARY-GLAND APOMUCIN; TRANSFERASE; ACETYLGLUCOSAMINE; MUCIN	A UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase from porcine submaxillary glands was purified to electrophoretic homogeneity. IgG prepared from antisera against the pure enzyme immunoprecipitated the transferase in Triton X-100 extracts of submaxillary glands. The submaxillary transferase is a membrane-bound enzyme in contrast to the pure bovine colostrum enzyme, which is soluble in the absence of detergents. Both transferases have similar properties but also differ significantly. Examination of the acceptor substrate specificity of the submaxillary gland transferase showed that it specifically transferred N-acetylgalactosamine from UDP-GalNAc to the hydroxyl group of threonine and was devoid of transferase activity toward serine-containing peptides. These results imply that more than one transferase is involved in forming the GalNAc-threonine and the GalNAc-serine linkages found in O-linked oligosaccharides in glycoproteins. The amino acid sequence adjacent to glycosylated threonine residues may influence the rate of glycosylation by the pure transferase. For example, the second threonine residue in the sequence, Thr-Thr, appears to be glycosylated about twice as fast as the first and more rapidly than single, isolated threonine residues. However, no unique consensus sequence for glycosylation of threonine residues is evident, and any accessible threonine residue appears to be a potential acceptor substrate.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM25766] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025766, R01GM025766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; BARKER R, 1972, J BIOL CHEM, V247, P7135; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BRUCKNER H, 1989, J CHROMATOGR, V476, P73, DOI 10.1016/S0021-9673(01)93857-9; BRUCKNER H, 1991, CHROMATOGRAPHIA, V32, P383, DOI 10.1007/BF02321438; DALE RMK, 1975, BIOCHEMISTRY-US, V14, P2447, DOI 10.1021/bi00682a027; DESALEGUI M, 1969, ARCH BIOCHEM BIOPHYS, V129, P49, DOI 10.1016/0003-9861(69)90148-9; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; HAGOPIAN A, 1969, ARCH BIOCHEM BIOPHYS, V129, P515, DOI 10.1016/0003-9861(69)90209-4; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P122; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HILL HD, 1977, J BIOL CHEM, V252, P3799; HILL HD, 1977, J BIOL CHEM, V252, P3791; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGUIRE EJ, 1967, J BIOL CHEM, V242, P3745; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	28	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12709	12716						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618775				2022-12-27	WOS:A1992HZ48300051
J	CAIN, CC; TRIMBLE, WS; LIENHARD, GE				CAIN, CC; TRIMBLE, WS; LIENHARD, GE			MEMBERS OF THE VAMP FAMILY OF SYNAPTIC VESICLE PROTEINS ARE COMPONENTS OF GLUCOSE TRANSPORTER-CONTAINING VESICLES FROM RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; ENDOCRINE-CELLS; 3T3-L1 ADIPOCYTES; ADIPOSE-CELLS; GENES; NEURONS; BRAIN	Existing data support the hypothesis that insulin triggers the exocytosis of small vesicles containing the GluT4 isoform of the glucose transporter. The data also suggest that these vesicles reform through endocytosis of GluT4. These processes resemble those described for synaptic vesicles after depolarization of nerve cells. To determine whether GluT4 vesicles are related to synaptic vesicles, rat adipocyte low density microsomes (LDM), which are rich in GluT4 vesicles, were screened for the synaptic vesicle proteins synaptotagmin, synaptophysin, SV2, p29, rab3, and VAMP (synaptobrevin) by immunoblotting. Two polypeptides that reacted with antibodies against the VAMPs were identified, one with the same apparent size as the two isoforms of VAMP in the brain (18 kDa) and one that was slightly smaller (17 kDa). These members of the VAMP family were highly enriched in GluT4 vesicles isolated by immunoadsorption and translocated from the LDM to the plasma membrane in response to insulin. With the exception of rab3, which was observed in the LDM but was not localized in the GluT4 vesicles, the other synaptic vesicle proteins were not detected. The presence of the VAMPs in both GluT4 and synaptic vesicles suggests that the genesis and/or exocytosis of these two types of vesicles involve shared processes.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO M5S 1A8,ONTARIO,CANADA	Dartmouth College; University of Toronto			Mastick, Cynthia/G-9841-2017	Mastick, Cynthia/0000-0003-4769-5412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025336, R55DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BROWN SJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P339, DOI 10.1016/S0005-2728(88)80049-5; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GROESCH M E, 1991, Journal of Cell Biology, V115, p62A; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIENHARD GE, 1984, BIOCHIM BIOPHYS ACTA, V769, P404, DOI 10.1016/0005-2736(84)90324-9; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WEBER TM, 1988, RECEPTOR BIOCH METHO, P171; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	33	262	267	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11681	11684						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601842				2022-12-27	WOS:A1992HY94700006
J	TANG, DC; STULL, JT; KUBOTA, Y; KAMM, KE				TANG, DC; STULL, JT; KUBOTA, Y; KAMM, KE			REGULATION OF THE CA2+ DEPENDENCE OF SMOOTH-MUSCLE CONTRACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; BETA-ADRENERGIC RELAXATION; PROTEIN-KINASE; MYOSIN PHOSPHORYLATION; CATALYTIC SUBUNIT; FREE-CALCIUM; INTRACELLULAR CALCIUM; CYTOSOLIC CA-2+; CELLS; CAMP	Cellular mechanisms for the regulation of Ca2+-dependent myosin light chain phosphorylation were investigated in bovine tracheal smooth muscle. Increases in the free intracellular Ca2+ concentration ([Ca2+]i), light chain phosphorylation, and force were proportional to carbachol concentration. K(CaM), the concentration of Ca2+/calmodulin required for half-maximal activation of myosin light chain kinase, also increased proportionally, presumably due to Ca2+-dependent phosphorylation of the kinase. Isoproterenol treatment inhibited agonist-induced contraction by decreasing [Ca2+]i and thereby light chain phosphorylation. Depolarization by increasing concentrations of KCl also resulted in proportional increases in [Ca2+]i, K(CaM), light chain phosphorylation, and force. However, the [Ca2+]i required to obtain a given value of either light chain phosphorylation or K(CaM) was greater in KCl-depolarized tissues compared to carbachol-treated tissues. In muscles contracted with KCl, isoproterenol treatment resulted in diminished light chain phosphorylation and force without alterations in [Ca2+]i or K(CaM). Thus, isoproterenol inhibition of KCl-induced contraction results from a cellular mechanism different from that found in agonist-induced contraction. In neither case does isoproterenol produce relaxation by altering the calmodulin activation properties of myosin light chain kinase.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL32607, HL26043] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032607, R01HL026043, R23HL032607, R37HL026043] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE A, 1989, J PHARMACOL EXP THER, V249, P895; ADELSTEIN RS, 1978, J BIOL CHEM, V253, P8347; AHMAD Z, 1989, J BIOL CHEM, V264, P3859; BECKER PL, 1987, AM J PHYSIOL, V253, pC613, DOI 10.1152/ajpcell.1987.253.4.C613; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CONTI MA, 1981, J BIOL CHEM, V256, P3178; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; FELBEL J, 1988, J BIOL CHEM, V263, P16764; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GERTHOFFER WT, 1989, AM J PHYSIOL, V257, pC1062, DOI 10.1152/ajpcell.1989.257.6.C1062; GILBERT EK, 1991, FASEB J, V5, P2593, DOI 10.1096/fasebj.5.11.1868983; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; HIMPENS B, 1988, J GEN PHYSIOL, V92, P713, DOI 10.1085/jgp.92.6.713; JOHNSON EM, 1991, J BIOL CHEM, V266, P12618; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARAKI H, 1989, TRENDS PHARMACOL SCI, V10, P320; KARGACIN G, 1991, BIOPHYS J, V60, P1088, DOI 10.1016/S0006-3495(91)82145-2; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LOW AM, 1991, J PHARMACOL EXP THER, V258, P1105; MCDANIEL NL, 1991, J PHYSIOL-LONDON, V439, P147, DOI 10.1113/jphysiol.1991.sp018661; MEISHERI KD, 1982, J PHYSL, V331, P420; MILLER JR, 1983, MOL PHARMACOL, V24, P235; MITSUI M, 1990, AM J PHYSIOL, V258, pC787, DOI 10.1152/ajpcell.1990.258.5.C787; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; MORGAN JP, 1991, AM  HEART J, V121; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; OZAKI H, 1990, PFLUG ARCH EUR J PHY, V416, P351, DOI 10.1007/BF00370740; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; REMBOLD CM, 1990, J PHYSIOL-LONDON, V429, P77, DOI 10.1113/jphysiol.1990.sp018245; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; REMBOLD CM, 1989, J PHYSIOL-LONDON, V416, P273, DOI 10.1113/jphysiol.1989.sp017760; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SATO K, 1988, N-S ARCH PHARMACOL, V338, P443; SCHEID CR, 1979, NATURE, V277, P32, DOI 10.1038/277032a0; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; SUEMATSU E, 1991, J PHYSIOL-LONDON, V440, P85, DOI 10.1113/jphysiol.1991.sp018697; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TANSEY MG, 1992, IN PRESS J BIOL CHEM, V266; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TAYLOR DA, 1989, J BIOL CHEM, V264, P6207; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	57	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11839	11845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601855				2022-12-27	WOS:A1992HY94700033
J	MCFARLAN, SC; TERRELL, CA; HOGENKAMP, HPC				MCFARLAN, SC; TERRELL, CA; HOGENKAMP, HPC			THE PURIFICATION, CHARACTERIZATION, AND PRIMARY STRUCTURE OF A SMALL REDOX PROTEIN FROM METHANOBACTERIUM-THERMOAUTOTROPHICUM, AN ARCHAEBACTERIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLUTATHIONE-DEPENDENT SYNTHESIS; ESCHERICHIA-COLI GLUTAREDOXIN; CALF THYMUS GLUTAREDOXIN; MOLECULAR-WEIGHT THIOLS; CELL-EXTRACTS; CORYNEBACTERIUM-NEPHRIDII; THIOREDOXIN REDUCTASE; METHANOGENIC BACTERIA; DEOXYRIBONUCLEOTIDES	A small redox-active protein has been purified to homogeneity from cell-free extracts of the strictly anaerobic thermophilic methanogen, Methanobacterium thermoautotrophicum (strain Marburg). The purification consisted of streptomycin sulfate and acid treatments and three chromatographic steps using Sephadex G-75, Mono Q HR 10/10, and Superose 12 HR 10/30 columns. When these procedures were carried out under strictly anaerobic conditions, approximately 3 mg of this protein could be isolated from 45 g of wet cell paste. Like the thioredoxins and glutaredoxins, it is a small acidic protein (pI = 4.2) consisting of 83 amino acids (M(r) = 9136). In the presence of dithiothreitol or dihydrolipoate, the protein serves as a hydrogen donor for the ribonucleotide reductase from Escherichia coli, and it catalyzes the reduction of insulin. However, it does not interact with the thioredoxin reductases from E. coli or Corynebacterium nephridii and does not function as a hydrogen donor for the ribonucleotide reductase of C. nephridii. The amino acid sequences determined by automated Edman degradation of the C-14-carboxymethylated protein and of peptides derived from trypsin and chymotrypsin digestions show a redox-active site -Cys-Pro-Tyr-Cys-, typical of the glutaredoxins. Its amino acid sequence shows moderate identity with the known glutaredoxins (E. coli, yeast, rabbit bone marrow, calf thymus, and pig liver) when the proteins are aligned at the active site. The secondary structure of the glutaredoxin-like protein predicted by the Chou-Fasman procedure shows that it is similar to the known glutaredoxins. However, surprisingly, the protein does not function as a glutathione-disulfide oxidoreductase in the presence of glutathione and glutathione reductase. This glutaredoxin-like protein may be a component of a ribonucleotide-reducing system distinct from the previously described systems utilizing thioredoxin or glutaredoxin.	UNIV MINNESOTA, SCH MED,DEPT BIOCHEM,4-225 MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033776] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33776] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONY C, 1982, BIOCH METHYLOTROPHS, P296; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; EJIRI SI, 1980, ANAL BIOCHEM, V102, P393, DOI 10.1016/0003-2697(80)90173-6; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; FISCHER R, 1990, FEBS LETT, V269, P368, DOI 10.1016/0014-5793(90)81195-T; FUCHS J, 1977, J BACTERIOL, V129, P967, DOI 10.1128/JB.129.2.967-972.1977; FUCHS JA, 1989, GLUTATHIONE CHEM B B, P551; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GOSWAMI A, 1985, J BIOL CHEM, V260, P6012; GREENE RC, 1973, J BACTERIOL, V116, P230, DOI 10.1128/JB.116.1.230-234.1973; HAMMEL KE, 1983, P NATL ACAD SCI-BIOL, V80, P3681, DOI 10.1073/pnas.80.12.3681; HOGENKAMP HPC, 1987, FEBS LETT, V219, P197, DOI 10.1016/0014-5793(87)81215-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1968, EUR J BIOCHEM, V6, P475, DOI 10.1111/j.1432-1033.1968.tb00470.x; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; HOPPER S, 1989, J BIOL CHEM, V264, P20438; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; LUNDELL DJ, 1978, J BIOL CHEM, V253, P3422; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MENG M, 1981, THESIS U MINNESOTA M; MOORE EC, 1964, J BIOL CHEM, V239, P3453; NEWTON GL, 1985, J BACTERIOL, V161, P438, DOI 10.1128/JB.161.1.438-441.1985; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; POLSON A, 1980, IMMUNOL COMMUN, V9, P495, DOI 10.3109/08820138009066011; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLICHT F, 1985, NATURWISSENSCHAFTEN, V72, P328, DOI 10.1007/BF00454779; SCHONHEIT P, 1979, ARCH MICROBIOL, V123, P105, DOI 10.1007/BF00403508; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; THAUER RK, 1990, BIOCHIM BIOPHYS ACTA, V1018, P256, DOI 10.1016/0005-2728(90)90261-2; TSAI PK, 1980, J BIOL CHEM, V255, P1273; TSANG MLS, 1981, P NATL ACAD SCI-BIOL, V78, P7478, DOI 10.1073/pnas.78.12.7478; WOLFE RS, 1985, TRENDS BIOCHEM SCI, V10, P396, DOI 10.1016/0968-0004(85)90068-4; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	52	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10561	10569						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587836				2022-12-27	WOS:A1992HV09000053
J	POLAKIS, P; RUBINFELD, B; MCCORMICK, F				POLAKIS, P; RUBINFELD, B; MCCORMICK, F			PHOSPHORYLATION OF RAP1GAP INVIVO AND BY CAMP-DEPENDENT KINASE AND THE CELL-CYCLE P34CDC2 KINASE INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; GEL-ELECTROPHORESIS; EFFECTOR DOMAIN; RAS-P21 GTPASE; CDC2 KINASE; PROTEIN; BINDING; SEPARATION; INHIBITION; SEQUENCE	rap1GAP is a GTPase activating protein that specifically stimulates the GTP hydrolytic rate of the ras-related protein p21rap1. rap1GAP undergoes posttranslational modification that causes a substantial change in its mobility on sodium dodecyl sulfate-polyacrylamide gels. At least part of this modification is due to the phosphorylation. Expression of a rap1GAP cDNA in insect cells labeled with P-32(i) resulted in high level incorporation of radioactivity into serine residues of the expressed protein. Purified raplGAP was phosphorylated in vitro by cAMP-dependent kinase and the cell cycle p34cdc2 kinase. The molar ratio of incorporated phosphate/rap1GAP was approximately 3 by cAMP-dependent kinase and 2 by p34cdc2. The sites of phosphorylation by both kinases were localized to a 100-residue segment contained in the carboxyl-terminal region of the predicted primary structure of rap1GAP. Highly favorable recognition sequences for the two kinases are contained within this fragment and are proposed as the sites of phosphorylation. Treatment of SK-MEL-3 cells with dibutyryl cAMP promoted phosphorylation of rap1GAP in vivo. Based on the results of comparative phosphopeptide mapping the sites of phosphorylation in vivo and in vitro are identical.			POLAKIS, P (corresponding author), CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775	NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER; NCI NIH HHS [CA51992-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1990, J BIOL CHEM, V265, P7104; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TOURNIER S, 1991, J BIOL CHEM, V266, P19018	28	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10780	10785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587853				2022-12-27	WOS:A1992HV09000086
J	WALKER, B; KRISHNASASTRY, M; ZORN, L; KASIANOWICZ, J; BAYLEY, H				WALKER, B; KRISHNASASTRY, M; ZORN, L; KASIANOWICZ, J; BAYLEY, H			FUNCTIONAL EXPRESSION OF THE ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS-AUREUS IN INTACT ESCHERICHIA-COLI AND IN CELL LYSATES - DELETION OF 5 C-TERMINAL AMINO-ACIDS SELECTIVELY IMPAIRS HEMOLYTIC-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MEMBRANE DAMAGE; REGULATORY SUBUNIT; TOXIN; BINDING; SITE; MECHANISM; CHANNEL; GENE; MUTAGENESIS	The alpha-hemolysin gene from Staphylococcus aureus, excluding the 5' region encoding the hydrophobic leader sequence, was amplified from genomic DNA. The identity of the disputed C terminus has been confirmed and revisions made to the internal sequence. The hemolysin is expressed at high levels in Escherichia coli and has been purified to homogeneity from this source. In addition, active [S-35-Met]alpha-hemolysin of high specific radioactivity can be generated in an E. coli transcription-translation system. By criteria based on protein chemistry, and biological and electrophysiological assays, the recombinant polypeptide is closely similar to the staphylococcal polypeptide ruling out the possibility of functionally important posttranslational modifications in S. aureus. Convenient new assays utilizing the S-35-labeled polypeptide to measure erythrocyte binding, oligomer formation in detergent and on target cells, and hemolysis have been developed. They have been used to demonstrate that a deletion mutant of alpha-hemolysin, in which five C-terminal amino acids are absent, is severely compromised in its ability both to oligomerize and to lyse rabbit erythrocytes. The mutant polypeptide nevertheless binds tightly to erythrocytes as a monomer, strengthening the idea that oligomerization is required for cell lysis.	UNIV MASSACHUSETTS,CTR MED,GRAD SCH BIOMED SCI,WORCESTER,MA 01655; NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	WALKER, B (corresponding author), WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545, USA.			Bayley, Hagan/0000-0003-2499-6116				ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BAYLEY H, 1991, MATER RES SOC SYMP P, V218, P69; BHAKDI S, 1983, TRENDS BIOCHEM SCI, V8, P134, DOI 10.1016/0968-0004(83)90237-2; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2342, DOI 10.1021/bi00656a015; CESCATTI L, 1991, J MEMBRANE BIOL, V119, P53, DOI 10.1007/BF01868540; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; COOPER LZ, 1966, J BACTERIOL, V91, P1686, DOI 10.1128/JB.91.5.1686-1692.1966; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; KASIANOWICZ J J, 1991, Biophysical Journal, V59, p458A; KATO I, 1980, TOXICON, V18, P361, DOI 10.1016/0041-0101(80)90018-5; KEHOE M, 1983, INFECT IMMUN, V41, P1105, DOI 10.1128/IAI.41.3.1105-1111.1983; KRASILNIKOV OV, 1988, GEN PHYSIOL BIOPHYS, V7, P467; KRASILNIKOV OV, 1989, GEN PHYSIOL BIOPHYS, V8, P213; KURET J, 1988, J BIOL CHEM, V263, P9149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MAKOFF AJ, 1989, NUCLEIC ACIDS RES, V17, P10191, DOI 10.1093/nar/17.24.10191; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; Montal M, 1974, Methods Enzymol, V32, P545; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; OREILLY M, 1986, MICROB PATHOGENESIS, V1, P125, DOI 10.1016/0882-4010(86)90015-X; PEDERZOLLI C, 1991, J MEMBRANE BIOL, V119, P41, DOI 10.1007/BF01868539; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SIX HR, 1973, BIOCHEMISTRY-US, V12, P2672, DOI 10.1021/bi00738a019; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THELESTAM M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P245, DOI 10.1016/0005-2736(91)90399-S; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017	45	88	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10902	10909						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587866				2022-12-27	WOS:A1992HV09000103
J	DECLERCQ, N; HEMSCHOOTE, K; DEVOS, A; PEETERS, B; HEYNS, W; ROMBAUTS, W				DECLERCQ, N; HEMSCHOOTE, K; DEVOS, A; PEETERS, B; HEYNS, W; ROMBAUTS, W			THE 4.4-KILODALTON PROLINE-RICH POLYPEPTIDES OF THE RAT VENTRAL PROSTATE ARE THE PROTEOLYTIC PRODUCTS OF A 637-KILODALTON PROTEIN DISPLAYING HIGHLY REPETITIVE SEQUENCES AND ENCODED IN A SINGLE EXON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID BINDING-PROTEIN; MULTIGENE FAMILY; SUBMANDIBULAR-GLAND; PLASMID DNA; GENE; ELEMENT; HYBRIDIZATION; TRANSCRIPTION; ORGANIZATION; UPSTREAM	We have determined the complete sequence of the 637-kilodalton precursor for the proline-rich polypeptides (PRPs). This protein is encoded in one large exon of a single copy gene. The acidic precursor of 5761 residues comprises a signal peptide and three large domains displaying a high proline content (11-15%). The sequence of domain A (928 residues) is unique and contains several small clusters of acidic amino acids. Domain B (830 residues) exhibits seven tandem repeats, four of them displaying a strongly diverged sequence. In domain C (3914 residues) 39 units, of which only 8 are degenerate, occur in a tandem repeat. Their sequences of 100 amino acids shows a high structural similarity (76-92%) and contains all the PRP variants which are produced by specific proteolytic processing. The COOH-terminal part (35 residues) is basic. Two variant PRP-precursor alleles occur which slightly differ in the number of repeats in domain C. The high degree of sequence conservation within the repeat regions suggests that the gene presumably evolved by multiple amplification and dispersion of two internal segments. In the 5097-base pair genomic region 5' upstream from the translation start, several control elements for transcription are recognized. A potential binding site for the Sp1 factor (GGGCGG) separated by 47 nucleotides from an initiator motif, most probably elements of the promoter, is detected in the vicinity of the ATG codon. Several putative androgen response elements (TGTYCT) are found in the 5' adjacent region and far upstream two Alu type III repeats and two (CA)n repeats are located. These results provide the basis for a detailed study of the androgen-regulated and tissue-specific expression of the PRP-precursor gene.	CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE,AFDELING BIOCHEM, CAMPUS GASTHUISBERG,HEREST 49, B-3000 LOUVAIN, BELGIUM	KU Leuven								ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1985, J BIOL CHEM, V260, P5863; ANN DK, 1988, J BIOL CHEM, V263, P10887; BAARENDS WM, 1990, MOL CELL ENDOCRINOL, V74, P75, DOI 10.1016/0303-7207(90)90207-O; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHAPDELAINE P, 1991, DNA CELL BIOL, V10, P49, DOI 10.1089/dna.1991.10.49; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1989, J MOL ENDOCRINOL, V3, P93, DOI 10.1677/jme.0.0030093; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; DELAEY B, 1987, NUCLEIC ACIDS RES, V15, P1627, DOI 10.1093/nar/15.4.1627; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DIRCKX L, 1987, THESIS KU LEUVEN BEL; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEINRICH G, 1987, J BIOL CHEM, V262, P5262; HEMSCHOOTE K, 1988, J BIOL CHEM, V263, P19159; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HEYNS W, 1983, BIOCHEM BIOPH RES CO, V111, P172, DOI 10.1016/S0006-291X(83)80132-6; HEYNS W, 1982, J BIOL CHEM, V257, P7407; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HURST HC, 1984, NUCLEIC ACIDS RES, V12, P4313, DOI 10.1093/nar/12.10.4313; HURST HC, 1983, EMBO J, V2, P769, DOI 10.1002/j.1460-2075.1983.tb01498.x; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; JOSEPH DR, 1988, MOL ENDOCRINOL, V2, P3, DOI 10.1210/mend-2-1-3; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; PARKER M, 1982, NUCLEIC ACIDS RES, V10, P5121, DOI 10.1093/nar/10.17.5121; PEETERS B, 1983, J BIOL CHEM, V258, P4206; PERRY ST, 1985, REGULATION ANDROGEN, P167; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; ROSINSKICHUPIN I, 1990, J BIOL CHEM, V265, P10709; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; SAFFER JD, 1984, NUCLEIC ACIDS RES, V12, P4769, DOI 10.1093/nar/12.11.4769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; VISKOCHIL DH, 1983, J BIOL CHEM, V258, P8861; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; ZHANG J, 1989, CYTOGENET CELL GENET, V52, P197, DOI 10.1159/000132877	49	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9884	9894						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577819				2022-12-27	WOS:A1992HT96500069
J	FLINK, IL; EDWARDS, JG; BAHL, JJ; LIEW, CC; SOLE, M; MORKIN, E				FLINK, IL; EDWARDS, JG; BAHL, JJ; LIEW, CC; SOLE, M; MORKIN, E			CHARACTERIZATION OF A STRONG POSITIVE CIS-ACTING ELEMENT OF THE HUMAN BETA-MYOSIN HEAVY-CHAIN GENE IN FETAL-RAT HEART-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CREATINE-KINASE GENE; THYROID-HORMONE; SKELETAL-MUSCLE; ALPHA-MYOSIN; TRANSCRIPTIONAL CONTROL; VENTRICULAR MYOCARDIUM; REGULATED EXPRESSION; MOLECULAR-CLONING; COMPLETE SEQUENCE	A strong positive element within the proximal promoter region of the human beta-myosin heavy chain (beta-MHC) gene that is required for high level expression in primary cultures of fetal rat heart cells was localized by transient assays and DNase I footprinting to positions-277/-298. Using gel shift studies, this sequence was found to bind specifically at high affinity (K(d) almost-equal-to 4 X 10(-9) M) to a transcriptional factor (beta-F1) found in nuclear extracts from rabbit heart. Dimethyl sulfate interference studies suggested that beta-F1 may bind as a dimer to two hexameric imperfect direct repeats containing the consensus sequence 5'-(C/G)-T-G-(T/A)-G-G-3". Gel shift analyses suggested that beta-F1 is related to the M-CAT factor, which is known to control muscle-specific expression of the cardiac troponin T gene. A clustered mutation of the region between the putative binding half-sites and within the "M-CAT"-like domain abolished beta-MHC promoter activity. The sequence of the Positive element also contains binding motifs for several transcriptional factors that regulate viral and cellular genes, including AP4, AP5, TEF-1, and MyoD-like proteins. When multiple copies of the beta-MHC element were inserted downstream from the transcriptional initiation site of the thymidine kinase gene, it did not act as a classical enhancer, showing some dependence upon orientation.	UNIV ARIZONA,HLTH SCI CTR,CTR HEART,TUCSON,AZ 85724; UNIV ARIZONA,HLTH SCI CTR,DEPT INTERNAL MED,TUCSON,AZ 85724; UNIV ARIZONA,HLTH SCI CTR,DEPT PHYSIOL & PHARMACOL,TUCSON,AZ 85724; UNIV TORONTO,CTR CARDIOVASC RES,TORONTO M5G 1L5,ONTARIO,CANADA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Toronto					NHLBI NIH HHS [P01HL20984] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGMAN Y, 1988, J IMMUNOL, V140, P2073; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRIGGS MM, 1990, DEV BIOL, V140, P253, DOI 10.1016/0012-1606(90)90075-T; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; GUSTAFSON TA, 1986, CIRC RES, V59, P194, DOI 10.1161/01.RES.59.2.194; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MATSUOKA R, 1988, AM J MED GENET, V29, P369, DOI 10.1002/ajmg.1320290217; MATSUOKA R, 1991, AM J MED GENET, V41, P537, DOI 10.1002/ajmg.1320410435; MEINNEL T, 1989, DEV BIOL, V131, P430, DOI 10.1016/S0012-1606(89)80015-6; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; MINTY A, 1986, MOL CELL BIOL, V6, P2137, DOI 10.1128/MCB.6.6.2137; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	51	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9917	9924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577822				2022-12-27	WOS:A1992HT96500073
J	REESE, JC; KATZENELLENBOGEN, BS				REESE, JC; KATZENELLENBOGEN, BS			CHARACTERIZATION OF A TEMPERATURE-SENSITIVE MUTATION IN THE HORMONE BINDING DOMAIN OF THE HUMAN ESTROGEN-RECEPTOR - STUDIES IN CELL-EXTRACTS AND INTACT-CELLS AND THEIR IMPLICATIONS FOR HORMONE-DEPENDENT TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; STEROID-BINDING; MAMMALIAN-CELLS; DNA; TRANSACTIVATION; IDENTIFICATION; PHARMACOLOGY; SEQUENCE; PROMOTER	A previous report from this laboratory (Reese, J. C., and Katzenellenbogen, B. S. (1991) J. Biol. Chem. 266, 10880-10887) identified an estrogen receptor (ER) mutant which had a similar binding affinity for estradiol as wild-type ER but displayed a dose-response shift for estradiol in transactivation studies. In this study, we have utilized hormone binding, DNA binding, and gene transfer experiments to further characterize this mutant, which contains an alanine substitution for a cysteine at amino acid 447 in the hormone binding domain of the receptor. Hormone binding studies indicate that the C447A receptor is a temperature-sensitive mutant, whose instability is only apparent at elevated temperatures, and that ligand can stabilize the mutant receptor. Western blot analysis reveals that the temperature-sensitive lose of hormone binding is not attributable to a degradation of receptor protein, but rather is an inactivation of the receptor's hormone binding ability. In addition to the loss in the hormone binding capacitY of the C447A mutant, this mutant shows a temperature-sensitive loss in the DNA binding ability of the receptor. Transactivation profiles of the mutant and wild-type receptors demonstrate that incubation of transfected cells with increasing concentrations of estradiol at more ambient temperatures shifts the mutant receptor's dose-response curves to the left, converging on the wild-type curve. Hence, these transactivation studies reveal that the dose-response shift observed for this mutant in cells reflects the measured instability of the hormone binding and DNA interaction of the C447A mutant that can be demonstrated in vitro. In addition, this temperature-sensitive ER mutant is of interest in that its DNA binding is now ligand-dependent with the result that transcriptional activation now parallels receptor occupancy by ligand, which is similar to other steroid hormone receptors.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				reese, joseph/0000-0003-3578-4266	NCI NIH HHS [CA18119] Funding Source: Medline; NIGMS NIH HHS [GM07283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROWN M, 1990, J BIOL CHEM, V265, P11238; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; FAWELL SE, 1989, MOL ENDOCRINOL, V3, P1002, DOI 10.1210/mend-3-6-1002; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; HEINEMAN.SF, 1970, P NATL ACAD SCI USA, V67, P1122, DOI 10.1073/pnas.67.3.1122; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JORDAN VC, 1984, PHARMACOL REV, V36, P245; KATZENELLENBOGEN BS, 1983, J STEROID BIOCHEM, V19, P59, DOI 10.1016/S0022-4731(83)80007-7; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; NORTHROP JP, 1985, J BIOL CHEM, V260, P6398; PAKDEL F, 1992, J BIOL CHEM, V267, P3429; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PIKE JW, 1984, SCIENCE, V224, P879, DOI 10.1126/science.6326262; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1991, J BIOL CHEM, V266, P10880; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUZUKI DT, 1970, SCIENCE, V170, P695, DOI 10.1126/science.170.3959.695; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN M, 1990, New Biologist, V2, P613; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	41	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9868	9873						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577818				2022-12-27	WOS:A1992HT96500067
J	DESCHAMPS, S; VIEL, A; GARRIGOS, M; DENIS, H; LEMAIRE, M				DESCHAMPS, S; VIEL, A; GARRIGOS, M; DENIS, H; LEMAIRE, M			MRNP4, A MAJOR MESSENGER RNA-BINDING PROTEIN FROM XENOPUS OOCYTES IS IDENTICAL TO TRANSCRIPTION FACTOR FRG-Y2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LAEVIS PREVITELLOGENIC OOCYTES; ELONGATION-FACTOR EF-1-ALPHA; 42 S PARTICLES; DODECYL-SULFATE; 5S RNA; DEVELOPMENTAL REGULATION; Y-BOX; GENE; IDENTIFICATION; RECOGNITION	Previous work has revealed a striking similarity between the sequence of mRNP4, a major mRNA-binding protein of Xenopus laevis oocytes and FRG Y2, a transcription factor specific for Y-box-containing promoters. However, the apparent molecular mass of mRNP4 exceeds by 50-60% the cDNA-deduced molecular mass of FRG Y2. To resolve this discrepancy we have measured the real molecular mass of mRNP4 by sedimentation equilibrium. The molecular mass of mRNP4 closely agrees with that of FRG Y2. We conclude that mRNP4 is identical to FRG Y2 and has a dual function in oocytes. As a DNA-binding protein, mRNP4 stimulates transcription from a specific set of promoters. As a mRNA-binding protein, mRNP4 favors accumulation of the transcripts it contributes to produce.	UNIV PIERRE & MARIE CURIE, CTR GENET MOLEC, CNRS LAB, F-91198 GIF SUR YVETTE, FRANCE; CENS, DEPT BIOL CELLULAIRE & MOLEC, BIOPHYS PROT & MEMBRANES, F-91191 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; CEA								BIENZ M, 1986, CELL, V46, P1037, DOI 10.1016/0092-8674(86)90703-8; COHEN I, 1991, NUCLEIC ACIDS RES, V19, P4753, DOI 10.1093/nar/19.17.4753; COHN EJ, 1943, PROTEINS AMINO ACIDS, P372; COZENS B, 1984, J BIOL CHEM, V259, P6248; CUMMINGS A, 1988, J CELL BIOL, V107, P45, DOI 10.1083/jcb.107.1.45; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEARSLEY AL, 1985, EUR J BIOCHEM, V150, P95, DOI 10.1111/j.1432-1033.1985.tb08993.x; Denis H, 1983, Subcell Biochem, V9, P263; DESCHAMPS S, 1991, FEBS LETT, V282, P110, DOI 10.1016/0014-5793(91)80456-D; DESCHAMPS S, 1991, J CELL BIOL, V114, P1109, DOI 10.1083/jcb.114.6.1109; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Helenius A, 1979, Methods Enzymol, V56, P734; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEMAIRE M, 1990, BIOCHEM J, V267, P431, DOI 10.1042/bj2670431; LEMAIRE M, 1989, ANAL BIOCHEM, V177, P50, DOI 10.1016/0003-2697(89)90012-2; LEMAIRE M, 1976, BIOCHEMISTRY-US, V15, P2336, DOI 10.1021/bi00656a014; LORENZ LJ, 1985, MOL CELL BIOL, V5, P2697, DOI 10.1128/MCB.5.10.2697; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIRE ML, 1976, BIOCHEMISTRY-US, V15, P5805, DOI 10.1021/bi00671a018; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; Nielsen T B, 1978, Methods Enzymol, V48, P3; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; POLLET RJ, 1979, J BIOL CHEM, V254, P30; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; REYNOLDS JA, 1970, P NATL ACAD SCI USA, V66, P1002, DOI 10.1073/pnas.66.3.1002; RICHTER JD, 1984, J BIOL CHEM, V259, P2190; RICHTER JD, 1983, J BIOL CHEM, V258, P4864; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; VERMA IM, 1984, NATURE, V308, P317, DOI 10.1038/308317a0; VIEL A, 1987, FEBS LETT, V223, P232, DOI 10.1016/0014-5793(87)80295-8; VIEL A, 1991, J BIOL CHEM, V266, P10392; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	47	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13799	13802						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629179				2022-12-27	WOS:A1992JD32500003
J	GOUT, E; BLIGNY, R; DOUCE, R				GOUT, E; BLIGNY, R; DOUCE, R			REGULATION OF INTRACELLULAR PH VALUES IN HIGHER-PLANT CELLS - C-13 AND P-31 NUCLEAR-MAGNETIC-RESONANCE STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACER-PSEUDOPLATANUS CELLS; EXTERNAL PH; P-31 NMR; PROTON TRANSPORT; PLASMA-MEMBRANE; CYTOPLASMIC PH; VACUOLAR PH; METABOLISM; NEUROSPORA	The regulation of the cytoplasmic and vacuolar pH values (pH(c) and pH(v)) in sycamore (Acer pseudoplatanus L.) cells was analyzed using P-31 and C-13 nuclear magnetic resonance spectroscopy. Suspension-cultured cells were compressed in the NMR tube and perfused with the help of an original arrangement enabling a tight control of the pH (external pH, pH(e)) of the carefully oxygenated circulating nutrient medium. Intracellular pH values were measured from the chemical shifts of: CH2-linked carboxyl groups of citric acid below pH 5.7; orthophosphate between pH 5.7 and 8.0; C-13-enriched bicarbonate over pH 8.0. pH(c) and pH(v) were independent of pH(e) over the range 4.5-7.5. In contrast intracellular pH values decreased rapidly below pH(e) 4.5 and increased progressively at pH(e) over 7.5. There was an acceleration in the rate of O2 consumption accompanied with a decrease in cytoplasmic ATP concentration as pH(e) decreased. When the rate of O2 consumption was approaching the uncoupled O2 uptake rate, a loss of pH(c) control was observed. It is concluded that as pH(e) decreased, the plasma membrane ATPase consumed more and more ATP to reject the invading H+ ions in order to maintain pH(c) at a constant value. Below pH(e) 4.5 the efficiency of the H+ pump to react to back leakage of H+ ions became insufficient, leading to an acidification of pH(c) and to an alkalinization of pH(e). On the other hand, over pH(e) 7.5 a passive influx of OH- ions was observed, and pH(c) increased proportionally to the increase of pH(e). Simultaneously appreciable amounts of organic acids (malate and citrate) were synthesized by cells during the course of the alkalinization of the cytoplasmic compartment. The synthesis of organic acids which partially counteract the alkalinization of the cytoplasmic compartment may result from a marked activation of the cytoplasmic phosphoenolpyruvate carboxylase induced by an increase in cytoplasmic bicarbonate concentration. The fluctuations of pH(v) followed a similar course to that of pH(c). It is concluded that the vacuole, which represents a potentially large H+ ions reservoir, can counteract H+ (or OH-) ion invasion observed at acidic (or alkaline) pH(e) contributing to the homeostasis of pH(c).	CEN,RESONANCE MAGNET BIOL & MED LAB,F-38041 GRENOBLE,FRANCE; UNIV GRENOBLE 1,F-38041 GRENOBLE,FRANCE; CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,F-38041 GRENOBLE,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)								BLIGNY R, 1976, PHYSIOL VEG, V14, P499; BLIGNY R, 1977, PLANT PHYSIOL, V59, P502, DOI 10.1104/pp.59.3.502; BLIGNY R, 1989, J BIOL CHEM, V264, P4888; BLIGNY R, 1989, NUCL MAGN RESON, P71; BUSH DR, 1989, PLANT PHYSIOL, V89, P1318, DOI 10.1104/pp.89.4.1318; DAVIES DD, 1986, PHYSIOL PLANTARUM, V67, P702, DOI 10.1111/j.1399-3054.1986.tb05081.x; DEAMER DW, 1987, J BIOENERG BIOMEMBR, V19, P457; EVANS FE, 1977, P NATL ACAD SCI USA, V74, P4909, DOI 10.1073/pnas.74.11.4909; FELLE H, 1987, J EXP BOT, V38, P340, DOI 10.1093/jxb/38.2.340; FOX GG, 1990, PLANT PHYSIOL, V93, P512, DOI 10.1104/pp.93.2.512; GADIAN DG, 1979, BIOL APPLICATIONS MA, P463; GENIX P, 1990, PLANT PHYSIOL, V94, P717, DOI 10.1104/pp.94.2.717; Gutmann I, 1974, METHOD ENZYMAT AN, P1585; KURKDJIAN A, 1989, ANNU REV PLANT PHYS, V40, P271, DOI 10.1146/annurev.pp.40.060189.001415; MARTIN JB, 1982, PLANT PHYSIOL, V70, P1156, DOI 10.1104/pp.70.4.1156; MATHIEU Y, 1986, PLANT PHYSIOL, V82, P846, DOI 10.1104/pp.82.3.846; NAVON G, 1979, BIOCHEMISTRY-US, V18, P4487, DOI 10.1021/bi00588a006; PFEFFER PE, 1986, PLANT PHYSIOL, V80, P77, DOI 10.1104/pp.80.1.77; PRADET A, 1983, ANNU REV PLANT PHYS, V34, P199, DOI 10.1146/annurev.pp.34.060183.001215; RAVEN JA, 1978, J EXP BOT, V29, P853, DOI 10.1093/jxb/29.4.853; RAVEN JA, 1988, NEW PHYTOL, V109, P1, DOI 10.1111/j.1469-8137.1988.tb00212.x; REBEILLE F, 1983, ARCH BIOCHEM BIOPHYS, V225, P143, DOI 10.1016/0003-9861(83)90017-6; REBEILLE F, 1982, ARCH BIOCHEM BIOPHYS, V219, P371, DOI 10.1016/0003-9861(82)90168-0; ROBERTS JKM, 1980, NATURE, V283, P870, DOI 10.1038/283870a0; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; ROBERTS JKM, 1982, PLANT PHYSIOL, V69, P1344, DOI 10.1104/pp.69.6.1344; ROBERTS JKM, 1981, BIOCHIM BIOPHYS ACTA, V639, P53, DOI 10.1016/0304-4173(81)90005-7; ROBY C, 1987, J BIOL CHEM, V262, P5000; ROSSIGNOL M, 1982, BIOCHIM BIOPHYS ACTA, V684, P195, DOI 10.1016/0005-2736(82)90005-0; SANDERS D, 1982, J GEN PHYSIOL, V80, P377, DOI 10.1085/jgp.80.3.377; SLAYMAN CL, 1987, J BIOENERG BIOMEMBR, V19, P1; SZE H, 1984, PHYSIOL PLANTARUM, V61, P683, DOI 10.1111/j.1399-3054.1984.tb05191.x; TORIMITSU K, 1984, PLANT CELL PHYSIOL, V25, P1403, DOI 10.1093/oxfordjournals.pcp.a076851	33	131	136	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13903	13909						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629190				2022-12-27	WOS:A1992JD32500021
J	NAKANISHI, T; NAKANO, A; NOMURA, K; SEKIMIZU, K; NATORI, S				NAKANISHI, T; NAKANO, A; NOMURA, K; SEKIMIZU, K; NATORI, S			PURIFICATION, GENE CLONING, AND GENE DISRUPTION OF THE TRANSCRIPTION ELONGATION-FACTOR S-II IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ASCITES TUMOR-CELLS; FACTOR-SII; STIMULATORY FACTORS; YEAST; DNA; SEQUENCE; SIMILARITY; ANTIBODY	Saccharomyces cerevisiae S-II was purified to near homogeneity as a protein stimulating RNA polymerase II. Four of seven lysyl endopeptidase-digested fragments of S-II were located in the PPR2 sequence reported previously. Analysis of a genomic clone of S-II revealed that S-II and PPR2 are the same protein consisting of 309 amino acid residues, and frame shifts were found in the sequence of PPR2 gene reported previously. Yeast S-II and mouse S-II showed high similarity in their amino acid sequences, especially in their amino-terminal and carboxyl-terminal regions. A gene disruption experiment showed that an S-II null mutant was not lethal under usual growth conditions, indicating that S-II is not essential for the growth of yeast.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo			Nakano, Akihiko/A-6420-2016; Nakano, Akihiko/G-4942-2014; Nakano, Akihiko/C-6185-2009	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X; 				AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ANDREADIS A, 1982, CELL, V31, P319, DOI 10.1016/0092-8674(82)90125-8; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KESZENMANPEREYRA D, 1988, CURR GENET, V13, P21, DOI 10.1007/BF00365751; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; VALENZUELA P, 1978, METHOD CELL BIOL, V19, P11; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	29	87	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13200	13204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618824				2022-12-27	WOS:A1992JB74600019
J	TOMITA, T; WATANABE, M; YASUDA, T				TOMITA, T; WATANABE, M; YASUDA, T			INFLUENCE OF MEMBRANE FLUIDITY ON THE ASSEMBLY OF STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN, A CHANNEL-FORMING PROTEIN, IN LIPOSOME MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y1 TUMOR-CELLS; PLASMA-MEMBRANE; PORE FORMATION; EARLY EVENTS; CHOLESTEROL; DAMAGE; MECHANISM; BILAYERS; BINDING	By use of multilamellar phosphatidylcholine (PC) liposomes of different acyl composition and cholesterol content as model membranes, we studied whether or not membrane fluidity affects the assembly process of Staphylococcus aureus alpha-toxin. Under conditions using fluid and solid membranes, we assayed accessibility (or hemolytic activity) of liposome-bound alpha-toxin to rabbit erythrocytes added, hexamerization of membrane-bound toxin using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under nondenaturating conditions, and susceptibility of liposome-bound toxin to trypsin digestion. Our data indicated 1) that alpha-toxin bound to PC membrane as a hemolytically active monomer (or reversibly bound state); 2) that when the membrane was fluidized either by phase transition of PC or by inclusion of cholesterol over 20 mol %, the hemolytically active monomer of the toxin was irreversibly converted to nonhemolytic monomer (and/or unstable oligomer) in a first-order kinetics with a t1/2 of about 1 min, and thereafter hexamerization of the toxin gradually proceeded in the following 60-90 min; 3) that alpha-toxin might have different topology and/or conformation in PC membrane, depending on the presence or absence of cholesterol in the PC membrane; and 4) that coexistence of unsaturated acyl chain-carrying PC and cholesterol was a prerequisite for efficient hexamerization of alpha-toxin in membrane. Thus, increase in membrane fluidity promoted the assembly process of S. aureus alpha-toxin.	OKAYAMA UNIV, SCH MED, OKAYAMA 700, JAPAN	Okayama University	TOMITA, T (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.							BASHFORD CL, 1986, J BIOL CHEM, V261, P9300; BELMONTE G, 1987, EUR BIOPHYS J BIOPHY, V14, P349; BERNHEIMER AW, 1965, ANN NY ACAD SCI, V128, P112, DOI 10.1111/j.1749-6632.1965.tb11633.x; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BLOMQVIST L, 1986, INFECT IMMUN, V53, P636, DOI 10.1128/IAI.53.3.636-640.1986; Chapman D., 1973, FORM FUNCTION PHOSPH, P117; DAVIS PJ, 1981, BIOCHEMISTRY-US, V20, P3633, DOI 10.1021/bi00515a051; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1982, PHARMACOL THERAPEUT, V19, P55, DOI 10.1016/0163-7258(82)90042-0; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GERLACH E, 1963, BIOCHEM Z, V337, P477; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGEE MP, 1983, INFECT IMMUN, V39, P439, DOI 10.1128/IAI.39.1.439-444.1983; MOELLBY, 1983, STAPHYLOCOCCI STAPHY, V2, P619; REICHWEIN J, 1987, INFECT IMMUN, V55, P2940, DOI 10.1128/IAI.55.12.2940-2944.1987; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; VANDIJCK PWM, 1976, BIOCHIM BIOPHYS ACTA, V455, P576, DOI 10.1016/0005-2736(76)90326-6; VERMA SP, 1976, BIOCHIM BIOPHYS ACTA, V436, P307, DOI 10.1016/0005-2736(76)90196-6; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4	30	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13391	13397						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618841				2022-12-27	WOS:A1992JB74600048
J	HATCH, GM; VANCE, DE				HATCH, GM; VANCE, DE			STIMULATION OF SPHINGOMYELIN BIOSYNTHESIS BY BREFELDIN-A AND SPHINGOMYELIN BREAKDOWN BY OKADAIC ACID TREATMENT OF RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GH3 PITUITARY-CELLS; PROTEIN KINASE-C; PHORBOL ESTERS; LIPOPROTEIN SECRETION; FATTY-ACIDS; HL-60 CELLS; PHOSPHATIDYLCHOLINE; GOLGI; DIFFERENTIATION; SPHINGOLIPIDS	Studies on sphingomyelin metabolism in rat hepatocytes were facilitated by the use of choline-deficient cells which allowed for the rapid labeling of phosphatidylcholine and as a result sphingomyelin. Pulse and pulse-chase studies with [methyl-H-3]choline and [methyl-H-3]methionine demonstrated that both compounds were effectively used for sphingomyelin biosynthesis and that newly made and pre-existing phosphatidylcholine could be used for sphingomyelin biosynthesis. When hepatocytes were incubated with brefeldin A, there was a 2.4-fold stimulation of the conversion of phosphatidylcholine into sphingomyelin. Since brefeldin A causes collapse of the cis/medial Golgi into the endoplasmic reticulum the stimulation of sphingomyelin biosynthesis could be due to more rapid access of the labeled phosphatidylcholine in the endoplasmic reticulum to sphingomyelin synthase in the collapsed Golgi. Forskolin inhibited the brefeldin A-induced stimulation of sphingomyelin biosynthesis. To investigate whether or not phosphorylation reactions regulate sphingomyelin metabolism, hepatocytes were incubated with okadaic acid, a potent inhibitor of protein phosphatases 1 and 2A. Rather than stimulating sphingomyelin biosynthesis, okadaic acid enhanced the catabolism of sphingomyelin. In contrast, a cyclic AMP analogue and forskolin had no effect on sphingomyelin biosynthesis or catabolism. Surprisingly, other pulse-chase studies demonstrated that okadaic acid stimulated the catabolism of only newly made sphingomyelin. The brefeldin A and okadaic acid effects were independent of lysosomal involvement. Subcellular fractionation studies revealed that brefeldin A and okadaic acid effects were generalized in all sphingomyelin containing membranes. The brefeldin A studies suggest that the rate of transfer of phosphatidylcholine from the endoplasmic reticulum to the Golgi might be limiting for sphingomyelin biosynthesis. The okadaic acid studies indicate that the catabolism of sphingomyelin by a sphingomyelinase is regulated by an unidentified protein kinase and by either protein phosphatase 1 and/or 2A activity in hepatocytes.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta	HATCH, GM (corresponding author), UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON T6G 2S2,ALBERTA,CANADA.							BAISTED DJ, 1988, BIOCHEM J, V253, P693, DOI 10.1042/bj2530693; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1988, FEBS LETT, V240, P221, DOI 10.1016/0014-5793(88)80372-7; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1989, J BIOL CHEM, V264, P11688; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; NELSON DH, 1982, P NATL ACAD SCI-BIOL, V79, P6690, DOI 10.1073/pnas.79.21.6690; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PELECH SL, 1983, BIOCHEM J, V216, P729; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SPENCE MW, 1989, PHOSPHATIDYLCHOLINE, P185; TOKMAKJIAN S, 1979, CAN J BIOCHEM CELL B, V57, P566, DOI 10.1139/o79-071; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; White D.A., 1973, FORM FUNCTION PHOSPH; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YAO ZM, 1988, J BIOL CHEM, V263, P2998	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12443	12451						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618752				2022-12-27	WOS:A1992HZ48300014
J	PACCAUD, JP; SIDDLE, K; CARPENTIER, JL				PACCAUD, JP; SIDDLE, K; CARPENTIER, JL			INTERNALIZATION OF THE HUMAN INSULIN-RECEPTOR - THE INSULIN-INDEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; MEDIATED INTERNALIZATION; ULTRASTRUCTURAL ANALYSIS; 3T3-L1 ADIPOCYTES; KINASE-ACTIVITY; DOWN-REGULATION; PROTEIN-KINASE; OWN RECEPTOR; COATED PITS	Internalization of the human insulin receptor requires the activation by insulin of the intrinsic kinase of the receptor. However, even in the absence of kinase activation, insulin receptors slowly enter the cells. In the present study, we adressed the question of this insulin-independent pathway of internalization. To that end, we traced insulin receptor internalization with a monoclonal antibody (mAb 83-14) directed against the alpha-subunit of the human insulin receptor. Internalization of this antibody was followed in Chinese hamster ovary (CHO) cells transfected with either normal (CHO.HIRC2) or kinase-deficient (CHO.A1018) human insulin receptors. The internalization rate of I-125-mAb 83-14 was comparable in CHO cells expressing kinase-active or kinase-inactive receptors and was similar to that observed for I-125-insulin in CHO.A1018 cells. Moreover, in CHO.HIRC2 cells, the internalization of I-125-mAb 83-14 was identical with that of its I-125-Fab fragments. Thus, mAb 83-14 represents an appropriate tool to study the constitutive internalization of the insulin receptor. Internalization of insulin receptors tagged with I-125-mAb 83-14 was unaffected by cytochalasin B, which excluded a macropinocytotic process. By contrast, internalization was sensitive to hypertonia, which abrogates clathrin-coated pits-mediated endocytosis. The implication of clathrin-coated pits in this internalization process was directly demonstrated by quantitative electron microscopic autoradiography, which showed that I-125-mAb 83-14 present on the nonvillous domain of the cell surface preferentially associate with clathrin-coated pits at all time points.	UNIV CAMBRIDGE, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND	University of Cambridge	PACCAUD, JP (corresponding author), UNIV GENEVA, UNIV MED CTR, DEPT MORPHOL, CH-1211 GENEVA, SWITZERLAND.							BACKER JM, 1990, J BIOL CHEM, V265, P16450; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CARPENTIER JL, 1991, CELL REGUL, V2, P41, DOI 10.1091/mbc.2.1.41; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CARPENTIER JL, 1982, J CELL BIOL, V95, P73, DOI 10.1083/jcb.95.1.73; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1985, DIABETES, V34, P1002, DOI 10.2337/diabetes.34.10.1002; CARPENTIER JL, 1989, CELL REGUL, V138, P519; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COBB MH, 1983, BIOCHIM BIOPHYS ACTA, V738, P1; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; FAN JY, 1983, J HISTOCHEM CYTOCHEM, V31, P859, DOI 10.1177/31.7.6343480; FREYCHET P, 1971, P NATL ACAD SCI USA, V68, P1833, DOI 10.1073/pnas.68.8.1833; GEIGER D, 1989, EXP CELL RES, V185, P33, DOI 10.1016/0014-4827(89)90034-7; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HEUSER JE, 1987, J CELL BIOL, V105, P1999, DOI 10.1083/jcb.105.5.1999; ILONDO MM, 1986, P NATL ACAD SCI USA, V83, P6460, DOI 10.1073/pnas.83.17.6460; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LYEN KR, 1983, DIABETES, V32, P648, DOI 10.2337/diab.32.7.648; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PARHAM P, 1986, HDB EXPT IMMUNOLOGY; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTHENBERG P, 1990, HDB EXPT PHARM INSUL, V92, P209; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SALISBURY JL, 1983, METHOD ENZYMOL, V98, P368; SMITH RM, 1991, J BIOL CHEM, V266, P17522; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; SMITH RM, 1985, J CELL PHYSIOL, V123, P167, DOI 10.1002/jcp.1041230204; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; THIES RS, 1990, J BIOL CHEM, V265, P10132; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WILLINGHAM MC, 1978, J CELL BIOL, V78, P480, DOI 10.1083/jcb.78.2.480; ZICK Y, 1983, J BIOL CHEM, V258, P3431	51	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13101	13106						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618809				2022-12-27	WOS:A1992HZ48300103
J	PAN, GH; SADOWSKI, PD				PAN, GH; SADOWSKI, PD			LIGATION ACTIVITY OF FLP RECOMBINASE - THE STRAND LIGATION ACTIVITY OF A SITE-SPECIFIC RECOMBINASE USING AN ACTIVATED DNA SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISM; MUTANTS	The FLP protein of the 2-mu-m plasmid of yeast belongs to the integrase family of site-specific recombinases whose members form a covalent bond between a conserved tyrosine of the recombinase and the 3'-phosphoryl group at the site of cleavage. We have made an activated DNA substrate and have shown that FLP can promote efficient strand ligation without forming a covalent intermediate with the DNA substrate. The strand ligation activity of FLP is independent of its ability to cleave DNA. Since site-specific recombinases are members of the larger class of topoisomerases, these findings may be generally applicable to other members of this class of enzymes.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cox M. M., 1989, MOBILE DNA, P661; CRAIG NL, 1988, ANNU REV GENET, V22, P77; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FRIESEN H, 1992, IN PRESS J MOL BIOL, V224; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; PROTEAU G, 1986, NUCLEIC ACIDS RES, V14, P4787, DOI 10.1093/nar/14.12.4787	12	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12397	12399						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618744				2022-12-27	WOS:A1992HZ48300002
J	KIKUCHI, Y; SASAKI, N				KIKUCHI, Y; SASAKI, N			HYPERPROCESSING OF TRANSFER-RNA BY THE CATALYTIC RNA OF RNASE-P - CLEAVAGE OF A NATURAL TRANSFER-RNA WITHIN THE MATURE TRANSFER-RNA SEQUENCE AND EVIDENCE FOR AN ALTERED CONFORMATION OF THE SUBSTRATE TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS-LIKE PARTICLES; COPIA; DROSOPHILA; ENZYME	In the transposon copia-related retrovirus-like particles of Drosophila, a 39-nucleotide-long fragment from the 5'-region of Drosophila initiator methionine tRNA (tRNA(i)Met) is used as the primer for copia minus-strand reverse transcription. This primer tRNA(i)Met fragment is thought to be produced by cleavage within the mature tRNA(i)Met sequence. We call this cleavage hyperprocessing. We have previously reported that catalytic RNA of RNase P from Escherichia coli (M1RNA) cleaves the synthetic tRNA(i)Met precursor in vitro at several sites within the mature tRNA sequence. Based on this result, we proposed a model for formation of the primer tRNA fragment involving RNase P. Here we show that natural tRNA(i)Met prepared from Drosophila adult flies can be cleaved by M1RNA. Using mutant tRNA(i)Met substrates, we also show that these cleavages are dependent on the occurrence of an altered conformation of the tRNA substrate. This is evidence that a tRNA can exist in aqueous solution at least in part in an altered conformation.			KIKUCHI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI, DEPT MOLEC BIOL, 11 MINAMIOOYA, MACHIDA, TOKYO 194, JAPAN.							ABELSON J, 1979, ANNU REV BIOCHEM, V48, P1035, DOI 10.1146/annurev.bi.48.070179.005131; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; Jowett T., 1986, DROSOPHILA, P275; KIKUCHI Y, 1986, NATURE, V323, P824, DOI 10.1038/323824a0; KIKUCHI Y, 1989, AGR BIOL CHEM TOKYO, V53, P2005, DOI 10.1080/00021369.1989.10869574; KIKUCHI Y, 1990, P NATL ACAD SCI USA, V87, P8105, DOI 10.1073/pnas.87.20.8105; Krupp G., 1983, MODIFIED NUCLEOSIDES, VII, P11; Maniatis T., 1982, MOL CLONING; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; SHIBA T, 1983, NATURE, V302, P119, DOI 10.1038/302119a0; SILVERMAN S, 1979, NUCLEIC ACIDS RES, V6, P421, DOI 10.1093/nar/6.2.421	15	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11972	11976						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601867				2022-12-27	WOS:A1992HY94700050
J	TAKI, T; ROKUKAWA, C; KASAMA, T; KON, K; ANDO, S; ABE, T; HANDA, S				TAKI, T; ROKUKAWA, C; KASAMA, T; KON, K; ANDO, S; ABE, T; HANDA, S			HUMAN MECONIUM GANGLIOSIDES - CHARACTERIZATION OF A NOVEL I-TYPE GANGLIOSIDE WITH THE NEUAC-ALPHA-2-6GAL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MILK; ERYTHROCYTE-MEMBRANES; GLYCOSPHINGOLIPIDS; OLIGOSACCHARIDES; HEXASACCHARIDE	Three monosialogangliosides containing the NeuAc-alpha-2-6Gal structure have been detected in human meconium by immunological analysis using a monoclonal antibody, MSG-15, and purified by repeated silica beads column chromatography. One was previously shown to be NeuAc-alpha-2-6Gal-beta-1-4GlcNAc-beta-1-3Gal-beta-1-4Glc-beta-1-1Cer. The remaining two were characterized by proton NMR, fast atom bombardment mass spectrometry, methylation analysis by gas chromatography-mass spectrometry, and immunological studies, and their structures were concluded to be as follows. [GRAPHICS] The second ganglioside has the same structure that was isolated from bovine buttermilk (Takamizawa, K., Iwamori, M., Mutai, M., and Nagai, Y. (1986) J. Biol. Chem. 261, 5625-5630), and this is the first description of the occurrence of the ganglioside with the branched structure with two N-acetyllactosamines linked to lactosylceramide via beta-1-6 and beta-1-3 in human tissues. The third ganglioside is a novel ganglioside with blood group I-type and a NeuAc-alpha-2-6Gal structure.	TOKYO MED & DENT UNIV,BIOMED ANAL LAB,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOCHEM,ITABASHI KU,TOKYO 173,JAPAN; KOSEI HOSP,DEPT OBSTET & GYNECOL,SHIZUOKA 420,JAPAN	Tokyo Medical & Dental University (TMDU)	TAKI, T (corresponding author), TOKYO MED & DENT UNIV,FAC MED,DEPT BIOCHEM,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.							CHIEN JL, 1978, J BIOL CHEM, V253, P4031; HAKOMORI S, 1983, BIOCHEM BIOPH RES CO, V113, P791, DOI 10.1016/0006-291X(83)91069-0; IWAMORI M, 1988, FEBS LETT, V233, P134, DOI 10.1016/0014-5793(88)81370-X; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1981, J BIOL CHEM, V256, P3512; KOBATA A, 1972, J BIOL CHEM, V247, P1525; KOBATA A, 1972, ARCH BIOCHEM BIOPHYS, V150, P273, DOI 10.1016/0003-9861(72)90036-7; MANSSON JE, 1986, FEBS LETT, V196, P259, DOI 10.1016/0014-5793(86)80259-9; MYOGA A, 1988, CANCER RES, V48, P1512; NILSSON O, 1985, BIOCHIM BIOPHYS ACTA, V835, P577, DOI 10.1016/0005-2760(85)90127-4; NILSSON O, 1981, FEBS LETT, V133, P197, DOI 10.1016/0014-5793(81)80504-2; SLOMIANY BL, 1977, CHEM PHYS LIPIDS, V20, P57, DOI 10.1016/0009-3084(77)90055-X; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; TAKAMIZAWA K, 1986, J BIOL CHEM, V261, P5625; TAKI T, 1988, LIPIDS, V23, P192, DOI 10.1007/BF02535457; TAKI T, 1990, CANCER RES, V50, P1284; TARRAGO MT, 1988, ARCH BIOCHEM BIOPHYS, V267, P353, DOI 10.1016/0003-9861(88)90041-0; UENO K, 1982, BIOCHEM BIOPH RES CO, V105, P681, DOI 10.1016/0006-291X(82)91488-7; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WIEGANDT H, 1973, H-S Z PHYSIOL CHEM, V354, P1049, DOI 10.1515/bchm2.1973.354.2.1049; YAMASHITA K, 1977, ARCH BIOCHEM BIOPHYS, V182, P546, DOI 10.1016/0003-9861(77)90536-7	22	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11811	11817						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601853				2022-12-27	WOS:A1992HY94700029
J	WANG, YC; RUBENSTEIN, PA				WANG, YC; RUBENSTEIN, PA			SPLICING OF 2 ALTERNATIVE EXON PAIRS IN BETA-TROPOMYOSIN PRE-MESSENGER-RNA IS INDEPENDENTLY CONTROLLED DURING MYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; ALPHA-TROPOMYOSIN; STRIATED-MUSCLE; SINGLE GENE; CELL LINE; ISOFORMS; CHICKEN; MOUSE; IDENTIFICATION; NONMUSCLE	Two known tissue-specific tropomyosin (TM) isoforms are produced from the rodent beta-TM gene. Skeletal muscle beta-TM uses the alternative exons 6b and 9a and the exon 9a-associated poly(A) site. Fibroblast and smooth muscle TM-1 use exons 6a and 9b and the exon-9b associated poly(A) site. We have identified a new skeletal muscle, beta-TM isoform, beta-TM2. Beta-TM2 contains exon 6b (muscle) and exon 9b (nonmuscle). Full-length beta-TM2 cDNA clones were isolated from a cDNA library of mouse muscle BC3H1 cells. Its mRNA was also found in mouse skeletal muscle tissue but not in other tissues. Beta-TM2 mRNA level and protein synthesis are differentiation-dependent, with a transient high level in the early stages of myogenesis both in BC3H1 cells and in mouse embryo limbs. Trace amounts of beta-TM3 mRNA, the other hybrid form (exons 6a + 9a), were found in less differentiated BC3H1 cells, mouse uterus, heart, and 3T3 fibroblasts but not skeletal muscle tissue. Thus, the selection of the two alternative exons appears to be controlled independently. Furthermore, during myogenesis, there is a sequential switch in the internal alternative exon, the terminal exon, and the poly(A) site from the nonmuscle to the muscle type.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC RES,IOWA CITY,IA 52242	University of Iowa; University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NHLBI NIH HHS [HL-14388] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAPLAN AI, 1983, SCIENCE, V221, P921, DOI 10.1126/science.6348946; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORRYSCHAUDIES S, 1991, J BIOL CHEM, V266, P13821; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MANIATIS T, 1982, MOL CLONING LABORATO, P458; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; RICHARDSON CC, ENZYMES, V2, P299; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; WANG YC, 1992, J BIOL CHEM, V267, P2728; WANG YC, 1988, J CELL BIOL, V106, P797, DOI 10.1083/jcb.106.3.797; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAWAKIKATAOKA Y, 1985, J BIOL CHEM, V260, P4440; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	34	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12004	12010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601870				2022-12-27	WOS:A1992HY94700055
J	YAFFE, MB; BEEGEN, H; ECKERT, RL				YAFFE, MB; BEEGEN, H; ECKERT, RL			BIOPHYSICAL CHARACTERIZATION OF INVOLUCRIN REVEALS A MOLECULE IDEALLY SUITED TO FUNCTION AS AN INTERMOLECULAR CROSS-BRIDGE OF THE KERATINOCYTE CORNIFIED ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-CELLS; CIRCULAR-DICHROISM; LINKED ENVELOPE; BETA-TURNS; PROTEINS; TRANSGLUTAMINASE; PEPTIDES; LINKING; GENE; DIFFERENTIATION	Involucrin is a 68-kDa precursor of the keratinocyte cornified envelope. During keratinocyte terminal differentiation glutamine residues of involucrin become covalently cross-linked to other envelope precursors via covalent epsilon-(gamma-glutamyl)lysine bonds. In the present study we examine the secondary and tertiary structure of human involucrin using computer algorithms, circular dichroism, and electron microscopy. Our results indicate that involucrin is an extended, flexible, rod-shaped molecule that has a length of 460 angstrom, an axial ratio of 30:1 and possesses between 50 and 75% alpha-helical content. Glutamine residues are circumferentially distributed along the length of the alpha-helical segments of the molecule, a distribution that is conserved in all species. We hypothesize that this distribution of glutamine residues together with the elongated shape of the molecule permits optimal interaction of involucrin glutamyl side chains with the lysine residues of other para-membranous proteins during transglutaminase-mediated cross-linking. Moreover, its long length allows involucrin to cross-link molecules that are separated by substantial distances in the cornified envelope. These properties allow a single involucrin molecule to form multiple cross-links, in multiple spatial planes, with other envelope precursors. Thus, the structure of involucrin is that of an ideal intermolecular cross-bridge.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043751] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07653] Funding Source: Medline; NIAMS NIH HHS [AR39750] Funding Source: Medline; NIGMS NIH HHS [GM43751] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDER AJ, 1973, METHOD ENZYMOL, V27, P675; BLANK GS, 1986, ANN NY ACAD SCI, V466, P467, DOI 10.1111/j.1749-6632.1986.tb38425.x; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BUXMAN MM, 1976, BIOCHIM BIOPHYS ACTA, V452, P356, DOI 10.1016/0005-2744(76)90185-6; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P554; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GORODESKI GI, 1989, ENDOCRINOLOGY, V126, P399; Green H, 1980, Harvey Lect, V74, P101; GREEN NM, 1972, J BIOL CHEM, V247, P6284; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; MAYS C, 1981, BIOCHEMISTRY-US, V20, P2810, DOI 10.1021/bi00513a016; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAGASAWA M, 1964, J AM CHEM SOC, V86, P538, DOI 10.1021/ja01058a002; ODERMATT E, 1982, J MOL BIOL, V159, P109, DOI 10.1016/0022-2836(82)90034-1; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PHILLIPS M, 1990, J BIOL CHEM, V265, P7804; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RORKE EA, 1991, J INVEST DERMATOL, V97, P543, DOI 10.1111/1523-1747.ep12481579; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TSENG H, 1990, MOL BIOL EVOL, V7, P293; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; YANG JT, 1982, MICRODOMAINS POLYM S, P311	46	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12233	12238						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601889				2022-12-27	WOS:A1992HY94700087
J	PIERCE, RA; KOLODZIEJ, ME; PARKS, WC				PIERCE, RA; KOLODZIEJ, ME; PARKS, WC			1,25-DIHYDROXYVITAMIN-D(3) REPRESSES TROPOELASTIN EXPRESSION BY A POSTTRANSCRIPTIONAL MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ELASTIN GENE-EXPRESSION; MESSENGER-RNA STABILITY; GROWTH-FACTOR-BETA; 5'-FLANKING REGION; DEVELOPMENTAL REGULATION; FUNCTIONAL PROMOTER; RAT TROPOELASTIN; HETEROGENEITY; INDUCTION	Tropoelastin expression is down-regulated by exposure to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), and we present data indicating that this repression is primarily controlled by a posttranscriptional mechanism. Steady-state and functional levels of tropoelastin mRNA were coordinately repressed by 10(-7) M 1,25 (OH)2D3 in fetal bovine chondrocytes, but transcription, as determined by nuclear runoff assay, was not appreciably influenced in fetal bovine chondrocytes or in rat lung fibroblasts. Similarly, exposure to 1,25(OH)2D3 did not influence chloramphenicol acetyltransferase activity expressed by a human tropoelastin promoter-expression construct in either cell type. Exposure to cycloheximide had little effect on tropoelastin mRNA levels in control cells but partially restored tropoelastin mRNA levels in cells pretreated with 1,25(OH)2D3 and prevented repression when added together with 1,25(OH)2D3. Similarly, simultaneous exposure to actinomycin D and 1,25(OH)2D3 attenuated the down-regulation of tropoelastin. These data indicate that repression of tropoelastin steady-state mRNA levels by 1,25(OH)2D3 is primarily mediated by a posttranscriptional mechanism that requires both transcription and protein synthesis for full effect.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)			Parks, William C./AAH-6786-2021		NHLBI NIH HHS [HL-41040] Funding Source: Medline; NIAMS NIH HHS [AR-07824] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADESCH DB, 1989, BIOCHEM BIOPH RES CO, V160, P382, DOI 10.1016/0006-291X(89)91667-7; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BERK JL, 1991, J BIOL CHEM, V266, P3192; Bittar, 1993, ADV MOL CELL BIOL, P133, DOI [10.1016/S1569-2558(08)60201-5, DOI 10.1016/S1569-2558(08)60201-5]; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN YQ, 1992, IN PRESS J INVEST DE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON JM, 1986, REGULATION MATRIX AC, P177; DEAK SB, 1988, J BIOL CHEM, V263, P13504; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER JA, 1990, J GERONTOL, V45, pB113, DOI 10.1093/geronj/45.4.B113; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GERSTENFELD LC, 1990, ENDOCRINOLOGY, V126, P1599, DOI 10.1210/endo-126-3-1599; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HINEK A, 1991, CONNECT TISSUE RES, V26, P155, DOI 10.3109/03008209109152434; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; INDIK Z, 1990, EXTRACELLULAR MATRIX, P221; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KATO Y, 1990, P NATL ACAD SCI USA, V87, P6522, DOI 10.1073/pnas.87.17.6522; KUHN C, 1976, LAB INVEST, V34, P372; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; MAYELAFSHAR S, 1988, J BIOL CHEM, V263, P4355; MCGOWAN SE, 1990, AM J RESP CELL MOL, V3, P369, DOI 10.1165/ajrcmb/3.4.369; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NOGUCHI A, 1990, PEDIATR RES, V28, P379, DOI 10.1203/00006450-199010000-00015; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1990, AM J RESP CELL MOL, V2, P399, DOI 10.1165/ajrcmb/2.5.399; PARKS WC, 1989, ELASTIN ELASTASES, V1, P213; PARKS WC, 1992, IN PRESS MATRIX, V12; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; PROSSER IW, 1989, AM J PATHOL, V135, P1073; RAVID A, 1984, BIOCHEM BIOPH RES CO, V123, P163, DOI 10.1016/0006-291X(84)90394-2; RUSSELL J, 1986, ENDOCRINOLOGY, V119, P2864, DOI 10.1210/endo-119-6-2864; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SCHWARTZ Z, 1989, J BONE MINER RES, V4, P199; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TOBLER A, 1988, J CLIN INVEST, V81, P1819, DOI 10.1172/JCI113525; WRENN DS, 1987, J BIOL CHEM, V262, P2244; YEH H, 1989, BIOCHEMISTRY-US, V28, P2365, DOI 10.1021/bi00432a003	51	72	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11593	11599						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597486				2022-12-27	WOS:A1992HX16900100
J	SWAROOP, M; BRADLEY, K; OHURA, T; TAHARA, T; ROPER, MD; ROSENBERG, LE; KRAUS, JP				SWAROOP, M; BRADLEY, K; OHURA, T; TAHARA, T; ROPER, MD; ROSENBERG, LE; KRAUS, JP			RAT CYSTATHIONINE BETA-SYNTHASE GENE ORGANIZATION AND ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPIONYL-COA CARBOXYLASE; SULFUR AMINO-ACIDS; ESCHERICHIA-COLI; S-ADENOSYLMETHIONINE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; HUMAN-LIVER; DNA; BIOSYNTHESIS; SUBUNIT	We elucidated the structure and alternative splicing patterns of the rat cystathionine beta-synthase gene. The gene is 20-25 kilobase pairs long, and its coding region is divided into 17 exons. These are alternatively spliced, forming four distinct mRNAs (types I through IV). The predicted open reading frames encode proteins of 61.5, 39, 60, and 52.5 kDa, respectively. Exons 13 and 16 are used alternatively and mutually exclusively. Exon 13 includes a stop codon and encodes the unique carboxyl-terminal sequence found in types II and IV. Exon 16 is present only in type I. Types I and III, which differ by 42 nucleotides (exon 16), are the predominant synthase mRNA forms in rat liver. Seventeen arginine peptides from pure liver synthase matched the deduced amino acid sequences of types I matched III. These two polypeptides are detectable in liver extracts; each exhibits enzymatic activity when expressed in transfected Chinese hamster cells. Synthase shows substantial sequence similarity with pyridoxal 5'-phosphate dependent enzymes from lower organisms. Similarity of synthase to Escherichia coli O-acetylserine (thiol)-lyase (cysK) is 52%; E. coli tryptophan synthase beta-chain (trpB), 36%; yeast serine deaminase, 33%. Lysine 116 in synthase aligns with the established pyridoxyllysine residue of these enzymes suggesting that it is the pyridoxal 5'-phosphate binding residue.	UNIV COLORADO,SCH MED,DEPT PEDIAT C233,DENVER,CO 80262; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Yale University				Swaroop, Manju/0000-0002-0576-1664	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009527] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26651] Funding Source: Medline; NIDDK NIH HHS [DK 09527] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FINKELSTEIN JD, 1983, FED PROC, V42, pA2789; GIOVANELLI J, 1987, METHOD ENZYMOL, V143, P419; GOSS SJ, 1986, J CELL SCI, V82, P309; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; KIELLANDBRANDT MC, 1984, CARLSBERG RES COMMUN, V49, P567, DOI 10.1007/BF02908685; KONDO K, 1987, J BIOL CHEM, V262, P8648; KORACEVIC D, 1977, EXPERIENTIA, V33, P1010; KRAUS JP, 1983, J BIOL CHEM, V258, P7245; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P2047, DOI 10.1073/pnas.83.7.2047; KRAUS JP, 1983, ARCH BIOCHEM BIOPHYS, V222, P44, DOI 10.1016/0003-9861(83)90500-3; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; MUNKE M, 1988, AM J HUM GENET, V42, P550; OGAWA H, 1989, J BIOL CHEM, V264, P15818; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOVBY F, 1984, J BIOL CHEM, V259, P588; SODA K, 1987, METHOD ENZYMOL, V143, P453; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647	28	142	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11455	11461						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597473				2022-12-27	WOS:A1992HX16900079
J	KIKUCHI, A; KURODA, S; SASAKI, T; KOTANI, K; HIRATA, K; KATAYAMA, M; TAKAI, Y				KIKUCHI, A; KURODA, S; SASAKI, T; KOTANI, K; HIRATA, K; KATAYAMA, M; TAKAI, Y			FUNCTIONAL INTERACTIONS OF STIMULATORY AND INHIBITORY GDP GTP EXCHANGE PROTEINS AND THEIR COMMON SUBSTRATE SMALL GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN CYTOSOL; C-TERMINAL REGION; BOTULINUM ADP-RIBOSYLTRANSFERASE; RHO GENE-PRODUCT; REGULATORY PROTEIN; SMG P21; MOLECULAR-CLONING; CATALYZED PHOSPHORYLATION; DISSOCIATION INHIBITOR; CLOSTRIDIUM-BOTULINUM	smg GDS and rho GDI are stimulatory and inhibitory GDP/GTP exchange proteins, respectively, for a group of ras p21-related small GTP-binding proteins (G proteins). rho p21 is a common substrate small G protein for both GDP/GTP exchange proteins. We examined here the functional interactions of these GDP/GTP exchange proteins with rho p21 as a substrate. smg GDS and rho GDI interacted with the GDP-bound form of rho p21 and thereby stimulated and inhibited, respectively, the dissociation of GDP. The inhibitory effect of rho GDI was much stronger than the stimulatory effect of smg GDS. The GDP-bound form of rho p21 formed a complex with rho GDI but not with smg GDS in their simultaneous presence. Since the content of smg GDS was generally less than that of rho GDI in cells, these results suggest that there is some mechanism to release the inhibitory action of rho GDI and to make rho p21 sensitive to the smg GDS action during the conversion of rhoA p21 from the GDP-bound inactive form to the GTP-bound active form in intact cells. On the other hand, rho p2 1 was previously shown to be ADP-ribosylated by bacterial ADP-ribosyltransferases, named C3 and EDIN, at Asn41 in the putative effector region of rho p21. This ADP-ribosylation was inhibited by rho GDI much more efficiently than by smg GDS. These results suggest that rho GDI may mask the putative effector region of rho p21 and thereby inhibit its interaction with the target protein even in the presence of smg GDS. Thus, both smg GDS and rho GDI are important to regulate the rho p21 activity and action in cooperation with each other.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University			KURODA, SHINYA/G-4961-2014					ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; ISOMURA M, 1991, ONCOGENE, V6, P119; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1990, J BIOL CHEM, V265, P9373; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	46	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14611	14615						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634508				2022-12-27	WOS:A1992JF08800021
J	RUTESHOUSER, EC; DECROMBRUGGHE, B				RUTESHOUSER, EC; DECROMBRUGGHE, B			PURIFICATION OF BBF, A DNA-BINDING PROTEIN RECOGNIZING A POSITIVE CIS-ACTING ELEMENT IN THE MOUSE ALPHA-1(III) COLLAGEN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS SUBUNITS; TRANSCRIPTION FACTOR; RNA-POLYMERASE; YEAST HAP2; IDENTIFICATION; GENE; UPSTREAM; ACTIVATION; INTERACT; NUCLEI	A positive cis-acting element, the B element, located between -83 and -61 in the mouse alpha-1(III) collagen promoter, binds a factor present in nuclear extracts of NIH 3T3 fibroblasts and HeLa cells. We have purified this factor using ion exchange chromatography, sequence-specific DNA affinity chromatography, and sodium dodecyl sulfate-polyacrylamide gel fractionation. The DNA sequence used for the affinity chromatography was a single-base substitution in the B element that increased the stability of the B element-protein complex by 50%. Purification of the B element-binding factor (BBF) by DNA affinity chromatography resulted in the apparent loss of most or all of the DNA-binding activity of this factor. The DNA-binding activity could, however, be reconstituted by combining two chromatographic fractions: the high-salt eluate and the column flow-through. When the partially purified high-salt eluate was size-fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis with subsequent renaturation of gel fractions from guanidine HCl, the purified BBF (apparent molecular weight of about 95,000) bound to the B element with high affinity. These results suggest that during DNA affinity purification of BBF a factor that inhibits BBF DNA binding was co-eluted with BBF. This inhibition of BBF DNA binding was reversed by the addition of the DNA affinity column flow-through. The binding of BBF to the B element of the mouse alpha-1(III) collagen promoter is therefore an apparently complex process involving interactions between BBF and other protein factors.			RUTESHOUSER, EC (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CELADA A, 1989, MOL CELL BIOL, V9, P3097, DOI 10.1128/MCB.9.7.3097; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KUHN K, 1982, IMMUNOCHEMISTRY EXTR, V1, P1; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANDEL G, 1986, P NATL ACAD SCI USA, V83, P6682; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; RUTESHOUSER EC, 1989, J BIOL CHEM, V264, P13740; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VUORIO T, 1990, J BIOL CHEM, V265, P22480	24	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14398	14404						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629225				2022-12-27	WOS:A1992JD32500092
J	VANCURA, A; HALDAR, D				VANCURA, A; HALDAR, D			REGULATION OF MITOCHONDRIAL AND MICROSOMAL PHOSPHOLIPID-SYNTHESIS BY LIVER FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-GLYCEROL 3-PHOSPHATE; RAT-LIVER; PHOSPHATIDIC-ACID; LYSOPHOSPHATIDIC ACID; ARACHIDONIC-ACID; GLYCEROPHOSPHATE ACYLTRANSFERASE; SIGNAL TRANSDUCTION; QUANTIFICATION; TRANSLOCATION; BIOSYNTHESIS	Recently we have detected and partially purified a 15-kDa cytosolic L-alpha-lysophosphatidic acid (LPA)-binding protein (LPABP), which stimulates export of LPA from mitochondria (Vancura, A., Carroll, M. A., and Haldar, D. (1991) Biochem. Biophys. Res. Commun. 175, 339-343). Now we have purified this protein to homogeneity. By Western immunoblot analysis, amino acid sequence analysis, and binding characteristics we have shown that LPABP is identical with liver fatty acid-binding protein (L-FABP). This protein binds LPA, and stimulates mitochondrial and microsomal glycerophosphate acyltransferase (GAT) and the export of LPA from both the organelles. The mitochondrially synthesized LPA exported by L-FABP can be converted to phosphatidic acid by microsomes. L-FABP also stimulates microsomal conversion of LPA to phosphatidic acid but strongly inhibits this reaction in mitochondria. However, in the absence of L-FABP mitochondria predominantly synthesize PA. Taken together, these findings are suggestive that L-FABP plays a major role in mitochondrial and microsomal phospholipid metabolism by regulating both the synthesis and utilization of LPA.	ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Saint John's University				Vancura, Ales/0000-0002-5895-1218				BANSAL MP, 1989, J BIOL CHEM, V264, P13780; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BASSUK JA, 1987, P NATL ACAD SCI USA, V84, P7547, DOI 10.1073/pnas.84.21.7547; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BUELT MK, 1991, J BIOL CHEM, V266, P12266; BURNETT DA, 1979, GASTROENTEROLOGY, V77, P241; BURRIER RE, 1986, BIOCHIM BIOPHYS ACTA, V879, P229; CARROLL MA, 1982, ARCH BIOCHEM BIOPHYS, V214, P17, DOI 10.1016/0003-9861(82)90003-0; DAAE LNW, 1973, BIOCHIM BIOPHYS ACTA, V306, P186, DOI 10.1016/0005-2760(73)90224-5; DAHLBERG E, 1980, ANAL BIOCHEM, V106, P380, DOI 10.1016/0003-2697(80)90537-0; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; FREEMAN M, 1989, BIOCHEM J, V263, P589, DOI 10.1042/bj2630589; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1979, J BIOL CHEM, V254, P4502; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HESLER CB, 1985, J BIOL CHEM, V260, P7452; HOSTETLER KY, 1982, PHOSPHOLIPIDS, P481; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MAYOREK N, 1989, J BIOL CHEM, V264, P4450; MISHKIN S, 1974, BIOCHEM BIOPH RES CO, V60, P376; MONROY G, 1972, J BIOL CHEM, V247, P6884; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NACHBAUR J, 1968, BIOCHEM BIOPH RES CO, V33, P315, DOI 10.1016/0006-291X(68)90786-9; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1976, J CLIN INVEST, V58, P632, DOI 10.1172/JCI108510; ODOHERTY PJA, 1975, FEBS LETT, V60, P256, DOI 10.1016/0014-5793(75)80725-3; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; RAZA H, 1989, BIOCHEM BIOPH RES CO, V161, P448, DOI 10.1016/0006-291X(89)92619-3; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SMITH ME, 1967, EUR J BIOCHEM, V3, P70, DOI 10.1111/j.1432-1033.1967.tb19499.x; SPECTOR AA, 1968, ANN NY ACAD SCI, V149, P768, DOI 10.1111/j.1749-6632.1968.tb53834.x; STERN W, 1978, J BIOL CHEM, V253, P8047; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; WOOD R, 1969, ARCH BIOCHEM BIOPHYS, V131, P478, DOI 10.1016/0003-9861(69)90420-2	59	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14353	14359						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629224				2022-12-27	WOS:A1992JD32500086
J	MIROUX, B; CASTEILLA, L; KLAUS, S; RAIMBAULT, S; GRANDIN, S; CLEMENT, JM; RICQUIER, D; BOUILLAUD, F				MIROUX, B; CASTEILLA, L; KLAUS, S; RAIMBAULT, S; GRANDIN, S; CLEMENT, JM; RICQUIER, D; BOUILLAUD, F			ANTIBODIES SELECTED FROM WHOLE ANTISERUM BY FUSION PROTEINS AS TOOLS FOR THE STUDY OF THE TOPOLOGY OF MITOCHONDRIAL-MEMBRANE PROTEINS - EVIDENCE THAT THE N-TERMINAL EXTREMITY OF THE 6TH ALPHA-HELIX OF THE UNCOUPLING PROTEIN IS FACING THE MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; ADP ATP CARRIER; MALTOSE-BINDING-PROTEIN; BEEF-HEART MITOCHONDRIA; ONE-STEP PURIFICATION; AMINO-ACID-SEQUENCE; NUCLEOTIDE-BINDING; FAT MITOCHONDRIA; ESCHERICHIA-COLI; STRUCTURAL RELATIONSHIP	The reactivity to freeze-thawed mitochondria or sub-mitochondrial particles of a whole antiserum raised against the uncoupling protein has been investigated. Incubation with freeze-thawed brown adipose tissue mitochondria trapped antibodies reactive toward accessible parts of the uncoupling protein. One-third to one-half of antibodies against uncoupling protein which were present in the serum remained free. These antibodies were highly reactive with the vesicles obtained by sonication of mitochondria, in which the matricial side of the inner membrane was made accessible. To define epitopes recognized by the antiserum, different fusion proteins made up of MalE protein and uncoupling protein fragments were used. Immunoaffinity chromatography, using an immobilized purified fusion protein containing amino acids 253 to 290 of uncoupling protein, selected antibodies specifically directed against this part of the protein. A more precise localization of the main epitope recognized by these antibodies is proposed. These purified antibodies reacted with the protein only in submitochondrial particles, indicating a matricial orientation of this epitope. This result, associated with other data concerning uncoupling protein or related mitochondrial carriers such as the ADP/ATP translocator and the phosphate carrier, allowed us to determine the orientation of the sixth alpha-helix of the uncoupling protein.	CNRS,UPR 1151,CTR RECH ENDOCRINOL MOLEC & DEV,9 RUE JULES HETZEL,F-92190 MEUDON,FRANCE; INST PASTEUR,CNRS,URA 144,UNITE PROGRAMMAT MOLEC TOXICOL GENET,DEPT BIOTECHNOL,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Klaus, Susanne/P-9299-2018; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017	Klaus, Susanne/0000-0001-8726-185X; Bouillaud, Frédéric R/0000-0002-7518-9237; Miroux, Bruno/0000-0002-3066-4700; Casteilla, Louis/0000-0001-9647-3248				AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; ARENDS H, 1984, EMBO J, V3, P377, DOI 10.1002/j.1460-2075.1984.tb01815.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BRANDOLIN G, 1989, BIOCHEMISTRY-US, V28, P1093, DOI 10.1021/bi00429a025; CAPOBIANCO L, 1991, BIOCHEMISTRY-US, V30, P4963, DOI 10.1021/bi00234a018; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; CASTEILLA L, 1989, NUCLEIC ACIDS RES, V17, P2131, DOI 10.1093/nar/17.5.2131; DALBON P, 1988, BIOCHEMISTRY-US, V27, P5141, DOI 10.1021/bi00414a029; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ECKERSKORN C, 1987, FEBS LETT, V226, P166, DOI 10.1016/0014-5793(87)80572-0; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FERNANDEZ M, 1987, EUR J BIOCHEM, V164, P675, DOI 10.1111/j.1432-1033.1987.tb11179.x; FERREIRA GC, 1990, J BIOL CHEM, V265, P21202; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HARLOW E, 1988, ANTIBODIES LABORATOR; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JEZEK P, 1989, EUR J BIOCHEM, V183, P89, DOI 10.1111/j.1432-1033.1989.tb14900.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; KATIYAR SS, 1989, P NATL ACAD SCI USA, V86, P2559, DOI 10.1073/pnas.86.8.2559; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1990, BIOCHEM BIOPH RES CO, V167, P784, DOI 10.1016/0006-291X(90)92094-G; KLINGENBERG M, 1989, EUR J BIOCHEM, V180, P123, DOI 10.1111/j.1432-1033.1989.tb14622.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LAUQUIN GJM, 1977, BIOCHIM BIOPHYS ACTA, V460, P331, DOI 10.1016/0005-2728(77)90219-5; LECLERC C, 1990, J IMMUNOL, V144, P3174; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; MARTINEAU P, 1991, BIO-TECHNOL, V9, P170, DOI 10.1038/nbt0291-170; MAYINGER P, 1990, EUR BIOENEGETICS C R, V6, P64; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; OCALLAGHAN D, 1990, RES MICROBIOL, V141, P963, DOI 10.1016/0923-2508(90)90136-E; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; RIAL E, 1989, EUR J BIOCHEM, V182, P187, DOI 10.1111/j.1432-1033.1989.tb14816.x; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; RODSETH LE, 1990, J MOL BIOL, V213, P607, DOI 10.1016/S0022-2836(05)80246-3; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; TUNWELL REA, 1991, BIOCHIM BIOPHYS ACTA, V1073, P585, DOI 10.1016/0304-4165(91)90234-8; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; ZARRILLI R, 1989, MOL ENDOCRINOL, V3, P1498, DOI 10.1210/mend-3-9-1498	51	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13603	13609						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618863				2022-12-27	WOS:A1992JB74600080
J	MORRIS, SM; KEPKALENHART, D; MCGILL, RL; CURTHOYS, NP; ADLER, S				MORRIS, SM; KEPKALENHART, D; MCGILL, RL; CURTHOYS, NP; ADLER, S			SPECIFIC DISRUPTION OF RENAL-FUNCTION AND GENE-TRANSCRIPTION BY CYCLOSPORINE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; UREA-CYCLE ENZYMES; MESSENGER-RNA; RAT-KIDNEY; EXPRESSION; CELLS; LIVER; TRANSPEPTIDASE; GLUTAMINASE; ACTIVATION	The effects of cyclosporin A (CsA) are cell-specific, ranging from its immunosuppressive action on cells of the immune system to a variety of nonimmunologic toxic side effects. The predominant undesirable side effects of CsA occur in the kidney. Although many toxic renal effects of CsA have been described, the molecular basis of the nephrotoxicity is unknown. Elucidation of the molecular basis for the renal action of CsA may shed light on the function of cyclophilin in nonimmune cell types. The present study demonstrates that CsA selectively reduces the gluconeogenic capacity of rat proximal tubules via a decrease in activity of phosphoenolpyruvate carboxykinase (GTP:oxaloacetate carboxy-lyase (transphosphorylating), E.C. 4.1.1.32; PEPCK). The decrease in renal PEPCK activity occurs within 3 days and reflects a corresponding reduction in renal PEPCK mRNA abundance. This, in turn, is due to a selective inhibition of renal PEPCK gene transcription. Expression of several other renal genes is unaffected by CsA, as is expression of the PEPCK gene in liver. Thus, the effects of CsA are organ-specific and do not represent a general cytotoxic effect on proximal tubule cells. These results suggest that selective inhibition of the activity of a transcription factor(s) required for expression of specific genes in renal tubules may play a role in CsA-induced nephrotoxicity.	MONTEFIORE UNIV HOSP,DIV NEPHROL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	MORRIS, SM (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261, USA.		Morris, Sidney M/I-3440-2015		NIDDK NIH HHS [DK 37124, DK 33144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BANNER C, 1988, MOL BRAIN RES, V3, P247, DOI 10.1016/0169-328X(88)90047-2; BERTY RM, 1991, J LAB CLIN MED, V118, P17; BURCH HB, 1984, J HISTOCHEM CYTOCHEM, V32, P731, DOI 10.1177/32.7.6588129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CURTHOYS NP, 1974, J BIOL CHEM, V249, P3261; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; KOPP JB, 1990, J AM SOC NEPHROL, V1, P162; KOSAKA T, 1989, FEBS LETT, V249, P42, DOI 10.1016/0014-5793(89)80011-0; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1988, BIOCHEM GENET, V26, P769, DOI 10.1007/BF02395522; MORRIS SM, 1991, PEDIATR RES, V29, P151, DOI 10.1203/00006450-199102000-00010; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MORRIS SM, 1991, TRANSPLANT P, V23, P3116; NAST CC, 1991, KIDNEY INT, V39, P631, DOI 10.1038/ki.1991.75; NEBES VL, 1990, BIOCHEM BIOPH RES CO, V166, P133, DOI 10.1016/0006-291X(90)91921-E; POGSON CI, 1975, BIOCHEM J, V152, P401, DOI 10.1042/bj1520401; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIGAL NH, 1990, BIOCHEM PHARMACOL, V40, P2201, DOI 10.1016/0006-2952(90)90712-T; TANNEN RL, 1984, KIDNEY INT, V25, P1, DOI 10.1038/ki.1984.1; TATE SS, 1974, J BIOL CHEM, V249, P7593; UCHIDA S, 1990, KIDNEY INT, V37, P380; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; VINAY P, 1981, AM J PHYSIOL, V241, pF403, DOI 10.1152/ajprenal.1981.241.4.F403; WOLF G, 1990, J AM SOC NEPHROL, V1, P918	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13768	13771						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618871				2022-12-27	WOS:A1992JB74600105
J	OHKI, R; KAWAMATA, T; KATOH, Y; HOSODA, F; OHKI, M				OHKI, R; KAWAMATA, T; KATOH, Y; HOSODA, F; OHKI, M			ESCHERICHIA-COLI DNAJ DELETION MUTATION RESULTS IN LOSS OF STABILITY OF A POSITIVE REGULATOR, CRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-MONOPHOSPHATE RECEPTOR; BACTERIOPHAGE-LAMBDA; HEAT-SHOCK; PROTEINS; REPLICATION; GENE; CLONING; PROTEOLYSIS; INITIATION; MUTANTS	The dnaJ deletion mutant K7052(lambda-dnaK) has a temperature-sensitive defect in the synthesis of beta-galactosidase. We confirmed this operon-specific and temperature-sensitive defect in cell-free extracts prepared from the mutant cells and found that the missing factor was CRP. In the mutant, the cellular concentration of CRP was too low to allow the expression of the lac operon at a nonpermissive temperature. Introduction of a CRP over-producing plasmid into the dnaJ deletion mutant suppressed the defect of beta-galactosidase synthesis. The lower content of CRP in the mutant was found to result from extreme instability of the protein. These results strongly suggested that the heat shock protein dnaJ is involved in the stabilization (or degradation) of CRP.	SAITAMA CANC CTR,RES INST,INA,SAITAMA 362,JAPAN		OHKI, R (corresponding author), KYORIN UNIV,SCH HLTH SCI,DEPT MOLEC BIOL,476 MIYASHITA,MITAKA,TOKYO 181,JAPAN.							AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; AMES GFL, 1974, J BIOL CHEM, V249, P634; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; DYK TKV, 1989, NATURE, V342, P451; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; HOPKINS AS, 1976, J MOL BIOL, V107, P549, DOI 10.1016/S0022-2836(76)80082-4; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; KUNG HF, 1974, ARCH BIOCHEM BIOPHYS, V160, P168, DOI 10.1016/S0003-9861(74)80023-8; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; MAKI S, 1983, MOL GEN GENET, V191, P231, DOI 10.1007/BF00334819; Maniatis T., 1982, MOL CLONING LABORATO, P76; MILLER JH, 1972, EXPT MOL GENETICS, P419; MIZUSAWA S, 1982, GENE, V20, P317, DOI 10.1016/0378-1119(82)90200-1; OHKI M, 1987, J BACTERIOL, V169, P1917, DOI 10.1128/jb.169.5.1917-1922.1987; OHKI M, 1979, BACTERIAL OUTER MEMB, P293; OHKI R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P94, DOI 10.1016/0167-4781(89)90085-7; OHKI R, 1975, J BACTERIOL, V123, P815, DOI 10.1128/JB.123.3.815-823.1975; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUNSHINE M, 1977, MOL GEN GENET, V151, P27, DOI 10.1007/BF00446909; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13180	13184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618821				2022-12-27	WOS:A1992JB74600016
J	PAI, SB; PAI, RB; JOHNSTON, RN				PAI, SB; PAI, RB; JOHNSTON, RN			OVEREXPRESSION OF C-MYC BY AMPLIFICATION OF NEGATIVE PROMOTER DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MODULATE EXPRESSION; GENE-EXPRESSION; PROTO-ONCOGENE; CELLS; ELEMENT; DNA; FOS; AUTOREGULATION; TRANSCRIPTION; UPSTREAM	Amplification of myc proto-oncogenes has been reported in many human malignancies, but whether the amplified genes are properly regulated has not been well studied. Transcription factors that control gene expression are of limited abundance, and we have previously shown (Johnston, R. N., and Kucey, B. L. (1988) Science 242, 1551-1554) that amplified heat shock promoter sequences can compete with natural heat shock genes for these factors, resulting in heat shock gene disregulation. To establish whether proto-oncogenes may also be disregulated in this manner, a previously identified negative regulatory domain from the human c-myc promoter was amplified by up to 800-fold in Chinese hamster ovary cells. The amplified cells showed up to a 14-fold increase in hamster c-myc transcript abundance when compared with controls and also displayed reduced doubling times, enhanced incorporation of tritiated thymidine, elevated growth in soft agar, and a fusiform morphology, consistent with an elevation in the degree of cellular transformation. We infer that overexpression of endogenous hamster c-myc genes in the experimental cells was elicited in trans by sequestration of an inhibitory factor or complex that bound to excess nonfunctional human c-myc promoter domains. The transcriptional inhibitory activity we detect is consistent with anti-oncogene function.	UNIV CALGARY, DEPT MED BIOCHEM, CALGARY T2N 4N1, ALBERTA, CANADA	University of Calgary			Johnston, Randal/B-9247-2009					BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GASSER CS, 1986, J BIOL CHEM, V261, P6938; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LANG JC, 1988, BRIT J CANCER, V58, P62; LANG JC, 1991, ONCOGENE, V6, P2067; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1	31	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12428	12431						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618750				2022-12-27	WOS:A1992HZ48300010
J	SKELTON, TP; KUMAR, S; SMITH, PL; BERANEK, MC; BAENZIGER, JU				SKELTON, TP; KUMAR, S; SMITH, PL; BERANEK, MC; BAENZIGER, JU			PROOPIOMELANOCORTIN SYNTHESIZED BY CORTICOTROPHS BEARS ASPARAGINE-LINKED OLIGOSACCHARIDES TERMINATING WITH SO4-4GALNAC-BETA-1,4GLCNAC-BETA-1,2MAN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PITUITARY GLYCOPROTEIN HORMONES; LIPOTROPIN PRECURSOR GENE; N-GLYCOSIDASE-F; SIALYLATED OLIGOSACCHARIDES; ANIONIC OLIGOSACCHARIDES; STRUCTURAL ELUCIDATION; BOVINE LUTROPIN; PEPTIDE; FOLLITROPIN	We have determined that greater-than-or-equal-to 80% of the Asn-linked oligosaccharides on the glycosylated form of mouse adrenocorticotropin (15-kDa adrenocorticotropin (ACTH)) bear one or more branches terminating with the sequence SO4-4GalNAc-beta-21,4GlcNAc-beta-1, 2Man-alpha (S4GGnM). Proopiomelanocortin (POMC), the precursor of ACTH, is the first example of a glycoprotein that is not a member of the glycoprotein hormone family to bear such sulfated structures. Like lutropin and thyrotropin, 15-kDa ACTH bears dibranched oligosaccharides terminating with SO4-4-GalNAc; however, at least half of the oligosaccharides on 15-kDa ACTH terminating with SO4-4-GalNAc consist of more highly branched structures that have not previously been described. Both the GalNAc-beta-1,4GlcNAc-beta-1, 2Man-4-sulfotransferase and the glycoprotein hormone-specific GalNAc-transferase are expressed in the corticotroph-derived AtT-20 cell line. A tripeptide recognition sequence, Pro-Val-Lys, similar to the Pro-Leu-Arg sequence required for recognition of glycoprotein hormone alpha- and beta-subunits by the glycoprotein hormone-specific GalNAc-transferase, is present 8 residues amino-terminal to the glycosylated Asn of 15-kDa ACTH. Thus, POMC has the features expected for specific addition of the S4GGnM sequence to its oligosaccharides. The recent discovery of a receptor in hepatic endothelial cells that recognizes oligosaccharides terminating with S4GGnM suggests these sulfated oligosaccharides will regulate the circulatory half-life of glycosylated POMC cleavage products.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Baenziger, Jacques U/E-9430-2012		NIDDK NIH HHS [R01-DK-41738] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1991, BIOL CARBOHYDRATES, V3, P1; BOURBONNAIS Y, 1985, J BIOL CHEM, V260, P5832; BUDARF ML, 1982, J BIOL CHEM, V257, P128; CHANG ACY, 1980, P NATL ACAD SCI-BIOL, V77, P4890, DOI 10.1073/pnas.77.8.4890; DROUIN J, 1985, FEBS LETT, V193, P54, DOI 10.1016/0014-5793(85)80078-8; Eipper B A, 1980, Endocr Rev, V1, P1; EVANS CJ, 1983, SCIENCE, V221, P957, DOI 10.1126/science.6308766; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, ANAL BIOCHEM, V158, P42, DOI 10.1016/0003-2697(86)90585-3; HOSHINA H, 1982, SCIENCE, V217, P63, DOI 10.1126/science.6283633; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; NAKANISHI S, 1981, EUR J BIOCHEM, V115, P429; NOTAKE M, 1983, FEBS LETT, V156, P67, DOI 10.1016/0014-5793(83)80250-6; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SKELTON TP, 1991, J BIOL CHEM, V266, P17142; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, J BIOL CHEM, V265, P874; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SRIVASTAVA V, 1989, CARBOHYD RES, V185, P163, DOI 10.1016/0008-6215(89)84031-5; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; UHLER M, 1983, J BIOL CHEM, V258, P9444; VANDANA HO, 1987, CAN J CHEM, V65, P1645	37	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12998	13006						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618797				2022-12-27	WOS:A1992HZ48300090
J	LEE, SW; ROBB, J; NAZAR, RN				LEE, SW; ROBB, J; NAZAR, RN			TRUNCATED PHENYLALANINE AMMONIA-LYASE EXPRESSION IN TOMATO (LYCOPERSICON-ESCULENTUM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PLANT DEVELOPMENT; GENE; INDUCTION; ELICITOR; SEQUENCES; INVITRO; POTATO	Southern blot analyses of genomic DNA fragments suggest there are five different classes of phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) genomic sequence in tomato (Lycopersicon esculentum). Isolation and subsequent sequence analysis of three examples from genomic libraries reveal highly homologous coding sequences but also a surprisingly high frequency of single point mutations which would truncate protein synthesis. The nucleotide sequence for one of the genes (PAL5) encodes a normal polypeptide of 721 amino acids, interrupted by a 710-base pair intron in the codon for amino acid 139. In contrast, premature stop codons, 363 triplets from the end in PAL1 and 304 triplets from the end in PAL3 would result in substantially (51-43%) shorter polypeptides that are consistent with the protein polymorphism, recently reported in alfalfa (Jorrin, J., and Dixon, R. A. (1990) Plant Physiol. 92, 447-445) but ascribed to protein degradation. S1 mapping of the mRNA termini and polymerase chain reaction analysis of cDNA transcripts indicate that at least one of these truncated coding sequences is expressed, strongly suggesting that at least some of the shorter polypeptides constitute original gene products with a potentially important function.			LEE, SW (corresponding author), UNIV GUELPH,DEPT MOLEC BIOL & GENET,GUELPH N1G 2W1,ONTARIO,CANADA.							BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BOLWELL GP, 1986, BIOCHIM BIOPHYS ACTA, V881, P210; CRAMER CL, 1989, PLANT MOL BIOL, V12, P367, DOI 10.1007/BF00017577; DIXON RA, 1983, ADV ENZYMOLOGY RELAT, V53, P1; EDWARDS K, 1985, P NATL ACAD SCI USA, V82, P6731, DOI 10.1073/pnas.82.20.6731; GERARD GF, 1987, FOCUS, V9, P5; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; JONES DH, 1984, PHYTOCHEMISTRY, V23, P1349, DOI 10.1016/S0031-9422(00)80465-3; JORRIN J, 1990, PLANT PHYSIOL, V92, P447, DOI 10.1104/pp.92.2.447; LEE SW, 1992, PLANT MOL BIOL, V18, P345, DOI 10.1007/BF00034961; LIANG X, 1989, P NATL ACAD SCI USA, V86, P9284, DOI 10.1073/pnas.86.23.9284; LIANG XW, 1989, J BIOL CHEM, V264, P14486; LOIS R, 1989, EMBO J, V8, P1641, DOI 10.1002/j.1460-2075.1989.tb03554.x; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MINAMI E, 1989, EUR J BIOCHEM, V185, P19, DOI 10.1111/j.1432-1033.1989.tb15075.x; OHL S, 1990, PLANT CELL, V2, P237; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1980, PLANT CELL PHYSIOL, V21, P137; SHARROCKS AD, 1991, BIOTECHNIQUES, V10, P426; TANAKA Y, 1989, PLANT PHYSIOL, V90, P1403, DOI 10.1104/pp.90.4.1403; VALLEJOS CE, 1986, GENETICS, V112, P93; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WILLIAMS BG, 1979, J VIROL, V29, P555, DOI 10.1128/JVI.29.2.555-575.1979	26	53	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11824	11830						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601854				2022-12-27	WOS:A1992HY94700031
J	NAGATA, Y; YAMASHIRO, S; YODOI, J; LLOYD, KO; SHIKU, H; FURUKAWA, K				NAGATA, Y; YAMASHIRO, S; YODOI, J; LLOYD, KO; SHIKU, H; FURUKAWA, K			EXPRESSION CLONING OF BETA-1,4 N-ACETYLGALACTOSAMINYLTRANSFERASE CDNAS THAT DETERMINE THE EXPRESSION OF GM2 AND GD2 GANGLIOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; PROTEIN KINASE-C; HUMAN-MELANOMA; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; PROMINENT GANGLIOSIDE; MEDIATED MODULATION; GENE-TRANSFER; SIALYL-LEX	G(M2) and G(D2) gangliosides are sialic acid-containing glycosphingolipids expressed in some normal tissues such as brain and in various tumors such as neuroblastomas, astrocytomas, and malignant melanomas. We used a eukaryotic cell transient expression system to isolate cDNA clones that determine G(M2) expression. We developed a new cell line from murine melanoma line B16 by transfecting with the polyoma T antigen gene that was suitable for this purpose. Two cDNA clones, both of which have a continuous open reading frame of 1683 base pairs, were isolated. Although the cloned cDNAs had no primary sequence similarity to reported glycosyltransferases, the deduced amino acid sequence predicted a type II transmembrane protein with an overall structure similar to other glycosyltransferases. The cDNA clones, when stably transfected, determined the expression of G(M2) in B16 cells and G(M2) and G(D2) in the human melanoma line MeWo. Northern blot analysis revealed two transcripts in all cells that expressed either G(M2) or G(D2) or both. These findings indicate that the cDNAs catalyze the transfer of GalNAc onto G(M3) and G(D2) by a beta-1,4 linkage, resulting in the synthesis of G(M2) and G(D2), respectively. Namely they suggest that these cDNAs derive from the UDP-GalNAc: G(M3)/B(D3) beta-1,4 N-acetylgalactosaminyltransferase (EC 2.4.1.92) gene.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; KYOTO UNIV,INST VIRUS RES,KYOTO 606,JAPAN; SLOAN KETTERING MEM CANC CTR,NEW YORK,NY 10021	Nagasaki University; Kyoto University; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 21445, CA 08478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHEUNG NKV, 1985, CANCER RES, V45, P2642; CUMAR FA, 1972, J BIOL CHEM, V247, P2322; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; DAVIS LG, 1986, BASIC METHODS MOL BI, P285; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KLEINMAN HK, 1979, P NATL ACAD SCI USA, V76, P3367, DOI 10.1073/pnas.76.7.3367; KOJIMA H, 1987, BIOCHEM BIOPH RES CO, V143, P716, DOI 10.1016/0006-291X(87)91413-6; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; Maniatis T., 1982, MOL CLONING LABORATO, P86; Maniatis T., 1982, MOL CLONING LABORATO, P76; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NATOLI EJ, 1986, CANCER RES, V46, P4116; PACUSZKA T, 1978, J BIOL CHEM, V253, P5839; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; THURIN J, 1986, FEBS LETT, V208, P17, DOI 10.1016/0014-5793(86)81522-8; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YODOI J, 1985, J IMMUNOL, V134, P1623	62	182	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12082	12089						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601877				2022-12-27	WOS:A1992HY94700067
J	RABOUDI, N; JULIAN, J; ROHDE, LH; CARSON, DD				RABOUDI, N; JULIAN, J; ROHDE, LH; CARSON, DD			IDENTIFICATION OF CELL-SURFACE HEPARIN HEPARAN SULFATE-BINDING PROTEINS OF A HUMAN UTERINE EPITHELIAL-CELL LINE (RL95)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SEQUENCE-ANALYSIS; EXPRESSION; PROTEOGLYCAN; GENE; CLONING; PURIFICATION; FIBRONECTIN; ENDOCYTOSIS; AFFINITY	The interaction of heparin (HP) with the cell-surface components of a human uterine epithelial carcinoma cell line (RL95) was studied. Binding of [H-3]HP to cell surfaces was saturable in a dose- and time-dependent manner. HP and certain forms of heparan sulfate (HS) efficiently compete for [H-2]HP binding. In contrast, other glycosaminoglycans, such as chondroitin sulfate, keratan sulfate, hyaluronic acid, and dermatan sulfate, do not compete for binding to these sites. Scatchard analysis revealed that [H-3]HP bound to these sites with an apparent K(D) of 0.7-0.9-mu-M and a binding capacity of 9 x 10(6) sites/cell to attached cells. EDTA-detached cells displayed a similar apparent K(D), but an approximately 2-fold increase in binding capacity. Protease digestion of cells on ice markedly reduced [H-3]HP binding, indicating that these binding sites were associated with proteins. In contrast, heparinase treatment of cells stimulated binding by approximately 2-fold, indicating that a large fraction of these binding sites were occupied with endogenous ligand. We examined the structural features of HP/HS required for HP/HS binding. O-Sulfation, substitution of amino groups, and, to a lesser extent, the presence of carboxyl groups were important recognition features of HP/HS by cell-surface HP/HS-binding sites. N-Sulfation was not required. Photoaffinity labeling with I-125-sulfosuccinimidyl 2-(p-azidosalicylamido)ethyl-1,3-dithiopropionate-HP was used to identify HP/HS-binding proteins on RL95 cell surfaces. Proteins with M(r) values of 14,000-18,500 and 31,000 were photolabeled at the surfaces of attached cells. Photolabeling was blocked by the addition of excess HP, but not chondroitin sulfate. Additional proteins with M(r) values >31,000 were photolabeled specifically on EDTA-detached cells. Moreover, the M(r) 14,00018, 500 and 31,000 proteins were retained on the EDTA-detached cells. These observations indicated that certain cell-surface HP/HS-binding proteins were not exposed when cells were attached to substrata. Proteins of similar M(r) values as the photolabeled components as well as many additional proteins were identified by heparin-agarose chromatographic selection of extracts of cells labeled metabolically with [S-35]methionine or vectorially with (NaI)-I-125 at the cell surface. Fragments of cell-surface HP/HS-binding proteins were released from intact RL95 and mouse uterine epithelial cells by mild trypsinization and isolated by heparin-agarose affinity chromatography. Three peptides with M(r) values between 6000 and 14,000 required > 0.5 M salt for elution from heparin-agarose, retained HP binding activity in a I-125-HP gel overlay assay, and selectively bound [H-2]HP in a solid-phase binding assay. Microsequencing demonstrated single unique amino-terminal sequences for each of the three peptides. Furthermore, these sequences each had similarities to other carbohydrate-binding proteins. Collectively, these studies indicate the presence of multiple HP/HS-binding proteins at the cell surface of human uterine cells. A role for some of these proteins in binding HP and certain forms of HS present in basal laminae and on peri-implantation-stage embryos is suggested by analogy with the indicated role for HS-binding proteins in mouse embryo implantation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025235, R37HD025235] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BISWAS C, 1988, J CELL PHYSIOL, V136, P147, DOI 10.1002/jcp.1041360119; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CERI H, 1990, BIOCHEM CELL BIOL, V68, P790, DOI 10.1139/o90-113; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTT A, 1986, ENDOCRINOLOGY, V118, P661, DOI 10.1210/endo-118-2-661; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; IOZZO RV, 1988, J CELL BIOCHEM, V37, P61, DOI 10.1002/jcb.240370107; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; JALKANEN M, 1987, MED BIOL, V65, P41; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KURAMOTO H, 1972, Acta Obstetrica et Gynaecologica Japonica (English Edition), V19, P47; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LEUNG PSC, 1987, J BACTERIOL, V169, P4355, DOI 10.1128/jb.169.9.4355-4360.1987; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; LOBB R, 1986, J BIOL CHEM, V261, P1924; MARASHI F, 1986, BIOCHEM CELL BIOL, V64, P277, DOI 10.1139/o86-039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MORAD N, 1984, BIOCHIM BIOPHYS ACTA, V801, P117, DOI 10.1016/0304-4165(84)90219-8; MURPHY PR, 1990, ANAL BIOCHEM, V187, P197, DOI 10.1016/0003-2697(90)90440-K; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RUOSLAHTI E, 1981, COLLAGEN REL RES, V1, P95; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT TC, 1987, J CELL PHYSIOL, V132, P255, DOI 10.1002/jcp.1041320209; YAMADA KM, 1980, J BIOL CHEM, V255, P6055	47	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11930	11939						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601862				2022-12-27	WOS:A1992HY94700044
J	SCHROTH, GP; CHOU, PJ; HO, PS				SCHROTH, GP; CHOU, PJ; HO, PS			MAPPING Z-DNA IN THE HUMAN GENOME - COMPUTER-AIDED MAPPING REVEALS A NONRANDOM DISTRIBUTION OF POTENTIAL Z-DNA-FORMING SEQUENCES IN HUMAN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE-PYRIMIDINE SEQUENCES; HANDED Z-DNA; MOLECULAR-STRUCTURE; ESCHERICHIA-COLI; Z TRANSITION; TRANSCRIPTION; TEMPLATE; INVITRO; INVIVO; TRACTS	In this work, we have predicted and mapped the potential Z-DNA-forming sequences in over one million base pairs of human DNA, containing 137 complete genes. The computer program (Z-Hunt-II) developed for this study uses a rigorous thermodynamic search strategy to map the occurrence of left-handed Z-DNA in genomic sequences. The search algorithm has been optimized to search large sequences for the potential occurrence of Z-DNA, taking into account sequence type, length, and cooperativity for a given stretch of potential Z-DNA-forming nucleotides. In this extensive data set we have identified 329 potential Z-DNA-forming sequences. The exact locations of the potential Z-DNA-forming sequences in the data set have been mapped with respect to the location of structural features of the genes. This analysis reveals a distinctly nonrandom distribution of potential Z-DNA-forming sequences across human genes and, most notably, that strong Z-DNA-forming sequences are more commonly found near the 5' ends of genes. We find that 35% of the Z-DNA-forming sequences are located upstream of the first expressed exon, while only 3% of the sequences are located downstream of the last expressed exon. The remaining 62% of the Z-DNA-forming sequences, which are located either in introns (47.1%) or exons (14.9%), are also nonrandomly distributed, with a strong bias toward locations near the site of transcription initiation. We interpret this distribution of potential Z-DNA-forming sequences toward the 5' end of human genes in terms of the well established "twin-domain model" of transcription-induced supercoiling and the effect of this topological strain on Z-DNA formation in eukaryotic cells.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,535 WENIGER HALL,CORVALLIS,OR 97331	Oregon State University			Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043133] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAATEN DC, 1988, NUCLEIC ACIDS RES, V16, P865, DOI 10.1093/nar/16.3.865; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; ELLISON MJ, 1985, P NATL ACAD SCI USA, V82, P8320, DOI 10.1073/pnas.82.24.8320; FIGUEROA N, 1988, P NATL ACAD SCI USA, V85, P9416, DOI 10.1073/pnas.85.24.9416; GIAVER GN, 1988, CELL, V55, P849; GILBERT W, 1991, NATURE, V349, P99, DOI 10.1038/349099a0; GROSS DS, 1986, MOL CELL BIOL, V6, P3010, DOI 10.1128/MCB.6.8.3010; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HAYES TE, 1985, J BIOL CHEM, V260, P8145; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; HOHEISEL JD, 1987, J MOL BIOL, V193, P447, DOI 10.1016/0022-2836(87)90259-2; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JIMENEZRUIZ A, 1991, P NATL ACAD SCI USA, V88, P31, DOI 10.1073/pnas.88.1.31; JOVIN TM, 1987, ANNU REV PHYS CHEM, V38, P521, DOI 10.1146/annurev.pc.38.100187.002513; KAGAWA TF, 1989, BIOCHEMISTRY-US, V28, P6642, DOI 10.1021/bi00442a017; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; KONOPKA AK, 1985, NUCLEIC ACIDS RES, V13, P1683, DOI 10.1093/nar/13.5.1683; LANCILLOTTI F, 1987, P NATL ACAD SCI USA, V84, P1560, DOI 10.1073/pnas.84.6.1560; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MADDOX J, 1991, NATURE, V352, P11, DOI 10.1038/352011a0; MCCLELLAN JA, 1986, NUCLEIC ACIDS RES, V14, P9291, DOI 10.1093/nar/14.23.9291; MCLEAN MJ, 1988, J BIOL CHEM, V263, P7378; MCLEAN MJ, 1988, BIOCHIM BIOPHYS ACTA, V950, P243, DOI 10.1016/0167-4781(88)90120-0; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; PANYUTIN I, 1985, J BIOMOL STRUCT DYN, V2, P1221, DOI 10.1080/07391102.1985.10507634; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; ROLLO F, 1989, J MOL EVOL, V28, P225, DOI 10.1007/BF02102480; TRIFONOV EN, 1985, FEBS LETT, V185, P197, DOI 10.1016/0014-5793(85)80769-9; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	46	181	189	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11846	11855						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601856				2022-12-27	WOS:A1992HY94700034
J	PORTLOCK, SH; LEE, Y; TOMICH, JM; TAMM, LK				PORTLOCK, SH; LEE, Y; TOMICH, JM; TAMM, LK			INSERTION AND FOLDING OF THE AMINO-TERMINAL AMPHIPHILIC SIGNAL SEQUENCES OF THE MANNITOL AND GLUCITOL PERMEASES OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOLAYERS; PROTEINS; MEMBRANE; BILAYERS; AREA	Peptides which correspond to the NH2-terminal 23 or 22 residues of the mannitol and glucitol permeases (enzymes II(mtl) and II(gut) of the bacterial phosphotransferase system; mtl-23 and gut-22) and which are believed to function in envelope targeting were synthesized chemically, and their interactions with lipid model membranes were studied. Both wild-type peptides penetrated phospholipid monolayers up to high surface pressures, and partition constants of 8.0 x 10(4) M-1 and 4.2 x 10(4) M-1, respectively, were derived from the incorporation isotherms of mtl-23 and gut-22 with monolayers of 1-palmitoyl-2-oleoyl-3-sn-phosphatidylcholine at 32 mN/m or bilayers of the same lipid. The mtl-23 peptide was highly alpha-helical in trifluoroethanol, sodium dodecyl sulfate, lysolecithin, or vesicles of 1-palmitoyl-2-oleoyl-3-sn-phosphatidylglycerol, with estimated percentages of alpha-helix ranging between 60 and 85%. The interactions with model membranes of several single site mutants (S3P, D4P, and D4K) of mtl-23 which were defective in properly assembling the mannitol permease in the cytoplasmic membrane of Escherichia coli were also studied. The contents of alpha-helix of these peptides in detergent micelles or phospholipid bilayers were not significantly changed compared with those of the wild type, suggesting that the amphiphilic NH2-terminal membrane-targeting domain could still be formed in these mutants. However, the mutants which contained a proline in positions 3 or 4, i.e. NH2-terminal to the proposed amphiphilic alpha-helix, partitioned into phospholipid monolayers with partition constants that were 2 or 4 times smaller than those of the wild type. Based on these data, a model of the amphiphilic structure of the NH2-terminal domain of the mannitol permease is discussed. This domain may interact physiologically with amphiphilic interfaces of lipids and/or proteins during membrane insertion.	CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California	PORTLOCK, SH (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908, USA.			TOMICH, JOHN M./0000-0001-7848-8307	NIAID NIH HHS [R37 AI030557, AI 30557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030557, R37AI030557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNI B, 1986, J BIOL CHEM, V261, P16398; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GROVE A, 1992, METHOD ENZYMOL, V207, P510; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; REYNOLDS JA, 1974, P NATL ACAD SCI USA, V71, P2925, DOI 10.1073/pnas.71.8.2925; ROISE D, 1988, J BIOL CHEM, V263, P4509; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; TAMM LK, 1986, BIOCHEMISTRY-US, V25, P7470, DOI 10.1021/bi00371a032; TAMM LK, 1989, J BIOL CHEM, V264, P2587; VOGEL H, 1987, BIOCHEMISTRY-US, V26, P4562, DOI 10.1021/bi00388a060; WHITE SH, 1985, P NATL ACAD SCI USA, V82, P6532, DOI 10.1073/pnas.82.19.6532; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA Y, 1991, J BIOL CHEM, V266, P17863	18	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11017	11022						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597443				2022-12-27	WOS:A1992HX16900016
J	WRIGHT, APH; GUSTAFSSON, JA				WRIGHT, APH; GUSTAFSSON, JA			GLUCOCORTICOID-SPECIFIC GENE ACTIVATION BY THE INTACT HUMAN GLUCOCORTICOID RECEPTOR EXPRESSED IN YEAST - GLUCOCORTICOID SPECIFICITY DEPENDS ON LOW-LEVEL RECEPTOR EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; HORMONE	In the presence of appropriate reporter genes mammalian nuclear receptors are competent to transactivate gene expression when expressed in yeast cells. Thus yeast genetics could be used to identify determinants of steroid specificity for these mammalian proteins. However, unlike the estrogen, progesterone, vitamin D3, and thyroid hormone receptors, the glucocorticoid receptor shows an apparently abnormal steroid specificity in yeast (Schena, M., and Yamamoto, K. (1988) Science 241, 965-967), suggesting that the expressed protein might be incorrectly folded. We show here that the glucocorticoid receptor does exhibit a normal steroid specificity in yeast cells, but only at low levels of expressed receptor protein. Thus, at least under these conditions, genetic studies on steroid specificity are possible. At least part of the abnormal specificity that is sometimes observed for the glucocorticoid receptor in yeast appears to result from an artifact of the assay system and is not due to an abnormal receptor structure. This mechanism could account for all our data and so could provide the sole explanation of the abnormal specificity observed. However, it is also possible that part of the abnormal specificity could result from structural or other changes in receptor function, which occur when the receptor expression level is increased.	KAROLINSKA INST,NOVUM,HUDDINGE UNIV HOSP,DEPT MED NUTR,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	WRIGHT, APH (corresponding author), KAROLINSKA INST,NOVUM,HUDDINGE UNIV HOSP,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN.		Wright, Anthony PH/J-8187-2015					ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; MAK P, 1989, J BIOL CHEM, V264, P21613; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; OHARANEMOTO Y, 1990, J STEROID BIOCHEM, V37, P481, DOI 10.1016/0960-0760(90)90391-W; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; WRIGHT APH, 1991, P NATL ACAD SCI USA, V88, P8283, DOI 10.1073/pnas.88.19.8283; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; WRIGHT APH, 1991, MOL ENDOCRINOL, V5, P1366, DOI 10.1210/mend-5-10-1366	18	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11191	11195						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597454				2022-12-27	WOS:A1992HX16900042
J	MURPHY, JE; KEEN, JH				MURPHY, JE; KEEN, JH			RECOGNITION SITES FOR CLATHRIN-ASSOCIATED PROTEIN-AP-2 AND PROTEIN-AP-3 ON CLATHRIN TRISKELIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; ASSEMBLY PROTEIN; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; HEAVY-CHAIN; BINDING; IDENTIFICATION; PURIFICATION; POLYPEPTIDES; RECEPTORS	AP-2 and AP-3 are cellular proteins that drive the in vitro polymerization of clathrin triskelia into cage structures. The interaction of these two types of assembly proteins (APs) with preassembled clathrin cages has been studied in order to identify the sites on the triskelia required for binding. Comparing binding of the APs to intact or to proteolytically clipped cages, we attempted to distinguish between binding to the terminal domain, the globular end of the heavy chain, and binding to the hub of the clathrin triskelia, the portion that remains assembled after trypsin treatment. AP-3 binds to intact clathrin cages but not to those that were treated with trypsin. AP-3 also bound to cages consisting solely of clathrin heavy chains; proteolysis of these cages also eliminated AP-3 binding. In addition, AP-3 did not bind to either isolated hubs or terminal domains that had been immobilized on Sepharose. These data indicate that clathrin light chains are not required for binding of AP-3, and that neither terminal domain nor hubs alone will suffice. However, an intact heavy chain is both necessary and sufficient for the binding of AP-3. Previous work has demonstrated one binding site for AP-2 on proteolyzed cages containing only clathrin hubs; the existence of a second binding site associated with the terminal domain was hypothesized. Here we provide direct evidence for recognition by AP-2 of isolated terminal domains immobilized on Sepharose and show that the core of the AP-2 molecule is responsible for this interaction. These results provide the first demonstration of a functional role for the conserved terminal domain of the clathrin heavy chain.	THOMAS JEFFERSON UNIV,SCH MED,DEPT PHARMACOL,BLSB RM 915,233 S 10TH ST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CAVANNI P, 1989, BIOCHEM BIOPH RES CO, V160, P174, DOI 10.1016/0006-291X(89)91637-9; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; HANSPAL M, 1984, J BIOL CHEM, V259, P1075; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KEEN JH, 1990, ADV CELL BIOL, V3, P153; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MUELLER SC, 1984, J CELL BIOL, V98, P341, DOI 10.1083/jcb.98.1.341; MURPHY J, 1991, J CELL BIOL, V115, P186; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	36	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10850	10855						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587861				2022-12-27	WOS:A1992HV09000096
J	SHAKINESHLEMAN, SH; REMALEY, AT; ESHLEMAN, JR; WUNNER, WH; SPITALNIK, SL				SHAKINESHLEMAN, SH; REMALEY, AT; ESHLEMAN, JR; WUNNER, WH; SPITALNIK, SL			N-LINKED GLYCOSYLATION OF RABIES VIRUS GLYCOPROTEIN - INDIVIDUAL SEQUONS DIFFER IN THEIR GLYCOSYLATION EFFICIENCIES AND INFLUENCE ON CELL-SURFACE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; SITE-DIRECTED MUTAGENESIS; HUMAN CHORIONIC-GONADOTROPIN; G-PROTEIN; OLIGOSACCHARIDE CHAINS; STRUCTURAL REQUIREMENTS; ENZYMATIC CONVERSION; VACCINIA VIRUS; ALPHA-SUBUNIT; TRANSPORT	Many eukaryotic proteins are modified by N-linked glycosylation, a process in which oligosaccharides are added to asparagine residues in the sequon Asn-X-Ser/Thr. However, not all such sequons are glycosylated. For example, rabies virus glycoprotein (RGP) contains three sequons, only two of which appear to be glycosylated in virions. To examine further the signals in proteins which regulate N-linked core glycosylation, the glycosylation efficiencies of each of the three sequons in the antigenic domain of RGP were compared. For these studies, mutants were generated in which one or more sequons were deleted by site-directed mutagenesis. Core glycosylation of these mutants was studied using two independent systems: 1) in vitro translation in rabbit reticulocyte lysate supplemented with dog pancreatic microsomes, and 2) transfection into glycosylation-deficient Chinese hamster ovary cells. Parallel results were obtained with both systems, demonstrating that the sequon at Asn37 is inefficiently glycosylated, the sequons at Asn247 and Asn319 are efficiently glycosylated, and the glycosylation efficiency of each sequon is not influenced by glycosylation at other sequons in this protein. High levels of cell surface expression of RGP in Chinese hamster ovary cells are seen with any mutant containing an intact sequon at Asn247 or Asn319, whereas low levels of cell surface expression are seen when the sequon at Asn37 is present alone; deletion of all three sequons completely blocks RGP cell surface expression. Thus, although core glycosylation at Asn37 is inefficient, it is still sufficient to support a biological function, cell surface expression. Future studies using mutagenesis of this model protein and its expression in these two well defined systems will aim to begin to unravel the rules governing core glycosylation of glycoproteins.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,220 JOHN MORGAN BLDG,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104; WISTAR INST,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute				Spitalnik, Steven/0000-0002-8528-4561	NATIONAL CANCER INSTITUTE [T32CA009140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014373] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09140-15] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM 14373-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; BURGER SR, 1991, J GEN VIROL, V72, P359, DOI 10.1099/0022-1317-72-2-359; BURKE B, 1984, EMBO J, V3, P551, DOI 10.1002/j.1460-2075.1984.tb01845.x; DUBE S, 1988, J BIOL CHEM, V263, P17516; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GIBSON R, 1981, J BIOL CHEM, V256, P456; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; GUAN JL, 1988, J BIOL CHEM, V263, P5306; HICKMAN S, 1978, J IMMUNOL, V121, P990; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOBMAN TC, 1991, VIROLOGY, V181, P768, DOI 10.1016/0042-6822(91)90915-X; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KLENK HD, 1990, IMMUNOCHEMISTRY VIRU, V2, P25; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOTWAL GJ, 1986, J BIOL CHEM, V261, P8936; KRONQUIST KE, 1978, J SUPRAMOL STR CELL, V8, P51, DOI 10.1002/jss.400080105; LAFON M, 1983, J GEN VIROL, V64, P843, DOI 10.1099/0022-1317-64-4-843; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MACHAMER CE, 1988, J BIOL CHEM, V263, P5948; Marshall R D, 1974, Biochem Soc Symp, P17; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MIZRAHI A, 1978, J BIOL CHEM, V253, P7612; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; NAKAI K, 1988, J BIOCHEM-TOKYO, V104, P693, DOI 10.1093/oxfordjournals.jbchem.a122535; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; NORRILD B, 1982, J VIROL, V43, P395, DOI 10.1128/JVI.43.2.395-402.1982; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; PITTA AM, 1989, J VIROL, V63, P3801, DOI 10.1128/JVI.63.9.3801-3809.1989; PIZER LI, 1980, J VIROL, V34, P142, DOI 10.1128/JVI.34.1.142-153.1980; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Sambrook J, 1989, MOL CLONING LABORATO; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SHEARES BT, 1988, J BIOL CHEM, V263, P12778; SMITH JS, 1984, J CLIN MICROBIOL, V19, P267, DOI 10.1128/JCM.19.2.267-272.1984; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; STRUCK DK, 1978, J BIOL CHEM, V253, P5332; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TAO MH, 1989, J IMMUNOL, V143, P2595; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WIKTOR TJ, 1984, P NATL ACAD SCI-BIOL, V81, P7194, DOI 10.1073/pnas.81.22.7194; WRIGHT KE, 1989, VIROLOGY, V171, P417, DOI 10.1016/0042-6822(89)90610-7; WUNNER WH, 1983, J GEN VIROL, V64, P1649, DOI 10.1099/0022-1317-64-8-1649; WUNNER WH, 1985, VIROLOGY, V140, P1, DOI 10.1016/0042-6822(85)90440-4; WUNNER WH, 1988, REV INFECT DIS, V10, P771; YELVERTON E, 1983, SCIENCE, V219, P614, DOI 10.1126/science.6297004	60	91	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10690	10698						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587845				2022-12-27	WOS:A1992HV09000073
J	GRIMSHAW, CE; MATTHEWS, DA; VARUGHESE, KI; SKINNER, M; XUONG, NH; BRAY, T; HOCH, J; WHITELEY, JM				GRIMSHAW, CE; MATTHEWS, DA; VARUGHESE, KI; SKINNER, M; XUONG, NH; BRAY, T; HOCH, J; WHITELEY, JM			CHARACTERIZATION AND NUCLEOTIDE BINDING-PROPERTIES OF A MUTANT DIHYDROPTERIDINE REDUCTASE CONTAINING AN ASPARTATE 37-ISOLEUCINE REPLACEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; AMINO-ACID SEQUENCE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; COENZYME SPECIFICITY; LIVER; SUBSTRATE; MECHANISM; PROTEIN; LACTATE; ENZYME	Kinetic constants for the interaction of NADH and NADPH with native rat dihydropteridine reductase (DHPR) and an Escherichia coli expressed mutant (D-37-I) have been determined. Comparison of k(cat) and K(m) values measured employing quinonoid 6,7-dimethyldihydropteridine (q-PtH2) as substrate indicate that the native enzyme has a considerable preference for NADH with an optimum k(cat)/K(m) of 12-mu-M-1 s-1 compared with a figure of 0.25-mu-M-1 s-1 for NADPH. Although the mutant enzyme still displays an apparent preference for NADH (k(cat)/K(m) = 1.2-mu-M-1 s-1) compared with NADPH (k(cat/K(m) = 0.6-mu-M-1 s-1), kinetic analysis indicates that NADH and NADPH have comparable stickiness in the D-37-I mutant. The dihydropteridine site is less affected, since the K(m) for q-PtH2 and K(is) for aminopterin are unchanged and the 14-26-fold synergy seen for aminopterin binding to E.NAD(P)H versus free E is decreased by less than 2-fold in the D-37-I mutant. No significant changes in log k(cat), and log k(cat)/K(m) versus pH profiles for NADH and NADPH were seen for the D-37-I mutant enzyme. However, the mutant enzyme is less stable to proteolytic degradation, to elevated temperature, and to increasing concentrations of urea and salt than the wild type. NADH provides maximal protection against inactivation in all cases for both the native and D-37-I mutant enzymes. Examination of the rat DHPR sequence shows a typical dinucleotide binding fold with Asp-37 located precisely in the position predicted for the acidic residue that participates in hydrogen bond formation with the 2'-hydroxyl moiety of all known NAD-dependent dehydrogenases. This assignment is consistent with x-ray crystallographic results that localize the aspartate 37 carboxyl within ideal hydrogen bonding distance of the 2'- and 3'-hydroxyl moieties of adenosine ribose in the binary E.NADH complex.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; WHITTIER INST, SAN DIEGO, CA 92093 USA; AGOVRON PHARMACEUT INC, SAN DIEGO, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego					NCI NIH HHS [CA11778] Funding Source: Medline; NCRR NIH HHS [RRO1644] Funding Source: Medline; NIGMS NIH HHS [GM19416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA011778] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019416, R37GM019416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSNES A, 1980, ARCH BIOCHEM BIOPHYS, V202, P342, DOI 10.1016/0003-9861(80)90436-1; BAILEY SW, 1983, BIOCHEMISTRY-US, V22, P1790, DOI 10.1021/bi00277a008; BLAKELY RL, 1969, FRONTIERS BIOL BIOCH, P139; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; CHEEMA S, 1973, CAN J BIOCHEM CELL B, V51, P1229, DOI 10.1139/o73-163; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CORBIER C, 1990, BIOCHEMISTRY-US, V29, P7101, DOI 10.1021/bi00482a022; CRAINE JE, 1972, J BIOL CHEM, V247, P6082; FERRI G, 1978, BIOCHIM BIOPHYS ACTA, V522, P19, DOI 10.1016/0005-2744(78)90318-2; FIRGAIRA FA, 1981, BIOCHEM J, V197, P31, DOI 10.1042/bj1970031; HEMMERICH P, 1964, PTERIDINE CHEMISTRY, P143; KAUFMAN S, 1985, FOLATES PTERINS, V2, P252; KORRI KK, 1977, CAN J BIOCHEM CELL B, V55, P1145, DOI 10.1139/o77-171; KREITMAN M, 1983, NATURE, V304, P412, DOI 10.1038/304412a0; LIND KE, 1973, EUR J BIOCHEM, V33, P67, DOI 10.1111/j.1432-1033.1973.tb02655.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTHEWS DA, 1986, J BIOL CHEM, V261, P3891; MATTHEWS DA, 1991, ARCH BIOCHEM BIOPHYS, V287, P234, DOI 10.1016/0003-9861(91)90412-C; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAKANISHI N, 1977, J BIOCHEM-TOKYO, V81, P681, DOI 10.1093/oxfordjournals.jbchem.a131504; NAKANISI N, 1982, J BIOCHEM, V92, P1033, DOI 10.1093/oxfordjournals.jbchem.a134018; NIELSEN KH, 1969, EUR J BIOCHEM, V9, P497, DOI 10.1111/j.1432-1033.1969.tb00636.x; PAI EF, 1983, J BIOL CHEM, V258, P1752; PODDAR S, 1984, BIOCHEMISTRY-US, V23, P3143, DOI 10.1021/bi00309a006; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Segel I. H., 1975, ENZYME KINETICS, P560; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; SUHADOLNIK RJ, 1977, J BIOL CHEM, V252, P4125; TAYLOR SS, 1977, J BIOL CHEM, V252, P1799; VARUGHESE KI, 1992, IN PRESS P NATL ACAD; VISCONTINI M, 1968, FORTSCHR CHEM FORSCH, V9, P605; WARD LD, 1985, METHODS ENZYMOL, V117; WEBBER S, 1978, ANAL BIOCHEM, V84, P491, DOI 10.1016/0003-2697(78)90068-4; WEBBER S, 1986, ARCH BIOCHEM BIOPHYS, V248, P358, DOI 10.1016/0003-9861(86)90432-7; WESSIAK A, 1981, J AM CHEM SOC, V103, P6996, DOI 10.1021/ja00413a052; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15334	15339						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639779				2022-12-27	WOS:A1992JG11300015
J	CARVER, TE; BRANTLEY, RE; SINGLETON, EW; ARDUINI, RM; QUILLIN, ML; PHILLIPS, GN; OLSON, JS				CARVER, TE; BRANTLEY, RE; SINGLETON, EW; ARDUINI, RM; QUILLIN, ML; PHILLIPS, GN; OLSON, JS			A NOVEL SITE-DIRECTED MUTANT OF MYOGLOBIN WITH AN UNUSUALLY HIGH O-2 AFFINITY AND LOW AUTOOXIDATION RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; LIGAND-BINDING; CARBON-MONOXIDE; CRYSTALLOGRAPHIC REFINEMENT; SYNTHETIC GENE; MUTAGENESIS; OXYGEN; MECHANISM; KINETICS; OXYMYOGLOBIN	Mutants of sperm whale myoglobin were constructed at position 29 (B10 in helix notation) to examine the effects of distal pocket size on the rates of ligand binding and autooxidation. Leu29 was replaced with Ala, Val, and Phe using the synthetic gene and Escherichia coli expression system of Springer and Sligar (Springer, B. A., and Sligar, S. G. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8961-8965). Structures of the ferric forms of Val29 and Phe29, and the oxy form of Phe29 myoglobin were determined to 1.7 angstrom by x-ray crystallography. The ferric mutant proteins are remarkably isomorphous with the wild type protein except in the immediate vicinity of residue 29. Thus, the protein structure in the distal pocket of myoglobin can accommodate either a large "hole" (i.e. Ala or Val) or a large side chain (i.e. Phe) at position 29 without perturbation of tertiary structure. Phe29 oxymyoglobin is also identical to the native oxy protein in terms of overall structure and interactions between the bound O2 and His64, Val68, Phe43, and Ile107. The distance between the nearest side chain atom of residue 29 and the second atom of the bound oxygen molecule is 3.2 angstrom in the Phe29 protein and 4.9 angstrom in native myoglobin. The equilibrium constants for O2 binding to Ala29, Val29, and Leu29 (native) myoglobin are the same, approximately 1.0 x 10(6) m-1 at 20-degrees-C, whereas that for the Phe29 protein is markedly greater, 15 x 10(6) M-1. This increase in affinity is due primarily to a 10-fold decrease in the O2 dissociation rate constant for the Phe29 mutant and appears to be the result of stabilizing interactions between the negative portion of the bound O2 dipole and the partially positive edge of the phenyl ring. Increasing the size of residue 29 causes large decreases in the rate of autooxidation of myoglobin: k(ox) = 0.24, 0.23, 0.055, and 0.005 h-1 for Ala29, Val29, Leu29 (native), and Phe29 myoglobin, respectively, in air at 37-degrees-C. Thus, the Leu29 --> Phe mutation produces a reduced protein that is remarkably stable and is expressed in E. coli as 100% MbO2. The selective pressure to conserve LeU29 at the B10 position probably represents a compromise between reducing the rate of autooxidation and maintaining a large enough O2 dissociation rate constant to allow rapid oxygen release during respiration.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	CARVER, TE (corresponding author), RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251, USA.			Olson, John/0000-0002-0760-5403	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008280] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM-08280, T32 GM008280, GM-07933] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANTLEY RE, 1992, BIOPHYS J, V61, P298; BRANTLEY RE, 1992, THESIS WM RICE U HOU; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; CARVER TE, 1990, J BIOL CHEM, V265, P20007; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FERMI G, 1981, HAEMOGLOBIN MYOGLOBI, P26; FINSEL BC, 1987, J APPL CRYSTALLOGR, V20, P53; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GREENWOO.C, 1967, J BIOL CHEM, V242, P1782; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Sambrook J, 1989, MOL CLONING LABORATO; SASSAROLI M, 1986, J BIOL CHEM, V261, P6292; SHIKAMA K, 1984, BIOCHEM J, V223, P279, DOI 10.1042/bj2230279; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; Vainshtein B. K., 1978, Soviet Physics - Crystallography, V23, P287; WALLACE WJ, 1982, J BIOL CHEM, V257, P4966; WEISS JJ, 1964, NATURE, V202, P83, DOI 10.1038/202083b0; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	34	200	201	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14443	14450						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629229				2022-12-27	WOS:A1992JD32500099
J	HAGMANN, J; GROB, M; BURGER, MM				HAGMANN, J; GROB, M; BURGER, MM			THE CYTOSKELETAL PROTEIN TALIN IS O-GLYCOSYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSCRIPTION FACTORS; N-ACETYLGLUCOSAMINE; LINKED GLCNAC; CYTOPLASMIC GLYCOPROTEINS; SMOOTH-MUSCLE; ADHESION; LOCALIZATION; VINCULIN; NUCLEAR; CELL	Talin is a 215-kDa cytoskeletal protein implicated in linking actin filaments to the plasma membrane. We show here that chicken gizzard talin is galactosylated by incubation with UDP-[H-3]galactose and galactosyltransferase. The labeled carbohydrate moiety is removed by beta-elimination and comigrates with Gal-beta-1-4GlcNAcitol, indicating that talin belongs to a recently discovered class of cytosolic proteins carrying N-acetylglucosamine (GlcNAc) O-linked to serine or threonine (Holt, G. D., and Hart, G. W. (1986) J. Biol. Chem. 261, 8049-8057). Two glycosylated sequences were identified in the tail domain of talin: ANQAIQMAXQNLVDPAXTQ and GILANQLTNDYGQLAQQ, corresponding to amino acids 1470-1488 and 1883-1899, respectively, of the mouse talin amino acid sequence (Rees, D. J. G., Ades, S. E., Singer, S. J., and Hynes, R. O. (1990) Nature 347, 685-689). The putative glycosylation sites are PAXTQ and QLTND. At most 6% of chicken gizzard talin and 3% of porcine stomach talin are galactosylated by galactosyltransferase. Furthermore, human platelet talin is not labeled at all by the procedure, indicating that it may not be glycosylated.			HAGMANN, J (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.							BECKERLE MC, 1990, CELL MOTIL CYTOSKEL, V16, P7, DOI 10.1002/cm.970160103; BECKERLE MC, 1989, J CELL BIOL, V109, P3333, DOI 10.1083/jcb.109.6.3333; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BELKIN AM, 1986, FEBS LETT, V200, P32, DOI 10.1016/0014-5793(86)80505-1; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; HART GW, 1989, CIBA F SYMP, V145, P102; HART GW, 1988, TRENDS BIOCHEM SCI, V13, P380, DOI 10.1016/0968-0004(88)90179-X; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; INABA M, 1989, J BIOL CHEM, V264, P18149; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1976, BIOCHIM BIOPHYS ACTA, V443, P428, DOI 10.1016/0005-2787(76)90506-2; MOLONY L, 1987, J BIOL CHEM, V262, P7790; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; NUCKOLLS GH, 1990, J CELL BIOL, V110, P1635, DOI 10.1083/jcb.110.5.1635; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROCHLIN MW, 1989, J CELL SCI, V92, P461; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TURNER CE, 1989, J BIOL CHEM, V264, P11938; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085	29	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14424	14428						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629228				2022-12-27	WOS:A1992JD32500096
J	KU, G; THOMAS, CE; AKESON, AL; JACKSON, RL				KU, G; THOMAS, CE; AKESON, AL; JACKSON, RL			INDUCTION OF INTERLEUKIN-1-BETA EXPRESSION FROM HUMAN PERIPHERAL-BLOOD MONOCYTE-DERIVED MACROPHAGES BY 9-HYDROXYOCTADECADIENOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; HUMAN-ENDOTHELIAL-CELLS; CHOLESTEROL DEPOSITION; HUMAN ATHEROMA; LINOLEIC-ACID; MESSENGER-RNA; CYTO-TOXICITY; BINDING-SITE; DERIVATIVES	Oxidatively modified low density lipoproteins (LDL) have recently been proposed to play a role in atherogenesis by promoting foam cell formation and endothelial cell toxicity. The purpose of the present study was to determine whether modified LDL could also induce macrophage release of interleukin 1-beta (IL-1-beta), a cytokine which enhances vascular smooth muscle cell proliferation, another feature of the atherosclerotic process. LDL were oxidatively modified by incubation with either Cu2+ (Cu2+-LDL) or human peripheral blood monocyte-derived macrophages (M-LDL). Incubation of these modified LDL with macrophages (6 x 10(6) cells/culture) resulted in a dose-dependent induction of IL-1-beta release. At 300-mu-g protein/ml, Cu2+-LDL and M-LDL induced 422 and 333 pg of IL-1-beta/culture, respectively. Saponified Cu2+-LDL and M-LDL were shown to contain 9- and 13-hydroxyoctadecadienoic acid (HODE), lipid oxidation products of linoleate. When tested for activity in macrophage culture (3 x 10(6) cells/culture), it was found that 9-HODE and 13-HODE (final concentration 33-mu-M) induced the release of 122 and 43 pg of IL-1-beta/culture, respectively, whereas untreated cells released only 4 pg of IL-1-beta/culture. Incubation of macrophages with cholesteryl-9-HODE also induced IL-1-beta release; however, the degree of induction of IL-1-beta release by 9-HODE or its cholesteryl ester relative to modified LDL suggests that other components in oxidized LDL may also contribute to IL-1-beta induction. 9-HODE was rapidly taken up by macrophages, and the kinetics were similar to IL-1-beta release. A 1.5- to 6-fold increase in the level of IL-1-beta mRNA was detected as little as 3-h post-9-HODE treatment. The induction of IL-1-beta release from human monocyte-derived macrophages by 9-HODE and cholesteryl-9-HODE suggests a role for modified LDL, and its associated linoleate oxidation products, in vascular smooth muscle cell proliferation.			KU, G (corresponding author), MARION MERRELL DOW RES INST, 2110 E GALBRAITH RD, CINCINNATI, OH 45215 USA.							BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; BROOKS JCW, 1970, BIOCHIM BIOPHYS ACTA, V202, P563; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARDIN AD, 1984, METHOD PHARMACOL, V5, P141; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; EVENSEN SA, 1983, ATHEROSCLEROSIS, V49, P23, DOI 10.1016/0021-9150(83)90004-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURNEY RM, 1988, FOCUS, V10, P1; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; HASKILL S, 1988, J IMMUNOL, V140, P1690; IKEDA U, 1990, ATHEROSCLEROSIS, V84, P183, DOI 10.1016/0021-9150(90)90089-2; KADUCE TL, 1989, J BIOL CHEM, V264, P6823; KU G, 1990, FASEB J, V4, P1645, DOI 10.1096/fasebj.4.6.2318380; KU G, 1988, AM J CARDIOL, V62, P778; LENZ ML, 1990, J LIPID RES, V31, P1043; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MOREL DW, 1983, J LIPID RES, V24, P1070; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RANKIN SM, 1990, ARTERIOSCLEROSIS, V10, pA828; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SCHADE UF, 1990, ADV EXP MED BIOL, V256, P361; SCHADE UF, 1987, BIOCHEM BIOPH RES CO, V147, P695, DOI 10.1016/0006-291X(87)90986-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	36	137	141	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14183	14188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629217				2022-12-27	WOS:A1992JD32500062
J	BORA, PS; WU, XL; SPILBURG, CA; LANGE, LG				BORA, PS; WU, XL; SPILBURG, CA; LANGE, LG			PURIFICATION AND CHARACTERIZATION OF FATTY-ACID ETHYL-ESTER SYNTHASE-II FROM HUMAN MYOCARDIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; GLUTATHIONE-S-TRANSFERASE; PROTEINS; IDENTIFICATION; HOMOGENEITY; SEQUENCE	Fatty acid ethyl ester synthases metabolize ethanol nonoxidatively in those extrahepatic organs most commonly damaged by alcohol abuse. This study was designed to isolate and purify human myocardial synthase-II, one of the enzymes responsible for catalyzing the formation of fatty acid ethyl esters. DEAE-cellulose chromatography of human myocardial cytosol at pH 8.0 separated synthase-I, synthase-II, and synthase-III activities, eluting at conductivities of 5, 7, and 11 mS, respectively. From this elution profile, fatty acid ethyl ester synthase-II accounts for up to 50% of total synthesis in the human heart. This enzyme species was purified over 2200-fold to homogeneity after chromatography over hydroxylapatite, CM-cellulose, and hydroxylapatite. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of this homogeneous species showed a single band at 65 kDa which corresponded to its molecular weight determined by gel filtration. This molecular weight and its lack of glutathione transferase activity indicate that this species is not related to synthase-I and -III. Homogeneous synthase-II has a V(max) for palmitate, stearate, oleate, and linoleate of 70, 80, 140, and 120 nmol/mg/h, respectively. The K(m) for palmitate, stearate, oleate, and linoleate is 0.19, 0.12, 0.10, and 0.18 mM, respectively. The substrate specificity with respect to alcohol chain length was also investigated in the presence of 0.65 mM [C-14] oleic acid. The V(max) for methanol, ethanol, propanol, and butanol was 180, 100, 280, and 410 nmol/mg/h, respectively. The K(m) for methanol, ethanol, propanol, and butanol was 1.16, 1.04, 0.58, and 0.33 M, respectively. The N-terminal 17-amino acid sequence of human synthase-II does not correspond to any known N-terminal amino acid sequence, indicating that this may be a novel protein. However, it has over 70% homology to a sequence close to the C terminus of rabbit cytochrome P-450IIC1 and over 50% homology to a sequence of human hemopexin starting at residue 16. Synthase-II does not cross-react with human hemopexin antibody and rat cytochrome P-450C antibody. Thus, this study provides evidence that synthase-II is a novel protein, distinct from synthase-I and -III, and it also provides a foundation for subsequent cloning and genetic studies of fatty acid ethyl ester synthase-II in man.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV CARDIOL,STEINBURG 4,216 S KINGSHIGHWAY,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)				Bora, Puran/0000-0003-4781-1217	NIAAA NIH HHS [R01-AA08247-02, KO5-AA00139, R01-AA06989] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K05AA000139, R01AA006989, R01AA008247] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BORA PS, 1989, J CLIN INVEST, V84, P1942, DOI 10.1172/JCI114382; BORA PS, 1989, FEBS LETT, V258, P236, DOI 10.1016/0014-5793(89)81662-X; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BORA PS, 1991, ANN NY ACAD SCI, V625, P827, DOI 10.1111/j.1749-6632.1991.tb33927.x; BORA PS, 1990, ALCOHOL HLTH RES WOR, V14, P85; BORA PS, 1991, ALCOHOL DRUG ABUSE R, V2, P241; BORA PS, 1991, J BIOL CHEM, V266, P12670; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HABIG WH, 1974, J BIOL CHEM, V249, P7130; KYGER EM, 1990, BIOCHEMISTRY-US, V29, P3853, DOI 10.1021/bi00468a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1983, CIRC RES, V52, P479, DOI 10.1161/01.RES.52.4.479; LANGE LG, 1981, J BIOL CHEM, V256, P2968; LEIGHTON JK, 1984, BIOCHEMISTRY-US, V23, P204, DOI 10.1021/bi00297a005; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOGELSON S, 1984, BIOCHEMISTRY-US, V23, P4075, DOI 10.1021/bi00313a010; MOSCOW JA, 1989, CANCER RES, V49, P1422; SEGAL LD, 1979, CARDIOVASC RES, V13, P136; SHIMADA T, 1986, J BIOL CHEM, V261, P909; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; WRIGHT M, 1987, BIOCHEM BIOPH RES CO, V142, P979, DOI 10.1016/0006-291X(87)91510-5	23	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13217	13221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618826				2022-12-27	WOS:A1992JB74600022
J	FAY, PJ; SMUDZIN, TM				FAY, PJ; SMUDZIN, TM			CHARACTERIZATION OF THE INTERACTION BETWEEN THE A2-SUBUNIT AND A1/A3-C1-C2 DIMER IN HUMAN FACTOR-VIII(A)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-VIII; PORCINE FACTOR-VIII; THROMBIN; PROTEIN; INACTIVATION; ACTIVATION; COAGULANT; FORMS	Factor VIII(a) is a heterotrimer of the factor VIII heavy chain-derived A1 and A2 subunits plus the factor VIII light chain-derived A3-C1-C2 subunit. While the A1 and A3-C1-C2 subunits can be isolated as a stable dimer, the A2 subunit is weakly associated with the dimer. In the human protein, the association of A2 with dimer is reversible and governed by a pH-dependent dissociation constant. Using the specific activity of factor VIII(a) as an indicator of trimer concentration, the K(d) (pH 6.0) was determined to be 28 nM whereas at the more physiologic pH (pH 7.4) this value was approximately 260 nM. Results from pH shift experiments confirmed the reversible binding of A2 to dimer as did- the capacity for high levels of exogenous A2 subunit to inhibit the spontaneous decay of factor VIII(a) activity. A2 subunit associated with the A1 subunit in the A1/A3-C1-C2 dimer based upon the capacity for free A1 subunit to inhibit the reconstitution of factor VIII(a) from A2 subunit and dimer. These results indicate that the primary mechanism for the spontaneous decay of human factor VIII(a) is the reversible dissociation of A2 subunit from the A1 subunit of the A1/A3-C1-C2 dimer.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	FAY, PJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,MED CTR,DEPT MED,HEMATOL UNIT,POB 610,ROCHESTER,NY 14642, USA.				NHLBI NIH HHS [HL-38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	24	104	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13246	13250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618828				2022-12-27	WOS:A1992JB74600026
J	TUCK, SF; AOYAMA, Y; YOSHIDA, Y; DEMONTELLANO, PRO				TUCK, SF; AOYAMA, Y; YOSHIDA, Y; DEMONTELLANO, PRO			ACTIVE-SITE TOPOLOGY OF SACCHAROMYCES-CEREVISIAE LANOSTEROL 14-ALPHA-DEMETHYLASE (CYP51) AND ITS G310D MUTANT (CYTOCHROME-P-450SG1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED CYTOCHROME-P-45014DM; ALTERED CYTOCHROME-P-450; CANDIDA-ALBICANS; YEAST; PURIFICATION; BIOSYNTHESIS; INTERMEDIATE; DEMETHYLASE; MICROSOMES; MODEL	Incubation of phenyldiazene (PhN = NH) with lanosterol 14-alpha-demethylase, a cytochrome P-450 enzyme (CYP51) that oxidatively removes the 14-alpha-methyl group of lanosterol, results in the appearance of a 478nm band indicative of phenyl-iron complex formation. In situ oxidation of the phenyl-iron complex by ferricyanide yields exclusively the N-phenylprotoporphyrin IX regioisomer with the phenyl group on the nitrogen of pyrrole ring C (N(C)). The biphenyl-iron complex formed in the analogous reaction of the enzyme with biphenyldiazene similarly rearranges on treatment with ferricyanide to the Nc regioisomer of N-biphenylprotoporphyrin IX. The active site cavity must therefore be at least 10 angstrom high directly above the iron atom and pyrrole ring C of the heme group, and lanosterol binds to the enzyme in the region above pyrrole ring C. Phenyl-iron complex formation is not detected spectroscopically with cytochrome P-450SG1, a catalytically inactive G310D mutant of lanosterol 14-alpha-demethylase in which the sixth iron coordination site is thought to be occupied by an imidazole ligand. Nevertheless, oxidation of the phenyldiazene-treated enzyme with ferricyanide provides the N(A) and N(C) regioisomers of N-phenylprotoporphyrin IX in a 40:60 ratio. The single amino acid substitution in cytochrome P-450SG1 thus causes a conformational change that retracts the amino acid residues that cover pyrrole ring A and moves an imidazole ligand into the active site.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; MUKOGAWA WOMENS UNIV,FAC PHARMACEUT SCI,NISHINOMIYA,HYOGO 663,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mukogawa Women's University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDE.K, 1972, J CHEM SOC CHEM COMM, P383, DOI 10.1039/c39720000383; AOYAMA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1064, DOI 10.1016/0006-291X(91)91000-3; AOYAMA Y, 1987, J BIOL CHEM, V262, P14260; AOYAMA Y, 1991, BIOCHIM BIOPHYS ACTA, V1081, P262, DOI 10.1016/0005-2760(91)90280-U; AOYAMA Y, 1983, J BIOL CHEM, V258, P9040; AOYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P209, DOI 10.1016/0005-2760(89)90198-7; AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; AOYAMA Y, 1989, J BIOL CHEM, V264, P18502; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; Berg D., 1988, STEROL BIOSYNTHESIS; CANONICA L, 1968, J AM CHEM SOC, V90, P3597, DOI 10.1021/ja01015a074; CHEN C, 1988, DNA-J MOLEC CELL BIO, V7, P617, DOI 10.1089/dna.1988.7.617; CORREIA MA, 1992, FRONTIERS BIOTRANSFO, V8; FISCHER RT, 1991, J BIOL CHEM, V266, P6124; HITCHCOCK CA, 1989, BIOCHEM J, V263, P573, DOI 10.1042/bj2630573; HUNSBERGER IM, 1956, J ORG CHEM, V21, P394, DOI 10.1021/jo01110a004; ISHIDA N, 1988, BIOCHEM BIOPH RES CO, P317; KALB VF, 1987, DNA-J MOLEC CELL BIO, V6, P529, DOI 10.1089/dna.1987.6.529; LAI MH, 1989, NUCLEIC ACIDS RES, V17, P804, DOI 10.1093/nar/17.2.804; MORRIS GM, 1991, BIOCHEM SOC T, V19, P793, DOI 10.1042/bst0190793; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; SANTEN RJ, 1983, J CLIN ENDOCR METAB, V57, P732, DOI 10.1210/jcem-57-4-732; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; STEVENSON DE, 1988, J CHEM SOC PERK T 1, P2043, DOI 10.1039/p19880002043; SWANSON BA, 1991, J AM CHEM SOC, V113, P8146, DOI 10.1021/ja00021a046; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; SWANSON BA, 1992, ARCH BOCH BIOPHYS, V29, P42; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; TUCK SF, 1992, J BIOL CHEM, V267, P5614; VANDENBOSSCHE H, 1990, BIOCHEM SOC T, V18, P56; WATANABE Y, 1989, J AM CHEM SOC, V111, P8047, DOI 10.1021/ja00202a073; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0; YOSHIDA Y, 1990, CHIRALITY, V2, P10, DOI 10.1002/chir.530020103; Yoshida Y, 1988, Curr Top Med Mycol, V2, P388; YOSHIDA Y, 1991, BIOCHEM SOC T, V19, P778, DOI 10.1042/bst0190778	39	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13175	13179						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618820				2022-12-27	WOS:A1992JB74600015
J	GEBLER, J; GILKES, NR; CLAEYSSENS, M; WILSON, DB; BEGUIN, P; WAKARCHUK, WW; KILBURN, DG; MILLER, RC; WARREN, RAJ; WITHERS, SG				GEBLER, J; GILKES, NR; CLAEYSSENS, M; WILSON, DB; BEGUIN, P; WAKARCHUK, WW; KILBURN, DG; MILLER, RC; WARREN, RAJ; WITHERS, SG			STEREOSELECTIVE HYDROLYSIS CATALYZED BY RELATED BETA-1,4-GLUCANASES AND BETA-1,4-XYLANASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM; NUCLEOTIDE-SEQUENCE; TRICHODERMA-REESEI; ESCHERICHIA-COLI; XYLANASE GENE; CELLOBIOHYDROLASE-II; MOLECULAR-CLONING; BACILLUS-SUBTILIS; CELLULOMONAS-FIMI; DELETION ANALYSIS	Over 80 beta-1,4-glucanases and beta-1,4-xylanases can be classified into one of eight families on the basis of amino acid sequence similarities in their catalytic domains (Gilkes, N. R., Henrissat, B., Kilburn, D. G., Miller, R. C., Jr., and Warren, R. A. J. (1991) Microbiol. Rev. 55, 303-315). As a test of this classification, the stereochemical course of hydrolysis of 10 enzymes representative of five families has been determined using proton NMR. These data, together with published data for six additional enzymes, show that representatives of a given enzyme family have the same stereoselectivity: four families catalyze hydrolysis with retention of anomeric configuration, two with inversion. The results support the hypothesis that family members share a common general fold, active site topology, and catalytic mechanism.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER V6T 1Z3, BC, CANADA; STATE UNIV GHENT, BIOCHEM LAB, B-9000 GHENT, BELGIUM; CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA; INST PASTEUR, DEPT BIOTECHNOL, UNITE PHYSIOL CELLULAIRE, F-75724 PARIS 15, FRANCE; NATL RES COUNCIL CANADA, INST BIOL SCI, PROT STRUCT & DESIGN SECT, OTTAWA K1A 0R6, ONTARIO, CANADA	University of British Columbia; University of British Columbia; Ghent University; Cornell University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Research Council Canada			Withers, Stephen G/I-7229-2019; Wakarchuk, Warren/AAO-2774-2020; Wakarchuk, Warren/Q-9514-2017; Gebler, John/F-7114-2011	Withers, Stephen G/0000-0002-6722-5701; Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Beguin, Pierre/0000-0002-5372-6281; Gebler, John/0000-0003-0372-3725				BALLARDIE F, 1973, J CHEM SOC PERK T 1, P2418, DOI 10.1039/p19730002418; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BEGUIN P, 1988, METHOD ENZYMOL, V160, P355; BERNIER R, 1983, GENE, V26, P59, DOI 10.1016/0378-1119(83)90036-7; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLAEYSSENS M, 1990, BIOCHEM J, V270, P251, DOI 10.1042/bj2700251; EXCOFFIER G, 1975, CARBOHYD RES, V39, P368, DOI 10.1016/S0008-6215(00)86150-9; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1991, EUR J BIOCHEM, V202, P367, DOI 10.1111/j.1432-1033.1991.tb16384.x; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; GREPINET O, 1988, J BACTERIOL, V170, P4576, DOI 10.1128/jb.170.10.4576-4581.1988; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; JOLIFF G, 1986, NUCLEIC ACIDS RES, V14, P8605, DOI 10.1093/nar/14.21.8605; KNOWLES JKC, 1988, J CHEM SOC CHEM COMM, P1401, DOI 10.1039/c39880001401; KOENERS HJ, 1980, TRAV CHIM PAY BAS, V11, P355; LAO G, 1991, J BACTERIOL, V173, P3397, DOI 10.1128/jb.173.11.3397-3407.1991; MEAGHER MM, 1988, CARBOHYD RES, V173, P273, DOI 10.1016/S0008-6215(00)90823-1; MEINKE A, 1991, J BACTERIOL, V173, P7126, DOI 10.1128/jb.173.22.7126-7135.1991; MEINKE A, 1991, J BACTERIOL, V173, P308, DOI 10.1128/jb.173.1.308-314.1991; ONEILL G, 1986, GENE, V44, P325, DOI 10.1016/0378-1119(86)90197-6; PAICE MG, 1978, APPL ENVIRON MICROB, V36, P802, DOI 10.1128/AEM.36.6.802-808.1978; PAICE MG, 1986, ARCH MICROBIOL, V144, P201, DOI 10.1007/BF00410947; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SALOHEIMO M, 1988, GENE, V63, P11, DOI 10.1016/0378-1119(88)90541-0; SCHWARZ WH, 1988, APPL MICROBIOL BIOT, V29, P25, DOI 10.1007/BF00258346; SCHWARZ WH, 1988, GENE, V63, P23, DOI 10.1016/0378-1119(88)90542-2; SHOEMAKER S, 1983, BIO-TECHNOL, V1, P691, DOI 10.1038/nbt1083-691; SINNOTT ML, 1988, ENZYME MECHANISMS, P259; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; TOKATLIDIS K, 1991, FEBS LETT, V291, P185, DOI 10.1016/0014-5793(91)81279-H; WILSON DB, 1992, CRIT REV BIOTECHNOL, V12, P45, DOI 10.3109/07388559209069187; WITHERS SG, 1986, BIOCHEM BIOPH RES CO, V139, P487, DOI 10.1016/S0006-291X(86)80017-1; WONG WKR, 1986, GENE, V44, P315; Woodward J, 1984, TOP ENZYME FERMENT B, V8, P9; YAGUE E, 1990, GENE, V89, P61, DOI 10.1016/0378-1119(90)90206-7; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	38	215	217	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12559	12561						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618761				2022-12-27	WOS:A1992HZ48300030
J	KATSUYA, Y; SATO, M; KATSUBE, Y; MATSUURA, Y; TOMODA, K				KATSUYA, Y; SATO, M; KATSUBE, Y; MATSUURA, Y; TOMODA, K			SMALL-ANGLE X-RAY-SCATTERING STUDY OF METAL ION-INDUCED CONFORMATIONAL-CHANGES IN SERRATIA PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSAIC-VIRUS PROTEIN; SYNCHROTRON RADIATION; IMMUNOGLOBULIN	Metal ion-induced conformational changes in Serratia protease which contains one zinc ion per molecule were investigated by the small-angle x-ray scattering method. The molecule is an elongated ellipsoid of approximately 110 x 40 x 40 angstrom with a large cleft in its central region. Comparisons of the native (zinc-enzyme) with the zinc-free (apoenzyme) enzyme and with the zinc-replated metalloenzyme show small but significant differences in their radii of gyration, maximum particle dimensions, and intraparticle pair-distance distributions. The radius of gyration and maximum particle dimension of the native enzyme are almost the same as those of the cobalt-enzyme but are shorter and longer, respectively, than those of the apo- and cadmium-enzymes. Simulation analysis based on the intraparticle pair-distribution function showed that these modified enzymes are comparable with the native enzyme in overall structure, and, except for the cobalt-enzyme, differ in cleft size. The residual enzymatic activity of the cobalt-enzyme is the same as that of the native enzyme, but the apo- and cadmium-enzymes have considerably less activity. The size of the cleft therefore is strictly controlled to ensure optimal enzyme activity, and the position and coordination behavior of the zinc ion in the cleft appears to be essential both for biological functioning and for the maintenance of the gross tertiary structure.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; HYOGO PREFECTURAL INST IND RES,SUMA KU,KOBE 654,JAPAN; TAKEDA CHEM IND LTD,DIV RES & DEV,MICROBIOL RES LABS,YODOGAWA KU,OSAKA 532,JAPAN	Osaka University; Takeda Chemical Industries								GLATTER O, 1979, J APPL CRYSTALLOGR, V12, P166, DOI 10.1107/S0021889879012139; GLATTER O, 1974, J APPL CRYSTALLOGR, V7, P147, DOI 10.1107/S0021889874008983; GLATTER O, 1977, ACTA PHYS AUSTRIACA, V47, P83; Glatter O., 1982, SMALL ANGLE XRAY SCA, P119; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P243; Guinier A., 1955, SMALL ANGLE SCATTERI, P126; HIRAGI Y, 1988, J MOL BIOL, V204, P129, DOI 10.1016/0022-2836(88)90604-3; HIRAGI Y, 1990, J MOL BIOL, V213, P495, DOI 10.1016/S0022-2836(05)80210-4; HOZAKI T, 1986, B CHEM SOC JPN, V59, P3747, DOI 10.1246/bcsj.59.3747; KATAGIRI C, 1987, J BIOL CHEM, V262, P15857; MIYATA K, 1970, AGR BIOL CHEM TOKYO, V34, P310, DOI 10.1080/00021369.1970.10859598; MIYATA K, 1971, AGR BIOL CHEM TOKYO, V35, P460, DOI 10.1080/00021369.1971.10859949; NAKAHAMA K, 1986, NUCLEIC ACIDS RES, V14, P5843, DOI 10.1093/nar/14.14.5843; PILZ I, 1970, BIOCHEMISTRY-US, V9, P211, DOI 10.1021/bi00804a004; PILZ I, 1977, EUR J BIOCHEM, V75, P195, DOI 10.1111/j.1432-1033.1977.tb11517.x; PILZ I, 1982, SMALL ANGLE XRAY SCA, P250; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; SATO M, 1982, BIOCHEM INT, V5, P595; TURUTA H, 1990, FEBS LETT, V263, P66; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7	20	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12668	12672						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618772				2022-12-27	WOS:A1992HZ48300046
J	CASEY, JR; PIRRAGLIA, CA; REITHMEIER, RAF				CASEY, JR; PIRRAGLIA, CA; REITHMEIER, RAF			ENZYMATIC DEGLYCOSYLATION OF HUMAN BAND-3, THE ANION TRANSPORT PROTEIN OF THE ERYTHROCYTE-MEMBRANE - EFFECT ON PROTEIN-STRUCTURE AND TRANSPORT-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-GLYCOSIDASE-F; CARBOHYDRATE MOIETY; TRANSMEMBRANE POLYPEPTIDE; LINKED OLIGOSACCHARIDES; EXCHANGE PROTEIN; CELL-LINE; GLYCOPROTEIN; CDNA; CLONING; SYSTEM	The structural and functional roles of the single asparagine (N)-linked oligosaccharide chain of Band 3 (AE1), the anion transport protein of the human erythrocyte membrane, were examined. Purified Band 3 (M(r) = 95,000) in 0.1% octaethylene glycol mono n-dodecyl ether (C12E8) detergent solution was deglycosylated using N-glycosidase F. This treatment sharpened the protein band on sodium dodecyl sulfate gel electrophoresis and decreased its apparent molecular weight by 5,000. The purified membrane domain could be deglycosylated under similar conditions, causing a shift from a broad band centered at 55 kDa to a sharp 46-kDa band. Band 3 was shown to bind tomato lectin, and loss of lectin binding on blots provided a sensitive assay for deglycosylation. Carbohydrate analysis revealed that greater than 80% of the oligosaccharide could be removed from Band 3 by N-glycosidase F digestion. The deglycosylated protein maintained its dimeric structure and level of detergent binding but had a smaller Stokes radius (R(S) = 72 angstrom) than native Band 3 (R(S) = 75 Angstrom). The Stokes radius of the membrane domain (R(S)60 angstrom) also decreased upon deglycosylation (R(S) = 58 angstrom). Circular dichroism studies showed that deglycosylation did not change the secondary structure of Band 3 or the membrane domain. The sensitivity of Band 3 or the membrane domain to proteolytic digestion by trypsin or proteinase K was also unaffected by deglycosylation. The deglycosylated protein aggregated more rapidly and was much more readily precipitable by ammonium sulfate. The deglycosylated protein bound the anion transport inhibitor 4-benzamido-4'-aminostilbene-2,2'-disulfonate with the same affinity (K(d) = 1-mu-M) as the native protein. Transport studies using reconstituted Band 3 and resealed ghosts showed that deglycosylated Band 3 retained its ability to transport anions. We conclude that removal of the oligosaccharide chain from Band 3 and any resultant structural changes had no effect on the transport function of this protein.	UNIV TORONTO, DEPT MED,MRC,MEMBRANE BIOL GRP,RM 7307, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; ASANO T, 1991, J BIOL CHEM, V266, P24632; BECK WS, 1977, HEMATOLOGY, P265; BIRNIR B, 1990, BIOCHIM BIOPHYS ACTA, V1048, P100, DOI 10.1016/0167-4781(90)90028-Z; BOODHOO A, 1984, J BIOL CHEM, V259, P785; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; CHILDS RA, 1978, BIOCHEM J, V173, P333, DOI 10.1042/bj1730333; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; DEMUTH DR, 1986, EMBO J, V5, P1205, DOI 10.1002/j.1460-2075.1986.tb04348.x; DRICKAMER LK, 1976, J BIOL CHEM, V251, P5115; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; HO MK, 1975, J BIOL CHEM, V250, P675; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11448; LIBERMAN DM, 1983, BIOCHEMISTRY-US, V22, P4023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MUELLER TJ, 1979, J BIOL CHEM, V254, P8103; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OTT RJ, 1982, J BIOL CHEM, V267, P133; PAPPERT G, 1983, BIOCHIM BIOPHYS ACTA, V730, P32, DOI 10.1016/0005-2736(83)90313-9; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; RAO A, 1979, BIOCHEMISTRY-US, V18, P4505, DOI 10.1021/bi00588a008; Reithmeier R.A.F., 1989, ANION TRANSPORT PROT, P213; RESTREPO D, 1989, AM J PHYSIOL, V257, pC520, DOI 10.1152/ajpcell.1989.257.3.C520; SABBAN E, 1982, J CELL BIOL, V91, P637; SCHEURING U, 1986, J MEMBRANE BIOL, V90, P123, DOI 10.1007/BF01869930; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAKEDA K, 1988, FEBS LETT, V238, P201, DOI 10.1016/0014-5793(88)80256-4; TANNER MJA, 1988, CARBOHYD RES, V178, P203, DOI 10.1016/0008-6215(88)80112-5; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSUJI T, 1980, BIOCHEM J, V187, P677, DOI 10.1042/bj1870677; TSUJI T, 1981, J BIOL CHEM, V256, P497; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; WOLOSIN JM, 1980, BIOCHEM J, V189, P35, DOI 10.1042/bj1890035; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683	55	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11940	11948						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601863				2022-12-27	WOS:A1992HY94700045
J	DECLERCK, PJ; DEMOL, M; VAUGHAN, DE; COLLEN, D				DECLERCK, PJ; DEMOL, M; VAUGHAN, DE; COLLEN, D			IDENTIFICATION OF A CONFORMATIONALLY DISTINCT FORM OF PLASMINOGEN-ACTIVATOR INHIBITOR-1, ACTING AS A NONINHIBITORY SUBSTRATE FOR TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LINKED IMMUNOSORBENT-ASSAY; FIBRO-SARCOMA CELLS; ENDOTHELIAL-CELLS; MONOCLONAL-ANTIBODIES; REACTIVE CENTER; HUMAN-PLASMA; PURIFICATION; PROTEIN; GENE	Plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (t-PA) in plasma, is a serine proteinase inhibitor (serpin) that forms a 1:1 stoichiometric complex with its target proteinase leading to the formation of a stable inactive complex. The active, inhibitory form of PAI-1 spontaneously converts to a latent form that can be reactivated by protein denaturants. In the present study we have isolated another molecular form of intact PAI-1 that, in contrast with active PAI-1, does not form stable complexes with t-PA but is cleaved at the P1-P1' bond (Arg346-Met347). Other serine proteinases, e.g. urokinase-type plasminogen activator and thrombin, also cleaved this "substrate" form of PAI-1. Fluorescence spectroscopy revealed conformational differences between the latent, active, and substrate forms of PAI-1. This observation confirms our hypothesis that the three functionally different forms of PAI-1 are the consequence of conformational transitions. Thus PAI-1 may occur in three interconvertible conformations: latent, inhibitor, and substrate PAI-1. The identification of two distinct conformations of PAI-1 which interact with their target protease either as an inhibitor or as a substrate is a previously unrecognized phenomenon among the serpins. Conversion of substrate PAI-1 to its inactive degradation product may constitute a pathway for the physiological regulation of PAI-1 activity.	VET ADM MED CTR W ROXBURY, DIV CARDIOL, BOSTON, MA 02132 USA		DECLERCK, PJ (corresponding author), CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, O & N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BARTHA K, 1991, J BIOL CHEM, V266, P792; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DECLERCK PJ, 1982, FIBRINOLYSIS S2, V2, P77; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; KNUDSEN BS, 1988, J BIOL CHEM, V263, P9476; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; NIELSEN LS, 1986, FEBS LETT, V196, P269, DOI 10.1016/0014-5793(86)80261-7; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; PERRY DJ, 1989, MOL BIOL MED, V6, P239; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266	28	140	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11693	11696						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601844				2022-12-27	WOS:A1992HY94700009
J	WILSON, JM; GROSSMAN, M; CABRERA, JA; WU, CH; WU, GY				WILSON, JM; GROSSMAN, M; CABRERA, JA; WU, CH; WU, GY			A NOVEL MECHANISM FOR ACHIEVING TRANSGENE PERSISTENCE INVIVO AFTER SOMATIC GENE-TRANSFER INTO HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BIOLOGY; CELLS; EXPRESSION; DNA; REPLICATION; DELIVERY; VIRUS; MICE	Infusion of hepatocyte-specific DNA-protein complexes into rats leads to transient recombinant gene expression in liver. The eventual deterioration of gene expression is due in part to instability of the targeted DNA. In a previous report, we noted retention of transgene sequences in liver and persistent recombinant gene expression when the animals were subjected to partial hepatectomy following in vivo gene transfer. In an attempt to define the mechanism(s) responsible for persistent gene expression following partial hepatectomy, we characterized the molecular state of the retained, liver-associated transgenes. Southern blot analysis of DNA from liver tissues harvested various times after in vivo gene transfer and partial hepatectomy (10 min to 11 weeks) demonstrated high levels of transgene DNA (100-10,000 copies/cell). The predominant form of this DNA appeared to be episomal based on analyses of uncut DNA or DNA restricted by an endonuclease with one site in the plasmid. Livers from several animals contained a small proportion of transgene sequences of unknown structure. The existence of episomal DNA in liver was confirmed in experiments in which intact plasmid was rescued from total hepatocyte DNA by transformation of bacteria. Both strands of DNA in the liver-associated plasmid retained a bacterial pattern of methylation suggesting that the plasmid had not replicated in the eukaryotic cell. These results are consistent with the hypothesis that the majority of transgene sequences are retained as stabilized plasmids. The specific form of DNA which is transcriptionally active was not identified in these studies. This represents a new mechanism for retaining foreign DNA in eukaryotic cells in vivo and has implications both for the development of somatic gene therapies and the pathogenesis of viral diseases.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV CONNECTICUT,SCH MED,DEPT INTERNAL MED,FARMINGTON,CT 06030	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Connecticut	WILSON, JM (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,RM 4554,MSRB II,ANN ARBOR,MI 48109, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				BISHOP JO, 1989, MOL BIOL MED, V6, P283; BLUM HE, 1989, TRENDS GENET, V5, P154, DOI 10.1016/0168-9525(89)90057-7; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GEIER GE, 1979, J BIOL CHEM, V254, P1408; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; PUGH JC, 1990, BRIT MED BULL, V46, P329, DOI 10.1093/oxfordjournals.bmb.a072402; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; SELL S, 1990, CANCER RES, V50, P3811; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WILKIE TM, 1987, MOL CELL BIOL, V7, P1646, DOI 10.1128/MCB.7.5.1646; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	20	97	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11483	11489						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597475				2022-12-27	WOS:A1992HX16900083
J	FRADKIN, LG; KORNBERG, A				FRADKIN, LG; KORNBERG, A			PREREPLICATIVE COMPLEXES OF COMPONENTS OF DNA POLYMERASE-III HOLOENZYME OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSIVE SYNTHESIS; INITIATION COMPLEX; PRIMED DNA; REPLICATION; SUBUNIT; ATP; PURIFICATION; PROTEIN; BINDING; FORM	Stepwise reconstitution of the subunits of DNA polymerase III holoenzyme of Escherichia coli offers insights into the organization and function of this multisubunit assembly. A highly processive, holoenzyme-like activity can be generated when the gamma-complex, in the presence of ATP and a primed template, activates the beta-subunit to form a preinitiation complex, and this is then followed by addition of the core polymerase. Further analysis of early replicative complexes has now revealed: 1) that the gamma-complex can stably bind a single-stranded DNA binding protein (SSB)-coated template, 2) that neither SSB coating of the template nor a proper primer terminus is required to form the preinitiation complex, and 3) that the gamma-complex stabilizes the preinitiation complex in the presence of ATP and destabilizes it in the presence of adenosine 5'-O-(thiotriphosphate). Based on these findings, a sequence of stages can be formulated for an activation of the beta-subunit that enables it to bind the template-primer and thereby interact with the core to create a processive polymerase.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM007581, R37GM007581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002908] Funding Source: NIH RePORTER; NIA NIH HHS [AGO2908] Funding Source: Medline; NIGMS NIH HHS [GM07581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LOW RL, 1982, J BIOL CHEM, V257, P6242; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; WICKNER W, 1974, J BIOL CHEM, V249, P6244	23	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10318	10322						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587819				2022-12-27	WOS:A1992HV09000020
J	HILTON, DJ; NICOLA, NA				HILTON, DJ; NICOLA, NA			KINETIC ANALYSES OF THE BINDING OF LEUKEMIA INHIBITORY FACTOR TO RECEPTORS ON CELLS AND MEMBRANES AND IN DETERGENT SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; MOLECULAR-CLONING; HIGH-AFFINITY; HEMATOPOIETIC-CELLS; FATAL SYNDROME; FACTOR LIF; T-CELLS; GM-CSF; EXPRESSION	The equilibrium and kinetic properties of leukemia inhibitory factor (LIF) binding to a range of cell types have been compared. When binding was examined at 4-degrees-C, the majority of cells were found to express a single class of high affinity LIF receptor (K(D) = 20-100 pM; k(a) = 2-8 x 10(8) min-1 M-1; k(d) = 0.0004-0.0011 min-1). In contrast, certain activated macrophage populations expressed apparently independent classes of high and low affinity LIF receptor. The low affinity receptors differed from the high affinity receptors in terms of the dissociation rate of the receptor-ligand complex (K(D) = 1-2 nM; k(a) = 3-7 x 10(8) min-1 M-1; k(d) = 0.30-0.67 min-1). At 37-degrees-C, the interaction of LIF with its high affinity receptor was more complicated, since occupied LIF receptors were internalized more rapidly than unoccupied receptors, internalized LIF was hydrolyzed and released from the cell, and new receptors were synthesized and expressed on the cell surface. Interestingly, when membranes were prepared from cells that expressed only high affinity receptors, both high and low affinity receptors were detected, while after detergent solubilization of membranes only low affinity receptors were apparent. These results are discussed in terms of a structural model for the LIF receptor in which interaction of a low affinity binding subunit and a second nonbinding subunit is required for the generation of the high affinity receptor.	WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3054, AUSTRALIA	Walter & Eliza Hall Institute			Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1989, J BIOL CHEM, V264, P8941; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNARD O, 1989, J NEUROSCI RES, V24, P9, DOI 10.1002/jnr.490240104; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEWEY MJ, 1977, P NATL ACAD SCI USA, V74, P5564, DOI 10.1073/pnas.74.12.5564; Frost A.A., 1971, KINETICS MECH, P7; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HEATH JK, 1989, ENDOCRINOLOGY, V124, P3060; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LIMBIRD LE, 1987, CELL SURFACE RECEPTO; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; MAYO KH, 1989, J BIOL CHEM, V264, P17838; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; METCALF D, 1990, BLOOD, V76, P50; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; NICOLA NA, 1985, J CELL PHYSIOL, V124, P313, DOI 10.1002/jcp.1041240222; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLA NA, 1992, IN PRESS GROWTH FACT; Nicola NA, 1988, GROWTH FACTORS, V1, P29, DOI 10.3109/08977198809000244; Nicola NA, 1988, GROWTH FACTORS, V1, P41, DOI 10.3109/08977198809000245; PEASE S, 1990, EXP CELL RES, V190, P209, DOI 10.1016/0014-4827(90)90187-F; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TOMIDA M, 1984, J BIOL CHEM, V259, P978; WALKER F, 1985, EMBO J, V4, P933, DOI 10.1002/j.1460-2075.1985.tb03721.x; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	61	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10238	10247						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587813				2022-12-27	WOS:A1992HV09000009
J	PASCALE, MC; MALAGOLINI, N; SERAFINICESSI, F; MIGLIACCIO, G; LEONE, A; BONATTI, S				PASCALE, MC; MALAGOLINI, N; SERAFINICESSI, F; MIGLIACCIO, G; LEONE, A; BONATTI, S			BIOSYNTHESIS AND OLIGOSACCHARIDE STRUCTURE OF HUMAN CD8 GLYCOPROTEIN EXPRESSED IN A RAT EPITHELIAL-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; O-LINKED OLIGOSACCHARIDES; SIMPLEX VIRUS TYPE-1; SURFACE-ANTIGEN T8; ENDOPLASMIC-RETICULUM; MEMBRANE-GLYCOPROTEINS; CARBOHYDRATE UNITS; LYMPHOCYTES-T; SIALIC-ACID; SEQUENCE	The biosynthesis, post-translational modifications, and oligosaccharide structure of human CD8 glycoprotein have been studied in transfected rat epithelial cells. These cells synthesized and expressed on the plasma membrane high amounts of CD8 in a homodimeric form stabilized by a disulfide bridge. Three different CD8 forms were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis after metabolic labeling and immunoprecipitation: a newly synthesized, unglycosylated 27-kDa (CD8u), a palmitylated and initially O-glycosylated 29-kDa (CD8i), and the mature, terminally glycosylated 32-34-kDa doublet (CD8m). CD8i is a transient intermediate form between CD8u and CD8m: characterization of carbohydrate moiety of [H-3]glucosamine-labeled CD8i showed that it comprises for the vast majority non-elongated O-linked GalNAc closely spaced on the peptide backbone. Structural analysis of oligosaccharides released by mild alkaline borohydride treatment from the [H-3]glucosamine-labeled CD8 34-kDa form showed that the neutral tetrasaccharide Gal-beta-1,4GlcNAc-beta-1,6(Gal-beta-1,3)GalNAcOH, and an homologous monosialylated pentasaccharide, predominate; the disialylated NeuAc2,3Gal-beta-1,3(NeuAc-alpha-2,6) GalNAcOH tetrasaccharide appeared to be poorly present. In the CD8 32-kDa form the neutral tetrasaccharide was by far the prominent O-linked chain, and no disialyloligosaccharides were identified. These results indicate that the maturation of CD8 glycoprotein in transfected rat epithelial cells results in the formation of branched O-linked oligosaccharides and that a higher degree of sialylation is responsible for the production of the heavier 34-kDa form.	NAPLES UNIV,DEPT BIOCHEM & MED BIOTECHNOL,VIA S PANSINI 5,I-80131 NAPLES,ITALY; UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY	University of Naples Federico II; University of Bologna			Pascale, Maria/B-4273-2012					BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERGH MLE, 1981, CARBOHYD RES, V94, P225, DOI 10.1016/S0008-6215(00)80720-X; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CRIMMIN WRC, 1957, J CHEM SOC, P2838; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DALLOLIO F, 1985, J VIROL, V56, P127, DOI 10.1128/JVI.56.1.127-134.1985; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIES TE, 1986, EMBO J, V5, P931; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; NEIMANN H, 1984, EMBO J, V3, P665; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; RALSTON E, 1989, J CELL BIOL, V109, P2345, DOI 10.1083/jcb.109.5.2345; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SAITOH O, 1991, BLOOD, V77, P1491; SERAFINICESSI F, 1989, BIOCHEM J, V262, P479, DOI 10.1042/bj2620479; SERAFINICESSI F, 1986, CARBOHYD RES, V151, P65, DOI 10.1016/S0008-6215(00)90330-6; SERAFINICESSI F, 1985, ARCH BIOCHEM BIOPHYS, V240, P866, DOI 10.1016/0003-9861(85)90097-9; SERAFINICESSI F, 1983, BIOCHEM J, V215, P483, DOI 10.1042/bj2150483; SNOW PM, 1984, J IMMUNOL, V133, P2058; SNOW PM, 1985, J BIOL CHEM, V260, P2700; SNOW PM, 1983, J BIOL CHEM, V258, P4675; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; TAMAIODA S, 1991, BIOCHEM J, V280, P179; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529	37	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9940	9947						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577825				2022-12-27	WOS:A1992HT96500076
J	RAE, C; BUBB, WA; KUCHEL, PW				RAE, C; BUBB, WA; KUCHEL, PW			ALDOLASE-CATALYZED DIKETONE PHOSPHATE FORMATION FROM OXOALDEHYDES - NMR-STUDIES AND METABOLIC SIGNIFICANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; MAGNETIC-RESONANCE; HUMAN-ERYTHROCYTE; METHYLGLYOXAL; GLYCERALDEHYDE; H-1-NMR; PATHWAY	NMR spectroscopy showed fructose-1,6-bisphosphate aldolase from rabbit muscle accepts as substrates, in lieu of glyceraldehyde 3-phosphate, the oxoaldehydes methylglyoxal and phenylglyoxal but not hydroxymethylglyoxal. The enzyme catalyzed an aldol condensation between the oxoaldehyde and dihydroxyacetone phosphate to form a monophosphorylated diketone and was inactivated in the process. Circumvention of this reaction, by metabolism of oxoaldehydes to hydroxy acids, may be a metabolic role for the glyoxalase enzyme system. Transketolase and transaldolase were found not to accept oxoaldehydes as substrates in place of glyceraldehyde 3-phosphate.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			Rae, Caroline/B-7537-2008	Rae, Caroline/0000-0003-0673-8084; Kuchel, Philip/0000-0003-4100-7332				ARORA KK, 1988, BIOL CHEM H-S, V369, P549, DOI 10.1515/bchm3.1988.369.2.549; BEUTLER E, 1984, RED BLOOD CELL METAB, P47; BRANDT RB, 1979, CIBA F S, V67, P211; BRINDLE KM, 1982, BIOCHEM J, V208, P583, DOI 10.1042/bj2080583; BROWNE CA, 1976, J MOL BIOL, V100, P319, DOI 10.1016/S0022-2836(76)80066-6; CHRISTEN P, 1976, EUR J BIOCHEM, V63, P223, DOI 10.1111/j.1432-1033.1976.tb10224.x; CHRISTEN P, 1976, J BIOL CHEM, V251, P4220; Dakin HD, 1913, J BIOL CHEM, V14, P423; FURNISS BS, 1978, VOGELS TXB PRACTICAL, P917; GRAZI E, 1978, BIOCHEM J, V175, P361, DOI 10.1042/bj1750361; HEALY MJ, 1972, J AM CHEM SOC, V94, P7911, DOI 10.1021/ja00777a039; HOBERMAN HD, 1979, BIOCHEM BIOPH RES CO, V90, P757, DOI 10.1016/0006-291X(79)91892-8; IYENGAR R, 1981, BIOCHEMISTRY-US, V20, P1223, DOI 10.1021/bi00508a026; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; KUCHEL PW, 1988, J MAGN RESON, V76, P136, DOI 10.1016/0022-2364(88)90207-7; KUCHEL PW, 1990, BIOMED BIOCHIM ACTA, V49, pS105; LEONCINI G, 1980, FEBS LETT, V117, P17, DOI 10.1016/0014-5793(80)80903-3; LEONCINI G, 1989, CELL BIOCHEM FUNCT, V7, P65, DOI 10.1002/cbf.290070111; MEHLER AH, 1967, SCIENCE, V155, P1101, DOI 10.1126/science.155.3766.1101; Meyerhof O, 1936, BIOCHEM Z, V286, P301; PATTHY L, 1978, EUR J BIOCHEM, V88, P191, DOI 10.1111/j.1432-1033.1978.tb12437.x; RAE C, 1991, ARCH BIOCHEM BIOPHYS, V291, P291, DOI 10.1016/0003-9861(91)90137-8; RAE C, 1990, EUR J BIOCHEM, V193, P83, DOI 10.1111/j.1432-1033.1990.tb19307.x; REEVES HC, 1965, J BIOL CHEM, V240, P569; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; WEBB MR, 1977, BIOCHEMISTRY-US, V16, P2738, DOI 10.1021/bi00631a023; WOLFF SP, 1984, EXPERIENTIA, V40, P244, DOI 10.1007/BF01947562	27	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9713	9717						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577806				2022-12-27	WOS:A1992HT96500042
J	BRODOWSKY, ID; HAMBERG, M; OLIW, EH				BRODOWSKY, ID; HAMBERG, M; OLIW, EH			A LINOLEIC-ACID (8R)-DIOXYGENASE AND HYDROPEROXIDE ISOMERASE OF THE FUNGUS GAEUMANNOMYCES-GRAMINIS - BIOSYNTHESIS OF (8R)-HYDROXYLINOLEIC ACID AND (7S,8S)-DIHYDROXYLINOLEIC ACID FROM (8R)-HYDROPEROXYLINOLEIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; FATTY-ACIDS; LIQUID-CHROMATOGRAPHY; LAETISARIC ACID; STERIC ANALYSIS; ENZYME-SYSTEM; METABOLISM; CYTOCHROME-P-450; STEREOCHEMISTRY; OXYGENATION	The fungus Gaeumannomyces graminis metabolized linoleic acid extensively to (8R)-hydroperoxylinoleic acid, (8R)-hydroxylinoleic acid, and threo-(7S,8S)-dihydroxylinoleic acid. When G. graminis was incubated with linoleic acid under an atmosphere of oxygen-18, the isotope was incorporated into (8R)-hydroxylinoleic acid and 7,8-dihydroxylinoleic acid. The two hydroxyls of the latter contained either two oxygen-18 or two oxygen-16 atoms, whereas a molecular species that contained both oxygen isotopes was formed in negligible amounts. Glutathione peroxidase inhibited the biosynthesis of 7,8-dihydroxylinoleic acid. These findings demonstrated that the diol was formed from (8R)-hydroperoxylinoleic acid by intramolecular hydroxylation at carbon 7, catalyzed by a hydroperoxide isomerase. The (8R)-dioxygenase appeared to metabolize substrates with a saturated carboxylic side chain and a 9Z-double bond. G. graminis also formed omega-2- and omega-3-hydroxy metabolites of the fatty acids. In addition, linoleic acid was converted to small amounts of nearly (65% R) racemic 10-hydroxy-8,12-octadecadienoic acid by incorporation of atmospheric oxygen. An unstable metabolite, 11-hydroxylinoleic acid, could also be isolated as well as (13R,13S)-hydroxy-(9E,9Z), (11E)-octadecadienoic acids and (9R,9S)-hydroxy(10E), (12E,12Z)-octadecadienoic acids. In summary, G. graminis contains a prominent linoleic acid (8R)-dioxygenase, which differs from the lipoxygenase family of dioxygenases by catalyzing the formation of a hydroperoxide without affecting the double bonds of the substrate.	KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet	BRODOWSKY, ID (corresponding author), UPPSALA UNIV,CTR BIOMED,DEPT PHARMACEUT PHARMACOL,POB 591,S-75124 UPPSALA,SWEDEN.			Oliw, Ernst/0000-0002-7986-8130				AIKENS J, 1991, J BIOL CHEM, V266, P15091; Asher MJC, 1981, BIOL CONTROL TAKE AL; BOWERS WS, 1986, SCIENCE, V232, P105, DOI 10.1126/science.232.4746.105; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; EVANS PH, 1987, ACS SYM SER, V355, P353; GERWICK WH, 1991, ARCH BIOCHEM BIOPHYS, V290, P436, DOI 10.1016/0003-9861(91)90563-X; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1986, BIOCHIM BIOPHYS ACTA, V879, P410, DOI 10.1016/0005-2760(86)90233-X; HAMBERG M, 1971, ANAL BIOCHEM, V43, P515, DOI 10.1016/0003-2697(71)90282-X; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1991, LIPIDS, V26, P407, DOI 10.1007/BF02536065; HAMMARSTROM S, 1973, ANAL BIOCHEM, V52, P169, DOI 10.1016/0003-2697(73)90342-4; HASLBECK F, 1983, BIOCHIM BIOPHYS ACTA, V750, P185, DOI 10.1016/0005-2760(83)90219-9; HONECK H, 1985, PHARMAZIE, V40, P221; KUHN H, 1987, ANAL BIOCHEM, V160, P24, DOI 10.1016/0003-2697(87)90609-9; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OLIW EH, 1983, J CHROMATOGR, V275, P245, DOI 10.1016/S0378-4347(00)84372-8; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RULCO AJ, 1991, ANN REV PHARM TOXICO, V31, P177; SHOUN H, 1985, J BIOCHEM, V97, P755, DOI 10.1093/oxfordjournals.jbchem.a135115; SIH CJ, 1969, J AM CHEM SOC, V91, P3685, DOI 10.1021/ja01041a065; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; WURZENBERGER M, 1984, BIOCHIM BIOPHYS ACTA, V794, P25, DOI 10.1016/0005-2760(84)90293-5; WURZENBERGER M, 1983, BIOCHIM BIOPHYS ACTA, V794, P18	29	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14738	14745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634517				2022-12-27	WOS:A1992JF08800038
J	DOMIN, J; ROZENGURT, E				DOMIN, J; ROZENGURT, E			HETEROLOGOUS DESENSITIZATION OF PLATELET-DERIVED GROWTH FACTOR-MEDIATED ARACHIDONIC-ACID RELEASE AND PROSTAGLANDIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN KINASE-C; SIGNAL TRANSDUCTION; DNA-SYNTHESIS; MITOGENIC RESPONSE; BOMBESIN FAMILY; FACTOR RECEPTOR; RAS ONCOGENE; VASOPRESSIN; 3T3-CELLS	Prolonged treatment of quiescent Swiss 3T3 cells with vasopressin induced heterologous desensitization of specific early signals stimulated by platelet-derived growth factor (PDGF). PDGF caused a striking dose-dependent release of [H-3]arachidonic acid (EC50 = 2 ng/ml) and prostaglandin E2 (EC50 = 5 ng/ml). These responses are severely attenuated (>85%) by prior exposure to vasopressin in a dose-dependent manner (IC50 = 1.5 nM). Maximal loss of responsiveness occurred after 40 h of vasopressin treatment with a half-maximal desensitization after 11-13 h. The desensitization is dependent upon binding to the V1 receptor, since it can be prevented by the antagonist [Pmp1, O-Me-Tyr2, Arg8]vasopressin. In contrast, stimulation of inositol phosphate accumulation and production of diacylglycerol and phosphatidic acid by PDGF are unchanged. Thus, the observed heterologous desensitization cannot be attributed to an inability to activate phospholipase C. Furthermore, prior exposure to vasopressin did not affect the ability of PDGF to evoke tyrosine phosphorylation of cellular substrates, demonstrating that vasopressin-induced heterologous desensitization causes a block at a point distal to activation of receptor tyrosine kinase activity. Other downstream responses including transient induction of c-fos expression and stimulation of DNA synthesis were attenuated by vasopressin pretreatment. The findings demonstrate a novel mechanism of heterologous cellular desensitization namely, persistent occupancy of a guanine nucleotide-binding protein-coupled receptor, like the V1 type vasopressin receptor, attenuates responsiveness to a polypeptide growth factor like PDGF that initiates responses through a tyrosine kinase receptor.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COCHRAN BH, 1985, ADV CANCER RES, V45, P183, DOI 10.1016/S0065-230X(08)60269-9; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; GIL J, 1991, J CELL BIOL, V113, P9143; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZRIVAS A, 1984, AM J PHYSIOL, V247, pC156, DOI 10.1152/ajpcell.1984.247.3.C156; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5765; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; Mehmet H, 1990, GROWTH FACTORS, V3, P83, DOI 10.3109/08977199009108271; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MILLAR JBA, 1990, J BIOL CHEM, V265, P12052; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; RAKE JB, 1991, J BIOL CHEM, V266, P5348; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1981, J BIOL CHEM, V256, P716; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAKUWA N, 1987, J BIOL CHEM, V262, P182; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Woll PJ, 1988, GROWTH FACTORS, V1, P75, DOI 10.3109/08977198809000249; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	52	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15217	15223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634551				2022-12-27	WOS:A1992JF08800104
J	KIM, YT; TABOR, S; CHURCHICH, JE; RICHARDSON, CC				KIM, YT; TABOR, S; CHURCHICH, JE; RICHARDSON, CC			INTERACTIONS OF GENE 2.5 PROTEIN AND DNA-POLYMERASE OF BACTERIOPHAGE-T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ACID REPLICATION INVITRO; STRAND DISPLACEMENT SYNTHESIS; T7 DEOXYRIBONUCLEIC-ACID; DUPLEX DNA; RECOMBINATION; HELICASE; PRIMASE; PURIFICATION; STIMULATION	Bacteriophage T7 gene 2.5 protein has been shown to interact with T7 DNA polymerase (the complex of T7 gene 5 protein and Escherichia coli thioredoxin) by affinity chromatography and fluorescence emission anisotropy. T7 DNA polymerase binds specifically to a resin coupled to gene 2.5 protein and elutes from the resin when the ionic strength of the buffer is raised to 250 mM NaCl. In contrast, T7 gene 5 protein alone binds more weakly to gene 2.5 protein, eluting when the ionic strength of the buffer is 50 mM NaCl. Thioredoxin does not bind to gene 2.5 protein. Steady-state fluorescence emission anisotropy gives a dissociation constant of 1.1 +/- 0.2-mu-M for the complex of gene 2.5 protein and T7 DNA polymerase, with a ratio of gene 2.5 protein to T7 DNA polymerase in the complex of 1:1. Nanosecond emission anisotropic analysis suggests that the complex contains one monomer each of gene 2.5 protein, gene 5 protein, and thioredoxin. The ability of T7 gene 2.5 protein to stimulate the activity and processivity of T7 DNA polymerase is compared with the ability of three other single-stranded DNA-binding proteins: E. coli single-stranded DNA-binding protein, T4 gene 32 protein, and E. coli recA protein. All except E. coli recA protein stimulate the activity and processivity of T7 DNA polymerase; E. coli recA protein inhibits these activities.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115; UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	Harvard University; Harvard Medical School; University of Tennessee System; University of Tennessee Knoxville					NIAID NIH HHS [AI-06045] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; HAUGLAND RP, 1989, HDB FLUORESCENT PROB, P20; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; KIM YT, 1988, J BIOL CHEM, V263, P13712; KIM YT, 1992, J BIOL CHEM, V267, P15022; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MOSIG G, 1983, BACTERIOPHAGE T4, P120; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOSSAL NG, 1979, J BIOL CHEM, V254, P6032; O'Connor D. V., 1984, TIME CORRELATED SING; OEY JL, 1971, EUR J BIOCHEM, V23, P497, DOI 10.1111/j.1432-1033.1971.tb01646.x; POWLING A, 1974, MOL GEN GENET, V134, P173, DOI 10.1007/BF00268418; RADDING CM, 1991, J BIOL CHEM, V266, P5355; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1989, J BIOL CHEM, V264, P6447; TABOR S, 1986, THIOREDOXIN GLUTARED, P285; WARE WR, 1973, J PHYS CHEM-US, V77, P2038, DOI 10.1021/j100636a003; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	41	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15032	15040						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634539				2022-12-27	WOS:A1992JF08800078
J	FOURNIER, D; BRIDE, JM; HOFFMANN, F; KARCH, F				FOURNIER, D; BRIDE, JM; HOFFMANN, F; KARCH, F			ACETYLCHOLINESTERASE - 2 TYPES OF MODIFICATIONS CONFER RESISTANCE TO INSECTICIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; ESTERASE GENE; AMPLIFICATION; MALATHION; FLIES	Quantitative and qualitative changes in acetylcholinesterase confer resistance to insecticides. We have constructed several Drosophila melanogaster strains producing various amounts of enzyme by P-mediated transformation. Toxicological analysis of these strains demonstrates that resistance to organophosphorus insecticides is correlated with the amount of acetylcholinesterase in the central nervous system. Resistance may also be qualitatively determined. Comparison of the Drosophila acetylcholinesterase gene between a resistant strain caught in the wild and a wild type susceptible strain only revealed one nucleotide transition resulting in the replacement of a phenylalanine by a tyrosine. Flies mutant for acetylcholinesterase and rescued with a minigene mutagenized for this same transition produced an altered enzyme which renders flies resistant to pesticides.	UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1224 CHEONE BOUGERIES,SWITZERLAND	University of Geneva	FOURNIER, D (corresponding author), INRA,CTR RECH ANTIBES,BIOL INVERTEBRES LAB,F-06606 ANTIBES,FRANCE.							ALDRIDGE WN, 1950, BIOCHEM J, V46, P451, DOI 10.1042/bj0460451; DEVONSHIRE AL, 1984, PESTIC BIOCHEM PHYS, V21, P336, DOI 10.1016/0048-3575(84)90101-9; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FIELD LM, 1988, BIOCHEM J, V251, P309, DOI 10.1042/bj2510309; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; FOURNIER D, 1988, FEBS LETT, V238, P233; HALL JC, 1976, GENETICS, V83, P517; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HOFFMANN F, 1992, J MOL BIOL, V223, P17, DOI 10.1016/0022-2836(92)90710-2; KREJCI E, 1991, P NATL ACAD SCI USA, V88, P6647, DOI 10.1073/pnas.88.15.6647; MORTON RA, 1982, BIOCHEM GENET, V20, P179, DOI 10.1007/BF00484945; MORTON RA, 1985, PESTIC BIOCHEM PHYS, V24, P19, DOI 10.1016/0048-3575(85)90109-9; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; PAURON D, 1989, BIOCHEMISTRY-US, V28, P1673, DOI 10.1021/bi00430a037; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SMISSAERT HR, 1964, SCIENCE, V143, P129, DOI 10.1126/science.143.3602.129; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899	21	176	191	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14270	14274						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629220				2022-12-27	WOS:A1992JD32500075
J	RICHARDSON, D; BAKER, E				RICHARDSON, D; BAKER, E			2 MECHANISMS OF IRON UPTAKE FROM TRANSFERRIN BY MELANOMA-CELLS - THE EFFECT OF DESFERRIOXAMINE AND FERRIC AMMONIUM CITRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT SYSTEM; RECEPTOR MESSENGER-RNA; PLASMA-MEMBRANE; DIFERRIC TRANSFERRIN; HUMAN-FIBROBLASTS; RAT HEPATOCYTES; K562 CELLS; REDISTRIBUTION; REDUCTASE; BINDING	The effects of ferric ammonium citrate (FAC) and desferrioxamine (DFO) on iron (Fe), and transferrin (Tf) uptake have been investigated using SK-MEL-28 human melanoma cells, which express the Tf homologue, melanotransferrin, in high concentrations. Previously we demonstrated two separate Fe uptake mechanisms from Tf, viz. a specific process mediated by the transferrin receptor (TfR) and a nonspecific process (Richardson, D. R., and Baker, E. (1990) Biochim. Biophys. Acta 1053, 1-12). Cells exposed to DFO demonstrated up-regulation of the TfR with a concurrent increase in the rate of Fe uptake. Desferrioxamine also stimulated the nonspecific process of Fe uptake, resulting in a further increase in accumulation of Fe over Tf after saturation of the specific TfR. Ferric ammonium citrate had two effects. First, it resulted in down-regulation of the TfR. Second, and paradoxically, it markedly stimulated the rate of Fe uptake from Tf by the nonspecific process without increasing the rate of nonspecific Tf uptake. These data conclusively demonstrate that two entirely different mechanisms of iron uptake from Tf exist in melanoma cells and that ferric ammonium citrate may be a useful experimental tool to further characterize the specific and nonspecific mechanisms of Fe uptake from Tf.	UNIV WESTERN AUSTRALIA, DEPT PHYSIOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia				Richardson, Des/0000-0002-5506-3274; Richardson, Des/0000-0003-0960-6415				Baker E, 1988, Birth Defects Orig Artic Ser, V23, P89; BAKER E, 1985, BIOCHEM PHARMACOL, V34, P3011, DOI 10.1016/0006-2952(85)90142-X; BASS R, 1959, EXP CELL RES, V18, P560, DOI 10.1016/0014-4827(59)90321-0; BOMFORD AB, 1985, HEPATOLOGY, V5, P870, DOI 10.1002/hep.1840050528; BOTTOMLEY SS, 1985, J BIOL CHEM, V260, P6811; BRIDGES KR, 1984, J BIOL CHEM, V259, P2970; CRANE F L, 1985, Journal of Cell Biology, V101, p483A; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1985, ENZYMES BIOL MEMBR, V4, P465; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DORMANDY TL, 1965, J PHYSIOL-LONDON, V180, P684, DOI 10.1113/jphysiol.1965.sp007724; GOTO Y, 1983, J BIOL CHEM, V258, P5248; HANKS JH, 1949, P SOC EXP BIOL MED, V71, P196; HEMMAPLARDH D, 1976, INT J APPL RADIAT IS, V27, P89, DOI 10.1016/0020-708X(76)90182-4; HEMMAPLARDH D, 1974, BIOCHIM BIOPHYS ACTA, V373, P84, DOI 10.1016/0005-2736(74)90108-4; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HOLMES JM, 1989, AM J PHYSIOL, V256, pG1022, DOI 10.1152/ajpgi.1989.256.6.G1022; HUNT RC, 1989, J BIOL CHEM, V264, P9643; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; LOW H, 1987, J BIOENERG BIOMEMBR, V19, P535; LOW H, 1986, BIOCHEM BIOPH RES CO, V139, P1117, DOI 10.1016/S0006-291X(86)80293-5; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MORGAN EH, 1988, ANN NY ACAD SCI, V526, P65, DOI 10.1111/j.1749-6632.1988.tb55493.x; MORGAN EH, 1981, MOL ASPECTS MED, V4, P1, DOI 10.1016/0098-2997(81)90003-0; MULLEREBERHARD U, 1988, J BIOL CHEM, V263, P14753; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PAGE MA, 1984, AM J PHYSIOL, V246, pG26, DOI 10.1152/ajpgi.1984.246.1.G26; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; RICHARDSON DR, 1992, BIOCHIM BIOPHYS ACTA, V1103, P275, DOI 10.1016/0005-2736(92)90097-6; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1991, BIOCHIM BIOPHYS ACTA, V1091, P294, DOI 10.1016/0167-4889(91)90192-Z; RICHARDSON DR, 1990, THESIS U W AUSTR PER; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SUN IL, 1984, J BIOENERG BIOMEMBR, V16, P583, DOI 10.1007/BF00743247; SUN IL, 1986, BIOCHIM BIOPHYS ACTA, V886, P327, DOI 10.1016/0167-4889(86)90167-9; SUN IL, 1987, J BIOL CHEM, V262, P15915; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844; THORSTENSEN K, 1990, BIOCHIM BIOPHYS ACTA, V1052, P29, DOI 10.1016/0167-4889(90)90053-G; THORSTENSEN K, 1988, J BIOL CHEM, V263, P16837; TRINDER D, 1990, AM J PHYSIOL, V259, pG611, DOI 10.1152/ajpgi.1990.259.4.G611; WARD DM, 1986, BIOCHEM J, V238, P721, DOI 10.1042/bj2380721; WARD JH, 1982, J BIOL CHEM, V257, P317; WARD JH, 1984, J BIOL CHEM, V259, P3235; WARD JH, 1984, J LAB CLIN MED, V103, P246; WARD JH, 1982, BIOCHEM J, V208, P19, DOI 10.1042/bj2080019; WILEY HS, 1984, P NATL ACAD SCI-BIOL, V81, P7456, DOI 10.1073/pnas.81.23.7456; YOUNG SP, 1981, HEPATOLOGY, V1, P114, DOI 10.1002/hep.1840010205	55	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13972	13979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629195				2022-12-27	WOS:A1992JD32500032
J	CHUANG, WJ; VANWART, HE				CHUANG, WJ; VANWART, HE			RESONANCE RAMAN-SPECTRA OF HORSERADISH-PEROXIDASE AND BOVINE LIVER CATALASE COMPOUND-I SPECIES - EVIDENCE FOR PREDOMINANT (2)A(2U) PI-CATION RADICAL GROUND-STATE CONFIGURATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HEME-LINKED IONIZATION; ELECTRONIC-STRUCTURE; STRETCHING VIBRATION; ABSORPTION-SPECTRA; ENZYMIC CATALYSIS; SPECTROSCOPY; PORPHYRINS; OXIDATION; METALLOPORPHYRINS	The nature of the porphyrin-pi-cation radicals in the horseradish peroxidase and bovine liver catalase (BLC) compound I species have been investigated by studying their resonance Raman spectra. A variety of laser excitation and sample interrogation procedures have been employed in order to minimize previously documented problems arising from photoinduced conversions. With Soret band excitation, the spectra obtained for both species resemble that of a compound II-like photoproduct unless the samples are excited with residence times in the microsecond regime with very low (approximately 1 milliwatt) powers. When these precautions are taken, spectra attributable to the compound I species themselves are obtained. The spectrum for horseradish peroxidase compound I is similar to that reported by Paeng and Kincaid (Paeng, K.-J., and Kincaid, J. R. (1988) Am. Chem. Soc. 110, 7913-7915) using a similar approach. Both horseradish peroxidase and BLC compound I exhibit frequency shifts relative to their compound II species that are in the direction observed for model-pi-cation radicals with predominant 2A2u character. The magnitudes of these shifts are smaller than those observed for heme models that lack aromatic axial ligands, but agree well with those observed on formation of the compound I analog of N(alpha)-acetyl microperoxidase-8 that has His as a proximal ligand. This observation is consistent with partial delocalization of the radical density onto the proximal His-170 and Tyr-357 ligands in horseradish peroxidase and BLC, respectively. The strong ligand field provided by these ligands on the proximal side and oxo ligand on the distal side of the heme group is apparently sufficient to reverse the 2A1u radical ground state preference observed for heme-like porphyrin species (e.g. octaethylporphyrins) with weak axial fields. Enhancement of several bands assigned to the Tyr-357 ligand has also been observed for BLC compound I with 406.7-nm excitation. This is attributed either to resonance with a tyrosinate --> Fe(IV) charge transfer band or to the coupling provided by radical spin delocalization onto the tyrosinate ligand.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,INST MOLEC BIOPHYS,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University					NIGMS NIH HHS [GM27276] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027276] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; BROWETT WR, 1988, J AM CHEM SOC, V110, P3633, DOI 10.1021/ja00219a044; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DOLPHIN D, 1979, INT J QUANTUM CHEM, V16, P311, DOI 10.1002/qua.560160213; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DOLPHIN D, 1973, ANN NY ACAD SCI, V206, P177, DOI 10.1111/j.1749-6632.1973.tb43211.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DOLPHIN D, 1981, ISRAEL J CHEM, V21, P67, DOI 10.1002/ijch.198100017; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; FAJER J, 1970, J AM CHEM SOC, V92, P3451, DOI 10.1021/ja00714a038; FAJER J, 1973, ANN NY ACAD SCI, V206, P349, DOI 10.1111/j.1749-6632.1973.tb43221.x; FELTON RH, 1976, BIOCHIM BIOPHYS ACTA, V434, P82, DOI 10.1016/0005-2795(76)90037-4; FELTON RH, 1973, ANN NY ACAD SCI, V206, P504, DOI 10.1111/j.1749-6632.1973.tb43233.x; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FOOTE N, 1987, BIOCHEM J, V246, P659, DOI 10.1042/bj2460659; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HASHIMOTO S, 1991, J AM CHEM SOC, V113, P6542, DOI 10.1021/ja00017a027; HASHIMOTO S, 1987, J AM CHEM SOC, V109, P8096, DOI 10.1021/ja00260a030; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; KIM D, 1986, J PHYS CHEM-US, V90, P3320, DOI 10.1021/j100406a005; KINCAID JR, 1989, J AM CHEM SOC, V111, P735, DOI 10.1021/ja00184a054; LAMAR GN, 1981, J BIOL CHEM, V256, P237; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LOEW GH, 1980, J AM CHEM SOC, V102, P6173, DOI 10.1021/ja00539a047; MAGGIORA GM, 1973, J AM CHEM SOC, V95, P6555, DOI 10.1021/ja00801a005; MORISHIMA I, 1986, BIOCHEMISTRY-US, V25, P3576, DOI 10.1021/bi00360a016; MOSS TH, 1969, BIOCHEMISTRY-US, V8, P4159, DOI 10.1021/bi00838a037; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; OERTLING WA, 1987, J PHYS CHEM-US, V91, P3114, DOI 10.1021/j100295a095; OERTLING WA, 1985, J AM CHEM SOC, V107, P6406, DOI 10.1021/ja00308a050; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1987, J PHYS CHEM-US, V91, P5887, DOI 10.1021/j100307a016; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OGURA T, 1988, REV SCI INSTRUM, V59, P1316, DOI 10.1063/1.1139716; OGURA T, 1987, J AM CHEM SOC, V109, P2177, DOI 10.1021/ja00241a044; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; Que L, 1988, BIOL APPLICATIONS RA, P491; REID TJ, 1981, P NATL ACAD SCI-BIOL, V78, P4767, DOI 10.1073/pnas.78.8.4767; ROBERTS JE, 1981, J AM CHEM SOC, V103, P7654, DOI 10.1021/ja00415a044; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; SALEHI A, 1987, INORG CHEM, V26, P4296, DOI 10.1021/ic00272a033; SALEHI A, 1986, J AM CHEM SOC, V108, P5630, DOI 10.1021/ja00278a047; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SCHUMB WC, 1955, HYDROGEN PEROXIDE, P278; SEYMOUR RJ, 1983, APPL SPECTROSC, V37, P375, DOI 10.1366/0003702834634424; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; SIMPSON SF, 1986, ANAL CHEM, V58, P3163, DOI 10.1021/ac00127a054; SIMPSON SF, 1983, ANAL CHEM, V55, P1420, DOI 10.1021/ac00259a054; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SITTER AJ, 1984, J LABELLED COMPD RAD, V22, P461; SMULEVICH G, 1989, BIOCHEMISTRY-US, V28, P9905, DOI 10.1021/bi00452a004; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPIRO TG, 1983, IRON PORPHYRINS 2, P91; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STILLMAN JS, 1975, BIOCHEM BIOPH RES CO, V63, P32, DOI 10.1016/S0006-291X(75)80006-4; TERAOKA J, 1982, J AM CHEM SOC, V104, P7354, DOI 10.1021/ja00389a094; TERNER J, 1985, BIOCHIM BIOPHYS ACTA, V828, P73, DOI 10.1016/0167-4838(85)90011-1; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5; THANABAL V, 1987, J AM CHEM SOC, V109, P7516, DOI 10.1021/ja00258a043; THANABAL V, 1988, BIOCHEMISTRY-US, V27, P5400, DOI 10.1021/bi00415a003; VANWART HE, 1985, J AM CHEM SOC, V107, P3379, DOI 10.1021/ja00297a072; Varsanyi G., 1969, VIBRATIONAL SPECTRA, P141, DOI [DOI 10.1016/B978-0-12-714950-9.50007-7, 10.1016/B978-0-12-714950-9.50007-7]; WANG JS, 1991, BIOCHEM BIOPH RES CO, V179, P1320, DOI 10.1016/0006-291X(91)91717-Q; WOODRUFF WH, 1974, APPL SPECTROSC, V28, P576, DOI 10.1366/000370274774331886; YAMAGUCHI H, 1982, CHEM LETT, P1397, DOI 10.1246/cl.1982.1397	73	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13293	13301						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618830				2022-12-27	WOS:A1992JB74600034
J	HAUSMAN, SZ; BURNS, DL				HAUSMAN, SZ; BURNS, DL			INTERACTION OF PERTUSSIS TOXIN WITH CELLS AND MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; DIPHTHERIA-TOXIN; CHOLERA-TOXIN; BORDETELLA-PERTUSSIS; A-SUBUNIT; ADP-RIBOSYLTRANSFERASE; ADENINE-NUCLEOTIDES; NAD GLYCOHYDROLASE; ADENYLATE-CYCLASE; BINDING	The interaction of pertussis toxin (PT) with cells and model membranes was investigated by examining PT-induced intoxication of Chinese hamster ovary cells and by studying the binding of PT and its subunits to phospholipid vesicles. Since certain bacterial toxins require an acidic environment for efficient interaction with membranes and subsequent entry into the cell, the requirement for an acidic environment for PT action was examined. PT, unlike bacterial toxins such as diphtheria toxin, did not require an acidic environment for efficient intoxication of Chinese hamster ovary cells. Potential modes by which PT might interact with biological membranes were studied by examining the binding of PT to a model membrane system. PT was found to be capable of interacting with phospholipid vesicles, however, efficient binding of the toxin to the vesicles occurred only in the presence of both ATP and reducing agent. The A subunit portion of the toxin bound preferentially to the vesicles while little binding of the B oligomer portion of PT to the model membranes was observed. Isolated A subunit, in the absence of the B oligomer, also bound to the vesicles with optimal binding occurring in the presence of reducing agent. After cleavage of the A subunit by trypsin, probably at Arg-181, Arg-182, and/or Arg-193, large fragments which lacked the C-terminal portion of the A subunit of PT no longer associated with the lipid vesicles. These results suggest that the A subunit of PT can interact directly with a lipid matrix and, if freed from the constraints imposed by the B oligomer, may be capable of interacting with cellular membranes.	CTR BIOL EVALUAT & RES,DIV BACTERIAL PROD,BLDG 29,RM 418,8800 ROCKVILLE PIKE,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BONVENTRE PF, 1975, INFECT IMMUN, V11, P675, DOI 10.1128/IAI.11.4.675-684.1975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BURNS DL, 1987, J BIOL CHEM, V262, P17677; BURNS DL, 1987, INFECT IMMUN, V55, P24, DOI 10.1128/IAI.55.1.24-28.1987; BURNS DL, 1986, J BIOL CHEM, V261, P4324; BURNS DL, 1989, J BIOL CHEM, V264, P564; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FISHMAN PH, 1990, ADP RIBOSYLATING TOX, P127; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GUERRANT RL, 1974, INFECT IMMUN, V10, P320, DOI 10.1128/IAI.10.2.320-327.1974; HAUSMAN SZ, 1990, BIOCHEMISTRY-US, V29, P6128, DOI 10.1021/bi00478a003; HEWLETT EL, 1983, INFECT IMMUN, V40, P1198, DOI 10.1128/IAI.40.3.1198-1203.1983; IVINS B, 1975, INFECT IMMUN, V11, P665, DOI 10.1128/IAI.11.4.665-674.1975; JANICOT M, 1991, J BIOL CHEM, V266, P12858; JOSEPH KC, 1978, P NATL ACAD SCI USA, V75, P2815, DOI 10.1073/pnas.75.6.2815; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KIM K, 1965, J BACTERIOL, V90, P1557, DOI 10.1128/JB.90.6.1557-1562.1965; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; KRUEGER KM, 1991, J BIOL CHEM, V266, P8122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEADE BD, 1984, INFECT IMMUN, V46, P733, DOI 10.1128/IAI.46.3.733-739.1984; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MONTECUCCO C, 1986, FEBS LETT, V194, P301, DOI 10.1016/0014-5793(86)80105-3; MOSS J, 1977, J BIOL CHEM, V252, P797; MOSS J, 1983, J BIOL CHEM, V258, P1879; MOSS J, 1986, BIOCHEMISTRY-US, V25, P2720, DOI 10.1021/bi00357a066; MURPHY JR, 1978, J CLIN MICROBIOL, V7, P91; RIBI HO, 1988, SCIENCE, V239, P1272, DOI 10.1126/science.3344432; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; SAELINGER CB, 1990, TRAFFICKING BACTERIA, P26; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; TAMURA M, 1982, BIOCHEMISTRY-US, V21, P5516, DOI 10.1021/bi00265a021; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TUOMANEN E, 1988, J EXP MED, V168, P267, DOI 10.1084/jem.168.1.267; Ui M, 1988, PATHOGENESIS IMMUNIT, P121; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0; WITVLIET MH, 1989, INFECT IMMUN, V57, P3324, DOI 10.1128/IAI.57.11.3324-3330.1989	43	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13735	13739						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618869				2022-12-27	WOS:A1992JB74600100
J	HOGUE, CWV; MACMANUS, JP; BANVILLE, D; SZABO, AG				HOGUE, CWV; MACMANUS, JP; BANVILLE, D; SZABO, AG			COMPARISON OF TERBIUM(III) LUMINESCENCE ENHANCEMENT IN MUTANTS OF EF HAND CALCIUM-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPTOPHAN-CONTAINING PARVALBUMIN; SITE-SPECIFIC MUTAGENESIS; OPTICAL STOPPED-FLOW; METAL-ION BINDING; RAT ONCOMODULIN; CALMODULIN; LANTHANIDES; PROBES; CONFORMATION; SUBSTITUTION	The luminescent isomorphous Ca2+ analogue, Tb3+, can be bound in the 12-amino acid metal binding sites of proteins of the EF hand family, and its luminescence can be enhanced by energy transfer from a nearby aromatic amino acid. Tb3+ can be used as a sensitive luminescent probe of the structure and function of these proteins. The effect of changing the molecular environment around Tb3+ on its luminescence was studied using native Cod III parvalbumin and site-directed mutants of both oncomodulin and calmodulin. Titrations of these proteins showed stoichiometries of fill corresponding to the number of Ca2+ binding loops present. Tryptophan in binding loop position 7 best enhanced Tb3+ luminescence in the oncomodulin mutant Y57W, as well as VU-9 (F99W) and VU-32 (T26W) calmodulin. Excitation spectra of Y57F, F102W, Y65W oncomodulin, and Cod III parvalbumin revealed that the principal Tb3+ luminescence donor residues were phenylalanine or tyrosine located in position 7 of a loop, despite the presence of other nearby donors, including tryptophan. Spectra also revealed conformational differences between the Ca2+- and Tb3+-bound forms. An alternate binding loop, based on Tb3+ binding to model peptides, was inserted into the CD loop of oncomodulin by cassette mutagenesis. The order of fill of Tb3+ in this protein reversed, with the mutated loop binding Tb3+ first. This indicates a much higher affinity for the consensus-based mutant loop. The mutant loop inserted into oncomodulin had 32 times more Tb3+ luminescence than the identical synthetic peptide, despite having the same donor tryptophan and metal binding ligands. In this paper, a ranking of sensitivity of luminescence of bound Tb3+ is made among this subset of calcium binding proteins. This ranking is interpreted in light of the structural differences affecting Tb3+ luminescence enhancement intensity. The mechanism of energy transfer from an aromatic amino acid to Tb3+ is consistent with a short-range process involving the donor triplet state as described by Dexter (Dexter, D. L. (1953) J. Chem. Phys. 21, 836). This cautions against the use of the Forster equation in approximating distances in these systems.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA K1A 0R6, ONTARIO, CANADA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL H4P 2R2, QUEBEC, CANADA	National Research Council Canada; National Research Council Canada			Hogue, Christopher/B-6726-2008; Hogue, Christopher W V/AAZ-3934-2020	Hogue, Christopher W V/0000-0002-3107-5246				AHMED FR, 1990, J MOL BIOL, V216, P127, DOI 10.1016/S0022-2836(05)80065-8; BHAUMIK ML, 1965, J CHEM PHYS, V42, P787, DOI 10.1063/1.1696007; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P353; BREEN PJ, 1985, BIOCHEMISTRY-US, V24, P4991, DOI 10.1021/bi00340a005; BREEN PJ, 1985, BIOCHEMISTRY-US, V24, P4997, DOI 10.1021/bi00340a006; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; BUCCIGROSS JM, 1986, BIOCHEM BIOPH RES CO, V138, P1243, DOI 10.1016/S0006-291X(86)80416-8; CHEN R F, 1967, Analytical Letters, V1, P35; CHEUNG WY, 1983, CLACIUM CELL FUNCTIO; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; DEHORROCKS W, 1981, J AM CHEM SOC, V103, P2856, DOI 10.1021/ja00400a061; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; DOCKTER ME, 1983, CALCIUM CELL FUNCTIO, V4, P175; EBERSPACH I, 1988, BIOCHIM BIOPHYS ACTA, V952, P67, DOI 10.1016/0167-4838(88)90102-1; EISINGER J, 1969, PHOTOCHEM PHOTOBIOL, V9, P247, DOI 10.1111/j.1751-1097.1969.tb07289.x; EVANS CH, 1983, TRENDS BIOCHEM SCI, V8, P445, DOI 10.1016/0968-0004(83)90032-4; FASMAN GD, 1987, BIOPOLYMERS, V26, pS59, DOI 10.1002/bip.360260009; Forster T., 1965, MODERN QUANTUM CHEM, V3, P93; GERDAY C, 1988, CALCIUM CALCIUM BIND; GOLDEN LF, 1989, J BIOL CHEM, V264, P20314; HAIECH J, 1981, BIOCHEMISTRY-US, V20, P3890, DOI 10.1021/bi00516a035; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HENZL MT, 1986, BIOCHIM BIOPHYS ACTA, V872, P16, DOI 10.1016/0167-4838(86)90142-1; HENZL MT, 1988, J BIOL CHEM, V263, P10674; Horrocks W. D., 1982, ADV INORG BIOCHEM, P201; HORROCKS WD, 1977, J AM CHEM SOC, V99, P2378, DOI 10.1021/ja00449a079; HUTNIK CML, 1990, J BIOL CHEM, V265, P11456; HUTNIK CML, 1991, BIOCHEMISTRY-US, V30, P7652, DOI 10.1021/bi00244a038; KILHOFFER MC, 1988, J BIOL CHEM, V263, P17023; KLEINERMAN M, 1969, J CHEM PHYS, V51, P2370, DOI 10.1063/1.1672355; KLEINERMAN M, 1969, MOL LUMINESCENCE, P281; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAMDLA AA, 1969, ENERGY TRANSFER ORGA, V14, P46; Lyle S.J., 1963, TALANTA, V10, P1177, DOI [DOI 10.1016/0039-9140(63)80170-8, 10.1016/0039-9140(63)80170-8]; MACMANUS JP, 1990, J BIOL CHEM, V265, P10358; MACMANUS JP, 1989, J BIOL CHEM, V264, P3470; MARBAN E, 1980, NATURE, V286, P845, DOI 10.1038/286845a0; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MILLER TL, 1980, J MOL BIOL, V141, P223, DOI 10.1016/0022-2836(80)90387-3; MULQUEEN P, 1985, BIOCHEMISTRY-US, V24, P6639, DOI 10.1021/bi00344a051; NELSON DJ, 1979, INT J QUANTUM CHEM, V16, P159, DOI 10.1002/qua.560160118; OHARA PB, 1987, PHOTOCHEM PHOTOBIOL, V46, P1067, DOI 10.1111/j.1751-1097.1987.tb04894.x; PALMISANO WA, 1990, J BIOL CHEM, V265, P14450; PRIBIL R, 1967, TALANTA, V14, P619, DOI 10.1016/0039-9140(67)80028-6; RHEE MJ, 1981, BIOCHEMISTRY-US, V20, P3328, DOI 10.1021/bi00515a002; SALAMA S, 1980, J PHYS CHEM-US, V84, P512, DOI 10.1021/j100442a012; SOWADSKI J, 1978, J MOL BIOL, V124, P123, DOI 10.1016/0022-2836(78)90151-1; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TREVINO CL, 1991, J BIOL CHEM, V266, P11301; TREVINO CL, 1990, J BIOL CHEM, V265, P9694; TURRO NJ, 1978, MODERN MOL PHOTOCHEM, P335; WALLACE RW, 1982, J BIOL CHEM, V257, P1845; WILLIAMS TC, 1987, J BIOL CHEM, V262, P6248	54	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13340	13347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618836				2022-12-27	WOS:A1992JB74600041
J	ADACHI, S; SUNOHARA, N; ISHIMORI, K; MORISHIMA, I				ADACHI, S; SUNOHARA, N; ISHIMORI, K; MORISHIMA, I			STRUCTURE AND LIGAND-BINDING PROPERTIES OF LEUCINE-29(B10) MUTANTS OF HUMAN MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; NUCLEAR MAGNETIC-RESONANCE; DYNAMIC PROTEIN STRUCTURES; BOVINE HEART MYOGLOBIN; NORMAL MODE ANALYSIS; CARBON-MONOXIDE; DISTAL HISTIDINE; ESCHERICHIA-COLI; HIGH-PRESSURE	Site-specific mutants of human myoglobin (Mb) have been prepared, in which Leu29(B10) is replaced by Ala(L29A) or Ile(L29I), in order to examine the influence of this highly conserved residue in the hydrophobic clusters of the heme distal site on the heme environmental structure and ligand binding properties of Mb. Structural characterizations of these recombinant Mbs are studied by electronic absorption, infrared (IR), one- and two-dimensional proton nuclear magnetic resonance spectroscopies, and ligand-binding kinetics by laser photolysis measurements under ambient and high pressures (up to 2000 bar). Multiple split carbon monoxide (CO) stretch bands in the IR spectra of mutant Mbs exhibit a relative decrease of the 1945 cm-1 band (approximately 50%) which is associated with an upright binding geometry of CO, accompanied by an increase of the tilted CO conformer at 1932 cm-1. On the basis of these results, replacement of Leu29(B10) by Ala or Ile appears to allow bound CO to rotate from a conformation pointing toward the beta-meso carbon of the heme group to the one pointing toward the alpha-meso carbon atom, presumably filling the space left by removal of the delta-2 carbon atom of Leu29(B10). These substitutions cause the rate constants for CO and O2 association to decrease almost 3-5-fold. Present results show that CO and O2 bindings to the heme iron of Mb are controlled by Leu29(B10) by influencing the structure of close vicinity of the heme and the geometry of iron-bound ligand. Further, mutant Mbs (Leu72(E15)-->Ala and Leu104 (G5)-->Ala) which have altered residues in another hydrophobic clusters around proximal and distal site are also examined.	KYOTO UNIV,GRAD SCH ENGN,DIV MOLEC ENGN,KYOTO 606,JAPAN	Kyoto University			Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Adachi, Shin-ichi/0000-0002-3676-1165				ADACHI S, 1989, J BIOL CHEM, V264, P18896; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRAUNSTEIN D, 1988, P NATL ACAD SCI USA, V85, P8497, DOI 10.1073/pnas.85.22.8497; BROWN WE, 1983, BIOCHEMISTRY-US, V22, P2914, DOI 10.1021/bi00281a021; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CAUGHEY WS, 1981, P NATL ACAD SCI-BIOL, V78, P2903, DOI 10.1073/pnas.78.5.2903; CHANCE MR, 1987, J BIOL CHEM, V262, P6959; COLLMAN JP, 1983, J AM CHEM SOC, V105, P3052, DOI 10.1021/ja00348a019; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LACOMTE JTJ, 1985, BIOCHEMISTRY-US, V24, P7388; LAMAR GN, 1983, BIOPHYS J, V44, P177, DOI 10.1016/S0006-3495(83)84289-1; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; MAYER A, 1974, J MOL BIOL, V86, P746; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; PROJAHN HD, 1991, INORG CHEM, V30, P3288, DOI 10.1021/ic00017a014; PROJAHN HD, 1990, J AM CHEM SOC, V112, P17, DOI 10.1021/ja00157a005; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SENO Y, 1990, J MOL BIOL, V216, P111, DOI 10.1016/S0022-2836(05)80064-6; SENO Y, 1990, J MOL BIOL, V216, P95, DOI 10.1016/S0022-2836(05)80063-4; SHEARD B, 1970, J MOL BIOL, V53, P35, DOI 10.1016/0022-2836(70)90044-6; SHIMADA H, 1989, BIOCHEM BIOPH RES CO, V158, P110, DOI 10.1016/S0006-291X(89)80184-6; SHIMADA H, 1982, J BIOL CHEM, V257, P1893; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TAKANO T, 1977, J MOL BIOL, V110, P537, DOI 10.1016/S0022-2836(77)80111-3; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; TRAYLOR TG, 1985, J AM CHEM SOC, V107, P604, DOI 10.1021/ja00289a012; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681	48	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12614	12621						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618766				2022-12-27	WOS:A1992HZ48300038
J	JANSEN, FK; JANSEN, A; DEROCQ, JM; CARRIERE, D; CARAYON, P; VEAS, F; JAFFREZOU, JP				JANSEN, FK; JANSEN, A; DEROCQ, JM; CARRIERE, D; CARAYON, P; VEAS, F; JAFFREZOU, JP			GOLGI VACUOLIZATION AND IMMUNOTOXIN ENHANCEMENT BY MONENSIN AND PERHEXILINE DEPEND ON A SERUM-PROTEIN - IMPLICATIONS FOR INTRACELLULAR TRAFFICKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE GLYCOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; CARBOXYLIC IONOPHORES; HUMAN-FIBROBLASTS; HYBRID MOLECULES; COLLOIDAL GOLD; CYTO-TOXICITY; CELLS; RICIN; VESICLES	Vacuole formation around the Golgi and immunotoxin enhancement induced by low doses of the ionophore monensin were inhibited by 50% human plasma (final concentration), whereas the lysosomal pH increase remained unaffected. Immunotoxin enhancement by the Ca2+ antagonist perhexiline was also inhibited by plasma. The inhibiting factor was present in different species and highly concentration-dependent. After purification on DEAE- and CM-Sepharose it showed a heterogeneous distribution between 45 and 50 kDa, in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, an extreme isoelectric point near 3.5, and binding to wheat germ agglutinin-Sepharose. Maximum inhibition was found in the lower molecular mass fraction of 45 kDa. The 50-kDa fraction, although showing immunological identity reactions, remained almost inactive. The simultaneous inhibition of morphological alterations and the enhancement of immunotoxin activity by the highly enriched protein provides a first direct link between both events. Apart from a role of this serum glycoprotein on in vivo inhibition of immunotoxin enhancement, its ability to maintain normal intracellular trafficking in the presence of blocking agents, such as monensin and perhexiline, suggests a more fundamental role in the regulation of these mechanisms.	SANOFI RECH,F-34184 MONTPELLIER,FRANCE; CNRS,PHARMACOL LAB,F-31077 TOULOUSE,FRANCE	Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS)	JANSEN, FK (corresponding author), INST FRANCAIS RECH SCI DEV COOPERAT,PROJET SIDA,IMMUNOCIBLAGE LAB,911 AVE AGOPOLIS,BP 5045,F-34032 MONTPELLIER,FRANCE.							AKIYAMA S, 1985, CANCER RES, V45, P1005; BLYTHMAN HE, 1981, NATURE, V290, P145, DOI 10.1038/290145a0; CARRIERE D, 1985, EXP CELL RES, V156, P327; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; COLOMBATTI M, 1990, CANCER RES, V50, P1385; EINSTEIN R, 1989, J CELL BIOL, V109, P1037, DOI 10.1083/jcb.109.3.1037; GRIFFIN TW, 1987, CANCER RES, V47, P4266; GROS O, 1985, J IMMUNOL METHODS, V81, P283, DOI 10.1016/0022-1759(85)90213-3; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HEDIN U, 1985, EUR J CELL BIOL, V39, P130; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; JAFFREZOU JP, 1990, CANCER RES, V50, P5558; JANSEN FK, 1982, IMMUNOL REV, V62, P185, DOI 10.1111/j.1600-065X.1982.tb00394.x; JANSEN FK, 1987, MEMBRANE MEDIATED CY, P167; LEDGER PW, 1980, J CELL BIOL, V87, P663, DOI 10.1083/jcb.87.3.663; LININGTON C, 1983, J NEUROCHEM, V41, P426, DOI 10.1111/j.1471-4159.1983.tb04759.x; MARSH M, 1982, P NATL ACAD SCI-BIOL, V79, P5297, DOI 10.1073/pnas.79.17.5297; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MERION M, 1983, J CELL BIOL, V96, P644, DOI 10.1083/jcb.96.3.644; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; PIRKER R, 1989, CANCER RES, V49, P4791; POHLMANN R, 1984, BIOCHEM J, V217, P649, DOI 10.1042/bj2170649; PRESSMAN BC, 1968, FED PROC, V27, P1283; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RASO V, 1984, J EXP MED, V160, P1234, DOI 10.1084/jem.160.4.1234; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; VIDAL H, 1985, INT J CANCER, V36, P705, DOI 10.1002/ijc.2910360615; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445	29	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12577	12582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618762				2022-12-27	WOS:A1992HZ48300033
J	PANICKER, MM; MINKLEY, EG				PANICKER, MM; MINKLEY, EG			PURIFICATION AND PROPERTIES OF THE F-SEX FACTOR TRAD PROTEIN, AN INNER MEMBRANE CONJUGAL TRANSFER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PROMOTER-DISTAL REGION; BACTERIOPHAGE-LAMBDA; NUCLEOTIDE-SEQUENCE; BACTERIAL CONJUGATION; DNA TRANSFER; OVERPRODUCTION; SYSTEM; OPERON	Using a traD overexpression plasmid, we purified the F sex factor TraD protein in milligram quantities. The purified protein has an apparent molecular weight of 82,000 and an amino acid composition rich in acidic residues. Using specific antibodies, TraD was localized to the inner membrane of F+ cells under conditions where it is produced in physiologically normal amounts. Furthermore, the protein was soluble only in the presence of detergents, but there is evidence that the carboxyl terminus is water-soluble. The purified protein shows pH-sensitive binding to DNA cellulose columns.	CARNEGIE MELLON UNIV,RES INST,CTR BIOTECHNOL,4400 5TH AVE,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,RES INST,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University; Carnegie Mellon University				Panicker, Mitradas/0000-0002-0782-6222	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028925] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28925] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ACHTMAN M, 1979, P NATL ACAD SCI USA, V76, P4837, DOI 10.1073/pnas.76.10.4837; ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; BERNARD HU, 1979, GENE, V5, P59, DOI 10.1016/0378-1119(79)90092-1; CAPALDI RA, 1972, P NATL ACAD SCI USA, V69, P930, DOI 10.1073/pnas.69.4.930; CUOZZO M, 1986, J BIOL CHEM, V261, P5175; CUOZZO M, 1984, J BIOL CHEM, V259, P6659; DATE T, 1977, BIOCHEMISTRY-US, V16, P5579, DOI 10.1021/bi00644a030; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FRANKLIN NC, 1979, GENE, V8, P107, DOI 10.1016/0378-1119(79)90011-8; GARVEY JS, 1977, METHOD IMMUNOL, P218; GOTTESMAN ME, 1980, J MOL BIOL, V140, P57, DOI 10.1016/0022-2836(80)90356-3; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; JALAJAKUMARI MB, 1987, J MOL BIOL, V198, P1, DOI 10.1016/0022-2836(87)90452-9; JALAJAKUMARI MB, 1989, GENE, V81, P195, DOI 10.1016/0378-1119(89)90179-0; KENNEDY N, 1977, NATURE, V270, P580, DOI 10.1038/270580a0; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; MANNING PA, 1981, P NATL ACAD SCI-BIOL, V78, P7487, DOI 10.1073/pnas.78.12.7487; MANNING PA, 1982, J BACTERIOL, V150, P76, DOI 10.1128/JB.150.1.76-88.1982; MINKLEY EG, 1984, J BACTERIOL, V158, P464, DOI 10.1128/JB.158.2.464-473.1984; MINKLEY EG, 1984, MOL GEN GENET, V196, P225, DOI 10.1007/BF00328054; Neidhardt FC., 1987, ESCHERICHIA COLI SAL, V2nd ed, P3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PANICKER MM, 1985, J BACTERIOL, V162, P584, DOI 10.1128/JB.162.2.584-590.1985; PERUMAL NB, 1985, THESIS CARNEGIE MELL; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353; YOSHIOKA Y, 1990, J MOL BIOL, V214, P39, DOI 10.1016/0022-2836(90)90145-C	28	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12761	12766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618779				2022-12-27	WOS:A1992HZ48300058
J	NEWMAN, CMH; GIANNAKOUROS, T; HANCOCK, JF; FAWELL, EH; ARMSTRONG, J; MAGEE, AI				NEWMAN, CMH; GIANNAKOUROS, T; HANCOCK, JF; FAWELL, EH; ARMSTRONG, J; MAGEE, AI			POSTTRANSLATIONAL PROCESSING OF SCHIZOSACCHAROMYCES-POMBE YPT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-METHYLATION; TERMINAL CYSTEINE; PLASMA-MEMBRANE; RAS PROTEINS; YEAST; GENE; SEQUENCE; P21RAS; BINDING; RESIDUE	ras proteins are post-translationally processed at their carboxyl-terminal CAAX motif by a triplet of modifications: prenylation of C with farnesyl, proteolytic trimming of AAX, and carboxyl-methylation. These modifications co-operate with palmitoylation of nearby sites or a polybasic region to target plasma membrane localization. The related YPT/rab proteins in contrast are localized to compartments of the endomembrane system and may be involved in directing membrane traffic. These proteins end in XCC or CXC motifs. We have analyzed the processing of members of this subfamily from the fission yeast Schizosaccharomyces pombe. We find using in vitro translation in reticulocyte lysates that YPT1, -3, and -5 are prenylated with geranylgeranyl and that they incorporate label from [H-3]mevalonic acid when expressed in transfected COS cells in vivo. Furthermore, prenylation was necessary for membrane binding in vivo. The CXC protein YPT5, but neither of the two XCC proteins YPT1 and YPT3, was carboxyl-methylated in S. pombe and in COS cells in vivo. However, YPT5 was not carboxyl-methylated in vitro in lysates which were able to methylate ras protein. YPT3 was detectably palmitoylated when expressed in COS cells, though at a much lower level than ras.	NATL INST MED RES, MILL HILL, LONDON NW7 1AA, ENGLAND; ROYAL FREE HOSP, SCH MED, LONDON NW3 2QG, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	MRC National Institute for Medical Research; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Cancer Research UK			Magee, Anthony/V-8345-2019; GIANNAKOUROS, THOMAS/R-3204-2019	Hancock, John/0000-0003-0542-4710				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FAWELL E, 1989, NUCLEIC ACIDS RES, V17, P4373, DOI 10.1093/nar/17.11.4373; FAWELL E, 1990, NUCLEIC ACIDS RES, V18, P4264, DOI 10.1093/nar/18.14.4264; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GIANNAKOUROS T, 1992, FEBS LETT, V297, P103, DOI 10.1016/0014-5793(92)80337-G; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Gutz H., 1974, HDB GENETICS, V1, P395; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KAUFER NF, 1985, NATURE, V318, P78, DOI 10.1038/318078a0; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TAKAI Y, 1992, IN PRESS INT REV CYT; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	51	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11329	11336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597466				2022-12-27	WOS:A1992HX16900062
J	SEGUCHI, T; GOTO, Y; ONO, M; FUJIWARA, T; SHIMADA, T; KUNG, HF; NISHIOKA, M; IKEHARA, Y; KUWANO, M				SEGUCHI, T; GOTO, Y; ONO, M; FUJIWARA, T; SHIMADA, T; KUNG, HF; NISHIOKA, M; IKEHARA, Y; KUWANO, M			BREFELDIN-A-RESISTANT MUTANTS OF HUMAN EPIDERMOID CARCINOMA CELL-LINE WITH STRUCTURAL-CHANGES OF THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CULTURED RAT HEPATOCYTES; SECRETORY PROTEINS; INTRACELLULAR-TRANSPORT; VARIANTS RESISTANT; MONENSIN; ACCUMULATION; PATHWAY; ER	We have isolated brefeldin A (BFA)-resistant cell lines, KB/BF-1 and KB/BF-2, from the human epidermoid carcinoma KB cell line. The BFA-resistant phenotypes have been stably maintained for more than 3 months in the absence of BFA. KB/BF-1 and KB/BF-2 showed 10-30-fold higher resistance to cytotoxicity of BFA but were 2-3-fold more sensitive to monensin and nigericin, than KB cells. KB/BF-1 showed aberrant structures of the Golgi complex with poorly developed cisternae surrounded by many small vesicles. Immunocytochemical studies were done with antibodies against a Golgi-specific antigen (chronic rheumatoid arthritis antigen) and a coatomer subunit (beta-subunit for coat proteins of non-clathrin-coated vesicles). Golgi-specific markers were distributed into the small vesicles which were localized diffusely in cytoplasm of KB/BF-1 cells. Such Golgi markers were observed in a strictly confined perinuclear region of the parental KB cells, whereas in the mutant cells the markers were distributed more diffusely in dot-like structures at perinuclear regions. In addition, when exposed to BFA, the mutant and parental cells showed a different distribution of these markers. Synthesis and maturation of low density lipoprotein receptor showed apparently slower rates in processing of low density lipoprotein receptor in KB/BF-1 and KB/BF-2 cells than those observed in their parental KB cells. Protein secretion in KB/BF-1 and KB/BF-2 cells was about 30% less than that in KB cells. Much less inhibition by BFA on the secretion was observed in KB/BF-1 and KB/BF-2 cells. A BFA-resistant mutation in BFA-resistant KB cell lines appears to affect assembly of the Golgi apparatus as well as some Golgi-specific functions.	OITA MED UNIV, DEPT ANAT, OITA 87955, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, BIOCHEM PHYSIOL LAB, FREDERICK, MD 21702 USA; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81401, JAPAN; KAGAWA MED SCH, DEPT INTERNAL MED, KAGAWA 76107, JAPAN	Oita University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fukuoka University; Kagawa University	SEGUCHI, T (corresponding author), OITA MED UNIV, DEPT BIOCHEM, OITA 87955, JAPAN.							DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; HAGINO Y, 1988, JPN J CANCER RES, V79, P74, DOI 10.1111/j.1349-7006.1988.tb00013.x; KUWANO M, 1991, J CELL SCI, V98, P131; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MATSUO K, 1990, CANCER RES, V50, P5819; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIZOGUCHI H, 1990, BIOCHIM BIOPHYS ACTA, V1052, P475, DOI 10.1016/0167-4889(90)90158-A; NAKANO A, 1985, BIOCHIM BIOPHYS ACTA, V845, P324, DOI 10.1016/0167-4889(85)90195-8; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; ONO M, 1985, J CELL BIOL, V101, P60, DOI 10.1083/jcb.101.1.60; ONO M, 1984, J CELL PHYSIOL, V119, P198, DOI 10.1002/jcp.1041190209; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; SCHEKMAN R, 1985, ANNU REV CELL BIOL, V1, P115, DOI 10.1146/annurev.cellbio.1.1.115; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHITE S, 1988, J BIOL CHEM, V263, P19286; SHITE S, 1990, EUR J BIOCHEM, V191, P491, DOI 10.1111/j.1432-1033.1990.tb19148.x; SHITE S, 1990, J BIOL CHEM, V265, P17385; SHITE S, 1991, ARCH BIOCHEM BIOPHYS, V284, P245; TAKANO H, 1991, CANCER RES, V51, P3951; TANAKA S, 1989, J CLIN ELECT MISCROS, V22, P5; TARTAKOFF A, 1978, J CELL BIOL, V79, P694, DOI 10.1083/jcb.79.3.694; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299; ZUBER C, 1991, P NATL ACAD SCI USA, V88, P9818, DOI 10.1073/pnas.88.21.9818	35	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11626	11630						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597488				2022-12-27	WOS:A1992HX16900105
J	INOUE, A; OBATA, K; AKAGAWA, K				INOUE, A; OBATA, K; AKAGAWA, K			CLONING AND SEQUENCE-ANALYSIS OF CDNA FOR A NEURONAL CELL-MEMBRANE ANTIGEN, HPC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; NEURITE OUTGROWTH; RAT RETINA; SYNTHETIC PEPTIDE; CLEAVAGE SITES; A-CHAIN; LAMININ; PROTEINS; IDENTIFICATION	A monoclonal antibody (mAb), HPC-1, labels the plasma membrane of the amacrine cell soma and inner plexiform layer in rat retina and other central neurons. HPC-1 antigen recognizes several proteins of about 35 kDa. In this study, an HPC-1 positive cDNA, HPC-113, was isolated from a lambda-gt11 cDNA library of the rat hippocampus. HPC-113 had the 894-base pair nucleotide sequence in an open reading frame and the calculated molecular mass of the deduced amino acid sequence (298 residues) was 33,989 Da, implying that HPC-113 contains almost the full-length coding region of HPC-1 antigen mRNA. Sequence analysis suggested that HPC-1 antigen is an integrated membrane protein revealing the characteristic alpha-helical structure with periodical heptad repeats usually seen in proteins with coiled-coil structures. Although the entire amino acid sequence did not show significant homology to any proteins so far known, a few local sequences in the possible extracellular domain of the HPC-1 antigen molecule had notable homology to some partial sequences in the laminin B1 chain. These sequences of laminin are included in the portion which has neurite outgrowth and/or survival promoting activity. The HPC-1 gene was transcribed in nerve tissues much more predominantly than in non-neuronal tissues. Thus, HPC-1 antigen(s) was confined to be a newly identified neuronal cell membrane protein(s) localized in a subpopulation of neurons.	NATL INST PHYSIOL SCI,DEPT MOLEC PHYSIOL,NEUROCHEM LAB,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES OKAZAKI,SCH LIFE SCI,DEPT PHYSIOL SCI,OKAZAKI,AICHI,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan								AKAGAWA K, 1987, DEV BRAIN RES, V31, P124, DOI 10.1016/0165-3806(87)90089-7; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; AKAGAWA K, 1987, BRAIN RES, V437, P298, DOI 10.1016/0006-8993(87)91644-1; AKAGAWA K, 1990, BRAIN RES, V518, P1, DOI 10.1016/0006-8993(90)90945-8; AKAGAWA K, 1987, BRAIN RES, V408, P154, DOI 10.1016/0006-8993(87)90367-2; BARNSTABLE CJ, 1983, COLD SPRING HARB SYM, V48, P863, DOI 10.1101/SQB.1983.048.01.089; BARNSTABLE CJ, 1980, NATURE, V286, P231, DOI 10.1038/286231a0; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLE GJ, 1986, DEV BRAIN RES, V26, P133, DOI 10.1016/0165-3806(86)90015-5; DRAGER UC, 1984, J NEUROSCI, V4, P2025; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEKETE DM, 1983, J NEUROCYTOL, V12, P785, DOI 10.1007/BF01258151; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELLEBTER J, 1987, FOCUS, V9, P5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INOUE A, 1989, EUR J BIOCHEM, V183, P645, DOI 10.1111/j.1432-1033.1989.tb21094.x; JANIG F, 1990, TRENDS BIOCHEM SCI, V15, P93; KANEKO A, 1979, ANNU REV NEUROSCI, V2, P169, DOI 10.1146/annurev.ne.02.030179.001125; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON V, 1982, J NEUROSCI, V2, P531; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PARRY DAD, 1987, FIBROUS PROTEIN STRU, P141; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; SHIRAO T, 1986, DEV BRAIN RES, V29, P233, DOI 10.1016/0165-3806(86)90099-4; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YOUNG LHY, 1984, P NATL ACAD SCI-BIOL, V81, P6255, DOI 10.1073/pnas.81.19.6255; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	54	271	277	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10613	10619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587842				2022-12-27	WOS:A1992HV09000061
J	ROSENBERG, A; SAUER, A; NOBLE, EP; GROSS, HJ; CHANG, R; BROSSMER, R				ROSENBERG, A; SAUER, A; NOBLE, EP; GROSS, HJ; CHANG, R; BROSSMER, R			DEVELOPMENTAL PATTERNS OF GANGLIOSIDE SIALOSYLATION COINCIDENT WITH NEURITOGENESIS IN CULTURED EMBRYONIC CHICK BRAIN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INTRACELLULAR-TRANSPORT; BREFELDIN-A; CNS NEURONS; RAT-BRAIN; BIOSYNTHESIS; PROTEINS; GLYCOSPHINGOLIPIDS; SIALIDASE; MEMBRANE	Chick brain precursor neurons were observed to introduce sialic acid biosynthetically into only three specific gangliosides: monosialosyl lactosyl ceramide (G(M3)), disialosyl lactosyl ceramide (G(D3)), and disialosyl gangliotrihexosyl ceramide (G(D2)), when sialic acid was labeled metabolically by its obligate precursor, [H-3] ManNAc. Sialosyl donor CMP-[H-3]NeuAc supplied in the culture medium gave rise uniquely to surface-labeled G(D3). Thus sialosyl transferase/G(D3) synthase activity is expressed both intraneuronally and in the neuronal exofacial surface. Upon epidermal growth factor-induced onset of neurite outgrowth, labeled complex sialosyl gangliotetrahexosyl ceramide species of gangliosides began to appear in the embryonic neuronal plasma membrane. However, intraneuronal and exofacial sialosyl transferase/G(D3) synthase activities remained constant, with or without neurite outgrowth. Moreover, simpler species of gangliosides maintained a steady quantitative sialosyl level (1.6 +/- 0.2-mu-g of sialic acid/mg of protein), whereas more complex species completely absent before neurite outgrowth accrued and reached 4.8 +/- 0.9-mu-g of sialic acid/mg of protein with full neurite development. This analysis of developmental patterns of ganglioside sialosylation has provided evidence that stable neurite outgrowth depends upon generation by the neuron of special plasma membrane with a massive content of complex higher species of gangliosides.	UNIV CALIF LOS ANGELES,BRAIN RES INST,ALCOHOL RES CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	ROSENBERG, A (corresponding author), UNIV HEIDELBERG,INST BIOCHIM,W-6900 HEIDELBERG 1,GERMANY.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007653] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07653] Funding Source: Medline; NINDS NIH HHS [NS 24488] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTON NW, 1973, J BIOL CHEM, V248, P7353; BASU M, 1987, METHOD ENZYMOL, V138, P575; BREEN KC, 1986, J NEUROCHEM, V47, P1176; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; DAILEY ME, 1991, J NEUROSCI RES, V30, P242, DOI 10.1002/jnr.490300125; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DURRIE R, 1989, J LIPID RES, V30, P1259; DURRIE R, 1987, J NEUROSCI RES, V18, P456, DOI 10.1002/jnr.490180312; FISCHER S, 1970, Z ZELLFORSCH MIKROSK, V104, P165; GAMMON CM, 1985, J NEUROCHEM, V44, P376, DOI 10.1111/j.1471-4159.1985.tb05427.x; HANNEMAAIJER R, 1991, J NEUROSCI RES, V30, P163; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HESS HH, 1978, ANAL BIOCHEM, V85, P295, DOI 10.1016/0003-2697(78)90304-4; HOGAN MV, 1988, J NEUROSCI RES, V20, P390, DOI 10.1002/jnr.490200313; KINOSHITA A, 1990, J NEUROSCI RES, V25, P324, DOI 10.1002/jnr.490250308; LESKAWA KC, 1981, CELL MOL NEUROBIOL, V1, P373, DOI 10.1007/BF00716272; MASSERINI M, 1988, BIOCHEMISTRY-US, V27, P7973, DOI 10.1021/bi00420a057; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOMOI T, 1976, BIOCHIM BIOPHYS ACTA, V441, P488; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; PFENNINGER KH, 1982, AXOPLASMIC TRANSPORT, P52; PRETI A, 1980, J NEUROCHEM, V35, P281, DOI 10.1111/j.1471-4159.1980.tb06263.x; QUARLES RH, 1971, J NEUROCHEM, V18, P1809, DOI 10.1111/j.1471-4159.1971.tb09586.x; RIBCHESTER RR, 1986, MOL NERVE EMBRYO, P105; ROSENBERG A, 1966, J LIPID RES, V7, P122; ROSENBERG A, 1989, J NEUROSCI RES, V24, P531, DOI 10.1002/jnr.490240411; ROSENBERG A, 1956, NATURE, V177, P234, DOI 10.1038/177234a0; ROSENBERG A, 1992, IN PRESS BRAIN DIFFE; SAITO M, 1985, BIOCHEMISTRY-US, V24, P3054, DOI 10.1021/bi00333a038; SAITO M, 1984, BIOCHEMISTRY-US, V23, P3784, DOI 10.1021/bi00311a034; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SEYFRIED TN, 1985, MOL CELL BIOCHEM, V68, P3; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333	39	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10607	10612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587841				2022-12-27	WOS:A1992HV09000060
J	ITABE, H; KING, WC; REYNOLDS, CN; GLOMSET, JA				ITABE, H; KING, WC; REYNOLDS, CN; GLOMSET, JA			SUBSTRATE-SPECIFICITY OF A COA-DEPENDENT STEAROYL TRANSACYLASE FROM BOVINE TESTIS MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; RAT-LIVER MICROSOMES; PHOSPHATIDYLCHOLINE; PHOSPHOLIPIDS; CONVERSION; SEPARATION; ACYLATION	We identified a CoA-dependent stearoyl transacylase activity in bovine testis membranes, then examined the enzyme's specificity in mixed micelle systems containing the neutral detergent Triton X-100. The enzyme transferred stearoyl groups from a variety of phospholipids to sn-2-arachidonoyl lysophosphatidic acid (lysoPA), but showed very little palmitoyl transacylase activity. Its ability to transfer stearoyl groups was both donor- and acceptor-dependent. For example, it used weakly acidic phospholipids, such as sn-1-stearoyl-2-acyl species of phosphatidylinositol (PI), as donors, but did not use phosphatidylinositol-4,5-bisphosphate or sn-1-stearoyl-2-arachidonoyl phosphatidylcholine. Moreover, it used sn-2-acyl species of lysoPA and sn-2-arachidonoyl lysoPI as acceptors but did not use sn-2-arachidonoyl species of lysophosphatidylserine, lysophosphatidylethanolamine, or lysophosphatidylcholine. When taken together, our results raise the possibility that sn-1-stearoyl-2-acyl species of PI may be the primary acyl donors in the transacylase reaction in vivo, while sn-2-acyl species of lysoPA may be the primary acyl acceptors. Available evidence suggests that the PA that is formed may subsequently be converted into PI, but the metabolic fate of the other reaction product, sn-2-acyl lysoPI, remains to be determined.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SL-15,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			板部板部, 洋之/ABC-7746-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P292, DOI 10.1016/0005-2760(91)90071-O; DAVIDSON FM, 1958, BIOCHEM J, V69, P458, DOI 10.1042/bj0690458; Eggstein M., 1974, METHOD ENZYMAT AN, V4, P1825; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOLUB BJ, 1976, LIPIDS, V11, P251, DOI 10.1007/BF02544050; JUNEJA LR, 1988, BIOCHIM BIOPHYS ACTA, V960, P334, DOI 10.1016/0005-2760(88)90041-0; JUNEJA LR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P277, DOI 10.1016/0005-2760(89)90233-6; LEPAGE G, 1986, J LIPID RES, V27, P114; MASUZAWA Y, 1989, BIOCHIM BIOPHYS ACTA, V1005, P1, DOI 10.1016/0005-2760(89)90024-6; NAKAGAWA Y, 1986, J CHROMATOGR, V381, P225, DOI 10.1016/S0378-4347(00)83588-4; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; PATTON GM, 1982, J LIPID RES, V23, P190; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WALSH JP, 1990, J BIOL CHEM, V265, P4374	17	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15319	15325						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639778				2022-12-27	WOS:A1992JG11300013
J	PUSHKAREVA, MY; KHAN, WA; ALESSENKO, AV; SAHYOUN, N; HANNUN, YA				PUSHKAREVA, MY; KHAN, WA; ALESSENKO, AV; SAHYOUN, N; HANNUN, YA			SPHINGOSINE ACTIVATION OF PROTEIN-KINASES IN JURKAT T-CELLS - INVITRO PHOSPHORYLATION OF ENDOGENOUS PROTEIN SUBSTRATES AND SPECIFICITY OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EPIDERMOID CARCINOMA-CELLS; LONG-CHAIN BASES; SPHINGOMYELIN TURNOVER; SIGNAL TRANSDUCTION; HUMAN-PLATELETS; HL-60 CELLS; INHIBITION; DIFFERENTIATION; HEPARIN	Sphingosine displays multiple biochemical and biological effects, in particular inhibition and activation of protein kinases. To determine the predominant interaction of sphingosine with cellular kinases, the effects of sphingosine on endogenous protein phosphorylation in Jurkat T lymphoblastic cells were investigated in vitro. Sphingosine was found to cause prominent phosphorylation of a number of cytosolic proteins ranging in molecular mass from 18 to 165 kDa. Phosphorylation was calcium-independent. Phosphorylation of substrates was increased in response to concentrations of sphingosine as low as 10-mu-M and peaked at concentrations of 20-200-mu-M. Multiple lines of evidence suggested that sphingosine activated more than one protein kinase: 1) the concentration dependence on sphingosine differed from substrate to substrate, 2) phosphorylation of one group of substrates required ATP as the phosphate donor, whereas a second group showed no preference between ATP and GTP, and 3) phosphorylation of some substrates was inhibited by heparin, whereas other substrates were resistant. Activation of these kinases demonstrated a very specific requirement for D-erythro-sphingoid bases. DL-erythro-dihydrosphingosine was partially active, whereas DL-threo-dihydrosphingosine was not. Other related molecules such as stearylamine, sphingomyelin, and C2-ceramide were not active. Sphingosine-activated kinase(s) were distinct from protein kinase C, cyclic nucleotide-activated kinases, and calcium-dependent kinases. These observations demonstrate the existence of multiple sphingosine-activated protein kinases with high specificity for D-erythro-sphingosine, suggesting physiologic regulation of protein phosphorylation by sphingosine.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; ACAD SCI RUSSIA,INST CHEM PHYS,MOSCOW,USSR; BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709	Duke University; Russian Academy of Sciences; N.N. Semenov Federal Research Centre for Chemical Physics, Russian Academy of Sciences; Burroughs Wellcome Fund	PUSHKAREVA, MY (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3355 DUMC,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CONKLING PR, 1989, J BIOL CHEM, V264, P18440; CRISS WE, 1978, CANCER RES, V38, P3532; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1990, J BIOL CHEM, V265, P7345; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MORI T, 1980, J BIOL CHEM, V255, P8378; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ROSE KM, 1981, J BIOL CHEM, V256, P7468; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; TAUZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WEISS B, 1982, BIOCHEM PHARMACOL, V13, P2217; WILSON E, 1986, J BIOL CHEM, V261, P2616; WRENN RW, 1981, LIFE SCI, V29, P725, DOI 10.1016/0024-3205(81)90026-6; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHU XX, 1989, J BIOL CHEM, V264, P14556	44	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15246	15251						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634554				2022-12-27	WOS:A1992JF08800108
J	VOLLENWEIDER, F; IRMINGER, JC; GROSS, DJ; VILLAKOMAROFF, L; HALBAN, PA				VOLLENWEIDER, F; IRMINGER, JC; GROSS, DJ; VILLAKOMAROFF, L; HALBAN, PA			PROCESSING OF PROINSULIN BY TRANSFECTED HEPATOMA (FAO) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE SECRETORY PATHWAY; MURINE LEUKEMIA-VIRUS; PANCREATIC BETA-CELL; MAMMARY-TUMOR VIRUS; RAT HEPATOCYTES; EXPRESSION; INSULIN; PROALBUMIN; PRECURSOR; CDNA	Rat hepatoma (FAO) cells were stably transfected with the gene encoding either rat proinsulin II (using the DOL retroviral vector) or human proinsulin (using the RSV retroviral vector). Using the DOL vector, production of insulin immunoreactive material was stimulated up to 30-fold by dexamethasone (5 x 10(-7) M). For both proinsulins, fractional release of immunoreactive material relative to cellular content was high, in keeping with the absence of any storage compartment for secretory proteins in these cells. Pulse-chase experiments showed kinetics of release of newly synthesized products in keeping with release via the constitutive pathway. High performance liquid chromatography analysis showed immunoreactivity in the medium distributed between three peaks. For rat proinsulin II, the first coeluted with intact proinsulin; the second coeluted with des-64,65 split proinsulin (the product of endoproteolytic attack between the insulin A-chain and C-peptide followed by trimming of C-terminal basic residues by carboxypeptidase); the third (and minor peak) coeluted with native (fully processed) insulin. For human proinsulin, by contrast, the second peak coeluted with des-31,32 split proinsulin (split and trimmed at the B-chain/C-peptide junction). Analysis of cellular extracts showed intact proinsulin as the major product. The generation of the putative conversion intermediates and insulin was not due to proteolysis of proinsulin after its release but rather to an intracellular event. The data suggest that proinsulin, normally processed in secretory granules and released via the regulated pathway, may also be processed, albeit less efficiently, by the constitutive pathway conversion machinery. The comparison of the sites preferentially cleaved in rat II or human proinsulin suggests cleavage by endoprotease(s) with a preference for R/KXR/KR as substrate.	UNIV GENEVA,MED CTR,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND; HADASSAH UNIV HOSP,DEPT ENDOCRINOL & METAB,JERUSALEM,ISRAEL; CHILDRENS HOSP MED CTR,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of Geneva; Hebrew University of Jerusalem; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-35292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1990, J BIOL CHEM, V265, P14828; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; COHEN RM, 1986, METABOLISM, V35, P1137, DOI 10.1016/0026-0495(86)90027-2; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DUCKWORTH WC, 1988, BIOCHEM J, V255, P277; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GERMAIN D, 1990, MOL ENDOCRINOL, V4, P1572, DOI 10.1210/mend-4-10-1572; GOLD G, 1988, BIOCHEM BIOPH RES CO, V156, P457, DOI 10.1016/S0006-291X(88)80863-5; GROSS D, 1988, FEBS LETT, V241, P205, DOI 10.1016/0014-5793(88)81062-7; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; GRUSS P, 1981, P NATL ACAD SCI-BIOL, V78, P133, DOI 10.1073/pnas.78.1.133; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1990, TRENDS ENDOCRIN MET, V1, P261, DOI 10.1016/1043-2760(90)90007-P; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HEDO JA, 1983, J BIOL CHEM, V258, P20; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; JUDAH JD, 1978, NATURE, V271, P384, DOI 10.1038/271384a0; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LAUB O, 1983, J BIOL CHEM, V258, P6043; LOMEDICO PT, 1982, P NATL ACAD SCI-BIOL, V79, P5798, DOI 10.1073/pnas.79.19.5798; MISUMI Y, 1984, FEBS LETT, V175, P63, DOI 10.1016/0014-5793(84)80570-0; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, BIOCHEM BIOPH RES CO, V171, P236, DOI 10.1016/0006-291X(90)91382-3; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OVERHAUSER J, 1985, J VIROL, V54, P133, DOI 10.1128/JVI.54.1.133-144.1985; PODLECKI DA, 1984, DIABETES, V33, P111, DOI 10.2337/diabetes.33.2.111; QUINN D, 1991, J CELL BIOL, V113, P987, DOI 10.1083/jcb.113.5.987; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REDMAN CM, 1978, J CELL BIOL, V77, P400, DOI 10.1083/jcb.77.2.400; REDMAN CM, 1983, J BIOL CHEM, V258, P3446; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZOLLINGER L, 1988, MOL CELL ENDOCRINOL, V58, P31, DOI 10.1016/0303-7207(88)90051-2	62	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14629	14636						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634510				2022-12-27	WOS:A1992JF08800024
J	LEDUC, R; MOLLOY, SS; THORNE, BA; THOMAS, G				LEDUC, R; MOLLOY, SS; THORNE, BA; THOMAS, G			ACTIVATION OF HUMAN FURIN PRECURSOR PROCESSING ENDOPROTEASE OCCURS BY AN INTRAMOLECULAR AUTOPROTEOLYTIC CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN; ENZYME; KEX2; SITE; EXPRESSION; PROHORMONE; SEQUENCE; INVIVO	Human furin is a calcium-dependent serine endoprotease that can efficiently cleave many precursor proteins on the carboxyl side of the consensus cleavage sequence, -Arg-X-Lys/Arg-Arg-, both in vivo and in vitro. Analysis of furin proteins in extracts of cells infected with a vaccinia recombinant expressing human furin show that the enzyme is present as two prominent forms of 90 and 96 kDa. Because the structurally related bacterial subtilisins require endoproteolytic removal of the NH2-terminal pro-region by an autocatalytic intramolecular cleavage, we speculated that the size heterogeneity in the furin doublet similarly may result from a proteolytic removal of an NH2-terminal pro-region. Here we report identification of the 90-kDa furin NH2 terminus and, based on the reported sequence of the furin cDNA, demonstrate that this furin protein is derived from a larger precursor by an endoproteolytic cleavage on the COOH-terminal side of a consensus furin cleavage site, -Arg-Thr-Lys-Arg107-. Expression of mutant furin molecules containing an altered cleavage site (Arg104 --> Ala or Arg107 --> Gly) resulted in the production of only the 96-kDa furin protein. Assays of furin-dependent cleavage of a protein substrate in vitro showed that proteolytic activity was associated with the 90-kDa and not the 96-kDa furin protein, demonstrating that removal of the NH2-terminal pro-region is required for furin activity. Expression of a third furin construct containing a mutation of the active site aspartate (Asp153 --> Asn) similarly resulted in the expression of only the 96-kDa protein, suggesting that furin activation occurs by an autoproteolytic cleavage. Finally, the production of 90-kDa furin from either site-directed furin mutant could not be potentiated by overexpressing active furin, suggesting that the autoproteolytic activation was an intramolecular event.	OREGON HLTH SCI UNIV,INST VOLLUM,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044629, R01DK037274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44629, DK-37274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATHAUDA SBP, 1991, BIOCHEM BIOPH RES CO, V175, P152, DOI 10.1016/S0006-291X(05)81213-6; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRESNAHAN PA, 1992, IN PRESS MECHANISM I; CHANCE RE, 1968, SCIENCE, V161, P165, DOI 10.1126/science.161.3837.165; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAYFLICK JS, 1992, J NEUROSCI, V12, P705; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hruby D E, 1986, Methods Enzymol, V124, P295; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; ROEBROEK AJM, 1991, FEBS LETT, V289, P133, DOI 10.1016/0014-5793(91)81052-A; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; THORNE BA, 1990, J BIOL CHEM, V265, P8436; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	39	146	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14304	14308						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629222				2022-12-27	WOS:A1992JD32500079
J	YULE, DI; WILLIAMS, JA				YULE, DI; WILLIAMS, JA			U73122 INHIBITS CA2+ OSCILLATIONS IN RESPONSE TO CHOLECYSTOKININ AND CARBACHOL BUT NOT TO JMV-180 IN RAT PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; INOSITOL TRISPHOSPHATE; PHOSPHOLIPASE-C; POLYMORPHONUCLEAR NEUTROPHILS; CYTOSOLIC CALCIUM; AMYLASE SECRETION; TUMOR PROMOTER; G-PROTEINS; RECEPTORS; HYDROLYSIS	Stimulation of rat pancreatic acinar cells with low concentrations of phosphatidylinositol (PI)-linked secretagogues induces [Ca2+]i oscillations, without measurable changes in the formation of inositol 1,4,5-trisphosphate. Therefore, we tested U73122 a new phospholipase C inhibitor to determine if PI turnover is necessary for the generation of [Ca2+]i oscillations. In acini prelabeled with [H-3]inositol, PI hydrolysis on stimulation with either cholecystokinin or carbachol was inhibited dose-dependently by U73122, with a maximal effect seen at 10-mu-M; the formation of inositol 1,4,5-trisphosphate, measured using a radioreceptor assay, was also similarly inhibited. By contrast secretin- or vasoactive intestinal peptide-stimulated production of cAMP was unaffected by 10-mu-M U73122. These studies indicate that U73122 is a relatively specific inhibitor of G-protein-mediated phospholipase C activation in pancreatic acini. In fura-2-loaded acini, U73122 inhibited the increases in [Ca2+]i stimulated by these high concentrations of secretagogues which can be demonstrated to elicit PI turnover. The [Ca2+]i signal generated by directly stimulating G-proteins with sodium fluoride was also inhibited by U73122; however, the [Ca2+]i rise induced by thapsigargin was unaffected. These data indicate that the mechanism of inhibition was distal to the occupation of cell surface receptors but did not involve an interference of Ca2+ metabolism in general. When [Ca2+]i oscillations were elicited by low concentrations of cholecystokinin or carbachol, U73122 rapidly inhibited the oscillating [Ca2+]i signal. In contrast, oscillations induced by an analogue of cholecystokinin, JMV-180, which does not stimulate changes in PI metabolism at any concentration, were unaffected. This indicates that cholecystokinin- and carbachol-induced oscillations are probably initiated by small, localized changes in PI metabolism, which are not readily detectable. However, the inability of U73 122 to inhibit JMV-180-induced oscillations indicates that PI metabolism may not necessarily be a prerequisite for the generation of [Ca2+]i oscillations.			YULE, DI (corresponding author), UNIV MICHIGAN,DEPT PHYSIOL,7744 MED SCI 2,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41225] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HOOTMAN SR, 1987, PHYSL GASTROINTESTIN, P1129; KORMAN LY, 1980, AM J PHYSIOL, V239, pG324, DOI 10.1152/ajpgi.1980.239.4.G324; MATOZAKI T, 1988, AM J PHYSIOL, V255, pE652, DOI 10.1152/ajpendo.1988.255.5.E652; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1989, J BIOL CHEM, V264, P14729; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MOLERO X, 1990, MOL PHARMACOL, V39, P150; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; ROBBERECHT P, 1976, J BIOL CHEM, V251, P4635; ROWLEY WH, 1990, AM J PHYSIOL, V259, pG655, DOI 10.1152/ajpgi.1990.259.4.G655; SALUJA A, 1991, J CELL BIOL, V115, P272; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WILLIAMS JA, 1987, REGUL PEPTIDES, V18, P109, DOI 10.1016/0167-0115(87)90041-3; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, BIOCHEM BIOPH RES CO, V177, P159, DOI 10.1016/0006-291X(91)91962-C; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	45	340	340	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13830	13835						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629184				2022-12-27	WOS:A1992JD32500010
J	ZOVICH, DC; OROLOGA, A; OKUNO, M; KONG, LWY; TALMAGE, DA; PIANTEDOSI, R; GOODMAN, DS; BLANER, WS				ZOVICH, DC; OROLOGA, A; OKUNO, M; KONG, LWY; TALMAGE, DA; PIANTEDOSI, R; GOODMAN, DS; BLANER, WS			DIFFERENTIATION-DEPENDENT EXPRESSION OF RETINOID-BINDING PROTEINS IN BFC-1-BETA ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; EMBRYONAL CARCINOMA-CELLS; PREADIPOCYTE CLONAL LINE; VISCERAL YOLK-SAC; VITAMIN-A STATUS; ACID RECEPTOR; ADIPOSE CONVERSION; RAT-LIVER; GENE; INSULIN	Recently, we demonstrated that adipose tissue plays an important role in retinol storage and retinol-binding protein (RBP) synthesis. Our data suggested that RBP expression in adipose tissue is dependent on the state of adipocyte differentiation. To examine this possibility, we explored the differentiation-dependent expression of RBP using BFC-1-beta preadipocytes, which can be stimulated to undergo adipose differentiation. Total RNA was isolated from undifferentiated (preadipocytes) and differentiated (adipocytes) BFC-1-beta cells and analyzed by Northern blotting. RBP mRNA was not detected in the preadipocytes, but considerable RBP mRNA was present in differentiated BFC-1-beta cells. In BFC-1-beta cells, induced to differentiate with insulin and thyroid hormone, RBP mRNA was first detected after 4 days, reached a maximum level by day 10, and remained at this maximum level for at least 2 more days. Cellular retinol-binding protein was expressed at low levels in the BFC-1-beta preadipocytes and the level of expression increased for 6 days after induction to differentiate and slowly declined on later days. Neither the maximum level of RBP expression nor the day on which this level was reached was influenced by the level of retinol provided in the BFC-1-beta culture medium. BFC-1-beta cells secreted newly synthesized RBP into the culture medium at a rate of 43 +/- 14 ng RBP/24 h/10(6) adipocytes. When the BFC-1-beta adipocytes were provided 1.0-mu-M retinol in the medium, they accumulated the retinol and synthesized retinyl esters. These studies with BFC-1-beta cells confirm that RBP synthesis and secretion and retinol accumulation are intrinsic properties of differentiated adipocytes. Furthermore, they suggest that RBP and cellular retinol-binding protein gene expression are regulated as part of a package of genes which are modulated during adipocyte differentiation.	COLUMBIA UNIV, INST HUMAN NUTR, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University				Talmage, David/0000-0003-4627-3007	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005968, R37DK005968, R01DK043097] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26854] Funding Source: Medline; NIDDK NIH HHS [DK 43097, DK 05968] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1991, AM J PHYSIOL, V261, pE76, DOI 10.1152/ajpendo.1991.261.1.E76; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1986, J LIPID RES, V27, P1084; BLANER WS, 1990, METHOD ENZYMOL, V189, P193; BLANER WS, 1987, EUR J BIOCHEM, V164, P301, DOI 10.1111/j.1432-1033.1987.tb11058.x; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BROUWER A, 1988, CHEM-BIOL INTERACT, V68, P203, DOI 10.1016/0009-2797(88)90017-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; ESPESETH AS, 1989, GENE DEV, V3, P1647, DOI 10.1101/gad.3.11.1647; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; GOODMAN DS, 1984, RETINOIDS, V2, P1; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HERBERT J, 1991, INVEST OPHTH VIS SCI, V32, P302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LEWIS KC, 1990, J LIPID RES, V31, P1535; MAKOVER A, 1989, J LIPID RES, V30, P171; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1982, MOL CLONING LABORATO, P312; MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7; MUTO Y, 1972, J BIOL CHEM, V247, P2542; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; RAJAN N, 1990, J LIPID RES, V31, P821; RIAZULHAQ, 1991, BIOCHEM BIOPH RES CO, V176, P1539, DOI 10.1016/0006-291X(91)90462-G; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SOPRANO DR, 1986, P NATL ACAD SCI USA, V83, P7330, DOI 10.1073/pnas.83.19.7330; SOPRANO DR, 1986, J LIPID RES, V27, P166; SOPRANO DR, 1988, J BIOL CHEM, V263, P17897; SOPRANO DR, 1988, J BIOL CHEM, V263, P2934; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	47	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13884	13889						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629187				2022-12-27	WOS:A1992JD32500018
J	GRABER, SG; FIGLER, RA; KALMANMALTESE, VK; ROBISHAW, JD; GARRISON, JC				GRABER, SG; FIGLER, RA; KALMANMALTESE, VK; ROBISHAW, JD; GARRISON, JC			EXPRESSION OF FUNCTIONAL G-PROTEIN BETA-GAMMA DIMERS OF DEFINED SUBUNIT COMPOSITION USING A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC K+-CHANNEL; C-TERMINAL CYSTEINE; ADENYLATE-CYCLASE; INSECT CELLS; BRAIN; TRANSDUCIN; PURIFICATION; ACTIVATE; HOMOLOGY; CONTAIN	The 36-kDa-beta-1, 35-kDa-beta-2, and 6.5-kDa-gamma-2 subunits of the heterotrimeric guanine nucleotide-binding proteins have been overexpressed in Sf9 cells using a baculovirus expression system. The gamma-2 subunit expressed in Sf9 cells incorporated label derived from [H-3]mevalonate and is therefore likely to be isoprenylated, as is its mammalian counterpart. Extracts of Sf9 cells doubly infected with viruses encoding a beta-subunit and viruses encoding a gamma-subunit are active in promoting the pertussis toxin-catalyzed ADP-ribosylation of a G protein alpha-subunit. However, extracts from Sf9 cells singly infected with viruses encoding either a beta or gamma-subunit are not active in this assay. Results demonstrate utility of the insect/baculovirus system for expressing G protein beta-gamma-subunits of defined composition.	UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; GEISINGER MED CTR,WEISS CTR RES,DANVILLE,PA 17822	University of Virginia; Geisinger Medical Center	GRABER, SG (corresponding author), UNIV VIRGINIA,SCH MED,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039867, R01GM039867] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-39867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELO CS, 1987, J VIROL, V61, P361; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; DODSON MS, 1989, J BIOL CHEM, V264, P20835; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FOSTER KA, 1990, AM J PHYSIOL, V259, P1271; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRABER SG, 1992, J BIOL CHEM, V267, P1271; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWE PN, 1990, ONCOGENE, V5, P1045; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1984, J BIOL CHEM, V259, P4222; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SIMON MI, 1991, SCIENCE, V252, P804; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1983, J VIROL, V46, P584, DOI 10.1128/JVI.46.2.584-593.1983; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	40	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13123	13126						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618813				2022-12-27	WOS:A1992JB74600003
J	HAMANAKA, R; KOHNO, K; SEGUCHI, T; OKAMURA, K; MORIMOTO, A; ONO, M; OGATA, J; KUWANO, M				HAMANAKA, R; KOHNO, K; SEGUCHI, T; OKAMURA, K; MORIMOTO, A; ONO, M; OGATA, J; KUWANO, M			INDUCTION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR AND A TRANSCRIPTION FACTOR SP-1 BY TUMOR-NECROSIS-FACTOR IN HUMAN MICROVASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN-SKIN FIBROBLASTS; MONOCYTE-MACROPHAGES; FACTOR CACHECTIN; LDL RECEPTOR; FACTOR-ALPHA; KAPPA-B; GENE; INTERLEUKIN-1; EXPRESSION	We have previously reported that tumor necrosis factor-alpha (TNF-alpha) enhances expression of interleukin-6, collagenase, plasminogen activator inhibitor-1, and basic fibroblast growth factor genes in human omental microvascular endothelial (HOME) cells in culture. In this study, we found that treatment of HOME cells with TNF-alpha or interleukin-1 (IL-1) caused enhanced expression of low density lipoprotein (LDL) receptor. A few-fold increase in both LDL binding activity and the receptor mRNA levels was observed when HOME cells were treated with either TNF-alpha or IL-1. Northern blot analysis showed that cellular expression of LDL receptor gene was significantly increased 12-24 h after exposure to TNF-alpha. No significant changes in the life-span of LDL receptor mRNA were observed in untreated and TNF-alpha-treated cells. Scatchard analysis showed-an increased receptor number for LDL in TNF-alpha-treated cells. Parallel to increased LDL binding activity, internalization and degradation of LDL were also increased in HOME cells treated with TNF-alpha or IL-1. TNF-alpha-induced enhancement of LDL receptor gene expression was not observed when cycloheximide was present. Cellular mRNA level of SP-1 gene was increased about 3-4-fold at 12 h after treatment with TNF-alpha. Nuclear run-on assays showed increased transcription of LDL receptor gene as well as SP-1 gene by TNF-alpha. Gel retardation assay with the SP-1 consensus fragment showed that SP-1 binding activity was increased about 4-5-fold 12-24 h after treatment with TNF-alpha. NF-kB binding activity was also dramatically increased, but there is no NF-kB motif on the promoter for LDL receptor gene. The induction of LDL receptor by TNF might be mediated through a transcription factor, SP-1.	OITA MED UNIV,DEPT BIOCHEM,OITA 87955,JAPAN; OITA MED UNIV,DEPT UROL,OITA 87955,JAPAN	Oita University; Oita University								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; CHIAT A, 1980, P NATL ACAD SCI USA, V77, P4084; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FISHER R, 1985, J BIOL CHEM, V260, P1223; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GERRITY RG, 1979, AM J PATHOL, V95, P775; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARADA K, 1990, BIOCHEM BIOPH RES CO, V172, P1022, DOI 10.1016/0006-291X(90)91548-7; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESANIEMI YA, 1983, J CLIN INVEST, V71, P950, DOI 10.1172/JCI110849; KOHNO K, 1990, J BIOL CHEM, V265, P19690; LIBBY P, 1986, AM J PATHOL, V124, P179; LOWENTHAL JW, 1989, J IMMUNOL, V142, P3121; MATSUDA T, 1992, J CELL PHYSIOL, V150, P510, DOI 10.1002/jcp.1041500311; MAWATARI M, 1991, EXP CELL RES, V192, P574, DOI 10.1016/0014-4827(91)90078-9; MAWATARI M, 1989, J IMMUNOL, V143, P1619; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; NAWROTH PP, 1986, J EXP MED, V163, P1363, DOI 10.1084/jem.163.6.1363; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SATO Y, 1991, BIOCHEM BIOPH RES CO, V174, P1260, DOI 10.1016/0006-291X(91)91557-S; SHITE S, 1988, J BIOL CHEM, V263, P19286; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TOMITA K, 1987, J BIOL CHEM, V262, P1398; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	37	98	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13160	13165						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618817				2022-12-27	WOS:A1992JB74600012
J	VERGERES, G; WASKELL, L				VERGERES, G; WASKELL, L			EXPRESSION OF CYTOCHROME-B(5) IN YEAST AND CHARACTERIZATION OF MUTANTS OF THE MEMBRANE-ANCHORING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; PHOTOACTIVATABLE PHOSPHOLIPIDS; EMBEDDED SEGMENT; CROSS-LINKING; REDUCTASE; PROTEINS; BINDING; PURIFICATION; MUTAGENESIS; INSERTION	The soluble and membrane-bound forms of the synthetic rat cytochrome b5 gene have been expressed in Saccharomyces cerevisiae. In order to examine the topology and function of the COOH-terminal membrane binding domain of cytochrome b5, mutants have been constructed, expressed, purified, and partially characterized. Pro-115 is located in the middle of the putative alpha-helical membrane-anchoring domain of cytochrome b5 and has been hypothesized to give rise to either a hairpin-like loop or congruent-to 26-degrees kink in the helix, depending on whether it exists, respectively, in the cis or trans configuration. The Pro-115 --> Ala mutant, which is expected to have a straight transmembrane helix, inserted normally into the endoplasmic reticulum and exhibited wild type levels of activity in yeast microsomes and in vitro in the cytochrome P-450 mixed function oxidation system. Since a hairpin structure does not appear to be essential, it is likely that the membrane binding domain of cytochrome b5 spans the membrane. Characterization of the truncated cytochrome b5 molecule, Pro-115 --> Stop, lacking 19 amino acids at the COOH terminus indicates that the distal part of the membrane binding domain of cytochrome b5 is necessary for in vivo binding to the endoplasmic reticulum and for functioning with its membrane-associated electron transfer partners. Replacement of Ser-104 to Met-125, the putative membrane-anchoring domain of cytochrome b5, with 22 leucine residues results in a protein which targets to the endoplasmic reticulum but the extent of its reduction is only 50% of that of the wild type in yeast microsomes. In vitro, the polyleucine mutant is unable to support substrate oxidation by cytochrome P-450. The mutation of Ala-131 and Glu-132, amino acids flanking the transmembrane domain, to lysines resulted in a protein with normal membrane topology and function.	UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, DEPT ANESTHESIA, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIGMS NIH HHS [GM 35333] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P5425, DOI 10.1073/pnas.87.14.5425; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BENDZKO P, 1982, EUR J BIOCHEM, V123, P121, DOI 10.1111/j.1432-1033.1982.tb06507.x; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BUTT TR, 1987, MICROBIOL REV, V51, P351, DOI 10.1128/MMBR.51.3.351-364.1987; CANOVADAVIS E, 1985, BIOCHEM PHARMACOL, V34, P1907, DOI 10.1016/0006-2952(85)90307-7; CANOVADAVIS E, 1984, J BIOL CHEM, V259, P2541; CARLSEN J, 1988, BIOCHEM J, V256, P1051, DOI 10.1042/bj2561051; CHOU MM, 1990, J BIOL CHEM, V265, P2873; Coon M J, 1978, Methods Enzymol, V52, P109; DAILEY HA, 1981, J BIOL CHEM, V256, P1677; DAILEY HA, 1979, J BIOL CHEM, V254, P5388; DAILEY HA, 1978, J BIOL CHEM, V253, P8203; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENOCH HG, 1977, J BIOL CHEM, V252, P5656; ENOCH HG, 1979, J BIOL CHEM, V254, P6483; ETCHEVERRY T, 1986, BIO-TECHNOL, V4, P726, DOI 10.1038/nbt0886-726; ETCHEVERRY T, 1990, METHOD ENZYMOL, V185, P319; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEORGE SK, 1989, J BACTERIOL, V171, P4569, DOI 10.1128/jb.171.9.4569-4576.1989; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEGESH E, 1986, NEW ENGL J MED, V314, P757, DOI 10.1056/NEJM198603203141206; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HOLLOWAY PW, 1990, BIOCHEMISTRY-US, V29, P9631, DOI 10.1021/bi00493a018; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ISHIDATE K, 1969, J BIOCHEM, V65, P375, DOI 10.1093/oxfordjournals.jbchem.a129024; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; KONOPKA K, 1988, BIOCHIM BIOPHYS ACTA, V954, P189, DOI 10.1016/0167-4838(88)90071-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; OSHINO N, 1982, HEPATIC CYTOCHROME P, P407; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singer S. J., 1971, STRUCTURE FUNCTION B, P145; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SPIESS M, 1987, EMBO J, V6, P2683, DOI 10.1002/j.1460-2075.1987.tb02560.x; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9128; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; VATSIS KP, 1982, J BIOL CHEM, V257, P1221; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WASKELL LA, 1991, METHOD ENZYMOL, V206, P523; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YOSHIDA Y, 1983, ARCH BIOCHEM BIOPHYS, V220, P467, DOI 10.1016/0003-9861(83)90437-X; YOSHIDA Y, 1974, BIOCHEMISTRY-US, V75, P1211; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	65	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12583	12591						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618763				2022-12-27	WOS:A1992HZ48300034
J	WU, GY; WU, CH				WU, GY; WU, CH			SPECIFIC-INHIBITION OF HEPATITIS-B VIRAL GENE-EXPRESSION INVITRO BY TARGETED ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; CELLS; OLIGODEOXYNUCLEOTIDES; DNA; TRANSPORT; RECEPTOR	A 21-mer oligodeoxynucleotide complementary to the polyadenylation signal for human hepatitis B virus (HBV) was complexed to a soluble DNA-carrier system that is targetable to hepatocytes via asialoglycoprotein receptors present on those cells. A cell line, HepG2 (2.2.15) that possesses asialoglycoprotein receptors and is permanently transfected with hepatitis B virus (ayw subtype) was exposed to complexed antisense DNA or controls. In the presence of complexed anti-sense DNA, the concentration of hepatitis B surface antigen in medium was 80% lower than controls after 24 h. Furthermore, during the next 6 days, there was no significant increase in surface antigen concentration in the presence of complexed antisense DNA. The inhibition could be effectively blocked by competition with an excess of free asialoglycoprotein. Total protein synthesis remained unchanged by exposure to complexed antisense sequences under identical conditions. In addition, HBV DNA in the medium and cell layers after 24-h exposure to complexed antisense sequences was 80% lower than in controls. The data indicate that antisense oligonucleotides complexed by a soluble DNA-carrier system can be targeted to cells via asialoglycoprotein receptors resulting in specific inhibition of hepatitis B viral gene expression and replication.			WU, GY (corresponding author), UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,263 FARMINGTON AVE,FARMINGTON,CT 06030, USA.				NCI NIH HHS [CA-01110] Funding Source: Medline; NIDDK NIH HHS [DK-42182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BEVILACQUA A, 1988, P NATL ACAD SCI USA, V85, P831, DOI 10.1073/pnas.85.3.831; GANEM D, 1982, REV INFECT DIS, V4, P1026; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HIRSCHMAN SZ, 1980, P NATL ACAD SCI-BIOL, V77, P5507, DOI 10.1073/pnas.77.9.5507; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7705; MILLER JM, 1985, J AM COLL CARDIOL, V6, P769, DOI 10.1016/S0735-1097(85)80480-0; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; STEIN CA, 1988, CANCER RES, V48, P2659; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14261	18	183	233	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12436	12439						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618751				2022-12-27	WOS:A1992HZ48300012
J	ZIERE, GJ; VANDIJK, MCM; BIJSTERBOSCH, MK; VANBERKEL, TJC				ZIERE, GJ; VANDIJK, MCM; BIJSTERBOSCH, MK; VANBERKEL, TJC			LACTOFERRIN UPTAKE BY THE RAT-LIVER - CHARACTERIZATION OF THE RECOGNITION SITE AND EFFECT OF SELECTIVE MODIFICATION OF ARGININE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; BINDING; CELLS; INVIVO; GLYCOPROTEINS; RECEPTOR; LIGAND; LOCALIZATION; ENDOCYTOSIS; DEGRADATION	Recently it was found that lactoferrin, an iron-binding glycoprotein with a molecular weight of 76,500, inhibits the remnant receptor-mediated uptake of apo-lipoprotein E (apoE)-bearing lipoproteins by the liver. In the present study we characterized the hepatic recognition of lactoferrin. Intravenously injected I-125-lactoferrin was cleared rapidly from the circulation by the liver (92.8 +/- 9.5% of the dose at 5 min after injection). Parenchymal cells contained 97.1 +/- 1.5% of the hepatic radioactivity. Internalization, monitored by measuring the release of liver-associated radioactivity by the polysaccharide fucoidin, occurred slowly. Only about 40% of the liver-associated lactoferrin was internalized at 10 min after injection, and it took 180 min to internalize 90%. Subcellular fractionation indicated that internalized lactoferrin is transported to the lysosomes. Binding of lactoferrin to isolated parenchymal liver cells was saturable with a dissociation constant of 10-mu-M (20 x 10(6) binding sites/cell). The role of arginine residues on lactoferrin was studied by modifying these residues with 1,2-cyclohexanedione. The modification resulted in a strongly reduced liver association (15.9 +/- 1.6% of the dose at 5 min after injection). Furthermore, unlabeled 1,2-cyclohexanedione-modified lactoferrin did not inhibit the binding of I-125-lactoferrin to isolated parenchymal cells. Arginine residues on lactoferrin thus appear to be essential for its specific recognition by parenchymal liver cells. In particular the clustered N-terminal arginine residues, which resemble the arginine-rich receptor binding sequence in apoE, may be responsible for both the interaction of lactoferrin with its recognition site and the inhibition of the hepatic uptake of apoE-bearing lipoproteins.	LEIDEN UNIV, SYLVIUS LAB,CTR BIOPHARMACEUT SCI, DIV BIOPHARMACEUT,POB 9503, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021					ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BENNETT RM, 1979, CLIN SCI, V57, P453, DOI 10.1042/cs0570453; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BLUARDDECONINCK JM, 1978, BIOCHEM J, V171, P321, DOI 10.1042/bj1710321; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; CASTELEIJN E, 1986, FEBS LETT, V201, P193, DOI 10.1016/0014-5793(86)80607-X; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; COURTOY PJ, 1984, LAB INVEST, V50, P329; DORLAND L, 1977, FEBS LETT, V77, P15, DOI 10.1016/0014-5793(77)80183-X; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GORIUS JB, 1980, AM J PATHOL, V99, P413; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P259, DOI 10.1042/bj1990259; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; IMBER MJ, 1982, J BIOL CHEM, V257, P5129; IMBER MJ, 1983, BIOCHEM J, V212, P249, DOI 10.1042/bj2120249; KARLE H, 1979, SCAND J HAEMATOL, V23, P303; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; LEE BR, 1991, J LIPID RES, V32, P165; LEGER D, 1977, ANN BIOL ANIM BIOCH, V17, P737, DOI 10.1051/rnd:19770609; Masson P. L., 1966, PROTIDES BIOL FLUIDS, V14, P115; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MOGUILEVSKY N, 1984, LAB INVEST, V50, P335; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; PATTHY L, 1975, J BIOL CHEM, V250, P557; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PIZZO SV, 1981, BIOCHEM BIOPH RES CO, V101, P704, DOI 10.1016/0006-291X(81)91315-2; PRIEELS JP, 1978, P NATL ACAD SCI USA, V75, P2215, DOI 10.1073/pnas.75.5.2215; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; RECOECZI E, 1985, AM J PHYSIOL, V248, pG8; RETEGUI LA, 1984, LAB INVEST, V50, P323; SCHLEPPERSCHAFER J, 1986, EXP CELL RES, V165, P494, DOI 10.1016/0014-4827(86)90602-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPIK G, 1966, CR ACAD SCI D NAT, V263, P893; SPITZNAGEL JK, 1972, J CLIN INVEST, V51, pA93; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANDIJK MCM, 1992, IN PRESS EUR J BIOCH; VANSNICK JL, 1976, J EXP MED, V144, P1568, DOI 10.1084/jem.144.6.1568; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9	45	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11229	11235						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597458				2022-12-27	WOS:A1992HX16900048
J	MIURA, M; ASOU, H; KOBAYASHI, M; UYEMURA, K				MIURA, M; ASOU, H; KOBAYASHI, M; UYEMURA, K			FUNCTIONAL EXPRESSION OF A FULL-LENGTH CDNA CODING FOR RAT NEURAL CELL-ADHESION MOLECULE-L1 MEDIATES HOMOPHILIC INTERCELLULAR-ADHESION AND MIGRATION OF CEREBELLAR NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; IMMUNOGLOBULIN SUPERFAMILY; MICROEXPLANT CULTURES; POSTNATAL-DEVELOPMENT; MOUSE CEREBELLUM; L1; BINDING; PROTEIN; GLIA; GLYCOPROTEINS	Neural cell adhesion molecule L1 is postulated to be involved in cell-cell interaction, neurite elongation, fasciculation of axons, cell migration, and myelination. To determine the function of L1 directly, we have transfected rat L1 cDNA into mouse fibroblast L cells. Stable transformants expressing L1 showed uniform surface expression of the molecule without phenotypic changes. Dispersed L1-expressing transfectants aggregated with faster kinetics than control cells in a homophilic manner. Divalent cations were not required for this cell aggregation. L1-transfected cells markedly enhanced neuronal cell adhesion and migration in co-culture with rat cerebellar neurons. These results indicate that L1 is involved in a determinant step of neural development through molecular interactions.			MIURA, M (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.							ALTMAN J, 1969, J COMP NEUROL, V136, P269, DOI 10.1002/cne.901360303; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; BOCK E, 1985, EMBO J, V4, P2765, DOI 10.1002/j.1460-2075.1985.tb04001.x; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1984, J NEUROSCI, V4, P2354; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1984, EMBO J, V3, P733, DOI 10.1002/j.1460-2075.1984.tb01876.x; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FISCHER G, 1986, J NEUROSCI, V6, P605; FUSHIKI S, 1986, DEV BRAIN RES, V24, P153, DOI 10.1016/0165-3806(86)90183-5; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P7989, DOI 10.1073/pnas.81.24.7989; GRUMET M, 1984, J CELL BIOL, V98, P1746, DOI 10.1083/jcb.98.5.1746; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P267, DOI 10.1073/pnas.81.1.267; GUAN C, 1988, GENE, V67, P21; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HAVLIN ML, 1991, GENOMICS, V11, P416; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P238, DOI 10.1016/0167-4781(91)90108-X; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LINDNER J, 1986, BRAIN RES, V377, P298, DOI 10.1016/0006-8993(86)90872-3; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCGUIRE JC, 1978, CELL, V15, P357, DOI 10.1016/0092-8674(78)90004-1; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIRSKY R, 1986, J NEUROCYTOL, V15, P799, DOI 10.1007/BF01625196; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGATA I, 1990, DEV BRAIN RES, V52, P63, DOI 10.1016/0165-3806(90)90222-K; NAKATSUJI N, 1989, DEVELOPMENT, V106, P441; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; PERSOHN E, 1987, J CELL BIOL, V105, P569, DOI 10.1083/jcb.105.1.569; PIGOTT R, 1986, DEV BRAIN RES, V29, P111, DOI 10.1016/0165-3806(86)90087-8; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RATHJEN FG, 1984, EMBO J, V3, P461, DOI 10.1002/j.1460-2075.1984.tb01828.x; RATHJEN FG, 1984, EMBO J, V3, P1; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; SADOUL R, 1989, J NEUROCHEM, V53, P1471, DOI 10.1111/j.1471-4159.1989.tb08540.x; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; STALLCUP WB, 1983, J NEUROSCI, V3, P53; STALLCUP WB, 1985, BRAIN RES, V346, P287, DOI 10.1016/0006-8993(85)90862-5; SWEADNER KJ, 1983, J NEUROSCI, V3, P2504; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZUELLIG RA, 1991, SOC NEUR ABSTR, V17	65	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10752	10758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587850				2022-12-27	WOS:A1992HV09000082
J	BOCK, PE				BOCK, PE			ACTIVE-SITE-SELECTIVE LABELING OF BLOOD-COAGULATION PROTEINASES WITH FLUORESCENCE PROBES BY THE USE OF THIOESTER PEPTIDE CHLOROMETHYL KETONES .2. PROPERTIES OF THROMBIN DERIVATIVES AS REPORTERS OF PROTHROMBIN FRAGMENT-2 BINDING AND SPECIFICITY OF THE LABELING APPROACH FOR OTHER PROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-III; FACTOR-X; BOVINE PROTHROMBIN; CHRISTMAS-FACTOR; ALPHA-THROMBIN; FACTOR-IX; FACTOR-V; ACTIVATION; INHIBITION; ENZYME	The behavior of an array of fluorescent human alpha-thrombin derivatives in reporting binding of the fragment 2 domain of prothrombin was characterized as a representative application of the active-site-selective labeling approach to studies of blood coagulation proteinase regulatory interactions. An array of 16 thrombin derivatives was prepared by affinity labeling of the proteinase active site with the thioester peptide chloromethyl ketones, N(alpha)-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl or N(alpha)-[(acetylthio)acetyl]-D-Phe-Phe-Arg-CH2Cl, followed by selective modification of the NH2OH-generated thiol group on the covalently incorporated inhibitors with each of eight thiol-reactive fluorescence probes. The changes in probe fluorescence intensity of the derivatives, signaling changes in the environment of the catalytic site associated with fragment 2 binding, appeared to be a unique and unpredictable function of the structure of the probe and the connecting peptide. These results demonstrated the utility of the labeling approach for overcoming the problem of not being able to predict which fluorescent label will provide the most useful proteinase derivative for investigating an interaction by enabling a greater variety of them to be prepared and screened for those with the most desirable properties. To determine whether the approach could be extended to other proteinases, the specificity of labeling with the fluorescence probe iodoacetamide, 5-(iodoacetamido)fluorescein, by use of the two thioester inhibitors was evaluated for several other blood coagulation proteinases and related trypsin-like enzymes. All of the proteinases were labeled in an active-site-selective manner. The combined results of quantitating the labeling reactions for the proteinase and inhibitor combinations studied thus far showed active-site-specific incorporation of 0.98 +/- 0.10 mol of inhibitor/mol of active sites and 0.92 +/- 0.11 mol of probe/mol of active sites, representing an overall greater-than-or-equal-to 93% site-specificity of labeling. These results demonstrated the broad applicability of the labeling approach for fluorescence studies of proteinases that differ greatly in their catalytic specificities.	AMER RED CROSS,BLOOD SERV,SE MICHIGAN REG RES LAB,DETROIT,MI 48232	American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; HOGG PJ, 1990, J BIOL CHEM, V265, P248; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KISIEL W, 1979, J BIOL CHEM, V254, P2230; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OWEN WG, 1974, J BIOL CHEM, V249, P594; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; WALKER B, 1985, BIOCHEM J, V230, P645, DOI 10.1042/bj2300645; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536	33	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14974	14981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634536				2022-12-27	WOS:A1992JF08800071
J	CHAVAN, AJ; NEMOTO, Y; NARUMIYA, S; KOZAKI, S; HALEY, BE				CHAVAN, AJ; NEMOTO, Y; NARUMIYA, S; KOZAKI, S; HALEY, BE			NAD+ BINDING-SITE OF CLOSTRIDIUM-BOTULINUM C3 ADP-RIBOSYLTRANSFERASE - IDENTIFICATION OF PEPTIDE IN THE ADENINE RING BINDING DOMAIN USING 2-AZIDO NAD+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN; ACTIVE-SITE; PERTUSSIS TOXIN; STAPHYLOCOCCUS-AUREUS; S-1 SUBUNIT; GENE; RIBOSYLATION; DEHYDROGENASE; PURIFICATION; GLUTAMATE	C3 ADP-ribosyltransferase is an exoenzyme produced by certain strains of Clostridium botulinum types C and D, which specifically ADP-ribosylates rho-proteins in eukaryotic cells. Using the photoaffinity probe [alpha-P-32]nicotinamide-2-azidoadenine dinucleotide, we have identified the adenine ring binding domain of the NAD+ binding site. The specificity of labeling was demonstrated by saturation effects and protection by the natural compound at physiologically relevant concentrations. Saturation of labeling was observed at 50-mu-M. Protection experiments indicated an 80% protection of labeling by 100-mu-M NAD+ when protein was photolyzed in the presence of 10-mu-M probe. Trypsin or Staphylococcus aureus V8 protease digestion of the photolabeled protein, along with boronate affinity chromatography and immobilized metal affinity chromatography, was used to specifically isolate the peptide region photolabeled with the probe. The peptide corresponded to Phe9-Gly19 near the N terminus.	UNIV KENTUCKY, LUCILLE P MARKEY CANC CTR 058, 800 ROSE ST, LEXINGTON, KY 40536 USA; KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN; UNIV OSAKA PREFECTURE, COLL AGR, DEPT VET SCI, SAKAI, OSAKA 591, JAPAN	University of Kentucky; Kyoto University; Osaka Metropolitan University			Watanabe, Mamoru/AHE-0489-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; BARBIERI JT, 1988, INFECT IMMUN, V56, P1934, DOI 10.1128/IAI.56.8.1934-1941.1988; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; COCKLE SA, 1989, FEBS LETT, V249, P329, DOI 10.1016/0014-5793(89)80652-0; Collier RJ, 1980, MULTIFUNCTIONAL PROT, P261; CORTINA G, 1989, J BIOL CHEM, V264, P17322; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; Fishman P.H., 1990, ADP RIBOSYLATING TOX, P127; GALLOWAY TS, 1987, BIOCHEM J, V242, P927, DOI 10.1042/bj2420927; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HUGHES NA, 1957, J CHEM SOC, P3733, DOI 10.1039/jr9570003733; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KIM HT, 1990, J BIOL CHEM, V265, P3636; KING SM, 1991, METHOD ENZYMOL, V196, P449; LAI CY, 1986, ADV ENZYMOL RELAT AR, V58, P110; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; SALVUCCI ME, 1992, BIOCHEMISTRY-US, V31, P4479, DOI 10.1021/bi00133a014; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; SUGAI M, 1992, J BIOL CHEM, V267, P2600; SYMONS RH, 1968, BIOCHIM BIOPHYS ACTA, V155, P609, DOI 10.1016/0005-2787(68)90205-0; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; YOSHIKAWA M, 1967, TETRAHEDRON LETT, P5065; ZHAO JM, 1988, BIOCHEMISTRY-US, V27, P3398, DOI 10.1021/bi00409a041	32	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14866	14870						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634527				2022-12-27	WOS:A1992JF08800056
J	WOOD, ER; MCDONALD, OB; SAHYOUN, N				WOOD, ER; MCDONALD, OB; SAHYOUN, N			QUANTITATIVE-ANALYSIS OF SH2 DOMAIN BINDING - EVIDENCE FOR SPECIFICITY AND COMPETITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; GROWTH-FACTOR RECEPTORS; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; VIRAL ONCOGENE; PDGF RECEPTOR; PROTEIN; GAP	We report the development of a quantitative assay for measuring SH2 domain binding in vitro. Using this assay we have analyzed the binding of purified recombinant SH2 domains from ras GTPase activating protein (GAP) and the 85-kDa subunit of phosphatidylinositol 3-kinase (p85) to proteins from epidermal growth factor-stimulated and v-src-transformed cells. The purified recombinant SH2 domains from GAP and p85 bind to the tyrosine phosphorylated epidermal growth factor receptor with nanomolar affinities. Moreover, competition studies suggest that these two proteins bind to equivalent or overlapping sites on this receptor. In v-src-transformed cells the purified recombinant SH2 domains from GAP and p85 bind to distinct but overlapping sets of proteins.			WOOD, ER (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P362; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J, 1989, MOL CLONING LABORATO; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P543; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Warren L, 1974, Methods Enzymol, V31, P156; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14138	14144						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629214				2022-12-27	WOS:A1992JD32500056
J	SCHWENK, U; MORITA, E; ENGEL, R; SCHRODER, JM				SCHWENK, U; MORITA, E; ENGEL, R; SCHRODER, JM			IDENTIFICATION OF 5-OXO-15-HYDROXY-6,8,11,13-EICOSATETRAENOIC ACID AS A NOVEL AND POTENT HUMAN EOSINOPHIL CHEMOTACTIC EICOSANOID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; 15-LIPOXYGENASE PRODUCTS; SOYBEAN LIPOXYGENASE-1; LEUKOTRIENE FORMATION; DOUBLE DIOXYGENATION; PORCINE LEUKOCYTES; BIOSYNTHESIS; PATHWAY	Incubation of human eosinophils with arachidonic acid led to the formation of a novel and potent eosinophil chemotactic lipid (ECL) (Morita, E., Schroder, J.-M., and Christophers, E. (1990) J. Immunol. 144, 1893-1900). To test the working hypothesis of whether ECL could have been formed via eosinophil-arachidonic acid 15-lipoxygenase we investigated whether other arachidonic acid 15-lipoxygenases such as soybean lipoxygenase I catalyze formation of a similar ECL. In the presence of hemoproteins and soybean lipoxygenase I arachidonic acid is converted to an ECL, which has physicochemical properties similar to those found for the eosinophil-derived ECL. Purification of this ECL by high performance liquid chromatography revealed that ECL is structurally different from well known eosinophil chemotactic eicosanoids such as leukotriene B4, 5,15-(6E,8Z,11Z,13E)-dihydroxyeicosatetraenoic acid (5,15-diHETE), and (8S,15S)-(5Z,9E, 11Z,13E)-dihydroxyeicosatetraenoic acid ((8S,15S)-diHETE). UV spectra of this ECL with absorbance maxima at 230 and 278 nm revealed the presence of two independent chromophores such as a conjugated oxodiene and a conjugated diene. Catalytic hydrogenation of ECL methyl ester led to the formation of 5,15-dihydroxyarachidic acid methyl ester. Reduction of ECL with sodium borohydride produced a product which is identical with authentic (5S,15S)-(6E,8Z,11Z,13E)-diHETE. Formation of an ECL monomethoxime derivative supports the conclusion that this highly potent eosinophil chemotactic eicosanoid is structurally identical with 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid.	UNIV KIEL,DEPT DERMATOL,SCHITTENHELMSTR 7,W-2300 KIEL 1,GERMANY; FORSCHUNGSINST BORSTEL,W-2061 BORSTEL,GERMANY	University of Kiel; Forschungszentrum Borstel			Schroeder, Jens M/B-3994-2009					BILD GS, 1977, BIOCHEM BIOPH RES CO, V74, P949, DOI 10.1016/0006-291X(77)91610-2; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CREAMER HR, 1983, INFLAMMATION, V7, P321, DOI 10.1007/BF00916296; DELACLOS BF, 1988, BIOCHIM BIOPHYS ACTA, V958, P424, DOI 10.1016/0005-2760(88)90228-7; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; GLASGOW WC, 1986, J BIOL CHEM, V261, P200; LEVINE JD, 1986, P NATL ACAD SCI USA, V83, P5331, DOI 10.1073/pnas.83.14.5331; MAAS RL, 1981, P NATL ACAD SCI-BIOL, V78, P5523, DOI 10.1073/pnas.78.9.5523; MORITA E, 1990, J IMMUNOL, V144, P1893; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; RADMARK O, 1984, BIOCHIM BIOPHYS ACTA, V792, P324, DOI 10.1016/0005-2760(84)90200-5; RYHAGE R, 1960, ARK KEMI, V15, P545; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHRODER JM, 1989, J EXP MED, V170, P847, DOI 10.1084/jem.170.3.847; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SEHMI R, 1991, J IMMUNOL, V147, P2276; SHAK S, 1983, J BIOL CHEM, V258, P4948; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TAO CNR, 1975, ULTRAVIOLET VISIBLE, P42; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1985, J BIOL CHEM, V260, P5482; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; VIOQUE E, 1962, ARCH BIOCHEM BIOPHYS, V99, P522, DOI 10.1016/0003-9861(62)90301-6	23	85	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12482	12488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618754				2022-12-27	WOS:A1992HZ48300019
J	TAKAHASHI, T; SUCHI, M; DESNICK, RJ; TAKADA, G; SCHUCHMAN, EH				TAKAHASHI, T; SUCHI, M; DESNICK, RJ; TAKADA, G; SCHUCHMAN, EH			IDENTIFICATION AND EXPRESSION OF 5 MUTATIONS IN THE HUMAN ACID SPHINGOMYELINASE GENE CAUSING TYPE-A AND TYPE-B NIEMANN-PICK DISEASE - MOLECULAR EVIDENCE FOR GENETIC-HETEROGENEITY IN THE NEURONOPATHIC AND NON-NEURONOPATHIC FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GALACTOSIDASE; OVERLAP EXTENSION; POLYMERASE; DIAGNOSIS; SPLEEN; DNA	The deficient activity of the human lysosomal hydrolase, acid sphingomyelinase (ASM, EC 3.1.4.12), results in the neuronopathic (Type A) and non-neuronopathic (Type B) forms of Niemann-Pick disease (NPD). To investigate the genetic basis of the phenotypic heterogeneity in NPD, the molecular lesions in the ASM gene were determined from three unrelated NPD patients and evaluated by transient expression in COS-1 cells. A Type A NPD patient of Asian Indian ancestry (proband 1) was homoallelic for a T to A transversion in exon 2 of the ASM gene which predicted a premature stop at codon 261 of the ASM polypeptide (designated L261X). In contrast, an unrelated Type A patient of European ancestry (proband 2) was heteroallelic for a two-base (TT) deletion in exon 2 which caused a frame-shift mutation at ASM codon 178 (designated fsL178), leading to a premature stop at codon 190, and a G to A transition in exon 3 which caused a methionine to isoleucine substitution at codon 382 (designated M382I). Transient expression of the fsL178, L261X, and M382I mutations in COS-1 cells demonstrated that these lesions did not produce catalytically active ASM, consistent with the severe neuronopathic Type A NPD phenotype. In contrast, an unrelated Type B patient of European descent (proband 3) was heteroallelic for two missense mutations, a G to A transition in exon 2 which predicted a glycine to arginine substitution at ASM codon 242 (designated G242R), and an A to G transition in exon 3 which resulted in an asparagine to serine substitution at codon 383 (designated N383S). Interestingly, the G242R allele produced ASM activity in COS-1 cells at levels about 40% of that expressed by the normal allele, thereby explaining the mild Type B phenotype of proband 3 and the high residual activity (i.e. approximately 15% of normal) in cultured lymphoblasts. In contrast, the N383S allele did not produce catalytically active enzyme. None of these five ASM mutations was detected in over 60 other unrelated NPD patients analyzed, nor were these mutations found in over 100 normal ASM alleles. Thus, small deletions or nonsense mutations which trunctated the ASM polypeptide, or missense mutations that rendered the enzyme noncatalytic, resulted in Type A NPD disease, whereas a missense mutation that produced a defective enzyme with residual catalytic activity caused the milder non-neuronopathic Type B phenotype. These findings have facilitated genotype/phenotype correlations for this lysosomal storage disease and provided insights into the functional organization of the ASM polypeptide.	CUNY MT SINAI SCH MED,DIV MED & MOLEC GENET,100TH ST & 5TH AVE,NEW YORK,NY 10029; AKITA UNIV,SCH MED,DEPT PEDIAT,AKITA 010,JAPAN	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Akita University					NCRR NIH HHS [5 MO1 RR0071] Funding Source: Medline; NICHD NIH HHS [1 RO1 HD28607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERNSTEIN HS, 1989, J CLIN INVEST, V83, P1390, DOI 10.1172/JCI114027; BISHOP DF, 1981, J BIOL CHEM, V256, P1307; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; CHAN WC, 1977, J PATHOL, V121, P177, DOI 10.1002/path.1711210308; CHEN C, 1987, MOL CELL BIOL, V7, P2747; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DAWSON PJ, 1982, HUM PATHOL, V13, P1115, DOI 10.1016/S0046-8177(82)80249-9; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; FREDRICKSON DONALD S., 1966, P586; GAL AE, 1975, NEW ENGL J MED, V293, P632, DOI 10.1056/NEJM197509252931304; Gatt S, 1981, Methods Enzymol, V72, P351; GATT S, 1980, CLIN CHEM, V26, P93; GOODMAN RM, 1979, GENETIC DISORDERS JE, P96; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JOBB E, 1987, J INHERIT METAB DIS, V10, P326, DOI 10.1007/BF01811441; KAUFMAN RJ, 1982, MOL CELL BIOL, V2, P1304, DOI 10.1128/MCB.2.11.1304; KLAR R, 1988, CLIN CHIM ACTA, V176, P259, DOI 10.1016/0009-8981(88)90185-4; LEVADE T, 1986, PEDIATR RES, V19, P153; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEVRAN O, 1991, J CLIN INVEST, V88, P806, DOI 10.1172/JCI115380; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; ROUSSON R, 1986, ENZYMES LIPID METABO, V2, P273; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUCHMAN EH, 1991, NUCLEIC ACIDS RES, V19, P3160, DOI 10.1093/nar/19.11.3160; SOGAWA H, 1978, EUR J PEDIATR, V128, P235, DOI 10.1007/BF00445608; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; TAKAHASHI T, 1992, IN PRESS HUM MUT; VANIER MT, 1985, CLIN GENET, V27, P20	35	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12552	12558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618760				2022-12-27	WOS:A1992HZ48300029
J	KALINSKI, A; MELROY, DL; DWIVEDI, RS; HERMAN, EM				KALINSKI, A; MELROY, DL; DWIVEDI, RS; HERMAN, EM			A SOYBEAN VACUOLAR PROTEIN (P34) RELATED TO THIOL PROTEASES IS SYNTHESIZED AS A GLYCOPROTEIN PRECURSOR DURING SEED MATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIGNA-MUNGO SEEDS; REGULATED CYSTEINE PROTEINASE; BARLEY ALEURONE LAYERS; RAT CATHEPSIN-L; DICTYOSTELIUM-DISCOIDEUM; CONCANAVALIN-A; OIL-BODIES; SULFHYDRYL-ENDOPEPTIDASE; VICILIN PEPTIDOHYDROLASE; GLYCOSYLATED PRECURSOR	We have examined the synthesis, posttranslational processing, and localization of soybean P34, a member of the papain superfamily. P34 has been identified as a constituent of oil storage organelles or oil bodies isolated from seed lysates and has been assumed to be one of the oil body proteins. Electron microscopic immunocytochemistry with a monoclonal antibody demonstrated that P34 is localized in the protein storage vacuoles but not in the oil bodies. Immunocytochemical observations of partially disrupted seed cells showed that the association of P34 with oil bodies appears to occur as a consequence of cell lysis. In vitro synthesis of P34 results in the formation of a 46-kDa polypeptide that increases to 47 kDa due to core glycosylation by canine microsomes. In vivo synthesis studies in the presence and absence of tunicamycin, an inhibitor of N-linked glycosylation, indicate that pro-P34 is 47 kDa. Since the cDNA sequence of prepro-P34 contains a single putative glycosylation site in the precursor domain, we conclude that P34, like a few other vacuolar proteins, is synthesized as a glycoprotein precursor. Pulse-chase experiments showed that the processing of pro-P34 to mature P34 occurs in a single step and that this posttranslational cleavage occurs on the carboxyl side of an Asn, which is typical of seed vacuolar proteins. Pro-P34 (47 kDa) is detected in immunoblots of maturing seeds. Analysis of RNA indicates that the P34 genes are expressed only during seed maturation and that the P34 mRNA is related to other thiol protease mRNAs detectable in other organs and plants. Unlike other seed thiol proteases that are synthesized only after seed germination, P34 accumulates during seed maturation.	USDA ARS,BELTSVILLE AGR RES CTR,PLANT MOLEC BIOL LAB,BELTSVILLE,MD 20705; HOWARD UNIV,DEPT BOT,WASHINGTON,DC 20059	United States Department of Agriculture (USDA); Howard University								AKASOFU H, 1989, NUCLEIC ACIDS RES, V17, P6733, DOI 10.1093/nar/17.16.6733; BAUMGARTNER B, 1978, J CELL BIOL, V79, P10, DOI 10.1083/jcb.79.1.10; BAUMGARTNER B, 1977, EUR J BIOCHEM, V77, P223, DOI 10.1111/j.1432-1033.1977.tb11661.x; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; DATTA S, 1987, MOL CELL BIOL, V7, P149, DOI 10.1128/MCB.7.1.149; DIETRICH RA, 1989, PLANT CELL, V1, P73, DOI 10.1105/tpc.1.1.73; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; FAYE L, 1987, PLANTA, V170, P217, DOI 10.1007/BF00397891; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GUERRERO FD, 1990, PLANT MOL BIOL, V15, P11, DOI 10.1007/BF00017720; HERMAN EM, 1990, PLANT PHYSIOL, V94, P341, DOI 10.1104/pp.94.1.341; HERMAN EM, 1987, PLANTA, V172, P336, DOI 10.1007/BF00398662; HERMAN EM, 1985, PLANT PHYSIOL, V77, P886, DOI 10.1104/pp.77.4.886; HERMAN EM, 1985, PLANTA, V165, P23, DOI 10.1007/BF00392207; HERMAN EM, 1988, ANNU REV PLANT PHYS, V39, P139, DOI 10.1146/annurev.arplant.39.1.139; HERMAN EM, 1992, IN PRESS ADV STRUCTU; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; ISHIDOH K, 1989, FEBS LETT, V259, P71, DOI 10.1016/0014-5793(89)81497-8; KALINSKI A, 1990, J BIOL CHEM, V265, P13843; KALINSKI A, 1991, PLANT MOL BIOL, V17, P1095, DOI 10.1007/BF00037150; KOEHLER S, 1988, PLANT PHYSIOL, V87, P95, DOI 10.1104/pp.87.1.95; KOEHLER SM, 1990, PLANT CELL, V2, P769, DOI 10.1105/tpc.2.8.769; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; MITSUHASHI W, 1986, PLANT PHYSIOL, V80, P628, DOI 10.1104/pp.80.3.628; MITSUHASHI W, 1989, PLANT PHYSIOL, V89, P274, DOI 10.1104/pp.89.1.274; MURPHY DJ, 1989, PHYTOCHEMISTRY, V28, P2063, DOI 10.1016/S0031-9422(00)97921-4; NORTH MJ, 1986, BIOCHEM J, V238, P623, DOI 10.1042/bj2380623; PAPASTOITSIS G, 1991, PLANT PHYSIOL, V96, P1086, DOI 10.1104/pp.96.4.1086; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PODIVINSKY E, 1989, NUCLEIC ACIDS RES, V17, P8363, DOI 10.1093/nar/17.20.8363; PREAKELT UA, 1988, PLANT MOL BIOL, V10, P193; ROGERS JC, 1985, P NATL ACAD SCI USA, V82, P6512, DOI 10.1073/pnas.82.19.6512; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; TAHIO K, 1983, P NATL ACAD SCI USA, V80, P3666; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TZEN JTC, 1990, PLANT PHYSIOL, V94, P1282, DOI 10.1104/pp.94.3.1282; VERNET T, 1990, J BIOL CHEM, V265, P16661; WATANABE H, 1991, J BIOL CHEM, V266, P16897; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x; WILSON KA, 1988, PLANT PHYSIOL, V88, P355, DOI 10.1104/pp.88.2.355	52	95	104	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12068	12076						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601876				2022-12-27	WOS:A1992HY94700065
J	GAUGITSCH, HW; PRIESCHL, EE; KALTHOFF, F; HUBER, NE; BAUMRUKER, T				GAUGITSCH, HW; PRIESCHL, EE; KALTHOFF, F; HUBER, NE; BAUMRUKER, T			A NOVEL TRANSIENTLY EXPRESSED, INTEGRAL MEMBRANE-PROTEIN LINKED TO CELL ACTIVATION - MOLECULAR-CLONING VIA THE RAPID DEGRADATION SIGNAL AUUUA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GROWTH-FACTOR; HUMAN INTERLEUKIN; GM-CSF; MITOGENIC ACTIVATION; COMPLEMENTARY-DNA; GENETIC RESPONSE; CDNA	A novel cDNA clone termed E16 which codes for an integral membrane protein of 241 amino acids with six transmembrane domains was isolated from peripheral blood lymphocytes. The cDNA clone is 4000 base pairs in length and exhibits an unusually long 3'-untranslated region of about 3000 nucleotides. Its expression at the mRNA level is closely linked to cellular activation and division. In all myeloid and lymphoid cells, as well as in primary lymphocytes from peripheral blood, E16 transcripts are rapidly induced and rapidly degraded after stimulation. This pattern of expression is unusual for an integral membrane protein and resembles more closely the kinetic seen for protooncogenes and lymphokines in the T cell system. Its isolation was made possible by a novel approach especially designed to selectively clone cDNAs which exhibit such an expression kinetic. It is based on a combination of the differential screening of a subtracted cDNA library and the subsequent hybridization of the resulting phages to a short oligonucleotide (5'-TAAATAAA-TAAATA-3'). This oligonucleotide is complementary to a trimer of the rapid degradation signal (AUUUA) which is present as a single or reiterated motif in the 3'-untranslated region of many short-lived transcripts.	SANDOZ GMBH,DEPT IMMUNOPHARMACOL,BRUNNERSTR 59,A-1235 VIENNA,AUSTRIA	Novartis; Sandoz								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRAY PW, 1982, NATURE, V295, P503, DOI 10.1038/295503a0; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KALTHOFF FS, 1991, IMMUNOL LETT, V27, P141, DOI 10.1016/0165-2478(91)90142-W; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEBEAU MM, 1986, COLD SPRING HARB SYM, V51, P899, DOI 10.1101/SQB.1986.051.01.103; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OTSUKA T, 1988, J IMMUNOL, V140, P2288; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	41	61	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11267	11273						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597461				2022-12-27	WOS:A1992HX16900054
J	RATAJCZAK, T; WILLIAMS, PM; DILORENZO, D; RINGOLD, GM				RATAJCZAK, T; WILLIAMS, PM; DILORENZO, D; RINGOLD, GM			MULTIPLE ELEMENTS WITHIN THE GLUCOCORTICOID REGULATORY UNIT OF THE RAT ALPHA-1-ACID GLYCOPROTEIN GENE ARE RECOGNITION SITES FOR C/EBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; ACUTE-PHASE RESPONSE; ENRICHED TRANSCRIPTIONAL ACTIVATOR; HEPATOCYTE-STIMULATING FACTOR; STEROID-HORMONE RECEPTORS; COLI RNA-POLYMERASE; DNA-BINDING; POLYACRYLAMIDE GELS; LEUCINE ZIPPER; EXPRESSION	Sequences between -106 and -42, located immediately downstream of the glucocorticoid response element, are essential for efficient glucocorticoid-stimulated expression of the alpha-1-acid glycoprotein (AGP) gene. We have used mobility shift assays with oligonucleotides bearing wild type and mutated sequences from segmented portions of this region to characterize the specific interaction of similar binding factors from rat liver and HTC rat hepatoma cell nuclear extracts. One of these factors, AGP nuclear factor 2 (ANF-2), appears capable of dual interaction with the homologous recognition sites, HA (-133 to -104) and HB (-81 to -72), which overlap and are located downstream of the glucocorticoid response element, respectively. Using an affinity matrix containing the HB sequence we have isolated ANF-2 from rat liver nuclear extracts. On the basis of immunological evidence rat liver ANF-2 was confirmed to be highly related and probably identical to CCAAT/enhancer-binding protein (C/EBP). Methylation protection analyses with partially purified, rat liver ANF-2 confirmed HA and HB as recognition sites for C/EBP-related factors and are consistent with the location of a third interaction site for these transactivating proteins at HX (-102 to -93). We propose that the sequences HA, HX, and HB, spanning residues -113 to -72 of the AGP promoter, might serve as recognition sites for a family of C/EBP-like nuclear factors that coordinate the glucocorticoid-mediated induction of the AGP gene.	SYNTEX INC,INST CANC & DEV BIOL,PALO ALTO,CA 94304	Syntex Corporation					NIGMS NIH HHS [GM25821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; AKURA S, 1990, EMBO J, V9, P1897; BAUMANN H, 1981, J BIOL CHEM, V256, P145; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BENNETT M, 1980, P NATL ACAD SCI-BIOL, V77, P6109, DOI 10.1073/pnas.77.10.6109; BETHELL GS, 1981, J CHROMATOGR, V219, P361; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, MOL ENDOCRINOL, V4, P1921, DOI 10.1210/mend-4-12-1921; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DILORENZO D, 1991, BIOCHEM BIOPH RES CO, V176, P1326, DOI 10.1016/0006-291X(91)90431-6; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORTENSEN RF, 1988, J IMMUNOL, V140, P2260; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; REINKE R, 1985, J BIOL CHEM, V260, P4397; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; VANNICE JL, 1983, DNA-J MOLEC CELL BIO, V2, P205, DOI 10.1089/dna.1983.2.205; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959	45	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11111	11119						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597449				2022-12-27	WOS:A1992HX16900030
J	LARSEN, JL				LARSEN, JL			HUMAN GROWTH-HORMONE ENHANCES PERTUSSIS TOXIN-STIMULATED ADP-RIBOSYLATION OF GI IN NB2 CELL-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; LYMPHOMA-CELLS; PROLACTIN RECEPTOR; COMPLEMENTARY-DNA; ADENYLYL CYCLASE; CHOLERA-TOXIN; IDENTIFICATION; SUBUNITS; MITOGENESIS; EXPRESSION	he Nb2 node lymphoma cell line has been widely used as a model for investigating lactogen cellular actions. Both pertussis (PTX) and cholera (CTX) toxins modulate lactogen-stimulated Nb2 cell mitogenesis, suggesting G protein involvement in lactogen signal transduction. The following studies were performed to further investigate this possibility. Both PTX-sensitive (41 kDa) and CTX-sensitive substrates (42 and 45 kDa) were identified in Nb2 cell membrane and recognized by specific anti-G(i) and anti-G(s) antibodies, respectively. Equal numbers of Nb2 cells were then incubated with the lactogen human growth hormone (hGH, 10 ng/ml) for 0-72 h. Membrane protein prepared from each time point (50-mu-g) was compared in toxin-stimulated ADP-ribosylation studies. CTX-stimulated ADP-ribosylation was unaffected by prior hGH incubation. PTX-stimulated ADP-ribosylation increased 237 +/- 69% (X +/- S.E.) compared with 0-h controls (n = 11; p < 0.01) after 4-7 h of hGH incubation then decreased toward 0-h samples by 24 and 72 h. No change in G(i-alpha). concentration was observed, but beta-subunit concentration increased (145 +/- 14% at 7 h; p < 0.01; n = 3) in a time course that paralleled the changes in PTX-stimulated ADP-ribosylation. In summary, 1) both G(i) and G(s) were present in Nb2 cell membrane, 2) incubation of cells with a lactogen, hGH, for 4-7 h markedly enhanced PTX-stimulated ADP-ribosylation of G(i-alpha) in vitro, whereas CTX-stimulated ADP-ribosylation of G(s-alpha) was unchanged, and 3) although no change in G(i-alpha) concentration was observed, beta-subunit concentration increased in parallel with the increase in PTX-stimulated ADP-ribosylation of G(i-alpha). These results suggest that hGH may modify PTX-stimulated ADP-ribosylation of G(i) not by changing G(i-alpha) concentration, perhaps by increasing beta-subunit concentration, enhancing association of G(i-alpha) by beta-gamma-subunits, which, in turn, is preferentially ADP-ribosylated. This may represent a late signal transduction event and may also have implications for other effectors dependent on G(i)-mediated events.			LARSEN, JL (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,42ND & DEWEY,OMAHA,NE 68198, USA.				PHS HHS [REN 5 R29 DL40752-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARKEY RJ, 1988, BIOCHEM BIOPH RES CO, V156, P776, DOI 10.1016/S0006-291X(88)80911-2; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CORDA D, 1987, EUR J BIOCHEM, V166, P475, DOI 10.1111/j.1432-1033.1987.tb13540.x; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELSHOLTZ HP, 1986, BIOCHEM CELL BIOL, V64, P381, DOI 10.1139/o86-053; FLEMING WH, 1985, ENDOCRINOLOGY, V117, P2547, DOI 10.1210/endo-117-6-2547; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; KLAINER LM, 1962, J BIOL CHEM, V237, P1239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JL, 1988, ENDOCRINOLOGY, V123, P438, DOI 10.1210/endo-123-1-438; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MOSS J, 1983, J BIOL CHEM, V258, P1879; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NOBLE RL, 1980, CANCER RES, V40, P2437; REPIEJKO PJ, 1989, J BIOL CHEM, V264, P16183; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1990, BIOCHEM BIOPH RES CO, V173, P48, DOI 10.1016/S0006-291X(05)81019-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	31	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10583	10587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587839				2022-12-27	WOS:A1992HV09000056
J	RUAN, ZS; ANANTHARAM, V; CRAWFORD, IT; AMBUDKAR, SV; RHEE, SY; ALLISON, MJ; MALONEY, PC				RUAN, ZS; ANANTHARAM, V; CRAWFORD, IT; AMBUDKAR, SV; RHEE, SY; ALLISON, MJ; MALONEY, PC			IDENTIFICATION, PURIFICATION, AND RECONSTITUTION OF OXLT, THE OXALATE - FORMATE ANTIPORT PROTEIN OF OXALOBACTER-FORMIGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; TRANSPORT-SYSTEM; DNA-SEQUENCE; CARRIER PROTEIN; DILUTE-SOLUTION; PROTON SYMPORT; GENE; MEMBRANE	We had proposed earlier that the anaerobe Oxalobacter formigenes sustains a proton-motive force by exploiting a secondary carrier rather than a primary proton pump. In this view, a carrier protein would catalyze the exchange of extracellular oxalate, a divalent anion, and intracellular formate, the monovalent product of oxalate decarboxylation. Such an electrogenic exchange develops an internally negative membrane potential, and since the decarboxylation reaction consumes an internal proton, the combined activity of the carrier and the soluble decarboxylase would constitute an "indirect" proton pump with a stoichiometry of 1H+ per turnover. This model is now verified by identification and purification of OxlT, the protein responsible for the anion exchange reaction. Membranes of O. formigenes were solubilized at pH 7 with 1.25% octyl glucoside in 20 mm 3-(N-morpholino)propanesulfonic acid/K, in the presence of 0.4% Escherichia coli phospholipids and with 20% glycerol present as the osmolyte stabilant. Rapid methods for reconstitution were developed to monitor the distribution of OxlT during biochemical fractionation, allowing its purification by sequential anion and cation exchange chromatography. OxlT proved to be a single hydrophobic polypeptide, of 38 kDa mobility during sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with a turnover number estimated as at least 1000/s. The properties of OxlT point to an indirect proton pump as the mechanism by which a proton-motive force arises in O. formigenes, and one may reasonably argue that indirect proton pumps take part in bacterial events such as acetogenesis, malolactate fermentation, and perhaps methanogenesis.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV NEPHROL,BALTIMORE,MD 21205; USDA ARS,NATL ANIM DIS CTR,AMES,IA 50010	Johns Hopkins University; United States Department of Agriculture (USDA)	RUAN, ZS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.		Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BERG HC, 1983, RANDOM WALKS BIOL, P17; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; COX DJ, 1989, J BACTERIOL, V171, P5750, DOI 10.1128/jb.171.10.5750-5752.1989; DAVIS EO, 1987, J BIOL CHEM, V262, P13928; ECKERT B, 1989, J BIOL CHEM, V264, P11663; EIGLMEIER K, 1987, MOL MICROBIOL, V1, P251, DOI 10.1111/j.1365-2958.1987.tb01931.x; FLUGGE UI, 1981, BIOCHIM BIOPHYS ACTA, V638, P296, DOI 10.1016/0005-2728(81)90240-1; GOLDRICK D, 1988, J BACTERIOL, V170, P3421, DOI 10.1128/jb.170.8.3421-3426.1988; HANADA K, 1988, J BIOL CHEM, V263, P7181; JANSSEN PH, 1990, J GEN MICROBIOL, V136, P1037, DOI 10.1099/00221287-136-6-1037; JONES WJ, 1987, MICROBIOL REV, V51, P135, DOI 10.1128/MMBR.51.1.135-177.1987; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LUKACOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145, DOI 10.1021/bi00514a025; MAIDEN MCJ, 1988, J BIOL CHEM, V263, P8003; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1987, ESCHERICHIA COLI SAL, P222; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OLSEN EB, 1991, J BACTERIOL, V173, P6199, DOI 10.1128/jb.173.19.6199-6206.1991; PEERCE BE, 1990, J BIOL CHEM, V265, P1731; QUAYLE JR, 1961, BIOCHEM J, V78, P225, DOI 10.1042/bj0780225; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHEURING U, 1986, J MEMBRANE BIOL, V90, P123, DOI 10.1007/BF01869930; Smith B J, 1984, Methods Mol Biol, V1, P41, DOI 10.1385/0-89603-062-8:41; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; Walsh C., 1979, ENZYMATIC REACTION M, P24; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; YAZYU H, 1984, J BIOL CHEM, V259, P4320	48	83	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10537	10543						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587834				2022-12-27	WOS:A1992HV09000050
J	LIM, K; CHAE, CB				LIM, K; CHAE, CB			PRESENCE OF A REPRESSOR PROTEIN FOR TESTIS-SPECIFIC H2B (TH2B) HISTONE GENE IN EARLY STAGES OF SPERMATOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION REGULATORY ELEMENTS; DNA; EXPRESSION; PROMOTER; RNA	The rat testis-specific TH2B histone gene assumes a hypomethylated chromatin structure at all stages of spermatogenesis. However, the TH2B mRNA level is very low in pre-meiotic spermatogenic cells and rises sharply in meiotic pachytene spermatocytes. The low level of TH2B mRNA in pre-meiotic spermatogenic cells appears to be a result of transcriptional repression of the gene by a pre-meiotic cell-specific protein which binds to a site between the TATA element and the transcription initiation site of TH2B gene.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020136] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20136] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRANSON RE, 1975, ARCH BIOCHEM BIOPHYS, V168, P403, DOI 10.1016/0003-9861(75)90269-6; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; HWANG I, 1990, MOL CELL BIOL, V10, P585, DOI 10.1128/MCB.10.2.585; HWANG IH, 1989, MOL CELL BIOL, V9, P1005, DOI 10.1128/MCB.9.3.1005; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; MEISTRICH M L, 1987, P333; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Setchell B.P., 1978, THE MAMMALIAN TESTIS; VERNON RG, 1971, CAN J BIOCHEM CELL B, V49, P761, DOI 10.1139/o71-107; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	13	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15271	15273						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639772				2022-12-27	WOS:A1992JG11300004
J	MASLINSKI, W; REMILLARD, B; TSUDO, M; STROM, TB				MASLINSKI, W; REMILLARD, B; TSUDO, M; STROM, TB			INTERLEUKIN-2 (IL-2) INDUCES TYROSINE KINASE-DEPENDENT TRANSLOCATION OF ACTIVE RAF-1 FROM THE IL-2 RECEPTOR INTO THE CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							P70-75 BETA-SUBUNIT; SIGNAL TRANSDUCTION; PROTEIN-KINASE; ALPHA-CHAIN; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DISTINCT; BINDING; INTERNALIZATION	Stimulation of the interleukin-2 (IL-2) receptor results in phosphorylation and activation of cytosolic Raf-1 serine/threonine kinase. Herein, we report that enzymatically active Raf-1 is physically associated with the IL-2 receptor beta-chain (p75) in T-cell blasts. Following stimulation with IL-2, Raf-1 dissociates from the IL-2 receptor complex and translocates to the cytosol. Genistein, a protein tyrosine kinase inhibitor, prevents the dissociation of enzymatically active Raf-1 from the ligand-stimulated IL-2 receptor complex. These data favor a model of IL-2 receptor activation in which an IL-2-activated protein tyrosine kinase phosphorylates the IL-2 receptor and/or receptor-bound Raf-1. Following tyrosine phosphorylation, enzymatically active Raf-1 dissociates from the IL-2 receptor and translocates into the cytosol.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEACONESS JOSLIN DIV NEPHROL,BOSTON,MA 02215; UNITIKA CENT HOSP,KYOTO,JAPAN	Harvard University; Harvard Medical School	MASLINSKI, W (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV IMMUNOL,RM RE 319,BOSTON,MA 02215, USA.		Maslinski, Wlodzimierz/T-7078-2019	Maslinski, Wlodzimierz/0000-0001-5597-9373	NCI NIH HHS [UO1 CA 48626] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA048626] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENEDICT SH, 1987, J IMMUNOL, V139, P1694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FERRIS DK, 1989, J IMMUNOL, V143, P870; FUNG MR, 1991, J IMMUNOL, V147, P1253; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1987, J EXP MED, V166, P362, DOI 10.1084/jem.166.2.362; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KONDO S, 1987, NATURE, V327, P64, DOI 10.1038/327064a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6959; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	37	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15281	15284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639773				2022-12-27	WOS:A1992JG11300007
J	GALLAGHER, MJ; BLUMENTHAL, KM				GALLAGHER, MJ; BLUMENTHAL, KM			CLONING AND EXPRESSION OF WILD-TYPE AND MUTANT FORMS OF THE CARDIOTONIC POLYPEPTIDE ANTHOPLEURIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SEA-ANEMONE TOXIN; XANTHOGRAMMICA HEART STIMULANT; SODIUM-CHANNEL; EXCITABLE CELLS; SCORPION TOXINS; RECEPTOR-SITE; BINDING; MUTAGENESIS; IONOPHORE	Venom of the sea anemone Anthopleura xanthogrammica contains a minimum of three polypeptide toxins capable of prolonging the repolarization phase of the action potential. A synthetic gene for the most toxic of the Anthopleura toxins, anthopleurin B (ApB), has been designed, synthesized, and expressed as a fusion protein with the gene 9 product of bacteriophage T7 in Escherichia coli. The fusion protein has been purified and its disulfide bonds reoxidized using glutathione redox couples. Upon cleavage with staphylococcal protease, this protocol yields approximately 1 mg of native ApB/liter of original culture. The recombinant protein has been shown to be identical to natural ApB with respect to amino acid composition, amino-terminal sequence, secondary structure, high pressure liquid chromatographic mobility, and biological activity. A second form of ApB containing additional residues of glycine and arginine at its amino terminus has also been characterized. This protein, termed GR-ApB, is identical in specific activity to the wild-type form. This work lays the groundwork for a detailed analysis of ApB structure and action by site-directed mutagenesis.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati				Whiting, Paul/0000-0002-4121-1379	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSEN C, 1983, FED PROC, V42, P101; BERGMAN C, 1976, BIOCHIM BIOPHYS ACTA, V455, P173, DOI 10.1016/0005-2736(76)90162-0; BLAIR RW, 1978, J PHARMACOL EXP THER, V207, P271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cleland W W, 1979, Methods Enzymol, V63, P103; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; FIORDALISI JJ, 1991, BIOCHEMISTRY-US, V30, P10337, DOI 10.1021/bi00106a035; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; GUESDON JL, 1977, IMMUNOCHEMISTRY, V14, P443, DOI 10.1016/0019-2791(77)90170-7; HASHIMOTO K, 1980, J PHARMACOL EXP THER, V215, P479; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KODAMA I, 1981, BRIT J PHARMACOL, V74, P29, DOI 10.1111/j.1476-5381.1981.tb09952.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM SK, 1991, J BIOL CHEM, V266, P3709; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; MANIATIS T, 1982, MOL CLONING LABORATO, P224; MEVES H, 1986, ANN NY ACAD SCI, V479, P113, DOI 10.1111/j.1749-6632.1986.tb15565.x; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; PETERS ID, 1989, PROTEIN ENG, V3, P145, DOI 10.1093/protein/3.2.145; REIMER NS, 1985, J BIOL CHEM, V260, P8690; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; ROMEY G, 1980, J PHARMACOL EXP THER, V213, P607; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCRIABINE A, 1979, J CARDIOVASC PHARM, V1, P571, DOI 10.1097/00005344-197909000-00009; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; SHIBATA S, 1978, J PHARMACOL EXP THER, V205, P683; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; TANAKA M, 1977, BIOCHEMISTRY-US, V16, P204, DOI 10.1021/bi00621a007; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	39	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13958	13963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629194				2022-12-27	WOS:A1992JD32500030
J	HSU, DK; ZUBERI, RI; LIU, FT				HSU, DK; ZUBERI, RI; LIU, FT			BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION OF HUMAN RECOMBINANT IGE-BINDING PROTEIN, AN S-TYPE ANIMAL LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; ENDOGENOUS LECTINS; SELF-ASSOCIATION; 3T3 FIBROBLASTS; CULTURED-CELLS; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCE; HOMOLOGY	IgE-binding protein (epsilon-BP) was originally identified by virtue of its affinity for IgE. It is now known to be a beta-galactoside-binding lectin with the characteristic of an S-type carbohydrate recognition domain. The protein is composed of two domains: the amino-terminal domain consisting of tandem repeats and the carboxyl-terminal domain containing sequences shared by other S-type carbohydrate recognition domains. The amino-terminal domain also contains a number of potential recognition sites for collagenase cleavage. In this study, human epsilon-BP was first expressed in Escherichia coli, and the carboxyl-terminal domain (epsilon-BP-C) was then generated by collagenase digestion of epsilon-BP. By equilibrium dialysis, the association constants of epsilon-BP and epsilon-BP-C for lactose were found to be similar (6.0 +/- 0.70) x 10(4) M-1 and (4.7 +/- 0.27) x 10(4) M-1, respectively. Both polypeptides contain only one lactose-binding site/molecule. By an assay involving binding of I-125-labeled epsilon-BP or epsilon-BP-C to solid phase IgE, and inhibition of this binding by saccharides, it was determined that epsilon-BP-C retains the saccharide specificity of epsilon-BP. Importantly, although unlabeled epsilon-BP-C inhibited the binding of the radiolabeled epsilon-BP to IgE, unlabeled epsilon-BP caused increased binding to IgE, suggesting self-association among epsilon-BP molecules. Oligomeric structures resulting from self-association of epsilon-BP were confirmed by chemical cross-linking studies. Furthermore, epsilon-BP possesses hemagglutination activity on rabbit erythrocytes, whereas epsilon-BP-C lacks such activity. Based on these results, we propose a structural model for multivalency of epsilon-BP: dimerization or oligomerization of epsilon-BP occurs through intermolecular interaction involving the amino-terminal domain.			HSU, DK (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	NIAID NIH HHS [AI19747, AI20958, AI32834] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019747, U01AI032834, R01AI020958] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINEL M, 1987, BIOCHIM BIOPHYS ACTA, V894, P174, DOI 10.1016/0005-2728(87)90187-3; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GRITZMACHER CA, 1988, J IMMUNOL, V141, P2801; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; JIA SH, 1988, J BIOL CHEM, V263, P6009; KORNBLATT JA, 1980, CAN J BIOCHEM CELL B, V58, P219, DOI 10.1139/o80-030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVI G, 1981, J BIOL CHEM, V256, P5735; LIU FT, 1990, CRIT REV IMMUNOL, V10, P289; LIU FT, 1980, J IMMUNOL, V124, P2728; LIU FT, 1985, P NATL ACAD SCI USA, V82, P4100, DOI 10.1073/pnas.82.12.4100; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; ODA Y, 1991, GENE, V99, P279; PINCKARD RN, 1978, HDB EXPT IMMUNOLOGY; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TARVERS RC, 1982, J BIOL CHEM, V257, P708; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; WOO HJ, 1990, J BIOL CHEM, V265, P7097; WOO HJ, 1991, J BIOL CHEM, V266, P18419	40	245	251	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14167	14174						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629216				2022-12-27	WOS:A1992JD32500060
J	STRIEDER, S; SCHAIBLE, K; SCHERER, HJ; DIETZ, R; RUF, HH				STRIEDER, S; SCHAIBLE, K; SCHERER, HJ; DIETZ, R; RUF, HH			PROSTAGLANDIN ENDOPEROXIDE SYNTHASE SUBSTITUTED WITH MANGANESE PROTOPORPHYRIN-IX - FORMATION OF A HIGHER OXIDATION-STATE AND ITS RELATION TO CYCLOOXYGENASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; FREE-RADICAL INTERMEDIATE; H SYNTHASE; PEROXIDASE REACTION; ARACHIDONIC-ACID; VESICULAR GLAND; BIOSYNTHESIS; MECHANISM; SYNTHETASE; KINETICS	The heme in prostaglandin endoperoxide synthase (PGH synthase) was substituted with Mn(III)-protoporphyrin IX. The resulting enzyme, Mn-PGH synthase, showed full cyclooxygenase activity but only 0.9% of the peroxidase activity of the native iron enzyme. During the reaction with exogenous or endogenously produced hydroperoxides, a spectral intermediate of Mn-PGH synthase was observed. The electronic absorption bands of the resting enzyme at 376, 472, and 561 nm decreased, and the intermediate's bands at 417, around 513, and 625 nm appeared. The rate constant of the formation of the intermediate was about 10(4) M-1.s-1 at 22-degrees-C, three orders of magnitude lower than with the iron enzyme. Spectral properties, conditions of formation, and the suppressed formation in the presence of electron donors provide evidence for a higher oxidation state of Mn-PGH synthase, tentatively a Mn(IV) species. This species was assigned to an intermediate in the peroxidase reaction of Mn-PGH synthase, the low activity of which was explained by the rate-limiting slow reaction of Mn-PGH synthase with hydroperoxides. The findings and interpretation are consistent with the published properties of other manganese-substituted peroxidases. Although the cyclooxygenase activity was similar to that of Fe-PGH synthase, the cyclooxygenase reaction of Mn-PGH synthase showed distinct differences in comparison with Fe-PGH synthase. A longer activation phase was observed which resembled the time course of the formation of the higher oxidation state. Glutathione peroxidase with glutathione, a hydroperoxide-scavenging system, inhibited the cyclooxygenase of Mn-PGH synthase at concentrations where the activity of Fe-PGH synthase was not affected. It is demonstrated that Mn-PGH synthase requires higher concentrations of hydroperoxides for the activation of the cyclooxygenase. These findings suggest that the substitution of iron with manganese in PGH synthase does not change the mechanism of the enzyme. The main difference is the much lower rate of the reaction with hydroperoxides which affects both the peroxidase activity and the hydroperoxide-dependent activation of the cyclooxygenase. A reaction scheme for Mn-PGH synthase is proposed analogous to that suggested for Fe-PGH synthase (Karthein, R., Dietz, R., Nastainczyk, W., and Ruf, H. H. (1988) Eur. J. Biochem. 171, 313-320).	UNIV SAARLAND, FRAUNHOFER INST BIOMED TECH, FHG IBMT, ENSHEIMERSTR 48, W-6670 ST INGBERT, GERMANY; UNIV SAARLAND, FACHRICHTUNG MED TECH, W-6670 ST INGBERT, GERMANY	Fraunhofer Gesellschaft; Saarland University; Saarland University			Dietz, Rune/F-9154-2015	Dietz, Rune/0000-0001-9652-317X				COOK HW, 1979, ANAL BIOCHEM, V96, P341, DOI 10.1016/0003-2697(79)90591-8; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1976, J BIOL CHEM, V251, P7329; GJESSING EC, 1943, ARCH BIOCHEM, V1, P1; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; HORI H, 1987, BIOCHIM BIOPHYS ACTA, V912, P74, DOI 10.1016/0167-4838(87)90249-4; HSUANYU Y, 1990, ARCH BIOCHEM BIOPHYS, V281, P282, DOI 10.1016/0003-9861(90)90445-5; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LANDS WEM, 1976, ADV PROSTAG THROMB R, V1, P7; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MACDONALD ID, 1989, ARCH BIOCHEM BIOPHYS, V272, P194, DOI 10.1016/0003-9861(89)90210-5; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MASON RP, 1980, J BIOL CHEM, V255, P5019; NASTAINCZYK W, 1984, EUR J BIOCHEM, V144, P381, DOI 10.1111/j.1432-1033.1984.tb08475.x; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; ODENWALLER R, 1992, IN PRESS J BIOL CHEM; OGINO N, 1978, J BIOL CHEM, V253, P5061; PORTER NA, 1980, FREE RADICALS BIOL, V4, P261; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; RUF HH, 1992, EUR J BIOCHEM, V204, P1069, DOI 10.1111/j.1432-1033.1992.tb16730.x; SCHREIBER J, 1986, ARCH BIOCHEM BIOPHYS, V249, P126, DOI 10.1016/0003-9861(86)90567-9; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; THOMPSON D, 1989, MOL PHARMACOL, V36, P809; YONETANI T, 1969, J BIOL CHEM, V244, P4580	35	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13870	13878						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629186				2022-12-27	WOS:A1992JD32500016
J	GRUBER, JR; OHNO, S; NILES, RM				GRUBER, JR; OHNO, S; NILES, RM			INCREASED EXPRESSION OF PROTEIN KINASE-C-ALPHA PLAYS A KEY ROLE IN RETINOIC ACID-INDUCED MELANOMA DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIRSTEN SARCOMA-VIRUSES; PHORBOL ESTER; RECEPTOR PROTEIN; DOWN-REGULATION; CELL-LINE; TRANSFORMATION; KERATINOCYTES; INDUCTION; ISOZYMES; LEUKEMIA	Differentiation of B16 mouse melanoma cells induced by retinoic acid (RA) is preceded by a large increase in protein kinase C(alpha) (PKC(alpha)) mRNA and protein. To determine the-role of PKC(alpha) in the differentiation program, we stably transfected B16-F1 cells with a plasmid containing the full length PKC(alpha) cDNA driven by an SV40 promoter. Two out of thirty-two colonies screened were determined to overexpress PKC by 2-4-fold according to Western blot analysis and PKC enzyme activity. When compared to control cells (wild-type cells and cells transfected only with the neomycin resistance gene), PKC(alpha) overexpressing clones displayed longer doubling times, diminished anchorage-independent growth, and increased melanin production. RA treatment of control cells mimicked these phenotypic characteristics. When injected subcutaneously into syngeneic mice, PKC(alpha) overexpressing clones produced smaller tumors and had longer latencies than control cells. These findings, combined with the fact that phorbol esters down-regulate PKC and antagonize RA action suggest that PKC(alpha) plays a key role in the RA-induced melanoma differentiation.	BOSTON UNIV, MED CTR, DEPT BIOCHEM, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT PATHOL, BOSTON, MA 02118 USA; YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, YOKOHAMA 236, JAPAN	Boston University; Boston University; Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	NATIONAL CANCER INSTITUTE [R01CA032543] Funding Source: NIH RePORTER; NCI NIH HHS [CA32543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDA K, 1986, J BIOL CHEM, V261, P3013; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG FL, 1989, J BIOL CHEM, V264, P4238; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MUFSON RA, 1979, CANCER RES, V39, P3915; MURRAY AW, 1987, TRENDS BIOCHEM SCI, V12, P53, DOI 10.1016/0968-0004(87)90026-0; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NILES R, 1992, CANCER RES, V294, P123; NILES RM, 1989, CANCER RES, V49, P4483; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; ROSENBAUM SE, 1992, ARCH BIOCHEM BIOPHYS, V294, P123, DOI 10.1016/0003-9861(92)90145-M; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1975, NATURE, V256, P225, DOI 10.1038/256225a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	28	121	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13356	13360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618838				2022-12-27	WOS:A1992JB74600043
J	NGUYEN, T; PICKETT, CB				NGUYEN, T; PICKETT, CB			REGULATION OF RAT GLUTATHIONE S-TRANSFERASE-YA SUBUNIT GENE-EXPRESSION - DNA-PROTEIN INTERACTION AT THE ANTIOXIDANT RESPONSIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; RNA-POLYMERASE; BINDING; JUN; FOS; IDENTIFICATION; PURIFICATION; CONTACTS; COMPLEX	We have characterized the interaction of the antioxidant responsive element (ARE) in the 5'-flanking region of the rat glutathione S-transferase Ya subunit gene with its trans-acting factor. The ARE core sequence, 5'-ggTGACaaaGC-3', previously identified as the cis-acting element required for activation of the Ya subunit gene by planar aromatic compounds and phenolic antioxidants, is shown to be the high affinity recognition motif for a trans-acting factor(s) as determined by gel mobility shift assays as well as methylation interference and protection studies. The DNA-protein interaction appears to occur in the major groove and involves the GpG dinucleotide preceding and the G residue within the TGAC tetramer on the coding strand of the core sequence. In addition, DNase I protection analysis maps an extended region 5' from the core recognition motif, which was shown previously to be essential for basal activity of the ARE. The trans-acting factor is present in nuclear extracts from untreated and tert-butylhydroquinone-treated cells as determined by photochemical cross-linking experiments. The cross-linked protein appears to be a heterodimer with subunit molecular weights of approximately 28,000 and approximately 45,000.			NGUYEN, T (corresponding author), MERCK FROSST CTR THERAPEUT RES,POB 1005,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JAKOBY WB, 1984, BIOCHEM PHARMACOL, V33, P2539, DOI 10.1016/0006-2952(84)90621-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SHEN ES, 1989, J BIOL CHEM, V264, P17754; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	29	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13535	13539						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618854				2022-12-27	WOS:A1992JB74600069
J	SAKAMOTO, H; BELLALOU, J; SEBO, P; LADANT, D				SAKAMOTO, H; BELLALOU, J; SEBO, P; LADANT, D			BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE TOXIN - STRUCTURAL AND FUNCTIONAL INDEPENDENCE OF THE CATALYTIC AND HEMOLYTIC ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; VIRULENCE FACTORS; CALMODULIN; BINDING; IDENTIFICATION; PROTEIN; CLONING	The Bordetella pertussis calmodulin-dependent adenylate cyclase (CyaA) is a 1706-residue-long toxin, endowed with hemolytic activity. We have constructed B. pertussis mutant strains producing modified CyaAs devoid of adenylate cyclase activity. Our results show that such modified CyaAs display hemolytic activity identical to the wild-type toxin, thus demonstrating that the hemolytic activity is independent of the adenylate cyclase activity. Furthermore, B. pertussis and Escherichia coli strains producing CyaA lacking the catalytic domain (residues 1-373) were constructed. The truncated protein exhibits hemolytic activity comparable to the wild-type toxin, thus establishing that the carboxyl-terminal 1332 residues alone are endowed with hemolytic activity. Together, these findings show that adenylate cyclase and hemolytic activities are located in two distinct regions of the molecule (respectively, approximately amino acids 1-400 and 401-1706) and that the two regions of CyaA are functionally independent.			SAKAMOTO, H (corresponding author), INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE.		SEBO, Peter/F-7423-2011; SEBO, Peter/N-2043-2019	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; LADANT, Daniel/0000-0003-1955-548X; Sakamoto, Hiroshi/0000-0002-8767-2111				AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BHAKDI S, 1991, INFECT IMMUN, V59, P2955, DOI 10.1128/IAI.59.9.2955-2962.1991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CZUPRYNSKI CJ, 1991, INFECT IMMUN, V59, P3126, DOI 10.1128/IAI.59.9.3126-3133.1991; EHRMANN I, 1990, 1990 AM SOC MICR ANN; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; KHELEF N, 1992, IN PRESS MICROBIOL P; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1986, J BIOL CHEM, V261, P6264; LADANT D, 1992, IN PRESS J BIOL CHEM, V267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONNERON A, 1988, BIOCHEMISTRY-US, V27, P536, DOI 10.1021/bi00402a005; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Pittman M., 1984, BERGEYS MANUAL SYSTE, V1, P388; ROGEL A, 1991, J BIOL CHEM, V266, P3154; Sambrook J, 1989, MOL CLONING LABORATO; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STIBITZ S, 1986, GENE, V50, P133, DOI 10.1016/0378-1119(86)90318-5; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WELSH RA, 1991, MOL MICROBIOL, V5, P521; Wolff J, 1980, P NATL ACAD SCI USA, V77, P3840; ZEALEY G, 1988, FEMS MICROBIOL LETT, V56, P123, DOI 10.1016/S0378-1097(97)00413-8	34	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13598	13602						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618862				2022-12-27	WOS:A1992JB74600079
J	HERRLER, G; GROSS, HJ; IMHOF, A; BROSSMER, R; MILKS, G; PAULSON, JC				HERRLER, G; GROSS, HJ; IMHOF, A; BROSSMER, R; MILKS, G; PAULSON, JC			A SYNTHETIC SIALIC-ACID ANALOG IS RECOGNIZED BY INFLUENZA-C VIRUS AS A RECEPTOR DETERMINANT BUT IS RESISTANT TO THE RECEPTOR-DESTROYING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYL-9-O-ACETYLNEURAMINIC ACID; BOVINE CORONAVIRUS; ERYTHROCYTES; ACETYLESTERASE; GLYCOPROTEIN; ESTERASE; FUSION; SPECIFICITY; RETROVIRUS; ACTIVATION	Synthetic sialic acid analogues varying in the substituents at position C-9 were analyzed for their ability to replace the natural receptor determinant for influenza C virus, N-acetyl-9-O-acetylneuraminic acid (Neu-5,9Ac-2). By incubation of erythrocytes with sialyltransferase and the CMP-activated analogues, the cell surface was modified to contain sialic acid with one of the following C-9 substituents: an azido, an amino, an acetamido, or a hexanoylamido group. Among these, only 9-acetamido-N-acetylneuraminic acid (9-acetamido-Neu5Ac) was able to function as a receptor determinant for influenza C virus as indicated by the ability of the virus to agglutinate the modified red blood cells. In contrast to the natural receptors, 9-acetamido-Neu5Ac-containing receptors were found to be resistant against the action of sialate 9-O-acetylesterase, the viral receptor-destroying enzyme. No difference in the hemolytic activity of influenza C virus was detected when analyzed with erythrocytes containing either Neu5,9Ac-2 or 9-acetamido-Neu5Ac on their surface. This finding indicates that cleavage of the receptor is not required for the viral fusion activity. The sialic acid analogues should be useful for analyzing not only the importance of the receptor-destroying enzyme of influenza C virus, but also other biological processes involving sialic acid.	UNIV HEIDELBERG,INST BIOCHEM 2,W-6900 HEIDELBERG,GERMANY; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	Ruprecht Karls University Heidelberg; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HERRLER, G (corresponding author), UNIV MARBURG,INST VIROL,W-3550 MARBURG,GERMANY.		Paulson, James/AAG-3565-2019					DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; GROSS HJ, 1990, ANAL BIOCHEM, V186, P127, DOI 10.1016/0003-2697(90)90585-W; GROSS HJ, 1989, BIOCHEMISTRY-US, V28, P7386, DOI 10.1021/bi00444a036; GROSS HJ, 1987, EUR J BIOCHEM, V168, P595, DOI 10.1111/j.1432-1033.1987.tb13458.x; GROSS HJ, 1988, EUR J BIOCHEM, V177, P583, DOI 10.1111/j.1432-1033.1988.tb14410.x; GROSS HJ, 1991, CLIN CHIM ACTA, V197, P237, DOI 10.1016/0009-8981(91)90144-2; HERRLER G, 1987, VIROLOGY, V159, P102, DOI 10.1016/0042-6822(87)90352-7; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; HERRLER G, 1988, ARCH VIROL, V102, P269, DOI 10.1007/BF01310831; HERRLER G, 1985, VIRUS RES, V2, P183, DOI 10.1016/0168-1702(85)90248-5; HERRLER G, 1985, VIROLOGY, V141, P144, DOI 10.1016/0042-6822(85)90190-4; HERRLER G, 1987, BIOL CHEM H-S, V368, P451, DOI 10.1515/bchm3.1987.368.1.451; KITAME F, 1985, VIRUS RES, V3, P231; KITAME F, 1982, ARCH VIROL, V73, P357, DOI 10.1007/BF01318090; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LENTZ TL, 1990, J GEN VIROL, V71, P751, DOI 10.1099/0022-1317-71-4-751; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982; Paulson J, 1985, THE RECEPTORS, V2, P131; PAULSON JC, 1987, METHOD ENZYMOL, V138, P162; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; SCHULTZE B, 1991, VIROLOGY, V180, P221, DOI 10.1016/0042-6822(91)90026-8; SCHULTZE B, 1990, VIRUS RES, V16, P185, DOI 10.1016/0168-1702(90)90022-4; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; VLASAK R, 1988, J VIROL, V62, P4686, DOI 10.1128/JVI.62.12.4686-4690.1988	30	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12501	12505						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618756				2022-12-27	WOS:A1992HZ48300022
J	BOURGOIN, S; GRINSTEIN, S				BOURGOIN, S; GRINSTEIN, S			PEROXIDES OF VANADATE INDUCE ACTIVATION OF PHOSPHOLIPASE-D IN HL-60 CELLS - ROLE OF TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; COLONY-STIMULATING FACTOR; HUMAN-NEUTROPHILS; PHOSPHATIDIC-ACID; NADPH-OXIDASE; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; PHORBOL ESTERS; MECHANISMS	To determine the role of protein tyrosine phosphorylation in the activation of phospholipase D (PLD), electropermeabilized HL-60 cells labeled in [H-3]alkylphosphatidylcholine were treated with vanadate derivatives. Micromolar concentrations of vanadyl hydroperoxide (V4+-OOH) induced accumulation of tyrosine-phosphorylated proteins. Concomitantly, V4+-OOH or a combination of vanadate and NADPH elicited a concentration- and time-dependent accumulation of phosphatidic acid (PtdOH). In the presence of ethanol a sustained formation of phosphatidylethanol was observed, indicating that a type D phospholipase was activated. A good correlation was found to exist between the accumulation of tyrosine-phosphorylated proteins and activation of PLD. The V4+-OOH concentration dependence of the two responses was nearly identical, and the time course of activation was similar, with tyrosine phosphorylation preceding PLD activation by almost-equal-to 1 min. The ability of V4+-OOH to induce both responses was found to be strictly dependent on the presence of ATP and/or Mg2+, suggesting that PLD activation involves phosphotransferase reactions. Accordingly, ST638, a tyrosine kinase inhibitor, reduced concomitantly tyrosine phosphorylation and PLD activation elicited by V4+-OOH. The mechanism of action of V4+-OOH was investigated. The diacylglycerol kinase inhibitors, dioctanoylethylene glycol and R59022 potentiated PLD stimulation by exogenous diacylglycerol but not by V4+-OOH. Moreover, stimulation by V4+-OOH and by phorbol esters was synergystic. Therefore, diacylglycerol-induced activation of protein kinase C is unlikely to mediate the effects of V4+-OOH. The response of PLD to V4+-OOH was larger than that to guanosine 5'-(gamma-thio)triphosphate. Moreover, the effects of GTP-gamma-S and V4+-OOH were additive. Hence, activation of G proteins cannot account for the stimulation of PLD by V4+-OOH. V4+-OOH also triggers a burst of O2 consumption by the NADPH oxidase. Inhibition of PtdOH accumulation by addition of ethanol or by ST638 abolished this respiratory burst. Together, the results establish a strong correlation between tyrosine phosphorylation, PLD activation, and stimulation of the NADPH oxidase in HL-60 cells, suggesting a causal relationship.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Bourgoin, Sylvain/0000-0001-9779-0368				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BERRIDGE MJ, 1984, NATURE, V312, P312; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BOURGOIN S, 1991, J LEUKOCYTE BIOL S, V2, P79; ENGLISH D, 1991, BLOOD, V77, P2746; FABIATO A, 1989, J PHYSL, V75, P464; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FISHER GJ, 1991, J CELL PHYSIOL, V146, P309, DOI 10.1002/jcp.1041460216; GALLIN JI, 1982, FED PROC, V42, P2851; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEYWORTH PG, 1990, J BIOENERG BIOMEMBR, V22, P1, DOI 10.1007/BF00762842; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; KAMPS MP, 1988, ONCOGENE, V2, P305; NACCACHE PH, 1990, BIOL CHEMOTACTIC RES, V24, P347; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMITH GA, 1978, LIPIDS, V13, P92, DOI 10.1007/BF02533373; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAUBER AI, 1987, BLOOD, V69, P711; TETTENBORN CS, 1987, BIOCHIM BIOPHYS ACTA, V931, P242, DOI 10.1016/0167-4889(87)90212-6; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TRUDEL S, 1990, BIOCHEM J, V269, P127, DOI 10.1042/bj2690127; WANG P, 1991, J BIOL CHEM, V266, P14877; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081	46	149	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11908	11916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601860				2022-12-27	WOS:A1992HY94700041
J	HANLON, DW; MARQUEZMAGANA, LM; CARPENTER, PB; CHAMBERLIN, MJ; ORDAL, GW				HANLON, DW; MARQUEZMAGANA, LM; CARPENTER, PB; CHAMBERLIN, MJ; ORDAL, GW			SEQUENCE AND CHARACTERIZATION OF BACILLUS-SUBTILIS CHEW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTING CHEMOTAXIS PROTEINS; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; GENE-EXPRESSION; PHOSPHORYLATION; SYSTEM; METHYLESTERASE; METHYLATION; MUTATIONS	A Bacillus subtilis open reading frame (ORF) encoding a predicted polypeptide of 156 amino acids was subcloned and sequenced. The polypeptide was found to be homologous to CheW of Escherichia coli, sharing 28.6% amino acid identity. The ORF was verified by using a bacteriophage T7 expression system in E. coli. The gene was inactivated by insertion of a nonpolor chloramphenicol acetyltransferase cassette in its N-terminal region. In the absence of chemoeffectors, the mutant displayed a smooth swimming bias, with some tumbling. The CheW- mutant was defective on swarm plates but was complemented by a plasmid that expressed wild type CheW. Addition of attractant or repellent to the CheW- mutant resulted in transient smooth swimming or tumbling, respectively. However, capillary assays revealed that chemotaxis was substantially impaired in the mutant strain.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,COLL LIBERAL ARTS & SCI,URBANA,IL 61801; UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Berkeley					NIAID NIH HHS [AI20336] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM M, 1991, J BACTERIOL, V173, P5837, DOI 10.1128/jb.173.18.5837-5842.1991; BAND L, 1984, DNA-J MOLEC CELL BIO, V3, P17, DOI 10.1089/dna.1.1984.3.17; BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; BISCHOFF DS, 1991, J BIOL CHEM, V266, P12301; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MCBRIDE MJ, 1989, P NATL ACAD SCI USA, V86, P424, DOI 10.1073/pnas.86.2.424; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; PARKINSON JS, 1978, CELL, V15, P1221, DOI 10.1016/0092-8674(78)90048-X; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1987, J BIOL CHEM, V262, P2811; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; ZUBERI AR, 1990, J BACTERIOL, V172, P1870, DOI 10.1128/jb.172.4.1870-1876.1990	37	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12055	12060						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601874				2022-12-27	WOS:A1992HY94700063
J	SCHWARTZ, HL; STRAIT, KA; LING, NC; OPPENHEIMER, JH				SCHWARTZ, HL; STRAIT, KA; LING, NC; OPPENHEIMER, JH			QUANTITATION OF RAT-TISSUE THYROID-HORMONE BINDING-RECEPTOR ISOFORMS BY IMMUNOPRECIPITATION OF NUCLEAR TRIIODOTHYRONINE BINDING-CAPACITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER NUCLEI; HUMAN TESTIS; CDNA CLONE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; AFFINITY; ENCODES; INVITRO; SITES	A panel of anti-thyroid hormone receptor (TR) antisera were generated to allow direct assay of the concentrations of the alpha-1 and,beta-1 receptor isoforms in nuclear extracts from adult rat liver, kidney, brain and heart, and fetal brain. An antiserum, immunoglobulin G (IgG)-beta-1, raised against amino acid sequence 62-92 of the rat TR-beta-1 specifically precipitated only TR-beta-1 in vitro translation products. A second antiserum, IgG-alpha-1/8, generated against a sequence that is identical in the ligand binding region of rat TR-alpha-1 and TR-beta isoforms immunoprecipitated both TR-alpha-1 and -beta-1 translation products. These IgG preparations were used to specifically immunoprecipitate thyroid hormone receptor binding activity from nuclear extracts. IgG-beta-1 cleared almost 80%, and the IgG-alpha-1/beta-immunoprecipitated nearly all binding from hepatic nuclear extracts. This distribution of TR protein, 80% beta-1 and 20%-alpha-1, is the same as previously reported for their respective mRNAs in liver. In heart, kidney, and brain IgG-beta-1 cleared 45, 43, and 28% of total binding, respectively, and IgG-alpha-1/beta-cleared all T3 binding activity from these tissues. In agreement with an earlier study, marked variations in specific protein/mRNA ratios were noted among these tissues. Consistent with our earlier report of the presence of only very low levels of TR-beta-1 mRNA in fetal brain, IgG-beta-1 cleared just 5% of binding in this tissue. Studies using an antiserum (IgG-ch) generated against homologous segments of the hinge region in both TR-alpha-1 and -beta-1 yielded results which contrasted sharply with those of IgG-alpha-1/beta. Whereas IgG-ch could also immunoprecipitate virtually all binding from hepatic extracts it cleared only 40-50% of binding from the other tissues, including fetal brain in which TR-alpha-1 accounts for >90% of binding protein. The data suggest the presence of posttranslational modification of the TR-alpha-1 protein in the hinge region, consistent with the presence in this segment of potential phosphorylation sites.	UNIV MINNESOTA,DEPT MED,ENDOCRINOL & METAB SECT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; WHITTIER INST,LA JOLLA,CA 92073	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK-19812] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019812] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BROWN TA, 1990, J BIOL CHEM, V265, P10025; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LATHAM KR, 1976, J BIOL CHEM, V251, P7388; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LING N, 1984, P NATL ACAD SCI-BIOL, V81, P4302, DOI 10.1073/pnas.81.14.4302; MIGLIACCIO A, 1981, J STEROID BIOCHEM, V15, P369, DOI 10.1016/0022-4731(81)90299-5; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; SAMUELS HH, 1973, SCIENCE, V181, P1253, DOI 10.1126/science.181.4106.1253; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SILVA ES, 1977, J BIOL CHEM, V252, P6799; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; SURKS MI, 1973, J BIOL CHEM, V248, P7066; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TORRESANI J, 1975, ENDOCRINOLOGY, V96, P1201, DOI 10.1210/endo-96-5-1201; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	28	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11794	11799						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601852				2022-12-27	WOS:A1992HY94700026
J	SUBRAMANIAM, VN; YUSOFF, ARB; WONG, SH; LIM, GB; CHEW, M; HONG, WJ				SUBRAMANIAM, VN; YUSOFF, ARB; WONG, SH; LIM, GB; CHEW, M; HONG, WJ			BIOCHEMICAL FRACTIONATION AND CHARACTERIZATION OF PROTEINS FROM GOLGI-ENRICHED MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ENDOPLASMIC-RETICULUM; BINDING-PROTEIN; CDNA CLONING; APPARATUS; IDENTIFICATION; PURIFICATION; EXPRESSION; SEQUENCE; OLIGOSACCHARIDES	Fractions enriched in Golgi membranes were prepared from rat liver by sucrose gradient ultracentrifugation. These enriched membranes were further subfractionated on the basis of their solubilities in EGTA, 150 mM sodium carbonate, pH 11.5, sodium deoxycholate, Triton X-100, or sodium dodecyl sulfate. This led to isolation of peripheral, luminal, and integral membrane proteins of the Golgi-enriched membranes. Luminal and membrane proteins were further purified by wheat germ agglutinin and concanavalin A lectin affinity chromatographies. Some proteins from these lectin columns were resolved by preparative gel electrophoresis and microsequenced. Subsequently, antibodies were produced for two proteins by immunization of either mice or rabbits. Immunofluorescence microscopy suggests that these proteins are confined to Golgi apparatus-like structures. The protocol described is well suited for the study of organelle structure and function.			SUBRAMANIAM, VN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, MOLEC & CELL BIOL MEMBRANES LAB, SINGAPORE 0511, SINGAPORE.		HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				BERGERON JJM, 1979, BIOCHIM BIOPHYS ACTA, V555, P493, DOI 10.1016/0005-2736(79)90402-4; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRADA D, 1990, J CELL BIOL, V110, P309, DOI 10.1083/jcb.110.2.309; BRANDLI AW, 1991, BIOCHEM J, V276, P1; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EHRENREICH JH, 1973, J CELL BIOL, V59, P45, DOI 10.1083/jcb.59.1.45; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FLEISCHER B, 1983, METHOD ENZYMOL, V98, P60; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GONATAS JO, 1989, J BIOL CHEM, V264, P646; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LOW SH, 1991, J BIOL CHEM, V266, P13391; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SCHREIBER G, 1979, J BIOL CHEM, V254, P2013; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WELLNER D, 1988, BIOCHEM BIOPH RES CO, V155, P622, DOI 10.1016/S0006-291X(88)80540-0; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	47	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12016	12021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601872				2022-12-27	WOS:A1992HY94700057
J	MACKAY, K; DANIELPOUR, D; MILLER, D; BORDER, WA; ROBBINS, AR				MACKAY, K; DANIELPOUR, D; MILLER, D; BORDER, WA; ROBBINS, AR			THE 260-KDA TRANSFORMING GROWTH-FACTOR (TGF)-BETA BINDING-PROTEIN IN RAT GLOMERULI IS A COMPLEX COMPRISED OF 170-KDA AND 85-KDA TGF-BETA BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; CELLS	In a previous study (MacKay, K., Robbins, A. R., Bruce, M. D., and Danielpour, D. (1990) J. Biol. Chem. 265, 9351-9356) we showed that rat glomeruli contain transforming growth factor (TGF)-beta-1 binding proteins with apparent molecular masses of 260, 170, and 85 kDa (Gl-260, Gl-170, Gl-85) as determined by electrophoresis under nonreducing conditions. We demonstrate here that Gl-260 is a complex of 170- and 85-kDa TGF-beta binding proteins. Under denaturing conditions the integrity of Gl-260 is maintained through the cross-linking of one monomer of the disulfide-linked TGF-beta-1 homodimer to Gl-85 and of the other monomer to the 100-kDa subunit of Gl-170. In addition, some Gl-260 complexes are maintained by direct cross-linking of Gl-85 to the 100-kDa subunit of Gl-170. One-dimensional peptide maps of Gl-85 and the 100-kDa subunit of Gl-170 indicate that they have distinctly different ligand binding domains. In contrast, peptide maps of Gl-85 and the type II receptor of normal rat kidney fibroblasts are similar. The biological responses of isolated glomeruli to TGF-beta appear to parallel those of cultured glomerular cells which are without detectable Gl-170 and Gl-260 binding proteins.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892; UNIV UTAH,SCH MED,DIV NEPHROL,SALT LAKE CITY,UT 84132	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah	MACKAY, K (corresponding author), NIDDKD,METAB DIS BRANCH,KIDNEY DIS SECT,BETHESDA,MD 20892, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043609, R37DK043609] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43609] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COIMBRA T, 1991, AM J PATHOL, V138, P223; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; FROLIK CA, 1984, J BIOL CHEM, V259, P995; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKAY K, 1989, J CLIN INVEST, V83, P1160, DOI 10.1172/JCI113996; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MACKAY K, 1990, KIDNEY INT, V38, P1095, DOI 10.1038/ki.1990.318; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SMITH RJ, 1978, BIOCHEMISTRY-US, V17, P3719, DOI 10.1021/bi00611a007; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	20	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11449	11454						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597472				2022-12-27	WOS:A1992HX16900078
J	NISHIMOTO, SK; ARAKI, N; ROBINSON, FD; WAITE, JH				NISHIMOTO, SK; ARAKI, N; ROBINSON, FD; WAITE, JH			DISCOVERY OF BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN IN MINERALIZED SCALES - THE ABUNDANCE AND STRUCTURE OF LEPOMIS-MACROCHIRUS BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL TISSUE RESORPTION; K-DEPENDENT PROTEIN; MATRIX GLA PROTEIN; FUNDULUS-HETEROCLITUS; CALCIUM HOMEOSTASIS; CARASSIUS-AURATUS; ESTRADIOL; KILLIFISH; GOLDFISH; SEQUENCE	The mineralized scale of the freshwater sunfish Lepomis macrochirus (bluegill) contains a Gla protein. The protein was identified in extracts of scale by a new colorimetric assay for Gla-containing proteins. The protein was purified by gel filtration chromatography followed by reversed phase high performance liquid chromatography (HPLC). Several tests establish the identity of scale Gla protein and bone Gla protein (BGP). First, the proteins exhibit identical mobilities on electrophoresis and by reversed phase HPLC. Second, they have identical amino-terminal amino acid sequences. Finally, identical peptides are generated by proteolytic digestion. The 45-residue amino acid sequence of the bone Gla protein from L. macrochirus has a high sequence homology with swordfish, as well as homology to mammalian bone Gla protein. The BGP of bluegill shares with swordfish BGP a truncated NH2 terminus and an extended COOH terminus. These features may be unique to fish, as they have not been observed in terrestrial vertebrates. The bluegill BGP is the first vitamin K-dependent protein to contain a non-gamma-carboxylated residue to the NH2-terminal side of all of its Gla residues. In all other vitamin K-dependent proteins, Gla always appears to the NH2-terminal side of the first Glu. The implications of this result are discussed. The bluegill rib bone is curiously enriched in BGP, as are other mineralized tissues of this species. One hypothesis is that this may be due to the acellular nature of the bone in this species. The abundance of BGP in the bones of this fish may provide clues to the unknown function of this bone protein.	UNIV DELAWARE,COLL MARINE STUDIES,LEWES,DE 19958	University of Delaware	NISHIMOTO, SK (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,858 MADISON ST,SUITE G01,MEMPHIS,TN 38163, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035056] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35056] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN G, SEQUENCING PROTEINS, P90; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; KLARSKOV K, 1989, ANAL BIOCHEM, V180, P28; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY RJ, 1979, BIOCHEM BIOPH RES CO, V91, P41, DOI 10.1016/0006-291X(79)90580-1; LIAN JB, 1984, J CLIN INVEST, V73, P1223, DOI 10.1172/JCI111308; LIAN JB, 1977, J CLIN INVEST, V59, P1151, DOI 10.1172/JCI108739; LINDE A, 1980, J BIOL CHEM, V255, P5931; MOSS ML, 1962, ACTA ANAT, V48, P46; MOSS ML, 1965, ACTA ANAT, V60, P262; MUGIYA Y, 1977, COMP BIOCHEM PHYS A, V57, P197, DOI 10.1016/0300-9629(77)90455-8; NISHIMOTO SK, 1990, ANAL BIOCHEM, V186, P273, DOI 10.1016/0003-2697(90)90079-O; OTSUKA AS, 1978, THESIS U CALIFORNIA; POSER JW, 1980, J BIOL CHEM, V255, P8685; PRICE PA, 1980, P NATL ACAD SCI-BIOL, V77, P2234, DOI 10.1073/pnas.77.4.2234; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; PRICE PA, 1977, CALCIUM BINDING PROT, P333; SAUK JJ, 1984, BIOCHIM BIOPHYS ACTA, V798, P199, DOI 10.1016/0304-4165(84)90304-0; SUGITA A, 1987, J BIOCHEM-TOKYO, V101, P1593; WAITE JH, 1991, ANAL BIOCHEM, V192, P429, DOI 10.1016/0003-2697(91)90560-G; WEISS RE, 1978, COMP BIOCHEM PHYS A, V60, P207, DOI 10.1016/0300-9629(78)90233-5; YAMADA J, 1979, J MORPHOL, V159, P49, DOI 10.1002/jmor.1051590105	25	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11600	11605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597487				2022-12-27	WOS:A1992HX16900101
J	TAKAHASHI, N; HIROSE, M				TAKAHASHI, N; HIROSE, M			REVERSIBLE DENATURATION OF DISULFIDE-REDUCED OVALBUMIN AND ITS REOXIDATION GENERATING THE NATIVE CYSTINE CROSS-LINK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEN OVALBUMIN; PROTEINS; RENATURATION; INHIBITOR; SEQUENCE; BRIDGES; FORM; GEL	The authors in a previous report (Klausner, R. D., Kempf, C., Weinstein, J. N., Blumenthal, R., and van Renswoude, J. (1983) Biochem. J. 212, 801-810) have argued that native folding of ovalbumin occurs during translation, but not in a renaturation system of the denatured form. To re-examine the possibility, we searched for the conditions of correct oxidative refolding of denatured disulfide-reduced ovalbumin. Data of trypsin resistance, CD-spectrum, and selective reactivity of cysteine sulfhydryls revealed that the fully denatured protein can refold into the native conformation under disulfide-reduced conditions. The interconversion between the native and denatured forms was fully reversible with a free energy change for unfolding of 6.6 kcal/mol at 25-degrees-C. Subsequent reoxidation under a variety of redox conditions generated only one disulfide bond in the reduced refolded protein with six cysteine sulfhydryls. Furthermore, the regenerated disulfide was found by peptide analyses to correspond to the native disulfide pairing, Cys73-Cys120. We, therefore, concluded that co-translational folding, if any, is not requisite for the correct oxidative folding of ovalbumin.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University								AHMAD F, 1976, BIOCHEMISTRY-US, V15, P5168, DOI 10.1021/bi00668a034; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Creighton T E, 1986, Methods Enzymol, V131, P83; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FOSTER JF, 1952, ARCH BIOCHEM BIOPHYS, V40, P437, DOI 10.1016/0003-9861(52)90131-8; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HOLT JC, 1972, BIOCHEM J, V129, P665, DOI 10.1042/bj1290665; IMAHORI K, 1960, BIOCHIM BIOPHYS ACTA, V37, P336, DOI 10.1016/0006-3002(60)90242-0; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KLAUSNER RD, 1983, BIOCHEM J, V212, P801, DOI 10.1042/bj2120801; KOSEKI T, 1988, J BIOCHEM-TOKYO, V103, P425, DOI 10.1093/oxfordjournals.jbchem.a122286; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MOORE S, 1963, J BIOL CHEM, V238, P235; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; ODANI S, 1973, J BIOCHEM-TOKYO, V74, P697, DOI 10.1093/oxfordjournals.jbchem.a130295; OTTESEN M, 1968, BIOCHIM BIOPHYS ACTA, V160, P262, DOI 10.1016/0005-2795(68)90098-6; OTTESEN M, 1958, C R Trav Lab Carlsberg Chim, V30, P211; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON RB, 1953, J AM CHEM SOC, V75, P5139, DOI 10.1021/ja01117a001; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; TAKAHASHI N, 1990, ANAL BIOCHEM, V188, P359, DOI 10.1016/0003-2697(90)90621-F; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; WRIGHT HT, 1990, J MOL BIOL, V213, P513	29	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11565	11572						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597484				2022-12-27	WOS:A1992HX16900096
J	KONIG, G; MONNING, U; CZECH, C; PRIOR, R; BANATI, R; SCHREITERGASSER, U; BAUER, J; MASTERS, CL; BEYREUTHER, K				KONIG, G; MONNING, U; CZECH, C; PRIOR, R; BANATI, R; SCHREITERGASSER, U; BAUER, J; MASTERS, CL; BEYREUTHER, K			IDENTIFICATION AND DIFFERENTIAL EXPRESSION OF A NOVEL ALTERNATIVE SPLICE ISOFORM OF THE BETA-A4 AMYLOID PRECURSOR PROTEIN (APP) MESSENGER-RNA IN LEUKOCYTES AND BRAIN MICROGLIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; DNA-POLYMERASE; GENE; ACID; LOCALIZATION; MACROPHAGES; RECEPTOR; ADHESION; SYSTEM; CDNA	The gene for the beta-A4-amyloid precursor protein (APP) consists of 19 exons which code for a typical N- and O-glycosylated transmembrane protein with four extracellular domains followed by the transmembrane domain and a short cytoplasmic domain. The beta-A4-amyloid sequence is part of exons 16 and 17. Several APP isoforms can be generated by alternative splicing of exons 7 and 8, encoding domains with homologies to Kunitz-type protease inhibitors and the MRC OX-2 antigen, respectively. The mechanism by which the pathological beta-A4 is generated is unknown, it is however a critical event in Alzheimer's disease and is distinct from the normally occurring cleavage and secretion of APPs within the beta-A4 sequence. We report here for the first time considerable APP mRNA expression by rat brain microglial cells. In addition we showed by S1 nuclease protection and polymerase chain reaction analysis of reverse transcribed RNA (RT-PCR(TM)) that T-lymphocytes, macrophages, and microglial cells expressed a new APP isoform by selection of a novel alternative splice site and exclusion of exon 15 of the APP gene. This leads to a transmembrane, beta-A4 sequence containing APP variant, lacking 18 amino acid residues close to the amyloidogenic region. The use of this novel alternative splice site alters the structure of APP in close proximity to the beta-A4 region and thus may determine a variant, potentially pathogenic processing of leukocyte-derived APP in brain.	CENT INST MENTAL HLTH, W-6800 MANNHEIM, GERMANY; MAX PLANCK INST PSYCHIAT, W-8033 MARTINSRIED, GERMANY; UNIV HOSP FREIBURG, DEPT PSYCHIAT, W-7800 FREIBURG, GERMANY; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA	Central Institute of Mental Health; Max Planck Society; University of Freiburg; University of Melbourne	KONIG, G (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, INF 282, W-6900 HEIDELBERG, GERMANY.			Czech, Christian/0000-0001-7746-0134				AUSBUBEL FM, 1989, CURRENT PROTOCOLS MO; BANATI RB, 1991, NEUROPATH APPL NEURO, V17, P223, DOI 10.1111/j.1365-2990.1991.tb00718.x; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P31; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE L, 1976, CELL, V9, P91, DOI 10.1016/0092-8674(76)90055-6; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P267, DOI 10.1016/0197-4580(89)90061-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONNING U, 1990, FEBS LETT, V277, P261, DOI 10.1016/0014-5793(90)80861-C; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N; [No title captured]	41	220	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10804	10809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587857				2022-12-27	WOS:A1992HV09000090
J	SHIBANUMA, M; KUROKI, T; NOSE, K				SHIBANUMA, M; KUROKI, T; NOSE, K			ISOLATION OF A GENE ENCODING A PUTATIVE LEUCINE ZIPPER STRUCTURE THAT IS INDUCED BY TRANSFORMING GROWTH FACTOR-BETA-1 AND OTHER GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; HUMAN-LUNG FIBROBLASTS; FACTOR-BETA; MESSENGER-RNA; EXTRACELLULAR-MATRIX; C-MYC; CELL PROLIFERATION; PROTO-ONCOGENE; EXPRESSION; BINDING	A gene sequence (TSC-22) that is induced by transforming growth factor (TGF) beta-1 was isolated by differential screening of a lambda-gt10 cDNA library constructed from poly(A)+ RNA of mouse osteoblastic cells treated with TGF-beta-1 for 2 h. TSC-22 gene expression was transcriptionally activated by TGF-beta-1. It was also induced by phorbol 12-myristate 13-acetate, serum, cholera toxin, or dexamethasone, but not appreciably by epidermal growth factor. Its induction was rapid and transient, reaching a peak 2 h after TGF-beta-1 treatment, and was resistant to cycloheximide like that of c-jun. The nucleotide sequences of TSC-22 cDNA showed no homology with any known gene sequence. The open reading frame and in vitro translation product indicated that the gene encodes a polypeptide of 143 amino acids with a molecular mass of 18 kDa that contains a putative leucine zipper structure. Polyclonal antibody was raised against TSC-22 protein expressed in Escherichia coli cells, and the antibody detected a 18-kDa protein in both the cytoplasmic and nuclear fractions of [S-35]Met-labeled cells. These results indicate that the TSC-22 gene is a new member of the family of early response genes, and encodes a small polypeptide that is a putative transcriptional regulator.	UNIV TOKYO, INST MED SCI,DEPT CANC CELL RES, SHIROKANEDAI 4-6-1,MINATO KU, TOKYO 108, JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHIANG CP, 1986, J BIOL CHEM, V261, P478; CHILDS CB, 1982, P NATL ACAD SCI-BIOL, V79, P5312, DOI 10.1073/pnas.79.17.5312; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KURIHARA N, 1986, ENDOCRINOLOGY, V118, P940, DOI 10.1210/endo-118-3-940; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LUND LR, 1987, EMBO J, V6, P1281, DOI 10.1002/j.1460-2075.1987.tb02365.x; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NODA M, 1988, J BIOL CHEM, V263, P13916; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAKAI M, 1989, CANCER RES, V49, P5633; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SPORN MB, 1989, JAMA-J AM MED ASSOC, V262, P938, DOI 10.1001/jama.262.7.938; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THOMPSON KL, 1988, J BIOL CHEM, V263, P19519; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	61	141	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10219	10224						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587811				2022-12-27	WOS:A1992HV09000006
J	CHEN, JY; JOYCE, PBM; WOLFE, CL; STEFFEN, MC; MARTIN, NC				CHEN, JY; JOYCE, PBM; WOLFE, CL; STEFFEN, MC; MARTIN, NC			CYTOPLASMIC AND MITOCHONDRIAL TRANSFER-RNA NUCLEOTIDYLTRANSFERASE ACTIVITIES ARE DERIVED FROM THE SAME GENE IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST TRANSFER-RNA; SPLICED TRANSFER-RNA; XENOPUS OOCYTES; NUCLEAR; PRECURSORS; TRANSCRIPTION; PROTEINS; EXTRACT; ENCODES; IMPORT	ATP (CTP):tRNA-specific tRNA nucleotidyltransferase, is an enzyme required for the synthesis of functional tRNAs in eukaryotic cells. Neither the tRNA genes in the nucleus nor in organelles encode the CCA end, so it must be added post-transcriptionally. The gene that codes for the enzyme that adds the CCA end to nuclear coded tRNAs in Saccharomyces cerevisiae has been isolated (Aebi, M., Kirchner, G., Chen, J.-Y., Vijayraghavan, U., Jacobson, A., Martin, N. C., and Abelson, J. (1990) J. Biol. Chem. 265,16216-16220). We now demonstrate that there is a mitochondrial tRNA nucleotidyltransferase activity in yeast and that it is a matrix enzyme. A comparison of purified mitochondrial enzyme with its cytoplasmic counterpart revealed no differences. These results suggest that proteins responsible for this step in the maturation of tRNAs in the nucleus and mitochondria might be identical and coded by the same nuclear gene. Accumulation of shortened mitochondrial as well as cytoplasmic tRNAs in a strain with a temperature-sensitive tRNA nucleotidyltransferase is consistent with this hypothesis. Alteration of the wild type gene such that amino-terminal truncated proteins are produced leads to a defect in mitochondrial function and a decrease in mitochondrial nucleotidyltransferase activity. This provides a direct demonstration that one gene provides this enzyme activity for the biosynthesis of tRNAs in both the nuclear/cytoplasmic and mitochondrial compartments in yeast.	UNIV LOUISVILLE,DEPT BIOCHEM,LOUISVILLE,KY 40292	University of Louisville			Joyce, Paul/K-3989-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027597] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27597] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; [Anonymous], 1969, METHODS ENZYMOL; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEN JY, 1988, J BIOL CHEM, V263, P13677; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P450; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ELLIS SR, 1987, P NATL ACAD SCI USA, V84, P5172, DOI 10.1073/pnas.84.15.5172; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GREENBERG BM, 1986, PLANT MOL BIOL, V6, P89, DOI 10.1007/BF00027302; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; GRUISSEM W, 1983, CELL, V35, P815, DOI 10.1016/0092-8674(83)90114-9; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOYCE PBM, 1989, NUCLEIC ACIDS RES, V17, P5461, DOI 10.1093/nar/17.14.5461; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; MANAM S, 1987, J BIOL CHEM, V262, P10272; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MUKERJI SK, 1972, J BIOL CHEM, V247, P481; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NISHIKURA K, 1981, J MOL BIOL, V145, P405, DOI 10.1016/0022-2836(81)90212-6; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P657; ROSSET R, 1965, BIOCHIM BIOPHYS ACTA, V108, P376, DOI 10.1016/0005-2787(65)90030-4; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SMITH L, 1955, METHOD ENZYMOL, V2, P735; SOLARI A, 1982, NUCLEIC ACIDS RES, V10, P4397, DOI 10.1093/nar/10.14.4397; SUYAMA Y, 1967, BIOCHEMISTRY-US, V6, P2829, DOI 10.1021/bi00861a025; TOLLEY E, 1975, BIOCHEM GENET, V13, P867, DOI 10.1007/BF00484417; WANG MJ, 1988, EMBO J, V7, P1567, DOI 10.1002/j.1460-2075.1988.tb02981.x; WU M, 1987, J BIOL CHEM, V262, P12275; ZINN AB, 1986, NEW ENGL J MED, V315, P469, DOI 10.1056/NEJM198608213150801	48	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14879	14883						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634528				2022-12-27	WOS:A1992JF08800058
J	DESCHEEMAEKER, KA; WYNS, S; NELLES, L; AUWERX, J; NY, T; COLLEN, D				DESCHEEMAEKER, KA; WYNS, S; NELLES, L; AUWERX, J; NY, T; COLLEN, D			INTERACTION OF AP-1-LIKE, AP-2-LIKE, AND SP1-LIKE PROTEINS WITH 2 DISTINCT SITES IN THE UPSTREAM REGULATORY REGION OF THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE MEDIATES THE PHORBOL 12-MYRISTATE 13-ACETATE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-1; CHLORAMPHENICOL ACETYLTRANSFERASE; VENOUS THROMBOSIS; SOMATOSTATIN GENE; BINDING; ELEMENT; DNA; IDENTIFICATION; STIMULATION; ENHANCER	Phorbol 12-myristate 13-acetate induces a 3- and 10-fold induction of chloramphenicol acetyltransferase (CAT) activity in HT1080 and HeLa cells, respectively, following transient transfection of a 336-base pair plasminogen activator inhibitor-1 (PAI-1) promoter fragment linked to a CAT reporter gene. Substitution mutations in the regions encompassing nucleotides -78 to -69 (TGGGTGGGGC) or -61 to -54 (TGAGTTCA), but not in the regions -155 to -149 (TGCCTCA) or -84 to -76 (AGTGAGTGG) reduced this induction. Gel electrophoresis of double-stranded -65 to -50 oligonucleotides of the PAI-1 promoter region and nuclear extracts from Hela cells produced a gel shift pattern similar to that obtained with a AP-1 consensus oligomer, and excess unlabeled AP-1 oligomer reverted binding, suggesting that this region of the PAI-1 promoter is an AP-1-like binding site. Gel electrophoresis of double-stranded -82 to -65 oligonucleotides with HeLa nuclear extracts revealed a gel shift pattern of three bands; Sp1 consensus oligomer competed with the binding to two of these bands and AP-2 consensus sequence oligomer with the binding to the third band. The -82 to -65 oligomer also bound to purified AP-2 and Sp1 proteins. Southwestern blotting of HeLa nuclear extracts revealed that the labeled oligomer spanning region -82 to -65 bound to proteins with molecular masses of 52 and 72 kDa. Consensus AP-2 oligonucleotides competed for binding of the labeled -82 to -65 oligonucleotide to the 52-kDa protein, but consensus Sp-1 oligonucleotides did not compete for binding to the 72-kDa compound. The 72-kDa component binding to the -82 to -65 region may represent a new protein involved in transcriptional regulation.	CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, B-3000 LOUVAIN, BELGIUM; CATHOLIC UNIV LEUVEN, LEGENDO, B-3000 LOUVAIN, BELGIUM; UMEA UNIV, APPL CELL & MOLEC BIOL UNIT, S-90187 UMEA, SWEDEN	KU Leuven; KU Leuven; Umea University			Auwerx, Johan/ABE-9307-2021	Auwerx, Johan/0000-0002-5065-5393				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; COLLEN D, 1991, BLOOD, V78, P3114; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DESCHEEMAEKER KA, 1992, IN PRESS FIBRINOLYSI; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; GINSBURG D, 1991, THROMBOLYSIS, P17; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KATAI H, 1991, MOL CELL BIOCHEM, V101, P73; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUSCHER B, 1991, GENE DEV, V2, P1507; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maniatis T., 1982, MOL CLONING; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SLIVKA SR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P317, DOI 10.1016/0167-4889(91)90092-C; STRANDBERG L, 1988, EUR J BIOCHEM, V176, P609, DOI 10.1111/j.1432-1033.1988.tb14320.x; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	39	112	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15086	15091						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634545				2022-12-27	WOS:A1992JF08800085
J	NELSON, DA; AGUILARBRYAN, L; BRYAN, J				NELSON, DA; AGUILARBRYAN, L; BRYAN, J			SPECIFICITY OF PHOTOLABELING OF BETA-CELL MEMBRANE-PROTEINS WITH AN I-125 LABELED GLYBURIDE ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 GLIBENCLAMIDE-BINDING; SENSITIVE POTASSIUM CHANNEL; SULFONYLUREA RECEPTOR; RADIOLIGAND; RAT; PURIFICATION; LIGAND; BRAIN; TUMOR; SITE	The interaction between sulfonylureas and membrane proteins from a hamster insulin-secreting tumor (HIT) cell line has been examined. Four HIT cell membrane proteins were covalently linked to an I-125-labeled glyburide analog by photolabeling. Three photolabeled polypeptides of M(r) 65,000, 55,000, and 30,000 were identified as low affinity "glyburide receptors." These proteins appear to be of similar abundance, when quantitated by photolabeling, with half-maximal displacements (K(i) values) by glyburide, glipizide, and tolbutamide in the low micromolar range. The glyburide analog is more tightly bound to a M(r) 140,000 protein with dissociation constants, determined by filtration binding assays and by photolabeling, of 7 and 9.0 nM, respectively. The labeled analog was displaced from the M(r) 140,000 protein by glyburide, glipizide and tolbutamide with K(i) values of 3.3 nM, 103 nM, and 25-mu-M, respectively, as estimated by photolabeling. Optimal conditions established for visualizing the M(r) 140,000 band on autoradiograms prepared after UV cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis include irradiating the radioligand-receptor complex at 1.5 J/cm2 at 312 nm, followed by heating samples in pH 9.0 sodium dodecyl sulfate-gel sample buffer. With receptor sites partially occupied (5 nM radioligand), approximately 0.75% of the protein is photocoupled to the radioligand and visualized by autoradiography. Our results confirm that the M(r) 140,000 polypeptide contains the beta-cell high affinity glyburide binding site and show that the second generation sulfonylurea antidiabetic drugs have a selective increase in affinity for this receptor.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	NELSON, DA (corresponding author), BAYLOR COLL MED,DEPT MED,1 BAYLOR PL,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK027635] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41898, DK27635] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROOKS MJ, 1974, J PHARM PHARMACOL, V26, P304, DOI 10.1111/j.2042-7158.1974.tb09280.x; de Weille J R, 1989, Pflugers Arch, V414 Suppl 1, pS80; ELSAYED YM, 1989, INT J CLIN PHARM TH, V27, P551; FOSSET M, 1988, J BIOL CHEM, V263, P7933; FRENCH JF, 1990, BIOCHEM BIOPH RES CO, V167, P1400, DOI 10.1016/0006-291X(90)90678-G; FRENCH JF, 1991, EUR J PHARM-MOLEC PH, V207, P23, DOI 10.1016/S0922-4106(05)80033-1; GAINES KL, 1988, J BIOL CHEM, V263, P2589; GEISEN K, 1985, ARZNEIMITTEL-FORSCH, V35-1, P707; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GOPALAKRISHNAN M, 1991, J PHARMACOL EXP THER, V257, P1162; HELLMAN B, 1971, BIOCHEM BIOPH RES CO, V45, P1384, DOI 10.1016/0006-291X(71)90174-4; IKEGAMI H, 1986, ACTA ENDOCRINOL-COP, V111, P528, DOI 10.1530/acta.0.1110528; KAUBISCH N, 1982, BIOCHEM PHARMACOL, V31, P1171, DOI 10.1016/0006-2952(82)90363-X; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPO B, 1987, EUR J PHARMACOL, V140, P157, DOI 10.1016/0014-2999(87)90801-6; MARTZ A, 1989, J BIOL CHEM, V264, P13672; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MILLER JA, 1991, J PHARMACOL EXP THER, V256, P358; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; NIKI I, 1991, BIOCHEM J, V277, P619, DOI 10.1042/bj2770619; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; ROBERTSON DW, 1990, J MED CHEM, V33, P3124, DOI 10.1021/jm00174a003; STURGESS NC, 1985, LANCET, V2, P474; ZINI S, 1991, BRAIN RES, V542, P151, DOI 10.1016/0006-8993(91)91010-X	31	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14928	14933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634533				2022-12-27	WOS:A1992JF08800065
J	JOHNSON, E; HENZEL, W; DEISSEROTH, A				JOHNSON, E; HENZEL, W; DEISSEROTH, A			AN ISOFORM OF PROTEIN DISULFIDE ISOMERASE ISOLATED FROM CHRONIC MYELOGENOUS LEUKEMIA-CELLS ALTERS COMPLEX-FORMATION BETWEEN NUCLEAR PROTEINS AND REGULATORY REGIONS OF INTERFERON-INDUCIBLE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATL-DERIVED FACTOR; PHOSPHOLIPASE-C; TRANSCRIPTIONAL REGULATOR; SYNTHETASE GENE; THIOREDOXIN; PROMOTER; PURIFICATION; ACTIVATION; SEQUENCE; BINDING	We have previously shown that the electrophoretic mobility of complexes formed in vitro between nuclear proteins and the regulatory domains of interferon-inducible genes is altered by an extranuclear protein present in elevated levels in the myeloid cells of chronic myelogenous leukemia patients. Interferon-alpha reduces the level of this activity only in the cells of patients who are clinically sensitive to the antiproliferative effects of interferon-alpha. We have purified this protein to homogeneity and found it to be a 57-kDa protein which corresponds to an isoform of protein disulfide isomerase. Protein disulfide isomerase is an oxidoreductase which catalyzes the interconversion between the reduced and oxidized states of proteins which contain multiple sulfhydryl groups and disulfide bonds. These studies suggest that this protein may play an important role in the transcriptional activation of interferon-inducible genes, perhaps through redox mechanisms.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA	University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797	NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA49639-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ERICKSON RR, 1987, J PHARMACOL EXP THER, V242, P472; FLEGEL L, 1990, J BIOL CHEM, V265, P15496; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HEMPEL WM, 1991, J IMMUNOL, V146, P3713; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOWARD OMZ, 1990, BLOOD, V76, P1117; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARTIN JL, 1991, BIOCHEM BIOPH RES CO, V178, P679, DOI 10.1016/0006-291X(91)90161-Y; MCCONKEY DJ, 1986, LIFE SCI, V38, P2139, DOI 10.1016/0024-3205(86)90213-4; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SEONG DC, 1990, J CLIN INVEST, V86, P1664, DOI 10.1172/JCI114889; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHRINER CL, 1984, J BIOL CHEM, V259, P1383; SIPES NJ, 1990, CELL GROWTH DIFFER, V1, P241; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRIFE A, 1990, CHRONIC MYELOGENOUS, P1; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; TAGAYA Y, 1988, J IMMUNOL, V140, P2614; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; YAMAMOTO S, 1986, BLOOD, V67, P1714; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	43	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14412	14417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629227				2022-12-27	WOS:A1992JD32500094
J	PAYNE, DW; PACKMAN, JN; ADASHI, EY				PAYNE, DW; PACKMAN, JN; ADASHI, EY			FOLLICLE-STIMULATING-HORMONE INHIBITS GRANULOSA-CELL 5-ALPHA-REDUCTASE ACTIVITY - POSSIBLE ROLE OF 5-ALPHA-REDUCTASE AS A STEROIDOGENIC PUBERTAL SWITCH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; 1ST OVULATION; IMMATURE RAT; PROLACTIN; DIFFERENTIATION; EXPRESSION; OVARIES; GROWTH	In order to elucidate the role of 5-alpha-reductase in the ovarian pubertal transition from 5-alpha-reduced to non-5-alpha-reduced steroids, we examined the characteristics and regulation of granulosa cell (GC) 5-alpha-reductase activity. Maximum activity was observed at 37-degrees-C and at a pH of 6.5-8.0. Synthetic 4-aza-3-oxosteroids proved to be potent inhibitors (76% inhibition at 0.1-mu-M) of ovarian 5-alpha-reductase activity, and 20-alpha-DHP was a better substrate than either progesterone or testosterone (4- or 7-fold higher affinity constants, respectively). The K(m) (20-alpha-DHP) of the enzyme was 0.50 +/- 0.03-mu-M and 0.75 +/- 0.20-mu-M in homogenates of whole ovaries and GC, respectively. 17-beta-Estradiol was a non-competitive inhibitor (K(I) = 6.97-mu-M). 5-alpha-Reductase activity was 22-fold (immature) to 68-fold (mature) higher in liver than ovary and 4-fold higher in thecainterstitial shells than in isolated GC. Ovarian 5-alpha-reductase activity decreased markedly with age (>60% inhibition in mature, randomly cycling rats as compared to immature rats). In vivo administration of follicle-stimulating hormone (FSH) to immature rats produced a dose-dependent decrease in GC 5-alpha-reductase activity (36 +/- 1.1% and 46 +/- 5.9% inhibition following 12-mu-g and 24-mu-g FSH, respectively). Similarly, the in vitro provision of FSH (100 ng/ml) to cultured GC from immature rats resulted in (36-59%) inhibition in 5-alpha-reduced steroids. Inasmuch as FSH promotes GC development and the advancement of puberty, its ability to "switch-off" ovarian 5-alpha-reductase activity may enhance the formation of biologically potent (i.e. non-5-alpha-reduced) progestins as well as the availability of aromatizable androgens, in the best interests of pubertal steroidogenesis.			PAYNE, DW (corresponding author), UNIV MARYLAND,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL,BRESSLER RES BLDG 11-011,BALTIMORE,MD 21201, USA.				NICHD NIH HHS [HD-00697, HD-19998] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019998] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE DJ, 1985, BIOL REPROD, V33, P637, DOI 10.1095/biolreprod33.3.637; ECKSTEIN B, 1977, BIOCHIM BIOPHYS ACTA, V499, P1, DOI 10.1016/0304-4165(77)90222-7; ECKSTEIN B, 1977, BIOCHIM BIOPHYS ACTA, V489, P143, DOI 10.1016/0005-2760(77)90240-5; FARKASH Y, 1988, P NATL ACAD SCI USA, V85, P5824, DOI 10.1073/pnas.85.16.5824; FREDERIKSEN DW, 1971, J BIOL CHEM, V246, P2584; FUKUDA S, 1979, J STEROID BIOCHEM, V11, P1421, DOI 10.1016/0022-4731(79)90116-X; GOLDRING NB, 1985, J BIOL CHEM, V260, P913; HERNANDEZ ER, 1988, ENDOCRINOLOGY, V122, P1603, DOI 10.1210/endo-122-4-1603; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; KARAKAWA T, 1976, ENDOCRINOLOGY, V98, P571, DOI 10.1210/endo-98-3-571; LERNER N, 1976, ENDOCRINOLOGY, V98, P179, DOI 10.1210/endo-98-1-179; LERNER N, 1978, ENDOCRINOLOGY, V103, P1039, DOI 10.1210/endo-103-4-1039; LIANG T, 1983, J STEROID BIOCHEM, V19, P385, DOI 10.1016/S0022-4731(83)80051-X; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MARTEL C, 1990, ENDOCRINOLOGY, V127, P2726, DOI 10.1210/endo-127-6-2726; MEIJSROELOFS HMA, 1975, J ENDOCRINOL, V67, P275, DOI 10.1677/joe.0.0670275; OJEDA SR, 1972, ENDOCRINOLOGY, V90, P466, DOI 10.1210/endo-90-2-466; OJEDA SR, 1976, ENDOCRINOLOGY, V98, P630, DOI 10.1210/endo-98-3-630; ORLY J, 1979, CELL, V17, P295, DOI 10.1016/0092-8674(79)90155-7; PAYNE DW, 1985, J BIOL CHEM, V260, P3648; PAYNE DW, 1988, BIOL REPROD, V39, P581, DOI 10.1095/biolreprod39.3.581; SUZUKI K, 1978, ENDOCRINOLOGY, V102, P1595, DOI 10.1210/endo-102-5-1595; TAKEYAMA M, 1986, ENDOCRINOLOGY, V118, P2268, DOI 10.1210/endo-118-6-2268; TOOROP AI, 1984, J ENDOCRINOL, V100, P281, DOI 10.1677/joe.0.1000281; UILENBROEK JTJ, 1985, J ENDOCRINOL, V107, P113, DOI 10.1677/joe.0.1070113	31	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13348	13355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618837				2022-12-27	WOS:A1992JB74600042
J	BYRNE, BJ; KACZOROWSKI, YJ; COUTU, MD; CRAIG, SW				BYRNE, BJ; KACZOROWSKI, YJ; COUTU, MD; CRAIG, SW			CHICKEN VINCULIN AND META-VINCULIN ARE DERIVED FROM A SINGLE GENE BY ALTERNATIVE SPLICING OF A 207-BASE PAIR EXON UNIQUE TO META-VINCULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC VARIANTS; SMOOTH-MUSCLE; MICROFILAMENT BUNDLES; OVERLAY TECHNIQUE; MOLECULAR-WEIGHT; BINDING-PROTEINS; METAVINCULIN; ATTACHMENT; SARCOLEMMA; EXPRESSION	meta-Vinculin and vinculin are closely related proteins that are cytoplasmic components of microfilament-associated cell junctions. This report describes the structural relationship between these two proteins and the genetic basis for tissue-specific expression of meta-vinculin. Analysis of genomic DNA coding for amino acids 676-1066 of vinculin revealed 9 exons spanning an 11.7-kilobase pair region of the genome. In the 4 kilobase pairs of intervening sequence that separates vinculin exons E896-E915 and E916-E984, there is an open reading frame that predicts a sequence homologous to the 68-amino acid peptide specific to porcine meta-vinculin (Gimona, M., Small, J. V., Moeremans, M., Van Damme, J., Puype, M., and Vandekerckhove, J. (1988) EMBO J. 7, 2329-2334). Analysis of the corresponding cDNA established that chicken meta-vinculin contains a 69-amino acid insertion between residues 915 and 916 of vinculin and that there are no other amino acid sequence differences between chicken vinculin and meta-vinculin. Muscle-specific expression of meta-vinculin occurs by alternative splicing of a transcript produced from a single gene because: all 20 genomic isolates that contain the 3' vinculin exons, also contain the meta-vinculin-specific exon; Southern blots performed at high stringency with exon-specific probes indicate the presence of a single gene; and the 3'-untranslated sequences of vinculin and meta-vinculin cDNAs are identical.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM041605, R01GM041605] Funding Source: NIH RePORTER; NICHD NIH HHS [5 P30-HD27799-02] Funding Source: Medline; NIGMS NIH HHS [GM 41605] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; BELKIN AM, 1988, J CELL BIOL, V107, P545, DOI 10.1083/jcb.107.2.545; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BYRNE BJ, 1991, J CELL BIOL, V111, pA38; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COUTU MD, 1987, BIOCHEM BIOPH RES CO, V147, P637, DOI 10.1016/0006-291X(87)90978-8; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DANOWSKI B A, 1991, Journal of Cell Biology, V115, p368A; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEIGER B, 1982, J MOL BIOL, V159, P685, DOI 10.1016/0022-2836(82)90108-5; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; ITO S, 1983, J BIOL CHEM, V258, P4626; JONES P, 1989, J CELL BIOL, V109, P2917, DOI 10.1083/jcb.109.6.2917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLONY L, 1985, J CELL BIOCHEM, V29, P3136; NIGGLI V, 1986, J BIOL CHEM, V261, P6912; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PARDO JV, 1983, J CELL BIOL, V97, P1081, DOI 10.1083/jcb.97.4.1081; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; SAGA S, 1985, EXP CELL RES, V156, P45, DOI 10.1016/0014-4827(85)90260-5; Sambrook J, 1989, MOL CLONING LABORATO; SILICIANO JD, 1987, J CELL BIOL, V104, P473, DOI 10.1083/jcb.104.3.473; SILICIANO JD, 1982, NATURE, V300, P533, DOI 10.1038/300533a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1983, BIOCHEM BIOPH RES CO, V116, P1026, DOI 10.1016/S0006-291X(83)80245-9	41	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12845	12850						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618784				2022-12-27	WOS:A1992HZ48300070
J	CHOY, LN; ROSEN, BS; SPIEGELMAN, BM				CHOY, LN; ROSEN, BS; SPIEGELMAN, BM			ADIPSIN AND AN ENDOGENOUS PATHWAY OF COMPLEMENT FROM ADIPOSE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SERINE PROTEASE HOMOLOG; FACTOR-B; ALTERNATIVE PATHWAY; GENE-EXPRESSION; HORMONAL-REGULATION; HUMAN-FIBROBLASTS; HUMAN-MONOCYTES; MESSENGER-RNA; FACTOR-ALPHA	The alternative complement pathway is best known for its role in humoral suppression of infectious agents. We have previously shown that adipose cells synthesize adipsin, the mouse homolog of human complement factor D, and that the synthesis of this protein is reduced in several rodent models of obesity. We show here that adipose cells and adipose tissue also synthesize two other essential components of the alternative pathway of complement, factors C3 and B, and activate the proximal portion of this pathway. This activation occurs in the absence of infectious agents and without triggering the terminal, lytic part of this pathway. We demonstrate the production in vitro of several polypeptides characteristic of complement activation that are known to have potent biological activities, including the anaphylatoxin C3a. Cultured adipocytes require stimulation with cytokines to activate complement, while explanted adipose tissue has no such requirement. The adipose tissue from obese mice is deficient in this localized activation of the alternative pathway. These results indicate that complement activation occurs in a localized site, adipose tissue, in normal mice and is impaired in a state of metabolic dysfunction. This suggests a novel function for the proximal portion of this complement pathway related to adipose cell biology or energy balance.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	CHOY, LN (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							AMBRUS JL, 1990, J IMMUNOL, V144, P1549; AREND WP, 1989, J IMMUNOL, V142, P173; Ausubel FM, 1988, MOL REPROD DEV; BIANCO C, 1979, P NATL ACAD SCI USA, V76, P888, DOI 10.1073/pnas.76.2.888; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DANI C, 1989, MOL CELL ENDOCRINOL, V63, P199, DOI 10.1016/0303-7207(89)90096-8; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FAUST IM, 1979, P SOC EXP BIOL MED, V161, P111, DOI 10.3181/00379727-161-40501; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHELSON Z, 1984, J IMMUNOL, V132, P1425; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FLIER JS, 1989, RECENT PROG HORM RES, V45, P567; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOSTER DW, 1987, HARRISONS PRINCIPLES, P1677; HAEFFNERCAVAILLON N, 1987, J IMMUNOL, V139, P794; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Jarett L, 1974, Methods Enzymol, V31, P60; KAM CM, 1987, J BIOL CHEM, V262, P3444; KATZ Y, 1989, J IMMUNOL, V142, P3862; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPIN DF, 1990, BIOCHEM J, V268, P387, DOI 10.1042/bj2680387; LAW SKA, 1988, COMPLEMENT; LESAVRE P, 1982, EUR J IMMUNOL, V12, P252, DOI 10.1002/eji.1830120317; LESAVRE PH, 1979, J IMMUNOL, V123, P529; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; LOWELL BB, 1990, ENDOCRINOLOGY, V126, P1514, DOI 10.1210/endo-126-3-1514; MAY LT, 1988, J BIOL CHEM, V263, P7760; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PEKALA P, 1990, J BIOL CHEM, V265, P18051; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; PRAZ F, 1986, J EXP MED, V163, P1349, DOI 10.1084/jem.163.5.1349; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SPIEGELMAN BM, 1989, J BIOL CHEM, V264, P1811; SUNDSMO JS, 1981, J EXP MED, V154, P763, DOI 10.1084/jem.154.3.763; WHITE RT, 1991, IN PRESS MOL CELL BI; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	46	260	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12736	12741						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618777				2022-12-27	WOS:A1992HZ48300055
J	NAIR, S; DEY, R; SANFORD, JP; DOYLE, D				NAIR, S; DEY, R; SANFORD, JP; DOYLE, D			MOLECULAR-CLONING AND ANALYSIS OF AN EIF-4A-RELATED RAT-LIVER NUCLEAR-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4A; HEPATOCYTE BILE CANALICULUS; ATP-BINDING SITE; PLASMA-MEMBRANE; FACTOR EIF-4A; RNA HELICASE; ANTIGEN; EXPRESSION; GENES; LIBRARIES	In this paper, we report the cloning and analysis of a cDNA encoding a protein of M(r) congruent-to 47,000 (p47), which is localized to the nucleus of rat hepatocytes. The cDNA showed 37% overall sequence identity with a mouse translation initiation factor, eIF-4A, which belongs to a family of putative ATP-dependent RNA helicases. We raised polyclonal antibodies against the fusion protein and by indirect immunofluorescence on primary cultures of hepatocytes have demonstrated that p47 is located in the nucleus. Although only approximately 27% of hepatocytes showed this nuclear staining, most of the nuclei in proliferating transformed cell lines such as 3T3, PtK-1, and Hela were fluorescently labeled. Studies on serum-starved cells in culture indicated that p47 was expressed in a cell cycle-dependent manner. Northern analyses demonstrated that the levels of p47 mRNA were high in fetal liver and dropped significantly after birth to low levels in adult liver. Our data suggest that p47 is developmentally regulated in rat liver at the mRNA level.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL CANCER INSTITUTE [R01CA038773] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BENEDETTI AD, 1990, P NATL ACAD SCI USA, V87, P8212; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CHING G, 1990, J CELL BIOL, V110, P255, DOI 10.1083/jcb.110.2.255; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; CROY RG, 1983, P NATL ACAD SCI-BIOL, V80, P4699, DOI 10.1073/pnas.80.15.4699; DIAMOND M, 1987, J BIOL CHEM, V262, P14760; DOBBERSTEIN B, 1979, CELL, V17, P759, DOI 10.1016/0092-8674(79)90316-7; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LIN SH, 1989, J BIOL CHEM, V264, P14408; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANIATIS T, 1982, MOL CLONING, V1; NAIR S, 1991, THESIS STATE U NEW Y; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NIELSEN PJ, 1985, NUCLEIC ACIDS RES, V13, P6867, DOI 10.1093/nar/13.19.6867; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; PETELL JK, 1987, J BIOL CHEM, V262, P14753; ROBINSON PA, 1988, J IMMUNOL METHODS, V108, P115, DOI 10.1016/0022-1759(88)90409-7; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5453; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SMITH HC, 1982, BIOCHEMISTRY-US, V21, P6751, DOI 10.1021/bi00269a021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVALI S, 1990, FASEB J, V4, P3209, DOI 10.1096/fasebj.4.14.2227212; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	47	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12928	12935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618789				2022-12-27	WOS:A1992HZ48300080
J	BAXTER, A; FITZGERALD, BJ; HUTSON, JL; MCCARTHY, AD; MOTTERAM, JM; ROSS, BC; SAPRA, M; SNOWDEN, MA; WATSON, NS; WILLIAMS, RJ; WRIGHT, C				BAXTER, A; FITZGERALD, BJ; HUTSON, JL; MCCARTHY, AD; MOTTERAM, JM; ROSS, BC; SAPRA, M; SNOWDEN, MA; WATSON, NS; WILLIAMS, RJ; WRIGHT, C			SQUALESTATIN-1, A POTENT INHIBITOR OF SQUALENE SYNTHASE, WHICH LOWERS SERUM-CHOLESTEROL INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HMG COA REDUCTASE; ISOPRENOID SYNTHESIS; LIVER-MITOCHONDRIA; TISSUE; RAT; LOVASTATIN; CELLS	Squalestatin 1 is a member of a novel family of fermentation products isolated from a previously unknown Phoma species (Coelomycetes). Squalestatin 1 is a potent, selective inhibitor of squalene synthase, a key enzyme in cholesterol biosynthesis; in vitro, 50% inhibition of enzyme activity is observed at a concentration of 12 +/- 5 nM (range of 4-22 nM). Squalestatin 1 inhibits cholesterol biosynthesis from [C-14]acetate by isolated rat hepatocytes (50% inhibition at 39 nM) and by rat liver in vivo. In marmosets, a species with a lipoprotein profile similar to that of man, squalestatin 1 lowers serum cholesterol by up to 75%. This compound will allow further investigation of the control of the sterol biosynthesis pathway and could also lead to the development of new therapies for elevated serum cholesterol.	GLAXO GRP RES LTD,GREENFORD RD,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO GRP RES LTD,WARE SG12 OD5,HERTS,ENGLAND	GlaxoSmithKline; GlaxoSmithKline								BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BROWN MS, 1980, J LIPID RES, V21, P505; BRUENGER E, 1986, BIOCHIM BIOPHYS ACTA, V876, P500, DOI 10.1016/0005-2760(86)90037-8; CLAEYS D, 1989, J BIOL CHEM, V264, P14627; CROOK D, 1990, ARTERIOSCLEROSIS, V10, P625, DOI 10.1161/01.ATV.10.4.625; DAWSON MJ, 1992, J ANTIBIOT, V45, P614; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; HARPER RD, 1975, BIOCHEM J, V152, P485, DOI 10.1042/bj1520485; MAHER VMG, 1990, Q J MED, V74, P165; ROBINSON BH, 1970, EUR J BIOCHEM, V15, P263, DOI 10.1111/j.1432-1033.1970.tb01003.x; SEGLEN PO, 1973, EXP CELL RES, V76, P25, DOI 10.1016/0014-4827(73)90414-X; SIDEBOTTOM PJ, 1992, J ANTIBIOT, V45, P623; TAIT RM, 1992, IN PRESS ANAL BIOCH; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3; WATSON JA, 1985, J BIOL CHEM, V260, P4083; 1984, JAMA-J AM MED ASSOC, V251, P365; 1984, JAMA-J AM MED ASSOC, V251, P351	19	213	228	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11705	11708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601846				2022-12-27	WOS:A1992HY94700012
J	JOHNSON, MR; BRUZDZINSKI, CJ; WINOGRAD, SS; GELEHRTER, TD				JOHNSON, MR; BRUZDZINSKI, CJ; WINOGRAD, SS; GELEHRTER, TD			REGULATORY SEQUENCES AND PROTEIN-BINDING SITES INVOLVED IN THE EXPRESSION OF THE RAT PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; CYCLIC-NUCLEOTIDE REGULATION; RNA POLYMERASE-II; NUCLEAR FACTOR-I; HANDED Z-DNA; HEPATOMA-CELLS; TRANSCRIPTIONAL ACTIVATION; DEXAMETHASONE INHIBITION; EUKARYOTIC TRANSCRIPTION; ENZYMATIC AMPLIFICATION	Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that inhibits both tissue-type and urokinase-type plasminogen activators. Expression of PAI-1 is regulated-by growth factors, cytokines, and hormones. To determine the molecular mechanisms involved in the basal expression of the rat PAI-1 gene, we have analyzed the cis-acting sequences and the trans-acting factors involved in the transcription of this gene in the HTC rat hepatoma cell line. DNase I protection analyses revealed eight regions within the first 764 base pairs of 5'-flanking sequence that interact specifically with HTC cell nuclear proteins. The proteins that bind to five of the eight footprinted sites were identified as PEA3-, Sp1-, and CTF/NF-1-like proteins using competition electrophoretic mobility shift assays. The expression of fusion genes containing progressive 5' deletions of the rat PAI-1 promoter linked to the chloramphenicol acetyltransferase reporter gene were analyzed in transient transfection experiments in HTC cells. These studies demonstrated the Sp1 and CTF/NF-1 sites to be important for transcriptional activation. Two of the footprinted sites contain the sequence 5'-TTTGn(n)TCAAT-3' and were shown in competition electrophoretic mobility shift assays to bind the same or related protein(s). Sequences containing these sites, from -764 to -628 base pairs, and from -266 to -188 base pairs, were identified in functional studies as repressor elements of transcription.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA022729, R37CA022729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NCI NIH HHS [CA22729] Funding Source: Medline; NIGMS NIH HHS [T32GM07544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAROUSKIMILLER PA, 1982, P NATL ACAD SCI-BIOL, V79, P2319, DOI 10.1073/pnas.79.7.2319; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; BRUZDZINSKI CJ, 1989, DNA CELL BIOL, V9, P691; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; COLEMAN PL, 1986, J BIOL CHEM, V261, P4352; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GELEHRTER TD, 1987, MOL ENDOCRINOL, V1, P97, DOI 10.1210/mend-1-1-97; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P150; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY T A, 1990, Technique (Philadelphia), V2, P147; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HEATON JH, 1990, MOL ENDOCRINOL, V4, P171, DOI 10.1210/mend-4-1-171; HEATON JH, 1989, MOL ENDOCRINOL, V3, P349, DOI 10.1210/mend-3-2-349; HEATON JH, 1992, MOL ENDOCRINOL, V6, P53, DOI 10.1210/me.6.1.53; HEATON JH, 1989, MOL ENDOCRINOL, V3, P185, DOI 10.1210/mend-3-1-185; HUBER P, 1987, NUCLEIC ACIDS RES, V15, P1615, DOI 10.1093/nar/15.4.1615; HUDSPETH MES, 1982, CELL, V30, P617, DOI 10.1016/0092-8674(82)90258-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANSON L, 1989, J MOL BIOL, V205, P387, DOI 10.1016/0022-2836(89)90349-5; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LEITH IR, 1988, NUCLEIC ACIDS RES, V16, P8277, DOI 10.1093/nar/16.17.8277; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NORDHEIM A, 1982, P NATL ACAD SCI-BIOL, V79, P7729, DOI 10.1073/pnas.79.24.7729; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SEIFERT SC, 1978, P NATL ACAD SCI USA, V75, P6130, DOI 10.1073/pnas.75.12.6130; SERVENIUS B, 1987, J BIOL CHEM, V262, P8759; SPRENGERS ED, 1987, BLOOD, V69, P381; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	72	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12202	12210						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601887				2022-12-27	WOS:A1992HY94700083
J	NEGRI, A; CECILIANI, F; TEDESCHI, G; SIMONIC, T; RONCHI, S				NEGRI, A; CECILIANI, F; TEDESCHI, G; SIMONIC, T; RONCHI, S			THE PRIMARY STRUCTURE OF THE FLAVOPROTEIN D-ASPARTATE OXIDASE FROM BEEF KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; MOLECULAR-CLONING; PIG-KIDNEY; SEQUENCE; PROTEINS; PEPTIDES; CDNA	The complete primary structure of the peroxisomal flavoenzyme D-aspartate oxidase from beef kidney has been determined by analyses of the peptides obtained through fragmentation of the carboxymethylated protein with trypsin, CNBr, heptafluorobutyric acid/CNBr and Staphylococcus aureus V8 protease. The protein consists of a single polypeptide of 338 residues, accounting for a M(r) of 37,305 for the apoprotein. A form of the enzyme lacking Lys-338 and therefore ending with Pro-337 has been detected. The N-terminal residue is blocked. Seven cysteines and no disulfide bridges are present. Residue 228 can be either Ile or Val. ThuS, D-aspartate oxidase presents two types of heterogeneity in the polypeptide chain in addition to the one already described concerning the possible content of FAD or 6-hydroxyflavin adenine dinucleotide. Comparison of the primary structure Of D-aspartate oxidase with other known sequences reveals that D-aspartate oxidase is homologous with D-amino acid oxidase (another flavo-oxidase) and does not present significant sequence similarities with any other protein, including flavoenzymes.	UNIV MILANO,IST FISIOL VET & BIOCHIM,VIA CELORIA 10,I-20133 MILAN,ITALY; CTR INTERUNIV MACROMOLEC INFORMAZ,I-20100 MILAN,ITALY	University of Milan			Negri, Armando/H-7914-2017; Tedeschi, Gabriella/I-6247-2017; Ceciliani, Fabrizio/Q-6551-2017	Negri, Armando/0000-0002-8401-7437; Tedeschi, Gabriella/0000-0003-2082-6443; Ceciliani, Fabrizio/0000-0002-9199-5757				CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CURTI B, 1991, CHEM BIOCH FLAVOENZY, V3, P69; DANIELLO A, 1972, COMP BIOCHEM PHYSIOL, V41, P625, DOI 10.1016/0305-0491(72)90124-1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLACHMANN R, 1988, EUR J BIOCHEM, V175, P221, DOI 10.1111/j.1432-1033.1988.tb14187.x; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; FUJIWARA M, 1987, ANAL BIOCHEM, V166, P72, DOI 10.1016/0003-2697(87)90547-1; GEIGEL D, 1990, J BIOL CHEM, V265, P6626; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; ISOGAI T, 1990, J BIOCHEM-TOKYO, V108, P1063, DOI 10.1093/oxfordjournals.jbchem.a123306; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KOMATSU K, 1988, CHEM ABSTR 49619S, V108; LEDERER F, 1985, EUR J BIOCHEM, V139, P59; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAKE Y, 1991, FLAVINS AND FLAVOPROTEINS 1990, P135; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; NEGRI A, 1988, J BIOL CHEM, V263, P13557; NIEDERMANN DM, 1990, J BIOL CHEM, V265, P17246; RONCHI S, 1982, J BIOL CHEM, V257, P8824; STILL JL, 1949, J BIOL CHEM, V179, P831; SWENSON RP, 1982, J BIOL CHEM, V257, P8817; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	23	53	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11865	11871						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601857				2022-12-27	WOS:A1992HY94700036
J	MURGIA, M; PIZZO, P; SANDONA, D; ZANOVELLO, P; RIZZUTO, R; DIVIRGILIO, F				MURGIA, M; PIZZO, P; SANDONA, D; ZANOVELLO, P; RIZZUTO, R; DIVIRGILIO, F			MITOCHONDRIAL-DNA IS NOT FRAGMENTED DURING APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL; DEATH; LYMPHOCYTES; LYSIS	We have exposed mouse thymocytes and P-815 mastocytoma cells to four different conditions reported to cause apoptosis: 1) incubation in the absence of mitogenic factors; 2) incubation in the presence of dexamethasone; 3) stimulation with external ATP; 4) treatment with high concentrations of the K+ ionophore valinomycin. These treatments caused DNA fragmentation to a varying extent in the two cell types. High stringency hybridization with a cDNA probe specific to a mitochondrial DNA sequence revealed that during apoptosis induced by lack of mitogenic factors, dexamethasone, or extracellular ATP, mitochondrial DNA was not fragmented. On the contrary, valinomycin caused extensive degradation of mitochondrial DNA. These results support the notion that DNA fragmentation during apoptosis is a specific nuclear event and suggest that other agents, such as valinomycin, may act less selectively.	UNIV PADUA,CHAIR IMMUNOL,I-35100 PADUA,ITALY; UNIV PADUA,NATL RES COUNCIL STUDY PHYSIOL MITOCHONDRIA,I-35100 PADUA,ITALY; UNIV FERRARA,INST GEN PATHOL,I-44100 FERRARA,ITALY	University of Padua; University of Padua; University of Ferrara	MURGIA, M (corresponding author), UNIV PADUA,INST GEN PATHOL,VIA TRIESTE 75,I-35121 PADUA,ITALY.		Di Virgilio, Francesco/J-3754-2018; sandona, dorianna/AAB-9480-2020; DI VIRGILIO, Francesco/O-4634-2019; Pizzo, Paola/T-4874-2018; Rizzuto, Rosario/B-6312-2008	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Pizzo, Paola/0000-0001-6077-3265; Zanovello, Paola/0000-0002-9996-2669; Rizzuto, Rosario/0000-0001-7044-5097				ALBRITTON NL, 1988, J EXP MED, V167, P514; BUSCH H, 1967, METHODS ENZYMOLOGY A, V12, P421; BUSCH W, 1990, BIOCH CELL BIOL, V68, P1071; COLLINS RJ, 1989, BRIT J HAEMATOL, V71, P343; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; HALWELL B, 1991, FEBS LETT, V281, P9; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LASTER SM, 1988, J IMMUNOL, V141, P2629; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; PALVA TK, 1985, FEBS LETT, V192, P267, DOI 10.1016/0014-5793(85)80122-8; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1987, NATURE, V327, P62, DOI 10.1038/327062a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIE AH, 1980, INT REV CYTOL, V68, P251; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	18	65	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10939	10941						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597435				2022-12-27	WOS:A1992HX16900003
J	PAUL, HS; ADIBI, SA				PAUL, HS; ADIBI, SA			MECHANISM OF INCREASED CONVERSION OF BRANCHED-CHAIN KETO ACID DEHYDROGENASE FROM INACTIVE TO ACTIVE FORM BY A MEDIUM CHAIN FATTY-ACID (OCTANOATE) IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-HEART; AMINO-ACIDS; METABOLISM; LEUCINE; OXIDATION; ACTIVATION; INVIVO; HINDQUARTER; PHOSPHATASE; INHIBITION	We and others have previously shown that octanoate increases the oxidation of branched chain amino acids (BCAA) in skeletal muscle. The present study was designed to investigate the mechanism of this increased oxidation. Studies were performed with rat hind limbs perfused with 0.50 mM L-[1-C-14]leucine with or without octanoate. The flux through branched chain keto acid (BCKA) dehydrogenase was measured, and the basal and total activity of BCKA dehydrogenase in skeletal muscle was determined. The rate of flux through BCKA dehydrogenase increased by 37, 119, and 297% with 0.5, 1.0, and 2.0 mM octanoate, respectively. This increase in flux was not due to a change in BCAA aminotransferase activity but was due to an increase in the basal activity of BCKA dehydrogenase. There was a strong correlation (r = 0.96) between increases in flux through BCKA dehydrogenase and increases in the basal activities of BCKA dehydrogenase. Preincubation of BCKA dehydrogenase with Mg2+ caused full activation of this enzyme, but preincubation with octanoate did not activate this enzyme. On the other hand, octanoate completely prevented the ATP-dependent inactivation of fully activated BCKA dehydrogenase. We conclude that octanoate increases the oxidation of leucine in skeletal muscle by increasing the activation of BCKA dehydrogenase. The mechanism of this activation is the inhibition of BCKA dehydrogenase kinase rather than the stimulation of a specific or nonspecific protein phosphatase.	UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM015855] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-15855] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADIBI SA, 1971, AM J PHYSIOL, V221, P829; AFTRING RP, 1986, AM J PHYSIOL, V250, pE599, DOI 10.1152/ajpendo.1986.250.5.E599; BLOCK KP, 1987, AM J PHYSIOL, V252, pE396, DOI 10.1152/ajpendo.1987.252.3.E396; BUFFINGTON CK, 1979, J BIOL CHEM, V254, P453; BUSE MG, 1972, J BIOL CHEM, V247, P8085; BUXTON DB, 1984, BIOCHEM J, V221, P593, DOI 10.1042/bj2210593; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DAVIS EJ, 1988, METHOD ENZYMOL, V166, P476; GORSKI J, 1986, AM J PHYSIOL, V250, pE441, DOI 10.1152/ajpendo.1986.250.4.E441; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARRIS RA, 1982, BIOCHEM BIOPH RES CO, V107, P1497, DOI 10.1016/S0006-291X(82)80168-X; HARRIS RA, 1982, J BIOL CHEM, V257, P3915; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HOOD DA, 1987, AM J PHYSIOL, V253, pE636, DOI 10.1152/ajpendo.1987.253.6.E636; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; Lamprecht W., 1974, METHOD ENZYMAT AN, V7, P1777; Lamprecht W, 1974, METHOD ENZYMAT AN, P2101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAWABI MD, 1990, J CLIN INVEST, V85, P256, DOI 10.1172/JCI114421; NORDENSTROM J, 1991, EUR J CLIN INVEST, V21, P580, DOI 10.1111/j.1365-2362.1991.tb01412.x; ODESSEY R, 1972, AM J PHYSIOL, V223, P1376, DOI 10.1152/ajplegacy.1972.223.6.1376; ODLE J, 1991, J NUTR, V121, P605, DOI 10.1093/jn/121.5.605; PAUL HS, 1980, J CLIN INVEST, V65, P1285, DOI 10.1172/JCI109791; PAUL HS, 1982, J BIOL CHEM, V257, P2581; PAUL HS, 1976, J NUTR, V106, P1079, DOI 10.1093/jn/106.8.1079; PAUL HS, 1984, BRANCHED CHAIN AMINO, P182; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; PAXTON R, 1982, J BIOL CHEM, V257, P4433; RODRIGUEZ N, 1986, AM J PHYSIOL, V251, pE343, DOI 10.1152/ajpendo.1986.251.3.E343; RUDERMAN NB, 1980, BIOCHEM J, V190, P57, DOI 10.1042/bj1900057; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SHINNICK FL, 1976, BIOCHIM BIOPHYS ACTA, V437, P477, DOI 10.1016/0304-4165(76)90016-7; SHIOTA M, 1986, AM J PHYSIOL, V251, pC78, DOI 10.1152/ajpcell.1986.251.1.C78; SNEDECOR GW, 1955, STATISTICAL METHODS, P54; SPYDEVOLD O, 1981, BIOCHIM BIOPHYS ACTA, V676, P279, DOI 10.1016/0304-4165(81)90161-6; SPYDEVOLD O, 1979, EUR J BIOCHEM, V97, P389, DOI 10.1111/j.1432-1033.1979.tb13125.x; TREEM WR, 1989, J INHERIT METAB DIS, V12, P112, DOI 10.1007/BF01800712; VANTOL A, 1975, MOL CELL BIOCHEM, V7, P19, DOI 10.1007/BF01732160; VAZQUEZ JA, 1988, J CLIN INVEST, V82, P1606, DOI 10.1172/JCI113772; WAYMACK PP, 1980, J BIOL CHEM, V255, P9773	41	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11208	11214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597456				2022-12-27	WOS:A1992HX16900045
J	CHILDS, RA; WRIGHT, JR; ROSS, GF; YUEN, CT; LAWSON, AM; CHAI, WG; DRICKAMER, K; FEIZI, T				CHILDS, RA; WRIGHT, JR; ROSS, GF; YUEN, CT; LAWSON, AM; CHAI, WG; DRICKAMER, K; FEIZI, T			SPECIFICITY OF LUNG SURFACTANT PROTEIN SP-A FOR BOTH THE CARBOHYDRATE AND THE LIPID MOIETIES OF CERTAIN NEUTRAL GLYCOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE PROBES NEOGLYCOLIPIDS; MANNOSE-BINDING PROTEINS; PULMONARY SURFACTANT; II CELLS; RECOGNITION DOMAINS; APOPROTEIN; RECOMBINANT; CDNA	Binding specificity of the major surfactant protein SP-A from human and dog lung has been investigated. Radiobinding experiments have shown that both proteins bind in a Ca2+-dependent manner to galactose, mannose, fucose, and glucose linked to bovine serum albumin. These results are in accord with a previous study in which monosaccharides were linked to agarose (Haagsman, H. P., Hawgood, S., Sargeant, T., Buckley, D., White, R. T., Drickamer, K., and Benson, B. J. (1987) J. Biol. Chem. 262, 13877-13880). Chromatogram overlays in conjunction with in situ liquid secondary ion mass spectrometry (TLC-LSIMS) of several purified glycosphingolipids and neoglycolipids as well as binding assays with glycolipids immobilized on plastic wells, demonstrate recognition of galactose (human and dog SP-A), glucose, and lactose (human SP-A) in association with specific lipids. In addition, the occurrence of several neutral and acidic glycosphingolipids in human and rat extracellular surfactants and rat alveolar type II cells is described. Selected components among the neutral glycolipids are bound by radiolabeled human SP-A; these are identified by TLC-LSIMS as predominantly ceramide mono- and disaccharides (human surfactant) and ceramide tri- and tetrasaccharides (rat surfactant and type II cells). A recombinant carbohydrate recognition domain (CRD) of human SP-A inhibits the binding of human SP-A to galactosyl ceramide and to galactose- and mannose- bovine serum albumin, indicating that the CRD is directly involved in the binding of SP-A to these ligands. These results provide evidence for a novel type of binding specificity for proteins that have Ca2+-dependent CRDs and raise the possibility that glycosphingolipids are endogenous ligands for SP-A.	MRC,CLIN RES CTR,GYCOCONJUGATES SECT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,CLIN MASS SPECTROMETRY SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; UNIV CALIF SAN FRANCISCO,SCH MED,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CINCINNATI,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45267; COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati; Columbia University				Chai, Wengang/0000-0003-2977-5347; Feizi, Ten/0000-0001-6495-0329	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030923, R01HL030923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30923] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; CHILDS RA, 1983, BIOCHEM J, V215, P491, DOI 10.1042/bj2150491; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1987, KIDNEY INT       S23, V32, P67; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FLOROS J, 1986, J BIOL CHEM, V261, P9029; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; LAWSON AM, 1990, CARBOHYD RES, V200, P47, DOI 10.1016/0008-6215(90)84181-S; Maniatis T., 1982, MOL CLONING; MANZKEINKE H, 1991, EXP CELL RES, V192, P597, DOI 10.1016/0014-4827(91)90081-5; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; PERSSON A, 1990, J BIOL CHEM, V265, P5755; POSSMAYER F, 1988, AM REV RESPIR DIS, V138, P990, DOI 10.1164/ajrccm/138.4.990; PRAKASH UBS, 1987, MAYO CLIN PROC, V62, P499, DOI 10.1016/S0025-6196(12)65477-9; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; ROSENSTEIN IJ, 1988, LANCET, V2, P1327; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SLOMIANY A, 1979, EUR J BIOCHEM, V98, P47, DOI 10.1111/j.1432-1033.1979.tb13158.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOORHOUT WF, 1991, J HISTOCHEM CYTOCHEM, V39, P1331, DOI 10.1177/39.10.1940306; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT J R, 1990, American Review of Respiratory Disease, V141, pA694; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426	34	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9972	9979						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577827				2022-12-27	WOS:A1992HT96500080
J	KAUPPINEN, RA; NISSINEN, T; KARKKAINEN, AM; PIRTTILA, TRM; PALVIMO, J; KOKKO, H; WILLIAMS, SR				KAUPPINEN, RA; NISSINEN, T; KARKKAINEN, AM; PIRTTILA, TRM; PALVIMO, J; KOKKO, H; WILLIAMS, SR			DETECTION OF THYMOSIN BETA-4 INSITU IN A GUINEA-PIG CEREBRAL-CORTEX PREPARATION USING H-1-NMR SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; H-1-NMR SPECTROSCOPY; RAT-BRAIN; INVIVO; PEPTIDES; PROTEINS; HYPOXIA; BINDING; SPECTRA; HMG-14	In the present work we have investigated the macromolecules that contribute to the brain H-1 NMR spectrum. The cerebral cortex showed distinct resonances at the uncrowded methyl- and methylene chemical shift scale of the spin-echo H-1 NMR spectrum. The peaks at 1.22 and 1.40 ppm (relative to the methyl protons of N-acetyl aspartate at 2.02 ppm) arise from cerebral macromolecules without evidence for co-resonances from low molecular weight metabolites as shown by the spin-spin relaxation decays of these resonances. In addition to these NMR signals, peaks at 0.9 and 1.7 ppm from macromolecules were detected. These resonances are from proteins, and we have identified the polypeptides that contributed to the H-1 NMR peaks. Two proteins that were present at concentrations of 250 and 350-mu-g/g of dryed tissue showed H-1 NMR spectra that resembled the macromolecular pattern in the cerebral H-1 NMR spectrum. They were identified as thymosin beta-4 and histone H1, respectively. Thymosin beta-4 was present in soluble high speed cytoplasmic fraction and in P2 pellet, whereas histone H1 was detected in nuclear enriched fraction. A chemical shift-correlated two-dimensional H-1 NMR spectrum of thymosin beta-4 in vitro revealed a coupling pattern that matched the macromolecule in the cerebral cortex which we have previously noted (Kauppinen R. A., Kokko, H., and Williams, S. R. (1992) J. Neurochem. 58, 967-974). On the basis of both one- and two-dimensional NMR evidence, subcellular distribution and high concentration, we assign the H-1 NMR signals at 0.9, 1.22, 1.40, and 1.7 ppm in the cerebral cortex to thymosin beta-4.	UNIV KUOPIO,NMR,RES GRP,SF-70211 KUOPIO,FINLAND; ROYAL COLL SURG ENGLAND,DIV BIOPHYS,LONDON WC2A 3PN,ENGLAND	University of Eastern Finland; Royal College of Surgeons of England	KAUPPINEN, RA (corresponding author), UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,POB 1627,SF-70211 KUOPIO,FINLAND.		Kauppinen, Risto A/F-3274-2011; Williams, Steve C/D-6979-2011; kokko, Harri/C-4289-2011; Williams, Steve R/C-8945-2011	Williams, Steve C/0000-0003-4299-1941; Williams, Steve R/0000-0001-5940-1675; Palvimo, Jorma/0000-0003-2373-0578				ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; ARUS C, 1985, PHYSIOL CHEM PHYS, V17, P23; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BATES TE, 1989, J NEUROCHEM, V53, P102, DOI 10.1111/j.1471-4159.1989.tb07300.x; BEHAR KL, 1983, P NATL ACAD SCI-BIOL, V80, P4945, DOI 10.1073/pnas.80.16.4945; BEHAR KL, 1991, MAGNET RESON MED, V17, P285, DOI 10.1002/mrm.1910170202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell I D, 1979, Methods Biochem Anal, V25, P1, DOI 10.1002/9780470110454.ch1; CARY PD, 1980, EUR J BIOCHEM, V112, P577; COOK GR, 1989, J BIOL CHEM, V264, P1799; DALAKAS MC, 1986, ANN NEUROL, V19, P349, DOI 10.1002/ana.410190407; DEGRAAF AA, 1990, MAGNET RESON MED, V15, P305, DOI 10.1002/mrm.1910150212; GOODWIN GH, 1977, FEBS LETT, V80, P413, DOI 10.1016/0014-5793(77)80488-2; HALL AK, 1991, MOL CELL ENDOCRINOL, V79, P37, DOI 10.1016/0303-7207(91)90093-8; HANNAPPEL E, 1986, ANAL BIOCHEM, V156, P390, DOI 10.1016/0003-2697(86)90270-8; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; JOHNS EW, 1976, SUBNUCLEAR COMPONENT, P187; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P967, DOI 10.1111/j.1471-4159.1992.tb09350.x; KAUPPINEN RA, 1991, J NEUROCHEM, V57, P1136, DOI 10.1111/j.1471-4159.1991.tb08271.x; KAUPPINEN RA, 1990, J NEUROSCI RES, V26, P356, DOI 10.1002/jnr.490260313; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P831, DOI 10.1111/j.1471-4159.1992.tb09332.x; LUGO DI, 1991, J NEUROCHEM, V56, P457, DOI 10.1111/j.1471-4159.1991.tb08172.x; MCEWEN BS, 1970, BRAIN RES, V17, P471, DOI 10.1016/0006-8993(70)90254-4; NAGAYAYAMA K, 1985, EUR J BIOCHEM, V114, P365; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; PALVIMO J, 1990, FEBS LETT, V277, P257, DOI 10.1016/0014-5793(90)80860-L; PARK IR, 1987, J NEUROCHEM, V49, P781; PETROFF OAC, 1988, COMP BIOCHEM PHYS B, V90, P249, DOI 10.1016/0305-0491(88)90069-7; REBAR RW, 1981, SCIENCE, V214, P669, DOI 10.1126/science.7027442; SAFER D, 1991, J BIOL CHEM, V266, P4029; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x; WEISBROD S, 1982, NATURE, V297, P289, DOI 10.1038/297289a0; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WILLIAMS SR, 1986, J MAGN RESON, V66, P562, DOI 10.1016/0022-2364(86)90203-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	35	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9905	9910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577821				2022-12-27	WOS:A1992HT96500071
J	WETTERAUER, B; JACQUOT, JP; VERON, M				WETTERAUER, B; JACQUOT, JP; VERON, M			THIOREDOXINS FROM DICTYOSTELIUM-DISCOIDEUM ARE A DEVELOPMENTALLY REGULATED MULTIGENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP-MALATE DEHYDROGENASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; DIFFERENTIAL EXPRESSION; SULFATE REDUCTION; GENES; PURIFICATION; GLUTAREDOXIN; PROTEINS; SUBUNIT	Thioredoxins are low molecular weight proteins which serve as hydrogen donors in a wide variety of redox reactions via reversible formation of a disulfide bridge between two neighboring cysteins. We present data demonstrating that in Dictyostelium discoideum thioredoxins constitute a highly conserved multigene family. We have isolated cDNA clones coding for three different Dictyostelium thioredoxins which show 80% mutual identity. Analysis of genomic Southern blots suggests the presence of additional genes. Except for the active site (Trp-Cys-Gly-Pro-Cys), there are only a few amino acid identities with thioredoxins from other organisms. Identity scores do not exceed 43%, the value found with the human lymphocyte protein. DdTRX1 was expressed in Escherichia coli, purified, and shown to have thioredoxin activity, as judged by its capacity to activate the NADP-malate dehydrogenase. Due to its life cycle, during which individual amoebae form a multicellular fruiting body, Dictyostelium is used to study developmental processes such as cell-type differentiation and regulation of gene expression. Transcript levels of Dictyostelium thioredoxins were regulated during the developmental cycle. Low levels of mRNAs could be detected during growth. After the onset of development, where essentially no cell divisions take place, message levels increased with maximal expression during aggregation. In later multicellular stages, RNA levels declined again. The same expression pattern could be seen for all cloned thioredoxins. Protein levels paralleled this time course with a delay of several hours as judged by Western blot and activity measurements.	INST PASTEUR, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE; UNIV PARIS 11, PHYSIOL VEGETALE MOLEC LAB, F-91405 ORSAY, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Saclay			Jacquot, Jean-Pierre/A-1571-2012	Jacquot, Jean-Pierre/0000-0003-4975-8587				ALEXANDER S, 1991, MOL CELL BIOL, V11, P3171, DOI 10.1128/MCB.11.6.3171; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BODENSTEINLANG J, 1989, FEBS LETT, V258, P22, DOI 10.1016/0014-5793(89)81606-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN BB, 1986, THIOREDOXIN GLUTARED, P233; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DECOTTIGNIES P, 1991, EUR J BIOCHEM, V198, P505, DOI 10.1111/j.1432-1033.1991.tb16043.x; DECOTTIGNIES P, 1990, ARCH BIOCHEM BIOPHYS, V280, P112, DOI 10.1016/0003-9861(90)90525-4; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DEVINE JM, 1982, CELL, V28, P793, DOI 10.1016/0092-8674(82)90058-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS J, 1983, THIOREDOXIN STRUCTUR, P111; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hansson H.A., 1986, THIOREDOXIN GLUTARED, P177; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JACQUOT JP, 1983, BIOCHIM BIOPHYS ACTA, V745, P97, DOI 10.1016/0167-4838(83)90174-7; JACQUOT JP, 1990, BIOCHEM BIOPH RES CO, V173, P1375, DOI 10.1016/S0006-291X(05)80940-4; JACQUOT JPP, 1981, PLANT PHYSIOL, V68, P300, DOI 10.1104/pp.68.2.300; KAMO M, 1989, EUR J BIOCHEM, V182, P315, DOI 10.1111/j.1432-1033.1989.tb14832.x; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLOTZ P, 1986, Z NATURFORSCH C, V41, P275; Loomis W., 2012, DEV DICTYOSTELIUM DI; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; LOOMIS WF, 1969, J BACTERIOL, V100, P417, DOI 10.1128/JB.100.1.417-422.1969; LUNN CA, 1986, THIOREDOXIN GLUTARED, P165; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MAEDA K, 1986, EUR J BIOCHEM, V154, P197, DOI 10.1111/j.1432-1033.1986.tb09379.x; MCFARLAN SC, 1989, EUR J BIOCHEM, V179, P389, DOI 10.1111/j.1432-1033.1989.tb14565.x; MCKEOWN M, 1981, CELL, V24, P799, DOI 10.1016/0092-8674(81)90105-7; MENG M, 1981, J BIOL CHEM, V256, P9174; MULLER EGD, 1989, J BIOL CHEM, V264, P4008; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROBBINS SM, 1990, NUCLEIC ACIDS RES, V18, P5265, DOI 10.1093/nar/18.17.5265; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; STEEL LF, 1987, NUCLEIC ACIDS RES, V15, P10285, DOI 10.1093/nar/15.24.10285; TONISSEN KF, 1989, NUCLEIC ACIDS RES, V17, P3973, DOI 10.1093/nar/17.10.3973; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEIJER CJ, 1984, J CELL SCI, V70, P111; WESTPHAL M, 1986, FEBS LETT, V209, P92, DOI 10.1016/0014-5793(86)81090-0; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	61	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9895	9904						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577820				2022-12-27	WOS:A1992HT96500070
J	WANG, SY				WANG, SY			STRUCTURE OF THE GENE AND ITS RETINOIC ACID-REGULATORY REGION FOR MURINE-J6 SERPIN - AN F9 TERATOCARCINOMA CELL RETINOIC ACID-INDUCIBLE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-BINDING PROTEIN; HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; ALPHA-1-ANTITRYPSIN GENES; EMBRYO FIBROBLASTS; INHIBITOR HOMOLOG; MAMMALIAN-CELLS; MESSENGER-RNA; DIFFERENTIATION; EXPRESSION	We have recently reported a protein sequence deduced from the retinoic acid (RA)-inducible mRNA J6 as a novel serine protease inhibitor (serpin). In this study we have reported that the J6 serpin gene is 7.7 kilobases in length and consists of five exons with an additional option. Comparison of the organization of the J6 gene and other serpin genes reveals that the structure of the J6 gene is different from the reported four serpin gene groups. Nonetheless, intron B of the J6 gene and members of the alpha-antitrypsin gene group are at the equivalent positions, suggesting that the J6 gene is more closely related to the members of alpha-antitrypsin gene group than other serpins. To identify the RA response region, we have further examined the nucleotide sequence of the 1-kilobase 5'-flanking region of the J6 gene. The DNA sequence from position -1050 to -738 is essential for the gene activation by RA as revealed by the stable transfection experiments. Within this region, present are four GA-GATAG motifs which are the known binding sites for GATA transcription factor family. Interestingly, there is a potential heat shock element with alternate arrays of blocks XGAAX and XTTCX spanning from -88 to -59, indicating that the J6 gene perhaps is heat-inducible.			WANG, SY (corresponding author), SUNY COLL BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14222, USA.				NCI NIH HHS [R29 CA44955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BOCK SC, 1988, BIOCHEMISTRY-US, V27, P6171, DOI 10.1021/bi00416a052; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING LABORATO, P76; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; NANDAN D, 1990, J CELL BIOL, V110, P1673, DOI 10.1083/jcb.110.5.1673; NANDAN D, 1988, EXP CELL RES, V179, P289, DOI 10.1016/0014-4827(88)90368-0; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TANAKA T, 1984, J BIOL CHEM, V259, P8063; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WANG SY, 1991, J BIOL CHEM, V266, P14135; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495	41	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15362	15366						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639782				2022-12-27	WOS:A1992JG11300019
J	MURTHY, KGK; MANLEY, JL				MURTHY, KGK; MANLEY, JL			CHARACTERIZATION OF THE MULTISUBUNIT CLEAVAGE-POLYADENYLATION SPECIFICITY FACTOR FROM CALF THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SEQUENCES DOWNSTREAM; AAUAAA SEQUENCE; INVITRO; PRECURSORS; RECOGNITION; PURIFICATION; ACCURATE; PROTEINS	Cleavage-polyadenylation specificity factor (CPSF) is one of five separable factors known to be required for 3' cleavage and polyadenylation of mRNA precursors in vitro. Previous studies have shown that the cleavage and poly(A) addition reactions can be uncoupled in vitro and have suggested that CPSF may be the only factor essential for both of these subreactions. Here we report the purification of CPSF to near homogeneity from calf thymus and show that the purified factor contains three polypeptides of 165, 105, and 70 kDa. These polypeptides cosediment precisely with CPSF activity, which has a sedimentation coefficient of 11.5 S. Consistent with previous reports from our laboratory, purified CPSF does not contain a detectable RNA component, indicating that it is a multisubunit protein and not a small nuclear ribonucleoprotein. Extensively purified bovine CPSF can function with human poly(A) polymerase to bring about AAUAAA-dependent poly(A) addition or with human cleavage factors to catalyze accurate 3' cleavage of a pre-mRNA substrate. UV cross-linking and gel retention analyses demonstrate that highly purified CPSF interacts with one of these cleavage factors, the multisubunit cleavage-stimulation factor, to facilitate stable binding of both to an AAUAAA-containing pre-mRNA. Likewise, evidence is presented indicating that poly(A) polymerase and CPSF can interact directly.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Manley, James/0000-0002-8341-1459				BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; EDMONDS M, 1960, J BIOL CHEM, V235, P1142; EDMONDS M, 1982, ENZYMES, V15, P217; England T E, 1980, Methods Enzymol, V65, P65; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JACOB ST, 1983, ENZYMES NUCLEIC ACID, V2, P135; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; MANLEY JL, 1983, CELL, V33, P595, DOI 10.1016/0092-8674(83)90440-3; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MANLEY JL, 1985, MOL CELL BIOL, V5, P373, DOI 10.1128/MCB.5.2.373; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; QIAN ZW, 1991, MOL CELL BIOL, V11, P5312, DOI 10.1128/MCB.11.10.5312; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TERNS MP, 1989, MOL CELL BIOL, V9, P1435, DOI 10.1128/MCB.9.4.1435; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; VALSAMAKIS A, 1991, P NATL ACAD SCI USA, V88, P2108, DOI 10.1073/pnas.88.6.2108; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1992, IN PRESS ANN REV BIO, V61; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317	38	148	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14804	14811						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634525				2022-12-27	WOS:A1992JF08800047
J	MARCOTTE, PA; KOZAN, IM; DORWIN, SA; RYAN, JM				MARCOTTE, PA; KOZAN, IM; DORWIN, SA; RYAN, JM			THE MATRIX METALLOPROTEINASE PUMP-1 CATALYZES FORMATION OF LOW-MOLECULAR-WEIGHT (PRO)UROKINASE IN CULTURES OF NORMAL HUMAN KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; PURIFICATION; UROKINASE; RECEPTOR; SEQUENCE; INVASION; BINDING	The enzyme responsible for the metalloproteinase activity which cleaves the Glu143-Leu144 bond of (pro)urokinase has been isolated from the conditioned medium of cultured normal human kidney cells. Using S-Sepharose and Cibacron Blue-agarose chromatography, then C-4 reversed phase high pressure liquid chromatography, a protein of about 20,000 Da was isolated. Through an identical amino-terminal sequence, the protein was shown to be the matrix metalloproteinase previously referred to in the literature as " pump-1" (putative metalloproteinase). When aprotinin was added during the course of the purification, the major species isolated was the zymogen form (28,000 Da) of pump-1. Pump-1 has been shown to efficiently cleave the susceptible bond of both pro-urokinase (single-chain) and active (two-chain) urokinase and thereby produce the corresponding low molecular weight forms. The amino-terminal sequences of the A and B chains of low molecular weight urokinase prepared by action of pump-1 on recombinant high molecular weight urokinase are identical to those of the low molecular weight urokinase isolated from human kidney cell culture. Since the reaction of urokinase with this metalloproteinase results in separation of its serine proteinase region from the domain which mediates binding to the urokinase receptor, it may be of importance in the regulation of the functional activity of the plasminogen activator in cellular processes.	ABBOTT LABS, DEPT BIOL DEV, DIV CHEM & AGR PROD, N CHICAGO, IL 60064 USA	Abbott Laboratories	MARCOTTE, PA (corresponding author), ABBOTT LABS, CORP MOLEC BIOL, DIV PHARMACEUT PROD, THROMBOLYT VENTURE, DEPT 48R, N CHICAGO, IL 60064 USA.							APPELLA E, 1987, J BIOL CHEM, V262, P4437; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Blasi F, 1990, Semin Cancer Biol, V1, P117; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMONARD H, 1990, CELL MOL BIOL, V36, P131; HOMANDBERG GA, 1990, BIOCHIM BIOPHYS ACTA, V1038, P209, DOI 10.1016/0167-4838(90)90207-V; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P57, DOI 10.1016/0268-9499(92)90095-Y; MARCOTTE PA, 1992, FIBRINOLYSIS, V6, P69, DOI 10.1016/0268-9499(92)90063-N; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1991, AM J MED SCI, V302, P157, DOI 10.1097/00000441-199109000-00008; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; POLLANEN J, 1991, ADV CANCER RES, V57, P273; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RABBANI SA, 1990, BIOCHEM BIOPH RES CO, V173, P1058, DOI 10.1016/S0006-291X(05)80893-9; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUMP DC, 1986, J BIOL CHEM, V261, P7120; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; 1992, ENZYME NOMENCLATURE, P412	30	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13803	13806						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629180				2022-12-27	WOS:A1992JD32500004
J	LEW, J; BEAUDETTE, K; LITWIN, CME; WANG, JH				LEW, J; BEAUDETTE, K; LITWIN, CME; WANG, JH			PURIFICATION AND CHARACTERIZATION OF A NOVEL PROLINE-DIRECTED PROTEIN-KINASE FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; HUMAN CDC2 PROTEIN; FISSION YEAST; POLYACRYLAMIDE GELS; M-PHASE; TYROSINE PHOSPHORYLATION; P34CDC2 KINASE; NUCLEAR LAMINA; MITOSIS; ACTIVATION	A novel protein kinase which phosphorylates a synthetic peptide substrate (RRPDAHRTPNRAF) has been purified approximately 200,000-fold from bovine brain. This peptide contains the consensus sequence for phosphorylation by the p34cdc2 kinase. The purification procedure took advantage of the phenomenon that this novel brain kinase, in partially purified extracts, chromatographed on a gel filtration column as a high molecular weight complex which dissociated in buffer containing 1 M NaCl. The purified native enzyme was estimated to be approximately 63,000, and displayed two bands of M(r) = 33,000 and 25,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. On Western immunoblot, the M(r) = 33,000 peptide reacted strongly with antibodies specific for a conserved amino-terminal sequence, weakly with antibodies to the conserved PSTAIRE sequence, and not at all with antibodies to the carboxyl terminus, of HeLa cell p34cdc2. The brain kinase and p34cdc2 were similar in displaying good activity toward the parent peptide substrate, but no activity toward peptide analogues in which the -T-P- motif was substituted with either -T-G- or -T-A-. Both kinases showed marked preference in phosphorylating a peptide derived from H1 histone (KTPKKAKKPKTPKKAKKL), and both kinases could be phosphorylated by the src-family tyrosine kinase, p56lyn, purified from bovine spleen. However, the brain kinase did not co-purify with a subunit having a molecular weight corresponding to known cyclins, nor did it undergo specific interaction with p13suc1 beads, suggesting that this enzyme is distinct from p34cdc2.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,ALBERTA,CANADA	University of Calgary								BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN RK, 1991, ARCH BIOCHEM BIOPHYS, V28, P187; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAK AS, 1991, J BIOL CHEM, V266, P6678; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; TOH A, 1988, MOL GEN GENET, V214, P162; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	65	219	226	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13383	13390						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618840				2022-12-27	WOS:A1992JB74600047
J	SWEENY, DJ; NELLANS, HN				SWEENY, DJ; NELLANS, HN			ENANTIOMERIC ACTIVATION OF GLUCURONIDATION IN DOG HEPATIC MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSELECTIVITY; SUBSTRATE; PROPRANOLOL	Isomer-specific mechanisms of conjugation were investigated by evaluating the hepatic glucuronidation of the enantiomers of the 5-lipoxygenase inhibitor zileuton. The glucuronidation of the individual isomers was stereoselective, as dog hepatic microsomes glucuronidated the S-isomer but failed to generate a glucuronide conjugate of the R-isomer. In combination, the nonglucuronidated R-isomer caused a concentration-dependent increase in the rate of glucuronidation of its enantiomorph. Kinetic analysis of this interaction indicated that the R-isomer affected rates of glucuronidation by decreasing the K(m) of the S-isomer for this process. This effect appeared enantioselective as the achiral analogue A-65838 had no effect on the V(max) and K(m) of S-isomer glucuronidation. The data were modeled using Michaelis-Menten kinetics in which the K(m) of S-isomer glucuronidation was reduced in a saturable manner by the concentration of the R-isomer. These data indicate that the nonconjugated R-isomer competitively activates the glucuronidation of its enantiomorph. To our knowledge, these data represent the first demonstration of enantiomeric activation of an enzyme involved in hepatic drug metabolism.			SWEENY, DJ (corresponding author), ABBOTT LABS,DEPT GEN PHARMACOL,N CHICAGO,IL 60064, USA.							AMES MM, 1982, BIOCHEM PHARMACOL, V31, P5, DOI 10.1016/0006-2952(82)90228-3; BOCK KW, 1983, BIOCHEM PHARMACOL, V32, P953, DOI 10.1016/0006-2952(83)90610-X; BRAECKMAN RA, 1989, J CLIN PHARMACOL, V29, P22; CARTER GW, 1991, J PHARMACOL EXP THER, V256, P929; CUNDY KC, 1985, BIOCHEM BIOPH RES CO, V128, P312, DOI 10.1016/0006-291X(85)91680-8; OKAZAKI O, 1991, DRUG METAB DISPOS, V19, P376; SISENWINE SF, 1982, DRUG METAB DISPOS, V10, P605; STEVENSON T, 1968, BIOCHEM BIOPH RES CO, V32, P866; SWEENY DJ, 1992, DRUG METAB DISPOS, V20, P328; TESTA B, 1988, BIOCHEM PHARMACOL, V37, P85, DOI 10.1016/0006-2952(88)90757-5; THOMPSON JA, 1981, DRUG METAB DISPOS, V9, P466; VESSEY DA, 1971, J BIOL CHEM, V246, P4649; WILSON BK, 1984, DRUG METAB DISPOS, V12, P161; WINSNES A, 1969, BIOCHIM BIOPHYS ACTA, V191, P279, DOI 10.1016/0005-2744(69)90247-2; ZAKIM D, 1973, BIOCHEMISTRY-US, V12, P4068, DOI 10.1021/bi00745a007	15	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13171	13174						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618819				2022-12-27	WOS:A1992JB74600014
J	CASTLE, AM; STAHL, LE; CASTLE, JD				CASTLE, AM; STAHL, LE; CASTLE, JD			A 13-AMINO ACID N-TERMINAL DOMAIN OF A BASIC PROLINE-RICH PROTEIN IS NECESSARY FOR STORAGE IN SECRETORY GRANULES AND FACILITATES EXIT FROM THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PITUITARY CELL-LINE; PAROTID-GLANDS; ANTERIOR-PITUITARY; MULTIGENE FAMILIES; GROWTH-HORMONE; MESSENGER-RNAS; PATHWAYS; CDNA; GENE	We have investigated the role of different domains of a salivary basic proline-rich protein in intracellular transport and sorting of proline-rich proteins to the secretory granules. We have cloned a full-length cDNA of a basic proline-rich protein from the rat parotid and expressed it in AtT-20 cells. It was correctly sorted into secretory granules as shown by EM immunolocalization and by its presence in 8-bromocyclic AMP-stimulated secretion. Deletion of the N-terminal thirteen amino acid domain upstream from the proline-rich domain eliminated storage whereas deletion of the C-terminal 20-amino acid domain downstream from the proline-rich domain had no effect. Intracellular transport of full-length and mutant proline-rich proteins was unusually slow due to slow exit from the endoplasmic reticulum. However, the rate of transport increased with increasing level of expression for the full-length protein and the C-terminal deletion mutant. In contrast, the rate of transport of the N-terminal deletion mutant was independent of the level of expression. These results imply that the N-terminal domain is necessary for both storage and efficient intracellular transport. Moreover, interactions (self-aggregation?) that mediate sorting may begin as early as the endoplasmic reticulum.	UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, BOX 439, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005529, R01DE008941] Funding Source: NIH RePORTER; NIDCR NIH HHS [F32 DE05529, DE08941] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1985, J BIOL CHEM, V260, P5863; ARVAN P, 1986, J CELL BIOL, V103, P1257, DOI 10.1083/jcb.103.4.1257; BERRYMAN MA, 1990, J HISTOCHEM CYTOCHEM, V38, P159, DOI 10.1177/38.2.1688894; BLAIR EA, 1991, AM J PHYSIOL, V261, pC897, DOI 10.1152/ajpcell.1991.261.5.C897; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FUMAGALLI G, 1985, J CELL BIOL, V100, P2019, DOI 10.1083/jcb.100.6.2019; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GUMBINER B, 1981, P NATL ACAD SCI-BIOL, V78, P318, DOI 10.1073/pnas.78.1.318; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIRSHMEIER PI, 1988, DNA CELL BIOL, V1, P219; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH Y P, 1990, Journal of Cell Biology, V111, p319A; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAINS RE, 1983, ENDOCRINOLOGY, V112, P1986, DOI 10.1210/endo-112-6-1986; MAINS RE, 1981, J CELL BIOL, V89, P21, DOI 10.1083/jcb.89.1.21; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MUENZER J, 1979, J BIOL CHEM, V254, P5629; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER M K, 1990, Journal of Cell Biology, V111, p313A; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TOOZE J, 1987, J CELL BIOL, V105, P1215, DOI 10.1083/jcb.105.3.1215; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WALTER P, 1983, METHOD ENZYMOL, V96, P84; ZIEMER MA, 1982, J BIOL CHEM, V257, P1176	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13093	13100						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618808				2022-12-27	WOS:A1992HZ48300102
J	LARSEN, IK; CORNETT, C; KARLSSON, M; SAHLIN, M; SJOBERG, BM				LARSEN, IK; CORNETT, C; KARLSSON, M; SAHLIN, M; SJOBERG, BM			CARACEMIDE, A SITE-SPECIFIC IRREVERSIBLE INHIBITOR OF PROTEIN-R1 OF ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR AGENT CARACEMIDE; CHOLINE-ACETYLTRANSFERASE; ACTIVE-SITE; TRIPHOSPHATE REDUCTASE; DIPHOSPHATE REDUCTASE; PHASE-I; INACTIVATION; MECHANISM; HYDROXYUREA; CISPLATIN	The anticancer drug caracemide, N-acetyl-N,O-di(methylcarbamoyl)hydroxylamine, and one of its degradation products, N-acetyl-O-methylcarbamoyl-hydroxylamine, were found to inhibit the enzyme ribonucleotide reductase of Escherichia coli by specific interaction with its larger component protein R1. No effect on the smaller protein R2 was observed. The effect of the degradation product was about 30 times lower than that of caracemide itself. The caracemide inactivation of R1 is irreversible, with an apparent second-order rate constant of 150 M-1 s-1. The R1R2 holoenzyme was approximately 30 times more sensitive to caracemide inactivation than the isolated R1 protein. The ribonucleotide reductase substrates were potent competitors of the caracemide inhibition, with a K(diss) for GDP binding to R1 of 80-mu-M. The reducing agent dithiothreitol was also found to be a potent competitor of caracemide inactivation. These results indicate that caracemide inactivates R1 by covalent modification at the substrate-binding site. By analogy with the known interaction between caracemide and acetylcholinesterase or choline acetyltransferase, we propose that the modification of R1 occurs at an activated cysteine or serine residue in the active site of the enzyme.	ROYAL DANISH SCH PHARM, DEPT ORGAN CHEM, DK-2100 COPENHAGEN, DENMARK; UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Royal Danish School of Pharmacy; Stockholm University			Cornett, Claus/B-8893-2009	Cornett, Claus/0000-0001-6991-5362; Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ATOR MA, 1985, BIOCHEMISTRY-US, V24, P7214, DOI 10.1021/bi00346a029; BUCCAFUSCO JJ, 1990, RES COMMUN CHEM PATH, V67, P219; CANTWELL BMJ, 1989, CANCER CHEMOTH PHARM, V23, P252, DOI 10.1007/BF00451651; CARBINI L, 1990, BRAIN RES BULL, V24, P119, DOI 10.1016/0361-9230(90)90295-B; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DIXON M, 1979, ENZYMES, P369; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; HERSH LB, 1979, J BIOL CHEM, V254, P1988; HO BT, 1988, J NEUROSCI RES, V19, P119, DOI 10.1002/jnr.490190116; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; LAM KY, 1990, J CHEM SOC CHEM COMM, P658, DOI 10.1039/c39900000658; LAMMERS M, 1983, STRUCT BOND, V54, P27; LARSEN IK, 1990, ACTA CRYSTALLOGR C, V46, P600, DOI 10.1107/S010827018900836X; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LARSEN IK, 1990, ALFRED BENZON SYMP S, V28, P47; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEE MS, 1986, MUTAT RES, V172, P199, DOI 10.1016/0165-1218(86)90057-1; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MCKINNEY M, 1986, BIOCHEM PHARMACOL, V35, P2615, DOI 10.1016/0006-2952(86)90061-4; MILDVAN AS, 1964, BIOCHIM BIOPHYS ACTA, V89, P393, DOI 10.1016/0926-6569(64)90065-3; MOORE EC, 1984, CANCER TREAT REP, V68, P1293; NEWMAN RA, 1986, BIOCHEM PHARMACOL, V35, P2781, DOI 10.1016/0006-2952(86)90190-5; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PAZDUR R, 1987, INVEST NEW DRUG, V5, P365; RABER MN, 1987, CANCER TREAT REP, V71, P349; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SMITH SL, 1989, BIOCHEM BIOPH RES CO, V162, P715, DOI 10.1016/0006-291X(89)92369-3; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12627	12631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618768				2022-12-27	WOS:A1992HZ48300040
J	LIGHT, DR; DENNIS, MS; FORSYTHE, IJ; LIU, CC; GREEN, DW; KRATZER, DA; PLAPP, BV				LIGHT, DR; DENNIS, MS; FORSYTHE, IJ; LIU, CC; GREEN, DW; KRATZER, DA; PLAPP, BV			ALPHA-ISOENZYME OF ALCOHOL-DEHYDROGENASE FROM MONKEY LIVER - CLONING, EXPRESSION, MECHANISM, COENZYME, AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; KINETIC CHARACTERIZATION; TERNARY COMPLEX; HORSE; YEAST; BINDING; ISOZYMES; ETHANOL; DNA; METABOLISM	The cDNA for the alpha-isoenzyme from rhesus monkey (Macaca mulatta) liver was cloned and expressed in yeast. The alpha-isoenzymes of human and monkey liver alcohol dehydrogenase differ from the other human and horse liver enzymes in having Met57, Ala93, and Val116 instead of Leu57, Phe93, and Leu116 in the substrate binding pocket and Gly47 instead of Arg47 near the pyrophosphate moiety of the coenzyme. The effects of these differences on the kinetic mechanism, substrate specificity, and coenzyme binding were studied with the purified, recombinant monkey alpha-isoenzyme (MmADH-alpha) and mutated enzymes with Gly47 substituted with His or Arg. The mechanism appears to be random for the binding of NAD+ and ethanol and ordered for NADH and acetaldehyde, with formation of a dead-end enzyme-NADH-ethanol complex. MmADH-alpha reacts 130-fold slower (V/K) with ethanol and 3-25-fold slower with 2-methyl alcohols but 20-fold faster with cyclohexanol, as compared with horse (Equus caballus) liver EE isoenzyme (EqADH). MmADH-alpha is stereoselective for the R isomer of 2-butanol, whereas EqADH favors the S isomer. Both enzymes have comparable reactivity with larger primary alcohols. MmADH-alpha is more reactive with secondary alcohols and has highest activity with cyclohexanol. However, it does not react with steroids such as 5-beta-androstane-17-beta-ol-3-one. Molecular modeling suggests that the differences between MmADH-alpha and EqADH are a result of the substitution of Ala for Phe93 and Thr for Ser48. MmADH-alpha binds NAD+ most rapidly when a group with a pK of 7.4 is unprotonated, implicating His51 in this reaction. The G47R substitution decreased the dissociation constants for NAD+ and NADH and turnover numbers only about 2-fold, whereas the G47H substitution increased dissociation constants 7-14-fold and turnover numbers 4-fold. A basic residue at position 47 is not crucial for activity, as multiple interactions determine coenzyme affinity.	UNIV IOWA,DEPT BIOCHEM,4-370 BOWEN SCI BLDG,IOWA CITY,IA 52242; GENENTECH INC,S SAN FRANCISCO,CA 94080	University of Iowa; Roche Holding; Genentech			Plapp, Bryce V/F-6353-2010		NIAAA NIH HHS [AA00279, AA06223] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006223] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AINSLIE GR, 1972, J BIOL CHEM, V247, P946; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEMISTRY-US, V22, P1852, DOI 10.1021/bi00277a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CHADHA VK, 1985, J MED CHEM, V28, P36, DOI 10.1021/jm00379a009; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; Cleland W W, 1979, Methods Enzymol, V63, P103; CORNELL NW, 1983, PHARMACOL BIOCHEM BE, V18, P215, DOI 10.1016/0091-3057(83)90174-0; CRONHOLM T, 1975, ACTA CHEM SCAND B, V29, P571, DOI 10.3891/acta.chem.scand.29b-0571; DAFELDECKER WP, 1981, BIOCHEMISTRY-US, V20, P6729, DOI 10.1021/bi00526a031; DAFELDECKER WP, 1981, BIOCHEMISTRY-US, V20, P856, DOI 10.1021/bi00507a031; DAFELDECKER WP, 1985, BIOCHEMISTRY-US, V24, P6474, DOI 10.1021/bi00344a025; DALZIEL K, 1966, BIOCHEM J, V100, P34, DOI 10.1042/bj1000034; DALZIEL K, 1966, BIOCHEM J, V100, P491, DOI 10.1042/bj1000491; DALZIEL K, 1963, J BIOL CHEM, V238, P2850; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; DICKENSON CJ, 1978, BIOCHEM J, V171, P613, DOI 10.1042/bj1710613; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P111, DOI 10.1021/bi00620a018; EKLUND H, 1987, EUR J BIOCHEM, V167, P185, DOI 10.1111/j.1432-1033.1987.tb13322.x; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; GANZHORN AJ, 1987, J BIOL CHEM, V262, P3754; GANZHORN AJ, 1988, J BIOL CHEM, V263, P5446; GOULD RM, 1990, BIOCHEMISTRY-US, V29, P5463, DOI 10.1021/bi00475a009; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MCEVILY AJ, 1988, BIOCHEMISTRY-US, V27, P4284, DOI 10.1021/bi00412a013; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSER K, 1968, ENZYMOL BIOL CLIN, V9, P447, DOI 10.1159/000458284; PAPENBER.J, 1965, BIOCHEM Z, V342, P95; PARK DH, 1992, J BIOL CHEM, V267, P5527; PARK DH, 1991, J BIOL CHEM, V266, P13296; PETTERSSON G, 1987, CRIT REV BIOCHEM MOL, V21, P349, DOI 10.3109/10409238609113616; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; RAO GSJ, 1987, J BIOL CHEM, V262, P14074; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; STONE CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, IN PRESS J MOL EVOL, V34; TOPHAM CM, 1986, EUR J BIOCHEM, V156, P555, DOI 10.1111/j.1432-1033.1986.tb09615.x; WILLS C, 1976, NATURE, V261, P26, DOI 10.1038/261026a0; WRATTEN CC, 1963, BIOCHEMISTRY-US, V2, P935, DOI 10.1021/bi00905a007; YIN SJ, 1984, BIOCHEMISTRY-US, V23, P5847, DOI 10.1021/bi00319a026; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	52	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12592	12599						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618764				2022-12-27	WOS:A1992HZ48300035
J	PANINI, SR; DELATE, TA; SINENSKY, M				PANINI, SR; DELATE, TA; SINENSKY, M			POSTTRANSCRIPTIONAL REGULATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE BY 24(S),25-OXIDOLANOSTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HAMSTER OVARY CELLS; MEVALONATE-DERIVED PRODUCT; HMG-COA REDUCTASE; CULTURED FIBROBLASTS; NUCLEOTIDE-SEQUENCE; ALPHA-TUBULIN; EXPRESSION; 25-HYDROXYCHOLESTEROL; REPRESSION	We have examined the mechanism of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by 24(S),25-oxidolanosterol, a C30-sterol naturally occurring in mammalian tissues. In the absence of enzymatic demethylation to the C27-sterol, 24(S),25-epoxycholesterol, oxidolanosterol is shown to be a post-transcriptional regulator of reductase synthesis in both primary rat hepatocytes and Chinese hamster ovary cells. Under these conditions, oxidolanosterol also increases the rate of degradation of reductase protein in these cells. When demethylation is not inhibited, oxidolanosterol treatment produces transcriptional regulation of sterol-sensitive genes in Chinese hamster ovary cells. In contrast to previous findings with the oxygenated C27-sterol, 25-hydroxycholesterol, oxidolanosterol can act as a post-transcriptional regulator in cells starved for mevalonate. These findings are consistent with the hypothesis that oxidolanosterol down-regulates sterol synthesis in a fashion mechanistically distinct from that of C27-sterols.			PANINI, SR (corresponding author), ELEANOR ROOSEVELT INST,1899 GAYLORD ST,DENVER,CO 80206, USA.				NIDDK NIH HHS [DK 40804, DK 42270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042270, R01DK040804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASTIAN LS, 1991, MOL ENDOCRINOL, V5, P619, DOI 10.1210/mend-5-5-619; BLIGH EG, 1959, J BIOCH PHYSL, V32, P911; BROWN MS, 1980, J LIPID RES, V21, P505; CHAM BE, 1976, J LIPID RES, V17, P176; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Davis R A, 1986, Methods Enzymol, V129, P272; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; DREVON CA, 1981, J LIPID RES, V22, P37; ELLIOTT EM, 1985, MOL CELL BIOL, V5, P236, DOI 10.1128/MCB.5.1.236; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FAVATA MF, 1987, J BIOL CHEM, V262, P12254; FAVATA MF, 1990, FASEB J, V4, pA1746; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1980, J BIOL CHEM, V256, P13068; LEE LY, 1989, NUCLEIC ACIDS RES, V17, P1259, DOI 10.1093/nar/17.3.1259; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NELSON JA, 1981, J BIOL CHEM, V256, P1067; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; PANINI SR, 1986, J LIPID RES, V27, P1190; PANINI SR, 1989, J BIOL CHEM, V264, P11044; PANINI SR, 1990, J BIOL CHEM, V265, P14118; PEFFLEY D, 1988, SOMAT CELL MOLEC GEN, V14, P527, DOI 10.1007/BF01535308; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SAUCIER SE, 1985, J BIOL CHEM, V260, P4571; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHNITZERPOLOKOFF R, 1982, J BIOL CHEM, V257, P472; SCHNITZERPOLOKOFF R, 1983, ARCH BIOCHEM BIOPHYS, V227, P71, DOI 10.1016/0003-9861(83)90348-X; SINENSKY M, 1980, P NATL ACAD SCI-BIOL, V77, P6621, DOI 10.1073/pnas.77.11.6621; SINENSKY M, 1987, EXP CELL RES, V171, P492, DOI 10.1016/0014-4827(87)90180-7; SINENSKY M, 1981, J BIOL CHEM, V256, P1774; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; TAYLOR FR, 1986, J BIOL CHEM, V261, P5039; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941	47	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12647	12654						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618770				2022-12-27	WOS:A1992HZ48300043
J	TAKAHASHI, S; INOUE, H; MIYAKE, Y				TAKAHASHI, S; INOUE, H; MIYAKE, Y			THE HUMAN GENE FOR RENIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-ZIPPER; PORCINE KIDNEY; INSITU HYBRIDIZATION; NUCLEOTIDE-SEQUENCE; CDNA; PURIFICATION; EXPRESSION; CHROMOSOME; PROMOTER; CLONING	The human renin-binding protein (RnBP) gene was isolated from a human placental genomic library and characterized. The gene spans about 10 kilobases and consists of 11 exons separated by 10 introns. The 5'-flanking region and the exon-intron boundaries were sequenced. Residue G* in 5'-CGAG*TGG-3' was identified as the major transcription initiation site, and "GC" boxes were found in the vicinity of the cap site. No typical "TATA" or "CCAAT" box exists in the 5'-flanking region. The hydrophobic domain followed by a leucine-zipper motif in RnBP is encoded by the sixth exon. A fragment of the human RnBP gene (nucleotides -739 to +244) linked to the chloramphenicol acetyltransferase gene was transfected into human Wilms' tumor G401 and mouse L929 cells. The expression of this chimeric gene in G401 cells was 4-fold higher than that in L929 cells, the tissue-specific regulation of RnBP gene expression thus being suggested. The promoter for the RnBP gene was shown to be localized in nucleotides -35 to +244 on assaying of the promoter activity using deletion mutants of the chimeric constructs. The RnBP gene was found to be located in human chromosome X by means of polymerase chain reaction of hybrid DNAs from human and hamster somatic cells.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,5-7-1 FUJISHIRO DAI,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; DRAYNA D, 1985, SCIENCE, V230, P753, DOI 10.1126/science.4059909; DUSH MK, 1985, P NATL ACAD SCI USA, V82, P2731, DOI 10.1073/pnas.82.9.2731; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUKUI K, 1989, BIOCHEM BIOPH RES CO, V164, P265, DOI 10.1016/0006-291X(89)91712-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HURBY DE, 1990, BIOTECHNIQUES, V8, P170; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; INOUE H, 1991, J BIOCHEM-TOKYO, V110, P493, DOI 10.1093/oxfordjournals.jbchem.a123609; INOUE H, 1990, J BIOL CHEM, V265, P6556; INOUE H, 1991, J BIOL CHEM, V266, P11896; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MCCORMACK K, 1989, NATURE, V340, P103, DOI 10.1038/340103a0; MCGILL JR, 1987, CYTOGENET CELL GENET, V45, P55, DOI 10.1159/000132425; MIYAZAKI H, 1984, P NATL ACAD SCI-BIOL, V81, P5999, DOI 10.1073/pnas.81.19.5999; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAI H, 1988, CYTOGENET CELL GENET, V47, P90, DOI 10.1159/000132515; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; TAKAHASHI S, 1983, J BIOCHEM, V93, P1583, DOI 10.1093/oxfordjournals.jbchem.a134297; TAKAHASHI S, 1983, J BIOCHEM-TOKYO, V93, P265, DOI 10.1093/oxfordjournals.jbchem.a134162; TAKAHASHI S, 1988, BIOCHEM INT, V16, P1053; TAKAHASHI S, 1985, J BIOCHEM-TOKYO, V97, P671, DOI 10.1093/oxfordjournals.jbchem.a135103; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; WIERINGA B, 1983, NATURE, V301, P38, DOI 10.1038/301038a0; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	42	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13007	13013						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618798				2022-12-27	WOS:A1992HZ48300091
J	BARNETT, T; CLARK, GF				BARNETT, T; CLARK, GF			POLYGLYCOSYLCERAMIDES WITH BRANCHED N-ACETYLLACTOSAMINE SEQUENCES ARE SYNTHESIZED BY THE HUMAN PANCREATIC-CARCINOMA CELL-LINE PANC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANES; HUMAN MONOCLONAL-ANTIBODY; WHEAT-GERM-AGGLUTININ; HUMAN-MILK; AFFINITY-CHROMATOGRAPHY; LINKED OLIGOSACCHARIDES; CARBOHYDRATE ANTIGENS; METHYLATION ANALYSIS; GLYCOLIPID ANTIGENS; MALIGNANT-MELANOMA	We have metabolically labeled the human pancreatic tumor cell line PANC-1 with high specific activity tritiated sugar precursors to study the expression of glycosphingolipids by this cell type. We have used a combination of detergent solubilization, exhaustive protease digestion, ceramide glycanase digestion, and reverse-phase chromatography to isolate glycosphingolipid-derived oligosaccharides specifically labeled in their component sugars. A significant proportion of the oligosaccharides derived from polar glycosphingolipids were of high molecular mass (>2000 Da). The results of compositional studies, lectin affinity chromatography, and methylation analysis suggested that this high molecular weight fraction consists of lactosaminoglycan type oligosaccharides derived from polyglycosylceramides. There are on average three beta-1-6 linked N-acetyllactosamine branches attached to the polylactosamine backbone in this type of glycosphingolipid-derived oligosaccharide. The majority of the oligosaccharides also contain 1-2 mol of sialic acid that are linked alpha-2-3 to penultimate galactose. The results indicate that PANC-1 cells, like human colorectal tumor cells, express highly extended neolacto type glycosphingolipids. However, the lactosaminoglycan sequences are highly branched, unlike those associated with colorectal tumor cells.	EASTERN VIRGINIA MED SCH, DEPT BIOCHEM, NORFOLK, VA 23501 USA	Eastern Virginia Medical School								ABRAMS PG, 1985, MONOCLONAL ANTIBODY, P103; ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BJORNDAL H, 1967, ACTA CHEM SCAND, V21, P1801, DOI 10.3891/acta.chem.scand.21-1801; BLANCHARD D, 1985, J BIOL CHEM, V260, P7813; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; CHEUNG NKV, 1987, J CLIN ONCOL, V5, P1430, DOI 10.1200/JCO.1987.5.9.1430; CHING CK, 1988, J CLIN PATHOL, V41, P324, DOI 10.1136/jcp.41.3.324; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; CLARK GF, 1987, ARCH BIOCHEM BIOPHYS, V257, P217, DOI 10.1016/0003-9861(87)90561-3; CLAUSEN H, 1986, BIOCHEMISTRY-US, V25, P7075, DOI 10.1021/bi00370a048; COOPER CS, 1984, CANCER RES, V44, P1; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DEIXONNE B, 1986, EXOCRINE PANCREATIC, P11; DENNIS JW, 1989, ONCOGENE, V4, P853; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DUTT A, 1988, J BIOL CHEM, V263, P2270; ESSELMAN WJ, 1972, METHOD ENZYMOL, V28, P140; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GALLAGHER JT, 1985, BIOCHEM J, V231, P115, DOI 10.1042/bj2310115; GARDAS A, 1974, FEBS LETT, V42, P101, DOI 10.1016/0014-5793(74)80289-9; GARDAS A, 1973, EUR J BIOCHEM, V32, P178, DOI 10.1111/j.1432-1033.1973.tb02595.x; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1986, CHEM PHYS LIPIDS, V42, P209, DOI 10.1016/0009-3084(86)90054-X; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HANFLAND P, 1984, EUR J BIOCHEM, V145, P531, DOI 10.1111/j.1432-1033.1984.tb08589.x; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; IRIE RF, 1986, P NATL ACAD SCI USA, V83, P8694, DOI 10.1073/pnas.83.22.8694; IRIMURA T, 1983, CARBOHYD RES, V120, P187, DOI 10.1016/0008-6215(83)88016-1; KANFER JN, 1983, SPHINGOLIPID BIOCH; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Klenk E, 1941, H-S Z PHYSIOL CHEM, V270, P185, DOI 10.1515/bchm2.1941.270.3-4.185; KOSCIELAK J, 1976, EUR J BIOCHEM, V71, P9, DOI 10.1111/j.1432-1033.1976.tb11083.x; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LEVERY SB, 1989, BIOCHEMISTRY-US, V28, P7772, DOI 10.1021/bi00445a037; LI E, 1978, J BIOL CHEM, V253, P7762; MAZZETTA C, 1975, INT J CANCER, V15, P741; MURAMATSU H, 1988, J BIOCHEM-TOKYO, V107, P629; MURAMATSU T, 1988, J CELL BIOCHEM, V36, P1, DOI 10.1002/jcb.240360102; NAKAISHI H, 1988, CANCER RES, V48, P1753; NOWACK WJ, 1984, FED PROC, V43, P926; NUDELMAN ED, 1989, J BIOL CHEM, V264, P18719; OKU N, 1983, J BIOL CHEM, V258, P8733; Schauer R, 1978, Methods Enzymol, V50, P64; SMITH DF, 1980, J BIOL CHEM, V255, P55; SMITH DF, 1987, J BIOL CHEM, V262, P12040; SMITH DF, 1978, ANAL BIOCHEM, V85, P602, DOI 10.1016/0003-2697(78)90261-0; STOFFYN P, 1971, J LIPID RES, V12, P318; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TARRAGO MT, 1988, ARCH BIOCHEM BIOPHYS, V267, P353, DOI 10.1016/0003-9861(88)90041-0; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; TSUJI Y, 1988, J EXP MED, V168, P343, DOI 10.1084/jem.168.1.343; VANCE DE, 1967, J LIPID RES, V8, P621; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1980, J BIOL CHEM, V255, P847; WANG WC, 1988, ANAL BIOCHEM, V175, P390, DOI 10.1016/0003-2697(88)90562-3; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WOOD C, 1978, ANN INST PASTEUR IMM, VC129, P143; YAGEL S, 1989, INT J CANCER, V44, P685, DOI 10.1002/ijc.2910440422; YAMADA H, 1986, BIOCHEM BIOPH RES CO, V140, P167, DOI 10.1016/0006-291X(86)91072-7; Yurchenco P D, 1978, Methods Enzymol, V50, P175; ZHOU B, 1989, J BIOL CHEM, V264, P12272	67	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11760	11768						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601851				2022-12-27	WOS:A1992HY94700021
J	YOO, SH; LEWIS, MS				YOO, SH; LEWIS, MS			EFFECTS OF PH AND CA2+ ON MONOMER-DIMER AND MONOMER-TETRAMER EQUILIBRIA OF CHROMOGRANIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; ADRENAL CHROMAFFIN GRANULES; PURIFIED RYANODINE RECEPTOR; AMINO-ACID SEQUENCE; SARCOPLASMIC-RETICULUM; HIGH-AFFINITY; TERMINAL CISTERNAE; MOLECULAR-CLONING; RELEASE CHANNEL	Chromogranin A is a high capacity, low affinity Ca2+ binding protein which undergoes Ca2+- and pH-dependent conformational changes, and has recently been suggested to play a Ca2+-buffering role in the secretory vesicle of adrenal medullary chromaffin cell, the major inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ store of chromaffin cell (Yoo, S. H., and Albanesi, J. P. (1990) J. Biol. Chem. 265, 13446-13448). In the present study, it is shown that chromogranin A exists in a monomer-dimer equilibrium at pH 7.5 and in a monomer-tetramer equilibrium at pH 5.5. The pH appears to be a necessary and sufficient factor determining the types of oligomers formed. Although Ca2+ did not change the type of oligomerization, it had a very significant effect on the values of the thermodynamic parameters characterizing the associations. The DELTA-G0 values for a monomer-dimer equilibrium were -7 to -8 kcal/mol, while those for a monomer-tetramer equilibrium were -20 to -23 kcal/mol. At pH 5.5, the values of DELTA-H0, DELTA-S0, and DELTA-C(p)0 were large and negative in the absence of Ca2+ and large and positive in the presence of 35 mM Ca2+, implying markedly different reaction mechanisms. Extrapolation of the results to 37-degrees-C and 1 mM chromogranin A suggests that chromogranin A is virtually 100% tetramer at pH 5.5 in the presence of 35 mM Ca2+ but is 96% dimer at pH 7.5 in the absence of Ca2+, the two conditions resembling those seen in vivo. These results suggest that chromogranin A is mostly dimer in the endoplasmic reticulum and cis-Golgi area and is essentially all tetramer in the vesicle.	NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	YOO, SH (corresponding author), NIDOCD, CELLULAR BIOL LAB, BETHESDA, MD 20892 USA.							ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; CLARKE ECW, 1966, T FARADAY SOC, V62, P539, DOI 10.1039/tf9666200539; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; COZENS B, 1984, J BIOL CHEM, V259, P6248; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAI FA, 1989, NATURE, V28, P315; MACLENNAN DH, 1973, COLD SPRING HARB SYM, V37, P469, DOI 10.1101/SQB.1973.037.01.058; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; MILOS M, 1987, J BIOL CHEM, V262, P2746; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; REITHMEIER RAF, 1987, CALCIUM BINDING PROT, P62; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SELLERS P, 1991, BIOPHYS CHEM, V39, P199, DOI 10.1016/0301-4622(91)85022-I; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VAN PN, 1989, J BIOL CHEM, V264, P17494; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WINKLER H, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1991, J BIOL CHEM, V266, P7740; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	37	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11236	11241						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597459				2022-12-27	WOS:A1992HX16900049
J	ARAKI, N; UENO, N; CHAKRABARTI, B; MORINO, Y; HORIUCHI, S				ARAKI, N; UENO, N; CHAKRABARTI, B; MORINO, Y; HORIUCHI, S			IMMUNOCHEMICAL EVIDENCE FOR THE PRESENCE OF ADVANCED GLYCATION END-PRODUCTS IN HUMAN LENS PROTEINS AND ITS POSITIVE CORRELATION WITH AGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NON-ENZYMATIC GLYCOSYLATION; GLUCOSE-MODIFIED PROTEINS; DIABETES-MELLITUS; STRUCTURAL PROTEINS; MAILLARD REACTION; HUMAN COLLAGEN; HUMAN-SERUM; RECEPTOR; INVIVO; AGE	Prolonged incubation of protein with reducing sugar proceeds through a series of reactions involving early stage products to the advanced glycation end products with fluorescence, brown color, and cross-linking. Known collectively as the Maillard reaction, these changes have been suggested as factors in diabetic complications and the aging process. The early stage products have been demonstrated in vivo, but evidence for the presence in vivo of the advanced glycation end products has been limited. We sought to provide immunochemical evidence by the preparation and use of polyclonal and monoclonal antibodies to these end products (Horiuchi, S., Araki, N., and Morino, Y. (1991) J. Biol. Chem. 266, 7329-7332) as probes to identify and quantitate such compounds in human lens crystallins. Neither of the antibodies reacted with extracts from infant lenses, but fractions from adult lenses showed a significant reactivity, correlating with lens age. Our findings provide the first immunochemical evidence that human lens crystallins contain advanced glycation end products and that these products increase with tissue age.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; HARVARD UNIV,SCH MED,BOSTON,MA 02115; SCHEPENS EYE RES INST,BOSTON,MA 02114	Kumamoto University; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute					NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NEI NIH HHS [EY04161] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARAKI N, 1992, POSTTRANSLATIONAL MO, P253; BAILEY AJ, 1973, FRONTIERS MATRIX BIO, V1, P130; BANDYOPADHYAY S, 1992, PHOTOCHEM PHOTOBIOL, V55, P765; BUNN HF, 1978, SCIENCE, V200, P21, DOI 10.1126/science.635569; CHANG JCF, 1985, J BIOL CHEM, V260, P7970; DAY JF, 1979, J BIOL CHEM, V254, P595; DYER DG, 1991, J BIOL CHEM, V266, P11654; Finot P. A., 1982, Advances in Chemistry Series, V198, P91; GRANDHEE KS, 1991, J BIOL CHEM, V266, P11649; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HAYASE F, 1989, J BIOL CHEM, V264, P3758; HORIUCHI S, 1991, J BIOL CHEM, V266, P7329; HORIUCHI S, 1988, J BIOL CHEM, V263, P18821; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; KUCK JFR, 1970, BIOCH EYE, P183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG JN, 1990, INT J BIOL MACROMOL, V12, P273, DOI 10.1016/0141-8130(90)90009-Y; LOW MF, 1967, BIOCHIM BIOPHYS ACTA, V141, P547; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; MAKITA Z, 1991, NEW ENGL J MED, V325, P832; MILLER JA, 1980, J CLIN INVEST, V65, P896, DOI 10.1172/JCI109743; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; NJOROGE FG, 1987, CARBOHYD RES, V167, P211; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RAHBAR S, 1968, CLIN CHIM ACTA, V22, P296, DOI 10.1016/0009-8981(68)90372-0; Reynolds T M, 1965, Adv Food Res, V14, P167; SCHLEICHER E, 1981, FEBS LETT, V129, P1, DOI 10.1016/0014-5793(81)80741-7; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SEN AC, 1992, PHOTOCHEM PHOTOBIOL, V55, P753; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; STEVENS VJ, 1978, P NATL ACAD SCI USA, V75, P2918, DOI 10.1073/pnas.75.6.2918; TAKATA K, 1988, J BIOL CHEM, V263, P14819; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588	39	246	249	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10211	10214						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587810				2022-12-27	WOS:A1992HV09000004
J	ISHIMI, Y				ISHIMI, Y			PREINCUBATION OF T-ANTIGEN WITH DNA OVERCOMES REPRESSION OF SV40 DNA-REPLICATION BY NUCLEOSOME ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INVITRO REPLICATION; PURIFICATION; ORIGIN; INITIATION; BINDING; PROTEIN; INVIVO; CELLS	Circular duplex DNA containing the SV40 replication origin was assembled into chromosomes in vitro with core histones and nucleosome assembly factor from HeLa cells. Their ability to serve as a template for replication was examined by incubating them with SV40 T antigen and HeLa cell extract. Nucleosome assembly of the template prevented DNA replication. Replication of chromosomes was severely inhibited at more than two-thirds of physiological nucleosome density. When the DNA was preincubated with T antigen and then assembled into chromosomes, however, inhibition of DNA replication was greatly reduced. These results suggest that nucleosome assembly of the template inhibits initiation of SV40 DNA replication and that the inhibition can be overcome by formation of an initiation complex before nucleosome assembly.			ISHIMI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; GOTTESFELD J, 1982, CELL, V28, P781, DOI 10.1016/0092-8674(82)90057-5; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1991, J BIOL CHEM, V266, P16141; ISHIMI Y, 1985, CELL STRUCT FUNCT, V10, P373, DOI 10.1247/csf.10.373; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	21	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10910	10913						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587867				2022-12-27	WOS:A1992HV09000104
J	SASAKI, A; GOLDBERG, IJ				SASAKI, A; GOLDBERG, IJ			LIPOPROTEIN-LIPASE RELEASE FROM BFC-1-BETA ADIPOCYTES - EFFECTS OF TRIGLYCERIDE-RICH LIPOPROTEINS AND LIPOLYSIS PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ADIPOSE-TISSUE; APOLIPOPROTEIN-C-II; PHOSPHOLIPASE-C; PLASMA-LIPOPROTEINS; INSULIN; CELLS; PHOSPHATIDYLINOSITOL; PROTEOGLYCANS; METABOLISM; DEFICIENCY	Lipoprotein lipase (LPL), synthesized by adipocytes and myocytes, must be transported to the luminal endothelial cell surface where it then interacts with circulating lipoproteins. The first step in this extracellular LPL transport pathway is LPL release from the surface of LPL-synthesizing cells. Because hydrolysis of triglyceride (TG)-rich lipoproteins releases LPL from the apical surface of endothelial cells, we hypothesized that the same substances dissociate LPL from adipocytes. I-125-LPL was bound to the surface of brown adipocytes (BFC-1-beta). LPL binding to the adipocyte surface was greater than to endothelial cell surfaces. Using low concentrations of heparin, more LPL was released from endothelial cells than BFC-1-beta suggesting that the affinity of LPL binding to the adipocytes was greater than LPL affinity for endothelial cells. >3-fold more LPL was released from the cell surface when very low density lipoproteins (VLDL) were added to culture medium containing 3% bovine serum albumin. LPL remaining on the cell surface decreased with VLDL addition. Endogenously produced LPL activity was also released from the cells by VLDL. Low and high density lipoproteins did not release I-125-LPL or LPL activity from the adipocytes. To assess whether lipolysis was necessary for LPL release, BFC-1-beta were incubated with TG-rich lipoproteins from a patient with apoCII deficiency. The apoCII-deficient lipoproteins did not release LPL unless an exogenous source of apoCII was added. Apolipoproteins E and Cs and high molar ratios of oleic acid:bovine serum albumin did not release surface-associated LPL. Lysolecithin (25 and 100-mu-M), but not lecithin, monoglycerides, or diglycerides, released adipocyte surface LPL. Because lysolecithin also released LPL during a 4-degrees-C incubation, cellular metabolic functions are not required for LPL dissociation from the cells. Lysolecithin also inhibited LPL binding to endothelial cells; however, this effect was abrogated by addition of bovine serum albumin. We hypothesize that lipolysis products from TG-rich lipoproteins release adipocyte surface LPL, which can then be transported to the luminal endothelial cell surface.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,SPECIALIZED CTR RES ARTERIOSCLEROSIS,NEW YORK,NY 10032	Columbia University; Columbia University					NHLBI NIH HHS [HL 45095, HL 21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, P50HL021006, R37HL045095] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELFRAGE P, 1969, J LIPID RES, V10, P341; BRAUN JEA, 1991, AM J PHYSIOL, V260, pE477, DOI 10.1152/ajpendo.1991.260.3.E477; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; CAMPS L, 1990, AM J PHYSIOL, V258, pC673, DOI 10.1152/ajpcell.1990.258.4.C673; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1014, P178, DOI 10.1016/0167-4889(89)90031-1; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CORNICELLI JA, 1963, ARTERIOSCLEROSIS, V3, P560; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1981, INT J OBESITY, V5, P571; ECKEL RH, 1984, ENDOCRINOLOGY, V114, P1665, DOI 10.1210/endo-114-5-1665; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; FOJO SS, 1989, J CLIN INVEST, V84, P1215, DOI 10.1172/JCI114287; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; GARFINKEL AS, 1987, PLASMA LIPOPROTEINS, P335; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIETANEN E, 1977, J LIPID RES, V18, P480; ISHIHARA M, 1987, J BIOL CHEM, V262, P4708; JONASSON L, 1984, ATHEROSCLEROSIS, V51, P313, DOI 10.1016/0021-9150(84)90179-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NICOLL A, 1981, ATHEROSCLEROSIS, V39, P229, DOI 10.1016/0021-9150(81)90073-3; NIEUWENHUIZEN W, 1977, ATHEROSCLEROSIS, V27, P97, DOI 10.1016/0021-9150(77)90029-6; NILSSONE.P, 1973, J BIOL CHEM, V248, P6734; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SCOW RO, 1976, BIOCHIM BIOPHYS ACTA, V431, P538, DOI 10.1016/0005-2760(76)90219-8; SEMB H, 1989, BIOCHEM J, V262, P505, DOI 10.1042/bj2620505; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; STENDER S, 1981, ARTERIOSCLEROSIS, V1, P38, DOI 10.1161/01.ATV.1.1.38; STEWART JE, 1974, J BIOL CHEM, V249, P904; SWITZER S, 1965, J LIPID RES, V6, P506; WANGIVERSON P, 1980, ATHEROSCLEROSIS, V5, P375; WISE LS, 1978, CELL, V13, P233, DOI 10.1016/0092-8674(78)90192-7; YLAHERTTUALA S, 1988, J LIPID RES, V29, P563; ZOVICH DC, 1991, FASEB J, V5, pA717	40	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15198	15204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634549				2022-12-27	WOS:A1992JF08800101
J	SPEICHER, DW; WEGLARZ, L; DESILVA, TM				SPEICHER, DW; WEGLARZ, L; DESILVA, TM			PROPERTIES OF HUMAN RED-CELL SPECTRIN HETERODIMER (SIDE-TO-SIDE) ASSEMBLY AND IDENTIFICATION OF AN ESSENTIAL NUCLEATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; ALPHA-ACTININ; STRUCTURAL DOMAINS; FUNCTIONAL DOMAINS; COMPLETE SEQUENCE; SUBUNIT; CALMODULIN; MEMBRANE; PROTEIN; CDNA	The antiparallel side-to-side association of spectrin alpha and beta-monomers is a two-step process which occurs in seconds even at 0-degrees-C and at low concentrations. Assembly involves initial contact of complementary nucleation sites on each subunit, which are located near the actin binding end of the long, flexible heterodimer rod. The minimum nucleation sites are comprised of approximately four contiguous 106-residue homologous segments or repeats. Three repeats in the nucleation site contain an 8-residue insertion and have the highest homology to the four spectrin-like repeats in alpha-actinin. The adjacent actin binding domain on the beta-subunit and the adjacent EF hand motifs on the alpha-subunit are not required for heterodimer assembly. The nucleation sites probably have a specific lock and key structure which defines the unique side-to-side pairing of the many homologous segments in both subunits. Assembly of spectrin heterodimers is probably most analogous to a zipper. After initial nucleation site binding, the remainder of the subunits quickly associate along their full lengths to reconstitute a normal dimer by supercoiling around each other to form a rope-like, flexible rod. Assembly is terminated if either polypeptide is interrupted by a protease cleavage. Heterozygotic mutations involving either nucleation site are predicted to affect allele incorporation into the mature membrane skeleton.			SPEICHER, DW (corresponding author), WISTAR INST, 3601 SPRUCE ST, ROOM C102, PHILADELPHIA, PA 19104 USA.			Weglarz, Ludmila/0000-0003-4217-5274	NCI NIH HHS [CA10815] Funding Source: Medline; NHLBI NIH HHS [HL38794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1991, J CLIN INVEST, V87, P2169, DOI 10.1172/JCI115250; BARON MD, 1987, J BIOL CHEM, V262, P17623; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P248, DOI 10.1002/cm.970120406; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITMAN D, 1980, J CELL SCI, V42, P1; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MCGUIRE M, 1988, Hematologic Pathology, V2, P1; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; PALEK J, 1987, Blood Reviews, V1, P147, DOI 10.1016/0268-960X(87)90031-2; REIM DF, 1992, TECHNIQUES PROTEIN C, P53; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SEARS DE, 1986, BIOCHIM BIOPHYS ACTA, V870, P432, DOI 10.1016/0167-4838(86)90251-7; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1982, J BIOL CHEM, V257, P9093; SPEICHER DW, 1986, J CELL BIOCHEM, V30, P245, DOI 10.1002/jcb.240300306; WASENIUS VM, 1987, FEBS LETT, V221, P73, DOI 10.1016/0014-5793(87)80354-X; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YOSHINO H, 1984, J BIOL CHEM, V259, P4496; YURCHENCO PD, 1982, J BIOL CHEM, V257, P9102	30	141	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14775	14782						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634521				2022-12-27	WOS:A1992JF08800043
J	BAHOU, WF; CAMPBELL, AD; WICHA, MS				BAHOU, WF; CAMPBELL, AD; WICHA, MS			CDNA CLONING AND MOLECULAR CHARACTERIZATION OF MSE55, A NOVEL HUMAN SERUM CONSTITUENT PROTEIN THAT DISPLAYS BONE-MARROW STROMAL ENDOTHELIAL CELL-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR VWF; DNA; BINDING; SEQUENCE; DIFFERENTIATION; LOCALIZATION; ENVIRONMENT; FRAGMENTS; CULTURES; ADHESION	Hemonectin is a lineage-specific cytoadhesive protein that may be involved in the developmentally regulated adhesion of granulocytic cells to bone marrow stroma. Immunoblot analysis using an anti-hemonectin antibody recognizes two distinct immunoreactive species in endothelial cell lysates (is similar to M(r) 65,000) and human serum (is similar to M(r) 55,000). Initial characterization of the 55-kDa protein has now been completed by isolating the cDNA from a human endothelial cell expression library. Sequence analysis of overlapping clones identifies a composite sequence spanning 2030 nucleotides with an open reading frame of 1173 base pairs. No significant sequence similarity was observed on analysis of current GenBank databases. The open reading frame was expressed as a recombinant protein in Escherichia coli and used as an immunogen for the production of a specific polyclonal antibody. Immunoblotting with this antibody identifies a single immunoreactive species of apparent M(r) 55,000 in HUVEC lysates and human serum, confirming that a secreted form normally circulates as a serum constituent protein. This antibody fails to recognize purified hemonectin, suggesting that the M(r) 55,000 protein is not hemonectin. Cross-species Southern blot analysis reveals persistent hybridizing fragments in all species tested, suggestive of a developmentally conserved function. Northern blot analysis demonstrates expression limited to endothelial and bone marrow stromal cells, but not poly(A) RNA from monkey liver, spleen, brain, lung, and kidney. On this basis, we have designated this novel protein MSE55, for marrow stromal/endothelial cell protein with a molecular mass of 55,000 daltons. Its tissue-specific expression may suggest a functional role in hematopoiesis.	UNIV MICHIGAN,DIV HEMATOL ONCOL,ANN ARBOR,MI	University of Michigan System; University of Michigan	BAHOU, WF (corresponding author), SUNY STONY BROOK,DIV HEMATOL,STONY BROOK,NY 11794, USA.		Wicha, Max/AAE-7268-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035255, K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02431, HL35255] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; ANKLESARIA P, 1987, EXP HEMATOL, V15, P636; ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BAHOU WF, 1988, BLOOD, V72, P308; BRAELL WA, 1982, J BIOL CHEM, V257, P4578; CAMPBELL A, 1985, J CLIN INVEST, V75, P2085, DOI 10.1172/JCI111928; CAMPBELL AD, 1990, BLOOD, V76, P1758; CAMPBELL AD, 1987, NATURE, V329, P744, DOI 10.1038/329744a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1973, J CELL PHYSL, V83, P461; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KONKLE BA, 1988, J CLIN INVEST, V82, P579, DOI 10.1172/JCI113635; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KYLE J, 1982, J MOL BIOL, V157, P105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; Maniatis T., 1982, MOL CLONING; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; PATEL VP, 1984, SCIENCE, V224, P996, DOI 10.1126/science.6585955; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PUSTELL J, 1986, NUCLEIC ACIDS RES, V14, P479, DOI 10.1093/nar/14.1.479; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WOLF NS, 1979, CLIN HAEMATOL, V8, P469; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595; ZUCKERMAN KS, 1983, BLOOD, V61, P540	42	20	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13986	13992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629197				2022-12-27	WOS:A1992JD32500034
J	MASSIA, SP; HUBBELL, JA				MASSIA, SP; HUBBELL, JA			VASCULAR ENDOTHELIAL-CELL ADHESION AND SPREADING PROMOTED BY THE PEPTIDE REDV OF THE IIICS REGION OF PLASMA FIBRONECTIN IS MEDIATED BY INTEGRIN ALPHA-4-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; EXTRACELLULAR-MATRIX; CONNECTING SEGMENT; SURFACE RECEPTORS; VONWILLEBRAND-FACTOR; MESSENGER-RNAS; ATTACHMENT; IDENTIFICATION; BINDING; SITES	We have recently reported the attachment and spreading of human umbilical vein endothelial cells (HUVECs) upon substrates containing covalently grafted Arg-Glu-Asp-Val (REDV) peptide (Hubbell, J. A., Massia, S. P., Desai, N. P., and Drumheller, P. D. (1991) Bio/Technology 9, 568-572). This peptide has been reported to be the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin, and the integrin alpha-4-beta-1 has been identified as the receptor on melanoma cells for this site. The integrin alpha-4-beta-1 has also been identified as the receptor for the CS1 site in the IIICS region on cells of neural crest origin, melanoma cells, lymphocytes, and hematopoietic stem cells. In this study, we demonstrate that this integrin also serves as a receptor on HUVECs for the peptide REDV from the CS5 site. The alpha-4 subunit was shown to be expressed upon HUVEC membranes by whole-cell enzyme-linked immunosorbent assay. Antifunctional antibodies directed against integrin subunits alpha-4 and beta-1 inhibited cell adhesion on REDV-grafted substrates, but not on RGD-grafted substrates. The alpha-4 subunit localized into fibrillar structures within spread cells on the REDV-grafted substrates, but not within spread cells on RGD-grafted substrates. Two proteins (144 and 120 kDa) were isolated from HUVEC extracts by REDV ligand affinity chromatography and were demonstrated by immunoprecipitation and Western blot to be the integrin subunits alpha-4 (144 kDa) and beta-1 (120 kDa); furthermore, the immunoprecipitation analyses demonstrated that the subunits formed a complex. HUVEC binding to REDV-grafted substrates was inhibited by both soluble REDV and RGD, demonstrating that adhesion was biospecific and that the REDV peptide is RGD-like. In this report we demonstrate for the first time that alpha-4 is present in the endothelial cell membrane, in contrast to previous reports by others, and that integrin alpha-4-beta-1 is the receptor for REDV-mediated adhesion to the IIICS region of region of plasma fibronectin.	UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712; UNIV TEXAS,DIV BIOL SCI,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Hubbell, Jeffrey A/A-9266-2008	Hubbell, Jeffrey A/0000-0003-0276-5456	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039714] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cb.03.110187.001143; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHENG YF, 1991, EXP CELL RES, V194, P69, DOI 10.1016/0014-4827(91)90131-D; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CONFORTI G, 1989, BLOOD, V73, P1576; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEJANA E, 1989, J CELL BIOL, V109, P367, DOI 10.1083/jcb.109.1.367; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DEJANA E, 1988, BLOOD, V71, P566; DEJANA E, 1987, J CELL BIOL, V104, P1403, DOI 10.1083/jcb.104.5.1403; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; FERREIRA OC, 1990, J EXP MED, V171, P351, DOI 10.1084/jem.171.1.351; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HUBBELL JA, 1991, BIO-TECHNOL, V9, P568, DOI 10.1038/nbt0691-568; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 1990, FIBRONECTINS; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MACARAK EJ, 1983, J CELL PHYSIOL, V116, P76, DOI 10.1002/jcp.1041160112; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MASSIA SP, 1992, J BIOL CHEM, V267, P10133; MASSIA SP, 1990, ANAL BIOCHEM, V187, P292, DOI 10.1016/0003-2697(90)90459-M; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; Mosher DF, 1988, FIBRONECTIN; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; PRATT BM, 1985, ANN NY ACAD SCI, V460, P274, DOI 10.1111/j.1749-6632.1985.tb51175.x; PYTELA R, 1987, METHOD ENZYMOL, V28, P490; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STAMATOGLOU SC, 1990, J CELL SCI, V97, P595; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANNARIELLOBROWN J, 1988, J CELL BIOL, V106, P1773, DOI 10.1083/jcb.106.5.1773	60	233	256	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14019	14026						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629200				2022-12-27	WOS:A1992JD32500039
J	OBLONG, JE; LAMPPA, GK				OBLONG, JE; LAMPPA, GK			PRECURSOR FOR THE LIGHT-HARVESTING CHLOROPHYLL A/B-BINDING PROTEIN SYNTHESIZED IN ESCHERICHIA-COLI BLOCKS IMPORT OF THE SMALL SUBUNIT OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST IMPORT; TRANSLOCATION; MEMBRANE; RECEPTOR; ENZYME	When synthesized in Escherichia coli, the light-harvesting chlorophyll a/b-binding protein (LHCP) precursor accumulates in inclusion-like bodies (Abad, M. S., Oblong, J. E., and Lamppa, G. K. (1991) Plant Physiol. 96, 1220-1227). In this study we show that after solubilization in 6 M urea and dialysis into 20 mM Tris-HCl (pH 8.0) the recombinant LHCP precursor (preLHCP) was not found as a monomer (31 kDa), but instead produced a heterogeneous population of oligomeric complexes, ranging from 60-300 kDa as determined by gel filtration chromatography. Circular dichroism analysis indicated that the oligomers had folded structure, and that it was composed of both alpha-helix and beta-sheet. Approximately half of recombinant preLHCP found in these complexes was cleavable at the transit peptide-mature protein junction by a soluble chloroplast-processing enzyme in an organelle-free reaction. At 1.5-mu-M the recombinant precursor inhibited the import of radiolabeled preLHCP and the precursor of the small subunit of ribulose-1,5-bisphosphate carboxylase/oxygenase generated by reticulocyte lysate translations. When chloroplasts were preincubated with the precursor, followed by their reisolation, import was still blocked, providing evidence that competition between recombinant preLHCP and these substrates occurred at the chloroplast per se. Recombinant preLHCP was visualized on the envelope by immunofluorescence microscopy, and its presence there was mediated by a thermolysin-sensitive factor.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM36419] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; ABADMS, 1991, PLANT PHYSIOL, V96, P1220; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BUVINGER WE, 1989, J BIOL CHEM, V264, P1195; Cantor, 1980, BIOPHYS CHEM; CLARK SE, 1989, J BIOL CHEM, V264, P17544; CLARK SE, 1991, J CELL BIOL, V114, P681, DOI 10.1083/jcb.114.4.681; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1985, J BIOL CHEM, V260, P3691; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PICK U, 1982, METHODS CHLOROPLAST, P873; PILON M, 1990, J BIOL CHEM, V265, P3358; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1991, J BIOL CHEM, V266, P3335; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W	25	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14328	14334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629223				2022-12-27	WOS:A1992JD32500083
J	YANAGAWA, H; OGAWA, Y; UENO, M				YANAGAWA, H; OGAWA, Y; UENO, M			REDOX RIBONUCLEOSIDES - ISOLATION AND CHARACTERIZATION OF 5-HYDROXYURIDINE, 8-HYDROXYGUANOSINE, AND 8-HYDROXYADENOSINE FROM TORULA YEAST RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; OXYGEN RADICALS; DNA; EVOLUTION; ORIGIN; DAMAGE; LIFE; CATALYSIS; RADIATION; REPAIR	Three hydroxyribonucleosides catalyzing the oxido-reduction of NADH and K3Fe(CN)6 were purified from Torula yeast RNA by a series of steps including sodium dodecyl sulfate/phenol extraction, nuclease P1 digestion, alkaline phosphatase digestion, anion-exchange chromatography, and high performance liquid chromatography on an ODS column. Analysis by fast atom bombardment-mass spectrometry and H-1 and C-13 NMR spectroscopy led to identification of the redox ribonucleosides as 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine. Their mass spectra, chromatographic behavior, UV spectra, NMR spectra, and IR spectra were identical to those from natural and synthetic sources. Oxidoreduction activities were specific for K3Fe(CN)6 as the oxidant and NADH as the reductant; and their magnitudes decreased in the order 5-hydroxycytidine, 5-hydroxyuridine, 8-hydroxyguanosine, and 8-hydroxyadenosine. The fact that these nucleosides have redox activities suggests new functional roles for RNAs as catalysts.	TOHOKU UNIV,FAC SCI,CTR INSTRUMENTAL ANAL,SENDAI,MIYAGI 980,JAPAN	Tohoku University	YANAGAWA, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BECK MT, 1977, NATURWISSENSCHAFTEN, V64, P91, DOI 10.1007/BF00437354; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CHILDERSPETERSON T, 1987, ANAL CHIM ACTA, V202, P167, DOI 10.1016/S0003-2670(00)85912-7; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; CUTLER RG, 1985, P NATL ACAD SCI USA, V82, P4798, DOI 10.1073/pnas.82.14.4798; DAVIES DB, 1974, BIOCHEMISTRY-US, V13, P4417, DOI 10.1021/bi00718a027; DIZDAROGLU M, 1985, ANAL BIOCHEM, V144, P593, DOI 10.1016/0003-2697(85)90158-7; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; EGAMI F, 1974, J MOL EVOL, V4, P113, DOI 10.1007/BF01732017; FIALA ES, 1989, CANCER RES, V49, P5518; FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HAJDU J, 1977, BIOCHEMISTRY-US, V16, P2841, DOI 10.1021/bi00632a006; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARTMAN H, 1975, J MOL EVOL, V4, P359, DOI 10.1007/BF01732537; IKEHARA M, 1968, CHEM PHARM BULL, V16, P1330; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAMALUDDIN MS, 1986, ORIGINS LIFE EVOL B, V17, P59, DOI 10.1007/BF01809813; KAPLAN F, 1969, ARCH BIOCHEM BIOPHYS, V132, P91, DOI 10.1016/0003-9861(69)90340-3; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASAI H, 1984, JPN J CANCER RES, V75, P1037; LIS AW, 1966, ARCH BIOCHEM BIOPHYS, V114, P593, DOI 10.1016/0003-9861(66)90384-5; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; Michaelis L, 1938, CHEM REV, V22, P437, DOI 10.1021/cr60073a003; OREILLY JE, 1973, BIOCHIM BIOPHYS ACTA, V292, P509, DOI 10.1016/0005-2728(73)90001-7; Orgel L. E., 1974, ORIGIN LIFE EVOLUTIO, P369; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; RODKEY FL, 1955, J BIOL CHEM, V213, P777; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; UHL W, 1983, NUCLEIC ACIDS RES, V11, P1167, DOI 10.1093/nar/11.4.1167; VISSER W, 1968, SYNTHETIC PROCEDURES, V1, P428; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; YAMANO T, 1964, ARCH BIOCHEM BIOPHYS, V106, P360, DOI 10.1016/0003-9861(64)90201-2; YANAGAWA H, 1990, BIOCHEMISTRY-US, V29, P10585, DOI 10.1021/bi00499a002	39	115	115	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13320	13326						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618833				2022-12-27	WOS:A1992JB74600038
J	AKAKI, Y; HOTTA, Y; MASHIMA, Y; MURAKAMI, A; KENNAWAY, NG; WELEBER, RG; INANA, G				AKAKI, Y; HOTTA, Y; MASHIMA, Y; MURAKAMI, A; KENNAWAY, NG; WELEBER, RG; INANA, G			A DELETION IN THE ORNITHINE AMINOTRANSFERASE GENE IN GYRATE ATROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DELTA-AMINOTRANSFERASE; NONSENSE MUTATIONS; THALASSEMIA GENE; RETINA; FAMILY; DEFECT; DNA; BREAKPOINTS; DEFICIENCY	Gyrate atrophy (GA) is an autosomal recessive chorioretinal degenerative disease of the eye caused by an inborn defect of the nuclear encoded mitochondrial enzyme ornithine aminotransferase (OAT). We have described previously a GA patient with a 5.0-kilobase pair truncated EcoRI OAT gene fragment and the absence of OAT mRNA on Northern blot analysis. Cloning and sequencing analysis of the truncated gene fragment revealed a 1,072-base pair (bp) deletion including the entire exon 6, starting in intron 5, 172 bp upstream of exon 6 and ending in intron 6, 772 bp downstream of exon 6. A short direct repeat sequence (AGGAGC), resembling the sequence shown to cause DNA polymerase-alpha to pause, and sequences capable of forming hairpin loops were both present at the 5' and 3' break-points of the deletion. Reverse transcription-polymerase chain reaction amplification of the patient's RNA with OAT primers yielded DNA fragments of two different sizes, consistent with a low level expression of OAT mRNA. Direct sequencing of the smaller fragment demonstrated the complete absence of exon 6 sequence in the mRNA predicted from the deletion, causing a reading frame shift which results in a premature termination codon at position 192. The mutation in the other allele has been demonstrated by polymerase chain reaction, denaturing gradient gel electrophoresis, and direct sequencing also to be a premature termination codon in exon 6. The absence of detectable OAT mRNA in this patient is consistent with these premature termination mutations because they have been shown to decrease the level of mRNA, especially if present early in the coding sequence.	UNIV MIAMI, SCH MED, BASCOM PALMER EYE INST, 1638 NW 10TH AVE, MIAMI, FL 33136 USA; OREGON HLTH SCI UNIV, DEPT OPHTHALMOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT MOLEC & MED GENET, PORTLAND, OR 97201 USA	Bascom Palmer Eye Institute; University of Miami; Oregon Health & Science University; Oregon Health & Science University			Hotta, Yoshihiro/O-5115-2019	Hotta, Yoshihiro/0000-0003-4052-5066	NATIONAL EYE INSTITUTE [R01EY008904] Funding Source: NIH RePORTER; NEI NIH HHS [EY08904] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; ANAND R, 1988, BLOOD, V72, P636; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHALLBERG MD, 1979, J BIOL CHEM, V254, P7820; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; HENTHORN PS, 1990, GENOMICS, V6, P226, DOI 10.1016/0888-7543(90)90561-8; HOTTA Y, 1989, AM J HUM GENET, V44, P353; HUMPHRIES RK, 1984, BLOOD, V64, P23; INANA G, 1988, INVEST OPHTH VIS SCI, V29, P1001; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; INANA G, 1989, J BIOL CHEM, V264, P17432; INANA G, 1983, NATURE, V302, P310, DOI 10.1038/302310a0; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KENNAWAY NG, 1989, AM J HUM GENET, V44, P344; MCCLATCHEY AI, 1990, AM J HUM GENET, V47, P790; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; RAMESH V, 1988, P NATL ACAD SCI USA, V85, P3777, DOI 10.1073/pnas.85.11.3777; SPRITZ RA, 1982, NUCLEIC ACIDS RES, V10, P8025, DOI 10.1093/nar/10.24.8025; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAKKI KK, 1981, OPHTHALMOLOGY, V88, P292; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VALLE D, 1989, METABOLIC BASIS INHE, P599; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; WEAVER DT, 1982, J BIOL CHEM, V257, P2075; WELEBER RG, 1982, BIRTH DEFECTS-ORIG, V18, P219; WELEBER RG, 1988, RETINITIS PIGMENTOSA, P198; ZINTZ CB, 1990, EXP EYE RES, V50, P759, DOI 10.1016/0014-4835(90)90126-F	33	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12950	12954						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618792				2022-12-27	WOS:A1992HZ48300083
J	LUND, E; DICZFALUSY, U; BJORKHEM, I				LUND, E; DICZFALUSY, U; BJORKHEM, I			ON THE MECHANISM OF OXIDATION OF CHOLESTEROL AT C-7 IN A LIPOXYGENASE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPE; ACID	Incubation of [7-H-2(2)]cholesterol with soybean lipoxygenase and linoleic acid in the presence of oxygen gave a mixture of 5-cholestene-3-beta,7-alpha-diol, 5-cholestene-3-beta, 7-beta-diol, 3-beta-hydroxy-5-cholesten-7-one,5-alpha,6-alpha-epoxy-cholestan-3-beta-ol, and 5-beta,6-beta-epoxycholestan-3-beta-ol. The conversion into the 7-oxygenated products was associated with a very high intermolecular isotope effect (K(H)/K(D) = 15-17), suggesting that the rate-limiting step in the overall conversion is likely to be the abstraction of hydrogen at C-7 in a radical reaction. Evidence that linoleic acid is to some extent directly involved was obtained with the use of [7-H-3]cholesterol. Incubation of [7-H-3]cholesterol resulted in a significant incorporation of H-3 in the reisolated linoleic acid fraction. The isotope effect associated with conversion of [7-alpha-H-2]cholesterol into 7-oxygenated products in the lipoxygenase system was 2-3, indicating that the extraction of hydrogen is nonstereospecific. Incubation of [7-H-2(2)]cholesterol with 13-hydroperoxy-9,11-octadecadienoic acid gave the above 7-oxygenated products with relatively small isotope effects (K(H)/K(D) = 3-4). It is concluded that the most important mechanism for oxidation of cholesterol at C-7 in the lipoxygenase system involves participation of radicals and that a carbon-centered linoleic acid radical can extract hydrogen directly from cholesterol. Fatty acid hydroperoxides and their secondary products seem to be less important as initiators in connection with oxidation of cholesterol.	KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet			Diczfalusy, Ulf/A-5336-2008	Bjorkhem, Ingemar/0000-0001-6087-9190; Bjorkhem, Ingemar/0000-0002-0575-9425				ARINGER L, 1980, LIPIDS, V15, P563, DOI 10.1007/BF02534180; BIEMANN K, 1966, MASS SPECTROMETRY OR, P204; BJORKHEM I, 1988, J LIPID RES, V29, P136; BJORKHEM I, 1971, EUR J BIOCHEM, V18, P299; COREY EJ, 1958, J AM CHEM SOC, V81, P3127; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; GIROTTI AW, 1985, FREE RAD BIOL, V5, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1984, BIOCHIM BIOPHYS ACTA, V793, P129, DOI 10.1016/0005-2760(84)90062-6; JOHANSSON G, 1971, EUR J BIOCHEM, V21, P68, DOI 10.1111/j.1432-1033.1971.tb01441.x; KALUZNY MA, 1985, J LIPID RES, V26, P135; MAKITA A, 1973, ANAL BIOCHEM, V5, P523; MELANDER L, 1960, ISOTOPE EFFECTS REAC, P65; NORTHROP DB, 1981, ANNU REV BIOCHEM, V50, P103, DOI 10.1146/annurev.bi.50.070181.000535; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46; SMITH LL, 1981, CHOLESTEROL AUTOOXID, P214; TENG JI, 1973, J AM CHEM SOC, V95, P4060, DOI 10.1021/ja00793a045; TENG JI, 1976, BIOORG CHEM, V5, P99, DOI 10.1016/0045-2068(76)90017-1	20	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12462	12467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618753				2022-12-27	WOS:A1992HZ48300016
J	REN, SL; SCARSDALE, JN; ARIGA, T; ZHANG, YJ; KLEIN, RA; HARTMANN, R; KUSHI, Y; EGGE, H; YU, RK				REN, SL; SCARSDALE, JN; ARIGA, T; ZHANG, YJ; KLEIN, RA; HARTMANN, R; KUSHI, Y; EGGE, H; YU, RK			O-ACETYLATED GANGLIOSIDES IN BOVINE BUTTERMILK - CHARACTERIZATION OF 7-O-ACETYL, 9-O-ACETYL, AND 7,9-DI-O-ACETYL G(D3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA-ASSOCIATED GANGLIOSIDE; FAT GLOBULE-MEMBRANE; GERMINAL CELLS; PROTON NMR; ANTIBODY; MILK; ANTIGENS; RAT; DETERMINANT; ACID	Three O-acetylated gangliosides, G1, G2, and G3, were purified from bovine buttermilk by using chloroform/methanol methanol extraction, Folch partitioning, chromatography on DEAE-Sephadex A-25, and Iatrobeads columns. The final yields of gangliosides G1, G2, and G3 were 2 mg, 37 mg, and 40 mg per 1.7 kg of the buttermilk powder, respectively. On the basis of immunostaining on high performance thin layer chromatography with specific monoclonal antibodies, mild alkaline treatment, gas-liquid chromatographic analysis, fast atom bombardment mass spectrometry, and proton nuclear magnetic resonance studies, G1 and G2 are characterized as O-acetylated G(D3) and G3 as O-acetylated G(T3), and the structures of these gangliosides are as follows: [GRAPHICS] The major fatty acids of these gangliosides were C18:0, C22:0, C23:0, and C24:0, and the long chain base was C18-sphingosine.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOCHEM & MOLEC BIOPHYS,RICHMOND,VA 23298; TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN; UNIV BONN,INST PHYSIOL CHEM,W-5300 BONN,GERMANY	Virginia Commonwealth University; Tokyo Medical & Dental University (TMDU); University of Bonn			Hartmann, Rudolf/H-9345-2017	Hartmann, Rudolf/0000-0001-7807-6273	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011853, R01NS023102, R01NS026994] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11853, NS 26994, NS-23102] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO S, 1989, J BIOL CHEM, V264, P3478; ARIGA T, 1988, BIOCHEMISTRY-US, V27, P52, DOI 10.1021/bi00401a010; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BONAFEDE DM, 1989, LIPIDS, V24, P680, DOI 10.1007/BF02535204; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; FOLCH J, 1957, J BIOL CHEM, V226, P139; HIRABAYASHI Y, 1989, NEUROSCI LETT, V106, P193, DOI 10.1016/0304-3940(89)90225-5; HUANG RTC, 1973, BIOCHIM BIOPHYS ACTA, V306, P82, DOI 10.1016/0005-2760(73)90211-7; KASAI N, 1983, BRAIN RES, V277, P155, DOI 10.1016/0006-8993(83)90918-6; KASAI N, 1984, J BIOCHEM-TOKYO, V96, P261, DOI 10.1093/oxfordjournals.jbchem.a134821; KEENAN TW, 1974, BIOCHIM BIOPHYS ACTA, V337, P255, DOI 10.1016/0005-2760(74)90207-0; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEVINE JM, 1984, J NEUROSCI, V4, P820; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; MCPHERSON AV, 1983, J DAIRY RES, V50, P107, DOI 10.1017/S0022029900032581; MENDEZOTERO R, 1988, J NEUROSCI, V8, P564; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; OSTRANDER GK, 1991, ARCH BIOCHEM BIOPHYS, V284, P413, DOI 10.1016/0003-9861(91)90317-C; PATTON S, 1975, BIOCHIM BIOPHYS ACTA, V415, P273, DOI 10.1016/0304-4157(75)90011-8; RAVINDRANATHS MH, 1988, J BIOL CHEM, V263, P2079; REID PE, 1984, HISTOCHEM J, V16, P235, DOI 10.1007/BF01003608; REN S, 1989, CANCER RES, V49, P7051; RITTER G, 1990, CANCER RES, V50, P1403; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; Rosenberg Abraham, 1976, BIOL ROLES SIALIC AC; SCHAUER R, 1982, CELL BIOL MONOGR, V10, P32; SCHLOSSHAUER B, 1988, J NEUROSCI, V8, P580; SPARROW JR, 1988, J NEUROSCI, V8, P580; STALLCUP WB, 1989, DEV BIOL, V132, P212, DOI 10.1016/0012-1606(89)90218-2; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKAMIZAWA K, 1986, J BIOL CHEM, V261, P5625; THURIN J, 1985, J BIOL CHEM, V260, P4556; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; YU RK, 1986, CHEM PHYS LIPIDS, V42, P27, DOI 10.1016/0009-3084(86)90041-1; 1978, BIOCHEM J, V171, P21	41	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12632	12638						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618769				2022-12-27	WOS:A1992HZ48300041
J	REMACHA, M; SANTOS, C; BERMEJO, B; NARANDA, T; BALLESTA, JPG				REMACHA, M; SANTOS, C; BERMEJO, B; NARANDA, T; BALLESTA, JPG			STABLE BINDING OF THE EUKARYOTIC ACIDIC PHOSPHOPROTEINS TO THE RIBOSOME IS NOT AN ABSOLUTE REQUIREMENT FOR INVIVO PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; IMMUNE ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; LARGE SUBUNIT; ARTEMIA-SALINA; 60S RIBOSOMES; RAT-LIVER; GENES; TRANSFORMATION; FAMILY	The genes encoding the four acidic ribosomal phosphoproteins have been inactivated in Saccharomyces cerevisae by recombination with truncated genes carrying different genetic markers. By crossing single haploid disruptants, strains harboring two simultanously inactivated acidic protein genes were constructed. None of the six possible double disruptions was lethal, but the simultaneous inactivation of either YP1-alpha and YP1-beta(L44') or YP2-alpha(L44) and YP2-beta(L45) caused an important decrease in the cell growth rate. Ribosomes isolated from these slow-growing strains did not contain acidic proteins, not even the two polypeptides whose genes were still intact, although these proteins were present in the cell extracts and they seem to be able to form high-molecular weight protein complexes. Transformation of a slow-growing double transformant with a plasmid containing one of the disrupted genes restored the presence of the acidic proteins in the ribosomes and normal growth rates. The particles of the slow-growing strains were active in an in vitro amino acid polymerizing system, although their activity could be stimulated by the exogenous addition of the missing proteins. These results indicate that in the absence of either YP1-alpha and YP1-beta(L44') or YP2-alpha(L44) and YP2-beta(L45), the remaining acidic proteins are unable to interact with the ribosome in a stable manner, but that a strong interaction of these ribosomal components with the particle is not an absolute requirement for in vivo and in vitro protein synthesis.	UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN	Autonomous University of Madrid	REMACHA, M (corresponding author), CSIC,CTR BIOL MOLEC,MADRID 6,SPAIN.		Remacha, Miguel/G-1250-2016; Santos, Cruz/ABG-3054-2020	Santos, Cruz/0000-0001-5164-5050				BELTRAME M, 1990, MOL CELL BIOL, V10, P2341, DOI 10.1128/MCB.10.5.2341; BERNABEU C, 1976, EUR J BIOCHEM, V69, P233, DOI 10.1111/j.1432-1033.1976.tb10878.x; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUANVIDALES F, 1984, BIOCHEMISTRY-US, V23, P390; KOTELIANSKY VE, 1978, EUR J BIOCHEM, V90, P319, DOI 10.1111/j.1432-1033.1978.tb12607.x; LAVERGNE JP, 1987, FEBS LETT, V216, P83, DOI 10.1016/0014-5793(87)80761-5; MAASSEN JA, 1981, BIOCHEMISTRY-US, V20, P1020, DOI 10.1021/bi00507a057; MARQUIS DM, 1981, J MOL BIOL, V150, P121, DOI 10.1016/0022-2836(81)90327-2; MCCONNELL WP, 1982, J BIOL CHEM, V257, P5359; MITSUI K, 1989, BIOCHEM BIOPH RES CO, V161, P1001, DOI 10.1016/0006-291X(89)91342-9; MITSUI K, 1988, J BIOCHEM-TOKYO, V104, P908, DOI 10.1093/oxfordjournals.jbchem.a122581; MITSUI K, 1988, NUCLEIC ACIDS RES, V16, P3574, DOI 10.1093/nar/16.8.3574; MOLLER W, 1975, P NATL ACAD SCI USA, V72, P4744, DOI 10.1073/pnas.72.12.4744; Moller W., 1986, STRUCTURE FUNCTION G, P309; NARANDA T, 1991, P NATL ACAD SCI USA, V88, P10563, DOI 10.1073/pnas.88.23.10563; NEWTON CH, 1990, J BACTERIOL, V172, P579, DOI 10.1128/jb.172.2.579-588.1990; OLSON HM, 1986, J BIOL CHEM, V261, P6924; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; REMACHA M, 1990, MOL CELL BIOL, V10, P2182, DOI 10.1128/MCB.10.5.2182; REMACHA M, 1988, J BIOL CHEM, V263, P9094; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAENZROBLES MT, 1990, BIOCHIM BIOPHYS ACTA, V1050, P51, DOI 10.1016/0167-4781(90)90140-W; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZMADRID F, 1979, EUR J BIOCHEM, V98, P409, DOI 10.1111/j.1432-1033.1979.tb13200.x; SANCHEZMADRID F, 1981, BIOCHEMISTRY-US, V20, P3263, DOI 10.1021/bi00514a043; SANCHEZMADRID F, 1981, EUR J BIOCHEM, V114, P609, DOI 10.1111/j.1432-1033.1981.tb05187.x; Sherman F., 1983, METHODS YEAST GENETI; SHIMMIN LC, 1989, J MOL EVOL, V29, P448, DOI 10.1007/BF02602915; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; VANAGTHOVEN A, 1978, EUR J BIOCHEM, V91, P553; VANAGTHOVEN AJ, 1977, BIOCHEM BIOPH RES CO, V77, P989, DOI 10.1016/S0006-291X(77)80075-2; VILELLA MD, 1991, EUR J BIOCHEM, V196, P407, DOI 10.1111/j.1432-1033.1991.tb15831.x; WOOL IG, 1991, BIOCHIMIE, V73, P861, DOI 10.1016/0300-9084(91)90127-M; WOOL IG, 1974, RIBOSOMES, P417; ZINKER S, 1980, BIOCHIM BIOPHYS ACTA, V606, P76, DOI 10.1016/0005-2787(80)90099-4; ZINKER S, 1976, J BIOL CHEM, V251, P1799	41	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12061	12067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601875				2022-12-27	WOS:A1992HY94700064
J	SEN, AC; WALSH, MT; CHAKRABARTI, B				SEN, AC; WALSH, MT; CHAKRABARTI, B			AN INSIGHT INTO DOMAIN-STRUCTURES AND THERMAL-STABILITY OF GAMMA-CRYSTALLINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; BOVINE LENS CRYSTALLINS; X-RAY-ANALYSIS; EYE-LENS; MAMMALIAN LENS; II-CRYSTALLIN; PROTEINS; DENATURATION; CATARACT; THERMODYNAMICS	The thermal behavior of gamma-II, gamma-IIIA, gamma-IIIB, and gamma-IVA crystallin, from calorimetric and spectral studies, has been analyzed in terms of selective unfolding of domains, interdomain interactions, conformational stability, and the existence of intermediates in the order-disorder transition equilibrium. The major endothermic transition (T(m)) observed calorimetrically for all four fractions occurs between 67 and 78-degrees-C, with enthalpy change (DELTA-H) from 80 to 150 kcal/mol, values that agree reasonably well with those from spectroscopic measurements. Gamma-II and gamma-IIIB show a second thermal event at T < T(m) whereas gamma-IIIA and gamma-IVA showed no additional transition. Urea-induced equilibrium unfolding of gamma-II at acidic pH, unlike gamma-IVA, is biphasic as monitored by CD and fluorescence, indicating the existence of an intermediate. The absence of a cooperative transition in gamma-IVA in acidic urea and the appearance of a single endotherm in differential scanning calorimetry at low pH have been attributed to a structured intermediate that melts at low temperature. The difference in the folding/unfolding of gamma-II and gamma-IVA has been explained by subtle differences in the packing arrangement of their two domains and interactions between them. Thermal aggregation of gamma-crystallins could be prevented either by preincubation with ionic detergents or at low pH or in the presence of chemical denaturant, indicating that the protein surface charge and solvent polarity influence their stability. An increase in the 8-anilino-1-naphthalenesulfonate-bound fluorescence during heat denaturation also suggests that the thermal aggregation is governed by hydrophobic interactions.	EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Harvard University; Harvard Medical School; Boston University; Boston University					NEI NIH HHS [EY04161] Funding Source: Medline; NHLBI NIH HHS [HL26335] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDLEY UP, 1982, BIOCHEMISTRY-US, V21, P1853, DOI 10.1021/bi00537a023; AUGUSTEYN RC, 1981, MECHANISMS CATARACT, P71; BESSEMS GJH, 1983, EXP EYE RES, V37, P627, DOI 10.1016/0014-4835(83)90137-9; BJORK I, 1964, EXP EYE RES, V3, P254, DOI 10.1016/S0014-4835(64)80018-X; BLOEMENDAL H, 1982, CRC CR REV BIOCH MOL, V12, P1, DOI 10.3109/10409238209105849; BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; BROIDE ML, 1991, P NATL ACAD SCI USA, V88, P5660, DOI 10.1073/pnas.88.13.5660; CHIRGADZE YN, 1986, DOKL AKAD NAUK SSSR, V209, P492; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DRENTH J, 1970, PHILOS T R SOC B, V257, P231, DOI 10.1098/rstb.1970.0022; GERNER WH, 1981, BIOCHEM BIOPH RES CO, V98, P439; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; JACKSON WM, 1970, BIOCHEMISTRY-US, V9, P2294, DOI 10.1021/bi00813a011; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JONES MN, 1973, BIOCHEM J, V135, P231, DOI 10.1042/bj1350231; KONO M, 1988, PHOTOCHEM PHOTOBIOL, V47, P593, DOI 10.1111/j.1751-1097.1988.tb08849.x; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MACH H, 1990, J BIOL CHEM, V265, P4844; MANDAL K, 1985, BIOCHIM BIOPHYS ACTA, V832, P156, DOI 10.1016/0167-4838(85)90327-9; MANDAL K, 1987, BIOCHIM BIOPHYS ACTA, V911, P277, DOI 10.1016/0167-4838(87)90068-9; MANDAL K, 1987, J BIOL CHEM, V262, P8096; MANDAL K, 1988, PHOTOCHEM PHOTOBIOL, V47, P583, DOI 10.1111/j.1751-1097.1988.tb08848.x; MANDAL K, 1988, BIOCHEMISTRY-US, V27, P4564, DOI 10.1021/bi00412a051; NELSON CA, 1971, J BIOL CHEM, V246, P3895; PANDE A, 1987, INVEST OPHTH VIS SCI, V30, P266; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RUDOLPH R, 1990, P NATL ACAD SCI USA, V87, P4625, DOI 10.1073/pnas.87.12.4625; SHOENMAKERS JGG, 1984, CIBA F S, V106, P208; SHRIVER JW, 1990, BIOCHEMISTRY-US, V29, P2556, DOI 10.1021/bi00462a018; SIEZEN RJ, 1985, P NATL ACAD SCI USA, V82, P1701, DOI 10.1073/pnas.82.6.1701; SLINGSBY C, 1983, EXP EYE RES, V37, P517, DOI 10.1016/0014-4835(83)90028-3; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TIKTOPULO EI, 1978, FEBS LETT, V91, P57, DOI 10.1016/0014-5793(78)80016-7; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WALSH MT, 1990, J LIPID RES, V31, P1051; WHITE HE, 1989, J MOL BIOL, V207, P217, DOI 10.1016/0022-2836(89)90452-X; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	41	21	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11898	11907						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601859				2022-12-27	WOS:A1992HY94700040
J	CARROLL, J; SWANN, K				CARROLL, J; SWANN, K			SPONTANEOUS CYTOSOLIC CALCIUM OSCILLATIONS DRIVEN BY INOSITOL TRISPHOSPHATE OCCUR DURING INVITRO MATURATION OF MOUSE OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL VESICLE BREAKDOWN; PROTEIN KINASE-C; INTRACELLULAR CALCIUM; MAMMALIAN OOCYTES; HAMSTER EGGS; CELL-CYCLE; CA-2+; FERTILIZATION; RELEASE; ACTIVATION	Immature mouse oocytes undergo spontaneous meiotic maturation when released from antral follicles into culture media. The first sign of meiotic resumption is germinal vesicle breakdown (GVB). Cytosolic free Ca2+ was measured in mouse oocytes during spontaneous maturation by monitoring fluorescence of indo-1 or fluo-3. The majority of oocytes showed a series of Ca2+ oscillations that continued for 1-3 h. Repetitive Ca2+ increases occurred every 1-3 min and lasted for 10-60 s. The Ca2+ oscillations appeared to be caused by an increase in inositol 1,4,5-trisphosphate (InsP3) because once they ceased, similar oscillations were triggered by injection of exogenous InsP3. Also, injection of the InsP3 receptor antagonist heparin (final concentration, 100-mu-g/ml) blocked the spontaneous Ca2+ oscillations. In contrast, Ca2+ oscillations induced by thimerosal were not inhibited by heparin. Treating oocytes with media containing 20-mu-M BAPTA/AM abolished Ca2+ oscillations in oocytes but did not affect the rate of GVB. The data show that cytosolic Ca2+ oscillations apparently caused by polyphosphoinositide turnover occur during mammalian oocyte maturation. However, the spontaneous oscillations do not appear to trigger GVB. Also, the data indicate that there are two separate Ca2+ release mechanisms in mouse oocytes, one sensitive to InsP3, the other to thimerosal.			CARROLL, J (corresponding author), ST GEORGE HOSP,SCH MED,MRC,EXPTL EMBRYOL & TERATOL UNIT,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Carroll, John/0000-0001-9644-5861; Swann, Karl/0000-0002-4355-1449				ALBERTINI DF, 1987, DEV BIOL, V120, P121, DOI 10.1016/0012-1606(87)90110-2; ANDERSON E, 1976, J CELL BIOL, V71, P680, DOI 10.1083/jcb.71.2.680; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BORNSLAEGER EA, 1986, EXP CELL RES, V165, P507, DOI 10.1016/0014-4827(86)90603-8; CHO WK, 1974, J EXP ZOOL, V187, P383, DOI 10.1002/jez.1401870307; CICIRELLI MF, 1987, DEV BIOL, V121, P48, DOI 10.1016/0012-1606(87)90137-0; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DEFELICI M, 1982, DEV BIOL, V92, P539, DOI 10.1016/0012-1606(82)90198-1; EDWARDS RG, 1965, NATURE, V208, P349, DOI 10.1038/208349a0; EUSEBI F, 1979, NATURE, V277, P651, DOI 10.1038/277651a0; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLL RW, 1988, J BIOL CHEM, V263, P9682; HOMA ST, 1991, DEV BIOL, V146, P461, DOI 10.1016/0012-1606(91)90247-Z; HOMA ST, 1991, J EXP ZOOL, V258, P95, DOI 10.1002/jez.1402580111; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; JACONI MEE, 1988, J BIOL CHEM, V263, P10557; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1991, CELL CALCIUM, V12, P205, DOI 10.1016/0143-4160(91)90021-6; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1988, DEV GROWTH DIFFER, V30, P603; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; PERES A, 1991, CELL CALCIUM, V12, P457, DOI 10.1016/0143-4160(91)90028-D; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; Pincus G, 1935, J EXP MED, V62, P665, DOI 10.1084/jem.62.5.665; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; POWERS RD, 1982, J REPROD FERTIL, V66, P1, DOI 10.1530/jrf.0.0660001; RACOWSKY C, 1986, J EXP ZOOL, V239, P263, DOI 10.1002/jez.1402390214; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; SCHROEDER AC, 1984, DEV BIOL, V102, P493, DOI 10.1016/0012-1606(84)90215-X; SCHULTZ RM, 1988, MEIOTIC INHIBITION M, P137; SMITH LD, 1989, DEVELOPMENT, V107, P685; STAIGMILLER RB, 1984, GAMETE RES, V9, P221, DOI 10.1002/mrd.1120090211; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; SWANN K, 1990, DEVELOPMENT, V110, P1295; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKUWA Y, 1986, J BIOL CHEM, V261, P4670; THIBAULT C, 1977, J REPROD FERTIL, V51, P1; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; URNER F, 1984, EXP CELL RES, V154, P600, DOI 10.1016/0014-4827(84)90184-8; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Whittingham D.G., 1980, Oxford Reviews of Reproductive Biology, V2, P205; WITCHEL HJ, 1990, DEV BIOL, V141, P393, DOI 10.1016/0012-1606(90)90393-W	54	173	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11196	11201						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597455				2022-12-27	WOS:A1992HX16900043
J	LIM, HM; HUGHES, KT; SIMON, MI				LIM, HM; HUGHES, KT; SIMON, MI			THE EFFECTS OF SYMMETRICAL RECOMBINATION SITE HIXC ON HIN RECOMBINASE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-DELTA-RESOLVASE; DNA INVERSION; CROSSOVER POINT; STRAND EXCHANGE; SUPERCOILED DNA; PHASE VARIATION; ENHANCER; PROTEIN; BINDING; INVIVO	An artificial recombination site hixC composed of two identical half-sites that bind the Hin recombinase served as a better operator in vivo than the wild type site hixL (Hughes, K. T., Youderian, P., and Simon, M. I (1988) Genes & Dev. 2, 937-948). In vitro binding assays such as gel retardation assay and methylation protection assay demonstrated that Hin binds to hixC as tightly as it binds to hixL, even when the sites are located in negatively supercoiled plasmids. However, hixC served as a poor recombination site when it was subjected to the standard inversion assay in vitro. hixC showed a 16-fold slower inversion rate than the wild type. A series of biochemical assays designed to probe different stages of the Hin-mediated inversion reaction, demonstrated that Hin dimers bound to hixC have difficulty in forming paired hix site intermediates. KMnO4 and S1 nuclease assays detected an anomalous structure of the center of hixC only when the site was in negatively supercoiled plasmids. Mutational analysis in the central region of hixC and assays of paired hix site formation with topoisomers of the hixC substrate plasmid suggested that Hin is not able to pair hixC sites because of the presence of the anomalous structure in the center of the site. The structure does not behave like a DNA "cruciform" since Hin dimers still bind efficiently to the site. It is thought to consist of a short denatured "bubble" encompassing 2 base pairs. During the study of mutations in the center of hixC, it was found that Hin is not able to cleave DNA if a guanine residue is one of the two central nucleotides close to the cleavage site. Furthermore, Hin acts in a concerted fashion and cannot cleave any DNA strand if one of the four strands in the inversion intermediate is not cleavable.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	California Institute of Technology; University of Washington; University of Washington Seattle				Lim, Heon/0000-0003-1711-2589				AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWIEC JA, 1987, J MOL BIOL, V196, P101; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; BRUIST MF, 1984, J BACTERIOL, V159, P71, DOI 10.1128/JB.159.1.71-79.1984; FALVEY E, 1988, NATURE, V332, P861, DOI 10.1038/332861a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES KT, 1988, GENE DEV, V2, P937, DOI 10.1101/gad.2.8.937; HUGHES KT, 1992, IN PRESS EMBO J; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; Lilley D.M.J., 1988, UNUSUAL DNA STRUCTUR, P55, DOI 10.1007/978-1-4612-3800-3_4; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; LIM HM, 1992, J BIOL CHEM, V267, P11176; MERTENS G, 1988, EMBO J, V7, P1219, DOI 10.1002/j.1460-2075.1988.tb02934.x; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; MURCHIE AIH, 1987, NUCLEIC ACIDS RES, V15, P9641, DOI 10.1093/nar/15.23.9641; RICHET E, 1986, CELL, V46, P1011, DOI 10.1016/0092-8674(86)90700-2; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; ZIEG J, 1977, SCIENCE, V196, P170, DOI 10.1126/science.322276; ZIEG J, 1980, P NATL ACAD SCI-BIOL, V77, P4196, DOI 10.1073/pnas.77.7.4196	36	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11183	11190						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597453				2022-12-27	WOS:A1992HX16900041
J	MARSHALL, BC; XU, QP; RAO, NV; BROWN, BR; HOIDAL, JR				MARSHALL, BC; XU, QP; RAO, NV; BROWN, BR; HOIDAL, JR			PULMONARY EPITHELIAL-CELL UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - INDUCTION BY INTERLEUKIN-1-BETA AND TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; RESPIRATORY-DISTRESS SYNDROME; PHORBOL-MYRISTATE ACETATE; HUMAN-LUNG CARCINOMA; SMOOTH-MUSCLE CELLS; GENE-EXPRESSION; ENDOTHELIAL-CELLS; TISSUE-TYPE; SIGNAL TRANSDUCTION	Diffuse alveolar damage, presenting clinically as adult respiratory distress syndrome, is characterized initially by widespread intra-alveolar fibrin deposition. Alveolar epithelial cells play a central role in the subsequent repair process. We have recently shown that alveolar epithelial cells have the capacity to promote fibrinolysis (Marshall, B. C., Sageser, D. S., Rao, N. V., Emi, M., and Hoidal, J. R. (1990) J. Biol. Chem. 265, 8198-8204) and may therefore directly participate in the extensive remodeling that follows acute lung injury. Because the tissue repair process occurs in an acute inflammatory setting, we investigated the effects of inflammatory mediators on urokinase-type plasminogen activator (u-PA) expression by pulmonary epithelial cells. We found that interleukin-1-beta (IL-1-beta) and tumor necrosis factor-alpha (TNF-alpha) upregulated PA activity in A549 human pulmonary epithelial cells. Biosynthetic labeling and immunoprecipitation showed that both cytokines caused marked accumulation of newly synthesized u-PA. Northern blot analyses demonstrated that both IL-1-beta and TNF-alpha induced relatively rapid accumulation of u-PA mRNA which did not require de novo protein synthesis and was substantially inhibited by glucocorticoids. Nuclear run-off transcription studies showed that both cytokines caused rapid transcriptional activation of the u-PA gene. While the effects of IL-1-beta and TNF-alpha were qualitatively similar, some differences emerged. Most notably, TNF-alpha led to a more sustained accumulation of u-PA mRNA than did IL-1-beta. In contrast to their effects on u-PA expression, IL-1-beta and TNF-alpha had minimal effect on PA inhibitor-1 expression. These effects of IL-1-beta and TNF-alpha, mediators known to play a key role in acute lung injury and inflammation, may promote lysis of alveolar fibrin by alveolar epithelium, thereby aiding in restoration of normal lung architecture.	UNIV UTAH, MED CTR, DEPT MED, DIV PULM, RM 4R240, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002370] Funding Source: NIH RePORTER; NHLBI NIH HHS [1KO8HL02370] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; ALBERTS WM, 1983, CHEST, V84, P272, DOI 10.1378/chest.84.3.272; ALTUS MS, 1987, BIOCHEM J, V242, P387, DOI 10.1042/bj2420387; ANDREWS HJ, 1990, BIOCHIM BIOPHYS ACTA, V1051, P84, DOI 10.1016/0167-4889(90)90177-F; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERTOZZI P, 1990, NEW ENGL J MED, V322, P890, DOI 10.1056/NEJM199003293221304; BIRD TA, 1989, J IMMUNOL, V142, P126; BLASI F, 1986, J CELL BIOCHEM, V32, P179, DOI 10.1002/jcb.240320303; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSO N, 1986, J BIOL CHEM, V261, P9309; CAMPBELL IK, 1988, BIOCHIM BIOPHYS ACTA, V967, P183, DOI 10.1016/0304-4165(88)90008-6; CHAPMAN HA, 1988, CHEST, V93, P1256, DOI 10.1378/chest.93.6.1256; CHEDID M, 1990, MOL CELL BIOL, V10, P3824, DOI 10.1128/MCB.10.7.3824; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DONATI D, 1990, J IMMUNOL, V145, P4115; ELLIOTT CG, 1981, AM REV RESPIR DIS, V123, P492; EVANS DB, 1990, BIOCHEM BIOPH RES CO, V166, P208, DOI 10.1016/0006-291X(90)91932-I; EVANS MJ, 1973, AM J PATHOL, V70, P175; GARVEY WT, 1989, MOL ENDOCRINOL, V3, P1132, DOI 10.1210/mend-3-7-1132; GERWIN BI, 1990, AM J PHYSIOL, V259, pL262, DOI 10.1152/ajplung.1990.259.4.L262; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; GRANELLIPIPERNO A, 1978, J EXP MED, V148, P223, DOI 10.1084/jem.148.1.223; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; GROSS TJ, 1990, AM J RESP CELL MOL, V3, P449, DOI 10.1165/ajrcmb/3.5.449; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HEATON JH, 1989, MOL ENDOCRINOL, V3, P185, DOI 10.1210/mend-3-1-185; IDELL S, 1989, J CLIN INVEST, V84, P181, DOI 10.1172/JCI114139; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KATZ Y, 1989, J IMMUNOL, V142, P3862; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KEHRER JP, 1984, AM REV RESPIR DIS, V130, P256; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; LANE TA, 1990, BIOCHEM BIOPH RES CO, V172, P1273, DOI 10.1016/0006-291X(90)91587-I; LE JM, 1987, LAB INVEST, V56, P234; LEIZER T, 1989, J IMMUNOL, V143, P971; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LUND LR, 1991, J BIOL CHEM, V266, P5177; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MARSHALL BC, 1990, J BIOL CHEM, V265, P8198; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MOCHAN E, 1986, J RHEUMATOL, V13, P15; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P7669; PICONE R, 1989, J CELL BIOL, V108, P693, DOI 10.1083/jcb.108.2.693; PRATT PC, 1979, AM J PATHOL, V95, P191; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SALONEN EM, 1985, J BIOL CHEM, V260, P2302; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHAPIRO DL, 1978, BIOCHIM BIOPHYS ACTA, V530, P197, DOI 10.1016/0005-2760(78)90005-X; SHIMADA H, 1981, THROMB HAEMOSTASIS, V46, P507; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SMITH LJ, 1981, AM REV RESPIR DIS, V123, P459; SPRENGERS ED, 1987, BLOOD, V69, P381; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; VANHINSBERGH VWM, 1990, BLOOD, V75, P1991; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	76	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11462	11469						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597474				2022-12-27	WOS:A1992HX16900080
J	AUCHINCLOSS, AH; ALEXANDER, A; KOHORN, BD				AUCHINCLOSS, AH; ALEXANDER, A; KOHORN, BD			REQUIREMENT FOR 3 MEMBRANE-SPANNING ALPHA-HELICES IN THE POSTTRANSLATIONAL INSERTION OF A THYLAKOID MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEIN; LIGHT-HARVESTING COMPLEX; CHARGED AMINO-ACIDS; PRECURSOR PROTEIN; TRANSIT PEPTIDE; ESCHERICHIA-COLI; CHLOROPLAST MEMBRANES; BINDING POLYPEPTIDES; POLYACRYLAMIDE GELS; IMPORT	The insertion of a protein into a lipid bilayer usually involves a short signal sequence and can occur either during or after translation. A light-harvesting chlorophyll a/b-binding protein (LHCP) is synthesized in the cytoplasm of plant cells as a precursor and is post-translationally imported into chloroplasts where it subsequently inserts into the thylakoid membrane. Only mature LHCP is required for insertion into the thylakoid. To define which sequences of the mature protein are necessary and sufficient for thylakoid integration, fusion and deletion proteins and proteins with internal rearrangements were synthesized and incubated with isolated thylakoids and stroma. No evidence is found for the existence of a short signal sequence within LHCP, and, with the exception of the amino terminus and a short lumenal loop, the entire mature protein with consecutively ordered alpha-helices is required for insertion into thylakoid membranes. The addition of positive charges into stromal but not lumenal segments permits the insertion of mutant LHCPs into isolated thylakoids. Replacement of the LHCP transit peptide with the transit peptide from plastocyanin has no effect on LHCP insertion and does not restore insertion of the lumenal charge addition mutants.	DUKE UNIV,DEPT BOT,139 BIOL SCI,DURHAM,NC 27706	Duke University				Auchincloss, Andrea/0000-0002-5297-5390	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39696-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUERLE C, 1991, J BIOL CHEM, V266, P5876; BELLEMARE G, 1982, J BIOL CHEM, V257, P7762; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CASHMORE AR, 1984, P NATL ACAD SCI-BIOL, V81, P2960, DOI 10.1073/pnas.81.10.2960; CHUA NH, 1973, P NATL ACAD SCI USA, V70, P1554, DOI 10.1073/pnas.70.5.1554; CLARK SE, 1990, PLANT CELL, V2, P173, DOI 10.1105/tpc.2.2.173; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EVANS MCW, 1991, NATURE, V350, P109, DOI 10.1038/350109a0; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GELLER BL, 1985, J BIOL CHEM, V260, P3281; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P493; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; KARLINNEUMANN GA, 1985, J MOL APPL GENET, V3, P45; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KOHORN BD, 1989, PLANT CELL, V1, P159; KOHORN BD, 1986, J CELL BIOL, V102, P972, DOI 10.1083/jcb.102.3.972; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KOHORN BD, 1987, J BIOL CHEM, V262, P12897; KUHLBRANDT W, 1984, NATURE, V307, P478, DOI 10.1038/307478a0; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1989, J MOL BIOL, V207, P823, DOI 10.1016/0022-2836(89)90247-7; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MULLET JE, 1983, J BIOL CHEM, V258, P9941; MURPHY DJ, 1986, BIOCHIM BIOPHYS ACTA, V864, P33, DOI 10.1016/0304-4157(86)90015-8; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1885; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; VORST O, 1988, GENE, V65, P59, DOI 10.1016/0378-1119(88)90417-9; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; WILLEY DL, 1984, CELL, V36, P555, DOI 10.1016/0092-8674(84)90248-4	58	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10439	10446						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587827				2022-12-27	WOS:A1992HV09000038
J	EVANS, AJ; SAWYEZ, CG; WOLFE, BM; HUFF, MW				EVANS, AJ; SAWYEZ, CG; WOLFE, BM; HUFF, MW			LIPOLYSIS IS A PREREQUISITE FOR LIPID-ACCUMULATION IN HEPG2 CELLS INDUCED BY LARGE HYPERTRIGLYCERIDEMIC VERY LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; MOUSE PERITONEAL-MACROPHAGES; CORONARY-ARTERY DISEASE; HUMAN HEPATOMA HEP-G2; APOLIPOPROTEIN-E; RECEPTOR PATHWAY; HUMAN-PLASMA; CHOLESTEROL-METABOLISM; MONOCLONAL-ANTIBODIES; HUMAN-FIBROBLASTS	Lipoprotein kinetic studies have demonstrated that a large proportion of S(f) 60-400 very low density lipoprotein (VLDL) is cleared directly from the circulation in Type IV hypertriglyceridemic subjects, at an unknown tissue site. The present studies were designed to investigate the role of hepatocytes in this process and to define the conditions, whereby Type IV S(f) 60-400 VLDL would induce lipid accumulation in HepG2 cells. Type IV VLDL (S(f) 60-400) failed to augment the total cholesterol, esterified cholesterol, or triglyceride content of HepG2 cells following 24-h incubations. Coincubation of bovine milk lipoprotein lipase (LPL) and Type IV VLDL with HepG2 cells induced a 3-fold increment in cellular esterified cholesterol mass (p < 0.005) and a 7-fold increase in cellular triglyceride mass (p < 0.005), compared to VLDL alone. The increased cellular lipid mass was associated with increased oleate incorporation into cellular cholesterol esters and triglycerides. Exogenous LPL hydrolyzed 76% of the VLDL triglyceride over 24 h. LPL action on Type IV VLDL was sufficient to promote cellular uptake of these lipoproteins, while elevated media-free fatty acid levels were not. Although HepG2 cells secrete apolipoprotein (apo) E, we assessed the role of VLDL-associated apoE in the lipid accumulation induced by VLDL plus LPL. ApoE-rich and apoE-poor Type IV VLDL subfractions induced similar increments in cellular esterified cholesterol in the presence of LPL, despite a 4-fold difference in apoE content. S(f) 60-400 VLDL, from subjects homozygous for the defective apoE2, plus LPL, behaved identically to Type IV VLDL plus LPL. Type IV VLDL plus LPL, preincubated with anti-apoE (1D7) and apoB (5E11) monoclonal antibodies, known to block the binding of apoE and -B, respectively, to the LDL receptor failed to block lipid accumulation. In contrast, apoE-poor Type IV VLDL, apoE2 VLDL, and VLDL plus 1D7 were taken up poorly by J774 cells, cells that secrete LPL, but not apoE. These studies suggest that lipolytic remodeling of large Type IV VLDL by LPL is a prerequisite for their uptake by HepG2 cells and that HepG2 cell-secreted apoE rather than VLDL-associated apoE is the ligand involved in uptake.	UNIV WESTERN ONTARIO,ROBARTS RES INST,LONDON N6A 5K8,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5K8,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	EVANS, AJ (corresponding author), UNIV WESTERN ONTARIO,DEPT MED,LONDON N6A 5K8,ONTARIO,CANADA.		Huff, Murray/G-3307-2011					BARBIR M, 1988, BRIT HEART J, V60, P397; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BLACHE D, 1983, CLIN CHEM, V29, P154; BRADLEY WA, 1984, J BIOL CHEM, V259, P4728; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BURY J, 1985, CLIN CHEM, V31, P247; BUSCH SJ, 1989, LIFE SCI, V45, P615, DOI 10.1016/0024-3205(89)90047-7; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; CRAIG WY, 1988, J LIPID RES, V29, P299; DASHTI N, 1986, BIOCHIM BIOPHYS ACTA, V875, P473, DOI 10.1016/0005-2760(86)90067-6; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; ERICKSON SK, 1986, J LIPID RES, V27, P875; EVANS AJ, 1989, J LIPID RES, V30, P1691; FAUST RA, 1989, ATHEROSCLEROSIS, V77, P77, DOI 10.1016/0021-9150(89)90012-9; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; FRIEDMAN G, 1990, BIOCHIM BIOPHYS ACTA, V1044, P118, DOI 10.1016/0005-2760(90)90226-N; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GIANTURCO SH, 1982, J CLIN INVEST, V70, P168, DOI 10.1172/JCI110590; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GIANTURCO SH, 1986, J LIPID RES, V27, P412; GUSTAFSON S, 1985, BIOCHIM BIOPHYS ACTA, V834, P308, DOI 10.1016/0005-2760(85)90003-7; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HUFF MW, 1988, ARTERIOSCLEROSIS, V8, P471, DOI 10.1161/01.ATV.8.5.471; HUFF MW, 1991, ARTERIOSCLER THROMB, V11, P221, DOI 10.1161/01.ATV.11.2.221; HUFF MW, 1990, J LIPID RES, V31, P385; HUFF MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P251, DOI 10.1016/0005-2760(84)90125-5; INNERARITY TL, 1986, LIPOPROTEIN DEFICIEN, P273; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KREMPLER F, 1987, J CLIN INVEST, V80, P401, DOI 10.1172/JCI113086; KRUL ES, 1984, J CLIN INVEST, V75, P361; KUO P, 1990, BIOCHEMISTRY-US, V29, P6626, DOI 10.1021/bi00480a011; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, ARTERIOSCLER, V9, P14; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MILNE RW, 1983, FEBS LETT, V146, P97; MUDLER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P277, DOI 10.1016/0005-2760(79)90029-8; NERI BP, 1973, CLIN CHEM, V19, P1201; NOVAK M, 1965, J LIPID RES, V6, P431; ORDOVAS JM, 1987, J LIPID RES, V28, P1216; OSWALD B, 1987, J LIPID RES, V28, P798; PERSOON NLM, 1986, LIFE SCI, V38, P1029, DOI 10.1016/0024-3205(86)90237-7; RANGANATHAN S, 1989, HEPATOLOGY, V9, P547, DOI 10.1002/hep.1840090407; REARDON MF, 1978, J CLIN INVEST, V61, P850, DOI 10.1172/JCI108999; RUDLING MJ, 1985, BIOCHIM BIOPHYS ACTA, V833, P359, DOI 10.1016/0005-2760(85)90091-8; SACKS FM, 1987, ARTERIOSCLEROSIS, V7, P35, DOI 10.1161/01.ATV.7.1.35; SCHAEFER EJ, 1985, NEW ENGL J MED, V312, P1300, DOI 10.1056/NEJM198505163122007; SCHNEIDER WJ, 1981, J CLIN INVEST, V68, P1075, DOI 10.1172/JCI110330; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SHEPHERD J, 1987, AM HEART J, V113, P503, DOI 10.1016/0002-8703(87)90621-1; SOCORRO L, 1985, J BIOL CHEM, V260, P6324; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V26, P556; YEN FT, 1989, CIRCULATION, V80, P487; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P7089, DOI 10.1021/bi00528a006	62	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10743	10751						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587849				2022-12-27	WOS:A1992HV09000081
J	QUESENBERRY, MS; DRICKAMER, K				QUESENBERRY, MS; DRICKAMER, K			ROLE OF CONSERVED AND NONCONSERVED RESIDUES IN THE CA2+-DEPENDENT CARBOHYDRATE-RECOGNITION DOMAIN OF A RAT MANNOSE-BINDING PROTEIN - ANALYSIS BY RANDOM CASSETTE MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; CONTAINS; LECTIN	The carbohydrate-recognition domain of rat serum mannose-binding protein A has been subjected to random cassette mutagenesis. Mutant domains, expressed in bacteria, were initially screened for binding to invertase-coated nitrocellulose and then analyzed further for Ca2+ affinity, saccharide binding, resistance to proteolysis, and oligomerization. The results are consistent with previous evolutionary and structural studies. Six out of seven completely inactive mutants have changes in residues directly involved in ligating Ca2+. Most changes in conserved residues which form part of the hydrophobic core characteristic of Ca2+-dependent (C-type) animal lectins result in decreased affinity for Ca2+, even though these residues are distant from the Ca2+ sites. Changes can be made in large portions of the surface without affecting saccharide binding. The results indicate that the precise arrangement of the regular portion of the domain containing the hydrophobic core is necessary for formation of a stable Ca2+-ligated structure under physiological conditions. The data also suggest that the saccharide-binding site is likely to be in close proximity to the bound Ca2+.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University					NIDDK NIH HHS [DK07328] Funding Source: Medline; NIGMS NIH HHS [GM42628] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTON E, 1985, J CHEM SOC CHEM COMM, P165, DOI 10.1039/c39850000165; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLAND EC, 1986, J BIOL CHEM, V261, P1286; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEE RT, 1991, J BIOL CHEM, V266, P4810; LOEB JA, 1987, J BIOL CHEM, V262, P3022; Maniatis T., 1982, MOL CLONING; MURRAY R, 1988, P NATL ACAD SCI USA, V85, P3535, DOI 10.1073/pnas.85.10.3535; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; REEKE GN, 1978, P NATL ACAD SCI USA, V75, P2286, DOI 10.1073/pnas.75.5.2286; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241	26	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10831	10841						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587859				2022-12-27	WOS:A1992HV09000094
J	ZIEGELBAUER, K; OVERATH, P				ZIEGELBAUER, K; OVERATH, P			IDENTIFICATION OF INVARIANT SURFACE GLYCOPROTEINS IN THE BLOOD-STREAM STAGE OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; PLASMA-MEMBRANE; PROTEINS; TRANSPORT; ANTIGENS; PURIFICATION; RHODESIENSE; INVOLVEMENT; DOMAINS; COAT	Surface proteins of the mammalian stage of the parasitic protozoan, Trypanosoma brucei, were biotinylated with sulfosuccinimidyl 6-(biotinamido) hexanoate. Since the predominant protein labeled by this reagent is the membrane form of the variant surface glycoprotein (mfVSG), a procedure was developed to convert mfVSG to its soluble form by the endogenous glycosylphosphatidylinositol-specific phospholipase C while retaining other biotinylated surface proteins in a membrane-bound state. From these membranes, three novel glycoproteins of 60, 65, and 75 kDa could be isolated by a combination of Triton X-114 phase separation and precipitations by streptavidin and concanavalin A coupled to solid supports. These polypeptides were detected in trypanosomes expressing different mfVSGs and are thus considered to be invariant. In a variant clone in which the mfVSG is trypsin-sensitive, the invariant surface glycoproteins of 65 and 75 kDa, designated ISG65 and ISG75, respectively, were proteolytically degraded with similar kinetics as the mfVSG. Neither ISG65 nor ISG75 could be detected in procyclic trypanosomes, the stage of the parasite characteristic for the insect midgut. Gene cloning reported in the accompanying paper (Ziegelbauer, K., Multhaup, G., and Overath, P. (1992) J. Biol. Chem. 267, 10797-10803) suggests that ISG65 and ISG75 are transmembrane proteins.			ZIEGELBAUER, K (corresponding author), MAX PLANCK INST BIOL, MEMBRANE BIOCHEM ABT, CORRENSSTR 38, W-7400 TUBINGEN, GERMANY.							BARRY JD, 1979, J CELL SCI, V37, P287; BEAT DA, 1984, J PROTOZOOL, V31, P541, DOI 10.1111/j.1550-7408.1984.tb05499.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BULOW R, 1989, J CELL SCI, V93, P233; BURGESS DE, 1985, INFECT IMMUN, V50, P893, DOI 10.1128/IAI.50.3.893-899.1985; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; GAME S, 1986, FEBS LETT, V194, P126, DOI 10.1016/0014-5793(86)80063-1; GARDINER PR, 1987, SCIENCE, V235, P774, DOI 10.1126/science.3810164; GRUENBERG J, 1978, EUR J BIOCHEM, V89, P461, DOI 10.1111/j.1432-1033.1978.tb12549.x; Helenius A, 1979, Methods Enzymol, V56, P734; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; HURLEY WL, 1985, J IMMUNOL METHODS, V85, P195, DOI 10.1016/0022-1759(85)90287-X; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MANCINI PE, 1982, BIOCHIM BIOPHYS ACTA, V688, P399, DOI 10.1016/0005-2736(82)90351-0; MCLAUGHLIN J, 1982, J IMMUNOL, V128, P2656; Overath Peter, 1992, NATO ASI (Advanced Science Institute) Series Series H Cell Biology, V63, P333; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; RAUTENBERG P, 1981, MOL BIOCHEM PARASIT, V4, P129, DOI 10.1016/0166-6851(81)90012-8; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; ROVIS L, 1978, NATURE, V271, P654, DOI 10.1038/271654a0; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; SHAPIRO S Z, 1986, P215; TERKUILE BH, 1991, J BIOL CHEM, V266, P857; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P1; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	42	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10791	10796						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587855				2022-12-27	WOS:A1992HV09000088
J	KIM, YT; TABOR, S; BORTNER, C; GRIFFITH, JD; RICHARDSON, CC				KIM, YT; TABOR, S; BORTNER, C; GRIFFITH, JD; RICHARDSON, CC			PURIFICATION AND CHARACTERIZATION OF THE BACTERIOPHAGE-T7 GENE 2.5 PROTEIN - A SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECA-PROTEIN; DEOXYRIBONUCLEIC-ACID; T4-GENE 32-PROTEIN; RNA-POLYMERASE; NUCLEIC-ACIDS; 32 PROTEIN; REPLICATION; STIMULATION; RECOMBINATION	Bacteriophage T7 gene 2.5 protein has been purified to homogeneity from cells overexpressing its gene. Native gene 2.5 protein consists of a dimer of two identical subunits of molecular weight 25,562. Gene 2.5 protein binds specifically to single-stranded DNA with a stoichiometry of approximately 7 nucleotides bound per monomer of gene 2.5 protein; binding appears to be noncooperative. Electron microscopic analysis shows that gene 2.5 protein is able to disrupt the secondary structure of single-stranded DNA. The single-stranded DNA is extended into a chain of gene 2.5 protein dimers bound along the DNA. In fluorescence quenching and nitrocellulose filter binding assays, the binding constants of gene 2.5 protein to single-stranded DNA are 1.2 x 10(6) m-1 and 3.8 x 10(6) m-1, respectively. Escherichia coli single-stranded DNA-binding protein and phage T4 gene 32 protein bind to single-stranded DNA more tightly by a factor of 25. Fluorescence spectroscopy suggests that tyrosine residue(s), but not tryptophan residues, on gene 2.5 protein interacts with single-stranded DNA.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,240 LONGWOOD AVE,BOSTON,MA 02115; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27514	Harvard University; Harvard Medical School; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline; NIGMS NIH HHS [GM 31819] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FUJISAWA H, 1985, NUCLEIC ACIDS RES, V13, P7473, DOI 10.1093/nar/13.20.7473; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HUBER HE, 1987, J BIOL CHEM, V262, P16224; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; KEATING KM, 1988, BIOCHEMISTRY-US, V27, P5240, DOI 10.1021/bi00414a044; KELLY RC, 1976, J BIOL CHEM, V251, P7240; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P43; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOLINEUX IJ, 1974, P NATL ACAD SCI USA, V71, P3858, DOI 10.1073/pnas.71.10.3858; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; NAKAI H, 1988, J BIOL CHEM, V263, P9831; REGISTER JC, 1986, P NATL ACAD SCI USA, V83, P624, DOI 10.1073/pnas.83.3.624; REUBEN RC, 1974, J BIOL CHEM, V249, P3843; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; RUYECHAN WT, 1984, J VIROL, V52, P727, DOI 10.1128/JVI.52.3.727-733.1984; SADOWSKI PD, 1980, MECHANISTIC STUDIES, P941; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIGAL N, 1972, P NATL ACAD SCI USA, V69, P3537, DOI 10.1073/pnas.69.12.3537; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1987, J BIOL CHEM, V262, P16212; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITTIER RF, 1980, ANAL BIOCHEM, V106, P99, DOI 10.1016/0003-2697(80)90123-2; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WILLIAMS KR, 1990, BIOL NONSPECIFIC DNA, P197; WILLIAMS KR, 1983, BACTERIOPHAGE T4, P82; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018	57	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15022	15031						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634538				2022-12-27	WOS:A1992JF08800077
J	RONCERO, C; GOODRIDGE, AG				RONCERO, C; GOODRIDGE, AG			HEXANOATE AND OCTANOATE INHIBIT TRANSCRIPTION OF THE MALIC ENZYME AND FATTY-ACID SYNTHASE GENES IN CHICK-EMBRYO HEPATOCYTES IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE NUCLEAR RECEPTOR; THYROID-HORMONE; SODIUM-BUTYRATE; MESSENGER-RNA; NUTRITIONAL REGULATION; RAT HEPATOCYTES; LIVER-CELLS; CYCLIC-AMP; HISTONE DEACETYLATION; LIPOGENIC ENZYMES	Hexanoate and octanoate inhibit the triiodothyronine (T3)-induced increases in the activities of malic enzyme and fatty acid synthase in chick embryo hepatocytes in culture. Butanoate was less effective as an inhibitor, and palmitate, stearate, and oleate had no effect or small stimulatory effects. Hexanoate and octanoate inhibited the lipogenic enzyme activities at a transcriptional step, and did so within 30 min of addition. Incubation for 2 h in the absence of fatty acid reversed the inhibition of transcription caused by hexanoate. The inhibitory effect of hexanoate was selective because DNA content and transcription of the glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes were not inhibited. Hexanoate-mediated inhibition of transcription rates of the lipogenic genes was not correlated with an inhibition of binding of T3 to its nuclear receptor. 2-Bromooctanoate and carnitine stimulated the T3-induced accumulation of the mRNAs for malic enzyme and fatty acid synthase. The presence of hexanoate stimulated by 2- to 3-fold the increase caused by carnitine, suggesting that hexanoate and carnitine may regulate lipogenic gene expression by a common pathway. Hexanedioate, acetoacetate, beta-hydroxybutyrate, branched chain fatty acids, and branched chain keto acids had little or no effect on abundance of the lipogenic mRNAs. We suggest that the active inhibitor is a metabolite derived from hexanoate or octanoate, possibly an intermediate derived from an acyl-CoA derivative.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa			Roncero, Cesáreo/H-9039-2015	Roncero, Cesáreo/0000-0001-7608-8553	NIDDK NIH HHS [DK 25295, DK 21954] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; AMRI EZ, 1991, J LIPID RES, V32, P1449; ARMSTRONG MK, 1991, BIOCHEM BIOPH RES CO, V177, P1056, DOI 10.1016/0006-291X(91)90645-N; BACK DW, 1986, J BIOL CHEM, V261, P4190; BACK DW, 1986, J BIOL CHEM, V261, P2555; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; BUECHLER KF, 1990, ARCH BIOCHEM BIOPHYS, V281, P233, DOI 10.1016/0003-9861(90)90437-4; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE SD, 1990, J NUTR, V120, P625, DOI 10.1093/jn/120.6.625; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1932; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1972, J BIOL CHEM, V247, P6946; GOODRIDGE AG, 1975, FED PROC, V34, P117; GOODRIDGE AG, 1986, ANN NY ACAD SCI, V478, P46, DOI 10.1111/j.1749-6632.1986.tb15520.x; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; GREENBAUM AL, 1971, ARCH BIOCHEM BIOPHYS, V143, P617, DOI 10.1016/0003-9861(71)90247-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HEERDT BG, 1991, J BIOL CHEM, V266, P19120; INOUE A, 1989, EUR J BIOCHEM, V183, P565, DOI 10.1111/j.1432-1033.1989.tb21085.x; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAZAR MA, 1990, J BIOL CHEM, V265, P17474; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MA XJ, 1990, J BIOL CHEM, V265, P18435; MAYOREK N, 1985, J BIOL CHEM, V260, P6528; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MITSUHASHI T, 1987, J BIOL CHEM, V262, P3993; MORRIS SM, 1982, J BIOL CHEM, V257, P3225; NUMA S, 1965, BIOCHEM Z, V343, P243; PLESKO MM, 1983, J BIOL CHEM, V258, P3738; RAAKA BM, 1979, J BIOL CHEM, V254, P6755; RAAKA BM, 1979, J BIOL CHEM, V254, P3303; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1980, J BIOL CHEM, V255, P2499; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHULZ H, 1991, BIOCH LIPIDS LIPOPRO, P87; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; STAECKER JL, 1988, J CELL PHYSIOL, V135, P367, DOI 10.1002/jcp.1041350303; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VANDERKLIS FRM, 1989, FEBS LETT, V246, P6, DOI 10.1016/0014-5793(89)80242-X; WIERSINGA WM, 1990, INT J BIOCHEM, V22, P269, DOI 10.1016/0020-711X(90)90339-5; WIERSINGA WM, 1988, METABOLISM, V37, P996, DOI 10.1016/0026-0495(88)90159-X; WINBERRY LK, 1983, J BIOL CHEM, V258, P1337; WISE EM, 1964, P NATL ACAD SCI USA, V52, P1255, DOI 10.1073/pnas.52.5.1255; YUAN ZY, 1988, P NATL ACAD SCI USA, V85, P6328, DOI 10.1073/pnas.85.17.6328	63	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14918	14927						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634532				2022-12-27	WOS:A1992JF08800064
J	HAUSER, F; ROEBEN, C; HOFFMANN, W				HAUSER, F; ROEBEN, C; HOFFMANN, W			XP2, A NEW MEMBER OF THE P-DOMAIN PEPTIDE FAMILY OF POTENTIAL GROWTH-FACTORS, IS SYNTHESIZED IN XENOPUS-LAEVIS SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; AMINO-ACID-SEQUENCE; PS2 MESSENGER-RNA; CANCER CELL-LINE; INTEGUMENTARY MUCIN; DERMAL GLANDS; EXPRESSION; PROTEIN; SECRETION; STOMACH	Similarly to epidermal growth factor (EGF) and EGF-like repeats, the "P-domain" represents a cysteine-rich module that has been detected in the past in a variety of polypeptides, as well as in high molecular weight proteins. Here, a precursor for a secretory polypeptide (xP2) is characterized that consists of two P-domains. xP2 has been discovered in Xenopus laevis with the help of the polymerase chain reaction. In contrast to all other P-domain peptides, it is synthesized in the skin but not in the stomach or the pancreas. By this and other criteria, it cannot be considered simply as the X. laevis homologue of recently described P-domain peptides, viz. the spasmolytic polypeptides (PSP/hSP/mSP). Furthermore, a polyclonal antiserum was generated against the deduced C-terminal end of xP2. Due to its immunoreactivity with granular glands, as well as with the epidermis, the possibility of a growth factor activity for xP2 in the germinal layer is discussed.	MAX PLANCK INST PSYCHIAT,NEUROCHEM ABT,W-8033 MARTINSRIED,GERMANY	Max Planck Society			Hauser, Frank/M-2952-2014; Hoffmann, Werner/AAY-9182-2020	Hauser, Frank/0000-0001-5563-2345; Hoffmann, Werner/0000-0003-0031-9540				BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BORK P, 1991, FEBS LETT, V286, P47, DOI 10.1016/0014-5793(91)80937-X; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; FLUCHER BE, 1986, J CELL BIOL, V103, P2299, DOI 10.1083/jcb.103.6.2299; GMACHL M, 1990, FEBS LETT, V260, P145, DOI 10.1016/0014-5793(90)80088-Z; HAUSER F, 1991, J BIOL CHEM, V266, P21306; HAUSER F, 1990, EXP CELL RES, V189, P157, DOI 10.1016/0014-4827(90)90230-8; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; HOOSEIN NM, 1989, FEBS LETT, V247, P303, DOI 10.1016/0014-5793(89)81357-2; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; KONIGSTORFER A, 1989, J BIOL CHEM, V264, P13689; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; MAEDA N, 1985, J BIOL CHEM, V260, P1123; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; PODOLSKY DK, 1988, CANCER RES, V48, P418; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; PROBST JC, 1992, J BIOL CHEM, V267, P6310; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Romeis B., 1989, MIKROSKOPISCHE TECHN; ROSE K, 1989, BIOCHIM BIOPHYS ACTA, V998, P297, DOI 10.1016/0167-4838(89)90288-4; SCHWARTZ LH, 1991, CANCER RES, V51, P624; SEITZ G, 1991, AM J GASTROENTEROL, V86, P1491; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402; WYSOCKI SJ, 1990, CANCER RES, V50, P1800	36	46	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14451	14455						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629230				2022-12-27	WOS:A1992JD32500100
J	TEAGUE, WE; DOBSON, GP				TEAGUE, WE; DOBSON, GP			EFFECT OF TEMPERATURE ON THE CREATINE-KINASE EQUILIBRIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SATURATION-TRANSFER; SKELETAL-MUSCLE; ATP SYNTHESIS; RAT-HEART	The effect of temperature on the apparent equilibrium constant of creatine kinase (ATP:creatine N-phosphotransferase (EC 2.7.3.2)) was determined. At equilibrium the apparent K' for the biochemical reaction was defined as K' = [SIGMA-ATP][Cr]/[SIGMA-ADP][SIGMA-PCr] The symbol SIGMA-denotes the sum of all the ionic and metal complex species of the reactant components in m. The K' at pH 7.0, 1.0 mM free Mg2+, and ionic strength of 0.25 M at experimental conditions was 177 +/- 7.0, 217 +/- 11, 255 +/- 10, and 307 +/- 13 (n = 8) at 38, 25, 15, and 5-degrees-C, respectively. The standard apparent enthalpy or heat of the reaction at the specified conditions (DELTA-H'degrees) was calculated from a van't Hoff plot of log10.K' versus 1/T, and found to be -11.93 kJ mol-1 (-2852 cal mol-1) in the direction of ATP formation. The corresponding standard apparent entropy of the reaction (DELTA-S'degrees) was +4.70 J K-1 mol-1. The linear function (r2 = 0.99) between log10 K' and 1/K demonstrates that both DELTA-H'degrees and DELTA-S'degrees are independent of temperature for the creatine kinase reaction, and that DELTA-C(p)'degrees, the standard apparent heat capacity of products minus reactants in their standard states, is negligible between 5 and 38-degrees-C. We further show from our data that the sign and magnitude of the standard apparent Gibbs energy (DELTA-G'degrees) of the creatine kinase reaction was comprised mostly of the enthalpy of the reaction, with 11% coming from the entropy T-DELTA-S'degrees term. The thermodynamic quantities for the following two reference reactions of creatine kinase were also determined. PCr2- + ADP3- + H+ = ATP4- + Cr (2) MgPCr + MgADP1- + H+ = MgATP2- + Cr + Mg2+ (3) The DELTA-H-degrees for Reaction 2 was -16.73 kJ mol-1 (-3998 cal mol-1) and for Reaction 3 was -23.23 kJ mol-1 (-5552 cal mol-1) over the temperature range 5-38-degrees-C. The corresponding DELTA-S-degrees values for the reactions were +110.43 and +83.49 J K-1 mol-1, respectively. Using the DELTA-H'degrees of -11.93 kJ mol-1, and one K' value at one temperature, a second K' at a second temperature can be calculated, thus permitting bioenergetic investigations of organs and tissues using the creatine kinase equilibria over the entire physiological temperature range.	NIAAA,12501 WASHINGTON AVE,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								ALBERTY RA, 1991, BIOPHYS CHEM, V4242, P117; ALBERTY RA, 1987, PHYSICAL CHEM, P934; BATES RG, 1964, DETERMINATION PH; BITTL JA, 1985, J BIOL CHEM, V260, P3512; CARLSON FD, 1959, J GEN PHYSIOL, V43, P301, DOI 10.1085/jgp.43.2.301; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CLARKE ECW, 1980, J CHEM SOC F1, V76, P1911; DANFORTH WILLIAM H., 1965, P287; DOBSON GP, 1991, NMR BIOMED, V5, P20; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GELLERT M, 1960, J AM CHEM SOC, V82, P1497, DOI 10.1021/ja01491a053; HOHORST HJ, 1962, BIOCHEM BIOPH RES CO, V7, P142, DOI 10.1016/0006-291X(62)90163-8; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KUBY S, 1962, ENZYMES, P515; KUBY SA, 1954, J BIOL CHEM, V210, P65; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; Lehmann H, 1936, BIOCHEM Z, V286, P336; Lohmann K, 1934, BIOCHEM Z, V271, P264; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; MATTHEWS PM, 1981, BIOCHEM BIOPH RES CO, V103, P1052, DOI 10.1016/0006-291X(81)90915-3; NODA L, 1954, J BIOL CHEM, V210, P83; OESPER P, 1951, PHOSPHORUS METABOL, P523; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PODOLSKY RJ, 1955, J BIOL CHEM, V217, P603; VANTHOFF JH, 1898, LECTURES THEORETICAL; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WATTS DC, 1973, ENZYMES, P384; WOLEDGE RC, 1972, COLD SPRING HARB SYM, V37, P629; [No title captured]	30	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14084	14093						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629208				2022-12-27	WOS:A1992JD32500049
J	BLACKSHEAR, PJ; VERGHESE, GM; JOHNSON, JD; HAUPT, DM; STUMPO, DJ				BLACKSHEAR, PJ; VERGHESE, GM; JOHNSON, JD; HAUPT, DM; STUMPO, DJ			CHARACTERISTICS OF THE F52 PROTEIN, A MARCKS HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; MANNOSE 6-PHOSPHATE RECEPTOR; C-KINASE SUBSTRATE; GROWTH FACTOR-II; PHORBOL ESTERS; PHOSPHORYLATION; CALMODULIN; INSULIN; EXPRESSION; BINDING	A recently cloned mouse cDNA designated F52 encodes a putative protein with striking sequence similarity to the MARCKS protein, a major cellular substrate for protein kinase C (PKC). Major regions of sequence similarity include the amino-terminal myristoylation consensus sequence and the central calmodulin-binding/PKC phosphorylation site domain. The F52 protein was expressed in Escherichia coli with apparent M(r) 50,000; it was a substrate for PKC and comigrated on two-dimensional electrophoresis with a myristoylated protein whose phosphorylation was stimulated by phorbol 12-myristate 13-acetate in mouse neuroblastoma cells. The F52 protein also was myristoylated in E. coli by co-expression with N-myristoyltransferase. A 24-amino acid peptide derived from the protein's phosphorylation site domain was a good substrate for PKC; like the cognate MARCKS peptide, it was phosphorylated with high affinity (S0.5 = 173 nM) and positive cooperativity (K(H) = 5.4). The F52 peptide also bound calmodulin with high affinity (K(d) = <3 nM); this binding could be disrupted by phosphorylation of the peptide with PKC, with a half-time of 8 min. The F52 protein is clearly a member of the MARCKS family as defined by primary sequence; in addition, the two proteins share several key attributes that may be functionally important.	DUKE UNIV, MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR, DIABET & METAB SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; OHIO STATE UNIV, COLL MED, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA	Duke University; Duke University; Ohio State University	BLACKSHEAR, PJ (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, POB 3897, DURHAM, NC 27710 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727, R01DK040408] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40408, DK-33727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2	28	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13540	13546						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618855				2022-12-27	WOS:A1992JB74600070
J	WALSH, CT; ZYDOWSKY, LD; MCKEON, FD				WALSH, CT; ZYDOWSKY, LD; MCKEON, FD			CYCLOSPORINE-A, THE CYCLOPHILIN CLASS OF PEPTIDYLPROLYL ISOMERASES, AND BLOCKADE OF T-CELL SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CIS-TRANS-ISOMERASE; NF-KAPPA-B; BINDING PROTEIN CYCLOPHILIN; FK506-BINDING PROTEIN; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; TRANSCRIPTION FACTOR; PROLYL ISOMERASE		HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	WALSH, CT (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NIEHS NIH HHS [ES05459] Funding Source: Medline; NIGMS NIH HHS [GM20011] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020011, R01GM020011] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 2015, CELL MOL IMMUNOL, V8th; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BIERER BE, 1991, EUR J IMMUNOL, V21, P439, DOI 10.1002/eji.1830210228; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CARONI P, 1991, J BIOL CHEM, V266, P10739; DIETMEIER K, 1990, NUCLEIC ACIDS RES, V18, P373, DOI 10.1093/nar/18.2.373; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1990, SCIENCE, V250, P1406, DOI 10.1126/science.2255910; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FREIDMAN J, 1991, CELL, V66, P799; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDLER B, 1987, EMBO J, V6, P947; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3053, DOI 10.1021/bi00464a023; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KOSER PL, 1990, GENE, V96, P189, DOI 10.1016/0378-1119(90)90252-M; KOSER PL, 1991, GENE, V108, P73, DOI 10.1016/0378-1119(91)90489-X; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LEVY MA, 1991, TRANSPLANT P, V23, P319; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LIU J, 1991, BIOCHEMISTRY-US, V30, P2036; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALLEN CJ, 1988, CALCIUM BINDING PROT, V1, P51; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPIK G, 1991, J BIOL CHEM, V266, P10735; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANAKA H, 1987, J AM CHEM SOC, V109, P5031, DOI 10.1021/ja00250a050; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENGER RM, 1990, BIOCH PEPTIDE ANTIBI, P246; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G; ZYDOWSKY LD, 1992, IN PRESS PROTEIN SCI	80	239	250	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13115	13118						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618811				2022-12-27	WOS:A1992JB74600001
J	KASTERN, W; SJOBRING, U; BJORCK, L				KASTERN, W; SJOBRING, U; BJORCK, L			STRUCTURE OF PEPTOSTREPTOCOCCAL PROTEIN-L AND IDENTIFICATION OF A REPEATED IMMUNOGLOBULIN LIGHT CHAIN-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGG-BINDING; ESCHERICHIA-COLI; BACTERIAL PROTEIN; FC-BINDING; STREPTOCOCCI; SEQUENCE; RECEPTOR; ALBUMIN; REGIONS; GENE	The gene for protein L, an immunoglobulin (Ig) light chain-binding protein expressed by some strains of the anaerobic bacterial species Peptostreptococcus magnus, was cloned and sequenced. The gene translates into a protein of 719 amino acid residues. Following a signal sequence of 18 amino acids and a NH2-terminal region ("A") of 79 residues, the molecule contains five homologous "B" repeats of 72-76 amino acids each. Further, toward the COOH terminus, two additional repeats ("C") were found. These are not related to the "B" repeats, but are highly homologous to each other. After the C repeats (52 amino acids each), a hydrophilic, proline-rich putative cell wall-spanning region ("W") was found, followed at the COOH-terminal end by a hydrophobic membrane anchor ("M"). Fragments of the gene were expressed, and the corresponding peptides were analyzed for Ig-binding activity. The B repeats were found to be responsible for the interaction with Ig light chains. An Escherichia coli high level expression system was adapted for the production of large amounts of two Ig-binding protein L fragments comprising one and four B repeats, respectively.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; UNIV LUND,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN	Lund University; Lund University	KASTERN, W (corresponding author), UNIV FLORIDA,COLL MED,DEPT PATHOL,GAINESVILLE,FL 32610, USA.							AKERSTROM B, 1991, MOL IMMUNOL, V28, P349, DOI 10.1016/0161-5890(91)90147-C; AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKERSTROM B, 1986, J BIOL CHEM, V261, P240; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BJORCK L, 1984, J IMMUNOL, V133, P969; BJORCK L, 1990, MOL MICROBIOL, V4, P1439, DOI 10.1111/j.1365-2958.1990.tb02054.x; BJORCK L, 1990, P267; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; GOMI H, 1990, J IMMUNOL, V144, P4046; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MYHRE EB, 1984, J MED MICROBIOL, V18, P189, DOI 10.1099/00222615-18-2-189; MYHRE EB, 1985, MOL IMMUNOL, V22, P879, DOI 10.1016/0161-5890(85)90073-2; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; PATELLA V, 1990, J IMMUNOL, V145, P3054; PLUCKTHUN A, 1991, BIO-TECHNOL, V9, P545, DOI 10.1038/nbt0691-545; REIS KJ, 1984, J IMMUNOL, V132, P3091; RUAN M, 1990, J IMMUNOL, V145, P3379; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; SAIKI RK, 1988, SCIENCE, V239, P489; SJOBRING U, 1989, J IMMUNOL, V143, P2948; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; STONE GC, 1989, J IMMUNOL, V143, P565; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	39	108	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12820	12825						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618782				2022-12-27	WOS:A1992HZ48300066
J	PLOWMAN, GD; GREEN, JM; NEUBAUER, MG; BUCKLEY, SD; MCDONALD, VL; TODARO, GJ; SHOYAB, M				PLOWMAN, GD; GREEN, JM; NEUBAUER, MG; BUCKLEY, SD; MCDONALD, VL; TODARO, GJ; SHOYAB, M			THE EPITHELIN PRECURSOR ENCODES 2 PROTEINS WITH OPPOSING ACTIVITIES ON EPITHELIAL-CELL GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 RECEPTOR ANTAGONIST; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GENE; DNA; AMPHIREGULIN; EXPRESSION; PITUITARY; INHIBIN; LENGTH	Epithelin 1 and 2 were originally purified from rat kidneys based on their ability to inhibit the growth of A-431 human epidermoid carcinoma cells (Shoyab, M., McDonald, V. L., Byles, C., Todaro, G. J., and Plowman, G. D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7912-7916). This study presents the complete amino acid sequence of these two growth factors and the cloning of their cDNAs from rat, mouse, and human sources. Epithelins 1 and 2 are 56- and 57-amino acid polypeptides, respectively, and share 47% amino acid sequence identity with the conserved spacing of 12 cysteine residues. Molecular cloning revealed that both proteins are encoded by a single precursor that contains 7 1/2 copies of this novel 12-cysteine motif, 2 of which represent the known active molecules. Recombinant expression in COS cells demonstrated that the epithelin 1 protein was mitogenic on rodent keratinocytes and fibroblasts. In contrast, epithelin 2 had no activity on these cells, but at high concentrations was capable of antagonizing the growth proliferative activities of epithelin 1. Northern analysis shows the epithelin mRNA to be expressed in many types of epithelial cells. The broad expression profile of epithelin transcripts, along with the opposing activities of the two mature protein products, implicates these factors as natural mediators of epithelial homeostasis.			PLOWMAN, GD (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SEATTLE, WA 98121 USA.		PLOWMAN, Greg D/E-2012-2011					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BERG JM, 1990, J BIOL CHEM, V265, P6513; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FERNIG DG, 1991, REGULATORY MECHANISM, P47; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOMEZ F, 1989, EUR J BIOCHEM, V186, P23, DOI 10.1111/j.1432-1033.1989.tb15172.x; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RUGIN JS, 1989, P NATL ACAD SCI USA, V86, P802; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHARPLES K, 1987, DNA-J MOLEC CELL BIO, V6, P239, DOI 10.1089/dna.1987.6.239; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258	29	167	181	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13073	13078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618805				2022-12-27	WOS:A1992HZ48300099
J	BRAY, KM; QUAST, U				BRAY, KM; QUAST, U			A SPECIFIC BINDING-SITE FOR K+ CHANNEL OPENERS IN RAT AORTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SMOOTH-MUSCLE; PORTAL-VEIN; CROMAKALIM; CELLS; BRL-34915; DIAZOXIDE	The K+ channel openers, including cromakalim, pinacidil, minoxidil sulfate, diazoxide, and nicorandil, form a chemically heterogeneous group of compounds, which relax smooth muscle by opening plasmalemmal K+ channels. At present it is not known whether these drugs elicit their effects by binding to the same target, presumably the K+ channel. In order to address this question, a binding assay for K+ channel openers has been developed in vascular smooth muscle. The novel tritiated K+ channel opener, [H-3]P1075, an analogue of pinacidil, binds with high affinity (K(D) = 6 +/- 1 nM) to endothelium-denuded rings of rat aorta. Inhibition studies indicate that the different families of K+ channel openers bind to a common target. Evidence is presented to suggest that the binding site for the sulfonylurea, glibenclamide, the major blocker of the K+ channel openers, is coupled in a negative allosteric manner to the binding site(s) for the openers. The binding assay described here may open the way to the biochemical characterization of the drug receptor for the K+ channel openers.	SANDOZ PHARMA LTD,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz								BEECH DJ, 1989, BRIT J PHARMACOL, V98, P851, DOI 10.1111/j.1476-5381.1989.tb14614.x; BRAY K, 1991, N-S ARCH PHARMACOL, V344, P351; COOK N S, 1989, British Journal of Pharmacology, V96, p181P; Cook NS, 1990, POTASSIUM CHANNELS S, P181; DRAPER NR, 1981, APPLIED REGRESSION A, P85; EDWARDS G, 1990, TRENDS PHARMACOL SCI, V11, P417, DOI 10.1016/0165-6147(90)90149-3; EDWARDS G, 1990, PHARMACOL THERAPEUT, V48, P237, DOI 10.1016/0163-7258(90)90082-D; FURUKAWA K, 1981, J PHARMACOL EXP THER, V218, P248; GARRINO MG, 1988, BRIT J PHARMACOL, V93, P61, DOI 10.1111/j.1476-5381.1988.tb11405.x; GELBAND CH, 1989, EUR J PHARMACOL, V167, P201, DOI 10.1016/0014-2999(89)90580-3; GOPALAKRISHNAN M, 1991, J PHARMACOL EXP THER, V257, P1162; HAMILTON TC, 1986, BRIT J PHARMACOL, V88, P103, DOI 10.1111/j.1476-5381.1986.tb09476.x; KITAMURA K, 1990, Japanese Journal of Pharmacology, V52, p36P; KLOCKNER U, 1989, ARZNEIMITTELFORSCH, V39-1, P120; NEWGREEN DT, 1990, BRIT J PHARMACOL, V100, P605, DOI 10.1111/j.1476-5381.1990.tb15854.x; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; QUAST U, 1988, N-S ARCH PHARMACOL, V338, P319; QUAST U, 1989, TRENDS PHARMACOL SCI, V10, P431, DOI 10.1016/S0165-6147(89)80003-3; QUAST U, 1988, BRIT J PHARMACOL, V93, pP204; QUAST U, 1990, BRIT J PHARMACOL, V99, pP7; ROBERTSON DW, 1990, J MED CHEM, V33, P1529, DOI 10.1021/jm00168a001; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; STEINBERG MI, 1988, J CARDIOVASC PHARM, V12, pS30, DOI 10.1097/00005344-198812002-00007; STEINBERG MI, 1991, J PHARMACOL EXP THER, V256, P222; WILSON C, 1988, BRIT J PHARMACOL, V93, pP126; ZINI S, 1991, J PHARMACOL EXP THER, V259, P566; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225	27	126	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11689	11692						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601843				2022-12-27	WOS:A1992HY94700008
J	KOSKI, P; SAARILAHTI, H; SUKUPOLVI, S; TAIRA, S; RIIKONEN, P; OSTERLUND, K; HURME, R; RHEN, M				KOSKI, P; SAARILAHTI, H; SUKUPOLVI, S; TAIRA, S; RIIKONEN, P; OSTERLUND, K; HURME, R; RHEN, M			A NEW ALPHA-HELICAL COILED COIL PROTEIN ENCODED BY THE SALMONELLA-TYPHIMURIUM VIRULENCE PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCAL M-PROTEIN; MYOSIN HEAVY-CHAIN; COMPLETE NUCLEOTIDE-SEQUENCE; GROUP-A STREPTOCOCCUS; AMINO-ACID-SEQUENCES; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; SECONDARY STRUCTURE; CLONING VEHICLES; M13 VECTORS	A new protein of Salmonella typhimurium was identified and characterized. The gene (tlpA) encoding this protein (TlpA) was isolated from the large virulence-associated plasmid of S. typhimurium and sequenced in order to predict the primary structure of TlpA. tlpA encodes a 371-amino acid soluble protein with a calculated M(r) of 41600 and pI of 4.63. Secondary structure predictions and sequence statistics of TlpA indicated a predominant alpha-helical configuration and presence of heptapeptide repeat motifs characteristic of coiled coil proteins. Purified TlpA was shown to have biochemical properties similar to those of coiled coil proteins, including adoption of an alpha-helical configuration and a tendency to form homodimers. Furthermore, TlpA possessed heat resistance, evidence for a chain register and altered mobility in urea/sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels which are characteristics of tropomyosins. TlpA shows 32% overall sequence similarity with rat cardiac myosin and 36% similarity with horse platelet-beta-tropomyosin over 226 residues, whereas selected regions possessed significant sequence identities with myosins, tropomyosins, and alpha-helical surface proteins of Streptococcus pyogenes. Our results indicate that TlpA represents a new member of prokaryotic coiled coil proteins.	UNIV HELSINKI,DEPT BIOCHEM,UNIONINKATU 35,SF-00170 HELSINKI 17,FINLAND; NATL PUBL HLTH INST,MOLEC BIOL UNIT,SF-00300 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; Finland National Institute for Health & Welfare								BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BILLETER R, 1981, FEBS LETT, V132, P133, DOI 10.1016/0014-5793(81)80446-2; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASAREGOLA S, 1990, MOL MICROBIOL, V4, P505, DOI 10.1111/j.1365-2958.1990.tb00617.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLEMENT RR, 1990, J BACTERIOL, V172, P6217; COHEN C, 1981, P NATL ACAD SCI-BIOL, V78, P5303, DOI 10.1073/pnas.78.9.5303; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CUNNINGHAM MW, 1986, J IMMUNOL, V136, P293; CUNNINGHAM MW, 1986, J EXP MED, V164, P998, DOI 10.1084/jem.164.4.998; CUNNINGHAM MW, 1988, J IMMUNOL, V141, P2760; DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEISENHOFER J, 1978, H-S Z PHYSIOL CHEM, V359, P975, DOI 10.1515/bchm2.1978.359.2.975; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; ELLER M, 1982, NUCLEIC ACIDS RES, V17, P3591; FENDERSON PC, 1989, J IMMUNOL, V143, P2475; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; HALLAUER PL, 1987, J BIOL CHEM, V262, P3590; HANSON J, 1963, J MOL BIOL, V6, P46, DOI 10.1016/S0022-2836(63)80081-9; HELANDER IM, 1989, EUR J BIOCHEM, V185, P541, DOI 10.1111/j.1432-1033.1989.tb15147.x; HELMUTH R, 1985, INFECT IMMUN, V48, P175, DOI 10.1128/IAI.48.1.175-182.1985; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOLTZER ME, 1990, BIOCHEM BIOPH RES CO, V166, P1279, DOI 10.1016/0006-291X(90)91004-C; HOSEIN B, 1979, P NATL ACAD SCI USA, V76, P3765, DOI 10.1073/pnas.76.8.3765; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KRAFT R, 1989, NUCLEIC ACIDS RES, V17, P7529, DOI 10.1093/nar/17.18.7529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LEINONEN M, 1985, ENTEROBACTERIAL SURF, P179; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LILJESTROM P, 1982, MOL GEN GENET, V188, P190, DOI 10.1007/BF00332674; MANJULA BN, 1985, P NATL ACAD SCI USA, V82, P1064, DOI 10.1073/pnas.82.4.1064; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; NAKAMURA K, 1978, J BIOCHEM-TOKYO, V84, P1453, DOI 10.1093/oxfordjournals.jbchem.a132268; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; NOHMI T, 1991, J BACTERIOL, V173, P1051, DOI 10.1128/jb.173.3.1051-1063.1991; NOREL F, 1989, MOL MICROBIOL, V3, P733, DOI 10.1111/j.1365-2958.1989.tb00222.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSONWHITE SH, 1987, J BIOL CHEM, V262, P15998; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RHEN M, 1986, GENE, V49, P351, DOI 10.1016/0378-1119(86)90371-9; RHEN M, 1988, MICROB PATHOGENESIS, V5, P275, DOI 10.1016/0882-4010(88)90100-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER B, 1970, J BIOL CHEM, V245, P1438; SENDER PM, 1971, FEBS LETT, V17, P106, DOI 10.1016/0014-5793(71)80575-6; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P495; TAIRA S, 1989, FEBS LETT, V257, P274, DOI 10.1016/0014-5793(89)81551-0; TAIRA S, 1991, FEMS MICROBIOL LETT, V77, P319, DOI 10.1016/S0378-1097(99)00333-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; VARTIAINEN J, 1964, ACTA MED SCAND, V175, P771; WARAVDEKAR VS, 1959, J BIOL CHEM, V234, P1945; WARREN CPW, 1970, ANN RHEUM DIS, V29, P483, DOI 10.1136/ard.29.5.483; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115	72	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12258	12265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601892				2022-12-27	WOS:A1992HY94700091
J	ROSA, P; MANTOVANI, S; ROSBOCH, R; HUTTNER, WB				ROSA, P; MANTOVANI, S; ROSBOCH, R; HUTTNER, WB			MONENSIN AND BREFELDIN-A DIFFERENTIALLY AFFECT THE PHOSPHORYLATION AND SULFATION OF SECRETORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI CISTERNAE; TYROSYLPROTEIN SULFOTRANSFERASE; LINKED OLIGOSACCHARIDES; INTRACELLULAR-TRANSPORT; N-ACETYLGALACTOSAMINE; ENDOPLASMIC-RETICULUM; TYROSINE SULFATION; SECRETOGRANIN-I; MAMMARY-GLAND; RAT-LIVER	Chromogranin B and secretogranin II, two members of the granin family, are known to be post-translationally modified by the addition of O-linked carbohydrates to serine and/or threonine, phosphate to serine and threonine, and sulfate to carbohydrate and tyrosine residues. In the present study, chromogranin B and secretogranin II were used as model proteins to investigate in which subcompartment of the Golgi complex secretory proteins become phosphorylated. Monensin, a drug known to block the transport from the medial to the trans cisternae of the Golgi stack, inhibited the phosphorylation of the granins, indicating that this modification occurred distal to the medial Golgi. Monensin also blocked the addition of galactose to O-linked carbohydrates and the sulfation of the granins, confirming previous data that these modifications take place in the trans Golgi. To distinguish, within the trans Golgi, between the trans cisternae of the Golgi stack and the trans Golgi network, we made use of the previous observation that brefeldin A results in the redistribution to the endoplasmic reticulum of membrane-bound enzymes of the trans cisternae of the Golgi stack, but not of the trans Golgi network. Brefeldin A treatment abolished granin sulfation but resulted in the accumulation of phosphorylated and galactosylated granins. Differential effects of brefeldin A on membranes of the Golgi stack versus the trans Golgi network were also observed by immunofluorescence analysis of marker proteins specific for either compartment. Our results suggest that the phosphorylation of secretory proteins, like their galactosylation, largely occurs in the trans cisternae of the Golgi stack, whereas the sulfation of secretory proteins on both carbohydrate and tyrosine residues takes place selectively in the trans Golgi network.	UNIV HEIDELBERG, INST NEUROBIOL, W-6900 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	ROSA, P (corresponding author), CNR, CTR CYTOPHARMACOL, DEPT PHARMACOL, VIA VANVITELLI 32, I-20129 MILAN, ITALY.		Huttner, Wieland B./P-4080-2018	Rosa, Patrizia/0000-0002-2590-6955				ABEIJON C, 1987, J BIOL CHEM, V262, P4153; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EIPPER BA, 1982, J BIOL CHEM, V257, P4907; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLOSSL J, 1986, J BIOL CHEM, V261, P1920; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HANOVER JA, 1980, J BIOL CHEM, V255, P6713; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; KAARIAINEN L, 1980, J CELL BIOL, V87, P783, DOI 10.1083/jcb.87.3.783; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE RWH, 1985, P NATL ACAD SCI USA, V82, P6143, DOI 10.1073/pnas.82.18.6143; LEE RWH, 1983, J BIOL CHEM, V258, P1326; LIBERTI JP, 1985, BIOCHEM BIOPH RES CO, V128, P713, DOI 10.1016/0006-291X(85)90105-6; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; OETTING WS, 1986, J BIOL CHEM, V261, P1649; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PAUL JI, 1984, J BIOL CHEM, V259, P3477; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1985, J CELL BIOL, V100, P928, DOI 10.1083/jcb.100.3.928; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; TARTAKOFF A, 1978, J CELL BIOL, V79, P694, DOI 10.1083/jcb.79.3.694; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WANG SY, 1982, J BIOL CHEM, V257, P3837; WATKINSON A, 1989, J BIOL CHEM, V264, P3061; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	51	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12227	12232						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601888				2022-12-27	WOS:A1992HY94700086
J	BELL, JD; BILTONEN, RL				BELL, JD; BILTONEN, RL			MOLECULAR DETAILS OF THE ACTIVATION OF SOLUBLE PHOSPHOLIPASE-A(2) ON LIPID BILAYERS - COMPARISON OF COMPUTER-SIMULATIONS WITH EXPERIMENTAL RESULTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC PHOSPHOLIPASE-A2; LARGE UNILAMELLAR VESICLES; INTERFACIAL CATALYSIS; PHOSPHATIDYLCHOLINE VESICLES; PRODUCT INHIBITION; HYDROLYSIS; KINETICS; AGGREGATION; SUBSTRATE; MONOLAYERS	The initial rate of hydrolysis of large unilamellar vesicles of dipalmitoylphosphatidylcholine by phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus is small and elevates gradually until it suddenly increases by a factor of 10 to 1000 depending on the experimental conditions. This abrupt onset of high enzyme activity appears to be correlated to a specific mole fraction of reaction product at which point a cooperative compositional phase transition in the bilayer occurs. Five models that describe the activation process in terms of its being coupled to the putative product-induced lipid transition are presented. These models include one in which the lipid structure enhances the affinity of enzyme binding to the bilayer surface, two in which the equilibrium position between an active and an inactive form of the enzyme-substrate complex is altered, and two in which the rate of a quasi-irreversible spontaneous activation process is increased. Whether the active form of the enzyme is a monomer or dimer is also considered in the last two pairs of models. Computer simulations of time courses for the different models show how a set of four experimental observables distinguishes qualitatively among them. Comparison of the experimental behavior with the computer-simulated behavior of the observables for each model indicates that activation of phospholipase A2 on the lipid surface involves formation of an enzyme dimer which spontaneously converts to an active form. The active enzyme persists in the active state as it exchanges between vesicles. This model of activation is similar to that proposed previously for activation of porcine pancreatic phospholipase A2.	UNIV VIRGINIA, SCH MED, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA; BRIGHAM YOUNG UNIV, DEPT ZOOL, PROVO, UT 84602 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; Brigham Young University; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037658, R15GM044235, F32GM011838] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM11838, GM37658, GM44235] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARI A, 1987, COLD SPRING HARB SYM, V52, P441, DOI 10.1101/SQB.1987.052.01.051; APITZCASTRO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P349, DOI 10.1016/0005-2736(82)90346-7; BELL JD, 1991, METHOD ENZYMOL, V197, P249; BELL JD, 1989, J BIOL CHEM, V264, P12194; BILTONEN RL, 1991, BIOCH MOL BIOL PHYSL, P85; BOMALASKI JS, 1989, J IMMUNOL, V142, P3957; CHO WW, 1988, J BIOL CHEM, V263, P11237; CUNNINGHAM BA, 1989, BIOCHEMISTRY-US, V28, P32, DOI 10.1021/bi00427a006; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; GHERIANIGRUSZKA N, 1988, J BIOL CHEM, V263, P11808; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V980, P23, DOI 10.1016/0005-2736(89)90195-8; KUPFERBERG JP, 1981, J BIOL CHEM, V256, P6274; LICHTENBERG D, 1986, J BIOL CHEM, V261, P5334; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MENASHE M, 1986, J BIOL CHEM, V261, P5328; MENASHE M, 1981, J BIOL CHEM, V256, P4541; Nieuwenhuizen W, 1974, Methods Enzymol, V32, P147; NISHIYA T, 1991, J BIOCHEM-TOKYO, V109, P383, DOI 10.1093/oxfordjournals.jbchem.a123390; OPDENKAMP JA, 1974, BIOCHIM BIOPHYS ACTA, V345, P253, DOI 10.1016/0005-2736(74)90263-6; PLUCKTHUN A, 1985, J BIOL CHEM, V260, P1099; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; ROMERO G, 1987, J BIOL CHEM, V262, P13476; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; TANFORD C, 1973, HYDROPHOBIC EFFECT F, P13; TINKER DO, 1979, CAN J BIOCHEM CELL B, V57, P97, DOI 10.1139/o79-012; TOMASSELLI AG, 1989, J BIOL CHEM, V264, P10041; VERGER R, 1973, J BIOL CHEM, V248, P4023; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WONG M, 1982, BIOCHEMISTRY-US, V21, P4126, DOI 10.1021/bi00260a032	32	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11046	11056						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597446				2022-12-27	WOS:A1992HX16900021
J	IKEDA, RA				IKEDA, RA			THE EFFICIENCY OF PROMOTER CLEARANCE DISTINGUISHES T7 CLASS-II AND CLASS-III PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; RIBONUCLEIC-ACID POLYMERASE; INVITRO TRANSCRIPTION PROPERTIES; LAC UV5 PROMOTER; NUCLEOTIDE-SEQUENCE; ENZYMATIC-REACTION; T7-RNA POLYMERASE; POINT MUTATIONS; INITIATION; DNA	Promoter strength has been defined as the relative production of transcripts from a promoter. For T7 transcription it has frequently been observed that T7 class III promoters are qualitatively stronger than T7 class II promoters. In previous work it was observed that the maximum rates of initiation of three class III and three class II promoters show no class distinctions (Ikeda, R. A., Lin, A. C., and Clarke, J. (1992) J. Biol. Chem. 267, 2640-2649). This suggests that the efficiency of the conversion of the polymerase initiation complex to a stable transcription complex contributes to the overall strength of T7 promoters. The class differences in the strengths of T7 class II and class III promoters are confirmed by measuring the relative synthesis of run-off transcripts. These results show that the relative strengths of the class III promoters, phi-6.5, phi-10, and phi-13, are all comparable ranging from 0.61 for phi-6.5 to 1.00 for phi-10, while the relative strengths of the T7 class II promoters, phi-1.1B, phi-1.3, and phi-3.8, vary widely. One T7 class II promoter, phi-1.1B (relative strength = 0.34), approaches the strength of the class III promoters, while the other T7 class II promoters, phi-1.3 (relative strength = 0.045) and phi-3.8 (relative strength = 0.070) are nearly inactive. The efficiency of promoter clearance is then determined by measuring the relative production of small transcription products in comparison with the production of run-off transcripts. These measurements clearly distinguish the T7 class III promoters from the T7 class II promoters. It is found that 68-75% of all initiations at the T7 class III promoters phi-6.5, phi-10, and phi-13 produce a run-off transcript, while only 16-36% of the initiations at the T7 class II promoters phi-1.1B, phi-1.3, and phi-3.8 produce a run-off transcript. Clearly, promoter clearance contributes to the difference in promoter strengths of the T7 class II and III promoters.			IKEDA, RA (corresponding author), GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATLANTA,GA 30332, USA.			Ikeda, Richard/0000-0003-4015-5528	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24905] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARTER AD, 1981, J VIROL, V37, P636, DOI 10.1128/JVI.37.2.636-642.1981; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; CHAMBERLIN M, 1982, ENZYMES, V15, P92; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAPMAN KA, 1982, NUCLEIC ACIDS RES, V10, P6331, DOI 10.1093/nar/10.20.6331; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHAPMAN KA, 1988, NUCLEIC ACIDS RES, V16, P4511, DOI 10.1093/nar/16.10.4511; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOULOMB M, 1974, P NATL ACAD SCI USA, V71, P760; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JOLLIFFE LK, 1982, NATURE, V299, P653, DOI 10.1038/299653a0; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCALLISTER WT, 1980, NUCLEIC ACIDS RES, V8, P4821, DOI 10.1093/nar/8.20.4821; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; NILES EG, 1975, J MOL BIOL, V98, P57, DOI 10.1016/S0022-2836(75)80101-X; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; RABKIN SD, 1988, J MOL BIOL, V204, P903, DOI 10.1016/0022-2836(88)90050-2; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SMEEKENS SP, 1986, NUCLEIC ACIDS RES, V14, P2811, DOI 10.1093/nar/14.6.2811; STAHL SJ, 1981, J MOL BIOL, V148, P481, DOI 10.1016/0022-2836(81)90187-X; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	42	26	29	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11322	11328						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597465				2022-12-27	WOS:A1992HX16900061
J	JUST, I; MOHR, C; SCHALLEHN, G; MENARD, L; DIDSBURY, JR; VANDEKERCKHOVE, J; VANDAMME, J; AKTORIES, K				JUST, I; MOHR, C; SCHALLEHN, G; MENARD, L; DIDSBURY, JR; VANDEKERCKHOVE, J; VANDAMME, J; AKTORIES, K			PURIFICATION AND CHARACTERIZATION OF AN ADP-RIBOSYLTRANSFERASE PRODUCED BY CLOSTRIDIUM-LIMOSUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GENE-PRODUCT; PERFRINGENS IOTA TOXIN; GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE-C3; POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; SKELETAL-MUSCLE; ACTIN; RIBOSYLATION; SUBSTRATE	We purified a novel ADP-ribosyltransferase produced by a Clostridium limosum strain isolated from a lung abscess and compared the exoenzyme with Clostridium botulinum ADP-ribosyltransferase C3. The C. limosum exoenzyme has a molecular weight of about 25,000 and a pl of 10.3. The specific activity of the ADP-ribosyltransferase is 3.1 nmol/mg/min with a K(m) for NAD of 0.3-mu-M. Partial amino acid sequence analysis of the tryptic peptides revealed about 70% homology with C3. The novel exoenzyme modifies selectively the small GTP-binding proteins of the rho family in human platelet membranes presumably at the same amino acid (asparagine 41) as known for C3. Recombinant rhoA and rhoB serve as substrates for C3 and the C. limosum exoenzyme. Whereas recombinant rac1 protein is only marginally ADP-ribosylated by C3 or by the C. limosum exoenzyme in the absence of detergent, in the presence of 0.01% sodium dodecyl sulfate rac1 is modified by C3 but not by the C. limosum exoenzyme. Recombinant CDC42Hs protein is a poor substrate for C. limosum exoenzyme and is even less modified by C3. The C. limosum exoenzyme is auto-ADP-ribosylated in the presence of 0.01% sodium dodecyl sulfate by forming an ADP-ribose protein bond highly stable toward hydroxylamine. The data indicate that ADP-ribosylation of small GTP-binding proteins of the rho family is not unique to C. botulinum C3 ADP-ribosyltransferase but is also catalyzed by a C3-related exoenzyme from C. limosum.	UNIV SAARLAND,INST PHARMACOL & TOXIKOL,W-6650 HOMBURG,GERMANY; UNIV BONN,INST MED MIKROBIOL & IMMUNOL,W-5300 BONN,GERMANY; LAB FYSIOL SCHEIKUNDE,B-9000 GHENT,BELGIUM; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Saarland University; University of Bonn; Duke University			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1988, BIOCHEM BIOPH RES CO, V156, P361, DOI 10.1016/S0006-291X(88)80849-0; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, P3, DOI DOI 10.1126/SCIENCE.250.4982.841-A; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; HABERMANN B, 1991, BIOCHIM BIOPHYS ACTA, V1077, P253, DOI 10.1016/0167-4838(91)90537-A; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALL A, 1986, J BIOL CHEM, V261, P963; HONJO T, 1968, J BIOL CHEM, V243, P2553; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEHAMA T, 1990, FEBS LETT, V263, P376, DOI 10.1016/0014-5793(90)81418-N; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; ROSENER S, 1987, FEBS LETT, V224, P38, DOI 10.1016/0014-5793(87)80418-0; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHERING B, 1988, EUR J BIOCHEM, V171, P225, DOI 10.1111/j.1432-1033.1988.tb13780.x; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMPSON LL, 1989, INFECT IMMUN, V57, P255, DOI 10.1128/IAI.57.1.255-261.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEKERCKHOVE J, 1987, FEBS LETT, V225, P48, DOI 10.1016/0014-5793(87)81129-8	39	141	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10274	10280						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587816				2022-12-27	WOS:A1992HV09000014
J	WO, YYP; MCCORMACK, AL; SHABANOWITZ, J; HUNT, DF; DAVIS, JP; MITCHELL, GL; VANETTEN, RI				WO, YYP; MCCORMACK, AL; SHABANOWITZ, J; HUNT, DF; DAVIS, JP; MITCHELL, GL; VANETTEN, RI			SEQUENCING, CLONING, AND EXPRESSION OF HUMAN RED CELL-TYPE ACID-PHOSPHATASE, A CYTOPLASMIC PHOSPHOTYROSYL PROTEIN PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; BOVINE HEART; PURIFICATION; POLYMERASE; ASSIGNMENT; LOCUS; ACP1; GELS; PCR	Low molecular weight phosphotyrosyl protein phosphatases of human placenta and human red cell were purified and sequenced by a combination of Edman degradation and tandem mass spectrometry. Screening of a human placental lambda-gt11 cDNA library yielded over-lapping cDNA clones coding for two distinct human cytoplasmic low molecular weight phosphotyrosyl protein phosphatases (HCPTPs). The two longest clones, designated HCPTP1-1 and HCPTP2-1, were found to have identical nucleotide sequences, with the exception of a 108-base pair segment in the middle of the open reading frame. Polymerase chain reaction studies with human genomic DNA suggest that the difference between HCPTP1-1 and HCPTP2-1 does not result from alternative RNA splicing. Studies with a human chromosome 2-specific library confirmed that these sequences are located on chromosome 2, which is known to be the location of red cell acid phosphatase locus ACP1. The coding sequences of HCPTP1-1 and HCPTP2-1 were placed downstream from a bacteriophage T7 promoter and the proteins were expressed in Escherichia coli. The resulting recombinant enzymes (designated HCPTP-A and HCPTP-B, respectively) showed molecular weights of 18,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and both of them exhibited immunoreactivity with antisera raised against authentic human placental and bovine heart enzymes. The expressed proteins were highly active towards the phosphatase substrates p-nitrophenyl phosphate beta-naphthyl phosphate, and O-phospho-L-tyrosine, but not alpha-naphthyl phosphate, threonine phosphate, or O-phospho-L-serine. HCPTP-A and -B possessed effectively identical amino acid compositions, immunoreactivities, inhibition by formaldehyde, and kinetic properties when compared with two human red cell acid phosphatase isoenzymes. It is concluded that HCPTP-A and -B are the fast and slow forms of red cell acid phosphatase, respectively, and that this enzyme is not unique to the red cell but is instead expressed in all human tissues.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003, R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27713] Funding Source: Medline; NIGMS NIH HHS [GM 37537, GM 27003] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; BLAKE NM, 1973, JPN J HUM GENET, V18, P10; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CHIEN A, 1976, J BACTERIOL, V127, P1550, DOI 10.1128/JB.127.3.1550-1557.1976; DIONNE CA, 1990, BIOTECHNIQUES, V8, P190; DISSING J, 1987, BIOCHEM GENET, V25, P919, DOI 10.1007/BF00502610; DISSING J, 1990, BIOCHIM BIOPHYS ACTA, V1041, P232, DOI 10.1016/0167-4838(90)90277-M; DISSING J, 1991, J BIOL CHEM, V266, P20619; DOOLITTLE RF, 1979, PROTEINS, V4, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENTON MR, 1971, ARCH BIOCHEM BIOPHYS, V142, P13, DOI 10.1016/0003-9861(71)90254-2; FERGUSONSMITH MA, 1973, NATURE-NEW BIOL, V243, P271, DOI 10.1038/newbio243271a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GILMAN JG, 1972, SCIENCE, V178, P873, DOI 10.1126/science.178.4063.873; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; HOPKINSON DA, 1963, NATURE, V199, P969, DOI 10.1038/199969a0; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; HUNT DF, 1991, CURRENT RES PROTEIN, P441; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KLEPPE K, 1971, J MOL BIOL, V56, P341, DOI 10.1016/0022-2836(71)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIDLER PM, 1982, ARCH BIOCHEM BIOPHYS, V216, P512, DOI 10.1016/0003-9861(82)90240-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MERCIER B, 1990, NUCLEIC ACIDS RES, V18, P5908, DOI 10.1093/nar/18.19.5908; MILLER SA, 1987, HUM HERED, V37, P371, DOI 10.1159/000153737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWALLOW DM, 1973, ANN HUM GENET, V37, P31, DOI 10.1111/j.1469-1809.1973.tb01812.x; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO SGS, 1983, ANAL BIOCHEM, V131, P365, DOI 10.1016/0003-2697(83)90185-9; WAHEED A, 1988, BIOCHEMISTRY-US, V27, P4265, DOI 10.1021/bi00412a010; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; ZHANG ZY, 1990, THESIS PURDUE U	46	108	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10856	10865						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587862				2022-12-27	WOS:A1992HV09000097
J	DAS, AK; HORIE, S; HAJRA, AK				DAS, AK; HORIE, S; HAJRA, AK			BIOSYNTHESIS OF GLYCEROLIPID PRECURSORS IN RAT-LIVER PEROXISOMES AND THEIR TRANSPORT AND CONVERSION TO PHOSPHATIDATE IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL DIHYDROXYACETONE PHOSPHATE; CRITICAL MICELLE CONCENTRATION; ACYL-COENZYME-A; LYSOPHOSPHATIDIC ACID; COA; ENZYMES; ACYLTRANSFERASE; LOCALIZATION; MICROBODIES; EXTRACTION	The transport of glycerolipid intermediates, viz. palmitoyl dihydroxyacetone phosphate (DHAP) and lysophosphatidate from peroxisomes and their conversion to phosphatidate in endoplasmic reticulum (microsomes) were studied in cell-free systems. The lipids were biosynthesized from [P-32]DHAP, palmitoyl-CoA, and freshly made rat liver peroxisomes and microsomes in the presence or absence of Mg2+, NADPH, and bovine serum albumin (BSA). After incubation, the soluble fraction and the membranes were separated, and the distribution of radioactive lipids in these fractions were determined. The results showed that palmitoyl-DHAP and lysophosphatidate were recovered in the supernatant when BSA was present or when BSA was absent, but Mg2+ was removed after incubation by chelation with EDTA (or ATP). At low optimum palmitoyl-CoA concentration or when palmitoyl-CoA was generated in peroxisomes, and in the absence of BSA, the biosynthesized keto ether and ester lipids and lysophosphatidate were similarly present in the supernatant. Phosphatidate, however, was always localized lin the membranes. Further fractionation showed that phosphatidate was associated with the microsomes. The critical micellar concentrations of palmitoyl-DHAP and 1-palmitoyl-rac-glycerol 3-phosphate, under the incubation conditions used, were determined to be 58 and 70-mu-M, respectively. These results suggest that at physiological concentrations the biosynthesized lysolipids are water soluble, and therefore, a carrier protein is unnecessary for their transport. These lipids freely diffuse from peroxisomes to endoplasmic reticulum where they are converted to membrane-bound phosphatidate.	UNIV MICHIGAN, MENTAL HLTH RES INST, NEUROSCI LAB, 1103 E HURON ST, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Das, Arun/0000-0002-0883-1816	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747, R01NS008841] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 08841, NS15747] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLAS LM, 1984, BIOCHIM BIOPHYS ACTA, V795, P297, DOI 10.1016/0005-2760(84)90079-1; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BISHOP JE, 1982, ANN NY ACAD SCI, V386, P411, DOI 10.1111/j.1749-6632.1982.tb21437.x; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDES R, 1963, BIOCHEM J, V86, P244, DOI 10.1042/bj0860244; BURDETT K, 1991, J BIOL CHEM, V266, P12201; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DAS AK, 1984, BIOCHIM BIOPHYS ACTA, V796, P178, DOI 10.1016/0005-2760(84)90346-1; DAS AK, 1989, LIPIDS, V24, P329, DOI 10.1007/BF02535172; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; GHOSH MK, 1986, ARCH BIOCHEM BIOPHYS, V245, P523, DOI 10.1016/0003-9861(86)90245-6; GHOSH MK, 1986, ANAL BIOCHEM, V159, P169, DOI 10.1016/0003-2697(86)90323-4; GLATZ JFC, 1989, MOL CELL BIOCHEM, V88, P37, DOI 10.1007/BF00223421; Hajra A K, 1988, Prog Clin Biol Res, V282, P99; HAJRA AK, 1968, BIOCHEM BIOPH RES CO, V33, P929, DOI 10.1016/0006-291X(68)90401-4; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HAJRA AK, 1983, CHEM PHYS LIPIDS, V33, P179, DOI 10.1016/0009-3084(83)90020-8; HAJRA AK, 1979, J BIOL CHEM, V254, P896; HAJRA AK, 1986, ENZYMES LIPID METABO, V2, P199; Haldar D, 1983, Trans N Y Acad Sci, V41, P173; HALDAR D, 1990, J BIOL CHEM, V265, P11014; HARDEMAN D, 1988, BIOCHIM BIOPHYS ACTA, V963, P1, DOI 10.1016/0005-2760(88)90331-1; HARDEMAN D, 1989, BIOCHIM BIOPHYS ACTA, V1006, P1, DOI 10.1016/0005-2760(89)90315-9; HORIE S, 1987, FASEB J, V46, P2287; HSU KHL, 1975, P NATL ACAD SCI USA, V72, P4729, DOI 10.1073/pnas.72.12.4729; JONES CL, 1980, J BIOL CHEM, V255, P8289; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LABELLE EF, 1972, J BIOL CHEM, V247, P5835; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P373; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; NOVIKOFF AB, 1982, ANN NY ACAD SCI, V386, P138, DOI 10.1111/j.1749-6632.1982.tb21412.x; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RABERT U, 1986, BIOL CHEM H-S, V367, P215, DOI 10.1515/bchm3.1986.367.1.215; ROCK CO, 1977, J BIOL CHEM, V252, P6363; Schenkman J B, 1978, Methods Enzymol, V52, P83; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Simoni R D, 1988, Prog Clin Biol Res, V282, P29; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; Tanford C., 1980, HYDROPHOBIC EFFECT F, P63; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; VANCURA A, 1991, BIOCHEM BIOPH RES CO, V175, P339, DOI 10.1016/S0006-291X(05)81240-9; VANDENBOSCH H, 1974, ANNU REV BIOCHEM, V43, P243; WILGRAM GF, 1963, J BIOL CHEM, V238, P2615; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; WOLDEGIORGIS G, 1985, ANAL BIOCHEM, V150, P8, DOI 10.1016/0003-2697(85)90434-8; ZAHLER WL, 1968, BIOCHIM BIOPHYS ACTA, V164, P1, DOI 10.1016/0005-2760(68)90065-9; ZAHLER WL, 1969, BIOCHIM BIOPHYS ACTA, V176, P699, DOI 10.1016/0005-2760(69)90250-1; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9724	9730						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577808				2022-12-27	WOS:A1992HT96500044
J	KANAYA, E; KIKUCHI, M				KANAYA, E; KIKUCHI, M			FOLDING OF HUMAN LYSOZYME INVIVO BY THE FORMATION OF AN ALTERNATIVE DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SECRETION; PROTEIN; YEAST; MUTAGENESIS; CHAIN; ISOMERASE	The mutant h-lysozyme, W64CC65A, with Trp64 and Cys65 replaced by Cys and Ala, respectively, was secreted by yeast and purified. Peptide mapping confirmed that W64CC65A contained a nonnative Cys64-Cys81 bond and three native disulfide bonds. The mutant had 2% of the lytic activity of the wild-type lysozyme. The midpoint concentration of the guanidine hydrochloride denaturation curve, the [D]1/2, was 2.7 M for W64CC65A at pH 3.0 and 25-degrees-C, whereas the [D]1/2 for the wild-type h-lysozyme was 2.9 M. These results show that the W64CC65A protein is a compactly folded molecule. Our previous results, using the mutant C81A, indicate that Cys81 is not required for correct folding and activity, whereas Cys65 is indispensable (Taniyama, Y., Yamamoto, Y., Kuroki, R., and Kikuchi, M. (1990) J. Biol. Chem. 65, 7570-7575). Cys64 substituted for Cys65 in W64CC65A, even though the distance between the a-carbons at positions 64 and 81 in the wild-type h-lysozyme is not favorable for forming a disulfide bond. Unlike C81A, the mutant W64CC65/81A, which has the additional substitution of Ala for Cys81, did not fold. These results suggest that the absence of both the Cys64-Cys81 bond and the amino acid residue Trp64 caused the misfolding or destabilization of W64CC65/81A in vivo. It is proposed that the formation of the alternative bond, Cys64-Cys81 is important for the folding of W64CC65A in vivo.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN									ANDRIA G, 1978, J BIOL CHEM, V253, P2262; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; FURUKAWA K, 1990, Protein Engineering, V3, P353; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; INAKA K, 1991, J BIOL CHEM, V266, P12599; ISHIWATA A, 1991, BIOCHEMISTRY-US, V30, P7766, DOI 10.1021/bi00245a014; KANAYA E, 1990, BIOCHEM BIOPH RES CO, V173, P1194, DOI 10.1016/S0006-291X(05)80912-X; KIDERA A, 1985, J PROTEIN CHEM, V4, P23, DOI 10.1007/BF01025492; KIKUCHI M, 1990, EUR J BIOCHEM, V187, P315, DOI 10.1111/j.1432-1033.1990.tb15307.x; KIKUCHI M, 1988, P NATL ACAD SCI USA, V85, P9411, DOI 10.1073/pnas.85.24.9411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; MURAKI M, 1986, AGR BIOL CHEM TOKYO, V50, P713, DOI 10.1080/00021369.1986.10867445; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; OMURA F, 1991, EUR J BIOCHEM, V198, P477, DOI 10.1111/j.1432-1033.1991.tb16038.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; TANIYAMA Y, 1990, J BIOL CHEM, V265, P16767; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; VITA C, 1987, MACROMOL BIORECOGNIT, P51; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	30	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15111	15115						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634546				2022-12-27	WOS:A1992JF08800089
J	LINARDIC, CM; JAYADEV, S; HANNUN, YA				LINARDIC, CM; JAYADEV, S; HANNUN, YA			BREFELDIN-A PROMOTES HYDROLYSIS OF SPHINGOMYELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-APPARATUS; CELL-DIFFERENTIATION; MEMBRANE; PROTEINS; SPHINGOLIPIDS; TURNOVER; ER	The hydrolysis of sphingomyelin (SM) is a key reaction in the "sphingomyelin cycle," which plays a role in the regulation of cell proliferation and differentiation (Okazaki, T., Bell, R. M., and Hannun, Y. A. (1989) J. Biol. Chem. 264, 19076-19080). SM is produced from endoplasmic reticulum-derived ceramide and is delivered to organelle membranes in a regulated manner, presumably through the same endomembrane trafficking system used for sorting and delivery of proteins. Since brefeldin A (BFA) interferes with this endomembrane trafficking system and thus alters normal membrane and organelle distribution, we investigated the effect of BFA on SM levels in HL-60 leukemia cells. BFA caused a dose-dependent decrease of 20-25% in cellular SM levels, with effects observed at concentrations of BFA as low as 0.10-mu-g/ml. BFA effects on SM levels were noted as early as 5 min and were maximal by 20 min, with no further SM hydrolysis observed up to 60 min following treatment with BFA, suggesting the presence of a fixed SM-sensitive pool. BFA did not cause SM hydrolysis at 16-degrees-C, a temperature that inhibits the effects of BFA on endomembrane mixing. The very early effects and temperature dependence of BFA-induced SM hydrolysis suggest that the mechanism of hydrolysis may be closely related to endomembrane mixing. These studies are beginning to define important interrelationships between membrane trafficking and topology, SM metabolism, and cell regulation.	DUKE UNIV,MED CTR,DEPT MED,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRUNING A, 1992, J BIOL CHEM, V267, P5052; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KIM MY, 1991, J BIOL CHEM, V266, P484; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; TAMURA G, 1968, J ANTIBIOT, V21, P160, DOI 10.7164/antibiotics.21.160; VANCE JE, 1991, J BIOL CHEM, V266, P8241; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14909	14911						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634530				2022-12-27	WOS:A1992JF08800062
J	OSULLIVAN, MG; CHILTON, FH; HUGGINS, EM; MCCALL, CE				OSULLIVAN, MG; CHILTON, FH; HUGGINS, EM; MCCALL, CE			LIPOPOLYSACCHARIDE PRIMING OF ALVEOLAR MACROPHAGES FOR ENHANCED SYNTHESIS OF PROSTANOIDS INVOLVES INDUCTION OF A NOVEL PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ARACHIDONIC-ACID METABOLISM; HUMAN-ENDOTHELIAL-CELLS; ENDOPEROXIDE SYNTHASE; PHORBOL ESTER; MESSENGER-RNA; CYCLOOXYGENASE; THROMBOXANE; STIMULATION; INHIBITORS; PROTEIN	We report here that lipopolysaccharide (LPS) priming of rabbit alveolar macrophages leads to amplified synthesis of prostanoids, at least in part, by induction of a novel prostaglandin H synthase (PGH synthase). Rabbit alveolar macrophages were cultured with or without added LPS derived from Escherichia coli 0111:B4 for 4 h and then stimulated with opsonized zymosan (OPZ). LPS priming of alveolar macrophages resulted in enhanced release of thromboxane (TX) upon stimulation with OPZ, when compared to stimulated non-LPS controls. Addition of exogenous arachidonic acid to LPS-primed alveolar macrophages also resulted in increased production of TX. The LPS-induced increase in TX formation, in response to OPZ or arachidonic acid, was abolished by the addition of actinomycin D or cycloheximide during the priming period. Gas chromatography/mass spectrometry analysis indicated that levels of prostaglandins D2, E2, and F2-alpha, along with TX, were augmented in stimulated LPS-primed alveolar macrophages, implicating PGH synthase in the priming process. PGH synthase enzymatic activity, as determined by addition of arachidonic acid to macrophage sonicates, was markedly enhanced in LPS-primed alveolar macrophages. This correlated with increased PGH synthase levels detected by immunoprecipitation of S-35-labeled proteins and by Western blot analysis. Finally, Northern blot analysis using a cDNA probe to the recently described mitogen-inducible mouse PGH synthase revealed strong induction of approximately 4.3-kilobase mRNA in LPS-primed alveolar macrophages. Taken together, these results reveal that induction of a novel PGH synthase, probably the rabbit homologue of PGH synthase-2, plays a role in the enhanced synthesis of prostanoids by LPS-primed alveolar macrophages.			OSULLIVAN, MG (corresponding author), WAKE FOREST UNIV,MED CTR,DEPT MED,INFECT DIS SECT,WINSTON SALEM,NC 27157, USA.			Chilton, Floyd/0000-0002-3686-0198	NHLBI NIH HHS [HL29293] Funding Source: Medline; NIAID NIH HHS [AI-09169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009169, R21AI009169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; BALL HA, 1986, INTENS CARE MED, V12, P116; BNE RC, 1991, ANN INTERN MED, V115, P457; COCHRANE CG, 1987, AM REV RESPIR DIS, V135, P1; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FAGAN JM, 1986, P NATL ACAD SCI USA, V83, P2771, DOI 10.1073/pnas.83.8.2771; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FU JY, 1990, J BIOL CHEM, V265, P16737; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LARGEN MT, 1986, J IMMUNOL, V136, P988; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; NAKAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1085, P191, DOI 10.1016/0005-2760(91)90094-X; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Olson N C, 1988, Mol Aspects Med, V10, P511, DOI 10.1016/0098-2997(88)90024-6; OSULLIVAN MG, 1990, AM J VET RES, V51, P1820; PUERINGER RJ, 1992, AM J PHYSIOL, V262, pL78, DOI 10.1152/ajplung.1992.262.1.L78; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	28	220	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14547	14550						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634505				2022-12-27	WOS:A1992JF08800009
J	STRIPP, BR; SAWAYA, PL; LUSE, DS; WIKENHEISER, KA; WERT, SE; HUFFMAN, JA; LATTIER, DL; SINGH, G; KATYAL, SL; WHITSETT, JA				STRIPP, BR; SAWAYA, PL; LUSE, DS; WIKENHEISER, KA; WERT, SE; HUFFMAN, JA; LATTIER, DL; SINGH, G; KATYAL, SL; WHITSETT, JA			CIS-ACTING ELEMENTS THAT CONFER LUNG EPITHELIAL-CELL EXPRESSION OF THE CC10 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CLARA CELL; TRANSGENIC MICE; MAMMALIAN LUNG; PROTEIN; MOUSE; PROMOTER; BINDING; RABBIT; ULTRASTRUCTURE	To define cis-acting genetic elements responsible for cell-specific transcriptional regulation of the CC10 gene, DNA sequences spanning nucleotides -2338 to +49 of the rat CC10 gene were linked to a reporter gene coding for chloramphenicol acetyltransferase (CAT). In transient expression assays, CC10 sequences were capable of restricting CAT expression to a human lung adenocarcinoma cell line similar to pulmonary Clara cells. Transgenic mice harboring the hybrid RtCC10-CAT construct expressed high levels of CAT activity specifically within protein extracts of lung and trachea. Transcripts for the CAT reporter gene colocalized with those for the endogenous murine CC10 gene within the airways of transgenic mice. Functional analysis of deletion mutants identified stimulatory, inhibitory, and cell type-specific transcriptional regulatory elements. The results of gel retention and DNaseI protection assays suggest that a transcriptional stimulatory region located between -320 and -175, and a cell type-specific regulatory element located between -175 and +49, result from a series of protein-DNA interactions occurring at -220 to -205 and -128 to -86, respectively. Lung epithelial specific transcriptional regulatory elements described herein will be useful for expression of chimeric genes within epithelial cells lining the trachea, bronchi, and bronchioles of mice.	CHILDRENS HOSP RES FDN,MED CTR,DIV PULM BIOL,ELLAND & BETHESDA AVE,CINCINNATI,OH 45229; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261; UNIV CINCINNATI,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45221	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; University of Cincinnati			Stripp, Barry/AAI-1467-2021	Stripp, Barry/0000-0003-4348-2137	NHLBI NIH HHS [HL-41496, HL-28193] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, R01HL028193] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGERER LM, 1987, IN SITU HYDRIDIZATIO; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS MJ, 1978, LAB INVEST, V38, P648; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; JACOB GA, 1991, J BIOL CHEM, V266, P22537; KATYAL SL, 1990, PROG R RES, V25, P29; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; MANIATIS T, 1982, MOL CLONING LABORATO, P77; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller J. H, 1972, EXPT MOL GENETICS; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V19, P2849, DOI 10.1093/nar/19.11.2849; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; OREILLY MA, 1989, AM J PHYSIOL, V257, pL385, DOI 10.1152/ajplung.1989.257.6.L385; PACK RJ, 1981, J ANAT, V132, P71; PLOPPER CG, 1980, EXP LUNG RES, V1, P171, DOI 10.3109/01902148009069646; PLOPPER CG, 1980, EXP LUNG RES, V1, P139, DOI 10.3109/01902148009069644; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SANDMOLLER A, 1991, MECH DEVELOP, V34, P57, DOI 10.1016/0925-4773(91)90091-J; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Walter C A, 1989, Biotechniques, V7, P1065; WAREMBOURG M, 1986, ENDOCRINOLOGY, V119, P1632, DOI 10.1210/endo-119-4-1632; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	31	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14703	14712						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634515				2022-12-27	WOS:A1992JF08800034
J	REDDY, MK; WEITZEL, SE; VONHIPPEL, PH				REDDY, MK; WEITZEL, SE; VONHIPPEL, PH			PROCESSIVE PROOFREADING IS INTRINSIC TO T4 DNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; SPONTANEOUS MUTATION; GEL-ELECTROPHORESIS; REPLICATION SYSTEM; III HOLOENZYME; AMBER MUTANT; SIZE CLASSES; PROTEIN	DNA replication occurs in vivo with very high processivity, meaning that the replication complex assembles at the origin(s) of replication and then performs template-directed synthesis of DNA over virtually the entire genome without dissociation. Such processivity also characterizes reconstituted replication holoenzyme complexes in vitro. However, the isolated DNA polymerases are much less processive, especially under physiological conditions. In this paper we monitor the degree of processivity displayed by the bacteriophage T4-coded DNA polymerase while in its proofreading mode by asking whether an isolated polymerase can "edit-out" the 3'-terminal nucleotide from the primer (using the 3'-->5'-exonuclease activity of the polymerase) and then switch into the synthesis mode without dissociating from the DNA template. This "switch experiment" is accomplished by using mismatched primer/template substrates as an experimental tool to mimic the situation that T4 DNA polymerase encounters after a misincorporation event has occurred. By performing experiments under single-turnover conditions (obtained using a heparin trap), we demonstrate that T4 DNA polymerase, upon encountering a misincorporated base, neither synthesizes the next base nor dissociates into solution. Instead, with a greater than 80% probability, it removes the misincorporated base and then continues synthesis in a fully processive manner. We also show that the removal of a doubly mispaired sequence from the 3'-terminus of the primer, followed by synthesis, is comparably processive. In contrast, the apparent processivity of removing a triply mispaired terminus is much reduced. Taken together, these observations are consistent with the notion that the "editing active site" of the T4 enzyme optimally accommodates only two unpaired nucleotide residues. Our results do not support the idea that the exonuclease activity of T4 DNA polymerase is highly selective for mismatched termini; they suggest instead that the dwell time at a misincorporated base determines overall editing efficiency. The integrated results of this study provide additional insight into the structure of the T4 DNA polymerase, as well as into the interactions between the polymerase and the polymerase accessory proteins that are required to provide the holoenzyme complex with full processivity.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015792, R01GM029158, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DAS SK, 1980, J BIOL CHEM, V255, P7149; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DOLEJSI MK, 1988, THESIS U OREGON; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODMAN MF, 1983, J BIOL CHEM, V258, P3469; GOULIAN M, 1968, J BIOL CHEM, V243, P627; GREIP MA, 1989, J BIOL CHEM, V264, P11294; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HUANG WM, 1972, J BIOL CHEM, V247, P3139; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1990, UCLA SYM BI, V127, P261; JARVIS TC, 1990, J BIOL CHEM, V265, P15160; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1988, DNA REPLICATION MUTA, P220; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1981, J BIOL CHEM, V256, P9883; KUNKEL TA, 1984, J BIOL CHEM, V259, P1539; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY D, 1976, J MOL BIOL, V106, P963, DOI 10.1016/0022-2836(76)90346-6; MIZRAHI V, 1986, ADV ENZYMOL RELAT AR, V61, P437; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OVERMAN LB, 1988, BIOCHEMISTRY-US, V34, P440; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; RUSH J, 1989, PREP BIOCHEM, V19, P329, DOI 10.1080/10826068908544921; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; von Hippel P.H., 1975, PROTEIN LIGAND INTER, P270; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	60	84	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14157	14166						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629215				2022-12-27	WOS:A1992JD32500059
J	SOBOTKABRINER, C; CHELSKY, D				SOBOTKABRINER, C; CHELSKY, D			COOH-TERMINAL METHYLATION OF LAMIN-B AND INHIBITION OF METHYLATION BY FARNESYLATED PEPTIDES CORRESPONDING TO LAMIN-B AND OTHER CAAX MOTIF PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; SACCHAROMYCES-CEREVISIAE; CARBOXYL-METHYLATION; NUCLEAR-ENVELOPE; POSTTRANSLATIONAL MODIFICATION; ESTERIFIED PROTEINS; GAMMA-SUBUNIT; RAS2 PROTEIN; CDNA CLONES; CELL LINE	Previous reports from this laboratory have demonstrated that lamin B is reversibly methylesterified in a cell cycle-dependent manner. The site of this methylation, however, was not identified. In this report, we describe a single major methylated product obtained following reversed-phase high-performance liquid chromatographic analysis of peptides generated by proteolytic digestion of lamin B from rat liver nuclear envelopes. This peptide was retained on a lamin B COOH-terminal-specific antibody-affinity column, and COOH-terminal localization was confirmed by amino acid sequencing. Two other COOH-terminal peptides were found but were not methylated and differed in sequence by at least a single residue from the methylated peptide, indicating the existence of two lamin B gene products. Tetrapeptides, representing the putative mature COOH termini of lamin B, K-ras-2A, and unprocessed lamin A, were synthesized with or without farnesyl modification of the COOH-terminal cysteines. All three farnesylated peptides served as substrates for the partially purified lamin B methyltransferase with apparent K(m) values of 4.5, 0.69, and 21-mu-M, respectively. Nonfarnesylated peptides were not substrates for the enzyme. The three farnesylated peptides were also effective to varying degrees at inhibiting the methylation of lamin B and other cellular proteins in cell lysates.	DUPONT MERCK PHARMACEUT CO,CANC DISCOVERY RES,WILMINGTON,DE 19880	DuPont								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ATHERTON E, 1985, J CHEM SOC CHEM COMM, V3, P165; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HOGER TH, 1988, EUR J CELL BIOL, V47, P283; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; RUEGG R, 1959, HELV CHIM ACTA, V42, P2616, DOI 10.1002/hlca.19590420733; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	35	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12116	12122						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601879				2022-12-27	WOS:A1992HY94700071
J	XU, Q; LEIVA, MC; FISCHKOFF, SA; HANDSCHUMACHER, RE; LYTTLE, CR				XU, Q; LEIVA, MC; FISCHKOFF, SA; HANDSCHUMACHER, RE; LYTTLE, CR			LEUKOCYTE CHEMOTACTIC ACTIVITY OF CYCLOPHILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE RAT UTERUS; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; LEUKEMIA-CELLS; EOSINOPHIL; ESTROGEN; CYCLOSPORINE; PURIFICATION; INHIBITION; DISTINCT	During the purification of eosinophil chemotactic factors synthesized by the uterus in response to estrogen we isolated a protein having an N-terminal (15 amino acids) sequence identical to that of rat cyclophilin. Our data demonstrate that cyclophilin, a cytosolic protein isolated from bovine thymocytes, which specifically binds the immunosuppressive drug cyclosporin A, as well as recombinant human cyclophilin, displays eosinophil chemotactic activity. In addition to its chemotactic activity, cyclophilin stimulated the release of peroxidase activity from eosinophils. Maximal chemotactic activity of cyclophilin was achieved at a concentration of approximately 10 nM. At similar concentrations cyclophilin was also able to stimulate the migration of neutrophils. This chemotactic activity could be prevented by the addition of cyclosporin A, but not by a nonimmunosuppressive analog (1-fur-furyl-cyclosporin A) at similar concentrations. This chemotactic activity may represent an additional mechanism by which immunosuppressive drugs function to prevent tissue rejection.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,CLIN RES BLDG,422 CURIE BLVD,RM 778,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06520	University of Pennsylvania; University of Pennsylvania; Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020025, P01HD006274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-20025, HD06274] Funding Source: Medline; NIGMS NIH HHS [GM-40660] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJERSING L, 1964, ACTA PATHOL MIC SC, V60, P27, DOI 10.1111/apm.1964.60.1.27; CARONI P, 1991, J BIOL CHEM, V266, P10739; CORNER GW, 1969, J ENDOCRINOL, V131, P3; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DRATH DB, 1983, TRANSPLANT P, V15, P2367; DURETTE PL, 1988, TRANSPLANT P, V20, P51; ETIENNE A, 1989, INT ARCH ALLER A IMM, V88, P216, DOI 10.1159/000234790; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1980, EOSINOPHIL HLTH DISE, P158; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HIRASAWA K, 1990, TRANSPLANTATION, V50, P637, DOI 10.1097/00007890-199010000-00022; HOWE RS, 1990, ENDOCRINOLOGY, V126, P3193, DOI 10.1210/endo-126-6-3193; HOWE RS, 1990, EXP HEMATOL, V18, P299; HULTSCH T, 1990, J IMMUNOL, V144, P2659; LEE YH, 1989, ENDOCRINOLOGY, V125, P3022, DOI 10.1210/endo-125-6-3022; LIMBERG MB, 1986, BRIT J OPHTHALMOL, V70, P343, DOI 10.1136/bjo.70.5.343; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LYTTLE CR, 1977, P NATL ACAD SCI USA, V74, P3162, DOI 10.1073/pnas.74.8.3162; MAKI N, 1990, P NATL ACAD SCI USA, V87, P5440, DOI 10.1073/pnas.87.14.5440; Rytomaa T., 1960, ACTA PATHOL MIC S140, V50, P111; SCHLUTER E, 1975, VIRCHOWS ARCH A, V368, P191, DOI 10.1007/BF00432522; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SPIK G, 1991, J BIOL CHEM, V266, P10735; STACK G, 1984, ENDOCRINOLOGY, V115, P1141, DOI 10.1210/endo-115-3-1141; TCHERNITCHIN A, 1974, NATURE, V248, P142, DOI 10.1038/248142a0; VENGE P, 1990, AGENTS ACTIONS, V29, P122, DOI 10.1007/BF01964739; ZHENG Y, 1988, J LEUKOCYTE BIOL, V44, P27, DOI 10.1002/jlb.44.1.27	34	162	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11968	11971						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601866				2022-12-27	WOS:A1992HY94700049
J	BEAUMELLE, B; BENSAMMAR, L; BIENVENUE, A				BEAUMELLE, B; BENSAMMAR, L; BIENVENUE, A			SELECTIVE TRANSLOCATION OF THE A-CHAIN OF DIPHTHERIA-TOXIN ACROSS THE MEMBRANE OF PURIFIED ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; CELL-MEMBRANE; PROTEIN; PH; LYMPHOCYTES; ENTRY; REQUIREMENTS; FRAGMENT; BINDING	Translocation is a necessary and rate-limiting step for diphtheria toxin (DT) cytotoxicity. We have reconstituted DT translocation in a cell-free system using endosomes purified from lymphocytes and have demonstrated this using two different probe/cell systems, which provided identical results: I-125-DT/human CEM cells and I-125-transferrin-DT/mouse BW cells. The cell-free DT translocation process was found to be dependent on the presence of the pH gradient endosome (pH 5.3)/cytosol (pH 7). Among the pH equilibrating agents, nigericin (5-mu-M) was found to be the most effective, inhibiting DT translocation by 88%. An optimum pH value of 7 on the cytosolic side of the membrane (pH gradient almost-equal-to 1.7) was determined. ATP per se is not required for DT translocation. I-125-DT translocation was 3-fold more active from late than from early endosomes, probably because of their slightly more acidic pH. Only the A chain of the toxin was found to escape from either I-125-DT/CEM or I-125-transferrin-DT/BW endosomes. Translocation of control endosome labels (I-125-transferrin and I-125-horseradish peroxidase) was never observed. We also show that DT receptors present on resistant (mouse) cells block the translocation of the toxin and are responsible for the resistance of these cells to DT.			BEAUMELLE, B (corresponding author), UNIV MONTPELLIER 2, DEPT BIOL SANTE, CNRS, URA 530, CASE 107, F-34095 MONTPELLIER 5, FRANCE.			Beaumelle, Bruno/0000-0002-4912-9134				BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CARRIERE D, 1989, EXP CELL RES, V182, P114, DOI 10.1016/0014-4827(89)90284-X; DOMINGO DL, 1985, METHOD ENZYMOL, V112, P238; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONZALEZ JE, 1988, J BIOL CHEM, V263, P15257; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; JIANG JX, 1991, J BIOL CHEM, V266, P24003; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KEEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P2912, DOI 10.1073/pnas.79.9.2912; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; MARSH JW, 1988, J BIOL CHEM, V263, P15993; MARSH M, 1984, BIOCHEM J, V218, P1; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; NAKAMURA LT, 1990, J BIOL CHEM, V265, P5237; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S., 1988, IMMUNOTOXINS, P39; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAINTEMARIE J, 1989, BIOCHIM BIOPHYS ACTA, V982, P265, DOI 10.1016/0005-2736(89)90063-1; STENMARK H, 1988, J BIOL CHEM, V263, P13449; URADE R, 1988, BIOCHIM BIOPHYS ACTA, V946, P151, DOI 10.1016/0005-2736(88)90468-3; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WILSON BA, 1990, SCIENCE, V250, P834, DOI 10.1126/science.250.4982.834	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11525	11531						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597480				2022-12-27	WOS:A1992HX16900090
J	TELLER, JK; FAHIEN, LA; DAVIS, JW				TELLER, JK; FAHIEN, LA; DAVIS, JW			KINETICS AND REGULATION OF HEPATOMA MITOCHONDRIAL NAD(P) MALIC ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; RAT-LIVER MITOCHONDRIA; TUMOR MITOCHONDRIA; DEHYDROGENASE COMPLEX; MALATE-DEHYDROGENASE; ALPHA-KETOGLUTARATE; CITRATE SYNTHASE; CELLS; PURIFICATION; GLUTAMATE	Kinetic studies of Morris 7777 hepatoma mitochondrial NAD(P) malic enzyme were consistent with an ordered mechanism where NAD adds to the enzyme before malate and dissociation of NADH from the enzyme is rate-limiting. In addition to its active site, malate apparently also associates with a lower affinity with an activator site. The activator fumarate competes with malate at the activator site and facilitates dissociation of NADH from the enzyme. The ratio of NAD(P) malic enzyme to malate dehydrogenase activity in the hepatoma mitochondrial extract was found to be too low, even in the presence of known inhibitors of malate dehydrogenase, to account for the known ability of NAD(P) malic enzyme to intercept exogenous malate from malate dehydrogenase in intact tumor mitochondria (Moreadith, R. W., and Lehninger, A. L. (1984) J. Biol. Chem. 259, 6215-6221). However, NAD(P) malic enzyme may be able to intercept exogenous malate because according to the present results, it can associate with the pyruvate dehydrogenase complex, which could localize NAD(P) malic enzyme in the vicinity of the inner mitochondrial membrane. The activity levels of some key metabolic enzymes were found to be different in Morris 7777 mitochondria than in liver or mitochondria of other rapidly dividing tumors. These results are discussed in terms of differences among tumors in their ability to utilize malate, glutamate, and citrate as respiratory fuels.	UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, 1300 UNIV AVE, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 40445] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; Barritt G. J., 1976, GLUCONEOGENESIS ITS, P3; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DENYER GS, 1986, BIOCHEM J, V239, P347, DOI 10.1042/bj2390347; DSOUZA SF, 1983, J BIOL CHEM, V258, P4706; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P478, DOI 10.1016/0003-9861(69)90060-5; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P449, DOI 10.1016/0003-9861(69)90057-5; FAHIEN LA, 1992, J BIOL CHEM, V267, P10411; FAHIEN LA, 1964, J BIOL CHEM, V239, P1925; FAHIEN LA, 1989, J BIOL CHEM, V264, P12303; FAHIEN LA, 1970, MOL PHARMACOL, V6, P156; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P468, DOI 10.1016/0003-9861(69)90059-9; FAHIEN LA, 1988, J BIOL CHEM, V263, P10687; FAHIEN LA, 1969, ARCH BIOCHEM BIOPHYS, V130, P456, DOI 10.1016/0003-9861(69)90058-7; FRIEDEN C, 1964, J BIOL CHEM, V239, P3522; FUKUSHIMA T, 1989, J BIOL CHEM, V264, P16483; HANSFORD RG, 1973, BIOCHEM BIOPH RES CO, V51, P480, DOI 10.1016/0006-291X(73)91282-5; HARARY I, 1953, J BIOL CHEM, V203, P595; HOEK JB, 1974, BIOCHIM BIOPHYS ACTA, V333, P546, DOI 10.1016/0005-2728(74)90138-8; HSU RY, 1967, J BIOL CHEM, V242, P5315; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KOVACEVIC Z, 1971, BIOCHEM J, V125, P757, DOI 10.1042/bj1250757; KOVACEVIC Z, 1991, BIOCHEM J, V273, P271, DOI 10.1042/bj2730271; KOVACEVIC Z, 1972, CANCER RES, V32, P326; LAWSON D, 1975, CANCER RES, V35, P156; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LAZO PA, 1981, EUR J BIOCHEM, V117, P19; LAZO PA, 1980, BIOCHEM J, V190, P705, DOI 10.1042/bj1900705; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LENARTOWICZ E, 1979, BIOCHIM BIOPHYS ACTA, V586, P31, DOI 10.1016/0304-4165(79)90402-1; LINDERHOROWITZ M, 1969, CANCER RES, V29, P1195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARESPERLMAN JA, 1988, CANCER RES, V48, P602; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; NAGEL WO, 1982, J BIOL CHEM, V257, P2405; PARLO RA, 1984, J BIOL CHEM, V259, P9997; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; REED LJ, 1981, COLD SPRING HARBOR C, V8, P701; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROBINSON JB, 1987, J BIOL CHEM, V262, P1786; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; SAUER LA, 1973, BIOCHEM BIOPH RES CO, V50, P524, DOI 10.1016/0006-291X(73)90871-1; SAUER LA, 1973, FEBS LETT, V33, P251, DOI 10.1016/0014-5793(73)80205-4; SAUER LA, 1980, J BIOL CHEM, V255, P3844; SCHIMERLIK MI, 1977, BIOCHEMISTRY-US, V16, P571, DOI 10.1021/bi00623a002; SIESS EA, 1976, CANCER RES, V36, P55; SILVERSTEIN E, 1969, BIOCHIM BIOPHYS ACTA, V185, P297, DOI 10.1016/0005-2744(69)90422-7; SILVERSTEIN E, 1969, BIOCHEMISTRY-US, V8, P2543, DOI 10.1021/bi00834a042; SMITH CM, 1979, EUR J BIOCHEM, V97, P283, DOI 10.1111/j.1432-1033.1979.tb13113.x; SRERE PA, 1976, GLUCONEOGENESIS ITS, P153; STANLEY CJ, 1980, BIOCHEM J, V191, P147, DOI 10.1042/bj1910147; SUMEGI B, 1980, BIOCHIM BIOPHYS ACTA, V616, P158, DOI 10.1016/0005-2744(80)90134-5; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; SWICK RW, 1965, J BIOL CHEM, V240, P3334; Teller J K, 1990, Protein Expr Purif, V1, P151, DOI 10.1016/1046-5928(90)90009-N; TELLER JK, 1990, J BIOL CHEM, V265, P19486; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; WICE BM, 1981, J BIOL CHEM, V256, P7812; ZOLNIEROWICZ S, 1988, BIOCHEM MED METAB B, V39, P208, DOI 10.1016/0885-4505(88)90078-3	63	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10423	10432						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587826				2022-12-27	WOS:A1992HV09000036
J	NEUENSCHWANDER, PF; MORRISSEY, JH				NEUENSCHWANDER, PF; MORRISSEY, JH			DELETION OF THE MEMBRANE ANCHORING REGION OF TISSUE FACTOR ABOLISHES AUTOACTIVATION OF FACTOR-VII BUT NOT COFACTOR FUNCTION - ANALYSIS OF A MUTANT WITH A SELECTIVE DEFICIENCY IN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; ACTIVATED FACTOR-IX; BOVINE FACTOR-VII; FACTOR-X; BLOOD-COAGULATION; PROTEIN; MECHANISM; THROMBIN; CLEAVAGE; CALCIUM	The activation of human blood coagulation factor VII can occur by the feedback activity of either factor VIIa (autoactivation) or factor Xa. Both of these reactions are known to be enhanced by the presence of tissue factor, an integral membrane protein and the cofactor for factor VIIa. We examine here the activation of I-125-factor VII by both factor VIIa and factor Xa employing a mutant soluble form of tissue factor which has had its transmembrane and cytoplasmic domains deleted (sTF1-219). This mutant soluble tissue factor retains cofactor activity toward factor VIIa in a single-stage clotting assay but shows a strong dependence on initial plasma levels of factor VIIa (from 1 to 10,000 ng/ml) when compared to wild-type tissue factor. We show that this dependence is due to a deficiency of sTF1-219 in ability to both promote autoactivation and enhance the factor Xa-catalyzed activation of I-125-factor VII. sTF1-219 does not, however, inhibit the tissue factor-independent activation of I-125-factor VII by factor Xa. The results strongly suggest that the phospholipid anchoring region of tissue factor is essential for autoactivation and beneficial for factor Xa-catalyzed activation of I-125-factor VII. In addition, when taken together with the dependence of clotting times on initial factor VIIa levels observed with sTF1-219, these results indicate that factor VII autoactivation may be of greater importance in the initiation of blood coagulation via tissue factor than has been previously realized.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NHLBI NIH HHS [HL-44225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Bevington P.R., 1969, DATA REDUCTION ERROR; BJORKLID E, 1977, BIOCHEM J, V165, P89, DOI 10.1042/bj1650089; COMP PC, 1984, BLOOD, V63, P15; GUHA A, 1992, FASEB J, V6, pA328; HAPAK RC, 1992, FASEB J, V6, pA330; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASYS DR, 1982, BLOOD, V60, P1143; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1984, MET IONS BIOL SYST, V17, P353; NEMERSON Y, 1973, P NATL ACAD SCI USA, V70, P310, DOI 10.1073/pnas.70.2.310; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1991, ARTERIOSCL THROMB, V11, P1544; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1985, BLOOD, V65, P218; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SELIGSOHN U, 1979, J CLIN INVEST, V64, P1056, DOI 10.1172/JCI109543	34	112	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14477	14482						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629232				2022-12-27	WOS:A1992JD32500104
J	SCHMIDT, CJ; THOMAS, TC; LEVINE, MA; NEER, EJ				SCHMIDT, CJ; THOMAS, TC; LEVINE, MA; NEER, EJ			SPECIFICITY OF G-PROTEIN-BETA-SUBUNIT AND GAMMA-SUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; MUSCARINIC K+-CHANNEL; LIMITED PROTEOLYSIS; RETINAL ROD; CDNA CLONE; TRANSDUCIN; PHOSPHOLIPASE-A2; IDENTIFICATION; HOMOLOGY; BRAIN	Multiple heterotrimeric guanine nucleotide binding protein (G protein) subunits have evolved to couple a large variety of receptors to intracellular effectors. G protein beta-gamma subunits are essential for efficient coupling of alpha-subunits to receptors, and they are also important for modulation of effectors. Several different beta and gamma-subunits exist, but it is not known whether all possible combinations of beta and gamma can form functional dimers. To answer this question, we have compared the ability of in vitro translated beta-1, beta-2, and beta-3 to form dimers with either gamma-1 or gamma-2. Dimerization was monitored by gel filtration, resistance to tryptic digestion, and chemical cross-linking. The results indicate that beta-1 binds both gamma-subunits, beta-2 binds only gamma-2, and beta-3 will bind neither gamma-1 or gamma-2. Hence, the occurrence of beta-gamma dimers may be partially regulated by the ability of the subunits to associate. Specificity of dimerization might allow cells to co-express multiple beta and gamma-subunits while maintaining efficient and specific signal transduction.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,BALTIMORE,MD 21205	Harvard University; Harvard Medical School; Johns Hopkins University	SCHMIDT, CJ (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.			Levine, Michael/0000-0003-0036-7809; Schmidt, Carl/0000-0002-8386-4781	NIDDK NIH HHS [R01 DK34281, T32 DK07737] Funding Source: Medline; NIGMS NIH HHS [GM36295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034281, T32DK007737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; CHRISTY KG, 1989, BIOTECHNIQUES, V7, P692; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5983; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YI F, 1991, J BIOL CHEM, V266, P3900	30	170	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13807	13810						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629181				2022-12-27	WOS:A1992JD32500005
J	WARD, CR; STOREY, BT; KOPF, GS				WARD, CR; STOREY, BT; KOPF, GS			ACTIVATION OF A GI PROTEIN IN MOUSE SPERM MEMBRANES BY SOLUBILIZED PROTEINS OF THE ZONA-PELLUCIDA, THE EGGS EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROINJECTED INOSITOL 1,4,5-TRISPHOSPHATE; NUCLEOTIDE REGULATORY PROTEINS; MANNOSE 6-PHOSPHATE RECEPTOR; INDUCED ACROSOME REACTION; PERTUSSIS TOXIN; MAMMALIAN SPERM; FERTILIZATION INVITRO; PHOSPHOLIPID-VESICLES; GAMETE INTERACTIONS; BINDING PROTEINS	Zona pellucida (ZP)-induced acrosomal exocytosis in mammalian spermatozoa is thought to be mediated by signal transduction cascades similar to those found in hormonally responsive cells. In order to characterize this process further, we have examined the role of GTP-binding regulatory proteins (G proteins) in coupling sperm-ZP interaction to intracellular second messenger systems in mouse sperm. An in vitro signal transduction assay was developed to assess ZP-G protein dynamics in sperm membrane preparations. Guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S), a poorly hydrolyzable analogue of GTP, bound to these membranes in a specific and concentration-dependent fashion which reached saturation at 100 nm. Incubation of the membrane preparations with heat-solubilized ZP resulted in a significant increase in specific GTP-gamma-S binding in a concentration-dependent fashion with a half-maximal response at 1.25-2 ZP/mu-l. Solubilized ZP also caused a significant increase in high affinity GTPase activity in the membranes over basal levels. Mastoparan increased specific GTP-gamma-S binding to the sperm membranes and stimulated high-affinity membrane GTPase activity to levels consistently greater than that seen with the solubilized ZP. Mastoparan, together with solubilized ZP, gave the same level of stimulation of GTP-gamma-S binding as mastoparan alone. Pertussis toxin completely inhibited the ZP-stimulated GTP-gamma-S binding, but only decreased mastoparan-stimulated GTP-gamma-S binding by 70-80%. Purified ZP3, the ZP component which possesses quantitatively all of the acrosomal exocytosis-inducing activity of the intact ZP, stimulated GTP-gamma-S binding to the same level as solubilized ZP; ZP1 and ZP2 did not stimulate GTP-gamma-S binding. ZP from fertilized eggs (ZP(f)), which does not possess acrosome reaction-inducing activity, also failed to stimulate GTP-gamma-S binding to sperm membranes. These data demonstrate the direct activation of a G(i) protein in sperm membrane preparations in response to the ZP glycoprotein, ZP3, that induces the acrosome reaction. These data imply that G(i) protein activation is an early event in the signal sequence leading to sperm acrosomal exocytosis.			WARD, CR (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, PHILADELPHIA, PA 19104 USA.				NICHD NIH HHS [HD06274, HD07725, HD22732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDFORD JM, 1978, CELL SURF REV, V5, P65; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAMORATTO AM, 1985, ENDOCRINOLOGY, V116, P1506, DOI 10.1210/endo-116-4-1506; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FAUNDES DF, 1991, J CELL BIOL, V4115, pA141; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; GREVE JM, 1985, J MOL BIOL, V181, P253, DOI 10.1016/0022-2836(85)90089-0; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KALAB P, 1991, BIOL REPROD, V45, P783, DOI 10.1095/biolreprod45.5.783; KARNIK NS, 1992, IN PRESS DEV BIOL; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KLIGMAN I, 1991, DEV BIOL, V145, P344, DOI 10.1016/0012-1606(91)90133-N; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KOPF GS, 1986, J BIOL CHEM, V261, P7327; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KURASAWA S, 1989, DEV BIOL, V133, P295, DOI 10.1016/0012-1606(89)90320-5; KURODA Y, 1980, P JPN ACAD B-PHYS, V56, P660, DOI 10.2183/pjab.56.660; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1985, BIOL REPROD, V33, P235, DOI 10.1095/biolreprod33.1.235; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1989, DEV BIOL, V132, P174, DOI 10.1016/0012-1606(89)90215-7; LIANG M, 1991, J BIOL CHEM, V266, P13342; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; SALING PM, 1979, J CELL BIOL, V83, P544, DOI 10.1083/jcb.83.3.544; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P414; WILDE MW, 1992, MOL REPROD DEV, V31, P297, DOI 10.1002/mrd.1080310411; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4	60	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14061	14067						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629205				2022-12-27	WOS:A1992JD32500045
J	ALLEN, LAH; RAETZ, CRH				ALLEN, LAH; RAETZ, CRH			PARTIAL PHENOTYPIC SUPPRESSION OF A PEROXISOME-DEFICIENT ANIMAL-CELL MUTANT TREATED WITH AMINOGLYCOSIDE-G418	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION ENZYMES; HAMSTER OVARY CELLS; ZELLWEGER SYNDROME; MEMBRANE-PROTEINS; LIGNOCERIC ACID; BIOSYNTHESIS; FIBROBLASTS; LIVER; DISORDERS; PLASMALOGENS	Certain enzymes normally associated with peroxisomes, such as the dihydroxyacetone phosphate (DHAP) acyltransferase involved in plasmalogen biosynthesis, are present at low levels in peroxisomedeficient mutants of Chinese hamster ovary (CHO) cells. We now show that the aminoglycoside G418 increases the residual DHAP acyltransferase in mutant ZR-82 by 60-fold. This is accompanied by a dose- and time-dependent restoration of the plasmalogen content. G418 treatment of ZR-82 also increases residual peroxisomal beta-oxidation activity by 3.8-fold. G418 does not affect wild-type CHO cells (CHO-K1) or a different peroxisome-deficient mutant, ZR-78.1. The effects of G418 on ZR-82 are transient, since plasmalogens and DHAP-acyltransferase decline to basal levels 5 days after G418 withdrawal. Other aminoglycosides and lysosomotropic agents do not alter plasmalogen levels in ZR-82. The subcellular distribution of catalase (an enzyme of the peroxisomal matrix which is present in normal amounts in peroxisome-deficient mutants but is mislocalized in the cytosol) is unaffected by G418 treatment of ZR-82, demonstrating that G418 does not restore peroxisomes. Localization of catalase by immunofluorescence microscopy confirms a total absence of intact peroxisomes in ZR-82, either before or after exposure to G418. This study is the first to demonstrate that some peroxisome-deficient mutants can be induced to accumulate functional DHAP acyltransferase and other peroxisomal enzymes, usually missing in the absence of peroxisomes. G418 may have some theraputic value in selected patients with inborn errors of peroxisome assembly, such as Zellweger syndrome.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000,RAHWAY,NJ 07065; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	Merck & Company; University of Wisconsin System; University of Wisconsin Madison				Allen, Lee-Ann/0000-0001-8929-6968				ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; ALLEN LAH, 1990, FASEB J, V4, P2246; AUBERTTULKENS G, 1979, LAB INVEST, V40, P481; BALLAS LM, 1984, BIOCHIM BIOPHYS ACTA, V795, P297, DOI 10.1016/0005-2760(84)90079-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHANAN JH, 1987, EUR J CELL BIOL, V43, P141; DANIELSON KG, 1989, IN VITRO CELL DEV B, V25, P535; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EUSTICE DC, 1984, BIOCHEMISTRY-US, V23, P1462, DOI 10.1021/bi00302a019; EUSTICE DC, 1984, ANTIMICROB AGENTS CH, V26, P53, DOI 10.1128/AAC.26.1.53; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HYMAN R, 1989, CELL SURFACE ANTIGEN, V1, P223; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MINGEOTLECLERCQ MP, 1988, BIOCHEM PHARMACOL, V37, P591, DOI 10.1016/0006-2952(88)90130-X; MORAND OH, 1990, BIOCHIM BIOPHYS ACTA, V1034, P132, DOI 10.1016/0304-4165(90)90066-6; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSER HW, 1987, DEV NEUROSCI-BASEL, V9, P1, DOI 10.1159/000111604; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SCHRAM AW, 1986, P NATL ACAD SCI USA, V83, P6156, DOI 10.1073/pnas.83.16.6156; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SINGH I, 1983, J LIPID RES, V24, P662; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; STEVENS VL, 1990, J BIOL CHEM, V265, P15653; SUZUKI Y, 1986, J INHERIT METAB DIS, V9, P292, DOI 10.1007/BF01799668; SUZUKI Y, 1987, J INHERIT METAB DIS, V10, P297, DOI 10.1007/BF01800086; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VAZQUEZ D, 1978, INT REV BIOCH AMINO, V18, P169; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WEBBER KO, 1987, ARCH BIOCHEM BIOPHYS, V254, P611, DOI 10.1016/0003-9861(87)90144-5; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	47	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13191	13199						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618823				2022-12-27	WOS:A1992JB74600018
J	CLELAND, JL; HEDGEPETH, C; WANG, DIC				CLELAND, JL; HEDGEPETH, C; WANG, DIC			POLYETHYLENE-GLYCOL ENHANCED REFOLDING OF BOVINE CARBONIC ANHYDRASE-B - REACTION STOICHIOMETRY AND REFOLDING MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER ADSORPTION; REARRANGEMENT; FLUORESCENCE	Polyethylene glycol (PEG) inhibited aggregation during refolding of bovine carbonic anhydrase B (CAB) through the formation of a nonassociating PEG-intermediate complex. Stoichiometric concentrations of PEG were required for complete recovery of active protein during refolding at aggregating conditions. For example, a PEG (M(r) = 3350) to CAB molar ratio ([PEG] /[CAB]) of 2 was sufficient to inhibit aggregation during refolding at 1.0 mg/ml (33.3-mu-M) protein and 0.5 M guanidine hydrochloride. In addition, the PEG concentration required for enhancement was dependent upon the molecular weight and only molecular weights between 1000 and 8000 were effective in inhibiting aggregation. In the presence of PEG, the rate of refolding was the same as that observed for refolding without the formation of associated species. Refolding in the presence of PEG resulted in the rapid formation of a PEG complex with the molten globule first intermediate, and this PEG-intermediate complex did not aggregate. The CAB refolding kinetics in the presence of PEG were determined and used to develop a model of the PEG enhanced refolding pathway. The mathematical model was validated by independent activity measurements of CAB refolding. This model predicted that PEG enhanced refolding of CAB occurred by a specific interaction of PEG with the molten globule first intermediate to form a nonassociating complex which continued to fold at the same rate as the first intermediate. The predicted pathway and binding properties of PEG indicate that PEG enhanced refolding may be analogous to chaperonin mediated protein folding.	MIT,DEPT CHEM ENGN,CTR BIOTECHNOL PROC ENGN,CAMBRIDGE,MA 02139; GENENTECH INC,PHARMACEUT RES & DEV,SAN FRANCISCO,CA 94080; UNIV MARYLAND,DEPT BIOL,CATONSVILLE,MD 21228	Massachusetts Institute of Technology (MIT); Roche Holding; Genentech								ARAWAKA T, 1985, BIOCHEMISTRY-US, V24, P6756; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAR K, 1988, LANGMUIR, V4, P989, DOI 10.1021/la00082a034; CHAR K, 1989, LANGMUIR, V5, P1096, DOI 10.1021/la00088a038; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1992, BIOTECHNOL PROGR, V8, P97, DOI 10.1021/bp00014a002; CLELAND JL, 1990, BIO-TECHNOL, V8, P1274, DOI 10.1038/nbt1290-1274; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1991, ACS SYM SER, V470, P169; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; POCKER Y, 1967, BIOCHEMISTRY-US, V6, P668, DOI 10.1021/bi00855a005; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; WONG KP, 1973, J BIOL CHEM, V248, P8518	15	160	173	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13327	13334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618834				2022-12-27	WOS:A1992JB74600039
J	KAISER, SM; LANEUVILLE, P; BERNIER, SM; RHIM, JS; KREMER, R; GOLTZMAN, D				KAISER, SM; LANEUVILLE, P; BERNIER, SM; RHIM, JS; KREMER, R; GOLTZMAN, D			ENHANCED GROWTH OF A HUMAN KERATINOCYTE CELL-LINE INDUCED BY ANTISENSE RNA FOR PARATHYROID HORMONE-RELATED PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE; ADENYLATE-CYCLASE; BONE-RESORPTION; GENE-EXPRESSION; PROTEIN; MALIGNANCY; INVITRO; INVIVO; DIFFERENTIATION; HYPERCALCEMIA	We have used antisense RNA technology to inhibit endogenous parathyroid hormone-related peptide (PTHRP) production in the established human keratinocyte cell line, HPK1A, in order to assess the role of PTHRP as a potential modulator of cell growth. Rat PTHRP cDNA was cloned into the replication defective retroviral vector pYN in an antisense orientation and a stable cell line (HPK1A-AS) was generated after infection by amphotropic virus and selection by the neomycin derivative, G418. Expression of the transfected antisense sequence was confirmed with an RNA sense probe for PTHRP. The effect of the retrovirally mediated gene transfer on the endogenous PTHRP transcript was examined with an RNA antisense probe which demonstrated an absence of the endogenous transcript in HPK1A-AS cells. A 1.6-kilobase transcript was, however, present in equivalent quantities in both uninfected HPK1A and pYN-infected (HPK1A-pYN) cells. Immunocytochemistry and assessment of PTHRP secretion into the medium using an NH2-terminal radioimmunoassay and a UMR 106 adenylate cyclase bioassay confirmed the absence of PTHRP in HPK1A-AS cells. Examination of the inhibition of PTHRP production on cell growth demonstrated a reduction in doubling time and an increase in [H-3]thymidine incorporation. Cell cycle analysis showed an increase in the proportion of the cell population in the S phase (relative to G0/G1) in HPK1A-AS cells compared to HPK1A or HPK1A-pYN cells. These data, therefore, indicate that endogenous PTHRP acts as an effective inhibitor of cell growth in this keratinocyte model and that this action occurs, at least in part, by diminishing entry into the S phase of the cell cycle. Furthermore, the antisense RNA method is a potent one to evaluate the cellular actions of PTHRP.	ROYAL VICTORIA HOSP,CALCIUM RES LAB,RM H467,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3A 1A1,QUEBEC,CANADA; NCI,BETHESDA,MD 20892	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Laneuville, Pierre/AAH-2293-2021	Kremer, Richard/0000-0002-7053-2139				ADACHI N, 1990, BIOCHEM BIOPH RES CO, V166, P1088, DOI 10.1016/0006-291X(90)90978-V; ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem-71-5-1112; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BRADY G, 1988, ONCOGENE, V3, P687; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURTON PBJ, 1990, BIOCHEM BIOPH RES CO, V167, P1134, DOI 10.1016/0006-291X(90)90641-Y; CHAN SDH, 1990, MOL ENDOCRINOL, V4, P638, DOI 10.1210/mend-4-4-638; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAUGHERTY BL, 1989, GENE ANAL TECH, V6, P1, DOI 10.1016/0735-0651(89)90007-1; DEFTOS LJ, 1989, MOL ENDOCRINOL, V3, P503, DOI 10.1210/mend-3-3-503; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRUCKER DJ, 1989, MOL ENDOCRINOL, V3, P1589, DOI 10.1210/mend-3-10-1589; DURST M, 1987, ONCOGENE, V1, P251; ERNST M, 1989, J BONE MINER RES, V3, pS309; FUKAYAMA S, 1988, ENDOCRINOLOGY, V123, P2841, DOI 10.1210/endo-123-6-2841; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON J, 1991, CANCER RES, V51, P6521; HENDERSON JE, 1992, ENDOCRINOLOGY, V130, P449, DOI 10.1210/en.130.1.449; HENDERSON JE, 1990, J BONE MINER RES, V5, P105, DOI 10.1002/jbmr.5650050203; Holick M. F., 1988, J BONE MINERAL RES S, V3, pS214; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HORIUCHI N, 1987, SCIENCE, V238, P1566, DOI 10.1126/science.3685994; IKEDA K, 1988, MOL ENDOCRINOL, V2, P1230, DOI 10.1210/mend-2-12-1230; IKEDA K, 1990, J BIOL CHEM, V265, P5398; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCGARRY TJ, 1986, P NATL ACAD SCI USA, V83, P399, DOI 10.1073/pnas.83.2.399; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; MILSTONE L, 1988, Journal of Cell Biology, V107, p73A; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; STEWART AF, 1991, J BONE MINER RES, V6, P305; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; YASUDA T, 1989, J BIOL CHEM, V264, P7720; YASUDA T, 1989, MOL ENDOCRINOL, V3, P518, DOI 10.1210/mend-3-3-518; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406	51	133	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13623	13628						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618864				2022-12-27	WOS:A1992JB74600083
J	YIP, CC; JACK, E				YIP, CC; JACK, E			INSULIN-RECEPTORS ARE BIVALENT AS DEMONSTRATED BY PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH FACTOR-I; SITE-SITE INTERACTIONS; NEGATIVE COOPERATIVITY; BINDING; SPECIFICITY	Insulin receptors in human placental membranes were photoaffinity-labeled with a radioactive human insulin-like growth factor I (hIGF-I) photoprobe N(epsilon-B28)-monoazidobenzoyl I-125-hIGF-I either alone or together with a non-radioactive insulin photoprobe N(epsilon-B29)-monoazidobenzoyl insulin. Precipitation of the solubilized receptors with anti-insulin antibody showed that receptors labeled with the radioactive hIGF-I photoprobe were detected in the immunoprecipitate only when photolabeling was carried out in the presence of the non-radioactive insulin photoprobe. Comparable results were obtained in converse experiments using a radioactive insulin photoprobe N(epsilon-B29)-monoazidobenzoyl I-125-insulin, a non-radioactive hIGF-I photoprobe N(epsilon-B28)-monoazidobenzoyl hIGF-I, and an antibody to hIGF-I. The amount of radioactive receptors precipitated by either the anti-insulin antibody or the anti-hIGHF-I antibody was close to the expected amount. These observations demonstrate that the insulin receptor is bivalent being capable of binding two molecules of ligand.			YIP, CC (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,112 COLL ST,TORONTO M5G 1L6,ONTARIO,CANADA.							ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; CZECH MP, 1985, ANN REV PHYSL, V47, P375; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEVRIES CP, 1991, ENDOCR RES, V17, P331, DOI 10.1080/07435809109106811; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HELMERHORST E, 1987, BIOCHEM BIOPH RES CO, V147, P399, DOI 10.1016/S0006-291X(87)80135-3; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; YIP CC, 1984, METHODS DIABETES RES, V1, P3; YIP CC, 1969, BIOCHEMISTRY-US, V62, P415; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	19	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13131	13134						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618814				2022-12-27	WOS:A1992JB74600005
J	BORNER, C; GUADAGNO, SN; FABBRO, D; WEINSTEIN, IB				BORNER, C; GUADAGNO, SN; FABBRO, D; WEINSTEIN, IB			EXPRESSION OF 4 PROTEIN-KINASE-C ISOFORMS IN RAT FIBROBLASTS - DISTINCT SUBCELLULAR-DISTRIBUTION AND REGULATION BY CALCIUM AND PHORBOL ESTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DOWN-REGULATION; BREAST CANCER-CELLS; ALLOSTERIC REGULATION; SIGNAL TRANSDUCTION; LIMITED PROTEOLYSIS; KINETIC-ANALYSIS; GH4C1 CELLS; PKC-EPSILON; PURIFICATION; RECEPTOR	Protein kinase C (PKC), the major receptor for tumor-promoting phorbol esters, consists of a family of at least eight distinct lipid-regulated enzymes. How the various PKC isozymes are regulated in vivo and how they couple to particular cellular responses is largely unknown. We have examined the expression and regulation of PKC isoforms in R6 rat embryo fibroblasts. Northern and Western blot analyses indicate that these cells express four PKC isoforms, cPKC-alpha, nPKC-epsilon, nPKC-delta, and nPKC-zeta; of which nPKC-epsilon and nPKC-delta are the most abundant. In agreement with the simultaneous presence of cPKC and nPKC isozymes, both Ca2+-dependent and -independent PKC activities were detected in extracts of these cells. cPKC-alpha and nPKC-zeta were predominantly localized in the cytosol when subcellular fractionation was carried out in the presence of [ethylenebis(oxyethylenenitrilo)]tetraacetic acid. When cell lysis was carried out in the presence of Ca2+, >50% of cPKC-alpha redistributed to the particulate fraction, whereas nPKC-zeta remained in the cytosol. In contrast to cPKC-alpha and nPKC-zeta, 60-80% of nPKC-epsilon and nPKC-delta were located in a Ca2+-insensitive, membrane-bound form. Treatment of R6 cells with 12-O-tetradecanoyl phorbol 13-acetate (TPA), resulted in the translocation of all four PKC isozymes to the membrane fraction, and the subsequent down-regulation of cPKC-alpha, nPKC-zeta, and nPKC-delta, nPKC-epsilon, however, was only partially down-regulated in response to long-term TPA exposure. Overproduction of exogenous cPKC-beta-I in R6 cells conferred partial resistance of nPKC-delta to TPA-induced down-regulation and potentiated the resistance of nPKC-epsilon to down-regulation. These results demonstrate that the multiple isoforms of PKC which coexist within a single cell type are differentially regulated by extra- and intracellular stimuli and may thereby influence growth control and transformation via distinct mechanisms.	COLUMBIA UNIV, CTR COMPREHENS CANC, 701 W 168TH ST, NEW YORK, NY 10027 USA; COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10027 USA; COLUMBIA UNIV, DEPT PHARMACOL, NEW YORK, NY 10027 USA; CIBA GEIGY AG, DEPT PHARMACEUT RES, ONCOL K125, CH-4002 BASEL, SWITZERLAND	Columbia University; Columbia University; Columbia University; Novartis					NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; AKITA Y, 1990, J BIOL CHEM, V265, P354; ANDERSON WB, 1985, ADV CYCLIC NUCL PROT, V19, P287; ASE K, 1988, FEBS LETT, V236, P396, DOI 10.1016/0014-5793(88)80064-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1989, J BIOL CHEM, V264, P13902; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, IN PRESS PROTEIN KIN; BORNER C, 1991, J BIOL CHEM, V267, P12900; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; EXTON JH, 1990, J BIOL CHEM, V265, P1; FOURNIER A, 1989, BIOCHEM BIOPH RES CO, V161, P556, DOI 10.1016/0006-291X(89)92635-1; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; GODSON C, 1990, J BIOL CHEM, V265, P8369; GUADAGNO SN, 1992, IN PRESS J BIOL CHEM; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOMAN EC, 1991, J BIOL CHEM, V266, P5676; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUANG KP, 1989, ACTA ENDOCRINOL-COP, V121, P307, DOI 10.1530/acta.0.1210307; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCCAFFREY PG, 1987, BIOCHEM BIOPH RES CO, V146, P140, DOI 10.1016/0006-291X(87)90702-9; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISHAK H, 1991, BIOCHEMISTRY-US, V30, P7925; MISHAK H, 1991, J IMMUNOL, V147, P3981; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STRULOVICI B, 1989, BIOCHEMISTRY-US, V28, P3569, DOI 10.1021/bi00434a063; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEYMAN CM, 1988, CANCER RES, V48, P6535; WOLF M, 1990, BIOCHEM J, V269, P723, DOI 10.1042/bj2690723; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x	82	186	188	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12892	12899						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618787				2022-12-27	WOS:A1992HZ48300076
J	GERTLER, A; HAUSER, SD; SAKAL, E; VASHDI, D; STATEN, N; FREEMAN, JJ; KRIVI, GG				GERTLER, A; HAUSER, SD; SAKAL, E; VASHDI, D; STATEN, N; FREEMAN, JJ; KRIVI, GG			PREPARATION, PURIFICATION, AND DETERMINATION OF THE BIOLOGICAL-ACTIVITIES OF 12-N TERMINUS-TRUNCATED RECOMBINANT ANALOGS OF BOVINE PLACENTAL-LACTOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SCANNING MUTAGENESIS; BINDING-PROPERTIES; MAMMARY-GLAND; PROLACTIN; RECEPTOR; OVINE; TECHNOLOGY; PROTEINS; CELLS	Removal of 13 to 15 amino acids from the N terminus of bovine placental lactogen (bPL), which according to the three-dimensional structure of pGH corresponds to a nonhelical part of bPL, did not effect its secondary structure or change the monomer content of the protein preparation. However, it remarkably decreased the binding to the prolactin (PRL) type of receptors on Nb2 cells with subsequent reduction in bioactivity. The binding to the growth hormone (somatogen) receptors either did not change or was increased, resulting in an increase of somatogen receptor-mediated bioactivity. Further truncation (17-18 amino acids) resulted in a decrease of alpha-helical content and loss of binding properties and biological activity mediated through interaction of the analogues with both somatogen (3T3-F442A cells) and lactogen (PRL) receptors (NB2-11C cells). Truncation of 19-27 amino acids caused additional loss in activity, without further change in the secondary structure. Replacement of Leu28 by a more hydrophobic Phe has only minor, if any, effect on the bioactivity of bPL. Occasional point mutations due to polymerase chain reaction errors in several analogues did not seem to have any major effect on the hormone properties. It can thus be suggested that the N-terminal part of the nonhelical portion of bPL, which corresponds to the portion of the molecule that does not exist in growth hormones, is required for efficient binding to the lactogen (PRL) but not to the somatogen or unique bPL receptors. Removal of the N-terminal part of bPL changed the specificity of bPL by decreasing its PRL receptor-mediated activities and increasing its somatogen receptor-mediated activities.	MONSANTO CO, DEPT BIOL SCI, ST LOUIS, MO 63198 USA	Monsanto	GERTLER, A (corresponding author), HEBREW UNIV JERUSALEM, FAC AGR, DEPT AGR BIOCHEM, IL-76100 REHOVOT, ISRAEL.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ASHKENAZI A, 1987, ENDOCRINOLOGY, V121, P414, DOI 10.1210/endo-121-1-414; BINDER L, 1989, MOL ENDOCRINOL, V3, P923, DOI 10.1210/mend-3-6-923; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BYATT JC, 1986, ENDOCRINOLOGY, V119, P1343, DOI 10.1210/endo-119-3-1343; BYATT JC, 1990, ENDOCRINOLOGY, V127, P1041, DOI 10.1210/endo-127-3-1041; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CORIN RE, 1990, P NATL ACAD SCI USA, V87, P7507, DOI 10.1073/pnas.87.19.7507; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P949, DOI 10.1210/mend-3-6-949; FORSYTH IA, 1986, J DAIRY SCI, V69, P866; GALOSY SS, 1991, MOL CELL ENDOCRINOL, V78, P229, DOI 10.1016/0303-7207(91)90127-E; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR276, DOI 10.1152/ajpregu.1989.256.1.R276; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GERTLER A, 1986, ENDOCRINOLOGY, V118, P720, DOI 10.1210/endo-118-2-720; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; GERTLER A, 1991, 73RD P M END SOC BET, P216; GLENN KC, 1988, J CELL BIOCHEM, V37, P371, DOI 10.1002/jcb.240370405; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KRIVI GG, 1989, 71ST P M END SOC BET, P403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1989, MOL ENDOCRINOL, V3, P822, DOI 10.1210/mend-3-5-822; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; MUNSON PJ, 1987, USERS GUIDE LIGAND, P107; MURTHY GS, 1982, ENDOCRINOLOGY, V111, P2117, DOI 10.1210/endo-111-6-2117; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5464; SHAMAY A, 1989, THESIS HEBREW U JERU; SHIMOMURA K, 1988, MOL ENDOCRINOL, V2, P845, DOI 10.1210/mend-2-9-845; SOBER HA, 1978, CRC HDB BIOCH MOL BI, V1, P187; TALAMANTES F, 1988, PHYSL REPRODUCTION, P2053; TOWNS R, 1992, ENDOCRINOLOGY, V130, P1225, DOI 10.1210/en.130.3.1225; VASHDI D, 1991, P ANN M ISRAELI ENDO, P93; YANG JT, 1986, METHOD ENZYMOL, V130, P256	37	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12655	12659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618771				2022-12-27	WOS:A1992HZ48300044
J	GEE, JE; BLUME, S; SNYDER, RC; RAY, R; MILLER, DM				GEE, JE; BLUME, S; SNYDER, RC; RAY, R; MILLER, DM			TRIPLEX FORMATION PREVENTS SP1 BINDING TO THE DIHYDROFOLATE-REDUCTASE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNUSUAL DNA STRUCTURES; GENE AMPLIFICATION; TRANSCRIPTION FACTOR; CELL-CYCLE; METHOTREXATE; RESISTANCE; EXPRESSION; SEQUENCES; ESTROGEN; LINE	The human dihydrofolate reductase (DHFR) promoter sequence contains two consensus binding sites for the Sp1 regulatory protein. We have determined the effect of intermolecular triplex DNA formation on Sp1 binding to the DHFR promoter. The DHFR Sp1 binding site I (-39 to -48 relative to the DHFR transcription start site) demonstrates concentration-dependent triplex formation with a 19-base pair G-rich oligonucleotide (GR19) which is complementary to the polypyrimidine strand. DNase I footprint analysis demonstrates that GR19 forms a DNA triplex structure with the DHFR promoter fragment in a sequence-specific manner. DNase I footprinting analysis also indicates that the orientation of binding of these G-rich oligonucleotides is antiparallel. CR19, a C-rich complementary oligonucleotide, on the other hand, does not form triplex. The DNase I protection pattern of DHFR promoter fragment incubated with both recombinant Sp1 and triplex-forming oligonucleotide suggests that triplex formation prevents Sp1 binding. This is confirmed by gel shift analysis which demonstrates that triplex formation by the Sp1 binding sequences of t he DHFR promoter prevents recombinant Sp1 binding in a concentration-dependent manner. These results demonstrate that intermolecular triplex formation prevents regulatory protein binding in a sequence-specific manner.	UNIV ALABAMA, DEPT INTERNAL MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, CTR COMPREHENS CANC, BIRMINGHAM, AL 35294 USA; VET ADM MED CTR, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	GEE, JE (corresponding author), UNIV ALABAMA, DEPT BIOCHEM, BIRMINGHAM, AL 35294 USA.			Gee, Jay/0000-0003-4308-1659	NCI NIH HHS [CA 42337, CA 42664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARMAN MD, 1984, J CLIN ONCOL, V2, P16, DOI 10.1200/JCO.1984.2.1.16; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COWAN KH, 1982, J BIOL CHEM, V257, P5079; DURLAND RH, 1990, JERUS SYM Q, V23, P565; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; GOLDSMITH ME, 1986, MOL CELL BIOL, V6, P878, DOI 10.1128/MCB.6.3.878; HENDRICKSON SL, 1980, P NATL ACAD SCI-BIOL, V77, P5140, DOI 10.1073/pnas.77.9.5140; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LEVINE RM, 1985, CANCER RES, V45, P1644; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; SCHIMKE RT, 1986, CANCER, V57, P1912, DOI 10.1002/1097-0142(19860515)57:10<1912::AID-CNCR2820571004>3.0.CO;2-O; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	23	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11163	11167						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597451				2022-12-27	WOS:A1992HX16900038
J	RAULO, E; JULKUNEN, I; MERENMIES, J; PIHLASKARI, R; RAUVALA, H				RAULO, E; JULKUNEN, I; MERENMIES, J; PIHLASKARI, R; RAUVALA, H			SECRETION AND BIOLOGICAL-ACTIVITIES OF HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE - NEURITE OUTGROWTH-PROMOTING AND MITOGENIC ACTIONS OF THE RECOMBINANT AND TISSUE-DERIVED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; AMINO-ACID-SEQUENCE; MOUSE EMBRYOGENESIS; DEVELOPING BRAIN; CLONING; BOVINE; DIFFERENTIATION; PURIFICATION; EXPRESSION; PEPTIDES	The cDNA for the developmentally regulated, neurite outgrowth-promoting protein HB-GAM (heparin-binding growth-associated molecule) was recently cloned and shown to encode a novel lysine-rich sequence that is homologous with retinoic acid-induced sequences suggested to function in cell differentiation (Merenmies, J., and Rauvala, H. (1990) J. Biol. Chem. 265, 16721-16724). The same sequence was found for the mitogenic and neurite outgrowth-promoting protein pleiotrophin (Li, Y.-S., Milner, P. G., Chauhan, A. K., Watson, M. A., Hoffman, R. M., Kodner, C. M., Milbrandt, J., and Deuel, T. F. (1990) Science 250, 1690-1694). In this study, we have constructed a recombinant baculovirus using the cDNA that encodes the putative preprotein of HB-GAM. The putative secretion signal of HB-GAM is cleaved off in the baculovirus expression system, and the recombinant protein is rapidly secreted to the culture medium. Recombinant HB-GAM purified from the culture medium retains the biochemical characteristics and the neurite outgrowth-promoting activity found for the tissue-derived protein. Studies on the neurite outgrowth-promoting activity suggest that HB-GAM functions as an extracellular matrix-associated protein that enhances axonal growth in perinatal cerebral neurons of the rat. Since the same predicted amino acid sequence has been ascribed to a mitogenic protein, mitogenic activities of the recombinant HB-GAM and of tissue-derived HB-GAM fractions were also studied. Recombinant HB-GAM did not display any significant mitogenic activity, suggesting that tissue-derived HB-GAM preparations may contain other heparin-binding mitogenic factors. We identified in brain-derived HB-GAM fractions a 17-kDa protein (p17) that is detached from heparin by a slightly higher salt concentration as compared to HB-GAM. We suggest that p17 is structurally distinct from HB-GAM and responsible for the mitogenic actions of tissue-derived HB-GAM fractions.	NATL PUBL HLTH INST,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,NEUROBIOL RES UNIT,SF-00170 HELSINKI 17,FINLAND; UNIV HELSINKI,DEPT MED CHEM,SF-00170 HELSINKI 17,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki	RAULO, E (corresponding author), UNIV HELSINKI,INST BIOTECHNOL,KARVAAMOKUJA 3,SF-00380 HELSINKI,FINLAND.			Rauvala, Heikki/0000-0001-7809-9811				BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; Engvall E, 1980, Methods Enzymol, V70, P419; HUBER D, 1990, NEUROCHEM RES, V15, P435, DOI 10.1007/BF00969930; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KLAGSBRUN M, 1987, METHOD ENZYMOL, V147, P95; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; KUO MD, 1990, J BIOL CHEM, V265, P18749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOECKLI ET, 1991, J CELL BIOL, V112, P449, DOI 10.1083/jcb.112.3.449; SUMMERS M, 1986, TEXAS AGR EXPT STATI, V1555; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O; VIGNY M, 1989, EUR J BIOCHEM, V186, P733, DOI 10.1111/j.1432-1033.1989.tb15267.x; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6	29	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11408	11416						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597470				2022-12-27	WOS:A1992HX16900073
J	SIROIS, J; SIMMONS, DL; RICHARDS, JS				SIROIS, J; SIMMONS, DL; RICHARDS, JS			HORMONAL-REGULATION OF MESSENGER-RIBONUCLEIC-ACID ENCODING A NOVEL ISOFORM OF PROSTAGLANDIN ENDOPEROXIDE-H SYNTHASE IN RAT PREOVULATORY FOLLICLES - INDUCTION INVIVO AND INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; GRANULOSA-CELLS; FOLLICULAR DEVELOPMENT; OVARIAN FOLLICLES; CORPORA-LUTEA; LUTEINIZING-HORMONE; GM-CSF; SEQUENCE; OVULATION; ESTRADIOL	Recent purification and amino-terminal analysis of t he isoform of prostaglandin endoperoxide H synthase (PGS) induced in rat preovulatory follicles by gonadotropins identified it as a novel distinct isoform of PGS (rPGS(i)) which exhibited a high degree of homology to the deduced sequence of PGS-related cDNAs recently cloned in chicken and mice. To further verify the similarities of these novel gene products and to examine the hormonal regulation of rPGS(i) mRNA in ovarian cells, three different in vivo and in vitro models were used. Northern blots using a cDNA encoding the mouse homologue of rPGS(i) detected a 4.4-kilobase transcript which was rapidly but transiently induced in granulosa cells of preovulatory follicles exposed in vivo to an ovulatory dose of human chorionic gonadotropin. The rPGS(i) mRNA was undetectable at 0 h, peaked 4 h after human chorionic gonadotropin, and had almost disappeared by 6 h. Increases in rPGS(i) protein (immunoblots) lagged by about 1 h, peaked at 5 h, and remained present at 11 h. PGS(i) mRNA and protein were also induced in a time- and dose-dependent manner when preovulatory follicles were isolated and incubated with elevated levels of follicle-stimulating hormone (500 ng/ml) or luteinizing hormone (500 ng/ml), or when differentiated granulosa cell cultures were stimulated with follicle-stimulating hormone, luteinizing hormone, or with gonadotropin-releasing hormone (10(-6) M). In both in vitro systems, rPGS(i) mRNA peaked at 4-5 h. When the same RNA samples were probed with the mouse cDNA encoding the other PGS isoform, no mRNA transcripts (2.8 kilobases) were observed. These results show for the first time that a rapid and transient induction of mRNA encoding a novel PGS enzyme occurs in granulosa cells of preovulatory follicles prior to ovulation and that results in vitro closely mimicked those in vivo and thereby provide models for studying the molecular mechanisms of rPGS(i) gene expression.	BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; BRIGHAM YOUNG UNIV, DEPT CHEM, PROVO, UT 84602 USA	Baylor College of Medicine; Brigham Young University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CLARK MR, 1980, ENDOCRINOLOGY, V107, P17, DOI 10.1210/endo-107-1-17; CROMWELL O, 1988, EICOSANOIDS INFLAMMA, P21; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GALWAY AB, 1989, ENDOCRINOLOGY, V125, P126, DOI 10.1210/endo-125-1-126; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; IWAI M, 1991, ENDOCRINOLOGY, V129, P1621, DOI 10.1210/endo-129-3-1621; KEIRSE MJN, 1990, EICOSANOIDS REPRODUC, P199; KOOS RD, 1985, ENDOCRINOLOGY, V116, P628, DOI 10.1210/endo-116-2-628; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, CRC HDB EICOSANOID A, V1, P163; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MOORE PK, 1988, PROSTANOIDS PHARM PH, P173; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Niswender G.D., 1988, P489; OIKAWA M, 1990, ENDOCRINOLOGY, V127, P2350, DOI 10.1210/endo-127-5-2350; OONK RB, 1989, J BIOL CHEM, V264, P21934; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PLESCIA OJ, 1988, PROG ALLERGY, V44, P153; QUILLEY J, 1988, EICOSANOIDS CARDIOVA, P16; RAISZ LG, 1988, NEW ENGL J MED, V318, P818; RATOOSH SL, 1985, ENDOCRINOLOGY, V117, P917, DOI 10.1210/endo-117-3-917; RICHARDS JS, 1988, ANNU REV PHYSIOL, V50, P441; RICHARDS JS, 1975, ENDOCRINOLOGY, V97, P1174, DOI 10.1210/endo-97-5-1174; RICHARDS JS, 1982, ENDOCRINOLOGY, V111, P1429, DOI 10.1210/endo-111-5-1429; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; SIMMONS DL, 1992, PROSTAGLANDINS LEUKO, P67; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WEKSLER BB, 1982, CARDIOVASCULAR PHARM, P137; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; WONG WYL, 1992, IN PRESS ENDOCRINOLO; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Zurier RB, 1988, PROSTAGLANDINS BIOL, P595	51	248	254	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11586	11592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597485				2022-12-27	WOS:A1992HX16900099
J	BELUNIS, CJ; RAETZ, CRH				BELUNIS, CJ; RAETZ, CRH			BIOSYNTHESIS OF ENDOTOXINS - PURIFICATION AND CATALYTIC PROPERTIES OF 3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A PRECURSORS; PHOSPHATIDYLGLYCEROL-DEFICIENT MUTANT; POLYMERASE CHAIN-REACTION; SALMONELLA-TYPHIMURIUM; GLUCOSAMINE 1-PHOSPHATE; SYNTHETASE; SYNTHASE; CYTIDYLYLTRANSFERASE; PROTEINS; ENZYMES	The enzyme 3-deoxy-D-manno-octulosonic acid (Kdo) transferase is encoded by the kdtA gene of Escherichia coli and plays a key role in lipopolysaccharide biosynthesis. It transfers Kdo from CMP-Kdo to lipid A or its tetraacyldisaccharide-1,4'-bisphosphate precursor, lipid IV(A). Using a strain that overproduces the transferase approximately 500-fold, we have purified the enzyme to near homogeneity. The subunit molecular mass is approximately 43 kDa. Activity is stimulated by Triton X-100, is maximal at pH 7, but does not require Mg2+. The apparent K(m) values for lipid IV(A) and CMP-Kdo are 52 and 88-mu-M, respectively. V(max) is 15-18-mu-mol/min/mg when both substrates are added near saturation at pH 8. The purified enzyme transfers 2 Kdo residues to lipid A precursors or analogs bearing four to six fatty acyl chains and a 4'-monophosphate moiety. Activity is inhibited by polymixin B and Re endotoxin. At low Kdo concentrations small amounts of the intermediate, (Kdo)1-IV(A), accumulate. When this substance is isolated and incubated with purified enzyme in the presence of CMP-Kdo, it is converted to (Kdo)2-IV(A). Formation of (Kdo)1-IV(A) is also observed when purified enzyme is incubated with (Kdo)2-IV(A) and 5 mM CMP, demonstrating that Kdo transfer is reversible. In summary, Kdo transferase consists of a single bifunctional polypeptide that incorporates the 2 innermost Kdo residues common to all lipopolysaccharide molecules in E. coli.	MERCK SHARP & DOHME LTD, DEPT BIOCHEM, RAHWAY, NJ 07065 USA	Merck & Company								ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; AUSUBEL FM, 1989, CURRENT PROTOLS MOL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CARMAN GM, 1979, J BIOL CHEM, V254, P8391; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; DUTT A, 1985, BIOCHEMISTRY-US, V24, P1074, DOI 10.1021/bi00326a001; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3207; GHALAMBOR MA, 1963, BIOCHEM BIOPH RES CO, V10, P346, DOI 10.1016/0006-291X(63)90536-9; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEATH EC, 1966, ANN NY ACAD SCI, V133, P315, DOI 10.1111/j.1749-6632.1966.tb52374.x; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KOHLBRENNER WE, 1985, J BIOL CHEM, V260, P4695; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN V, 1977, EUR J BIOCHEM, V81, P443, DOI 10.1111/j.1432-1033.1977.tb11969.x; MACFERRIN KD, 1990, P NATL ACAD SCI USA, V87, P1937, DOI 10.1073/pnas.87.5.1937; MUNSON RS, 1978, J BIOL CHEM, V253, P1503; NAKAMURA K, 1979, J BACTERIOL, V137, P595, DOI 10.1128/JB.137.1.595-604.1979; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAY PH, 1982, METHOD ENZYMOL, V83, P525; RAY PH, 1982, METHOD ENZYMOL, V83, P535; RICK PD, 1977, J BIOL CHEM, V252, P4895; Rietschel E. T., 1984, HDB ENDOTOXIN CHEM E, VI; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; STRAIN SM, 1985, J BIOL CHEM, V260, P2974; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; SUTCLIFFE J, 1985, FED PROC, V44, P652; TAKAYAMA K, 1983, J BIOL CHEM, V258, P4245; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; WHITE A, 1978, PRINCIPLES BIOCH, P489; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	119	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9988	9997						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577828				2022-12-27	WOS:A1992HT96500082
J	OKAMOTO, CT; SHIA, SP; BIRD, C; MOSTOV, KE; ROTH, MG				OKAMOTO, CT; SHIA, SP; BIRD, C; MOSTOV, KE; ROTH, MG			THE CYTOPLASMIC DOMAIN OF THE POLYMERIC IMMUNOGLOBULIN RECEPTOR CONTAINS 2 INTERNALIZATION SIGNALS THAT ARE DISTINCT FROM ITS BASOLATERAL SORTING SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; DENSITY-LIPOPROTEIN RECEPTOR; MEMBRANE-PROTEIN; LDL-RECEPTOR; ENDOCYTOSIS; EXPRESSION; IGA; SEQUENCE; TRANSCYTOSIS	The C-terminal cytoplasmic domain of the polymeric immunoglobulin receptor (pIgR) contains two tyrosine residues, Tyr668 and Tyr734. Previous work identifying Tyr734 as a critical residue in the endocytosis of the pIgR in Madin-Darby canine kidney (MDCK) cells also suggested that a second functional internalization signal was present (Breitfeld, P. P., Casanova, J. E., McKinnon, W. C., and Mostov, K. E. (1990) J. Biol. Chem. 265, 13750-13757). To test this hypothesis, Tyr668 and Tyr734 were mutated singly or together by oligonucleotide-directed mutagenesis of pIgR cDNA, and the mutants were expressed in MDCK cells. The amount of ligand internalized within 5 min from the basolateral membrane by the pIgR in which cytoplasmic tyrosines were mutated separately to Cys668 or Ser734 or together to Cys668, Ser734 Was 58, 39, and 20%, respectively, of that internalized by the wild-type pIgR. The cytoplasmic and transmembrane domain of the pIgR, when joined to the external domain of the influenza virus hemagglutinin, retained the capacity to mediate rapid internalization. As with the full-length pIgR, mutation of either tyrosine in the chimera resulted in impairment of endocytosis, with mutation of Tyr734 having a significantly greater effect than mutation on Tyr668 on the initial rate of endocytosis (3 and 44% of control values, respectively). However, unlike the full-length pIgR, mutation of both tyrosines together in the chimera did not reduce internalization further. The two tyrosines in the cytoplasmic sequence of the pIgR, although widely separated in the linear amino acid sequence, both contribute to internalization of the protein, suggesting that both can function as internalization signals. In addition, the correlation between endocytosis and basolateral targeting of the pIgR in MDCK cells was investigated. Neither tyrosine of the cytoplasmic domain was necessary for basolateral targeting of the pIgR.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	OKAMOTO, CT (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.			Roth, Michael/0000-0002-9056-332X; mostov, keith/0000-0002-8123-6247	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [R01 AI25144] Funding Source: Medline; NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; BANTING G, 1989, FEBS LETT, V254, P177, DOI 10.1016/0014-5793(89)81034-8; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARTER C, 1990, J CELL BIOL, V111, P66; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KRAJCI P, 1989, BIOCHEM BIOPH RES CO, V158, P783, DOI 10.1016/0006-291X(89)92790-3; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LIMET JN, 1985, EUR J BIOCHEM, V146, P539, DOI 10.1111/j.1432-1033.1985.tb08685.x; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Sambrook J, 1989, MOL CLONING LABORATO; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	44	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9925	9932						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577823				2022-12-27	WOS:A1992HT96500074
J	TERRAS, FRG; SCHOOFS, HME; DEBOLLE, MFC; VANLEUVEN, F; REES, SB; VANDERLEYDEN, J; CAMMUE, BPA; BROEKAERT, WF				TERRAS, FRG; SCHOOFS, HME; DEBOLLE, MFC; VANLEUVEN, F; REES, SB; VANDERLEYDEN, J; CAMMUE, BPA; BROEKAERT, WF			ANALYSIS OF 2 NOVEL CLASSES OF PLANT ANTIFUNGAL PROTEINS FROM RADISH (RAPHANUS-SATIVUS L) SEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL-BOUND THIONINS; AMINO-ACID-SEQUENCE; GAMMA-PUROTHIONINS; STORAGE PROTEIN; HIGH CYSTEINE; GENE FAMILY; BARLEY; PEPTIDES; IDENTIFICATION; INHIBITION	Two novel classes of antifungal proteins were isolated from radish seeds. The first class consists of two homologous proteins (Rs-AFP1 and Rs-AFP2) that were purified to homogeneity. They are highly basic oligomeric proteins composed of small (5-kDa) polypeptides that are rich in cysteine. Both Rs-AFPs have a broad antifungal spectrum and are among the most potent antifungal proteins hitherto characterized. In comparison with many other plant antifungal proteins, the activity of the Rs-AFPs is less sensitive to the presence of cations. Moreover, their antibiotic activity shows a high degree of specificity to filamentous fungi. The amino-terminal regions of the Rs-AFPs show homology with the derived amino acid sequences of two pea genes specifically induced upon fungal attack, to gamma-thionins and to sorghum alpha-amylase inhibitors. The radish 2S storage albumins were identified as the second novel class of antifungal proteins. All isoforms inhibit growth of different plant pathogenic fungi and some bacteria. However, their antimicrobial activities are strongly antagonized by cations.	CATHOLIC UNIV LEUVEN,FA JANSSENS LAB GENET,WILLEM DE CROYLAAN 42,B-3001 HEVERLEE,BELGIUM; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; ICI AGROCHEM,JEALOTTS HILL RES STR,BRACKNELL RG12 GEY,BERKS,ENGLAND	KU Leuven; KU Leuven			Cammue, Bruno/M-9575-2013					ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; APEL K, 1991, ANN REV PLANT PHYSL, V42, P227; BLOCH C, 1991, FEBS LETT, V279, P101, DOI 10.1016/0014-5793(91)80261-Z; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CHIANG CC, 1991, MOL PLANT MICROBE IN, V4, P324, DOI 10.1094/MPMI-4-324; CLARKSON DT, 1980, ANNU REV PLANT PHYS, V31, P239, DOI 10.1146/annurev.pp.31.060180.001323; COLILLA FJ, 1990, FEBS LETT, V270, P191, DOI 10.1016/0014-5793(90)81265-P; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; DEBOLLE MFC, 1991, ELECTROPHORESIS, V12, P442, DOI 10.1002/elps.1150120612; DECALEYA RF, 1972, APPL MICROBIOL, V23, P998, DOI 10.1128/AEM.23.5.998-1000.1972; EBRAHIMNESBAT F, 1989, PLANTA, V179, P203, DOI 10.1007/BF00393690; ERICSON ML, 1986, J BIOL CHEM, V261, P4576; FLOWERS TJ, 1983, ENCY PLANT PHYSL B, V15, P651; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GRIGNON C, 1991, ANNU REV PLANT PHYS, V42, P103, DOI 10.1146/annurev.pp.42.060191.000535; HARKER FR, 1991, PLANT CELL ENVIRON, V14, P525, DOI 10.1111/j.1365-3040.1991.tb01523.x; HEDRICK SA, 1988, PLANT PHYSIOL, V86, P182, DOI 10.1104/pp.86.1.182; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGGINS TJV, 1984, ANNU REV PLANT PHYS, V35, P191, DOI 10.1146/annurev.pp.35.060184.001203; JOOSTEN MHAJ, 1989, PLANT PHYSIOL, V89, P945, DOI 10.1104/pp.89.3.945; KOVARIK A, 1987, FOLIA BIOL-PRAGUE, V33, P253; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEAH R, 1991, J BIOL CHEM, V266, P1564; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MACKLON AES, 1984, PLANT CELL ENVIRON, V7, P407, DOI 10.1111/j.1365-3040.1984.tb01430.x; MANNERS DJ, 1973, PHYTOCHEMISTRY, V12, P547, DOI 10.1016/S0031-9422(00)84441-6; MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; NAKAYA K, 1990, EUR J BIOCHEM, V193, P31, DOI 10.1111/j.1432-1033.1990.tb19300.x; PEUMANS WJ, 1983, FEBS LETT, V177, P99; RAYNAL M, 1991, GENE, V99, P77, DOI 10.1016/0378-1119(91)90036-B; REDMAN DG, 1969, J SCI FOOD AGR, V20, P427, DOI 10.1002/jsfa.2740200715; REIMANNPHILIPP U, 1989, J BIOL CHEM, V264, P8978; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771, DOI 10.1099/00221287-136-9-1771; ROBSON GD, 1991, EXP MYCOL, V15, P263, DOI 10.1016/0147-5975(91)90028-C; SEE YP, 1990, PROTEIN STRUCTURE PR, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; VANDAMME J, 1987, EUR J IMMUNOL, V17, P1, DOI 10.1002/eji.1830170102; VIGERS AJ, 1991, MOL PLANT MICROBE IN, V4, P315, DOI 10.1094/MPMI-4-315; WOLOSHUK CP, 1991, PLANT CELL, V3, P619, DOI 10.1105/tpc.3.6.619; YOULE RJ, 1978, PLANT PHYSIOL, V61, P1040, DOI 10.1104/pp.61.6.1040; YOULE RJ, 1979, J AGR FOOD CHEM, V27, P500, DOI 10.1021/jf60223a017; YOULE RJ, 1981, AM J BOT, V68, P44, DOI 10.2307/2442990	50	480	542	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15301	15309						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639777				2022-12-27	WOS:A1992JG11300011
J	WELLS, RG; LEE, WS; KANAI, Y; LEIDEN, JM; HEDIGER, MA				WELLS, RG; LEE, WS; KANAI, Y; LEIDEN, JM; HEDIGER, MA			THE 4F2 ANTIGEN HEAVY-CHAIN INDUCES UPTAKE OF NEUTRAL AND DIBASIC AMINO-ACIDS IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODY 4F2; NA+-DEPENDENT TRANSPORT; CELL-SURFACE ANTIGEN; BROAD-SCOPE SYSTEM; MOUSE BLASTOCYSTS; LYMPHOCYTE-ACTIVATION; STRUCTURAL HOMOLOGY; INHIBITION; RECEPTOR; MEMBRANE	The 4F2 cell surface antigen is a disulfide-linked heterodimer induced during the process of cellular activation and expressed widely in mammalian tissues (Parmacek, M. S., Karpinski, B. A., Gottesdiener, K. M., Thompson, C. B., and Leiden, J. M. (1989) Nucleic Acids Res. 17, 1915-1931). The human heavy chain component, a type II membrane glycoprotein, has 29% identity to the amino acid transport-related protein encoded by the recently cloned rat D2 cDNA. We have demonstrated that Xenopus oocytes injected with in vitro transcribed cRNA from D2 take up cystine and dibasic and neutral amino acids (Wells, R. G., and Hediger, M. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5596-5600). In the present study, we examine the role of the human 4F2 heavy chain in amino acid transport. In vitro transcribed 4F2 cRNA was injected into Xenopus oocytes which were assayed for the uptake of radiolabeled amino acids. Our results show that cRNA from 4F2 stimulates the uptake of dibasic and neutral amino acids into oocytes at levels up to 3-fold higher than for water-injected control oocytes. There is no demonstrable uptake of cystine. Uptake is saturable, with characteristics of high affinity transport, and inhibition data suggest that uptake occurs via a single transporter. Dibasic amino acids are taken up by both 4F2 and D2 cRNA-injected oocytes in a sodium-independent manner. In contrast, 4F2-induced but not D2-induced neutral amino acid uptake has a significant component of sodium dependence. Likewise, neutral amino acids in excess inhibit the 4F2-induced uptake of radiolabeled arginine but not leucine in a sodium-dependent manner. The 4F2-induced uptake we observe most likely represents the activity of a single transport system with some characteristics of systems y+, b0,+, and B0,+. We suggest that 4F2 and D2 represent a new family of proteins which induce amino acid transport with distinct characteristics, possibly functioning as transport activators or regulators.	BETH ISRAEL HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT MED,ANN ARBOR,MI 48109	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43171] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BRON C, 1986, J IMMUNOL, V137, P397; EISENBARTH GS, 1980, J IMMUNOL, V124, P1237; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEMLER ME, 1982, J IMMUNOL, V129, P623; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MICHALAK M, 1986, J BIOL CHEM, V261, P92; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; POSILLICO JT, 1987, ARCH SURG-CHICAGO, V122, P436; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P215, DOI 10.1016/0005-2736(90)90100-3; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; YAGITA H, 1986, CANCER RES, V46, P1478	21	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15285	15288						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639774				2022-12-27	WOS:A1992JG11300008
J	HOLMES, WM; ANDRAOSSELIM, C; ROBERTS, I; WAHAB, SZ				HOLMES, WM; ANDRAOSSELIM, C; ROBERTS, I; WAHAB, SZ			STRUCTURAL REQUIREMENTS FOR TRANSFER-RNA METHYLATION - ACTION OF ESCHERICHIA-COLI TRANSFER RNA(GUANOSINE-1)METHYLTRANSFERASE ON TRANSFER RNA(1)LEU STRUCTURAL VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA(M1G)METHYLTRANSFERASE; GENE TRMD; SEQUENCE; OPERON; K-12	The Escherichia coli enzyme tRNA(m1G)methyltransferase, one of a group of post-transcription tRNA-modifying enzymes, shows remarkable specificity in selecting the tRNA species and the specific guanosine base to be methylated. To examine the structural basis of this specificity, we synthesized a total of 15 modifications of tRNA1Leu and measured their methylation reaction kinetics in vitro. Elimination of any one of the three tRNA side loops, the V loop, the T loop, or the D loop, reduced the V(max) for methylation by about 1 order of magnitude. Elimination of all three side loops reduced V(max) by about 2 orders of magnitude. Clearly, gross tRNA structure is important for full enzyme activity. At the bottom of the stem proximal to the anticodon loop, in the pair at positions 31-39, substitution of a G-C for a C-G, a change that should not weaken the helical structure, had little effect on V(max) or K(m). However, substitution of a G for a C increased V(max) and K(m), whereas substitution of a C for G sharply reduced V(max) and, to a lesser extent, K(m). These results appear to be a consequence of the principle that purines are better than pyrimidines in the stacking of adjacent bases for stability. Stacking in the stem structure appears to be important for methylation enzyme activity. In the anticodon loop itself, changing a U to a C had little effect, but changing the G of the anticodon to a C reduced V(max) over 20-fold, demonstrating the importance of the presence of the anticodon G adjacent to the G being methylated for enzyme recognition.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298	Virginia Commonwealth University	HOLMES, WM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL,RICHMOND,VA 23298, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025871] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM25871] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORK GR, 1989, SCIENCE, V244, P986, DOI 10.1126/science.2471265; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; BYSTROM AS, 1982, MOL GEN GENET, V188, P447, DOI 10.1007/BF00330047; BYSTROM AS, 1982, MOL GEN GENET, V188, P440, DOI 10.1007/BF00330046; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; GROSJEAN H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P267, DOI 10.1016/0167-4781(90)90179-6; HJALMARSSON KJ, 1983, J BIOL CHEM, V258, P1343; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; RAJBHANDARY UL, 1982, NUCLEASES; Roberts I, 1991, Protein Expr Purif, V2, P117, DOI 10.1016/1046-5928(91)90059-R; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAENGER W, 1984, PRINCIPLES NUCLEIC A, V1, P34; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P228, DOI 10.1016/0003-2697(77)90531-0; VOLCKAERT G, 1976, ANAL BIOCHEM, V72, P433, DOI 10.1016/0003-2697(76)90551-0	18	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13440	13445						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618846				2022-12-27	WOS:A1992JB74600055
J	JOHNSON, MG; ESCALANTESEMERENA, JC				JOHNSON, MG; ESCALANTESEMERENA, JC			IDENTIFICATION OF 5,6-DIMETHYLBENZIMIDAZOLE AS THE CO-ALPHA LIGAND OF THE COBAMIDE SYNTHESIZED BY SALMONELLA-TYPHIMURIUM - NUTRITIONAL CHARACTERIZATION OF MUTANTS DEFECTIVE IN BIOSYNTHESIS OF THE IMIDAZOLE RING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COBALAMIN; VITAMIN-B12; COENZYME-B12; CORRINOIDS; DENOVO	The Co-beta-cyano derivative of the cobamide isolated from Salmonella typhimurium was identified as Co-alpha-(alpha-5,6-dimethylbenzimidazolyl)-Co-beta-cyanocobamide, indicating that this bacterium synthesizes 5,6-dimethylbenzimidazole (DMB) de novo. We found that mutants deficient in the synthesis of DMB can incorporate benzimidazole without modification to form Co-alpha-(alpha-benzimidazolyl) cobamide, a cobamide that is physiologically active. The analysis of the nutritional requirements of mutants deficient in DMB synthesis identified 4,5-dimethylphenylenediamine as a putative intermediate in the synthesis of the imidazole ring of DMB. Our results suggest that the CobII region of the cob operon of S. typhimurium only encodes functions involved in the synthesis of the imidazole ring of DMB.	UNIV WISCONSIN,DEPT BACTERIOL,1550 LINDEN DR,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCRR NIH HHS [RR02301, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM40313, R01 GM040313] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR002781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040313] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1987, J AM CHEM SOC, V109, P566, DOI 10.1021/ja00236a040; BLANCHE F, 1990, ANAL BIOCHEM, V189, P24, DOI 10.1016/0003-2697(90)90038-B; CAUTHEN SE, 1966, BIOCHEM J, V98, P630, DOI 10.1042/bj0980630; DAWSON RMC, 1986, DATA BIOCH RES, P120; ESCALANTESEMERENA JC, 1992, J BACTERIOL, V174, P24, DOI 10.1128/jb.174.1.24-29.1992; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; ESCALANTESEMERENA JC, 1990, J BACTERIOL, V172, P273, DOI 10.1128/JB.172.1.273-280.1990; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HITCHMAN ML, 1978, MEASUREMENT DISSOLVE, V49, P7; HOGENKAMP HPC, 1971, METHODS ENZYMOL    C, V18, P57; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; RENZ P, 1987, EUR J BIOCHEM, V163, P175, DOI 10.1111/j.1432-1033.1987.tb10752.x; STUPPERICH E, 1986, ANAL BIOCHEM, V155, P365, DOI 10.1016/0003-2697(86)90447-1; STUPPERICH E, 1987, J BACTERIOL, V169, P3076, DOI 10.1128/jb.169.7.3076-3081.1987; STUPPERICH E, 1988, EUR J BIOCHEM, V172, P459, DOI 10.1111/j.1432-1033.1988.tb13910.x; STUPPERICH E, 1988, ADV SPACE SCI, V9, P117; TAYLOR RT, 1973, ENZYMES, V9, P121; VOGEL HJ, 1956, J BIOL CHEM, V218, P97	18	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13302	13305						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618831				2022-12-27	WOS:A1992JB74600035
J	KIM, SJ; PARK, K; KOELLER, D; KIM, KY; WAKEFIELD, LM; SPORN, MB; ROBERTS, AB				KIM, SJ; PARK, K; KOELLER, D; KIM, KY; WAKEFIELD, LM; SPORN, MB; ROBERTS, AB			POSTTRANSCRIPTIONAL REGULATION OF THE HUMAN TRANSFORMING GROWTH FACTOR-BETA-1 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCOMPANIES VIRAL TRANSFORMATION; IRON-RESPONSIVE ELEMENT; FERRITIN MESSENGER-RNA; FACTOR-BETA; TRANSLATIONAL REGULATION; MOUSE EPIDERMIS; AP-1 COMPLEX; CELL-LINE; EXPRESSION; PROMOTER	Since many lines of evidence suggest that expression of the transforming growth factor-beta-1 (TGF-beta-1) gene may be regulated post-transcriptionally, we examined the effect of the 5'-untranslated region (UTR) of this gene on TGF-beta-1 expression. For this purpose, fragments of the 840-nucleotide highly GC-rich TGF-beta-1 5'-UTR were inserted into the 5'-UTR of the structural gene for human growth hormone driven by the simian virus 40 early promoter. A portion of the 5'-UTR of TGF-beta-1 mRNA spanning the sequences from +11 to +147 was shown to inhibit growth hormone expression by as much as 22-fold. This effect was cell-specific; growth hormone production was inhibited in PC-3 human prostate adenocarcinoma and A-549 human lung adenocarcinoma cells, while no effect was seen in rat pheochromocytoma PC12 cells, which show efficient translation of endogenous TGF-beta-1 mRNA. Computer analysis showed that this region of the 5'-UTR contained a stable secondary stem-loop structure spanning sequences +49 to +76. This stem-loop region alone is sufficient to inhibit expression of the growth hormone gene, suggesting that it plays an important role in post-transcriptional regulation of TGF-beta-1 gene expression.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.		Wakefield, Lalage M/M-1963-2017	Wakefield, Lalage M/0000-0003-4124-5250				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DICKEY LF, 1988, J BIOL CHEM, V263, P3071; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JAKOWLEW SB, 1988, ONCOGENE RES, V2, P135; KAIGHN ME, 1979, INVEST UROL, V17, P16; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIM SJ, 1989, J BIOL CHEM, V264, P402; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2580; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; WALDEN WE, 1989, J BIOL CHEM, V264, P13765	38	177	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13702	13707						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618868				2022-12-27	WOS:A1992JB74600095
J	LAMEH, J; PHILIP, M; SHARMA, YK; MORO, O; RAMACHANDRAN, J; SADEE, W				LAMEH, J; PHILIP, M; SHARMA, YK; MORO, O; RAMACHANDRAN, J; SADEE, W			HM1 MUSCARINIC CHOLINERGIC RECEPTOR INTERNALIZATION REQUIRES A DOMAIN IN THE 3RD CYTOPLASMIC LOOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SITE-DIRECTED MUTAGENESIS; HUMAN ASTROCYTOMA-CELLS; ACETYLCHOLINE-RECEPTOR; DOWN-REGULATION; BETA-2-ADRENERGIC RECEPTOR; PHORBOL ESTERS; GROWTH-FACTOR; ENDOCYTOSIS; PHOSPHORYLATION	Selected regions of the Hm1 muscarinic cholinergic receptor were mutated to analyze the molecular mechanisms of agonist-induced receptor internalization (or sequestration). The wild-type and mutant Hm1 genes were expressed, using pSG5, in U293 human kidney cells. Whereas surface receptor density measured with the polar tracer N-[H-3]methylscopolamine was rapidly reduced by carbachol exposure, total receptor content measured with [H-3]quinuclidinyl benzilate did not decline for at least 24 h, indicating the absence of extensive receptor down-regulation in U293 cells. Carbachol stimulation of phosphatidylinositol turnover paralleled receptor internalization, both with EC50 values of 10-20-mu-M. Furthermore, a D71N point mutation that prevented receptor activation also abolished carbachol-induced receptor internalization, indicating that receptor activation (but not necessarily second messenger stimulation) was required for internalization. Truncation of the COOH-terminal tail (K447 trunc) and point mutations of several potential Ser and Thr phosphorylation sites to Ala failed to affect receptor activation and internalization. In contrast, partial deletions of the third intracellular loop (i3) (Tyr208-Thr366) resulted in receptor mutants deficient in agonist-induced receptor internalization/sequestration. Various deletions caused either complete loss of internalization (d 232-358) or impaired internalization, ranging from 10 to 30% over 2 h, whereas wild-type Hm1 internalized to approximately 50%. Whereas the reason for the observed differences among the deficient deletion mutants remains unclear, the initial rate of N-[H-3]methylscopolamine binding loss from the cell surface was much slower than that of wild-type Hm1 in each case. The deletion of only one single domain, 284-292 (SMESLTSSE), in the middle of i3 was consistently associated with impaired internalization. Domain 284-292 is partially conserved among closely related muscarinic receptors, whereas most of the remainder of i3 is not (except for the i3 membrane junctions), and similar Ser- and Thr-rich regions are present in many other G protein-coupled receptors. We propose that a small receptor domain in the middle of the i3 loop of Hm1 is involved in agonist-induced receptor internalization.	NEUREX CORP,MENLO PK,CA 94025; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	LAMEH, J (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004166] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 04166] Funding Source: Medline; NIGMS NIH HHS [GM 43102] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; CONE RI, 1991, LIFE SCI, V49, pPL147, DOI 10.1016/0024-3205(91)90396-S; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FRASER CM, 1989, MOL PHARMACOL, V36, P840; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HERTEL C, 1985, J BIOL CHEM, V260, P2547; HOOVER RK, 1990, J PHARMACOL EXP THER, V253, P185; HOOVER RK, 1989, J PHARMACOL EXP THER, V251, P63; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LAI WS, 1990, BIOCHEM J, V267, P23, DOI 10.1042/bj2670023; LAMEH J, 1990, PHARMACEUT RES, V7, P1213, DOI 10.1023/A:1015969301407; LILES WC, 1986, J BIOL CHEM, V261, P5307; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SERRA M, 1986, BIOCHEM BIOPH RES CO, V140, P160, DOI 10.1016/0006-291X(86)91071-5; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SHAPIRO RA, 1989, P NATL ACAD SCI USA, V86, P9039, DOI 10.1073/pnas.86.22.9039; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; STRASSER RH, 1988, J CARDIOVASC PHARM, V12, pS15, DOI 10.1097/00005344-198806121-00004; THIES RS, 1990, J BIOL CHEM, V265, P10132; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089	36	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13406	13412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618842				2022-12-27	WOS:A1992JB74600050
J	MEIGS, TE; SIMONI, RD				MEIGS, TE; SIMONI, RD			REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE IN PERMEABILIZED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; MEVALONATE-DERIVED PRODUCT; MEMBRANE-BOUND DOMAIN; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; RAT-LIVER; PROTEIN; ENZYME; 25-HYDROXYCHOLESTEROL	We have studied the regulated degradation of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase within the endoplasmic reticulum in cells permeabilized with digitonin. Using Chinese hamster ovary cells transfected with a plasmid encoding HMGal, a chimeric protein containing the membrane domain of HMG-CoA reductase coupled to beta-galactosidase, we have demonstrated mevalonate and sterol-stimulated loss of beta-galactosidase activity. In pulse-chase experiments we have demonstrated mevalonate-stimulated degradation of both HMGal and HMG-CoA reductase. The rate of mevalonate-stimulated degradation observed in permeabilized cells tends to be slightly slower than that observed in intact cells treated with mevalonate and is dependent upon incubation of cells with mevalonate prior to permeabilization. The degradation process measured in this report extends a previous report of HMG-CoA reductase degradation in digitonin-permeabilized cells (Leonard, D. A., and Chen, H. W. (1987) J. Biol. Chem. 262, 7914-7919) by mimicking key physiological features of the in vivo process, including: stimulation by regulatory molecules, specifically mevalonate and sterols; inhibition by cycloheximide; and inhibition by an inhibitor of neutral cysteine proteases.			MEIGS, TE (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUFAY H, 1974, J CELL BIOL, V61, P213, DOI 10.1083/jcb.61.1.213; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; INOUE S, 1991, J BIOL CHEM, V266, P13311; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KATZ J, 1985, J CELL BIOCHEM, V28, P207, DOI 10.1002/jcb.240280304; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROITELMAN J, 1992, IN PRESS J CELL BIOL; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	30	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13547	13552						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618856				2022-12-27	WOS:A1992JB74600071
J	URUSHIBARA, N; KUMAZAKI, T; ISHII, S				URUSHIBARA, N; KUMAZAKI, T; ISHII, S			HEMOGLOBIN-BINDING SITE ON HUMAN HAPTOGLOBIN - IDENTIFICATION OF LYSYL RESIDUES PARTICIPATING IN THE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-CHAIN; CDNA; RESOLUTION; CLEAVAGE; PRODUCT; COMPLEX	The locus of human haptoglobin (Hp) molecules that interacts with human hemoglobin (Hb) was examined by the differential labeling technique. First, amino groups of Hp were extensively labeled with ethyl acetimidate (EAI) either in the free state (experiment A) or in the equimolar complex with Hb (experiment B). Each of the labeled Hp samples was reduced and S-carboxymethylated, and the remaining amino groups were then allowed to react with trinitrobenzenesulfonic acid (TNBS) under denatured conditions. Only 0.6 mol/mol of the trinitrophenyl (TNP) group was introduced into the heavy chain of Hp in experiment A, whereas 2.5 mol/mol of TNP groups were into the same chain in experiment B. The extent of TNP modification for the light chain was very low in either of the experiments. The amino acid residues carrying TNP groups in the heavy chain were identified by the peptide mapping procedure. They were Ile1, Lys136, and Lys218 in experiment B, and only Ile1 in experiment A. These findings suggest that epsilon-amino groups of Lys136 and Lys218 in the heavy chain are both situated within the Hb-binding locus of Hp, and that the alpha-amino group of Ile1 is buried inside the molecule either in the presence or absence of Hb.			URUSHIBARA, N (corresponding author), HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN.		Urushibara, Noriko/AAQ-9883-2021	Urushibara, Noriko/0000-0003-0363-567X				ARCOLEO JP, 1982, J BIOL CHEM, V257, P63; BENESCH RE, 1972, BIOCHEMISTRY-US, V11, P3576, DOI 10.1021/bi00769a013; BERNINI L F, 1970, Biochimica et Biophysica Acta, V200, P203, DOI 10.1016/0005-2795(70)90165-0; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BIRKTOFT JJ, 1969, BIOCHEM BIOPH RES CO, V36, P131, DOI 10.1016/0006-291X(69)90659-7; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; CHANG JY, 1989, J BIOL CHEM, V264, P7141; CHIAO MT, 1972, BIOCHIM BIOPHYS ACTA, V263, P60, DOI 10.1016/0005-2795(72)90159-6; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P20; DOBRYSZYCKA W, 1969, BIOCHIM BIOPHYS ACTA, V175, P271, DOI 10.1016/0005-2795(69)90005-1; FEHLHAMMER H, 1975, J MOL BIOL, V98, P683, DOI 10.1016/S0022-2836(75)80004-0; FERRIS TG, 1966, AM J CLIN PATHOL, V46, P385, DOI 10.1093/ajcp/46.3_ts.385; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; HIGA Y, 1981, J BIOL CHEM, V256, P2322; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; HUNTER MJ, 1962, J AM CHEM SOC, V84, P3491, DOI 10.1021/ja00877a016; KINO K, 1980, J BIOL CHEM, V255, P9616; KUMAZAKI T, 1979, J BIOCHEM, V85, P581, DOI 10.1093/oxfordjournals.jbchem.a132367; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTBADER JW, 1983, J BIOL CHEM, V258, P1227; MAKINEN MW, 1972, BIOCHEMISTRY-US, V11, P3851, DOI 10.1021/bi00771a004; MALCHY B, 1973, CAN J BIOCHEM CELL B, V51, P265, DOI 10.1139/o73-033; MALCHY B, 1973, CAN J BIOCHEM CELL B, V51, P249, DOI 10.1139/o73-032; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MCCORMICK DJ, 1990, J PROTEIN CHEM, V9, P735, DOI 10.1007/BF01024768; NAGEL RL, 1971, J BIOL CHEM, V246, P69; NUREDDIN A, 1975, BIOCHEM J, V147, P71, DOI 10.1042/bj1470071; PERUTZ MF, 1965, J MOL BIOL, V13, P646, DOI 10.1016/S0022-2836(65)80133-4; PLAPP BV, 1974, ANAL BIOCHEM, V62, P291, DOI 10.1016/0003-2697(74)90390-X; PUTNAM FW, 1975, PLASMA PROTEIN STRUC, V2, P1; RAFELSON ME, 1961, NATURE, V191, P279, DOI 10.1038/191279b0; RAUGEI G, 1983, NUCLEIC ACIDS RES, V11, P5811, DOI 10.1093/nar/11.17.5811; RICHARDSON RH, 1980, J BIOL CHEM, V255, P3377; SATAKE K, 1960, J BIOCHEM-TOKYO, V47, P654, DOI 10.1093/oxfordjournals.jbchem.a127107; SHINODA T, 1965, J BIOCHEM-TOKYO, V57, P100, DOI 10.1093/oxfordjournals.jbchem.a128048; STROUD RM, 1971, S QUANTITATIVE BIOL, V36, P125; VALETTE I, 1981, J BIOL CHEM, V256, P672; VANDERSTRATEN A, 1984, FEBS LETT, V168, P103, DOI 10.1016/0014-5793(84)80215-X; VANDERSTRATEN A, 1983, EMBO J, V2, P1003, DOI 10.1002/j.1460-2075.1983.tb01534.x; WAKS M, 1966, ARCH BIOCHEM BIOPHYS, V113, P268; WEJMAN JC, 1984, J MOL BIOL, V174, P319, DOI 10.1016/0022-2836(84)90341-3; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; YOSHIOKA N, 1986, BIOCHEM J, V234, P453, DOI 10.1042/bj2340453	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13413	13417						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618843				2022-12-27	WOS:A1992JB74600051
J	WAN, JS; TAUB, ME; SHAH, D; SHEN, WC				WAN, JS; TAUB, ME; SHAH, D; SHEN, WC			BREFELDIN-A ENHANCES RECEPTOR-MEDIATED TRANSCYTOSIS OF TRANSFERRIN IN FILTER-GROWN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COTURNIX-COTURNIX-JAPONICA; CULTURED OVIDUCT CELLS; BLOOD-BRAIN-BARRIER; EGG-WHITE PROTEINS; SECRETORY PROTEINS; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; GOLGI-COMPLEX; MDCK CELLS	The effects of brefeldin A (BFA) on transferrin (Tf) transcellular transport, Tf receptor (TfR) distribution, and TfR-mediated endocytosis in filter-grown Madin-Darby canine kidney (MDCK) cells were studied. BFA (1.6-mu-g/ml) markedly enhanced the transcytosis of I-125-labeled Tf (I-125-Tf) in both apical-to-basal and basal-to-apical directions; yet, BFA did not enhance the transcytosis of either native horseradish peroxidase (HRP) or membrane-bound HRP-poly(L-lysine) conjugates. Furthermore, this enhanced transcytosis of I-125 Tf was abolished either by competition with excess unlabeled Tf or by incubation at temperatures less-than-or-equal-to 25-degrees-C. In addition, BFA treatment to MDCK cells: (a) increased I-125-Tf specific binding to the apical membrane and decreased I-125-Tf specific binding to the basal membrane; (b) decreased TfR recycling at the basolateral membrane; (c) altered the apical/basolateral distribution of TfRs in favor of the apical side; and (d) markedly increased Fe-59 extraction, but not transcytosis, from apically endocytosed Fe-59-loaded Tf. These effects are consistent with a model in which BFA alters the traffic pattern of internalized Tf by decreasing basolateral TfR recycling, while diverting the nonrecycled fraction to the apical side of the cell. Our results indicate that, unlike the reported inhibition of polymeric IgA transcytosis (Hunziker, W., Whitney, J. A., and Mellman, I. (1991) Cell 67, 617-627), BFA can enhance the transcytosis of Tf in MDCK cells. Thus, by altering the intracellular traffic of ligand-receptor complexes, BFA can elicit either a decrease or an increase in transcytosis depending on the nature of the intracellular receptor processing.	UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT SCI,1985 ZONAL AVE,RM 404B,LOS ANGELES,CA 90089	University of Southern California					NCI NIH HHS [CA-34798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCH WE, 1989, J BIOL CHEM, V264, P16965; BANERJEE D, 1986, GASTROENTEROLOGY, V91, P861, DOI 10.1016/0016-5085(86)90687-6; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CERNEUS DP, 1991, J CELL BIOL, V114, P1149, DOI 10.1083/jcb.114.6.1149; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FULLER SD, 1986, J CELL BIOL, V103, P1767, DOI 10.1083/jcb.103.5.1767; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KATO S, 1989, BIOCHIM BIOPHYS ACTA, V991, P36, DOI 10.1016/0304-4165(89)90025-1; KLAUSNER RD, 1984, J CELL BIOL, V98, P1098, DOI 10.1083/jcb.98.3.1098; LARRICK JW, 1979, BIOCHIM BIOPHYS ACTA, V583, P483, DOI 10.1016/0304-4165(79)90065-5; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOSTOV KE, 1985, CELL, V43, P389, DOI 10.1016/0092-8674(85)90166-7; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PERKEL VS, 1988, ENDOCRINOLOGY, V123, P310, DOI 10.1210/endo-123-1-310; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; RODRIGUEZBOULAN E, 1989, ANNU REV PHYSIOL, V51, P741, DOI 10.1146/annurev.physiol.51.1.741; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SHEN WC, 1990, BIOCHEM BIOPH RES CO, V166, P316, DOI 10.1016/0006-291X(90)91947-Q; SIMIONESCU M, 1989, ENDOTHELIAL CLEL BIO, P69; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; TAUB ME, 1992, J CELL PHYSIOL, V150, P283, DOI 10.1002/jcp.1041500210; TIMCHAK LM, 1986, J BIOL CHEM, V261, P14154; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; ULMER JB, 1991, J BIOL CHEM, V266, P9173; WAN J, 1991, Pharmaceutical Research (New York), V8, pS4; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; 1972, WORTHINGTON ENZYME M, P43	41	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13446	13450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618847				2022-12-27	WOS:A1992JB74600056
J	BALCH, WE; KAHN, RA; SCHWANINGER, R				BALCH, WE; KAHN, RA; SCHWANINGER, R			ADP-RIBOSYLATION FACTOR IS REQUIRED FOR VESICULAR TRAFFICKING BETWEEN THE ENDOPLASMIC-RETICULUM AND THE CIS-GOLGI COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; YPT1 GENE-PRODUCT; SECRETORY PATHWAY; EUKARYOTIC PROTEIN; ADENYLATE-CYCLASE; CHOLERA-TOXIN; BREFELDIN-A; YEAST YPT1; TRANSPORT; APPARATUS	We describe the potential role of ADP-ribosylation factor (ARF) in vesicular trafficking using an in vitro assay that efficiently reconstitutes transport between the endoplasmic reticulum (ER) and the cis-Golgi compartment in mammalian semi-intact cells, a population of cells in which the plasma membrane is physically perforated to reveal intact ER and Golgi compartments. We demonstrate that peptides identical to the amino-terminal domain of ARF, which inhibit ARF cofactor activity in cholera toxin-catalyzed ADP-ribosylation of G(alpha-s) (Kahn, R. A., Randazzo, P., Serafini, T., Weiss, O., Rulka, C., Clark, J., Amherdt, M., Roller, P., Orci, L., and Rothman, J. E. (1992) J. Biol. Chem. 267, 13039-13046), inhibit transport of the vesicular stomatitis virus G protein between the ER and cis-Golgi compartment. Inhibition of transport was rapid (t1/2 = 30-60 s) and irreversible. Half-maximal inhibition was observed at concentrations of 15 and 22-mu-M with peptides identical to the amino-terminal domain of the human ARF4 (hARF4) protein and the human ARF1 protein, respectively. Kinetic analysis of vesicular stomatitis virus G protein transport suggested that the hARF4 peptide inhibits a late vesicle fusion step. In addition, incubation of semi-intact cells in the presence of the myristoylated form human ARF1 (hARF1myr) protein, but not the nonmyristoylated form of ARF1, inhibited transport. In contrast to peptide, the hARF1myr blocked an early transport step, similar to that observed with guanosine 5'-3-O-(thio)triphosphate. These results suggest that ARF and components facilitating ARF function play an important role in the cyclical fission and fusion of transport vesicles mediating ER to Golgi trafficking.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BALCH, WE (corresponding author), SCRIPPS RES INST, DEPT CELLULAR BIOL, LA JOLLA, CA 92037 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336, R01GM033301] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27489] Funding Source: Medline; NIGMS NIH HHS [GM 42336, GM33301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V253, P451; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PFEFFER S, 1992, IN PRESS TRENDS CELL; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAYLOR R, 1992, IN PRESS J CELL BIOL; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WILSON DW, 1991, TRENDS BIOCHEM SCI, V16, P334, DOI 10.1016/0968-0004(91)90138-L; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	66	204	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13053	13061						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618803				2022-12-27	WOS:A1992HZ48300097
J	LODISH, HF; KONG, N; WIKSTROM, L				LODISH, HF; KONG, N; WIKSTROM, L			CALCIUM IS REQUIRED FOR FOLDING OF NEWLY MADE SUBUNITS OF THE ASIALOGLYCOPROTEIN RECEPTOR WITHIN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE ISOMERASE; HUMAN HEPATOMA-CELLS; HAMSTER OVARY CELLS; SECRETORY PROTEINS; BINDING-PROTEINS; INTRACELLULAR DEGRADATION; EXOCRINE PANCREAS; GOLGI-COMPLEX; PRE-GOLGI; GLYCOPROTEINS	By resolving immunoprecipitates on nonreducing sodium dodecyl sulfate gels, we have detected several disulfide-bonded intermediates in folding within the endoplasmic reticulum of newly made H1 subunits of t he asialoglycoprotein receptor. H1 in the endoplasmic reticulum (ER) can be partially unfolded by treatment of cells with dithiothreitol, but H1 in Golgi or post-Golgi organelles is resistant to such unfolding. This defines a late step in H1 folding that occurs just prior to exit from the ER. Depletion of calcium from the endoplasmic reticulum, either by treatment with A23187 or thapsigargin, has no effect on folding or secretion of newly made albumin, but totally blocks H1 maturation from the ER. No ER intermediates in H1 folding are formed in cells treated with A23187 or thapsigargin, indicating that at least an early step in H1 folding requires a high Ca2+ concentration in the ER lumen. As judged by cross-linking experiments, formation of H1 dimers and trimers occurs immediately after biosynthesis of the peptide chain, before monomer folding, and occurs normally in cells in which ER Ca2+ is reduced and where the monomer never folds properly. Calcium is essential for the asialoglycoprotein receptor to bind galactose, and our results suggest that Ca2+ is also essential for the receptor polypeptides to fold in the ER.	LUDWIG INST CANC RES, S-10401 STOCKHOLM, SWEDEN; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Ludwig Institute for Cancer Research; Massachusetts Institute of Technology (MIT)	LODISH, HF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; COLLINS PL, 1991, J VIROL, V65, P2362, DOI 10.1128/JVI.65.5.2362-2371.1991; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LE A, 1990, J BIOL CHEM, V265, P14001; LEDFORD BE, 1983, J BIOL CHEM, V258, P3304; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MACER DRJ, 1988, J CELL SCI, V91, P61; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; OLSON TS, 1989, FASEB J, V3, P1618, DOI 10.1096/fasebj.3.5.2537774; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHEELE G, 1985, J BIOL CHEM, V260, P926; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; Stamnes MA, 1990, CURR OPIN CELL BIOL, V2, P1104, DOI 10.1016/0955-0674(90)90163-9; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	61	227	232	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12753	12760						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618778				2022-12-27	WOS:A1992HZ48300057
J	LONGO, N; SHUSTER, RC; GRIFFIN, LD; LANGLEY, SD; ELSAS, LJ				LONGO, N; SHUSTER, RC; GRIFFIN, LD; LANGLEY, SD; ELSAS, LJ			ACTIVATION OF INSULIN-RECEPTOR SIGNALING BY A SINGLE AMINO-ACID SUBSTITUTION IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTOR; KINASE-ACTIVITY; HUMAN-FIBROBLASTS; POINT MUTATION; NEU ONCOGENE; PROTEIN; BINDING; 2-DEOXYGLUCOSE; REPLACEMENT; TRANSPORT	The insulin receptor is a ligand-activated tyrosine kinase composed of two alpha and two beta-subunits. A single transmembrane domain composed of 23 hydrophobic residues is contained in each beta-subunit. We examined the role of the transmembrane domain in regulating insulin receptor signaling by inserting a negatively charged amino acid (Asp) for Val938 (V938D). Chinese hamster ovary (CHO) cells were stably transfected with a plasmid containing both the neomycin-resistance gene and either the wild-type or the mutant (V938D) insulin receptor cDNA. Insulin binding increased similarly in CHO cells stably transfected with the wild-type and the V938D-mutant insulin receptor cDNA. Insulin stimulated glucose transport and cell growth in cells expressing the normal insulin receptor. By contrast, in the absence of insulin, glucose transport and cell growth in CHO-V938D cells were as high as in insulin-stimulated control cells and no longer responsive to insulin stimulation. Phosphorylation of the beta-subunit of the insulin receptor was also increased in CHO-V938D cells not exposed to insulin. These results support an essential role of the transmembrane domain of the insulin receptor in the transduction of insulin signaling.	EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University	LONGO, N (corresponding author), EMORY UNIV,DEPT PEDIAT,DIV MED GENET,2040 RIDGEWOOD DR,ATLANTA,GA 30322, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 40362] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONGO N, 1988, AM J PHYSIOL, V254, pC628, DOI 10.1152/ajpcell.1988.254.5.C628; LONGO N, 1985, BIOCHIM BIOPHYS ACTA, V844, P216, DOI 10.1016/0167-4889(85)90093-X; LONGO N, 1989, METABOLISM, V38, P690, DOI 10.1016/0026-0495(89)90109-1; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WELNER DB, 1989, NATURE, V339, P230	25	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12416	12419						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618747				2022-12-27	WOS:A1992HZ48300007
J	ARAKAWA, T; OSHIMA, T; KISHIMOTO, K; YOSHIMOTO, T; YAMAMOTO, S				ARAKAWA, T; OSHIMA, T; KISHIMOTO, K; YOSHIMOTO, T; YAMAMOTO, S			MOLECULAR-STRUCTURE AND FUNCTION OF THE PORCINE ARACHIDONATE 12-LIPOXYGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 5-LIPOXYGENASE GENE; PROMOTER; CLONING; EXPRESSION; SEQUENCE; TRANSCRIPTION; LEUKOCYTES; CDNA; SP1	The gene encoding arachidonate 12-lipoxygenase was cloned from a porcine EMBL3 genomic library using a cDNA probe of the enzyme, and its nucleotide sequence was determined. The gene consists of 14 exons with 13 introns, and spans approximately 8 kilobases. Analysis of splice junctions indicated that all of the splice donor and acceptor sites conformed to the GT/AG rule. An approximately 1-kilobase region upstream of the coding sequence contains nine GC-boxes for potential Sp1-binding sites at positions -77, -135, -145, -165, -214, -636, -643, -684, and -813. There are two sets of AP-2 binding sequence at positions -234 and -402. Neither typical TATA box nor CCAAT box is found in this region. The transcriptional start site was determined by primer extension analysis, and was tentatively identified as a cytidine residue located 19 bases upstream from initiation codon. Southern blot analysis revealed the presence of one copy of 12-lipoxygenase gene per haploid genome. We found striking similarities in genomic organization as well as the promoter sequences between the porcine 12-lipoxygenase and the rabbit 15-lipoxygenase genes, suggesting that these genes are evolutionarily related.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,KURAMOTO CHO,TOKUSHIMA 770,JAPAN	Tokushima University								BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YAMAMOTO S, 1989, PROSTAG LEUKOTR ESS, V35, P219, DOI 10.1016/0952-3278(89)90005-7; YAMAMOTO S, 1988, PROSTAGLANDINS BIOL, P37; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1990, BIOCHEM BIOPH RES CO, V172, P1230, DOI 10.1016/0006-291X(90)91580-L; YOSHIMOTO T, 1991, INT S OXYGENASES OXY, P59	22	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12188	12191						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601885				2022-12-27	WOS:A1992HY94700080
J	LANG, P; GUIZANI, L; VITTEMONY, I; STANCOU, R; DORSEUIL, O; GACON, G; BERTOGLIO, J				LANG, P; GUIZANI, L; VITTEMONY, I; STANCOU, R; DORSEUIL, O; GACON, G; BERTOGLIO, J			ADP-RIBOSYLATION OF THE RAS-RELATED, GTP-BINDING PROTEIN RHOA INHIBITS LYMPHOCYTE-MEDIATED CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLOSTRIDIUM-BOTULINUM; NATURAL-KILLER; CELLS; FAMILY	The Rho proteins are identified as a subgroup of the Ras superfamily of low molecular weight GTP-binding proteins. We have studied the expression of these proteins in human cytotoxic natural killer cells and found that RhoA is the most abundantly expressed member of the Rho family. The Rho proteins are specific substrates for ADP-ribosylation catalyzed by the C3 exoenzyme from Clostridium botulinum. We report here that introduction of recombinant C3 in electropermeabilized natural killer cells or in cytotoxic T lymphocytes resulted in a dose-dependent inhibition of their cytolytic function. Furthermore, a single substrate is efficiently ADP-ribosylated by C3 in extracts from cytotoxic cells. Biochemical analyses indicate that this substrate is RhoA, and subcellular fractionation experiments demonstrate that it is essentially present in the cytosol of the cells. Western blot analysis, however, revealed that a small proportion of the Rho protein can be found associated with the cell membrane as well as with the cytotoxic granules. These results indicate that the low molecular weight GTP-binding protein RhoA is present in cytotoxic lymphocytes and plays a critical role in cell-mediated cytotoxicity.	INST GUSTAVE ROUSSY,INSERM,U333,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE; INST COCHIN GENET MOLEC,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VITTEMONY I, 1990, J IMMUNOL, V145, P4272; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YODOI J, 1985, J IMMUNOL, V134, P1623; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	28	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11677	11680						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601841				2022-12-27	WOS:A1992HY94700005
J	OSBAKKEN, M; IVANICS, T; ZHANG, DN; MITRA, R; BLUM, H				OSBAKKEN, M; IVANICS, T; ZHANG, DN; MITRA, R; BLUM, H			ISOLATED CARDIOMYOCYTES IN CONJUNCTION WITH NMR-SPECTROSCOPY TECHNIQUES TO STUDY METABOLISM AND ION FLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; CITRIC-ACID CYCLE; RAT-HEART; CARDIAC MYOCYTES; C-13 NMR; VASOACTIVE AGENTS; PERFUSED HEART; MUSCLE-CELLS; FREE CALCIUM; ATP	To distinguish cellular from vascular responses to physiological and pathophysiological stimuli, we developed methods to perform NMR spectroscopy on isolated ventricular cardiomyocytes. Isolated adult rat cardiomyocytes, placed in agarose beads and superfused with phosphate-free buffer (Media 199 (GIBCO 400-1100) gassed with 95% O2, 5% CO2), were used to evaluate a variety of cellular processes during different pharmacological and physiological interventions. Bioenergetic function was monitored with P-31 NMR. Intermediary metabolism, gluconeogenesis, and glycolysis were monitored with C-13 NMR. Sodium flux was monitored with Na-23 NMR. Calcium flux was monitored with F-19 NMR in conjunction with an intracellular calcium-chelating agent, 5F-1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. Creatine kinase kinetics (forward rate constant (K(f)) and flux of phosphocreatine to ATP) were estimated with P-31 NMR saturation transfer data. Various combinations of NMR parameters were monitored simultaneously so that the interaction of metabolism and ion flux could be evaluated. We have demonstrated that it is possible to simultaneously monitor a variety of cellular processes in intact heart cells in real time, without the confounding influences of perfusion, contractile function, and extrinsic blood-borne neurohumoral agents. This model will be useful for longitudinal studies of myocyte metabolism and ion flux.	UNIV PENN, SCH MED, DEPT BIOCHEM BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	OSBAKKEN, M (corresponding author), UNIV PENN, SCH MED, DEPT MED CARDIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039208] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENTAL M, 1990, EUR J BIOCHEM, V188, P111, DOI 10.1111/j.1432-1033.1990.tb15377.x; BLUM H, 1991, MAGNET RESON MED, V18, P348, DOI 10.1002/mrm.1910180209; BLUMENTHAL MR, 1968, AM J PHYSIOL, V214, P1280, DOI 10.1152/ajplegacy.1968.214.6.1280; BORGERS M, 1988, ANN NY ACAD SCI, V522, P433; BROOKS WM, 1986, J MOL CELL CARDIOL, V18, P149, DOI 10.1016/S0022-2828(86)80467-9; CHANCE EM, 1983, J BIOL CHEM, V258, P3785; CORDIS GA, 1988, J CHROMATOGR, V459, P229, DOI 10.1016/S0021-9673(01)82031-8; DAS AM, 1990, BIOCHEM J, V266, P355, DOI 10.1042/bj2660355; DOELLER JE, 1990, AM J PHYSIOL, V259, pH1851, DOI 10.1152/ajpheart.1990.259.6.H1851; GUPTA RK, 1991, AM J PHYSIOL, V261, pH1155, DOI 10.1152/ajpheart.1991.261.4.H1155; HEADRICK JP, 1990, AM J PHYSIOL, V258, pH617, DOI 10.1152/ajpheart.1990.258.3.H617; HOERTER JA, 1986, CIRC RES, V58, P539, DOI 10.1161/01.RES.58.4.539; HORACKOVA M, 1991, CARDIOVASC RES, V25, P1023, DOI 10.1093/cvr/25.12.1023; HUMPHREY SM, 1991, AM J PHYSIOL, V260, pH6, DOI 10.1152/ajpheart.1991.260.1.H6; IVANICS T, 1991, J APPL CARDIOL, V6, P211; IVANICS T, 1991, J APPL CARDIOL, V6, P283; KAMMERMEIER H, 1988, BASIC RES CARDIOL, V83, P343, DOI 10.1007/BF02005819; KOHLER SJ, 1991, MAGNET RESON MED, V18, P15, DOI 10.1002/mrm.1910180104; KONDRASHOVA MN, 1989, FEBS LETT, V243, P153, DOI 10.1016/0014-5793(89)80119-X; LLOYD TR, 1990, J MOL CELL CARDIOL, V22, P333, DOI 10.1016/0022-2828(90)91466-K; MALLOY CR, 1990, BIOCHEMISTRY-US, V29, P6756, DOI 10.1021/bi00481a002; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; NAG AC, 1987, IN VITRO CELL DEV B, V23, P261, DOI 10.1007/BF02623708; NICHOLS CG, 1990, CAN J PHYSIOL PHARM, V68, P183, DOI 10.1139/y90-029; OSBAKKEN M, 1991, CARDIOLOGY, V79, P1, DOI 10.1159/000174851; OSBAKKEN MD, 1989, CLIN RES, V37, pA283; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; SAKO EY, 1988, J BIOL CHEM, V263, P10600; SEEHOLZER SH, 1985, THESIS U PENNSYLVANI; SEN LY, 1990, CIRC RES, V67, P1182, DOI 10.1161/01.RES.67.5.1182; SERAYDARIAN MW, 1976, J MOL CELL CARDIOL, V8, P669, DOI 10.1016/0022-2828(76)90009-2; SIEGMUND B, 1990, AM J PHYSIOL, V258, pH285, DOI 10.1152/ajpheart.1990.258.2.H285; SIEGMUND B, 1991, AM J PHYSIOL, V260, pH426, DOI 10.1152/ajpheart.1991.260.2.H426; SPRINGER CS, 1988, NMR TECHNIQUES STUDY, P289; STEENBERGEN C, 1990, CIRC RES, V66, P135, DOI 10.1161/01.RES.66.1.135; Taylor D J, 1983, Mol Biol Med, V1, P77; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; WITTENBERG BA, 1985, J BIOL CHEM, V260, P2031; WITTENBERG BA, 1991, BIOPHYS J, V57, pA164; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015	42	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15340	15347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639780				2022-12-27	WOS:A1992JG11300016
J	QUEST, AFG; CHADWICK, JK; WOTHE, DD; MCILHINNEY, RAJ; SHAPIRO, BM				QUEST, AFG; CHADWICK, JK; WOTHE, DD; MCILHINNEY, RAJ; SHAPIRO, BM			MYRISTOYLATION OF FLAGELLAR CREATINE-KINASE IN THE SPERM PHOSPHOCREATINE SHUTTLE IS LINKED TO ITS MEMBRANE ASSOCIATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; PROTEIN ALPHA-SUBUNIT; CARCINOMA CELL-LINES; TRANSFORMING PROTEIN; ACYLATED PROTEINS; P60SRC; ACID; EXPRESSION; SEQUENCE; MYRISTYLATION	TCK, the flagellar creatine kinase (ATP:creatine N-phosphotransferase) of sperm from the sea urchin Strongylocentrotus purpuratus is a membrane-associated lipophilic protein involved in energy transport. The cDNA derived protein sequence contains a consensus site sufficient for the covalent attachment of myristate. To examine whether TCK was myristoylated, mouse fibroblast Swiss 3T3 and baby hamster kidney cell lines were transfected with a cDNA encoding the entire TCK protein linked to a metallothionein promotor. TCK expression was induced by zinc and paralleled by incorporation of [H-3]myristic acid derived label into the protein. H-3 Label incorporated into TCK was resistant to hydroxylamine treatment. The H-3-labeled material released from TCK by acid methanolysis eluted from a C18 reverse phase high pressure liquid chromatography column at the positions of myristic acid and methylmyristate. Thus, TCK expressed in transfected mammalian cell lines contains authentic myristic acid, covalently attached through amide linkage. [H-3]Myristoyl TCK comigrated on two-dimensional gels with the purified lipophilic isoform TCK II from sea urchins. Furthermore, like TCK II, [H-3]myristoyl TCK associated with phospholipid liposomes, suggesting that myristoylation may mediate the observed membrane association of TCK. Myristoylation of sea urchin sperm flagellar creatine kinase may play a role in confining this enzyme to the flagellum during spermatogenesis.	MRC,ANAT NEUROPHARMACOL UNIT,OXFORD OX1 3TH,ENGLAND; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023910] Funding Source: NIH RePORTER; NCI NIH HHS [CA09437] Funding Source: Medline; NIGMS NIH HHS [GM23910] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DURNAM DM, 1984, MOL CELL BIOL, V4, P484, DOI 10.1128/MCB.4.3.484; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KREIL G, 1981, ANNU REV BIOCHEM, V50, P317, DOI 10.1146/annurev.bi.50.070181.001533; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUSIL LS, 1988, J CELL BIOL, V107, P1113, DOI 10.1083/jcb.107.3.1113; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PERRYMAN MB, 1983, BIOCHIM BIOPHYS ACTA, V747, P284, DOI 10.1016/0167-4838(83)90107-3; QUEST AFG, 1991, J BIOL CHEM, V266, P19803; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SCHATZ G, 1983, CELL, V32, P316, DOI 10.1016/0092-8674(83)90450-6; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TOMBES RM, 1987, BIOPHYS J, V52, P75, DOI 10.1016/S0006-3495(87)83190-9; TOMBES RM, 1987, J BIOL CHEM, V262, P16011; TOMBES RM, 1985, CELL, V41, P325, DOI 10.1016/0092-8674(85)90085-6; TOMBES RM, 1988, EXP CELL RES, V178, P307, DOI 10.1016/0014-4827(88)90401-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203	39	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15080	15085						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634544				2022-12-27	WOS:A1992JF08800084
J	BLACKLOCK, BJ; SMILLIE, M; RYAN, RO				BLACKLOCK, BJ; SMILLIE, M; RYAN, RO			INSECT LIPID TRANSFER PARTICLE CAN FACILITATE NET VECTORIAL LIPID TRANSFER VIA A CARRIER-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEINS; HUMAN-PLASMA LOW; MANDUCA-SEXTA; TRANSFER PROTEIN; CHOLESTERYL ESTER; LIPOPHORIN; HEMOLYMPH; TRANSPORT; DIACYLGLYCEROL; EXCHANGE	The mechanism of facilitated lipid transfer by insect or mammalian plasma lipid transfer proteins has not been elucidated. Transfer catalysts may act as carriers of lipid between donor and acceptor lipoproteins or, alternatively, transfer may require formation of a ternary complex. This study was designed to determine if Manduca sexta hemolymph lipid transfer particle (LTP) can facilitate net vectorial transfer of lipid without concomitant contact between donor and acceptor lipoproteins and LTP. M. sexta [H-3]diacylglycerol-high density lipophorin-larval ([H-3]DAG-HDLp-L) and human low density lipoprotein (LDL) were covalently bound to Sepharose matrices and packed into separate columns. In incubations lacking LTP, greater than 98% of the recovered DAG remained associated with HDLp-L. An unrelated hemolymph storage protein, arylphorin, was unable to catalyze the transfer of DAG between solid-phase lipoproteins. Facilitated transfer of DAG from HDLp-L to LDL was observed when LTP was circulated between the columns. Under these conditions, facilitated transfer occurred at a rate of 2.24 ng of DAG/h (versus 0.16-mu-g of DAG/h in the control), and after 16 h greater than 26% of recovered labeled DAG was transferred to LDL. This corresponds to a 14-fold rate enhancement induced by LTP. The LTP-specific transfer of DAG between physically separated lipoproteins demonstrates the ability of LTP to facilitate net lipid transfer via a carrier-mediated mechanism in the absence of a ternary complex involving donor, acceptor, and catalyst. In experiments aimed at assessing the relative contribution of ternary complex formation to DAG transfer, acceptor LDL was circulated with HDLp-L remaining immobilized. Under these conditions, LTP induced a 13-fold rate enhancement from 1.3 to 16.3-mu-g of DAG/h. The similar rate enhancements observed with both lipoproteins bound and only donor bound suggest the overall contribution of ternary complex formation to facilitated lipid transfer is insignificant. The described system should prove useful in mechanistic studies of other transfer proteins as well as studies of transfer of other lipids.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,328 HERITAGE BLDG,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta; University of Alberta					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; BARTER PJ, 1980, J LIPID RES, V21, P238; CHARLTON SC, 1978, BIOCHEMISTRY-US, V17, P3301; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; DOWNER RGH, 1985, INSECT BIOCHEM, V15, P62; HIRAYAMA Y, 1990, J LIPID RES, V31, P793; IHM J, 1982, J LIPID RES, V23, P1328; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P112, DOI 10.1016/0005-2760(91)90238-D; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MORTON RE, 1985, J BIOL CHEM, V260, P2593; POWNALL HJ, 1983, J AM CHEM SOC, V105, P2440, DOI 10.1021/ja00346a055; PRASAD SV, 1986, J BIOL CHEM, V261, P558; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1985, ARCH BIOCHEM BIOPHYS, V243, P115, DOI 10.1016/0003-9861(85)90779-9; RYAN RO, 1990, J BIOL CHEM, V265, P546; RYAN RO, 1988, BIOCHIM BIOPHYS ACTA, V962, P143, DOI 10.1016/0005-2760(88)90105-1; RYAN RO, 1986, J BIOL CHEM, V261, P563; RYAN RO, 1990, J LIPID RES, V31, P871; RYAN RO, 1986, BIOCHEM BIOPH RES CO, V136, P260, DOI 10.1016/0006-291X(86)90903-4; RYAN RO, 1992, J LIPID RES, V1, P55; SHAPIRO JP, 1988, ANNU REV ENTOMOL, V33, P297, DOI 10.1146/annurev.en.33.010188.001501; SHAPIRO JP, 1984, J BIOL CHEM, V259, P3680; SILVER ET, 1990, J BIOL CHEM, V265, P22487; SINGH TKA, 1991, ARCH BIOCHEM BIOPHYS, V286, P376, DOI 10.1016/0003-9861(91)90054-M; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TALL AR, 1986, J LIPID RES, V27, P361; VANHEUSDEN MC, 1989, J BIOL CHEM, V264, P17287; YAN RO, 1988, J BIOL CHEM, V263, P14140	31	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14033	14037						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629202				2022-12-27	WOS:A1992JD32500041
J	PONTIUS, BW; BERG, P				PONTIUS, BW; BERG, P			RAPID ASSEMBLY AND DISASSEMBLY OF COMPLEMENTARY-DNA STRANDS THROUGH AN EQUILIBRIUM INTERMEDIATE STATE MEDIATED BY A1 HNRNP PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; RNA-BINDING PROTEINS; COMPLEX PROTEIN-A1; CALF THYMUS; PARTICLES; PURIFICATION; DOMAIN; SEX	A1 hnRNP protein, which rapidly renatures complementary strands of nucleic acids in vitro, affects both the equilibrium and kinetic properties of the reaction (single-stranded DNA double-line arrow pointing left and right double-stranded DNA). Al lowers the melting transition of duplex DNA. However, at temperatures above this new T(m), both single- and double-stranded DNAs are present at equilibrium and are rapidly interconverting. Although the ratio of single and double strands under these conditions is a function of both the A1 protein and complementary DNA strand concentrations, it is not strongly affected by further increases in temperature. These surprising results demonstrate that A1 does not act as a simple catalyst in promoting renaturation and indicate how A1 and other proteins could act to speed the turnover of intermediate complexes in important biological processes.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					PHS HHS [13235] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER BS, 1989, GENOME, V31, P638, DOI 10.1139/g89-117; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DOTY P., 1959, PROC NATL ACAD SCI, V45, P482, DOI 10.1073/pnas.45.4.482; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HERRICK G, 1976, J BIOL CHEM, V251, P2133; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1990, J BIOL CHEM, V265, P17094; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; MARMUR J, 1961, J MOL BIOL, V3, P585, DOI 10.1016/S0022-2836(61)80023-5; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERRILL BM, 1986, J BIOL CHEM, V261, P878; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MUKKUR TKS, 1980, TRENDS BIOCHEM SCI, V5, P72, DOI 10.1016/0968-0004(80)90072-9; MUNROE SH, 1992, P NATL ACAD SCI USA, V89, P895, DOI 10.1073/pnas.89.3.895; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHILDKRAUT C, 1965, BIOPOLYMERS, V3, P195, DOI 10.1002/bip.360030207; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; SWANSON MS, 1987, MOL CELL BIOL, V6, P2932; WETMUR JG, 1976, ANNU REV BIOPHYS BIO, V29, P336	31	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13815	13818						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629182				2022-12-27	WOS:A1992JD32500007
J	MORRISON, JR; MCPHERSON, GA; FIDGE, NH				MORRISON, JR; MCPHERSON, GA; FIDGE, NH			EVIDENCE FOR 2 SITES ON RAT-LIVER PLASMA-MEMBRANES WHICH INTERACT WITH HIGH-DENSITY LIPOPROTEIN(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; A-I; PURIFICATION; CHOLESTEROL; LIGAND; CELLS; IDENTIFICATION; FIBROBLASTS; RECEPTORS; HDL3	There is little dispute that high density lipoprotein (HDL) binds to cells, however, the nature of the interaction is not fully understood. We now present evidence for a new binding site of higher affinity but lower capacity than the sites previously described in the literature. This new site is characterized by high affinity/low capacity for HDL binding (K(d) = 0.94-mu-g/ml, B(max) = 36 ng/mg), while the low affinity site (K(d) = 36-mu-g/ml, B(max) almost-equal-to 700 ng/mg) appears to be consistent with the literature values for the interaction of HDL with cells and isolated membranes. Proteolysis of HDL with trypsin abolished its interaction with the high affinity site, suggesting an apolipoprotein requirement, while having no effect on binding to the lower affinity site. Kinetic rates of association/dissociation were determined in order to further characterize the high affinity site. At a concentration which favored the binding of HDL with the high affinity site (1-mu-g/ml, 37-degrees-C), the time course of association of HDL with rat liver plasma membranes, displayed a biphasic pattern, requiring 6-8 h to reach the level of binding predicted from the saturation studies. The second phase was highly sensitive to temperature, being considerably slower at 24-degrees-C and totally abolished at 0-degrees-C. A kinetic K(d), derived from the measured association and dissociation rate constants (K(d) = 0.31-mu-g/ml), was found to be of a similar magnitude to the K(d) calculated for the high affinity site by Scatchard analysis (K(d) = 0.94-mu-g/ml). In summary, the high affinity site on rat liver plasma membranes displays an apoprotein requirement and kinetic parameters, consistent with a ligand-receptor interaction.	BAKER MED RES INST,POB 348,PRAHRAN,VIC 3181,AUSTRALIA	Baker Heart and Diabetes Institute								BARBARAS R, 1990, BIOCHEM J, V269, P767, DOI 10.1042/bj2690767; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHACKO GK, 1982, BIOCHIM BIOPHYS ACTA, V712, P129, DOI 10.1016/0005-2760(82)90094-7; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIDGE N, 1985, BIOCHEM BIOPH RES CO, V129, P759, DOI 10.1016/0006-291X(85)91957-6; FIDGE NH, 1974, CLIN CHIM ACTA, V52, P15, DOI 10.1016/0009-8981(74)90383-0; Fleischer S, 1974, Methods Enzymol, V31, P6; GLASS C, 1985, J BIOL CHEM, V260, P744; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOPKINS GJ, 1984, BIOCHIM BIOPHYS ACTA, V794, P31, DOI 10.1016/0005-2760(84)90294-7; KESO L, 1987, FEBS LETT, V215, P105, DOI 10.1016/0014-5793(87)80122-9; LEBLOND L, 1991, J BIOL CHEM, V266, P5058; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHAI D, 1990, ARTERIOSCLEROSIS, V10, P1045, DOI 10.1161/01.ATV.10.6.1045; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MENDEL CM, 1988, J BIOL CHEM, V263, P1314; MITCHEL YB, 1987, BIOCHIM BIOPHYS ACTA, V917, P324, DOI 10.1016/0005-2760(87)90137-8; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; RAY TK, 1970, BIOCHIM BIOPHYS ACTA, V196, P1, DOI 10.1016/0005-2736(70)90159-8; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; TABAS I, 1984, J BIOL CHEM, V259, P3897; TILLEY L, 1988, J BIOL CHEM, V263, P17541; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; POLYACRYLAMIDE GEL E, P26	30	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13205	13209						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618825				2022-12-27	WOS:A1992JB74600020
J	SINGH, I; LAZO, O; DHAUNSI, GS; CONTRERAS, M				SINGH, I; LAZO, O; DHAUNSI, GS; CONTRERAS, M			TRANSPORT OF FATTY-ACIDS INTO HUMAN AND RAT PEROXISOMES - DIFFERENTIAL TRANSPORT OF PALMITIC AND LIGNOCERIC ACIDS AND ITS IMPLICATION TO X-ADRENOLEUKODYSTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA LIGASE DEFICIENCY; LIVER PEROXISOMES; BETA-OXIDATION; LONG-CHAIN; TOPOGRAPHICAL LOCALIZATION; BRAIN MICROSOMES; SYNTHETASE; MEMBRANE; PROTEIN; FRACTIONATION	The different topology of palmitoyl-CoA ligase (on the cytoplasmic surface) and of lignoceroyl-CoA ligase (on the luminal surface) in peroxisomal membranes suggests that these fatty acids may be transported in different form through the peroxisomal membrane (Lazo, O., Contreras, M., and Singh, I. (1990) Biochemistry 29, 3981-3986), and this differential transport may account for deficient oxidation of lignoceric acid in X-adrenoleukodystrophy (X-ALD) (Singh, I., Moser, A. B., Goldfisher, S., and Moser, H. W. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 4203-4207). To define the transport mechanism for these fatty acids through the peroxisomal membrane and its possible implication to lignoceric acid metabolism in X-ALD, we examined cofactors and energy requirements for the transport of palmitic and lignoceric acids in isolated peroxisomes from rat liver and peroxisomes isolated from X-ALD and control fibroblasts. The similar rates of transport of palmitoyl-CoA (87.6 +/- 6.3 nmol/h/mg protein) and palmitic acid in the fatty acid activating conditions (83.4 +/- 5.1 nmol/h/mg protein) and lack of transport of palmitic acid (4% of palmitoyl-CoA transport) when ATP and/or CoASH were removed or substituted by alpha,beta-methyleneadenosine-5'-triphosphate (AMPCPOP) and/or desulfoCo-Aagarose from assay medium clearly demonstrate that transport of palmitic acid requires prior synthesis of palmitoyl-CoA by palmitoyl-CoA ligase on the cytoplasmic surface of peroxisomes. The 10-fold higher rate of transport of lignoceric acid (5.3 +/- 0.6 nmol/h/mg protein) as compared with lignoceroyl-CoA (0.41 +/- 0.11 nmol/h/mg protein) and lack of inhibition of transport of lignoceric acid when ATP and/or CoASH were removed or substituted with AMPCPOP or desulfoCoA-agarose suggest that lignoceric acid is transported through the peroxisomal membrane as such. Moreover, the lack of effect of removal of ATP or substitution with AMPOPCP (a nonhydrolyzable substrate) demonstrates that the translocation of palmitoyl-CoA and lignoceric acid across peroxisomal membrane does not require energy. The transport, activation, and oxidation of palmitic acid are normal in peroxisomes from X-ALD. The deficient lignoceroyl-CoA ligase (13% of control) and oxidation of lignoceric acid (10% of control) as compared with normal transport of lignoceric acid into peroxisomes from X-ALD clearly demonstrates that pathognomonic accumulation of very long chain fatty acids (>C22) in X-ALD is due to the deficiency of peroxisomal lignoceroyl-CoA ligase activity.			SINGH, I (corresponding author), MED UNIV S CAROLINA,DEPT PEDIAT,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKANUMA H, 1979, J BIOL CHEM, V254, P1050; APPELKVIST EL, 1980, BIOCHIM BIOPHYS ACTA, V617, P156, DOI 10.1016/0005-2760(80)90233-7; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIEBER LL, 1982, ANN NY ACAD SCI, V386, P395, DOI 10.1111/j.1749-6632.1982.tb21431.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CORNELL NW, 1980, ANAL BIOCHEM, V102, P326, DOI 10.1016/0003-2697(80)90162-1; DOLE VP, 1956, J CLIN INVEST, V35, P150, DOI 10.1172/JCI103259; FARRELL SO, 1983, ARCH BIOCHEM BIOPHYS, V222, P123, DOI 10.1016/0003-9861(83)90509-X; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; HOSHI M, 1973, J BIOL CHEM, V248, P4123; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAGEWEG W, 1991, BIOCHEM J, V276, P53, DOI 10.1042/bj2760053; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LAZO O, 1989, ARCH BIOCHEM BIOPHYS, V270, P722, DOI 10.1016/0003-9861(89)90555-9; LAZO O, 1990, J LIPID RES, V31, P583; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LAZO O, 1990, BIOCHEMISTRY-US, V29, P3981, DOI 10.1021/bi00468a027; LAZO O, 1981, MOL CELL BIOCHEM, V100, P159; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; MANNAERTS GP, 1979, J BIOL CHEM, V254, P4585; MANNAERTS GP, 1982, ANN NY ACAD SCI, V386, P30, DOI 10.1111/j.1749-6632.1982.tb21405.x; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; Osmundsen H., 1987, PEROXISOMES BIOL MED, P152; SELLINGER OZ, 1960, BIOCHEM J, V74, P450, DOI 10.1042/bj0740450; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH I, 1985, ARCH BIOCHEM BIOPHYS, V236, P418, DOI 10.1016/0003-9861(85)90642-3; SINGH I, 1988, BIOCHIM BIOPHYS ACTA, V963, P509, DOI 10.1016/0005-2760(88)90319-0; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9	40	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13306	13313						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618832				2022-12-27	WOS:A1992JB74600036
J	CHAKRABARTI, A; MAITRA, U				CHAKRABARTI, A; MAITRA, U			RELEASE AND RECYCLING OF EUKARYOTIC INITIATION FACTOR-II IN THE FORMATION OF AN 80 S-RIBOSOMAL POLYPEPTIDE-CHAIN INITIATION COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR-II; REVERSING FACTOR; ALPHA-SUBUNIT; RABBIT RETICULOCYTES; CALF LIVER; PHOSPHORYLATION; PURIFICATION; INHIBITION; MECHANISM	The eukaryotic initiation factor (eIF)-5 mediates hydrolysis of GTP bound to the 40 S initiation complex in the absence of 60 S ribosomal subunits. The eIF-2.GDP formed under these conditions is released from the 40 S ribosomal subunit while initiator Met-tRNA(f) remains bound. The released eIF-2.GDP can participate in an eIF-2B-catalyzed GDP/GTP exchange reaction to reform the Met-tRNA(f).eIF-2.GTP ternary complex. In contrast, when 60 S ribosomal subunits were also present in an eIF-5-catalyzed reaction, the eIF-2.GDP produced remained bound to the 60 S ribosomal subunit of the 80 S initiation complex. When such an 80 S initiation complex, containing bound eIF-2.GDP, was incubated with GTP and eIF-2B, GDP was released. However, eIF-2 still remained bound to the ribosomes and was unable to form a Met-tRNA(f).eIF-2.GTP ternary complex. In contrast, when 60 S ribosomal subunits were preincubated with either free eIF-2 or with eIF-2.eIF-2B complex and then added to a reaction containing both the 40 S initiation complex and eIF-5, the eIF-2.GDP produced did not bind to the 60 S ribosomal subunits but was released from the ribosomes. Thus, the 80 S initiation complex formed under these conditions did not contain bound eIF-2.GDP. Under similar experimental conditions, preincubation of 60 S ribosomal subunits with purified eIF-2B (free of eIF-2) failed to cause release of eIF-2.GDP from the ribosomal initiation complex. These results suggest that 60 S ribosome-bound eIF-2.GDP does not act as a direct substrate for eIF-2B-mediated release of eIF-2 from ribosomes. Rather, the affinity of 60 S ribosomal subunits for either eIF-2, or the eIF-2 moiety of the eIF-2.eIF-2B complex, prevents association of 60 S ribosomal subunits with eIF-2.GDP formed in the initiation reaction. This ensures release of eIF-2 from ribosomes following hydrolysis of GTP bound to the 40 S initiation complex.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,DIV BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMESZ H, 1979, EUR J BIOCHEM, V98, P513, DOI 10.1111/j.1432-1033.1979.tb13212.x; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAUDHURI A, 1981, J BIOL CHEM, V256, P3988; CLARK SJ, 1989, BIOCHIM BIOPHYS ACTA, V1010, P377, DOI 10.1016/0167-4889(89)90065-7; GHOSH S, 1989, J BIOL CHEM, V264, P5134; GROSS M, 1985, J BIOL CHEM, V260, P9491; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; PAIN VM, 1983, BIOCHEMISTRY-US, V22, P726, DOI 10.1021/bi00273a003; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PATHAK VK, 1988, MOL CELL BIOL, V8, P9930; RAYCHAUDHURI P, 1987, J BIOL CHEM, V262, P14222; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; SAFER B, 1982, FEBS LETT, V147, P1, DOI 10.1016/0014-5793(82)81000-4; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SIEKIERKA J, 1982, P NATL ACAD SCI-BIOL, V79, P2537, DOI 10.1073/pnas.79.8.2537; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; THOMAS NSB, 1984, P NATL ACAD SCI-BIOL, V81, P6998, DOI 10.1073/pnas.81.22.6998	25	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12964	12972						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618793				2022-12-27	WOS:A1992HZ48300085
J	MARSCHAL, P; HERRMANN, J; LEFFLER, H; BARONDES, SH; COOPER, DNW				MARSCHAL, P; HERRMANN, J; LEFFLER, H; BARONDES, SH; COOPER, DNW			SEQUENCE AND SPECIFICITY OF A SOLUBLE LACTOSE-BINDING LECTIN FROM XENOPUS-LAEVIS SKIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FULL-LENGTH CDNA; S-TYPE LECTIN; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ANIMAL LECTINS; PROTEIN; GENE; HEART; LUNG	A 16-kDa lactose-binding lectin comprises 5% or more of the soluble protein in Xenopus laevis skin. This lectin is mainly localized in the cytoplasm of granular gland cells. In response to stress, the lectin along with a variety of toxic and antibiotic peptides are released onto the skin surface by holocrine secretion. We have purified the lectin, sequenced tryptic peptides using tandem mass spectrometry and Edman degradation, and isolated full-length cDNA using a deduced oligonucleotide. Comparison of the cDNA and peptide sequences revealed expression of at least two isolectins, which differ in sequence at only two or three amino acids. Comparison of cDNA with complementary message by ribonuclease protection confirmed expression in approximately equal abundance of two nearly identical messages. The major soluble lactose-binding lectin expressed in Xenopus muscle is composed of these same isolectins, but at 100-fold lower levels. Similarities and distinctions in sequence and carbohydrate-binding specificity indicate that this lectin is a novel member of a family of soluble lactose-binding lectins expressed in a wide range of vertebrate tissues.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,BOX F,401 PARNASSUS AVE,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER; NCRR NIH HHS [DRR-RRO1614] Funding Source: Medline; NHLBI NIH HHS [1-RO1-HL38627] Funding Source: Medline; PHS HHS [2KT0032] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOLS NC, 1986, J CELL BIOL, V102, P492, DOI 10.1083/jcb.102.2.492; CATT JW, 1985, J CELL SCI, V73, P347; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DECABUTTI NEF, 1987, FEBS LETT, V223, P330, DOI 10.1016/0014-5793(87)80314-9; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FRITZ AF, 1989, DEV BIOL, V131, P584, DOI 10.1016/S0012-1606(89)80029-6; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HARRISON FL, 1991, J CELL SCI, V100, P9; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P2320; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HOLT G D, 1991, Glycobiology, V1, P329, DOI 10.1093/glycob/1.4.329; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JEFFREYS AJ, 1980, CELL, V21, P555, DOI 10.1016/0092-8674(80)90493-6; JIA SH, 1988, J BIOL CHEM, V263, P6009; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; MATSUDAIRA PT, 1989, PRACTICAL GUIDE PROT, P33; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MERKLE RK, 1989, ARCH BIOCHEM BIOPHYS, V274, P404, DOI 10.1016/0003-9861(89)90453-0; ODA Y, 1991, GENE, V99, P279; OGILVIE ML, 1984, J HERPETOL, V18, P285, DOI 10.2307/1564082; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; OZEKI Y, 1991, BIOCHEM BIOPH RES CO, V178, P407, DOI 10.1016/0006-291X(91)91828-Z; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SHET MS, 1989, BIOCHIM BIOPHYS ACTA, V991, P465, DOI 10.1016/0304-4165(89)90074-3; SHULDINER AR, 1989, J BIOL CHEM, V264, P9428; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WASANO K, 1990, CELL TISSUE RES, V259, P43, DOI 10.1007/BF00571428; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	69	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12942	12949						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618791				2022-12-27	WOS:A1992HZ48300082
J	GRIFF, IC; SCHEKMAN, R; ROTHMAN, JE; KAISER, CA				GRIFF, IC; SCHEKMAN, R; ROTHMAN, JE; KAISER, CA			THE YEAST SEC17 GENE-PRODUCT IS FUNCTIONALLY EQUIVALENT TO MAMMALIAN ALPHA-SNAP PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; SECRETORY PATHWAY; GOLGI STACK; SHUTTLE VECTORS; IDENTIFICATION; REQUIRES; COMPONENT; PURIFICATION	The SEC17 gene of Saccharomyces cerevisiae is required for vesicular transport between the endoplasmic reticulum and the Golgi apparatus. Here we report that the product of the SEC17 gene has the exact biochemical properties expected for a yeast homologue of the mammalian transport factor, alpha-SNAP. The DNA sequence of SEC17 codes for a protein of predicted molecular mass of 33 kDa. Immunoblotting indicates that Sec17p fractionates as a peripheral membrane protein and is mostly soluble when overexpressed, suggesting the presence of a saturable membrane receptor for Sec17p. Sec17p was purified from yeast cytosol using a SNAP-dependent in vitro mammalian Golgi transport assay. Kinetic analysis using this assay shows Sec17p acts temporally close to the fusion of transport vesicles with the medial Golgi compartment. In yeast extracts, Sec17p binds to Sec18p with a 1:1 stoichiometry. The interaction between Sec17p and Sec18p requires an activity provided by yeast membranes, and this putative membrane receptor activity is not extracted by high salt treatment of membranes.	MIT,DEPT BIOL,77 MASSACHUSETTS AVE,RM 56-534,CAMBRIDGE,MA 02139; SLOAN KETTERING MEM CANC CTR,PROGRAM CELLULAR BIOPHYS & BIOCHEM,NEW YORK,NY 10021; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center; Princeton University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIDDK NIH HHS [DK27044] Funding Source: Medline; NIGMS NIH HHS [GM26755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026755] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LOWENADLER B, 1986, EMBO J, V5, P2393, DOI 10.1002/j.1460-2075.1986.tb04509.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; SIKORSKI RS, 1989, GENETICS, V122, P19; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2202; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	26	136	143	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12106	12115						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601878				2022-12-27	WOS:A1992HY94700070
J	KAWASAKI, Y; WADA, C; YURA, T				KAWASAKI, Y; WADA, C; YURA, T			BINDING OF REPE INITIATOR PROTEIN TO MINI-F DNA ORIGIN (ORI2) - ENHANCING EFFECTS OF REPE MUTATIONS AND DNAJ HEAT-SHOCK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPY NUMBER CONTROL; P1 PLASMID REPLICATION; ESCHERICHIA-COLI; REPEATING SEQUENCES; AUTONOMOUS CONTROL; GENE-PRODUCT; PURIFICATION; REGION; INCOMPATIBILITY; EXPRESSION	Replication of mini-F plasmid in Escherichia coli requires the plasmid-encoded RepE initiator protein and a number of host factors and is regulated by interaction of RepE with specific sequences near the replication origin, ori2. We have examined DNA binding properties of several hyperactive mutant RepE proteins with single amino acid substitutions. Plasmids carrying these (repE) mutations, unlike the parental plasmid, can replicate in bacterial hosts lacking the heat shock sigma-factor (sigma-32) or deficient in the DnaK, DnaJ, or GrpE heat shock protein. Using gel-retardation assays, the mutant RepE proteins were shown to bind the ori2 repeated sequences with much increased affinities compared to the wild type RepE, whereas they bound to the repE operator with slightly reduced affinities. These results agreed well with the properties of mutant RepE proteins studied in vivo and accounted for the high RepE initiator activities and the high copy numbers of mutant plasmids. In addition, the DnaJ heat shock protein was found to markedly enhance the binding of wild type RepE to ori2 or the operator. DnaK protein with or without ATP failed to show such enhancements. Thus, among the heat shock proteins required for mini-F replication, DnaJ appears to play a major role in RepE binding to ori2 and the operator, perhaps accompanied by RepE activation.	KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN	Kyoto University								ABELES AL, 1986, J BIOL CHEM, V261, P3548; BEX F, 1986, J MOL BIOL, V189, P293; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; HELSBERG M, 1985, PLASMID, V14, P53, DOI 10.1016/0147-619X(85)90032-0; IMBER R, 1987, GENE, V52, P1, DOI 10.1016/0378-1119(87)90389-1; KAWASAKI Y, 1991, J BACTERIOL, V173, P1064, DOI 10.1128/jb.173.3.1064-1072.1991; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KLINE BC, 1992, IN PRESS J BACTERIOL; MAKI S, 1983, MOL GEN GENET, V191, P231, DOI 10.1007/BF00334819; MASSON L, 1988, NUCLEIC ACIDS RES, V16, P413, DOI 10.1093/nar/16.2.413; MASSON L, 1986, NUCLEIC ACIDS RES, V14, P5693, DOI 10.1093/nar/14.14.5693; MUROTSU T, 1984, MOL GEN GENET, V196, P373, DOI 10.1007/BF00328075; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; OHKI M, 1986, J BIOL CHEM, V261, P1778; ROKEACH LA, 1985, J BACTERIOL, V164, P1262, DOI 10.1128/JB.164.3.1262-1270.1985; SEELKE RW, 1982, PLASMID, V7, P163, DOI 10.1016/0147-619X(82)90075-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; TOKINO T, 1986, P NATL ACAD SCI USA, V83, P4109, DOI 10.1073/pnas.83.12.4109; TOLUN A, 1982, MOL GEN GENET, V186, P3072; TSUTSUI H, 1983, J BACTERIOL, V155, P337, DOI 10.1128/JB.155.1.337-344.1983; WADA C, 1986, MOL GEN GENET, V203, P208, DOI 10.1007/BF00333956; WADA C, 1987, P NATL ACAD SCI USA, V84, P8849, DOI 10.1073/pnas.84.24.8849; WATSON LA, 1982, GENE AMST, P173; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; XIA GX, 1991, MOL MICROBIOL, V5, P631, DOI 10.1111/j.1365-2958.1991.tb00734.x	30	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11520	11524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597479				2022-12-27	WOS:A1992HX16900089
J	TASANEN, K; OIKARINEN, J; KIVIRIKKO, KI; PIHLAJANIEMI, T				TASANEN, K; OIKARINEN, J; KIVIRIKKO, KI; PIHLAJANIEMI, T			PROMOTER OF THE GENE FOR THE MULTIFUNCTIONAL PROTEIN DISULFIDE ISOMERASE POLYPEPTIDE - FUNCTIONAL-SIGNIFICANCE OF THE 6 CCAAT BOXES AND OTHER PROMOTER ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING-PROTEIN; HUMAN GROWTH-HORMONE; NUCLEAR FACTOR-I; PROLYL 4-HYDROXYLASE; BETA-SUBUNIT; ENDOPLASMIC-RETICULUM; DISULPHIDE-ISOMERASE; SECRETORY PROTEINS; MOLECULAR-CLONING; COLLAGEN PROMOTER	Protein disulfide isomerase (PDI) is a highly unusual multifunctional polypeptide that is identical to the beta-subunit of prolyl 4-hydroxylase, a cellular thyroid hormone-binding protein and a subunit of the microsomal triglyceride transfer protein complex, and very similar to a polypeptide functioning in vitro as a glycosylation site binding protein of oligosaccharyl transferase. The human PDI gene possesses several putative transcriptional control elements, including the highly unusual presence of six CCAAT boxes between -108 and -378 of the 5'-flanking region. We report here on a promoter analysis of this gene. Eleven PDI promoter elements recognized by DNA-binding proteins present in HeLa cell and HT-1080 cell nuclear extracts were identified by DNase I footprinting analysis within the first 630 nucleotides of the 5'-flanking region. Interestingly, these included all six CCAAT elements. Functional 5' deletion analysis suggested that only two or three of the CCAAT elements may contribute significantly to the promoter activity in HeLa cells. Mutations introduced into each of the CCAAT boxes separately indicated, however, that all six appear to contribute to the promoter strength, the largest decreases (approximately 50%) being seen with mutations in the second or fifth CCAAT box. These data thus suggested that efficient expression of the multifunctional PDI polypeptide is secured by multiple CCAAT elements, some of which appear to be functionally redundant. The 5' deletion analysis further suggested that a region between -623 and -518 may contain additional positively and negatively acting elements.	UNIV OULU, DEPT MED BIOCHEM, KAJAANINTIE 52A, SF-90220 OULU, FINLAND; UNIV OULU, BIOCTR, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045; Tasanen, Kaisa/0000-0001-8056-5949				Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHENKIANG S, 1978, P NATL ACAD SCI USA, V75, P1379, DOI 10.1073/pnas.75.3.1379; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HELAAKOSKI T, 1990, J BIOL CHEM, V265, P11413; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MYLLYLA R, 1983, EUR J BIOCHEM, V134, P7, DOI 10.1111/j.1432-1033.1983.tb07523.x; NAKAZAWA M, 1988, GENE, V71, P451, DOI 10.1016/0378-1119(88)90062-5; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PAJUNEN L, 1991, CYTOGENET CELL GENET, V56, P165, DOI 10.1159/000133078; PAJUNEN L, 1988, CYTOGENET CELL GENET, V42, P560; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PIHLAJANIEMI T, 1987, METHOD ENZYMOL, V145, P213; PIHLAJANIEMI T, 1981, BIOCHEMISTRY-US, V20, P7409, DOI 10.1021/bi00529a014; POPESCU NC, 1988, AM J HUM GENET, V42, P560; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RISTINIEMI J, 1989, J BIOL CHEM, V264, P2164; ROGUSKA MA, 1985, J BIOL CHEM, V260, P3893; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; TASANEN K, 1988, J BIOL CHEM, V263, P16218; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	48	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11513	11519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597478				2022-12-27	WOS:A1992HX16900088
J	DIAZ, A; REGINATO, AM; JIMENEZ, SA				DIAZ, A; REGINATO, AM; JIMENEZ, SA			ALTERNATIVE SPLICING OF HUMAN PROSTAGLANDIN G/H SYNTHASE MESSENGER-RNA AND EVIDENCE OF DIFFERENTIAL REGULATION OF THE RESULTING TRANSCRIPTS BY TRANSFORMING GROWTH FACTOR-BETA-1, INTERLEUKIN-1-BETA, AND TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; ENDOPEROXIDE SYNTHASE; FACTOR-BETA; RECOMBINANT INTERLEUKIN-1; PEROXIDASE-ACTIVITIES; COMPLEMENTARY-DNA; H SYNTHASE; CYCLOOXYGENASE; CELLS; STIMULATION	Prostaglandin G/H synthase (PGG/HS) is the rate-limiting enzyme in the conversion of arachidonic acid to prostaglandins and thromboxanes. We screened a human lung fibroblast cDNA library with an ovine PGG/HS cDNA and isolated a 2.3-kilobase clone (HCO-T9). Sequence analysis of this clone showed that (a) it contained the entire translated region of PGG/HS and (b) it displayed an in-frame splicing of the last 111 base pairs encoded by exon 9, which resulted in the elimination of the N-glycosylation site at residue 409. Polymerase chain reaction amplification with specific oligonucleotides of reverse-transcribed mRNA from diverse human tissues and cultured cells yielded 400-and 300-base pair fragments that corresponded, respectively, to the intact and spliced transcripts. The expression of these two transcripts in cultured human lung fibroblasts was differentially regulated by serum, transforming growth factor beta-1, interleukin 1-beta, tumor necrosis factor-alpha, and phorbol 12-myristate 13-acetate, as each of these conditions stimulated preferentially the expression of the unspliced transcripts. The elimination of one of the four N-glycosylation sites by the alternative splicing of exon 9 and the differential regulation of this process by relevant cytokines and growth factors may represent a mechanism for the regulation of PGG/HS enzymatic activity under physiological or pathological conditions.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,RM 509, BLUEMLE LIFE SCI BLDG, PHILADELPHIA, PA 19107 USA	Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NHLBI NIH HHS [HL41214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, J LIPID RES, V26, P54; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BASHEY RI, 1977, J MOL MED, V2, P153; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1989, ADV PROSTAG THROMB L, V19, P454; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1990, ADV PROSTAGLANDIN TH, V21, P65; DIAZ A, 1990, ANN NY ACAD SCI, V593, P306, DOI 10.1111/j.1749-6632.1990.tb16126.x; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DUNIEC ZM, 1991, MOL PHARMACOL, V39, P164; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HLA T, 1991, J BIOL CHEM, V266, P24059; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OHKI S, 1979, J BIOL CHEM, V254, P829; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; RAZ A, 1988, J BIOL CHEM, V263, P3022; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SIONSON MS, 1990, ADV PROSTAGLANDIN TH, V21, P69; SMITH WL, 1991, PROSTAGLANDIN LEUKOT; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; TSAI AL, 1990, ADV PROSTAGLANDIN TH, V21, P141; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384; WU KK, 1988, J BIOL CHEM, V263, P19043; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZURIER RB, 1990, ADV PROSTAGLANDIN TH, V21, P947	49	101	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10816	10822						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587858				2022-12-27	WOS:A1992HV09000092
J	MORROW, CS; CHIU, J; COWAN, KH				MORROW, CS; CHIU, J; COWAN, KH			POSTTRANSCRIPTIONAL CONTROL OF GLUTATHIONE-S-TRANSFERASE-PI GENE-EXPRESSION IN HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR CONTENT; MESSENGER-RNA STABILITY; C-MYC ONCOGENE; DRUG-RESISTANCE; PLACENTAL FORM; STEM-LOOP; RAT; REGION; CDNA; HEPATOCARCINOGENESIS	The glutathione S-transferase pi-gene (GST-pi) is highly expressed in estrogen receptor negative (ER-) but not expressed in ER+ human breast cancer cell lines. To define regulatory mechanisms of GST-pi gene expression, we analyzed both the activity of the GST-pi promoter and the posttranscriptional fate of GST-pi RNA sequences in three ER+ and three ER- breast cancer cell lines. Expression of a transiently transfected CAT reporter gene driven by the GST-pi promoter and 2203 nucleotides of 5'-flanking sequences were similar in all six cell lines regardless of ER status. Endogenous GST-pi transcription rates in nuclei isolated from ER- cells were quite low despite high steady state levels of cytoplasmic mRNA. Furthermore, the endogenous GST-pi gene was transcribed in ER+ nuclei at rates similar to those obtained in ER- nuclei. We determined the stabilities of mRNAs transcribed from the endogenous GST-pi gene (ER- cells) and from a stably transfected GST-pi cDNA expression vector (ER+ and ER- cells). The endogenous GST-pi mRNA was extraordinarily stable in ER- cells. Comparisons between transfected ER+ and ER- cells revealed no significant differences in the stabilities of transfection-derived GST-pi mRNA sequences. We conclude that GST-pi mRNA stability contributes significantly to the high levels of cytoplasmic mRNA observed in ER-cells, but that the differential expression of GST-pi in ER+ versus ER- cells is governed by other posttranscriptional processes.			MORROW, CS (corresponding author), NCI,MED BRANCH,BLDG 10,RM 12N226,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BATIST G, 1986, J BIOL CHEM, V261, P5544; Battey, 1986, BASIC METHODS MOL BI; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHANG CD, 1991, J BIOL CHEM, V266, P8663; CLEVELAND D W, 1989, New Biologist, V1, P121; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; DUBIK D, 1988, J BIOL CHEM, V263, P12705; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; KETTERER B, 1986, XENOBIOTICA, V16, P957, DOI 10.3109/00498258609038976; Lamond AI, 1991, CURR OPIN CELL BIOL, V3, P493, DOI 10.1016/0955-0674(91)90078-D; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LIU TJ, 1989, MOL CELL BIOL, V9, P3499, DOI 10.1128/MCB.9.8.3499; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MIYAZAKI M, 1990, BIOCHEM BIOPH RES CO, V166, P1368; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MOSCOW JA, 1989, CANCER RES, V49, P1422; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NAKAGAWA K, 1990, J BIOL CHEM, V265, P4296; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; SATO K, 1988, JPN J CANCER RES, V79, P556, DOI 10.1111/j.1349-7006.1988.tb00022.x; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; SHIRATORI Y, 1987, CANCER RES, V47, P6806; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TOWNSEND A J, 1989, Cancer Bulletin (Houston), V41, P31; TOWNSEND AJ, 1991, CANC COMM, V3, P1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUTSUMI M, 1987, JPN J CANCER RES, V78, P631; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	54	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10544	10550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587835				2022-12-27	WOS:A1992HV09000051
J	MARIE, I; HOVANESSIAN, AG				MARIE, I; HOVANESSIAN, AG			THE 69-KDA 2-5A SYNTHETASE IS COMPOSED OF 2 HOMOLOGOUS AND ADJACENT FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-TREATED CELLS; DOUBLE-STRANDED-RNA; OLIGO-A SYNTHETASE; PROTEIN-SYNTHESIS; 2',5'-OLIGOADENYLATE SYNTHETASE; CONSTITUTIVE EXPRESSION; 2'-5' OLIGO; GENE; KINASE; FORMS	The existence of three distinct forms of 2-5A synthetase, p40-p46, p69, and p100, has been established in interferon-treated human cells. The expression of these enzymes varies according to the cell type studied, and their properties are relatively different. By the use of polyclonal antibodies specific to p69, we have cloned several cDNAs which identify four interferon-induced RNAs of 5.7, 4.5, 3.7, and 3.2 kilobases (kb). Analysis of the nucleotide sequence of three full-length cDNAs (5.6, 3.1, and 2.9 kb) revealed that they have a common open reading frame of 683 amino acids with different 3' termini; cDNAs 5.6 and 3.1 have an extension of 4 amino acids, whereas cDNA 2.9 has an extension of 44 amino acids. In vitro transcription-translation of cDNAs 3.1 and 2.9 kb generated proteins of 69 and 71 kDa, respectively. Both proteins bind a monoclonal antibody specific for p69 and can synthesize 2-5A. The deduced amino acid sequence of p69 revealed that it can be divided into two homologous and adjacent domains, each sharing strong homology to the first 346 amino acids common to the two isoforms of the small 2-5A synthetase (p40, p46). These results suggest that p69 might have two functional catalytic domains required for 2-5A synthetase activity and favor the hypothesis that its gene might have derived from the fusion of two ancestral genes analogous to the small 2-5A synthetase gene.	INST PASTEUR, UNITE VIROL & IMMUNOL CELLULAIRE,CNRS,UA 1157, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BAGLIONI C, 1978, NATURE, V273, P684, DOI 10.1038/273684a0; Ball L.A., 1979, REGULATION MACROMOLE, P303; BENECH P, 1985, NUCLEIC ACIDS RES, V13, P1267; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; CHEBATH J, 1987, J BIOL CHEM, V262, P3852; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DARDEL F, 1988, COMPUT APPL BIOSCI, V4, P483; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GALABRU J, 1987, J BIOL CHEM, V262, P15538; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1979, P NATL ACAD SCI USA, V76, P3261, DOI 10.1073/pnas.76.7.3261; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1988, J BIOL CHEM, V263, P4945; HOVANESSIAN AG, 1979, EUR J BIOCHEM, V93, P515, DOI 10.1111/j.1432-1033.1979.tb12850.x; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; HOVANESSIAN AG, 1978, EUR J BIOCHEM, V84, P149, DOI 10.1111/j.1432-1033.1978.tb12151.x; HOVANESSIAN AG, 1980, VIROLOGY, V101, P81, DOI 10.1016/0042-6822(80)90485-7; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; JUSTESEN J, 1980, P NATL ACAD SCI-BIOL, V77, P4618, DOI 10.1073/pnas.77.8.4618; JUSTESEN J, 1985, BIOCHIMIE, V67, P651, DOI 10.1016/S0300-9084(85)80207-8; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST B, 1982, VIROLOGY, V120, P240, DOI 10.1016/0042-6822(82)90022-8; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; Lebleu B, 1982, Interferon, V4, P47; MAGEE T, 1988, NATURE, V335, P114, DOI 10.1038/335114a0; Maniatis T., 1982, MOL CLONING; MARIE I, 1990, J INTERFERON RES, V10, P571, DOI 10.1089/jir.1990.10.571; MARIE I, 1990, J BIOL CHEM, V265, P18601; MARIE I, 1989, BIOCHEM BIOPH RES CO, V160, P580, DOI 10.1016/0006-291X(89)92472-8; MERLIN G, 1983, P NATL ACAD SCI-BIOL, V80, P4904, DOI 10.1073/pnas.80.16.4904; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MIELE MB, 1991, J INTERFERON RES, V11, P33, DOI 10.1089/jir.1991.11.33; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MORY Y, 1989, J INTERFERON RES, V9, P295, DOI 10.1089/jir.1989.9.295; PERHAM RN, 1989, ANN NY ACAD SCI, V573, P1, DOI 10.1111/j.1749-6632.1989.tb14983.x; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHMIDT A, 1979, P NATL ACAD SCI USA, V76, P4788, DOI 10.1073/pnas.76.10.4788; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; WATHELET M, 1986, FEBS LETT, V196, P113, DOI 10.1016/0014-5793(86)80224-1; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WILLIAMS BRG, 1986, SOMAT CELL MOLEC GEN, V12, P403, DOI 10.1007/BF01570735; WILLIAMS BRG, 1978, NATURE, V276, P88, DOI 10.1038/276088a0; WILLIAMS BRG, 1985, 2 5A SYSTEM; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	56	88	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9933	9939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577824				2022-12-27	WOS:A1992HT96500075
J	HATFIELD, PM; VIERSTRA, RD				HATFIELD, PM; VIERSTRA, RD			MULTIPLE FORMS OF UBIQUITIN-ACTIVATING ENZYME E1 FROM WHEAT - IDENTIFICATION OF AN ESSENTIAL CYSTEINE BY INVITRO MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; RNA-POLYMERASE; PROTEIN; EXPRESSION; GENE; PURIFICATION; DNA; CHROMOSOME; MECHANISM	Ubiquitin-activating enzyme, E1, directs the ATP-dependent formation of a thiol ester linkage between itself and ubiquitin. The energy in this bond is ultimately used to attach ubiquitin to various intracellular proteins. We previously reported the isolation of multiple E1s from wheat and the characterization of a cDNA encoding this protein (UBA1). We now report the derived amino acid sequence of two additional members of this gene family (UBA2 and UBA3). Whereas the amino acid sequence of UBA2 is nearly identical to UBA1, the sequence of UBA3 is significantly different. Nevertheless, the protein encoded by UBA3 catalyzes the ATP-dependent activation of ubiquitin in vitro. Comparison of derived amino acid sequences of genes encoding E1 from plant, yeast, and animal tissues revealed 5 conserved cysteine residues, with one potentially involved in thiol ester bond formation. To identify this essential residue, codons corresponding to each of the 5 cysteines in UBA1 were individually altered using site-directed mutagenesis. The mutagenized enzymes were expressed in Escherichia coli and assayed for their ability to activate ubiquitin. Only substitution of the cysteine at position 626 abolishes E1 activity, suggesting that this residue forms the thiol ester linkage with ubiquitin.	UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J MOL BIOL, V223, P1183, DOI 10.1016/0022-2836(92)90270-T; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOEFER M, 1991, FEBS LETT, V289, P54, DOI 10.1016/0014-5793(91)80907-K; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOEB KR, 1992, J BIOL CHEM, V267, P7806; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; SULLIVAN ML, 1990, PLANT PHYSIOL, V94, P710, DOI 10.1104/pp.94.2.710; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIERSTRA RD, 1985, J BIOL CHEM, V260, P2015; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	32	68	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14799	14803						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634524				2022-12-27	WOS:A1992JF08800046
J	LLORENSCORTES, C; HUANG, H; VICART, P; GASC, JM; PAULIN, D; CORVOL, P				LLORENSCORTES, C; HUANG, H; VICART, P; GASC, JM; PAULIN, D; CORVOL, P			IDENTIFICATION AND CHARACTERIZATION OF NEUTRAL ENDOPEPTIDASE IN ENDOTHELIAL-CELLS FROM VENOUS OR ARTERIAL ORIGINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; ANGIOTENSIN-CONVERTING ENZYME; ENKEPHALINASE EC 3.4.24.11; AMINO-ACID SEQUENCE; DIPEPTIDYL-CARBOXYPEPTIDASE ENKEPHALINASE; MOLECULAR-CLONING; 24.11 ENKEPHALINASE; LEUKEMIA ANTIGEN; METALLOENDOPEPTIDASE INHIBITOR; KIDNEY ENKEPHALINASE	Neutral endopeptidase (NEP; enkephalinase, EC 3.4.24.11) is a cell membrane-associated zinc metalloprotease, which cleaves peptides like atrial natriuretic peptide (ANP) on the amino side of hydrophobic amino acids. Although NEP is mainly located in reabsorptive epithelia (kidney proximal tubule), it is also present in non-epithelial cells such as neuronal cells. As the renal NEP cannot account for the entire ANP metabolism, other locations were postulated. The present experiments show its expression in endothelial cells (EC) from arterial (bovine pulmonary, porcine, and human aorta) and venous (human umbilical, rabbit ear marginal) origins. Three different methods were used to demonstrate the presence of the protein and its mRNA. 1) NEP enzymatic activity was estimated using both a synthetic ([D-Ala2,Leu5]enkephalin) and a natural substrate (bradykinin). Using the synthetic substrate the enzymatic activity in EC was completely blocked by thiorphan, a specific NEP inhibitor with an IC50 value in the nanomolar range. In contrast, captopril, bestatin, [2-guanidinoethylmercapto]succinic acid, inhibitors of angiotensin-converting enzyme, aminopeptidases, and carboxypeptidases, respectively, were 10,000 times less active, revealing an inhibition profile similar to that of the purified enzyme. Bradykinin, a natural substrate of NEP, was in part metabolized by NEP, in the presence of captopril, since 50% of the formation of the major metabolite bradykinin 1-7 was inhibited by thiorphan. 2) Immunoreactive NEP was detected on the plasma membrane of rabbit EC using a monoclonal antibody directed against the homologous renal enzyme. 3) NEP mRNA was detected by Northern blot analysis of rabbit EC as a major transcript of 3.9 kilobases. Reverse transcriptase polymerase chain reaction amplification showed the presence of a specific transcript in all EC tested. Therefore, endothelial NEP may play an important role in the inactivation of ANP, bradykinin, and endothelins by its localization facing the circulating vasoactive peptides.	INST PASTEUR,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LLORENSCORTES, C (corresponding author), COLL FRANCE,INSERM,U36,3 RUE ULM,F-75005 PARIS,FRANCE.		Llorens-Cortès, catherine/AAL-3893-2021; Llorens-Cortes, Catherine/E-5839-2016	Llorens-Cortès, catherine/0000-0002-7667-0401; Llorens-Cortes, Catherine/0000-0002-7667-0401				ALMENOFF J, 1981, BIOCHEM BIOPH RES CO, V102, P206, DOI 10.1016/0006-291X(81)91508-4; BARCLAY RK, 1978, BIOCHEM BIOPH RES CO, V81, P1119, DOI 10.1016/0006-291X(78)91252-4; BRALET J, 1990, EUR J PHARMACOL, V179, P57, DOI 10.1016/0014-2999(90)90401-Q; CANTIN M, 1985, ENDOCR REV, V6, P107, DOI 10.1210/edrv-6-2-107; CAVERO PG, 1990, CIRCULATION, V82, P196, DOI 10.1161/01.CIR.82.1.196; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU PJS, 1991, AM J PHYSIOL, V260, pR208, DOI 10.1152/ajpregu.1991.260.1.R208; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; DELABAUME S, 1988, EUR J PHARMACOL, V149, P121, DOI 10.1016/0014-2999(88)90049-0; DELVECCHIO PJ, 1981, J CELL PHYSIOL, V108, P337, DOI 10.1002/jcp.1041080307; DELVECCHIO PJ, 1983, ENDOTHELIAL CELL PLU, P67; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DICKINSON KEJ, 1991, BIOCHEM BIOPH RES CO, V176, P423, DOI 10.1016/0006-291X(91)90941-Y; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; FEINBERG AP, 1983, ANAL BIOCHEM, V95, P540; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519; GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035; GEE NS, 1985, BIOCHEM J, V228, P119, DOI 10.1042/bj2280119; GERBES AL, 1990, LIFE SCI, V47, P1173, DOI 10.1016/0024-3205(90)90208-9; GROS C, 1989, P NATL ACAD SCI USA, V86, P7580, DOI 10.1073/pnas.86.19.7580; HERSH LB, 1984, J NEUROCHEM, V43, P487, DOI 10.1111/j.1471-4159.1984.tb00925.x; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P564; KATSUBE N, 1986, J PHARMACOL EXP THER, V239, P474; KERR MA, 1974, BIOCHEM J, V137, P477, DOI 10.1042/bj1370477; LAFFERTY HM, 1989, CIRC RES, V65, P640, DOI 10.1161/01.RES.65.3.640; LECOMTE JM, 1990, EUR J PHARMACOL, V179, P65, DOI 10.1016/0014-2999(90)90402-R; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LLORENS C, 1982, J NEUROCHEM, V39, P1081, DOI 10.1111/j.1471-4159.1982.tb11500.x; LLORENS C, 1981, EUR J PHARMACOL, V69, P113, DOI 10.1016/0014-2999(81)90609-9; LLORENSCORTES C, 1990, J NEUROCHEM, V55, P2146, DOI 10.1111/j.1471-4159.1990.tb05810.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUFT FC, 1986, J PHARMACOL EXP THER, V236, P416; MALFROY B, 1982, BIOCHEM BIOPH RES CO, V106, P276, DOI 10.1016/0006-291X(82)91106-8; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MALFROY B, 1982, LIFE SCI, V31, P1745, DOI 10.1016/0024-3205(82)90200-4; NEEDLEMAN P, 1985, HYPERTENSION, V7, P469, DOI 10.1161/01.HYP.7.4.469; NORTHRIDGE DB, 1989, LANCET, V2, P591; ORLOWSKI M, 1981, BIOCHEMISTRY-US, V20, P4942, DOI 10.1021/bi00520a021; PARKER RB, 1971, J PHARMACOL EXP THER, V177, P1; PERT CB, 1976, SCIENCE, V194, P330, DOI 10.1126/science.968485; RONCO P, 1988, LAB INVEST, V58, P210; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; SCHWARTZ JC, 1990, LIFE SCI, V47, P1279, DOI 10.1016/0024-3205(90)90192-T; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; SCHWARTZ JC, 1989, DESIGN ENZYME INHIBI, P206; SEYMOUR AA, 1991, J CARDIOVASC PHARM, V17, P456, DOI 10.1097/00005344-199103000-00015; SEYMOUR AA, 1990, J CARDIOVASC PHARM, V16, P163, DOI 10.1097/00005344-199007000-00022; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; SKIDGEL RA, 1991, BIOCHEM PHARMACOL, V41, P1335, DOI 10.1016/0006-2952(91)90106-F; SOFFER RL, 1976, ANNU REV BIOCHEM, V45, P73, DOI 10.1146/annurev.bi.45.070176.000445; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; SOLEILHAC JM, 1992, IN PRESS MOL PHARM; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEPHENSON SL, 1987, BIOCHEM J, V243, P183, DOI 10.1042/bj2430183; SYBERTZ EJ, 1989, J PHARMACOL EXP THER, V250, P624; SYBERTZ EJ, 1990, HYPERTENSION, V15, P152, DOI 10.1161/01.HYP.15.2.152; TANG J, 1984, REGUL PEPTIDES, V9, P53, DOI 10.1016/0167-0115(84)90007-7; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; URA N, 1987, KIDNEY INT, V32, P507, DOI 10.1038/ki.1987.239; VALENTIN JP, 1992, AM J HYPERTENS, V5, P88, DOI 10.1093/ajh/5.2.88; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150	66	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14012	14018						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629199				2022-12-27	WOS:A1992JD32500038
J	LOCKER, JK; GRIFFITHS, G; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; GRIFFITHS, G; HORZINEK, MC; ROTTIER, PJM			O-GLYCOSYLATION OF THE CORONAVIRUS-M PROTEIN - DIFFERENTIAL LOCALIZATION OF SIALYLTRANSFERASES IN N-LINKED AND O-LINKED GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; DENSITY-LIPOPROTEIN RECEPTOR; TRANS-GOLGI NETWORK; BREFELDIN-A; ENDOPLASMIC-RETICULUM; E1 GLYCOPROTEIN; SUBCELLULAR ORGANIZATION; INTRACELLULAR-TRANSPORT; CELLULAR COMPARTMENTS; SECRETORY PROTEINS	It has previously been shown that the M (E1) glycoprotein of mouse hepatitis virus strain A59 (MHV-A59) contains only O-linked oligosaccharides and localizes to the Golgi region when expressed independently. A detailed pulse-chase analysis was made of the addition of O-linked sugars to the M protein; upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, three different electrophoretic forms could be distinguished that corresponded to the sequential acquisition of N-acetylgalactosamine (GalNAc), galactose (Gal), and sialic acid (SA). A fourth and fifth form could also be detected which we were unable to identify. Following Brefeldin A treatment, the M protein still acquired GalNAc, Gal, and SA, but the fourth and fifth forms were absent, suggesting that these modifications occur in the trans-Golgi network (TGN). In contrast, in the presence of BFA, the G protein of vesicular stomatitis virus (VSV), which contains N-linked oligosaccharides, acquired Gal and fucose but not SA. These results are consistent with earlier published data showing that Golgi compartments proximal to the TGN, but not the TGN itself, relocate to the endoplasmatic reticulum/intermediate compartment. More importantly, our data argue that, whereas addition of SA to N-linked sugars occurs in the TGN the acquisition of both SA on O-linked sugars and the addition of fucose to N-linked oligosaccharides must occur in Golgi compartments proximal to the TGN. The glycosylation of the M protein moreover indicates that it is transported to trans-Golgi and TGN. This was confirmed by electron microscopy immunocytochemistry, showing that the protein is targeted to cisternae on the trans side of the Golgi and co-localizes, at least in part, with TGN 38, a marker of the TGN, as well as with a lectin specific for sialic acid.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	LOCKER, JK (corresponding author), UNIV UTRECHT,FAC VET MED,INST VIROL,UTRECHT,NETHERLANDS.		Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020					ABEIJON C, 1987, J BIOL CHEM, V262, P4153; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN SSL, 1988, J VIROL, V62, P2552, DOI 10.1128/JVI.62.8.2552-2556.1988; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DENBOON JA, 1991, VIROLOGY, V182, P655, DOI 10.1016/0042-6822(91)90606-C; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER A, 1984, J CELL BIOL, V98, P327; ELLINGER A, 1988, EUR J CELL BIOL, V47, P62; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HOLMES KV, 1981, VIROLOGY, V115, P334, DOI 10.1016/0042-6822(81)90115-X; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P8221; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NIEMANN H, 1982, EMBO J, V1, P1499, DOI 10.1002/j.1460-2075.1982.tb01346.x; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; NIEMANN H, 1981, J MOL BIOL, V153, P993, DOI 10.1016/0022-2836(81)90463-0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PATHAK RK, 1988, J CELL BIOL, V326, P191; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; ROTTIER PJM, 1987, J VIROL, V61, P2042, DOI 10.1128/JVI.61.6.2042-2045.1987; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; ROTTIER PJM, 1981, J VIROL, V38, P20, DOI 10.1128/JVI.38.1.20-26.1981; SHITE S, 1990, J BIOL CHEM, V265, P17385; SIMONS K, 1992, IN PRESS CELL; SPAAN WJM, 1981, VIROLOGY, V108, P424, DOI 10.1016/0042-6822(81)90449-9; STERN DF, 1982, J VIROL, V44, P804, DOI 10.1128/JVI.44.3.804-812.1982; STROUS GJA, 1979, P NATL ACAD SCI USA, V76, P2691; STURMAN LS, 1985, J VIROL, V56, P904, DOI 10.1128/JVI.56.3.904-911.1985; TOOZE J, 1984, EUR J CELL BIOL, V33, P281; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; ULMER JB, 1989, BIOCH BIPHYS ACTA, P6992; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	49	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14094	14101						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629209				2022-12-27	WOS:A1992JD32500050
J	BORNER, C; GUADAGNO, SN; HSIAO, WWL; FABBRO, D; BARR, M; WEINSTEIN, IB				BORNER, C; GUADAGNO, SN; HSIAO, WWL; FABBRO, D; BARR, M; WEINSTEIN, IB			EXPRESSION OF 4 PROTEIN-KINASE-C ISOFORMS IN RAT FIBROBLASTS - DIFFERENTIAL ALTERATIONS IN RAS-TRANSFORMED, SRC-TRANSFORMED, AND FOS-TRANSFORMED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHOLIPID-METABOLISM; EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER RECEPTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR PROMOTERS; GENE-EXPRESSION; DOWN-REGULATION; NEU ONCOGENE; 3T3 CELLS; PURIFICATION	In the accompanying study (Borner, C. B., Guadagno, S. N., and Weinstein, 1. B. (1992) J. Biol. Chem. 267, 12892-12899) we found that R6 embryo fibroblasts express four isoforms of PKC, cPKC-alpha, nPKC-epsilon, nPKC-delta, and nPKC-zeta whose subcellular distribution, activation, and down-regulation are differentially regulated. Furthermore, we demonstrated that overproduction of an exogenous cPKC-beta-I isoform in these cells (R6-PKC3) altered the TPA-induced down-regulation of nPKC-delta and nPKC-epsilon. In this paper we show that transformation of R6 or R6-PKC3 cells with a variety of different oncogenes results in differential alterations in expression of individual PKC isoforms. R6 or R6-PKC3 cells transformed by an activated c-H-ras oncogene displayed a marked increase in the expression of both cPKC-alpha and nPKC-delta, decreased expression of nPKC-epsilon, and no change in the expression of nPKC-zeta. These alterations occurred at both the mRNA and protein levels but did not significantly affect the subcellular distribution of any of the four isoforms. Studies using actinomycin D and nuclear run-off assays indicated that the increased expression of cPKC-alpha in ras-transformed cells was due to increased de novo transcription rather than increased mRNA stability. Qualitatively similar, but less extensive changes in the expression of the four PKC isoforms were seen in v-fos-transformed R6-PKC3 cells. Decreased expression of nPKC-epsilon was also seen in the v-src-transformed R6- and R6-PKC3 lines; however, the cellular level of cPKC-beta-I appeared to be a limiting factor in mediating the effects of v-src on the increased expression of cPKC-alpha and nPKC-delta. Interestingly, no major changes in the levels of expression of any of the four PKC isoforms were found when R6 cells were transformed by myc, neu/erb-B2, or mos oncogenes. These results demonstrate that transformation of R6 cells by the oncogenes ras, src, and fos differentially alter the expression of three isoforms of PKC in the same host cell, and they suggest that individual isoforms may play distinct roles in mediating cellular transformation by specific oncogenes.	COLUMBIA UNIV, INST CANC RES, NEW YORK, NY 10027 USA; COLUMBIA UNIV, DEPT PHARMACOL, NEW YORK, NY 10027 USA; CIBA GEIGY AG, DEPT PHARMACEUT RES, ONCOL K125, CH-4002 BASEL, SWITZERLAND; UNIV CALIF IRVINE, DEPT BIOCHEM & MOLEC BIOL, IRVINE, CA 92717 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10027 USA	Columbia University; Columbia University; Novartis; University of California System; University of California Irvine; Columbia University	BORNER, C (corresponding author), COLUMBIA UNIV, CTR COMPREHENS CANC, 701 W 168TH ST, NEW YORK, NY 10027 USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CUADRADO A, 1990, FEBS LETT, V260, P281, DOI 10.1016/0014-5793(90)80123-Z; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Curran T, 1988, ONCOGENE HDB, P307; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOTTO GP, 1985, NATURE, V318, P472; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; HUANG KP, 1989, ACTA ENDOCRINOL-COP, V121, P307, DOI 10.1530/acta.0.1210307; HUANG M, 1988, J BIOL CHEM, V263, P17975; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KATO M, 1987, J BIOL CHEM, V262, P5696; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAUSS RS, 1989, ONCOGENE, V4, P991; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRIESS J, 1986, J BIOL CHEM, V261, P8597; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SLAGA TJ, 1984, MECHANISMS TUMOR PRO, V2, P1; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STACEY DW, 1987, MOL CELL BIOL, V9, P3174; SUGIMOTO Y, 1984, P NATL ACAD SCI USA, V81, P16546; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WEYMAN CM, 1988, CANCER RES, V48, P6535; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; Woodgett JR., 1987, CELL MEMBRANES, P215, DOI [10.1007/978-1-4613-1915-3_6, DOI 10.1007/978-1-4613-1915-3_6]	76	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12900	12910						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618788				2022-12-27	WOS:A1992HZ48300077
J	KOUNNAS, MZ; MORRIS, RE; THOMPSON, MR; FITZGERALD, DJ; STRICKLAND, DK; SAELINGER, CB				KOUNNAS, MZ; MORRIS, RE; THOMPSON, MR; FITZGERALD, DJ; STRICKLAND, DK; SAELINGER, CB			THE ALPHA-2-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN BINDS AND INTERNALIZES PSEUDOMONAS EXOTOXIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LDL-RECEPTOR; CULTURED FIBROBLASTS; ESCHERICHIA-COLI; APOLIPOPROTEIN-E; PLASMA-MEMBRANE; MAMMALIAN-CELLS; DOMAIN-I; AERUGINOSA; TOXIN; SEQUENCE	The alpha-2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha-2MR/LRP) is a large cell-surface glycoprotein consisting of a 515-kDa and an 85-kDa polypeptide; this receptor is thought to be responsible for the binding and endocytosis of activated alpha-2-macroglobulin and apoE-enriched beta-very low density lipoprotein. A similar high molecular weight glycoprotein has been identified as a potential receptor for Pseudomonas exotoxin A (PE). We demonstrate that the alpha-2MR/LRP and the PE-binding glycoprotein have a similar mobility upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis and are immunologically indistinguishable. Furthermore, affinity-purified alpha-2MR/LRP binds specifically to PE but not to a mutant toxin defective in its ability to bind cells. The 39-kDa receptor-associated protein, which blocks binding of ligands to alpha-2MR/LRP, also prevents binding and subsequent toxicity of PE for mouse fibroblasts. The concentration of receptor-associated protein that was required to reduce binding and toxicity to 50% was approximately 14 nM, a value virtually identical to the, K(D) measured for the interaction of receptor-associated protein with the purified receptor. Overall, the studies strongly suggest that the alpha-2MR/LRP is responsible for internalizing PE.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855; UNIV CINCINNATI,COLL MED,DEPT ANAT & CELL BIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DIV DIGEST DIS,CINCINNATI,OH 45267; NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; American Red Cross; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NHLBI NIH HHS [HL30200/ +] Funding Source: Medline; NIAID NIH HHS [AI17529] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATRA JK, 1991, MOL CELL BIOL, V11, P2200, DOI 10.1128/MCB.11.4.2200; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; FELDMAN SR, 1985, BIOCHEM BIOPH RES CO, V128, P795, DOI 10.1016/0006-291X(85)90117-2; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; FORRISTAL JJ, 1991, INFECT IMMUN, V59, P2880, DOI 10.1128/IAI.59.9.2880-2884.1991; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HANOVER JA, 1983, J BIOL CHEM, V258, P370; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLDER IA, 1989, J BURN CARE REHABIL, V9, P285; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MANHART MD, 1984, INFECT IMMUN, V45, P596, DOI 10.1128/IAI.45.3.596-603.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORRIS RE, 1985, SURV SYN PATHOL RES, V4, P34; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PASTAN I, 1989, J BIOL CHEM, V264, P15157; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SNELL K, 1978, INFECT IMMUN, V19, P839, DOI 10.1128/IAI.19.3.839-845.1978; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THOMPSON MR, 1991, J BIOL CHEM, V266, P2390; VANDENPOL AN, 1984, Q J EXP PHYSIOL CMS, V69, P1; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; VASIL ML, 1978, J GEN MICROBIOL, V108, P333, DOI 10.1099/00221287-108-2-333; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLINGHAM MC, 1979, J CELL BIOL, V82, P614, DOI 10.1083/jcb.82.3.614	47	413	432	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12420	12423						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618748				2022-12-27	WOS:A1992HZ48300008
J	NYHUS, KJ; IKEUCHI, M; INOUE, Y; WHITMARSH, J; PAKRASI, HB				NYHUS, KJ; IKEUCHI, M; INOUE, Y; WHITMARSH, J; PAKRASI, HB			PURIFICATION AND CHARACTERIZATION OF THE PHOTOSYSTEM-I COMPLEX FROM THE FILAMENTOUS CYANOBACTERIUM ANABAENA-VARIABILIS ATCC-29413	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTIRE PRECURSOR POLYPEPTIDES; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SUBUNIT-II; SPINACH; CHLOROPHYLL; GENE; P700; PHOTOSYNTHESIS; IDENTIFICATION	A photoactive photosystem I complex has been purified from the filamentous, nitrogen-fixing cyanobacterium Anabaena variabilis ATCC 29413. Cells were broken using glass beads, and the membrane fraction was solubilized with beta-dodecyl maltoside followed by two rounds of fast protein liquid chromatography on anion exchange columns. The polypeptide composition of the isolated complex was determined by sodium dodecyl sulfate-urea-polyacrylamide gel electrophoresis and N-terminal amino acid sequencing of the fractionated proteins. The purified complex consists of at least 11 proteins, identified as the PsaA, PsaB, PsaC, PsaD, PsaE, PsaF, PsaI, PsaJ, PsaK, PsaL, and PsaN proteins. The spectrum of the flash-induced absorbance change measured between 670 and 830 nm shows that the purified complex contains 99 +/- 11 chlorophyll alpha-molecules per P700, the primary donor in photosystem I. The kinetics of the rereduction of oxidized P700 following an actinic flash indicate that forward electron transfer from P700 to the F(A)/F(B) iron-sulfur center acceptors is functional in the isolated complex.	WASHINGTON UNIV, DEPT BIOL, PLANT BIOL PROGRAM, ST LOUIS, MO 63130 USA; INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, WAKO, SAITAMA 35101, JAPAN; UNIV ILLINOIS, USDA ARS, PHOTOSYNTH RES UNIT, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PLANT BIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, URBANA, IL 61801 USA	Washington University (WUSTL); RIKEN; United States Department of Agriculture (USDA); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NIGMS NIH HHS [GM 41841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY BA, 1988, ISRAEL J CHEM, V28, P129; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOSE S, 1982, PHOTOCHEM PHOTOBIOL, V36, P725, DOI 10.1111/j.1751-1097.1982.tb09496.x; BRICKER TM, 1985, ARCH BIOCHEM BIOPHYS, V237, P170, DOI 10.1016/0003-9861(85)90266-8; BRYANT DA, 1992, IN PRESS CURRENT TOP, V11; BRYANT DA, 1990, CURRENT RES PHOTOSYN, V2, P1; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; DEKKER JP, 1989, FEBS LETT, V254, P150, DOI 10.1016/0014-5793(89)81028-2; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; IKEUCHI M, 1991, FEBS LETT, V280, P332, DOI 10.1016/0014-5793(91)80324-V; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1990, FEBS LETT, V263, P274, DOI 10.1016/0014-5793(90)81391-Z; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; KIRSCH W, 1986, CURR GENET, V10, P843, DOI 10.1007/BF00418531; KOIKE H, 1989, FEBS LETT, V253, P257, DOI 10.1016/0014-5793(89)80971-8; LAGOUTTE B, 1989, PHOTOCHEM PHOTOBIOL, V49, P833, DOI 10.1111/j.1751-1097.1989.tb05580.x; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOCKAU W, 1981, ARCH MICROBIOL, V128, P336, DOI 10.1007/BF00422541; LUNDELL DJ, 1985, J BIOL CHEM, V260, P646; MacKinney G, 1941, J BIOL CHEM, V140, P315; MALDENER I, 1991, MOL GEN GENET, V225, P113, DOI 10.1007/BF00282649; MANNAN RM, 1991, P NATL ACAD SCI USA, V88, P10168, DOI 10.1073/pnas.88.22.10168; MANNAN RM, 1992, PLANT PHYSIOL, V98, P798, DOI 10.1104/pp.98.2.798; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; OGAWA T, 1969, BIOCHIM BIOPHYS ACTA, V172, P216, DOI 10.1016/0005-2728(69)90065-6; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHAFFERNICHT H, 1981, PHOTOCHEM PHOTOBIOL, V34, P223; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; SONOIKE K, 1989, BIOCHIM BIOPHYS ACTA, V976, P210, DOI 10.1016/S0005-2728(89)80232-4; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; STEPPUHN J, 1989, CURR GENET, V16, P99, DOI 10.1007/BF00393402; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TOELGE M, 1991, BIOCHIM BIOPHYS ACTA, V1060, P233, DOI 10.1016/S0005-2728(09)91011-8; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WHITMARSH J, 1984, ARCH BIOCHEM BIOPHYS, V231, P378, DOI 10.1016/0003-9861(84)90401-6; WOLK CP, 1976, ARCH MICROBIOL, V110, P145; WOLK CP, 1971, J PHYCOL, V7, P339, DOI 10.1111/j.0022-3646.1971.00339.x; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11	47	25	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12489	12495						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618755				2022-12-27	WOS:A1992HZ48300020
J	DUDLEY, B; HAMMOND, A; DEUTSCH, WA				DUDLEY, B; HAMMOND, A; DEUTSCH, WA			THE PRESENCE OF URACIL-DNA GLYCOSYLASE IN INSECTS IS DEPENDENT UPON DEVELOPMENTAL COMPLEXITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; INHIBITOR; RESIDUES; REPAIR; ENZYME; AGE	The metamorphosis of insects can, in a general way, be divided between those organisms that undergo pupation accompanied by cellular histolysis and those that gradually develop into adults without an intervening pupal stage of development. In the former case, the death of a cell population is an integral part of development that is tightly associated with massive DNA degradation during pupation. In that regard, it has been suggested that uracil-containing DNA acts as a target for the nucleolytic breakdown of DNA during histolysis in insects (Deutsch, W. A. (1987) Mutat. Res. 184, 209-215), thus placing into question how compatible the existence of uracil-DNA glycosylases would be for this form of developmental signal. As a result, we tested for the presence of a uracil-DNA glycosylase in insects representative of those having an intervening pupal stage of development and those that do not. We show here that a nonpupating insect contains a uracil-DNA glycosylase activity. Conversely, crude extracts of Drosophila melanogaster, as well as of three other insect populations that undergo pupation similar to that found in Drosophila, do not contain detectable levels of this DNA repair activity. Thus, there appears to be a consistent correlation between cellular destruction during development and the absence of a uracil-DNA glycosylase, which supports the possibility that uracil-containing DNA may play an important role in those cells targeted for death.	LOUISIANA STATE UNIV, DEPT BIOCHEM, BATON ROUGE, LA 70803 USA; LOUISIANA STATE UNIV, DEPT ENTOMOL, BATON ROUGE, LA 70803 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University								BICKLE TA, 1982, NUCLEASES, P85; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER LH, 1986, BIOCHEM BIOPH RES CO, V134, P201, DOI 10.1016/0006-291X(86)90547-4; BURTON WG, 1979, P NATL ACAD SCI USA, V76, P1390, DOI 10.1073/pnas.76.3.1390; CLIFFORD CW, 1977, ANN ENTOMOL SOC AM, V70, P69, DOI 10.1093/aesa/70.1.69; DEUTSCH WA, 1987, MUTAT RES, V184, P209, DOI 10.1016/0167-8817(87)90018-6; DEUTSCH WA, 1982, J BIOL CHEM, V257, P3366; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FESCEMYER HW, 1986, ENVIRON ENTOMOL, V15, P784, DOI 10.1093/ee/15.4.784; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1978, DNA REPAIR MECHANISM, P163; GATES FT, 1977, J BIOL CHEM, V252, P1647; GIROIR IE, 1987, J BIOL CHEM, V262, P130; HENSLEY SD, 1968, J ECON ENTOMOL, V61, P1742, DOI 10.1093/jee/61.6.1742; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; MORGAN AR, 1989, J BIOL CHEM, V264, P9911; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; PRICE AR, 1975, J BIOL CHEM, V250, P8804; ROE RM, 1982, ANN ENTOMOL SOC AM, V75, P421, DOI 10.1093/aesa/75.4.421; SADOWSKI PD, 1969, J BIOL CHEM, V244, P6192; WITTWER CU, 1985, BIOCHIM BIOPHYS ACTA, V832, P308, DOI 10.1016/0167-4838(85)90264-X; WYLIE AH, 1980, NATURE, V284, P555	23	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11964	11967						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601865				2022-12-27	WOS:A1992HY94700048
J	MIYAMOTO, I; MIURA, N; NIWA, H; MIYAZAKI, J; TANAKA, K				MIYAMOTO, I; MIURA, N; NIWA, H; MIYAZAKI, J; TANAKA, K			MUTATIONAL ANALYSIS OF THE STRUCTURE AND FUNCTION OF THE XERODERMA-PIGMENTOSUM GROUP-A COMPLEMENTING PROTEIN - IDENTIFICATION OF ESSENTIAL DOMAINS FOR NUCLEAR-LOCALIZATION AND DNA EXCISION REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGERS; MOLECULAR CHARACTERIZATION; CDNA CLONING; GENE; HOMOLOGY	We showed previously that the xeroderma pigmentosum group A complementing (XPAC) protein involved in the DNA excision repair pathway contains a zinc-finger motif and is localized in the nucleus of normal human cells. For detailed structural and functional analyses of the XPAC protein, we constructed various XPAC cDNAs by site-directed mutagenesis and isolated permanent cell lines expressing mutant proteins. Immunofluorescent analysis of these lines indicated that the nuclear localization signal is located in the region encoded by Exon 1, especially centered at amino acids 30-42. A UV survival study showed that regions from Exons 2 through 6 were essential for DNA repair function, but that Exon 1 was not. Interestingly, deletion of the glutamic acid cluster in the region encoded by Exon 2 resulted in a dramatic loss of DNA repair activity. Furthermore, replacements of each of the 4 cysteines supposed to form a zinc-finger structure in the region encoded by Exon 3 by serine or glycine resulted in similar levels of loss of repair activity. These results suggest that all 4 cysteines forming a zinc-finger structure and also the glutamic acid cluster are important for DNA repair function.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN; HYOGO MED UNIV,DEPT UROL,NISHINOMIYA,HYOGO 663,JAPAN; KUMAMOTO UNIV,SCH MED,INST MED GENET,KUMAMOTO 862,JAPAN; UNIV TOKYO,FAC MED,DEPT DIS RELATED GENE REGULAT RES SANDOZ,TOKYO 113,JAPAN	Osaka University; Hyogo College of Medicine; University of Hyogo; Kumamoto University; Novartis; Sandoz; University of Tokyo			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				BERG JM, 1990, J BIOL CHEM, V265, P6513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HARLOW H, 1988, ANTIBODIES LABORATOR, P647; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; MIURA N, 1991, J BIOL CHEM, V266, P19786; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; SATOKATA I, 1992, IN PRESS HUM GENET; SHIMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V181, P1231, DOI 10.1016/0006-291X(91)92070-Z; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	26	120	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12182	12187						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601884				2022-12-27	WOS:A1992HY94700079
J	PITARRESI, TM; RUBATTU, S; HEINRIKSON, R; SEALEY, JE				PITARRESI, TM; RUBATTU, S; HEINRIKSON, R; SEALEY, JE			REVERSIBLE CRYOACTIVATION OF RECOMBINANT HUMAN PRORENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVE RENIN; HUMAN-PLASMA; ASPARTIC PROTEINASES; BIG RENIN; ACTIVATION; MECHANISM; ANGIOTENSINOGEN; IDENTIFICATION; PREKALLIKREIN; ALDOSTERONE	Cleavage of prorenin's prosegment causes irreversible formation of renin. In contrast, renin activity is reversibly exposed when prorenin is acidified to pH 3.3. Nonetheless, acidification of plasma results in irreversible activation of prorenin, because endogenous proteases cleave the prosegment of acid-activated prorenin. Chilling of plasma results in irreversible cryoactivation of prorenin. In this study we investigated whether cryoactivation of purified prorenin is reversible. The intrinsic renin activity of recombinant human prorenin was measured by an enzyme kinetic assay using partially purified human angiotensinogen as substrate. Results are expressed as a percent (mean +/- S.E.) of the maximal activity exposed after limited proteolysis by trypsin. The intrinsic renin activity of two pools (0.3 and 0.06 Goldblatt units/ml) was 1.5% +/- 0.3 and 1.2% +/- 0.6 at 37-degrees-C. Activity increased to 19% +/- 0.3 and 26% +/- 0.5 after incubation at 0-degrees-C and to 5.4% +/- 0.5 and 2.1% +/- 1.2 at room temperature. Cryoactivation did not occur in buffers containing more than 1 M NaCl. It took 8 min at 37-degrees-C or 180 min at room temperature for cryoactivated prorenin to lose half of its intrinsic renin activity. It took 48 and 26 h, respectively, at 0-degrees-C for the two pools of prorenin at 37-degrees-C to regain half of their maximum intrinsic activity at 0-degrees-C. A direct immunoradiometric assay that detects active renin but not prorenin was able to detect cryoactivated prorenin. These results show that human prorenin can be reversibly cryoactivated in buffers of low ionic strength and has greater intrinsic activity at room temperature than at 37-degrees-C.	CORNELL UNIV, MED CTR, COLL MED, CTR CARDIOVASC, 525 E 68TH ST, NEW YORK, NY 10021 USA	Cornell University			Rubattu, S./K-4036-2016; Sealey, Jean/A-9562-2009	Rubattu, Speranza/0000-0002-9808-7970; RUBATTU, Speranza Donatella/0000-0001-5921-7368	NHLBI NIH HHS [HL 18323, HL 40152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040152, P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLAS SA, 1982, HYPERTENSION, V4, P86, DOI 10.1161/01.HYP.4.3_Pt_2.86; ATLAS SA, 1985, BIOCHEM BIOPH RES CO, V132, P1038, DOI 10.1016/0006-291X(85)91911-4; ATLAS SA, 1978, CIRC RES, V43, pI128; BOUHNIK J, 1985, J CLIN ENDOCR METAB, V60, P399, DOI 10.1210/jcem-60-2-399; CARILLI CT, 1988, HYPERTENSION, V11, P713, DOI 10.1161/01.HYP.11.6.713; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DANSER AHJ, 1989, J CLIN ENDOCR METAB, V68, P160, DOI 10.1210/jcem-68-1-160; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DAY RP, 1974, J CLIN ENDOCR METAB, V38, P923, DOI 10.1210/jcem-38-5-923; DELEIVA A, 1976, NEW ENGL J MED, V295, P639, DOI 10.1056/NEJM197609162951203; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1979, NATURE, V280, P315, DOI 10.1038/280315a0; GALEN FX, 1984, J CLIN INVEST, V73, P1144, DOI 10.1172/JCI111300; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HOBART PM, 1987, DIURETICS, V2, P510; HSUEH WA, 1981, HYPERTENSION, V3, P22; HUI KY, 1985, PEPTIDES STRUCTURE F, P771; INAGAMI T, 1980, BIOMED RES-TOKYO, V1, P456, DOI 10.2220/biomedres.1.456; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KAGEYAMA T, 1987, EUR J BIOCHEM, V165, P483, DOI 10.1111/j.1432-1033.1987.tb11464.x; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIM SJ, 1985, BIOCHEM BIOPH RES CO, V126, P641, DOI 10.1016/0006-291X(85)90232-3; LARAGH JH, 1992, HDB RENAL PHYSL, P1409; LECKIE BJ, 1980, NATURE, V288, P702, DOI 10.1038/288702a0; LENZ T, 1990, AM J HYPERTENS, V3, P257, DOI 10.1093/ajh/3.4.257; LENZ T, 1989, J CLIN ENDOCR METAB, V69, P31, DOI 10.1210/jcem-69-1-31; LENZ T, 1990, HYPERTENSION PATHOPH, P1319; LUETSCHER JA, 1989, AM J HYPERTENS, V2, P382, DOI 10.1093/ajh/2.5.382; MCGIFF JC, 1970, NATURE, V227, P1255, DOI 10.1038/2271255b0; MCPHIE P, 1989, BIOCHEM BIOPH RES CO, V158, P115, DOI 10.1016/S0006-291X(89)80185-8; NARUSE M, 1983, J CLIN ENDOCR METAB, V57, P482, DOI 10.1210/jcem-57-3-482; NETER J, 1974, APPLIED LINEAR STATI; OSMOND DH, 1973, CAN J PHYSIOL PHARM, V51, P705, DOI 10.1139/y73-107; PREIBISZ JJ, 1982, CARDIOVASC REV REP, V3, P787; Sealey J E, 1980, Endocr Rev, V1, P365; SEALEY JE, 1991, AM J HYPERTENS, V4, P972, DOI 10.1093/ajh/4.12.972; SEALEY JE, 1976, AM J MED, V61, P731, DOI 10.1016/0002-9343(76)90154-6; SEALEY JE, 1979, P NATL ACAD SCI USA, V76, P5914, DOI 10.1073/pnas.76.11.5914; SEALEY JE, 1988, J CLIN ENDOCR METAB, V66, P974, DOI 10.1210/jcem-66-5-974; SEALEY JE, 1975, CIRC RES, V36, P10, DOI 10.1161/01.RES.36.6.10; SEALEY JE, 1990, FRONT NEUROENDOCRIN, V11, P213; SKINNER SL, 1975, AM J OBSTET GYNECOL, V121, P626, DOI 10.1016/0002-9378(75)90463-9	42	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11753	11759						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601850				2022-12-27	WOS:A1992HY94700020
J	VOS, HL; DEVARAYALU, S; DEVRIES, Y; BORNSTEIN, P				VOS, HL; DEVARAYALU, S; DEVRIES, Y; BORNSTEIN, P			THROMBOSPONDIN-3 (THBS3), A NEW MEMBER OF THE THROMBOSPONDIN GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESIVE GLYCOPROTEIN; SEQUENCE; ANGIOGENESIS; CHROMOSOME-1; PLATELETS; REGION; INTRON; SITES	A third member of the thrombospondin gene family (Thbs3) has been partially characterized in the mouse. In both the mouse and humans, the Thbs3/THBS3 gene is located immediately upstream from the Muc1/MUC1 (episialin) gene; <3 kilobases separate the polyadenylation signal of one gene from the start of transcription of the other. The available coding sequence in Thbs3 shows a high degree of amino acid sequence identity to Thbs1 and Thbs2 (58 and 59%, respectively, in exons 15 and 16), but the exon/intron organization of Thbs3 appears to be more disparate than that of the two previously described members of the family. The shorter length of the Thbs3 mRNA (3.5 kilobases) can be attributed largely to a shorter 3'-untranslated region. The Thbs3 gene is expressed in a distinctive pattern in mouse tissues, with the highest level of expression in lung. This pattern suggests a unique function for the translation product of the Thbs3 gene.	UNIV WASHINGTON, DEPT BIOCHEM, SJ-70, SEATTLE, WA 98195 USA; NETHERLANDS CANC INST, DIV TUMOR BIOL, 1066 CX AMSTERDAM, NETHERLANDS	University of Washington; University of Washington Seattle; Netherlands Cancer Institute					NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDCR NIH HHS [DE 08229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; ASCH AS, 1991, J BIOL CHEM, V266, P1740; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BOUCK N, 1986, CANCER RES, V46, P5101; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GIL A, 1984, NATURE, V312, P473, DOI 10.1038/312473a0; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAFFE E, 1990, GENOMICS, V7, P123, DOI 10.1016/0888-7543(90)90528-3; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MAJACK RA, 1987, CELL MEMBRANES METHO, V3, P55; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452	32	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12192	12196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601886				2022-12-27	WOS:A1992HY94700081
J	NUNEZ, MT; ESCOBAR, A; AHUMADA, A; GONZALEZSEPULVEDA, M				NUNEZ, MT; ESCOBAR, A; AHUMADA, A; GONZALEZSEPULVEDA, M			SEALED RETICULOCYTE GHOSTS - AN EXPERIMENTAL-MODEL FOR THE STUDY OF FE2+ TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN-BOUND IRON; RAT-LIVER; MEMBRANE-VESICLES; CLEARANCE; MOUSE	Sealed right-side-out reticulocyte ghosts transported and accumulated iron offered as Fe-59(2+)-ascorbate (K(m) = 1.1-mu-M). The uptake of iron by ghosts presented the characteristics of a transporter-mediated process: it responded to osmotic challenge, the rate of transport increased when iron was present in the opposing side, and the transport rate showed the temperature dependence typical of membrane-mediated processes. The transport of iron was dependent on an associated influx of Cl- in order to keep electroneutrality. Other transition metals, such as Cu2+, Zn2+, and Co2+, inhibited the transport of Fe2+. The overall characteristics of the system make reticulocyte sealed ghosts a very useful model in determining the basic mechanisms of membrane iron transport.			NUNEZ, MT (corresponding author), UNIV CHILE,FAC CIENCIAS,DEPT BIOL,CASILLA 653,SANTIAGO,CHILE.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570				ANDERSON TF, 1951, T NEW YORK ACAD SCI, V13, P130, DOI 10.1111/j.2164-0947.1951.tb01007.x; BRISSOT P, 1985, J CLIN INVEST, V76, P1463, DOI 10.1172/JCI112125; CRAVEN CM, 1987, P NATL ACAD SCI USA, V84, P3457, DOI 10.1073/pnas.84.10.3457; DEVES R, 1979, BIOCHIM BIOPHYS ACTA, V556, P524, DOI 10.1016/0005-2736(79)90138-X; DEVES R, 1989, PROC R SOC SER B-BIO, V237, P85, DOI 10.1098/rspb.1989.0038; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; EVANS RM, 1982, BR J NUTR, V47, P353; HUEBERS H, 1975, IRON METABOLISM ITS, P13; JACQUEZ JA, 1980, MEMBRANE PHYSL, P147; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LODISH HF, 1975, J CELL BIOL, V65, P51, DOI 10.1083/jcb.65.1.51; MARX JJM, 1981, BIOCHIM BIOPHYS ACTA, V649, P297, DOI 10.1016/0005-2736(81)90418-1; MORGAN EH, 1988, BIOCHIM BIOPHYS ACTA, V943, P428, DOI 10.1016/0005-2736(88)90374-4; MUIR WA, 1984, J BIOL CHEM, V259, P4896; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; NUNEZ MT, 1983, J BIOL CHEM, V258, P1146; QUIAN ZM, 1991, BIOCHIM BIOPHYS ACTA, V1073, P456; SIMPSON RJ, 1984, BIOCHIM BIOPHYS ACTA, V772, P220, DOI 10.1016/0005-2736(84)90047-6; Steck T L, 1974, Methods Enzymol, V31, P172; STURROCK A, 1990, J BIOL CHEM, V265, P3139; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WRIGHT TL, 1986, J BIOL CHEM, V261, P909; WRIGHT TL, 1988, J BIOL CHEM, V263, P1842; YOUNG SP, 1977, BIOCHIM BIOPHYS ACTA, V469, P281, DOI 10.1016/0005-2736(77)90164-X	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11490	11494						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597476				2022-12-27	WOS:A1992HX16900084
J	DELAROSA, J; LEGROS, HL; GELLER, AM; KOTB, M				DELAROSA, J; LEGROS, HL; GELLER, AM; KOTB, M			CHANGES IN THE RELATIVE AMOUNT OF SUBUNITS OF METHIONINE ADENOSYLTRANSFERASE IN HUMAN-LYMPHOCYTES UPON STIMULATION WITH A POLYCLONAL T-CELL MITOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; STREPTOCOCCAL-M-PROTEIN; GENE; METHYLATION	Activation of resting human peripheral blood T lymphocytes by the lectin phytohemagglutinin results in an increase in methionine adenosyltransferase (MAT) activity, accompanied by an increase in the amount of the alpha/alpha' catalytic subunits of the enzyme. In contrast, the amount of the noncatalytic beta-subunit remains constant throughout the course of the response. Using both polyclonal antibodies to the holoenzyme and monoclonal antibodies to the alpha/alpha' subunits, we detected a cross-reactive 68-kDa protein, which we refer to as lambda. This protein is present in high abundance in resting T cells but decreases upon cell stimulation, as both MAT activity and the amount of the catalytic alpha/alpha' subunits increase. The decrease in lambda and increase in alpha/alpha' occurs after interleukin-2 production and before DNA synthesis. Lambda virtually disappears when the cells are actively dividing. Several continuous T cell lines (HPB-ALL, MOLT-4, and Jurkat) as well as a freshly isolated T cell leukemia (ALL-2) had no detectable lambda. The K(m) for L-methionine for enzyme from resting peripheral blood mononuclear cells was 19-23-mu-M, which is 3-8-fold higher than purified MAT from fresh leukemic cells or enzyme from Jurkat cells, both of which have a K(m) of 3.5-3.8-mu-M. Kinetic analysis of enzyme activity from activated peripheral blood mononuclear cells suggested the presence of two forms of enzyme catalyzing the synthesis of AdoMet. After separation of lambda from the alpha and beta-subunits by hydrophobic chromatography, it was determined that lambda has MAT activity but that it is significantly less active than the form containing the alpha-subunit. It therefore appears that in resting T cells MAT is sequestered as a less active form. We hypothesize that lambda is a precursor to the catalytic subunits of human lymphocyte MAT and propose that the transition from lambda to alpha/alpha' may be important in the response of T cells to mitogenic signals.	VET ADM MED CTR,RES SERV,1030 JEFFERSON AVE,MEMPHIS,TN 38104; UNIV TENNESSEE CTR HLTH SCI,DEPT SURG,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOCHEM,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; CHOW O, 1972, BIOCHIM BIOPHYS ACTA, V276, P399; DELAROSA J, 1991, BIOCHIM BIOPHYS ACTA, V1077, P225, DOI 10.1016/0167-4838(91)90062-5; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; GERMAN DC, 1983, J BIOL CHEM, V258, P997; GILLIS S, 1978, J IMMUNOL, V120, P2027; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; KOTB M, 1990, J IMMUNOL, V145, P1332; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; KOTB M, 1987, J IMMUNOL, V139, P202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU MC, 1979, CANCER RES, V39, P2113; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; ODEN KL, 1983, BIOCHIM BIOPHYS ACTA, V760, P270, DOI 10.1016/0304-4165(83)90173-3; SAKAMOTO S, 1989, J BIOL CHEM, V264, P251; Segel I.H., 1975, ENZYME KINETICS; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TSUKADA K, 1980, BIOCHEM BIOPH RES CO, V94, P1078, DOI 10.1016/0006-291X(80)90529-X	22	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10699	10704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587846				2022-12-27	WOS:A1992HV09000074
J	ISHIGURO, K; TAKAMATSU, M; TOMIZAWA, K; OMORI, A; TAKAHASHI, M; ARIOKA, M; UCHIDA, T; IMAHORI, K				ISHIGURO, K; TAKAMATSU, M; TOMIZAWA, K; OMORI, A; TAKAHASHI, M; ARIOKA, M; UCHIDA, T; IMAHORI, K			TAU PROTEIN KINASE-I CONVERTS NORMAL TAU PROTEIN INTO A68-LIKE COMPONENT OF PAIRED HELICAL FILAMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-DISEASE; DEPENDENT KINASE; SENSITIVE METHOD; PHOSPHORYLATION; IDENTIFICATION; BRAIN; NEUROFILAMENTS; TANGLES; BINDING; CORE	From bovine brain microtubules we purified tau protein kinase I (TPKI, M(r) 45,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)) and tau protein kinase II (TPKII) whose activity was attributed to a 30-kDa protein on SDS-PAGE by affinity-labeling using an ATP analog. Both kinases were activated by tubulin. TPKII, but not TPKI, phosphorylated tau fragment peptides previously used for detection of a Ser/ThrPro kinase activity. Therefore, TPKII was considered to be the Ser/ThrPro kinase. TPKI was more effective than TPKII for producing the decrease of tau-1 immunoreactivity and mobility shift of tau on SDS-PAGE. Moreover, TPKI, but not TPKII nor other well-known protein kinases, generated an epitope present on paired helical filaments. These findings suggested that tau phosphorylated by TPKI resembled A-68, a component of paired helical filaments.			ISHIGURO, K (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN MP, 1990, J NEUROCHEM, V54, P1548, DOI 10.1111/j.1471-4159.1990.tb01203.x; COLES LS, 1987, J BIOL CHEM, V262, P9656; FLAMENT S, 1989, J NEUROL SCI, V92, P133, DOI 10.1016/0022-510X(89)90131-7; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IHARA Y, 1988, BRAIN RES, V459, P138, DOI 10.1016/0006-8993(88)90293-4; IHARA Y, 1979, J BIOCHEM, V86, P587, DOI 10.1093/oxfordjournals.jbchem.a132560; IIMOTO DS, 1989, BRAIN RES, V507, P273; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ISHIGURO K, 1991, NEUROSCI LETT, V128, P195, DOI 10.1016/0304-3940(91)90259-V; ISHIGURO K, 1988, J BIOCHEM-TOKYO, V104, P319, DOI 10.1093/oxfordjournals.jbchem.a122465; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOODFORD TA, 1986, J BIOL CHEM, V261, P4669; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x	27	249	271	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10897	10901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587865				2022-12-27	WOS:A1992HV09000102
J	LEE, YC; ASA, SL; DRUCKER, DJ				LEE, YC; ASA, SL; DRUCKER, DJ			GLUCAGON GENE 5'-FLANKING SEQUENCES DIRECT EXPRESSION OF SIMIAN VIRUS-40 LARGE T-ANTIGEN TO THE INTESTINE, PRODUCING CARCINOMA OF THE LARGE-BOWEL IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROGLUCAGON CONTAINS; PRE-PROGLUCAGON; PANCREAS; PEPTIDES; BRAIN; ACID; RNA	Glucagon and the glucagon-like peptides play important roles in the regulation of glucose homeostasis. Previous studies have demonstrated that approximately 1300 base pairs of rat glucagon gene 5'-flanking sequences direct transgene expression to the pancreas and brain, but not to the intestine, of transgenic mice. These observations suggested that different tissue-specific enhancer elements mediate activation of glucagon gene transcription in the pancreas and intestine. We have now generated mice that express SV40 large T antigen under the control of approximately 2000 base pairs of glucagon gene 5'-flanking sequences. Transgene expression was observed in the brain and pancreas in association with the development of pancreatic endocrine tumors. In contrast to the mice described previously, we also detected transgene expression throughout the gastrointestinal tract in endocrine cells of the stomach and small and large intestine. Focal areas of enteroendocrine cell hyperplasia in the large bowel invariably progressed to invasive and metastasizing plurihormonal endocrine carcinoma, which was clinically and pathologically evident by 4 weeks of age. In contrast, transgene expression in the small bowel and stomach was not associated with progression to either hyperplasia or carcinoma. The results of these studies provide functional evidence for the existence of an upstream cis-acting regulatory domain that directs glucagon gene transcription to the endocrine cells of the intestine in transgenic mice.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,DEPT GENET,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO M5G 2C4,ONTARIO,CANADA; UNIV TORONTO,BANTING & BEST DIABET CTR,TORONTO M5G 2C4,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto	LEE, YC (corresponding author), UNIV TORONTO,DEPT MED,TORONTO M5G 2C4,ONTARIO,CANADA.		Drucker, Daniel J/A-4092-2010	Asa, Sylvia/0000-0001-8418-5054				ASA SL, 1987, ACTA ENDOCRINOL-COP, V115, P331, DOI 10.1530/acta.0.1150331; BELL GI, 1983, NATURE, V302, P716, DOI 10.1038/302716a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONG J, 1991, IN PRESS MOL ENDOCRI, V5; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; HAN VKM, 1986, J NEUROSCI RES, V16, P97, DOI 10.1002/jnr.490160110; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEINRICH G, 1984, J BIOL CHEM, V259, P4082; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; HOGAN B, 1986, MANIPULATING MOUSE E, P1633; LEE YC, 1990, ENDOCRINOLOGY, V127, P2217, DOI 10.1210/endo-127-5-2217; LOPEZ LC, 1983, P NATL ACAD SCI-BIOL, V80, P5485, DOI 10.1073/pnas.80.18.5485; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; SEINO S, 1986, FEBS LETT, V203, P25, DOI 10.1016/0014-5793(86)81429-6; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991	20	113	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10705	10708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587847				2022-12-27	WOS:A1992HV09000075
J	SWERTS, JP; SOULA, C; SAGOT, Y; GUINAUDY, MJ; GUILLEMOT, JC; FERRARA, P; DUPRAT, AM; COCHARD, P				SWERTS, JP; SOULA, C; SAGOT, Y; GUINAUDY, MJ; GUILLEMOT, JC; FERRARA, P; DUPRAT, AM; COCHARD, P			HEMOPEXIN IS SYNTHESIZED IN PERIPHERAL-NERVES BUT NOT IN CENTRAL-NERVOUS-SYSTEM AND ACCUMULATES AFTER AXOTOMY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT HEPATOCYTES; GENE-EXPRESSION; REGENERATION; HEME; GROWTH; CELLS; DIFFERENTIATION; MATURATION; RECEPTOR	In adult mammals, injured axons regrow over long distances in peripheral nerves but fail to do so in the central nervous system. Analysis of molecular components of tissue environments that allow axonal regrowth revealed a dramatic increase in the level of hemopexin, a heme-transporting protein, in long-term axotomized peripheral nerve. In contrast, hemopexin did not accumulate in lesioned optic nerve. Sciatic nerve and skeletal muscle, but not brain, were shown to be sites of synthesis of hemopexin. Thus, hemopexin expression, which can no longer be considered to be liver-specific, correlates with tissular permissivity for axonal regeneration.	SANOFI ELF BIORECH, UNITE BIOCHIM PROT, F-31328 LABEGE, FRANCE	Sanofi-Aventis	SWERTS, JP (corresponding author), UNIV TOULOUSE 3, INSERM,CNRS,URA 675,CTR BIOL DEV, 118 ROUTE NARBONNE, F-31062 TOULOUSE, FRANCE.			SOULA, Cathy/0000-0002-9027-9994				Aguayo A., 1979, ADV CELL NEUROBIOL, V3, P215; Aguayo A.J., 1985, SYNAPTIC PLASTICITY, P457; ALAM J, 1989, J BIOL CHEM, V264, P17637; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERNARD N, 1983, BIOCHIMIE, V65, P185, DOI 10.1016/S0300-9084(83)80083-2; BERNARD N, 1980, EUR J BIOCHEM, V103, P271, DOI 10.1111/j.1432-1033.1980.tb04311.x; BONYHADY RE, 1982, DEV NEUROSCI-BASEL, V5, P125, DOI 10.1159/000112669; BOSCH EP, 1989, J NEUROSCI, V9, P3690; BUNGE RP, 1988, PROG BRAIN RES, V78, P321; CARBONETTO S, 1988, CURRENT ISSUES NEURA, P147; FAWCETT J W, 1991, Current Biology, V1, P55, DOI 10.1016/0960-9822(91)90129-K; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FUNANAGE VL, 1989, J CELL PHYSIOL, V141, P591, DOI 10.1002/jcp.1041410318; GOLDFARB V, 1986, BIOCHEMISTRY-US, V25, P6555, DOI 10.1021/bi00369a033; GRIENINGER G, 1986, J BIOL CHEM, V261, P5719; GUILLOUZO A, 1984, BIOCHEM BIOPH RES CO, V120, P311, DOI 10.1016/0006-291X(84)91255-5; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; ISHII DN, 1978, NATURE, V274, P372, DOI 10.1038/274372a0; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KATZ NR, 1985, EUR J BIOCHEM, V146, P155, DOI 10.1111/j.1432-1033.1985.tb08632.x; Lander AD, 1990, CURR OPIN CELL BIOL, V2, P907, DOI 10.1016/0955-0674(90)90091-R; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LONDON IM, 1987, ENZYMES, V18, P359; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; LUTTON JD, 1991, P SOC EXP BIOL MED, V196, P260; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; REICHARDT LF, 1988, CURRENT ISSUES NEURA, P119; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SASSA S, 1988, SEMIN HEMATOL, V25, P312; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SMITH GM, 1988, PROG BRAIN RES, V78, P353; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; TAKETANI S, 1990, J BIOL CHEM, V265, P13981; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; WALDMAN SA, 1984, J BIOL CHEM, V259, P4038; WELLNER D, 1988, BIOCHEM BIOPH RES CO, V155, P622, DOI 10.1016/S0006-291X(88)80540-0	46	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10596	10600						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587840				2022-12-27	WOS:A1992HV09000058
J	AGOSTINIS, P; VANLINT, J; SARNO, S; DEWITTE, P; VANDENHEEDE, JR; MERLEVEDE, W				AGOSTINIS, P; VANLINT, J; SARNO, S; DEWITTE, P; VANDENHEEDE, JR; MERLEVEDE, W			RAPID STIMULATION OF SER THR PROTEIN-KINASES FOLLOWING TREATMENT OF SWISS 3T3 CELLS WITH BOMBESIN - INVOLVEMENT OF CASEIN KINASE-2 IN THE SIGNALING PATHWAY OF BOMBESIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; II ACTIVITY; SYNTHETIC PEPTIDES; TYROSINE KINASES; SKELETAL-MUSCLE; PHOSPHORYLATION; IDENTIFICATION; INSULIN; PURIFICATION	Treatment of quiescent Swiss 3T3 mouse fibroblasts with bombesin resulted in a rapid 6-8-fold stimulation of cytosolic Ser/Thr kinase activities toward the S6 Peptide (RRLSSLR), myelin basic protein (MBP), and the G peptide (SPQPSRRGSESSEE). Anion exchange Mono Q chromatography resolved multiple S6 peptide- and G peptide kinase activities and two MBP kinase peaks. Both MBP- and several S6 Peptide kinase peaks could be inactivated by PCS(L) (PP2A2) phosphatase action. This indicates that the bombesin-induced activation of these enzymes is mediated by a Ser/Thr phosPhorylation event. The S6 peptide kinases as well as the two MBP kinases stimulated in response to bombesin are similar to those activated by epidermal growth factor in Swiss 3T3 fibroblasts which suggests that the early events of the signal transduction pathway mediated by these growth factors in Swiss 3T3 cells may converge in the activation of common Ser/Thr kinases. Bombesin, which acts as a sole mitogen for Swiss 3T3 fibroblasts, also Produced a several-fold increase in the kinase activity toward the RRREEESEEE peptide, a specific substrate for CK-2. This kinase activity was heparin-sensitive and also measurable with the G peptide (SPQPSRRGSESSEE) and GS-1 peptide (YRRAAVPPSPSPSLSRHSSPHQSEDEE), which contain consensus sequences for phosphorylation by CK-2. The bombesin-stimulated CK-2 activity could not be measured in whole cytosols but was revealed by the anion exchange chromatography step. The activation of CK-2 was not reversed by PCSL phosphatase action. The implication of CK-2 in the signal transduction pathway of bombesin is discussed.	CATHOLIC UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT FARMACEUT WETENSCHAPPEN,B-3000 LOUVAIN,BELGIUM	KU Leuven; KU Leuven			Agostinis, Patrizia/ABI-1177-2020; Van Lint, Johan/P-9073-2019; Agostinis, Patrizia/AAO-2468-2020	Agostinis, Patrizia/0000-0003-1314-2115; 				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; BASERGA R, 1989, CELL GROWTH DIVISION; BATTEY YF, 1990, P NATL ACAD SCI USA, V88, P395; BRUNATI AM, 1986, FEBS LETT, V206, P59, DOI 10.1016/0014-5793(86)81340-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHESSA G, 1983, EUR J BIOCHEM, V135, P609, DOI 10.1111/j.1432-1033.1983.tb07695.x; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MUNRO J, 1990, BIOCHIM BIOPHYS ACTA, V1054, P225, DOI 10.1016/0167-4889(90)90245-9; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PEREZ M, 1987, EUR J BIOCHEM, V170, P493, DOI 10.1111/j.1432-1033.1987.tb13726.x; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEITZ G, 1989, BIOCHEM BIOPH RES CO, V163, P635, DOI 10.1016/0006-291X(89)92184-0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	52	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9732	9737						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577810				2022-12-27	WOS:A1992HT96500046
J	ELSNER, RH; ZIEGLER, K				ELSNER, RH; ZIEGLER, K			RADIATION INACTIVATION OF MULTISPECIFIC TRANSPORT-SYSTEMS FOR BILE-ACIDS AND XENOBIOTICS IN BASOLATERAL RAT-LIVER PLASMA-MEMBRANE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED HEPATOCYTES; CHOLIC-ACID; COMPETITIVE-INHIBITION; TAUROCHOLATE UPTAKE; NAK-ATPASE; BINDING; PHALLOIDIN; CHOLATE; PROTEINS; COTRANSPORTER	The functional molecular mass of the cholate, phallotoxin, iodipamide, and ouabain transport proteins in isolated basolateral plasma membrane vesicles was determined by radiation inactivation. Purified basolateral plasma membrane vesicles were irradiated (- 90 to - 120-degrees-C) with high energy electrons from a 10-MeV linear accelerator at doses from 0 to 30 megarads. After each dose, the initial uptake, the equilibrium binding, and the binding of the substrates at 4-degrees-C were checked. The size of the transporting function was, for cholate, 107 +/- 8.9 kDa; for phallotoxin, 104 +/- 7 kDa; and for ouabain, 120 +/- 4.7 kDa. The target size for the binding proteins was 56 +/- 4.2, 57 +/- 5, and 47.2 +/- 1.95 kDa for cholate, phallotoxin, and taurocholate, respectively. In the case of iodipamide, the functional molecular mass for both the transport and binding proteins was 54 +/- 4.8 kDa.	UNIV GIESSEN,INST PHARMACOL & TOXIKOL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen								AMES BN, 1960, J BIOL CHEM, V235, P769; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ANWER MS, 1977, H-S Z PHYSIOL CHEM, V358, P543, DOI 10.1515/bchm2.1977.358.1.543; ANWER MS, 1976, H-S Z PHYSIOL CHEM, V357, P1477, DOI 10.1515/bchm2.1976.357.2.1477; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BLITZER BL, 1985, AM J PHYSIOL, V249, pG120, DOI 10.1152/ajpgi.1985.249.1.G120; BLITZER BL, 1986, J BIOL CHEM, V261, P2042; BLITZER BL, 1984, J BIOL CHEM, V259, P9295; CAFLISCH C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P70, DOI 10.1016/0005-2736(90)90386-3; DUFFY MC, 1983, J CLIN INVEST, V72, P1470, DOI 10.1172/JCI111103; ELSNER R, 1989, BIOCHIM BIOPHYS ACTA, V983, P113, DOI 10.1016/0005-2736(89)90387-8; ELSNER RH, 1989, N-S ARCH PHARMACOL, V340, pR69; Fricke H, 1927, AM J ROENTGENOL RADI, V18, P426; FRIMMER M, 1980, N-S ARCH PHARMACOL, V313, P85, DOI 10.1007/BF00505808; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HARPER AE, 1962, METHODEN ENZYMATISCH, P788; INOUE M, 1982, HEPATOLOGY, V2, P572; JUNG CY, 1984, MOL CHEM CHARACTERIZ, P193; KEEFFE EB, 1979, J CLIN INVEST, V64, P1590, DOI 10.1172/JCI109620; KEMPNER ES, 1982, J BIOL CHEM, V257, P13297; KEPNER GR, 1968, BIOCHIM BIOPHYS ACTA, V163, P188, DOI 10.1016/0005-2736(68)90097-7; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; LUTZ F, 1972, N-S ARCH PHARMACOL, V273, P341, DOI 10.1007/BF00499668; MICHELL RH, 1965, BIOCHEM BIOPH RES CO, V21, P333, DOI 10.1016/0006-291X(65)90198-1; PETZINGER E, 1983, N-S ARCH PHARMACOL, V322, P174, DOI 10.1007/BF00512393; PETZINGER E, 1981, N-S ARCH PHARMACOL, V316, P345, DOI 10.1007/BF00501368; PETZINGER E, 1985, BIOCHIM BIOPHYS ACTA, V815, P334, DOI 10.1016/0005-2736(85)90359-1; PETZINGER E, 1986, CARDIAC GLYCOSIDES 1, P297; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SCHWENK M, 1981, N-S ARCH PHARMACOL, V316, P340, DOI 10.1007/BF00501367; STEVENS BR, 1990, P NATL ACAD SCI USA, V87, P1456, DOI 10.1073/pnas.87.4.1456; TAFLER M, 1986, BIOCHIM BIOPHYS ACTA, V855, P157, DOI 10.1016/0005-2736(86)90200-2; TAFLER M, 1988, N-S ARCH PHARMACOL, V337, P231; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; ZIEGLER K, 1982, N-S ARCH PHARMACOL, V319, P254, DOI 10.1007/BF00495875; ZIEGLER K, 1984, BIOCHIM BIOPHYS ACTA, V773, P11, DOI 10.1016/0005-2736(84)90545-5; ZIEGLER K, 1988, BIOCHIM BIOPHYS ACTA, V945, P263, DOI 10.1016/0005-2736(88)90488-9; ZIEGLER K, 1989, BIOCHIM BIOPHYS ACTA, V980, P161, DOI 10.1016/0005-2736(89)90395-7; ZIEGLER K, 1985, BIOCHIM BIOPHYS ACTA, V845, P86, DOI 10.1016/0167-4889(85)90058-8; ZIMMERLI B, 1989, J PHARMACOL EXP THER, V250, P301	42	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9788	9793						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577813				2022-12-27	WOS:A1992HT96500055
J	MCMASTER, CR; CHOY, PC				MCMASTER, CR; CHOY, PC			SERINE REGULATES PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS IN THE HAMSTER HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; RAT-LIVER; PHOSPHATIDYLCHOLINE; ETHANOLAMINE; ENZYMES; CELLS; PURIFICATION; PATHWAYS	The role of serine as a precursor and metabolic regulator for phosphatidylethanolamine biosynthesis in the hamster heart was investigated. Hearts were perfused with 50-mu-M [1-H-3]ethanolamine in the presence or absence of serine for up to 60 min. Ethanolamine uptake was attenuated by 0.05-10 mM serine in a noncompetitive manner, and the incorporation of labeled ethanolamine into phosphatidylethanolamine was also inhibited by serine. Analysis of the ethanolamine-containing metabolites in the CDP-ethanolamine pathway revealed that the conversion of ethanolamine to phosphoethanolamine was reduced. The reduction was a result of an inhibition of ethanolamine kinase activity by an elevated pool of intracellular serine. Perfusion of the heart with 1 mM serine caused a 5-fold increase in intracellular serine pool. In order to examine the action of serine on other phosphatidylethanolamine metabolic pathways, hearts were perfused with [1-H-3]glycerol in the presence and absence of serine. Serine did not cause any enhancement of phosphatidylethanolamine hydrolysis. The base-exchange reaction for phosphatidylserine formation or the decarboxylation of phosphatidylserine was not affected by serine perfusion. We conclude that circulating serine plays an important role in the modulation of phosphatidylethanolamine biosynthesis via the CDP-ethanolamine pathway in the hamster heart but does not affect the contribution of the decarboxylase pathway for phosphatidylethanolamine formation.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,770 BANNATYNE AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba				McMaster, Christopher/0000-0003-0822-5776				ARTHUR G, 1991, BIOCHEM J, V273, P121, DOI 10.1042/bj2730121; BABA S, 1984, CLIN CHIM ACTA, V136, P49, DOI 10.1016/0009-8981(84)90246-8; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CAO YZ, 1987, J BIOL CHEM, V262, P16927; EXTON JH, 1990, J BIOL CHEM, V265, P1; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; KATZ AM, 1982, AM HEART J, V102, P491; KUGE O, 1986, J BIOL CHEM, V261, P5795; LIPTON BA, 1990, J BIOL CHEM, V265, P7195; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAN RYK, 1982, J MOL CELL CARDIOL, V14, P173, DOI 10.1016/0022-2828(82)90115-8; MCMASTER CR, 1992, IN PRESS BIOCH BIOPH; MILAKOFSKY L, 1985, LIFE SCI, V36, P753, DOI 10.1016/0024-3205(85)90195-X; MILLER MA, 1986, J BIOL CHEM, V261, P9753; O KM, 1989, BIOCHEM CELL BIOL, V67, P680; PERRY TL, 1975, J NEUROCHEM, V24, P587, DOI 10.1111/j.1471-4159.1975.tb07680.x; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SIMELL O, 1989, METABOLIC BASIS INHE, P2497; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; SWEELEY CC, 1969, METHOD ENZYMOL, V14, P254; TALLAN HH, 1954, J BIOL CHEM, V211, P927; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P242; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5153; WESTALL RG, 1962, AMINO ACID POOLS, P195; XU ZL, 1991, J BIOL CHEM, V266, P2143; YOREK MA, 1985, J BIOL CHEM, V260, P2930; ZELINSKI TA, 1982, J BIOL CHEM, V257, P13201; ZELINSKI TA, 1982, CAN J BIOCHEM CELL B, V60, P817, DOI 10.1139/o82-102	32	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14586	14591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634506				2022-12-27	WOS:A1992JF08800017
J	OSTEROP, APRM; MEDEMA, RH; BOS, JL; VONDERZON, GCM; MOLLER, DE; FLIER, JS; MOLLER, W; MAASSEN, JA				OSTEROP, APRM; MEDEMA, RH; BOS, JL; VONDERZON, GCM; MOLLER, DE; FLIER, JS; MOLLER, W; MAASSEN, JA			RELATION BETWEEN THE INSULIN-RECEPTOR NUMBER IN CELLS, AUTOPHOSPHORYLATION AND INSULIN-STIMULATED RAS-BULLET-GTP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PDGF BETA-RECEPTOR; GLUCOSE-TRANSPORT; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; PROTEIN; GAP; ONCOGENES; PHOSPHORYLATION; ACTIVATION	We showed previously that upon insulin stimulation of an insulin receptor overexpressing cell line, most of the p21ras was rapidly converted into the GTP bound state (Burgering, B. M. T., Medema, R. H., Maassen, J. A., Van de Wetering, M. L., Van der Eb, A. J., McCormick, F., and Bos, J. L. (1991) EMBO J. 10, 1103-1109). To determine whether this process also occurs in cells expressing physiologically relevant numbers of insulin receptors, insulin stimulated Ras . GTP formation was quantitated in Chinese hamster ovary (CHO)-derived cell lines expressing varying numbers of insulin receptors. In the parental CHO9 cells, expressing only 5.10(3) insulin receptors, insulin stimulation for 3 min increased Ras . GTP levels with 10%. Upon increasing the number of insulin receptors in these cells, Ras . GTP levels increased almost proportionally until a plateau value of 60% is reached at high receptor numbers. These data show that receptor overexpression is not a prerequisite for insulin-stimulated Ras . GTP formation. The yield of Ras . GTP generated is 0.2-1.0 mol/mol autophosphorylated insulin receptor in CHO9- and NIH3T3-derived cell lines, respectively. These values argue against signal-amplifying processes between the insulin receptor and p21ras. To determine whether receptor autophosphorylation is required for Ras . GTP formation, NIH3T3 cells overexpressing insulin receptors were stimulated with a monoclonal antibody which activates the receptor and subsequent glucose transport without inducing detectable autophosphorylation. Also, CHO cells expressing the mutant Ser1200 receptor, which has markedly impaired tyrosyl autophosphorylation but is capable of mediating insulin-stimulated metabolic effects in CHO cells, were used. In both cases, no Ras . GTP formation was observed. Furthermore, Rat-1-derived cell lines expressing mutant p21ras, which is permanently in the active GTP-bound form, still responded to insulin by increasing the glucose uptake. These results support our hypothesis that Ras . GTP formation is activated by the tyrosyl-phosphorylated insulin receptor and suggest that an active Ras . GTP complex does not mediate metabolic signaling.	SYLVIUS LAB,PROT SYNTH & HORMONE REGULAT LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS; UNIV UTRECHT,PHYSIOL CHEM LAB,3521 GG UTRECHT,NETHERLANDS; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215	Leiden University; Leiden University - Excl LUMC; Utrecht University; Harvard University; Beth Israel Deaconess Medical Center			Flier, jeffrey/AAG-6223-2019	Medema, Rene/0000-0002-6754-0381				AKEDO H, 1962, J BIOL CHEM, V237, P118; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUMM AF, 1956, J BIOL CHEM, V220, P713; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FORSAYETH JR, 1987, P NATL ACAD SCI USA, V84, P3448, DOI 10.1073/pnas.84.10.3448; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; MAASSEN JA, 1988, EUR J BIOCHEM, V172, P725, DOI 10.1111/j.1432-1033.1988.tb13949.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER DS, 1989, J BIOL CHEM, V264, P10438; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	37	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14647	14653						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634512				2022-12-27	WOS:A1992JF08800026
J	RUSSO, FD; SILHAVY, TJ				RUSSO, FD; SILHAVY, TJ			ALPHA - THE CINDERELLA SUBUNIT OF RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LATE-GENE-EXPRESSION; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; RPOA MUTATION; TRANSCRIPTION; IDENTIFICATION; IMPAIRS; ALLELE; ENVZ; OMPR				RUSSO, FD (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Silhavy, Thomas/0000-0001-7672-5153				ADHYA S, 1990, J BIOL CHEM, V265, P10797; CHRISTIE GE, 1986, P NATL ACAD SCI USA, V83, P3238, DOI 10.1073/pnas.83.10.3238; FUJIKI H, 1976, MOL GEN GENET, V145, P19, DOI 10.1007/BF00331552; GARRETT S, 1987, J BACTERIOL, V169, P1379, DOI 10.1128/jb.169.4.1379-1385.1987; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V1, P93; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HALLING C, 1990, J BACTERIOL, V172, P3541, DOI 10.1128/jb.172.7.3541-3548.1990; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Ishihama A, 1981, Adv Biophys, V14, P1; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; LOMBARDO MJ, 1991, J BACTERIOL, V173, P7511, DOI 10.1128/jb.173.23.7511-7518.1991; MAGASANIK B, 1989, New Biologist, V1, P247; MATSUYAMA S, 1987, J MOL BIOL, V195, P847, DOI 10.1016/0022-2836(87)90489-X; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROWLAND GC, 1985, J BACTERIOL, V164, P972, DOI 10.1128/JB.164.2.972-975.1985; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; THOMAS MS, 1991, MOL MICROBIOL, V5, P2719, DOI 10.1111/j.1365-2958.1991.tb01980.x; VENEZIA ND, 1990, J BIOL CHEM, V265, P8122	24	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14515	14518						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634503				2022-12-27	WOS:A1992JF08800001
J	MIURA, S; KASUYAARAI, I; MORI, H; MIYAZAWA, S; OSUMI, T; HASHIMOTO, T; FUJIKI, Y				MIURA, S; KASUYAARAI, I; MORI, H; MIYAZAWA, S; OSUMI, T; HASHIMOTO, T; FUJIKI, Y			CARBOXYL-TERMINAL CONSENSUS SER-LYS-LEU-RELATED TRIPEPTIDE OF PEROXISOMAL PROTEINS FUNCTIONS INVITRO AS A MINIMAL PEROXISOME-TARGETING SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; AMINO-ACID OXIDASE; MITOCHONDRIAL PRECURSOR PROTEINS; COMPLETE NUCLEOTIDE-SEQUENCE; STEROL CARRIER PROTEIN-2; COENZYME-A OXIDASE; RAT-LIVER; MOLECULAR-CLONING; MALATE SYNTHASE; SACCHAROMYCES-CEREVISIAE	The minimal sequence requirement for a peroxisome-targeting signal was investigated using an in vitro import system. Carboxyl-terminal sequences Ser-Lys-Leu (SKL) and Leu-Gln-Ser-Lys-Leu (LQSKL) of acyl-CoA oxidase (AOX) directed to peroxisomes the fused proteins with import-incompetent forms of AOX and catalase that had been truncated, implying that the SKL tripeptide functions as a targeting signal. Elimination of the entire SKL sequence or deletion of any 1 or 2 amino acids in the sequence abolished the import activity of AOX. Substitution of alanine for serine did not affect the import activity. Topogenic activity was retained when lysine was mutated to either arginine or histidine, whereas mutation to glutamic acid completely abolished the activity. A synthetic peptide comprising the carboxyl-terminal 10 amino acid residues of AOX inhibited the import of the authentic AOX polypeptide, whereas other peptides in which SKL was mutated, deleted, or internally located were not effective. The uptake of AOX was little affected by the peptide with an amidated alpha-carboxyl group. These results strongly suggest that the carboxyl-terminal SKL motif sequence (Ser/Ala)-(Lys/Arg/His)-Leu functions as a topogenic signal in translocation of proteins into peroxisomes, requiring the whole tripeptide sequence with a free alpha-COOH group at the carboxyl terminus.	MEIJI INST HLTH SCI, MOLEC CELL BIOL LAB, ODAWARA 250, JAPAN; SHINSHU UNIV, SCH MED, DEPT BIOCHEM, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University								AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; CHU TW, 1989, J BIOL CHEM, V264, P9552; COMAI L, 1989, J BIOL CHEM, V264, P2778; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FUJIKI Y, 1985, J BIOL CHEM, V260, P5603; FURUTA S, 1982, J BIOCHEM, V92, P319, DOI 10.1093/oxfordjournals.jbchem.a133937; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; FURUYA S, 1987, J BIOCHEM, V102, P821, DOI 10.1093/oxfordjournals.jbchem.a122121; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KAMIRYO T, 1989, AGR BIOL CHEM TOKYO, V53, P179, DOI 10.1080/00021369.1989.10869248; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; MITCHELL AR, 1978, J ORG CHEM, V43, P2845, DOI 10.1021/jo00408a022; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOMOI K, 1988, FEBS LETT, V238, P180, DOI 10.1016/0014-5793(88)80252-7; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI H, 1991, EUR J BIOCHEM, V197, P331, DOI 10.1111/j.1432-1033.1991.tb15915.x; MORI M, 1981, J BIOL CHEM, V256, P4127; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; MORRIS HR, 1988, BIOCHEM BIOPH RES CO, V154, P476, DOI 10.1016/0006-291X(88)90711-5; MOTOJIMA K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P116, DOI 10.1016/0167-4781(89)90178-4; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NGUYEN T, 1985, P NATL ACAD SCI USA, V82, P5040, DOI 10.1073/pnas.82.15.5040; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1990, BIOESSAYS, V12, P217, DOI 10.1002/bies.950120505; OSUMI T, 1985, J BIOL CHEM, V260, P8905; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1991, J BIOL CHEM, V266, P11882; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; REDDY PG, 1988, P NATL ACAD SCI USA, V85, P9081, DOI 10.1073/pnas.85.23.9081; RONCHI S, 1982, J BIOL CHEM, V257, P8824; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SMALL GM, 1988, EMBO J, V7, P1167, DOI 10.1002/j.1460-2075.1988.tb02927.x; SMITH SM, 1986, PLANT PHYSIOL, V81, P762, DOI 10.1104/pp.81.3.762; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SWINKELS BW, 1988, EMBO J, V7, P1159, DOI 10.1002/j.1460-2075.1988.tb02926.x; TADA M, 1990, GENE, V90, P293, DOI 10.1016/0378-1119(90)90193-U; TAM JP, 1986, J AM CHEM SOC, V108, P5242, DOI 10.1021/ja00277a031; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510; TURLEY RB, 1990, NUCLEIC ACIDS RES, V18, P3643, DOI 10.1093/nar/18.12.3643; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	70	114	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14405	14411						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629226				2022-12-27	WOS:A1992JD32500093
J	WANG, ZY; LIN, XH; NOBYUOSHI, M; QIU, QQ; DEUEL, TF				WANG, ZY; LIN, XH; NOBYUOSHI, M; QIU, QQ; DEUEL, TF			BINDING OF SINGLE-STRANDED OLIGONUCLEOTIDES TO A NON-B-FORM DNA-STRUCTURE RESULTS IN LOSS OF PROMOTOR ACTIVITY OF THE PLATELET-DERIVED GROWTH FACTOR-A-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; NUCLEASE; TRANSCRIPTION; SITE; CHROMATIN; REGIONS; CELLS; CONFORMATION; CLEAVAGE; CHICKEN	Levels of expression of the platelet-derived growth factor (PDGF) A-chain gene differ significantly in normal and transformed cells. We have identified an S1 nuclease-sensitive site in a GC box located at -55 to -72 in the PDGF A-chain promoter region. We now demonstrate that a 24-base, G-rich complementary oligonucleotide anneals specifically to the C-rich strand of the GC box and protects the GC box from nicking by S1 nuclease whereas the C-rich complementary oligonucleotide and its double-stranded counterpart do not. In transient transfection assays, expression of the PDGF A-chain gene is sharply reduced by deletions within the GC box or if the 24-base G-rich complementary oligonucleotide is preincubated with the promoter construct prior to transfection. The data suggest that the GC box of the PDGF A-chain gene may promote a non-B-form DNA structure, which is recognized by S1 nuclease and which anneals to a short complementary G-rich oligonucleotide. The data also suggest that this non-B-form DNA is important for efficient transcription of PDGF A-chain gene.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT BIOCHEM MOLEC BIOPHYS,216 S KINGSHIGHWAY,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031102, P50HL014147, R37HL031102] Funding Source: NIH RePORTER; NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; CHRISTY BA, 1988, P NATL ACAD SCI USA, V86, P8737; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DYAN WS, 1985, NATURE, V316, P774; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; EVANS T, 1984, NUCLEIC ACIDS RES, V12, P8043, DOI 10.1093/nar/12.21.8043; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KOHWI Y, 1988, P NATL ACAD SCI USA, V84, P2223; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM K, 1989, BIOTECHNIQUES, V7, P576; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NICKOL JM, 1983, CELL, V35, P467, DOI 10.1016/0092-8674(83)90180-0; SETA FD, 1988, J BIOL CHEM, V263, P15888; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YU YT, 1986, CELL, V45, P743, DOI 10.1016/0092-8674(86)90788-9	30	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13669	13674						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618866				2022-12-27	WOS:A1992JB74600090
J	FATTAL, PG; SCHNEIDER, DJ; SOBEL, BE; BILLADELLO, JJ				FATTAL, PG; SCHNEIDER, DJ; SOBEL, BE; BILLADELLO, JJ			POSTTRANSCRIPTIONAL REGULATION OF EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 MESSENGER-RNA BY INSULIN AND INSULIN-LIKE GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-I; PLASMA-INSULIN; IGF-I; CELLS; GENE; RAT; SEQUENCES; HYPERINSULINEMIA; STIMULATION; TRANSLATION	In humans and non-human primates, alternative cleavage and polyadenylation of plasminogen activator inhibitor type-1 (PAI-1) pre-mRNA transcripts results in two forms of mature mRNA, an unstable 3.2-kilo-base (kb) form, and a relatively more stable 2.2-kb form. Insulin and insulin-like growth factor I (IGF-1) increase steady state levels of PAI-1 mRNA in Hep G2 cells independently and synergistically. In the present study we found that the rate of transcription of the PAI-1 gene is not affected by insulin, IGF-1, or both but that insulin prolongs the half-life of the 3.2-kb PAI-1 mRNA species 2.7-fold without affecting the half-life of the 2.2-kb species. In contrast IGF-1, alone or with insulin, markedly prolongs the half-lives of both species. Our results demonstrate a novel mechanism of regulation of expression of the PAI-I gene by insulin and IGF-1 operating at the post-transcriptional level.			FATTAL, PG (corresponding author), WASHINGTON UNIV, SCH MED, DIV CARDIOVASC, BOX 8086, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Schneider, David/AAQ-4970-2021	Schneider, David/0000-0002-2751-6870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, R01HL038868, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646, HL38868] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADASHI EY, 1985, ENDOCRINOLOGY, V116, P2135, DOI 10.1210/endo-116-6-2135; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DAMANTE G, 1988, BIOCHEM BIOPH RES CO, V151, P1194, DOI 10.1016/S0006-291X(88)80492-3; DEUTSCH E, 1965, THROMBOSIS ANTICOAGU, P128; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII S, 1990, THROMB HAEMOSTASIS, V64, P412; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HOPKINS WE, 1991, NUCLEIC ACIDS RES, V19, P163, DOI 10.1093/nar/19.1.163; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; JUHANVAGUE I, 1987, DIABETES METAB, V13, P331; JUHANVAGUE I, 1989, ARTERIOSCLEROSIS, V9, P362, DOI 10.1161/01.ATV.9.3.362; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; LUCORE CL, 1988, CIRCULATION, V77, P660, DOI 10.1161/01.CIR.77.3.660; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCQUILLAN DJ, 1986, BIOCHEM J, V240, P423, DOI 10.1042/bj2400423; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; OSBORN L, 1988, J BIOL CHEM, V263, P16519; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PANREKOEK H, 1986, EMBO J, V9, P2539; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RASMUSSEN SM, 1975, DIABETOLOGIA, V11, P151; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; SPRENGERS ED, 1987, BLOOD, V69, P381; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; THIEBAUD D, 1990, J BONE MINER RES, V5, P761; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WERNER H, 1991, INSULIN LIKE GROWTH, P17; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WUN TC, 1987, FEBS LETT, V210, P11, DOI 10.1016/0014-5793(87)81288-7; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; ZAPF J, 1984, CLIN ENDOCRINOL META, V13, P3, DOI 10.1016/S0300-595X(84)80006-7	54	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12412	12415						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618746				2022-12-27	WOS:A1992HZ48300006
J	BHATTACHARJEE, H; BHADURI, A				BHATTACHARJEE, H; BHADURI, A			DISTINCT FUNCTIONAL ROLES OF 2 ACTIVE-SITE THIOLS IN UDPGLUCOSE 4-EPIMERASE FROM KLUYVEROMYCES-FRAGILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GALACTOSE 4-EPIMERASE; SUBSTRATE; MECHANISM; REDUCTION; REAGENT; ENZYME	UDPglucose 4-epimerase from Kluyveromyces fragilis was earlier shown to have two conformationally vicinal thiols at the active site. Upon treatment with diamide, these thiols form a disulfide linkage across the subunits that results in coordinated loss of catalytic activity and coenzyme fluorescence (Ray, M., and Bhaduri, A. (1980) J. Biol. Chem. 255, 10777-10786). Employing a number of thiol-specific reagents, we now suggest discriminatory and nonidentical roles for these two thiols. Kinetic and statistical analysis of 5,5'-dithiobis-(2-nitrobenzoic acid) and N-ethylmaleimide modification reaction of epimerase show that only one thiol is essential for activity. Consecutive modification experiments clearly show that the same active thiol is modified in both cases. However, significant differences are observed when the reactivity of these reagents is monitored in terms of coenzyme fluorescence. Treatment with N-ethylmaleimide leads to a form of inactive enzyme that fully retains its fluorescent properties whereas modification with 5,5'-dithiobis-(2-nitrobenzoic acid), on the other hand, results in the loss of both activity and fluorescence. The closely spaced nonessential second thiol, which is not modified by N-ethylmaleimide is therefore involved in generating and maintaining the coenzyme fluorescence. Modification studies with a series of spin-labeled maleimide shows that only 3-(maleimidomethyl)proxyl causes partial quenching of coenzyme fluorescence. This suggests that the active thiol is situated at a distance of 4.5 angstrom approximately from the coenzyme fluorophore.			BHATTACHARJEE, H (corresponding author), INDIAN INST CHEM BIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ADAIR WL, 1973, J BIOL CHEM, V248, P4635; ARABSHAHI A, 1988, J BIOL CHEM, V263, P2638; BAUER AJ, 1991, PROTEINS, V9, P135, DOI 10.1002/prot.340090207; Berliner L J, 1978, Methods Enzymol, V49, P418; BERTLAND AU, 1970, BIOCHEMISTRY-US, V9, P4649, DOI 10.1021/bi00826a005; BERTLAND LH, 1971, BIOCHEMISTRY-US, V10, P3145, DOI 10.1021/bi00792a025; Branden C.-I., 1975, ENZYMES, V11, P103; CARLSON GM, 1978, BIOCHEMISTRY-US, V17, P5329, DOI 10.1021/bi00618a002; CREVELING CR, 1965, BIOCHEM BIOPH RES CO, V21, P624, DOI 10.1016/0006-291X(65)90532-2; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLENTKE GR, 1990, BIOCHEMISTRY-US, V29, P2430, DOI 10.1021/bi00461a029; FLUHARTY AL, 1961, J BIOL CHEM, V236, P2772; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GABRIEL O, 1975, SUBUNIT ENZYMES BIOC, P85; HANKER JS, 1957, ANAL CHEM, V29, P879, DOI 10.1021/ac60126a005; HARRIS JI, 1976, ENZYMES, V13, P1; Holbrook JJ., 1975, ENZYMES, P191; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; KAPLAN NO, 1951, J BIOL CHEM, V191, P461; LEVY HM, 1963, J BIOL CHEM, V238, P3654; MAITRA US, 1971, P NATL ACAD SCI USA, V68, P2660, DOI 10.1073/pnas.68.11.2660; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MAXWELL ES, 1958, ARCH BIOCHEM BIOPHYS, V78, P407, DOI 10.1016/0003-9861(58)90366-7; MORRISETT JD, 1975, J BIOL CHEM, V250, P2487; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; RAY M, 1980, J BIOL CHEM, V255, P777; RAY M, 1980, J BIOL CHEM, V255, P782; RAY M, 1978, BIOCHIM BIOPHYS ACTA, V526, P635, DOI 10.1016/0005-2744(78)90154-7; RAY WJ, 1962, J BIOL CHEM, V237, P2493; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SAMANTA AK, 1982, BIOCHIM BIOPHYS ACTA, V707, P129, DOI 10.1016/0167-4838(82)90405-8; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TSOU C, 1962, SCI SINICA, V11, P1535; UDENFRIEND S, 1962, FLUORESCENCE ASSAY B, V1, P249; UDENFRIEND S, 1969, FLUORESCENCE ASSAY B, V2, P253; WEE TG, 1973, J BIOL CHEM, V248, P33; WU CW, 1976, BIOCHEMISTRY-US, V15, P2863, DOI 10.1021/bi00658a025	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11714	11720						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601848				2022-12-27	WOS:A1992HY94700014
J	LIU, ML; OLSON, AL; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE				LIU, ML; OLSON, AL; MOYEROWLEY, WS; BUSE, JB; BELL, GI; PESSIN, JE			EXPRESSION AND REGULATION OF THE HUMAN GLUT4/MUSCLE-FAT FACILITATIVE GLUCOSE TRANSPORTER GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INSULIN-RESPONSIVE TISSUES; ADIPOSE-CELLS; MESSENGER-RNA; PROTEIN; ENHANCER; EFFICIENT; PROMOTER; CLONING; MUSCLE; INVIVO	To study the molecular basis of tissue-specific expression of the GLUT4/muscle-fat facilitative glucose transporter gene, we generated lines of transgenic mice carrying 2.4 kilobases of the 5'-flanking region of the human GLUT4 gene fused to a chloramphenicol acetyltransferase (CAT) reporter gene (hGLUT4[2.4]-CAT). This reporter gene construct was specifically expressed in tissues that normally express GLUT4 mRNA, which include both brown and white adipose tissues as well as cardiac, skeletal, and smooth muscle. In contrast, CAT reporter activity was not detected in brain or liver, two tissues that do not express the GLUT4 gene. In addition, the relative levels of CAT mRNA driven by the human GLUT4 promoter in various tissues of these transgenic animals mirrored those of the endogenous mouse GLUT4 mRNA. Since previous studies have observed alterations in GLUT4 mRNA levels induced by fasting and refeeding (Sivitz, W. I., DeSautel, S. L., Kayano, T., Bell, G. I., and Pessin, J. E. (1989) Nature 340, 72-74), the regulated expression the hGLUT4[2.4]-CAT transgene was also assessed in these animals. Fasting was observed to decrease CAT activity in white adipose tissue which was super-induced upon refeeding. These alterations in CAT expression occurred in parallel to the changes in endogenous mouse GLUT4 mRNA levels. Although CAT expression in skeletal muscle and brown adipose tissue was unaffected, the endogenous mouse GLUT4 mRNA was also refractory to the effects of fasting/refeeding in these tissues. These data demonstrate that 2.4 kilobases of the 5'-flanking region of the human GLUT4 gene contain all the necessary sequence elements to confer tissue-specific expression and at least some of the sequence elements controlling the hormonal/metabolic regulation of this gene.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Iowa; Howard Hughes Medical Institute; University of Chicago; University of Chicago			Buse, John Bernard/J-9742-2019; Moye-Rowley, Scott/AFL-7135-2022	Buse, John Bernard/0000-0002-9723-3876; Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001822, R01DK042452] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25925, DK01822, DK42452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sambrook J, 1989, MOL CLONING LABORATO; SINHA MK, 1991, DIABETES, V40, P473; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0	28	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11673	11676						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601840				2022-12-27	WOS:A1992HY94700004
J	MORRISON, BW; LEDER, P				MORRISON, BW; LEDER, P			A RECEPTOR-BINDING DOMAIN OF MOUSE INTERLEUKIN-4 DEFINED BY A SOLID-PHASE BINDING ASSAY AND INVITRO MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; EXPRESSES B-CELL; T-CELL; CDNA CLONE; PROTEINS; IL-4; SEQUENCE; INVIVO; LIGAND; MUTANT	Interleukin 4 (IL-4) is a Potent, pleiotropic lymphokine that affects a variety of cells, especially those of hematopoietic origin. Although murine and human IL-4 are homologous proteins, they display a species specificity in which murine IL-4 acts only upon mouse cells, and human IL-4 only upon human cells. We have used a mutagenesis strategy to define both the structural determinants of this specificity and a receptor binding domain of murine IL-4. To do this, we developed convenient solid-phase binding assays for mouse and for human IL-4, each utilizing receptor-immunoglobulin fusion proteins and alkaline phosphatase-tagged ligands. These were employed to assess the receptor binding activities of wild type and mutant forms of IL-4. In a separate biological assay, we measured the ability of each version of IL-4 to induce proliferation of a cultured mouse T-cell line. By replacing regions of mouse IL-4 with homologous segments of human IL-4, we found that the amino-terminal 16 residues and the carboxyl-terminal 20 residues of murine IL-4 are required for species-specific receptor binding as well as for T-cell proliferation. A major portion of the amino acid sequence between these regions can be substituted between mouse and human without loss of receptor binding or biological activity. Further, alanine-scanning mutagenesis revealed specific residues in the amino- and carboxyl-terminal regions (Glu-12, Ile-14, Leu-104, Asp-106, Phe-107, and Leu-111) that bear side chains critical for function. An analysis of the carboxyl-terminal region of murine IL-4 and its comparison with carboxyl-terminal regions of other related cytokines suggest an evolutionary conservation of structural and functional features.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED ONCOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [T32CA009172] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LE HV, 1991, BIOCHEMISTRY-US, V30, P9576, DOI 10.1021/bi00104a003; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1991, BLOOD, V77, P1859; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	39	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11957	11963						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601864				2022-12-27	WOS:A1992HY94700047
J	SHIRATAKI, H; KAIBUCHI, K; YAMAGUCHI, T; WADA, K; HORIUCHI, H; TAKAI, Y				SHIRATAKI, H; KAIBUCHI, K; YAMAGUCHI, T; WADA, K; HORIUCHI, H; TAKAI, Y			A POSSIBLE TARGET PROTEIN FOR SMG-25A/RAB3A SMALL GTP-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN CYTOSOL; AFFECT ONCOGENIC MUTANTS; RAS P21 GTPASE; REGULATORY PROTEIN; SMG P25A; SUBSEQUENT BINDING; PURIFICATION; DISSOCIATION; GDP; MEMBRANES	The smg-25A/rab3A protein (smg p25A) is a small GTP-binding protein implicated in intracellular vesicle traffic, particularly in neurotransmitter release from the presynapse. In the present study, we attempted to identify a target protein in bovine brain crude membranes that might be interacted with the GTP-bound form of smg p25A. When the guanosine-5'-(3-O-thio)triphosphate (GTP-gamma-S)-bound form of radioiodinated smg p25A and the crude membrane fraction of bovine brain were incubated with a cross-linker, disuccinimidyl suberate, and the sample was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by autoradiography, one radioactive band with a M(r) of about 110,000 was detected. This radioactive band appeared to be composed of radioiodinated smg p25A and a molecule with a M(r) of about 86,000. This molecule, tentatively termed here smg p25A target, was extracted from the membranes by a detergent and highly purified by column chromatographies and sucrose density gradient ultracentrifugation. The purified smg p25A target was sensitive to heat boiling and tryptic digestion, indicating that smg p25A target is a protein molecule. The M(r) of the purified smg p25A target was estimated to be about 85,000-86,000 from SDS-PAGE and to be about 100,000 from the S value. The cross-linking of radioiodinated smg p25A with the purified smg p25A target was inhibited by the GTP-gamma-S-bound form of non-radioactive smg p25A with an IC50 of about 8 nm. The GDP-bound form of smg p25A was much less effective. Other small GTP-binding proteins, such as c-Ki-ras p21, rhoA p21, smg p21B, and rab11 p24 were ineffective. These results indicate that a protein with a M(r) of about 85,000-100,000 is a target for smg p25A.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HART MJ, 1991, J BIOL CHEM, V266, P20840; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; SASAKI T, 1990, J BIOL CHEM, V265, P2333; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	22	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10946	10949						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597436				2022-12-27	WOS:A1992HX16900005
J	HRYCYNA, CA; CLARKE, S				HRYCYNA, CA; CLARKE, S			MATURATION OF ISOPRENYLATED PROTEINS IN SACCHAROMYCES-CEREVISIAE - MULTIPLE ACTIVITIES CATALYZE THE CLEAVAGE OF THE 3 CARBOXYL-TERMINAL AMINO-ACIDS FROM FARNESYLATED SUBSTRATES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; METHYL-ESTER; A-FACTOR; SEQUENCE DETERMINATION; CYSTEINE; YEAST; GENE; METHYLTRANSFERASE; IDENTIFICATION; PHEROMONE	Eukaryotic polypeptides containing COOH-terminal -CXXX sequences can be posttranslationally modified by isoprenylation of the cysteine residue via a thioether linkage, proteolytic removal of the three terminal amino acids, and alpha-carboxyl methylation of the cysteine residue. Through the development of an indirect coupled assay, we have identified three in vitro activities in the yeast Saccharomyces cerevisiae that can catalyze the proteolytic cleavage of the three COOH-terminal amino acids of the synthetic peptide substrate N-acetyl-KSKTK[S-farnesyl-Cys]VIM. One of these is the vacuolar protease carboxypeptidase Y. Using a mutant strain deficient in this enzyme, we find evidence for an additional soluble activity as well as for a membrane-associated activity. These latter activities are candidates for roles in the physiological processing of isoprenylated protein precursors. They are both insensitive to inhibitors of serine and aspartyl proteinases but are sensitive to sulfhydryl reagents and 0.5 mm ZnCl2. The soluble activity appears to be a metalloenzyme, inhibitable by 2 mm o-phenanthroline but not by 1 mm N-ethylmaleimide, whereas the membrane-associated enzyme is inhibitable by 1 mm N-ethylmaleimide but not 2 mm o-phenanthroline. We show that the membrane-bound protease is not an activity of the membrane-bound methyltransferase, because protease activity is observed in membrane preparations that lack the STE14-encoded methyltransferase. The soluble activity appears to be a novel carboxypeptidase of approximately 1 10 kDa that catalyzes a processive removal of amino acids from the COOH terminus from both the farnesylated and non-farnesylated substrate, but not from three other unrelated peptides. Finally, we find no evidence for non-vacuolar membrane or soluble activities that catalyze the ester hydrolysis of N-acetyl-S-farnesyl-L-cysteine methyl ester.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	HRYCYNA, CA (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07185, GM-26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1992, IN PRESS P NATL ACAD, V89; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DER CJ, 1991, CANCER CELL, V3, P1; FAGAN JM, 1991, BIOCHEM J, V277, P779, DOI 10.1042/bj2770779; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FOLK JE, 1960, J BIOL CHEM, V235, P2272; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GILBERT JM, 1988, BIOCHEMISTRY-US, V27, P5227, DOI 10.1021/bi00414a042; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HEIKKILA RE, 1976, ANAL BIOCHEM, V75, P356, DOI 10.1016/0003-2697(76)90089-0; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JOHNSON DI, 1991, GENE, V98, P149, DOI 10.1016/0378-1119(91)90119-V; JOHNSON DI, 1991, GENE, V90, P93; JOLY A, 1991, J BIOL CHEM, V266, P13495; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; JONES EW, 1991, J BIOL CHEM, V266, P7963; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; OHYA Y, 1991, J BIOL CHEM, V266, P12356; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OTA IM, 1989, J BIOL CHEM, V264, P12879; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; PFEIFER R, 1983, AM LAB, V15, P78; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RINE J, 1990, New Biologist, V2, P219; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STACHELEK C, 1986, NUCLEIC ACIDS RES, V14, P945, DOI 10.1093/nar/14.2.945; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; STEPHENSON RC, 1992, IN PRESS J BIOL CHEM, V267; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VENKATASUBRAMANIAN K, 1980, MOL IMMUNOL, V17, P201, DOI 10.1016/0161-5890(80)90072-3; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WOLF DH, 1986, MICROBIOL SCI, V3, P107; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKAYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; YUE RH, 1969, J BIOL CHEM, V244, P1353	63	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10457	10464						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587828				2022-12-27	WOS:A1992HV09000040
J	MALONEY, PC; ANANTHARAM, V; ALLISON, MJ				MALONEY, PC; ANANTHARAM, V; ALLISON, MJ			MEASUREMENT OF THE SUBSTRATE DISSOCIATION-CONSTANT OF A SOLUBILIZED MEMBRANE CARRIER - SUBSTRATE STABILIZATION OF OXLT, THE ANION-EXCHANGE PROTEIN OF OXALOBACTER-FORMIGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECONSTITUTION; TRANSPORT; PERMEASE	OxlT, a secondary carrier found in Oxalobacter formigenes, mediates the exchange of divalent oxalate and monovalent formate. Because OxlT has an unusually high turnover number (greater-than-or-equal-to 1000/s), and because formate, one its substrates, shows high passive membrane permeability as formic acid, it has been difficult to obtain information on protein-substrate interactions using traditional methods in membrane biology. For this reason, we devised a new way to measure substrate dissociation constants. Detergent-solubilized material was exposed to inactivating temperatures in the absence or presence of OxlT substrates, and periodic reconstitution was used to monitor the kinetics of thermal decay. The data were consistent with a simple scheme in which only unliganded OxlT was temperature-sensitive; this premise, along with the assumption of equilibrium between liganded and unliganded species, allowed calculation of substrate dissociation constants for oxalate (18 +/- 3-mu-M), malonate (1.2 +/- 0.2 mm), and formate (3.1 +/- 0.6 mM). Further analysis revealed that substrate binding energy contributed at least 3.5 kcal/mol to stabilization of solubilized OxlT. Accordingly, we suggest that substrate binding energy is directly involved in driving protein structure reorganization during membrane transport. This new approach to analyzing protein-substrate interactions may have wider application in the study of membrane carriers.	USDA ARS,NATL ANIM DIS CTR,AMES,IA 50010	United States Department of Agriculture (USDA)	MALONEY, PC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM 24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; KENNEDY EP, 1970, LACTOSE OPERON, P49; Klingenberg M, 1980, Ann N Y Acad Sci, V358, P83, DOI 10.1111/j.1749-6632.1980.tb15388.x; LANCASTER JR, 1977, J BIOL CHEM, V252, P7657; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MOORE WT, 1963, PHYSICAL CHEM; OVERATH P, 1987, P NATL ACAD SCI USA, V84, P5535, DOI 10.1073/pnas.84.16.5535; PAGE MGP, 1981, BIOCHEM J, V196, P721, DOI 10.1042/bj1960721; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TEATHER RM, 1977, BIOCHIM BIOPHYS ACTA, V467, P386, DOI 10.1016/0005-2736(77)90316-9; WEST IC, 1983, BIOCH MEMBRANE TRANS; WRIGHT JK, 1981, BIOCHEMISTRY-US, V20, P6404, DOI 10.1021/bi00525a019	19	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10531	10536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587833				2022-12-27	WOS:A1992HV09000049
J	TRIMBUR, DE; WARREN, RAJ; WITHERS, SG				TRIMBUR, DE; WARREN, RAJ; WITHERS, SG			REGION-DIRECTED MUTAGENESIS OF RESIDUES SURROUNDING THE ACTIVE-SITE NUCLEOPHILE IN BETA-GLUCOSIDASE FROM AGROBACTERIUM-FAECALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GALACTOSIDASE GENE; ESCHERICHIA-COLI; EXPRESSION; CELLOBIASE; CELLULOSE; LYSOZYME; BINDING; INVITRO; CLONING	The active site nucleophile of the beta-glucosidase of Agrobacterium faecalis has recently been identified by the use of inhibitors. A combination of site-directed and in vitro enzymatic mutagenesis was carried out on the beta-glucosidase to probe the structure of the active site region. Forty-three point mutations were generated at 22 different residues in the region surrounding the active site nucleophile, Glu358. Only five positions were identified which affected enzyme activity indicating that only a few key residues are important to enzyme activity, thus the enzyme can tolerate a number of single residue changes and still function. The importance of Glu358 to enzymatic function has been confirmed and other residues important to enzyme structure or function have been identified.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL, VANCOUVER V6T 1Y5, BC, CANADA	University of British Columbia	TRIMBUR, DE (corresponding author), UNIV BRITISH COLUMBIA, DEPT CHEM, VANCOUVER V6T 1Y5, BC, CANADA.		Withers, Stephen G/I-7229-2019	Withers, Stephen G/0000-0002-6722-5701				ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; BOIZET B, 1988, GENE, V62, P249, DOI 10.1016/0378-1119(88)90563-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; DAY AG, 1986, BIOCHEM CELL BIOL, V64, P914, DOI 10.1139/o86-122; GERHARDT P, 1981, MANUAL METHODS GENER; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Imoto T., 1972, ENZYMES, V7, P665; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; LITTLE S, 1989, NUCLEIC ACIDS RES, V17, P7980, DOI 10.1093/nar/17.19.7980; LOVE DR, 1988, MOL GEN GENET, V213, P84, DOI 10.1007/BF00333402; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; Maniatis T, 1989, MOL CLONING; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Miller J.H., 1972, EXPT MOL GENETICS; PORTER EV, 1988, GENE, V62, P263; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SHEWALE JG, 1982, INT J BIOCHEM, V14, P435, DOI 10.1016/0020-711X(82)90109-4; SINNOTT ML, 1990, CHEM REV, V90, P1173; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WAKARCHUK WW, 1986, MOL GEN GENET, V205, P146, DOI 10.1007/BF02428044; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; 1990, GENE AMST, V94, P89	37	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10248	10251						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587814				2022-12-27	WOS:A1992HV09000010
J	TURNBULL, JE; FERNIG, DG; KE, YQ; WILKINSON, MC; GALLAGHER, JT				TURNBULL, JE; FERNIG, DG; KE, YQ; WILKINSON, MC; GALLAGHER, JT			IDENTIFICATION OF THE BASIC FIBROBLAST GROWTH-FACTOR BINDING SEQUENCE IN FIBROBLAST HEPARAN-SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; PROTEOLYTIC DEGRADATION; ANGIOGENIC PROTEIN; ESCHERICHIA-COLI; HIGH-AFFINITY; EHS TUMOR; CELLS; OLIGOSACCHARIDES; PROTEOGLYCANS; ORGANIZATION	The structural properties of fibroblast heparan sulfate (HS) that are necessary for it to bind strongly to basic fibroblast growth factor (bFGF) have been investigated using bFGF affinity chromatography. Specific enzymic and chemical scission of HS, together with chemical N-desulfation, revealed that N-sulfate groups and iduronate-2-sulfates (IdoA(2-OSO3)) were essential for the interaction. bFGF-affinity chromatography of sulfated oligosaccharides released from HS by treatment with heparitinase led to the identification of an oligosaccharide component (oligo-H), seven disaccharides in length, with a similar affinity for bFGF as the parent molecule. Heparinase treatment of this fraction abolished the high affinity binding to bFGF. Analysis of oligo-H indicated that 74% of the disaccharide units had the structure IdoA(2-OSO3)alpha-1,4GlCNSO3; the remainder comprised N-acetylated and N-sulfated units, the majority of which were devoid of O-sulfate groups. Oligo-H was fully degraded to disaccharides by treatment with nitrous acid. These results indicate that the sequence of oligo-H is as shown below. DELTA-GlcA-beta-1,4GlcNSO3-alpha-1,4[IdoA(2-OSO3)alpha-1,4GlcNSO3]5-alpha-1, 4IdoA-alpha-1,4GlcNAc Sulfated oligosaccharides of similar size but with a lower affinity for bFGF had a reduced concentration of IdoA(2-OSO3) but significant quantities of Glc-NSO3(6-OSO3) and GlcNAc(6-OSO3). The data indicate a primary role for contiguous sequences of IdoA(2-OSO3)alpha-1,4GlcNSO3 in mediating the high affinity binding between fibroblast HS and bFGF.	UNIV MANCHESTER,CHRISTIE HOSP,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M13 9PL,LANCS,ENGLAND; UNIV LIVERPOOL,DEPT BIOCHEM,CANC & POLIO RES FUND LAB,LIVERPOOL L69 3BX,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Liverpool	TURNBULL, JE (corresponding author), UNIV MANCHESTER,CHRISTIE HOSP,CLIN RES DEPT,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND.		Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Wilkinson, Mark/0000-0003-3109-6888				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1990, BIOCHEM SOC T, V18, P207, DOI 10.1042/bst0180207; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1989, HEPARIN, P135; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; KE YQ, 1990, BIOCHEM BIOPH RES CO, V171, P963, DOI 10.1016/0006-291X(90)90778-L; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5499; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PRESTA M, 1989, J CELL PHYSL, V140, P67; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TRESCONY PV, 1989, CONNECT TISSUE RES, V19, P219, DOI 10.3109/03008208909043898; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	504	516	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10337	10341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587820				2022-12-27	WOS:A1992HV09000023
J	WIESMULLER, L; WITTINGHOFER, A				WIESMULLER, L; WITTINGHOFER, A			EXPRESSION OF THE GTPASE ACTIVATING DOMAIN OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GENE IN ESCHERICHIA-COLI AND ROLE OF THE CONSERVED LYSINE RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN; PURIFICATION; BINDING; P21	A small catalytic domain from the neurofibromatosis type 1 gene, NF1-333, consisting of 333 amino acids between residues 1197 and 1528, including an additional N-terminal methionine, was expressed in Escherichia coli as a soluble protein. Its catalytic activity under non-saturating conditions is similar to the full-length p120-GAP but different from truncated GAP-334. Under saturating conditions its k(cat) and K(M) are lower. Lys-1422, which is totally conserved in all GAP proteins, was mutated and the properties of the mutant protein investigated. Lys-1422 seems to be essential for the stability of the proteins and not for its catalytic activity.			WIESMULLER, L (corresponding author), MAX PLANCK INST MED RES,BIOPHYS ABT,JAHNSTR 29,W-6900 HEIDELBERG 1,GERMANY.							AMMAN E, 1988, GENE, V69, P301; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, IN PRESS MOL CELL BI; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9568; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; IMAI Y, 1991, MOL CELL BIOL, V11, P3088, DOI 10.1128/MCB.11.6.3088; JOHN J, 1989, J BIOL CHEM, V264, P13086; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, COLD SPRING HARB SYM, V53, P849; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	24	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10207	10210						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587809				2022-12-27	WOS:A1992HV09000003
J	DENKER, BM; SCHMIDT, CJ; NEER, EJ				DENKER, BM; SCHMIDT, CJ; NEER, EJ			PROMOTION OF THE GTP-LIGANDED STATE OF THE G0-ALPHA PROTEIN BY DELETION OF THE C-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; H-RAS P21; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADP-RIBOSYLATION; TRANSDUCIN; SITE; IDENTIFICATION	G proteins are active as long as GTP is bound to the alpha-subunit. Activation ends when GTP is cleaved to GDP that then stays bound to the active site. Agonist-liganded receptors allow formation of the active state by decreasing the affinity of alpha-subunits for GDP allowing exchange of GDP for GTP. Since receptors interact with the C terminus of the alpha-subunits, we tested whether deletion of the C terminus could mimic activation by receptors. Three deletions and one point mutation at the C terminus of alpha(o) were engineered in alpha(o) cDNA by the polymerase chain reaction, transcribed into RNA, and translated in a rabbit reticulocyte lysate. The ability of in vitro synthesized protein to bind guanine nucleotide was inferred from analysis of native tryptic cleavage patterns, while the ability of the proteins to associate with beta-gamma was measured by sucrose density gradient centrifugation. Deletion of 14 amino acids, alpha(o)D[341], from the C terminus causes a large decrease in GDP affinity, with little or no change in guanosine 5'-3-O-(thio)triphosphate affinity. When GTP is present, alpha(o)D[341] remains in the activated conformation because exchange of GTP for GDP is rapid. Deletion of 10 amino acids, alpha(o)D[345], lowers GDP affinity, but less dramatically than in alpha(o)D[341]. Deletion of 5 amino acids, alpha(o)D[350], or mutation of Arg349 to proline alpha(o)R[349P] has no detectable effects on GDP affinity. Deletion of up to 10 amino acids from the C terminus does not prevent formation of alpha-beta-gamma heterotrimers. We propose that the C terminus of the alpha-subunit is a mobile region that blocks dissociation of GDP. Agonist-liganded receptors may move it aside to allow release of GDP, exchange for GTP, and activation of the alpha-subunit.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Schmidt, Carl/0000-0002-8386-4781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035417, R37GM036259, F32GM012578, R01GM036259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36259, GM35417, GM12578] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FANG BKK, 1983, J BIOL CHEM, V258, P10503; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES DT, 1987, J BIOL CHEM, V262, P14241; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P695; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAVON SE, 1988, J BIOL CHEM, V263, P489; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PENNEL RB, 1974, RED BLOOD CELL; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; VANDOP C, 1984, J BIOL CHEM, V259, P23; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	35	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9998	10002						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577829				2022-12-27	WOS:A1992HT96500083
J	MATA, NL; TSIN, ATC; CHAMBERS, JP				MATA, NL; TSIN, ATC; CHAMBERS, JP			HYDROLYSIS OF 11-CIS-RETINYL AND ALL-TRANS-RETINYL PALMITATE BY RETINAL-PIGMENT EPITHELIUM MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; RAT-LIVER; EYE; RETINOIDS; ESTERIFICATION; ISOMERIZATION; REGENERATION; BIOSYNTHESIS; ISOMERASE; RHODOPSIN	A partial characterization of the enzymatic hydrolysis of 11-cis- and all-trans-retinyl palmitate by bovine retinal pigment epithelium microsomes was carried out using a micro-radiometric method to quantitate liberated palmitic acid. Retinyl ester hydrolase (REH) activity was examined in the absence of detergent. Hydrolysis of 11-cis- and all-trans-retinyl palmitate was protein- and time-dependent. Optimal enzyme activity occurred at slightly alkaline pH (8-9). Apparent kinetic constants (V(max) and K(m)) for the 11-cis-REH were 2.1 nmol/min/mg protein and 66-mu-M, respectively. All-trans-REH demonstrated a lower maximum velocity of 0.3 nmol/min/mg protein and a slightly higher substrate affinity of 27-mu-M. Further characterization of 11-cis-retinyl palmitate hydrolysis involved monitoring formation of reaction products, 11-cis retinol and palmitic acid, which were found to be released in essentially a 1:1 stoichiometry. Addition of all-trans retinyl bromoacetate, a known inhibitor of lecithin:retinol acyltransferase reduced both 11-cis and all-trans-REH activities but to significantly different degrees (50 and 76%, respectively). Although the microsomal preparation exhibited LRAT activity, acyl transfer was not readily reversible as labeled palmitic acid was not transferred to added acyl acceptor compounds. These findings suggest that hydrolysis of 11-cis-retinyl palmitate by bovine retinal pigment epithelium microsomes may occur at a catalytic site distinct from that for the all-trans isomer and that this hydrolysis is not representative of a reverse transesterification reaction.	UNIV TEXAS,DIV LIFE SCI,6900 LOOP 1604 NW,SAN ANTONIO,TX 78249	University of Texas System					NATIONAL EYE INSTITUTE [R01EY006438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008194] Funding Source: NIH RePORTER; NEI NIH HHS [EY06438] Funding Source: Medline; NIGMS NIH HHS [GM08194] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERMAN ER, 1980, BIOCHIM BIOPHYS ACTA, V630, P36, DOI 10.1016/0304-4165(80)90135-X; BERNSTEIN PS, 1987, J BIOL CHEM, V262, P16848; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BLANER WS, 1987, J BIOL CHEM, V262, P53; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1977, EXP EYE RES, V24, P571, DOI 10.1016/0014-4835(77)90114-2; BRIDGES CDB, 1984, VISION RES, V24, P1581, DOI 10.1016/0042-6989(84)90316-X; BRIDGES CDB, 1984, RETINOIDS, V2, P125; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; GAWINOWICZ MA, 1982, BIOCHEMISTRY-US, V21, P1899, DOI 10.1021/bi00537a030; GUELI MC, 1991, ARCH BIOCHEM BIOPHYS, V288, P572, DOI 10.1016/0003-9861(91)90238-E; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; KRINSKY NI, 1958, J BIOL CHEM, V232, P881; LAI YL, 1985, BRAIN RES BULL, V15, P143, DOI 10.1016/0361-9230(85)90130-3; LAW WC, 1988, BIOCHEMISTRY-US, V27, P4147, DOI 10.1021/bi00411a037; LENTZ BR, 1975, CHEM PHYS LIPIDS, V15, P216, DOI 10.1016/0009-3084(75)90044-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1988, J BIOL CHEM, V263, P8084; SANDERSSANCHEZ SR, 1990, EXPERIENTIA, V46, P498; SELINGER Z, 1966, J LIPID RES, V7, P174; SZUTS EZ, 1991, ARCH BIOCHEM BIOPHYS, V287, P297, DOI 10.1016/0003-9861(91)90482-X; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Wald G, 1936, J GEN PHYSIOL, V19, P781, DOI 10.1085/jgp.19.5.781; Wald G, 1934, NATURE, V134, P65, DOI 10.1038/134065a0; ZIMMERMAN WF, 1974, EXP EYE RES, V23, P159	32	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9794	9799						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577814				2022-12-27	WOS:A1992HT96500056
J	TEASDALE, RD; DAGOSTARO, G; GLEESON, PA				TEASDALE, RD; DAGOSTARO, G; GLEESON, PA			THE SIGNAL FOR GOLGI RETENTION OF BOVINE-BETA-1,4-GALACTOSYLTRANSFERASE IS IN THE TRANSMEMBRANE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; CELL-SURFACE GALACTOSYLTRANSFERASE; HUMAN-MILK GALACTOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; BREFELDIN-A; ESCHERICHIA-COLI; E1 GLYCOPROTEIN; CDNA; PROTEINS	The expression and localization of bovine beta-1.4-galactosyltransferase (Gal T) has been studied in mammalian cells transfected with Gal T cDNA constructs, and the role of the amino-terminal domains of Gal T in Golgi localization examined. Here we demonstrate that the transmembrane (signal/anchor) domain of bovine Gal T contains a positive Golgi retention signal. Bovine Gal T was characterized in transfected cells with anti-bovine Gal T antibodies, affinity-purified from a rabbit antiserum using a bacterial recombinant fusion protein. These affinity-purified antibodies recognized native bovine Gal T and showed minimum cross-reactivity with Gal T from non-bovine sources. Bovine Gal T cDNA was expressed, as active enzyme, transiently in COS-1 cells and stably in murine L cells, and the product was shown to be localized to the Golgi complex by immunofluorescence using the polypeptide-specific antibodies. A low level of surface bovine Gal T was also detected in the transfected L cells by flow cytometry. The removal of 18 of the 24 amino acids from the cytoplasmic domain of bovine Gal T did not alter the Golgi localization of the product transiently expressed in COS-1 cells or stably expressed in L cells. Both the full-length bovine Gal T and the cytoplasmic domain deletion mutant were N-glycosylated in the transfected L cells, indicating both proteins have the correct N(in)/C(out) membrane orientation. Deletion of both the cytoplasmic and signal/anchor domains of bovine Gal T and incorporation of a cleavable signal sequence resulted in a truncated soluble bovine Gal T that was rapidly secreted (within 1 h) from transfected COS-1 cells. Replacement of the signal/anchor domain of bovine Gal T with the signal/anchor domain of the human transferrin receptor resulted in the transport of the hybrid molecule to the cell surface of transfected COS-1 cells. Furthermore, a hybrid construct containing the signal/anchor domain of Gal T with ovalbumin was efficiently retained in the Golgi complex, whereas ovalbumin anchored to the membrane by the transferrin receptor signal/anchor was expressed at the cell surface of transfected COS-1 cells. Overall, these studies show that the hydrophobic, signal/anchor domain of Gal T is both necessary and sufficient for Golgi localization.	MONASH UNIV, SCH MED, DEPT PATHOL & IMMUNOL, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA; ENERGIA NUCL & ENERGIA ALTERNAT, BIOPHYS LAB, I-0006 ROME, ITALY	Monash University; Italian National Agency New Technical Energy & Sustainable Economics Development			Teasdale, Rohan D/B-2538-2009; Teasdale, Rohan/AAD-6698-2019	Teasdale, Rohan D/0000-0001-7455-5269; Teasdale, Rohan/0000-0001-7455-5269; Gleeson, Paul/0000-0002-5336-6503				ANSORGE W, 1983, ELECTROPHORESIS 82, P235; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BENDIAK B, 1990, BIOCHEM BIOPH RES CO, V170, P879, DOI 10.1016/0006-291X(90)92173-W; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CHILDS RA, 1986, BIOCHEM J, V238, P605, DOI 10.1042/bj2380605; COLLEY K, 1989, 18TH P ANN M SOC COM; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; FEIZI T, 1987, BIOCHEM SOC T, V15, P614, DOI 10.1042/bst0150614; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GLEESON PA, 1988, CURR TOP MICROBIOL, V139, P1; GODING JW, 1983, MONOCLONAL ANTIBODIE, P140; HAPER NL, 1988, J BIOL CHEM, V263, P10420; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LOPEZ LC, 1991, J BIOL CHEM, V266, P15984; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MARCHASE RB, 1988, J CELL BIOCHEM, V36, P453, DOI 10.1002/jcb.240360413; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MEEK RL, 1982, J BIOL CHEM, V257, P2245; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; ORCI L, 1991, CELL, V64, P1183; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PAQUET MR, 1984, BIOCHEM J, V218, P745, DOI 10.1042/bj2180745; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, J CELL BIOL, V100, P118, DOI 10.1083/jcb.100.1.118; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1984, DEV BIOL, V102, P514, DOI 10.1016/0012-1606(84)90219-7; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHAPER NL, 1985, J CELL BIOCHEM, V28, P229, DOI 10.1002/jcb.240280305; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SHUR BD, 1982, J BIOL CHEM, V257, P6871; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TASSIN AM, 1985, J CELL BIOL, V101, P630, DOI 10.1083/jcb.101.2.630; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYER IP, 1971, J BIOL CHEM, V246, P6666; ULRICH JT, 1986, J BIOL CHEM, V261, P7975; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	73	138	144	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4084	4096						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1637374				2022-12-27	WOS:A1992HE60700078
J	GUO, Q; LU, M; KALLENBACH, NR				GUO, Q; LU, M; KALLENBACH, NR			ADENINE AFFECTS THE STRUCTURE AND STABILITY OF TELOMERIC SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSFERASE-ACTIVITY; DNA-MOLECULES; 3' TERMINUS; TETRAHYMENA; RIBONUCLEOPROTEIN; TRANSITIONS; REPEATS; BINDING; ENZYME; MODEL	Adenine occurs in the strand containing repeated G clusters in the telomeric DNA of a variety of organisms, including that of humans. The role of adenine has been investigated by constructing two sets of oligonucleotides each with one, two, or four copies of the telomeric sequence dTTTAGGG together with a control sequence in which T replaces the A residue, dTTTTGGG. Comparison of the stability and spectral properties of these two sequences in the presence of Na+ or K+ affords a basis for defining the role of adenine in these structures. In Na+, the A residue stabilizes the structure formed by each oligomer significantly, presumably by a base-pairing interaction with T. In K+, by contrast, there is little difference in stability. In two- and four-copy oligomers, the A sequence has a different structure from its T analog, as detected by CD spectroscopy. In the presence of either Na+ or K+, the tetraplexes of A and T interact with intercalators.	NYU,DEPT CHEM,NEW YORK,NY 10003	New York University					NATIONAL CANCER INSTITUTE [R01CA024101] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24101] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CARUTHERS MH, 1982, CHEM ENZYMATIC SYNTH, P71; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUO Q, 1992, BIOCHEMISTRY-US, V31, P2451, DOI 10.1021/bi00124a002; GUO Q, 1989, BIOCHEMISTRY-US, V28, P2355, DOI 10.1021/bi00432a001; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HERTZBERG RP, 1982, J AM CHEM SOC, V104, P313, DOI 10.1021/ja00365a069; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Maxam A M, 1980, Methods Enzymol, V65, P499; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8878; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; VANDYKE MW, 1983, NUCLEIC ACIDS RES, V11, P5555; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WINKLE SA, 1982, NUCLEIC ACIDS RES, V10, P8211, DOI 10.1093/nar/10.24.8211; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	36	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15293	15300						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639776				2022-12-27	WOS:A1992JG11300010
J	BOCK, PE				BOCK, PE			ACTIVE-SITE-SELECTIVE LABELING OF BLOOD-COAGULATION PROTEINASES WITH FLUORESCENCE PROBES BY THE USE OF THIOESTER PEPTIDE CHLOROMETHYL KETONES .1. SPECIFICITY OF THROMBIN LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; FACTOR-XA; FACTOR-VA; CONFORMATIONAL SENSITIVITY; PROTHROMBINASE COMPLEX; PHOSPHOLIPID SURFACE; ANTITHROMBIN-III; INACTIVATION; BINDING; MEIZOTHROMBIN	In a, new strategy for labeling the active sites of serine proteinases with fluorescence probes (Bock, P. E. (1988) Biochemistry 27, 6633-6639), a thioester peptide chloromethyl ketone inhibitor is incorporated into the enzyme active center and used to produce a unique thiol group which provides a site for selective chemical modification with any one of many thiol-reactive fluorescence probes. This approach was developed to increase the opportunities for identifying fluorescent proteinase derivatives that act as reporters of binding interactions by allowing a large number of derivatives, representing a broad range of probe spectral properties, to be readily prepared. In the studies described here, the specificity of the labeling approach was evaluated quantitatively for the labeling of human alpha and beta/gamma-thrombin with the thioester peptide chloromethyl ketones, N(alpha)-[(acetylthio)acetyl]-D-Phe-Pro-Arg-CH2Cl and N(alpha)-[(acetylthio)acetyl]-D-Phe-Phe-Arg-CH2Cl, and the thiol-reactive fluorescence probe, 5-(iodoacetamido)fluorescein. Irreversible inactivation of thrombin by the inhibitors was accompanied by incorporation of 0.98 +/- 0.06 mol/mol of the thioester group into the active site, independent of a 470-fold difference between the thioester peptide chloromethyl ketones in the bimolecular rate constants of alpha-thrombin affinity labeling. Subsequent mild treatment of the covalent thrombin-inhibitor complexes with NH2OH in the presence of 5-(iodoacetamido)fluorescein resulted in generation of the thiol group together with its selective modification and incorporation of 0.96 +/- 0.07 mol of probe/mol of active sites. The incorporated label was localized to a 9000 molecular weight region of a and beta/gamma-thrombin containing the catalytic-site histidine residue. Evaluation of competing, side reactions showed that they did not significantly compromise the active site specificity of labeling. These results demonstrated equivalent, active-site-selective fluorescence probe labeling of alpha and beta/gamma-thrombin by use of either of the thioester peptide chloromethyl ketones, with a site specificity of greater-than-or-equal-to 94%.	AMER RED CROSS, BLOOD SERV, SE MICHIGAN REG RES LAB, DETROIT, MI 48232 USA	American Red Cross					NHLBI NIH HHS [HL-38779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038779, R29HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOISSEL JP, 1984, J BIOL CHEM, V259, P5691; Bornstein P, 1977, Methods Enzymol, V47, P132; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; CHANG JY, 1986, BIOCHEM J, V240, P797, DOI 10.1042/bj2400797; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; ELION J, 1986, ANN NY ACAD SCI, V485, P16, DOI 10.1111/j.1749-6632.1986.tb34564.x; FENTON JW, 1974, THROMB RES, V4, P809, DOI 10.1016/0049-3848(74)90024-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KETTNER C, 1978, BIOCHEMISTRY-US, V17, P4778, DOI 10.1021/bi00615a027; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NIENABER VL, 1991, THROMB HAEMOSTASIS, V65, P40; Orsi B A, 1979, Methods Enzymol, V63, P159; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; TAIT JF, 1982, ARCH BIOCHEM BIOPHYS, V216, P133, DOI 10.1016/0003-9861(82)90197-7; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; WALKER B, 1985, BIOCHEM J, V230, P645, DOI 10.1042/bj2300645; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; 1980, POLYACRYLAMIDE GEL E, P54	42	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14963	14973						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634535				2022-12-27	WOS:A1992JF08800070
J	LEE, JY; HIROSE, M				LEE, JY; HIROSE, M			PARTIALLY FOLDED STATE OF THE DISULFIDE-REDUCED FORM OF HUMAN SERUM-ALBUMIN AS AN INTERMEDIATE FOR REVERSIBLE DENATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLTEN-GLOBULE STATE; CIRCULAR-DICHROISM; CONFORMATIONAL STATES; IMMUNOLOGICAL PROBE; SECONDARY STRUCTURE; BOVINE; PROTEINS; OVOTRANSFERRIN; SPECTROSCOPY	The conformation of the fully disulfide-reduced state of human serum albumin was investigated by tryptophan fluorescence spectrum, CD analyses, and size-exclusion chromatography. Both the reduction of the native disulfide-bonded form under nondenaturing conditions and the refolding of the urea-denatured disulfide-reduced form under reduced conditions yielded almost exactly the same disulfide-reduced state with partially folded unique conformation that was clearly distinguished from either the native or fully denatured state. In addition, the interconversion between the urea-denatured reduced form and the partially folded reduced form was reversible with each other; by reoxidation, the partially folded reduced form was converted to the disulfide-bonded form. The conformation of disulfide-reduced serum albumin was highly variable depending on pH and ionic strength conditions. Thus, we concluded that the disulfide-reduced state with partially folded variable conformation is involved in the reversible interconversion between the denatured reduced form and the native disulfide-bonded form of human serum albumin.	KYOTO UNIV, FOOD SCI RES INST, UJI, KYOTO 611, JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				BEYCHOK S, 1966, SCIENCE, V154, P1288, DOI 10.1126/science.154.3754.1288; BOS OJM, 1989, J BIOL CHEM, V264, P953; BURTON SJ, 1989, EUR J BIOCHEM, V179, P379, DOI 10.1111/j.1432-1033.1989.tb14564.x; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DAMODARAN S, 1986, INT J PEPT PROT RES, V27, P589; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ERA S, 1985, INT J PEPT PROT RES, V26, P575; GALAT A, 1981, BIOCHEMISTRY-US, V20, P594, DOI 10.1021/bi00506a023; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GOTO Y, 1982, J MOL BIOL, V156, P911, DOI 10.1016/0022-2836(82)90147-4; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; JOHANSON KO, 1981, J BIOL CHEM, V256, P445; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KOSEN PA, 1983, BIOCHEMISTRY-US, V22, P2433, DOI 10.1021/bi00279a020; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAPANJE S, 1969, CROAT CHEM ACTA, V41, P115; OE H, 1986, AGR BIOL CHEM TOKYO, V50, P2469, DOI 10.1080/00021369.1986.10867773; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; SEETHARAMA A, 1982, MOL CELL BIOCHEM, V44, P129; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SUN SF, 1989, INT J PEPT PROT RES, V34, P46; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; TAKAHASHI N, 1992, IN PRESS J BIOL CHEM; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; TEALE JM, 1977, J BIOL CHEM, V252, P4521; TEALE JM, 1976, J BIOL CHEM, V251, P4609; TEALE JM, 1976, J BIOL CHEM, V251, P4603; WHITE FH, 1982, BIOCHEMISTRY-US, V21, P967, DOI 10.1021/bi00534a023	34	84	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14753	14758						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634518				2022-12-27	WOS:A1992JF08800040
J	ZHANG, WG; BROOKS, RL; SILVERSIDES, DW; WEST, BL; LEIDIG, F; BAXTER, JD; EBERHARDT, NL				ZHANG, WG; BROOKS, RL; SILVERSIDES, DW; WEST, BL; LEIDIG, F; BAXTER, JD; EBERHARDT, NL			NEGATIVE THYROID-HORMONE CONTROL OF HUMAN GROWTH-HORMONE GENE-EXPRESSION IS MEDIATED BY 3'-UNTRANSLATED 3'-FLANKING DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR-CELLS; RESPONSE ELEMENT; GLUCOCORTICOID RECEPTOR; RNA-POLYMERASE; BINDING PROTEIN; C-JUN; RAT; PROMOTER; TRANSCRIPTION; SEQUENCE	The intact human growth hormone (hGH) gene is negatively regulated by triiodothyronine (T3) treatment in transfected rat pituitary tumor cells. We now demonstrate that this responsiveness is mediated by a negative thyroid hormone response element (nTRE) localized to the proximal 3'-untranslated/3'-flanking region (3'-UT/FR). This region binds thyroid hormone receptors specifically and with high affinity. nTRE function was promoter-dependent, since it suppressed the activity of a positive TRE in the human chorionic somatomammotropin promoter, partially repressed activity of the herpes simplex virus TK promoter, but did not function with the human actin or Rous sarcoma virus promoters. T3 treatment did not alter transcript termination sites nor selectively affect the stability of transcripts containing the hGH 3'-UT/FR when transcription was blocked by actinomycin D treatment. The function of the nTRE depended on its location in the 3'-UT/FR; it was inactive when positioned downstream of the simian virus 40 (SV40) 3'-UT/FR, and it acted as a positive TRE when placed upstream of the hGH promoter. These results demonstrate a novel localization of a TRE with unique properties which suggests expanded mechanisms by which thyroid hormone receptors can affect gene expression.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,4-407 ALFRED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MOLEC BIOL BIOCHEM,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT MED,METAB RES UNIT,SAN FRANCISCO,CA 94143	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco				West, Brian/0000-0002-5320-3691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842, DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CARR FE, 1989, MOL ENDOCRINOL, V3, P706; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARTIAL JA, 1977, P NATL ACAD SCI USA, V74, P1816, DOI 10.1073/pnas.74.5.1816; MARTIAL JA, 1979, SCIENCE, V205, P602, DOI 10.1126/science.377496; MORIN A, 1990, MOL CELL ENDOCRINOL, V71, P261, DOI 10.1016/0303-7207(90)90031-3; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON C, 1986, NATURE, V322, P557, DOI 10.1038/322557a0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKARNES WC, 1988, J MOL BIOL, V203, P609; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; SPENCER CA, 1990, ONCOGENE, V5, P777; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	45	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15056	15063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634542				2022-12-27	WOS:A1992JF08800081
J	COMBEAU, C; DIDRY, D; CARLIER, MF				COMBEAU, C; DIDRY, D; CARLIER, MF			INTERACTION BETWEEN G-ACTIN AND MYOSIN SUBFRAGMENT-1 PROBED BY COVALENT CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BINDING-SITES; HEAVY-CHAIN; NH2-TERMINAL SEGMENT; ATOMIC MODEL; POLYMERIZATION; PROTEINS; COMPLEX; STOICHIOMETRY; TROPOMYOSIN	The topography of rapid equilibrium complexes formed between G-actin and myosin subfragment-1, which are the first kinetic intermediates in the polymerization process into F-acto-S1 filaments, has been probed by chemical cross-linking. In the absence of ATP, cross-linking of G-actin-S1 complexes by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) yielded a major 165-170-kDa and a fainter 200-205-kDa doublet polypeptide. The actin:S1 molar ratio was 1 in the EDC-cross-linked complexes, using either double labeling techniques or the method combining EDC + N-hydroxysuccinimide. Chemical cleavages of the covalently cross-linked complexes by formic acid and N-hydroxylamine (Sutoh, K. (1983) Biochemistry 22, 1579-1585) showed that in the main cross-linked 165-kDa polypeptide, the 1-12 acidic N-terminal region of actin was covalently linked to the lysine-rich region connecting the central 50-kDa domain to the C-terminal 20-kDa domain of S1, as in F-acto-S1 complexes. G-actin, but not F-actin, was covalently cross-linked to S1 by N,N'-paraphenylenedimaleimide (p-PDM). A major 195-kDa and a minor 165-kDa polypeptide were obtained, could be separated from actin and S1 by DEAE-cellulose chromatography, and did not exhibit actin-activated Mg-ATPase activity. Both EDC-cross-linked and p-PDM-cross-linked complexes between G-actin and S1 could be incorporated into F-acto-S1 decorated filaments. The C-terminal cysteine 374 of actin is involved in the p-PDM cross-linked 195-kDa complex. Accordingly, a covalent photocross-linked 200-kDa conjugate was formed between S1 heavy chain and benzophenone-G-actin, obtained by covalent modification of Cys374 by benzophenonemaleimide (Tao, T., Lamkin, M., and Scheiner, C. J. (1985) Arch. Biochem. Biophys. 240, 627-634). These results demonstrate that (i) G-actin-S1 and F-actin-S1 complexes display a large similarity in the EDC-cross-linked electrostatic close contacts and (ii) a change in the environment of Cys374 is linked to the polymerization into F-actin-S1 decorated filaments.	CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								AUDEMARD E, 1988, J MUSCLE RES CELL M, V9, P197, DOI 10.1007/BF01773891; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BERTRAND R, 1988, BIOCHEMISTRY-US, V27, P5728, DOI 10.1021/bi00415a050; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CHAUSSEPIED P, 1989, J BIOL CHEM, V264, P20752; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; CHEN T, 1985, BIOCHEMISTRY-US, V24, P137, DOI 10.1021/bi00322a019; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, BIOCHEMISTRY-US, V31, P300, DOI 10.1021/bi00116a041; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; DOI YK, 1991, BIOCHEMISTRY-US, V30, P5769, DOI 10.1021/bi00237a020; DUONG AM, 1989, BIOCHEMISTRY-US, V28, P3502, DOI 10.1021/bi00434a053; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; ELZINGA M, 1991, BIOPHYS J, V59, P52; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; GRAZI E, 1980, FEBS LETT, V12, P67; GREENE LE, 1984, J BIOL CHEM, V259, P7363; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEAPHY S, 1984, BIOCHEMISTRY-US, V23, P2211, DOI 10.1021/bi00305a017; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU RC, 1991, BIOPHYS J, V59, P411; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V9, P5358; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; REISLER E, 1982, METHOD ENZYMOL, V85, P84; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TAO T, 1985, ARCH BIOCHEM BIOPHYS, V240, P627, DOI 10.1016/0003-9861(85)90070-0; TAO T, 1984, FEBS LETT, V168, P169, DOI 10.1016/0014-5793(84)80229-X; TAWADA K, 1969, BIOCHIM BIOPHYS ACTA, V180, P199, DOI 10.1016/0005-2728(69)90209-6; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; WEEDS A, 1991, Current Biology, V1, P307, DOI 10.1016/0960-9822(91)90093-C; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAMAMOTO K, 1989, BIOCHEMISTRY-US, V28, P5573, DOI 10.1021/bi00439a035	54	39	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14038	14046						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629203				2022-12-27	WOS:A1992JD32500042
J	HOFFMAN, RD; LANE, MD				HOFFMAN, RD; LANE, MD			IODOPHENYLARSINE OXIDE AND ARSENICAL AFFINITY-CHROMATOGRAPHY - NEW PROBES FOR DITHIOL PROTEINS - APPLICATION TO TUBULINS AND TO COMPONENTS OF THE INSULIN RECEPTOR-GLUCOSE TRANSPORTER SIGNAL TRANSDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTI-ENZYME COMPLEX; 3T3-L1 ADIPOCYTES; PHENYLARSINE OXIDE; TYROSINE KINASE; BRAIN BETA-1-TUBULIN; ESCHERICHIA-COLI; HEXOSE-TRANSPORT; 422(AP2) PROTEIN; RAT ADIPOCYTES; MESSENGER-RNA	In our studies of the effects of the trivalent arsenical phenylarsine oxide on insulin-dependent hexose uptake in 3T3-L1 adipocytes, we needed direct methods to study arsenical-protein interactions. In this report, we describe two such new tools. The first is the radiolabeled covalent affinity reagent 4-[I-125]iodophenylarsine oxide. This compound has effects on 3T3-L1 adipocytes similar to those of phenylarsine oxide both with respect to effects of hexose uptake and the accumulation of pp15, a phosphotyrosine-containing putative mediator of insulin action. Iodophenylarsine oxide labels numerous proteins in intact cells in a concentration-dependent, but apparently insulin-independent fashion. The second tool is trivalent arsenical affinity chromatography, which we use to show novel direct interactions between trivalent arsenicals and several proteins from 3T3-L1 adipocytes including the insulin-responsive glucose transporter GLUT4, the insulin proreceptor, and both the alpha and beta-subunits of tubulin. The non-insulin-dependent glucose transporter GLUT1, the mature insulin receptor, and the fatty acid-binding protein 422(aP2) do not show strong interactions with arsenical resin. These results provide a new chemical approach to the study of both insulin-dependent hexose transport and tubulin function.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University	HOFFMAN, RD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.				NIDDK NIH HHS [DK 14574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK014574, R01DK014574] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMSON SR, 1981, BIOCHEMISTRY-US, V20, P3418, DOI 10.1021/bi00515a018; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; DOUEN A G, 1990, Biofactors, V2, P153; DOUEN AG, 1988, BIOCHIM BIOPHYS ACTA, V944, P444, DOI 10.1016/0005-2736(88)90515-9; DOUEN AG, 1988, BIOCHIM BIOPHYS ACTA, V968, P109, DOI 10.1016/0167-4889(88)90050-X; DUSTIN P, 1984, MICROTUBULES, P12; EZAKI O, 1990, J BIOL CHEM, V265, P1124; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; FROST SC, 1989, J CELL PHYSIOL, V141, P467, DOI 10.1002/jcp.1041410304; FROST SC, 1985, J BIOL CHEM, V260, P2646; FROST SC, 1987, J BIOL CHEM, V262, P9872; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; HANNESTAD U, 1982, ANAL BIOCHEM, V126, P200, DOI 10.1016/0003-2697(82)90129-4; HENRIKSEN EJ, 1990, AM J PHYSIOL, V258, pC648, DOI 10.1152/ajpcell.1990.258.4.C648; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; JHUN BH, 1991, J BIOL CHEM, V266, P22260; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; LANGLEY KE, 1976, BIOCHEMISTRY-US, V15, P4866, DOI 10.1021/bi00667a018; LIAO K, 1991, J BIOL CHEM, V266, P6544; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LITTLE M, 1985, EMBO J, V4, P51, DOI 10.1002/j.1460-2075.1985.tb02316.x; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MAMELI E, 1909, CHEM ZENTR, V21, P1856; Miller J. H, 1972, EXPT MOL GENETICS; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PORTMANN JE, 1964, ANAL CHIM ACTA, V31, P509, DOI 10.1016/S0003-2670(00)88870-4; RAIZISS GW, 1923, ORGANIC ARSENICAL CO, P17; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SAMAAN S, 1978, HOUBENWEYL METHODE 8, V13, P164; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOWELL MO, 1988, AM J PHYSIOL, V255, pE159, DOI 10.1152/ajpendo.1988.255.2.E159; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; TAKATA K, 1990, BIOCHEM BIOPH RES CO, V173, P67, DOI 10.1016/S0006-291X(05)81022-8; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; WANG C, 1991, BIOCHEM BIOPH RES CO, V176, P201, DOI 10.1016/0006-291X(91)90909-Q; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHOU G, 1991, J CHROMATOGR-BIOMED, V568, P69, DOI 10.1016/0378-4347(91)80341-9	45	84	87	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14005	14011						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629198				2022-12-27	WOS:A1992JD32500037
J	MORGELIN, M; ENGEL, J; HEINEGARD, D; PAULSSON, M				MORGELIN, M; ENGEL, J; HEINEGARD, D; PAULSSON, M			PROTEOGLYCANS FROM THE SWARM RAT CHONDROSARCOMA - STRUCTURE OF THE AGGREGATES EXTRACTED WITH ASSOCIATIVE AND DISSOCIATIVE SOLVENTS AS REVEALED BY ELECTRON-MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARTILAGE PROTEOGLYCAN; LINK-PROTEIN; BINDING REGION; CORE PROTEIN; KERATAN SULFATE; HYALURONIC-ACID; NASAL CARTILAGE; PARTIAL CDNA; MOLECULES; SEQUENCE	Proteoglycan aggregates were extracted from Swarm rat chondrosarcoma tissue in the native state and compared with proteoglycan aggregates isolated dissociatively with 4 m guanidine HCl. Purified aggregates were examined with a variety of electron microscopic techniques. In some cases they showed a structure of the central filament identical to that of the link-stabilized central filament observed in earlier experiments where the separated constituents were allowed to reconstitute (Morgelin, M., Paulsson, M., Hardingham, T. E., Heinegard, D., and Engel, J. (1988) Biochem. J. 253, 175-185). The tight packing of proteoglycan monomers along the hyaluronate with a minimum distance of 12 nm between adjacent E1 strands also could thus be confirmed for never dissociated aggregates. The results therefore show that the organization of proteoglycan aggregates assembled in vitro from the participating molecules is representative for conditions in situ. An additional structural type of central filament was observed in the preparations. This contained long stretches of free hyaluronate interspaced by short stretches of central filament with condensed arrays of link protein-proteoglycan. Chemical cross-linking in combination with low shear electron microscopical techniques showed that this discontinuous central filament structure is not an artifact of specimen preparation. The addition of suprastoichiometric amounts of exogenous link protein did not affect the central filament structure with the low packing density. Densely and loosely packed types of central filament were isolated in varying relative amounts with different associative and dissociative solvents.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND; UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22100 LUND,SWEDEN; UNIV BERN,ME MULLER INST BIOMECH,CH-3010 BERN,SWITZERLAND	University of Basel; Lund University; University of Bern	MORGELIN, M (corresponding author), UNIV BASEL,BIOCTR,ME MULLER INST HIGH RESOLUT ELECTRON MICROSCOPY,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE K, 1986, J BIOL CHEM, V261, P8108; FALTZ LL, 1979, J BIOL CHEM, V254, P1381; FALTZ LL, 1979, J BIOL CHEM, V254, P1375; FRANZEN A, 1981, BIOCHEM J, V197, P669, DOI 10.1042/bj1970669; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HARDINGHAM TE, 1986, RHEUMATOLOGY, V10, P143; HASCALL VC, 1972, J BIOL CHEM, V247, P4521; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; HEINEGARD D, 1985, BIOCHEM J, V225, P95, DOI 10.1042/bj2250095; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; HEINEGARD D, 1977, J BIOL CHEM, V252, P1980; HEINEGARD D, 1977, J BIOL CHEM, V252, P1971; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORGELIN M, 1990, BIOCHEM SOC T, V18, P204; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; OEGEMA TE, 1977, J BIOL CHEM, V25, P6470; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SAJDERA S, 1969, J BIOL CHEM, V244, P77; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; TENGBLAD A, 1981, BIOCHEM J, V199, P297, DOI 10.1042/bj1990297; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WIEDEMANN H, 1985, BIOCHEM J, V224, P331	39	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14275	14284						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629221				2022-12-27	WOS:A1992JD32500076
J	SENER, A; MALAISSE, WJ				SENER, A; MALAISSE, WJ			HEXOSE METABOLISM IN PANCREATIC-ISLETS - CA2+-DEPENDENT ACTIVATION OF THE GLYCEROL PHOSPHATE SHUTTLE BY NUTRIENT SECRETAGOGUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSE; PHOSPHORYLATION; DEHYDROGENASE; OXIDATION; EVENTS	A method is proposed for the measurement of the flux through the glycerol phosphate shuttle in pancreatic islets. Such a flux is taken as the ratio between the production of (HOH)-H-3 and the specific radioactivity of L-[2-H-3]glycerophosphate in islets exposed to [2-H-3] glycerol. D-Glucose and non-glucidic nutrient secretagogues, such as 2-ketoisocaproate and 2-aminobicyclo[2,2,1]heptane-2-carboxylate, stimulate, in a Ca2+-dependent manner, circulation in the glycerol phosphate shuttle. The shuttle flux is commensurate with the fraction of pyruvate generation which is not coupled with L-lactate production. These findings support the view that a rise in D-glucose concentration leads to activation of the FAD-linked mitochondrial glycerophosphate dehydrogenase through an increase in cytosolic Ca2+ concentration.			SENER, A (corresponding author), FREE UNIV BRUSSELS,EXPTL MED LAB,B-1070 BRUSSELS,BELGIUM.		SENER, Abdullah/A-1769-2008	SENER, Abdullah/0000-0003-2718-5423				CARPINELLI AR, 1987, MED SCI RES-BIOCHEM, V15, P481; CRONHOLM T, 1984, BIOCHEM J, V224, P731, DOI 10.1042/bj2240731; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P141; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, HORM METAB RES, V14, P678, DOI 10.1055/s-2007-1019117; MALAISSE WJ, 1991, MOL CELL BIOCHEM, V107, P95; MALAISSE WJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P246, DOI 10.1016/S0005-2728(88)80038-0; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P955, DOI 10.1016/0020-711X(91)90085-2; Malaisse WJ, 1984, METHODS DIABETES RES, V1, P147; OSTLUND AK, 1983, BIOCHEM MED METAB B, V30, P231, DOI 10.1016/0006-2944(83)90089-3; RASSCHAERT J, 1991, BIOCHEM J, V278, P335, DOI 10.1042/bj2780335; SENER A, 1988, INT J BIOCHEM, V20, P595, DOI 10.1016/0020-711X(88)90098-5; SENER A, 1990, ANAL BIOCHEM, V186, P236, DOI 10.1016/0003-2697(90)90073-I; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; SENER A, 1991, BIOCHIMIE, V73, P1287, DOI 10.1016/0300-9084(91)90090-N; YILMAZ MT, 1987, MOL CELL ENDOCRINOL, V52, P251, DOI 10.1016/0303-7207(87)90051-7	17	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13251	13256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618829				2022-12-27	WOS:A1992JB74600027
J	STEPHENS, JM; PEKALA, PH				STEPHENS, JM; PEKALA, PH			TRANSCRIPTIONAL REPRESSION OF THE C/EBP-ALPHA AND GLUT4 GENES IN 3T3-L1 ADIPOCYTES BY TUMOR-NECROSIS-FACTOR-ALPHA - REGULATION IS COORDINATE AND INDEPENDENT OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER BINDING-PROTEIN; MESSENGER-RNA; GLUCOSE TRANSPORTER; EXPRESSION; DIFFERENTIATION; FAMILY; CELLS; PREADIPOCYTES; MEMBER; BETA	We have previously demonstrated the ability of tumor necrosis factor-alpha (TNF) to down-regulate the expression of GLUT4 (insulin-responsive glucose transporter) and C/EBP-alpha (CCAAT/enhancer-binding protein) (Stephens J. M., and Pekala, P. H. (1991) J. Biol. Chem. 266, 21839-21845). As C/EBP-alpha has been suggested to control GLUT4 expression, we have examined the time course for attenuation of transcription of these genes. Run-on transcription assays indicate a coordinate transcriptional repression of both GLUT4 and C/EBP-alpha-genes (as well as the 422/aP2 gene, the adipocyte lipid-binding protein, whose expression has also been proposed to be controlled by C/EBP-alpha). Inhibition of transcription was observed within 1 h of TNF addition, with maximal suppression observed after 4 h. The inhibition was not blocked by cycloheximide. Okadaic acid treatment (1 h, 0.5-mu-M) also resulted in the coordinate transcriptional repression of the C/EBP-alpha, GLUT4, and 422/aP2 genes, consistent with involvement of a kinase-phosphatase system in the regulation of these genes. The decrease in C/EBP-alpha-protein content was detectable 4 h after TNF addition and declined to 25% of controls within 24 h. A minor decrease in the protein content of GLUT4 was observed during the first 24 h of exposure to TNF; however, after 72 h of exposure GLUT4 protein was not detectable. The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor. However, the rapid loss of C/EBP-alpha-protein may be a contributing factor to further transcriptional suppression of the GLUT4 gene at the later time points. In addition to the transcriptional effect, we report that TNF-induced destabilization of these mRNAs contributes to decreased expression of all three genes.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27834	University of North Carolina; East Carolina University			Stephens, Jacqueline M/R-5217-2018		NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05812-12] Funding Source: Medline; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5394; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FROST SC, 1985, J BIOL CHEM, V260, P2646; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	34	180	185	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13580	13584						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618860				2022-12-27	WOS:A1992JB74600076
J	DEARRUDA, MV; BAZARI, H; WALLEK, M; MATSUDAIRA, P				DEARRUDA, MV; BAZARI, H; WALLEK, M; MATSUDAIRA, P			AN ACTIN FOOTPRINT ON VILLIN - SINGLE SITE SUBSTITUTIONS IN A CLUSTER OF BASIC RESIDUES INHIBIT THE ACTIN SEVERING BUT NOT CAPPING ACTIVITY OF VILLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MICROVILLUS CYTOSKELETON; VISCERAL ENDODERM; ESCHERICHIA-COLI; CALCIUM CONTROL; BINDING DOMAIN; GELSOLIN; PROTEINS; SEQUENCE; EXPRESSION	Villin is a multidomain protein that severs, caps, and bundles actin filaments. We employed a chemical modification/cleavage strategy to identify residues whose chemical reactivities are reduced when villin is complexed with actin. We found that actin protects 3 methionine residues, Met125, Met379, and Met711 from oxidation by N-chlorosuccinimide. Because Met125 lies within the actin-severing domain of villin (44T), we probed this region for actin binding sites using a series of overlapping peptides each with an additional cysteine residue at their C terminus. Each peptide, as a disulfide-bonded dimer, was examined for actin cross-linking activity by electron microscopy and light scattering. Our results with M3R suggest this region contains an F-actin binding site and are consistent with proteolysis and deletion mutagenesis studies of gelsolin. Single substitution of the basic residues modulated actin severing but not capping activity of 44T. Circular dichroism and protease digestions did not detect alterations in secondary structure or conformational changes in the mutants, although some are cleaved more rapidly, thereby suggesting a change in the packing of the domains. Our results highlight that basic residues comprise part of the F-actin binding site that is involved in the actin severing activity of villin.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	DEARRUDA, MV (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NIDDK NIH HHS [DK35306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; DOERING D, 1992, THESIS MIT; EICHINGER L, 1991, J CELL BIOL, V112, P665, DOI 10.1083/jcb.112.4.665; EZZELL RM, 1989, DEVELOPMENT, V106, P407; GLENNEY JR, 1980, P NATL ACAD SCI-BIOL, V77, P6458, DOI 10.1073/pnas.77.11.6458; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1986, J MUSCLE RES CELL M, V7, P446, DOI 10.1007/BF01753587; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1992, J BIOL CHEM, P11818; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; JOPPICHKUHN R, 1982, ANAL BIOCHEM, V119, P73, DOI 10.1016/0003-2697(82)90666-2; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MATSUDAIRA P, 1985, P NATL ACAD SCI USA, V82, P6788, DOI 10.1073/pnas.82.20.6788; MATSUDAIRA P, 1985, NATURE, V315, P248, DOI 10.1038/315248a0; MATSUDAIRA P, 1992, P73; MATSUDAIRA P, 1983, NATURE, V301, P209, DOI 10.1038/301209a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P657, DOI 10.1083/jcb.92.3.657; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; Sambrook J, 1989, MOL CLONING LABORATO; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; TAYLOR RS, 1976, BIOCHEM J, V159, P301, DOI 10.1042/bj1590301; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1990, FEBS LETT, V264, P78, DOI 10.1016/0014-5793(90)80769-F; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	50	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13079	13085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618806				2022-12-27	WOS:A1992HZ48300100
J	CHATTOPADHYAY, A; JAMES, HL; FAIR, DS				CHATTOPADHYAY, A; JAMES, HL; FAIR, DS			MOLECULAR RECOGNITION SITES ON FACTOR-XA WHICH PARTICIPATE IN THE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; SERINE PROTEASES; FACTOR-V; ACTIVATION	Coagulation factor X, when activated to factor Xa by proteolytic cleavage, itself becomes an active serine protease which participates as a component of the macromolecular prothrombinase complex along with factor Va, phospholipid, and calcium ions. To identify specific structural regions on factor Xa responsible for mediating its function in activating prothrombin, we used 21 synthetic peptides corresponding to 65% of the primary structure of factor X as potential inhibitors of prothrombin activation. Using purified components, thrombin formation was inhibited by seven peptides in a dose-dependent noncompetitive manner. Antibodies to selected inhibitory peptides affinity purified on a factor Xa-agarose column inhibited thrombin formation in a dose-dependent manner, indicating that the corresponding regions on factor Xa are surface-exposed. Kinetic analyses varying the order of reagent addition suggested that peptides 211-222, 254-269, and 263-274 were highly effective in preventing the factor Xa-factor Va interaction. Peptides 275-287 and 415-425 were considered to derive from a distal region involved in substrate binding, based upon mixed inhibition kinetic analyses and assuming that inhibitory peptides not inhibitory in factor Va binding are related to a specific region of substrate interaction. Cross-linking studies confirmed that peptides 263-274 and 263-276 could bind specifically to the light chain of factor V/Va. These findings provide the basis for further pursuing the precise definition of interactive sites on factor Xa using site-directed mutagenesis and molecular modeling.	UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, POB 2003, TYLER, TX 75710 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; FUNG MR, 1988, THESIS U BRIT COLUMB; FURIE B, 1982, J BIOL CHEM, V257, P3875; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; Hartley BS, 1971, ENZYMES, V3, P323; Hewett-Emmett D, 1981, Ann N Y Acad Sci, V370, P511, DOI 10.1111/j.1749-6632.1981.tb29759.x; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; NEMERSON Y, 1980, CRC CR REV BIOCH MOL, V9, P45, DOI 10.3109/10409238009105472; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NOSSEL HL, 1964, THROMB DIATH HAEMOST, V12, P505; SCHWARTZ BS, 1981, J CLIN INVEST, V67, P1650, DOI 10.1172/JCI110201; Segel I.H., 1975, ENZYME KINETICS; SEGERS WH, 1962, PROTHROMBIN, P213; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1	22	61	66	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12323	12329						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601896				2022-12-27	WOS:A1992HY94700100
J	ARNER, ESJ; VALENTIN, A; ERIKSSON, S				ARNER, ESJ; VALENTIN, A; ERIKSSON, S			THYMIDINE AND 3'-AZIDO-3'-DEOXYTHYMIDINE METABOLISM IN HUMAN PERIPHERAL-BLOOD LYMPHOCYTES AND MONOCYTE-DERIVED MACROPHAGES - A STUDY OF BOTH ANABOLIC AND CATABOLIC PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HUMAN LYMPHOID-CELLS; PYRIMIDINE NUCLEOSIDES; ESCHERICHIA-COLI; DNA-SYNTHESIS; BRAIN-TISSUE; PHOSPHORYLASE; REPLICATION; INHIBITION; AIDS	3'-Azido-3'-deoxythymidine (AZT) is HIV-inhibitory in human macrophages, which is surprising in view of the low AZT phosphorylation reported in macrophage extracts. To elucidate the mechanism of AZT activation, we studied AZT anabolism as well as catabolism in human lymphocytes and macrophages, and compared it to that of thymidine. Thymidine kinase (TK)-specific activity in mitogen-stimulated lymphocytes was 15 times higher than in macrophages. However, the TK activity per cell was only 1.3 times higher, because of the large macrophage cell volume. Total cellular TK activity, but not specific activity, matched the level of intracellular AZT anabolism. The substrate specificity of TK in macrophages strongly suggests that mitochondrial TK2 was the enzyme phosphorylating thymidine and AZT in these cells, whereas it was cytosolic TK1 in stimulated lymphocytes. In vivo thymidine catabolism was extensive, forming thymine and dihydrothymine. In macrophages more than 95% of the added thymidine (0.5-mu-M) was degraded within 60 min. AZT, in contrast, was not catabolized, which explains the high AZT nucleotide accumulation, a process opposed only by AZTMP excretion. The lack of catabolism together with phosphorylation by TK2 clarifies how AZT can inhibit human immunodeficiency virus in macrophages. The fact that TK2 and not TK1 phosphorylates AZT in macrophages should have important implications for combination chemotherapy.	KAROLINSKA INST,DEPT VIROL,S-10521 STOCKHOLM,SWEDEN	Karolinska Institutet	ARNER, ESJ (corresponding author), KAROLINSKA INST,INST MED NOBEL,DEPT BIOCHEM 1,S-10401 STOCKHOLM 60,SWEDEN.		Arnér, Elias S.J./J-5832-2012; Arnér, Elias/K-6737-2019	Arnér, Elias S.J./0000-0002-4807-6114; Arnér, Elias/0000-0002-4807-6114				BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BALZARINI J, 1987, MOL PHARMACOL, V32, P798; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BOHMAN C, 1990, BIOCH LIFE SCI ADV, V9, P11; BOLS NC, 1980, ANAL BIOCHEM, V106, P230, DOI 10.1016/0003-2697(80)90142-6; BROWNE MJ, 1990, 6TH P INT C AIDS SAN, P200; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; COHEN A, 1983, J BIOL CHEM, V258, P2334; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; COHN ZA, 1965, J EXP MED, V121, P279, DOI 10.1084/jem.121.2.279; COOK WJ, 1987, J BIOL CHEM, V262, P3788; DESGRANGES C, 1982, BIOCHEM PHARMACOL, V31, P2755, DOI 10.1016/0006-2952(82)90129-0; DESGRANGES C, 1981, BIOCHIM BIOPHYS ACTA, V654, P211, DOI 10.1016/0005-2787(81)90174-X; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FINK RM, 1956, J BIOL CHEM, V218, P1; FRIDLAND A, 1990, MOL PHARMACOL, V37, P665; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GARTNER S, 1986, JAMA-J AM MED ASSOC, V256, P2365, DOI 10.1001/jama.256.17.2365; HAMAMOTO Y, 1987, ANTIMICROB AGENTS CH, V31, P907, DOI 10.1128/AAC.31.6.907; HAO Z, 1988, MOL PHARMACOL, V34, P431; HOLSTEGE A, 1986, CANCER RES, V46, P5576; Ives D H, 1978, Methods Enzymol, V51, P337; KARLSSON A, 1990, THESIS KAROLINSKA I, V2, P369; KIT S, 1985, MICROBIOL SCI, V2, P369; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KRAJEWSKA E, 1978, BIOCHEM PHARMACOL, V27, P1421, DOI 10.1016/0006-2952(78)90095-3; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MOYER JD, 1985, J BIOL CHEM, V260, P2812; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; NIEMANN MA, 1981, BIOCHIM BIOPHYS ACTA, V652, P347, DOI 10.1016/0005-2787(81)90124-6; PERIGNON JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P130, DOI 10.1016/0167-4889(87)90113-3; PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111; PERO RW, 1984, CANCER RES, V44, P4955; PETIT AJC, 1988, J IMMUNOL, V140, P1485; POGOLOTTI AL, 1981, ANAL BIOCHEM, V117, P178, DOI 10.1016/0003-2697(81)90708-9; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SPYROU G, 1987, J BIOL CHEM, V262, P16425; SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305; SZEBENI J, 1991, ANTIMICROB AGENTS CH, V35, P198, DOI 10.1128/AAC.35.1.198; TERAI C, 1991, EXP CELL RES, V193, P375, DOI 10.1016/0014-4827(91)90110-G; TORNEVIK Y, 1991, AIDS RES HUM RETROV, V7, P751, DOI 10.1089/aid.1991.7.751; WALTER MR, 1990, J BIOL CHEM, V265, P14016; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; YARCHOAN R, 1989, PHARMACOL THERAPEUT, V40, P329, DOI 10.1016/0163-7258(89)90083-1; ZHU Z, 1990, MOL PHARMACOL, V38, P929	48	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10968	10975						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597439				2022-12-27	WOS:A1992HX16900009
J	LIM, HM; SIMON, MI				LIM, HM; SIMON, MI			THE ROLE OF NEGATIVE SUPERCOILING IN HIN-MEDIATED SITE-SPECIFIC RECOMBINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA INVERSION; ENHANCER ACTIVITY; BACTERIOPHAGE-MU; STRAND EXCHANGE; PHASE VARIATION; FIS BINDING; PROTEIN; INVIVO; SYSTEM	A series of biochemical assays were developed and performed to monitor the molecular events that occur during the Hin-mediated DNA inversion reaction. These events can be divided into five different stages: 1) binding of proteins (Hin, Fis, and HU) to DNA; 2) pairing of Hin-binding sites; 3) invertasome formation; 4) DNA strand cleavage; 5) strand rotation and religation. A series of topoisomers of the wild type DNA substrate plasmid (ranging from fully relaxed molecules to those with more than the physiological superhelical density (the physiological superhelical density of pKH336 from Escherichia coli DH10B(TM) is -0.072 in this study)) was generated, and the role of negative supercoiling in each step of the inversion reaction was investigated. We found differences in the dependence of the formation of paired Hin-binding sites and of the invertasome formation on the superhelical density of the substrate plasmid. Pairing of Hin-binding sites occurs independently from invertasome formation, and a relatively low degree of negative supercoiling is enough to promote maximal pairing. However, efficient invertasome formation requires higher levels of negative supercoiling.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology								BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUIST MF, 1987, GENE DEV, V1, P762, DOI 10.1101/gad.1.8.762; BRUIST MF, 1984, J BACTERIOL, V159, P71, DOI 10.1128/JB.159.1.71-79.1984; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; GLASGOW AC, 1989, MOBILE DNA, P637; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUBNER P, 1989, J MOL BIOL, V205, P493, DOI 10.1016/0022-2836(89)90220-9; HUGHES KT, 1988, GENE DEV, V2, P937, DOI 10.1101/gad.2.8.937; IIDA S, 1984, VIROLOGY, V134, P421, DOI 10.1016/0042-6822(84)90309-X; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1987, NATURE, V329, P462, DOI 10.1038/329462a0; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; JOHNSON RC, 1984, COLD SPRING HARB SYM, V49, P751, DOI 10.1101/SQB.1984.049.01.085; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; LEDERBERG J, 1956, GENETICS, V41, P743; LIM HM, 1992, J BIOL CHEM, V267, P11183; PLASTERK RHA, 1983, P NATL ACAD SCI-BIOL, V80, P5355, DOI 10.1073/pnas.80.17.5355; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; VANDEPUTTE P, 1980, NATURE, V286, P218, DOI 10.1038/286218a0; ZIEG J, 1977, SCIENCE, V196, P170, DOI 10.1126/science.322276; ZIEG J, 1980, P NATL ACAD SCI-BIOL, V77, P4196, DOI 10.1073/pnas.77.7.4196	30	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11176	11182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597452				2022-12-27	WOS:A1992HX16900040
J	READ, C; LAROSE, AM; LEBLANC, B; BANNISTER, AJ; FIREK, S; SMITH, DR; MOSS, T				READ, C; LAROSE, AM; LEBLANC, B; BANNISTER, AJ; FIREK, S; SMITH, DR; MOSS, T			HIGH-RESOLUTION STUDIES OF THE XENOPUS-LAEVIS RIBOSOMAL GENE PROMOTER INVIVO AND INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; TRANSCRIPTION FACTOR; BASE SUBSTITUTIONS; INITIATION-FACTOR; RDNA PROMOTER; CORE PROMOTER; UPSTREAM; DNA; MUTAGENESIS; SEQUENCES	The first high resolution maps of the Xenopus laevis ribosomal promoter and its flanking regions (-179 to +14) have been created by assaying point mutants both in oocyte and in vitro. Within the promoter boundaries (-141(-145) to +3(+4)), domains analogous to the Core Promoter and "Upstream Control Element" (UCE) were clearly detected. The base pairs at -133, within the UCE, and -20, -10, -7, and +3, within the Core, were all shown to be especially important for promotion. Between the Core and UCE, two central promoter elements (CPEs) were also resolved. Surprisingly, these CPEs did not correspond to the highly conserved enhancer homology (approximately -70 to -110), but to CCCGGCC motifs immediately flanking it. Although xUBF was shown to be a limiting component for in vitro transcription, none of the point mutations was found to affect the interaction of this factor with the promoter.	UNIV LAVAL,HOTEL DIEU QUEBEC,CTR RECH CANCEROL,QUEBEC CITY G1R 2J6,QUEBEC,CANADA	Laval University	READ, C (corresponding author), PORTSMOUTH POLYTECH,BIOPHYS LABS,PORTSMOUTH PO1 2DT,ENGLAND.			Bannister, Andrew/0000-0002-6312-4436; Moss, Thomas (Tom)/0000-0003-2047-4783				BATEMAN E, 1988, CELL, V54, P985, DOI 10.1016/0092-8674(88)90113-4; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BIRKENMEIER EH, 1978, CELL, V15, P1077, DOI 10.1016/0092-8674(78)90291-X; CASSIDY B, 1987, BIOCHIM BIOPHYS ACTA, V909, P133, DOI 10.1016/0167-4781(87)90035-2; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWINTER RFJ, 1986, NUCLEIC ACIDS RES, V14, P6041, DOI 10.1093/nar/14.15.6041; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; FIREK S, 1989, MOL CELL BIOL, V9, P3777, DOI 10.1128/MCB.9.9.3777; FIREK S, 1990, NUCLEIC ACIDS RES, V18, P105, DOI 10.1093/nar/18.1.105; GRUMMT I, 1982, P NATL ACAD SCI-BIOL, V79, P6908, DOI 10.1073/pnas.79.22.6908; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; HENDERSON SL, 1990, MOL CELL BIOL, V10, P4970, DOI 10.1128/MCB.10.9.4970; HENDERSON SL, 1989, GENE DEV, V3, P12; JONES MH, 1988, P NATL ACAD SCI USA, V85, P669, DOI 10.1073/pnas.85.3.669; KEMPERSVEENSTRA AE, 1985, CURR GENET, V10, P253, DOI 10.1007/BF00365621; KOHORN BD, 1983, P NATL ACAD SCI-BIOL, V80, P3265, DOI 10.1073/pnas.80.11.3265; KOHORN BD, 1983, NATURE, V304, P179, DOI 10.1038/304179a0; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LEARNED RM, 1983, P NATL ACAD SCI-BIOL, V80, P3558, DOI 10.1073/pnas.80.12.3558; Maxam A M, 1980, Methods Enzymol, V65, P499; MCSTAY B, 1990, GENE DEV, V4, P1240, DOI 10.1101/gad.4.7.1240; MILLER KG, 1985, MOL CELL BIOL, V5, P554, DOI 10.1128/MCB.5.3.554; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MITCHELSON K, 1987, NUCLEIC ACIDS RES, V15, P9577, DOI 10.1093/nar/15.22.9577; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; Moss T, 1985, Oxf Surv Eukaryot Genes, V2, P207; MOSS T, 1982, CELL, V30, P835, DOI 10.1016/0092-8674(82)90288-4; MUSTERS W, 1989, NUCLEIC ACIDS RES, V17, P9661, DOI 10.1093/nar/17.23.9661; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; REEDER RH, 1987, NUCLEIC ACIDS RES, V15, P7429, DOI 10.1093/nar/15.18.7429; SCHNAPP A, 1990, NUCLEIC ACIDS RES, V18, P1385, DOI 10.1093/nar/18.6.1385; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHORTLE D, 1978, P NATL ACAD SCI USA, V75, P2170, DOI 10.1073/pnas.75.5.2170; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1983, CELL, V35, P199, DOI 10.1016/0092-8674(83)90222-2; TANAKA N, 1990, J BIOL CHEM, V265, P13836; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; WALKER P, 1988, NUCLEIC ACIDS RES, V16, P10657, DOI 10.1093/nar/16.22.10657; WINDLE J, 1986, MOL CELL BIOL, V6, P1228, DOI 10.1128/MCB.6.4.1228; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YAMAMOTO O, 1984, P NATL ACAD SCI-BIOL, V81, P299, DOI 10.1073/pnas.81.2.299	51	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10961	10967						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597438				2022-12-27	WOS:A1992HX16900008
J	SANT, ME; LYONS, SD; PHILLIPS, L; CHRISTOPHERSON, RI				SANT, ME; LYONS, SD; PHILLIPS, L; CHRISTOPHERSON, RI			ANTIFOLATES INDUCE INHIBITION OF AMIDO PHOSPHORIBOSYLTRANSFERASE IN LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L1210 LEUKEMIA; DENOVO PURINE SYNTHESIS; DIHYDROFOLATE-REDUCTASE; METHOTREXATE; LYMPHOBLASTS; MECHANISMS; SYNERGISM; PATHWAY; LIVER	The pathway for de novo biosynthesis of purine, nucleotides contains two one-carbon transfer reactions catalyzed by glycinamide ribotide (GAR) and 5-aminoimidazole-4-carboxamide ribotide (AICAR) transformylases in which N-10-formyltetrahydrofolate is the one-carbon donor. We have found that the antifolates methotrexate (MTX) and piritrexim (PTX) completely block the de novo purine pathway in mouse L1210 leukemia cells growing in culture but with only minor accumulations of GAR and AICAR to less than 5% of the polyphosphate derivatives of N-formylglycinamide ribotide (FGAR) which accumulate when the pathway is blocked completely by azaserine. This azaserine-induced accumulation of FGAR polyphosphates is completely abolished by MTX, indicating that inhibition of the pathway is at or before GAR transformylase (reaction 3; Lyons, S. D., and Christopherson, R. I. (1991) Biochem. Int. 24, 187-197). Three h after the addition of MTX (0.1-mu-M), cellular 5-phosphoribosyl-1-pyrophosphate has accumulated 3.4-fold while 6-methylmercaptopurine riboside (25-mu-M) induces a 6.3-fold accumulation. These data suggest that amido phosphoribosyltransferase catalyzing reaction 1 of the pathway is the primary site of inhibition. In support of this conclusion, we have found that dihydrofolate-Glu5, which accumulates in MTX-treated cells, is a noncompetitive inhibitor of amido phosphoribosyltransferase with a dissociation constant of 3.41 +/- 0.08-mu-M for interaction with the enzyme-glutamine complex in vitro. Folate-Glu5, MTX-Glu5, PTX, dihydrotriazine benzenesulfonyl fluoride, and AICAR also inhibit amido phosphoribosyltransferase.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			Lyons, Stephen/AAH-2528-2020; Christopherson, Richard/AAM-3115-2020					ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ALLEGRA CJ, 1987, J BIOL CHEM, V262, P13520; BERTINO JR, 1965, BIOCHEMISTRY-US, V4, P839, DOI 10.1021/bi00881a007; BOKKERINK JPM, 1986, BIOCHEM PHARMACOL, V35, P3549, DOI 10.1016/0006-2952(86)90625-8; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; COWARD JK, 1974, BIOCHEMISTRY-US, V13, P3899, DOI 10.1021/bi00716a013; DUCH DS, 1982, CANCER RES, V42, P3987; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; HILL DL, 1969, BIOCHEMISTRY-US, V8, P122, DOI 10.1021/bi00829a017; HOLMES EW, 1980, ADV ENZYME REGUL, V19, P215; ITAKURA M, 1979, J BIOL CHEM, V254, P333; KUMAR AA, 1981, J BIOL CHEM, V256, P8970; LYONS SD, 1990, J BIOL CHEM, V265, P11377; LYONS SD, 1991, BIOCHEM INT, V24, P187; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NELSON JA, 1972, CANCER RES, V32, P2034; ROWE PB, 1978, J BIOL CHEM, V253, P7711; SANT ME, 1989, CANCER RES, V49, P2645; SANT ME, 1989, ANAL BIOCHEM, V182, P121, DOI 10.1016/0003-2697(89)90728-8; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; THILLET J, 1988, J BIOL CHEM, V263, P12500; WALTHAM MC, 1989, P AUST BIOCHEM SOC, V21, pSP38; WERKHEISER W, 1961, J BIOL CHEM, V236, P888; WOOD AW, 1973, J BIOL CHEM, V248, P138	27	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11038	11045						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597445				2022-12-27	WOS:A1992HX16900020
J	WAN, J; XU, HX; GRUNSTEIN, M				WAN, J; XU, HX; GRUNSTEIN, M			CDC14 OF SACCHAROMYCES-CEREVISIAE - CLONING, SEQUENCE-ANALYSIS, AND TRANSCRIPTION DURING THE CELL-CYCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHATASES; SINGLE-DIVISION MEIOSIS; HISTONE GENES; YEAST; SEGREGATION; DNA; MUTANTS; REPLICATION; NUCLEOSOME; PATHWAY	We have cloned, mapped and sequenced the complete CDC14 gene of Saccharomyces cerevisiae and characterized its transcription during the cell cycle. CDC14 was found within a 3.5-kilobase pair XhoI-XbaI fragment of chromosome VI. The DNA sequence reveals an open reading frame capable of encoding a 423-amino acid polypeptide. Protein sequence comparisons through the Prosite, GenBank and EMBL databases allowed us to identify a conserved protein tyrosine phosphatase active site in the encoded CDC14 protein beginning at amino acid 153. Disruption demonstrates that CDC14 is an essential gene. The level of the CDC14 transcript appears to be weakly cell cycle-regulated and has a periodicity which lags approximately 15 min behind histone HTB1 mRNA accumulation levels. DNA sequence analysis has identified a region within the CDC14 promoter which bears a striking resemblance (15 out of 21 base pairs identity) to the cell cycle regulation region of the promoter of the histone H2A1-H2B1 (HTA1-HTB1) gene pair. The cell cycle regulation sequence is responsible for the periodic accumulation and hydroxyurea sensitivity of the histone HTA1-HTB1 message. However, unlike histone mRNA, which is repressed upon hydroxyurea arrest, CDC14 mRNA appears to be unaffected. This suggests that CDC14 and histone genes are regulated by different mechanisms during the cell cycle. Furthermore, superhelical density measurements suggest that CDC14 is not involved in nucleosome assembly.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	WAN, J (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023674, R01GM023674, T32GM007185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23674, GM07185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN K, 1991, J BIOL CHEM, V266, P12964; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1985, GENETICS, V110, P381; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HEREFORD L, 1979, CELL, V18, P1261, DOI 10.1016/0092-8674(79)90237-X; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; LYCAN DE, 1987, MOL CELL BIOL, V7, P614, DOI 10.1128/MCB.7.2.614; MOIR D, 1982, GENETICS, V100, P565; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAMBROOK J, 1989, MOL CLONIGN LABORATO; SHARON G, 1990, GENETICS, V125, P487; SHARON G, 1990, GENETICS, V125, P475; SIKORSKI RS, 1989, GENETICS, V122, P19; STRABY KB, 1988, NUCLEIC ACIDS RES, V16, P2841, DOI 10.1093/nar/16.7.2841; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; WANG JC, 1982, CELL, V29, P724, DOI 10.1016/0092-8674(82)90433-0; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; XU HX, 1990, MOL CELL BIOL, V10, P2687, DOI 10.1128/MCB.10.6.2687	32	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11274	11280						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597462				2022-12-27	WOS:A1992HX16900055
J	DEKKER, EE; KITSON, RP				DEKKER, EE; KITSON, RP			2-KETO-4-HYDROXYGLUTARATE ALDOLASE - PURIFICATION AND CHARACTERIZATION OF THE HOMOGENEOUS ENZYME FROM BOVINE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; BINDING	2-Keto-4-hydroxyglutarate aldolase, which catalyzes the reversible cleavage of 2-keto-4-hydroxyglutarate, yielding pyruvate plus glyoxylate, has been purified from extracts of bovine kidney to apparent homogeneity as judged by polyacrylamide gel electrophoresis, gel filtration chromatography, sucrose density gradient centrifugation, and meniscus depletion sedimentation equilibrium experiments. The enzyme from this source has a native and a subunit mass of 144 and 36 kDa, respectively; the pH-activity optimum is 8.8. Rather than being stimulated, aldolase activity is inhibited to varying degrees by added divalent metal ions, whereas a number of metal ion-chelating agents have no effect. An absolute requirement for added thiol compounds could not be shown, but 2-mercaptoethanol enhances activity 2-fold, and added Hg2+ as well as p-mercuribenzoate or dithiodipyridine markedly inhibit catalysis. Incubation of the enzyme with either pyruvate or glyoxylate in the presence of NaBH4 causes extensive loss of aldolase activity concomitant with stable binding of approximately 1.0-1.5 mol of C-14-labeled substrate/mol of enzyme. The circular dichroism spectrum for native aldolase is characteristic of an alpha-helix; incubation of the enzyme with glyoxylate has no effect on this spectrum, but it is considerably altered by pyruvate. Bovine kidney aldolase shows no stereospecificity in catalyzing the aldol cleavage of the two optical isomers of 2-keto-4-hydroxyglutarate, and although it also catalyzes the beta-decarboxylation of oxalacetate, its decarboxylase/aldolase activity ratio is lower than that seen with the pure enzyme from either bovine liver or Escherichia coli.			DEKKER, EE (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NIDDK NIH HHS [DK-03718] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003718] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON WS, 1966, METHOD ENZYMOL, V9, P212; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RK, 1957, METHOD ENZYMOL, V11, P917; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dekker E E, 1975, Methods Enzymol, V42, P285; Dekker E E, 1975, Methods Enzymol, V42, P280; DEKKER EE, 1962, J BIOL CHEM, V237, P2218; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; Friedemann TE, 1943, J BIOL CHEM, V147, P415; GOLDSTEIN IJ, 1965, ARCH BIOCHEM BIOPHYS, V111, P407, DOI 10.1016/0003-9861(65)90203-1; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUPTA SC, 1984, J BIOL CHEM, V259, P12; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HORECKER BL, 1963, BIOCHEM Z, V338, P36; KOBES RD, 1969, J BIOL CHEM, V244, P1919; KOBES RD, 1971, BIOCHEMISTRY-US, V10, P388, DOI 10.1021/bi00779a005; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; LAI CY, 1965, J BIOL CHEM, V240, P1347; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Liu T Y, 1972, Methods Enzymol, V25, P55, DOI 10.1016/S0076-6879(72)25007-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAITRA U, 1963, J BIOL CHEM, V238, P3660; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NISHIHARA H, 1972, J BIOL CHEM, V247, P5079; Parikh I, 1974, Methods Enzymol, V34, P77; PATIL RV, 1992, J BACTERIOL, V174, P102, DOI 10.1128/jb.174.1.102-107.1992; RUTTER WJ, 1964, FED PROC, V23, P1248; TAKAHASHI K, 1973, J BIOCHEM, V74, P1083, DOI 10.1093/oxfordjournals.jbchem.a130335; VLAHOS CJ, 1990, J BIOL CHEM, V265, P20384; VLAHOS CJ, 1985, J BIOL CHEM, V260, P5480; VLAHOS CJ, 1988, J BIOL CHEM, V263, P11683; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; WANG JK, 1981, J BIOL CHEM, V256, P1793; WEBER K, 1975, PROTEINS, V1, P180; WESTHEIMER FH, 1963, P CHEM SOC LONDON, P253; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	42	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10507	10514						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587831				2022-12-27	WOS:A1992HV09000046
J	FLACHMANN, R; BOHNERT, HJ				FLACHMANN, R; BOHNERT, HJ			REPLACEMENT OF A CONSERVED ARGININE IN THE ASSEMBLY DOMAIN OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE SMALL SUBUNIT INTERFERES WITH HOLOENZYME FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; 1,5-BISPHOSPHATE CARBOXYLASE; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCES; QUATERNARY STRUCTURE; PLANT RUBISCO; HYDROGEN-BOND; PROTEIN; MUTATIONS; SITE	In higher plants the small subunit (S) of ribulose-1,5-bisphosphate carboxylase/oxygenase (ribulose-P2 carboxylase, EC 4.1.1.39) contains a segment of 16 amino acids which is absent from cyanobacterial S. This segment connecting two beta-sheets has been shown, by crystallographic analysis, to form a hairpin loop. The quaternary structure of ribulose-P2 carboxylase indicates several S to large subunit (L) interactions. Eleven of 22 residues within the loop form the interface with 20 residues from two different L dimers. Eight of the loop residues are involved in hydrogen bonds, salt links, and hydrophobic interactions. To test the hypothesis, whether this loop had a function in the assembly of L and S into the hexadecameric enzyme, 6 amino acids within the loop were modified by site-directed mutagenesis of the pea rbcS-3A gene. All substituted S were imported by isolated chloroplasts from pea with wild type efficiency. Mutants E54-R, H55-A, P59-A, D63-G, D63-L, and Y66-A were assembly-competent, indicating that changes of side chains at these positions are tolerated. Replacement of arginine 53, whose side chain forms H-bonds with L residues Y226 and G261, with glutamate completely abolished assembly into holoenzyme. We suggest that arginine 53 in S is essential for ribulose-P2 carboxylase quaternary structure in higher plants.	UNIV ARIZONA,DEPT BIOCHEM,BIOSCI W,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona			Bohnert, Hans J/A-7104-2009					ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVNI A, 1989, EMBO J, V8, P1915, DOI 10.1002/j.1460-2075.1989.tb03594.x; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P91; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BARTLETT PA, 1987, SCIENCE, V235, P569, DOI 10.1126/science.3810155; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORUZZI G, 1983, J BIOL CHEM, V258, P1399; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FITCHEN JH, 1990, P NATL ACAD SCI USA, V87, P5768, DOI 10.1073/pnas.87.15.5768; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNDQVIST T, 1988, J BIOL CHEM, V263, P3343; Maniatis T., 1982, MOL CLONING; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PAGE MI, 1984, CHEM ENZYME ACTION, P1; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PONGOR S, 1987, METHOD ENZYMOL, V154, P450; RAMAGE RT, 1989, TECHNIQUES NEW DEV P, P307; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROY H, 1989, PLANT CELL, V1, P1035, DOI 10.1105/tpc.1.11.1035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; TRONRUD DE, 1987, SCIENCE, V235, P571, DOI 10.1126/science.3810156; WASMANN CC, 1988, J BIOL CHEM, V263, P617; WASMANN CC, 1989, P NATL ACAD SCI USA, V86, P1198, DOI 10.1073/pnas.86.4.1198; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10576	10582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587838				2022-12-27	WOS:A1992HV09000055
J	PAPOULAS, O; WILLIAMS, NG; KINGSTON, RE				PAPOULAS, O; WILLIAMS, NG; KINGSTON, RE			DNA-BINDING ACTIVITIES OF C-MYC PURIFIED FROM EUKARYOTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; LOOP-HELIX PROTEINS; LEUCINE ZIPPER; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; SEX DETERMINATION; GENE FAMILY; EXPRESSION; ONCOGENE; SEQUENCE	c-Myc is a nuclear phosphoprotein which contains both a leucine zipper and a helix-loop-helix dimerization motif. These are adjacent to a basic region believed to make specific contacts with DNA upon dimerization. We report the purification of full-length c-Myc to near homogeneity from two independent eukaryotic systems: the baculovirus overexpression system using an insect cell host, and Chinese hamster ovary cells containing heat-inducible c-myc genes. The DNA binding capabilities of these preparations were characterized. Both preparations contain two distinct activities that bind specifically to sequences with a core of CACGTG. The Myc protein is solely responsible for one of these binding activities. Specific sequences that bound to c-Myc were selected from a large pool of random DNA sequence. Sequencing of individual binding sites selected by this procedure yielded a 12-base consensus, PuACCACGTGCTC, for c-Myc binding. Both protein preparations additionally demonstrated a distinct complex, containing both c-Myc and a copurifying 26-29-kDa protein, that bound to DNA with higher affinity than Myc alone. Selection of specific DNA sequences by this complex revealed a consensus binding site similar to the 12-base consensus described above. These data demonstrate that c-Myc isolated from eukaryotic cells is capable of sequence-specific DNA binding and further refine the optimal sequence for c-Myc binding. These protein preparations should prove useful in further characterizing the biochemical properties of c-Myc.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,WELLMAN 10,FRUIT ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School								ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BAGCHI MK, 1987, MOL CELL BIOL, V7, P4151, DOI 10.1128/MCB.7.12.4151; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BREYER RM, 1989, J BIOL CHEM, V264, P13348; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1988, ANAL BIOCHEM, V174, P313, DOI 10.1016/0003-2697(88)90551-9; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUDWIG SR, 1990, CELL, V62, P849, DOI 10.1016/0092-8674(90)90259-H; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Penn L J, 1990, Semin Cancer Biol, V1, P69; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P12; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291	60	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10470	10480						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587829				2022-12-27	WOS:A1992HV09000042
J	SIERRA, F; COEYTAUX, S; JUILLERAT, M; RUFFIEUX, C; GAULDIE, J; GUIGOZ, Y				SIERRA, F; COEYTAUX, S; JUILLERAT, M; RUFFIEUX, C; GAULDIE, J; GUIGOZ, Y			SERUM T-KININOGEN LEVELS INCREASE 2 TO 4 MONTHS BEFORE DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE PROTEIN; PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; DIETARY RESTRICTION; GENE-EXPRESSION; RNA ISOLATION; POLYACRYLAMIDE; INFLAMMATION; INHIBITOR; CELLS	We have reported an accumulation of T-kininogen mRNA in the liver of aging Sprague-Dawley rats. T-kininogen is a cysteine proteinase inhibitor. Since a disruption of the intracellular protein degradation machinery is known to occur during senescence, we wished to further define the role of this protein in the aging process. As a first step, we have measured T-kininogen levels both in serum and within the liver. We have found that serum protein levels are indeed augmented during senescence, although not as dramatically as the mRNA (2.5-fold versus 8.3-fold). Immunocytochemistry, as well as Western blot analysis suggests that this is due to the presence of T-kininogen within hepatic cells in aged rats. Life-long dietary restriction, a known age-prolonging treatment, decreases the overexpression of the protein in 24-month-old rats. Later, diet-restricted animals still show an increased expression from the gene, the effect being delayed but not abolished by dietary manipulation. Interestingly, a longitudinal study indicated the existence of a positive correlation between the time of increase of serum T-kininogen and the time of death of the animal. Serum T-kininogen was found to increase 2.5-4 months before death.	MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University	SIERRA, F (corresponding author), NESTEC LTD,RES CTR,VERS CHEZ LES BLANC,POB 44,CH-1000 LAUSANNE 26,SWITZERLAND.							ANDERSON KP, 1985, J BIOL CHEM, V260, P2065; ANDERSON KP, 1984, ARCH BIOCHEM BIOPHYS, V233, P624, DOI 10.1016/0003-9861(84)90488-0; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BIRCH HE, 1986, J BIOL CHEM, V261, P8077; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAO J, 1988, BIOCHIM BIOPHYS ACTA, V964, P329, DOI 10.1016/0304-4165(88)90033-5; CHATTERJEE B, 1989, FASEB J, V172, P169; CHEN JC, 1973, BIOCHIM BIOPHYS ACTA, V312, P598, DOI 10.1016/0005-2787(73)90458-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; FEY GH, 1990, PROGR LIVER DISEASE; FURUTOKATO S, 1985, J BIOL CHEM, V260, P2054; GLECKMAN R, 1982, JAMA-J AM MED ASSOC, V248, P1478, DOI 10.1001/jama.248.12.1478; GUIGOZ Y, 1985, HDB BIOL AGEING; IVY GO, 1989, BRAIN RES, V498, P360, DOI 10.1016/0006-8993(89)91117-7; IVY GO, 1984, SCIENCE, V226, P958; IVY GO, 1987, NEURAL PLASTICITY LE; IVY GO, 1990, LIPOFUSCIN CEROID PI; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KNOOK DL, 1989, IMMUNOL INVEST, V18, P339; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAURELL CB, 1981, METHOD ENZYMOL, V73, P339; LAVIE L, 1982, BIOCHEM J, V202, P47, DOI 10.1042/bj2020047; MARTIN LW, 1989, AM J PHYSIOL, V257, pR189, DOI 10.1152/ajpregu.1989.257.1.R189; MASORO EJ, 1982, P NATL ACAD SCI-BIOL, V79, P4239, DOI 10.1073/pnas.79.13.4239; MASORO EJ, 1989, LAB INVEST, V60, P165; MASORO EJ, 1988, J GERONTOL BIOL SCI, V43, P1359; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; OKAMOTO H, 1983, BIOCHEM BIOPH RES CO, V112, P701, DOI 10.1016/0006-291X(83)91519-X; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RICHARDSON A, 1987, J BIOL CHEM, V262, P12821; ROTHSTEIN M, 1985, MODIFICATION PROTEIN; SIERRA F, 1989, MOL CELL BIOL, V9, P5610, DOI 10.1128/MCB.9.12.5610; THOMAN ML, 1981, J IMMUNOL, V127, P2102; VANBEZOOIJEN CFA, 1984, MECH AGEING DEV, V25, P1, DOI 10.1016/0047-6374(84)90126-X; WARD WF, 1988, J GERONTOL B-PSYCHOL, V43, P50; WEINDRUCH RH, 1979, FED PROC, V38, P2007; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130; YU BP, 1987, REV BIOL RES AGING, V3	40	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10665	10669						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587844				2022-12-27	WOS:A1992HV09000069
J	GASBARRINI, A; BORLE, AB; FARGHALI, H; BENDER, C; FRANCAVILLA, A; VANTHIEL, D				GASBARRINI, A; BORLE, AB; FARGHALI, H; BENDER, C; FRANCAVILLA, A; VANTHIEL, D			EFFECT OF ANOXIA ON INTRACELLULAR ATP, NA+(I), CA2+(I), MG2+(I), AND CYTOTOXICITY IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; FREE CA-2+; PLASMA-MEMBRANE; LIVER-CELL; EXTRACELLULAR CALCIUM; CEREBRAL-ISCHEMIA; MAMMALIAN-CELLS; HYPOXIC INJURY; BLEB FORMATION; FREE MAGNESIUM	The effects of anoxia were studied in freshly isolated rat hepatocytes maintained in agarose gel threads and perfused with Krebs-Henseleit bicarbonate buffer (KHB). Cytosolic free calcium (Ca2+i) was measured with aequorin, intracellular sodium (Na+i) with SBFI, intracellular pH (pH(i)) with BCECF, lactic dehydrogenase (LDH) by the increase in NADH absorbance during lactate oxidation to pyruvate, ATP by P-31 NMR spectroscopy in real time, and intracellular free Mg2+ (Mg2+i) from the chemical shift of beta-ATP relative to alpha-ATP in the NMR spectra. Anoxia was induced by perfusing the cells with KHB saturated with 95% N2, 5% CO2. After 1 h of anoxia, beta-ATP fell 66%, and 85% after 2 h, while the P(i)/ATP ratio increased 10-fold from 2.75 to 28.3. Under control conditions, the resting cytosolic free calcium was 127 +/- 6 nM. Anoxia increased Ca2+i in two distinct phases: a first rise occurred within 15 min and reached a mean value of 389 +/- 35 nM (p < 0.001). A second peak reached a maximum value of 1.45 +/- 0.12-mu-M (p < 0.001) after 1 h. During the first hour of anoxia, Na+i increased from 15.9 +/- 2.4 mM to 32.2 +/- 1.2 mM (p < 0.001), Mg2+i doubled from 0.51 +/- 0.05 to 1.12 +/- 0.01 mM (p < 0.001), and pH(i) decreased from 7.41 +/- 0.03 to 7.06 +/- 0.1 (p < 0.001). LDH release doubled during the first hour and increased 6-fold during the second hour of anoxia. Upon reoxygenation, ATP, Ca2+i, Mg2+i, Na+i, and LDH returned near the control levels within 45 min. To determine whether the increased LDH release was related to the rise in Ca2+i, and whether the increased Ca2+i was caused by Ca2+ influx, the cells were perfused with Ca2+-free KHB (+ 0.1 mM EGTA) during the anoxic period. After 2 h of anoxia in Ca2+-free medium, beta-ATP again fell 90%, but Ca2+i, after the first initial peak, fell below control levels, and LDH release increased only 2.7-fold. During reoxygenation, Ca2+i, ATP, Na+i, and LDH returned near the control levels within 45 min. These results suggest that the rise in Ca2+i induced by anoxia is caused by an influx of Ca2+ from the extracellular fluid, and that LDH release and cell injury may be related to the resulting rise in Ca2+i.	UNIV PITTSBURGH,SCH MED,DEPT PHYSIOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Farghali, Hassan/K-6582-2017	Farghali, Hassan/0000-0001-6467-9532	NCRR NIH HHS [P41RR03631] Funding Source: Medline; NIAAA NIH HHS [AA04425] Funding Source: Medline; NIADDK NIH HHS [AM39789] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA004425, R01AA004425] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLEN DG, 1983, J PHYSIOL-LONDON, V335, P555, DOI 10.1113/jphysiol.1983.sp014550; ALLSHIRE A, 1987, BIOCHEM J, V244, P381, DOI 10.1042/bj2440381; AW TY, 1987, AM J PHYSIOL, V252, pC362, DOI 10.1152/ajpcell.1987.252.4.C362; BARRY WH, 1987, CIRC RES, V61, P726, DOI 10.1161/01.RES.61.5.726; BERNSTEIN J, 1985, RES COMMUN CHEM PATH, V47, P3; Blinks J.R., 1978, Methods in Enzymology, V57, P292; Blinks J. R., 1985, BIOLUMINESCENCE CHEM, V2, P185; BLINKS JR, 1978, LIFE SCI, V22, P1237, DOI 10.1016/0024-3205(78)90092-9; Borle A B, 1986, Methods Enzymol, V124, P90; BORLE AB, 1986, AM J PHYSIOL, V251, pC323, DOI 10.1152/ajpcell.1986.251.2.C323; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; BORLE AB, 1990, AM J PHYSIOL, V259, pC19, DOI 10.1152/ajpcell.1990.259.1.C19; CHIEN KR, 1977, AM J PATHOL, V88, P539; COBBOLD PH, 1984, NATURE, V312, P444, DOI 10.1038/312444a0; COLCA JR, 1983, BIOCHIM BIOPHYS ACTA, V729, P176, DOI 10.1016/0005-2736(83)90483-2; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; ELMOFTY SK, 1975, AM J PATHOL, V79, P579; EPSTEIN FH, 1985, NEW ENGL J MED, V312, P159; FARBER JL, 1990, ENVIRON HEALTH PERSP, V84, P107, DOI 10.2307/3430711; FARGHALI H, 1990, 9TH ANN SCI M SOC MA, V2, P957; FARISS MW, 1985, SCIENCE, V227, P751, DOI 10.1126/science.3918345; GASBARRINI A, 1990, HEPATOLOGY, V12, P1010; GASBARRINI A, 1991, Gastroenterology, V100, pA745; GASBARRINI A, 1991, Gastroenterology, V100, pA744; GOLIGORSKY MS, 1986, MINER ELECTROL METAB, V12, P363; GOLIGORSKY MS, 1988, MINER ELECTROL METAB, V14, P58; GREENBERG JH, 1990, STROKE, V21, P72; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; HEMS DA, 1970, BIOCHEM J, V120, P105, DOI 10.1042/bj1200105; HEXUM T, 1970, BIOCHIM BIOPHYS ACTA, V212, P322, DOI 10.1016/0005-2744(70)90213-5; IWASA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P229, DOI 10.1016/0005-2736(83)90013-5; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P212; KAUPPINEN RA, 1988, NEUROSCIENCE, V27, P175, DOI 10.1016/0306-4522(88)90228-X; KORETSUNE Y, 1990, CIRCULATION, V82, P528, DOI 10.1161/01.CIR.82.2.528; KORETSUNE Y, 1990, AM J PHYSIOL, V258, pH9, DOI 10.1152/ajpheart.1990.258.1.H9; KUSUOKA H, 1990, CIRC RES, V66, P1268, DOI 10.1161/01.RES.66.5.1268; LEE JA, 1988, PFLUG ARCH EUR J PHY, V413, P83, DOI 10.1007/BF00581232; LEMASTERS JJ, 1990, ENVIRON HEALTH PERSP, V84, P83, DOI 10.2307/3430708; LEMASTERS JJ, 1987, NATURE, V325, P79; LUTAYA G, 1983, BIOCHEM J, V214, P645, DOI 10.1042/bj2140645; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MARBAN E, 1990, CIRC RES, V66, P1255, DOI 10.1161/01.RES.66.5.1255; MCCOY CE, 1988, J CLIN INVEST, V82, P1326, DOI 10.1172/JCI113734; MICHAELIS EK, 1983, J BIOL CHEM, V258, P6101; MOULE SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P383, DOI 10.1016/0304-4157(90)90016-6; NAKAO M, 1974, ANN NY ACAD SCI, V242, P24, DOI 10.1111/j.1749-6632.1974.tb19076.x; NAYLER WG, 1987, INT J CARDIOL, V15, P267, DOI 10.1016/0167-5273(87)90332-9; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; NICOTERA P, 1989, FASEB J, V3, P59, DOI 10.1096/fasebj.3.1.2910738; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; NISHIDA T, 1986, BIOCHEMISTRY-US, V106, P533; OKUNO F, 1983, RES COMMUN CHEM PATH, V39, P437; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PEDERSON PL, 1991, BIOENERGETICS, V6, P243; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; SAKAIDA I, 1991, J BIOL CHEM, V266, P717; SCHANNE FAX, 1986, J BIOL CHEM, V261, P9886; Sharma RJ, 1978, BIOCHEM SOC T, V6, P1319, DOI 10.1042/bst0061319; SHARMA RJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P414, DOI 10.1016/0304-4165(80)90290-1; SILVER IA, 1990, J GEN PHYSIOL, V95, P837, DOI 10.1085/jgp.95.5.837; SMITH GL, 1988, CIRC RES, V62, P1223, DOI 10.1161/01.RES.62.6.1223; SMITH MT, 1981, SCIENCE, V213, P1257, DOI 10.1126/science.7268433; SNOWDOWNE KW, 1984, AM J PHYSIOL, V247, pC396, DOI 10.1152/ajpcell.1984.247.5.C396; SNOWDOWNE KW, 1985, J BIOL CHEM, V260, P1619; SNOWDOWNE KW, 1985, J MOL CELL CARDIOL, V17, P233, DOI 10.1016/S0022-2828(85)80006-7; STEENBERGEN C, 1987, CIRC RES, V60, P700, DOI 10.1161/01.RES.60.5.700; STRUBELT O, 1988, RES COMMUN CHEM PATH, V61, P327; STUDER RK, 1982, J BIOL CHEM, V257, P7987; SWANLJUNG P, 1973, BIOCHIM BIOPHYS ACTA, V305, P519, DOI 10.1016/0005-2728(73)90073-X; THEEN J, 1982, AM J PHYSIOL, V342, pE182; UEMATSU D, 1989, STROKE, V20, P1531, DOI 10.1161/01.STR.20.11.1531; UEMATSU D, 1988, ANN NEUROL, V24, P420, DOI 10.1002/ana.410240311; WATTS JA, 1990, J CARDIOVASC PHARM, V15, P44, DOI 10.1097/00005344-199001000-00007	76	192	193	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1992	267	10					6654	6663						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM053	1637381				2022-12-27	WOS:A1992HM05300033
J	FABRE, E; THARAUD, C; GAILLARDIN, C				FABRE, E; THARAUD, C; GAILLARDIN, C			INTRACELLULAR TRANSIT OF A YEAST PROTEASE IS RESCUED BY TRANSCOMPLEMENTATION WITH ITS PRODOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE EXTRACELLULAR PROTEASE; TRANSFORMING GROWTH FACTOR-BETA-1; YARROWIA-LIPOLYTICA; ESCHERICHIA-COLI; PRO-SEQUENCE; SUBTILISIN; PROPEPTIDE; SECRETION; REQUIREMENT; PRECURSORS	The alkaline extracellular protease (AEP) of the yeast Yarrowia lipolytica is synthesized as a preproprotein. The precursor undergoes a complex maturation during its intracellular transit, successively involving signal peptide cleavage, dipeptidyl aminopeptidase processing, and cleavage at a dibasic site which results in the extracellular release of the active enzyme. It was previously shown that various deletions within the proregion affect the intracellular transit of the protease. Prodeleted precursors are translocated and have their signal sequences removed, but they accumulate in the secretion apparatus. We show here that the secretion of partially active proteins is restored when the prodomain is supplied in trans as an independent peptide. The secretion rescue and maturation processing that are reconstituted by the free propeptide do not reach wild type efficiency. The results of pulse-chase experiments indicate that a rate-limiting step occurs during the intracellular transit of the rescued precursors, before Kex2p proteolytic cleavage. This delayed maturation seems to be responsible for an overall slower release of the rescued polypeptides. Propeptide and AEP were secreted in equimolar amounts by both wild type and trans-complemented strains, but none could be detected in the supernatant when expressed alone. These experiments suggest that the prodomain of AEP initially acts as a crucial folding aid for the early secretory transit of the translocated precursor. They further suggest that the prodomain is also required for a second structural change of the AEP precursor during its activation.	INRA,CNRS,GENET MICROORGANISMES LAB,F-78850 THIVERVAL GRIGNON,FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay				FABRE, Emmanuelle/0000-0002-0009-4604				BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; COLL M, 1991, EMBO J, V10, P1; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; FABRE E, 1991, J BIOL CHEM, V266, P3782; GAILLARDIN C, 1987, CURR GENET, V11, P369, DOI 10.1007/BF00378179; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KISER J, 1991, BIOCHEM BIOPH RES CO, V174, P586; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MATOBA S, 1989, J BIOL CHEM, V264, P6037; MCCRACKEN AA, 1989, J BIOL CHEM, V264, P20843; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NICAUD JM, 1989, J BIOTECHNOL, V12, P285, DOI 10.1016/0168-1656(89)90048-5; OGRYDZIAK DM, 1982, J GEN MICROBIOL, V128, P1225; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	32	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15049	15055						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634541				2022-12-27	WOS:A1992JF08800080
J	HUTCHISON, KA; STANCATO, LF; JOVE, R; PRATT, WB				HUTCHISON, KA; STANCATO, LF; JOVE, R; PRATT, WB			THE PROTEIN-PROTEIN COMPLEX BETWEEN PP60(V-SRC) AND HSP90 IS STABILIZED BY MOLYBDATE, VANADATE, TUNGSTATE, AND AN ENDOGENOUS CYTOSOLIC METAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ROUS-SARCOMA VIRUS; CELL GLUCOCORTICOID RECEPTOR; STEROID-BINDING DOMAIN; TRANSFORMING PROTEIN; DNA-BINDING; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODY; PHOSPHOPROTEIN; RECONSTITUTION	In a recent study demonstrating the cell-free reconstitution of the pp60v-src-hsp90 complex, we found that the tyrosine kinase-hsp90 complex is stabilized by molybdate (Hutchison, K. A., Brott, B. K., De Leon, J. H., Perdew, G. H., Jove, R., and Pratt, W. B. (1992) J. Biol. Chem. 267, 2902-2908). In this paper, we examine in detail the stabilization of this protein-protein interaction by transition metal oxyanions. The pp60v-src-hsp90 complex is stabilized by sodium molybdate with the same concentration dependence as the glucocorticoid receptor-hsp90 complex. As with the steroid receptor heterocomplexes, vanadate and tungstate also stabilize the pp60v-src-hsp90 interaction. Passage of cytosol through a Chelex-100 metal-chelating resin destabilizes the native pp60v-src-hsp90 complex, suggesting that the complex is normally stabilized by an endogenous metal factor. Readdition of either the heat-stable components of cytosol or a partially purified endogenous metal factor stabilizes the metal-depleted complex. Molybdate also stabilizes the presence of p50, a known hsp90-associated protein, in the pp60v-src heterocomplex. Given the identical effects of transition metal oxyanions on both pp60v-src- and steroid receptor-hsp90 complexes and the lack of any sequence homology between pp60v-src and the receptors, it seems very likely that it is the common component, hsp90, that contains the site of the metal interaction.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,6322 MED SCI BLDG 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA47809] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1990, BIOCHEMISTRY-US, V29, P520, DOI 10.1021/bi00454a028; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1981, CELL, V25, P3633; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DAHMER MK, 1981, J BIOL CHEM, V256, P9401; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, J BIOL CHEM, V263, P18520; DIEMANN E, 1973, COORDIN CHEM REV, V10, P79, DOI 10.1016/S0010-8545(00)80232-5; ERHART JC, 1988, ONCOGENE, V3, P595; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOUSLEY PR, 1985, J BIOL CHEM, V260, P3810; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEACH KL, 1982, J BIOL CHEM, V257, P381; LEACH KL, 1979, J BIOL CHEM, V254, P1884; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MESHINCHI S, 1988, J BIOL CHEM, V263, P16809; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MESHINCHI S, 1991, BIOCHEMISTRY-US, V30, P8617, DOI 10.1021/bi00099a018; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; NIELSEN CJ, 1977, J BIOL CHEM, V252, P7568; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; PRATT WB, 1988, J BIOL CHEM, V263, P267; REXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SANDO JJ, 1979, J BIOL CHEM, V254, P4772; SATO B, 1980, ENDOCRINOLOGY, V106, P1142, DOI 10.1210/endo-106-4-1142; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; THUCHISON KA, 1992, J BIOL CHEM, V267, P2902; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436	55	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13952	13957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629193				2022-12-27	WOS:A1992JD32500029
J	NOMIZU, M; UTANI, A; SHIRAISHI, N; KIBBEY, MC; YAMADA, Y; ROLLER, PP				NOMIZU, M; UTANI, A; SHIRAISHI, N; KIBBEY, MC; YAMADA, Y; ROLLER, PP			THE ALL-D-CONFIGURATION SEGMENT CONTAINING THE IKVAV SEQUENCE OF LAMININ A-CHAIN HAS SIMILAR ACTIVITIES TO THE ALL-L-PEPTIDE INVITRO AND INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SYNTHETIC PEPTIDE; CELL-ADHESION; NEURITE OUTGROWTH; IDENTIFICATION; GLYCOPROTEIN; ATTACHMENT; RESISTANCE; SECONDARY; PROTEINS	Laminin is a basement membrane glycoprotein that has diverse biological activities. A sequence on the A chain containing IKVAV (Ile-Lys-Val-Ala-Val) has been shown to promote neurite outgrowth, cell adhesion, and tumor growth and metastasis. Here we have determined the structural requirements of this synthetic peptide for biological activity. Twelve-amino acid-long all-L- (LAM-L) and all-D-peptide (LAM-D) segments as well as an alternating D- and L-amino acid-containing peptide (LAM-DL), which included the IKVAV sequence (residues 2097-2108), were synthesized. Circular dichroism spectral analysis revealed a mirror image conformation of LAM-D and LAM-L with mainly beta-sheet and to a minor extent alpha-helical structure. LAM-DL did not exhibit any significant ordered conformational features. LAM-D and LAM-L showed similar cell attachment activities for rat pheochromocytoma cells (PC12), whereas LAM-DL was inactive. A peptide analog with randomized IKVAV sequence (LAM-RM) was also inactive. A similar trend was observed in competition experiments of the four peptides with laminin in analogous cell attachment assays. In in vivo experiments, both LAM-D and LAM-L were capable of increasing tumor growth when subcutaneously injected into mice with murine melanoma cells B16F10. Results indicate that the conformational status of the IKVAV domain is a contributing factor in determining the biological activity but that there is no strict requirement for a specific chirality. There is a likely sequence specificity to the IKVAV region.	NCI,DIV CANC TREATMENT,MEDICINAL CHEM LAB,DEV THERAPEUT PROGRAM,BLDG 37,RM 5C02,BETHESDA,MD 20892; NIDR,DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KUBOTA S, 1992, J BIOL CHEM, V267, P4285; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NOMIZU M, 1991, J CHEM SOC CHEM COMM, P1434, DOI 10.1039/c39910001434; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SCARBOROUGH RM, 1988, J BIOL CHEM, V263, P16818; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	32	42	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14118	14121						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629212				2022-12-27	WOS:A1992JD32500053
J	SANTAMBROGIO, P; LEVI, S; AROSIO, P; PALAGI, L; VECCHIO, G; LAWSON, DM; YEWDALL, SJ; ARTYMIUK, PJ; HARRISON, PM; JAPPELLI, R; CESARENI, G				SANTAMBROGIO, P; LEVI, S; AROSIO, P; PALAGI, L; VECCHIO, G; LAWSON, DM; YEWDALL, SJ; ARTYMIUK, PJ; HARRISON, PM; JAPPELLI, R; CESARENI, G			EVIDENCE THAT A SALT BRIDGE IN THE LIGHT CHAIN CONTRIBUTES TO THE PHYSICAL STABILITY DIFFERENCE BETWEEN HEAVY AND LIGHT HUMAN FERRITINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN APOFERRITIN; MOLTEN GLOBULE STATE; H-CHAIN; ESCHERICHIA-COLI; IRON UPTAKE; EXPRESSION; MECHANISM; PROTEINS; SUBUNIT; LIVER	Human ferritin, a multimeric iron storage protein, is composed by various proportions of two subunit types: the H- and L-chains. The biological functions of these two genic products have not been clarified, although differences in reactivity with iron have been shown. Starting from the hypothesis that the high stability typical of ferritin is an important property which may be relevant for its iron storage function, we studied ferritin homopolymers of H- and L-chains in different denaturing conditions. In addition we analyzed 13 H-chain variants with alterations in regions conserved within mammalian H-chains. In all the denaturation experiments H-chain ferritin showed lower stability than L-chain ferritin. The difference was greater in guanidine HCl denaturation experiments, where the end products are fully unfolded peptides, than in acidic denaturation experiments, where the end products are peptides with properties analogous to "molten globule." The study on H-chain variants showed: (i) ferritin stability was not affected by alterations of regions exposed to the inner or outer surface of the shell and not involved in intra- or inter-chain interactions; (ii) stability was reduced by alterations of sequences involved in inter-subunit interactions such as the deletion of the N-terminal extension or substitutions along the hydrophobic and hydrophilic channels; (iii) stability was increased by the substitution of 2 amino acids inside the four-helix bundle with those of the homologous L-chain. One of the residues is involved in a salt bridge in the L-chain, and we concluded that the stability difference between H- and L-ferritins is to a large extent due to the stabilizing effect of this salt bridge on the L-subunit fold.	UNIV MILANO,SAN RAFFAELE HOSP,DEPT BIOMED SCI & TECHNOL,VIA OLGETTINA 60,I-20132 MILAN,ITALY; CNR,I-20131 MILAN,ITALY; UNIV SHEFFIELD,KREBS INST,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,ENGLAND; UNIV ROME TOR VERGATA,DEPT BIOL CHEM,I-00173 ROME,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Sheffield; University of Rome Tor Vergata			levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020; Lawson, David M/D-1810-2009; arosio, paolo/E-6817-2010; Cesareni, Gianni/AAW-1382-2020	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; AROSIO P, 1978, J BIOL CHEM, V253, P4451; AROSIO P, 1989, IRON IMMUNITY CANCER, P55; BOYD D, 1985, J BIOL CHEM, V260, P1755; BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770; BROXMEYER HE, 1989, BLOOD, V73, P74; CHAM BE, 1989, BIOCHEM J, V3, P989; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; CRICHTON RR, 1973, BIOCHEM J, V133, P289, DOI 10.1042/bj1330289; FARGION S, 1988, BLOOD, V71, P753; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GERL M, 1987, BIOL CHEM H-S, V368, P387, DOI 10.1515/bchm3.1987.368.1.387; GOLDBERG ME, 1990, FEBS LETT, V263, P51, DOI 10.1016/0014-5793(90)80703-L; HARRISON PM, 1987, BIOCHEM SOC T, V15, P744, DOI 10.1042/bst0150744; HARRISON PM, 1988, BIOCHEM SOC T, V16, P838; KHOGO Y, 1980, J BIOL CHEM, V255, P5195; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LAWSON DM, 1989, THESIS U SHEFFIELD S; LEACH BS, 1976, J BIOL CHEM, V251, P3856; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LEVI S, 1987, GENE, V51, P267; LINDER MC, 1989, ARCH BIOCHEM BIOPHYS, V269, P485, DOI 10.1016/0003-9861(89)90132-X; LISTOWSKY I, 1972, BIOCHEMISTRY-US, V11, P2176, DOI 10.1021/bi00761a026; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MILLER LL, 1991, P NATL ACAD SCI USA, V86, P4946; MUNRO HN, 1978, PHYSIOL REV, V58, P317, DOI 10.1152/physrev.1978.58.2.317; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SOLLAZZO M, 1985, GENE, V37, P199, DOI 10.1016/0378-1119(85)90273-2; STEFANINI S, 1987, BIOCHEMISTRY-US, V26, P1831, DOI 10.1021/bi00381a007; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TREFFRY A, 1980, BIOCHIM BIOPHYS ACTA, V610, P421, DOI 10.1016/0005-2787(80)90023-4; TREFFRY A, 1984, BIOCHEM J, V220, P717, DOI 10.1042/bj2200717; TREFFRY A, 1989, FEBS LETT, V247, P263; YEWDALL SJ, 1990, BIOCHEM SOC T, V18, P1028, DOI 10.1042/bst0181028	41	118	122	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14077	14083						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629207				2022-12-27	WOS:A1992JD32500048
J	SOTERIADOU, KP; REMOUNDOS, MS; KATSIKAS, MC; TZINIA, AK; TSIKARIS, V; SAKARELLOS, C; TZARTOS, SJ				SOTERIADOU, KP; REMOUNDOS, MS; KATSIKAS, MC; TZINIA, AK; TSIKARIS, V; SAKARELLOS, C; TZARTOS, SJ			THE SER-ARG-TYR-ASP REGION OF THE MAJOR SURFACE GLYCOPROTEIN OF LEISHMANIA MIMICS THE ARG-GLY-ASP-SER CELL ATTACHMENT REGION OF FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; PEPTIDE-SYNTHESIS; AMINO-ACID; MEMBRANE; PROMASTIGOTES; RECEPTOR; IDENTIFICATION; ANTIGEN; PROTEIN; MACROPHAGES	The major surface glycoprotein of Leishmania, gp63, a fibronectin-like molecule, plays a key role in parasite-macrophage interaction. Binding of gp63 to macrophage receptors is inhibited by Arg-Gly-Asp-Ser (RGDS)-containing synthetic peptides of fibronectin and by antibodies to these peptides. However, gp63 lacks an RGDS tetrapeptide. We sought to identify the region of gp63 that antigenically and functionally mimics the RGDS-containing region of fibronectin. We thus synthesized on polyethylene rods overlapping tetracosapeptides covering the whole sequence of Leishmania major gp63. gp63 affinity-purified antibodies raised against fibronectin and against the RGDS-containing fibronectin decapeptide RGDSPASSKP bound specifically to gp63 residues 241-264. Subsequently, by the use of smaller peptides, the gp63 tetrapeptide 252-255 (SRYD) was identified as the minimum antibody binding segment. Single residue substitution peptide analogues showed that indeed Tyr and Gly can be alternatively substituted in the SRYD- and RGDS-containing peptides of gp63 and fibronectin, respectively, without major effects on their antibody binding capacity. Subsequently, we investigated the effect of an SRYD peptide on promastigote-macrophage interaction in vitro; treatment of macrophages with an SRYD-containing gp63 octapeptide efficiently inhibited parasite attachment to macrophage receptors. Thus, the conserved among species sequence SRYD of gp63, with significant hydrophilicity, flexibility, and beta-turn propensity features, mimics antigenically and functionally the RGDS sequence of fibronectin. We suggest that this segment constitutes the putative gp63 adhesion site.	UNIV IOANNINA,DEPT CHEM,GR-45110 IOANNINA,GREECE	University of Ioannina	SOTERIADOU, KP (corresponding author), HELLEN INST PASTEUR,DEPT BIOCHEM,127 VAS SOFIAS AVE,GR-11521 ATHENS,GREECE.							AUFFRY C, 1986, HUMAN IMMUNOL, V5, P381; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BOUVIER J, 1985, J BIOL CHEM, V260, P5504; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHANG KP, 1983, CIBA F SYMP, V99, P113; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GISIN BF, 1972, ANAL CHIM ACTA, V58, P248, DOI 10.1016/S0003-2670(00)86882-8; GISIN BF, 1973, HELV CHIM ACTA, V56, P1476, DOI 10.1002/hlca.19730560503; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KARA U, 1989, J IMMUNOL, V143, P1334; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KLEMPNER MS, 1983, J INFECT DIS, V148, P377, DOI 10.1093/infdis/148.3.377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER RA, 1990, MOL BIOCHEM PARASIT, V39, P267, DOI 10.1016/0166-6851(90)90065-T; PETERSON DS, 1986, NATURE, V322, P566, DOI 10.1038/322566a0; RIZVI FS, 1988, EUR J IMMUNOL, V18, P473, DOI 10.1002/eji.1830180323; RUSELL DG, 1989, INFECT IMMUN, V57, P630; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHUKLA DD, 1989, P NATL ACAD SCI USA, V86, P8192, DOI 10.1073/pnas.86.21.8192; SOTERIADOU KP, 1988, INFECT IMMUN, V56, P1180, DOI 10.1128/IAI.56.5.1180-1186.1988; TAUB R, 1989, J BIOL CHEM, V264, P259; TZARTOS SJ, 1990, J BIOL CHEM, V265, P21462; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; VOYIATZAKI CS, 1990, J BIOL CHEM, V265, P22380; WILSON ME, 1986, J IMMUNOL, V136, P4681	36	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13980	13985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629196				2022-12-27	WOS:A1992JD32500033
J	MURAKAMI, Y; MATSUFUJI, S; MIYAZAKI, Y; HAYASHI, S				MURAKAMI, Y; MATSUFUJI, S; MIYAZAKI, Y; HAYASHI, S			DESTABILIZATION OF ORNITHINE DECARBOXYLASE BY TRANSFECTED ANTIZYME GENE-EXPRESSION IN HEPATOMA TISSUE-CULTURE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT-LIVER; MONOCLONAL-ANTIBODY; DEGRADATION; PUTRESCINE; PROTEIN; POLYAMINES; SPERMIDINE; INHIBITOR; ENZYME	The degradation of ornithine decarboxylase (ODC) is stimulated by polyamines in a protein synthesis-dependent manner. It has been suggested that antizyme, an ODC-inhibiting protein induced by polyamines, is involved in the process of polyamine-stimulated ODC decay. In this study, we investigated the direct effect of antizyme on ODC decay in hepatoma tissue culture (HTC) cells. A truncated rat antizyme cDNA, Z1, was inserted into an expression vector at a site under the control of a glucocorticoid-inducible promoter and transfected into HTC cells. In the transfected cells dexamethasone increased the amount of Z1 mRNA and induced active antizyme in the absence of exogenous polyamines. When dexamethasone was added to cells with a high level of ODC, rapid decays of ODC activity and protein were elicited after a lag time. Cycloheximide abolished the effect of dexamethasone. These effects of dexamethasone were not observed in control HTC cells transfected with the chloramphenicol acetyltransferase gene. This study indicated that, once induced, antizyme stimulated ODC degradation independently of polyamines and strongly supported our previous hypothesis that the ODC decay-accelerating action of polyamines is mediated by antizyme.			MURAKAMI, Y (corresponding author), JIKEI UNIV,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN.							CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HOLTTA E, 1986, J BIOL CHEM, V261, P9502; KANAMOTO R, 1986, EUR J BIOCHEM, V154, P539, DOI 10.1111/j.1432-1033.1986.tb09432.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MATSUFUJI S, 1984, J BIOCHEM-TOKYO, V96, P1525, DOI 10.1093/oxfordjournals.jbchem.a134981; MCCANN PP, 1979, J CELL PHYSIOL, V99, P183, DOI 10.1002/jcp.1040990204; MITCHELL JLA, 1985, BIOCHIM BIOPHYS ACTA, V840, P309, DOI 10.1016/0304-4165(85)90210-7; MURAKAMI Y, 1989, BIOCHEM J, V259, P839, DOI 10.1042/bj2590839; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1988, BIOCHEM J, V254, P367, DOI 10.1042/bj2540367; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; SEELY JE, 1983, BIOCHEM J, V216, P701, DOI 10.1042/bj2160701; UTSUNOMIYA K, 1985, Jikeikai Medical Journal, V32, P575	21	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13138	13141						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618815				2022-12-27	WOS:A1992JB74600007
J	KAHN, RA; RANDAZZO, P; SERAFINI, T; WEISS, O; RULKA, C; CLARK, J; AMHERDT, M; ROLLER, P; ORCI, L; ROTHMAN, JE				KAHN, RA; RANDAZZO, P; SERAFINI, T; WEISS, O; RULKA, C; CLARK, J; AMHERDT, M; ROLLER, P; ORCI, L; ROTHMAN, JE			THE AMINO TERMINUS OF ADP-RIBOSYLATION FACTOR (ARF) IS A CRITICAL DETERMINANT OF ARF ACTIVITIES AND IS A POTENT AND SPECIFIC INHIBITOR OF PROTEIN-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI STACK; ADENYLATE-CYCLASE; CHOLERA-TOXIN; REGULATORY COMPONENT; VESICULAR TRANSPORT; RNA-POLYMERASE; BOVINE BRAIN; BINDING; PURIFICATION; EXPRESSION	Deletion of the amino-terminal 17 residues from human ADP-ribosylation factor (ARF) resulted in a protein ([DELTA-1-17]mARF1p) devoid of ARF activity but which retained the ability to bind guanine nucleotides with high affinity. Unlike the wild type, the binding of guanine nucleotides to this deletion mutant was found to be independent of added phospholipids. A chimeric protein was produced, consisting of 10% (the amino-terminal 17 amino acids) human ARF1p and 90% ARL1p, an ARF-like protein (55% identical protein sequence) from Drosophila. This chimera was found to have ARF activity, lacking in the parental ARL1 protein. Thus, the amino terminus of ARF1p was shown to be a critical component of ARF activity. A synthetic peptide, derived from the amino terminus of ARF1p, has no ARF activity. Rather, the peptide was found to be a specific inhibitor of ARF activities. This peptide was also found to be a potent and specific inhibitor of both an in vitro intra-Golgi transport assay and the guanosine 5'-3-O-(thio)triphosphate-stimulated accumulation of coated vesicles and buds from Golgi preparations. We conclude that ARF is required for the budding of coated vesicles from the Golgi stacks and serves a regulatory role in protein secretion through the Golgi in eukaryotic cells.	NCI, DIV CANC TREATMENT, MEDICINAL CHEM LAB, DEV THERAPEUT PROGRAM, BETHESDA, MD 20892 USA; PRINCETON UNIV, DEPT BIOL, PRINCETON, NJ 08544 USA; UNIV GENEVA, INST HISTOL & EMBRYOL, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Princeton University; University of Geneva	KAHN, RA (corresponding author), NCI, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; WEISS O, 1989, J BIOL CHEM, V264, P21066; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	33	239	243	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13039	13046						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618801				2022-12-27	WOS:A1992HZ48300095
J	LENHARD, JM; KAHN, RA; STAHL, PD				LENHARD, JM; KAHN, RA; STAHL, PD			EVIDENCE FOR ADP-RIBOSYLATION FACTOR (ARF) AS A REGULATOR OF INVITRO ENDOSOME-ENDOSOME FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; G-PROTEINS; BINDING; TRANSPORT	We have used an in vitro endosome fusion assay, recombinant ARF, synthetic peptides, and guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) to study the role of ARF during endocytosis. Previous work has shown that GTP-gamma-S stimulates in vitro endosome fusion in dilute cytosol (<0.5 mg/ml) but inhibits fusion in concentrated cytosol (>1.0 mg/ml). Two peptides corresponding to the NH2-terminal 16 amino acids of human ARF1 and ARF4 blocked GTP-gamma-S stimulation of fusion in dilute cytosol and reversed GTP-gamma-S inhibition of fusion in concentrated cytosol. The addition of recombinant human ARF1 to endosomes in dilute or concentrated cytosol resulted in GTP-gamma-S-dependent inhibition of fusion. Only the myristoylated form of ARF inhibited fusion. The NH2-terminal ARF1 peptide reversed inhibition by recombinant ARF1. Preincubation experiments showed that endosomes could form an ARF-resistant intermediate during the fusion process. Western blot analysis revealed clathrin-coated vesicles extracted with detergent retained ARF. The results suggest that ARF is involved in both the stimulatory and inhibitory effects of GTP-gamma-S in dilute and concentrated cytosol, respectively. Furthermore, myristoylation, the NH2-terminal domain, and binding to GTP appear to be critical for ARF activity during an early prefusion step required for endocytosis.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID,ST LOUIS,MO 63110; NCI,DIV CANC TREATMENT,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kahn, Richard/ABD-2666-2020; Stahl, Philip/D-6315-2012	Kahn, Richard/0000-0002-0259-0601; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MAYORGA LS, 1989, SCIENCE, V244, P1474; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WEISS O, 1989, J BIOL CHEM, V264, P21066	25	179	179	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13047	13052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618802				2022-12-27	WOS:A1992HZ48300096
J	LUO, Y; NEET, KE				LUO, Y; NEET, KE			THE UNPROCESSED C-TERMINAL DIPEPTIDE OF RECOMBINANT BETA-NERVE GROWTH-FACTOR DETERMINES 3 STABLE FORMS WITH DISTINCT BIOLOGICAL-ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; GAMMA-SUBUNIT; FACTOR RECEPTORS; PC12 CELLS; SUBMAXILLARY GLAND; FACTOR BINDING; ALPHA-SUBUNIT; FACTOR FAMILY	The processing of polypeptide neurotrophins in the nervous system is poorly understood. In this paper, we provide information on the effects of C-terminal processing of nerve growth factor. Three forms of recombinant mouse-beta-nerve growth factor (rNGF) were produced and isolated from insect cells infected with a recombinant baculovirus. The three purified forms of rNGF exhibited distinct biological activities and differed in their abilities to compete with high affinity binding of mouse-beta-nerve growth factor (mNGF). However, they were chemically and structurally indistinguishable from each other. All three forms of rNGF differed from mature mNGF from mouse submaxillary gland in that the C-terminal Arg-Gly dipeptide had not been proteolytically removed. Removal of the C-terminal dipeptide by gamma-NGF peptidase treatment converted the three forms into a single form identical with mature mNGF. The above results demonstrate that a single polypeptide of rNGF, due to the presence of a C-terminal dipeptide, exhibits three stable dimeric protein conformations with distinct biological activities. The apparent lack of gamma-NGF peptidase in the nervous system raises the possibility that the biologically significant form of NGF may differ from mature mNGF; such a difference may be of physiological relevance.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; UNIV HLTH SCI CHICAGO MED SCH, DEPT BIOL CHEM, N CHICAGO, IL 60064 USA	Case Western Reserve University; Chicago Medical School					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24380] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGELETT.RH, 1971, P NATL ACAD SCI USA, V68, P2417, DOI 10.1073/pnas.68.10.2417; ANGELETT.RH, 1973, BIOCHEMISTRY-US, V12, P100, DOI 10.1021/bi00725a018; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARNETT J, 1990, EXP NEUROL, V110, P11, DOI 10.1016/0014-4886(90)90047-V; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERGER EA, 1977, P NATL ACAD SCI USA, V74, P3647, DOI 10.1073/pnas.74.9.3647; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BRADSHAW RA, 1978, ANNU REV BIOCHEM, V47, P191, DOI 10.1146/annurev.bi.47.070178.001203; BRADSHAW RA, 1983, NATURE, V303, P751, DOI 10.1038/303751a0; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BUXSER S, 1991, J NEUROCHEM, V56, P1012, DOI 10.1111/j.1471-4159.1991.tb02022.x; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FIELDS KL, 1978, CELL, V14, P43, DOI 10.1016/0092-8674(78)90299-4; GREENE L A, 1971, Neurobiology (Copenhagen), V1, P37; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; ISACKSON PJ, 1987, J CELL BIOCHEM, V33, P65, DOI 10.1002/jcb.240330107; ISACKSON PJ, 1984, BIOCHEMISTRY-US, V23, P5997, DOI 10.1021/bi00320a015; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASAIAN MT, 1988, J BIOL CHEM, V263, P5083; KIM IS, 1985, EXP CELL RES, V156, P391, DOI 10.1016/0014-4827(85)90546-4; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1990, EXP NEUROL, V110, P274, DOI 10.1016/0014-4886(90)90039-U; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEIER R, 1986, EMBO J, V5, P1489, DOI 10.1002/j.1460-2075.1986.tb04387.x; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOORE JB, 1974, BIOCHEMISTRY-US, V13, P833, DOI 10.1021/bi00701a030; MOWRY MD, 1984, CELL TISSUE RES, V238, P627; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURPHY RA, 1989, J BIOL CHEM, V264, P12502; NEET KE, 1987, METHOD ENZYMOL, V147, P186; PALMER TE, 1980, ARCH BIOCHEM BIOPHYS, V205, P412, DOI 10.1016/0003-9861(80)90124-1; PANTAZIS NJ, 1983, BIOCHEMISTRY-US, V22, P4264, DOI 10.1021/bi00287a016; PHELPS CH, 1989, SCIENCE, V243, P1189; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHWARZ MA, 1989, J NEUROCHEM, V52, P1203, DOI 10.1111/j.1471-4159.1989.tb01867.x; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SELBY MJ, 1987, J NEUROSCI RES, V18, P293, DOI 10.1002/jnr.490180205; SIMINOSKI K, 1987, BRAIN RES, V435, P273, DOI 10.1016/0006-8993(87)91610-6; SMITH AP, 1969, BIOCHEMISTRY-US, V8, P4918, DOI 10.1021/bi00840a040; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SNYDER SH, 1991, NATURE, V350, P195, DOI 10.1038/350195a0; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STACH RW, 1977, ANAL BIOCHEM, V83, P26, DOI 10.1016/0003-2697(77)90505-X; SUMMERS MD, 1987, MANUAL METHODS BACUL, P16; SUTER U, 1992, J NEUROSCI, V12, P306; SUTTER A, 1979, J BIOL CHEM, V254, P5972; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; THOMAS KA, 1981, J BIOL CHEM, V256, P9156; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0; VARON S, 1967, BIOCHEMISTRY-US, V6, P2202, DOI 10.1021/bi00859a043; VARON S, 1967, P NATL ACAD SCI USA, V57, P1782, DOI 10.1073/pnas.57.6.1782; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WION D, 1986, FEBS LETT, V203, P82, DOI 10.1016/0014-5793(86)81441-7; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; ZIMMERMANN A, 1978, J SUPRAMOL STR CELL, V9, P351, DOI 10.1002/jss.400090306	75	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12275	12283						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601893				2022-12-27	WOS:A1992HY94700093
J	NEWTON, DL; WALES, R; RICHARDSON, PT; WALBRIDGE, S; SAXENA, SK; ACKERMAN, EJ; ROBERTS, LM; LORD, JM; YOULE, RJ				NEWTON, DL; WALES, R; RICHARDSON, PT; WALBRIDGE, S; SAXENA, SK; ACKERMAN, EJ; ROBERTS, LM; LORD, JM; YOULE, RJ			CELL-SURFACE AND INTRACELLULAR FUNCTIONS FOR RICIN GALACTOSE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INACTIVATION; CHAIN-CONTAINING IMMUNOTOXINS; B-CHAIN; A-CHAIN; INTERNALIZED RICIN; GOLGI-APPARATUS; ANTIBODY; MACROPHAGES; SITE; RECEPTORS	The role of the two galactose binding sites of ricin B chain in ricin toxicity was evaluated by studying a series of ricin point mutants. Wild-type (WT) ricin and three ricin B chain point mutants having mutations in either 1) the first galactose binding domain (site 1 mutant, Met in place of Lys-40 and Gly in place of Asn-46), 2) the second galactose binding domain (site 2 mutant, Gly in place of Asn-255), or 3) both galactose binding domains (double site mutant containing all three amino acid replacements formerly stated) were expressed in Xenopus oocytes and then reassociated with recombinant ricin A chain. The different ricin B chains were mannosylated to the same extent. Cytotoxicity of these toxins was evaluated when cell entry was mediated either by galactose-containing receptors or through an alternate receptor, the mannose receptor of macrophages. WT ricin and each of the single domain mutants was able to kill Vero cells following uptake by galactose containing receptors. Lactose blocked the toxicity of each of these ricins. Site 1 and 2 mutants were 20-40 times less potent than WT ricin, and the double site mutant had no detectable cytotoxicity. WT ricin, the site 1 mutant, and the site 2 mutant also inhibited protein synthesis of mannose receptor-containing cells. Ricin can enter these cells through either a cell-surface galactose-containing receptor or through the mannose receptor. By including lactose in the cell medium, galactose-containing receptor-mediated uptake is blocked and cytotoxicity occurs solely via the mannose receptor. WT ricin, site 1, and site 2 mutants were cytotoxic to macrophages in the presence of lactose with the relative potency, WT > site 2 mutant> site 1 mutant. The double site mutant lacked cytotoxicity either in the absence or presence of lactose. Thus, even for mannose receptor-mediated toxicity of ricin, at least one galactose binding site remains necessary for cytotoxicity and two galactose binding sites further increases potency. These results are consistent with the model that the ricin B chain galactose binding activity plays a role not only in cell surface binding but also intracellularly for ricin cytotoxicity.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Warwick	NEWTON, DL (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892, USA.		Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185				ENDO Y, 1987, J BIOL CHEM, V262, P5908; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; GONATAS NK, 1975, EXP CELL RES, V94, P426, DOI 10.1016/0014-4827(75)90508-X; GREGG EO, 1987, J IMMUNOL, V138, P4502; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HATAKEYAMA T, 1986, J BIOCHEM-TOKYO, V100, P781, DOI 10.1093/oxfordjournals.jbchem.a121771; HUDSON TH, 1991, J BIOL CHEM, V266, P18586; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KONISH M, 1983, METHOD ENZYMOL, V98, P301; KORNFELD SB, 1991, CANCER RES, V51, P1689; LAMBERT JM, 1991, CANCER RES, V51, P6236; LEONARD JE, 1985, CANCER RES, V45, P5263; MCINTOSH DP, 1983, FEBS LETT, V164, P17, DOI 10.1016/0014-5793(83)80009-X; MISE T, 1986, AGR BIOL CHEM TOKYO, V50, P151, DOI 10.1080/00021369.1986.10867335; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; RICHARDSON PT, 1988, BIO-TECHNOL, V6, P565, DOI 10.1038/nbt0588-565; ROTH J, 1982, J CELL BIOL, V92, P223; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; SKILLETER DN, 1981, BIOCHIM BIOPHYS ACTA, V677, P495, DOI 10.1016/0304-4165(81)90264-6; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; THORPE PE, 1984, EUR J BIOCHEM, V140, P63, DOI 10.1111/j.1432-1033.1984.tb08067.x; TIETZE C, 1982, J CELL BIOL, V92, P417, DOI 10.1083/jcb.92.2.417; TIMAR J, 1991, BRIT J CANCER, V64, P655, DOI 10.1038/bjc.1991.377; UCKUN FM, 1985, J IMMUNOL, V134, P3504; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VITETTA ES, 1983, P NATL ACAD SCI-BIOL, V80, P6332, DOI 10.1073/pnas.80.20.6332; VITETTA ES, 1986, J IMMUNOL, V136, P1880; WALES R, 1991, J BIOL CHEM, V266, P19172; WAWRZYNCZAK EJ, 1991, CANCER IMMUNOL IMMUN, V32, P289, DOI 10.1007/BF01789046; WAWRZYNCZAK EJ, 1988, BIOCHIM BIOPHYS ACTA, V971, P55, DOI 10.1016/0167-4889(88)90161-9; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; YOKOYAMA M, 1980, EXP CELL RES, V125, P47, DOI 10.1016/0014-4827(80)90187-1; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1979, P NATL ACAD SCI USA, V76, P5559, DOI 10.1073/pnas.76.11.5559; YOULE RJ, 1987, J BIOL CHEM, V262, P4676; YOULE RJ, 1981, CELL, V23, P551, DOI 10.1016/0092-8674(81)90151-3; ZENTZ C, 1978, BIOCHIM BIOPHYS ACTA, V536, P18, DOI 10.1016/0005-2795(78)90047-8	45	80	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11917	11922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601861				2022-12-27	WOS:A1992HY94700042
J	REZAIE, AR; ESMON, NL; ESMON, CT				REZAIE, AR; ESMON, NL; ESMON, CT			THE HIGH-AFFINITY CALCIUM-BINDING SITE INVOLVED IN PROTEIN-C ACTIVATION IS OUTSIDE THE 1ST EPIDERMAL GROWTH-FACTOR HOMOLOGY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-CARBOXYGLUTAMIC ACID; BETA-HYDROXYASPARTIC ACID; BOVINE FACTOR-X; PROTEOLYTIC FORMATION; BLOOD-COAGULATION; CA-2+ BINDING; REGION; THROMBOMODULIN; THROMBIN; ANTICOAGULANT	Binding Ca2+ to a high affinity site in protein C and 4-carboxyglutamic acid (Gla)-domainless protein C results in a conformational change that is required for activation by the thrombin-thrombomodulin complex, the natural activator of protein C. It has been hypothesized that this high affinity Ca2+-binding site is located in the NH2-terminal epidermal growth factor (EGF) homology region of protein C. We have expressed in human 293 cells a deletion mutant of protein C (E2-PD) which lacks the entire Gla region as well as the NH2-terminal EGF homology region of protein C. Ca2+ inhibits activation of E2-PD or Gla-domainless protein C by thrombin with half-maximal inhibition occurring at Ca2+ concentrations of 103 +/- 11 and 70 +/- 7-mu-M, respectively, but is required for both E2-PD and Gla-domainless protein C activation by the thrombin-thrombomodulin complex with half-maximal acceleration occurring at Ca2+ concentrations of 87 +/- 8 and 89 +/- 8-mu-M, respectively. Both E2-PD and Gla-domainless protein C exhibit a reversible, Ca2+- but not Mg2+-dependent decrease (6 +/- 1%) in fluorescence emission intensity with K(d) = 38 +/- 3-mu-M Ca2+. We conclude that the high affinity Ca2+-binding site important for the activation of protein C is located outside of the NH2-terminal EGF homology region and that the metal-binding site in the NH2-terminal EGF homology region may not be a high affinity site in intact protein C.	OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,825 NE 13,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NHLBI NIH HHS [R01 HL-29807, R37 HL-30340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL029807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1982, J BIOL CHEM, V257, P859; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRINNELL BW, 1991, ADV APPL BIOTECHNOL, V11, P29; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; OWEN WG, 1974, J BIOL CHEM, V249, P594; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902	28	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11701	11704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601845				2022-12-27	WOS:A1992HY94700011
J	MOHN, H; CHALIFA, V; LISCOVITCH, M				MOHN, H; CHALIFA, V; LISCOVITCH, M			SUBSTRATE-SPECIFICITY OF NEUTRAL PHOSPHOLIPASE-D FROM RAT-BRAIN STUDIED BY SELECTIVE LABELING OF ENDOGENOUS SYNAPTIC MEMBRANE PHOSPHOLIPIDS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDATE PHOSPHATASE; MIXED MICELLES; HUMAN-PLASMA; PHOSPHATIDYLCHOLINE; PURIFICATION; HYDROLYSIS; DIACYLGLYCEROL; NEUTROPHILS; BREAKDOWN; PATHWAY	We have designed a novel approach for studying the specificity of neutral phospholipase D from rat brain synaptic plasma membranes for endogenous phospholipid substrates in native membranes. A procedure was established that provides synaptic membranes labeled in selected phospholipids. This labeling procedure exploits the presence of endogenous acyl-coenzyme A synthetase and acyl-coenzyme A:lysophospholipid acyltransferase in synaptosomes for acylating various lysophospholipid acceptors with radioactive fatty acid. With [H-3]arachidonate for acylation and optimal concentrations of the respective lysophospholipids, membranes were labeled in either of the following phospholipids: phosphatidylcholine (93% of total label in phospholipids), 1-O-alkyl-phosphatidylcholine (87%), phosphatidylinositol (90%), phosphatidylethanolamine (85%), phosphatidylethanolamine-plasmalogen (81%) or phosphatidylserine (59%). These membranes were employed to study the substrate specificity of the neutral, oleate-activated rat brain phospholipase D. This phospholipase exhibited almost absolute specificity for the choline-phospholipids phosphatidylcholine and 1-O-alkyl-phosphatidylcholine: 0.34% of the former labeled substrate were transphosphatidylated to phosphatidylpropanol during the assay and 0.28% of the latter. Activity toward other phospholipids was barely detectable and could largely be accounted for by utilization of residual labeled phosphatidylcholine present in those preparations. The phospholipase D exhibited some preference for fatty acids in the C-2 position of phosphatidylcholine in the following order: 2-oleoyl-phosphatidylcholine (0.67% of this labeled phosphatidylcholine were converted to phosphatidylpropanol), 2-myristoyl-phosphatidylcholine (0.60%), 2-palmitoyl-phosphatidylcholine (0.46%) and 2-arachidonoyl-phosphatidylcholine (0.34%). The present approach of labeling membrane phospholipids in vitro could be useful in studies of phospholipase specificity as an alternative to the use of sonicated vesicles or mixed detergent-phospholipid micellar systems.	WEIZMANN INST SCI,DEPT HORMONE RES,POB 26,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Welch, Heidi/0000-0001-7865-7000; Chalifa-Caspi, Vered/0000-0001-6030-5816				BALSINDE J, 1990, FEBS LETT, V259, P237, DOI 10.1016/0014-5793(90)80017-D; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CHALIFOUR RJ, 1980, CAN J BIOCHEM CELL B, V58, P1189, DOI 10.1139/o80-159; COCKCROFT S, 1985, FEBS LETT, V181, P259, DOI 10.1016/0014-5793(85)80271-4; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1990, J BIOL CHEM, V265, P1; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KS, 1990, J BIOL CHEM, V265, P17738; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; KISS Z, 1990, J BIOL CHEM, V265, P7345; LIN YP, 1989, J BIOL CHEM, V264, P8641; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; PANAGIA V, 1991, BIOCHIM BIOPHYS ACTA, V1064, P242, DOI 10.1016/0005-2736(91)90308-U; QIAN Z, 1989, J BIOL CHEM, V264, P21720; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; STROSZNAJDER J, 1983, J NEUROCHEM, V40, P84, DOI 10.1111/j.1471-4159.1983.tb12656.x; TAKI T, 1979, J BIOL CHEM, V254, P9761; WANG P, 1991, J BIOL CHEM, V266, P14877; [No title captured]	34	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11131	11136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597450				2022-12-27	WOS:A1992HX16900033
J	ULLRICH, SJ; ANDERSON, CW; MERCER, WE; APPELLA, E				ULLRICH, SJ; ANDERSON, CW; MERCER, WE; APPELLA, E			THE P53 TUMOR SUPPRESSOR PROTEIN, A MODULATOR OF CELL-PROLIFERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LARGE-T-ANTIGEN; WILD-TYPE P53; NUCLEAR-LOCALIZATION; MONOCLONAL-ANTIBODY; DNA-REPLICATION; CYCLE CONTROL; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; GROWTH-REGULATION		BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	United States Department of Energy (DOE); Brookhaven National Laboratory; Jefferson University	ULLRICH, SJ (corresponding author), NCI,CELL BIOL LAB,BETHESDA,MD 20892, USA.				NCI NIH HHS [CA 42866] Funding Source: Medline; NCRR NIH HHS [S07 RR05417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042866] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADDISON C, 1990, ONCOGENE, V5, P423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CALABRETTA B, 1986, CANCER RES, V46, P5738; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; COULIER F, 1985, EMBO J, V4, P3413, DOI 10.1002/j.1460-2075.1985.tb04098.x; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINDLAY CA, 1989, CELL, V57, P1083; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, IN PRESS P NATL ACAD; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, IN PRESS ONCOGENE; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V20, P8375; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1990, ONCOGENE, V5, P945; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANROY F, 1990, ONCOGENE, V5, P207; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	86	228	234	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15259	15262						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639769				2022-12-27	WOS:A1992JG11300001
J	BURANT, CF; TAKEDA, J; BROTLAROCHE, E; BELL, GI; DAVIDSON, NO				BURANT, CF; TAKEDA, J; BROTLAROCHE, E; BELL, GI; DAVIDSON, NO			FRUCTOSE TRANSPORTER IN HUMAN SPERMATOZOA AND SMALL-INTESTINE IS GLUT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE TRANSPORTER; LOCALIZATION; ERYTHROCYTE	We recently reported that the glucose transporter isoform, GLUT5, is expressed on the brush border membrane of human small intestinal enterocytes (Davidson, N. O., Hausman, A. M. L., Ifkovits, C. A., Buse, J. B., Gould, G. W., Burant, C. F., and Bell, G. I. (1992) Am. J. Physiol. 262, C795-C800). To define its role in sugar transport, human GLUT5 was expressed in Xenopus oocytes and its substrate specifiicity and kinetic properties determined. GLUT5 exhibits selectivity for fructose transport, as determined by inhibition studies, with a K(m) of 6 mM. In addition, fructose transport by GLUT5 is not inhibited by cytochalasin B, a competitive inhibitor of facilitative glucose transporters. RNA and protein blotting studies showed the presence of high levels of GLUT5 mRNA and protein in human testis and spermatozoa, and immunocytochemical studies localize GLUT5 to the plasma membrane of mature spermatids and spermatozoa. The biochemical properties and tissue distribution of GLUT5 are consistent with a physiological role for this protein as a fructose transporter.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; INSERM, U178, F-94807 VILLEJUIF, FRANCE	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Institut National de la Sante et de la Recherche Medicale (Inserm)	BURANT, CF (corresponding author), UNIV CHICAGO, DEPT MED, 5841 S MARYLAND AVE, MC1027, CHICAGO, IL 60637 USA.		Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	NHLBI NIH HHS [HL-02166] Funding Source: Medline; NIDDK NIH HHS [DK-42086, DK-20595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUR H, 1977, EUR J BIOCHEM, V74, P397, DOI 10.1111/j.1432-1033.1977.tb11404.x; BROWN CR, 1983, J CELL BIOL, V96, P256, DOI 10.1083/jcb.96.1.256; BURANT CF, 1991, RECENT PROG HORM RES, V47, P343; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DAVIDSONNO, 1992, AM J PHYSIOL, V262, pC795; GLANDER HJ, 1978, ANDROLOGIA, V10, P69; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Greep, 1977, HISTOLOGY, P979; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KING APJ, 1991, BIOCHEMISTRY-US, V30, P11546, DOI 10.1021/bi00113a009; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PETERSON RN, 1977, BIOL REPROD, V17, P198, DOI 10.1095/biolreprod17.2.198; PETERSON RN, 1975, HUMAN SEMEN FERTILIT, P176; PTERSON RN, 1977, FERTIL STERIL, V28, P257; ROGERS BJ, 1990, BIOL REPROD, V43, P1064, DOI 10.1095/biolreprod43.6.1064; SHAFRIR E, 1991, NESTLE NUTR WORKS SE, V25, P131; SIGRISTNELSON K, 1974, BIOCHIM BIOPHYS ACTA, V367, P179; THORENS B, 1990, AM J PHYSIOL, V259, pC279; THORENS B, 1990, AM J PHYSIOL, V259, pC286; WRIGHT EM, 1991, J CLIN INVEST, V88, P1435, DOI 10.1172/JCI115451	20	446	454	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14523	14526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634504				2022-12-27	WOS:A1992JF08800003
J	BUSSOLINO, F; SIRONI, M; BOCCHIETTO, E; MANTOVANI, A				BUSSOLINO, F; SIRONI, M; BOCCHIETTO, E; MANTOVANI, A			SYNTHESIS OF PLATELET-ACTIVATING-FACTOR BY POLYMORPHONUCLEAR NEUTROPHILS STIMULATED WITH INTERLEUKIN-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PERIPHERAL-BLOOD GRANULOCYTES; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; DE-GRANULATION; FACTOR PAF; FUNCTIONAL EXPRESSION; HUMAN-MONOCYTES; FACTOR-ALPHA; RELEASE	Human interleukin-8 (IL-8) was evaluated for its capability to induce the synthesis and release of platelet-activating factor (PAF) from human polymorphonuclear neutrophils (PMN). IL-8 promotes in a dose-dependent fashion (1-100 ng/ml) a rapid synthesis of PAF, which is only partially released. The synthesis of PAF is preceded by the activation of acetyl-CoA: 1-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase, suggesting that IL-8 activates the "remodeling pathway" of PAF synthesis. By thin layer chromatography and reverse-phase high pressure liquid chromatography, we demonstrated that PAF synthesized by human PMN stimulated with IL-8 is heterogeneous: the 2-acetylated phospholipids having the biological and physicochemical characteristics of PAF include the 1-0-alkyl form, which is produced in large extent (51%), and the 1-acyl form (20%). The analysis of the individual molecular species of radyl chain indicated nine peaks, 16:0 and 18:0 being the predominant forms. These results identify PAF as a direct product of IL-8 stimulation in PMN.	IST RIC FARMACOL MARIO NEGRI,I-20100 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	BUSSOLINO, F (corresponding author), DIPARTIMENTO GENET BIOL & CHIM MED,VIA SANTENA 5 BIS,I-10126 TURIN,ITALY.		Mantovani, Alberto/HCI-7449-2022; Bussolino, Federico/AES-3951-2022; Sironi, Marina/AAB-5757-2020; Bussolino, Federico/K-2500-2016	Mantovani, Alberto/0000-0001-5578-236X; Sironi, Marina/0000-0002-3342-1149; Bussolino, Federico/0000-0002-5348-1341				BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BLANK ML, 1982, RES COMMUN CHEM PATH, V38, P3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1986, J CLIN INVEST, V77, P2027, DOI 10.1172/JCI112532; BUSSOLINO F, 1989, J BIOL CHEM, V264, P21711; BUSSOLINO F, 1986, J BIOL CHEM, V261, P6502; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CAMUSSI G, 1989, EUR J BIOCHEM, V182, P661, DOI 10.1111/j.1432-1033.1989.tb14876.x; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CAROLAN EJ, 1990, J IMMUNOL, V145, P2561; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENICHILO MO, 1991, J BIOL CHEM, V266, P4896; DUBOIS C, 1989, J IMMUNOL, V143, P964; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; FURUTA R, 1989, J BIOCHEM-TOKYO, V106, P436, DOI 10.1093/oxfordjournals.jbchem.a122870; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V94, P881, DOI 10.1016/0006-291X(80)91317-0; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; HANAHAN DJ, 1980, J BIOL CHEM, V255, P5514; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; LEVI R, 1989, BIOCHEM BIOPH RES CO, V161, P1341, DOI 10.1016/0006-291X(89)91390-9; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MIZOGUCHI Y, 1991, J GASTROEN HEPATOL, V6, P283, DOI 10.1111/j.1440-1746.1991.tb01479.x; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; MUELLER HW, 1984, J BIOL CHEM, V259, P4554; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NATHAN CF, 1989, BLOOD, V73, P301; OFLAHERTY JT, 1983, RES COMMUN CHEM PATH, V39, P291; OFLAHERTY JT, 1981, AM J PATHOL, V105, P107; OFLAHERTY JT, 1985, J CELL PHYSIOL, V122, P229, DOI 10.1002/jcp.1041220211; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PACCAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187, DOI 10.1016/0006-291X(90)91929-M; PATTON GM, 1982, J LIPID RES, V23, P190; POUBELLE PE, 1991, IMMUNOLOGY, V72, P181; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAMESHA CS, 1987, J IMMUNOL, V138, P1559; RICHES DWH, 1990, J IMMUNOL, V145, P3062; ROUBIN R, 1987, CLIN EXP IMMUNOL, V70, P484; SALEM P, 1990, J IMMUNOL, V144, P1338; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHAW JO, 1981, J IMMUNOL, V127, P1250; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1987, PLATELET ACTIVATING; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3251; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; TRIGGIANI M, 1990, J IMMUNOL, V144, P4773; VALONE FH, 1988, J IMMUNOL, V141, P3945; WAKU K, 1972, J BIOCHEM-TOKYO, V72, P149, DOI 10.1093/oxfordjournals.jbchem.a129880; WANG JM, 1987, J IMMUNOL, V138, P1469; WEINTRAUB ST, 1985, BIOCHEM BIOPH RES CO, V129, P868, DOI 10.1016/0006-291X(85)91972-2; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WIRTHMUELLER U, 1991, BIOCHEM BIOPH RES CO, V176, P972, DOI 10.1016/0006-291X(91)90377-J; WIRTHMUELLER U, 1989, J IMMUNOL, V142, P3213; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; YAMAZAKI M, 1989, P NATL ACAD SCI USA, V86, P5791, DOI 10.1073/pnas.86.15.5791; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993	72	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14598	14603						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634507				2022-12-27	WOS:A1992JF08800019
J	NOHARA, K; SUZUKI, M; INAGAKI, F; SANO, T; KAYA, K				NOHARA, K; SUZUKI, M; INAGAKI, F; SANO, T; KAYA, K			A NOVEL DISIALOGANGLIOSIDE IN RAT SPLEEN LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; GANGLIOSIDES; DIFFERENTIATION; HL-60; LIVER; GD3	A novel ganglioside has been identified as the predominant disialoganglioside of the lymphocytes prepared from rat spleen. The ganglioside was isolated from rat spleen and characterized by compositional analysis, methylation analysis, sialidase hydrolysis, proton NMR spectroscopy, and negative ion fast atom bombardment mass spectrometry. The structure was determined as follows. [GRAPHICS] This ganglioside is a unique derivative of N-acetyllactosaminyl-G(M1). The three monosialogangliosides containing N-acetyllactosaminyl-G(M1) structure, which had been originally isolated from rat spleen (Nohara, K., Suzuki, M., Inagaki, F., Ito, H., and Kaya, K. (1990) J. Biol. Chem. 265, 14335-14339), were also found in the lymphocytes and were hardly detected in the spleen remnant tissue depleted of single cells. On the other hand, G(D1C)(NeuGc,NeuGC) (IV3(NeuGc-alpha-2-8NeuGc)-Gg4Cer), the overwhelmingly predominant gangLioside of rat thymocytes (Nohara, K., Suzuki, M., Inagaki, F., and Kaya, K. (1991) J. Biochem. (Tokyo) 110, 274-278), was demonstrated to be only a minor component of the gangliosides of the spleen Lymphocytes. These results suggested that G(D1c) is characteristic for the immature T lineage lymphoid cells and the gangliosides having lactosaminyl-G(M1) structure are specific for other populations of the lymphocytes in rat.	NATL INST ENVIRONM STUDIES,DIV ENVIRONM CHEM,YATABE,IBARAKI 305,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MEMBRANE BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYSIOL,TOKYO 113,JAPAN	National Institute for Environmental Studies - Japan; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	NOHARA, K (corresponding author), NATL INST ENVIRONM STUDIES,DIV ENVIRONM HLTH SCI,YATABE,IBARAKI 305,JAPAN.							BARTOSZEWICZ Z, 1986, CARBOHYD RES, V151, P77, DOI 10.1016/S0008-6215(00)90331-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HBU S, 1986, ZOKU SEIKAGAKU JIKKE, V5, P169; HERSEY P, 1989, CELL IMMUNOL, V119, P263, DOI 10.1016/0008-8749(89)90243-8; INAGAKI F, 1987, FEBS LETT, V212, P91, DOI 10.1016/0014-5793(87)81563-6; MARCUS DM, 1984, MOL IMMUNOL, V21, P1083, DOI 10.1016/0161-5890(84)90118-4; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; NOHARA K, 1990, J BIOCHEM, V108, P684, DOI 10.1093/oxfordjournals.jbchem.a123263; NOHARA K, 1990, J BIOL CHEM, V265, P14335; NOHARA K, 1991, J BIOCHEM-TOKYO, V110, P274, DOI 10.1093/oxfordjournals.jbchem.a123570; NOHARAUCHIDA K, 1987, J BIOCHEM-TOKYO, V102, P923, DOI 10.1093/oxfordjournals.jbchem.a122133; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OFFNER H, 1987, J IMMUNOL, V139, P3295; ROKUKAWA C, 1982, J BIOCHEM-TOKYO, V92, P1481, DOI 10.1093/oxfordjournals.jbchem.a134072; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; WELTE K, 1987, J IMMUNOL, V139, P1763; YU RK, 1970, J LIPID RES, V11, P506	19	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14982	14986						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634537				2022-12-27	WOS:A1992JF08800072
J	CARR, DW; HAUSKEN, ZE; FRASER, IDC; STOFKOHAHN, RE; SCOTT, JD				CARR, DW; HAUSKEN, ZE; FRASER, IDC; STOFKOHAHN, RE; SCOTT, JD			ASSOCIATION OF THE TYPE-II CAMP-DEPENDENT PROTEIN-KINASE WITH A HUMAN THYROID RII-ANCHORING PROTEIN - CLONING AND CHARACTERIZATION OF THE RII-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; REGULATORY SUBUNIT; BOVINE BRAIN; RAT-BRAIN; IDENTIFICATION; LOCALIZATION; EXPRESSION; COMPARTMENTALIZATION; ACCUMULATION	The type II cAMP-dependent protein kinase (PKA) is localized to specific subcellular environments through binding of the dimeric regulatory subunit (RII) to anchoring proteins. Subcellular localization is likely to influence which substrates are most accessible to the catalytic subunit upon activation. We have previously shown that the RII-binding domains of four anchoring proteins contain sequences which exhibit a high probability of amphipathic helix formation (Carr, D. W., Stofko-Hahn, R. E., Fraser, I. D. C., Bishop, S. M., Acott, T. E., Brennan, R. G., and Scott J. D. (1991) J. Biol. Chem. 266, 14188-14192). In the present study we describe the cloning of a cDNA which encodes a 1015-amino acid segment of Ht 31. A synthetic peptide (Asp-Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys-Ala-Ala-Tyr) representing residues 493-515 encompasses the minimum region of Ht 31 required for RII binding and blocks anchoring protein interaction with RII as detected by band-shift analysis. Structural analysis by circular dichroism suggests that this peptide can adopt an alpha-helical conformation. Both Ht 31 (493-515) peptide and its parent protein bind RII-alpha or the type II PKA holoenzyme with high affinity. Equilibrium dialysis was used to calculate dissociation constants of 4.0 and 3.8 nM for Ht 31 peptide interaction with RII-alpha and the type II PKA, respectively. A survey of nine different bovine tissues was conducted to identify RII binding proteins. Several bands were detected in each tissues using a P-32-RII overlay method. Addition of 0.4-mu-M Ht 31 (493-515) peptide to the reaction mixture blocked all RII binding. These data suggest that all anchoring proteins bind RII-alpha at the same site as the Ht 31 peptide. The nanomolar affinity constant and the different patterns of RII-anchoring proteins in each tissue suggest that the type II-alpha PKA holoenzyme may be specifically targeted to different locations in each type of cell.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University			Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239, F32DK008767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044427] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 08767, DK 44239] Funding Source: Medline; NIGMS NIH HHS [GM 44427] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1991, J BIOL CHEM, V266, P14188; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; EARP HS, 1978, ANNU REV PHARMACOL, V18, P431, DOI 10.1146/annurev.pa.18.040178.002243; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P123; FRASER IDC, 1991, FED PROC, V75, P1530; HARPER JF, 1985, VITAM HORM, V42, P197; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLOTZ IM, 1989, PROTEIN FUNCTION PRA, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOHMANN SM, 1980, J BIOL CHEM, V255, P9985; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; LUO Z, 1991, J BIOL CHEM, V265, P21804; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; PARKER CW, 1990, METHOD ENZYMOL, V182, P721; RUBIN CS, 1979, J BIOL CHEM, V254, P797; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SCOTT JD, 1992, IN PRESS NEWS PHYSL; SHARMA RK, 1983, METHOD ENZYMOL, V102, P210; STEIN JC, 1987, J BIOL CHEM, V262, P3002; STUDIER FW, 1990, GENE EXPRESSION TECH, V185, P60; SUTHERLAND E, 1969, CIRCULATION, V37, P279; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THREURKAUF W, 1982, J BIOL CHEM, V257, P3284	37	293	306	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13376	13382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618839				2022-12-27	WOS:A1992JB74600046
J	DESBOIS, C; CAPEAU, J; HAINAULT, I; WICEK, D; REYNET, C; VEISSIERE, D; CARON, M; PICARD, J; GUERREMILLO, M; CHERQUI, G				DESBOIS, C; CAPEAU, J; HAINAULT, I; WICEK, D; REYNET, C; VEISSIERE, D; CARON, M; PICARD, J; GUERREMILLO, M; CHERQUI, G			DIFFERENTIAL ROLE OF INSULIN-RECEPTOR AUTOPHOSPHORYLATION SITE-1162 AND SITE-1163 IN THE LONG-TERM INSULIN STIMULATION OF GLUCOSE-TRANSPORT, GLYCOGENESIS, AND PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PRIMARY CULTURED ADIPOCYTES; TYROSINE KINASE-ACTIVITY; SUBSTRATE PHOSPHORYLATION; HYBRID RECEPTORS; PLASMA-MEMBRANE; GENE-EXPRESSION; 3T3 ADIPOCYTES; CELLS; RESIDUE-1162	The long-term regulatory effect of insulin on glucose transport activity and glucose transporter expression was examined in Chinese hamster ovary (CHO) transfectants that overexpress either human insulin receptors of the wild type (CHO-R cells) or human insulin receptors mutated at two major autophosphorylation sites, Tyr1162 and Tyr1163 (CHO-Y2 cells). Previous studies showed that, when acutely stimulated by insulin, CHO-Y2 cells exhibit decreased receptor kinase activity along with decreased signaling of several pathways, including that for glucose transport, as compared with CHO-R cells. We now report the following. (i) When treated for 24 h with insulin (10(-10) to 10(-6) M), CHO-R and CHO-Y2 cells displayed closely similar concentration-dependent increases in 2-deoxyglucose uptake. In both transfectants, the maximal insulin-induced increase (approximately 3.5-fold) in uptake was cycloheximide-sensitive and was paralleled by equivalent increases in the levels of GLUT-1 immunoreactive protein and mRNA. (ii) By contrast, under similar conditions, CHO-Y2 cells exhibited a marked decrease in their response to insulin for [U-C-14]glucose incorporation into glycogen (decreased sensitivity and maximal responsiveness) and for [U-C-14]leucine incorporation into protein (decreased sensitivity) as compared with CHO-R cells. (iii) After a 24-h treatment with 10(-7) M insulin, CHO-R (but not CHO-Y2) cells showed a decreased ability to respond to a subsequent acute insulin stimulation of either receptor exogenous kinase activity or 2-deoxyglucose uptake as compared with respective untreated controls. These results indicate that (i) insulin receptors mutated at Tyr1162 and Tyr1163 retain normal signaling of the long-term stimulatory effect of insulin on glucose transport activity and GLUT-1 expression, but not on glycogenesis and overall protein synthesis; (ii) these three insulin signaling pathways may be triggered by distinct domains of the insulin receptor-beta-subunit; and (iii) wild-type (but not twin-tyrosine mutant) receptors undergo negative regulation by chronic insulin treatment for subsequent signaling of acute biological actions of insulin.	UNIV PARIS 06,BIOCHIM LAB,INSERM,U181,27 RUE CHALIGNY,F-75571 PARIS 12,FRANCE; INSERM,U177,INST BIOMED CORDELIERS,F-75006 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite			Desbois-Mouthon, Christele/M-7076-2017	Desbois-Mouthon, Christele/0000-0002-0772-1711				BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPEAU J, 1984, ENDOCRINOLOGY, V115, P654, DOI 10.1210/endo-115-2-654; CARON M, 1989, HORM METAB RES, V21, P295, DOI 10.1055/s-2007-1009219; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHERQUI G, 1990, J BIOL CHEM, V265, P21254; CHIN JE, 1991, J BIOL CHEM, V266, P15587; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAINAULT I, 1991, J CLIN INVEST, V87, P1127, DOI 10.1172/JCI115077; HAINQUE B, 1990, J BIOL CHEM, V265, P7982; HARING H, 1989, DIABETES METAB REV, V5, P431; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KLIP A, 1989, J MEMBRANE BIOL, V111, P1, DOI 10.1007/BF01869205; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOSAKI A, 1988, DIABETES, V37, P1583, DOI 10.2337/diabetes.37.11.1583; KOZKA IJ, 1991, J BIOL CHEM, V266, P11729; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MURUKAMI MS, 1991, J BIOL CHEM, V266, P22653; OKUBO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P126, DOI 10.1016/0003-9861(91)90173-G; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OLEFSKY JM, 1981, AM J MED, V70, P151, DOI 10.1016/0002-9343(81)90422-8; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SINHA MK, 1989, DIABETES, V38, P1217, DOI 10.2337/diabetes.38.10.1217; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THIES RS, 1989, J BIOL CHEM, V264, P12820; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1990, J BIOL CHEM, V265, P18879; TRAXINGER RR, 1989, J BIOL CHEM, V264, P8156; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; VANPUTTEN JPM, 1985, DIABETOLOGIA, V28, P51, DOI 10.1007/BF00277000; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZHANG B, 1991, J BIOL CHEM, V266, P990	60	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13488	13497						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618850				2022-12-27	WOS:A1992JB74600063
J	KIDO, H; YOKOGOSHI, Y; SAKAI, K; TASHIRO, M; KISHINO, Y; FUKUTOMI, A; KATUNUMA, N				KIDO, H; YOKOGOSHI, Y; SAKAI, K; TASHIRO, M; KISHINO, Y; FUKUTOMI, A; KATUNUMA, N			ISOLATION AND CHARACTERIZATION OF A NOVEL TRYPSIN-LIKE PROTEASE FOUND IN RAT BRONCHIOLAR EPITHELIAL CLARA CELLS - A POSSIBLE ACTIVATOR OF THE VIRAL FUSION GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; SENDAI VIRUS; SERINE PROTEASES; MAST-CELLS; INFLUENZA-VIRUS; FACTOR-X; CLEAVAGE; PURIFICATION; ESTERASE; LOCALIZATION	A novel trypsin-like protease associated with rat bronchiolar epithelial Clara cells, named Tryptase Clara, was purified to homogeneity from rat lung by a series of standard chromatographic procedures. The enzyme has apparent molecular masses of 180 +/- 16 kDa on gel filtration and 30 +/- 1.5 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Its isoelectric point is pH 4.75. Studies with model peptide substrates showed that the enzyme preferentially recognizes a single arginine cleavage site, cleaving Boc-Gln-Ala-Arg-4-methylcoumaryl-7-amide most efficiently and having a pH optimum of 7.5 with this substrate. The enzyme is strongly inhibited by aprotinin, diisopropylfluorophosphate, antipain, leupeptin, and Kunitz-type soybean trypsin inhibitor, but inhibited only slightly by Bowman-Birk soybean trypsin inhibitor, benzamidine, and alpha-1-anti-trypsin. Immunohistochemical studies indicated that the enzyme is located exclusively in the bronchiolar epithelial Clara cells and colocalized with surfactant. An immunoreactive protein with a molecular mass of 28.5 kDa was also detected in airway secretions by Western blotting analyses, suggesting that the 30-kDa protease in Clara cells is processed before or after its secretion. Proteolytic cleavage of the hemagglutinin of influenza virus is a prerequisite for the virus to become infectious. Tryptase Clara was shown to cleave the hemagglutinin and activate infectivity of influenza A virus in a dose-dependent way. These results suggest that the enzyme is a possible activator of inactive viral fusion glycoprotein in the respiratory tract and thus responsible for pneumopathogenicity of the virus.	UNIV TOKUSHIMA, SCH MED, DEPT NUTR, TOKUSHIMA 770, JAPAN; JICHI MED SCH, DEPT VIROL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN	Tokushima University; Jichi Medical University	KIDO, H (corresponding author), UNIV TOKUSHIMA, INST ENZYME RES, DIV ENZYME CHEM, TOKUSHIMA 770, JAPAN.							BARBEYMOREL CL, 1987, J INFECT DIS, V155, P667, DOI 10.1093/infdis/155.4.667; FRUTH U, 1987, EUR J IMMUNOL, V17, P1625, DOI 10.1002/eji.1830171116; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GOTOH B, 1990, EMBO J, V9, P4189, DOI 10.1002/j.1460-2075.1990.tb07643.x; HAYASHI T, 1991, J GEN VIROL, V72, P979, DOI 10.1099/0022-1317-72-4-979; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; KASHIWAZ.H, 1965, P SOC EXP BIOL MED, V120, P134, DOI 10.3181/00379727-120-30467; KATUNUMA N, 1988, J CELL BIOCHEM, V38, P291, DOI 10.1002/jcb.240380408; KETTNER C, 1981, THROMB RES, V22, P645, DOI 10.1016/0049-3848(81)90062-1; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; Klenk H D, 1980, Curr Top Microbiol Immunol, V90, P19; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; KRAHENBUHL O, 1988, J IMMUNOL, V141, P3471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSON D, 1978, CELL, V49, P769; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; RICE RH, 1971, J BIOL CHEM, V246, P831; Rott R., 1977, CELL SURF REV, V2, P47; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; Schwartz L B, 1990, Monogr Allergy, V27, P90; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SINGH G, 1984, J HISTOCHEM CYTOCHEM, V32, P49, DOI 10.1177/32.1.6418790; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; TASHIRO M, 1983, INFECT IMMUN, V39, P879, DOI 10.1128/IAI.39.2.879-888.1983; TASHIRO M, 1990, J VIROL, V64, P3627, DOI 10.1128/JVI.64.8.3627-3634.1990; TASHIRO M, 1987, VIROLOGY, V157, P421, DOI 10.1016/0042-6822(87)90284-4; TOYODA T, 1987, VIROLOGY, V158, P242, DOI 10.1016/0042-6822(87)90261-3; WALKER SR, 1986, J HISTOCHEM CYTOCHEM, V34, P1137, DOI 10.1177/34.9.2426341; WOODBURY RG, 1980, FEBS LETT, V114, P189, DOI 10.1016/0014-5793(80)81112-4; YOUNG JDE, 1986, CELL, V47, P183, DOI 10.1016/0092-8674(86)90441-1; [No title captured]	37	225	244	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13573	13579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618859				2022-12-27	WOS:A1992JB74600075
J	TURNER, SR; IRELAND, R; MORGAN, C; RAWSTHORNE, S				TURNER, SR; IRELAND, R; MORGAN, C; RAWSTHORNE, S			IDENTIFICATION AND LOCALIZATION OF MULTIPLE FORMS OF SERINE HYDROXYMETHYLTRANSFERASE IN PEA (PISUM-SATIVUM) AND CHARACTERIZATION OF A CDNA-ENCODING A MITOCHONDRIAL ISOFORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE DECARBOXYLASE; ESCHERICHIA-COLI; LEAF MITOCHONDRIA; H-PROTEIN; PURIFICATION; GENE; EXPRESSION; HISTIDINE; COMPONENT; CLONING	Serine hydroxymethyltransferase (SHMT) has been purified from the mitochondria of green pea leaves. Activity can be fractionated into two distinct peaks by ion exchange chromatography. While these two forms of the enzyme are immunologically indistinguishable, immunoinhibition experiments show the presence of a distinct non-mitochondrial third form of the enzyme to also be present in green pea leaves. While this mitochondrial form of SHMT is abundant in leaves it is absent from roots, although the two tissues have comparable SHMT activity. An antibody raised to purified mitochondrial SHMT was used to screen a cDNA expression library. The sequence of one of the isolated positive clones contained an open reading frame, which encoded a sequence that matched the amino acid sequence determined from the N terminus of the mature protein. The open reading frame encodes a mature protein of 487 amino acids with a M(r) of 54,000, together with a 27-31 amino acid serine-rich leader sequence, presumably required for mitochondrial targeting. The cDNA hybridizes to a small multigene family of 2-3 genes, which appear to be expressed predominantly in leaves. Comparison of the deduced amino acid sequence with the amino acid sequences of the rabbit mitochondrial and cytoplasmic SHMT, show that pea mitochondrial SHMT is equally similar to both of these enzymes. In addition, the rabbit sequences are more like one another than they are to the pea sequence, suggesting an interesting evolutionary relationship for these proteins.	MT ALLISON UNIV,DEPT BIOL,SACKVILLE E0A 3C0,NB,CANADA	Mount Allison University	TURNER, SR (corresponding author), AFRC,INST PLANT SCI RES,JOHN INNES CTR,CAMBRIDGE LAB,COLNEY LANE,NORWICH NR4 7UA,NORFOLK,ENGLAND.		Turner, Simon/K-7580-2012	Turner, Simon/0000-0003-4859-1068				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARTIGUES A, 1990, J BIOL CHEM, V265, P4853; BOURGUIGNON J, 1988, BIOCHEM J, V255, P169, DOI 10.1042/bj2550169; COMBETTE B, 1991, 3RD PLANT RESP M UTR; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; FUJIOKA M, 1969, BIOCHIM BIOPHYS ACTA, V185, P338, DOI 10.1016/0005-2744(69)90427-6; GARDESTROM P, 1985, PHYSIOL PLANTARUM, V64, P29, DOI 10.1111/j.1399-3054.1985.tb01208.x; GRAY MW, 1989, P NATL ACAD SCI USA, V86, P2267, DOI 10.1073/pnas.86.7.2267; HENRICSON D, 1988, PHYSIOL PLANTARUM, V74, P602, DOI 10.1111/j.1399-3054.1988.tb02024.x; HOPKINS S, 1986, J BIOL CHEM, V261, P3363; KIM YH, 1990, J BIOL CHEM, V265, P848; KISAKI T, 1971, PLANT CELL PHYSIOL, V12, P267; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MACHEREL D, 1990, BIOCHEM J, V268, P783, DOI 10.1042/bj2680783; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCALISTERHENN L, 1988, TRENDS BIOCHEM SCI, V13, P178, DOI 10.1016/0968-0004(88)90146-6; MITCHELL MK, 1986, PLANT PHYSIOL, V81, P553, DOI 10.1104/pp.81.2.553; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORRIS DR, 1983, METHOD ENZYMOL, V94, P125; OLIVER DJ, 1990, PLANT PHYSIOL, V94, P833, DOI 10.1104/pp.94.2.833; PALEKAR AG, 1973, J BIOL CHEM, V248, P1158; PIZER LI, 1965, J BACTERIOL, V89, P1145, DOI 10.1128/JB.89.4.1145-1150.1965; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO DN, 1982, PLANT PHYSIOL, V69, P11, DOI 10.1104/pp.69.1.11; RAWSTHORNE S, 1988, PLANTA HEIDELB, V175, P452; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHIRCH V, 1984, CHEM BIOL ASPECTS A, P301; SHINGLES R, 1984, PLANT PHYSIOL, V74, P705, DOI 10.1104/pp.74.3.705; SOMERVILLE CR, 1981, PLANT PHYSIOL, V67, P666, DOI 10.1104/pp.67.4.666; STAUFFER GV, 1981, GENE, V14, P63, DOI 10.1016/0378-1119(81)90148-7; TURNER SR, 1992, J BIOL CHEM, V267, P7745; TURNER SR, 1992, J BIOL CHEM, V267, P5355; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; WALTON NJ, 1986, PLANTA, V167, P119, DOI 10.1007/BF00446378	38	60	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13528	13534						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618853				2022-12-27	WOS:A1992JB74600068
J	ANDO, A; MOMOMURA, K; TOBE, K; YAMAMOTOHONDA, R; SAKURA, H; TAMORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M; KADOWAKI, T				ANDO, A; MOMOMURA, K; TOBE, K; YAMAMOTOHONDA, R; SAKURA, H; TAMORI, Y; KABURAGI, Y; KOSHIO, O; AKANUMA, Y; YAZAKI, Y; KASUGA, M; KADOWAKI, T			ENHANCED INSULIN-INDUCED MITOGENESIS AND MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVITIES IN MUTANT INSULIN-RECEPTORS WITH SUBSTITUTION OF 2 COOH-TERMINAL TYROSINE AUTOPHOSPHORYLATION SITES BY PHENYLALANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PHOSPHORYLATION; CELLS; BINDING; SUBUNIT; IDENTIFICATION; MUTAGENESIS; ADIPOCYTES; PP60C-SRC; ANTIBODY	We have studied the function of a mutant human insulin receptor in which two COOH-terminal autophosphorylation sites (Tyr-1316 and -1322) were replaced by phenylalanine (F/Y COOH-terminal 2 tyrosines (CT2)). In addition, we have also constructed a mutant receptor in which Lys-1018 in the ATP-binding site was changed to arginine (R/K 1018). Both the wild type insulin receptor (HIR) and the mutant receptors were expressed in Chinese hamster ovary (CHO) cells by stable transfection. Autophosphorylation of solubilized and partially purified F/Y CT2 was decreased by approximately 30% compared with the HIR. Tyrosine kinase activities of F/Y CT2 and HIR toward exogenous substrates were almost equal. When CHO cells transfected with F/Y CT2 (CHO-F/Y CT2) were stimulated with insulin, autophosphorylation of the beta-subunit of the insulin receptor and the phosphorylation of an endogenous substrate (pp185) in the intact cell were normal compared with cells expressing HIR (CHO-HIR). CHO-F/Y CT2 exhibited the same insulin sensitivity as CHO-HIR with respect to 2-deoxyglucose uptake. However, the dose-response curve of insulin-stimulated thymidine incorporation in CHO-F/Y CT2 was shifted to the left (approximately 5-7-fold) compared with that in CHO-HIR. There was no significant difference in insulin-like growth factor 1-stimulated thymidine incorporation between CHO-F/Y CT2 and CHO-HIR. Furthermore, the dose-response curve of insulin-stimulated kinase activity toward myelin basic protein in CHO-F/Y CT2 was also shifted to the left (approximately 5-fold) compared with that in CHO-HIR. Kinase assays in myelin basic protein-containing gels revealed that both species of MAP kinases (M(r) 44,000, 42,000) were more sensitive to activation by insulin in CHO-F/Y CT2 than in CHO-HIR. This observation was confirmed in immune complex kinase assays toward microtubule-associated protein 2 (MAP2) using specific antibodies against mitogen-activated protein (MAP) kinase. R/K 1018 mutant insulin receptors showed an absence of insulin-stimulated kinase activity and CHO cells transfected with R/K 1018 (CHO-R/K 1018) failed to enhance 2-deoxyglucose uptake or thymidine incorporation in response to insulin. In addition, R/K 1018 kinase-defective insulin receptors were unable to mediate insulin-stimulated MAP kinase activation. These data suggest that: 1) tyrosine kinase activity of the insulin receptor is required for activation of insulin-stimulated MAP kinases and 2) phosphorylation of COOH-terminal tyrosine residues may play an inhibitory role in mitogenic signaling through regulation of MAP kinases.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYUDA KU,TOKYO 100,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	University of Tokyo; Asahi Life Foundation; Kobe University								AHN NG, 1991, J BIOL CHEM, V266, P4220; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HARI J, 1987, J BIOL CHEM, V262, P15341; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1982, J BIOL CHEM, V257, P392; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THIES RS, 1989, J BIOL CHEM, V264, P12820; TOBE K, 1991, J BIOL CHEM, V266, P24793; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777	47	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12788	12796						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618780				2022-12-27	WOS:A1992HZ48300062
J	HIRABAYASHI, Y; NAKAO, T; IRIE, F; WHITTAKER, VP; KON, K; ANDO, S				HIRABAYASHI, Y; NAKAO, T; IRIE, F; WHITTAKER, VP; KON, K; ANDO, S			STRUCTURAL CHARACTERIZATION OF A NOVEL CHOLINERGIC NEURON-SPECIFIC GANGLIOSIDE IN BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-CONTAINING GLYCOSPHINGOLIPIDS; HANGANUTZIU-DEICHER ANTIGENS; CHROMATOGRAPHY; TRISIALOGANGLIOSIDE; CHOL-1	A new ganglioside antigen, termed Chol-1-alpha-b, recognized by cholinergic neuron-specific antibody, Cholla, was isolated from bovine brain ganglioside mixture using Q-Sepharose. The yield was approximately 1.3 mg from 5 g of the total ganglioside. The chemical structure was characterized as a novel ganglioside by means of gas-liquid chromatography, a permethylation study, mild acid hydrolysis, thin layer chromatography-enzyme immunostaining, fast atom bombardment mass spectrometry, and proton nuclear magnetic resonance spectroscopy. The ganglioside has the following unique structure. [GRAPHICS] When examined by thin layer chromatography immunostaining and enzyme-linked immunosorbant assays, this ganglioside has the most intense immunoreactivity with Chol-1-alpha antibody among bovine brain gangliosides. As combined with our previous results (Hirabayashi, Y., Hyogo, A., Nakao, T., Tsuchiya, K., Suzuki, Y., Matsumoto, M., Kon, K., and Ando, S. (1990) J. Biol. Chem. 265, 8144-8151; Ando, S., Hirabayashi, Y., Kon, K., Inagaki, F., Tate, S., and Whittaker, X. (1992) J. Biochem. (Tokyo), 111, 287-290), the present study indicates the occurrence of a new series of gangliosides containing N-acetylneuraminic acid residue attaching to N-acetylgalactosamine as cholinergic specific antigens.	UNIV SHIZUOKA, SCH PHARMACEUT SCI, DEPT BIOCHEM, OYA, SHIZUOKA 422, JAPAN; UNIV MAINZ, INST ANAT, ARBEITSGRP NEUROCHEM, W-6500 MAINZ, GERMANY; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN	University of Shizuoka; Johannes Gutenberg University of Mainz				Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1991, J BIOCHEM-TOKYO, V11, P287; BHATTI T, 1970, BIOCHIM BIOPHYS ACTA, V222, P339, DOI 10.1016/0304-4165(70)90122-4; FERRETTI P, 1986, J NEUROCHEM, V46, P1888; GIULIANI A, 1990, ARCH BIOCHEM BIOPHYS, V280, P211, DOI 10.1016/0003-9861(90)90538-A; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIGASHI H, 1984, J BIOCHEM, V95, P785, DOI 10.1093/oxfordjournals.jbchem.a134670; HIGASHI H, 1984, J BIOCHEM-TOKYO, V95, P1517, DOI 10.1093/oxfordjournals.jbchem.a134760; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1991, J BIOL CHEM, V266, P10268; HIRABAYASHI Y, 1990, J BIOL CHEM, V265, P8144; ISHIZUKA I, 1972, BIOCHIM BIOPHYS ACTA, V260, P279, DOI 10.1016/0005-2760(72)90039-2; JONES RT, 1981, CELL TISSUE RES, V218, P355; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; NAKAMURA K, 1988, J BIOL CHEM, V263, P9896; NAKAO T, 1991, BIOCHIM BIOPHYS ACTA, V1086, P305, DOI 10.1016/0005-2760(91)90174-G; OBROCKI J, 1988, EXP BRAIN RES, V72, P71, DOI 10.1007/BF00248502; RICHARDSON PJ, 1982, J NEUROCHEM, V38, P1605, DOI 10.1111/j.1471-4159.1982.tb06640.x; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAKI T, 1986, J BIOL CHEM, V261, P3075; WALKER JH, 1982, CELL TISSUE RES, V223, P101; WU GS, 1988, ANAL BIOCHEM, V173, P368, DOI 10.1016/0003-2697(88)90201-1; YUKI N, 1991, IN PRESS NEUROLOGY	24	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12973	12978						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618794				2022-12-27	WOS:A1992HZ48300086
J	FOSTER, DN; MIN, BH; FOSTER, LK; STOFLET, ES; SUN, SQ; GETZ, MJ; STRAUCH, AR				FOSTER, DN; MIN, BH; FOSTER, LK; STOFLET, ES; SUN, SQ; GETZ, MJ; STRAUCH, AR			POSITIVE AND NEGATIVE CIS-ACTING REGULATORY ELEMENTS MEDIATE EXPRESSION OF THE MOUSE VASCULAR SMOOTH-MUSCLE ALPHA-ACTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC3H1 CELL-DIFFERENTIATION; SERUM RESPONSE ELEMENT; C-FOS; BINDING-FACTOR; PURIFICATION; PROMOTER; TRANSCRIPTION; POLYPEPTIDE; MODULATE; REGIONS	Segments of the 5'-flanking region of the mouse vascular smooth muscle a-actin gene were assayed for promoter activity in transfected mouse BC3H1 myogenic cells and AKR-2B embryonic fibroblasts. The region between -150 and -191 that functions as a positive transcriptional element in myogenic and fibroblastic cells contains a mammalian-specific inverted CC(A/T)6GG-type consensus sequence. Expression was restricted to fully differentiated myogenic cells when an additional sequence spanning -191 to -224 was included in reporter gene constructs. This 33-base pair (bp) negative regulatory element is 70% conserved between the mouse and human genes and contains a 10-bp motif at its 3' end that only partially resembles a CC(A/T)6GG element. Retention of a GGGA motif at the 3' boundary of the 33-bp region is sufficient to maintain full transcriptional repression in fibroblasts and is partly responsible for repression in undifferentiated myoblasts. Complete muscle tissue-restrictive expression requires an additional 8 bp from the CC(A/T)6GG-like element immediately 5' to the GGGA motif, since replacement of this region with an unrelated 10-bp sequence completely eliminated restrictive transcriptional behavior in undifferentiated myoblasts. The distal portion of the 5'-flanking region between -224 and -1074 contains six E-box motifs (CANNTG) and mediates high level transcription only in post-confluent BC3H1 myoblasts. Analysis of reporter gene constructs including either the proximal E-box at -240 or all six E-boxes indicate that the five distal E-boxes are not required for high level transcription. A 724-bp segment of the 5'-flanking region consisting of the proximal E-box flanked upstream by a mammalian-specific 352-bp region was sufficient for maximal transcriptional activation in postconfluent BC3H1 myoblasts. Deletion of the 352-bp region restricts the early transcriptional response to high cell density in temporal studies of promoter activity during BC3H1 myogenic cell differentiation.	OHIO STATE UNIV,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,333 W 10TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Mayo Clinic					NCI NIH HHS [CA 33643] Funding Source: Medline; NHLBI NIH HHS [HL 43370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLANK RS, 1992, J BIOL CHEM, V267, P984; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; KEDES LH, 1989, CELLULAR MOL BIOL MU, P429; LIAU G, 1990, J CELL PHYSIOL, V142, P236, DOI 10.1002/jcp.1041420204; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; STRAUCH AR, 1984, J BIOL CHEM, V259, P3152; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; STRAUCH AR, 1991, J CELL PHYSIOL, V146, P337, DOI 10.1002/jcp.1041460302; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	28	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11995	12003						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601869				2022-12-27	WOS:A1992HY94700054
J	SHIMOKAWA, T; SMITH, WL				SHIMOKAWA, T; SMITH, WL			PROSTAGLANDIN ENDOPEROXIDE SYNTHASE - THE ASPIRIN ACETYLATION REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INFLAMMATORY DRUGS; VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; H-SYNTHASE; PEROXIDASE REACTION; COMPLEMENTARY-DNA; BINDING-SITES; SYNTHETASE; SHEEP; CYCLOOXYGENASE	Aspirin selectively acetylates Ser-530 of prostaglandin endoperoxide (PGH) synthase-1. This causes inactivation of the cyclooxygenase activity of the enzyme, but does not appreciably affect its peroxidase activity. Although the aspirin-acetylated enzyme is inactive, we found that PGH synthase-1 in which Ser-530 had been replaced with an alanine was catalytically active; accordingly, we proposed that aspirin inhibits cyclooxygenase activity by placing a larger than normal side chain at position 530 thereby interfering with arachidonate binding (DeWitt, D. L., El-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. F., Armstrong, R. L., and Smith, W. L. (1990) J. Biol. Chem. 265, 5192-5198). As a further test of this hypothesis we have used site-directed mutagenesis and transient expression in cos-1 cells to prepare and characterize five additional substitutions of Ser-530. Consistent with our proposal, the presence of amino acids with bulky side chains at position 530 inhibited cyclooxygenase activity and decreased the apparent affinity of the enzyme for arachidonate. In related work, we characterized a series of mutant PGH synthases-1 having substitutions at residues adjoining Ser-530, including Phe-529, Leu-531, Lys-532, and Gly-533, in order to evaluate the contributions of each residue to cyclooxygenase catalysis. The most significant conclusion of this part of the study is that residues 529-533 all are important for the peroxidase activity as well as the cyclooxygenase activity of PGH synthase-1. Phe-529, in particular, was found to be critical for PGH synthase-I structure and catalysis; some substitutions at this position led to the production of proteins lacking about 100 amino acids from their COOH termini.	MICHIGAN STATE UNIV,DEPT BIOCHEM,RM 510,BIOCHEM BLDG,E LANSING,MI 48824	Michigan State University			SHIMOKAWA, Teruhiko/GZA-4834-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42509] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GRENIER FC, 1978, PROSTAG OTH LIPID M, V16, P759, DOI 10.1016/0090-6980(78)90009-6; HEMLER ME, 1976, J BIOL CHEM, V250, P5575; HOLTZMAN MJ, 1991, CLIN RES, V39, P182; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MARNETT JJ, 1990, PEROXIDASES CHEM BIO, P1; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OGINO N, 1978, J BIOL CHEM, V253, P5061; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; ROTH GJ, 1980, J BIOL CHEM, V255, P1301; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1971, J BIOL CHEM, V246, P6700; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SMITH WL, 1990, STROKE, V21, P24; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	42	119	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12387	12392						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601897				2022-12-27	WOS:A1992HY94700110
J	HOOPES, BC; LEBLANC, JF; HAWLEY, DK				HOOPES, BC; LEBLANC, JF; HAWLEY, DK			KINETIC-ANALYSIS OF YEAST TFIID-TATA BOX COMPLEX-FORMATION SUGGESTS A MULTISTEP PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION; BINDING-PROTEIN; FUNCTIONAL DOMAINS; PROMOTER; ACTIVATION; MECHANISM; ELEMENTS; SEQUENCES; INVITRO	The eukaryotic transcription factor TFIID recognizes and binds a promoter sequence element called the TATA box. We have analyzed the interaction of yeast TFIID with the consensus TATA box sequence of the adenovirus major late promoter. To facilitate this detailed characterization, we developed a method for obtaining quantitative information from a gel retardation (bandshift) assay, allowing measurement of the rate and extent of TFIID-TATA box complex formation. Using this assay and DNase I protection assays, we determined that the association rate constant for TFIID binding to the major late promoter was too low to be consistent with a simple diffusion-limited association, suggesting that the binding proceeds by a multi-step pathway. Furthermore, we found that the slow rate of TFIID binding reported by other research groups was not the consequence of a rate-limiting conformational change, as has been previously suggested. Instead, we observed that the formation of a stable TFIID-TATA box complex was relatively rapid (complete in less than 1 min) at saturating concentrations of TFIID. We have proposed a two-step pathway consistent with the observed kinetics and have considered the possible contributions of each step to the overall rate of TFIID binding. This study lays the groundwork for a systematic characterization of the interaction of TFIID with additional TATA box sequences, including an experimental test of the possibility that different steps in the binding reaction are rate-limiting for different promoters.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon								BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; FIRE A, 1984, J BIOL CHEM, V259, P2509; GARNER MM, 1986, TRENDS BIOCHEM SCI, V11, P395, DOI 10.1016/0968-0004(86)90149-0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; Maniatis T., 1982, MOL CLONING; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J.H., 1972, EXPT MOL GENETICS; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PENOTTI FE, 1990, J MOL BIOL, V213, P37, DOI 10.1016/S0022-2836(05)80120-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHIH MC, 1984, J MOL BIOL, V172, P489, DOI 10.1016/S0022-2836(84)80019-4; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	52	177	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11539	11547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597482				2022-12-27	WOS:A1992HX16900092
J	MALHOTRA, KT; NICHOLAS, RA				MALHOTRA, KT; NICHOLAS, RA			SUBSTITUTION OF LYSINE-213 WITH ARGININE IN PENICILLIN-BINDING PROTEIN-5 OF ESCHERICHIA-COLI ABOLISHES D-ALANINE CARBOXYPEPTIDASE ACTIVITY WITHOUT AFFECTING PENICILLIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PEPTIDOGLYCAN; NUCLEOTIDE-SEQUENCE; BETA-LACTAMASE; ENZYME-ACTIVITIES; TRANSPEPTIDASE; PEPTIDASE; GENE; PURIFICATION; MEMBRANE; IA	All penicillin-binding proteins (PBPs) contain a conserved box of homology in the carboxyl-terminal half of their primary sequence that can be Lys-Thr-Gly, Lys-Ser-Gly, or His-Thr-Gly. Site-saturation mutagenesis was used to address the role of the lysine residue at this position (Lys213) in Escherichia coli PBP 5, a D-alanine carboxypeptidase enzyme. A soluble form of PBP 5 was used to replace Lys213 with 18 other amino acids, and the ability of these mutant proteins to bind [H-3]penicillin G was assessed. Only the substitution of lysine with arginine resulted in a protein that was capable of forming a stable covalent complex with antibiotic. The affinity of [C-14]penicillin G for the arginine mutant was 1.2-fold higher than for wild-type PBP 5 (4.4 versus 5.1-mu-g/ml for 20 min at 30-degrees-C), and both proteins showed identical rates of hydrolysis of the [C-14]penicilloyl-bound complex (t1/2 = 9.1 min). Surprisingly, the arginine-substituted protein was unable to catalyze D-alanine carboxypeptidase activity in vitro, which suggests that there is a substantial difference in the geometries of the peptide substrate and penicillin G within the active site of PBP 5.	UNIV N CAROLINA, DEPT PHARMACOL, CB 7365 FLOB, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIAID NIH HHS [AI-27039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANUMA H, 1980, J BIOL CHEM, V255, P1173; AMANUMA H, 1984, J BIOL CHEM, V259, P1294; AMBLER RP, 1975, BIOCHEM J, V151, P197, DOI 10.1042/bj1510197; AMBLER RP, 1969, NATURE, V222, P24, DOI 10.1038/222024a0; ASOH S, 1986, EUR J BIOCHEM, V160, P231, DOI 10.1111/j.1432-1033.1986.tb09961.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOISSINOT M, 1990, J BIOL CHEM, V265, P1225; BROOMESMITH J, 1983, TARGET PENICILLIN, P403; BROOMESMITH JK, 1985, EUR J BIOCHEM, V147, P437, DOI 10.1111/j.1432-1033.1985.tb08768.x; BROOMESMITH JK, 1988, NUCLEIC ACIDS RES, V16, P1617, DOI 10.1093/nar/16.4.1617; DEPEDRO MA, 1981, P NATL ACAD SCI-BIOL, V78, P5856; DUEZ C, 1987, EUR J BIOCHEM, V162, P509, DOI 10.1111/j.1432-1033.1987.tb10669.x; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; Frere J M, 1976, Methods Enzymol, V45, P610; GHUYSEN JM, 1986, BIOCHEM J, V235, P159, DOI 10.1042/bj2350159; HARLOW E, 1988, ANTIBODIES LABORATOR; ISHINO F, 1981, BIOCHEM BIOPH RES CO, V101, P905, DOI 10.1016/0006-291X(81)91835-0; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSTU SG, 1974, J BIOL CHEM, V249, P6976; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUHASHI M, 1978, P NATL ACAD SCI USA, V75, P2631, DOI 10.1073/pnas.75.6.2631; MATSUHASHI M, 1979, J BACTERIOL, V137, P644, DOI 10.1128/JB.137.1.644-647.1979; MEDEIROS AA, 1984, BRIT MED BULL, V40, P18, DOI 10.1093/oxfordjournals.bmb.a071942; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; NAKAGAWA J, 1979, AGR BIOL CHEM TOKYO, V43, P1379, DOI 10.1080/00021369.1979.10863634; NAKAMURA M, 1983, MOL GEN GENET, V191, P1, DOI 10.1007/BF00330881; NICHOLAS RA, 1988, J BIOL CHEM, V263, P2034; PRATT JM, 1981, NATURE, V293, P307, DOI 10.1038/293307a0; PRATT JM, 1986, EMBO J, V5, P2399, DOI 10.1002/j.1460-2075.1986.tb04510.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMRAOUI B, 1986, NATURE, V320, P378, DOI 10.1038/320378a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SMITH JB, 1984, FEBS LETT, V165, P185, DOI 10.1016/0014-5793(84)80166-0; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; SPRATT BG, 1976, J BACTERIOL, V127, P660, DOI 10.1128/JB.127.1.660-663.1976; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; TAMURA T, 1976, J BIOL CHEM, V251, P414; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133	45	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11386	11391						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597468				2022-12-27	WOS:A1992HX16900070
J	SAVAGE, B; SHATTIL, SJ; RUGGERI, ZM				SAVAGE, B; SHATTIL, SJ; RUGGERI, ZM			MODULATION OF PLATELET-FUNCTION THROUGH ADHESION RECEPTORS - A DUAL ROLE FOR GLYCOPROTEIN-IIB-IIIA (INTEGRIN-ALPHA(IIB)BETA(3) MEDIATED BY FIBRINOGEN AND GLYCOPROTEIN-IB-VON-WILLEBRAND FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; PROTEIN-KINASE-C; FACTOR-VIII; SPHINGOSINE INHIBITION; CYCLIC-AMP; AGGREGATION; ACTIVATION; SUBENDOTHELIUM; COMPLEX; FORSKOLIN	We have found that the form of glycoprotein (GP) IIb-IIIa (integrin-alpha(IIb)beta-3) expressed on nonstimulated platelets is a functional receptor that mediates selective and irreversible adhesion to immobilized fibrinogen. This occurs even in the presence of the elevated intracellular cAMP levels induced by prostaglandin E1 or after inhibition of protein kinase C activity by sphingosine. In the absence of inhibitors, platelets adhering to fibrinogen through GP IIb-IIIa become fully activated and aggregate with one another. Immobilized von Willebrand factor (vWF), in contrast, is recognized by nonstimulated platelets through another receptor, GP Ib. This interaction leads to a change in the ligand recognition specificity of GP IIb-IIIa that can then bind to immobilized vWF and mediate irreversible platelet adhesion and aggregation; this process, however, is inhibited by elevated intracellular cAMP levels or blockade of protein kinase C activity. Therefore, GP Ib and GP IIb-IIIa induce platelet activation through the selective recognition of immobilized vWF and fibrinogen, respectively, in the absence of exogenous agonists. Moreover, "nonactivated" and "activated" GP IIb-IIIa exhibits distinctly different reactivity toward surface-bound vWF, and the functional switch can be induced by the binding of vWF to GP Ib. These findings demonstrate the modulation of platelet function by two different adhesion receptors, GP Ib and GP IIb-IIIa, as well as the distinct dual role of the latter as the necessary common mediator of irreversible adhesion and aggregation on both fibrinogen and vWF.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	SAVAGE, B (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL040387] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00833] Funding Source: Medline; NHLBI NIH HHS [HL-40387, HL-31950] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER S, 1988, J BIOL CHEM, V263, P7500; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DECOURCELLES DD, 1987, BIOCHEM J, V244, P93, DOI 10.1042/bj2440093; DEMARCO L, 1987, J CLIN INVEST, V80, P475, DOI 10.1172/JCI113095; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FEINSTEIN MB, 1983, BIOCHEM BIOPH RES CO, V113, P598, DOI 10.1016/0006-291X(83)91768-0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUSTER V, 1985, J AM COLL CARDIOL, V5, pB175, DOI 10.1016/S0735-1097(85)80552-0; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HAVERSTICK DM, 1985, BLOOD, V66, P946; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; INSEL PA, 1982, J BIOL CHEM, V257, P7485; JEN CJ, 1987, AM J PHYSIOL, V253, pH745, DOI 10.1152/ajpheart.1987.253.4.H745; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KUNICKI TJ, 1981, BLOOD, V58, P268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDON JN, 1986, BLOOD, V68, P355; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MUSTARD JF, 1978, BLOOD, V52, P453; NEWMAN J, 1971, BRIT J HAEMATOL, V21, P1, DOI 10.1111/j.1365-2141.1971.tb03413.x; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SALZMAN EW, 1972, NEW ENGL J MED, V286, P358; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SWITZER ME, 1976, J CLIN INVEST, V57, P925, DOI 10.1172/JCI108369; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1978, BLOOD, V51, P267; [No title captured]	44	304	312	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11300	11306						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597464				2022-12-27	WOS:A1992HX16900058
J	YANG, J; CLARK, AE; KOZKA, IJ; CUSHMAN, SW; HOLMAN, GD				YANG, J; CLARK, AE; KOZKA, IJ; CUSHMAN, SW; HOLMAN, GD			DEVELOPMENT OF AN INTRACELLULAR POOL OF GLUCOSE TRANSPORTERS IN 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; RAT SKELETAL-MUSCLE; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; MURINE FIBROBLASTS; ADIPOSE-CELLS; MESSENGER-RNA; ADIPOCYTES; HEPG2; EXPRESSION	The membrane-impermeant bis-mannose photolabel 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis-(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA) has been used to study the development of an intracellular pool of glucose transporters in 3T3-L1 cells. The subcellular distributions of the transporter isoforms GLUT1 and GLUT4 were determined by comparing the labeling obtained in cells in which the impermeant reagent only had access to the cell surface and the labeling obtained in digitonin-permeabilized cells. ATB-BMPA labeling showed that only GLUT1 was present in preconfluent fibroblasts and that most of the transporters were distributed to the cell surface. In preconfluent fibroblasts, the 2-deoxy-D-glucose transport activity was almost-equal-to 5 times higher than in confluent fibroblasts. ATB-BMPA labeling showed that the decrease in transport as cells reached confluence was associated with a decrease in the proportion of GLUT1 distributed to the cell surface. The sequestration of these transporters was associated with the development of an insulin-responsive transport activity which increased by almost-equal-to 2.5-fold compared with unstimulated confluent cells. ATB-BMPA labeling showed that insulin stimulation resulted in an almost-equal-to 2-fold increase in surface GLUT1 so that about one-half of the available transporters became recruited to the cell surface. Measurements of the changes in the distribution of both GLUT1 and GLUT4 throughout the differentiation of confluent fibroblasts into adipocytes showed that both transporters were sequestered in parallel. Basal levels of transport and photolabeling remained low throughout the differentiation period when the total pool of transporters (GLUTI plus GLUT4) was increased by almost-equal-to 5-fold. These results suggest that the sequestration process was present before new transporters were synthesized. Thus, the sequestration mechanism develops in confluent growth-arrested fibroblasts although the capacity to sequester additional transporters may increase as differentiation proceeds.	NIDDKD,DIABET BRANCH,EXPTL DIABET METAB & NUTR SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	YANG, J (corresponding author), UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND.			Holman, Geoffrey/0000-0001-7045-1358				BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FROST SC, 1985, J BIOL CHEM, V260, P2646; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; PALFREYMAN RW, 1992, IN PRESS BIOCH J; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; SATOH S, 1991, DIABETES S1, V40, pA85; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; WARDZALA LJ, 1983, BIOCHIM BIOPHYS ACTA, V730, P49, DOI 10.1016/0005-2736(83)90315-2; WATANABE T, 1984, J BIOL CHEM, V259, P3117; WEILAND M, 1990, BIOCHEM J, V270, P331, DOI 10.1042/bj2700331; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	37	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10393	10399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587825				2022-12-27	WOS:A1992HV09000032
J	ZIEGELBAUER, K; MULTHAUP, G; OVERATH, P				ZIEGELBAUER, K; MULTHAUP, G; OVERATH, P			MOLECULAR CHARACTERIZATION OF 2 INVARIANT SURFACE GLYCOPROTEINS SPECIFIC FOR THE BLOOD-STREAM STAGE OF TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; SEQUENCE-ANALYSIS; TUBULIN GENES; BLOOD-STREAM; PROTEIN; DNA; PURIFICATION; COAT; DIFFERENTIATION; ACTIVATION	In the accompanying paper (Ziegelbauer, K., and Overath, P. (1992) J. Biol. Chem. 267,10791-10796), two invariant surface glycoproteins, ISG65 and ISG75, were identified in the mammalian stage of the parasitic protozoan, Trypanosoma brucei. In this study, the genes coding for these proteins have been isolated. Their nucleotide sequence suggests no relationship to other known genes and predicts polypeptides with NH2-terminal signal sequences, hydrophilic extracellular domains, single trans-membrane alpha-helices, and short cytoplasmic domains. ISG65 and ISG75 are expressed in bloodstream forms (70,000 and 50,000 molecules/cell, respectively) but not in the insect midgut stage. They can be detected in all T. brucei brucei variant clones investigated. Both polypeptides are distributed over the entire surface of the parasite.	MAX PLANCK INST BIOL, MEMBRANE BIOCHEM ABT, CORRENSSTR 38, W-7400 TUBINGEN, GERMANY; UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg								ALLINGTON WB, 1978, ANAL BIOCHEM, V85, P188, DOI 10.1016/0003-2697(78)90289-0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUN R, 1979, ACTA TROP, V36, P289; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1988, BIOCHEMISTRY-US, V27, P2384; CLAYTON CE, 1992, IN PRESS PROG NUCLEI, V43; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHLERS B, 1987, MOL CELL BIOL, V7, P1242, DOI 10.1128/MCB.7.3.1242; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; GLASS DJ, 1986, MOL CELL BIOL, V6, P4657, DOI 10.1128/MCB.6.12.4657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IMBODEN M, 1986, J MOL BIOL, V188, P393, DOI 10.1016/0022-2836(86)90163-4; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEEFLANG P, 1976, INT J PARASITOL, V6, P413, DOI 10.1016/0020-7519(76)90027-8; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MICHELS PAM, 1983, J MOL BIOL, V166, P537, DOI 10.1016/S0022-2836(83)80283-6; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; MOTTRAM JC, 1989, MOL BIOCHEM PARASIT, V37, P115, DOI 10.1016/0166-6851(89)90108-4; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; OVERATH P, 1983, EMBO J, V2, P1721, DOI 10.1002/j.1460-2075.1983.tb01648.x; REINWALD E, 1978, H-S Z PHYSIOL CHEM, V359, P939, DOI 10.1515/bchm2.1978.359.2.939; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; STEPHEN D, 1990, NUCLEIC ACIDS RES, V18, P7463, DOI 10.1093/nar/18.24.7463; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TSCHUDI C, 1985, P NATL ACAD SCI USA, V82, P3998, DOI 10.1073/pnas.82.12.3998; VANDERPLOEG LHT, 1985, SCIENCE, V228, P1443, DOI 10.1126/science.4012301; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791	41	88	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10797	10803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587856				2022-12-27	WOS:A1992HV09000089
J	LIU, JN; PANNELL, R; GUREWICH, V				LIU, JN; PANNELL, R; GUREWICH, V			A TRANSITIONAL STATE OF PROUROKINASE THAT HAS A HIGHER CATALYTIC EFFICIENCY AGAINST GLU-PLASMINOGEN THAN UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-CHAIN UROKINASE; PRO-UROKINASE; CLOT LYSIS; 2-CHAIN UROKINASE; ACTIVATOR; FIBRIN; FORM; PURIFICATION; MECHANISM; PROENZYME	Plasminogen activation by single-chain urokinase-type plasminogen activator or pro-urokinase (pro-UK) is accompanied by the generation of two-chain urokinase (UK) by plasmin which provides a positive feedback. In the present study, the time course of the activation of Glu-plasminogen and of Lys-plasminogen (10-mu-M) by pro-UK (1.0 nM) was studied. In the presence of native plasminogen (Glu-plasminogen), three distinct phases with different rates of plasmin generation were observed. The initial phase was slow and corresponded to the intrinsic activity of pro-UK as reflected by the activity of a plasmin-resistant mutant (Lys158 --> Ala). This was followed by a second phase which had the most rapid rate. The third phase had a plasminogen activation rate which was significantly slower than the second and paralleled the rate of activation by UK (1.0 nM). The second phase coincided with the time at which there was only about 50% conversion of pro-UK to UK, whereas the final phase coincided with essentially complete conversion. In the presence of fibrin fragment E-2 (20-mu-M), previously shown to strongly promote plasminogen activation by pro-UK, the identical phenomenon was observed, but at one-tenth the concentration of pro-UK. The most rapid rate of plasmin generation again coincided with transitional (25-60%) pro-UK to UK conversion. To further examine this phenomenon, the rate of pro-UK to UK conversion was controlled by using kallikrein in the presence of a plasmin inhibitor. In this experiment, the activation of Glu-plasminogen bound to solid-phase fibrin was measured. A similar three-phase sequence was observed, the highest rate of plasmin generation coinciding with about 45% conversion of pro-UK to UK. A mechanism for this transitional state phenomenon was postulated based on the established significantly higher affinity of pro-UK than of UK for Glu-plasminogen. This exceptional property for a proenzyme may enable a transient activity to be generated during the transition from pro-UK to UK corresponding to the more favorable K(M) of pro-UK and the k(cat) of UK. This hypothesis was supported by the results from experiments in which Lys-plasminogen was substituted for the Glu form. No transitional state activity was observed, consistent with the relatively high K(M) of pro-UK against Lys-plasminogen.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								ANGLESCANO E, 1986, ANAL BIOCHEM, V153, P201, DOI 10.1016/0003-2697(86)90082-5; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; COLLEN D, 1986, J BIOL CHEM, V261, P1259; DECLERCK PJ, 1990, BLOOD, V75, P1794; ELLIS V, 1987, J BIOL CHEM, V262, P14998; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; LIU J, 1992, IN PRESS BIOCHEMISTR; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; STUMP DC, 1986, J BIOL CHEM, V261, P1274; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VARADI A, 1984, BIOCHEMISTRY-US, V23, P2108, DOI 10.1021/bi00304a036; White W.F., 1970, METHOD ENZYMOL, V19, P665; WUN TC, 1982, J BIOL CHEM, V257, P7262	21	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15289	15292						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639775				2022-12-27	WOS:A1992JG11300009
J	PORTER, RK; SCOTT, JM; BRAND, MD				PORTER, RK; SCOTT, JM; BRAND, MD			CHOLINE TRANSPORT INTO RAT-LIVER MITOCHONDRIA - CHARACTERIZATION AND KINETICS OF A SPECIFIC TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLCARNITINE TRANSLOCASE; S-ADENOSYLMETHIONINE; RUTHENIUM RED; INHIBITION; BETAINE; DEHYDROGENASE; METABOLISM; DEFICIENCY; COMPLEX; QUININE	Rat liver mitochondria possess a specific choline transporter in the inner membrane. The transporter shows saturable kinetics at high membrane potential with a K(m) of 220-mu-M and a V(max) of 0.4 nmol/mg of protein/min at pH 7.0 and 25-degrees-C. At physiological concentrations of choline, the rate of choline uptake by the transporter shows a linear dependence on membrane potential; uptake is distinct from the nonspecific cation diffusion process. Hemicholinium-3, hemicholinium-15, quinine, and quinidine, all analogues of choline, are high affinity competitive inhibitors of choline transport with K(i) values of 17, 55, 15, and 127-mu-M, respectively. The choline transporter is distinct from other known mitochondrial transporters. Rat heart mitochondria do not appear to possess a choline transporter. Evidence suggests that the transporter is an electrophoretic uniporter. Analogue studies have shown that the hydroxyl and the quaternary ammonium groups of choline are necessary for binding to the transporter. A comparison of molecular models of choline and the high affinity inhibitors has provided evidence for the preferred conformation of choline for binding to the transporter. The presence of a choline transporter in the mitochondrial inner membrane provides a potential site for control of choline oxidation and hence supply of endogenous betaine.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND	Trinity College Dublin	PORTER, RK (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153; Porter, Richard/0000-0001-9854-5161				ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BIANCHI G, 1964, J BIOL CHEM, V239, P3947; BROWN GC, 1986, BIOCHEM J, V234, P75, DOI 10.1042/bj2340075; BROWN GC, 1988, BIOCHEM J, V252, P473, DOI 10.1042/bj2520473; BRYLA J, 1976, FEBS LETT, V72, P331, DOI 10.1016/0014-5793(76)80998-2; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CYBULSKI RL, 1977, BIOCHEMISTRY-US, V16, P5116, DOI 10.1021/bi00642a026; DERIDDER JJ, 1973, BIOCHIM BIOPHYS ACTA, V291, P557, DOI 10.1016/0005-2736(73)90507-5; DERIDDER JJ, 1973, BIOCHIM BIOPHYS ACTA, V325, P397, DOI 10.1016/0005-2728(73)90200-4; DERIDDER JJM, 1976, BIOCHIM BIOPHYS ACTA, V449, P236, DOI 10.1016/0005-2728(76)90136-5; DERIDDER JJM, 1975, BIOCHIM BIOPHYS ACTA, V408, P112, DOI 10.1016/0005-2728(75)90003-1; DIWAN JJ, 1986, BIOCHEM BIOPH RES CO, V135, P830, DOI 10.1016/0006-291X(86)91003-X; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELFORD BC, 1990, J PHYSIOL-LONDON, V426, pP100; FEINBERG RH, 1967, J BIOL CHEM, V242, P4614; FINKELSTEIN JD, 1974, METABOLISM, V23, P387, DOI 10.1016/0026-0495(74)90057-2; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROEN AK, 1982, J BIOL CHEM, V257, P2754; GROSSMAN EB, 1989, AM J PHYSIOL, V256, pF107; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; HALESTRAP AP, 1974, BIOCHEM J, V138, P313, DOI 10.1042/bj1380313; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; HOFFMAN DR, 1979, CAN J BIOCHEM CELL B, V57, P56, DOI 10.1139/o79-007; IDELLWENGER JA, 1981, J BIOL CHEM, V256, P5597; JOHNSON RN, 1973, BIOCHEM J, V134, P769, DOI 10.1042/bj1340769; KEATING JN, 1991, LANCET, V337, P935, DOI 10.1016/0140-6736(91)91570-K; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LAYZER RB, 1978, NEUROLOGY, V28, P485; LERNER J, 1989, COMP BIOCHEM PHYS C, V93, P1, DOI 10.1016/0742-8413(89)90002-9; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LUMB M, 1983, BIOCHIM BIOPHYS ACTA, V756, P354, DOI 10.1016/0304-4165(83)90345-8; MATSUZAWA T, 1974, J BIOCHEM, V75, P601, DOI 10.1093/oxfordjournals.jbchem.a130428; MCGIVAN JD, 1977, BIOCHEM J, V162, P147, DOI 10.1042/bj1620147; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; MEIJER AJ, 1970, FEBS LETT, V8, P41, DOI 10.1016/0014-5793(70)80220-4; MITCHELL AD, 1979, J ANIM SCI, V49, P764, DOI 10.2527/jas1979.493764x; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PARVIN R, 1978, J BIOL CHEM, V253, P1944; QIU ZH, 1990, SCI CHINA SER B, V33, P955; REED KC, 1974, BIOCHEM J, V140, P143, DOI 10.1042/bj1400143; ROBINSON BH, 1972, J MEMBRANE BIOL, V7, P391, DOI 10.1007/BF01867928; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SCOTT JM, 1981, LANCET, V2, P334; SCOTT JM, 1979, CHEM BIOL PTERIDINES, P335; SEBALD W, 1981, CURR TOP BIOENERG, V12, P1; SMOLIN LA, 1981, J PEDIATR-US, V99, P467, DOI 10.1016/S0022-3476(81)80352-6; TSUGE H, 1980, BIOCHIM BIOPHYS ACTA, V614, P274, DOI 10.1016/0005-2744(80)90217-X; TYLER DD, 1977, BIOCHEM J, V166, P571, DOI 10.1042/bj1660571; TYLER DD, 1966, ARCH BIOCHEM BIOPHYS, V115, P373, DOI 10.1016/0003-9861(66)90287-6; VANDERWESTHUYZE.J, 1982, LIFE SCI, V31, P325; VANDERWESTHUYZEN J, 1984, J NUTR, V114, P1106, DOI 10.1093/jn/114.6.1106; VIGNAIS PV, 1971, FEBS LETT, V13, P28, DOI 10.1016/0014-5793(71)80656-7; WEIR DG, 1988, J NEUROCHEM, V51, P1949, DOI 10.1111/j.1471-4159.1988.tb01184.x; WILKEN DR, 1970, BIOCHIM BIOPHYS ACTA, V216, P305, DOI 10.1016/0005-2728(70)90222-7; Zeisel S.H., 1988, MODERN NUTR HLTH DIS, P440	62	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14637	14646						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634511				2022-12-27	WOS:A1992JF08800025
J	THON, VJ; VIGNERONLESENS, C; MARIANNEPEPIN, T; MONTREUIL, J; DECQ, A; RACHEZ, C; BALL, SG; CANNON, JF				THON, VJ; VIGNERONLESENS, C; MARIANNEPEPIN, T; MONTREUIL, J; DECQ, A; RACHEZ, C; BALL, SG; CANNON, JF			COORDINATE REGULATION OF GLYCOGEN-METABOLISM IN THE YEAST SACCHAROMYCES-CEREVISIAE - INDUCTION OF GLYCOGEN BRANCHING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; NUCLEOTIDE-SEQUENCE; 2 FORMS; SYNTHASE; GENE; DNA; PHOSPHORYLASE; INTERCONVERSION; PURIFICATION; SYSTEM	The yeast glycogen branching enzyme (EC 2.4.1.18) is shown to be induced in batch culture simultaneously with the onset of intracellular glycogen accumulation. The branching enzyme structural gene (GLC3) has been cloned. Its predicted amino acid sequence is very similar to procaryotic branching enzymes. Northern analysis indicates that GLC3 mRNA abundance increases in late exponential growth phase coincident with glycogen accumulation. Disruption of the branching enzyme structural gene establishes that branching enzyme activity is an absolute requirement for maximal glycogen synthesis.	UNIV MISSOURI, SCH MED M642, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, CNRS, UNITE MIXTE RECH 111, F-59655 VILLENEUVE DASCQ, FRANCE	University of Missouri System; University of Missouri Columbia; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			Rachez, Christophe/GLR-0102-2022	Cannon, John/0000-0001-6698-176X; Rachez, Christophe/0000-0001-8502-4738; Ball, Steven/0000-0003-1629-1650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040326, R01GM040326] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAECKER PA, 1986, J BIOL CHEM, V261, P8738; BAI G, 1990, J BIOL CHEM, V265, P7843; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown B. I., 1966, METHOD ENZYMOL, V8, P395; BROWN DH, 1961, P NATL ACAD SCI USA, V47, P479, DOI 10.1073/pnas.47.4.479; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1990, J BIOL CHEM, V265, P11897; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; DAMOTTE M, 1968, BIOCHEM BIOPH RES CO, V32, P916, DOI 10.1016/0006-291X(68)90114-9; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; GUNJA ZH, 1960, BIOCHEM J, V75, P441, DOI 10.1042/bj0750441; GUNJA-SMITH Z, 1977, Journal of Bacteriology, V130, P818; HENIKOFF S, 1984, GENE, V28, P352; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIEL JAKW, 1990, GENE, V89, P77, DOI 10.1016/0378-1119(90)90208-9; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; Maniatis T., 1982, MOL CLONING; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMAN LB, 1969, BIOCHEMISTRY-US, V8, P3332, DOI 10.1021/bi00836a030; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; SWINTON SJ, 1989, FOOD BIOTECHNOL, V3, P197, DOI 10.1080/08905438909549708	39	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15224	15228						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634552				2022-12-27	WOS:A1992JF08800105
J	OGAWA, Y; SCHMIDT, DK; NATHAN, RM; ARMSTRONG, RM; MILLER, KL; SAWAMURA, SJ; ZIMAN, JM; ERICKSON, KL; DELEON, ER; ROSEN, DM; SEYEDIN, SM; GLASER, CB; CHANG, RJ; CORRIGAN, AZ; VALE, W				OGAWA, Y; SCHMIDT, DK; NATHAN, RM; ARMSTRONG, RM; MILLER, KL; SAWAMURA, SJ; ZIMAN, JM; ERICKSON, KL; DELEON, ER; ROSEN, DM; SEYEDIN, SM; GLASER, CB; CHANG, RJ; CORRIGAN, AZ; VALE, W			BOVINE BONE ACTIVIN ENHANCES BONE MORPHOGENETIC PROTEIN-INDUCED ECTOPIC BONE-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PURIFICATION; INHIBIN; SUBUNITS; FSH	A 25-kDa homodimeric protein was purified from demineralized bovine bone extract and identified as activin A. The bovine bone activin enhanced formation of ectopic bone in rat subcutis when implanted in combination with partially purified bovine bone morphogenetic protein (BMP-2, BMP-3) in collagen/ceramic carrier. The implants, removed at 14 days, contained markedly elevated levels of alkaline phosphatase activity. Histological examination revealed an extensive formation of woven bone with very little cartilage. In contrast, a combination of transforming growth factor-beta-2 and BMP promoted formation of bone with an abundance of cartilage. The implants with BMP alone exhibited some osteoinductive activity, while the implants with activin alone showed no activity. These results demonstrate that bone is a rich source of activin and that activin plays an important role in modulating bone formation.	BERLEX BIOSCI, San Francisco, CA 94080 USA; CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Salk Institute	OGAWA, Y (corresponding author), CELTRIX PHARMACEUT INC, 3055 PATRICK HENRY DR, SANTA CLARA, CA 95052 USA.			Sawamura, Steven/0000-0002-9018-6990				BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; GOODMAN JW, 1985, P NATL ACAD SCI USA, V82, P3291, DOI 10.1073/pnas.82.10.3291; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING N, 1986, BIOCHEM BIOPH RES CO, V138, P1129, DOI 10.1016/S0006-291X(86)80400-4; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OGAWA Y, 1991, METHOD ENZYMOL, V198, P317; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSEN DM, 1990, CALCIUM REGULATIO BO, V10, P344; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; STEWART S, 1984, EXP HEMATOL, V12, P309; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X	21	118	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14233	14237						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629219				2022-12-27	WOS:A1992JD32500069
J	BANERJEE, A; LUDUENA, RF				BANERJEE, A; LUDUENA, RF			KINETICS OF COLCHICINE BINDING TO PURIFIED BETA-TUBULIN ISOTYPES FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE; COMPLEX; DISSOCIATION; MICROTUBULES; LOCALIZATION; EXPRESSION; PROTEIN	Tubulin, the constituent protein of microtubules, is an alpha-beta-heterodimer; both alpha and beta exist in several isotypic forms whose functional significance is not precisely known. The antimitotic alkaloid colchicine binds to mammalian brain tubulin in a biphasic manner under pseudo-first-order conditions in the presence of a large excess of colchicine (Garland, D. L. (1978) Biochemistry 17, 4266-4272). We have studied the kinetics of colchicine binding to purified beta-tubulin isotypes and find that each of the purified beta-tubulin isotypes binds colchicine in a monophasic manner. The apparent onrate constants for the binding of colchicine to alpha-beta(II)-, alpha-beta(III)-, and alpha-beta(IV)-tubulin dimers are respectively 132 +/- 5, 30 +/- 2, and 236 +/- 7 m-1 s-1. When the isotypes are mixed, the kinetics become biphasic. Scatchard analysis revealed that the isotypes differ significantly in their affinity constants (K(alpha)) for binding colchicine. The affinity constants are 0.24 x 10(6), 0.12 x 10(6), and 3.31 x 10(6) M-1, respectively, for alpha-beta(II)-, alpha-beta(III)-, and alpha-beta(IV)-tubulin dimers. Our results are in agreement with the hypothesis that the beta-subunit of tubulin plays a major role in the interaction of colchicine with tubulin. Our binding data raise the possibility that the tubulin isotypes might play important regulatory roles by interacting differently with other non-tubulin proteins in vivo, which in turn, may regulate microtubule-based functions in living cells.			BANERJEE, A (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R01CA026376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023476] Funding Source: NIH RePORTER; NCI NIH HHS [CA26376] Funding Source: Medline; NIGMS NIH HHS [GM23476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI T, 1975, ANAL BIOCHEM, V69, P443, DOI 10.1016/0003-2697(75)90146-3; BANE S, 1984, J BIOL CHEM, V259, P7391; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1987, FEBS LETT, V219, P103, DOI 10.1016/0014-5793(87)81199-7; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; DETRICH HW, 1981, BIOCHEMISTRY-US, V20, P5999, DOI 10.1021/bi00524a012; DIAZ JF, 1991, J BIOL CHEM, V266, P2890; Dustin P., 1978, MICROTUBULES; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; FLOID LJ, 1989, BIOCHEMISTRY-US, V28, P8515; Fulton C., 1976, CELL MOTILITY, P987; GARLAND DL, 1978, BIOCHEMISTRY-US, V17, P4266, DOI 10.1021/bi00613a024; IDE G, 1981, J BIOL CHEM, V256, P1684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P1; LAMBEIR A, 1981, J BIOL CHEM, V256, P3279; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; MUKHOPADHYAY K, 1990, BIOCHEMISTRY-US, V29, P6845, DOI 10.1021/bi00481a013; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SERRANO L, 1984, J BIOL CHEM, V259, P6607; SHERLINE P, 1975, J BIOL CHEM, V250, P5481; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; WILLIAMS RF, 1985, J BIOL CHEM, V260, P3794; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	34	130	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13335	13339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618835				2022-12-27	WOS:A1992JB74600040
J	CRISE, B; ROSE, JK				CRISE, B; ROSE, JK			IDENTIFICATION OF PALMITOYLATION SITES ON CD4, THE HUMAN-IMMUNODEFICIENCY-VIRUS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; AMINO-TERMINAL DOMAIN; VESICULAR STOMATITIS; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAINS; MEMBRANE-GLYCOPROTEINS; COVALENT MODIFICATION; POLYACRYLAMIDE GELS; VIRAL GLYCOPROTEIN; PLASMA-MEMBRANE	We report that the cell surface glycoprotein CD4 expressed in HeLa cells can be metabolically labeled with [H-3]palmitic acid. Analysis of the H-3-label after hydrolysis of the protein indicated that it was incorporated predominantly as palmitic acid. Comparison of the amount of [H-3]palmitate incorporated into CD4 with that incorporated into a protein known to contain one molecule of esterified palmitate suggested that one to two molecules of palmitate were added to CD4. The fatty acid was readily cleaved from CD4 by treatment with weak base suggesting a thioester linkage. Mutations of each of 2 cysteine residues, Cys394 and Cys397, in CD4 at the junction of the transmembrane and cytoplasmic domains reduced labeling with [H-3]palmitic acid, and mutation of both cysteines eliminated labeling. These results indicate that both cysteines are esterified to palmitate. Modification with palmitate was not required for expression of CD4 on the cell surface or for binding of p56lck to its cytoplasmic domain.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University; Yale University					NIAID NIH HHS [AI-30374, AI-07019, AI-24345] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030374, R37AI024345, T32AI007019, R01AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DIAMOND DC, 1990, P NATL ACAD SCI USA, V87, P5001, DOI 10.1073/pnas.87.13.5001; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTMAN DR, 1988, CELL, V55, P541, DOI 10.1016/0092-8674(88)90211-5; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1984, EMBO J, V3, P2295, DOI 10.1002/j.1460-2075.1984.tb02129.x; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCHMIDT MFG, 1980, J BIOL CHEM, V255, P3334; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEWART SJ, 1986, J IMMUNOL, V136, P3773; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WHITT MA, 1991, VIROLOGY, V185, P875, DOI 10.1016/0042-6822(91)90563-Q	43	99	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13593	13597						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618861				2022-12-27	WOS:A1992JB74600078
J	SHARIFI, J; STGERMAIN, DL				SHARIFI, J; STGERMAIN, DL			THE CDNA FOR THE TYPE-I IODOTHYRONINE 5'-DEIODINASE ENCODES AN ENZYME MANIFESTING BOTH HIGH KM AND LOW KM ACTIVITY - EVIDENCE THAT RAT-LIVER AND KIDNEY CONTAIN A SINGLE ENZYME WHICH CONVERTS THYROXINE TO 3,5,3'-TRIIODOTHYRONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS-OOCYTES; 5'-MONODEIODINASE; DIHYDROLIPOAMIDE; IDENTIFICATION; BINDING	The enzymatic conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) by iodothyronine 5'-deiodinase(s) is an obligate step in the physiologic action of thyroid hormones in most extrathyroidal tissues. In the rat liver and kidney, 5'-deiodinase processes having either high K(m) (micromolar range) or low K(m) (nanomolar range) values for thyroid hormone substrates have been described. The number of enzymes mediating these reactions, however, remains uncertain and controversial. To examine this question we have compared the 5'-deiodinase activity expressed in membrane preparations of Xenopus laevis oocytes after the injection of either rat liver poly(A)+ RNA or in vitro prepared RNA transcribed using the G21 full-length type I 5'-deiodinase cDNA. In oocytes injected with rat liver poly(A)+ RNA, high K(m) (i.e. type I) activity was observed when 20 mM dithiothreitol was used as the thiol cofactor, whereas K(m) values in the nanomolar range were noted with 0.5 mM dithiothreitol, glutathione, one, or a reconstituted thioredoxin cofactor system. This complex pattern of 5'-deiodinase activity, which mimics that found in homogenates and subcellular fractions of rat liver and kidney, was reproduced exactly in oocytes by the microinjection of G21-derived RNA transcripts. Furthermore, hybrid arrest of translation in oocytes using a partial type I 5'-deiodinase cDNA completely inhibited the expression of both high and low K(m) activity after the injection of rat liver poly(A)+ RNA. These findings demonstrate that rat liver and kidney contain only a single 5'-deiodinase which manifests either high or low K(m) activity depending on the reduced thiol cofactor utilized in the reaction.	DARTMOUTH COLL,DEPT MED,LEBANON,NH 03756; DARTMOUTH COLL,DEPT PHYSIOL,LEBANON,NH 03756	Dartmouth College; Dartmouth College					NCI NIH HHS [CA23108] Funding Source: Medline; NIDDK NIH HHS [DK-42271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BHAT GB, 1989, BIOCHEM J, V258, P785, DOI 10.1042/bj2580785; BOADO RJ, 1989, ENDOCRINOLOGY, V124, P2245, DOI 10.1210/endo-124-5-2245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOPRA IJ, 1991, THYROID HORMONE META, P41; GALTON VA, 1987, ENDOCRINOLOGY, V120, P2604, DOI 10.1210/endo-120-6-2604; GOSWAMI A, 1988, ENDOCRINOLOGY, V123, P192, DOI 10.1210/endo-123-1-192; GOSWAMI A, 1987, ENDOCRINOLOGY, V121, P1937, DOI 10.1210/endo-121-6-1937; GOSWAMI A, 1984, J CLIN INVEST, V74, P2097, DOI 10.1172/JCI111634; GOSWAMI A, 1983, ENDOCRINOLOGY, V112, P1180, DOI 10.1210/endo-112-4-1180; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V17, P6; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; Leonard JL, 1986, THYROID HORMONE META, P189; ROSENBERG IN, 1991, THYROID HORMONE META, P29; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAKANE S, 1990, ENDOCRINOLOGY, V127, P2709, DOI 10.1210/endo-127-6-2709; SAWADA K, 1985, ENDOCRINOLOGY, V117, P1259, DOI 10.1210/endo-117-3-1259; SILVA JE, 1987, ENDOCRINOLOGY, V121, P650, DOI 10.1210/endo-121-2-650; STGERMAIN DL, 1989, J BIOL CHEM, V264, P3054; STGERMAIN DL, 1989, ENDOCRINOLOGY, V125, P2735; STGERMAIN DL, 1990, J BIOL CHEM, V265, P20087	24	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12539	12544						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618759				2022-12-27	WOS:A1992HZ48300027
J	PAIETTA, E; STOCKERT, RJ; RACEVSKIS, J				PAIETTA, E; STOCKERT, RJ; RACEVSKIS, J			ALTERNATIVELY SPLICED VARIANTS OF THE HUMAN HEPATIC ASIALOGLYCOPROTEIN RECEPTOR, H2, DIFFER IN CELLULAR TRAFFICKING AND REGULATION OF PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; BETA-CHAIN; DEGRADATION; EXPRESSION; SUBUNITS; SEQUENCE; DOMAIN; DNA	The less abundant subunit of the asialoglycoprotein receptor, H2, may be encoded by at least four variant transcripts as a result of alternative mRNA splicing. We had cloned two H2-cDNAs that differed predominantly by the presence (clone H2') or absence (clone L-H2) of two presumed exons; one of 57 nucleotides was near the 5' end of the sequence, and the other was within the transmembrane region consisting of 15 nucleotides. The relevance of these two segments to H2 processing was studied after expression in rat-6 fibroblasts of these two isolates and of artificial constructs containing either only the 57-nucleotide (transfectant-57) or the 15-nucleotide (transfectant-15) region. H2 proteins encoded by cDNAs containing the 15-nucleotide region were intracellularly retained and degraded independently of the presence of the 57-nucleotide sequence. Of proteins derived from clones lacking the 15-nucleotide region, only a fraction was processed through the trans-Golgi, as evidenced by sensitivity to O-glycanase and neuraminidase, and reached the cell surface. The presence of the 57-nucleotide sequence was necessary for protein phosphorylation. Phosphorylation of serine residue(s) was detected in the endoglycosidase H-sensitive and mature forms of H2 protein encoded by transfectant-57. Since the 57-nucleotide region does not encode for serine residues, it per se cannot be the site of phosphorylation but rather constitutes a regulatory element for post-translational modification.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	PAIETTA, E (corresponding author), MONTEFIORE MED CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NCI NIH HHS [P30CA13330] Funding Source: Medline; NIDDK NIH HHS [DK-17702, DK-32972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032972, P50DK017702] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEVEZI P, 1991, J VIROL, V65, P5333, DOI 10.1128/JVI.65.10.5333-5341.1991; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAIETTA E, 1989, J IMMUNOL, V143, P2850; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PAIETTA E, 1990, CANCER RES, V50, P2049; PRICER WE, 1971, J BIOL CHEM, V246, P4825; Sambrook J, 1989, MOL CLONING LAB MANU, P121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOCKERT RJ, 1977, SCIENCE, V197, P667, DOI 10.1126/science.877581; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11078	11084						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597447				2022-12-27	WOS:A1992HX16900025
J	OLAH, ME; REN, HZ; OSTROWSKI, J; JACOBSON, KA; STILES, GL				OLAH, ME; REN, HZ; OSTROWSKI, J; JACOBSON, KA; STILES, GL			CLONING, EXPRESSION, AND CHARACTERIZATION OF THE UNIQUE BOVINE-A1 ADENOSINE RECEPTOR - STUDIES ON THE LIGAND-BINDING SITE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; ADENYLATE CYCLASE SYSTEM; MOLECULAR-CLONING; ALPHA-1-ADRENERGIC RECEPTOR; CEREBRAL-CORTEX; BRAIN MEMBRANES; CDNA; A1-ADENOSINE; ANTAGONIST; SUBTYPES	The bovine brain A1 adenosine receptor (A1AR) is distinct from other A1ARs in that it displays the unique agonist potency series of N6-R-phenylisopropyladenosine (R-PIA) > N6-S-phenylisopropyladenosine (S-PIA) > 5'-N-ethylcarboxamidoadenosine and has a 5-10-fold higher affinity for both agonists and antagonists. The cDNA for this receptor has been cloned from a size-selected (2-4-kb) bovine brain library and sequenced. The 2.0-kb cDNA encodes a protein of 326 amino acid residues with a molecular mass of 36,570 daltons. The amino acid sequence fits well into the seven-transmembrane domain motif typical of G protein-coupled receptors. Northern analysis in bovine tissue using the full length cDNA demonstrates mRNAs of 3.4 and 5.7 kb with a tissue distribution consistent with A1AR binding. Subcloning of the cDNA in a pCMV5 expression vector with subsequent transfection into both COS7 and Chinese hamster ovary cells revealed a fully functional A1AR which could inhibit adenylylcyclase and retained the unique pharmacologic properties of the bovine brain A1AR. The A1AR was found to have a single histidine residue in each of transmembrane domains 6 and 7. Histidine residues have been postulated by biochemical studies to be important for ligand binding. Mutation of His-278 to Leu-278 (seventh transmembrane domain) dramatically decreased both agonist and antagonist binding by > 90%. In contrast, mutation of His-251 to Leu-251 decreased antagonist affinity and the number of receptors recognized by an antagonist radioligand. In contrast, agonist affinity was not perturbed but the number of receptors detected by an agonist radioligand was also reduced. These data suggest that both histidines are important for both agonist and antagonist binding, but His-278 appears critical for ligand binding to occur.	DUKE UNIV,MED CTR,DEPT MED,BOX 3444,DURHAM,NC 27710; NIDDKD,CHEM LAB,BETHESDA,MD 20892; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Duke University; Duke University; Howard Hughes Medical Institute			Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013713] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK031117-20, Z99 DK999999] Funding Source: Medline; NHLBI NIH HHS [R01-HL35134] Funding Source: Medline; NIGMS NIH HHS [1F32-GM-13713-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN PH, 1990, TRENDS PHARMACOL SCI, V11, P231, DOI 10.1016/0165-6147(90)90249-8; BARRINGTON WW, 1989, J BIOL CHEM, V264, P13157; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALY JW, 1985, ADV CYCLIC NUCL PROT, V19, P29; DELEAN A, 1982, MOL PHARMACOL, V21, P5; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; LORENZ W, 1990, MOL PHARMACOL, V38, P599; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; Maniatis T, 1989, DECONTAMINATION DILU; MURPHY KMM, 1982, MOL PHARMACOL, V22, P250; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OLAH ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P440, DOI 10.1016/0003-9861(90)90665-L; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RAMKUMAR V, 1990, MOL PHARMACOL, V37, P149; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; RAMKUMAR V, 1988, J CLIN INVEST, V82, P242, DOI 10.1172/JCI113577; RAPIEJKO PJ, 1987, BIOCHEM J, V241, P765, DOI 10.1042/bj2410765; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; STILES GL, 1990, CLIN RES, V38, P10; STILES GL, 1986, J BIOL CHEM, V261, P839; STILES GL, 1985, J BIOL CHEM, V260, P806; STILES GL, 1988, J NEUROCHEM, V51, P1592, DOI 10.1111/j.1471-4159.1988.tb01129.x; STILES GL, 1991, NEWS PHYSIOL SCI, V6, P161; STILES GL, 1987, MOL PHARMACOL, V32, P184; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; UKENA D, 1986, FEBS LETT, V209, P122, DOI 10.1016/0014-5793(86)81096-1; YEUNG SMH, 1983, J BIOL CHEM, V258, P2334	46	157	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10764	10770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587851				2022-12-27	WOS:A1992HV09000084
J	PEDERSEN, SE; SHARP, SD; LIU, WS; COHEN, JB				PEDERSEN, SE; SHARP, SD; LIU, WS; COHEN, JB			STRUCTURE OF THE NONCOMPETITIVE ANTAGONIST-BINDING SITE OF THE TORPEDO NICOTINIC ACETYLCHOLINE-RECEPTOR - [H-3] MEPROADIFEN MUSTARD REACTS SELECTIVELY WITH ALPHA-SUBUNIT-GLU-262	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ALPHA-SUBUNIT; AMINO-ACIDS; ION CHANNEL; POSTSYNAPTIC MEMBRANES; PROTEINS; IDENTIFICATION; MARMORATA; LIGAND; CALIFORNICA	[H-3]Meproadifen mustard, an affinity label for the noncompetitive antagonist site of the nicotinic acetylcholine receptor (AChR), specifically alkylates the AChR alpha-subunit when the acetylcholine-binding sites are occupied by agonist (Dreyer, E. B., Hasan, F., Cohen, S. G., and Cohen, J. B. (1986) J. Biol. Chem. 261, 13727-13734). In this report, we identify the site of alkylation within the alpha-subunit as Glu-262. AChR-rich membranes from Torpedo californica electric organ were reacted with [H-3]meproadifen mustard in the presence of carbamylcholine and in the absence or presence of nonradioactive meproadifen to define specific alkylation of the noncompetitive antagonist site. Alkylated alpha-subunits were isolated and subjected to chemical or enzymatic cleavage. When digests with CNBr in 70% trifluoroacetic acid or 70% formic acid were fractionated by gel filtration high performance liquid chromatography (HPLC), specifically labeled material was recovered in the void volume fractions. Based upon NH2-terminal sequence analysis, for both digests, the void volume fractions contained a fragment beginning at Gln-208 before the M1 hydrophobic sequence, whereas the sample from the digest in trifluoroacetic acid also contained as a primary sequence a fragment beginning at Thr-244 and extending through the M2 hydrophobic sequence. Sequence analysis revealed no release of H-3 for the sample from digestion in formic acid, whereas for the trifluoroacetic acid digest, there was specific release of H-3 in cycle 19, which would correspond to Glu-262. This site of alkylation was confirmed by isolation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and reversed-phase HPLC of a specifically labeled fragment from an endoproteinase Lys-C digest of the alkylated alpha-subunit. NH2-terminal amino acid sequencing revealed release of H-3 at cycle 20 from a fragment beginning at Met-243 and extending into the M3 hydrophobic sequence. Because [H-3]meproadifen mustard contains, as its reactive group, a positively charged quaternary aziridinium ion, Glu-262 of the alpha-subunit is identified as a contributor to the cation-binding domain of the noncompetitive antagonist-binding site and thus of the ion channel.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Pedersen, Steen E./0000-0001-8755-8899	NINDS NIH HHS [NS 19522, NS 22828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022828, R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN G, 1989, SEQUENCING PROTEINS; ARAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLANTON MP, 1992, IN PRESS BIOCHEMISTR; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; Cohen J. B., 1986, MOL CELLULAR MECHANI, P111; COHEN JB, 1991, J BIOL CHEM, V266, P23354; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; COLQUHOUN D, 1986, HDB EXPT PHARM, V79, P59; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DERMER OC, 1969, ETHYLENIMINE OTHER A, P205; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DREYER EB, 1986, J BIOL CHEM, V261, P3727; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; FORMAN SA, 1989, TRENDS PHARMACOL SCI, V10, P447, DOI 10.1016/S0165-6147(89)80009-4; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GERBER GE, 1979, P NATL ACAD SCI USA, V76, P227, DOI 10.1073/pnas.76.1.227; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KAO PN, 1984, J BIOL CHEM, V259, P1662; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; NEHER E, 1983, J PHYSIOL-LONDON, V335, P123; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NEUBIG RR, 1980, BIOCHEMISTRY-US, V19, P2770, DOI 10.1021/bi00553a036; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OGDEN DC, 1981, NATURE, V289, P596, DOI 10.1038/289596a0; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PEDERSEN SE, 1990, J BIOL CHEM, V265, P569; PEPER K, 1982, PHYSIOL REV, V62, P1271, DOI 10.1152/physrev.1982.62.4.1271; PORTER S, 1983, J BIOL CHEM, V258, P34; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; STRNAD NP, 1988, THESIS WASHINGTON U; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; TARR GE, 1986, MICROCHARACTERIZATIO, P155; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1991, NEUR ABSTR, V17, pA22; WHITE BH, 1991, THESIS WASHINGTON U	60	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10489	10499						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587830				2022-12-27	WOS:A1992HV09000044
J	AVENT, ND; BUTCHER, SK; LIU, W; MAWBY, WJ; MALLINSON, G; PARSONS, SF; ANSTEE, DJ; TANNER, MJA				AVENT, ND; BUTCHER, SK; LIU, W; MAWBY, WJ; MALLINSON, G; PARSONS, SF; ANSTEE, DJ; TANNER, MJA			LOCALIZATION OF THE C-TERMINI OF THE RH (RHESUS) POLYPEPTIDES TO THE CYTOPLASMIC FACE OF THE HUMAN ERYTHROCYTE-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; ANION TRANSPORT PROTEIN; RH(D) POLYPEPTIDE; ANTIGENS; IDENTIFICATION; POLYMORPHISM; ORIENTATION; SEQUENCE; CLONING	We have raised a rabbit antiserum to a synthetic peptide corresponding to the C terminus (residues 400-416) of the Rh30A polypeptide. The rabbit antiserum reacted with the Rh30B (D30) polypeptide in addition to the Rh30A (C/c and/or E/e) polypeptide(s), indicating that these proteins share homology at their C termini. The antiserum did not react with erythrocyte membranes from an individual with Rh(null) syndrome. The rabbit antiserum immunoprecipitated Rh polypeptides from erythrocyte membranes and alkali-stripped membranes, but not from intact erythrocytes. Treatment of intact red cells with carboxypeptidase Y did not affect the reactivity of the antiserum, whereas treatment of alkali-stripped and unsealed erythrocyte ghost membranes resulted in the loss of antibody binding. Carboxypeptidase A treatment of intact erythrocytes and alkali-stripped membranes had no effect on antibody binding, indicating that the C-terminal domains of the Rh polypeptides contain lysine, arginine, proline, or histidine residues. These results show that the C termini of the Rh polypeptides are located toward the cytoplasmic face of the erythrocyte membrane. Treatment of intact radioiodinated erythrocytes with bromelain followed by immunoprecipitation with monoclonal anti-D gave a band of M(r) 24,000-25,000, indicating that the Rh30B (D30) polypeptide is cleaved at an extracellular domain close to the N or C terminus, with loss of the major radioiodinated domain. Immunoblotting of bromelain treated D-positive erythrocyte membranes with the rabbit antiserum to the C-terminal peptide revealed a new band of M(r) 6000-6500, indicating that the extracellular bromelain cleavage site is located near the C terminus of the molecule. The band of M(r) 6000-6500 was not obtained in erythrocyte membranes derived from bromelain treated D-negative erythrocytes. Erythrocytes of the rare -D- phenotype appear to either totally lack, or have gross alterations in, the Cc/Ee polypeptide(s), since the bromelain treatment of these cells resulted in the total loss of staining in the M(r) 35,000-37,000 region and the concomitant appearance of the new band of M(r) 6000-6500.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; BRISTOL POLYTECH,DEPT BIOL,BRISTOL BS16 1QY,ENGLAND	University of Bristol; University of West England	AVENT, ND (corresponding author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,ENGLAND.		Anstee, David/AAE-9231-2020					AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; Atherton E., 1981, J CHEM SOC P1, V1, P538; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLOY C, 1990, J BIOL CHEM, V265, P21482; BLOY C, 1988, BLOOD, V72, P661; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; COLIN Y, 1991, BLOOD, V78, P2747; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; DRYLAND A, 1986, J CHEM SOC P1, V1, P125; GAHMBERG CG, 1984, J IMMUNOL, V133, P334; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; Gardner B, 1991, Transfus Med, V1, P77, DOI 10.1111/j.1365-3148.1991.tb00013.x; GREEN FA, 1967, IMMUNOCHEMISTRY, V4, P247, DOI 10.1016/0019-2791(67)90186-3; GREEN FA, 1965, VOX SANG, V10, P32, DOI 10.1111/j.1423-0410.1965.tb04317.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hayashi R, 1977, Methods Enzymol, V47, P84; KISFALUDY L, 1983, SYNTHESIS-STUTTGART, P325; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KRAHMER M, 1987, FEBS LETT, V226, P105, DOI 10.1016/0014-5793(87)80560-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMAN DM, 1987, BIOCHIM BIOPHYS ACTA, V903, P37, DOI 10.1016/0005-2736(87)90153-2; MACGEOCH C, 1992, CYTOGENET CELL GENET, V59, P261, DOI 10.1159/000133264; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; RIDGWELL K, 1984, FEBS LETT, V174, P7, DOI 10.1016/0014-5793(84)81066-2; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; RIDGWELL K, 1992, IN PRESS BIOCH J; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUYAMA K, 1990, BLOOD, V75, P255; SUYAMA K, 1988, BLOOD, V72, P1622; SUYAMA K, 1992, BLOOD, V79, P808; SUYAMA K, 1991, BLOOD, V77, P411; TIPPETT P, 1987, BLOOD GROUP SYSTEMS, P25; TSCHESCHE H, 1977, METHOD ENZYMOL, V247, P73; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211	44	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15134	15139						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634548				2022-12-27	WOS:A1992JF08800092
J	GASSAMADIAGNE, A; ROGALLE, P; FAUVEL, J; WILLSON, M; KLAEBE, A; CHAP, H				GASSAMADIAGNE, A; ROGALLE, P; FAUVEL, J; WILLSON, M; KLAEBE, A; CHAP, H			SUBSTRATE-SPECIFICITY OF PHOSPHOLIPASE-B FROM GUINEA-PIG INTESTINE - A GLYCEROL ESTER LIPASE WITH BROAD SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; 2 CATIONIC LIPASES; PENICILLIUM-NOTATUM; SACCHAROMYCES-CEREVISIAE; PURIFICATION; GLYCEROPHOSPHOLIPIDS; PANCREAS; PROTEINS; ENZYMES; PLASMA	The substrate specificity of a calcium-independent, 97-kDa phospholipase B purified from guinea pig intestine was further investigated using various natural and synthetic lipids. The enzyme was equally active toward enantiomeric phosphatidylcholines under conditions allowing a strict phospholipase A activity. The lysophospholipase activity declined with the following substrates: 1-acyl-sn-glycero-3-phosphocholine > 1-palmitoyl-propanediol-3-phosphocholine > 1-palmitoyl-glycol-2-phosphocholine, suggesting some influence of the polar residue vicinal to the cleavage site. The enzyme also acted on various neutral lipids including triacylglycerol, diacylglycerol, and monoacylglycerol, whereas cholesteryl oleate remained refractory to enzymatic hydrolysis. The lipase hydrolyzed sequentially the sn-2 and sn-1 acyl ester bonds of diacylglycerol, although some direct cleavage of the external acyl ester bond could also occur, as shown with diacylglycerol analogues bearing a nonhydrolyzable alkyl ether or amide bond in the sn-1 or sn-2 position. The three main activities of the enzyme (phospholipase A2, lysophospholipase, and diacylglycerol lipase) were resistant to 4-bromophenacyl bromide, but they were inhibited by N-ethylmaleimide, 5,5'-dithiobis-(2-nitrobenzoic acid), and diisopropyl fluorophosphate, suggesting the possible involvement of both cysteine and serine residues in a single active site. It is concluded that guinea pig intestinal phospholipase B, which was also detected in rat and rabbit, is actually a glycerol ester lipase with broad substrate specificity and some unique enzymatic properties.	UNIV TOULOUSE 3, CNRS, URA 454, CHIM ORGAN BIOL GRP, F-31062 TOULOUSE, FRANCE; UNIV TOULOUSE 3, CNRS, URA 470, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier								BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; DIJKMAN R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P67, DOI 10.1016/0005-2760(90)90111-A; FAUVEL J, 1984, BIOCHIM BIOPHYS ACTA, V792, P72, DOI 10.1016/0005-2760(84)90284-4; FAUVEL J, 1981, BIOCHIM BIOPHYS ACTA, V663, P446, DOI 10.1016/0005-2760(81)90173-9; FAUVEL J, 1984, BIOCHIM BIOPHYS ACTA, V792, P65, DOI 10.1016/0005-2760(84)90283-2; FIELDING CJ, 1981, J BIOL CHEM, V256, P876; GASSAMADIAGNE A, 1991, METHOD ENZYMOL, V197, P316; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HERMETTER A, 1983, ETHER LIPIDS BIOCH B, P389; ICHIMASA M, 1984, J BIOCHEM, V95, P137; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KUCERA GL, 1988, J BIOL CHEM, V263, P12964; KUWABARA Y, 1988, J BIOCHEM, V104, P236, DOI 10.1093/oxfordjournals.jbchem.a122449; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; MAROUX S, 1987, MAMMALIAN ECTOENZYME, P15; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; MATTSON FH, 1962, J LIPID RES, V3, P281; NEISES B, 1978, ANGEW CHEM INT EDIT, V17, P522, DOI 10.1002/anie.197805221; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; NISHIJIMA M, 1974, J BIOL CHEM, V249, P5658; OKUMURA T, 1980, BIOCHIM BIOPHYS ACTA, V617, P264; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1988, BIOCHIM BIOPHYS ACTA, V938, P211, DOI 10.1016/0005-2736(88)90160-5; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; SAITO K, 1991, METHOD ENZYMOL, V197, P446; SAITO K, 1974, BIOCHIM BIOPHYS ACTA, V369, P245, DOI 10.1016/0005-2760(74)90255-0; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUGATANI J, 1978, BIOCHIM BIOPHYS ACTA, V529, P29; SUGATANI J, 1980, BIOCHIM BIOPHYS ACTA, V620, P372; TAKEUCHI Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P206, DOI 10.1016/0003-9861(87)90025-7; VANDENBOSCH H, 1968, BIOCHIM BIOPHYS ACTA, V152, P694, DOI 10.1016/0005-2760(68)90115-X; Verkade PE, 1942, RECL TRAV CHIM PAY-B, V61, P831; WAITE M, 1967, BIOCHIM BIOPHYS ACTA, V137, P498, DOI 10.1016/0005-2760(67)90131-2; WAITE M, 1991, METHOD ENZYMOL, V197, P331; WAITE M, 1987, HDB LIPID RES, V5, P1; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P117, DOI 10.1016/0005-2760(84)90111-5; WITT W, 1984, BIOCHIM BIOPHYS ACTA, V795, P108, DOI 10.1016/0005-2760(84)90110-3	45	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13418	13424						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618844				2022-12-27	WOS:A1992JB74600052
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			FACTOR-STIMULATED RNA POLYMERASE-II TRANSCRIBES AT PHYSIOLOGICAL ELONGATION RATES ON NAKED DNA BUT VERY POORLY ON CHROMATIN TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT PROTEIN; FACTOR-SII; DROSOPHILA-MELANOGASTER; ACCURATE TRANSCRIPTION; PHAGE-LAMBDA; CALF THYMUS; S-II; GENE; INITIATION; INVITRO	We used an in vitro assay system based on HeLa cell core transcription components to examine transcript elongation by RNA polymerase II on either naked DNA or chromatin templates as a function of the three known elongation factors, IIS, TFIIF, and TFIIX. We demonstrate for the first time that mammalian RNA polymerase II can achieve physiological elongation rates on naked DNA templates in vitro. The addition of TFIIF alone gave this rate, although IIS was required to minimize the block to elongation at intrinsic termination sites. However, IIS and TFIIF provided only a slight increase in the very poor elongation efficiency of RNA polymerase II on chromatin templates. The addition of TFIIX to reactions containing IIS and TFIIF reduced the elongation rate on naked DNA templates but slightly increased the elongation efficiency on chromatin. The ability of elongation factors either separately or in combination to stimulate transcription on naked DNA and chromatin templates was also examined.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, F32GM014111] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 14111, GM 29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHAFIN DR, 1991, J BIOL CHEM, V266, P9256; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; COULTER DE, 1985, J BIOL CHEM, V260, P3190; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FALVEY E, 1991, FASEB J, V5, P9; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; GARIGLIO P, 1981, NUCLEIC ACIDS RES, V9, P2589, DOI 10.1093/nar/9.11.2589; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIRAI H, 1988, FEBS LETT, V238, P119, DOI 10.1016/0014-5793(88)80239-4; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REINES D, 1989, J BIOL CHEM, V264, P10799; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPENCER CA, 1990, ONCOGENE, V5, P777; TURNER BM, 1991, J CELL SCI, V99, P13; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WHALEN W, 1988, P NATL ACAD SCI USA, V85, P2494, DOI 10.1073/pnas.85.8.2494; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817	52	193	199	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13647	13655						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618865				2022-12-27	WOS:A1992JB74600087
J	MELAUGH, W; PHILLIPS, NJ; CAMPAGNARI, AA; KARALUS, R; GIBSON, BW				MELAUGH, W; PHILLIPS, NJ; CAMPAGNARI, AA; KARALUS, R; GIBSON, BW			PARTIAL CHARACTERIZATION OF THE MAJOR LIPOOLIGOSACCHARIDE FROM A STRAIN OF HAEMOPHILUS-DUCREYI, THE CAUSATIVE AGENT OF CHANCROID, A GENITAL ULCER DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPHILUS-DUCREYI; NEISSERIA-GONORRHOEAE; NAIROBI PROSTITUTES; LIPOPOLYSACCHARIDE; INFLUENZAE; VIRULENCE; OUTBREAK; VIRUS	The first preliminary structure of a surface lipooligosaccharide from Haemophilus ducreyi has been determined. The major oligosaccharide was released by mild acid hydrolysis and analyzed by liquid secondary ion and tandem mass spectrometry. The mass spectral data combined with composition and methylation analysis yielded the most probable structure; Gal1-->4GlcNAc1-->3Gal1-->4Hep1-->6Glc1-->(Hep1-->2Hep1 -->)3,4Hep1-->KDO, where the reducing terminal 3-deoxy-D-manno-octulosonic acid (or KDO) exists in an anhydro form. This anhydro species results from the elimination of a phosphate from C-4 of KDO during mild acid hydrolysis. The core heptose trisaccharide consists of L-glycero-D-manno-heptose, but analysis of the peracetylated sugars indicated that the 1,4-linked heptose is likely D-glycero-D-manno-heptose. The monoclonal antibody 3F11 generated against Neisseria gonorrhoeae also binds to this lipooligosaccharide and suggests that the terminal trisaccharide is Gal-beta-1-->4GlcNAc-beta-1-->3Gal-beta-1-->, an epitope found in the glycose moiety of the human erythrocyte glycosphingolipid lactoneotetraglycosylceramide. Mass spectrometric and composition analysis of the lipid A moiety shows that it is similar to the lipid A of Haemophilus influenzae strain I-69 Rd-/b+ proposed by Helander et al. (Helander, I. M., Lindner, B., Brade, H., Altmann, K., Lindberg, A. A., Rietschel, E. T., and Zahringer, U. (1988) Eur. J. Biochem. 177, 483-492). Electrospray mass spectrometric analysis of the intact O-deacylated lipooligosaccharides gave an average M(r) of 2710, and supported an overall structure consisting of the above nonasaccharide linked directly to a diphosphorylated lipid A moiety through the single KDO which is phosphorylated. This structure should provide a framework to investigate the roles of lipooligosaccharides in the host immunochemical response and pathology of H. ducreyi infection, a leading cause of genital ulcer disease.	UNIV CALIF SAN FRANCISCO, SCH PHARM 9265, DEPT PHARMACEUT CHEM, 513 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR IMMUNOCHEM, SAN FRANCISCO, CA 94143 USA; SUNY BUFFALO, INST INFECT DIS, BUFFALO, NY 14260 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024616, R01AI030006, R01AI021620, R01AI024616] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 30006, AI 24616, AI 21620] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABECK D, 1987, FEMS MICROBIOL LETT, V42, P159; BATLEY M, 1985, BIOCHIM BIOPHYS ACTA, V821, P205, DOI 10.1016/0005-2736(85)90089-6; BLACKMORE CA, 1985, J INFECT DIS, V151, P840, DOI 10.1093/infdis/151.5.840; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GREGG CR, 1981, J INFECT DIS, V143, P432, DOI 10.1093/infdis/143.3.432; HAMMOND GW, 1980, REV INFECT DIS, V2, P867; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; JOHN CM, 1991, J BIOL CHEM, V266, P19303; JOHN CM, 1990, ANAL BIOCHEM, V187, P281, DOI 10.1016/0003-2697(90)90458-L; JOHNSON RS, 1990, J BIOL CHEM, V265, P8108; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; KUBUKAMUSOKE JW, 1965, T R SOC TROP MED HYG, V59, P642; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MAMMOND GW, 1978, ANTIMICROB AGENTS CH, V13, P608; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MORSE SA, 1989, CLIN MICROBIOL REV, V2, P137, DOI 10.1128/CMR.2.2.137-157.1989; ODUMERU JA, 1984, INFECT IMMUN, V43, P607, DOI 10.1128/IAI.43.2.607-611.1984; ODUMERU JA, 1987, J MED MICROBIOL, V23, P155, DOI 10.1099/00222615-23-2-155; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; PHILLIPS NJ, 1992, BIOCHEMISTRY-US, V31, P4515, DOI 10.1021/bi00133a019; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RADZIEJEWSKALEBRECHT J, 1989, EUR J BIOCHEM, V183, P573, DOI 10.1111/j.1432-1033.1989.tb21086.x; RONALD AR, 1985, ANN INTERN MED, V102, P705, DOI 10.7326/0003-4819-102-5-705; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; TUFFREY M, 1990, J EXP PATHOL, V71, P233; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; Westphal O., 1965, METHODS CARBOHYDRATE, V5, P83, DOI DOI 10.1016/J.WATRES.2010.04.030	32	59	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13434	13439						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618845				2022-12-27	WOS:A1992JB74600054
J	WINSTON, JH; HANTEN, GR; OVERBEEK, PA; KELLEMS, RE				WINSTON, JH; HANTEN, GR; OVERBEEK, PA; KELLEMS, RE			5' FLANKING SEQUENCES OF THE MURINE ADENOSINE-DEAMINASE GENE DIRECT EXPRESSION OF A REPORTER GENE TO SPECIFIC PRENATAL AND POSTNATAL TISSUES IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; ACID-BINDING-PROTEIN; HORMONE FUSION GENES; ALPHA-SUBUNIT GENE; KERATIN GENE; DEVELOPMENTAL EXPRESSION; TRANSCRIPTIONAL ENHANCER; GROWTH-FACTOR; IDENTIFICATION; PLACENTA	Adenosine deaminase (ADA), an enzyme of purine metabolism, is highly expressed in four tissues of the mouse: the maternal decidua, the fetal placenta, the keratinizing epithelium of the upper alimentary tract (tongue, esophagus, and forestomach), and the absorptive epithelium of the proximal small intestine. ADA is produced at relatively low levels in all other tissues. To identify genetic elements that direct appropriate prenatal and postnatal expression of the ADA gene, a segment of DNA including the ADA promoter and 6.4 kilobases of the adjacent 5' flanking region was tested for the ability to direct the expression of a reporter gene in transgenic mice. In seven lines of transgenic mice studied, this construct directed high levels of reporter gene expression in the placenta and forestomach and exhibited correct developmental regulation in these tissues. This construct failed to direct significant reporter gene expression to either the maternal decidua or the proximal small intestine. Thus, different gene regulatory elements are required to target high expression to the four tissues characterized by high levels of ADA.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	WINSTON, JH (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.			Overbeek, Paul/0000-0001-9784-2084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030204] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM30204] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R P, 1978, Methods Enzymol, V51, P502; ALUBAIDI MR, 1989, GENOMICS, V7, P476; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEGINI N, 1985, J CLIN ENDOCR METAB, V61, P529, DOI 10.1210/jcem-61-3-529; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE SK, 1989, DEVELOPMENT, V107, P611; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; INNIS JW, 1991, J BIOL CHEM, V266, P21765; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; KNUDSEN TB, 1989, TERATOLOGY, V40, P615, DOI 10.1002/tera.1420400609; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; PALMITER RD, 1982, CELL, V29, P701, DOI 10.1016/0092-8674(82)90186-6; PLOUZEK CA, 1991, BIOCHEM BIOPH RES CO, V176, P1532, DOI 10.1016/0006-291X(91)90461-F; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RAUTH S, 1990, SOMAT CELL MOLEC GEN, V16, P129, DOI 10.1007/BF01233043; SAJI F, 1990, AM J REPROD IMMUNOL, V24, P99, DOI 10.1111/j.1600-0897.1990.tb01046.x; Sambrook J, 1989, MOL CLONING LABORATO; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; VALERIO D, 1988, NUCLEIC ACIDS RES, V16, P10083, DOI 10.1093/nar/16.21.10083; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WALKER WH, 1990, J BIOL CHEM, V265, P12940	40	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13472	13479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618849				2022-12-27	WOS:A1992JB74600061
J	BOHELER, KR; CHASSAGNE, C; MARTIN, X; WISNEWSKY, C; SCHWARTZ, K				BOHELER, KR; CHASSAGNE, C; MARTIN, X; WISNEWSKY, C; SCHWARTZ, K			CARDIAC EXPRESSIONS OF ALPHA-MYOSIN AND BETA-MYOSIN HEAVY-CHAINS AND SARCOMERIC ALPHA-ACTINS ARE REGULATED THROUGH TRANSCRIPTIONAL MECHANISMS - RESULTS FROM NUCLEAR RUN-ON ASSAYS IN ISOLATED RAT CARDIAC NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-CELL NUCLEI; MESSENGER-RNA LEVELS; SKELETAL-MUSCLE; THYROID-HORMONE; BINDING-FACTOR; HEART; GENE; HYPERTROPHY; RABBIT; DIFFERENTIATION	In the heart, mRNA accumulations for sarcomeric actins and myosin heavy chains (MHC) are subject to diverse regulatorial processes. To study cardiac contractile protein transcriptional regulations, an in vitro transcription system using nonenzymatically isolated rat cardiac nuclei was characterized. Transcription was shown to be rapid and continuous during the first 20 min of incubation and 5.4-fold less than that seen from comparably isolated hepatocyte nuclei. Neither RNase nor DNase activities were detectable. Direct transcriptional analyses of the alpha- and beta-MHC and cardiac and skeletal alpha-actin genes from cardiac nuclei were performed. In 23-24-day-old rats, significant levels of transcription were seen for alpha-MHC and for the sarcomeric alpha-actins. Beta-MHC was just detectable, and no positive signals were ever seen for fibronectin. We then compared the percentages of MHC and sarcomeric alpha-actin expressions determined from 1) the transcriptional assays and 2) total isolated RNA (alpha-MHC: 90.1 +/- 4.8% (transcription), 93.0 +/- 4.7% (accumulation); beta-MHC: 9.9 +/- 4.8%, 7.0 +/- 4.7%; cardiac alpha-actin: 84.0 +/- 2.5%, 84.9 +/- 2.5%; skeletal alpha-actin: 16.1 +/- 2.5%. 15.0 +/- 2.5%). The results support the conclusion that the primary mechanisms controlling the accumulations of these gene products are transcriptional. Additionally, we show that an anti-sense mRNA showing strong homology or identity with the 5' end of the beta-MHC gene is transcribed in cardiac nuclei but not in hepatocyte nuclei.			BOHELER, KR (corresponding author), HOP LARIBOISIERE, INSERM, U127, 41 BLVD CHAPELLE, F-75475 PARIS 10, FRANCE.							ALPERT NR, 1982, CIRC RES, V50, P491, DOI 10.1161/01.RES.50.4.491; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BENNETTS BH, 1986, J MOL CELL CARDIOL, V18, P993, DOI 10.1016/S0022-2828(86)80013-X; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BOHELER KR, 1991, MOL CELL BIOCHEM, V104, P101, DOI 10.1007/BF00229809; BOHELER KR, 1988, THESIS U CALIF, P94; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BOXER LM, 1989, J BIOL CHEM, V264, P1284; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CARRIER L, 1992, IN PRESS CIRC RES; CHASSAGNE C, 1991, CR ACAD SCI III-VIE, V312, P7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX RD, 1991, DEV BIOL, V143, P36, DOI 10.1016/0012-1606(91)90052-5; COX RD, 1990, DIFFERENTIATION, V43, P183, DOI 10.1111/j.1432-0436.1990.tb00445.x; EFFRON MB, 1987, CIRC RES, V60, P238, DOI 10.1161/01.RES.60.2.238; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; LEE HR, 1988, J BIOL CHEM, V263, P7352; LIEW CCG, 1983, AM J PHYSIOL, V244, pC3, DOI 10.1152/ajpcell.1983.244.1.C3; LOMPRE AM, 1991, INT REV CYTOL, V124, P137; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MAHDAVI V, 1991, J CELL BIOCHEM     S, V15, P151; MAHDAVI V, 1989, CELLULAR MOL BIOL MU, P369; MANIATIS T, 1982, MOL CLONING LABORATO, P363; MARINO TA, 1991, CIRC RES, V69, P1353, DOI 10.1161/01.RES.69.5.1353; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MCCULLY JD, 1988, BIOCHEM J, V256, P441, DOI 10.1042/bj2560441; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAGAI R, 1987, CIRC RES, V60, P692, DOI 10.1161/01.RES.60.5.692; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHIAFFINO S, 1989, CIRC RES, V64, P937, DOI 10.1161/01.RES.64.5.937; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	53	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12979	12985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618795				2022-12-27	WOS:A1992HZ48300087
J	BROWN, ED; WOOD, JM				BROWN, ED; WOOD, JM			REDESIGNED PURIFICATION YIELDS A FULLY FUNCTIONAL PUTA PROTEIN DIMER FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE DEHYDROGENASE; SALMONELLA-TYPHIMURIUM; MEMBRANE ASSOCIATION; MOLECULAR-WEIGHT; PRODUCT; ENZYME; SIZE; ACID	Proline utilization by Escherichia coli and Salmonella typhimurium requires expression of genes putP (encoding a proline transporter) and putA. Genetic data indicate that the PutA protein is both put repressor and a respiratory chain-linked dehydrogenase. We report a redesigned purification procedure as well as the physical characteristics and biological activities of the PutA protein purified from E. coli. The purified protein was homogeneous as determined by electrophoresis performed under denaturing and nondenaturing conditions. Its N-terminal sequence corresponded to that predicted by the DNA sequence. We showed copurification of proline and DELTA-1-pyrroline-5-carboxylate dehydrogenase activities. Purified PutA protein bound put DNA in vitro in an electrophoretic band-shift assay and it could be reconstituted to inverted membrane vesicles, yielding proline dehydrogenase activity. The Stokes radius and Svedberg coefficient of the protein were determined to be 7.1 nm and 9.9 S, respectively. These hydrodynamic data revealed that the protein in our preparation was dimeric with a molecular mass of 293 kDa and that it had an irregular shape indicated by the friction factor (f/f0) of 1.6.	UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT MICROBIOL, GUELPH N1G 2W1, ONTARIO, CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry								ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; Andrews P, 1970, Methods Biochem Anal, V18, P1, DOI 10.1002/9780470110362.ch1; BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; Cantor C.R., 1980, BIOPHYSICAL CHEM PAR, P584; DENDINGER S, 1970, J BACTERIOL, V103, P144, DOI 10.1128/JB.103.1.144-152.1970; DESPICER PO, 1991, J BACTEIOL, V1730, P2114; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; HALLETT FR, 1989, CAN J SPECTROSC, V34, P63; HENDRICKSON W, 1985, Biotechniques, V3, P198; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KEESEY J, 1987, BIOCH INFORMATION, P106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; MALOY SR, 1987, ESCHERICHIA COLI SAL, V1, P1513; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MEILE L, 1982, EUR J BIOCHEM, V129, P67, DOI 10.1111/j.1432-1033.1982.tb07021.x; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J MOL BIOL, V148, P21, DOI 10.1016/0022-2836(81)90233-3; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; MITCHELL DR, 1988, THESIS U GUELPH ONTA; MIXSON AJ, 1988, J BIOL CHEM, V263, P10720; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; SCARPULLA RC, 1978, J BIOL CHEM, V253, P5997; SCHACHMAN HK, 1957, METHOD ENZYMOL, V4, P32, DOI 10.1016/0076-6879(57)04050-1; SCHEIBE R, 1987, PHYSIOL PLANTARUM, V71, P393, DOI 10.1111/j.1399-3054.1987.tb04362.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRECKER HJ, 1957, J BIOL CHEM, V225, P825; WILLIAMS FR, 1966, ARCH BIOCHEM BIOPHYS, V116, P168, DOI 10.1016/0003-9861(66)90025-7; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; WOOD JM, 1979, CAN J BIOCHEM CELL B, V57, P1191, DOI 10.1139/o79-155; WOOD JM, 1987, P NATL ACAD SCI USA, V84, P373, DOI 10.1073/pnas.84.2.373	38	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13086	13092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618807				2022-12-27	WOS:A1992HZ48300101
J	TEASDALE, RD				TEASDALE, RD			CORRECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition														Gleeson, Paul/0000-0002-5336-6503				TEASDALE RD, 1992, J BIOL CHEM, V267, P4084	1	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13113	13113						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618810				2022-12-27	WOS:A1992HZ48300105
J	YOUNG, WW; LUTZ, MS; BLACKBURN, WA				YOUNG, WW; LUTZ, MS; BLACKBURN, WA			ENDOGENOUS GLYCOSPHINGOLIPIDS MOVE TO THE CELL-SURFACE AT A RATE CONSISTENT WITH BULK FLOW ESTIMATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI VESICLE MEMBRANES; ENDOPLASMIC-RETICULUM; MUTANT DEFICIENT; PLASMA-MEMBRANE; SIALIC-ACID; BREFELDIN-A; TRANSPORT; PROTEIN; GANGLIOSIDES; TRANSLOCATION	The bulk flow model of intracellular trafficking predicts that forward transport from the ER through the Golgi to the plasma membrane proceeds by default without a special signal being required (Wieland, F. T., Gleason, M. L., Serafini, T. A., and Rothman, J. E. (1987) Cell 50, 289-300). We tested a crucial prediction of this model, which is that the endogenous lipid components of the transport vesicles would reach the plasma membrane at the rapid rate of bulk flow. The rate at which endogenous glycosphingolipids moved from the ER through the Golgi to the plasma membrane was determined in Chinese hamster ovary cells using metabolic labeling with tritiated palmitate and oxidation of cell surface ganglioside NeuAc-alpha-2 --> 3Gal-beta-1 --> 4Glc-beta-1 --> 4Cer (G(M3)) With periodate. Whereas radioactive precursor became incorporated into ceramide and glucosyl ceramide without a detectable lag, synthesis of labeled lactosyl ceramide and ganglioside G(M3) did not begin until 5-6 min and 11-12 min, respectively, after addition of labeled precursor. Labeled G(M3) reached the plasma membrane 5-6 min following its synthesis. Overall, approximately 18 min transpired from the time that the ceramide precursor was synthesized in the ER until labeled G(M3) reached the plasma membrane. These results indicate that lipid transport vesicles move rapidly to the plasma membrane at a rate consistent with bulk flow estimates.	UNIV LOUISVILLE, HLTH SCI CTR, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville	YOUNG, WW (corresponding author), UNIV LOUISVILLE, HLTH SCI CTR, DEPT BIOL & BIOPHYS SCI, LOUISVILLE, KY 40292 USA.				NIGMS NIH HHS [GM42698] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILES EB, 1977, J BIOL CHEM, V252, P1107; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3265, DOI 10.1021/bi00257a003; MIYAZAKI K, 1986, BIOCHEM J, V235, P755, DOI 10.1042/bj2350755; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAITO T, 1971, J LIPID RES, V12, P257; SASAKI T, 1990, EXPERIENTIA, V46, P611, DOI 10.1007/BF01939700; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SONNINO S, 1986, CHEM PHYS LIPIDS, V42, P3, DOI 10.1016/0009-3084(86)90040-X; STANLEY P, 1980, ACS SYM SER, V128, P213; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; TANAKA T, 1988, CHEM PHYS LIPIDS, V48, P261, DOI 10.1016/0009-3084(88)90096-5; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; URBANI L, 1990, J BIOL CHEM, V265, P1919; USUKI S, 1988, J BIOL CHEM, V263, P6847; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; VOELKER DR, 1990, EXPERIENTIA, V46, P569, DOI 10.1007/BF01939695; WALTER VP, 1983, BIOCHIM BIOPHYS ACTA, V750, P346, DOI 10.1016/0005-2760(83)90039-5; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YEO KT, 1985, J BIOL CHEM, V260, P7896; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1986, J BIOL CHEM, V261, P2279; YU RK, 1972, J LIPID RES, V13, P680	38	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12011	12015						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601871				2022-12-27	WOS:A1992HY94700056
J	BASS, KE; SOMMER, JM; CHENG, QL; WANG, CC				BASS, KE; SOMMER, JM; CHENG, QL; WANG, CC			MOUSE ORNITHINE DECARBOXYLASE IS STABLE IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DEGRADATION; ENZYME; EXPRESSION; PROTOZOAN; TURNOVER; TARGET; GENE	The cDNA encoding mouse ornithine decarboxylase (ODC) was incorporated into a transforming vector pTSA-NEO2 carrying a procyclic acidic repetitive protein promoter and a neomycin phosphotransferase gene. The plasmid thus constructed, pMOD300, was introduced into the procyclic forms of Trypanosoma brucei via electroporation, and the transformants, selected under G418, expressed an ODC activity 100 times above the background level. Contrary to the commonly observed short half-life of mouse ODC in mammalian cells, however, the mouse ODC activity expressed in T. brucei remained stable for at least 6 h when protein synthesis was inhibited by cycloheximide. Pulse labelings and chase experiments with the irreversible ODC inhibitor [3,4-H-3]difluoromethylornithine followed by gel electrophoresis, or with L-[S-35] methionine followed by immunoprecipitation and gel electrophoresis indicated that the stable mouse ODC expressed in T. brucei has the same subunit molecular weight as the native enzyme. By an in vitro assay of protein stability in rabbit reticulocyte lysates (Loetscher, P., Pratt, G., and Rechsteiner, M. (1991) J. Biol. Chem. 266, 11213-11220), the native mouse ODC and the enzyme expressed in T. brucei had the same degree of instability. Thus, the mouse ODC expressed in T. brucei is probably identical to the native mouse ODC. Its remarkable stability in T. brucei must be due to the absence in trypanosomes of the proteolytic machinery present in mammalian cells responsible for rapid degradation of mouse ODC.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,BOX 0446,S-926,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BASS KE, 1991, MOL BIOCHEM PARASIT, V44, P261, DOI 10.1016/0166-6851(91)90012-U; BELLOFATTO V, 1989, SCIENCE, V244, P1167, DOI 10.1126/science.2499047; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MCCONLOGUE L, 1983, J BIOL CHEM, V258, P2083; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; ROGERS S, 1986, SCIENCE, V234, P334; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SJOERDSMA A, 1984, MOL BIOCHEM PARASIT, V20, P165	16	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11034	11037						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597444				2022-12-27	WOS:A1992HX16900019
J	BLACKMORE, RS; GIBSON, QH; GREENWOOD, C				BLACKMORE, RS; GIBSON, QH; GREENWOOD, C			THE RELATION OF LIGAND-BINDING TO REDOX STATE IN THE HEXA-HEME NITRITE REDUCTASE OF WOLINELLA-SUCCINOGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS; PURIFICATION; CYTOCHROME	Ligand binding reactions and the relation between redox state and ligand binding in the hexa-heme nitrite reductase of Wolinella succinogenes have been studied using laser flash photolysis. On a picosecond time scale, a rapid excursion was observed corresponding to the breaking and reforming of an iron histidine bond. With the CO derivative, a geminate reaction was observed with a rate of 3 ns-1. On a nanosecond time scale, no slower geminate reactions were observed. For the cyanide derivative, no geminate reactions were observed at either time scale. The second order reaction of CO with the enzyme had a time course consisting of two distinct components. This time course changed in form as the enzyme came to equilibrium with CO, and the slower rebinding component was replaced by a faster rebinding component. It is suggested that CO binding enhances reduction of a heme with an unusually low redox potential and opens the structure of the active site to allow a faster second order reaction of CO. The proportion of the geminate CO reaction was unchanged, consistent with changes relatively remote from the ligand binding site. The second order reactions of cyanide also showed that redox effects influence its rebinding reaction. Adding cyanide to the CO complex of nitrite reductase showed that the two ligands have distinct heme binding sites.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853; UNIV E ANGLIA,SCH BIOL SCI,NORWICH NR4 7TJ,NORFOLK,ENGLAND	Cornell University; University of East Anglia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 14276] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER D, 1978, BIOCHEM J, V175, P239, DOI 10.1042/bj1750239; BLACKMORE R, 1986, BIOCHEM J, V233, P553, DOI 10.1042/bj2330553; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; BLACKMORE RS, 1987, FEBS LETT, V219, P244, DOI 10.1016/0014-5793(87)81225-5; BLACKMORE RS, 1990, BIOCHEM J, V271, P253, DOI 10.1042/bj2710253; BLACKMORE RS, 1990, FEBS LETT, V264, P257, DOI 10.1016/0014-5793(90)80262-H; BLACKMORE RS, 1988, THESIS U E ANGLIA; COSTA C, 1990, J BIOL CHEM, V265, P14382; JONGEWARD KA, 1988, J BIOL CHEM, V263, P6027; LIU MC, 1987, FEBS LETT, V218, P227, DOI 10.1016/0014-5793(87)81051-7; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1988, ARCH BIOCHEM BIOPHYS, V262, P259, DOI 10.1016/0003-9861(88)90187-7; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; REHR B, 1986, FEMS MICROBIOL LETT, V35, P325, DOI 10.1111/j.1574-6968.1986.tb01551.x	15	1	1	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10950	10955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597437				2022-12-27	WOS:A1992HX16900006
J	FESCE, R; BENFENATI, F; GREENGARD, P; VALTORTA, F				FESCE, R; BENFENATI, F; GREENGARD, P; VALTORTA, F			EFFECTS OF THE NEURONAL PHOSPHOPROTEIN SYNAPSIN-I ON ACTIN POLYMERIZATION .2. ANALYTICAL INTERPRETATION OF KINETIC CURVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL SYNAPTIC VESICLES; F-ACTIN; BINDING; PROTEIN; NUCLEATION; ASSOCIATION; MECHANISM; FILAMENTS; MONOMER; SITES	The general features of the kinetics of actin polymerization are investigated by mathematical models, with the aim of identifying the kinetically relevant parameters in the process and detecting and interpreting the alterations occurring in actin polymerization under various experimental conditions. Polymerization curves, obtained by following the increase in fluorescence of actin derivatized with N-(1-pyrenyl) iodoacetamide, are fitted using analytical equations derived from biochemical models of the actin polymerization process. Particular attention is given to the evaluation of the effects of the neuronal phosphoprotein synapsin I. The models obtained under various ionic conditions reveal that synapsin I interacts with actin in a very complex fashion, sharing some of the properties of classical nucleating proteins but displaying also actions not described previously for other actin-binding proteins. Synapsin I appears to bind G-actin with a very high stoichiometry (1:2-4), and the complex behaves as an F-actin nucleus, producing actin filaments under conditions where spontaneous polymerization is negligible. These actions of synapsin I are markedly affected by site-specific phosphorylation of the protein. An original transformation of the fluorescence data, which estimates the disappearance rate of actin monomer toward the critical concentration, is presented and shown to be of general usefulness for the study of actin-binding proteins.	UNIV MILAN,SAN RAFFAELE SCI INST,NATL RES COUNCIL,CTR CYTOPHARMACOL,I-20129 MILAN,ITALY; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; UNIV MODENA,INST HUMAN PHYSIOL,I-41100 MODENA,ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Rockefeller University; Universita di Modena e Reggio Emilia			Flavia, Valtorta/F-3450-2012; fesce, riccardo/A-6317-2008	Flavia, Valtorta/0000-0001-9556-4746; fesce, riccardo/0000-0001-9473-896X	NIMH NIH HHS [MH 39327] Funding Source: Medline; Telethon [112] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039327, R37MH039327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BENENATI F, 1992, IN PRESS NEURON; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; CARLIER MF, 1991, J BIOL CHEM, V266, P1; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DOI Y, 1984, J BIOL CHEM, V259, P1868; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; FRIEDEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6513, DOI 10.1073/pnas.80.21.6513; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; GAERTNER A, 1989, J MUSCLE RES CELL M, V10, P1, DOI 10.1007/BF01739852; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GRAZI E, 1985, BIOCHEM BIOPH RES CO, V128, P1058, DOI 10.1016/0006-291X(85)91047-2; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; OOSAWA F, 1975, THERMODYNAMICS POLYM, P109; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; Vandekerckhove J, 1989, CURR OPIN CELL BIOL, V1, P15, DOI 10.1016/S0955-0674(89)80031-6; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; YIN HL, 1981, J BIOL CHEM, V256, P9693	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11289	11299						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597463				2022-12-27	WOS:A1992HX16900057
J	ESTES, PA; COOKE, NE; LIEBHABER, SA				ESTES, PA; COOKE, NE; LIEBHABER, SA			A NATIVE RNA SECONDARY STRUCTURE CONTROLS ALTERNATIVE SPLICE-SITE SELECTION AND GENERATES 2 HUMAN GROWTH-HORMONE ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EXON SEQUENCES; U2 SNRNP; GENE; DNA; INVITRO; INTRON; TRANSCRIPTS; EXPRESSION; PRECURSORS	Consensus sequences at the splice donor, splice acceptor, and lariat branch point regions are necessary but insufficient determinants of splice-site selection in nuclear precursor mRNAs. Sequences outside of these regions can have a significant effect on the utilization of splice sites. Although the mode of action of such sequences is undefined in most cases, higher order RNA structures have been suggested as a potential contributor to splice-site selection. During a detailed analysis of the splicing patterns of the human growth hormone transcript, we located 2 bases in the vicinity of the exon 3 major splice-acceptor site (B) which facilitate the utilization of a competing downstream acceptor (B'). The effects of a series of site-specific mutations on the splicing pattern demonstrate that these 2 bases function by stabilizing a specific stem-loop structure in the native transcript. This defined secondary structure selectively encompasses the upstream B splice-acceptor site together with its lariat branch point region. Increasing the predicted stability of this stem by point mutations results in a corresponding shift in splicing towards the alternative B' splice-acceptor site. These results indicate that a specific secondary structure within the native human growth hormone transcript controls the relative utilization of two competing splice-acceptor sites with the consequent generation of two functionally distinct hormone isoforms.	UNIV PENN,SCH MED,DEPT GENET,ROOM 437A CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NICHD NIH HHS [HD 25147] Funding Source: Medline; NIH HHS [MOD 1-1015] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD025147] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; COOKE NE, 1988, J BIOL CHEM, V263, P9001; COOKE NE, 1988, J CLIN INVEST, V82, P270, DOI 10.1172/JCI113582; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; ESTES PA, 1990, J BIOL CHEM, V265, P19863; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HWANG LHS, 1984, MOL CELL BIOL, V4, P2289, DOI 10.1128/MCB.4.11.2289; Lewis U J, 1980, Recent Prog Horm Res, V36, P477; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LIU CP, 1979, P NATL ACAD SCI USA, V76, P4503, DOI 10.1073/pnas.76.9.4503; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIF I, 1979, NUCLEIC ACIDS RES, V6, P3387, DOI 10.1093/nar/6.10.3387; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; WATAKABE A, 1989, NUCLEIC ACIDS RES, V17, P8159, DOI 10.1093/nar/17.20.8159; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	43	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14902	14908						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634529				2022-12-27	WOS:A1992JF08800061
J	HERTZBERG, MS; BENTAL, O; FURIE, B; FURIE, BC				HERTZBERG, MS; BENTAL, O; FURIE, B; FURIE, BC			CONSTRUCTION, EXPRESSION, AND CHARACTERIZATION OF A CHIMERA OF FACTOR-IX AND FACTOR-X - THE ROLE OF THE 2ND EPIDERMAL GROWTH-FACTOR DOMAIN AND SERINE PROTEASE DOMAIN IN FACTOR-VA BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; COAGULATION FACTOR-XA; VITAMIN-K; PROTHROMBINASE COMPLEX; BLOOD-COAGULATION; ENZYME COMPLEXES; GLUTAMIC-ACID; EGF DOMAIN; ACTIVATION; PROTEINS	The prothrombinase complex, which catalyzes the conversion of prothrombin to thrombin, consists of activated Factor X, Factor Va, a membrane surface and Ca2+. To examine the structures that support Factor Va binding to Factor X, we used in vitro mutagenesis to construct a chimeric molecule that includes regions of Factor IX and Factor X. This chimera (IX(Gla,E1)X(E2,SP)) was prepared from cDNA encoding the second epidermal growth factor (EGF) and serine protease domains of Factor X linked downstream from the cDNA encoding the signal peptide, propeptide, Gla domain, and first EGF domain of Factor IX. The cDNAs encoding the Factor IX/X chimera and wild-type Factor X were each expressed in Chinese hamster ovary cells and the secreted proteins purified by affinity chromatography using polyclonal anti-Factor X antibodies. The chimera migrated as a single major band corresponding to a molecular weight of 68,000. By Western blotting, the chimeric protein stained with both polyclonal anti-Factor X and anti-Factor IX antibodies. Gamma-carboxyglutamic acid analysis demonstrated near complete carboxylation of both the wild-type Factor X and the Factor IX/X chimera. Compared with Factor X, the rate of zymogen activation of the Factor IX/X chimera was about 50% that of Factor X when activated by Factor IXa, Factor VIIIa, phospholipid, and Ca2+. The enzyme form of the Factor IX/X chimera, activated Factor IX/X, generated using the coagulant protein of Russell's viper venom, expressed full amidolytic activity compared with Factor Xa. The activated Factor IX/X chimera had about 14% of the activity of Factor Xa when employed in a prothrombinase assay; this activity reached 100% with increasing concentrations of Factor Va. A binding assay was employed to test the ability of the active site-inactivated Factor IX/Xa chimera to inhibit the binding of Factor Xa to the Factor Va-phospholipid complex, thus inhibiting the activation of prothrombin to thrombin. In this assay the active site-inactivated form of the chimera competed with Factor Xa completely but with decreased affinity for the Factor Va-phospholipid complex. These data indicate that the second EGF domain and the serine protease domain of Factor Xa are sufficient to interact with Factor Va. The Factor IX/X chimera is a good substrate for the tenase complex; the defective enzymatic activity of the activated Factor IX/X chimera can be accounted for by its decreased affinity for Factor Va relative to Factor Xa.	NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,CTR HEMOSTASIS & THROMBOSIS RES,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018834, R37HL018834] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42433, HL18834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENTAL O, 1991, BLOOD S, V78, pA180; BLOOM JW, 1989, THROMB RES, V54, P261, DOI 10.1016/0049-3848(89)90084-4; CHEN PS, 1956, J BIOL CHEM, V252, P1756; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; Dacie J., 1984, PRACTICAL HAEMATOLOG, V6th; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HUBER P, 1990, CIRCULATION, V82, P365; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KOTKOW KJ, 1992, IN PRESS METHODS ENZ; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIN SW, 1990, J BIOL CHEM, V265, P144; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MCCRACKEN AA, 1984, BIOTECHNIQUES    MAR, P82; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; PERSSON E, 1991, J BIOL CHEM, V266, P2453; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROSING J, 1980, J BIOL CHEM, V255, P274; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SZOKA F, 1980, BIOCHIM BIOPHYS ACTA, V601, P559, DOI 10.1016/0005-2736(80)90558-1; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILDGOOSE P, 1988, BIOCHEM BIOPH RES CO, V152, P1207, DOI 10.1016/S0006-291X(88)80413-3	42	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14759	14766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634519				2022-12-27	WOS:A1992JF08800041
J	TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC				TAKEUCHI, Y; YANAGISHITA, M; HASCALL, VC			METABOLIC PATHWAYS OF HEPARAN-SULFATE PROTEOGLYCANS IN A RAT PARATHYROID CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; CULTURE; TRANSPORT; CALCIUM	The distribution of heparan sulfate (HS) proteoglycans in clonal rat parathyroid cells is regulated by the extracellular Ca2+ concentration, which is a principal factor for parathyroid cell function (Takeuchi, Y., Sakaguchi, K., Yanagishita, M., Aurbach, G. D., and Hascall, V. C. (1990) J. Biol. Chem. 265, 13661-13668). Increasing the concentration of extracellular Ca2+ in the physiological range redistributes HS proteoglycans from the cell surface to an intracellular compartment. We have now examined effects of the extracellular Ca2+ concentration on the metabolism of the HS proteoglycans in detail using [S-35]sulfate metabolic labeling-chase experiments. Two distinct metabolic pathways were demonstrated: (i) the intracellular generation of HS chains from HS proteoglycans in prelysosomal compartments followed by their release into the medium (pathway 1), and (ii) intracellular generation of HS oligosaccharides from HS chains in prelysosomal compartments, which are eventually degraded into free sulfate in lysosomes (pathway 2). The HS oligosaccharides were exclusively present within the cells, whereas HS chains were found primarily in the medium. The cells do not internalize either HS proteoglycans or HS chains from the medium. These observations indicate that these two degradation pathways are independent. In addition to these pathways, approximately 15% of the HS proteoglycans were released into the medium as a proteoglycan form. Treatment of cells with chloroquine, a lysosomotropic agent, did not affect generation of HS chains but inhibited conversion of HS chains to HS oligosaccharides or to free sulfate and resulted in the release of HS chains from the cells. The drug did not affect metabolic pathway 1. The extracellular Ca2+ concentration did not alter these intracellular degradation pathways for HS proteoglycans in the parathyroid cells. Thus, extracellular Ca2+ appears to regulate only the distribution of HS proteoglycans between the cell surface and intracellular compartments, and the process of cycling between these compartments when extracellular Ca2+ is low.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BROWN EM, 1982, MINER ELECTROL METAB, V8, P130; CUSHMAN SW, 1985, FED PROC, V43, P2251; FRANSSON LA, 1989, HEPARIN, P115; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PIEPKORN M, 1989, J BIOL CHEM, V264, P8662; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKAGUCHI K, 1987, P NATL ACAD SCI USA, V84, P3269, DOI 10.1073/pnas.84.10.3269; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; WILEMAN T, 1985, BIOCHEM J, V232, P1; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1989, J BIOL CHEM, V264, P15714; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	22	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14677	14684						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634513				2022-12-27	WOS:A1992JF08800030
J	LITCHFIELD, DW; LUSCHER, B; LOZEMAN, FJ; EISENMAN, RN; KREBS, EG				LITCHFIELD, DW; LUSCHER, B; LOZEMAN, FJ; EISENMAN, RN; KREBS, EG			PHOSPHORYLATION OF CASEIN KINASE-II BY P34(CDC2) INVITRO AND AT MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MEIOTIC CELL-DIVISION; CDC2 PROTEIN-KINASE; BETA-SUBUNIT; ALPHA-SUBUNIT; M-PHASE; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; XENOPUS OOCYTES; ACTIVATION	In human epidermal carcinoma A431 cells, the beta-subunit of casein kinase II is phosphorylated at an autophosphorylation site and at serine 209 which can be phosphorylated in vitro by p34cdc2 (Litchfield, D. W., Lozeman, F. J., Cicirelli, M. F., Harrylock, M., Ericsson, L. H., Piening, C. J., and Krebs, E. G. (1991) J. Biol. Chem. 266, 20380-20389). Given the importance of p34cdc2 in the regulation of cell cycle events, we were interested in examining the phosphorylation of casein kinase II during different stages of the cell cycle. In this study it is demonstrated that the extent of phosphorylation of serine 209 in the beta-subunit is significantly increased relative to phosphorylation of the autophosphorylation site when chicken bursal lymphoma BK3A cells are arrested at mitosis by nocodazole treatment. This result suggests that serine 209 is a likely physiological target for p34cdc2. In addition, the alpha-subunit of casein kinase II also undergoes dramatic phosphorylation with an associated alteration in its electrophoretic mobility when BK3A cells or human Jurkat cells are arrested with nocodazole. Phosphopeptide mapping studies indicate that p34cdc2 can phosphorylate in vitro the same peptides on the alpha-subunit that are phosphorylated in cells arrested at mitosis. These phosphorylation sites were localized to serine and threonine residues in the carboxyl-terminal domain of alpha. Taken together, the results of this study indicate that casein kinase II is a probable physiological substrate for p34cdc2 and suggest that its functional properties could be affected in a cell cycle-dependent manner.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; MED HSCH HANNOVER, INST MIKROBIOL, W-3000 HANNOVER 61, GERMANY	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Hannover Medical School			Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709	NCI NIH HHS [CA20525] Funding Source: Medline; NIDDK NIH HHS [DK45258] Funding Source: Medline; NIGMS NIH HHS [GM42508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020525, R37CA020525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOOLITTLE RF, 1986, URFS ORFS, P63; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRANDE J, 1989, ARCH BIOCHEM BIOPHYS, V275, P478, DOI 10.1016/0003-9861(89)90394-9; HALL FL, 1991, J BIOL CHEM, V266, P17430; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HU ED, 1990, J BIOL CHEM, V265, P5072; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	62	133	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13943	13951						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629192				2022-12-27	WOS:A1992JD32500028
J	WEN, DY; LAURSEN, RA				WEN, DY; LAURSEN, RA			STRUCTURE-FUNCTION-RELATIONSHIPS IN AN ANTIFREEZE POLYPEPTIDE - THE ROLE OF NEUTRAL, POLAR AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISH; PROTEINS; GLYCOPROTEINS; INHIBITION	An alanine-rich, alpha-helical antifreeze polypeptide (AFP) from the winter flounder and seven analogs with variations in the arrangement of neutral, polar amino acids were synthesized. Circular dichroism studies determined that all of the peptides, except for one containing a proline residue, were essentially 100% alpha-helical. Freezing point depression data, analyzed by three methods, showed that rearrangement of polar residues resulted in moderate to complete loss of antifreeze activity. It was observed that ice crystals grow as hexagonal bipyramids in dilute solutions, with a constant c to a axis ratio of about 3.3. Above a critical threshold concentration, which may depend on the AFP to ice binding constant and reflect the onset of coorerative interactions, growth ceases until the temperature is lowered to the freezing point. We conclude that a specific arrangement of both threonine and asparagine (or aspartic acid) residues is critical for maximal activity and that the AFPs probably bind to the pyramidal faces of ice with a specific orientation. These conclusions are consistent with a recent report (Knight, C. A., Cheng, C. C., and DeVries, A. L. (1991) Biophys. J. 59, 409-418) that a similar AFP adsorbs to the {2021BAR} pyramidal planes of ice in dilute solution.	BOSTON UNIV,DEPT CHEM,590 COMMONWEALTH AVE,BOSTON,MA 02215	Boston University								Ananthanarayanan VS, 1989, LIFE CHEM REPORTS, V7, P1; ATHERTON E, 1979, BIOORG CHEM, V8, P351, DOI 10.1016/0045-2068(79)90062-2; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HEW CL, 1976, BIOCHEM BIOPH RES CO, V71, P845, DOI 10.1016/0006-291X(76)90908-6; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; MULVIHILL DM, 1980, J BIOL CHEM, V255, P659; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	16	79	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14102	14108						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629210				2022-12-27	WOS:A1992JD32500051
J	MURAKAMI, K; TANASE, S; MORINO, Y; MORI, M				MURAKAMI, K; TANASE, S; MORINO, Y; MORI, M			PRESEQUENCE BINDING FACTOR-DEPENDENT AND FACTOR-INDEPENDENT IMPORT OF PROTEINS INTO MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ORNITHINE CARBAMOYLTRANSFERASE PRECURSOR; TRANSPORT; SEQUENCE; THIOLASE; CLONING	A cytosolic protein factor(s) is involved in the import of precursor proteins into mitochondria. PBF (presequence binding factor) is a protein factor which binds to the precursor form (pOTC) of rat ornithine carbamoyltransferase (OTC) but not to the mature OTC, and is required for the mitochondrial import of pOTC. The precursors for aspartate aminotransferase and malate dehydrogenase as well as pOTC synthesized in a reticulocyte lysate were efficiently imported into the mitochondria. However, the precursors synthesized in the lysate depleted for PBF by treatment with pOTC-Sepharose were not imported. Readdition of the purified PBF to the depleted lysate fully restored the import. pOTC synthesized in the untreated lysate sedimented as a complex with a broad peak of around 9 S, whereas pOTC synthesized in the PBF-depleted lysate sedimented at an expected position of monomer (2.5 S). When the purified PBF was readded to the depleted lysate, pOTC sedimented as a complex of about 7 S. In contrast to most mitochondrial proteins, rat 3-oxoacyl-CoA thiolase is synthesized with no cleavable presequence and an NH2-terminal portion of the mature protein functions as a mitochondrial import signal. The thiolase synthesized in the PBF-depleted lysate could be efficiently imported into the mitochondria, and readdition of PBF had little effect on the import. The thiolase synthesized in the untreated, the PBF-depleted, or the PBF-readded lysate sedimented at an expected position of monomer (2.5 S). These observations provide support for the existence of PBF-dependent and -independent pathways of mitochondrial protein import.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 862,JAPAN	Kumamoto University	MURAKAMI, K (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT MED GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN.							AMAYA Y, 1988, J BIOL CHEM, V263, P14463; ARGAN C, 1985, BIOCHEM BIOPH RES CO, V134, P21; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; JOH T, 1987, BIOCHEMISTRY-US, V26, P2515, DOI 10.1021/bi00383a017; MIURA S, 1983, J BIOL CHEM, V258, P6671; MORI M, 1985, EUR J BIOCHEM, V149, P181, DOI 10.1111/j.1432-1033.1985.tb08909.x; MORI M, 1981, J BIOL CHEM, V256, P4127; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1990, J BIOCHEM-TOKYO, V108, P2207; NISHI T, 1989, J BIOL CHEM, V264, P6044; OHTA S, 1984, EMBO J, V3, P651, DOI 10.1002/j.1460-2075.1984.tb01862.x; ONO H, 1988, J BIOL CHEM, V263, P3188; SCHNAITMAN C, 1968, J CELL BIOL, V38, P1158; TAKIGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P7412, DOI 10.1073/pnas.81.23.7412	17	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13119	13122						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618812				2022-12-27	WOS:A1992JB74600002
J	KARLSSON, M; SAHLIN, M; SJOBERG, BM				KARLSSON, M; SAHLIN, M; SJOBERG, BM			ESCHERICHIA-COLI RIBONUCLEOTIDE REDUCTASE - RADICAL SUSCEPTIBILITY TO HYDROXYUREA IS DEPENDENT ON THE REGULATORY STATE OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANGE ELECTRON-TRANSFER; BINUCLEAR IRON CENTER; CYTOCHROME-C; B2 SUBUNIT; TYROSINE; INHIBITION; REACTIVITY; RESONANCE; KINETICS; PROTEIN	Ribonucleotide reductase catalyzes the reduction of ribonucleotides to their corresponding deoxyribonucleotides via a radical-mediated mechanism. The enzyme from Escherichia coli consists of the two nonidentical proteins, R1 and R2 the latter of which contains the necessary free radical located to a tyrosine residue. The radical scavenger hydroxyurea was found to reduce the tyrosyl radical of R2 in a second-order reaction. The rate constant (0.50 M-1 s-1 at 25-degrees-C) for this process was several orders of magnitude lower than the hydroxyurea-dependent reduction of free tyrosyl radicals in solution. This difference probably reflects the fact that the R2 tyrosyl radical is buried in the interior of the protein. Formation of the R1R2 complex changed the susceptibility of the radical to hydroxyurea in a manner that reflects the regulatory state of the holoenzyme. Furthermore, binding of substrate or product to the holoenzyme complex made the R2 radical at least 10 times more susceptible to inactivation by hydroxyurea than it was in the isolated R2 protein. One active site mutation in the R1 protein was shown to affect the sensitivity of the tyrosyl radical of R2 differently than wild type protein R1 does. Our results clearly show that the susceptibility of the tyrosyl radical in R2 to inactivation by hydroxyurea can be used as an efficient probe for the regulatory state of the holoenzyme complex.	UNIV STOCKHOLM, ARRHENIUS LABS NAT SCI, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASHLEY GW, 1989, INT ENCY PHARM THERA, P55; ATOR M, 1984, J AM CHEM SOC, V106, P1886, DOI 10.1021/ja00318a082; BACKES G, 1989, BIOCHEMISTRY-US, V28, P1923, DOI 10.1021/bi00430a074; BERGLUND O, 1979, J BIOL CHEM, V254, P253; BOBROWSKI K, 1990, INT J RADIAT BIOL, V57, P919, DOI 10.1080/09553009014551041; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; CLIMENT I, 1992, IN PRESS BIOCHEMISTR, V31; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ELFORD HL, 1989, INHIBITORS RIBONUCLE, P217; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; GEREZ C, 1992, BIOCHEMISTRY-US, V31, P780, DOI 10.1021/bi00118a020; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; LAM KY, 1990, J CHEM SOC CHEM COMM, P658, DOI 10.1039/c39900000658; LAM KY, 1990, J CHEM SOC CHEM COMM, P1019, DOI 10.1039/c39900001019; LARSEN IK, 1982, EUR J BIOCHEM, V125, P75; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; NATAN MJ, 1990, J AM CHEM SOC, V112, P4081, DOI 10.1021/ja00166a079; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSENKRANZ HS, 1966, BIOCHIM BIOPHYS ACTA, V114, P501, DOI 10.1016/0005-2787(66)90099-2; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SAHLIN M, 1982, J BIOL CHEM, V257, P366; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1987, J BIOL CHEM, V262, P9736; SLABAUGH MB, 1991, J VIROL, V65, P2290, DOI 10.1128/JVI.65.5.2290-2298.1991; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THERIEN MJ, 1990, J AM CHEM SOC, V112, P2420, DOI 10.1021/ja00162a054	38	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12622	12626						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618767				2022-12-27	WOS:A1992HZ48300039
J	NAGAYA, T; MADISON, LD; JAMESON, JL				NAGAYA, T; MADISON, LD; JAMESON, JL			THYROID-HORMONE RECEPTOR MUTANTS THAT CAUSE RESISTANCE TO THYROID-HORMONE - EVIDENCE FOR RECEPTOR COMPETITION FOR DNA-SEQUENCES IN TARGET GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ERBA PROTOONCOGENES; RAT GROWTH-HORMONE; GLUCOCORTICOID RECEPTOR; GENERALIZED RESISTANCE; NEGATIVE REGULATION; BINDING; BETA; EXPRESSION; PROTEIN; MEDIATE	Several distinct mutations in the ligand-binding domain of the beta-form of the thyroid hormone receptor have been reported in kindreds with the autosomal dominant syndrome of generalized resistance to thyroid hormone (GRTH). GRTH receptor mutants are functionally inactive but capable of inhibiting normal receptor function in transient expression studies. We examined the possibility that this dominant negative activity of the GRTH mutants involves competition for receptor binding to DNA. Mutations introduced into either the T3 ligand-binding domain (LBD) or into the DNA-binding domain (DBD) of the receptor eliminated the transcriptional activity of the receptor. In cotransfection experiments, the LBD mutants, but not the DBD mutants, inhibited the transcriptional activity of the normal receptor. The inhibitory activity of the LBD mutants was abolished by the introduction of an additional mutation into the DBD, suggesting that the DBD is required for dominant negative activity. A chimeric receptor, in which the DNA-binding domain of the thyroid hormone receptor was exchanged with the homologous region in the glucocorticoid receptor (GTG), was used to study thyroid hormone receptor competition for GTG interactions with thyroid receptor target sequences. In the absence of thyroid hormone, the normal thyroid hormone receptor inhibited dexamethasone stimulated transcription by GTG. The transcriptional activity of GTG was also inhibited by the LBD mutants but not by a DBD mutant of the thyroid hormone receptor. These results indicate that the thyroid hormone receptor mutations that occur in GRTH compete with normal receptors at DNA-binding sites in target genes to block normal receptor function.	MASSACHUSETTS GEN HOSP,THYROID UNIT,JACKSON 1021,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Jameson, James/0000-0001-9538-4059	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042144] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28138] Funding Source: Medline; NIDDK NIH HHS [DK 42144] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENT GA, 1989, J BIOL CHEM, V264, P178; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; MAGNER JA, 1986, J ENDOCRINOL INVEST, V9, P459, DOI 10.1007/BF03346968; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PORRILLA R, 1991, J CLIN INVEST, V88, P2123; REFETOFF S, 1967, J CLIN ENDOCR METAB, V27, P279, DOI 10.1210/jcem-27-2-279; REFETOFF S, 1991, J CLIN ENDOCR METAB, V2, P140; REFETOFF S, 1982, AM J PHYSIOL, V243, P88; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; TAKEDA K, 1991, J CLIN INVEST, V87, P496, DOI 10.1172/JCI115023; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; USALA SJ, 1991, J CLIN ENDOCR METAB, V72, P32, DOI 10.1210/jcem-72-1-32; USALA SJ, 1991, MOL ENDOCRINOL, V5, P327, DOI 10.1210/mend-5-3-327; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; USALA SJ, 1991, TRENDS ENDOCRIN MET, V2, P140, DOI 10.1016/1043-2760(91)90004-7; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	48	109	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13014	13019						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618799				2022-12-27	WOS:A1992HZ48300092
J	OPIPARI, AW; HU, HM; YABKOWITZ, R; DIXIT, VM				OPIPARI, AW; HU, HM; YABKOWITZ, R; DIXIT, VM			THE A20 ZINC FINGER PROTEIN PROTECTS CELLS FROM TUMOR-NECROSIS-FACTOR CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-ALPHA; FIBROBLASTS; RESISTANCE; EXPRESSION; LINES; BCL-2; CDNA	Resistance against the cytotoxic actions of tumor necrosis factor-alpha (TNF) is an active process requiring the synthesis of TNF-inducible proteins. The specific TNF-induced proteins so far identified (manganese superoxide dismutase and plasminogen activator inhibitor type 2) as having a role in resistance against TNF cytotoxicity are able to confer only partial protection to cells, suggesting that other genes are involved. A20 is a TNF-induced primary response gene which encodes a novel zinc ringer protein. In this report we demonstrate that A20 protein is induced by TNF in a variety of cells. A survey of A20 expression in human breast carcinoma cell lines that are either sensitive or resistant to TNF cytotoxicity revealed increased expression of A20 message and protein in TNF-resistant cells. Constitutive expression of A20 after stable transfection of NIH 3T3 and WEHI 164 cells results in significant, but partial, resistance to TNF cytotoxicity. This work gives additional support to a role for TNF-induced immediate early response genes in protecting cells from TNF-induced death.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,BOX 0602,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Hu, Hong-Ming/0000-0002-2206-3470	NHLBI NIH HHS [HL 45351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GRUNFELD C, 1990, ADV INTERNAL MED, V35, P44; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KUMAR S, 1991, J BIOL CHEM, V266, P20960; NIKS M, 1990, J IMMUNOL METHODS, V130, P149, DOI 10.1016/0022-1759(90)90309-J; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0	22	407	422	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12424	12427						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618749				2022-12-27	WOS:A1992HZ48300009
J	SHASHIDHARA, LS; LIM, SH; SHACKLETON, JB; ROBINSON, C; SMITH, AG				SHASHIDHARA, LS; LIM, SH; SHACKLETON, JB; ROBINSON, C; SMITH, AG			PROTEIN TARGETING ACROSS THE 3 MEMBRANES OF THE EUGLENA CHLOROPLAST ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION SPECIFICITIES; PROCESSING PEPTIDASE; THYLAKOID LUMEN; TRANSIT PEPTIDE; MESSENGER-RNA; CDNA CLONE; PEA; PLASTOCYANIN; MATURATION; PRECURSORS	A system has been developed for the import in vitro of precursor proteins into Euglena chloroplasts, which have three envelope membranes. Preparation of functional chloroplasts with intact envelope membranes has been optimized. Import of the precursor (50 kDa) for the tetrapyrrole biosynthesis enzyme porphobilinogen deaminase (PBGD), and processing to the mature size (40 kDa), occurred at 25-degrees-C in the light and the presence of ATP, with an estimated efficiency of 62%. Pretreatment of the chloroplasts with proteases abolished this import, suggesting the involvement of specific protein receptors. The presequence of PBGD was found to be cleaved by Escherichia coli leader peptidase to an intermediate form (46 kDa). A construct in which the first 30 residues of the presequence (presumed to be the region removed by leader peptidase) had been deleted was no longer imported. Neither prePBGD nor the truncated precursor were imported into pea chloroplasts, although both bound to the pea chloroplast envelope. Conversely, a chimeric construct, in which the mature PBGD protein was fused downstream of the transit peptide for pea ferredoxin-NADP reductase, was efficiently imported into pea chloroplasts and processed to the mature size. However, this was not imported into Euglena chloroplasts, although again it bound to them. These results provide preliminary evidence for the possibility of two functional domains within the Euglena PBGD presequence. The implications of these findings with respect to the evolution of Euglena chloroplasts are discussed.	UNIV CAMBRIDGE, DEPT PLANT SCI, DOWNING ST, CAMBRIDGE CB2 3EA, ENGLAND; UNIV WARWICK, DEPT BIOL SCI, COVENTRY CV4 7AL, W MIDLANDS, ENGLAND	University of Cambridge; University of Warwick				Smith, Alison Gail/0000-0001-6511-5704; Lim, Saw Hoon/0000-0001-7629-2888				BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P273, DOI 10.1039/p19760000273; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CHAN RL, 1990, EMBO J, V9, P333, DOI 10.1002/j.1460-2075.1990.tb08115.x; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; GIBBS SP, 1978, CAN J BOT, V56, P2883, DOI 10.1139/b78-345; GIBBS SP, 1970, ANN NY ACAD SCI, V175, P454, DOI 10.1111/j.1749-6632.1970.tb45167.x; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HOULNE G, 1988, MOL GEN GENET, V213, P479, DOI 10.1007/BF00339619; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; KOHORN BD, 1989, PLANT CELL, V1, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFORTTRAN M, 1981, BER DEUT BOT GES, V94, P463; MORGENTHALER JJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P289, DOI 10.1016/0003-9861(75)90253-2; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; OSAFUNE T, 1991, EXP CELL RES, V193, P320, DOI 10.1016/0014-4827(91)90103-2; OSAFUNE T, 1991, J ELECTRON MICROSC, V40, P41; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PRICE CA, 1982, METHODS CHLOROPLAST, P189; REINBOTHE S, 1990, PLANTA, V181, P176, DOI 10.1007/BF02411535; SAMBROOK J, 1990, MOL CLONING LABORATO; SHARIF AL, 1989, EUR J BIOCHEM, V184, P353, DOI 10.1111/j.1432-1033.1989.tb15026.x; SHASHIDHARA LS, 1991, P NATL ACAD SCI USA, V88, P63, DOI 10.1073/pnas.88.1.63; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE TP, 1990, FEBS LETT, V272, P141, DOI 10.1016/0014-5793(90)80468-X; WHATLEY JM, 1981, ANN NY ACAD SCI, V361, P154, DOI 10.1111/j.1749-6632.1981.tb46517.x	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12885	12891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618786				2022-12-27	WOS:A1992HZ48300075
J	STRACK, B; LESSL, M; CALENDAR, R; LANKA, E				STRACK, B; LESSL, M; CALENDAR, R; LANKA, E			A COMMON SEQUENCE MOTIF, -E-G-Y-A-T-A-, IDENTIFIED WITHIN THE PRIMASE DOMAINS OF PLASMID-ENCODED I-TYPE AND P-TYPE DNA PRIMASES AND THE ALPHA-PROTEIN OF THE ESCHERICHIA-COLI SATELLITE PHAGE P4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; BACTERIAL CONJUGATION; MOLECULAR-CLONING; RECIPIENT CELL; M13 PHAGE; GENE; REPLICATION; HELICASE; REGION	DNA primases encoded by the conjugative plasmids ColIb-P9 (Incl1), RP4, and R751 (IncP), and the protein of the Escherichia coli satellite phage P4-alpha were shown to contain a common amino acid sequence motif -E-G-Y-A-T-A-. The P4 alpha-gene product, required for initiation of phage DNA replication, exhibits primase activity on single-stranded circular DNA templates. This priming activity resembles the enzymatic activity of DNA primases encoded by conjugative plasmids in terms of template utilization and the ability to synthesize primers that can be elongated by DNA polymerase III holoenzyme. The -E-G-Y-A-T-A- motif is part of an extended sequence region most conserved within the primase domains of the four enzymes. Single amino acid substitutions generated in the -E-G-Y-A-T-A- motif of the RP4 TraC2 and the P4 alpha-protein affect priming activity, supporting the hypothesis that the conserved sequence motif is part of the active center for primase function. A mutation that eliminates priming activity causes P4 phage to grow poorly and to depend upon the host dnaG primase. Computer analysis identified two additional sequence motifs within the amino acid sequence of the P4 alpha-protein: a potential zinc-finger motif and a "type A" nucleotide binding site, both strikingly similar to sequence motifs described in various DNA primases and helicases.	MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Max Planck Society; University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008722, R21AI008722, R37AI008722] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08722] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND N, 1989, MOL GEN GENET, V216, P195, DOI 10.1007/BF00334356; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARRETT KJ, 1972, P NATL ACAD SCI USA, V69, P2986, DOI 10.1073/pnas.69.10.2986; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERTANI G, 1953, J BACTERIOL, V65, P113, DOI 10.1128/JB.65.2.113-121.1953; BERTANI G, 1969, J GEN VIROL, V5, P97, DOI 10.1099/0022-1317-5-1-97; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOULNOIS GJ, 1982, NUCLEIC ACIDS RES, V10, P855, DOI 10.1093/nar/10.3.855; BOWDEN DW, 1975, J BACTERIOL, V124, P167, DOI 10.1128/JB.124.1.167-175.1975; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALENDAR R, 1970, VIROLOGY, V40, P72, DOI 10.1016/0042-6822(70)90380-6; CAMPBELL JL, 1972, P NATL ACAD SCI USA, V69, P2090, DOI 10.1073/pnas.69.8.2090; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; CHATFIELD LK, 1982, J BACTERIOL, V152, P1188; CHATTORAJ DK, 1972, J MOL BIOL, V66, P423, DOI 10.1016/0022-2836(72)90424-X; CHOLI T, 1989, J CHROMATOGR, V476, P59, DOI 10.1016/S0021-9673(01)93856-7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMAS LB, 1974, J VIROL, V14, P1369, DOI 10.1128/JVI.14.6.1369-1379.1974; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FINCH PW, 1984, NUCLEIC ACIDS RES, V12, P5789, DOI 10.1093/nar/12.14.5789; FLENSBURG J, 1987, J MOL BIOL, V195, P439, DOI 10.1016/0022-2836(87)90664-4; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; FURUYA N, 1991, J BACTERIOL, V173, P2231, DOI 10.1128/JB.173.7.2231-2237.1991; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GOLDSTEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P515, DOI 10.1073/pnas.79.2.515; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GUINEY DG, 1989, PROMISCUOUS PLASMIDS, P27; HALLING C, 1990, NUCLEIC ACIDS RES, V18, P1649, DOI 10.1093/nar/18.6.1649; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HUSAIN I, 1986, J BIOL CHEM, V261, P4895; Kornberg A., 1982, DNA REPLICATION S; Kornberg A., 1980, DNA REPLICATION; KRANIAS EG, 1974, J VIROL, V13, P146, DOI 10.1128/JVI.13.1.146-154.1974; KREVOLIN MD, 1985, J MOL BIOL, V182, P509, DOI 10.1016/0022-2836(85)90237-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1979, P NATL ACAD SCI USA, V76, P3632, DOI 10.1073/pnas.76.8.3632; LANKA E, 1981, J BACTERIOL, V148, P769, DOI 10.1128/JB.148.3.769-781.1981; LANKA E, 1985, PLASMID, V14, P217, DOI 10.1016/0147-619X(85)90005-8; LANKA E, 1984, MOL GEN GENET, V194, P65, DOI 10.1007/BF00383499; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LIN CS, 1984, NUCLEIC ACIDS RES, V12, P8667, DOI 10.1093/nar/12.22.8667; LINDAHL G, 1971, VIROLOGY, V46, P620, DOI 10.1016/0042-6822(71)90065-1; LINDQVIST BH, 1971, VIROLOGY, V43, P1, DOI 10.1016/0042-6822(71)90218-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MERRYWEATHER A, 1986, J BACTERIOL, V167, P12, DOI 10.1128/jb.167.1.12-17.1986; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Miele L, 1991, DNA Seq, V2, P145, DOI 10.3109/10425179109039685; Miller J. H., 1972, EXPT MOL GENETICS, P433; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NASH J, 1988, FEMS MICROBIOL LETT, V49, P257; NOSSAL NG, 1983, ANNU REV BIOCHEM, V52, P581, DOI 10.1146/annurev.bi.52.070183.003053; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; REES CED, 1990, MOL MICROBIOL, V4, P1199, DOI 10.1111/j.1365-2958.1990.tb00695.x; REES CED, 1987, PLASMID, V18, P223, DOI 10.1016/0147-619X(87)90065-5; REES CED, 1989, J BACTERIOL, V171, P3152, DOI 10.1128/jb.171.6.3152-3157.1989; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI I, 1965, J GEN MICROBIOL, V40, P365, DOI 10.1099/00221287-40-3-365; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHERZINGER E, 1991, NUCLEIC ACIDS RES, V19, P1203, DOI 10.1093/nar/19.6.1203; SCHERZINGER E, 1974, MOL GEN GENET, V135, P73, DOI 10.1007/BF00433903; SCHUSTER H, 1977, MOL GEN GENET, V151, P11, DOI 10.1007/BF00446907; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIX EW, 1991, VIROLOGY, V182, P34, DOI 10.1016/0042-6822(91)90645-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; WILKINS B, 1992, BACTERIAL CONJUGATIO; WILKINS BM, 1981, NATURE, V290, P217, DOI 10.1038/290217a0; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P4907, DOI 10.1073/pnas.79.16.4907; WOOD ER, 1989, J BIOL CHEM, V264, P8297; YAKOBSON E, 1990, PLASMID, V23, P80, DOI 10.1016/0147-619X(90)90048-H; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786	84	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13062	13072						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618804				2022-12-27	WOS:A1992HZ48300098
J	KRUEGER, RC; HENNIG, AK; SCHWARTZ, NB				KRUEGER, RC; HENNIG, AK; SCHWARTZ, NB			2 IMMUNOLOGICALLY AND DEVELOPMENTALLY DISTINCT CHONDROITIN SULFATE PROTEOGLYCANS IN EMBRYONIC CHICK BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CARTILAGE PROTEOGLYCAN; MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; CORE PROTEIN; HNK-1 EPITOPE; IMMUNOCYTOCHEMICAL LOCALIZATION; ANTIGENIC DETERMINANTS; GLUCURONYL GLYCOLIPIDS; SPECIES DISTRIBUTION	Two different chondroitin sulfate proteoglycans (CSPG) in embryonic chick brain were distinguished by immunoreactivity either with S103L, a rat monoclonal antibody which reacts specifically with an 11-aminoacid region in the chondroitin sulfate domain of the core protein of chick cartilage CSPG (Krueger, R. C., Jr., Fields, T. A., Mensch, J. R., and Schwartz, N. B. (1990) J. Biol. Chem. 265, 12088-12097), or with HNK-1, a mouse monoclonal antibody which reacts with a 3-sulfoglucuronic acid residue on neural glycolipids and glycoproteins (Chou, D. K. H., Ilyas, A., Evans, J. E. Costello, C., Quarles, R. H., and Jungawala, F. B. (1986) J. Biol. Chem. 261, 11717-11725) but not with both antibodies. This specific immunoreactivity was used to separate the two CSPGs for further characterization. The S103L reactive brain proteoglycan had a core protein of similar size to cartilage CSPG (370 kDa) but exhibited a smaller hydrodynamic size (K(av) of 0.308). It was substituted predominantly with chondroitin sulfate chains and virtually no keratan sulfate chains. The HNK-1 reactive CSPG had a smaller core protein (340 kDa), an even smaller hydrodynamic size (K(av) of 0.564), and was substituted with both chondroitin sulfate and keratan sulfate chains. Glycosidase digestion patterns with endo-beta-galactosidase, N-glycosidase F, neuraminidase, and O-glycosidase, and reactivity with an antibody to the hyaluronate binding region also showed significant differences between the two brain CSPGs. Expression of the S103L reactive brain CSPG was developmentally regulated from embryonic day 7 through 19 with a peak in core protein on day 13, and in mRNA expression at day 10. In contrast the HNK-1 reactive brain CSPG was constitutively present from day 7 through hatching. These data suggest that these two distinct core proteins are immunologically and biochemically unique translation products of two different CSPG genes.	UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19266] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABO T, 1981, J IMMUNOL, V127, P1024; AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARIGA T, 1987, J BIOL CHEM, V262, P848; BONNET F, 1983, BIOCHIM BIOPHYS ACTA, V743, P82, DOI 10.1016/0167-4838(83)90420-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Caterson B., 1987, BIOL PROTEOGLYCANS; CATESON B, 1986, ARTICULAR CARTILAGE; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD T, 1988, BIOCHIM BIOPHYS ACTA, V964, P183, DOI 10.1016/0304-4165(88)90165-1; CRAWFORD T, 1983, CAN J BIOCHEM CELL B, V61, P1251, DOI 10.1139/o83-161; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DORFMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P3971, DOI 10.1073/pnas.77.7.3971; GARVEY JS, 1977, METHOD IMMUNOL, P227; GARVEY JS, 1977, METHOD IMMUNOL, P218; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; HANCOCK LW, 1988, BIOCHEM BIOPH RES CO, V152, P83, DOI 10.1016/S0006-291X(88)80683-1; HEINEGARD D, 1985, ANAL BIOCHEM, V151, P41, DOI 10.1016/0003-2697(85)90050-8; HENNIG A K, 1991, Journal of Cell Biology, V115, p126A; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; KIANG WL, 1981, J BIOL CHEM, V256, P529; KRUEGER RC, 1990, J BIOL CHEM, V265, P12088; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARGOLIS RK, 1989, NEUROBIOLOGY GLYCOCO, P85; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MARGOLIS RU, 1989, DEV NEUROSCI-BASEL, V11, P276, DOI 10.1159/000111906; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; MIKOL DD, 1988, J NEUROCHEM, V50, P1924, DOI 10.1111/j.1471-4159.1988.tb02498.x; NAKANISHI S, 1983, DEV BIOL, V95, P305, DOI 10.1016/0012-1606(83)90031-3; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; NORLING B, 1984, BIOCHEM J, V221, P845, DOI 10.1042/bj2210845; NORLING B, 1978, BIOCHEM BIOPH RES CO, V84, P914, DOI 10.1016/0006-291X(78)91670-4; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OSHANNESSY DJ, 1985, J NEUROIMMUNOL, V9, P255, DOI 10.1016/S0165-5728(85)80024-2; PERIN JP, 1984, FEBS LETT, V176, P37, DOI 10.1016/0014-5793(84)80907-2; RAUCHU, 1991, J BIOL CHEM, V266, P14785; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SZABO MM, 1962, ARCH BIOCHEM BIOPHYS, V98, P406, DOI 10.1016/0003-9861(62)90205-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	51	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12149	12161						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601881				2022-12-27	WOS:A1992HY94700075
J	LEE, C; GORISCH, H; KLEINKAUF, H; ZOCHER, R				LEE, C; GORISCH, H; KLEINKAUF, H; ZOCHER, R			A HIGHLY SPECIFIC D-HYDROXYISOVALERATE DEHYDROGENASE FROM THE ENNIATIN PRODUCER FUSARIUM-SAMBUCINUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEREOSPECIFIC REDUCTION; 2-KETOCARBOXYLIC ACIDS; KETO ACIDS; ENZYME; SYNTHETASE; OXYSPORUM; PROTEINS	A highly specific D-hydroxyisovalerate (D-HIV) dehydrogenase, which is a key enzyme in depsipeptide synthesis, was purified to near homogeneity from the enniatin-producing fungus Fusarium sambucinum. The enzyme catalyzes the reversible reaction of 2-ketoisovalerate (2-KIV) to D-HIV. It is strictly dependent on NADPH and exhibits a high substrate specificity with respect to 2-KIV. NADH was not accepted by the enzyme. K(m) values for 2-KIV and NADPH were found to be 200 and 333-mu-M, respectively. D-HIV dehydrogenase consists of a single polypeptide chain with a molecular mass of about 53 kDa. Optimum temperature for the reduction of 2-KIV was 35-degrees-C and for the oxidation reaction was 45-degrees-C. The optimum pH was found to be 7 for the reduction and 8-9 for the oxidation reaction.	TECH UNIV BERLIN, INST BIOCHEM & MOLEK BIOL, FRANKLINSTR 29, W-1000 BERLIN 10, GERMANY; TECH UNIV BERLIN, INST BIOTECHNOL, FACHGEBIET TECH BIOCHEM, W-1000 BERLIN 65, GERMANY	Technical University of Berlin; Technical University of Berlin								AUDHYA TK, 1973, ANAL LETT, V6, P265; AUDHYA TK, 1973, CAN J MICROBIOL, V19, P1051, DOI 10.1139/m73-166; BILLICH A, 1988, APPL ENVIRON MICROB, V54, P2504, DOI 10.1128/AEM.54.10.2504-2509.1988; BILLICH A, 1987, BIOCHEMISTRY-US, V26, P8417, DOI 10.1021/bi00399a058; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CROWELL PL, 1988, METHOD ENZYMOL, V166, P39; FROYSHOV O, 1977, FEBS LETT, V81, P315, DOI 10.1016/0014-5793(77)80543-7; GASKING AL, 1988, METHOD ENZYMOL, V166, P20; HUMMEL W, 1983, EUR J APPL MICROBIOL, V18, P75, DOI 10.1007/BF00500828; HUMMEL W, 1985, APPL MICROBIOL BIOT, V21, P7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVESEY G, 1988, METHOD ENZYMOL, V166, P3; MADRY N, 1983, EUR J APPL MICROBIOL, V17, P75, DOI 10.1007/BF00499854; MEISTER A, 1950, J BIOL CHEM, V184, P117; PAIS M, 1981, PHYTOCHEMISTRY, V20, P715, DOI 10.1016/0031-9422(81)85160-6; PEETERS H, 1983, J ANTIBIOT, V36, P1762, DOI 10.7164/antibiotics.36.1762; PLATTNER PA, 1948, HELV CHIM ACTA, V31, P594, DOI 10.1002/hlca.19480310240; RUDIGER HW, 1972, BIOCHEM J, V126, P445, DOI 10.1042/bj1260445; SCHUTTE H, 1984, APPL MICROBIOL BIOT, V19, P167, DOI 10.1007/BF00256449; SMITH GD, 1975, J AM CHEM SOC, V97, P7242, DOI 10.1021/ja00858a008; ZOCHER R, 1983, BIOCHEM BIOPH RES CO, V110, P292, DOI 10.1016/0006-291X(83)91294-9; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008; ZOCHER R, 1976, FEBS LETT, V71, P13, DOI 10.1016/0014-5793(76)80887-3	24	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11741	11744						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601849				2022-12-27	WOS:A1992HY94700018
J	MCLEAN, LR; THOMAS, CE; WEINTRAUB, B; HAGAMAN, KA				MCLEAN, LR; THOMAS, CE; WEINTRAUB, B; HAGAMAN, KA			MODULATION OF THE PHYSICAL STATE OF CELLULAR CHOLESTERYL ESTERS BY 4,4'-(ISOPROPYLIDENEDITHIO)BIS(2,6-DI-TERT-BUTYLPHENOL) (PROBUCOL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HERITABLE HYPERLIPIDEMIC RABBIT; FAMILIAL HYPERCHOLESTEROLEMIA; ATHEROSCLEROTIC LESIONS; FATTY STREAKS; FOAM CELLS; PROGRESSION; REGRESSION; HYDROLYSIS; METABOLISM	The effect of 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol) on cholesteryl ester physical state was examined in dry mixtures, phospholipid-containing dispersions, and cells. Probucol has little effect on the solid to isotropic transition of cholesteryl oleate, but broadens and decreases the enthalpy of the liquid-crystalline transitions at concentrations as low as 1-2 mol %. A probucol transition is only observed at concentrations > 20 mol %. The mesomorphic phases of the cholesteryl oleate/probucol mixtures were identified by visual inspection and polarized light microscopy. Mixtures are liquid at probucol concentrations in excess of 5 mol % at 37-degrees-C. Probucol also dramatically reduces the enthalpy of the liquid-crystalline transitions of the cholesteryl oleate core of dispersions of the ester with phospholipids at a concentration of 10 mol %, reducing the enthalpy by >80% and the transition temperatures by approximately 2-degrees-C. The phase state of cholesteryl esters in Fu5AH rat hepatoma cells was examined after incubation with cholesterol/phospholipid dispersions that caused the accumulation of anisotropic cholesteryl ester droplets. Differential scanning calorimetry scans of cells incubated with cholesterol-rich phospholipid dispersions indicated a phase transition near 48-degrees-C, which was abolished when the cells were co-incubated with 50-100-mu-g/ml of probucol in the loading medium. Subsequent to the formation of isotropic cholesteryl ester droplets in the presence of probucol, the rate of efflux of cholesterol from the cells to phosphatidylcholine-containing acceptors in the medium was increased. These data show that probucol is relatively soluble in cholesteryl esters and that probucol changes the phase state of cholesteryl ester droplets in cells to a more fluid phase in which the cholesteryl esters are more readily mobilized.			MCLEAN, LR (corresponding author), MARION MERRELL DOW RES INST, 2110 E GALBRAITH RD, CINCINNATI, OH 45215 USA.							ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; BAKER SG, 1982, S AFR MED J, V62, P7; BALASUBRAMANIAM S, 1981, CLIN SCI, V61, P615, DOI 10.1042/cs0610615; BARNHART JW, 1970, AM J CLIN NUTR, V23, P1229; BELLAMY MF, 1989, EUR J BIOCHEM, V183, P321, DOI 10.1111/j.1432-1033.1989.tb14932.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CORTESE C, 1982, ATHEROSCLEROSIS, V44, P319, DOI 10.1016/0021-9150(82)90006-5; CRAIG IF, 1982, J BIOL CHEM, V257, P330; CROLL DH, 1985, BIOCHEMISTRY-US, V24, P7971, DOI 10.1021/bi00348a020; DACHET C, 1985, ATHEROSCLEROSIS, V58, P261, DOI 10.1016/0021-9150(85)90071-1; FELLIN R, 1986, ATHEROSCLEROSIS, V59, P47, DOI 10.1016/0021-9150(86)90032-8; GLICK JM, 1983, J BIOL CHEM, V258, P3425; HAMILTON JA, 1977, J BIOL CHEM, V252, P8071; HARRIS RS, 1974, J AM GERIATR SOC, V22, P167, DOI 10.1111/j.1532-5415.1974.tb02163.x; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KESANIEMI YA, 1984, J LIPID RES, V25, P780; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LI JR, 1980, ATHEROSCLEROSIS, V36, P559, DOI 10.1016/0021-9150(80)90248-8; MAO SJT, 1991, J MED CHEM, V34, P298, DOI 10.1021/jm00105a046; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; MCLEAN LR, 1988, BIOCHIM BIOPHYS ACTA, V959, P201, DOI 10.1016/0005-2760(88)90191-9; MIETTINEN TA, 1986, AM J CARDIOL, V57, pH49, DOI 10.1016/0002-9149(86)90439-X; MINOR LK, 1989, J LIPID RES, V30, P189; NARUSZEWICZ M, 1984, J LIPID RES, V25, P1206; NESTEL PJ, 1981, ATHEROSCLEROSIS, V38, P203, DOI 10.1016/0021-9150(81)90117-9; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; ROSEVEAR FB, 1954, J AM OIL CHEM SOC, V31, P628, DOI 10.1007/BF02545595; SHANKAR R, 1989, ATHEROSCLEROSIS, V78, P91, DOI 10.1016/0021-9150(89)90212-8; Small D. M., 1970, SURFACE CHEM BIOL SY, P55; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMALL DM, 1986, HDB LIPID RES, V4, P395; SNOW JW, 1988, BIOCHEMISTRY-US, V27, P3640, DOI 10.1021/bi00410a018; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; YAMAMOTO A, 1986, AM J CARDIOL, V57, pH29, DOI 10.1016/0002-9149(86)90434-0; YAMAMOTO A, 1983, ATHEROSCLEROSIS, V48, P157, DOI 10.1016/0021-9150(83)90102-8	39	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12291	12298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601894				2022-12-27	WOS:A1992HY94700095
J	MEYER, ME; QUIRINSTRICKER, C; LEROUGE, T; BOCQUEL, MT; GRONEMEYER, H				MEYER, ME; QUIRINSTRICKER, C; LEROUGE, T; BOCQUEL, MT; GRONEMEYER, H			A LIMITING FACTOR MEDIATES THE DIFFERENTIAL ACTIVATION OF PROMOTERS BY THE HUMAN PROGESTERONE-RECEPTOR ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; RICH TRANSCRIPTIONAL ACTIVATOR; HUMAN GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; RESPONSIVE ELEMENT; BINDING DOMAIN; AMINO-ACIDS; CELL-TYPE; EXPRESSION; YEAST	The two transcription activation functions (TAFs) of the human progesterone receptor (hPR) have been characterized. TAF-1, located in the N-terminal region A/B, has been narrowed down to a 91-amino acid sequence, which is sufficient for transcription activation in chimeras with the GAL4 DNA binding domain. Both hPR TAF-1 and TAF-2 activate a minimal promoter in yeast. No autonomous TAF could be found in the N-terminal 164 amino acids (designated AB3) which are responsible for the differential activation of promoters by the hPR isoforms A and B. Reduction of the target gene promoter complexity did not alter this differential activation, indicating that AB3 does not require additional promoter-bound factors to exert its effect. Instead, the cell specificity of AB3 and its ability to squelch hPR-induced transcription suggest that this differential isoform activity is due to the effect of a limiting factor which binds to region AB3.	FAC MED STRASBOURG,FAC MED,INSERM,UNITE BIOL MOLEC & GEN GENET,CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GRONEMEYER H, 1991, J STEROID BIOCHEM, V40, P271, DOI 10.1016/0960-0760(91)90192-8; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; SCHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UEMSONO K, 1989, CELL, V57, P1139; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	42	139	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10882	10887						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587864				2022-12-27	WOS:A1992HV09000100
J	PETERSON, JA; LU, JY; GEISSELSODER, J; GRAHAMLORENCE, S; CARMONA, C; WITNEY, F; LORENCE, MC				PETERSON, JA; LU, JY; GEISSELSODER, J; GRAHAMLORENCE, S; CARMONA, C; WITNEY, F; LORENCE, MC			CYTOCHROME-P-450TERP - ISOLATION AND PURIFICATION OF THE PROTEIN AND CLONING AND SEQUENCING OF ITS OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LIVER ALCOHOL-DEHYDROGENASE; PUTIDAREDOXIN REDUCTASE; PSEUDOMONAS-PUTIDA; ALDEHYDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ADRENODOXIN REDUCTASE; BACILLUS-MEGATERIUM; CODING NUCLEOTIDE; MOLECULAR-CLONING	Cytochromes P-450 are extremely important in the oxidative metabolism of a variety of endogenous and exogenous compounds in pro- and eukaryotic organisms. Progress in understanding the structure and mechanism of action of this superfamily of enzymes has been hampered by the properties of the eukaryotic enzymes and the availability of only one well-characterized prokaryotic enzyme as a model. We report here the isolation of a Pseudomonas species which will utilize a monoterpene natural product, alpha-terpineol, as its sole source of carbon and energy. Approximately 1% of the soluble protein in the cell-free extract is a novel cytochrome P-450 (P-450terp). This enzyme and its associated iron sulfur protein electron carrier (terpredoxin) have been purified to homogeneity and their NH2-terminal amino acid sequences determined. The amino acid sequences of six tryptic peptide fragments of cytochrome P-450terp, have also been determined. This sequence information was used to clone the gene encoding cytochrome P-450terp. Three clones representing approximately 8 kilobase pairs of unique sequences were selected and sequenced. Five non-overlapping open reading frames (ORFs) were found in the sequences, and the translated sequences were used to search the Protein Identification Resource for comparable proteins. The ORFs were identified as: 1) an alcohol dehydrogenase, 2) an aldehyde dehydrogenase, 3) cytochrome P-450terp, 4) terpredoxin reductase, and 5) terpredoxin. The identification of both the cytochrome P-450terp and terpredoxin DNA sequence was confirmed by the presence of each of the corresponding amino acid sequences found in the purified proteins. The five ORFs were bounded on both the 5' and 3' ends by consensus factor-independent terminator sequences. A consensus promoter sequence was found immediately 5' to the first ORF. These results indicate that we have sequenced the complete terp operon. Comparison of the amino acid sequence of cytochrome P450terp to that of all other cytochromes P-450 has shown that it is the first member of the gene family CYP108. Preliminary characterization of the chemical and physical properties and the preparation of crystals of this new cytochrome P-450, suitable for x-ray diffraction analysis, indicate that it will be useful in comparison studies with other members of this class of proteins.	BIORAD LABS INC, DIV GENET SYST, RICHMOND, CA 94804 USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	PETERSON, JA (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHN KS, 1991, GENE, V98, P107, DOI 10.1016/0378-1119(91)90111-N; AKHREM AA, 1978, BIOORG KHIM+, V4, P462; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BODDUPALLI SS, 1992, IN PRESS P NATL ACAD; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG C, 1986, P NATL ACAD SCI USA, V83, P1408, DOI 10.1073/pnas.83.5.1408; CHANG CY, 1988, DNA-J MOLEC CELL BIO, V7, P609, DOI 10.1089/dna.1988.7.609; COLLINS JR, 1988, J BIOL CHEM, V263, P3164; CORBIN CJ, 1988, P NATL ACAD SCI USA, V85, P8948, DOI 10.1073/pnas.85.23.8948; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FERENCZY GG, 1989, J MOL GRAPHICS, V7, P206, DOI 10.1016/0263-7855(89)80004-9; GEORGE P, 1961, HAEMATIN ENZYMES, V1, P105; GERBER NC, 1990, BIOCHEM BIOPH RES CO, V169, P1016, DOI 10.1016/0006-291X(90)91995-5; GEREN L, 1986, J BIOL CHEM, V261, P5491; GRAHAMLORENCE S, 1991, J BIOL CHEM, V266, P11939; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HALLIWELL B, 1991, NATURE, V354, P191, DOI 10.1038/354191a0; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; HOOG JO, 1987, BIOCHEMISTRY-US, V26, P1926, DOI 10.1021/bi00381a021; HORII M, 1990, J BACTERIOL, V172, P3644, DOI 10.1128/jb.172.7.3644-3653.1990; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JULIA P, 1988, EUR J BIOCHEM, V172, P73, DOI 10.1111/j.1432-1033.1988.tb13857.x; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; KAISER R, 1989, BIOCHEMISTRY-US, V28, P8432, DOI 10.1021/bi00447a024; KANEMOTO RH, 1989, J BACTERIOL, V171, P2506, DOI 10.1128/jb.171.5.2506-2512.1989; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KOGA H, 1986, J BACTERIOL, V166, P1089, DOI 10.1128/jb.166.3.1089-1095.1986; KOGA H, 1989, J BIOCHEM-TOKYO, V106, P831, DOI 10.1093/oxfordjournals.jbchem.a122939; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LAUGHTON CA, 1990, BIOCHEM BIOPH RES CO, V171, P1160, DOI 10.1016/0006-291X(90)90806-X; LEE SY, 1990, BIOTECHNIQUES, V9, P676; MADYASTHA KM, 1984, CAN J MICROBIOL, V30, P1429, DOI 10.1139/m84-228; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OKAMURA T, 1987, J BIOL CHEM, V262, P10335; OMER CA, 1990, J BACTERIOL, V172, P3335, DOI 10.1128/jb.172.6.3335-3345.1990; OMURA T, 1964, J BIOL CHEM, V239, P2370; OUZOUNIS CA, 1991, EUR J BIOCHEM, V198, P307, DOI 10.1111/j.1432-1033.1991.tb16017.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON JA, 1991, METHOD ENZYMOL, V206, P612; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; POCHAPSKY TC, 1991, BIOCHEMISTRY-US, V30, P3850, DOI 10.1021/bi00230a007; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1982, J BIOL CHEM, V257, P427; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; ROOME PW, 1983, J BIOL CHEM, V258, P2593; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; Sambrook J, 1989, MOL CLONING LABORATO; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; Sokatch JR, 1986, BACTERIA, V10, P557; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; TRUDGILL PW, 1986, BACTERIA, V10, P483; TUCK SF, 1992, J BIOL CHEM, V267, P5614; ULLAH AJH, 1990, J BIOL CHEM, V265, P1345; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VONBAHRLINDSTROM H, 1984, EUR J BIOCHEM, V141, P37; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; WERRINGLOER J, 1979, ACTA BIOL MED GER, V38, P163; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YU CA, 1970, BIOCHEM BIOPH RES CO, V40, P1431, DOI 10.1016/0006-291X(70)90027-6; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	88	92	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14193	14203						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629218				2022-12-27	WOS:A1992JD32500064
J	YONAHA, K; NISHIE, M; AIBARA, S				YONAHA, K; NISHIE, M; AIBARA, S			THE PRIMARY STRUCTURE OF OMEGA-AMINO ACID-PYRUVATE AMINOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; TYROSINE AMINOTRANSFERASE; SEQUENCE; ENZYME; CLONING; PURIFICATION; TRYPTOPHAN; MECHANISM; PROTEINS	The complete amino acid sequence of bacterial omega-amino acid:pyruvate aminotransferase (omega-APT) was determined from its primary structure. The enzyme protein was fragmented by CNBr cleavage, trypsin, and Staphylococcus aureus V8 digestions. The peptides were purified and sequenced by Edman degradation. omega-ATP is composed of four identical subunits of 449 amino acids each. The calculated molecular weight of the enzyme subunit is 48,738 and that of the enzyme tetramer is 194,952. No disulfide bonds or bound sugar molecules were found in the enzyme structure, although 6 cysteine residues were determined per enzyme subunit. Sequence homologies were found between an omega-aminotransferase, i.e. mammalian and yeast ornithine delta-aminotransferases, fungal gamma-aminobutyrate aminotransferase and 7,8-diaminoperalgonate aminotransferase, and 2,2-dialkylglycine decarboxylase. The enzyme structure is not homologous to those of aspartate aminotransferases (AspATs) including the enzymes of Escherichia coli and Sufolobus salfactaricus, though significant homology in the three-dimensional structures around the cofactor binding site has been found between omega-APT and AspATs (Watanabe, N., Sakabe, K., Sakabe, N., Higashi, T., Sasaki, K., Aibara, S., Morita, Y., Yonaha, K., Toyama, S., and Fukutani, H. (1989) J. Biochem. 105, 1-3).	KYOTO UNIV, RES INST, UJI, KYOTO 611, JAPAN	Kyoto University	YONAHA, K (corresponding author), UNIV RYUKYUS, DEPT AGR CHEM, NISHIHARA, OKINAWA 90301, JAPAN.							ARNONE A, 1985, TRANSAMINASES, P139; Christen P, 1985, TRANSAMINASES; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; GOOD WB, 1982, NUCLEIC ACIDS RES, V10, P247; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HYDE CC, 1988, J BIOL CHEM, V263, P17857; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; JOHNSON LN, 1980, J MOL BIOL, V140, P565, DOI 10.1016/0022-2836(80)90271-5; KELLER JW, 1990, J BIOL CHEM, V265, P5531; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KONIGSBERG W, 1972, METHOD ENZYMOL, V25, P158; LIU TY, 1971, J BIOL CHEM, V246, P2842; MARCEAU M, 1988, J BIOL CHEM, V263, P16926; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MEHTA PK, 1991, INT UNION B, V199, P35; MUECKLER MM, 1985, J BIOL CHEM, V260, P2993; OTSUKA AJ, 1988, J BIOL CHEM, V263, P19577; RICHARDSON IB, 1989, MOL GEN GENET, V217, P118, DOI 10.1007/BF00330950; SEVILLE M, 1988, BIOCHEMISTRY-US, V27, P8344, DOI 10.1021/bi00422a009; TITANI K, 1972, BIOCHEMISTRY-US, V11, P2427, DOI 10.1021/bi00763a007; WATANABE N, 1989, J BIOCHEM, V105, P1, DOI 10.1093/oxfordjournals.jbchem.a122600; WATANABE N, 1991, INT UNION B, V199, P121; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; YONAHA K, 1983, AGR BIOL CHEM TOKYO, V47, P2257; YONAHA K, 1976, FEBS LETT, V71, P21, DOI 10.1016/0014-5793(76)80889-7; YONAHA K, 1983, J BIOL CHEM, V258, P2260	31	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12506	12510						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618757				2022-12-27	WOS:A1992HZ48300023
J	AU, KG; WELSH, K; MODRICH, P				AU, KG; WELSH, K; MODRICH, P			INITIATION OF METHYL-DIRECTED MISMATCH REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTS-ENCODED PROTEIN; BASE-PAIR MISMATCHES; ESCHERICHIA-COLI-B; D(GATC) SEQUENCES; GATC SEQUENCES; POLYMERASE-III; GENE-PRODUCT; DNA; INVITRO	Escherichia coli MutH possesses an extremely weak d(GATC) endonuclease that responds to the state of methylation of the sequence (Welsh, K. M., Lu, A.-L., Clark, S., and Modrich, P. (1987) J. Biol. Chem. 262, 15624-15629). MutH endonuclease is activated in a reaction that requires MutS, MutL, ATP, and Mg2+ and depends upon the presence of a mismatch within the DNA. The degree of activation correlates with the efficiency with which a particular mismatch is subject to methyl-directed repair (G-T > G-G > A-C > C-C), and activated MutH responds to the state of DNA adenine methylation. Incision of an unmethylated strand occurs immediately 5' to a d(GATC) sequence, leaving 5' phosphate and 3' hydroxy termini (p N down p G p A p-TpC). Unmethylated d(GATC) sites are subject to double strand cleavage by activated MutH, an effect that may account for the killing of dam- mutants by 2-aminopurine. The mechanism of activation apparently requires ATP hydrolysis since adenosine-5'-O-(3-thiotriphosphate) not only fails to support the reaction but also inhibits activation promoted by ATP. The process has no obligate polarity as d(GATC) site incision by the activated nuclease can occur either 3' or 5' to the mismatch on an unmethylated strand. However, activation is sensitive to DNA topology. Circular heteroduplexes are better substrates than linear molecules, and activity of DNAs of the latter class depends on placement of the mismatch and d(GATC) site within the molecule. MutH activation is supported by a 6-kilobase linear heteroduplex in which the mismatch and d(GATC) site are centrally located and separated by 1 kilobase, but a related molecule, in which the two sites are located near opposite ends of the DNA, is essentially inactive as substrate. We conclude that MutH activation represents the initiation stage of methyl-directed repair and suggest that interaction of a mismatch and a d(GATC) site is provoked by MutS binding to a mispair, with subsequent ATP-dependent translocation of one or more Mut proteins along the helix leading to cleavage at a d(GATC) sequence on either side of the mismatch.			AU, KG (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BENNETT SP, 1989, CURR TOP CELL REGUL, V30, P57; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; ENDLICH B, 1985, J BIOL CHEM, V260, P5720; GLICKMAN BW, 1980, P NATL ACAD SCI-BIOL, V77, P1063, DOI 10.1073/pnas.77.2.1063; GLICKMAN BW, 1982, MOL CELLULAR MECHANI, P65; GRAFSTROM RH, 1988, J BACTERIOL, V170, P3485, DOI 10.1128/jb.170.8.3485-3492.1988; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HORIUCHI K, 1972, P NATL ACAD SCI USA, V69, P3220, DOI 10.1073/pnas.69.11.3220; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Kornberg A., 1991, DNA REPLICATION; LAENGLEROUAULT F, 1986, EMBO J, V5, P2009, DOI 10.1002/j.1460-2075.1986.tb04457.x; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LANGLEROUAULT F, 1987, EMBO J, V6, P1121, DOI 10.1002/j.1460-2075.1987.tb04867.x; LIVINGSTON DM, 1975, J BIOL CHEM, V250, P470; LU AL, 1987, J BACTERIOL, V169, P1254, DOI 10.1128/jb.169.3.1254-1259.1987; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1984, COLD SPRING HARB SYM, V49, P589, DOI 10.1101/SQB.1984.049.01.066; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.biochem.56.1.435; MODRICH P, 1989, J BIOL CHEM, V264, P6597; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1989, GENOME, V31, P104, DOI 10.1139/g89-020; SU SS, 1988, J BIOL CHEM, V263, P6829; WELSH KM, 1987, J BIOL CHEM, V262, P15624; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	32	249	260	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12142	12148						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601880				2022-12-27	WOS:A1992HY94700074
J	LEE, YC; OEDA, T; DRISCOLL, WJ; FALES, HM; STROTT, CA				LEE, YC; OEDA, T; DRISCOLL, WJ; FALES, HM; STROTT, CA			PURIFICATION AND IDENTIFICATION OF THE HEAT-STABLE FACTOR REQUIRED FOR PREGNENOLONE-BINDING PROTEIN-ACTIVITY - EVIDENCE THAT THE FACTOR IS ADENOSINE 3',5'-DIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG ADRENAL-CORTEX; GUINEA-PIG; SOLUBLE FRACTION; PHOSPHORYLATION; ZONES	This paper presents data identifying adenosine 3',5'-diphosphate (3',5'-ADP) as the small heat-stable factor essential for the active steroid binding complex of the adrenocortical pregnenolone-binding protein (PBP). Factor activity obtained from the boiled supernatant of partially purified PBP was isolated by high performance liquid chromatography using weak anion-exchange and hydrophobic (C18) chromatography sequentially. The purified material retained characteristic factor activity and presented a UV spectrum identical to that for authentic 3',5'-ADP. Mass spectroscopic analysis of the isolated factor revealed an M-H ion of appropriate mass (m/z = 426) and a decomposition pattern for the M-H ion that was consistent with the structure of 3',5'-ADP. The studies presented here demonstrate that authentic 3',5'-ADP can categorically substitute for factor prepared from the soluble fraction of the guinea pig adrenal. Specifically, 3',5'-ADP potentiated ligand binding of partially purified native PBP and restored binding capacity to alkaline phosphatase-inactivated PBP in a dose-dependent manner. As is the case for adrenocortical factor activity, these effects were negated by pretreating the 3',5'-ADP with calf intestinal alkaline phosphatase. Other nucleotides similarly tested, including ADP isomers, were ineffective as factor substitutes. The sulfated form of 3',5'-ADP (i.e. 3'-phosphoadenosine 5-phosphosulfate) demonstrated some potential for restoring binding capacity to phosphatase-inactivated PBP; however, this compound was clearly inhibitory rather than stimulatory for native PBP activity. Taken collectively, the data overwhelmingly demonstrate that 3',5'-ADP is in fact the molecule required by the PBP for high affinity steroid binding complex formation. It is not yet known whether 3',5'-ADP acts allosterically or contributes directly to the structure of the steroid binding site.	NICHHD,ENDOCRINOL & REPROD RES BRANCH,ADRENAL CELL BIOL SECT,BLDG 10,RM B1-L400,BETHESDA,MD 20892; NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BODINE PV, 1988, J BIOL CHEM, V263, P3501; DEMURA T, 1990, ENDOCRINOLOGY, V127, P1114, DOI 10.1210/endo-127-3-1114; DRISCOLL WJ, 1990, J BIOL CHEM, V265, P12306; DRISCOLL WJ, 1991, MOL ENDOCRINOL, V5, P1229, DOI 10.1210/mend-5-9-1229; FERGUSON JJ, 1963, J BIOL CHEM, V238, P2754; Garren L D, 1968, Vitam Horm, V26, P119; KARABOYAS GC, 1965, BIOCHEMISTRY-US, V4, P462, DOI 10.1021/bi00879a014; LEE YC, 1990, P NATL ACAD SCI USA, V87, P2003, DOI 10.1073/pnas.87.5.2003; LEE YJC, 1988, BIOCHEM BIOPH RES CO, V150, P456, DOI 10.1016/0006-291X(88)90542-6; NISHIKAWA T, 1984, J STEROID BIOCHEM, V20, P1123, DOI 10.1016/0022-4731(84)90354-6; NISHIKAWA T, 1983, STEROIDS, V41, P105, DOI 10.1016/0039-128X(83)90021-1; Roy A.B., 1981, SULFATION DRUGS RELA, P83; SATO B, 1980, ENDOCRINOLOGY, V106, P1142, DOI 10.1210/endo-106-4-1142; STANLEY PE, 1975, ANAL BIOCHEM, V67, P540, DOI 10.1016/0003-2697(75)90330-9; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; STROTT CA, 1978, BIOCHEMISTRY-US, V17, P4557, DOI 10.1021/bi00614a030; STROTT CA, 1981, ENDOCRINOLOGY, V109, P2249, DOI 10.1210/endo-109-6-2249; STROTT CA, 1977, J BIOL CHEM, V252, P464; STROTT CA, 1983, J STEROID BIOCHEM, V18, P489, DOI 10.1016/0022-4731(83)90070-5; WHITNALL MH, 1990, J HISTOCHEM CYTOCHEM, V38, P1607, DOI 10.1177/38.11.2170503	20	4	4	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10982	10987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597440				2022-12-27	WOS:A1992HX16900011
J	HIGASHI, H; OMORI, A; YAMAGATA, T				HIGASHI, H; OMORI, A; YAMAGATA, T			CALMODULIN, A GANGLIOSIDE-BINDING PROTEIN - BINDING OF GANGLIOSIDES TO CALMODULIN IN THE PRESENCE OF CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; GROWTH-FACTOR RECEPTOR; AMINO-ACID-SEQUENCE; MEDIATED MODULATION; NEOLACTO-SERIES; CELL-GROWTH; SIALIC-ACID; BRAIN; GLYCOSPHINGOLIPIDS; SUBUNIT	Ca2+-dependent ganglioside-binding protein was isolated from a soluble cytosol fraction of mouse brains using a ganglioside affinity column prepared with a mixture of bovine brain gangliosides. It was identified as calmodulin based on the following features identical with those of calmodulin: molecular weight, pI, chromatographic profile and amino acid sequences of lysylendopeptidase digests, and ability to activate cyclic nucleotide phosphodiesterase. Bovine brain calmodulin derivatized with 5-dimethylaminonaphthalene-1-sulfonyl (dansyl-calmodulin), tetramethylrhodamine isothiocyanate, or biotin was also shown to bind to the ganglioside affinity column Ca2+ dependently and elute with gangliosides G(D1a), G(D1b), G(T1b), G(Q1b), G(M1), and G(M2), melittin, and trifluoperazine but not with GgOse4Cer and oligosaccharides of G(M1), G(D1a), and G(T1b). Modification of the Lys94 residue of calmodulin by biotinylation drastically reduced the capacity for ganglioside binding. Ganglioside G(D1b) caused a blue shift and increase in intensity of the fluorescence emission spectrum of dansyl-calmodulin in the presence of Ca2+. The increment in fluorescence was proportional to the amount of G(D1b) added and was maximal at the molar ratio of G(D1b) to calmodulin, approximately 7.8. Gangliosides are thus shown to specifically bind to calmodulin, and this binding may be a general mechanism for regulating camodulin-dependent enzymes with consequent cellular response, such as cell differentiation.	MITSUBISHI KASEI INST LIFE SCI,PROT RES RES LAB,MACHIDA,TOKYO 194,JAPAN		HIGASHI, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,GLYCOCONJUGATE RES LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; BENFENATI F, 1991, NEUROCHEM INT, V19, P271, DOI 10.1016/0197-0186(91)90011-2; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; BREMER EG, 1982, BIOCHEM BIOPH RES CO, V106, P711, DOI 10.1016/0006-291X(82)91769-7; Chan K F, 1991, Glycobiology, V1, P193, DOI 10.1093/glycob/1.2.193; Cheung W.Y., 1980, CALCIUM CELL FUNCTIO, V1; Cheung W. Y., 1975, CYCLIC NUCLEOTIDES D, P321; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; CHIGORNO V, 1990, FEBS LETT, V263, P329, DOI 10.1016/0014-5793(90)81406-E; CHIGORNO V, 1990, FEBS LETT, V277, P164, DOI 10.1016/0014-5793(90)80834-6; COMTE M, 1983, BIOCHEM J, V209, P269, DOI 10.1042/bj2090269; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; DAVIS CW, 1980, MOL PHARMACOL, V17, P206; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUKUNAGA K, 1990, J NEUROCHEM, V54, P102, DOI 10.1111/j.1471-4159.1990.tb13288.x; GNEGY ME, 1976, P NATL ACAD SCI USA, V73, P352, DOI 10.1073/pnas.73.2.352; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANDA S, 1984, J BIOCHEM-TOKYO, V95, P1323, DOI 10.1093/oxfordjournals.jbchem.a134738; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HIGASHI H, 1988, BIOCHIM BIOPHYS ACTA, V963, P333, DOI 10.1016/0005-2760(88)90299-8; HIGASHI H, 1982, ANAL BIOCHEM, V120, P159, DOI 10.1016/0003-2697(82)90331-1; HIGASHI H, 1991, J BIOL CHEM, V267, P9839; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; ITO M, 1989, J BIOL CHEM, V264, P9510; JARRETT HW, 1991, J BIOL CHEM, V266, P362; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; Kakiuchi S, 1978, Adv Cyclic Nucleotide Res, V9, P253; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledeen R W, 1976, Adv Exp Med Biol, V71, P83; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEDEEN RW, 1988, J NEUROCHEM, V51, P1465, DOI 10.1111/j.1471-4159.1988.tb01112.x; Leskawa K C, 1980, Adv Exp Med Biol, V125, P125; MANN DM, 1989, J BIOL CHEM, V264, P2373; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; MCKEON TA, 1991, ANAL BIOCHEM, V193, P125, DOI 10.1016/0003-2697(91)90051-T; MILLERPODRAZA H, 1983, J NEUROCHEM, V41, P860, DOI 10.1111/j.1471-4159.1983.tb04819.x; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; SAKAKIBARA K, 1981, NATURE, V293, P76, DOI 10.1038/293076a0; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SONNINO S, 1979, J NEUROCHEM, V33, P117, DOI 10.1111/j.1471-4159.1979.tb11713.x; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; TESHIMA Y, 1978, J CYCLIC NUCL PROT, V4, P219; TIEMEYER M, 1990, J BIOL CHEM, V265, P11990; TIEMEYER M, 1989, J BIOL CHEM, V264, P1671; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; WATANABE K, 1980, BIOCHEM BIOPH RES CO, V92, P638, DOI 10.1016/0006-291X(80)90381-2; WOLFF DJ, 1977, J BIOL CHEM, V252, P4108; YATES AJ, 1989, J NEUROCHEM, V53, P162, DOI 10.1111/j.1471-4159.1989.tb07308.x; Young W W Jr, 1978, Methods Enzymol, V50, P137	60	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9831	9838						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577817				2022-12-27	WOS:A1992HT96500062
J	SCHROTH, GP; SIINO, JS; COONEY, CA; THNG, JPH; HO, PS; BRADBURY, EM				SCHROTH, GP; SIINO, JS; COONEY, CA; THNG, JPH; HO, PS; BRADBURY, EM			INTRINSICALLY BENT DNA FLANKS BOTH SIDES OF AN RNA POLYMERASE-I TRANSCRIPTION START SITE - BOTH REGIONS DISPLAY NOVEL ELECTROPHORETIC MOBILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURVED DNA; PHYSARUM-POLYCEPHALUM; ESCHERICHIA-COLI; KINETOPLAST DNA; REPLICATION ORIGIN; REGULATORY REGION; BACILLUS-SUBTILIS; SALT DEPENDENCE; THYMINE TRACTS; GEL MIGRATION	We have identified two intrinsically bent regions of DNA which flank the transcription start site of the rRNA gene from Physarum polycephalum. DNA fragments from both regions were analyzed by circular permutation polyacrylamide gel electrophoresis assay and computer modeling. Both types of analysis indicate that one fragment contains a relatively simple bend centered about 160 base pairs (bp) upstream of the transcription start site while the other fragment contains multiple bends, the most prominent of which is centered about 150 bp downstream of the start site. According to both gel mobilities and computer modeling we estimate that the net bending in each is about 45-degrees. These fragments were studied in detail by varying parameters of electrophoresis that are known to affect bending. Previous work indicates that anomalous mobility should decrease when temperature or ethidium bromide concentration is increased, whereas anomalous mobility should increase when polyacrylamide gel percentage is increased. The anomalous mobility of both fragments decreases as temperature is raised from 4 to 65-degrees-C, although the bent structure centered at - 160 bp is more temperature labile than the bend at + 150 bp. Strikingly different behavior was observed for the two fragments as the polyacrylamide concentration was varied. As polyacrylamide concentrations are increased from 6 to 10%, the anomalous mobility of the bend centered at - 160 bp increases while that of the bend centered at + 150 bp decreases. The bend centered at + 150 bp is "straightened" at all ethidium concentrations tested. In sharp contrast and unexpectedly, the anomalous migration of the bend centered at - 160 bp increases dramatically in 0.1-mu-g/ml ethidium bromide. Many of the mobility differences we observe suggest that the two regions studied represent structurally distinct forms of bent DNA. The location of these strongly bent regions on either side of a RNA polymerase I transcription start site suggests important roles for such structures in chromatin structure and transcription initiation.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010; UNIV CALIF LOS ALAMOS SCI LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of California System; University of California Davis; City of Hope; Beckman Research Institute of City of Hope; United States Department of Energy (DOE); Los Alamos National Laboratory	SCHROTH, GP (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,535 WENIGER HALL,CORVALLIS,OR 97331, USA.		Ho, Pui S/F-6186-2014; Ho, Pui/AAF-8838-2020	Ho, Pui S/0000-0002-8082-4311; Ho, Pui/0000-0002-8082-4311; Cooney, Craig/0000-0003-4279-557X	NIA NIH HHS [R01AG08196] Funding Source: Medline; NIGMS NIH HHS [GM-26901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008196] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMERO SA, 1988, J BIOL CHEM, V263, P10734; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BLUM B, 1983, NUCLEIC ACIDS RES, V11, P8519, DOI 10.1093/nar/11.23.8519; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRADBURY EM, 1981, DNA CHROMATIN CHROMO; BRESLOFF JL, 1981, BIOCHEMISTRY-US, V20, P3547, DOI 10.1021/bi00515a038; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P5765, DOI 10.1093/nar/15.14.5765; DIEKMANN S, 1989, ELECTROPHORESIS, V10, P354, DOI 10.1002/elps.1150100513; DIEKMANN S, 1987, NUCLEIC ACIDS MOL BI, V1; DONG XN, 1989, J BACTERIOL, V171, P703, DOI 10.1128/jb.171.2.703-707.1989; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; DREW HR, 1990, DNA TOPOLOGY ITS BIO; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FERRIS PJ, 1982, J MOL BIOL, V159, P359, DOI 10.1016/0022-2836(82)90289-3; FERRIS PJ, 1985, GENE, V39, P203, DOI 10.1016/0378-1119(85)90314-2; Ferris PJ, 1984, THESIS CORNELL U ITH; FRANKKAMENETSKII M, 1989, NATURE, V342, P737, DOI 10.1038/342737a0; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GUBLER U, 1980, NUCLEIC ACIDS RES, V8, P4572; HERTZ GZ, 1987, J VIROL, V61, P2322, DOI 10.1128/JVI.61.7.2322-2325.1987; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; INOKUCHI K, 1988, NUCLEIC ACIDS RES, V16, P6693, DOI 10.1093/nar/16.14.6693; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KENNARD O, 1989, Q REV BIOPHYS, V22, P327, DOI 10.1017/S0033583500002997; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KODAMA H, 1987, CHROMOSOMA, V96, P18, DOI 10.1007/BF00285878; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1987, BIOCHEMISTRY-US, V26, P3745, DOI 10.1021/bi00386a070; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KRISHNAMURTHY G, 1990, BIOCHEMISTRY-US, V29, P981, DOI 10.1021/bi00456a021; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988, DOI 10.1021/bi00362a003; LEVENE SD, 1989, SCIENCE, V245, P396, DOI 10.1126/science.2756426; LUCCHINI R, 1987, J MOL BIOL, V196, P829, DOI 10.1016/0022-2836(87)90408-6; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; MILTON DL, 1990, J MOL BIOL, V213, P135, DOI 10.1016/S0022-2836(05)80126-3; MIZUNO T, 1988, MOL GEN GENET, V214, P249, DOI 10.1007/BF00337718; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P6827, DOI 10.1093/nar/15.17.6827; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; MURAMATSU S, 1988, MOL GEN GENET, V214, P433, DOI 10.1007/BF00330477; OHYAMA T, 1989, NUCLEIC ACIDS RES, V17, P3845, DOI 10.1093/nar/17.10.3845; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PEPE G, 1989, NUCLEIC ACIDS RES, V17, P8803, DOI 10.1093/nar/17.21.8803; PEREZMARTIN J, 1988, NUCLEIC ACIDS RES, V16, P9113, DOI 10.1093/nar/16.19.9113; POLJAK LG, 1987, NUCLEIC ACIDS RES, V15, P5433, DOI 10.1093/nar/15.13.5433; PRENTKI P, 1987, NUCLEIC ACIDS RES, V15, P10060, DOI 10.1093/nar/15.23.10060; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER TE, 1990, J MOL BIOL, V216, P69; SCHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418; SCHROTH GP, 1991, NUCLEIC ACIDS RES, V19, P511, DOI 10.1093/nar/19.3.511; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; SULLIVAN KM, 1987, J MOL BIOL, V193, P397, DOI 10.1016/0022-2836(87)90227-0; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMS JS, 1988, MOL CELL BIOL, V8, P2763, DOI 10.1128/MCB.8.7.2763; WILSON VG, 1989, VIRUS RES, V13, P1, DOI 10.1016/0168-1702(89)90083-X; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YEO A, 1990, VIROLOGY, V174, P329, DOI 10.1016/0042-6822(90)90085-6; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	81	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9958	9964						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577826				2022-12-27	WOS:A1992HT96500078
J	ORR, JW; KERANEN, LM; NEWTON, AC				ORR, JW; KERANEN, LM; NEWTON, AC			REVERSIBLE EXPOSURE OF THE PSEUDOSUBSTRATE DOMAIN OF PROTEIN-KINASE-C BY PHOSPHATIDYLSERINE AND DIACYLGLYCEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATION; MEMBRANES; SEQUENCE	The lipid activators of protein kinase C, phosphatidylserine and diacylglycerol, induce a reversible conformational change that exposes the auto-inhibitory pseudosubstrate domain of the enzyme. The pseudosubstrate domain of beta-II protein kinase C is cleaved after the first residue, arginine 19, by the endoproteinase Arg-C only when the kinase is bound to the activating lipid phosphatidylserine. Exposure of this residue is markedly enhanced by diacylglycerol. In contrast, the pseudosubstrate domain is not cleaved in the absence of lipids, when protein kinase C is bound to non-activating acidic lipids, when the kinase has autophosphorylated on the amino terminus, or after dilution of the activating lipids. This work reveals specificity in the interaction of protein kinase C with phosphatidylserine since only this phospholipid causes the specific conformational change detected in the regulatory domain of the enzyme, and demonstrates that allosteric regulators expose the intramolecular auto-inhibitory domain of a kinase.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043154, R37GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1974, J BIOL CHEM, V249, P634; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSIOR M, 1991, BIOPHYS J, V60, P149, DOI 10.1016/S0006-3495(91)82038-0; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WALKER JM, 1988, J BIOL CHEM, V263, P4537	27	181	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1992	267	22					15263	15266						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JG113	1639770				2022-12-27	WOS:A1992JG11300002
J	SHAPIRO, SD; KOBAYASHI, DK; WELGUS, HG				SHAPIRO, SD; KOBAYASHI, DK; WELGUS, HG			IDENTIFICATION OF TIMP-2 IN HUMAN ALVEOLAR MACROPHAGES - REGULATION OF BIOSYNTHESIS IS OPPOSITE TO THAT OF METALLOPROTEINASES AND TIMP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-CELLS; TISSUE INHIBITOR; COLLAGENASE INHIBITOR; STIMULATES COLLAGENASE; IV COLLAGENASE; MESSENGER-RNA; EXPRESSION; FIBROBLASTS; SECRETION; PROFILE	We have identified the metalloproteinase inhibitor TIMP-2 as a secreted product of human alveolar macrophages. In contrast to human fibroblasts, TIMP-2 was released from macrophages free of any apparent complexed metalloproteinases. Also in marked distinction to fibroblasts, TIMP-2 secretion from mononuclear phagocytes was subject to modulation by a variety of agents. TIMP-2 was synthesized by macrophages placed in culture under basal conditions in amounts approximately 30% of those secreted by fibroblasts on a per cell basis. The additions of lipopolysaccharide, denatured type I collagen, and zymosan to culture medium each resulted in a dose-dependent and profound decrease in macrophage TIMP-2 protein production and steady-state mRNA levels. In contrast, all of these agents markedly enhanced the biosynthesis of macrophage interstitial collagenase and TIMP-1 as assessed by analysis of identical cell and conditioned media samples. In human fibroblasts, TIMP-2 biosynthesis was unaffected by interleukin-1, tumor necrosis factor-alpha, platelet-derived growth factor, and phorbol ester despite the massive collagenase stimulation induced by each of these agents. We conclude that TIMP-2 is a potentially important mononuclear phagocyte product whose biosynthesis is regulated in a distinct and completely opposite manner to that of collagenase and TIMP- 1.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)	SHAPIRO, SD (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV RESP & CRIT CARE,216 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAMS NIH HHS [AR-32087, AR-35805] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR035805] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAUER EA, 1985, P NATL ACAD SCI USA, V82, P4132, DOI 10.1073/pnas.82.12.4132; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CAMPBELL EJ, 1987, J BIOL CHEM, V262, P15862; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; KING J, 1971, J MOL BIOL, V62, P464; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCCACHREN SS, 1990, J CLIN IMMUNOL, V10, P19, DOI 10.1007/BF00917494; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; WAHL LM, 1974, P NATL ACAD SCI USA, V71, P3598, DOI 10.1073/pnas.71.9.3598; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	33	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13890	13894						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629188				2022-12-27	WOS:A1992JD32500019
J	SHIH, HM; TOWLE, HC				SHIH, HM; TOWLE, HC			DEFINITION OF THE CARBOHYDRATE RESPONSE ELEMENT OF THE RAT S14 GENE - EVIDENCE FOR A COMMON FACTOR REQUIRED FOR CARBOHYDRATE REGULATION OF HEPATIC GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; MAJOR LATE PROMOTER; METALLOTHIONEIN-I PROMOTER; TRANSCRIPTION FACTOR BINDS; GAMMA-FIBRINOGEN PROMOTER; THYROID-HORMONE; DNA-BINDING; MESSENGER RNAS14; UPSTREAM ELEMENT; MALIC ENZYME	The 5'-flanking region of the S14 gene from -4316 to +18 contains regulatory sequences responsible for activation of promoter activity in response to elevated carbohydrate metabolism in primary hepatocytes. To map these sequences, a series of constructs containing various internal deletions of the S14 5'-flanking sequence were assayed in primary hepatocytes. The region from -1601 to -1395 was found to be essential for this response. Comparison of the sequence of this S14 region to a region of the L-type pyruvate kinase gene that has been shown to mediate carbohydrate regulation (Thompson, K. S., and Towle, H. C. (1991) J. Biol. Chem. 266, 8679-8682) revealed a segment with 9 out of 10 identity. In both cases, this conserved sequence aligned with a DNase I footprint formed with hepatic nuclear extract. Oligonucleotides (approximately 30 base pairs) from either S14 Or pyruvate kinase genes containing the conserved element bound to a hepatic nuclear factor(s) that gave identical complexes by mobility shift assay. Furthermore, these two oligonucleotides cross-competed for binding to the nuclear factor(s), suggesting that a common factor(s) binds to this conserved element. Reinsertion of the S14 oligonucleotide into an unresponsive S14 promoter construct restored the carbohydrate control. Moreover, this oligonucleotide could confer a glucose response when fused to a heterologous promoter. Thus, the S14 segment from -1457 to -1428 is a carbohydrate response element essential for the binding of nuclear factor(s) regulated by increased carbohydrate metabolism. This factor(s) may be common to the carbohydrate regulation of the S14 and pyruvate kinase genes.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Shih, Hsiu-Ming/S-7023-2018		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACK DW, 1986, J BIOL CHEM, V261, P4190; BACKMANN H, 1990, GENE DEV, V4, P167; BACKMANN H, 1991, GENE DEV, V5, P1057; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOZIN B, 1986, P NATL ACAD SCI USA, V83, P4705, DOI 10.1073/pnas.83.13.4705; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HROMAS R, 1986, NUCLEIC ACIDS RES, V14, P4837, DOI 10.1093/nar/14.12.4837; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INOUE H, 1984, J BIOCHEM-TOKYO, V96, P1457, DOI 10.1093/oxfordjournals.jbchem.a134974; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1984, J BIOL CHEM, V259, P2789; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENNARD AC, 1987, EMBO J, V6, P3027, DOI 10.1002/j.1460-2075.1987.tb02608.x; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MARIASH CN, 1981, J CLIN INVEST, V68, P1485, DOI 10.1172/JCI110401; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARIASH CN, 1983, METABOLISM, V33, P545; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; STROBL W, 1989, J BIOL CHEM, V264, P1190; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	50	147	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13222	13228						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618827				2022-12-27	WOS:A1992JB74600023
J	UGAROVA, TP; BUDZYNSKI, AZ				UGAROVA, TP; BUDZYNSKI, AZ			INTERACTION BETWEEN COMPLEMENTARY POLYMERIZATION SITES IN THE STRUCTURAL D-DOMAIN AND E-DOMAIN OF HUMAN FIBRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENT-D; LOCALIZATION; MONOMERS; PEPTIDES; BINDING	Plasmic degradation products of human fibrin, fragments DD, D, and E, bind to fibrin. It has been inferred from this observation that the binding occurs by attraction of complementary sites located in the NH2-and COOH-terminal domains of the fibrin molecule. The interaction between fragments D1 and E1 has been investigated in this work since it represents the first step in the process of fibrin clot formation. Fragment D1, that was initially as active as fragment DD, lost most of its anticoagulant activity after purification by cation-exchange chromatography. The lability of fragment D1 function explained the previous unsuccessful attempts to form a complex between fragments D1 and E1. The loss of fragment D1 anticoagulant activity was not associated with the cleavage of the gamma-63-85 chain segment, since fragments D1A and D1 identically inhibited the fibrin monomer polymerization rate. In order to demonstrate the formation of a complex between fragments D1 and E1, three lines of experiments were advanced. First, the anticoagulant activity of fragment D1 was neutralized by fragment E1 in a dose-dependent manner, demonstrating that the association between these fragments involved polymerization sites. Second, two products, D1.E1 and D1.E1.D1, were stabilized in a reaction with bifunctional cross-linking reagents, proving the formation of D.E complexes in aqueous solution. Third, immobilized fragment D1 bound fragments E1 and E2, but not fragment E3, showing that fragments E1 and E2 attached via a polymerization site to the complementary one in fragment D1, since this association was disrupted by fibrin polymerization inhibitory peptide GPRP. These results provided direct evidence for specific binding between the structural D and E domains of fibrin mediated through complementary polymerization sites. Thus, the initial formation of fibrin clot fibers appears to be driven by specific association of these sites.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036221] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36221] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUDZYNSKI AZ, 1979, BIOCHIM BIOPHYS ACTA, V584, P284, DOI 10.1016/0304-4165(79)90273-3; BUDZYNSKI AZ, 1983, ANN NY ACAD SCI, V408, P301, DOI 10.1111/j.1749-6632.1983.tb23253.x; BUDZYNSKI AZ, 1986, CRC CR REV ONCOL-HEM, V6, P97, DOI 10.1016/S1040-8428(86)80019-1; CIERNIEWSKI CS, 1986, J BIOL CHEM, V261, P9116; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DRAYATTALI L, 1977, THROMB RES, V10, P575, DOI 10.1016/0049-3848(77)90213-4; FOWLER WE, 1981, P NATL ACAD SCI-BIOL, V78, P4872, DOI 10.1073/pnas.78.8.4872; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; KLOCZEWIAK M, 1988, FIBRINOGEN, V3, P79; KNOLL D, 1984, BIOCHEMISTRY-US, V23, P3708, DOI 10.1021/bi00311a021; KRAKOW W, 1972, J MOL BIOL, V71, P95, DOI 10.1016/0022-2836(72)90403-2; KUDRYK B, 1973, Thrombosis Research, V2, P297, DOI 10.1016/0049-3848(73)90040-6; KUDRYK BJ, 1974, J BIOL CHEM, V249, P3322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1962, AM J PHYSIOL, V202, P681, DOI 10.1152/ajplegacy.1962.202.4.681; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1981, SCIENCE, V212, P457, DOI 10.1126/science.7209542; MATTHIAS F R, 1973, Thrombosis Research, V3, P657, DOI 10.1016/0049-3848(73)90013-3; MIHALYI E, 1976, THROMB RES, V8, P1, DOI 10.1016/0049-3848(76)90118-3; NORTON PA, 1981, P NATL ACAD SCI-BIOL, V78, P1661, DOI 10.1073/pnas.78.3.1661; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; OLEXA SA, 1979, J BIOL CHEM, V254, P4925; OLEXA SA, 1981, BIOCHEMISTRY-US, V20, P6139, DOI 10.1021/bi00524a035; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; POZDNYAKOVA TM, 1980, THROMB RES, V19, P807; PRICE TM, 1981, P NATL ACAD SCI-BIOL, V78, P200, DOI 10.1073/pnas.78.1.200; SAITO Y, 1983, ANN NY ACAD SCI, V408, P288, DOI 10.1111/j.1749-6632.1983.tb23252.x; SOUTHAN C, 1985, J BIOL CHEM, V260, P3095; TAKAGI T, 1975, BIOCHEMISTRY-US, V14, P940, DOI 10.1021/bi00676a010; TAKAGI T, 1975, THROMB RES, V7, P813, DOI 10.1016/0049-3848(75)90206-6; UGAROVA T P, 1987, Biokhimiya, V52, P255; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; WILLIAMS JE, 1981, BIOCHEM J, V197, P661, DOI 10.1042/bj1970661; WILLIAMS RC, 1981, J MOL BIOL, V150, P399, DOI 10.1016/0022-2836(81)90555-6	36	30	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13687	13693						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618867				2022-12-27	WOS:A1992JB74600093
J	WHITEHEART, SW; BRUNNER, M; WILSON, DW; WIEDMANN, M; ROTHMAN, JE				WHITEHEART, SW; BRUNNER, M; WILSON, DW; WIEDMANN, M; ROTHMAN, JE			SOLUBLE N-ETHYLMALEIMIDE-SENSITIVE FUSION ATTACHMENT PROTEINS (SNAPS) BIND TO A MULTI-SNAP RECEPTOR COMPLEX IN GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; PURIFICATION; VESICLES; YEAST; STACK	Soluble N-ethylmaleimide-sensitive fusion attachment proteins (SNAPs) are required for the binding of N-ethylmaleimide-sensitive fusion protein (NSF) to Golgi membranes and are, therefore, required for intra-Golgi transport. We report the existence of distinct alpha/beta-SNAP and gamma-SNAP-binding sites in Golgi membranes that appear to be part of the same receptor complex. Cross-linking studies with alpha-SNAP demonstrate that an integral membrane protein of between 30-40 kDa is the alpha-SNAP binding component of the multi-SNAP receptor complex. These data suggest that SNAPs function by independently binding to a multi-SNAP membrane-receptor complex, thereby activating them to serve as adaptors for the targeting of NSF.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Whiteheart, Sidney/0000-0001-5577-0473; Brunner, Michael/0000-0001-9798-3047	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027044, R01DK027044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; GORLICH D, 1991, IN PRESS METHODS CEL; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ROTHMAN JE, 1991, NATURE, V335, P409; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON DW, 1992, IN PRESS METHODS ENZ	13	81	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12239	12243						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601890				2022-12-27	WOS:A1992HY94700088
J	CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS				CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS			ROLE OF CYSTEINE-640, CYSTEINE-656, AND CYSTEINE-661 IN STEROID BINDING TO RAT GLUCOCORTICOID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-CULTURE CELLS; AMINO-ACID-RESIDUES; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; TRANSCRIPTIONAL ENHANCEMENT; MONOCLONAL-ANTIBODY; HORMONE RECEPTORS; SULFHYDRYL-GROUPS; DOMAINS; ACTIVATION	The involvement of a vicinally spaced dithiol group in steroid binding to the glucocorticoid receptor has been deduced from experiments with the thiol-specific reagent methyl methanethiolsulfonate and the vicinal dithiol-specific reagent sodium arsenite. The vicinally spaced dithiol appears to reside in the 16-kDa trypsin fragment of the receptor, which is thought to contain 3 cysteines (Cys-640, -656, and -661 of the rat receptor) and binds hormone with an approximately 23-fold lower affinity than does the intact 98-kDa receptor. We now report that the steroid binding specificity of preparations of this 16-kDa fragment and the intact receptor are virtually identical. This finding supports our designation of the 16-kDa fragment as a steroid-binding core domain and validates our continued use of this tryptic fragment in studies of steroid binding. To identify the cysteines which comprise the vicinally spaced dithiol group, and to examine further the role of cysteines in steroid binding, a total of five point mutant receptors were prepared: cysteine-to-serine for each suspected cysteine, cysteine-to-glycine for Cys-656, and the C656,661S double mutant. Unexpectedly, each receptor with a single point mutation still bound steroid. Even the double mutant (C656,661S) bound steroid with wild type affinity. These results suggest that none of these cysteines are directly required either for steroid binding to the glucocorticoid receptor or for heat shock protein 90 association with the receptor. However, the presence of Cys-656 was obligatory for covalent labeling of the receptor by [H-3]dexamethasone 21-mesylate. Studies with preparations of the 98 and 16 kDa forms of these mutant receptors revealed both that Cys-656 and -661 comprise the vicinally spaced dithiols reacting with arsenite and that any two of the three thiols could form an intramolecular disulfide after treatment with low concentrations of methyl methanethiolsulfonate. These data, in conjunction with those from experiments on the effects of steric bulk on various receptor functions, support a model for the ligand binding cavity of the receptor that involves all three thiols in a flexible cleft but where thiol-steroid interactions are not essential for binding.	NIDDKD,MOLEC & CELLULAR BIOL LAB,STEROID HORMONES SECT,BLDG 8,RM B2A-07,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco								BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; BYRAVAN S, 1991, MOL ENDOCRINOL, V5, P752, DOI 10.1210/mend-5-6-752; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; DISORBO DM, 1980, ENDOCRINOLOGY, V106, P922, DOI 10.1210/endo-106-3-922; EHRHART JC, 1988, ONCOGENE, V3, P595; EISEN LP, 1985, J BIOL CHEM, V260, P1805; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GABER BP, 1972, BIOINORG CHEM, V2, P135; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GEHRING U, 1988, AFFINITY LABELLING C, P144; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRANBERG JP, 1977, ENDOCRINOLOGY, V100, P160; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JANIN J, 1990, J BIOL CHEM, V265, P16027; KING RJB, 1974, STEROID CELL INTERAC, P109; KOBLINSKY M, 1972, J BIOL CHEM, V247, P7897; LAMONTAGNE N, 1984, ENDOCRINOLOGY, V114, P2252, DOI 10.1210/endo-114-6-2252; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MARCH J, 1985, ADV ORG CHEM, P1092; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER NR, 1988, J BIOL CHEM, V263, P15217; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; NARAY A, 1982, J STEROID BIOCHEM, V16, P199, DOI 10.1016/0022-4731(82)90168-6; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; OBRIEN JM, 1981, J STEROID BIOCHEM, V14, P9, DOI 10.1016/0022-4731(81)90186-2; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PONS M, 1985, J STEROID BIOCHEM, V23, P267, DOI 10.1016/0022-4731(85)90404-2; PRATT WB, 1988, J BIOL CHEM, V263, P267; Raynaud J.P., 1979, DRUG DESIGN, V8, P170; REES AM, 1975, BIOCHIM BIOPHYS ACTA, V411, P121, DOI 10.1016/0304-4165(75)90291-3; RICHARDSON JS, 1981, ADV PROTEIN CHEM, V34, P223; Rodbard D, 1973, RECEPTORS REPRODUCTI, V36, P289; ROUSSEAU GG, 1977, J STEROID BIOCHEM, V8, P911, DOI 10.1016/0022-4731(77)90187-X; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANCHEZ ER, 1992, J BIOL CHEM, V267, P17; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1979, BIOCHEM BIOPH RES CO, V86, P793, DOI 10.1016/0006-291X(79)91782-0; SIMONS SS, 1983, J BIOL CHEM, V258, P2229; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOLFF ME, 1978, BIOCHEMISTRY-US, V17, P3201, DOI 10.1021/bi00609a005; WRANGE O, 1978, J BIOL CHEM, V253, P856; Yen P M, 1991, Receptor, V1, P191; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	69	79	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11366	11373						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597467				2022-12-27	WOS:A1992HX16900067
J	MA, CP; SLAUGHTER, CA; DEMARTINO, GN				MA, CP; SLAUGHTER, CA; DEMARTINO, GN			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A PROTEIN ACTIVATOR (PA28) OF THE 20-S PROTEASOME (MACROPAIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT PROTEINASE; RAT HEPATOMA-CELLS; MULTICATALYTIC PROTEINASE; CDNA CLONING; HUMAN-ERYTHROCYTES; SKELETAL-MUSCLE; GENE FAMILY; LATENT FORM; UBIQUITIN; COMPLEX	A protein that greatly stimulates the multiple peptidase activities of the 20 S proteasome (also known as macropain, the multicatalytic protease complex, and 20 S protease) has been purified from bovine red blood cells and from bovine heart. The activator protein was a single polypeptide with an apparent molecular weight of 28,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and had a native molecular weight of approximately 180,000. This protein, which we have termed PA28, regulated all three of the putatively distinct peptidase activities displayed by each of two functionally different forms of the proteasome. This regulation usually included both an increase in the maximal reaction velocity and a decrease in the concentration of substrate required for half-maximal velocity and indicated that PA28 acted as a positive allosteric effector of the proteasome. PA28 failed, however, to stimulate the hydrolysis of large protein substrates such as casein and lysozyme. These results suggested that the hydrolysis of protein substrates occurred at a site or sites distinct from those that hydrolyzed small peptides and that the regulation of the two processes could be uncoupled. Evidence for direct binding of PA28 to the proteasome was obtained by glycerol density gradient centrifugation. PA28 may play an important regulatory role in intracellular proteolytic pathways mediated by the proteasome.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MA, CP (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL06296] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1073, P299, DOI 10.1016/0304-4165(91)90135-4; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAASS C, 1989, EMBO J, V8, P2373, DOI 10.1002/j.1460-2075.1989.tb08366.x; HAASS C, 1990, GENE, V90, P235, DOI 10.1016/0378-1119(90)90185-T; HAASS C, 1990, NUCLEIC ACIDS RES, V18, P4018, DOI 10.1093/nar/18.13.4018; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MCGUIRE MJ, 1989, BIOCHEM BIOPH RES CO, V160, P911, DOI 10.1016/0006-291X(89)92521-7; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; MCGUIRE MJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P272; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SORIMACHI H, 1990, EUR J BIOCHEM, V193, P775, DOI 10.1111/j.1432-1033.1990.tb19399.x; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1990, BIOCHEM BIOPH RES CO, V171, P676, DOI 10.1016/0006-291X(90)91199-3; TANAKA K, 1986, J BIOL CHEM, V261, P5197; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396	40	315	319	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10515	10523						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587832				2022-12-27	WOS:A1992HV09000047
J	OUSLEY, AH; MORELL, P				OUSLEY, AH; MORELL, P			INDIVIDUAL MOLECULAR-SPECIES OF PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE IN MYELIN TURN OVER AT DIFFERENT RATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TRANSFER PROTEINS; PHOSPHOLIPIDS; BRAIN; DEACYLATION; MICROSOMES	Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) of the myelin membrane exhibit heterogeneity with respect to metabolic turnover rate (Miller, S. L., Benjamins, J. A., and Morell, P. (1977) J. Biol. Chem. 252, 4025-4037). To test the hypothesis that this is due to differential turnover of individual molecular species (which differ in acyl chain composition), we have examined the relative turnover of individual molecular species of myelin PC and PE. Phospholipids were labeled by injection of [2-H-3]glycerol into the brains of young rats. Myelin was isolated at 1, 15, and 30 days post-injection, lipids were extracted, and phospholipid classes were separated by thin-layer chromatography. The PC and PE fractions were hydrolyzed with phospholipase C, and the resulting diacylglycerols were dinitrobenzoylated and fractionated by reverse-phase high performance liquid chromatography. The distribution of radioactivity among individual molecular species was determined. The labeled molecular species of myelin PC were 16:0-16:0, 16:0-18:0, 16:0-18:1, and 18:0- 18: 1, with most of the label present in 16:0-18:1 and 18:0-18:1. Changes in distribution of label with time after injection indicated that 16:0-18:1 turned over more rapidly than 18:0- 18: 1. The labeled molecular species of myelin PE were 18:0-20:4, 18:1-18:1, 16:0-18:1, 18:0-18:2, and 18:0-18:1. As with myelin PC, 16:0-18:1 (and 18:1-18:1) turned over more rapidly than 18:0-18: 1. The relative turnover of individual molecular species of PC in the microsomal fraction from forebrain was also examined. The molecular species profile was different from myelin PC, but again, 16:0-18:1 turned over more rapidly than the other molecular species. Thus, within the same membrane, individual molecular species of a phospholipid class are metabolized at different rates. Comparison of our results with previous studies of turnover of molecular classes of phospholipids indicates that in addition to polar head group composition (Miller et al., 1977), fatty acid composition is very important in determining the metabolic fate of a phospholipid.	UNIV N CAROLINA,BRAIN & DEV RES CTR,CB 7250,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NINDS NIH HHS [NS11615] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011615] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATLEY M, 1980, J CHROMATOGR, V198, P520, DOI 10.1016/S0021-9673(00)80524-5; BENJAMINS JA, 1976, J NEUROCHEM, V27, P565, DOI 10.1111/j.1471-4159.1976.tb12283.x; BENJAMINS JA, 1973, J NEUROCHEM, V20, P1111, DOI 10.1111/j.1471-4159.1973.tb00081.x; Benjamins JA, 1984, MYELIN, P225; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRECKENR.WC, 1968, LIPIDS, V3, P291, DOI 10.1007/BF02530927; COHEN BG, 1980, J BIOL CHEM, V255, P3075; DAWSON R. M. C., 1966, ESSAYS BIOCHEM, V2, P69; FUNKHOUSER JD, 1985, CHEM PHYS LIPIDS, V38, P17, DOI 10.1016/0009-3084(85)90054-4; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; HASSNER A, 1978, TETRAHEDRON, V34, P2069, DOI 10.1016/0040-4020(78)89005-X; HOLUB BJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P305, DOI 10.1016/0005-2760(82)90039-X; HORROCKS LA, 1976, FUNCTION METABOLISM, P37; HORROCKS LA, 1972, RESEARCH METHODS NEU, V1, P223; KASURINEN J, 1990, BIOCHEMISTRY-US, V29, P8548, DOI 10.1021/bi00489a007; KITO M, 1985, J BIOCHEM-TOKYO, V98, P327, DOI 10.1093/oxfordjournals.jbchem.a135285; LEE CH, 1991, J NEUROCHEM, V56, P370, DOI 10.1111/j.1471-4159.1991.tb08161.x; LEE TC, 1973, BIOCHIM BIOPHYS ACTA, V291, P86; LEWIS KA, 1990, BIOCHEMISTRY-US, V29, P9962, DOI 10.1021/bi00494a029; MILLER SL, 1978, J NEUROCHEM, V31, P771, DOI 10.1111/j.1471-4159.1978.tb00109.x; MILLER SL, 1977, J BIOL CHEM, V252, P4025; NORTON WT, 1973, J NEUROCHEM, V21, P759, DOI 10.1111/j.1471-4159.1973.tb07520.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; OMURA T, 1967, J BIOL CHEM, V242, P2389; PASQUINI JM, 1973, J NEUROCHEM, V21, P647, DOI 10.1111/j.1471-4159.1973.tb06009.x; PASTERNAK CA, 1970, BIOCHEM J, V119, P473, DOI 10.1042/bj1190473; PIND S, 1985, CAN J BIOCHEM CELL B, V63, P137, DOI 10.1139/o85-020; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SKRBIC TR, 1970, J NEUROCHEM, V17, P85, DOI 10.1111/j.1471-4159.1970.tb00504.x; Smith M E, 1967, Adv Lipid Res, V5, P241; SMITH ME, 1965, J AM OIL CHEM SOC, V42, P1013, DOI 10.1007/BF02636894; VERGER R, 1973, J BIOL CHEM, V248, P4023; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; WIGGINS RC, 1976, BRAIN RES, V107, P257, DOI 10.1016/0006-8993(76)90225-0; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, V1, P151; YEUNG SKF, 1974, CAN J BIOCHEM CELL B, V52, P830, DOI 10.1139/o74-119	38	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10362	10369						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587822				2022-12-27	WOS:A1992HV09000027
J	TOMASSELLI, AG; BANNOW, CA; DEIBEL, MR; HUI, JO; ZURCHERNEELY, HA; REARDON, IM; SMITH, CW; HEINRIKSON, RL				TOMASSELLI, AG; BANNOW, CA; DEIBEL, MR; HUI, JO; ZURCHERNEELY, HA; REARDON, IM; SMITH, CW; HEINRIKSON, RL			CHEMICAL SYNTHESIS OF A BIOTINYLATED DERIVATIVE OF THE SIMIAN IMMUNODEFICIENCY VIRUS PROTEASE - PURIFICATION BY AVIDIN AFFINITY-CHROMATOGRAPHY AND AUTOCATALYTIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC-ACTIVITY; ESCHERICHIA-COLI; HIV-1 PROTEASE; DESIGN; PEPTIDES; PROTEINASE; MATURATION; INHIBITORS; POTENT; AIDS	The protease from simian immunodeficiency virus (SIV) was chemically synthesized by automated solid-phase technology as an NH2-terminally extended derivative, capped with biotin. Biotin-linker-(SIV protease (1-99)): the linker segment, Gly-Gly-Asp-Arg-Gly-Phe-Ala-Ala, corresponds to the amino acid sequence preceding that of the protease in the SIV gag/pol precursor polyprotein. Accordingly, the Ala-Pro bond joining the octapeptide linker to the protease constitutes a site naturally cleaved by the protease during viral maturation. This strategy for synthesis was designed to facilitate purification of the biotinylated protein derivative from a complex mixture of reaction products by avidin/agarose-affinity chromatography and to provide the means for autocatalytic removal of the biotin-linker segment. As anticipated, folding of the full-length construct leads to activation of the enzyme and excision of the desired 99-residue SIV protease (overall yield, approximately 2%). The specificity of the synthetic SIV protease toward a number of well characterized protein substrates was the same as observed for the nearly identical enzyme from human immunodeficiency virus type 2 (HIV-2 protease) and distinct from that of the more disparate HIV-1 protease. The same functional ordering with respect to the human retroviral proteases was reflected in K(i) values observed with a number of protease inhibitors. Thus, the folded synthetic SIV protease shows patterns of specificity and susceptibility to inhibition that are in accord with what would be expected based upon its degree of structural similarity to proteases from HIV-1 and HIV-2.	UPJOHN CO,LABS,BIOCHEM RES LABS,7240-267-119,301 HENRIETTA ST,KALAMAZOO,MI 49001	Pfizer								ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; COPELAND TD, 1988, GENE ANAL TECH, V5, P109, DOI 10.1016/0735-0651(88)90010-6; DARKE PL, 1989, J BIOL CHEM, V264, P2307; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DEIBEL M R JR, 1989, Peptide Research, V2, P189; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUI J, 1990, 4TH PROT SOC S SAN D; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; KRAUSSLICH HG, 1989, CURRENT COMMUNICATIO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; LIN MC, 1972, J BIOL CHEM, V247, P4768; LOBL TJ, 1988, ANAL BIOCHEM, V170, P502, DOI 10.1016/0003-2697(88)90665-3; MEEK TD, 1990, DESIGN ANTIAIDS DRUG, V14, P225; MYERS G, 1990, HUMAN RETROVIRUSES A; NUTT RF, 1988, P NATL ACAD SCI USA, V85, P7129, DOI 10.1073/pnas.85.19.7129; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SAWYER TK, 1988, J MED CHEM, V31, P18, DOI 10.1021/jm00396a006; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005; THAISRIVONGS S, 1986, J MED CHEM, V29, P2088, DOI 10.1021/jm00160a049; THAISRIVONGS S, 1987, J MED CHEM, V30, P976, DOI 10.1021/jm00389a004; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P408; TOMASSELLI AG, 1991, PROTEINS, V10, P1, DOI 10.1002/prot.340100102; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; YEM AW, 1989, J BIOL CHEM, V264, P17691; [No title captured]	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10232	10237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587812				2022-12-27	WOS:A1992HV09000008
J	TRACEY, BM; FEIZI, T; ABBOTT, WM; CARRUTHERS, RA; GREEN, BN; LAWSON, AM				TRACEY, BM; FEIZI, T; ABBOTT, WM; CARRUTHERS, RA; GREEN, BN; LAWSON, AM			SUBUNIT MOLECULAR MASS ASSIGNMENT OF 14,654-DA TO THE SOLUBLE BETA-GALACTOSIDE-BINDING LECTIN FROM BOVINE HEART-MUSCLE AND DEMONSTRATION OF INTRAMOLECULAR DISULFIDE BONDING ASSOCIATED WITH OXIDATIVE INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEINS; CLONING; CDNA; ELECTROLECTIN; EXPRESSION; SPECTRA; GENE	The soluble dimeric beta-galactoside-binding lectin (subunit molecular mass, approximately 14 kDa) of bovine heart muscle, in common with the 14-kDa lectins of several other animal species, displays carbohydrate-binding activity when it is in the reduced state, but the purified lectin loses this activity upon oxidation. In the present study, the presence of any post-translational modification and the mechanism of the oxidative inactivation have been investigated by analyses of the reduced and oxidized forms of the purified bovine lectin by electrospray ionization-mass spectrometry (ESI-MS) and by liquid secondary ion mass spectrometry (LSIMS) of tryptic and peptic peptides. By ESI-MS, the molecular mass of the reduced lectin is determined to be 14,654.6 +/- 0.9 Da, and that of the oxidized lectin is 14,649.3 +/-1.1 Da. These masses correspond to the amino acid sequence of the protein with the cysteines having free sulfhydryl groups in the reduced state and forming disulfide bonds in the oxidized state. There is no evidence of post-translational modification in either lectin form except for monoacetylation already predicted for alanine at the blocked N-terminal end. Pronounced differences in charge distribution in the electrospray ionization mass spectra of the reduced and oxidized lectin, reflecting a change in the number of accessible protonation sites in the oxidized protein, are consistent with the protein being held in an altered conformation by covalent bonding. The results of LSIMS analyses of tryptic and peptic peptides in conjunction with Edman sequencing indicate that disulfide bonding occurs predominantly between Cys2 and Cys130, Cys16 and Cys88, and Cys42 and Cys60. There is no evidence of oxidation of Trp68. These results, taken together with observations that almost the complete polypeptide chain is necessary for the functional integrity of the carbohydrate recognition domain (Abbott, W. M., and Feizi, T. (1991) J. Biol. Chem. 266, 5552-5557) point to intramolecular disulfide bonding with a change in protein folding and conformation as the mechanism of oxidative inactivation of the purified bovine lectin.	MRC,CLIN RES CTR,CLIN MASS SPECTROMETRY SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,GLYCOCONJUGATES SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; VG BIOTECH LTD,ALTRINCHAM WA14 5RZ,CHESHIRE,ENGLAND	Medical Research Council Clinical Trials Unit; Medical Research Council Clinical Trials Unit				Feizi, Ten/0000-0001-6495-0329				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ARBERTH W, 1982, ANAL CHEM, V54, P2029; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRADSHAW RA, 1990, PROTEINS FORM FUNCTI, P183; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; COWLES EA, 1990, J BIOL CHEM, V265, P17706; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; JIA SH, 1988, J BIOL CHEM, V263, P6009; LEVI G, 1981, J BIOL CHEM, V256, P5735; LEVI G, 1985, BIOCHEM J, V226, P379, DOI 10.1042/bj2260379; LOO JA, 1990, ANAL CHEM, V62, P693, DOI 10.1021/ac00206a009; LOO JA, 1989, ANAL BIOCHEM, V179, P404, DOI 10.1016/0003-2697(89)90153-X; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; SMITH DL, 1990, METHOD ENZYMOL, V193, P374, DOI 10.1016/0076-6879(90)93428-N; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SOUTHAN C, 1987, FEBS LETT, V214, P301, DOI 10.1016/0014-5793(87)80074-1; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847	32	79	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10342	10347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587821				2022-12-27	WOS:A1992HV09000024
J	WILSON, KP; MALCOLM, BA; MATTHEWS, BW				WILSON, KP; MALCOLM, BA; MATTHEWS, BW			STRUCTURAL AND THERMODYNAMIC ANALYSIS OF COMPENSATING MUTATIONS WITHIN THE CORE OF CHICKEN EGG-WHITE LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILITY; STAPHYLOCOCCAL NUCLEASE; PACKING; REFINEMENT; ACIDS	High resolution crystal structures have been determined for six chicken-type lysozymes that were constructed to investigate putative intermediates in the evolution of the lysozymes of modern game birds (Malcolm, B. A., Wilson, K. P., Matthews, B. W., Kirsch, J. F., and Wilson, A. C. (1990) Nature 345, 86-89). The amino acid replacements include Thr-40 --> Ser, Ile-55 --> Val, and Ser-91 --> Thr, as well as combinations of these substitutions. Residues 40, 55, and 91 are buried within the core of chicken lysozyme. The replacements therefore involve the insertion and/or removal of methyl groups from the protein interior. The mutant proteins have normal activities, and their thermal stabilities span a range of 7-degrees-C, with some variants more stable and some less stable than the naturally occurring forms. Comparison of the crystal structures shows the overall structures to be very similar, but there are differences in the packing of side chains in the region of the replacements. The x-ray coordinates were used to evaluate the repacking of side chains in the protein interior and to attempt to evaluate the contributions of the different energetic interactions toward the overall stability of each variant. The results illustrate how proteins can compensate for potentially destabilizing substitutions in different ways and underscore the importance of high resolution structural data if changes in protein thermostability due to changes in protein sequence are to be understood. The findings also suggest that protein stability can be increased by mutations that lower strain in the protein interior while maintaining total buried hydrophobic surface area.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of Oregon	WILSON, KP (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM035393, R01GM020066] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20066, GM35393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Kimura M., 1985, J GENET, V64, P7, DOI [10.1007/BF02923549, DOI 10.1007/BF02923549]; KIRSCH JF, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P59; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEVITT M, 1974, J MOL BIOL, V82, P393, DOI 10.1016/0022-2836(74)90599-3; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V6, P142; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MCCAMMON JA, 1979, BIOCHEMISTRY-US, V18, P927, DOI 10.1021/bi00573a001; MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SANBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; SHORTLE D, 1985, GENETICS, V110, P539; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	32	156	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10842	10849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587860				2022-12-27	WOS:A1992HV09000095
J	CAPERELLI, CA; LIU, D				CAPERELLI, CA; LIU, D			CARBOCYCLIC SUBSTRATES FOR DENOVO PURINE BIOSYNTHESIS - ENANTIOSPECIFIC SYNTHESIS AND ENANTIOSPECIFICITY OF ENZYMATIC UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; CHICKEN LIVER; NEPLANOCIN-A; SYNTHETASE; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; OVERPRODUCTION; NUCLEOSIDES; CLONING	The carbocyclic analogues of phosphoribosylamine, glycinamide ribonucleotide, and formylglycinamide ribonucleotide have been prepared enantiospecifically from D-ribonic acid gamma-lactone. These carbocycles, which have the same absolute configuration as the natural D-ribose-derived intermediates of de novo purine biosynthesis, are utilized stoichiometrically by the initial enzymes of the pathway. A comparison of the enzymatic processing of the (-)-enantiomers with those of the racemates indicates that in some cases, the (+)-enantiomer acts to inhibit the enzymatic activity.			CAPERELLI, CA (corresponding author), UNIV CINCINNATI,MED CTR,COLL PHARM,DIV PHARMACOL & MED CHEM,CINCINNATI,OH 45267, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042024] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-42024] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ARAI Y, 1988, J CHEM SOC PERK T 1, P3133, DOI 10.1039/p19880003133; ARITA M, 1983, J AM CHEM SOC, V105, P4049, DOI 10.1021/ja00350a050; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; Bergmann M, 1932, BER DTSCH CHEM GES, V65, P1192, DOI 10.1002/cber.19320650722; Bestmann H.J., 1990, ANGEW CHEM, V102, P95; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1988, ARCH BIOCHEM BIOPHYS, V264, P340, DOI 10.1016/0003-9861(88)90602-9; CARDINI CE, 1957, METHOD ENZYMOL, V3, P835, DOI 10.1016/S0076-6879(57)03458-8; CHETTUR G, 1977, CARBOHYD RES, V56, P75, DOI 10.1016/S0008-6215(00)84238-X; Cleland W W, 1979, Methods Enzymol, V63, P103; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; Harwood LM., 1985, ALDRICHIM ACTA, V18, P25; LIM MI, 1983, TETRAHEDRON LETT, V24, P4051, DOI 10.1016/S0040-4039(00)88259-3; LIU DH, 1991, J BIOL CHEM, V266, P16699; LIU DS, 1991, SYNTHESIS-STUTTGART, P933; MORAN RG, 1989, J BIOL CHEM, V264, P21047; OHNO M, 1985, NUCLEOS NUCLEOT NUCL, V4, P21, DOI 10.1080/07328318508077828; PARRY RJ, 1991, J CHEM SOC CHEM COMM, P740, DOI 10.1039/c39910000740; PARRY RJ, 1990, TETRAHEDRON LETT, V31, P7549, DOI 10.1016/S0040-4039(00)97295-2; PATEY CAH, 1973, BIOCHEM J, V135, P543, DOI 10.1042/bj1350543; SCHENDEL FJ, 1986, BIOCHEMISTRY-US, V25, P2256, DOI 10.1021/bi00356a061; SCHENDEL FJ, 1989, BIOCHEMISTRY-US, V28, P2459, DOI 10.1021/bi00432a017; SCHNENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Smith M., 1961, BIOCH PREP, V8, P130; WOLFE MS, 1990, J ORG CHEM, V55, P4712, DOI 10.1021/jo00302a043; Woodward D O, 1978, Methods Enzymol, V51, P202; YOUNG M, 1984, BIOCHEMISTRY-US, V23, P3979, DOI 10.1021/bi00312a027	33	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9783	9787						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577812				2022-12-27	WOS:A1992HT96500054
J	MUNIER, H; BOUHSS, A; KRIN, E; DANCHIN, A; GILLES, AM; GLASER, P; BARZU, O				MUNIER, H; BOUHSS, A; KRIN, E; DANCHIN, A; GILLES, AM; GLASER, P; BARZU, O			THE ROLE OF HISTIDINE-63 IN THE CATALYTIC MECHANISM OF BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; ESCHERICHIA-COLI; STEREOCHEMISTRY; DNA	Of the 9 histidines located in the catalytic domain of Bordetella pertussis adenylate cyclase, three (His63, His106, and His298) were found to be conserved in the adenylate cyclase of Bacillus anthracis, another calmodulin-dependent enzyme. Substitution of His63 with Arg, Glu, Gln, or Val decreased the catalytic efficiency of adenylate cyclase between 2 and 3 orders of magnitude and altered the kinetic properties of the enzyme. These effects varied in relation to the nature of the substituting residue, pH, and direction of the reaction, i.e. ATP cyclization (forward) or ATP synthesis (reverse). Arg was the best substituent for His63 as catalyst in the forward reaction, with shift of the optimum pH to the alkaline side, whereas Glu was the best substituent for His63 in the reverse reaction, with shift of the optimum pH to the acidic side. Diethyl pyrocarbonate, which had a deleterious effect on wild-type adenylate cyclase was ineffective on His63 mutants. From these results we conclude that His63 is involved in the reaction mechanism of adenylate cyclase, which requires a general acid/base catalyst, most probably as an intermediate in a charge-relay system.	INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,28 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE REGULAT EXPRESS GENET,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782; Danchin, Antoine/0000-0002-6350-5001				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; ESCUYER V, 1988, GENE, V71, P293, DOI 10.1016/0378-1119(88)90045-5; GERLT JA, 1980, J BIOL CHEM, V255, P331; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; KLEANTHOUS C, 1985, BIOCHEMISTRY-US, V24, P5307, DOI 10.1021/bi00341a006; KOCH KW, 1990, J BIOL CHEM, V265, P9659; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; LADANT D, 1989, J BIOL CHEM, V264, P4015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miles E W, 1977, Methods Enzymol, V47, P431; Miller J.H., 1972, EXPT MOL GENETICS; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARFATI RS, 1990, J BIOL CHEM, V266, P18902; SENTER PD, 1988, J BIOL CHEM, V258, P6741; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WARSHEL A, 1989, BIOCHEM, V28, P3631; White A A, 1974, Methods Enzymol, V38, P41; YANG JK, 1983, J BIOL CHEM, V258, P3750; YOUNG RA, 1983, P NATL ACAD SCI USA, V80, P1199	28	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9816	9820						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577816				2022-12-27	WOS:A1992HT96500059
J	BENNETT, DL; BAILYES, EM; NIELSEN, E; GUEST, PC; RUTHERFORD, NG; ARDEN, SD; HUTTON, JC				BENNETT, DL; BAILYES, EM; NIELSEN, E; GUEST, PC; RUTHERFORD, NG; ARDEN, SD; HUTTON, JC			IDENTIFICATION OF THE TYPE-2 PROINSULIN PROCESSING ENDOPEPTIDASE AS PC2, A MEMBER OF THE EUKARYOTE SUBTILISIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY GRANULES; YEAST KEX2; CHROMOGRANIN-A; GENE ENCODES; CELL-LINE; PROTEINS; CLEAVAGE; SEQUENCE; SITE; ENDOPROTEASE	Enzymological studies have implicated two Ca2+-dependent endopeptidases in the conversion of proinsulin to insulin; a type 1 activity which cleaves on the C-terminal side of Arg31-Arg32 and a type 2 activity which cleaves C-terminally to Lys64-Arg65 in the proinsulin sequence. The possibility that these enzymes are related to the recently discovered family of mammalian subtilisin-like gene products (furin, PC2, and PC3) and the yeast propheromone-converting enzyme (KEX-2), was investigated. Degenerate oligonucleotide primers flanking the putative catalytic domain within this gene family were used in a polymerase chain reaction to amplify related sequences from rat insulinoma cDNA. One major product of 700 base pairs was obtained which was >99% identical to the corresponding rat PC2 sequence. This cDNA was subcloned into the bacterial expression vector pGEX-3X to generate a recombinant protein for antibody production. Western blot analysis showed the immunoreactivity was prominent in neuroendocrine tissues as a 65-kDa protein. It was concentrated in secretory granule-enriched fractions of insulinoma tissue, where it was present as a readily solubilized monomeric protein. Deglycosylation studies using endoglycosidase H and N-glycanase showed that the 65-kDa protein was comprised of approximately 9% carbohydrate, consistent with the presence of three consensus sequences for N-linked glycosylation in rat PC2. The immunoreactivity co-eluted with the type 2 proinsulin endopeptidase on gel filtration and ion-exchange chromatography and the antisera specifically immunoprecipitated type 2 activity from insulin granule extracts. N-terminal sequence analysis of the immunoreactive protein gave two sequences which corresponded to residues 109-112 and 112-119 of rat PC2. This indicated that posttranslational processing of PC2 itself occurs C-terminally to basic amino acids to produce the mature enzyme. It is concluded that PC2 is the type 2 endopeptidase involved in proinsulin conversion. Localization of PC2 immunoreactivity to other tissues of the diffuse neuroendocrine system suggests that the type 2 endopeptidase also functions in the processing of precursor forms of other prohormones and polypeptide neurotransmitters.	ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND; NOVO NORDISK,DK-28800 BAGSVAERD,DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge				guest, paul/0000-0002-5030-7137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1992, IN PRESS BIOCH J; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BENTLEY AK, 1986, CELL, V45, P345; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BULLER HA, 1989, BIOCHEM J, V263, P249; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAVIDSON HW, 1987, BIOCHEM J, V246, P279, DOI 10.1042/bj2460279; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; FALKENSAMMER G, 1985, NEUROSCIENCE, V14, P735, DOI 10.1016/0306-4522(85)90323-9; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; GUEST PC, 1991, ENDOCRINOLOGY, V129, P734, DOI 10.1210/endo-129-2-734; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG I, 1991, PEPTIDE BIOSYTHESIS, P00141; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V164, P780, DOI 10.1016/0006-291X(89)91527-1; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SLEEP D, 1990, BIO-TECHNOL, V8, P42, DOI 10.1038/nbt0190-42; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMITH D, 1988, GENE, V65, P31; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THORNE BA, 1989, J BIOL CHEM, V264, P3545; THORNE BA, 1991, J BIOL CHEM, V266, P13607; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZOLLINGER L, 1990, BIOCHEM CELL BIOL, V68, P635, DOI 10.1139/o90-090	52	155	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15229	15236						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634553				2022-12-27	WOS:A1992JF08800106
J	FRANKE, RR; SAKMAR, TP; GRAHAM, RM; KHORANA, HG				FRANKE, RR; SAKMAR, TP; GRAHAM, RM; KHORANA, HG			STRUCTURE AND FUNCTION IN RHODOPSIN - STUDIES OF THE INTERACTION BETWEEN THE RHODOPSIN CYTOPLASMIC DOMAIN AND TRANSDUCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BOVINE RHODOPSIN; MONOCLONAL-ANTIBODIES; VISUAL RHODOPSIN; MEMBRANE; GENE; ARRANGEMENT; SPECIFICITY; EXPRESSION; RECEPTORS	Structural requirements for the activation of transducin by rhodopsin have been studied by site-specific mutagenesis of bovine rhodopsin. A variety of single amino acid replacements and amino acid insertions and deletions of varying sizes were carried out in the two cytoplasmic loops CD (amino acids 134-151) and EF (amino acids 231-252). Except for deletion mutant DELTA-137-150, all the mutants bound 11-cis-retinal and displayed normal spectral characteristics. Deletion mutant A236-239 in loop EF caused a 50% reduction of transducin activation, whereas deletion mutant DELTA-244-249 and the larger deletions in loop EF abolished transducin activation. An 8-amino acid deletion in the cytoplasmic loop CD as well as a replacement of 13 amino acids with an unrelated sequence showed no transducin activation. Several single amino acid substitutions also caused significant reduction in transducin activation. The conserved charged pair Glu-134/Arg-135 in the cytoplasmic loop CD was required for transducin activation; its reversal or neutralization abolished transducin activation. Three amino acid replacements in loop EF (S240A, T243V, and K248L) resulted in significant reduction in transducin activation. We conclude that 1) both the cytoplasmic loops CD and EF are required for transducin activation, and 2) effective functional interaction between rhodopsin and transducin involves relatively large peptide sequences in the cytoplasmic loops.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NHLBI NIH HHS [HI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028289, R37GM028289] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P256; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HONG K, 1972, P NATL ACAD SCI USA, V69, P2617, DOI 10.1073/pnas.69.9.2617; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OVCHINNIKOV YA, 1983, BIOORG KHIM+, V9, P1331; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1424; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WEISS ER, 1988, J BIOL CHEM, V263, P6150; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	29	242	243	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14767	14774						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634520				2022-12-27	WOS:A1992JF08800042
J	ZOON, KC; MILLER, D; BEKISZ, J; NEDDEN, DZ; ENTERLINE, JC; NGUYEN, NY; HU, RQ				ZOON, KC; MILLER, D; BEKISZ, J; NEDDEN, DZ; ENTERLINE, JC; NGUYEN, NY; HU, RQ			PURIFICATION AND CHARACTERIZATION OF MULTIPLE COMPONENTS OF HUMAN LYMPHOBLASTOID INTERFERON-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE INTERFERON; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODY; CELLS; HOMOGENEITY; FAMILY; GENES	Twenty-two components of human interferon-alpha (IFN-alpha) derived from Sendai virus-induced Namalwa cells were purified by sequential immunoadsorbent affinity chromatography using four monoclonal antibody affinity columns followed by ultrafiltration and reversed-phase high-performance liquid chromatography. The specific activity ranged from 0.2 to 2.6 x 10(8) IU/mg protein on Madin-Darby bovine kidney cells, 0.3 to 4.6 x 10(8) IU/mg protein on human WISH cells, and 10(4) to 7 x 10(5) units/mg protein on mouse L929 cells. The apparent molecular weights of the components ranged from 17,500 to 23,300 using nonreducing sodium dodecyl polyacrylamide-gel electrophoresis and 17,500 to 27,600 using reducing sodium dodecyl polyacylamide-gel electrophoresis. The amino-terminal amino acid sequences were similar among the components as well as to those reported for the cloned human IFN-alpha genes (Pestka, S. (1986) Methods Enzymol. 119, 3-14). However, four components, f, i, l, and m, have amino-terminal amino acid sequences which appear to be unique when compared to those predicted from the cDNA clones. One component, pre-a, has a potential N-linked glycosylation site on the Asn of residues 2 through 4, Asn-Leu-Ser.			ZOON, KC (corresponding author), US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,RM 2D20,8800 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALLEN G, 1982, BIOCHEM J, V207, P397, DOI 10.1042/bj2070397; ALLEN G, 1980, NATURE, V287, P408, DOI 10.1038/287408a0; ARNHEITER H, 1981, NATURE, V294, P278, DOI 10.1038/294278a0; ARNHEITER H, 1983, P NATL ACAD SCI-BIOL, V80, P2539, DOI 10.1073/pnas.80.9.2539; BERG K, 1980, SCAND J IMMUNOL, V11, P489, DOI 10.1111/j.1365-3083.1980.tb00017.x; BOSE S, 1976, J BIOL CHEM, V251, P1659; FANTES KH, 1980, BIOCH CHARACTERIZATI, P343; FEINSTEIN SI, 1985, MOL CELL BIOL, V5, P510, DOI 10.1128/MCB.5.3.510; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; HAUPTMANN R, 1985, NUCLEIC ACIDS RES, V13, P4739, DOI 10.1093/nar/13.13.4739; HOBBS DS, 1982, J BIOL CHEM, V257, P4071; LABDON JE, 1984, ARCH BIOCHEM BIOPHYS, V232, P422, DOI 10.1016/0003-9861(84)90558-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY WP, 1981, P NATL ACAD SCI-BIOL, V78, P6186, DOI 10.1073/pnas.78.10.6186; LUND B, 1985, J INTERFERON RES, V5, P229, DOI 10.1089/jir.1985.5.229; MANTEI N, 1980, GENE, V10, P1, DOI 10.1016/0378-1119(80)90137-7; MEURS E, 1983, ANN INST PASTEUR VIR, V134, P361, DOI 10.1016/S0769-2617(83)80009-4; MILLER D M, 1990, Journal of Interferon Research, V10, pS6; PESTKA S, 1985, PHARMACOL THERAPEUT, V29, P299, DOI 10.1016/0163-7258(85)90006-3; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; RUBINSTEIN M, 1981, ARCH BIOCHEM BIOPHYS, V210, P307, DOI 10.1016/0003-9861(81)90194-6; RUBINSTEIN M, 1979, P NATL ACAD SCI USA, V76, P640, DOI 10.1073/pnas.76.2.640; SECHER DS, 1980, NATURE, V285, P446, DOI 10.1038/285446a0; WEBB DSA, 1989, CELL IMMUNOL, V124, P158, DOI 10.1016/0008-8749(89)90119-6; WECK PK, 1981, J GEN VIROL, V57, P233, DOI 10.1099/0022-1317-57-1-233; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; YONEHARA S, 1981, J BIOL CHEM, V256, P3770; Zoon K C, 1987, BIOL INTERFER SYST P, P567; ZOON KC, 1982, J INTERFERON RES, V2, P253, DOI 10.1089/jir.1982.2.253; ZOON KC, 1979, P NATL ACAD SCI USA, V76, P5601, DOI 10.1073/pnas.76.11.5601; ZOON KC, 1980, SCIENCE, V207, P527, DOI 10.1126/science.7352260; ZOON KC, 1978, J CLIN MICROBIOL, V7, P44; ZOON KC, 1986, BIOL INTERFERON SYST, P55; ZOON KC, 1985, BIOL INTERFERON SYST, P61; ZOON KC, 1984, HDB EXPT PHARM, V71, P79	37	50	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15210	15216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634550				2022-12-27	WOS:A1992JF08800103
J	SHIMBA, S; BUCKLEY, B; REDDY, R; KISS, T; FILIPOWICZ, W				SHIMBA, S; BUCKLEY, B; REDDY, R; KISS, T; FILIPOWICZ, W			CAP STRUCTURE OF U3 SMALL NUCLEOLAR RNA IN ANIMAL AND PLANT-CELLS IS DIFFERENT - GAMMA-MONOMETHYL PHOSPHATE CAP STRUCTURE IN PLANT RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR-RNA; EXTERNAL TRANSCRIBED SPACER; POLYMERASE-III; RIBOSOMAL-RNA; U6 SNRNA; SEQUENCE; DNA; U1; RIBONUCLEOPROTEIN; PROTOPLASTS	U3 small nucleolar RNA (snoRNA) is an abundant small RNA involved in the processing of pre-ribosomal RNA of eukaryotic cells. U3 snoRNA has been previously characterized from several sources, including human, rat, mouse, frog, fruit fly, dinoflagellates, slime mold, and yeast; in all these organisms, U3 snoRNA contains trimethylguanosine cap structure. In all instances where investigated, the trimethylguanosine-capped snRNAs including U3 snoRNA, are synthesized by RNA polymerase II. However, in higher plants, the U3 snoRNA is synthesized by RNA polymerase III and contains a cap structure different from trimethylguanosine (Kiss, T., and Solymosy, F. (1990) Nucleic Acids Res. 18, 1941-1949; Marshallsay, C., Kiss, T., and Filipowicz, W. (1990) Nucleic Acids Res. 18,3451-3458; Kiss, T., Marshallsay, C., and Filipowicz, W. (1991) Cell 65, 517-526). In this study, we present evidence that cowpea and, most likely, tomato plant U3 snoRNA contains a methyl-pppA cap structure. These data show that the same U3 snoRNA contains different cap structures in different species and suggest that the kind of cap structure that an uridylic acid-rich small nuclear RNA contains is dependent on the RNA polymerase responsible for its synthesis. In vitro synthesized plant U3 snoRNA, with pppA or pppG as its 5' end, was converted to methyl-pppA/G cap structure in vitro when incubated with extracts prepared from wheat germ or HeLa cells. These data show that the capping machinery is conserved in organisms as evolutionarily distant as plants and mammals. Nucleotides 1-45 of tomato U3 snoRNA, which are capable of forming a stem-loop structure, are sufficient to direct the methyl cap formation in vitro.	BAYLOR COLL MED, DEPT PHARMACOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Baylor College of Medicine; Baylor College of Medicine; Friedrich Miescher Institute for Biomedical Research				Kiss, Tamas/0000-0003-0293-3093	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BASERGA SJ, 1992, IN PRESS GENES DEV; BUCKLEY B, 1990, VIROLOGY, V177, P298, DOI 10.1016/0042-6822(90)90483-8; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HOAGLAND DR, 1950, 347 CAL AGR EXP STN; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KISS T, 1990, NUCLEIC ACIDS RES, V18, P1941, DOI 10.1093/nar/18.8.1941; KROL A, 1983, NUCLEIC ACIDS RES, V11, P8583, DOI 10.1093/nar/11.24.8583; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; MARSHALLSAY C, 1990, NUCLEIC ACIDS RES, V18, P3459, DOI 10.1093/nar/18.12.3459; MASER RL, 1989, P NATL ACAD SCI USA, V86, P6523, DOI 10.1073/pnas.86.17.6523; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; NAGATA T, 1971, PLANTA, V99, P12, DOI 10.1007/BF00392116; PORTER GL, 1988, NUCLEIC ACIDS RES, V16, P10131, DOI 10.1093/nar/16.21.10131; PRESTAYKO A W, 1970, Journal of Molecular Biology, V47, P505, DOI 10.1016/0022-2836(70)90318-9; Reddy R., 1991, Progress in Molecular and Subcellular Biology, V12, P1; REDDY R, 1983, J BIOL CHEM, V258, P1383; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V16, P10131; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; STROKE IL, 1989, J MOL BIOL, V210, P497, DOI 10.1016/0022-2836(89)90126-5; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VANKAN P, 1988, EMBO J, V7, P791, DOI 10.1002/j.1460-2075.1988.tb02877.x; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WIDHOLM JM, 1972, STAIN TECHNOL, V47, P189, DOI 10.3109/10520297209116483; WISE JA, 1981, J BIOL CHEM, V256, P956; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	46	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13772	13777						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618872				2022-12-27	WOS:A1992JB74600106
J	HAITOGLOU, CS; TSILIBARY, EC; BROWNLEE, M; CHARONIS, AS				HAITOGLOU, CS; TSILIBARY, EC; BROWNLEE, M; CHARONIS, AS			ALTERED CELLULAR INTERACTIONS BETWEEN ENDOTHELIAL-CELLS AND NONENZYMATICALLY GLUCOSYLATED LAMININ TYPE-IV COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NON-ENZYMATIC GLYCOSYLATION; HUMAN HEMOGLOBIN-A; DIABETIC COMPLICATIONS; BASEMENT-MEMBRANE; PROTEINS; INVITRO; COMPONENTS; MODULATION; EXPRESSION; ALBUMIN	Laminin and type IV collagen are two major basement membrane glycoproteins. In previous studies it has been shown that nonenzymatic glucosylation induces structural alterations of these macromolecules and also reduces their ability to self-associate. In the present study, endothelial cells were tested for their ability to adhere and spread on nonenzymatically glucosylated laminin and type IV collagen. Adhesion and spreading were reduced when glucosylated macromolecules were used as substrates. Glucosylation-induced changes in adhesion and spreading may be an important initial event signaling other phenotypic modifications of cells in the microvasculature and may be a crucial factor in order to understand the pathogenesis of diabetic microangiopathy at the molecular level.	UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 609 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455; ALBERT EINSTEIN COLL MED,DEPT INTERNAL MED,DIV ENDOCRINOL,BRONX,NY 10461	University of Minnesota System; University of Minnesota Twin Cities; Yeshiva University; Albert Einstein College of Medicine			Haitoglou, Costas/ABE-9369-2020; Haitoglou, Costas/ABE-2270-2020	Haitoglou, Costas/0000-0001-8372-2946; Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043569, R29DK039216] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43569, DK43754, DK39216] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHTON N, 1983, DIABETIC RETINOPATHY, P85; BAILEY AJ, 1976, BIOCHIM BIOPHYS ACTA, V434, P51, DOI 10.1016/0005-2795(76)90034-9; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; BETHEA CL, 1984, MOL CELL ENDOCRINOL, V37, P319, DOI 10.1016/0303-7207(84)90102-3; BISSEL MJ, 1982, J THEOR BIOL, V198, P31; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BUNN HF, 1979, J BIOL CHEM, V254, P3892; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; COHEN MP, 1981, BIOCHEM BIOPH RES CO, V100, P1549, DOI 10.1016/0006-291X(81)90695-1; CROWLEY ST, 1991, DIABETES, V40, P540, DOI 10.2337/diabetes.40.5.540; DAY JF, 1979, J BIOL CHEM, V254, P9394; GONEN B, 1981, DIABETES, V30, P875, DOI 10.2337/diabetes.30.10.875; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LORENZI M, 1985, DIABETES, V34, P621, DOI 10.2337/diabetes.34.7.621; MCDONALD MJ, 1979, J BIOL CHEM, V254, P702; MOGENSEN CE, 1988, DISEASES KIDNEY, P2395; MONNIER VM, 1979, J EXP MED, V150, P1098, DOI 10.1084/jem.150.5.1098; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; TRUEB B, 1980, J BIOL CHEM, V255, P6717; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; ZAR JH, 1974, BIOSTAT ANAL, P109	29	148	155	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12404	12407						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618745				2022-12-27	WOS:A1992HZ48300004
J	OLSON, ST; BJORK, I; SHEFFER, R; CRAIG, PA; SHORE, JD; CHOAY, J				OLSON, ST; BJORK, I; SHEFFER, R; CRAIG, PA; SHORE, JD; CHOAY, J			ROLE OF THE ANTITHROMBIN-BINDING PENTASACCHARIDE IN HEPARIN ACCELERATION OF ANTITHROMBIN-PROTEINASE REACTIONS - RESOLUTION OF THE ANTITHROMBIN CONFORMATIONAL CHANGE CONTRIBUTION TO HEPARIN RATE ENHANCEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; CATALYZED PROTEASE INACTIVATION; NUCLEIC ACID INTERACTIONS; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN-III; FACTOR-XA; ALPHA-THROMBIN; ACTIVE-SITE; H-1-NMR SPECTROSCOPY; BOVINE ANTITHROMBIN	The synthetic antithrombin-binding heparin pentasaccharide and a full-length heparin of approximately 26 saccharides containing this specific sequence have been compared with respect to their interactions with antithrombin and their ability to promote inhibition and substrate reactions of antithrombin with thrombin and factor Xa. The aim of these studies was to elucidate the pentasaccharide contribution to heparin's accelerating effect on antithrombin-proteinase reactions. Pentasaccharide and full-length heparins bound antithrombin with comparable high affinities (K(D) values of 36 +/- 11 and 10 +/- 3 nM, respectively, at I 0.15) and induced highly similar protein fluorescence, ultraviolet and circular dichroism changes in the inhibitor. Stopped-flow fluorescence kinetic studies of the heparin binding interactions at I 0.15 were consistent with a two-step binding process for both heparins, involving an initial weak encounter complex interaction formed with similar affinities (K(D) 20-30-mu-M), followed by an inhibitor conformational change with indistinguishable forward rate constants of 520-700 s-1 but dissimilar reverse rate constants of approximately 1 s-1 for the pentasaccharide and approximately 0.2 s-1 for the full-length heparin. Second order rate constants for antithrombin reactions with thrombin and factor Xa were maximally enhanced by the pentasaccharide only 1.7-fold for thrombin, but a substantial 270-fold for factor Xa, in an ionic strength-independent manner at saturating oligosaccharide. In contrast, the full-length heparin produced large ionic strength-dependent enhancements in second order rate constants for both antithrombin reactions of 4,300-fold for thrombin and 580-fold for factor Xa at I 0.15. These enhancements were resolvable into a nonionic component ascribable to the pentasaccharide and an ionic component responsible for the additional rate increase of the larger heparin. Stoichiometric titrations of thrombin and factor Xa inactivation by antithrombin, as well as sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the products of these reactions, indicated that pentasaccharide and full-length heparins similarly promoted the formation of proteolytically modified inhibitor during the inactivation of factor Xa by antithrombin, whereas only the full-length heparin was effective in promoting this substrate reaction of antithrombin during the reaction with thrombin. These results indicate that 1) the pentasaccharide is responsible for nearly all (93%) of the binding energy of the full-length heparin interaction with antithrombin as well as for inducing the inhibitor conformational change; 2) the pentasaccharide enhancement of the rate of thrombin and factor Xa inactivation represents the contribution of the antithrombin conformational change to the rate enhancement of the full-length heparin with any additional rate enhancement of the larger heparin resulting from the polysaccharide bridging antithrombin and the proteinase bound to the same chain; 3) the antithrombin conformational change is mainly responsible for heparin promoting both inhibitor and substrate reactions of antithrombin with factor Xa, whereas this conformational change contributes minimally to heparin promoting substrate and inhibitor reactions of antithrombin with thrombin. The sum of these observations indicates that antithrombin conformational change and heparin-bridging mechanisms make additive contributions to heparin promotion of inhibition and substrate reactions of antithrombin with proteinases, the relative contribution of these two mechanisms being a function of the target proteinase.	SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN; SANOFI RES, CTR CHOAY, F-94256 GENTILLY, FRANCE	Swedish University of Agricultural Sciences; Sanofi-Aventis	OLSON, ST (corresponding author), HENRY FORD HOSP, DIV BIOCHEM RES, EDUC & RES BLDG, RM 3126, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.			Craig, Paul/0000-0002-2085-7816	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOAY J, 1981, ANN NY ACAD SCI, V370, P640; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1989, CARBOHYD RES, V185, P69, DOI 10.1016/0008-6215(89)84022-4; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JORDAN RE, 1980, J BIOL CHEM, V255, P81; JORDAN RE, 1980, J BIOL CHEM, V255, P73; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LOHMAN TM, 1978, BIOPHYS CHEM, V8, P281, DOI 10.1016/0301-4622(78)80011-8; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1989, THROMB HAEMOSTASIS, V62, P326; OLSON ST, 1992, THROMBIN STRUCTURE F; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETERSON CB, 1985, J BIOL CHEM, V260, P610; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; RAGAZZI M, 1990, CARBOHYD RES, V195, P169, DOI 10.1016/0008-6215(90)84165-Q; RECORD MT, 1978, BIOPOLYMERS, V17, P159, DOI 10.1002/bip.1978.360170112; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2	51	464	475	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12528	12538						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618758				2022-12-27	WOS:A1992HZ48300026
J	SZYF, M; ROULEAU, J; THEBERGE, J; BOZOVIC, V				SZYF, M; ROULEAU, J; THEBERGE, J; BOZOVIC, V			INDUCTION OF MYOGENIC DIFFERENTIATION BY AN EXPRESSION VECTOR ENCODING THE DNA METHYLTRANSFERASE CDNA SEQUENCE IN THE ANTISENSE ORIENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; GENE-EXPRESSION; MOUSE CELLS; METHYLATION; INHIBITION; MYOBLASTS; 5-AZACYTIDINE; ESTABLISHMENT; FIBROBLASTS; CONVERSION	To test the hypothesis that DNA methylation controls the state of differentiation of a mammalian cell, we transfected the stable mesenchymal line 10T1/2 with an expression vector encoding sequences from the DNA methyltransferase (DNA MeTase) cDNA in the antisense orientation. 10T1/2 cells transfected with the antisense construct (pZ-alpha-M), but not with the vector alone, exhibit morphological changes, convert into multinucleated tubular cells, and express the skeletal myosin heavy chain protein. The conversion to myogenic phenotype is a late event and is dependent on the number of replication events that the cell has undergone, suggesting that induction of myogenesis is a multistep process. Demethylation of sequences that are not involved in the myogenic process is detected at early passages, while demethylation and expression of the MyoD gene is a late event. This report establishes for the first time that demethylation is a very early event in commitment to myogenic differentiation, while demethylation and expression of MyoD is a late event. We suggest that other genes serve as the initial targets for demethylation and commitment of mesenchymal cells to myogenesis. The cell lines described in this report can serve as an important system for identifying these genes.			SZYF, M (corresponding author), MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,QUEBEC,CANADA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BENEDICT WF, 1977, CANCER RES, V37, P2202; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ENVER T, 1987, GENE DEV, V48, P698; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KENIGSBERG RL, 1990, J HISTOCHEM CYTOCHEM, V38, P191, DOI 10.1177/38.2.2299180; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; ONEILL MC, 1974, DEV BIOL, V37, P117, DOI 10.1016/0012-1606(74)90173-0; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; STEIN R, 1982, P NATL ACAD SCI-BIOL, V79, P61, DOI 10.1073/pnas.79.1.61; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YISRAELI J, 1984, DNA METHYLATION BIOC, P353; ZINGG JM, NUCLEIC ACIDS RES, V19, P6433	38	56	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12831	12836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618783				2022-12-27	WOS:A1992HZ48300068
J	VASSEUR, C; BLOUQUIT, Y; KISTER, J; PROME, D; KAVANAUGH, JS; ROGERS, PH; GUILLEMIN, C; ARNONE, A; GALACTEROS, F; POYART, C; ROSA, J; WAJCMAN, H				VASSEUR, C; BLOUQUIT, Y; KISTER, J; PROME, D; KAVANAUGH, JS; ROGERS, PH; GUILLEMIN, C; ARNONE, A; GALACTEROS, F; POYART, C; ROSA, J; WAJCMAN, H			HEMOGLOBIN THIONVILLE - AN ALPHA-CHAIN VARIANT WITH A SUBSTITUTION OF A GLUTAMATE FOR VALINE AT NA-1 AND HAVING AN ACETYLATED METHIONINE NH2 TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-LINKED BINDING; BETA-CHAIN; X-RAY; FUNCTIONAL-PROPERTIES; HUMAN DEOXYHEMOGLOBIN; AMINO GROUPS; PROTEINS; IDENTIFICATION; SITE; RESOLUTION	In hemoglobin (Hb) Thionville, the substitution of a glutamic acid for the alpha-chain NH2-terminal valine inhibits the cleavage of the initiator methionine which is then acetylated. The elongation of the alpha-chain NH2 terminus modifies the three-dimensional structure of hemoglobin at a region that is known to have an important role in the allosteric regulation of oxygen binding. Relative to Hb A, Hb Thionville has a lower affinity for oxygen, and the heterotropic allosteric effects of protons, chloride, and bezafibrate are reduced. In contrast, the response to 2,3-diphosphoglycerate is normal. Analysis of oxygen equilibrium data within the framework of the two-state allosteric model indicates that the structure of deoxy Hb Thionville is stabilized relative to that of deoxy Hb A. The x-ray crystal structure of deoxy Hb Thionville shows that the glutamate side chain extends away from the alpha-1-alpha-2 interface, whereas the methionine side chain (which has two conformations) extends into the alpha-1-alpha-2 interface, physically displacing chloride and bezafibrate. The increased stability of deoxy Hb Thionville is due to new intrasubunit and intersubunit contacts made by the methionine. These interactions replace the indirect contacts, made through bound chloride ions, that Valla 1-alpha normally contributes to the alpha-1-alpha-2 interface.	HOP BICETRE,INSERM,U299,F-94275 LE KREMLIN BICETR,FRANCE; CTR REG TRANSFUS SANGUINE,NANCY,FRANCE; CHU HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; CNRS,CTR RECH BIOCHIM & GENET CELLULAIRE,F-31055 TOULOUSE,FRANCE; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); University of Iowa			Vasseur, Corinne/AAV-1384-2021	Vasseur, Corinne/0000-0002-4422-7069	NHLBI NIH HHS [HL-40453] Funding Source: Medline; NIGMS NIH HHS [GM-40852] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040852] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTER BP, 1980, BRIT J HAEMATOL, V44, P527, DOI 10.1111/j.1365-2141.1980.tb08706.x; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; ANTONINI E, 1961, J BIOL CHEM, V236, pPC60; ARNONE A, 1977, MOL INTERACTION HEMO, P15; BARWICK RC, 1985, P NATL ACAD SCI USA, V82, P4602, DOI 10.1073/pnas.82.14.4602; BAUDIN V, 1987, CLIN CHIM ACTA, V162, P75, DOI 10.1016/0009-8981(87)90235-X; BENESCH RE, 1973, ANAL BIOCHEM, V55, P245, DOI 10.1016/0003-2697(73)90309-6; Bevington P. R, 1969, DATA REDUCTION ERROR; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BLOUQUIT Y, 1984, FEBS LETT, V178, P315, DOI 10.1016/0014-5793(84)80624-9; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; CAMBILLAU C, 1989, SILICON GRAPHICS GEO, P61; CHIANCONE E, 1975, EUR J BIOCHEM, V55, P385, DOI 10.1111/j.1432-1033.1975.tb02173.x; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; FANTL WJ, 1987, J BIOL CHEM, V262, P12700; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAMEL K, 1985, BIOCHIM BIOPHYS ACTA, V831, P257, DOI 10.1016/0167-4838(85)90043-3; KILMARTIN JV, 1975, J MOL BIOL, V93, P203, DOI 10.1016/0022-2836(75)90128-X; KILMARTIN JV, 1973, J BIOL CHEM, V248, P7039; KILMARTIN JV, 1977, BIOCHEMISTRY-US, V16, P5393, DOI 10.1021/bi00643a035; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; LEE FJS, 1990, J BIOL CHEM, V265, P3603; MANNING JM, 1978, BIOCH CLIN ASPECTS H, P687; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOOPENN WF, 1977, BIOCHEMISTRY-US, V16, P4872, DOI 10.1021/bi00641a019; NIGEN AM, 1976, J BIOL CHEM, V251, P7638; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POYART C, 1980, J BIOL CHEM, V255, P9465; RADOLA BJ, 1973, ANN NY ACAD SCI, V209, P127, DOI 10.1111/j.1749-6632.1973.tb47523.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SCHNEIDER RG, 1986, CRC HDB SERIES, V4, P125; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P53	44	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12682	12691						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618774				2022-12-27	WOS:A1992HZ48300048
J	GERBER, LD; KODUKULA, K; UDENFRIEND, S				GERBER, LD; KODUKULA, K; UDENFRIEND, S			PHOSPHATIDYLINOSITOL GLYCAN (PI-G) ANCHORED MEMBRANE-PROTEINS - AMINO-ACID-REQUIREMENTS ADJACENT TO THE SITE OF CLEAVAGE AND PI-G ATTACHMENT IN THE COOH-TERMINAL SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ALKALINE-PHOSPHATASE; CELL-FREE SYSTEM; TRYPANOSOMA-BRUCEI; CARBOXYL TERMINUS; CARCINOEMBRYONIC ANTIGEN; SURFACE GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; THY-1 GENE; IDENTIFICATION	Secreted proteins are processed from a nascent form that contains an NH2-terminal signal peptide. During processing, the latter is cleaved by a specific NH2-terminal signal peptidase. The nascent form of phosphatidylinositol glycan (PI-G) tailed proteins contain both an NH2- and a COOH-terminal signal peptide. The two signal peptides have much in common, such as size and hydrophobicity. The COOH-terminal peptide is also cleaved during processing. We propose that the amino acid in a nascent protein that ultimately combines with the PI-G moiety be designated the omega-site. Amino acids adjacent and COOH-terminal to the omega-site would then be omega + 1, omega + 2, etc. In previous studies, we showed that allowable substitutions at the omega-site of an engineered form of placental alkaline phosphatase (miniPLAP) are limited to 6 small amino acids. In the present study, mutations were made at the omega + 1 and omega + 2 sites. At the omega + 1 site, processing to varying degrees was observed with 8 of the 9 amino acids substituted for alanine, the normal constituent. Only the proline mutant showed no processing. By contrast, the only substituents permitted at the omega + 2 site were glycine and alanine, with only trace activity observed with serine and cysteine. Thus, just as there is a -1, -3 rule for predicting cleavage by NH2-terminal signal peptidase, there appears to be a comparable omega, omega + 2 rule for predicting cleavage/PI-G addition by COOH-terminal signal transamidase.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT NEUROSCI,NUTLEY,NJ 07110	Roche Holding								ADACHI H, 1990, J BIOL CHEM, V265, P15341; AMTHAUER R, 1992, IN PRESS P NATL ACAD; BAILEY CA, 1989, P NATL ACAD SCI USA, V86, P22, DOI 10.1073/pnas.86.1.22; BERGER J, 1988, J BIOL CHEM, V263, P10016; BLOBEL G, 1983, METHOD ENZYMOL, V96, P663; BOOTHROYD JC, 1981, NUCLEIC ACIDS RES, V9, P4735, DOI 10.1093/nar/9.18.4735; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GARATTINI E, 1985, P NATL ACAD SCI USA, V82, P6080, DOI 10.1073/pnas.82.18.6080; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1992, IN PRESS P NATL ACAD; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAJUMDER HK, 1981, NUCLEIC ACIDS RES, V9, P4745, DOI 10.1093/nar/9.18.4745; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P7939, DOI 10.1073/pnas.87.20.7939; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1991, J BIOL CHEM, V266, P1250; MORAN P, 1991, J CELL BIOL, V115, P329, DOI 10.1083/jcb.115.2.329; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; OGATA S, 1990, BIOCHEMISTRY-US, V29, P7923, DOI 10.1021/bi00486a021; OGTA S, 1988, J BIOL CHEM, V263, P10489; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SEKI T, 1985, NATURE, V313, P485, DOI 10.1038/313485a0; SEKI T, 1985, P NATL ACAD SCI USA, V82, P6657, DOI 10.1073/pnas.82.19.6657; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; STRICKLER JE, 1987, BIOCHEMISTRY-US, V26, P796, DOI 10.1021/bi00377a021; TATE SS, 1981, MOL CELL BIOCHEM, V39, P357, DOI 10.1007/BF00232585; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543	57	195	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12168	12173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601882				2022-12-27	WOS:A1992HY94700077
J	MELHUS, H; LAURENT, B; RASK, L; PETERSON, PA				MELHUS, H; LAURENT, B; RASK, L; PETERSON, PA			LIGAND-DEPENDENT SECRETION OF RAT RETINOL-BINDING PROTEIN EXPRESSED IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; DEFICIENT RATS; METABOLISM; PREALBUMIN; LIVER; GLYCOPROTEINS; LOCALIZATION	A minigene encoding rat retinol-binding protein (RBP) was transfected into HeLa cells, which do not express endogenous RBP, transthyretin, or cellular retinol-binding protein. The HeLa cells manufactured and secreted the transfected gene product, demonstrating that RBP-transthyretin assembly is not a requirement for the secretion of RBP. When HeLa cells were grown under vitamin A-deficient conditions, RBP accumulated in the endoplasmic reticulum. Both serum and retinol stimulated secretion of RBP in a concentration-dependent manner. The retinol-regulated secretion occurred also after protein synthesis had been blocked by cycloheximide. Addition of holo-RBP or retinal, but not retinoic acid, stimulated secretion of RBP. Thus, an in vitro model system that resembles the rat hepatocyte in vivo with regard to the known regulation of RBP secretion has been established in a human cell line of extrahepatic origin. It can be concluded that cellular retinol-binding protein is not required for the transfer of retinol to RBP and that the mechanism whereby retinol controls the intracellular transport of RBP is neither specific for tissues synthesizing RBP nor species-specific. To investigate the structural properties responsible for the endoplasmic reticulum retention of RBP in the absence of its ligand, a cDNA encoding chicken purpurin, a protein that is 50% identical to RBP and that binds retinol, was expressed in HeLa cells. In contrast to RBP, purpurin was not retained in vitamin A-deficient HeLa cells.	SWEDISH UNIV AGR SCI, S-75007 UPPSALA, SWEDEN; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Swedish University of Agricultural Sciences; Columbia University; Scripps Research Institute	MELHUS, H (corresponding author), UNIV UPPSALA, DEPT CELL RES, S-75105 UPPSALA, SWEDEN.		Rask, Lars B/L-4177-2013		NIDDK NIH HHS [DK 35915] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERMAN P, 1987, CELL, V51, P135, DOI 10.1016/0092-8674(87)90018-3; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GOODMAN DS, 1972, J LIPID RES, V13, P338; Goodman DS, 1984, RETINOIDS, V2, P42; HELLER J, 1973, J BIOL CHEM, V248, P6308; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAMPE O, 1983, J BIOL CHEM, V258, P594; KINGSTON RE, 1987, CURRENT PROTOCOLS MO, V1; LAURENT BC, 1985, J BIOL CHEM, V260, P1476; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MARINARI L, 1987, J LIPID RES, V28, P941; MUTO Y, 1972, J BIOL CHEM, V247, P2542; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PETERSON PA, 1973, J BIOL CHEM, V248, P4009; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; RASK L, 1983, EXP CELL RES, V143, P91, DOI 10.1016/0014-4827(83)90112-X; RASK L, 1971, J BIOL CHEM, V246, P6638; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAARI JC, 1978, INVEST OPHTH VIS SCI, V17, P988; SEGE K, 1978, NATURE, V271, P167, DOI 10.1038/271167a0; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; SOPRANO DR, 1982, J BIOL CHEM, V257, P7693; SUNDELIN J, 1985, J BIOL CHEM, V260, P6481; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VAHLQUIST A, 1971, EUR J BIOCHEM, V20, P160, DOI 10.1111/j.1432-1033.1971.tb01374.x	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12036	12041						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601873				2022-12-27	WOS:A1992HY94700060
J	MUKHERJI, S; BHADURI, A				MUKHERJI, S; BHADURI, A			AN ESSENTIAL HISTIDINE RESIDUE FOR THE ACTIVITY OF UDPGLUCOSE 4-EPIMERASE FROM KLUYVEROMYCES-FRAGILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE; ENZYME	UDPglucose 4-epimerase from Kluyveromyces fragilis was completely inactivated by diethylpyrocarbonate following pseudo-first order reaction kinetics. The pH profile of diethylpyrocarbonate inhibition and reversal of inhibition by hydroxylamine suggested specific modification of histidyl residues. Statistical analysis of the residual enzyme activity and the extent of modification indicated modification of 1 essential histidine residue to be responsible for loss in catalytic activity of yeast epimerase. No major structural change in the quarternary structure was observed in the modified enzyme as shown by the identical elution pattern on a calibrated Sephacryl 200 column and association of coenzyme NAD to the apoenzyme. Failure of the substrates to afford any protection against diethylpyrocarbonate inactivation indicated the absence of the essential histidyl residue at the substrate binding region of the active site. Unlike the case of native enzyme, sodium borohydride failed to reduce the pyridine moiety of the coenzyme in the diethylpyrocarbonate-modified enzyme. This indicated the presence of the essential histidyl residue in close proximity to the coenzyme binding region of the active site. The abolition of energy transfer phenomenon between the tryptophan and coenzyme fluorophore on complete inactivation by diethylpyrocarbonate without any loss of protein or coenzyme fluorescence are also added evidences in this direction.			MUKHERJI, S (corresponding author), INDIAN INST CHEM BIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA.							ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; BANASZAK LJ, 1975, ENZYMES, V11, P369; BERTLAND LH, 1971, BIOCHEMISTRY-US, V10, P3145, DOI 10.1021/bi00792a025; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GABRIEL O, 1975, SUBUNIT ENZYMES BIOC, P85; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Holbrook JJ., 1975, ENZYMES, P191; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; LEONARD NJ, 1971, BIOCHEMISTRY-US, V10, P3335, DOI 10.1021/bi00794a003; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MEANS GE, 1971, CHEM MODIFICATION PR, P81; Miles E W, 1977, Methods Enzymol, V47, P431; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; NELSESTU.GL, 1971, J BIOL CHEM, V246, P7533; PAL DK, 1971, BIOCHIM BIOPHYS ACTA, V250, P588, DOI 10.1016/0005-2744(71)90259-2; RAY M, 1975, J BIOL CHEM, V250, P4373; RAY M, 1980, J BIOL CHEM, V255, P777; RAY M, 1980, J BIOL CHEM, V255, P782; RAY M, 1976, EUR J BIOCHEM, V70, P319, DOI 10.1111/j.1432-1033.1976.tb11020.x; SAMANTA AK, 1983, J BIOL CHEM, V258, P1118; SAMANTA AK, 1982, BIOCHIM BIOPHYS ACTA, V707, P129, DOI 10.1016/0167-4838(82)90405-8; TSOU C, 1962, SCI SINICA, V11, P1535; WONG SS, 1977, BIOCHEMISTRY-US, V16, P298, DOI 10.1021/bi00621a022; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5337, DOI 10.1021/bi00591a012; WONG YHH, 1979, BIOCHEMISTRY-US, V18, P5332, DOI 10.1021/bi00591a011	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11709	11713						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601847				2022-12-27	WOS:A1992HY94700013
J	TIEMEYER, M; BRANDLEY, BK; ISHIHARA, M; SWIEDLER, SJ; GREENE, J; HOYLE, GW; HILL, RL				TIEMEYER, M; BRANDLEY, BK; ISHIHARA, M; SWIEDLER, SJ; GREENE, J; HOYLE, GW; HILL, RL			THE BINDING-SPECIFICITY OF NORMAL AND VARIANT RAT KUPFFER CELL (LECTIN) RECEPTORS EXPRESSED IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; FUCOSE-CONTAINING GLYCOPROTEINS; MOLECULAR-CLONING; HEPATIC LECTINS; LIVER; ADHESION; LOCALIZATION; PROTEINS; CDNA	A receptor uniquely found on the surface of rat Kupffer cells was shown previously to bind oligosaccharides terminating in galactose, N-acetylgalactosamine, and fucose. To analyze further the binding specificity of the receptor, receptor-mediated adhesion of transfected COS cells to immobilized glycolipids of known structure was measured. The glycolipid Gb4Cer (GalNAc-beta-1-3Gal-alpha-1-4Gal-beta-1-4Glc-beta-1Cer) was the best ligand. Gb5Cer (GalNAc-alpha-1-3GalNAc-beta-1-3Gal-alpha-1-4Gal-beta-1-4Glc-beta -1Cer) and LacCer (Gal-beta-1-4Glc-beta-1Cer) bound more weakly (five times less than Gb4Cer) and Gb3Cer (Gal-alpha-1-4Gal-beta-1-4Glc-beta-1Cer), and g3Cer(Gal-NAc-beta-1-4Gal-beta-1-4Glc-beta-1Cer) bound even more weakly (60 times less than Gb4Cer). Gangliosides did not support adhesion of transfected cells. The adhesion of COS cells transfected with plasmids encoding variants of the receptor was also examined. In each variant, either tryptophan 498 or 523, which are conserved in most C-type lectins, was replaced by one of several amino acids. Variants that retained binding activity had the same specificity as the normal receptor. Differences between variants were noted, however, in maximal levels of adhesion and these differences correlated with altered expression of the receptor variants in COS cells.	GLYCOMED INC, ALAMEDA, CA 94501 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025766, R37GM025766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7433; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; KUNKEL TA, 1990, CURRENT PROTOCOLS MO, P811; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7426; MOHR M, 1987, BIOL CELL, V60, P217, DOI 10.1111/j.1768-322X.1987.tb00558.x; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; ROOS PH, 1985, BIOCHIM BIOPHYS ACTA, V847, P115, DOI 10.1016/0167-4889(85)90161-2; SCHNAAR RL, 1989, METHOD ENZYMOL, V179, P542; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Summers MD, 1987, MANUAL METHODS BACUL; SWANKHILL P, 1987, ANAL BIOCHEM, V163, P27, DOI 10.1016/0003-2697(87)90088-1; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WEIGEL PH, 1979, J BIOL CHEM, V254, P830; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241	22	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12252	12257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601891				2022-12-27	WOS:A1992HY94700090
J	YAMAZAKI, H; NOMOTO, S; MISHIMA, Y; KOMINAMI, R				YAMAZAKI, H; NOMOTO, S; MISHIMA, Y; KOMINAMI, R			A 35-KDA PROTEIN-BINDING TO A CYTOSINE-RICH STRAND OF HYPERVARIABLE MINISATELLITE DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS RECOMBINATION; VARIABLE NUMBER; POLYMERASE-II; TELOMERIC DNA; MUTATION; SEQUENCE; TRANSCRIPTION; MODEL; LOCI; POLYMORPHISM	A minisatellite-binding protein, Msbp-4, with a molecular mass of 35 kDa has been purified from mouse tumor cells that binds to hypervariable Pc-1 and Pc-2 minisatellites. The binding is much more efficient than that to genetically stable minisatellite homologues. As assayed by Southwestern analysis, Msbp-4 favors multiple copies of the Pc-2 repeat sequence GGCAGGA and requires the cytosine-rich single strand for the binding. The activity is also present in extracts from mouse testis but not from liver. The phosphatase treatment revealed that Msbp-4 is phosphorylated and may have a regulatory function, because dephosphorylation affects the activity and specificity of the binding. Sequence preference is demonstrated by a competition experiment using single-base substitution mutants. Thus, the binding properties of Msbp-4 observed here lead to an implication that the protein-DNA complexes result in formation of a single-stranded DNA loop of the G-rich strand in the minisatellite which may enhance the ability of the minisatellite to undergo recombination.			YAMAZAKI, H (corresponding author), NIIGATA UNIV,SCH MED,DEPT BIOCHEM,ASAHIMACHI DORI 1-757,NIIGATA 951,JAPAN.							ALI S, 1988, NUCLEIC ACIDS RES, V16, P8487, DOI 10.1093/nar/16.17.8487; ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; COLLICK A, 1990, NUCLEIC ACIDS RES, V18, P625, DOI 10.1093/nar/18.3.625; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDELMANN W, 1989, CELL, V57, P937, DOI 10.1016/0092-8674(89)90332-2; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P17136; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; HAMATAKE RK, 1989, J BIOL CHEM, V264, P13336; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOMINAMI R, 1988, NUCLEIC ACIDS RES, V16, P1197, DOI 10.1093/nar/16.3.1197; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDWITH BJ, 1990, CANCER RES, V50, P5245; LYAMICHEV VI, 1989, NATURE, V339, P634, DOI 10.1038/339634a0; Maniatis T., 1982, MOL CLONING; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MITANI K, 1990, J BIOL CHEM, V265, P15203; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; POTTER M, 1985, CURR TOP MICROBIOL I, V22, P1; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SIMMLER MC, 1987, EMBO J, V6, P963, DOI 10.1002/j.1460-2075.1987.tb04846.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUZUKI S, 1991, JPN J CANCER RES, V82, P1061, DOI 10.1111/j.1349-7006.1991.tb01757.x; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WAHLS WP, 1991, NUCLEIC ACIDS RES, V19, P3269, DOI 10.1093/nar/19.12.3269; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WHITE JH, 1988, MOL CELL BIOL, V8, P153; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	45	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					12311	12316						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601895				2022-12-27	WOS:A1992HY94700098
J	WADAKIYAMA, Y; PETERS, B; NOGUCHI, CT				WADAKIYAMA, Y; PETERS, B; NOGUCHI, CT			THE EPSILON-GLOBIN GENE SILENCER - CHARACTERIZATION BY INVITRO TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRACTIONATED NUCLEAR EXTRACT; DOMINANT CONTROL REGION; TRANSGENIC MICE; ACCURATE TRANSCRIPTION; NEGATIVE REGULATION; DNA-REPLICATION; GAMMA-GLOBIN; ENHANCER; PROTEIN; EXPRESSION	K562 human erythroleukemia cells constitutively express epsilon- and gamma- but not beta-globin genes. We have previously shown that the differential expression of globin genes observed in intact K562 cells could be simulated in vitro as K562 nuclear extract (NE) actively transcribes the epsilon-globin (with 2 kilobases of 5'-flanking sequence) and gamma-globin gene DNA templates but not beta-globin gene templates. We have now used the K562 in vitro transcription system to examine a silencer transcriptional control element which has been reported to be localized between -177 and -392 base pairs (bp) 5' of the canonical cap site for the epsilon-globin gene. We find that K562 NE has markedly reduced synthesis of RNA in vitro from epsilon-globin gene DNA deletion templates which contain the silencer sequence, or part thereof, but not the adjacent 5'-positive regulatory region (-453 to -535 bp). Furthermore, those transcripts generated in vitro from DNA templates extending to -453 bp or less of the epsilon-globin gene were not correctly initiated at the canonical cap site. Separating the K562 NE by ion exchange chromatography, we isolated a fraction (F175) transcriptionally active for all tested globin genes including the epsilon-globin gene containing the silencer sequence and a fraction (F50) which contains the trans-acting factors associated with the silencer activity. F50 showed a strong dose-dependent inhibitory effect on correctly initiated epsilon-globin gene transcription directed by either unfractionated K562 NE or F175. This suppression by F50 was not observed on transcriptional activity of the permissive adenovirus 2 major late promoter. In electrophoretic mobility shift assays using the epsilon-globin gene silencer region as probe, F50 and F175 exhibited different DNA binding protein patterns; a specific protein band in F50 appears to be associated with the silencer activity. These studies suggest that this protein may be specifically responsible for the activity of the silencer element of the epsilon-globin gene. The expression and silencing of the epsilon-globin gene during development may be modulated by the interactions of this protein with the cis-acting DNA silencer.	NIDDK,CHEM BIOL LAB,BLDG 10,RM 9N307,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BUSHEL P, 1990, MOL CELL BIOL, V10, P1199, DOI 10.1128/MCB.10.3.1199; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CAO SX, 1989, HEMOGLOBIN SWITCHI A, P301; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GUTMAN PD, 1992, GENE, V110, P197, DOI 10.1016/0378-1119(92)90648-9; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAGUIRE KA, 1987, J BIOL CHEM, V262, P3932; Maxam A M, 1980, Methods Enzymol, V65, P499; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; PETERS B, 1991, BLOOD S, V78, pA254; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1992, BLOOD, V79, P861; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WADA Y, 1988, J BIOL CHEM, V263, P12142; WADA Y, 1989, HEMOGLOBIN SWITCHI A, P301; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YU CY, 1991, J BIOL CHEM, V266, P8907	45	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11532	11538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597481				2022-12-27	WOS:A1992HX16900091
J	ANAND, B; CHOU, IN				ANAND, B; CHOU, IN			MICROTUBULES AND MICROTUBULE-ASSOCIATED PROTEINS IN RESTING AND MITOGENICALLY ACTIVATED NORMAL HUMAN PERIPHERAL-BLOOD T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULIN MESSENGER-RNAS; LYMPHOCYTES-T; SIGNAL TRANSDUCTION; CYTOSKELETAL MATRIX; GROWTH-FACTOR; DNA-SYNTHESIS; ACTIN; IDENTIFICATION; KINASE; TAXOL	The binding of an appropriate ligand to its specific receptor on the membrane of T cells triggers a cascade of events involved in T cell activation. An important yet unanswered question is how the mitogenic signals are transmitted through the cytoplasm and into the nucleus. The present study was carried out to determine changes in the microtubule (MT) system, following T cell activation. Fluorescence microscopy was employed to examine the organization of the microtubule network in human peripheral blood T cells in response to four different mitogens (phytohemagglutinin, concanavalin A, anti-CD3, and phorbol 12-myristate 13-acetate). The microtubules increase in length, number, and complexity of distribution 20 h after mitogenic stimulation. Using an in situ direct analysis protocol consisting of selective extraction of cells with detergent and Ca2+, 11 protein species, which fulfill the operational definition of microtubule-associated proteins (MAPs), were identified in resting human T cells. Alterations in the expression of these protein species were studied following mitogenic stimulation. These alterations in MAPs expression were also found in purified blast cell fractions indicating that they were specific changes occurring in activated T cell populations. These observations suggest a role for MT and MAPs in the cascade of human T cell activation.	BOSTON UNIV, SCH MED, DEPT MICROBIOL, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA	Boston University; Boston University								ALBERTS B, 1983, MOL BIOL CELL, P549; ALCOVER A, 1987, IMMUNOL REV, V95, P5, DOI 10.1111/j.1600-065X.1987.tb00498.x; BASERGA R, 1984, EXP CELL RES, V151, P1, DOI 10.1016/0014-4827(84)90349-5; BENZEEV A, 1979, CELL, V17, P319, DOI 10.1016/0092-8674(79)90157-0; BRAUN J, 1982, J IMMUNOL, V128, P1198; CARNEY DH, 1986, ANN NY ACAD SCI, V466, P919, DOI 10.1111/j.1749-6632.1986.tb38477.x; CHOU IN, 1984, P NATL ACAD SCI-BIOL, V81, P2401, DOI 10.1073/pnas.81.8.2401; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; CUTHBERT JA, 1983, J CELL PHYSIOL, V116, P127, DOI 10.1002/jcp.1041160202; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DUERR A, 1981, CELL, V24, P203, DOI 10.1016/0092-8674(81)90516-X; FARRAR WL, 1986, IMMUNOL REV, V92, P49, DOI 10.1111/j.1600-065X.1986.tb01493.x; FLANAGAN J, 1978, NATURE, V273, P278, DOI 10.1038/273278a0; GELFAND EW, 1987, IMMUNOL REV, V95, P59, DOI 10.1111/j.1600-065X.1987.tb00500.x; HALL DJ, 1984, J CELL BIOL, V99, P1814, DOI 10.1083/jcb.99.5.1814; HALL DJ, 1981, J CELL PHYSIOL, V108, P25, DOI 10.1002/jcp.1041080105; ISAKOV N, 1987, IMMUNOL REV, V95, P89, DOI 10.1111/j.1600-065X.1987.tb00501.x; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KECSKEMETHY N, 1982, EUR J BIOCHEM, V126, P573, DOI 10.1111/j.1432-1033.1982.tb06819.x; KURNICK JT, 1979, SCAND J IMMUNOL, V10, P563, DOI 10.1111/j.1365-3083.1979.tb01391.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER EP, 1981, J IMMUNOL, V126, P1428; LINCH DC, 1987, IMMUNOL REV, V95, P137, DOI 10.1111/j.1600-065X.1987.tb00503.x; LITVIN DA, 1984, METHOD ENZYMOL, V108, P298; MACDONALD HR, 1986, ANNU REV CELL BIOL, V2, P231; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCCAIRNS E, 1984, MOL CELL BIOL, V4, P1754, DOI 10.1128/MCB.4.9.1754; MURRAY LE, 1991, CELL PROLIFERAT, V24, P215, DOI 10.1111/j.1365-2184.1991.tb01151.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; RESCH K, 1981, EUR J BIOCHEM, V115, P659; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHULMAN H, 1984, J CELL BIOL, V99, P11, DOI 10.1083/jcb.99.1.11; SCHWEITZER I, 1984, BIOL CELL, V52, P147; SHAW JP, 1988, J BIOL CHEM, V263, P1459; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; SOLOMON F, 1979, CELL, V18, P431, DOI 10.1016/0092-8674(79)90062-X; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; VALLEE RB, 1984, J CELL BIOL, V99, pS38, DOI 10.1083/jcb.99.1.38s; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WALDMANN TA, 1986, SCIENCE, V232, P727, DOI 10.1126/science.3008337; WATERHOUSE PD, 1983, EXP CELL RES, V144, P367, DOI 10.1016/0014-4827(83)90416-0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE MW, 1987, MOL CELL BIOL, V7, P3004, DOI 10.1128/MCB.7.8.3004; WICHE G, 1985, TRENDS BIOCHEM SCI, V10, P67, DOI 10.1016/0968-0004(85)90235-X; WODA BA, 1984, J IMMUNOL, V133, P2767; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	50	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10716	10722						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587848				2022-12-27	WOS:A1992HV09000077
J	BASSE, CW; BOCK, K; BOLLER, T				BASSE, CW; BOCK, K; BOLLER, T			ELICITORS AND SUPPRESSORS OF THE DEFENSE RESPONSE IN TOMATO CELLS - PURIFICATION AND CHARACTERIZATION OF GLYCOPEPTIDE ELICITORS AND GLYCAN SUPPRESSORS GENERATED BY ENZYMATIC CLEAVAGE OF YEAST INVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-PATHOGEN INTERACTIONS; HIGH-MANNOSE OLIGOSACCHARIDES; F-SP GLYCINEA; EXTERNAL INVERTASE; PHYTOPHTHORA-INFESTANS; H-1-NMR SPECTROSCOPY; DISEASE RESISTANCE; ACCUMULATION; GLYCOPROTEINS; BIOSYNTHESIS	Cleavage of yeast invertase by alpha-chymotrypsin produced a number of small glycopeptides that were highly active as elicitors of ethylene biosynthesis and phenylalanine ammonia-lyase in suspension-cultured tomato cells. Five of these elicitors were purified and their amino acid sequence determined. They all had sequences corresponding to known sequences of yeast invertase, and all contained an asparagine known to carry a N-linked small high mannose glycan. The most active glycopeptide elicitor induced ethylene biosynthesis and phenylalanine ammonia-lyase half-maximally at a concentration of 5-10 nM. Structure-activity relationships of the peptide part were analyzed by further cleavage of a defined glycopeptide elicitor with various proteolytic enzymes. Removal of the C-terminal phenylalanine enhanced the elicitor activity, whereas removal of N-terminal arginine impaired it. A glycopeptide with the peptide part trimmed to the dipeptide arginine-asparagine was still fully active as elicitor. Glycopeptides with identical amino acid sequences were further separated into fractions differing in the oligosaccharide side chain. A given peptide had high elicitor activity when carrying a glycan with 10-12 mannosyl residues (Man10-12GlcNAc2), a 3-fold lower activity when carrying Man9GlcNAc2 and a 100-fold lower activity when carrying Man8GlcNAc2. The oligosaccharides, released by endo-beta-N-acetylglucosaminidase H from the pure glycopeptide elicitors, acted as suppressors of elicitor-induced ethylene biosynthesis and phenylalanine ammonia-lyase activity. A series of such oligosaccharides in the size range of Man8-13GlcNAc was purified. The structure and composition of the purified oligosaccharides corresponded to the known small high mannose glycans of yeast invertase as verified by H-1 NMR spectroscopy at 600 MHz. The highest suppressor activities were obtained with the oligosaccharides containing 10-12 mannosyl residues (Man10-12GlcNAc). The oligosaccharide Man8 GlcNAc was ineffective as a suppressor. Thus, the structural requirements for the free oligosaccharides to act as efficient suppressors were the same as for the oligosaccharide side chains of the glycopeptides for high elicitor activity. We propose that the glycan suppressors bind to the same recognition site as the glycopeptide elicitors without inducing a response.	CARLSBERG LAB, DEPT CHEM, DK-2500 COPENHAGEN, DENMARK		BASSE, CW (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				Ambler R P, 1972, Methods Enzymol, V25, P262, DOI 10.1016/S0076-6879(72)25023-6; BASSE CW, 1992, IN PRESS PLANT PHYSL, V98; BELL AA, 1981, ANNU REV PLANT PHYS, V32, P21, DOI 10.1146/annurev.pp.32.060181.000321; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; Boller T., 1986, PLANT PROTEOLYTIC EN, V2, P67; BOLLER T, 1989, 2ND MESSENGERS PLANT, P227; Boller T., 1991, PLANT HORMONE ETHYLE; BUSHNELL WR, 1981, PHYTOPATHOLOGY, V71, P1012, DOI 10.1094/Phyto-71-1012; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHEONG JJ, 1991, PLANT CELL, V3, P127, DOI 10.1105/tpc.3.2.127; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; COSIO EG, 1990, FEBS LETT, V264, P235, DOI 10.1016/0014-5793(90)80256-I; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOKE N, 1979, PHYSIOL PLANT PATHOL, V15, P127, DOI 10.1016/0048-4059(79)90061-4; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GROSSKOPF DG, 1991, J PLANT PHYSIOL, V138, P741, DOI 10.1016/S0176-1617(11)81325-8; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHN MG, 1978, PLANT PHYSIOL, V62, P107, DOI 10.1104/pp.62.1.107; HEATH MC, 1981, PHYTOPATHOLOGY, V71, P1121, DOI 10.1094/Phyto-71-1121; HERNANDEZ LM, 1989, J BIOL CHEM, V264, P13648; KESSMANN H, 1986, J PHYTOPATHOL, V117, P321, DOI 10.1111/j.1439-0434.1986.tb04370.x; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; NEESER JR, 1985, GLYCOCONJ J, V0002; NISHIGAKI M, 1978, J BIOCHEM-TOKYO, V84, P823, DOI 10.1093/oxfordjournals.jbchem.a132194; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; REDDY VA, 1988, J BIOL CHEM, V263, P6978; SCHEEL D, 1990, Z NATURFORSCH C, V45, P569; SHARP JK, 1984, J BIOL CHEM, V259, P1321; STORTI E, 1988, J PHYTOPATHOL, V121, P275, DOI 10.1111/j.1439-0434.1988.tb04454.x; STURM A, 1987, J BIOL CHEM, V262, P13392; STURM A, 1991, EUR J BIOCHEM, V199, P169, DOI 10.1111/j.1432-1033.1991.tb16106.x; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1977, J BIOL CHEM, V252, P4409; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; VANCE CP, 1980, ANNU REV PHYTOPATHOL, V18, P259, DOI 10.1146/annurev.py.18.090180.001355; YAMADA T, 1989, MOL PLANT MICROBE IN, V2, P256, DOI 10.1094/MPMI-2-256; ZIEGLER E, 1982, PHYSIOL PLANT PATHOL, V20, P321, DOI 10.1016/0048-4059(82)90057-1; ZIEGLER E, 1977, PLANT PHYSIOL, V59, P1104, DOI 10.1104/pp.59.6.1104; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	47	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10258	10265						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587815				2022-12-27	WOS:A1992HV09000012
J	GLASGOW, WC; AFSHARI, CA; BARRETT, JC; ELING, TE				GLASGOW, WC; AFSHARI, CA; BARRETT, JC; ELING, TE			MODULATION OF THE EPIDERMAL GROWTH-FACTOR MITOGENIC RESPONSE BY METABOLITES OF LINOLEIC AND ARACHIDONIC-ACID IN SYRIAN-HAMSTER EMBRYO FIBROBLASTS - DIFFERENTIAL-EFFECTS IN TUMOR SUPPRESSOR GENE (+) AND (-) PHENOTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PROTEIN-TYROSINE KINASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; MAMMARY EPITHELIAL-CELLS; PROSTAGLANDIN-H SYNTHASE; EGF RECEPTOR; 5-LIPOXYGENASE-ACTIVATING PROTEIN; PROLIFERATIVE RESPONSE; LEUKOTRIENE SYNTHESIS; ENDOTHELIAL-CELLS	Specific metabolites of arachidonic and linoleic acid have been proposed as serving a regulatory function in growth factor signal transduction in fibroblasts. In studies with Syrian hamster embryo (SHE) fibroblasts, we found lipoxygenase inhibitors to be potent blockers of epidermal growth factor (EGF)-dependent mitogenesis. Analytical chemical characterization of arachidonic and linoleic acid metabolism in SHE cells demonstrated that the major lipoxygenase product was 13-hydroxyoctadecadienoic acid (HODE). EGF stimulation of quiescent SHE cells resulted in an enhancement of HODE biosynthesis. The primary arachidonate products were prostaglandin E2 and F2-alpha formed via the cyclooxygenase pathway. Inhibition of cyclooxygenase activity did not alter the EGF-mitogenic response in SHE cells. Addition of lipoxygenase-derived linoleate metabolites (10(10)-10(-6) M) produced a 2-4-fold potentiation of EGF-stimulated [H-3]thymidine incorporation in SHE cells. Interestingly, the linoleate products did not enhance the EGF mitogenic effect in variant SHE cells that had lost tumor suppressor gene function. These results were confirmed by autoradiographic studies of DNA synthesis and suggest that loss of tumor suppressor phenotype correlates with a lack of responsiveness to linoleate products in signal transduction. In studies on the mechanism of EGF regulation of linoleic acid metabolism, inhibitors of EGF receptor tyrosine kinase activity were observed to block EGF-stimulated HODE biosynthesis. In addition, both cyclohexamide and actinomycin D attenuated the ability of EGF to increase linoleic acid metabolism in SHE cells. EGF induction of the linoleate pathway appears to be linked to activation of the EGF receptor and may be modulated at transcriptional or translational levels.	NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								BAER AN, 1990, J LIPID RES, V31, P125; BAILEY JM, 1985, J LIPID RES, V26, P54; BALAKRISHNAN A, 1989, CANCER RES, V49, P857; BANDYOPADHYAY GK, 1987, J BIOL CHEM, V262, P2750; BANDYOPADHYAY GK, 1988, J BIOL CHEM, V263, P7567; BARRETT JC, 1987, CANCER RES, V47, P2514; BULL AW, 1988, CANCER RES, V48, P1771; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CASEY ML, 1988, J BIOL CHEM, V263, P7846; CAVENEE WK, 1986, MUTAT RES, V168, P3, DOI 10.1016/0165-1110(86)90019-9; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DUNIEC ZM, 1991, MOL PHARMACOL, V39, P164; FRASIERSCOTT K, 1988, J CLIN INVEST, V82, P1877, DOI 10.1172/JCI113805; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GLASGOW WC, 1990, MOL PHARMACOL, V38, P503; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONN KV, 1981, PROSTAG OTH LIPID M, V21, P833, DOI 10.1016/0090-6980(81)90240-9; HUBBARD WC, 1980, PROSTAGLANDINS, V20, P431; KIM JW, 1990, J BIOL CHEM, V265, P3940; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NOLAN RD, 1986, BIOCHEM PHARMACOL, V35, P4273, DOI 10.1016/0006-2952(86)90706-9; NOLAN RD, 1988, MOL PHARMACOL, V33, P650; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; POSTOAK D, 1990, AM J PHYSIOL, V259, pC849, DOI 10.1152/ajpcell.1990.259.6.C849; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; REID GK, 1990, J BIOL CHEM, V265, P19818; SAGER R, 1986, CANCER RES, V46, P1573; SAVER L, 1988, CANCER RES, V48, P3106; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; THOMASSEN DG, 1985, CANCER RES, V45, P726; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	53	146	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10771	10779						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587852				2022-12-27	WOS:A1992HV09000085
J	PRANDINI, MH; UZAN, G; MARTIN, F; THEVENON, D; MARGUERIE, G				PRANDINI, MH; UZAN, G; MARTIN, F; THEVENON, D; MARGUERIE, G			CHARACTERIZATION OF A SPECIFIC ERYTHROMEGAKARYOCYTIC ENHANCER WITHIN THE GLYCOPROTEIN-IIB PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HUMAN MEGAKARYOCYTES; MAMMALIAN-CELLS; IMMUNOGLOBULIN GENES; NUCLEAR FACTOR; EXPRESSION; SEQUENCE; COMPLEX; FAMILY; IIIA	The gene coding for glycoprotein IIb (GPIIb), the alpha-subunit of platelet integrin GPIIb/IIIa is an early and specific marker of the megakaryocytic lineage. Thus, studies on the regulation of this gene may provide helpful information on the mechanisms controlling cell specificity and differentiation in this lineage. The promoter region of this gene was isolated and analyzed to understand its tissue-specific transcriptional activity. A region extending from nucleotides -414 to -554 was found to be extremely important for the promoter function. Deletion of this region results in a 70% decrease of the promoter activity, as measured in CAT assays. This region has the properties of an enhancer. It is able to activate a heterologous promoter, in a distance- and orientation-independent manner, in both megakaryocytic and erythroid cells. This enhancer contains binding sites for nuclear factors and mutation of these sites, individually or together, abolish the enhancer activity. These nuclear factors are present in megakaryocytic and erythroid cell lineages, but they are absent in the other tested cells. One of the sites, named domain D, contains a TTATC motif that may interact with the transcription factor GATA1, active in erythroid and megakaryocytic cells. These results indicate that the promoter of a megakaryocytic gene contains a tissue specific enhancer, active in both the erythroid and the megakaryocytic lineages, and may implicate the erythroid factor GATA1.			PRANDINI, MH (corresponding author), CEN,INSERM,U217,DEPT BIOL MOLEC & STRUCT,HEMATOL LAB,85X,F-38041 GRENOBLE,FRANCE.							BERRIDGE MV, 1985, BLOOD, V66, P76; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRASER JK, 1986, BLOOD, V68, P762; FRASER JK, 1989, EXP HEMATOL, V17, P10; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LEVENE RB, 1985, J EXP MED, V161, P457, DOI 10.1084/jem.161.3.457; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P1311; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MCLEOD DL, 1980, BLOOD, V56, P318; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1987, PERSPECTIVES INFLAMM, P267; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RABELLINO EM, 1981, J EXP MED, V154, P88, DOI 10.1084/jem.154.1.88; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; UZAN G, 1991, J BIOL CHEM, V266, P8932; UZAN G, 1991, BLOOD, V78, P720; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	34	62	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10370	10374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587823				2022-12-27	WOS:A1992HV09000028
J	TEALE, B; SINGH, S; KHANNA, KK; FINDIK, D; LAVIN, MF				TEALE, B; SINGH, S; KHANNA, KK; FINDIK, D; LAVIN, MF			PURIFICATION AND CHARACTERIZATION OF A DNA-BINDING PROTEIN ACTIVATED BY IONIZING-RADIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROTEIN; ADAPTIVE RESPONSE; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS; MESSENGER-RNA; GENES; EXPRESSION; INHIBITOR; ENHANCER; SEQUENCE	Exposure of mammalian cells to a variety of agents leads to the activation of pre-existing proteins and the induction of specific genes. We have recently described the appearance of a specific DNA-binding protein in nuclei from cells exposed to ionizing radiation (Singh, S. P., and Lavin, M. F. (1990) Mol. Cell. Biol. 10, 5279-5285). This protein is present in the cytoplasm of unperturbed cells and is apparently translocated to the nucleus in response to radiation damage. We describe here the purification and characterization of this specific DNA-binding protein. Purification involved the use of affinity chromatography employing a multimeric form of the DNA-binding motif conjugated to cyanogen bromide-activated Sepharose. Three DNA-binding species were recognized by UV-cross-linking and South-Western analysis. The major species or that with the highest affinity was approximately 70 kDa in size. DNase-1 footprint analysis revealed a single binding site in the kappa-immunoglobulin gene enhancer and in a putative control sequence upstream from the c-myc gene. At salt concentrations as high as 1 M, up to 40% of the DNA-binding activity was maintained and the K(d) was calculated to be 1.205 x 10(-6) M-1. Binding activity was found to be modulated by phosphorylation. Removal of phosphate groups from the protein resulted in a major loss of binding activity. It is not clear at this stage whether the factor(s) described here plays a role in transcription control or a more general DNA-processing role in response to radiation damage.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BANCROFT CTR,QUEENSLAND CANC FUND,RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; CSIRO,DIV PLANT IND,CANBERRA,ACT 2601,AUSTRALIA	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			singh, surinder/C-9528-2009; Lavin, Martin F/F-5961-2014	singh, surinder/0000-0003-4488-8147; Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P654; GLAZER PM, 1989, P NATL ACAD SCI USA, V86, P1163, DOI 10.1073/pnas.86.4.1163; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HANAWALT PC, 1989, MUTAT RES, V217, P173; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HERRLICH P, 1984, HUM GENET, V67, P360, DOI 10.1007/BF00291392; HOBSON K, 1991, ANAL BIOCHEM, V193, P220, DOI 10.1016/0003-2697(91)90012-I; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KELSEY KT, 1991, MUTAT RES, V263, P197, DOI 10.1016/0165-7992(91)90001-K; KRAMER M, 1990, RADIAT ENVIRON BIOPH, V29, P303, DOI 10.1007/BF01210410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MAX EE, 1981, J BIOL CHEM, V256, P5116; OLIVIERI G, 1984, SCIENCE, V223, P594, DOI 10.1126/science.6695170; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SHADLEY JD, 1987, MUTAGENESIS, V2, P95, DOI 10.1093/mutage/2.2.95; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; YOUNGBLOM JH, 1989, MUTAT RES, V227, P257, DOI 10.1016/0165-7992(89)90107-3	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10295	10301						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587818				2022-12-27	WOS:A1992HV09000017
J	BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK				BHATTACHARYYA, DK; BANDYOPADHYAY, U; BANERJEE, RK			CHEMICAL AND KINETIC EVIDENCE FOR AN ESSENTIAL HISTIDINE IN HORSERADISH-PEROXIDASE FOR IODIDE OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; HOG THYROID PEROXIDASE; ETHOXYFORMIC ANHYDRIDE; RESIDUE; DIETHYLPYROCARBONATE; LACTOPEROXIDASE; MECHANISM; BINDING; CHLOROPEROXIDASE; SEQUENCE	Horseradish peroxidase (HRP), when incubated with diethylpyrocarbonate (DEPC), shows a time-dependent loss of iodide oxidation activity. The inactivation follows pseudo-first order kinetics with a second order rate constant of 0.43 min-1 M-1 at 30-degrees-C and is reversed by neutralized hydroxylamine. The difference absorption spectrum of the modified versus native enzyme shows a peak at 244 nm, characteristic of N-carbethoxyhistidine, which is diminished by treatment with hydroxylamine. Correlation between the stoichiometry of histidine modification and the extent of inactivation indicates that out of 2 histidine residues modified, one is responsible for inactivation. A plot of the log of the reciprocal half-time of inactivation against log DEPC concentration further suggests that only 1 histidine is involved in catalysis. The rate of inactivation shows a pH dependence with an inflection point at 6.2, indicating histidine derivatization by DEPC. Inactivation due to modification of tyrosine, lysine, or cysteine has been excluded. CD studies reveal no significant change in the protein or heme conformation following DEPC modification. We suggest that a unique histidine residue is required for maximal catalytic activity of HRP for iodide oxidation.	INDIAN INST CHEM BIOL,DEPT PHYSIOL,4 RAJA SC MULLICK RD,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								AIBARA S, 1982, J BIOCHEM-TOKYO, V92, P531, DOI 10.1093/oxfordjournals.jbchem.a133961; ALEXANDER NM, 1962, ANAL BIOCHEM, V4, P341, DOI 10.1016/0003-2697(62)90097-0; BANERJEE RK, 1986, J BIOL CHEM, V261, P592; BJORKSTEN F, 1970, BIOCHIM BIOPHYS ACTA, V212, P396, DOI 10.1016/0005-2744(70)90245-7; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; CHANG KC, 1989, J BIOL CHEM, V264, P19666; CHURCH FC, 1985, J BIOL CHEM, V260, P4936; COUSINEAU J, 1976, BIOCHEMISTRY-US, V15, P4992, DOI 10.1021/bi00668a008; DUMAS DP, 1990, J BIOL CHEM, V265, P21498; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P410; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KENIGSBERG P, 1987, ARCH BIOCHEM BIOPHYS, V254, P409, DOI 10.1016/0003-9861(87)90118-4; KONPKA K, 1988, ARCH BIOCHEM BIOPHYS, V261, P55; LEVY HM, 1963, J BIOL CHEM, V238, P3654; Lundblad R.L, 1984, CHEM REAGENTS PROTEI, VI; MAGNUSSON RP, 1984, J BIOL CHEM, V259, P197; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MORRISON M, 1976, ANNU REV BIOCHEM, V45, P861, DOI 10.1146/annurev.bi.45.070176.004241; NAKAMURA M, 1985, J BIOL CHEM, V260, P3546; OHTAKI S, 1982, J BIOL CHEM, V257, P761; OHTAKI S, 1981, J BIOL CHEM, V256, P805; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PAUL KG, 1978, ACTA CHEM SCAND B, V32, P395, DOI 10.3891/acta.chem.scand.32b-0395; POMMIER J, 1973, EUR J BIOCHEM, V38, P497, DOI 10.1111/j.1432-1033.1973.tb03085.x; POULOS TL, 1980, J BIOL CHEM, V255, P8199; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SAKURADA J, 1985, CHEM LETT, P211, DOI 10.1246/cl.1985.211; SAKURADA J, 1987, J BIOL CHEM, V262, P4007; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SAKURADA J, 1987, BIOCHEMISTRY-US, V26, P6478, DOI 10.1021/bi00394a028; SAMS CF, 1988, BIOCHEMISTRY-US, V27, P2277, DOI 10.1021/bi00407a005; TAKEUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1571, DOI 10.1093/oxfordjournals.jbchem.a135630; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; TOPHAM CM, 1986, EUR J BIOCHEM, V155, P87, DOI 10.1111/j.1432-1033.1986.tb09461.x; UGAROVA NN, 1981, BIOCHIM BIOPHYS ACTA, V662, P210, DOI 10.1016/0005-2744(81)90032-2; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9800	9804						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577815				2022-12-27	WOS:A1992HT96500057
J	LINDSEY, GG; THOMPSON, P				LINDSEY, GG; THOMPSON, P			S(T)PXX MOTIFS PROMOTE THE INTERACTION BETWEEN THE EXTENDED N-TERMINAL TAILS OF HISTONE H2B WITH LINKER DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN SPERM CHROMATIN; CORE-HISTONE; PARTICLE; SEQUENCE; PROTEINS	The assembly of hybrid core particles onto long chicken DNA with histone H2B in the chicken histone octamer replaced with either wheat histone H2B(2) or sea urchin sperm histone H2B(1) or H2B(2) is described. All these histone H2B variants have N-terminal extensions of between 18 and 20 amino acids, although only those from sea urchin sperm have S(T)PXX motifs present. Whereas chicken histone octamers protected 167 base pairs (bp) (representing two full turns) of DNA against micrococcal nuclease digestion (Lindsey, G. G., Orgeig, S., Thompson, P., Davies, N., and Maeder, D. L. (1991) J. Mol. Biol. 218, 805-813), all the hybrid histone octamers protected an additional 17-bp DNA against nuclease digestion. This protection was more marked in the case of hybrid octamers containing sea urchin sperm histone H2B variants and similar to that described previously (Lindsey, G. G., Orgeig, S., Thompson, P., Davies, N., and Maeder, D. L. (1991) J. Mol. Biol. 218, 805-813) for hybrid histone octamers containing wheat histone H2A variants all of which also have S(T)PXX motifs present. Continued micrococcal nuclease digestion reduced the length of DNA associated with the core particle via 172-, 162-, and 152-bp intermediates until the 146-bp core particle was obtained. These DNA lengths were approximately 5 bp or half a helical turn longer than those reported previously for stripped chicken chromatin and for core particles containing histone octamers reconstituted using "normal" length histone H2B variants. This protection pattern was also found in stripped sea urchin sperm chromatin, demonstrating that the assembly/digestion methodology reflects the in vivo situation. The interaction between the N-terminal histone H2B extension and DNA of the "linker" region was confirmed by demonstrating that stripped sea urchin sperm chromatin precipitated between 120 and 500 mm NaCl in a manner analogous to unstripped chromatin whereas stripped chicken chromatin did not. Tryptic digestion to remove all the histone tails abolished this precipitation as well as the protection of DNA outside of the 167-bp core particle against nuclease digestion.			LINDSEY, GG (corresponding author), UNIV CAPE TOWN,DEPT BIOCHEM,RONDEBOSCH 7700,SOUTH AFRICA.							BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; BRANDT WF, 1988, EUR J BIOCHEM, V173, P547, DOI 10.1111/j.1432-1033.1988.tb14033.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSEY GG, 1985, FEBS LETT, V192, P230, DOI 10.1016/0014-5793(85)80113-7; LINDSEY GG, 1990, BIOCHIM BIOPHYS ACTA, V1049, P9, DOI 10.1016/0167-4781(90)90077-F; LINDSEY GG, 1989, BIOCHIM BIOPHYS ACTA, V1009, P257, DOI 10.1016/0167-4781(89)90111-5; LINDSEY GG, 1991, J MOL BIOL, V218, P805, DOI 10.1016/0022-2836(91)90268-B; LINDSEY GG, 1983, FEBS LETT, V155, P301, DOI 10.1016/0014-5793(82)80625-X; LINDSEY GG, 1982, FEBS LETT, V145, P131, DOI 10.1016/0014-5793(82)81221-0; Maniatis T., 1982, MOL CLONING; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; SAHASRABUDDHE CG, 1977, NUCLEIC ACIDS RES, V4, P853, DOI 10.1093/nar/4.4.853; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STRICKLAND M, 1981, FEBS LETT, V135, P86, DOI 10.1016/0014-5793(81)80949-0; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMAS JO, 1986, EUR J BIOCHEM, V154, P343, DOI 10.1111/j.1432-1033.1986.tb09403.x; VONHOLT C, 1989, METHOD ENZYMOL, V170, P428; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	21	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14622	14628						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634509				2022-12-27	WOS:A1992JF08800023
J	TREMETHICK, DJ; FROMMER, M				TREMETHICK, DJ; FROMMER, M			PARTIAL-PURIFICATION, FROM XENOPUS-LAEVIS OOCYTES, OF AN ATP-DEPENDENT ACTIVITY REQUIRED FOR NUCLEOSOME SPACING INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPACED CHROMATIN; ASSEMBLY INVITRO; CORE PARTICLE; TRANSCRIPTION COMPLEX; DNA-REPLICATION; REPEAT LENGTH; HISTONE; PROTEIN; YEAST; EXTRACTS	A critical feature of chromatin with regard to structure and function is the regular spacing of nucleosomes. In vivo, spacing of nucleosomes occurs in at least two steps, but the mechanism is not understood. In this report, we have mimicked the two-step process in vitro. A novel spacing activity has been partially purified from Xenopus laevis ovaries. When this activity is added, either at the beginning or at the end of a nucleosomal assembly reaction, it can convert a DNA template consisting of irregularly spaced nucleosomes into a chromatin structure made up of regularly spaced nucleosomes with a repeat length of about 165 base pairs. The reaction requires ATP. Histone H1 is able to increase the nucleosomal repeat from 165 to 190 base pairs. This two-step increase in nucleosomal repeat length suggests that both the spacing activity and histone H1 contribute to generating repeat lengths of greater than 165 base pairs and that their contributions may be additive. Alternatively, the critical step in the spacing reaction may not be the formation of the 165-base pair repeat but may be the sliding of nucleosomes or the reorganization of the octamer structure induced by the spacing activity.	CSIRO,DIV BIOMOLEC ENGN,MOLEC BIOL LAB,N RYDE,NSW 2113,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,KANEMATSU LABS,CAMPERDOWN,NSW 2050,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Sydney	TREMETHICK, DJ (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,POB 334,CANBERRA,ACT 2601,AUSTRALIA.			Tremethick, David/0000-0001-5274-8078				ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1990, NUCLEIC ACIDS RES, V18, P5767, DOI 10.1093/nar/18.19.5767; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ANNUNZIATO AT, 1982, BIOCHEMISTRY-US, V21, P5431, DOI 10.1021/bi00265a008; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; CERTA U, 1984, NUCLEIC ACIDS RES, V12, P7975, DOI 10.1093/nar/12.21.7975; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; JORCANO JL, 1979, BIOCHEMISTRY-US, V18, P768, DOI 10.1021/bi00572a005; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1990, TRENDS GENET, V6, P406, DOI 10.1016/0168-9525(90)90301-L; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SAPP M, 1990, J BIOL CHEM, V265, P9357; SESSA G, 1990, NUCLEIC ACIDS RES, V18, P5449, DOI 10.1093/nar/18.18.5449; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; STEIN A, 1984, J MOL BIOL, V178, P341, DOI 10.1016/0022-2836(84)90148-7; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; VANDONGEN WMAM, 1983, CELL DIFFER DEV, V12, P257, DOI 10.1016/0045-6039(83)90021-0; WEINTRAUB H, 1978, NUCLEIC ACIDS RES, V5, P1179, DOI 10.1093/nar/5.4.1179; WOLFFE A P, 1990, New Biologist, V2, P211; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15041	15048						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634540				2022-12-27	WOS:A1992JF08800079
J	GRESHAM, HD; ADAMS, SP; BROWN, EJ				GRESHAM, HD; ADAMS, SP; BROWN, EJ			LIGAND-BINDING SPECIFICITY OF THE LEUKOCYTE RESPONSE INTEGRIN EXPRESSED BY HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RECOGNITION SITE; RECEPTOR; FIBRINOGEN; FIBRONECTIN; PHAGOCYTOSIS; MACROPHAGES; CD11B/CD18; MONOCYTES; PROTEINS	The ligand binding specificity of the leukocyte response integrin (LRI) expressed by polymorphonuclear leukocyte (PMN) was investigated by examining its interaction with two adhesion motifs within fibrinogen: the alpha-chain sequence RGD and the gamma-chain sequence KQAGDV. The effect of the hexapeptides KQAGDV, KQRGDV, and KGAGDV on fibrinogen-stimulated phagocytosis, a LRI-dependent function, was examined. Surprisingly, the sequence KGAGDV was most potent for inhibition of fibrinogen-stimulated ingestion; the order of potency of these peptides was KGAGDV > KQAGDV > KQRGDV = GRGDSPA. Latex spheres coated with multivalent KGAGDV bound specifically to PMN and antibodies that recognized either the LRI beta-chain (7G2) or an associated protein (IAP)-abrogated bead binding. Various control and anti-beta-1 and anti-beta-2 antibodies did not affect bead binding. Monovalent peptides KGAGDV and KQRGDV were equipotent for inhibition of bead binding to unstimulated PMN (ID50 = 19-mu-M). In contrast, KGAGDV was more potent than KQRGDV for inhibition of bead binding to N-formylmethionylleucylphenylalanine-stimulated PMN (ID50 = 2.5-mu-M versus ID50 = 60-mu-M). A control peptide, KGALEVA, did not inhibit LRI ligand binding or function. These data suggest that the unique amino acid sequence KGAGDV may represent a specific ligand for LRI and that LRI ligand binding specificity may be regulated by the activation state of the cell.	UNIV MISSOURI,DEPT MED,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65201; HARRY S TRUMAN VET AFFAIRS MED CTR,RES SERV,COLUMBIA,MO 65201; MOSANTO CO,ST LOUIS,MO 63198; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63130	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	GRESHAM, HD (corresponding author), UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65201, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI023790, R01AI024674, R37AI024674, R23AI023790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24674, AI-23790] Funding Source: Medline; NIGMS NIH HHS [GM-38330] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; BOHNSACK JF, 1986, J IMMUNOL, V136, P3793; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FOK KF, 1991, INT J PEPT PROT RES, V38, P124; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RUGGERI ZM, 1986, P NATL ACAD SCI USA, V83, P5708, DOI 10.1073/pnas.83.15.5708; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SENIOR R, 1991, FASEB J, V5, pA1558; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH JW, 1990, J BIOL CHEM, V265, P12267; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1985, J EXP MED, V162, P762, DOI 10.1084/jem.162.2.762	23	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					13895	13902						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629189				2022-12-27	WOS:A1992JD32500020
J	TAKEYA, H; NISHIDA, S; MIYATA, T; KAWADA, SI; SAISAKA, Y; MORITA, T; IWANAGA, S				TAKEYA, H; NISHIDA, S; MIYATA, T; KAWADA, SI; SAISAKA, Y; MORITA, T; IWANAGA, S			COAGULATION FACTOR-X ACTIVATING ENZYME FROM RUSSELLS VIPER VENOM (RVV-X) - A NOVEL METALLOPROTEINASE WITH DISINTEGRIN (PLATELET-AGGREGATION INHIBITOR)-LIKE AND C-TYPE LECTIN-LIKE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CARBOHYDRATE-RECOGNITION DOMAINS; TRIMERESURUS-FLAVOVIRIDIS; HEMORRHAGIC METALLOPROTEINASE; ECHIS-CARINATUS; STUART FACTOR; HABU SNAKE; PROTEIN; RECEPTOR; FAMILY	We determined the complete amino acid sequence of RVV-X, the blood coagulation factor X activating enzyme, isolated from Russell's viper venom and studied structure-function relationships. RVV-X (M(r) 79,000) consists of a disulfide-bonded two-chain glycoprotein with a heavy chain of M(r) 59,000 and a light chain of heterogeneous M(r) 18,000 (LC1) and 21,000 (LC2). These chains were separated after reduction and S-pyridylethylation, and the isolated major component LC1 was used for sequence analysis. The heavy chain consists of 427 residues containing four asparagine-linked oligosaccharides, and its entire sequence was similar to that of the high molecular mass hemorrhagic protein, HR1B, isolated from the venom of Trimeresurus flavoviridis. The heavy chain contains three distinct domains, metalloproteinase, disintegrin (platelet aggregation inhibitor)-like and unknown cysteine-rich domains. On the other hand, light chain LC1 consists of 123 amino acid residues containing one asparagine-linked oligosaccharide and shows sequence homology similar to that found in the so-called C-type (Ca2+-dependent) lectins. Therefore, RVV-X is a novel metalloproteinase containing a mosaic structure with disintegrin-like, cysteine-rich, and C-type lectin-like domains. RVV-X potently inhibits collagen- and ADP-stimulated platelet aggregations, probably via its disintegrin-like domain, although this domain does not contain the Arg-Gly-Asp sequence which is conserved in various venom disintegrins and which is thought to be one of the interaction sites for platelet integrins. Our findings also indicate that snake venom factor IX/factor X-binding protein with a C-type lectin structure (Atoda, H., Hyuga, M., and Morita, T. (1991) J. Biol. Chem. 266, 14903-14911) inhibits RVV-X-catalyzed factor X activation; hence, the light chain of RVV-X probably participates in recognizing some portion of the zymogen factor X.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; MEIJI COLL PHARM,DEPT BIOCHEM,TOKYO 188,JAPAN	Kyushu University; Meiji Pharmaceutical University								ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AMPHLETT GW, 1982, BIOCHEMISTRY-US, V21, P125, DOI 10.1021/bi00530a022; ATODA H, 1991, J BIOL CHEM, V266, P14903; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLOROS J, 1986, J BIOL CHEM, V261, P9029; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; Furie B.C., 1976, Methods Enzymol, V45, P191; GAN ZR, 1988, J BIOL CHEM, V263, P19827; GIGA Y, 1987, J BIOL CHEM, V262, P6197; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P2320; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; HUNG TF, 1989, BIOCHEMISTRY-US, V28, P661; INOUE S, 1991, J BIOL CHEM, V266, P1001; Iwanaga S., 1979, HDB EXPT PHARMACOLOG, V52, P61; JACKSON CM, 1971, BIOCHIM BIOPHYS ACTA, V252, P255, DOI 10.1016/0304-4165(71)90005-5; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KISIEL W, 1981, METHOD ENZYMOL, V80, P275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MIYATA T, 1989, J BIOCHEM-TOKYO, V105, P847, DOI 10.1093/oxfordjournals.jbchem.a122756; MORITA T, 1981, METHOD ENZYMOL, V80, P303; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MURAMOTO K, 1986, BIOCHIM BIOPHYS ACTA, V874, P285, DOI 10.1016/0167-4838(86)90027-0; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; PENKE B, 1974, ANAL BIOCHEM, V60, P45, DOI 10.1016/0003-2697(74)90129-8; PIRKLE H, 1991, THROMB HAEMOSTASIS, V65, P444; ROSING J, 1991, THROMB HAEMOSTASIS, V65, P627; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKEYA H, 1990, J BIOCHEM-TOKYO, V108, P711, DOI 10.1093/oxfordjournals.jbchem.a123270; TAKEYA H, 1989, J BIOCHEM-TOKYO, V106, P151, DOI 10.1093/oxfordjournals.jbchem.a122805; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; TENG CM, 1991, THROMB HAEMOSTASIS, V65, P624; TOKUNAGA F, 1988, J BIOL CHEM, V263, P17471; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; YAMAMOTO A, 1989, J BIOCHEM-TOKYO, V106, P552, DOI 10.1093/oxfordjournals.jbchem.a122892	51	190	202	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14109	14117						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629211				2022-12-27	WOS:A1992JD32500052
J	HUGHES, EN; ENGELSBERG, BN; BILLINGS, PC				HUGHES, EN; ENGELSBERG, BN; BILLINGS, PC			PURIFICATION OF NUCLEAR PROTEINS THAT BIND TO CISPLATIN-DAMAGED DNA - IDENTITY WITH HIGH MOBILITY GROUP PROTEIN-1 AND PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; XERODERMA PIGMENTOSUM; DIFFERENTIAL REPAIR; HUMAN-FIBROBLASTS; APURINIC SITES; CELL-LINES; CIS-DIAMMINEDICHLOROPLATINUM(II); ADDUCTS	The biochemical processes responsible for the recognition and repair of cisplatin-damaged DNA in human cells are not well understood. We have developed a damaged DNA affinity precipitation technique that allows the direct visualization and characterization of cellular proteins that bind to cisplatin-damaged DNA. The method separates damaged DNA-binding proteins from complex radiolabeled cell mixtures and further resolves them into individual polypeptides by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This technique is complementary to gel retardation and Southwestern blotting analyses that have been previously used to identify cellular components that specifically bind to cisplatin-damaged DNA. Using this technique, we have characterized a set of HeLaS3 nuclear proteins of 26.5, 28, 90, and 97 kDa that specifically bind to cisplatin-DNA adducts. Competition studies with soluble cisplatin-damaged DNA confirmed these findings. The major cisplatin-damaged DNA-binding proteins of 26.5 and 28 kDa recognized adducts of DNA modified with cisplatin but not with its transisomer or with UV radiation. These proteins were purified 450-fold to near homogeneity by ion-exchange and cisplatin-damaged DNA affinity chromatography. Amino-terminal sequence analysis showed that the 26.5- and 28-kDa proteins were identical to high mobility group (HMG) proteins HMG-2 and HMG-1, respectively.	UNIV PENN,SCH MED,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NCI NIH HHS [CA-45734] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREWS PA, 1991, CANCER COMMUN, V3, P1; BEDFORD P, 1988, CANCER RES, V48, P3019; BONNE C, 1982, J BIOL CHEM, V257, P2722; BOOTHMAN DA, 1990, MOL CELL BIOCHEM, V136, P39; CARADONNA JP, 1983, ADV CHEM SER, V209, P14; CHAO CCK, 1991, MOL CELL BIOL, V11, P2075, DOI 10.1128/MCB.11.4.2075; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1987, MOL BIOL MED, V4, P277; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEUTSCH WA, 1979, P NATL ACAD SCI USA, V76, P141, DOI 10.1073/pnas.76.1.141; DEWIT L, 1987, INT J RADIAT ONCOL, V13, P403, DOI 10.1016/0360-3016(87)90015-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIJT FJ, 1988, CANCER RES, V48, P6058; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; EINHORN L, 1991, J CLIN ONCOL, V8, P1777; FELDBERG RS, 1982, J BIOL CHEM, V257, P6394; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJIWARA Y, 1990, JPN J CANCER RES, V81, P1210, DOI 10.1111/j.1349-7006.1990.tb02680.x; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HUGHES EN, 1981, J BIOL CHEM, V256, P664; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; KATOAKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139; KUHNLEIN U, 1985, J BIOL CHEM, V260, P4918; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MASUDA H, 1988, CANCER RES, V48, P5713; MORANELLI F, 1980, P NATL ACAD SCI-BIOL, V77, P3201, DOI 10.1073/pnas.77.6.3201; PATTERSON M, 1989, MOL CELL BIOL, V9, P5105, DOI 10.1128/MCB.9.11.5105; PINTO A L, 1985, Biochimica et Biophysica Acta, V780, P167, DOI 10.1016/0304-419X(85)90001-0; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SCOVELL WM, 1987, BIOCHEM BIOPH RES CO, V142, P826, DOI 10.1016/0006-291X(87)91488-4; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4119; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TOULME JJ, 1983, EMBO J, V2, P505, DOI 10.1002/j.1460-2075.1983.tb01454.x; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TSANG SS, 1982, BIOCHIM BIOPHYS ACTA, V697, P202, DOI 10.1016/0167-4781(82)90078-1; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; VIDALI G, 1977, CELL, V12, P409, DOI 10.1016/0092-8674(77)90117-9; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911	56	175	176	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13520	13527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618852				2022-12-27	WOS:A1992JB74600067
J	MIZUTANI, A; USUDA, N; TOKUMITSU, H; MINAMI, H; YASUI, K; KOBAYASHI, R; HIDAKA, H				MIZUTANI, A; USUDA, N; TOKUMITSU, H; MINAMI, H; YASUI, K; KOBAYASHI, R; HIDAKA, H			CAP-50, A NEWLY IDENTIFIED ANNEXIN, LOCALIZES IN NUCLEI OF CULTURED FIBROBLAST 3Y1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT PHOSPHOLIPID-BINDING; RAT-LIVER NUCLEI; CALPACTIN-I; CHROMAFFIN GRANULES; HEAVY-CHAIN; PROTEIN; CALCIUM; LIPOCORTIN; PHOSPHORYLATION; PURIFICATION	A 50-kDa protein, which binds to the growth-regulated gene (2A9) product, calcyclin in a calcium-dependent manner, was purified from bovine lung. Partial amino acid sequencing of the protein revealed it to be the bovine equivalent of rabbit lung CAP-50 (calcyclin-associated protein, 50 kDa), which is a member of the annexin family and binds to calcyclin in a calcium-dependent manner. Specific polyclonal antibodies to bovine lung CAP-50 were prepared. Comparative studies between CAP-50 and synexin (annexin VII) on the immunoreactivity against anti-CAP-50 antibodies and the ability of binding to calcyclin revealed that CAP-50 was a distinct molecule from synexin. Using specific polyclonal antibodies to bovine lung CAP-50, tissue distribution and subcellular distribution of CAP-50 were investigated. In most rat tissues, except those in the central nervous systems and kidney, CAP-50 is expressed at a high or moderate level. Both studies by subcellular fractionation and by indirect immunofluorescence staining of the rat embryonic fibroblast cell line, 3Y1, revealed that CAP-50 mainly localized in nuclei. Moreover, between the cells at interphase and at mitotic phase, different distributions of CAP-50 were observed. That is, in the cells at interphase, CAP-50 seemed to localize throughout the nucleoplasm. On the other hand, in the cells during mitosis, CAP-50 was concentrated at the loop-like structure around the mitotic apparatus. CAP-50 was found in isolated 3Y1 nuclei lacking outer nuclear membranes, and approximately 50% of CAP-50 was extracted from the nuclei by chelating calcium. Thus, CAP-50, a unique annexin, localizes in nuclei.	NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; SHINSHU UNIV,SCH MED,DEPT ANAT & CELL BIOL,MATSUMOTO,NAGANO 390,JAPAN	Nagoya University; Shinshu University			Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3798, DOI 10.1073/pnas.86.10.3798; BURNS AL, 1990, BIOCHEM SOC T, V18, P1118, DOI 10.1042/bst0181118; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DOWLING LG, 1985, BIOCHEM BIOPH RES CO, V132, P382, DOI 10.1016/0006-291X(85)91033-2; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; HAYASHI H, 1989, J BIOL CHEM, V264, P17222; HEPPEL LA, 1955, METHOD ENZYMOL, V2, P546, DOI 10.1016/S0076-6879(55)02249-0; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOBAYASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P203, DOI 10.1016/0003-9861(90)90570-O; KOBAYASHI R, 1990, BIOCHEM J, V262, P993; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUZNICKI J, 1989, FEBS LETT, V254, P141, DOI 10.1016/0014-5793(89)81026-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGENDZO K, 1991, J BIOL CHEM, V266, P3228; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MURPHY LC, 1988, J BIOL CHEM, V263, P2397; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NISHIDA E, 1979, J BIOCHEM, V85, P1257; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; SEMICH R, 1989, EUR J CELL BIOL, V50, P313; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TOKUMITSU H, 1991, ARCH BIOCHEM BIOPHYS, V288, P202, DOI 10.1016/0003-9861(91)90184-K; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOKUMITSU H, 1992, IN PRESS J BIOL CHEM; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	45	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13498	13504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618851				2022-12-27	WOS:A1992JB74600064
J	BRZOVIC, PS; SAWA, Y; HYDE, CC; MILES, EW; DUNN, MF				BRZOVIC, PS; SAWA, Y; HYDE, CC; MILES, EW; DUNN, MF			EVIDENCE THAT MUTATIONS IN A LOOP REGION OF THE ALPHA-SUBUNIT INHIBIT THE TRANSITION FROM AN OPEN TO A CLOSED CONFORMATION IN THE TRYPTOPHAN SYNTHASE BIENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ESCHERICHIA-COLI; L-SERINE; SALMONELLA-TYPHIMURIUM; BETA-SUBUNIT; TRIOSEPHOSPHATE ISOMERASE; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; MULTIENZYME COMPLEX; SECONDARY STRUCTURE	Rapid-scanning stopped-flow (RSSF) UV-visible spectroscopy has been used to investigate the effects of single amino acid mutations in the alpha-subunit of the Salmonella typhimurium tryptophan synthase bienzyme complex on the reactivity at the beta-subunit active site located 25 to 30 angstrom distant. The pyridoxal 5'-phosphate (PLP) cofactor provides a convenient spectroscopic probe to directly monitor catalytic events at the beta-active site. Single substitutions of Phe for Glu at position 49, Leu for Gly at position 51, or Tyr for Asp at position 60 in the alpha-subunit strongly alter the observed steady state and pre-steady state inhibitory effects of the alpha-subunit-specific ligand alpha-glycerophosphate (GP) on the PLP-dependent beta-reaction. However, similar GP-induced allosteric effects on the distribution of covalent intermediates bound at the beta-site that are observed with the wild-type enzyme (Houben, K. F., and Dunn, M. F. (1990) Biochemistry 29, 2421-2429) also are observed for each of the mutant bienzyme complexes. These results support the hypothesis that the preferred pathway of indole from solution into the beta-site is via the a-site and the interconnecting tunnel (Dunn, M. F., Aguilar, V., Brzovic', P., Drewe, W. F., Houben, K. F., Leja, C. A., and Roy, M. (1990) Biochemistry 29, 8598-8607). Residues alpha-E49, alpha-G51, and alpha-D60 are part of a highly conserved inserted sequence in the alpha/beta-barrel topology of the alpha-subunit. We propose that the GP-induced inhibition of the beta-reaction results, in part, from a ligand-dependent conformational change from an "open" to a "closed" structure of the alpha-subunit which involves this region of the alpha-subunit and serves to obstruct the direct access of indole into the tunnel. Our findings suggest that the altered kinetic behavior observed for the alpha-mutants in the presence of GP reflects an impaired ability of the modified bienzyme complex to undergo the conformational transition from the open to the closed form.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA; NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California Riverside; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sawa, Yoshihiro/F-8295-2017	Sawa, Yoshihiro/0000-0002-2379-470X				ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BRZOVIC P, 1990, BIOCHEMISTRY-US, V29, P442, DOI 10.1021/bi00454a020; BRZOVIC PS, 1991, 8TH P INT C VIT B6 C, P277; BRZOVIC PS, 1992, IN PRESS BIOCHEMISTR; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; DUNN MF, 1991, 8TH P INT C VIT B6 C, P257; DUNN MF, 1987, 1987 P INT C CHEM BI, P171; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GOLDBERG ME, 1967, BIOCHEMISTRY-US, V6, P2113, DOI 10.1021/bi00859a032; HEYN MP, 1975, BIOCHEMISTRY-US, V14, P2962, DOI 10.1021/bi00684a026; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HOUBEN KF, 1989, BIOCHEMISTRY-US, V28, P4140, DOI 10.1021/bi00436a003; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KANZAKI H, 1991, ARCH BIOCHEM BIOPHYS, V284, P174, DOI 10.1016/0003-9861(91)90280-V; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Kirschner K., 1975, PROTEIN LIGAND INTER, P27, DOI [10.1515/9783110830811-006, DOI 10.1515/9783110830811-006]; KOERBER SC, 1983, BIOCHEMISTRY-US, V22, P3424, DOI 10.1021/bi00283a019; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, J BIOL CHEM, V266, P10715; NAGATA S, 1989, J BIOL CHEM, V264, P6288; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; ROY M, 1988, BIOCHEMISTRY-US, V27, P6698, DOI 10.1021/bi00418a009; ROY M, 1988, BIOCHEMISTRY-US, V27, P8661, DOI 10.1021/bi00423a023; SHIRVANEE L, 1990, J BIOL CHEM, V265, P6624; WEISCHET WO, 1976, EUR J BIOCHEM, V64, P313, DOI 10.1111/j.1432-1033.1976.tb10303.x; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X; YANOFSKY C, 1972, ENZYMES, V8, P1; YUTANI K, 1987, J BIOL CHEM, V262, P13429	48	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					13028	13038						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618800				2022-12-27	WOS:A1992HZ48300094
J	DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A				DEJONGE, BLM; CHANG, YS; GAGE, D; TOMASZ, A			PEPTIDOGLYCAN COMPOSITION OF A HIGHLY METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS STRAIN - THE ROLE OF PENICILLIN BINDING PROTEIN-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; PERFORMANCE LIQUID-CHROMATOGRAPHY; NEISSERIA-GONORRHOEAE; MOLECULAR-CLONING; CROSS-LINKING; GENE; PHASE; DNA	All clinical isolates of methicillin-resistant Staphylococcus aureus contain an extra penicillin binding protein (PBP) 2A in addition to four PBPs present in all staphylococcal strains. This extra PBP is thought to be a transpeptidase essential for the continued cell wall synthesis and growth in the presence of beta-lactam antibiotics. As an approach of testing this hypothesis we compared the muropeptide composition of cell walls of a highly methicillin-resistant S. aureus strain containing PBP2A and its isogenic Tn551 derivative with reduced methicillin resistance, which contained no PBP2A because of the insertional inactivation of the PBP2A gene. Purified cell walls were hydrolyzed into muropeptides which were subsequently resolved by reversed-phase high-performance liquid chromatography and identified by chemical and mass spectrometric analysis. The peptidoglycan composition of the two strains were identical. Both peptidoglycans were highly cross-linked mainly through pentaglycine cross-bridges, although other, chemically distinct peptide cross-bridges were also present including mono-, tri-, and tetraglycine; alanine; and alanyl-tetraglycine. Our experiments provided no experimental data for a unique transpeptidase activity associated with PBP2A.	ROCKEFELLER UNIV,MICROBIOL LAB,1230 YORK AVE,NEW YORK,NY 10021; MICHIGAN STATE UNIV,DEPT BIOCHEM,MICHIGAN STATE UNIV NIH MASS SPECTROMETRY FACIL,E LANSING,MI 48824	Rockefeller University; Michigan State University			DeJonge, Boudewijn/AAR-6717-2020	Chang, Yoon-Seok/0000-0002-0623-2932; Tomasz, Alexander/0000-0003-1520-1983	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00480] Funding Source: Medline; NIAID NIH HHS [R01-AI16794] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherton D., 1989, TECHNIQUES PROTEIN C, P273; BECK WD, 1986, J BACTERIOL, V165, P373, DOI 10.1128/jb.165.2.373-378.1986; CHAMBERS HF, 1990, J INFECT DIS, V161, P1170, DOI 10.1093/infdis/161.6.1170; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11255; DELANCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632; DOUGHERTY TJ, 1985, J BACTERIOL, V163, P69, DOI 10.1128/JB.163.1.69-74.1985; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; GARCIABUSTOS JF, 1989, P NATL ACAD SCI USA, V87, P5415; GHUYSEN JM, 1963, BIOCHEMISTRY-US, V2, P1119, DOI 10.1021/bi00905a036; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; MARTIN SA, 1987, J BIOL CHEM, V262, P7514; MATSUHASHI M, 1986, J BACTERIOL, V167, P975, DOI 10.1128/jb.167.3.975-980.1986; MATTHEWS P, 1990, ANTIMICROB AGENTS CH, V34, P1777, DOI 10.1128/AAC.34.9.1777; MATTHEWS PR, 1987, J GEN MICROBIOL, V133, P1919; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; QUORONFLEH MW, 1986, ANTIMICROB AGENTS CH, V29, P250; REYNOLDS PE, 1986, FEMS MICROBIOL LETT, V33, P251; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; SASAGAWA T, 1982, J CHROMATOGR, V240, P329, DOI 10.1016/S0021-9673(00)99612-2; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHLEIFER KH, 1969, J GEN MICROBIOL, V57, pR14; SIDOW T, 1990, ARCH MICROBIOL, V154, P73; SNOWDEN MA, 1990, EUR J BIOCHEM, V191, P373, DOI 10.1111/j.1432-1033.1990.tb19132.x; SNOWDEN MA, 1989, J GEN MICROBIOL, V135, P3015; SNOWDEN MA, 1991, J GEN MICROBIOL, V137, P1661, DOI 10.1099/00221287-137-7-1661; SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3; TIPPER DJ, 1969, BIOCHEMISTRY-US, V8, P2183, DOI 10.1021/bi00833a060; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124; TOWNSEND DE, 1987, J HOSP INFECT, V9, P60, DOI 10.1016/0195-6701(87)90097-1; TUOMANEN E, 1989, J BIOL CHEM, V264, P11093; UBUKATA K, 1989, J BACTERIOL, V171, P2882, DOI 10.1128/jb.171.5.2882-2885.1989; WATSON JT, 1991, INT J MASS SPECTROM, V111, P191; WYKE AW, 1982, EUR J BIOCHEM, V127, P553	39	273	282	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11248	11254						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597460				2022-12-27	WOS:A1992HX16900051
J	FUKAMI, K; TAKENAWA, T				FUKAMI, K; TAKENAWA, T			PHOSPHATIDIC-ACID THAT ACCUMULATES IN PLATELET-DERIVED GROWTH FACTOR-STIMULATED BALB/C 3T3 CELLS IS A POTENTIAL MITOGENIC SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHOSPHOLIPASE-D; PHOSPHATIDYLCHOLINE HYDROLYSIS; DNA-SYNTHESIS; FIBROBLASTS; ACTIVATION; RAS; POLYPHOSPHOINOSITIDES; TRANSDUCTION; NEUTROPHILS	We developed a monoclonal antibody specific to phosphatidic acid (PA). Using this antibody, a novel method to quantify trace amounts of PA was achieved. With the method, PA can be measured in the range of 20-500 pmol. We applied this method to quantify changes in PA levels in Balb/c 3T3 cells stimulated by platelet-derived growth factor. PA contents were very low in quiescent cells and dramatically increased with time up to 15 min. On the other hand, a biphasic diacylglycerol (DG) increase was found. The early phase showed a transient small peak of DG at 30 s followed by a decrease to 1 min. In the second phase, DG accumulated gradually but very markedly up to 15 min. Treatment with propranolol, a PA phosphohydrolase inhibitor, enhanced the accumulation of PA and inhibited the formation of DG in the second phase. However, R59022, a DG kinase inhibitor, did not influence the accumulation of DG or PA, suggesting that platelet-derived growth factor stimulates mainly phospholipase D-catalyzed hydrolysis of phospholipids rather than phospholipase C-catalyzed hydrolysis in the second phase. PA, even after contaminating lyso-PA was removed, could stimulate DNA synthesis, although lyso-PA was 25 times more potent. Moreover, phospholipase D was found to be a much stronger mitogen than phospholipase C. Phospholipase D treatment caused a biphasic accumulation of PA. PA levels reached a maximum at 1 h, and then decreased between 1 and 2 h; finally, there was a gradual elevation up to 10 h. In this case, there was no significant DG accumulation. On the other hand, phospholipase C treatment induced only DG accumulation without any significant change in PA. These results indicate that PA accumulation, rather than an increase in DG, correlates well with mitogenesis.	TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,SAKAE CHO,ITABASHI KU,TOKYO 173,JAPAN									AGWU DE, 1989, J BIOL CHEM, V264, P1405; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG CF, 1990, J BIOL CHEM, V265, P17468; JALINK K, 1990, J BIOL CHEM, V265, P12232; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARUYAMA T, 1987, J BIOL CHEM, V262, P5522; MATSUOKA K, 1988, SCIENCE, V239, P640; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PUTNEY JW, 1980, NATURE, V284, P345, DOI 10.1038/284345a0; RYU EK, 1979, J LIPID RES, V20, P561; SALMON DM, 1980, NATURE, V284, P344, DOI 10.1038/284344a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHACHT J, 1978, J LIPID RES, V19, P1063; SEKIMORI RS, 1989, J CELL PHYSL, V140, P432; SERHAN C, 1981, J BIOL CHEM, V256, P2736; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	31	207	210	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					10988	10993						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597441				2022-12-27	WOS:A1992HX16900012
J	MCGLYNN, P; HUNTER, CN				MCGLYNN, P; HUNTER, CN			ISOLATION AND CHARACTERIZATION OF A PUTATIVE TRANSCRIPTION FACTOR INVOLVED IN THE REGULATION OF THE RHODOBACTER-SPHAEROIDES PUCBA OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; RHODOPSEUDOMONAS-SPHAEROIDES; NUCLEOTIDE-SEQUENCE; PROTEIN; CLONING; BINDING; GENES; CAPSULATUS; EXPRESSION; BACTERIA	The pucBA operon of the photosynthetic bacterium Rhodobacter sphaeroides encodes the light harvesting 2 (LH2) apoproteins of the photosynthetic apparatus, and transcription of this operon is markedly depressed under aerobic conditions. The region upstream of the LH2 genes has been subjected to gel retardation analysis, and two distinct bandshifts have been observed. The intensity of the upper bandshift was reduced upon lowering the oxygen tension under which the cells were grown, and this reduction preceded the appearance of LH2 in the cell membrane. Purification of the sequence-specific DNA binding protein responsible for this bandshift activity revealed a protein of M(r) 26000, and DNase I footprint analysis revealed that the binding site was located 120 base pairs upstream of the transcription initiation point. We propose that this protein is an oxygen-regulated repressor of pucBA transcription. This work, therefore, describes the first purification of a transcription factor from any photosynthetic bacterium.	UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,WESTERN BANK,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Sheffield				McGlynn, Peter/0000-0001-8629-4713				AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ASHBY MK, 1987, FEBS LETT, V213, P245, DOI 10.1016/0014-5793(87)81499-0; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HUNTER CN, 1988, J GEN MICROBIOL, V134, P1471; HUNTER CN, 1991, MOL MICROBIOL, V5, P2649, DOI 10.1111/j.1365-2958.1991.tb01974.x; HUNTER CN, 1987, BIOCHEM J, V247, P489, DOI 10.1042/bj2470489; HUNTER CN, 1982, CELL FUNCTION DIFF B, P257; KANSY JW, 1989, J BIOL CHEM, V264, P13751; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1987, J BACTERIOL, V169, P3268, DOI 10.1128/jb.169.7.3268-3275.1987; KLUG G, 1991, MOL MICROBIOL, V5, P1235, DOI 10.1111/j.1365-2958.1991.tb01897.x; KLUG G, 1991, MOL GEN GENET, V226, P167, DOI 10.1007/BF00273600; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Maxam A M, 1980, Methods Enzymol, V65, P499; NIEDERMAN RA, 1976, BIOCHIM BIOPHYS ACTA, V440, P429, DOI 10.1016/0005-2728(76)90076-1; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; Sambrook J, 1989, MOL CLONING LABORATO; THEILER R, 1984, FEBS LETT, V175, P231, DOI 10.1016/0014-5793(84)80742-5; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUCCONI AP, 1988, J BACTERIOL, V170, P877, DOI 10.1128/jb.170.2.877-882.1988	30	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11098	11103						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597448				2022-12-27	WOS:A1992HX16900028
J	NUDELMAN, ED; LEVERY, SB; IGARASHI, Y; HAKOMORI, S				NUDELMAN, ED; LEVERY, SB; IGARASHI, Y; HAKOMORI, S			PLASMALOPSYCHOSINE, A NOVEL PLASMAL (FATTY ALDEHYDE) CONJUGATE OF PSYCHOSINE WITH CYCLIC ACETAL LINKAGE - ISOLATION AND CHARACTERIZATION FROM HUMAN BRAIN WHITE MATTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; PROTEIN KINASE-C; LIQUID-CHROMATOGRAPHY; METHYLATION ANALYSIS; GLYCOSPHINGOLIPIDS; LYSOSPHINGOLIPIDS; SPHINGOLIPIDS; SPHINGOSINE; DERIVATIVES; MODULATION	Through a systematic examination of basic (cationic) lipids separated on Folch's lower phase from extracts of human brain by cation exchange chromatography on carboxymethyl Sephadex in a chloroform/methanol mixture, followed by successive chromatographies on Florisil and Iatrobeads columns, five compounds of basic lipids were separated. Two major unknown compounds A and B and a minor unknown compound C were separated, in addition to minor compounds sphingosine and N,N-dimethylsphingosine. This paper describes the isolation and chemical characterization of major unknown compounds A and B, which were found only in the white matter but not in the gray matter of the human brain. Unmodified psychosine (galactosylsphingosine) was essentially undetectable under the experimental conditions. Unknown compounds A and B were identified as novel plasmal (fatty aldehyde) conjugates of psychosine with cyclic acetal linkage at the galactosyl residue of psychosine. Fatty aldehydes were identified as mainly palmital (16:0) and stearal (18:0). Sphingosine was identified as d18:1 sphingosine. Faster migrating compound A had 3,4-cyclic acetal linkage, and slower migrating compound B had 4,6-cyclic acetal linkage (where m is 14 or 16 and n is 12) as shown below. [GRAPHICS] Preliminary studies showed that compounds A, B, and C had a weak inhibitory effect on protein kinase C (PKC) and had no cytotoxic effect. In contrast, psychosine displayed a strong cytotoxicity and inhibitory effect on PKC. Therefore, the process controlling the addition or deletion of plasmal cyclic linkage to psychosine could be a crucial step in regulation of PKC, src, or other kinases susceptible to psychosine.	BIOMEMBRANE INST, 201 ELLIOTT AVE W, SEATTLE, WA 98119 USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLOU CE, 1985, CARBOHYD RES, V140, P139, DOI 10.1016/0008-6215(85)85058-8; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COREY EJ, 1979, TETRAHEDRON LETT, P399; Feulgen R, 1924, PFLUG ARCH GES PHYS, V206, P389, DOI 10.1007/BF01722779; FEULGEN R, 1929, HOPPESEYLERS Z PHYSL, V2, P161; FOLCH J, 1951, J BIOL CHEM, V191, P819; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARA A, 1986, J BIOCHEM-TOKYO, V100, P415, DOI 10.1093/oxfordjournals.jbchem.a121729; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1990, J BIOL CHEM, V265, P5389; IGARASHI Y, 1989, METHOD ENZYMOL, V179, P521; IGARASHI Y, 1990, TRENDS GLYCOSCI GLYC, V2, P319; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KISHIMOTO Y, 1968, J LIPID RES, V9, P27; KLENK E, 1967, H-S Z PHYSIOL CHEM, V348, P1712; KLENK E, 1966, H-S Z PHYSIOL CHEM, V346, P296; Klenk E, 1963, PROGR CHEM FATS OTHE, P1; KOCHETKOV NK, 1963, BIOCHIM BIOPHYS ACTA, V70, P716, DOI 10.1016/0006-3002(63)90823-0; KUBOTA M, 1974, JPN J EXP MED, V44, P145; Laine RA, 1972, METHOD ENZYMOL, V28, P159, DOI [10.1016/0076-6879(72)28012-0, DOI 10.1016/0076-6879(72)28012-0]; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; NEUENHOFER S, 1986, BIOL CHEM H-S, V367, P241, DOI 10.1515/bchm3.1986.367.1.241; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; NORES GA, 1989, METHOD ENZYMOL, V179, P242; RAPPORT MM, 1957, J NEUROCHEM, V1, P303, DOI 10.1111/j.1471-4159.1957.tb12086.x; RAPPORT MM, 1957, J BIOL CHEM, V225, P859; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; TAMAI Y, 1967, JPN J EXP MED, V37, P79; TAMAI Y, 1968, JPN J EXP MED, V38, P65; WITTENBERG JB, 1956, J BIOL CHEM, V219, P39; Zemplen G, 1927, BER DTSCH CHEM GES, V60, P1555, DOI 10.1002/cber.19270600717	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11007	11016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597442				2022-12-27	WOS:A1992HX16900015
J	COVER, TL; BLASER, MJ				COVER, TL; BLASER, MJ			PURIFICATION AND CHARACTERIZATION OF THE VACUOLATING TOXIN FROM HELICOBACTER-PYLORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPYLOBACTER-PYLORI; MOLECULAR CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CDNA SEQUENCE; PERMEASE GENE; CHANNEL GENE; PROTEINS; CYTOTOXIN	A vacuolating toxin was purified to homogeneity from broth culture supernatant of the human gastric bacterium, Helicobacter pylori. The procedure for isolating the toxin included ammonium sulfate precipitation, hydrophobic interactive chromatography, size exclusion chromatography, and anion exchange chromatography, which together resulted in a greater than 5000-fold purification of toxin activity. The molecular mass of the purified, denatured toxin was 87,000 +/-320 daltons, and the native toxin was an aggregate with a molecular mass greater-than-or-equal-to 972,000 daltons. The amino-terminal sequence of the purified toxin was partially homologous with internal sequences of numerous transport or ion channel proteins. Antiserum raised against the M(r) = 87,000 protein neutralized toxin activity, whereas preimmune serum did not. When reacted with specific antiserum to the M(r) = 87,000 protein in an enzyme-linked immunosorbent (ELISA) assay, culture supernatants from eight tox+ H. pylori r.trains produced significantly higher optical density readings than eight tox- supernatants (0.614 +/- 0.11 versus 0.046 +/- 0.01, p < 0.0001). Sera from H. pylori-infected humans recognized the purified M(r) = 87,000 protein significantly better by ELISA than sera from uninfected persons (0.424 +/- 0.06 versus 0.182 +/- 0.02, p = 0.0009). Finally, ELISA recognition of the purified M(r) = 87,000 protein by human sera was significantly associated with toxin-neutralizing activity (p = 0.01 9, r = 0.518).	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,INFECT DIS SECT,NASHVILLE,TN 37212	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	COVER, TL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,MED CTR N A3310,NASHVILLE,TN 37232, USA.		Cover, Timothy/I-3814-2015	Cover, Timothy/0000-0001-8503-002X				AMES GFL, 1974, J BIOL CHEM, V249, P634; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BUCK GE, 1987, J CLIN MICROBIOL, V25, P597, DOI 10.1128/JCM.25.4.597-599.1987; COVER T L, 1991, Gastroenterology, V100, pA570; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1992, ANNU REV MED, V43, P135, DOI 10.1146/annurev.me.43.020192.001031; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; COVER TL, 1992, IN PRESS HUMAN PATHO; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DUNN BE, 1990, J BIOL CHEM, V265, P9464; EATON KA, 1989, INFECT IMMUN, V57, P1119, DOI 10.1128/IAI.57.4.1119-1125.1989; ERNI B, 1987, J BIOL CHEM, V262, P5238; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GOLDRICK D, 1988, J BACTERIOL, V170, P3421, DOI 10.1128/jb.170.8.3421-3426.1988; GOOSSENS H, 1991, Microbial Ecology in Health and Disease, V4, pS130; HARBITZ I, 1990, GENOMICS, V8, P243, DOI 10.1016/0888-7543(90)90278-3; HAWKINS AR, 1988, MOL GEN GENET, V214, P224, DOI 10.1007/BF00337715; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; LEUNK RD, 1990, J CLIN MICROBIOL, V28, P1181, DOI 10.1128/JCM.28.6.1181-1184.1990; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MARSHALL BJ, 1986, LANCET, V1, P965; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEI ZH, 1988, J BIOL CHEM, V263, P6416; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SALKOFF L, 1987, NUCLEIC ACIDS RES, V15, P8569, DOI 10.1093/nar/15.20.8569; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734	43	584	619	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10570	10575						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587837				2022-12-27	WOS:A1992HV09000054
J	RAJAGOPALAN, KV; JOHNSON, JL				RAJAGOPALAN, KV; JOHNSON, JL			THE PTERIN MOLYBDENUM COFACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ASSIMILATORY NITRATE REDUCTASE; CARBON-MONOXIDE DEHYDROGENASE; XANTHINE-OXIDASE; ESCHERICHIA-COLI; SULFITE OXIDASE; PSEUDOMONAS-CARBOXYDOFLAVA; NEUROSPORA MUTANT; BIOSYNTHESIS; COMPLEMENTATION				RAJAGOPALAN, KV (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.							AMY NK, 1981, J BACTERIOL, V148, P274, DOI 10.1128/JB.148.1.274-282.1981; AUKETT A, 1988, DEV MED CHILD NEUROL, V30, P531; BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; Coughlan M. P., 1980, Molybdenum and molybdenum-containing enzymes, P119; DEISTUNG J, 1989, BIOCHEM J, V263, P477, DOI 10.1042/bj2630477; ENDRES W, 1988, EUR J PEDIATR, V148, P246, DOI 10.1007/BF00441412; GARDLIK S, 1991, J BIOL CHEM, V266, P16627; GARDLIK S, 1991, J BIOL CHEM, V266, P4889; GARDLIK S, 1990, J BIOL CHEM, V265, P13047; GARNER CD, 1985, MOLYBDENUM ENZYMES, P343; GLASER JH, 1971, J BACTERIOL, V108, P854, DOI 10.1128/JB.108.2.854-860.1971; GRUBER S, 1990, J AM CHEM SOC, V112, P8179, DOI 10.1021/ja00178a059; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1987, J BIOL CHEM, V262, P10914; Johnson J. L., 1980, MOLYBDENUM MOLYBDENU, P345; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1977, J BIOL CHEM, V252, P4994; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1991, BIOFACTORS, V3, P103; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON JL, 1989, METABOLIC BASIS INHE, V1, P1463; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KETCHUM PA, 1973, BIOCHEM BIOPH RES CO, V52, P1450, DOI 10.1016/0006-291X(73)90663-3; KETCHUM PA, 1970, P NATL ACAD SCI USA, V66, P1016, DOI 10.1073/pnas.66.3.1016; Koschara W, 1940, H-S Z PHYSIOL CHEM, V263, P78, DOI 10.1515/bchm2.1940.263.1-2.78; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRUGER B, 1987, BIOCHIM BIOPHYS ACTA, V912, P357, DOI 10.1016/0167-4838(87)90040-9; KRUGER B, 1986, EUR J BIOCHEM, V157, P121, DOI 10.1111/j.1432-1033.1986.tb09647.x; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; NASON A, 1970, P NATL ACAD SCI USA, V65, P137, DOI 10.1073/pnas.65.1.137; NASON A, 1974, J LESS-COMMON MET, V36, P449, DOI 10.1016/0022-5088(74)90129-5; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1991, FASEB J, V5, pA468; PITTERLE DM, 1991, THESIS DUKE U; Pitterle DM, 1990, FASEB J, V4, pA1957; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; TAYLOR EC, 1988, J ORG CHEM, V53, P5839, DOI 10.1021/jo00260a008; TAYLOR EC, 1989, J AM CHEM SOC, V111, P285, DOI 10.1021/ja00183a043; TAYLOR EC, 1989, J AM CHEM SOC, V111, P7664, DOI 10.1021/ja00201a084; WAHL RC, 1984, ARCH BIOCHEM BIOPHYS, V230, P264, DOI 10.1016/0003-9861(84)90107-3; WUEBBENS MM, 1991, FASEB J, V5, pA468; WUEBBENS MM, 1990, FASEB J, V4, pA1957; ZURICK TR, 1991, FASEB J, V5, pA470	56	420	421	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10199	10202						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587808				2022-12-27	WOS:A1992HV09000001
J	AGUILARBRYAN, L; NICHOLS, CG; RAJAN, AS; PARKER, C; BRYAN, J				AGUILARBRYAN, L; NICHOLS, CG; RAJAN, AS; PARKER, C; BRYAN, J			COEXPRESSION OF SULFONYLUREA RECEPTORS AND KATP CHANNELS IN HAMSTER INSULINOMA TUMOR (HIT) CELLS - EVIDENCE FOR DIRECT ASSOCIATION OF THE RECEPTOR WITH THE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; LIGAND-BINDING SYSTEMS; DEPENDENT K+-CHANNELS; GLIBENCLAMIDE-BINDING; H-3 GLIBENCLAMIDE; POTASSIUM CHANNEL; B-CELLS; TOLBUTAMIDE; DIAZOXIDE; PURIFICATION	Cell membranes isolated from hamster insulinoma (HIT T15) cells at passages 65-74 contain high and low affinity receptors for a sulfonylurea derivative, 5-[I-125]iodo,2-hydroxyglyburide (K(D) values of approximately 7 nM and 16-mu-M). Between passages 75 and 85, the estimated B(max) for the high affinity receptor decreases approximately 10-fold from approximately 1.6 to 0.16 pmol/mg membrane protein. By contrast, the density of low affinity binding sites, 800-1000 pmol/mg, is unaltered. The drop in high affinity receptors is paralleled by a decrease in the density of K(ATP) channels assessed using patch-clamp and Rb-86(+) efflux techniques. These results strongly support the idea that the high affinity sulfonylurea receptor is an integral part of the K(ATP) channel.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL)	AGUILARBRYAN, L (corresponding author), BAYLOR COLL MED,DEPT MED,1 BAYLOR PL,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK027635] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK27635, DK41898] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT FM, 1989, J PHYSIOL-LONDON, V408, P413, DOI 10.1113/jphysiol.1989.sp017467; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FOSSET M, 1988, J BIOL CHEM, V263, P7933; FRENCH JF, 1990, BIOCHEM BIOPH RES CO, V167, P1400, DOI 10.1016/0006-291X(90)90678-G; KOVACS RJ, 1991, AM J PHYSIOL, V261, pH604, DOI 10.1152/ajpheart.1991.261.2.H604; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; PANTEN U, 1989, BIOCHEM PHARMACOL, V38, P1217, DOI 10.1016/0006-2952(89)90327-4; QIN D, 1988, AM J PHYSIOL, V255, pH980, DOI 10.1152/ajpheart.1988.255.4.H980; ROBERTSON DW, 1990, J MED CHEM, V33, P1529, DOI 10.1021/jm00168a001; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; STURGESS NC, 1985, LANCET, V2, P474; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44; ZUNKLER BJ, 1988, N-S ARCH PHARMACOL, V337, P225; ZUNKLER BJ, 1988, FEBS LETT, V239, P241, DOI 10.1016/0014-5793(88)80925-6	27	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14934	14940						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634534				2022-12-27	WOS:A1992JF08800066
J	FLORINCHRISTENSEN, J; FLORINCHRISTENSEN, M; DELFINO, JM; STEGMANN, T; RASMUSSEN, H				FLORINCHRISTENSEN, J; FLORINCHRISTENSEN, M; DELFINO, JM; STEGMANN, T; RASMUSSEN, H			METABOLIC-FATE OF PLASMA-MEMBRANE DIACYLGLYCEROLS IN NIH-3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; INTRACELLULAR TRANSLOCATION; PHOSPHATIDIC-ACID; LIPID TRANSFER; PHOSPHATIDYLCHOLINE; VESICLES; FUSION; KINASE; HYDROLYSIS; MESSENGER	We have examined the metabolism of three radiolabeled 1,2-diacylglycerols (DGs) in NIH 3T3 fibroblasts. Since the lipids used are not appreciably taken up by the cells, we used a phosphatidylserine (PS)-based liposome fusion system to rapidly associate the lipid species with the plasma membrane. When 1,2[1-C-14]dioleoyl-sn-3-glycerol ([C-14]DOG) is delivered in this way, it is rapidly converted predominantly to phosphatidylcholine (PC) and triacylglycerol (TG) and to a lesser extent, to monoacylglycerol (MG) and fatty acids (FA), as well as phosphatidic acid (PA) and phosphatidylinositol (PI). We present evidence that [C-14] DOG is largely utilized as an intact molecule rather than being broken down to FA and then incorporated to cell lipids. Examination of the metabolism of 1-stearoyl-2-[1-C-14]myristoyl-sn-3-glycerol ([C-14]SMG) and I-stearoyl-2-arachidonoyl-sn-3-glycerol ([C-14] SAG) reveal important differences. Both produce substantial labeling of PC but [C-14]SMG gives rise to the highest proportion of TG and the lowest of PA and PI, whereas [C-14]SAG yields the opposite pattern. When phosphatidic acid labeled on its glycerol backbone (1,2-dioleoyl-sn-[U-C-14]glycero-3-phosphate) was supplied to the cells via the liposomes, rapid appearance of labeled DG was found which then decreased with concomitant labeling of cellular PC and TG. Only small amounts of the glycerol backbone were recovered in Pl. Our experiments identify three types of processes involved in the metabolism of plasma membrane DGs: (i) transferase-catalyzed conversions to PC and TG, (ii) lipolytic breakdown to MG and FA, and (iii) phosphorylation to PA and then conversion to Pl. The relative proportions of each DG species converted to these different products are strongly dependent on the fatty acyl composition of the particular DG molecular species, even though formation of PC is the major event in all cases. Since DGs are important second messengers, our study supports the view that conversion to PC and TG can play a key role in DG signal attenuation.	YALE UNIV,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Florin-Christensen, Monica/0000-0003-0456-3970	NIAID NIH HHS [AI 18599] Funding Source: Medline; NIDDK NIH HHS [DK-19813] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018599, R37AI018599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019813, R01DK019813] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BISHOP WR, 1988, ONCOGENE RES, V2, P205; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLLAG WB, 1991, ENDOCRINOLOGY, V128, P231, DOI 10.1210/endo-128-1-231; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EXTON JH, 1990, J BIOL CHEM, V265, P1; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; PAGANO RE, 1983, TRENDS BIOCHEM SCI, V8, P157, DOI 10.1016/0968-0004(83)90161-5; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P24; SALINGER Z, 1966, J LIPID RES, V7, P174; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1986, J BIOL CHEM, V261, P966; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; TAKUWA N, 1987, BIOCHEM J, V243, P647, DOI 10.1042/bj2430647; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007; WIRTZ KWA, 1982, LIPID PROTEIN INTERA, V1, P151; ZILVERSMIT DB, 1984, J LIPID RES, V25, P1563	32	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14783	14789						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634522				2022-12-27	WOS:A1992JF08800044
J	GOTO, Y; DESILVA, MG; TOSCANI, A; PRABHAKAR, BS; NOTKINS, AL; LAN, MS				GOTO, Y; DESILVA, MG; TOSCANI, A; PRABHAKAR, BS; NOTKINS, AL; LAN, MS			A NOVEL HUMAN INSULINOMA-ASSOCIATED CDNA, IA-1, ENCODES A PROTEIN WITH ZINC-FINGER DNA-BINDING MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; MOLECULAR-CLONING; NUCLEOTIDE-SEQUENCE; G0/G1 TRANSITION; C-FOS; GENE; POLYPEPTIDE; CELLS; CLONES; REGION	A subtraction library was constructed from human insulinoma (beta-cell tumor) and glucagonoma (alpha-cell tumor) cDNA phagemid libraries. Differential screening of 153 clones with end-labeled mRNAs from insulinoma, glucagonoma, and HeLa cells resulted in the isolation of a novel cDNA clone designated IA-1. This cDNA clone has a 2838-base pair sequence consisting of an open reading frame of 1530 nucleotides, which translates into a protein of 510 amino acids with a pI value of 9.1 and a molecular mass of 52,923 daltons. At the 3'-untranslated region there are seven ATTTA sequences between two polyadenylation signals (AATAAA). The IA-1 protein can be divided into two domains based upon the features of its amino acid sequence. The NH2-terminal domain of the deduced protein sequence (amino acids 1-250) has four classical pro-hormone dibasic conversion sites and an amidation signal sequence, Pro-Gly-Lys-Arg. The COOH-terminal domain (amino acids 251-510) contains five putative "zinc-finger" DNA-binding motifs of the form X3-Cys-X2-4-Cys-X12-His-X3-4-His-X4 which has been described as a consensus sequence for members of the Cys2-His2 DNA-binding protein class. Northern blot analysis revealed IA-1 mRNA in five of five human insulinoma and three of three murine insulinoma cell lines. Expression of this gene was undetectable in normal tissues. Additional tissue studies revealed that the message is expressed in several tumor cell lines of neuroendocrine origin including pheochromocytoma, medullary thyroid carcinoma, insulinoma, pituitary tumor, and small cell lung carcinoma. The restricted tissue distribution and unique sequence motifs suggest that this novel cDNA clone may encode a protein associated with the transformation of neuroendocrine cells.	NIDR,ORAL MED LAB,BLDG 30,RM 121,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Lan, Michael/CAF-1839-2022					BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; Brunstedt J, 1984, METHODS DIABETES R C, P245; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMI M, 1986, GENE, V41, P305; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kreil G, 1986, PROTEIN COMPARTMENTA, P61; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHWARTZ TW, 1983, GASTROENTEROLOGY, V85, P1411; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRASU Y, 1988, J BIOCHEM-TOKYO, V104, P259, DOI 10.1093/oxfordjournals.jbchem.a122454; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TOMITA N, 1989, BIOCHEM BIOPH RES CO, V158, P569, DOI 10.1016/S0006-291X(89)80087-7; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	33	142	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15252	15257						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634555				2022-12-27	WOS:A1992JF08800109
J	KURAZONO, H; MOCHIDA, S; BINZ, T; EISEL, U; QUANZ, M; GREBENSTEIN, O; WERNARS, K; POULAIN, B; TAUC, L; NIEMANN, H				KURAZONO, H; MOCHIDA, S; BINZ, T; EISEL, U; QUANZ, M; GREBENSTEIN, O; WERNARS, K; POULAIN, B; TAUC, L; NIEMANN, H			MINIMAL ESSENTIAL DOMAINS SPECIFYING TOXICITY OF THE LIGHT-CHAINS OF TETANUS TOXIN AND BOTULINUM NEUROTOXIN TYPE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NERVE TERMINALS; MESSENGER-RNA; CLOSTRIDIAL NEUROTOXINS; TRANSMITTER RELEASE; CHROMAFFIN CELLS; NEUROTRANSMITTER RELEASE; INHIBITS EXOCYTOSIS; NUCLEOTIDE-SEQUENCE; APLYSIA NEURONS; FORMS CHANNELS	To define conserved domains within the light (L) chains of clostridial neurotoxins, we determined the sequence of botulinum neurotoxin type B (BoNT/B) and aligned it with those of tetanus toxin (TeTx) and BoNT/A, BoNT/Cl, BoNT/D, and BoNT/E. The L chains of BoNT/B and TeTx share 51.6% identical amino acid residues whereas the degree of identity to other clostridial neurotoxins does not exceed 36.5%. Each of the L chains contains a conserved motif, HExxHxxH, characteristic for metalloproteases. We then generated specific 5'- and 3'-deletion mutants of the L chain genes of TeTx and BoNT/A and tested the biological properties of the gene products by microinjection of the corresponding mRNAs into identified presynaptic cholinergic neurons of the buccal ganglia of Aplysia californica. Toxicity was determined by measurement of neurotransmitter release, as detected by depression of postsynaptic responses to presynaptic stimuli (Mochida, S., Poulain, B., Eisel, U., Binz, T., Kurazono, H., Niemann, H., and Tauc, L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7844-7848). Our studies allow the following conclusions. 1) Residues Cys439 of TeTx and Cys430 of BoNT/A, both of which participate in the interchain disulfide bond, play no role in the toxification reaction. 2) Derivatives of TeTx that lacked either 8 amino- or 65 carboxyl-terminal residues are still toxic, whereas those lacking 10 amino- or 68 carboxyl-terminal residues are nontoxic. 3) For BoNT/A, toxicity could be demonstrated only in the presence of added nontoxic heavy (H) chain. A deletion of 8 amino-terminal or 32 carboxyl-terminal residues from the L chain had no effect on toxicity, whereas a removal of 10 amino-terminal or 57 carboxyl-terminal amino acids abolished toxicity. 4) The synergistic effect mediated by the H chain is linked to the carboxyl-terminal portion of the H chain, as demonstrated by injection of H(C)-specific mRNA into neurons containing the L chain. This finding suggests that the H(C) domain of the H chain becomes exposed to the cytosol during or after the putative translocation step of the L chain.	FED RES CTR VIRUS DIS ANIM,INST MICROBIOL,PAUL EHRLICH STR 28,POB 1149,W-7400 TUBINGEN,GERMANY; RIJKSINST VOLKSGEZONDHEID MILIEUHYG,3720 BA BILTHOVEN,NETHERLANDS; CNRS,NEUROBIOL CELLULAIRE & MOLEC LAB,F-91198 GIF SUR YVETTE,FRANCE; TOKYO MED COLL,DEPT PHYSIOL,SHINJUKU KU,TOKYO 160,JAPAN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Tokyo Medical University				Eisel, Ulrich/0000-0003-4178-0384				AGUILERA J, 1992, FEMS MICROBIOL LETT, V90, P99; AHNERTHILGER G, 1989, FEBS LETT, V242, P245, DOI 10.1016/0014-5793(89)80478-8; BHATTACHARYYA SD, 1989, INFECT IMMUN, V57, P3053, DOI 10.1128/IAI.57.10.3053-3057.1989; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BLACK JD, 1986, J CELL BIOL, V103, P535, DOI 10.1083/jcb.103.2.535; BOQUET P, 1984, EUR J BIOCHEM, V144, P339, DOI 10.1111/j.1432-1033.1984.tb08469.x; BOQUET P, 1982, P NATL ACAD SCI-BIOL, V79, P7614, DOI 10.1073/pnas.79.24.7614; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; DEKLEVA ML, 1990, J BACTERIOL, V172, P2498, DOI 10.1128/jb.172.5.2498-2503.1990; DEPAIVA A, 1990, FEBS LETT, V277, P171, DOI 10.1016/0014-5793(90)80836-8; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KOZAK MJ, 1987, J MOL BIOL, V196, P631; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KRIEGLSTEIN K, 1990, EUR J BIOCHEM, V188, P39; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; MAYER T, 1988, J BIOL CHEM, V263, P14956; MCINNES C, 1990, FEBS LETT, V261, P323, DOI 10.1016/0014-5793(90)80582-4; MOCHIDA S, 1990, P NATL ACAD SCI USA, V87, P7844, DOI 10.1073/pnas.87.20.7844; MOCHIDA S, 1989, FEBS LETT, V253, P47, DOI 10.1016/0014-5793(89)80926-3; MORRIS RE, 1989, BOTULINUM NEUROTOXIN, P121; POULAIN B, 1991, J BIOL CHEM, V266, P9580; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1989, EUR J BIOCHEM, V185, P197, DOI 10.1111/j.1432-1033.1989.tb15102.x; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULAIN B, 1989, J BIOL CHEM, V264, P21928; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHMIDT JJ, 1984, BIOCHEM BIOPH RES CO, V119, P900, DOI 10.1016/0006-291X(84)90858-1; SCHMITT A, 1981, N-S ARCH PHARMACOL, V317, P326, DOI 10.1007/BF00501314; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHONE CC, 1987, EUR J BIOCHEM, V167, P175, DOI 10.1111/j.1432-1033.1987.tb13320.x; SHONE CC, 1985, EUR J BIOCHEM, V151, P75, DOI 10.1111/j.1432-1033.1985.tb09070.x; SIMPSON LL, 1988, J PHARMACOL EXP THER, V245, P867; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; STECHER B, 1989, FEBS LETT, V255, P391, DOI 10.1016/0014-5793(89)81129-9; STECHER B, 1989, FEBS LETT, V248, P23, DOI 10.1016/0014-5793(89)80424-7; STOEVA S, 1990, BIOCHEMISTRY-US, V29, P527, DOI 10.1021/bi00454a029; TAUC L, 1974, NATURE, V250, P496, DOI 10.1038/250496a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WELLER U, 1988, N-S ARCH PHARMACOL, V338, P99; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	57	74	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14721	14729						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634516				2022-12-27	WOS:A1992JF08800036
J	RUBIN, DC; SWIETLICKI, E; ROTH, KA; GORDON, JI				RUBIN, DC; SWIETLICKI, E; ROTH, KA; GORDON, JI			USE OF FETAL INTESTINAL ISOGRAFTS FROM NORMAL AND TRANSGENIC MICE TO STUDY THE PROGRAMMING OF POSITIONAL INFORMATION ALONG THE DUODENAL-TO-COLONIC AXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; ACID-BINDING-PROTEIN; HOMEOBOX-CONTAINING GENE; HORMONE FUSION GENES; AGGREGATION CHIMERAS; MESSENGER-RNA; PANETH CELLS; STEM-CELLS; IMMUNOCYTOCHEMICAL LOCALIZATION; SUBEPITHELIAL FIBROBLASTS	The four principal cellular constituents of the mouse intestinal epithelium are all derived from a multipotent stem cell functionally anchored near the base of its crypts. Differentiation of enterocytes, enteroendocrine, and goblet cells occurs during an orderly upward migration from monoclonal crypts supplied by a single active stem cell to adjacent polyclonal small intestinal villi or to their colonic homologs, the surface epithelial cuffs. Paneth cells differentiate as they descend to the base of crypts. This epithelium undergoes rapid and perpetual renewal yet is able to maintain cephalocaudal (duodenal-to-colonic) differences in the differentiation programs of its four cell types from the time of its initial cytodifferentiation in late fetal life (embryonic (E) days 16-17). Rat liver fatty acid-binding protein/human growth hormone transgenes (Fabpl/hGH) have been used as novel phenotypic markers to describe the biological properties of gut stem cells and the differentiation programs of their enterocytic and enteroendocrine lineages. To determine whether the multipotent stem cell is able to retain a "positional" address in the absence of luminal signals, we prepared isografts from the proximal small intestine or distal small intestine and colon of E15-E16 Fabpl/hGH transgenic mice and their normal littermates and implanted them into the subcutaneous tissues of young, adult male CBY/B6 nude mice. Immunocytochemical and histochemical studies indicate that appropriate position-specific differences in the differentiation programs of each of the four principal cell lineages are present along the cephalocaudal and crypt-to-villus (or crypt-to-epithelial cuff) axes of isografts harvested 4-6 weeks after implantation. This suggests that the gut stem cell can be characterized not only by its multipotency and enormous capacity for self-renewal but also by its ability to be programmed (? imprinted) with positional information. Transgene expression is reduced in a number of enteroendocrine subpopulations in small intestinal and colonic isografts compared to the intact gut. Moreover, the decision to express the Fabpl/hGH transgene appears to be coordinated between adjacent crypts as evidenced by (i) the presence of multicrypt patches of wholly reporter (hGH)-positive or reporter-negative cells in the intact colon and in colonic isografts and (ii) by the presence of coherent bands of reporter-positive or -negative cells that emanate from adjacent monophenotypic crypts and extend to the apical extrusion zone of distal small intestinal villi. The apparent coordination of transgene expression between adjacent crypts raises questions about whether cephalocaudal differences in the differentiation programs of gut epithelial cell populations may be determined by a smaller population of stem cells than one would have anticipated based on the number of anatomically definable crypts.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,BOX 8103,660 S EUCLID AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Rubin, Deborah/0000-0002-4192-909X; Roth, Kevin/0000-0002-0643-995X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00946] Funding Source: Medline; NIDDK NIH HHS [DK37960] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMSON S, 1977, J EXP MED, V145, P1567, DOI 10.1084/jem.145.6.1567; ALNAFUSSI AI, 1982, VIRCHOWS ARCH B, V40, P51, DOI 10.1007/BF02932850; CAIRNIE AB, 1975, CELL TISSUE KINET, V8, P189, DOI 10.1111/j.1365-2184.1975.tb01219.x; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; COHN SM, 1991, P NATL ACAD SCI USA, V88, P1034, DOI 10.1073/pnas.88.3.1034; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DONY C, 1987, EMBO J, V6, P2965, DOI 10.1002/j.1460-2075.1987.tb02602.x; DRESSLER GR, 1989, DIFFERENTIATION, V41, P193, DOI 10.1111/j.1432-0436.1989.tb00747.x; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GAUNT SJ, 1991, BIOESSAYS, V13, P505, DOI 10.1002/bies.950131004; GAUNT SJ, 1986, NATURE, V324, P662, DOI 10.1038/324662a0; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; GRIFFITHS DFR, 1988, NATURE, V333, P461, DOI 10.1038/333461a0; HAFFEN K, 1983, DIFFERENTIATION, V23, P226; HANSBROUGH JR, 1991, AM J PHYSIOL, V260, pG929, DOI 10.1152/ajpgi.1991.260.6.G929; HART MH, 1988, GASTROENTEROLOGY, V94, P682, DOI 10.1016/0016-5085(88)90239-9; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; HOLLAND PWH, 1988, DEVELOPMENT, V102, P159; INOUE M, 1988, AM J PATHOL, V132, P49; JAMES R, 1991, J BIOL CHEM, V266, P3246; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KEDINGER M, 1987, CELL DIFFER DEV, V20, P171, DOI 10.1016/0045-6039(87)90431-3; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MARSH MN, 1974, GASTROENTEROLOGY, V67, P636; MARSH MN, 1974, GASTROENTEROLOGY, V67, P622; MASKENS AP, 1979, GUT, V20, P775, DOI 10.1136/gut.20.9.775; MCKEEL DW, 1978, ARCH PATHOL LAB MED, V102, P122; MEAD R, 1987, DEV BIOL, V121, P273, DOI 10.1016/0012-1606(87)90159-X; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; OBUOFORIBO AA, 1977, J ANAT, V24, P779; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; PONDER BAJ, 1985, J EMBRYOL EXP MORPH, V87, P229; PONDER BAJ, 1986, HISTOCHEM J, V18, P217, DOI 10.1007/BF01676230; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROTH KA, 1992, IN PRESS AM J PHYSL; RUBIN DC, 1991, J CELL BIOL, V113, P1183, DOI 10.1083/jcb.113.5.1183; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1986, ANAT EMBRYOL, V173, P317, DOI 10.1007/BF00318915; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SCHMIDT GH, 1985, CELL, V40, P425, DOI 10.1016/0092-8674(85)90156-4; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V85, P121; SCHMIDT GH, 1985, J EMBRYOL EXP MORPH, V88, P219; SCHMIDT GH, 1984, ANAT REC, V210, P407, DOI 10.1002/ar.1092100216; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SIMO P, 1991, DEVELOPMENT, V112, P477; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SIMONASSMANN P, 1986, DIFFERENTIATION, V32, P59, DOI 10.1111/j.1432-0436.1986.tb00556.x; SIMONASSMANN P, 1990, J CELL BIOL, V110, P849, DOI 10.1083/jcb.110.3.849; SIMONASSMANN P, 1988, DEVELOPMENT, V102, P339; STCLAIR WH, 1985, CELL TISSUE KINET, V18, P255; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TAVASSOLI M, 1990, BLOOD, V76, P1059; THOMPSON EM, 1990, DEVELOPMENT, V110, P477; UITDERDYK HG, 1986, GENET RES, V47, P125; VOGELS R, 1990, DEVELOPMENT, V110, P1159; WESER E, 1977, GASTROENTEROLOGY, V73, P524; WINTON DJ, 1990, P ROY SOC B-BIOL SCI, V241, P13, DOI 10.1098/rspb.1990.0059; WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; WRIGHT NA, 1982, CELL TISSUE KINET, V15, P595, DOI 10.1111/j.1365-2184.1982.tb01066.x	82	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					15122	15133						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634547				2022-12-27	WOS:A1992JF08800091
J	SORRENTINO, S; GLITZ, DG; HAMANN, KJ; LOEGERING, DA; CHECKEL, JL; GLEICH, GJ				SORRENTINO, S; GLITZ, DG; HAMANN, KJ; LOEGERING, DA; CHECKEL, JL; GLEICH, GJ			EOSINOPHIL-DERIVED NEUROTOXIN AND HUMAN LIVER RIBONUCLEASE - IDENTITY OF STRUCTURE AND LINKAGE OF NEUROTOXICITY TO NUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; L-TRYPTOPHAN INGESTION; CATIONIC PROTEIN; MYALGIA-SYNDROME; MOLECULAR-CLONING; HUMAN ANGIOGENIN; HUMAN-PLACENTA; INHIBITOR; PURIFICATION; BINDING	Eosinophil-derived neurotoxin (EDN) and human liver RNase were found to be indistinguishable from each other but distinct from the pancreatic ribonucleases in their nucleolytic activity on polynucleotides or small defined substrates. Antibodies to EDN and liver RNase showed identical cross-reactivities in assays of nuclease inhibition and in a radioimmunoassay. In each instance, EDN and liver RNase were easily distinguished from bovine or human pancreatic RNase. When injected intrathecally into rabbits, 5-10-mu-g of EDN or liver RNase each was neurotoxic as judged by induction of the Gordon phenomenon. Human pancreatic RNase was less neurotoxic, and up to 20-fold higher levels of bovine pancreatic RNase showed no effect. Treatment of EDN, liver RNase, and eosinophil cationic protein with iodoacetic acid at pH 5.5 resulted in inactivation of their RNase activity and also destroyed their neurotoxicity. EDN conformation was not greatly affected by iodoacetate treatment since interaction of the modified protein with antibodies was only slightly altered. We conclude that RNase activity is necessary but not sufficient to induce neurotoxic action.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; MAYO CLIN & MAYO FDN, ALLERG DIS RES LAB, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR 585] Funding Source: Medline; NIAID NIH HHS [AI 07047, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009728, R37AI009728] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDHOUS P, 1991, NATURE, V353, P490; BARKER RL, 1989, J IMMUNOL, V143, P952; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BLACKBURN P, 1982, J BIOL CHEM, V257, P316; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; Blackburn P, 1982, ENZYMES, VXV, P317; BULPITT KJ, 1990, ARTHRITIS RHEUM, V33, P918, DOI 10.1002/art.1780330702; CHARBONNEAU H, 1989, PRACTICAL GUIDE PROT, P20; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; DURACK DT, 1979, P NATL ACAD SCI USA, V76, P1443, DOI 10.1073/pnas.76.3.1443; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; Gordon MH, 1933, BRIT MED J, V1933, P641, DOI 10.1136/bmj.1.3771.641; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HAMANN KJ, 1989, GENE, V83, P161, DOI 10.1016/0378-1119(89)90414-9; HARPER JW, 1988, P NATL ACAD SCI USA, V85, P7139, DOI 10.1073/pnas.85.19.7139; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MOLINA HA, 1988, AM J TROP MED HYG, V38, P327, DOI 10.4269/ajtmh.1988.38.327; NG SC, 1989, POSTGRAD MED J, V65, P843, DOI 10.1136/pgmj.65.769.843; PALACIOS R, 1972, J BIOL CHEM, V247, P2316; PALMER KA, 1986, P NATL ACAD SCI USA, V83, P1965, DOI 10.1073/pnas.83.7.1965; PLAPP BV, 1973, J BIOL CHEM, V248, P4896; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; ROUBENOFF R, 1990, ARTHRITIS RHEUM, V33, P930, DOI 10.1002/art.1780330703; SCHARSCHMIDT BF, 1988, CECIL TXB MED, P852; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; SHAPIRO R, 1988, BIOCHEM BIOPH RES CO, V156, P530, DOI 10.1016/S0006-291X(88)80874-X; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P8783, DOI 10.1073/pnas.84.24.8783; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; Sierakowska H, 1977, Prog Nucleic Acid Res Mol Biol, V20, P59; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1988, J BIOL CHEM, V263, P16125; SORRENTINO S, 1991, FEBS LETT, V288, P23, DOI 10.1016/0014-5793(91)80994-E; SORRENTINO S, 1985, BIOCHIM BIOPHYS ACTA, V827, P135, DOI 10.1016/0167-4838(85)90081-0; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TOLANDER LM, 1991, ARCH NEUROL-CHICAGO, V48, P436, DOI 10.1001/archneur.1991.00530160106024; WEICKMANN JL, 1981, BIOCHEMISTRY-US, V20, P1272, DOI 10.1021/bi00508a035; YAMASHITA K, 1986, ARCH BIOCHEM BIOPHYS, V250, P263, DOI 10.1016/0003-9861(86)90725-3	51	130	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1992	267	21					14859	14865						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JF088	1634526				2022-12-27	WOS:A1992JF08800055
J	TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH				TEPIKIN, AV; VORONINA, SG; GALLACHER, DV; PETERSEN, OH			PULSATILE CA2+ EXTRUSION FROM SINGLE PANCREATIC ACINAR-CELLS DURING RECEPTOR-ACTIVATED CYTOSOLIC CA2+ SPIKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; CALCIUM; OSCILLATIONS; RELEASE; FLUCTUATIONS; MECHANISM	Ca2+ extrusion was measured simultaneously with the free intracellular Ca2+ concentration ([Ca2+]i) from single pancreatic acinar cells placed in microdroplets of extracellular solution (Tepikin, A. V., Voronina, S. G., Gallacher, D. V., and Petersen, O. H. (1992) J. Biol. Chem. 267, 3569-3572). Submaximal stimulation with cholecystokinin usually evoked discrete cytosolic Ca2+ spikes and each of these spikes was associated with a discrete and virtually synchronous pulse of Ca2+ extrusion into the extracellular microdroplet solution. When ACh evoked repetitive discrete [Ca2+]i spikes, each spike was also accompanied by a discrete pulse of Ca2+ extrusion. The velocity of Ca2+ extrusion oscillated with a time course similar to that of [Ca2+]i. The extracellular solution in our experiments had a low total calcium concentration (15-35-mu-M) and only a limited number of [Ca2+]i spikes (2-8) could be evoked. The magnitudes of the [Ca2+]i spikes and the amounts of Ca2+ extruded during each spike gradually decreased in each experiment. During the first cholecystokinin-evoked cytosolic Ca2+ spike the Ca2+ extrusion corresponded to a loss of 15-70% (mean value 39% +/- 12) of the mobilizable cellular calcium pool. The substantial pulsatile Ca2+ extrusion occurring synchronously with the receptor-activated cytosolic Ca2+ spikes is therefore an important element in repetitively bringing back [Ca2+], to the resting level.	UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,POB 147,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool				Tepikin, Alexei/0000-0002-8172-7513; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GOLDBETER A, 1990, P NATL ACAD SCI USA, V86, P3423; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; KOSTYUK PG, 1989, J MEMBRANE BIOL, V110, P11, DOI 10.1007/BF01870988; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MUALLEM S, 1988, J MEMBRANE BIOL, V106, P57, DOI 10.1007/BF01871767; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN OH, 1990, J MEMBRANE BIOL, V118, P93, DOI 10.1007/BF01868467; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RANDRIAMAMPITA C, 1991, CELL REGUL, V2, P513, DOI 10.1091/mbc.2.7.513; TEPIKIN AV, 1991, J MEMBRANE BIOL, V123, P43, DOI 10.1007/BF01993961; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALKUI M, 1991, J MEMBRANE BIOL, V124, P179; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	29	117	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14073	14076						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629206				2022-12-27	WOS:A1992JD32500047
J	ZHOU, SL; STUMP, D; SORRENTINO, D; POTTER, BJ; BERK, PD				ZHOU, SL; STUMP, D; SORRENTINO, D; POTTER, BJ; BERK, PD			ADIPOCYTE DIFFERENTIATION OF 3T3-L1 CELLS INVOLVES AUGMENTED EXPRESSION OF A 43-KDA PLASMA-MEMBRANE FATTY ACID-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER-INSOLUBLE COMPOUNDS; PHYSICAL-CHEMICAL MODEL; RAT-LIVER; ADIPOSE CONVERSION; LIPOPROTEIN-LIPASE; CARDIAC MYOCYTES; OLEATE UPTAKE; INVITRO; TISSUE; PREADIPOCYTES	A previously described 43-kDa plasma membrane fatty acid-binding protein (FABP(PM)) was not observed by immunohistochemical methods in proliferating 3T3-L1 fibroblasts. However, it was detectable in plasma membranes by the second day of confluent growth, prior to accumulation of visible lipid droplets, and was strongly expressed in 8-day differentiated adipocytes. These observations were confirmed by extraction of plasma membrane proteins and subsequent immunoblotting. Kinetics of initial [H-3]oleate uptake by both fibroblasts and adipocytes consisted of the sum of a saturable and a non-saturable component. During differentiation the saturable component increased progressively. V(max) increased from 3 to 25 to 110 pmol . s-1. mg cell protein-1 between the fibroblast, the 4-day, and 8 day adipocyte stages; K(m) was 24 nM in fibroblasts and approximately 55 nM in both 4- and 8-day differentiated adipocytes. By contrast, the rate constant for nonsaturable oleate influx decreased progressively from 0.026 to 0.010 ml. s-1 . mg protein-1 between the fibroblast and 8 day adipocyte stages. In 8-day adipocytes saturable oleate uptake was inhibited by up to 55% by antibodies against rat liver FABP(PM); these antibodies had no effect on uptake of 2-deoxyglucose or the medium chain fatty acid octanoate. They also had no effect on oleate uptake by fibroblasts. These studies support the hypothesis that FABP(PM) is a component of a saturable transport mechanism for long chain fatty acids.	CUNY MT SINAI SCH MED,DEPT MED,DIV LIVER DIS,BOX 1039,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Sorrentino, Dario/K-7253-2019; Sorrentino, Dario/E-8131-2010		NIDDK NIH HHS [DK-26438] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026438] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; BERMAN M, 1967, US PHS PUBLICATION, V1703; BERNLOHR DA, 1985, BIOCHEM BIOPH RES CO, V132, P850, DOI 10.1016/0006-291X(85)91209-4; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUTNECHT J, 1988, J MEMBRANE BIOL, V106, P83; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HEIMBERG M, 1973, DISTURBANCES LIPID L, P251; Kleinfeld A. M., 1990, Comments on Molecular and Cellular Biophysics. Comments on Modern Biology: Part A, V6, P361; KOCHWA S, 1961, J CLIN INVEST, V40, P874, DOI 10.1172/JCI104322; KUHL WE, 1970, J LIPID RES, V11, P458; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; NUNN WD, 1986, J BIOL CHEM, V261, P167; POTTER BJ, 1987, BIOCHEM BIOPH RES CO, V148, P1370, DOI 10.1016/S0006-291X(87)80283-8; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REICHEN J, 1981, BIOCHIM BIOPHYS ACTA, V640, P298, DOI 10.1016/0005-2736(81)90554-X; RESH MD, 1982, J BIOL CHEM, V257, P6978; Robinson D.S., 1970, COMPREHENSIVE BIOCH, P51; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SINGER T P, 1957, Methods Biochem Anal, V4, P307, DOI 10.1002/9780470110201.ch9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORRENTINO D, 1989, HEPATOLOGY, V10, P620; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; SORRENTINO D, 1989, J CLIN INVEST, V84, P1325, DOI 10.1172/JCI114301; SPECTOR A A, 1978, P229; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; SPOONER PM, 1979, J BIOL CHEM, V254, P21; STOLL GH, 1991, J LIPID RES, V32, P843; STORCH J, 1991, J BIOL CHEM, V266, P13473; STORCH J, 1990, HEPATOLOGY, V12, P1447, DOI 10.1002/hep.1840120632; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P10527; STREMMEL W, 1983, BIOCHEM BIOPH RES CO, V112, P88, DOI 10.1016/0006-291X(83)91801-6; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1986, BIOCHIM BIOPHYS ACTA, V877, P191, DOI 10.1016/0005-2760(86)90134-7; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STREMMEL W, 1987, J BIOL CHEM, V262, P6284; STUMP D, 1992, IN PRESS J HEPATOL, V15; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; TURCOTTE LP, 1991, FEBS LETT, V279, P327, DOI 10.1016/0014-5793(91)80180-B; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; WISE LS, 1978, CELL, V13, P233, DOI 10.1016/0092-8674(78)90192-7; WOSILAIT WD, 1976, COMPUT PROG BIOMED, V6, P142, DOI 10.1016/0010-468X(76)90020-9; ZHOU SL, 1991, HEPATOLOGY, V14, P321	64	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1992	267	20					14456	14461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JD325	1629231				2022-12-27	WOS:A1992JD32500101
J	ISHIKAWA, Y; KATSUSHIKA, S; CHEN, L; HALNON, NJ; KAWABE, J; HOMCY, CJ				ISHIKAWA, Y; KATSUSHIKA, S; CHEN, L; HALNON, NJ; KAWABE, J; HOMCY, CJ			ISOLATION AND CHARACTERIZATION OF A NOVEL CARDIAC ADENYLYLCYCLASE CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; GUANYLATE-CYCLASE; DNA-POLYMERASE; SEQUENCE; PROTEIN; GENE; IDENTIFICATION; HOMOLOGY; RECEPTOR; SURFACE	A novel adenylylcyclase cDNA (type V) was isolated from a canine heart cDNA library. Northern blotting indicates that the expression of this message is most abundant in heart with a lesser amount in brain but is absent in a variety of other tissues including lung, kidney, skeletal muscle, lymphocyte, and testis. The putative protein product predicted from the cDNA sequence has the motif of tandem six-transmembrane spans separated by a large hydrophilic cytoplasmic loop as seen in other members of the adenylylcyclase family. When this protein is expressed using a CMT cell transient expression system, the adenylylcyclase activity was stimulated by NaF, GTP-gamma-S, and forskolin, but not by calmodulin. The activity was inhibited in a concentration-dependent manner with either P-site active agents such as adenosine or in the presence of calcium. These data indicate that the protein encoded by this cDNA is adenylylcyclase with the biochemical features characteristic of the cardiac isoform.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,CARDIOVAS CENT NERVOUS SYST RES,PEARL RIVER,NY 10965	Columbia University	ISHIKAWA, Y (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-38070] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038070] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHFIELD M, 1990, BIOCHEM SOC T, V18, P150, DOI 10.1042/bst0180150; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HOMCY CJ, 1991, ANNU REV PHYSIOL, V53, P137, DOI 10.1146/annurev.physiol.53.1.137; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KHAMBATY FM, 1990, BIOTECHNIQUES, V9, P714; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYNCH TJ, 1976, BIOCHEM BIOPH RES CO, V68, P616, DOI 10.1016/0006-291X(76)91190-6; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TANG WJ, 1991, J BIOL CHEM, V266, P8593; VATNER DE, 1984, J CLIN INVEST, V73, P1473, DOI 10.1172/JCI111351	27	207	219	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13553	13557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618857				2022-12-27	WOS:A1992JB74600072
J	LILLO, C; RUOFF, P				LILLO, C; RUOFF, P			HYSTERETIC BEHAVIOR OF NITRATE REDUCTASE - EVIDENCE OF AN ALLOSTERIC BINDING-SITE FOR REDUCED PYRIDINE-NUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAVES; NADH; INHIBITION	In the absence of NADH, at 25-degrees-C, partially purified NADH:nitrate reductase undergoes an approximately 50% reduction of its initial activity during 2 h. With the increase of inactivation, the NADH and nitrite concentration time curves become typical "sigmoidal," i.e. the reaction velocity of the nitrate reductase catalyzed reaction goes through a maximum before equilibrium is reached. About 80% of the original activity of nitrate reductase is restored when the enzyme is incubated for 2 min with 200-mu-M NADH or NADPH. Also other NADH substrate analogues have similar effects in restoring the lost activity. After incubation with the reduced pyridine nucleotides, the sigmoidal appearance of the NADH concentration time curve disappears almost completely. Despite the fact that NADPH increases the activity of the enzyme, NADPH does not show any competition with the NADH-binding site of nitrate reductase and does not produce nitrite in the absence of NADH. It is therefore concluded that there must be an additional allosteric site which binds either NADH or NADPH, or other pyridine nucleotides with the effect of increasing the activity of the enzyme. A kinetic model is presented which simulates the observed experimental findings.			LILLO, C (corresponding author), ROGALAND UNIV CTR,BOX 2557,N-4004 STAVANGER,NORWAY.			Ruoff, Peter/0000-0003-4430-0382				BONZON M, 1983, PLANTA, V159, P254, DOI 10.1007/BF00397533; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; Hindmarsh A. C., 1980, ACM SIGNUM NEWSLETTE, V15, P10, DOI DOI 10.1145/1218052.1218054; HOAGLAND DR, 1950, 347 CAL AGR EXP STN; KAISER WM, 1991, PLANT PHYSIOL, V96, P363, DOI 10.1104/pp.96.2.363; LILLO C, 1991, PLANT SCI, V73, P149, DOI 10.1016/0168-9452(91)90022-Z; LILLO C, 1983, PHYSIOL PLANTARUM, V57, P357, DOI 10.1111/j.1399-3054.1983.tb02300.x; LOPEZPOZOS R, 1990, J PLANT PHYSIOL, V136, P451, DOI 10.1016/S0176-1617(11)80034-9; Neet K E, 1980, Methods Enzymol, V64, P192; NOTTON BA, 1985, PLANTA, V165, P114, DOI 10.1007/BF00392219; RAO IM, 1990, PHOTOSYNTH RES, V23, P205, DOI 10.1007/BF00035011; RAYMOND P, 1987, BIOCH PLANTS COMPREH, V11, P129; REDINBAUGH MG, 1981, PLANT PHYSIOL, V68, P115, DOI 10.1104/pp.68.1.115; RUOFF P, 1990, BIOCHEM INT, V21, P349; RUOFF P, 1990, BIOCHEM BIOPH RES CO, V172, P1000, DOI 10.1016/0006-291X(90)91545-4; Segel I.H., 1975, ENZYME KINETICS, P353; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; TURPIN DH, 1990, PLANT PHYSL BIOCH MO, P422	19	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13456	13459						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618848				2022-12-27	WOS:A1992JB74600058
J	SUNG, M; DALBEY, RE				SUNG, M; DALBEY, RE			IDENTIFICATION OF POTENTIAL ACTIVE-SITE RESIDUES IN THE ESCHERICHIA-COLI LEADER PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC MEMBRANE; CLEAVAGE SITE; COAT PROTEIN; SEQUENCE; GENE; MUTATIONS; DOMAIN; SEC11	Leader peptidase of Escherichia coli cleaves the leader sequence from the amino terminus of membrane and secreted proteins after these proteins insert across the membrane. Despite considerable research, the mechanism of catalysis of leader peptidase remains unknown. This peptidase cannot be classified using protease inhibitors to the serine, cysteine, aspartic acid, or metallo- classes of proteases (Zwizinski, C., Date, T., and Wickner, W. (1981) J. Biol. Chem. 256, 3593-3597). Using site-directed mutagenesis, we have attempted to place leader peptidase in one of these groups. We found that leader peptidase, lacking all of the cysteine residues, can cleave the leader peptide from procoat, the precursor to bacteriophage M13 coat protein. Replacement of each histidine residue with an alanyl residue was without effect on catalysis. Among all the serine and aspartic acid residues, serine 90 and serine 185 as well as aspartic acid 99, 153, 273, and 276 are necessary to cleave procoat in a detergent extract. However, only serine 90 and aspartic acid 153 were required for processing using a highly sensitive in vivo assay. In addition to the residues directly affecting catalysis, aspartic acid 99 plays a role in maintaining the structure of leader peptidase. Replacement of this residue with alanine results in a very unstable leader peptidase protein. This study thus defines two critical residues, serine 90 and aspartic acid 153, that may be directly involved in catalysis and provides evidence that leader peptidase belongs to a novel class of serine proteases.	OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOEKE JD, 1980, J MOL BIOL, V144, P103, DOI 10.1016/0022-2836(80)90027-3; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; ITO K, 1980, J BIOL CHEM, V255, P2123; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KUHN A, 1985, J BIOL CHEM, V260, P5914; Maniatis T., 1982, MOL CLONING; MOORE KE, 1987, J BIOL CHEM, V262, P8806; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YAMANE K, 1987, J BIOL CHEM, V262, P2358; ZALKIN H, 1974, J BIOL CHEM, V249, P465; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	30	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13154	13159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618816				2022-12-27	WOS:A1992JB74600011
J	ZAKIM, D; EIBL, H				ZAKIM, D; EIBL, H			THE INFLUENCE OF CHARGE AND THE DISTRIBUTION OF CHARGE IN THE POLAR-REGION OF PHOSPHOLIPIDS ON THE ACTIVITY OF UDP-GLUCURONOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCURONYLTRANSFERASE; DEHYDROGENASE; ACTIVATION; PROTEINS; BILAYERS	Studies of the mechanism of lipid-induced regulation of the microsomal enzyme UDP-glucuronosyltransferase have been extended by examining the influence of charge within the polar region on the ability of lipids to activate delipidated pure enzyme. The effects of net negative charge, of charge separation in phosphocholine, and of the distribution of charge in the polar region of lipids were studied using the GT2p isoform isolated from pig liver. Prior experiments have shown that lipids with net negative charge inhibit the enzyme (Zakim, D., Cantor, M., and Eibl, H. (1988) J. Biol. Chem. 263, 5164-5169). The current experiments show that the extent of inhibition on a molar basis increases as the net negative charge increases from -1 to -2. The inhibitory effect of negatively charged lipids is on the functional state of the enzyme and is not due to electrostatic repulsion of negatively charged substrates of the enzyme. Although the inhibitory effect of net negative charge is removed when negative charge is balanced by a positive charge due to a quaternary nitrogen, neutrality of the polar region is not a sufficient condition for activation of the enzyme. In addition to a balance of charge between P(i) and the quaternary nitrogen, the distance between the negative and positive charges and the orientation of the dipole created by them are critical for activation of GT2p. The negative and positive charges must be separated by the equivalent of three -CH2- groups for optimal activation by a lipid. Shortening this distance by one -CH2- unit leads to a lipid that is ineffective in activating the enzyme. Reversal of the orientation of the dipole in which the negative charge is on the polymethylene side of the lipid-water interface and the positive charge extends into water also produces a lipid that is not effective for activating GT2p. On the other hand, lipids with phosphoserine as the polar region, which has the "normal" P-N distance but carries a net negative charge, do not inhibit GT2p. This result again illustrates the importance of the dipole of phosphocholine for modulating the functional state of GT2p.	MAX PLANCK INST BIOPHYS CHEM,W-3400 GOTTINGEN,GERMANY	Max Planck Society	ZAKIM, D (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV DIGEST DIS,NEW YORK,NY 10021, USA.							CHURCHILL P, 1983, J BIOL CHEM, V258, P208; CLARK PE, 1986, BIOCHIM BIOPHYS ACTA, V859, P143, DOI 10.1016/0005-2736(86)90209-9; DANNENBERG A, 1990, ANAL BIOCHEM, V191, P183, DOI 10.1016/0003-2697(90)90406-Y; EIBL H, 1978, P NATL ACAD SCI USA, V75, P4074, DOI 10.1073/pnas.75.9.4074; EIBL H, 1981, METHOD ENZYMOL, V72, P631; HOCHMAN J, 1981, J BIOL CHEM, V258, P4783; HOCHMAN Y, 1983, J BIOL CHEM, V258, P4143; HOCHMAN Y, 1983, J BIOL CHEM, V258, P6509; Jain M. K., 1988, INTRO BIOL MEMBRANES; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V906, P33, DOI 10.1016/0304-4157(87)90004-9; KASSAHARA MC, 1977, J BIOL CHEM, V252, P7384; KOVATCHEV S, 1981, J BIOL CHEM, V256, P369; MAGDALOU J, 1982, J BIOL CHEM, V257, P13624; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; RIES U, 1992, IN PRESS BIOCH BIOPH; ROTENBERG M, 1989, BIOCHEMISTRY-US, V28, P8577, DOI 10.1021/bi00447a046; ROTENBERG M, 1991, J BIOL CHEM, V266, P4159; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; VESSEY DA, 1972, J BIOL CHEM, V247, P3023; WANG S, 1988, BIOCHEMISTRY-US, V27, P2033, DOI 10.1021/bi00406a033; ZAKIM D, 1988, J BIOL CHEM, V263, P5164	22	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1992	267	19					13166	13170						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	JB746	1618818				2022-12-27	WOS:A1992JB74600013
J	LOPEZ, JA; LEUNG, B; REYNOLDS, CC; LI, CQ; FOX, JEB				LOPEZ, JA; LEUNG, B; REYNOLDS, CC; LI, CQ; FOX, JEB			EFFICIENT PLASMA-MEMBRANE EXPRESSION OF A FUNCTIONAL PLATELET GLYCOPROTEIN-IB-IX COMPLEX REQUIRES THE PRESENCE OF ITS 3 SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; CELL ANTIGEN RECEPTOR; AMINO-ACID-SEQUENCE; VONWILLEBRAND-FACTOR; GPIIB-IIIA; SURFACE; PROTEINS; ADHESION; MEGAKARYOCYTES; IDENTIFICATION	The glycoprotein (GP) Ib-IX complex of the platelet plasma membrane mediates the adhesion of platelets to damaged blood vessel wall. The complex is composed of three membrane-spanning polypeptides, GP Ib(alpha), GP Ib(beta), and GP IX, all of which are absent from the platelets of patients with the hereditary bleeding disorder Bernard-Soulier syndrome. In this study we report stable expression of the recombinant receptor in three cell lines and demonstrate that the three subunits of the complex are necessary for its efficient expression on the plasma membrane. The expressed complex associates with the cytoskeleton of the transfected cells through an interaction with actin-binding protein and binds its ligand, von Willebrand factor. These data suggest that the lack of plasma membrane GP Ib-IX complex in the Bernard-Soulier syndrome could potentially arise from mutations affecting any one of its three subunits.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LOPEZ, JA (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 1990, CURR OPIN CELL BIOL, V2, P894, DOI 10.1016/0955-0674(90)90089-W; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; BERKNER K, 1986, COLD SPRING HARB SYM, V51, P531, DOI 10.1101/SQB.1986.051.01.065; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1983, BLOOD, V62, P800; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1987, HEMOSTASIS THROMBOSI, P60; DROUIN J, 1988, BLOOD, V72, P1086; DU XP, 1987, BLOOD, V69, P1524; DUPERRAY A, 1989, BLOOD, V74, P1603; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANDIN RI, 1989, BLOOD S1, V74, pA129; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOURDILLE P, 1990, BRIT J HAEMATOL, V76, P521, DOI 10.1111/j.1365-2141.1990.tb07910.x; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MCMICHAEL AJ, 1981, BRIT J HAEMATOL, V49, P501, DOI 10.1111/j.1365-2141.1981.tb07258.x; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MOROI M, 1984, BLOOD, V64, P622; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; OTOOLE TE, 1989, BLOOD, V74, P14; ROSA JP, 1989, J BIOL CHEM, V264, P12596; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHIMOMURA T, 1990, BLOOD, V75, P2349; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOBELEM G, 1976, NATURE, V263, P427, DOI 10.1038/263427a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	40	183	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12851	12859						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618785				2022-12-27	WOS:A1992HZ48300071
J	NOVAK, A; GOYAL, N; GRONOSTAJSKI, RM				NOVAK, A; GOYAL, N; GRONOSTAJSKI, RM			4 CONSERVED CYSTEINE RESIDUES ARE REQUIRED FOR THE DNA-BINDING ACTIVITY OF NUCLEAR FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; RECOGNITION SITE; REPLICATION; PROTEIN; TRANSCRIPTION; INVITRO; PURIFICATION; POLYMERASE; CLONING; INVIVO	The role of Cys residues in the site-specific DNA binding activity of the nuclear factor I (NFI) family of proteins was assessed by chemical modification and site-specific mutagenesis. Treatment with the thiol-specific reagent N-ethylmaleimide abolished site-specific DNA binding of all forms of NFI present in HeLa nuclear extracts. Preincubation of cell extracts with an oligonucleotide containing an NFI-binding site provided partial protection of NFI from N-ethylmaleimide inactivation. Mutations were made in the cDNA encoding a truncated form of the NFI-C/CAAT box transcription factor-1 protein, converting each of the five Cys residues in the DNA-binding domain of the protein into Ser residues. NFI-C proteins containing mutations in any of four conserved Cys residues, expressed in Escherichia coli or in vitro, did not bind to DNA. NFI-C with a mutation in a nonconserved Cys residue had normal DNA binding activity. Both this active mutant and wild-type NFI-C protein were inactivated by modification of their sulfhydryl residues with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), and preincubation with an oligonucleotide containing an NFI-binding site gave partial protection against inactivation. After modification with DTNB, DNA binding activity was partially restored by subsequent incubation with dithiothreitol, indicating that inactivation of NFI by DTNB was reversible. These studies indicate an essential role for free sulfhydryl residues in NFI-DNA binding.	ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Gronostajski, Richard/0000-0003-4264-208X				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAHAM LJ, 1990, MOL CELL BIOL, V10, P3483, DOI 10.1128/MCB.10.7.3483; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GRONOSTAJSKI RM, 1988, NUCLEIC ACIDS RES, V16, P2087, DOI 10.1093/nar/16.5.2087; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANG K, 1985, NUCLEIC ACIDS RES, V13, P5173, DOI 10.1093/nar/13.14.5173	33	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12986	12990						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618796				2022-12-27	WOS:A1992HZ48300088
J	ZANTEMA, A; VERLAANDEVRIES, M; MAASDAM, D; BOL, S; VANDEREB, A				ZANTEMA, A; VERLAANDEVRIES, M; MAASDAM, D; BOL, S; VANDEREB, A			HEAT-SHOCK PROTEIN-27 AND ALPHA-B-CRYSTALLIN CAN FORM A COMPLEX, WHICH DISSOCIATES BY HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN STRESS PROTEINS; GEL-ELECTROPHORESIS; TRANSFORMED-CELLS; MOLECULAR-WEIGHT; LENS CRYSTALLINS; RAT LENS; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; TISSUES	We have previously demonstrated that in non-oncogeric adenovirus-transformed baby rat kidney cells a complex of hsp27 and a 22-kDa protein is present, which is lacking in oncogenic cells (Zantema, A., de Jong, E., Lardenoije, R., and van der Eb, A. J. (1989) J. Virol. 63, 3368-3375). Here we show that the 22-kDa protein is identical to alpha-B-crystallin. The complex of hsp27 and alpha-B-crystallin is also found in some other (non-transformed) cells. However, in most cells tested only hsp27 and no alpha-B-crystallin is synthesized. Gel filtration studies show that both proteins are present almost exclusively in a 700-kDa complex. Heat treatment makes the complex fall apart, which is accompanied by a change in the conformation of alpha-B-crystallin. Upon recovery, complexes are formed again from both pre-existing and newly synthesized proteins.			ZANTEMA, A (corresponding author), SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.							ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLIER NC, 1986, EXP EYE RES, V43, P103, DOI 10.1016/S0014-4835(86)80049-5; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1986, J CELL BIOL, V102, P104, DOI 10.1083/jcb.102.1.104; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI A, 1990, J BIOL CHEM, V265, P22197; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; TOMOKANE N, 1991, AM J PATHOL, V138, P875; UCHIUMI T, 1983, EXP EYE RES, V36, P125, DOI 10.1016/0014-4835(83)90095-7; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; WEITZEL G, 1987, EXP CELL RES, V170, P64, DOI 10.1016/0014-4827(87)90117-0; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	35	138	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1992	267	18					12936	12941						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HZ483	1618790				2022-12-27	WOS:A1992HZ48300081
J	BLEE, E; SCHUBER, F				BLEE, E; SCHUBER, F			REGIOSELECTIVITY AND ENANTIOSELECTIVITY OF SOYBEAN FATTY-ACID EPOXIDE HYDROLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE-DEPENDENT OXYGENASE; RICE BLAST DISEASE; PLANT; HYDROLYSIS; MECHANISMS; HYDRATION	Soluble epoxide hydrolase purified from soybean catalyzes trans-addition of water across the oxirane ring of cis-9,10-epoxystearic acid with inversion of configuration at the attacked carbon, yielding threo-9,10-dihydroxystearic acid. Kinetic analyses of the progress curves, obtained at low substrate concentrations (i.e. [S] << K(m)), and determination of the enantiomeric excess of the residual substrate by chiral-phase high-performance liquid chromatography at different reaction times, indicate that the epoxide hydrolase hydrates preferentially cis-9R,10S-epoxystearic acid (V/K(m) ratio, approximately 20). Interestingly, this enantiomer is obtained by epoxidation of oleic acid catalyzed by peroxygenase, a hydroperoxide-dependent oxidase, we have previously described in soybean (Blee, E., and Schuber, F. (1990) J. Biol. Chem. 265, 12887-12894). For the epoxide hydrolase to show high enantioselectivity there must be a free carboxylic acid functionality on the substrate which probably influences its positioning within the active site. This selectivity, which in principle can be used for kinetic resolution of the cis-9,10-epoxystearic acid enantiomers, is much reduced with methyl cis-9,10-epoxystearate. O-18-Labeling experiments indicate that water attacks both cis-9,10-epoxystearic acid enantiomers on the oxirane carbon which has the S-chirality. Results show that soybean epoxide hydrolase produces exclusively threo-9R,10R-dihydroxystearic acid, i.e. a naturally occurring metabolite in higher plants. cis-9,10-Epoxy-18-hydroxystearic acid, a cutin monomer, was a poorer substrate of the epoxide hydrolase than 9,10-epoxystearic acid (V/K(m) ratio for the preferred enantiomers, approximately 19). From a physiological point of view, peroxygenase and this newly described epoxide hydrolase could be responsible, in vivo, for the biosynthesis of a class of oxygenated fatty acid compounds known to be involved in cutin monomers production and in plant defense mechanisms.	FAC PHARM ILLKIRCH,CHIM BIOORGAN LAB,CNRS,URA 1386,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS)	BLEE, E (corresponding author), INST BOT,DECM,INST BIOL MOLEC PLANTES,CNRS,UPR 406,28 RUE GOETHE,F-67000 STRASBOURG,FRANCE.							AMSTRONG RN, 1987, CRC CRIT REV BIOCH, V22, P39; BELLUCCI G, 1989, J ORG CHEM, V54, P5978, DOI 10.1021/jo00286a034; BELLUCCI G, 1991, J CHEM SOC PERK T 1, P361, DOI 10.1039/p19910000361; BLEE E, 1990, J BIOL CHEM, V265, P12887; BLEE E, 1989, BIOCHEMISTRY-US, V28, P4962, DOI 10.1021/bi00438a009; BLEE E, 1992, BIOCHEM J, V282, P711, DOI 10.1042/bj2820711; BLEE E, 1990, BIOCHEM BIOPH RES CO, V173, P1354, DOI 10.1016/S0006-291X(05)80937-4; CHEN CS, 1982, J AM CHEM SOC, V104, P7294, DOI 10.1021/ja00389a064; CROTEAU R, 1975, ARCH BIOCHEM BIOPHYS, V170, P73, DOI 10.1016/0003-9861(75)90098-3; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; Fersht AR., 1977, ENZYME STRUCTURE MEC; FITZPATRICK PA, 1991, J AM CHEM SOC, V113, P3166, DOI 10.1021/ja00008a054; FRANCESCHI VR, 1991, P NATL ACAD SCI USA, V88, P6745, DOI 10.1073/pnas.88.15.6745; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GILL SS, 1979, BIOCHEM BIOPH RES CO, V89, P965, DOI 10.1016/0006-291X(79)91872-2; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HANZLIK RP, 1976, J AM CHEM SOC, V98, P1952, DOI 10.1021/ja00423a050; HOLLOWAY PJ, 1973, PHYTOCHEMISTRY, V12, P1721, DOI 10.1016/0031-9422(73)80393-0; KATO T, 1983, NATURWISSENSCHAFTEN, V70, P200, DOI 10.1007/BF01047565; KATO T, 1983, TETRAHEDRON LETT, V24, P4715, DOI 10.1016/S0040-4039(00)86236-X; KOLATTUKUDY PE, 1981, ANNU REV PLANT PHYS, V32, P539, DOI 10.1146/annurev.pp.32.060181.002543; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MORRIS LJ, 1966, LIPIDS, V1, P41, DOI 10.1007/BF02668123; MORRIS LJ, 1970, BIOCHEM J, V118, P681, DOI 10.1042/bj1180681g; MORRIS LJ, 1972, LIPIDS, V7, P372, DOI 10.1007/BF02531506; Orsi B A, 1979, Methods Enzymol, V63, P159; POWELL PG, 1967, LIPIDS, V2, P172; SAYER JM, 1985, J BIOL CHEM, V260, P1630; STASWICK PE, 1991, PLANT PHYSIOL, V96, P130, DOI 10.1104/pp.96.1.130; WATABE T, 1972, BIOCHIM BIOPHYS ACTA, V279, P297, DOI 10.1016/0304-4165(72)90146-8; WITSUBA D, 1986, ANGEW CHEM INT EDIT, V25, P1032	31	53	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11881	11887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601858				2022-12-27	WOS:A1992HY94700038
J	GIBSON, QH; BELLELLI, A; REGAN, R; SHARMA, PK; VINOGRADOV, SN				GIBSON, QH; BELLELLI, A; REGAN, R; SHARMA, PK; VINOGRADOV, SN			LIGAND-BINDING BY THE CHLOROCRUORIN FROM EUDISTYLIA-VANCOUVERII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; HEMOGLOBIN; PROTOHEME	Carbon monoxide chlorocruorin from Eudistylia vancouverii shows three distinct first-order relaxations with rates of 2.9 x 10(9) s-1, 6.5 x 10(7) s-1, and 3.2 x 10(6) s-1 (geminate reactions) and three second-order relaxations with rates of 4.7 x 10(6) M-1 s-1, 7 x 10(5) M-1 s-1, and 7 x 10(4) M-1 s-1, when studied by flash photolysis. The amplitudes of the second-order reactions depend on the extent of photolysis. This may be due to relaxation from the liganded (R) to the unliganded (T) conformation following photolysis and suggests that the combination rates contribute to cooperativity. In a stopped-flow experiment only the slowest phase with a rate of 7 x 10(4) M-1 s-1 is observed. It is assigned to binding to the T-state protein. Fragments of the native protein containing 12 and 4 hemes react like the holoprotein suggesting that the tetramer is a major cooperative unit. Oxygen binding shows three geminate relaxations with rates of 2.5 x 10(10) s-1, 3.5 x 10(7) s-1, and 4.5 x 10(6) s-1, and two second-order rates of 1.5 x 10(7) M-1 s-1 and 1 x 10(1) M-1 s-1. The amplitudes of the second-order phases do not correlate with the extent of photolysis. The results with the two ligands are consistent with an allosteric transition fast enough to compete with a rebinding rate of 500 s-1 in the R to T direction (CO rebinding) but not fast enough to compete with oxygen rebinding. There is significant heterogeneity in the R-state kinetics, but the T-state reaction is homogeneous.	UNIV LA SAPIENZA, CTR BIOL MOLEC, CNR, DIPARTIMENTO SCI BIOCHIM, I-00185 ROME, ITALY; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM, DETROIT, MI 48201 USA	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Wayne State University	GIBSON, QH (corresponding author), CORNELL UNIV, DEPT BIOCHEM & MOLEC & CELLULAR BIOL, ITHACA, NY 14853 USA.		Bellelli, Andrea/D-2785-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014276] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38674] Funding Source: Medline; NIGMS NIH HHS [GM 14276] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1962, ARCH BIOCHEM BIOPHYS, V97, P336, DOI 10.1016/0003-9861(62)90086-3; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BRUNORI M, 1965, ESTR PUBBLIC STAZ ZO, V34, P521; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CHUNG MCM, 1979, PROG BIOPHYS MOL BIO, V35, P53; COLOSIMO A, 1974, BIOPHYS CHEM, V2, P338, DOI 10.1016/0301-4622(74)80060-8; FOX HM, 1949, PROC R SOC SER B-BIO, V136, P378, DOI 10.1098/rspb.1949.0031; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1964, BIOCHEM J, V91, P161, DOI 10.1042/bj0910161; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; GUERRITORE D, 1965, J MOL BIOL, V13, P234, DOI 10.1016/S0022-2836(65)80092-4; IMAI K, 1985, EUR J BIOCHEM, V147, P453; IPPOLITI R, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P133; KAPP OH, 1990, J MOL BIOL, V213, P141, DOI 10.1016/S0022-2836(05)80127-5; LEMBERG R, 1951, BIOCHEM J, V49, P674, DOI 10.1042/bj0490674; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P2786, DOI 10.1021/bi00358a008; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QABAR AN, 1991, J MOL BIOL, V222, P1109, DOI 10.1016/0022-2836(91)90596-X; SAWICKI CA, 1979, J BIOL CHEM, V254, P4058; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1985, BIOCHIM BIOPHYS ACTA, V828, P43, DOI 10.1016/0167-4838(85)90007-X	22	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1992	267	17					11977	11981						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HY947	1601868				2022-12-27	WOS:A1992HY94700051
J	BAKER, BF; MIRAGLIA, L; HAGEDORN, CH				BAKER, BF; MIRAGLIA, L; HAGEDORN, CH			MODULATION OF EUKARYOTIC INITIATION FACTOR-4E BINDING TO 5'-CAPPED OLIGORIBONUCLEOTIDES BY MODIFIED ANTISENSE OLIGONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; CAP ANALOGS; PROTEIN; PHOSPHORYLATION; RECOGNITION; TRANSLATION; INVITRO	The 5' cap structure of eucaryotic mRNA plays a pivotal role in mRNA metabolism. This report demonstrates that anti-sense oligonucleotides equipped with 3'-overhanging nucleotides modulate the amount of recombinant human eucaryotic initiation factor-4E that binds to a 5'-capped oligoribonucleotide. The degree of inhibition or enhancement of protein binding is dependent upon the number and sequence of overhanging nucleotides. A 45% inhibition of complexation was observed by the addition of one 3'-overhanging guanosine residue. Addition of a second residue (+2/GN) resulted in a higher degree of inhibition, 77-88%. In contrast, addition of one adenosine residue enhanced the formation of the eucaryotic initiation factor-4E-m7GpppRNA complex by 213%. Modulation of protein interactions with the 5'-cap structure is likely to effect several biological events, including pre-mRNA processing, transport of the mRNA from the nucleus to the cytoplasm and translation of the target mRNA. This targeting strategy in anti-sense chemistry may have practical applications in experimental biology and medicine.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; VET ADM MED CTR, NASHVILLE, TN 37203 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BAKER, BF (corresponding author), ISIS PHARMACEUT, DEPT MOLEC & CELLULAR BIOL, CARLSBAD, CA 92008 USA.			Baker, Brenda/0000-0001-8586-768X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040219] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40219] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BL, 1978, J BIOL CHEM, V253, P2589; BANJEREE AK, 1980, MICROBIOL REV, V44, P175; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DARZYNKIEWICZ E, 1987, BIOCHEMISTRY-US, V26, P4372, DOI 10.1021/bi00388a028; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HICKEY ED, 1977, J MOL BIOL, V109, P173, DOI 10.1016/S0022-2836(77)80027-2; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; KIM CH, 1977, NATURE, V270, P223, DOI 10.1038/270223a0; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P340, DOI 10.1016/S0006-291X(88)81228-2; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; NISHIMURA Y, 1980, NUCLEIC ACIDS RES, V8, P1107, DOI 10.1093/nar/8.5.1107; PUGLISI JD, 1988, NATURE, V331, P283, DOI 10.1038/331283a0; RAY BK, 1985, J BIOL CHEM, V260, P7651; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Rhoads R. E, 1985, PROGR MOL SUBCELLULA, V9, P104; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; Saenger W., 1984, PRINCIPLES NUCL ACID, P116, DOI DOI 10.1007/978-1-4612-5190-3_6; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; STENBERG RM, 1984, J VIROL, V49, P190, DOI 10.1128/JVI.49.1.190-199.1984; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	41	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1992	267	16					11495	11499						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HX169	1597477				2022-12-27	WOS:A1992HX16900085
J	DONATE, LE; VALPUESTA, JM; ROCHER, A; MENDEZ, E; ROJO, F; SALAS, M; CARRASCOSA, JL				DONATE, LE; VALPUESTA, JM; ROCHER, A; MENDEZ, E; ROJO, F; SALAS, M; CARRASCOSA, JL			ROLE OF THE AMINO-TERMINAL DOMAIN OF BACTERIOPHAGE PHI-29 CONNECTOR IN DNA-BINDING AND PACKAGING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS PHAGE-PHI-29; STRUCTURAL PROTEINS; GENE-8 PRODUCT; LAMBDA; IDENTIFICATION; MORPHOGENESIS; PURIFICATION; EXPRESSION; HEAD; OVERPRODUCTION	The connector of bacteriophage phi-29 is required for prohead assembly, binds DNA, and drives DNA packaging into viral proheads. Limited proteolysis of the connector protein with endoproteinase Glu-C from Staphylococcus aureus V8 and chymotrypsin showed that a domain of the NH2-terminal region is involved in DNA binding and in the subsequent packaging into preformed proheads, but not in prohead assembly. Mutants in specific amino acids of the NH2-terminal domain, obtained by directed mutagenesis techniques, showed that the Ala1-Ar2-Lys3-Arg4 region of the connector is absolutely necessary for DNA packaging into the proheads as well as for efficient DNA binding.	UNIV AUTONOMA MADRID,CTR BIOL MOLEC,CANTOBLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid			Valpuesta, José M/T-1977-2017; Rojo, Fernando/A-7038-2008; Rocher, Asuncion/H-5411-2012; Salas, Margarita/J-9873-2014; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; Rojo, Fernando/0000-0003-1848-7745; Rocher, Asuncion/0000-0001-9043-0474; Salas, Margarita/0000-0001-5939-3441; 				BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; BUCHWALD M, 1970, VIROLOGY, V42, P390, DOI 10.1016/0042-6822(70)90282-5; CAMACHO A, 1977, EUR J BIOCHEM, V73, P39, DOI 10.1111/j.1432-1033.1977.tb11290.x; CARAZO JM, 1986, J ULTRA MOL STRUCT R, V94, P105, DOI 10.1016/0889-1605(86)90056-X; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; CARRASCOSA JL, 1985, VIROLOGY, V141, P190, DOI 10.1016/0042-6822(85)90251-X; CARRUTH JAS, 1986, IEEE ENG MED BIOL, V5, P37, DOI 10.1109/MEMB.1986.5006254; Casjens S., 1988, BACTERIOPHAGES, VI; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DONATE LE, 1988, J MOL BIOL, V201, P91, DOI 10.1016/0022-2836(88)90441-X; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; DONATE LE, 1991, VIROLOGY, V182, P534, DOI 10.1016/0042-6822(91)90594-2; DRIEDONKS RA, 1981, J MOL BIOL, V152, P641, DOI 10.1016/0022-2836(81)90121-2; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GARCIA JA, 1984, GENE, V30, P87, DOI 10.1016/0378-1119(84)90108-2; GRIMES S, 1989, J MOL BIOL, V209, P101, DOI 10.1016/0022-2836(89)90173-3; HERRANZ L, 1986, VIROLOGY, V155, P289, DOI 10.1016/0042-6822(86)90191-1; HERRANZ L, 1990, J MOL BIOL, V213, P263, DOI 10.1016/S0022-2836(05)80189-5; HSIAO CL, 1978, VIROLOGY, V91, P15, DOI 10.1016/0042-6822(78)90351-3; IBANEZ C, 1984, NUCLEIC ACIDS RES, V12, P2351, DOI 10.1093/nar/12.5.2351; KOCHAN J, 1983, VIROLOGY, V131, P100, DOI 10.1016/0042-6822(83)90537-8; KOCHAN J, 1984, J MOL BIOL, V174, P175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURIALDO H, 1978, MICROBIOL REV, V42, P529, DOI 10.1128/MMBR.42.3.529-576.1978; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; MURIALDO H, 1971, BACTERIOPHAGE LAMBDA, P711; NAKASU S, 1985, VIROLOGY, V143, P422, DOI 10.1016/0042-6822(85)90382-4; RAJ AS, 1974, MOL GEN GENET, V135, P175, DOI 10.1007/BF00264784; ROJO F, 1990, GENE, V96, P75, DOI 10.1016/0378-1119(90)90343-P; ZABALLOS A, 1987, GENE, V58, P67, DOI 10.1016/0378-1119(87)90030-8	30	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10919	10924						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587868				2022-12-27	WOS:A1992HV09000106
J	RINKERSCHAEFFER, CW; AUSTIN, V; ZIMMER, S; RHOADS, RE				RINKERSCHAEFFER, CW; AUSTIN, V; ZIMMER, S; RHOADS, RE			RAS TRANSFORMATION OF CLONED RAT EMBRYO FIBROBLASTS RESULTS IN INCREASED RATES OF PROTEIN-SYNTHESIS AND PHOSPHORYLATION OF EUKARYOTIC INITIATION FACTOR-4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA; POLYACRYLAMIDE GELS; COMPLEX; ASSOCIATION; ONCOGENE; SIGNAL; EIF-4F; INVOLVEMENT; TRANSLATION	Eukaryotic initiation factor 4E (eIF-4E) is a 25-kDa phosphoprotein that binds to the 7-methylguanosine cap of mRNA and acts, along with other eIF-4 polypeptides, to unwind mRNA secondary structure at the 5' terminus. Recent studies have indicated that eIF-4E acts as a protooncogene, but only in its phosphorylated state. In order to determine the role of eIF-4E in oncogenesis, we examined its regulation and expression in cloned rat embryo fibroblasts transformed with the Harvey ras (Ha-ras) oncogene. The expression of Ha-ras increased the rate of protein synthesis but did not increase the levels of eIF-4E mRNA or protein. However, a dramatic increase (7-fold) in phosphate incorporation into eIF-4E was observed. The percentage of eIF-4E in the phosphorylated state was the same in transfected and control cells, indicating that both phosphorylation and dephosphorylation of eIF-4E were increased. Phosphopeptide mapping of eIF-4E from transformed cells indicated a single site of phosphorylation at Ser-53, which is the same as that identified previously in eIF-4E from reticulocytes and HeLa cells. These results indicate that p21ras is part of the signal transduction pathway leading to phosphorylation of eIF-4E. These findings also provide a potential mechanism for cell transformation by p21ras which involves the preferential stimulation of translation of certain mRNAs.	UNIV KENTUCKY, COLL MED, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, COLL MED, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky					NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BASERGA R, 1990, CANCER RES, V50, P6769; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DURKIN JP, 1989, ANTICANCER RES, V9, P1313; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HAAS DW, 1991, ARCH BIOCHEM BIOPHYS, V284, P84, DOI 10.1016/0003-9861(91)90267-M; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; SMITH M R, 1990, New Biologist, V2, P648; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TUAZON PT, 1990, J BIOL CHEM, V265, P10617	44	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10659	10664						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587843				2022-12-27	WOS:A1992HV09000068
J	WEIDNER, KM; DENZIN, LK; VOSS, EW				WEIDNER, KM; DENZIN, LK; VOSS, EW			MOLECULAR STABILIZATION EFFECTS OF INTERACTIONS BETWEEN ANTI-METATYPE ANTIBODIES AND LIGANDED ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FLUORESCYL ANTIBODIES; HYDROGEN-EXCHANGE; BINDING; IDIOTYPE	Anti-metatype antibodies have been described as antibodies which recognize ligand-induced conformational changes in the antibody variable region. Additionally, anti-metatype antibodies, produced by multiple immunizations with liganded high affinity monoclonal anti-fluorescein antibody 4-4-20, enhanced the lifetime of monoclonal antibody 4-4-20-fluorescein complex. To better understand the mechanism of the delayed dissociation rate, deuterium oxide was used to probe the liganded active site. The rate and extent of deuterium oxide-mediated fluorescence enhancement of bound ligand served to monitor the conformational dynamics of the active site in the presence and absence of anti-metatype antibodies. Results showed that anti-metatype antibodies reduced the rate and extent of deuterium oxide-mediated fluorescence enhancement of 4-4-20, a single-chain derivative of 4-4-20 (consisting of the variable domains and a poly-linker), and idiotypically related monoclonal anti-fluorescein antibodies suggesting that anti-metatype stabilized the liganded active site. Size exclusion liquid chromatography was utilized to isolate the liganded antibody-anti-metatype complex. Liganded single chain antibody 4-4-20 was mixed with 10-fold molar excess anti-metatype Fab fragments, and a major complex eluted with an apparent M(r) 249,000. The apparent molecular weight of this complex inferred that one liganded single chain antibody was bound by five anti-metatype Fab fragments. Spectral analysis confirmed these results and the characteristic delayed rate of ligand dissociation was also observed for the isolated complex. The results suggest that anti-metatype antibodies stabilize the liganded conformation by forming a large, stable, macromolecular complex.			WEIDNER, KM (corresponding author), UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801, USA.							BALLARD DW, 1983, P NATL ACAD SCI-BIOL, V80, P5071, DOI 10.1073/pnas.80.16.5071; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1329; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRANDT P, 1987, BIOCHEMISTRY-US, V26, P3156, DOI 10.1021/bi00385a032; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; ENGLANDER JJ, 1987, BIOCHEMISTRY-US, V26, P1846, DOI 10.1021/bi00381a009; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GREENSPAN NS, 1989, BIOTECHNIQUES, V7, P1086; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HOLMES NJ, 1983, J BIOL CHEM, V258, P1580; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, J BIOL CHEM, V256, P4433; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; REINITZ DM, 1984, MOL IMMUNOL, V21, P775, DOI 10.1016/0161-5890(84)90164-0; STEVENS FJ, 1988, J IMMUNOL METHODS, V108, P271, DOI 10.1016/0022-1759(88)90429-2; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1989, MOL IMMUNOL, V26, P971, DOI 10.1016/0161-5890(89)90115-6; VOSS EW, 1980, MOL IMMUNOL, V17, P505, DOI 10.1016/0161-5890(80)90090-5; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513; WEIDNER KM, 1992, IN PRESS MOL IMMUNOL	29	33	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10281	10288						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587817				2022-12-27	WOS:A1992HV09000015
J	YOUNG, JP; MATHEWS, CK				YOUNG, JP; MATHEWS, CK			INTERACTIONS BETWEEN T4-PHAGE-CODED DEOXYCYTIDYLATE HYDROXYMETHYLASE AND THYMIDYLATE SYNTHASE AS REVEALED WITH AN ANTIIDIOTYPIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR ANTIBODIES; 3-DIMENSIONAL STRUCTURE; COMPLEX	Anti-idiotypic antibodies were used to mimic the binding surface of the T4 bacteriophage deoxycytidylate hydroxymethylase enzyme, providing an immunological probe for protein-protein interactions involving this enzyme. Polyclonal dCMP hydroxymethylase antibodies were affinity-purified and used to generate anti-idiotypic antibodies. The anti-idiotypic serum immunoprecipitated two native viral proteins, deoxycytidylate hydroxymethylase (EC 2.1.2.8) and thymidylate synthase (EC 2.1.1.45), from a sonicated detergent-treated extract of T4-infected Escherichia coli. The anti-anti-dCMP hydroxymethylase antibody was found to be specific in binding to the T4 dTMP synthase, with no detectable affinity for the host dTMP synthase. Previous work in our laboratory has demonstrated the viral dCMP hydroxymethylase and dTMP synthase to be associated in a deoxyribonucleotide synthetase enzyme complex. Our current approach, using anti-idiotypic antibodies as probes for protein-protein interactions, and complementary studies involving dCMP hydroxymethylase enzyme affinity columns indicate a direct association between bacteriophage T4 dCMP hydroxymethylase and dTMP synthase.	OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Oregon State University					NIGMS NIH HHS [GM37508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037508, R55GM037508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; CHIU CS, 1977, J BIOL CHEM, V252, P8603; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; GRAMSCH C, 1988, J BIOL CHEM, V263, P5853; HARLOW E, 1988, ANTIBODIES LABORATOR; JENNINGS I, 1990, J BIOL CHEM, V265, P1885; LAMM N, 1988, EUR J BIOCHEM, V172, P553, DOI 10.1111/j.1432-1033.1988.tb13925.x; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; REDDY GPV, 1977, P NATL ACAD SCI USA, V74, P3152, DOI 10.1073/pnas.74.8.3152; SCHULZ R, 1984, NEUROPEPTIDES, V5, P221, DOI 10.1016/0143-4179(84)90067-2; SCHULZ R, 1985, BIOCHEM BIOPH RES CO, V132, P658, DOI 10.1016/0006-291X(85)91183-0; SOMERVILLE RL, 1990, UCLA SYM BI, V133, P181; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VENTER JC, 1984, MONOCLONAL ANTIIDIOT; WANG Y, 1989, THESIS OREGON STATE; WARNER HR, 1983, BACTERIOPHAGE T4, P103; WHEELER L, 1992, J BIOL CHEM, V267, P7664	21	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1992	267	15					10786	10790						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HV090	1587854				2022-12-27	WOS:A1992HV09000087
J	DEGASPERI, R; DANIEL, PF; WARREN, CD				DEGASPERI, R; DANIEL, PF; WARREN, CD			A HUMAN LYSOSOMAL ALPHA-MANNOSIDASE SPECIFIC FOR THE CORE OF COMPLEX GLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY OLIGOSACCHARIDES; GLYCOPROTEIN CATABOLISM; SWAINSONINE; ENZYME; SHEEP; 1,4-DIDEOXY-1,4-IMINO-D-MANNITOL; BIOSYNTHESIS; SEPARATION; CATTLE; KIDNEY	A novel lysosomal alpha-mannosidase, with unique substrate specificity, has been partially purified from human spleen by chromatography through concanavalin A-Sepharose, DEAE-Sephadex, and Sephacryl S-300. This enzyme can catalyze the hydrolysis of only 1 mannose residue, that which is alpha(1 --> 6)-linked to the beta-linked mannose in the core of N-linked glycans, as found in the oligosaccharides Man-alpha(1 --> 6)[Man-alpha(1 --> 3] Man-beta(1 --> 4)GlcNAc and Man-alpha(1 --> 6)Man-beta(1 --> 4) GlcNAc. The newly described alpha-mannosidase does not catalyze the hydrolysis of mannose residues outside of the core, even if they are alpha(1 --> 6)-linked, and is not active on the other alpha-linked mannose in the core, which is (1 --> 3)-linked. The narrow specificity of the novel mannosidase contrasts sharply with that of the major lysosomal alpha-mannosidase, which is able to catalyze the degradation of oligosaccharides containing diverse linkage and branching patterns of the mannose residues. Importantly, although the major mannosidase readily catalyzes the hydrolysis of the core alpha(1 --> 3)-linked mannose, it is poorly active towards the alpha(1 --> 6)-linked mannose, i.e. the very same mannose residue for which the newly characterized mannosidase is specific. The novel enzyme is further differentiated from the major lysosomal alpha-mannosidase by its inability to catalyze the efficient hydrolysis of the synthetic substrate p-nitrophenyl alpha-mannoside, and by the strong stimulation of its activity by Co2+ and Zn2+. Similarly to the major mannosidase, it is strongly inhibited by swainsonine and 1,4-dideoxy-1,4-imino-D-mannitol, but not by deoxymannojirimycin. The presence of this novel alpha-mannosidase activity in human tissues provides the best explanation, to date, for the structures of the oligosaccharides stored in human alpha-mannosidosis. In this condition the major lysosomal alpha-mannosidase activity is severely deficient, but apparently the alpha(1 --> 6)-mannosidase is unaffected, so that the oligosaccharide structures reflect the unique specificity of this enzyme.	HARVARD UNIV,SCH MED,LOVETT LABS,CARBOHYDRATE UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,BOSTON,MA 02129; EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,WALTHAM,MA 02254	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016942] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040930] Funding Source: NIH RePORTER; NCRR NIH HHS [SO7 RR 05486-28] Funding Source: Medline; NICHD NIH HHS [HD 16942] Funding Source: Medline; NIDDK NIH HHS [DK 40930] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM D, 1986, BIOCHEM J, V233, P899, DOI 10.1042/bj2330899; ALDAHER S, 1991, BIOCHEM J, V277, P743, DOI 10.1042/bj2770743; ARONSON NN, 1989, FASEB J, V3, P2515; BEAUDET AL, 1976, BIOCHEM BIOPH RES CO, V68, P292, DOI 10.1016/0006-291X(76)90042-5; BISCHOFF J, 1986, J BIOL CHEM, V261, P4766; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; CHENG SH, 1986, BIOCHEM J, V233, P65, DOI 10.1042/bj2330065; DANIEL PF, 1984, BIOCHEM J, V221, P601, DOI 10.1042/bj2210601; DANIEL PF, 1989, GLYCOCONJUGATE J, V6, P229, DOI 10.1007/BF01050651; DANIEL PF, 1987, METHOD ENZYMOL, V138, P94; DANIEL PF, 1991, GLYCOCONJUGATE J, V8, P271; DEGASPERI R, 1991, J BIOL CHEM, V266, P16556; DEGASPERI R, 1989, J BIOL CHEM, V264, P9329; DESNICK RJ, 1976, PEDIATR RES, V19, P985; DIBELLO IC, 1983, BIOCHEM J, V215, P693, DOI 10.1042/bj2150693; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; HARD K, 1991, GLYCOCONJUGATE J, V8, P17, DOI 10.1007/BF00731639; HIRANI S, 1979, BIOCHEM J, V179, P583, DOI 10.1042/bj1790583; HUGHES RC, 1981, TRENDS BIOCHEM SCI, V6, P228, DOI 10.1016/0968-0004(81)90083-9; HULTBERG B, 1980, BIOCHEM BIOPH RES CO, V67, P1473; KISTLER JP, 1977, ARCH NEUROL-CHICAGO, V34, P45, DOI 10.1001/archneur.1977.00500130065013; LUNDBLAD A, 1976, EUR J BIOCHEM, V67, P209, DOI 10.1111/j.1432-1033.1976.tb10651.x; MATSUURA F, 1981, ARCH BIOCHEM BIOPHYS, V207, P337, DOI 10.1016/0003-9861(81)90041-2; PALAMARCZYK G, 1985, ARCH BIOCHEM BIOPHYS, V243, P35, DOI 10.1016/0003-9861(85)90771-4; PHILLIPS NC, 1974, BIOCHEM J, V137, P363, DOI 10.1042/bj1370363; SONG Z, 1987, BIOCHEM J, V248, P145, DOI 10.1042/bj2480145; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VANPELT J, 1990, J BIOL CHEM, V265, P19685; WARREN CD, 1988, J BIOL CHEM, V263, P15041; WARREN CD, 1989, SWAINSONINE AND RELATED GLYCOSIDASE INHIBITORS, P344; WARREN CD, 1983, CARBOHYD RES, V116, P171, DOI 10.1016/0008-6215(83)88107-5; Warren CD, 1988, CARBOHYD RES, V180, P325, DOI 10.1016/0008-6215(88)80089-2; WINCHESTER B, 1984, BIOCHEM SOC T, V12, P522, DOI 10.1042/bst0120522; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126	35	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1992	267	14					9706	9712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HT965	1577805				2022-12-27	WOS:A1992HT96500041
